{"id": "8908396_3", "context": "OBJECTIVE: To test the hypothesis that tumor necrosis factor (TNF)-alpha may mediate the loss and the dedifferentiation of subcutaneous fat tissue in the insulin-induced lipoatrophies of a diabetic patient who presented extensive lesions.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[162]], "entity_id": ["T4"]}, "Treatment": {"text": [["insulin"]], "start": [[154]], "entity_id": ["T3"], "Drug": {"text": [["insulin"]], "start": [[154]], "entity_id": ["T6"]}, "Disorder": {"text": [["diabetic"]], "start": [[189]], "entity_id": ["T7"]}}, "Effect": {"text": [["lipoatrophies"]], "start": [[170]], "entity_id": ["T5"]}}]}]}
{"id": "10891991_1", "context": "An evaluation of ovarian structure and function should be considered in women of reproductive age being treated with valproate for epilepsy, especially if they develop menstrual cycle disturbances during treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["develop"]], "start": [[160]], "entity_id": ["T5"]}, "Subject": {"text": [["women of reproductive age"]], "start": [[72]], "entity_id": ["T3"], "Gender": {"text": [["women"]], "start": [[72]], "entity_id": ["T7"]}, "Age": {"text": [["reproductive age"]], "start": [[81]], "entity_id": ["T8"]}}, "Treatment": {"text": [["valproate for epilepsy"]], "start": [[117]], "entity_id": ["T4"], "Drug": {"text": [["valproate"]], "start": [[117]], "entity_id": ["T9"]}, "Disorder": {"text": [["epilepsy"]], "start": [[131]], "entity_id": ["T10"]}}, "Effect": {"text": [["menstrual cycle disturbances"]], "start": [[168]], "entity_id": ["T6"]}}]}]}
{"id": "2332596_1", "context": "Phenobarbital hepatotoxicity in an 8-month-old infant.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[29]], "entity_id": ["T6"]}, "Subject": {"text": [["an 8-month-old infant"]], "start": [[32]], "entity_id": ["T3"], "Age": {"text": [["8-month-old infant"]], "start": [[35]], "entity_id": ["T7"]}}, "Treatment": {"text": [["Phenobarbital"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Phenobarbital"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["hepatotoxicity"]], "start": [[14]], "entity_id": ["T5"]}}]}]}
{"id": "12552054_1", "context": "The authors report a case of Balint syndrome with irreversible posterior leukoencephalopathy on MRI following intrathecal methotrexate and cytarabine.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[100]], "entity_id": ["T8"]}, "Treatment": {"text": [["intrathecal methotrexate and cytarabine"]], "start": [[110]], "entity_id": ["T9"], "Route": {"text": [["intrathecal"]], "start": [[110]], "entity_id": ["T10"]}, "Drug": {"text": [["methotrexate"], ["cytarabine"]], "start": [[122], [139]], "entity_id": ["T12", "T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[135]], "entity_id": ["T11"]}, "Drug": {"text": [["cytarabine"], ["methotrexate"]], "start": [[139], [122]], "entity_id": ["T13", "T12"]}}]}, "Effect": {"text": [["Balint syndrome with irreversible posterior leukoencephalopathy on MRI"]], "start": [[29]], "entity_id": ["T7"]}}]}]}
{"id": "19531695_12", "context": "According to the Naranjo probability scale, flecainide was the probable cause of the patient's delirium; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and paroxetine.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[72]], "entity_id": ["T11"]}, "Treatment": {"text": [["flecainide"]], "start": [[44]], "entity_id": ["T9"], "Drug": {"text": [["flecainide"], ["flecainide"], ["paroxetine"]], "start": [[44], [211], [226]], "entity_id": ["T14", "T15", "T16"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[191]], "entity_id": ["T17"]}, "Drug": {"text": [["flecainide"], ["paroxetine"]], "start": [[211], [226]], "entity_id": ["T15", "T16"]}}]}, "Effect": {"text": [["delirium"]], "start": [[95]], "entity_id": ["T12"]}, "Subject": {"text": [["the patient"]], "start": [[81]], "entity_id": ["T13"]}, "Speculated": {"text": [["probable"]], "start": [[63]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "8002140_2", "context": "Contact dermatitis due to budesonide: report of five cases and review of the Japanese literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[19]], "entity_id": ["T3"]}, "Effect": {"text": [["Contact dermatitis"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["budesonide"]], "start": [[26]], "entity_id": ["T5"], "Drug": {"text": [["budesonide"]], "start": [[26]], "entity_id": ["T6"]}}}]}]}
{"id": "8586895_3", "context": "Prolongation of the QT interval observed in a Japanese patient with vivax malaria following treatment with halofantrine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[82]], "entity_id": ["T6"]}, "Subject": {"text": [["a Japanese patient with vivax malaria"]], "start": [[44]], "entity_id": ["T3"], "Race": {"text": [["Japanese"]], "start": [[46]], "entity_id": ["T7"]}}, "Effect": {"text": [["Prolongation of the QT interval"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["halofantrine"]], "start": [[107]], "entity_id": ["T5"], "Disorder": {"text": [["vivax malaria"]], "start": [[68]], "entity_id": ["T8"]}, "Drug": {"text": [["halofantrine"]], "start": [[107]], "entity_id": ["T9"]}}}]}]}
{"id": "7776854_3", "context": "We report three cases of severe hepatotoxicity related to benzarone, a benzofuran derivative.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[47]], "entity_id": ["T5"]}, "Subject": {"text": [["three cases"]], "start": [[10]], "entity_id": ["T3"], "Population": {"text": [["three"]], "start": [[10]], "entity_id": ["T7"]}}, "Effect": {"text": [["severe hepatotoxicity"]], "start": [[25]], "entity_id": ["T4"]}, "Treatment": {"text": [["benzarone"]], "start": [[58]], "entity_id": ["T6"], "Drug": {"text": [["benzarone"]], "start": [[58]], "entity_id": ["T8"]}}}]}]}
{"id": "8024670_1", "context": "Four patients who manifested symptoms of the antiepileptic drug (AED) hypersensitivity syndrome during therapy with carbamazepine are reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["symptoms of"]], "start": [[29]], "entity_id": ["T6"]}, "Subject": {"text": [["Four patients"]], "start": [[0]], "entity_id": ["T4"], "Population": {"text": [["Four"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["hypersensitivity syndrome"]], "start": [[70]], "entity_id": ["T3"]}, "Treatment": {"text": [["antiepileptic drug (AED)", "during therapy with carbamazepine"]], "start": [[45, 96]], "entity_id": ["T5"], "Drug": {"text": [["antiepileptic drug (AED)"], ["carbamazepine"]], "start": [[45], [116]], "entity_id": ["T8", "T9"]}}}]}]}
{"id": "11026106_1", "context": "Minocycline as a cause of drug-induced autoimmune hepatitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[31]], "entity_id": ["T5"]}, "Effect": {"text": [["autoimmune hepatitis"]], "start": [[39]], "entity_id": ["T3"]}, "Treatment": {"text": [["Minocycline"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Minocycline"]], "start": [[0]], "entity_id": ["T6"]}}}]}]}
{"id": "19434733_1", "context": "Secondary acute myeloid leukemia after etoposide therapy for haemophagocytic lymphohistiocytosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[33]], "entity_id": ["T4"]}, "Effect": {"text": [["Secondary acute myeloid leukemia"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["etoposide therapy"]], "start": [[39]], "entity_id": ["T5"], "Drug": {"text": [["etoposide"]], "start": [[39]], "entity_id": ["T7"]}, "Disorder": {"text": [["haemophagocytic lymphohistiocytosis"]], "start": [[61]], "entity_id": ["T8"]}}}]}]}
{"id": "16882109_1", "context": "Allergic contact angioedema to benzoyl peroxide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["to"]], "start": [[28]], "entity_id": ["T4"]}, "Effect": {"text": [["Allergic contact angioedema"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["benzoyl peroxide"]], "start": [[31]], "entity_id": ["T5"], "Drug": {"text": [["benzoyl peroxide"]], "start": [[31]], "entity_id": ["T6"]}}}]}]}
{"id": "1244265_1", "context": "A 60-year-old white man with chronic bronchitis was noted to develop acute respiratory failure and metabolic acidosis four days after being started on methazolamide (Neptazane) for an ophthalmologic problem.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["develop"]], "start": [[61]], "entity_id": ["T8"]}, "Subject": {"text": [["A 60-year-old white man with chronic bronchitis"]], "start": [[0]], "entity_id": ["T7"], "Age": {"text": [["60-year-old"]], "start": [[2]], "entity_id": ["T12"]}, "Race": {"text": [["white"]], "start": [[14]], "entity_id": ["T13"]}, "Gender": {"text": [["man"]], "start": [[20]], "entity_id": ["T14"]}, "Disorder": {"text": [["chronic bronchitis"]], "start": [[29]], "entity_id": ["T15"]}}, "Effect": {"text": [["acute respiratory failure and metabolic acidosis"]], "start": [[69]], "entity_id": ["T9"]}, "Treatment": {"text": [["methazolamide (Neptazane)"]], "start": [[151]], "entity_id": ["T10"], "Drug": {"text": [["methazolamide"]], "start": [[151]], "entity_id": ["T16"]}, "Disorder": {"text": [["ophthalmologic problem"]], "start": [[184]], "entity_id": ["T17"]}, "Time_elapsed": {"text": [["four days after"]], "start": [[118]], "entity_id": ["T18"]}}}]}]}
{"id": "14557583_2", "context": "L-DOPA-induced excessive daytime sleepiness in PD: a placebo-controlled case with MSLT assessment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[7]], "entity_id": ["T4"]}, "Treatment": {"text": [["L-DOPA"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["DOPA"]], "start": [[2]], "entity_id": ["T6"]}}, "Effect": {"text": [["daytime sleepiness"]], "start": [[25]], "entity_id": ["T5"]}}]}]}
{"id": "8384030_1", "context": "CONCLUSIONS: It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["contributed"]], "start": [[43]], "entity_id": ["T4"]}, "Treatment": {"text": [["foscarnet"]], "start": [[33]], "entity_id": ["T3"], "Drug": {"text": [["foscarnet"]], "start": [[33]], "entity_id": ["T7"]}}, "Effect": {"text": [["electrolyte disorders and symptomatology"]], "start": [[62]], "entity_id": ["T5"]}, "Subject": {"text": [["this patient"]], "start": [[106]], "entity_id": ["T6"]}, "Speculated": {"text": [["probable"]], "start": [[19]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "17228132_1", "context": "Acute drug induced hepatitis due to erlotinib.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[29]], "entity_id": ["T6"]}, "Effect": {"text": [["Acute drug induced hepatitis"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["erlotinib"]], "start": [[36]], "entity_id": ["T5"], "Drug": {"text": [["erlotinib"]], "start": [[36]], "entity_id": ["T7"]}}}]}]}
{"id": "9804082_2", "context": "We observed 3 diabetic patients with intolerable dizziness followed by nausea and vomiting immediately after an initial administration of the alpha-glucosidase inhibitor, voglibose.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[103]], "entity_id": ["T10"]}, "Subject": {"text": [["3 diabetic patients"]], "start": [[12]], "entity_id": ["T7"], "Population": {"text": [["3"]], "start": [[12]], "entity_id": ["T11"]}}, "Effect": {"text": [["intolerable dizziness followed by nausea and vomiting"]], "start": [[37]], "entity_id": ["T8"]}, "Treatment": {"text": [["an initial administration of the alpha-glucosidase inhibitor, voglibose"]], "start": [[109]], "entity_id": ["T9"], "Disorder": {"text": [["diabetic"]], "start": [[14]], "entity_id": ["T12"]}, "Drug": {"text": [["voglibose"]], "start": [[171]], "entity_id": ["T13"]}}}]}]}
{"id": "9184269_1", "context": "Although risk factors for MTX-induced pulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account for a predisposition to the development of MTX pneumonitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[30]], "entity_id": ["T6"]}, "Treatment": {"text": [["MTX"]], "start": [[26]], "entity_id": ["T5"], "Drug": {"text": [["MTX"]], "start": [[26]], "entity_id": ["T11"]}}, "Effect": {"text": [["pulmonary toxicity"]], "start": [[38]], "entity_id": ["T7"]}, "Subject": {"text": [["the presence in 3 out of 5 of our patients of pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA"]], "start": [[80]], "entity_id": ["T8"], "Population": {"text": [["3 out of 5"]], "start": [[96]], "entity_id": ["T9"]}, "Disorder": {"text": [["pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA"]], "start": [[126]], "entity_id": ["T10"]}}}]}]}
{"id": "8936932_1", "context": "Acute esmolol toxicity may be self-limiting because of its extremely short half-life.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["be"]], "start": [[27]], "entity_id": ["T5"]}, "Treatment": {"text": [["esmolol"]], "start": [[6]], "entity_id": ["T3"], "Drug": {"text": [["esmolol"]], "start": [[6]], "entity_id": ["T6"]}}, "Effect": {"text": [["toxicity"]], "start": [[14]], "entity_id": ["T4"]}, "Speculated": {"text": [["may"]], "start": [[23]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "7835785_2", "context": "The association with prolonged unopposed estrogen-like stimulation with tamoxifen as a possible factor in the development of ovarian endometrioid carcinoma is discussed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[16]], "entity_id": ["T3"]}, "Effect": {"text": [["development of ovarian endometrioid carcinoma"]], "start": [[110]], "entity_id": ["T4"]}, "Treatment": {"text": [["prolonged unopposed estrogen-like stimulation with tamoxifen"]], "start": [[21]], "entity_id": ["T5"], "Duration": {"text": [["prolonged"]], "start": [[21]], "entity_id": ["T7"]}, "Drug": {"text": [["tamoxifen"]], "start": [[72]], "entity_id": ["T8"]}}, "Speculated": {"text": [["possible factor"]], "start": [[87]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "7019786_2", "context": "The other woman had rheumatoid arthritis and developed acute tubular necrosis after treatment with gentamicin and cefoxitin.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[45]], "entity_id": ["T6"]}, "Effect": {"text": [["acute tubular necrosis"]], "start": [[55]], "entity_id": ["T5"]}, "Subject": {"text": [["The other woman had rheumatoid arthritis"]], "start": [[0]], "entity_id": ["T7"], "Gender": {"text": [["woman"]], "start": [[10]], "entity_id": ["T9"]}}, "Treatment": {"text": [["gentamicin and cefoxitin"]], "start": [[99]], "entity_id": ["T4"], "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[20]], "entity_id": ["T8"]}, "Drug": {"text": [["gentamicin"], ["cefoxitin"]], "start": [[99], [114]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[110]], "entity_id": ["T12"]}, "Drug": {"text": [["gentamicin"], ["cefoxitin"]], "start": [[99], [114]], "entity_id": ["T10", "T11"]}}]}}]}]}
{"id": "8053440_2", "context": "One patient who received clindamycin had liver biopsy findings of marked cholestasis, portal inflammation, bile duct injury and bile duct paucity (ductopenia).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["had"]], "start": [[37]], "entity_id": ["T14"]}, "Treatment": {"text": [["clindamycin"]], "start": [[25]], "entity_id": ["T11"], "Drug": {"text": [["clindamycin"]], "start": [[25]], "entity_id": ["T17"]}}, "Subject": {"text": [["One patient"]], "start": [[0]], "entity_id": ["T12"], "Population": {"text": [["One"]], "start": [[0]], "entity_id": ["T15"]}}, "Effect": {"text": [["marked cholestasis, portal inflammation, bile duct injury and bile duct paucity (ductopenia)"]], "start": [[66]], "entity_id": ["T13"]}, "Severity": {"text": [["marked"]], "start": [[66]], "entity_id": ["T16"], "value": "High"}}]}]}
{"id": "19531695_11", "context": "A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between flecainide, a CYP2D6 substrate, and paroxetine, a CYP2D6 inhibitor, as well as 3 case reports of flecainide-induced delirium.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[215]], "entity_id": ["T7"]}, "Treatment": {"text": [["flecainide"]], "start": [[204]], "entity_id": ["T8"], "Drug": {"text": [["flecainide"]], "start": [[204]], "entity_id": ["T12"]}}, "Effect": {"text": [["delirium"]], "start": [[223]], "entity_id": ["T9"]}, "Subject": {"text": [["3 case reports"]], "start": [[186]], "entity_id": ["T10"], "Population": {"text": [["3"]], "start": [[186]], "entity_id": ["T11"]}}}]}]}
{"id": "11250985_1", "context": "As these cases revealed, close monitoring of blood chemistry is mandatory after starting spironolactone, and patients should be advised to stop spironolactone immediately if diarrhoea develops.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["develops"]], "start": [[184]], "entity_id": ["T5"]}, "Treatment": {"text": [["spironolactone"]], "start": [[89]], "entity_id": ["T3"], "Drug": {"text": [["spironolactone"]], "start": [[89]], "entity_id": ["T7"]}}, "Effect": {"text": [["diarrhoea"]], "start": [[174]], "entity_id": ["T4"]}, "Subject": {"text": [["patients"]], "start": [[109]], "entity_id": ["T6"]}}]}]}
{"id": "21045170_9", "context": "When these cells are exposed to nicotinic acid, an exaggerated immune response is produced that may lead to pain, redness, and swelling at the injection site.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["produced"]], "start": [[82]], "entity_id": ["T9"]}, "Treatment": {"text": [["nicotinic acid"]], "start": [[32]], "entity_id": ["T7"], "Drug": {"text": [["nicotinic acid"]], "start": [[32]], "entity_id": ["T12"]}}, "Effect": {"text": [["exaggerated immune response"], ["pain, redness, and swelling at the injection sit"]], "start": [[51], [108]], "entity_id": ["T8", "T10"]}, "Speculated": {"text": [["may"]], "start": [[96]], "entity_id": ["T11"], "value": true}}]}]}
{"id": "15107195_1", "context": "A case of heatstroke is reported in a 32-year-old man diagnosed with schizophrenia and on clozapine monotherapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["reported"]], "start": [[24]], "entity_id": ["T11"]}, "Effect": {"text": [["heatstroke"]], "start": [[10]], "entity_id": ["T3"]}, "Treatment": {"text": [["clozapine monotherapy"]], "start": [[90]], "entity_id": ["T6"], "Drug": {"text": [["clozapine"]], "start": [[90]], "entity_id": ["T10"]}, "Disorder": {"text": [["schizophrenia"]], "start": [[69]], "entity_id": ["T5"]}}, "Subject": {"text": [["a 32-year-old man diagnosed with schizophrenia"]], "start": [[36]], "entity_id": ["T4"], "Age": {"text": [["32-year-old"]], "start": [[38]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[50]], "entity_id": ["T8"]}}}]}]}
{"id": "282937_2", "context": "Paraplegia following intrathecal cytosine arabinoside.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[11]], "entity_id": ["T4"]}, "Effect": {"text": [["Paraplegia"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["intrathecal cytosine arabinoside"]], "start": [[21]], "entity_id": ["T5"], "Route": {"text": [["intrathecal"]], "start": [[21]], "entity_id": ["T6"]}, "Drug": {"text": [["cytosine arabinoside"]], "start": [[33]], "entity_id": ["T7"]}}}]}]}
{"id": "6733633_1", "context": "Cimetidine-induced fever.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T4"]}, "Treatment": {"text": [["Cimetidine"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Cimetidine"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["fever"]], "start": [[19]], "entity_id": ["T5"]}}]}]}
{"id": "3470173_5", "context": "This case report illustrates the neurotoxicity unique to HDARAC.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["to"]], "start": [[54]], "entity_id": ["T6"]}, "Treatment": {"text": [["HDARAC"]], "start": [[57]], "entity_id": ["T3"], "Drug": {"text": [["HDARAC"]], "start": [[57]], "entity_id": ["T7"]}}, "Subject": {"text": [["This case"]], "start": [[0]], "entity_id": ["T4"]}, "Effect": {"text": [["neurotoxicity unique"]], "start": [[33]], "entity_id": ["T5"]}}]}]}
{"id": "9433539_2", "context": "Agranulocytosis associated with ticlopidine: a possible benefit with filgastim.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[16]], "entity_id": ["T3"]}, "Treatment": {"text": [["ticlopidine"]], "start": [[32]], "entity_id": ["T4"], "Drug": {"text": [["ticlopidine"]], "start": [[32]], "entity_id": ["T6"]}}, "Effect": {"text": [["Agranulocytosis"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "16005413_10", "context": "Since SS is a clinical diagnosis, heightened clinician awareness of the possibility of SS among patients receiving SSRI or mirtazapine in combination with opioids may lead to earlier detection and avoidance of potentially lethal consequences.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["lead to"]], "start": [[167]], "entity_id": ["T10"]}, "Effect": {"text": [["potentially lethal consequences"]], "start": [[210]], "entity_id": ["T9"]}, "Subject": {"text": [["patients"]], "start": [[96]], "entity_id": ["T11"]}, "Treatment": {"text": [["SSRI or mirtazapine in combination with opioids"]], "start": [[115]], "entity_id": ["T12"], "Drug": {"text": [["SSRI"], ["mirtazapine"], ["opioids"]], "start": [[115], [123], [155]], "entity_id": ["T14", "T15", "T16"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combination"]], "start": [[138]], "entity_id": ["T13"]}, "Drug": {"text": [["mirtazapine"], ["opioids"], ["SSRI"]], "start": [[123], [155], [115]], "entity_id": ["T15", "T16", "T14"]}}]}}]}]}
{"id": "19499966_4", "context": "The mechanism by which sunitinib induces gynaecomastia is thought to be associated with an unknown direct action on breast hormonal receptors.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induces"]], "start": [[33]], "entity_id": ["T4"]}, "Treatment": {"text": [["sunitinib"]], "start": [[23]], "entity_id": ["T3"], "Drug": {"text": [["sunitinib"]], "start": [[23]], "entity_id": ["T6"]}}, "Effect": {"text": [["gynaecomastia"]], "start": [[41]], "entity_id": ["T5"]}}]}]}
{"id": "16463436_1", "context": "Some patients develop hypersensitivity rash in response to HCQ.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["develop"]], "start": [[14]], "entity_id": ["T4"]}, "Subject": {"text": [["Some patients"]], "start": [[0]], "entity_id": ["T3"], "Population": {"text": [["Some"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["hypersensitivity rash"]], "start": [[22]], "entity_id": ["T5"]}, "Treatment": {"text": [["HCQ"]], "start": [[59]], "entity_id": ["T6"], "Drug": {"text": [["HCQ"]], "start": [[59]], "entity_id": ["T8"]}}}]}]}
{"id": "18676387_2", "context": "To report a case of serotonin toxicity, presenting in the postoperative period, caused by an interaction between paroxetine (a selective serotonin reuptake inhibitor, SSRI) and fentanyl (a phenylpiperidine opioid).", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[80]], "entity_id": ["T10"]}, "Effect": {"text": [["serotonin toxicity"]], "start": [[20]], "entity_id": ["T9"]}, "Treatment": {"text": [["paroxetine", "fentanyl"]], "start": [[113, 177]], "entity_id": ["T11"], "Drug": {"text": [["paroxetine"], ["fentanyl"]], "start": [[113], [177]], "entity_id": ["T12", "T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[93]], "entity_id": ["T14"]}, "Drug": {"text": [["paroxetine"], ["fentanyl"]], "start": [[113], [177]], "entity_id": ["T12", "T13"]}}]}}]}]}
{"id": "20367573_1", "context": "However, to our knowledge, in newborns there have been no reported cases to date of thrombocytosis induced by enoxaparin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[99]], "entity_id": ["T5"]}, "Subject": {"text": [["newborns"]], "start": [[30]], "entity_id": ["T3"], "Age": {"text": [["newborns"]], "start": [[30]], "entity_id": ["T7"]}}, "Effect": {"text": [["thrombocytosis"]], "start": [[84]], "entity_id": ["T4"]}, "Treatment": {"text": [["enoxaparin"]], "start": [[110]], "entity_id": ["T6"], "Drug": {"text": [["enoxaparin"]], "start": [[110]], "entity_id": ["T8"]}}, "Negated": {"text": [["no"]], "start": [[55]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "9846036_7", "context": "The case presented here documents adverse cardiac effects in a 28-year-old man who intentionally ingested 24 mg of risperidone--4 times the recommended dose.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["ingested"]], "start": [[97]], "entity_id": ["T8"]}, "Effect": {"text": [["adverse cardiac effects"]], "start": [[34]], "entity_id": ["T5"]}, "Subject": {"text": [["28-year-old man"]], "start": [[63]], "entity_id": ["T6"], "Age": {"text": [["28-year-old"]], "start": [[63]], "entity_id": ["T9"]}, "Gender": {"text": [["man"]], "start": [[75]], "entity_id": ["T10"]}}, "Treatment": {"text": [["24 mg of risperidone"]], "start": [[106]], "entity_id": ["T7"], "Dosage": {"text": [["24 mg"]], "start": [[106]], "entity_id": ["T11"]}, "Drug": {"text": [["risperidone"]], "start": [[115]], "entity_id": ["T12"]}}}]}]}
{"id": "12494253_2", "context": "Anaphylaxis to cisplatin following nine previous uncomplicated cycles.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["to"]], "start": [[12]], "entity_id": ["T3"]}, "Effect": {"text": [["Anaphylaxis"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["cisplatin following nine previous uncomplicated cycles"]], "start": [[15]], "entity_id": ["T5"], "Drug": {"text": [["cisplatin"]], "start": [[15]], "entity_id": ["T6"]}, "Duration": {"text": [["nine previous uncomplicated cycles"]], "start": [[35]], "entity_id": ["T7"]}}}]}]}
{"id": "14746605_3", "context": "To the best of the authors' knowledge, this is the first reported case of Propecia-associated cataract.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[83]], "entity_id": ["T4"]}, "Treatment": {"text": [["Propecia"]], "start": [[74]], "entity_id": ["T3"], "Drug": {"text": [["Propecia"]], "start": [[74]], "entity_id": ["T6"]}}, "Effect": {"text": [["cataract"]], "start": [[94]], "entity_id": ["T5"]}}]}]}
{"id": "17381671_1", "context": "Serotonin syndrome caused by interaction between citalopram and fentanyl.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[19]], "entity_id": ["T7"]}, "Effect": {"text": [["Serotonin syndrome"]], "start": [[0]], "entity_id": ["T6"]}, "Treatment": {"text": [["citalopram and fentanyl"]], "start": [[49]], "entity_id": ["T8"], "Drug": {"text": [["citalopram"], ["fentanyl"]], "start": [[49], [64]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[29]], "entity_id": ["T9"]}, "Drug": {"text": [["citalopram"], ["fentanyl"]], "start": [[49], [64]], "entity_id": ["T10", "T11"]}}]}}]}]}
{"id": "8149366_2", "context": "We report on three observations of parkinsonian patients with levo-dopa-induced diphasic dyskinesias, who received subcutaneous apomorphine to reduce the duration of abnormal movements.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[72]], "entity_id": ["T5"]}, "Treatment": {"text": [["levo-dopa"]], "start": [[62]], "entity_id": ["T4"], "Drug": {"text": [["levo-dopa"]], "start": [[62]], "entity_id": ["T8"]}}, "Effect": {"text": [["diphasic dyskinesias"]], "start": [[80]], "entity_id": ["T6"]}, "Subject": {"text": [["parkinsonian patients"]], "start": [[35]], "entity_id": ["T3"], "Disorder": {"text": [["parkinsonian"]], "start": [[35]], "entity_id": ["T7"]}}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["reduce"]], "start": [[143]], "entity_id": ["T13"]}, "Subject": {"text": [["parkinsonian patients"]], "start": [[35]], "entity_id": ["T3"], "Disorder": {"text": [["parkinsonian"]], "start": [[35]], "entity_id": ["T7"]}}, "Treatment": {"text": [["subcutaneous apomorphine"]], "start": [[115]], "entity_id": ["T10"], "Disorder": {"text": [["abnormal movements"]], "start": [[166]], "entity_id": ["T9"]}, "Route": {"text": [["subcutaneous"]], "start": [[115]], "entity_id": ["T11"]}, "Drug": {"text": [["apomorphine"]], "start": [[128]], "entity_id": ["T12"]}}}]}]}
{"id": "11757641_3", "context": "This report presents a case of acute lung injury developing within hours after administration of mefloquine for a low-level Plasmodium falciparum malaria, which was persistent despite halofantrine therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[73]], "entity_id": ["T4"]}, "Effect": {"text": [["acute lung injury", "persistent despite halofantrine therapy"]], "start": [[31, 165]], "entity_id": ["T3"]}, "Treatment": {"text": [["administration of mefloquine for a low-level Plasmodium falciparum malaria", "halofantrine therapy"]], "start": [[79, 184]], "entity_id": ["T5"], "Time_elapsed": {"text": [["within hours"]], "start": [[60]], "entity_id": ["T6"]}, "Drug": {"text": [["mefloquine"], ["halofantrine"]], "start": [[97], [184]], "entity_id": ["T7", "T9"]}, "Disorder": {"text": [["low-level Plasmodium falciparum malaria"]], "start": [[114]], "entity_id": ["T8"]}}}]}]}
{"id": "11837564_3", "context": "Warfarin-associated bleeding generally is considered deleterious; however, in our patient it unmasked an early stage of colon cancer and thus may have saved the patient's life.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[9]], "entity_id": ["T4"]}, "Treatment": {"text": [["Warfarin"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Warfarin"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["bleeding"]], "start": [[20]], "entity_id": ["T5"]}, "Speculated": {"text": [["generally"], ["associated"]], "start": [[29], [9]], "entity_id": ["T7", "T8"], "value": true}}]}]}
{"id": "20076952_11", "context": "The clinical use of itraconazole in patients receiving multiple doses of oxycodone for pain relief may increase the risk of opioid-associated adverse effects.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["increase"]], "start": [[103]], "entity_id": ["T10"]}, "Treatment": {"text": [["itraconazole", "receiving multiple doses of oxycodone"]], "start": [[20, 45]], "entity_id": ["T11"], "Disorder": {"text": [["pain relief"]], "start": [[87]], "entity_id": ["T13"]}, "Drug": {"text": [["oxycodone"], ["itraconazole"]], "start": [[73], [20]], "entity_id": ["T16", "T18"]}, "Dosage": {"text": [["multiple doses"]], "start": [[55]], "entity_id": ["T17"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["receiving"]], "start": [[45]], "entity_id": ["T19"]}, "Drug": {"text": [["itraconazole"], ["oxycodone"]], "start": [[20], [73]], "entity_id": ["T18", "T16"]}}]}, "Effect": {"text": [["opioid-associated adverse effects"]], "start": [[124]], "entity_id": ["T14"]}, "Subject": {"text": [["patients"]], "start": [[36]], "entity_id": ["T12"]}, "Speculated": {"text": [["may"]], "start": [[99]], "entity_id": ["T15"], "value": true}}]}]}
{"id": "6251941_2", "context": "Three cases of gold-related neuropathy are reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[20]], "entity_id": ["T3"]}, "Treatment": {"text": [["gold"]], "start": [[15]], "entity_id": ["T4"], "Drug": {"text": [["gold"]], "start": [[15]], "entity_id": ["T8"]}}, "Effect": {"text": [["neuropathy"]], "start": [[28]], "entity_id": ["T5"]}, "Subject": {"text": [["Three cases"]], "start": [[0]], "entity_id": ["T6"], "Population": {"text": [["Three"]], "start": [[0]], "entity_id": ["T7"]}}}]}]}
{"id": "17224428_2", "context": "We report the case of a man, treated with mesalazine for Crohn's disease who developed drug-induced pericarditis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[77]], "entity_id": ["T3"]}, "Effect": {"text": [["drug-induced pericarditis"]], "start": [[87]], "entity_id": ["T4"]}, "Subject": {"text": [["a man"]], "start": [[22]], "entity_id": ["T6"], "Gender": {"text": [["man"]], "start": [[24]], "entity_id": ["T8"]}}, "Treatment": {"text": [["mesalazine"]], "start": [[42]], "entity_id": ["T7"], "Disorder": {"text": [["Crohn's disease"]], "start": [[57]], "entity_id": ["T5"]}, "Drug": {"text": [["mesalazine"]], "start": [[42]], "entity_id": ["T9"]}}}]}]}
{"id": "11483161_3", "context": "We report the occurrence of spontaneous intracranial bleeding in an human immunodeficiency virus (HIV)-infected adolescent with hemophilia A who was receiving amprenavir (APV).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurrence"]], "start": [[14]], "entity_id": ["T5"]}, "Effect": {"text": [["spontaneous intracranial bleeding"]], "start": [[28]], "entity_id": ["T3"]}, "Subject": {"text": [["an human immunodeficiency virus (HIV)-infected adolescent with hemophilia A"]], "start": [[65]], "entity_id": ["T4"]}, "Treatment": {"text": [["amprenavir (APV)"]], "start": [[159]], "entity_id": ["T6"], "Disorder": {"text": [["immunodeficiency virus (HIV)-infected adolescent with hemophilia A"]], "start": [[74]], "entity_id": ["T8"]}, "Drug": {"text": [["amprenavir (APV)"]], "start": [[159]], "entity_id": ["T9"]}}}]}]}
{"id": "17352036_3", "context": "Under the suspicion of amiodarone-induced acute pancreatitis, amiodarone was substituted by propafenone.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[34]], "entity_id": ["T6"]}, "Treatment": {"text": [["amiodarone"]], "start": [[23]], "entity_id": ["T4"], "Drug": {"text": [["amiodarone"]], "start": [[23]], "entity_id": ["T5"]}}, "Effect": {"text": [["acute pancreatitis"]], "start": [[42]], "entity_id": ["T7"]}}]}]}
{"id": "7661076_1", "context": "Evidence is shown in this report that adenosine was associated with dangerous worsening of arrhythmia in patients with atrial flutter.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[52]], "entity_id": ["T6"]}, "Effect": {"text": [["dangerous worsening of arrhythmia"]], "start": [[68]], "entity_id": ["T3"]}, "Subject": {"text": [["patients with atrial flutter"]], "start": [[105]], "entity_id": ["T4"]}, "Treatment": {"text": [["adenosine"]], "start": [[38]], "entity_id": ["T5"], "Disorder": {"text": [["atrial flutter."]], "start": [[119]], "entity_id": ["T7"]}, "Drug": {"text": [["adenosine"]], "start": [[38]], "entity_id": ["T8"]}}}]}]}
{"id": "6197014_1", "context": "Salicylate hepato toxicity in rheumatic fever.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["toxicity"]], "start": [[18]], "entity_id": ["T6"]}, "Treatment": {"text": [["Salicylate"]], "start": [[0]], "entity_id": ["T3"], "Disorder": {"text": [["rheumatic fever"]], "start": [[30]], "entity_id": ["T5"]}, "Drug": {"text": [["Salicylate"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["hepato toxicity"]], "start": [[11]], "entity_id": ["T4"]}}]}]}
{"id": "17189581_2", "context": "A case of serotonin syndrome that developed during concurrent linezolid and fluoxetine is presented.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[34]], "entity_id": ["T7"]}, "Treatment": {"text": [["concurrent linezolid and fluoxetine"]], "start": [[51]], "entity_id": ["T8"], "Drug": {"text": [["linezolid"], ["fluoxetine"]], "start": [[62], [76]], "entity_id": ["T11", "T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["concurrent"]], "start": [[51]], "entity_id": ["T10"]}, "Drug": {"text": [["linezolid"], ["fluoxetine"]], "start": [[62], [76]], "entity_id": ["T11", "T12"]}}]}, "Effect": {"text": [["serotonin syndrome"]], "start": [[10]], "entity_id": ["T9"]}}]}]}
{"id": "15866658_1", "context": "Herein we report four patients who underwent liver transplantation and developed neutropenia while receiving MMF.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[71]], "entity_id": ["T4"]}, "Treatment": {"text": [["MMF"]], "start": [[109]], "entity_id": ["T3"], "Drug": {"text": [["MMF"]], "start": [[109]], "entity_id": ["T9"]}}, "Effect": {"text": [["neutropenia"]], "start": [[81]], "entity_id": ["T5"]}, "Subject": {"text": [["four patients who underwent liver transplantation"]], "start": [[17]], "entity_id": ["T6"], "Population": {"text": [["four"]], "start": [[17]], "entity_id": ["T7"]}, "Disorder": {"text": [["liver transplantation"]], "start": [[45]], "entity_id": ["T8"]}}}]}]}
{"id": "2931445_2", "context": "A study of in vitro reactivity to L-T4, as assessed by peripheral blood lymphocyte transformation, was carried out in a patient with Hashimoto's disease who developed leukopenia during treatment with L-T4.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[157]], "entity_id": ["T8"]}, "Effect": {"text": [["leukopenia"]], "start": [[167]], "entity_id": ["T9"]}, "Subject": {"text": [["a patient with Hashimoto's disease"]], "start": [[118]], "entity_id": ["T10"]}, "Treatment": {"text": [["L-T4"]], "start": [[200]], "entity_id": ["T11"], "Disorder": {"text": [["Hashimoto's disease"]], "start": [[133]], "entity_id": ["T12"]}, "Drug": {"text": [["L-T4"]], "start": [[200]], "entity_id": ["T13"]}}}]}]}
{"id": "8792511_2", "context": "Methemoglobinemia is another common finding among patients receiving dapsone therapy, but rarely does it result in prominent symptoms other than transient pallor.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["receiving"]], "start": [[59]], "entity_id": ["T6"]}, "Treatment": {"text": [["dapsone therapy"]], "start": [[69]], "entity_id": ["T4"], "Drug": {"text": [["dapsone"]], "start": [[69]], "entity_id": ["T7"]}}, "Subject": {"text": [["patients"]], "start": [[50]], "entity_id": ["T5"]}, "Effect": {"text": [["Methemoglobinemia", "transient pallor"]], "start": [[0, 145]], "entity_id": ["T3"]}}]}]}
{"id": "3470173_3", "context": "During the first treatment, dysarthria and ataxia were seen after completion of the patient's eighth and final dose of HDARAC.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["seen"]], "start": [[55]], "entity_id": ["T6"]}, "Effect": {"text": [["dysarthria and ataxia"]], "start": [[28]], "entity_id": ["T5"]}, "Treatment": {"text": [["HDARAC"]], "start": [[119]], "entity_id": ["T7"], "Drug": {"text": [["HDARAC"]], "start": [[119]], "entity_id": ["T9"]}}, "Subject": {"text": [["the patient's"]], "start": [[80]], "entity_id": ["T8"]}}]}]}
{"id": "3143551_4", "context": "Four weeks earlier she had developed hepatopathy during a regimen of carbamazepine, lynestrenol and sodium valproate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[27]], "entity_id": ["T6"]}, "Subject": {"text": [["she"]], "start": [[19]], "entity_id": ["T5"], "Gender": {"text": [["she"]], "start": [[19]], "entity_id": ["T9"]}}, "Effect": {"text": [["hepatopathy"]], "start": [[37]], "entity_id": ["T7"]}, "Treatment": {"text": [["carbamazepine, lynestrenol and sodium valproate"]], "start": [[69]], "entity_id": ["T8"], "Drug": {"text": [["carbamazepine"], ["lynestrenol"], ["sodium valproate"]], "start": [[69], [84], [100]], "entity_id": ["T10", "T11", "T12"]}}}]}]}
{"id": "1420650_3", "context": "We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with CBZ.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occur"]], "start": [[82]], "entity_id": ["T12"]}, "Treatment": {"text": [["even at low or moderate dosage levels", "certain drugs as lithium or clozapine are used in combination with CBZ"]], "start": [[88, 130]], "entity_id": ["T9"], "Drug": {"text": [["CBZ"], ["lithium"], ["clozapine"]], "start": [[197], [147], [158]], "entity_id": ["T15", "T16", "T17"]}, "Dosage": {"text": [["low or moderate dosage"]], "start": [[96]], "entity_id": ["T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combination"]], "start": [[180]], "entity_id": ["T14"]}, "Drug": {"text": [["CBZ"], ["lithium"]], "start": [[197], [147]], "entity_id": ["T15", "T16"]}}, {"event_id": "E3", "event_type": "Combination", "Trigger": {"text": [["combination"]], "start": [[180]], "entity_id": ["T14"]}, "Drug": {"text": [["CBZ"], ["clozapine"]], "start": [[197], [158]], "entity_id": ["T15", "T17"]}}]}, "Effect": {"text": [["asterixis"]], "start": [[12]], "entity_id": ["T10"]}, "Speculated": {"text": [["may"]], "start": [[78]], "entity_id": ["T13"], "value": true}}]}]}
{"id": "20178709_3", "context": "We report here a rare case of pleuropericarditis due to methotrexate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[49]], "entity_id": ["T3"]}, "Effect": {"text": [["pleuropericarditis"]], "start": [[30]], "entity_id": ["T4"]}, "Treatment": {"text": [["methotrexate"]], "start": [[56]], "entity_id": ["T5"], "Drug": {"text": [["methotrexate"]], "start": [[56]], "entity_id": ["T7"]}}, "Subject": {"text": [["a rare case"]], "start": [[15]], "entity_id": ["T6"]}}]}]}
{"id": "3677571_2", "context": "A case of phenytoin-induced hepatitis with mononucleosis is reported, and syndromes associated with phenytoin hypersensitivity reactions are discussed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[20]], "entity_id": ["T9"]}, "Treatment": {"text": [["phenytoin"]], "start": [[10]], "entity_id": ["T8"], "Drug": {"text": [["phenytoin"]], "start": [[10]], "entity_id": ["T11"]}}, "Effect": {"text": [["hepatitis with mononucleosis"]], "start": [[28]], "entity_id": ["T10"]}}]}]}
{"id": "10099659_14", "context": "We also discuss whether screening for DPD deficiency is warranted to identify patients at risk for severe toxicities from 5-FU treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["risk"]], "start": [[90]], "entity_id": ["T8"]}, "Treatment": {"text": [["5-FU treatment"]], "start": [[122]], "entity_id": ["T10"], "Drug": {"text": [["5-FU"]], "start": [[122]], "entity_id": ["T12"]}}, "Effect": {"text": [["severe toxicities"]], "start": [[99]], "entity_id": ["T9"]}, "Subject": {"text": [["patients"]], "start": [[78]], "entity_id": ["T11"]}, "Severity": {"text": [["severe"]], "start": [[99]], "entity_id": ["T13"], "value": "High"}}]}]}
{"id": "10102531_2", "context": "We report a case of reversible encephalopathy syndrome in a 16-year-old girl with acute myelogenous leukemia (AML), who is undergoing during consolidation chemotherapy composed of BH-AC (N4-behenoyl-1-beta-D-arabinofuranosyl cytosine) and idarubicin.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["undergoing"]], "start": [[123]], "entity_id": ["T8"]}, "Effect": {"text": [["reversible encephalopathy syndrome"]], "start": [[20]], "entity_id": ["T7"]}, "Subject": {"text": [["a 16-year-old girl with acute myelogenous leukemia (AML)"]], "start": [[58]], "entity_id": ["T5"], "Age": {"text": [["16-year-old"]], "start": [[60]], "entity_id": ["T9"]}, "Gender": {"text": [["girl"]], "start": [[72]], "entity_id": ["T10"]}}, "Treatment": {"text": [["consolidation chemotherapy composed of BH-AC (N4-behenoyl-1-beta-D-arabinofuranosyl cytosine) and idarubicin"]], "start": [[141]], "entity_id": ["T15"], "Disorder": {"text": [["acute myelogenous leukemia"]], "start": [[82]], "entity_id": ["T11"]}, "Drug": {"text": [["idarubicin"], ["BH-AC"]], "start": [[239], [180]], "entity_id": ["T13", "T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[235]], "entity_id": ["T12"]}, "Drug": {"text": [["idarubicin"], ["BH-AC"]], "start": [[239], [180]], "entity_id": ["T13", "T14"]}}]}}]}]}
{"id": "24429012_10", "context": "Concurrent use of vismodegib and warfarin was deemed the probable cause of acute INR elevation in this case, suggesting the need for close monitoring of INR values in patients receiving this combination of drugs.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[66]], "entity_id": ["T9"]}, "Treatment": {"text": [["vismodegib and warfarin"]], "start": [[18]], "entity_id": ["T8"], "Drug": {"text": [["vismodegib"], ["warfarin"]], "start": [[18], [33]], "entity_id": ["T11", "T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[29]], "entity_id": ["T13"]}, "Drug": {"text": [["vismodegib"], ["warfarin"]], "start": [[18], [33]], "entity_id": ["T11", "T12"]}}]}, "Effect": {"text": [["acute INR elevation"]], "start": [[75]], "entity_id": ["T10"]}, "Speculated": {"text": [["probable"]], "start": [[57]], "entity_id": ["T14"], "value": true}}]}]}
{"id": "11834188_2", "context": "Captopril is an angiotensin-converting enzyme (ACE) inhibitor and their cutaneous side-effects are documented, but little has been published concerning the usefulness of patch test when they occur.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["documented"]], "start": [[99]], "entity_id": ["T5"]}, "Effect": {"text": [["cutaneous side-effects"]], "start": [[72]], "entity_id": ["T3"]}, "Treatment": {"text": [["Captopril"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Captopril"]], "start": [[0]], "entity_id": ["T6"]}}}]}]}
{"id": "18784429_3", "context": "High-dose methylprednisolone in a pregnant woman with Crohn's disease and adrenal suppression in her newborn.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[94]], "entity_id": ["T6"]}, "Subject": {"text": [["a pregnant woman with Crohn's disease"]], "start": [[32]], "entity_id": ["T3"], "Age": {"text": [["pregnant"]], "start": [[34]], "entity_id": ["T7"]}, "Gender": {"text": [["woman"]], "start": [[43]], "entity_id": ["T8"]}}, "Treatment": {"text": [["High-dose methylprednisolone"]], "start": [[0]], "entity_id": ["T4"], "Disorder": {"text": [["Crohn's disease"]], "start": [[54]], "entity_id": ["T9"]}, "Drug": {"text": [["High-dose"], ["methylprednisolone"]], "start": [[0], [10]], "entity_id": ["T11", "T12"]}}, "Effect": {"text": [["adrenal suppression in her newborn"]], "start": [[74]], "entity_id": ["T5"]}}]}]}
{"id": "17224428_1", "context": "Cardiac hypersensitivity and myopericarditis have been reported during long-term treatment with mesalazine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reported"]], "start": [[55]], "entity_id": ["T6"]}, "Effect": {"text": [["Cardiac hypersensitivity and myopericarditis"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["long-term treatment with mesalazine"]], "start": [[71]], "entity_id": ["T7"], "Duration": {"text": [["long-term"]], "start": [[71]], "entity_id": ["T8"]}, "Drug": {"text": [["mesalazine"]], "start": [[96]], "entity_id": ["T9"]}}}]}]}
{"id": "6311654_6", "context": "It is concluded that 'cerebral atrophy' on CT scans may represent an accumulative effect of ACTH and that ACTH should be given with the utmost discretion, and in as low a dose as possible.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["represent"]], "start": [[56]], "entity_id": ["T8"]}, "Effect": {"text": [["cerebral atrophy"]], "start": [[22]], "entity_id": ["T6"]}, "Treatment": {"text": [["ACTH"]], "start": [[92]], "entity_id": ["T7"], "Drug": {"text": [["ACTH"], ["ACTH"]], "start": [[92], [106]], "entity_id": ["T10", "T11"]}}, "Speculated": {"text": [["may"]], "start": [[52]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "12135176_1", "context": "Two cases of polymorphic ventricular tachycardia induced by the administration of verapamil against paroxysmal supraventricular tachycardia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[49]], "entity_id": ["T4"]}, "Effect": {"text": [["polymorphic ventricular tachycardia"]], "start": [[13]], "entity_id": ["T3"]}, "Treatment": {"text": [["verapamil"]], "start": [[82]], "entity_id": ["T6"], "Disorder": {"text": [["paroxysmal supraventricular tachycardia"]], "start": [[100]], "entity_id": ["T5"]}, "Drug": {"text": [["verapamil"]], "start": [[82]], "entity_id": ["T7"]}}}]}]}
{"id": "15162903_3", "context": "Fatal acute encephalomyelitis after a single dose of intrathecal methotrexate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[30]], "entity_id": ["T5"]}, "Effect": {"text": [["Fatal acute encephalomyelitis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["single dose of intrathecal methotrexate"]], "start": [[38]], "entity_id": ["T4"], "Dosage": {"text": [["single dose"]], "start": [[38]], "entity_id": ["T7"]}, "Route": {"text": [["intrathecal"]], "start": [[53]], "entity_id": ["T8"]}, "Drug": {"text": [["methotrexate"]], "start": [[65]], "entity_id": ["T9"]}}, "Severity": {"text": [["Fatal"]], "start": [[0]], "entity_id": ["T6"], "value": "High"}}]}]}
{"id": "18465737_2", "context": "The authors report one case of incomplete posterior hyaloid detachment (PHD) following intravitreal pegaptanib to treat DME.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[77]], "entity_id": ["T4"]}, "Effect": {"text": [["incomplete posterior hyaloid detachment (PHD)"]], "start": [[31]], "entity_id": ["T5"]}, "Treatment": {"text": [["intravitreal pegaptanib"]], "start": [[87]], "entity_id": ["T6"], "Route": {"text": [["intravitreal"]], "start": [[87]], "entity_id": ["T7"]}, "Drug": {"text": [["pegaptanib"]], "start": [[100]], "entity_id": ["T8"]}, "Disorder": {"text": [["DME"]], "start": [[120]], "entity_id": ["T9"]}}, "Subject": {"text": [["one case"]], "start": [[19]], "entity_id": ["T10"]}}]}]}
{"id": "3612639_1", "context": "Pulmonary edema as a delayed complication of ritodrine therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[29]], "entity_id": ["T3"]}, "Effect": {"text": [["Pulmonary edema"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["ritodrine"]], "start": [[45]], "entity_id": ["T5"], "Drug": {"text": [["ritodrine"]], "start": [[45]], "entity_id": ["T6"]}}}]}]}
{"id": "15685264_1", "context": "Carbamazepine toxicity following Oxybutynin and Dantrolene administration: a case report.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[23]], "entity_id": ["T9"]}, "Treatment": {"text": [["Oxybutynin and Dantrolene"]], "start": [[33]], "entity_id": ["T7"], "Drug": {"text": [["Oxybutynin"], ["Dantrolene"]], "start": [[33], [48]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[44]], "entity_id": ["T12"]}, "Drug": {"text": [["Dantrolene"], ["Oxybutynin"]], "start": [[48], [33]], "entity_id": ["T11", "T10"]}}]}, "Effect": {"text": [["Carbamazepine toxicity"]], "start": [[0]], "entity_id": ["T8"]}}]}]}
{"id": "18633310_1", "context": "Multiple seizures after bupropion overdose in a small child.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[18]], "entity_id": ["T6"]}, "Effect": {"text": [["Multiple seizures"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["bupropion overdose"]], "start": [[24]], "entity_id": ["T4"], "Drug": {"text": [["bupropion"]], "start": [[24]], "entity_id": ["T8"]}, "Dosage": {"text": [["overdose"]], "start": [[34]], "entity_id": ["T9"]}}, "Subject": {"text": [["a small child"]], "start": [[46]], "entity_id": ["T5"], "Age": {"text": [["small child"]], "start": [[48]], "entity_id": ["T7"]}}}]}]}
{"id": "19537383_2", "context": "Sorafenib, a multitargeted kinase inhibitor used for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinomas, received FDA approval in 2005.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatment"]], "start": [[57]], "entity_id": ["T7"]}, "Treatment": {"text": [["Sorafenib", "a multitargeted kinase inhibitor"]], "start": [[0, 11]], "entity_id": ["T6"], "Drug": {"text": [["Sorafenib"]], "start": [[0]], "entity_id": ["T9"]}, "Disorder": {"text": [["unresectable hepatocellular carcinoma"], ["advanced renal cell carcinomas"]], "start": [[70], [112]], "entity_id": ["T10", "T11"]}}}]}]}
{"id": "1174301_2", "context": "Triiodothyronine-induced thyrotoxicosis in ophthalmic Graves disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[17]], "entity_id": ["T5"]}, "Treatment": {"text": [["Triiodothyronine"]], "start": [[0]], "entity_id": ["T3"], "Disorder": {"text": [["ophthalmic Graves"]], "start": [[43]], "entity_id": ["T6"]}, "Drug": {"text": [["Triiodothyronine"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["thyrotoxicosis"]], "start": [[25]], "entity_id": ["T4"]}}]}]}
{"id": "17526968_1", "context": "Bleomycin induced hyperpigmentation with yolk sac tumor.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[10]], "entity_id": ["T6"]}, "Treatment": {"text": [["Bleomycin"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Bleomycin"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["hyperpigmentation with yolk sac tumor"]], "start": [[18]], "entity_id": ["T7"]}}]}]}
{"id": "19034138_5", "context": "PURPOSE: To describe bilateral corneal endothelial dysfunction in a patient with Parkinson disease who was treated with long-term amantadine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[63]], "entity_id": ["T6"]}, "Effect": {"text": [["bilateral corneal endothelial dysfunction"]], "start": [[21]], "entity_id": ["T3"]}, "Subject": {"text": [["a patient with Parkinson disease"]], "start": [[66]], "entity_id": ["T4"]}, "Treatment": {"text": [["long-term amantadine"]], "start": [[120]], "entity_id": ["T5"], "Disorder": {"text": [["Parkinson disease"]], "start": [[81]], "entity_id": ["T8"]}, "Drug": {"text": [["amantadine"]], "start": [[130]], "entity_id": ["T9"]}, "Duration": {"text": [["ong-term"]], "start": [[121]], "entity_id": ["T10"]}}}]}]}
{"id": "2140997_1", "context": "A case of severe acute hepatitis caused by cyproterone acetate in a 71 year old man with prostatic carcinoma is reported with a review of the literature on hepatic reactions to this drug.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[33]], "entity_id": ["T4"]}, "Effect": {"text": [["acute hepatitis"]], "start": [[17]], "entity_id": ["T3"]}, "Treatment": {"text": [["cyproterone acetate"]], "start": [[43]], "entity_id": ["T5"], "Drug": {"text": [["cyproterone acetate"]], "start": [[43]], "entity_id": ["T10"]}, "Disorder": {"text": [["prostatic carcinoma"]], "start": [[89]], "entity_id": ["T11"]}}, "Subject": {"text": [["a 71 year old man with prostatic carcinoma"]], "start": [[66]], "entity_id": ["T6"], "Age": {"text": [["71 year old"]], "start": [[68]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[80]], "entity_id": ["T8"]}}, "Severity": {"text": [["severe"]], "start": [[10]], "entity_id": ["T12"], "value": "High"}}]}]}
{"id": "2309833_2", "context": "Insulin-dependent diabetes mellitus associated with danazol.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[36]], "entity_id": ["T3"]}, "Treatment": {"text": [["danazol"]], "start": [[52]], "entity_id": ["T4"], "Drug": {"text": [["danazol"]], "start": [[52]], "entity_id": ["T6"]}}, "Effect": {"text": [["Insulin-dependent diabetes mellitus"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "10458196_4", "context": "CONCLUSIONS: Topical brimonidine may be associated with central nervous system depression in infants.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[40]], "entity_id": ["T4"]}, "Treatment": {"text": [["Topical brimonidine"]], "start": [[13]], "entity_id": ["T3"], "Drug": {"text": [["brimonidine"]], "start": [[21]], "entity_id": ["T8"]}, "Route": {"text": [["Topical"]], "start": [[13]], "entity_id": ["T9"]}}, "Effect": {"text": [["central nervous system depression"]], "start": [[56]], "entity_id": ["T5"]}, "Subject": {"text": [["infants"]], "start": [[93]], "entity_id": ["T6"], "Age": {"text": [["infants"]], "start": [[93]], "entity_id": ["T7"]}}, "Speculated": {"text": [["may"]], "start": [[33]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "10707759_1", "context": "Flecainide-associated pneumonitis with acute respiratory failure in a patient with the LEOPARD syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[11]], "entity_id": ["T7"]}, "Subject": {"text": [["a patient with the LEOPARD syndrome"]], "start": [[68]], "entity_id": ["T5"]}, "Treatment": {"text": [["Flecainide"]], "start": [[0]], "entity_id": ["T6"], "Drug": {"text": [["Flecainide"]], "start": [[0]], "entity_id": ["T10"]}, "Disorder": {"text": [["LEOPARD syndrome."]], "start": [[87]], "entity_id": ["T11"]}}, "Effect": {"text": [["pneumonitis with acute respiratory failure"]], "start": [[22]], "entity_id": ["T8"]}}]}]}
{"id": "1433432_1", "context": "Seizure with hyponatremia in a child prescribed desmopressin for nocturnal enuresis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[26]], "entity_id": ["T2"]}, "Treatment": {"text": [["desmopressin"]], "start": [[48]], "entity_id": ["T9"], "Drug": {"text": [["desmopressin"]], "start": [[48]], "entity_id": ["T14"]}, "Disorder": {"text": [["nocturnal enuresis"]], "start": [[65]], "entity_id": ["T15"]}}, "Effect": {"text": [["Seizure with hyponatremia"]], "start": [[0]], "entity_id": ["T13"]}, "Subject": {"text": [["a child"]], "start": [[29]], "entity_id": ["T1"], "Age": {"text": [["child"]], "start": [[31]], "entity_id": ["T12"]}}}]}]}
{"id": "23624139_10", "context": "Risks and benefits of co-treatment should be carefully considered and therapeutic alternatives to NSAIDs should be recommended to patients with central DI in order to improve DDAVP safety.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["recommended"]], "start": [[115]], "entity_id": ["T10"]}, "Treatment": {"text": [["therapeutic alternatives to NSAIDs"]], "start": [[70]], "entity_id": ["T9"], "Disorder": {"text": [["central DI"]], "start": [[144]], "entity_id": ["T12"]}, "Drug": {"text": [["NSAIDs"]], "start": [[98]], "entity_id": ["T13"]}}, "Subject": {"text": [["patients with central DI"]], "start": [[130]], "entity_id": ["T11"]}, "Effect": {"text": [["in order to improve DDAVP safety"]], "start": [[155]], "entity_id": ["T1"]}}]}]}
{"id": "15685264_6", "context": "She had been treated by Carbamazepine 1000 mg/day for neuropathic pain for 2 years without clinical or laboratory signs of toxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[13]], "entity_id": ["T8"]}, "Treatment": {"text": [["Carbamazepine 1000 mg/day"]], "start": [[24]], "entity_id": ["T6"], "Disorder": {"text": [["neuropathic pain"]], "start": [[54]], "entity_id": ["T7"]}, "Drug": {"text": [["Carbamazepine"]], "start": [[24]], "entity_id": ["T10"]}, "Dosage": {"text": [["1000 mg/day"]], "start": [[38]], "entity_id": ["T11"]}, "Time_elapsed": {"text": [["2 years"]], "start": [[75]], "entity_id": ["T13"]}}, "Subject": {"text": [["She"]], "start": [[0]], "entity_id": ["T9"]}}]}]}
{"id": "9509511_1", "context": "The chemotherapeutics, including vincristine, actinomycin D, and epirubicin in case 1 and vincristine and actinomycin D in case 2, were given before the hepatotoxicity developed.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["given"]], "start": [[136]], "entity_id": ["T9"]}, "Treatment": {"text": [["vincristine and actinomycin D"]], "start": [[90]], "entity_id": ["T18"], "Drug": {"text": [["vincristine"], ["actinomycin D"]], "start": [[90], [106]], "entity_id": ["T14", "T15"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[102]], "entity_id": ["T16"]}, "Drug": {"text": [["vincristine"], ["actinomycin D"]], "start": [[90], [106]], "entity_id": ["T14", "T15"]}}]}, "Effect": {"text": [["hepatotoxicity developed"]], "start": [[153]], "entity_id": ["T8"]}}, {"event_id": "E4", "event_type": "Adverse_event", "Trigger": {"text": [["given"]], "start": [[136]], "entity_id": ["T9"]}, "Effect": {"text": [["hepatotoxicity developed"]], "start": [[153]], "entity_id": ["T8"]}, "Treatment": {"text": [["chemotherapeutics, including vincristine, actinomycin D, and epirubicin"]], "start": [[4]], "entity_id": ["T7"], "Drug": {"text": [["vincristine"], ["actinomycin D"], ["epirubicin"]], "start": [[33], [46], [65]], "entity_id": ["T10", "T11", "T12"]}, "Combination": [{"event_id": "E3", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[61]], "entity_id": ["T17"]}, "Drug": {"text": [["epirubicin"], ["actinomycin D"], ["vincristine"]], "start": [[65], [46], [33]], "entity_id": ["T12", "T11", "T10"]}}]}}]}]}
{"id": "11816261_1", "context": "After a second dose of metoclopramide, these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, tachypnea, tachycardia, and hypertension.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[72]], "entity_id": ["T16"]}, "Treatment": {"text": [["second dose of metoclopramide"]], "start": [[8]], "entity_id": ["T15"], "Drug": {"text": [["metoclopramide"]], "start": [[23]], "entity_id": ["T19"]}}, "Effect": {"text": [["confusion, agitation, fever, diaphoresis, tachypnea, tachycardia, and hypertension"]], "start": [[88]], "entity_id": ["T17"]}}]}]}
{"id": "17364199_4", "context": "We report the first case of tuberculous uveitis due to etanercept.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due to"]], "start": [[48]], "entity_id": ["T5"]}, "Effect": {"text": [["tuberculous uveitis"]], "start": [[28]], "entity_id": ["T4"]}, "Treatment": {"text": [["etanercept"]], "start": [[55]], "entity_id": ["T6"], "Drug": {"text": [["etanercept"]], "start": [[55]], "entity_id": ["T7"]}}}]}]}
{"id": "10516999_1", "context": "Acute hyperphosphatemia caused by sodium phosphate enema in a patient with liver dysfunction and chronic renal failure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[24]], "entity_id": ["T4"]}, "Effect": {"text": [["Acute hyperphosphatemia"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["sodium phosphate enema"]], "start": [[34]], "entity_id": ["T5"], "Drug": {"text": [["sodium phosphate"]], "start": [[34]], "entity_id": ["T8"]}, "Route": {"text": [["enema"]], "start": [[51]], "entity_id": ["T10"]}}, "Subject": {"text": [["a patient with liver dysfunction and chronic renal failure"]], "start": [[60]], "entity_id": ["T6"], "Disorder": {"text": [["liver dysfunction and chronic renal failure"]], "start": [[75]], "entity_id": ["T9"]}}}]}]}
{"id": "12757344_2", "context": "We discuss the association between carbamazepine and hyponatremia and the causes of hyponatremia after cardiopulmonary bypass.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["association"]], "start": [[15]], "entity_id": ["T5"]}, "Treatment": {"text": [["carbamazepine"]], "start": [[35]], "entity_id": ["T3"], "Drug": {"text": [["carbamazepine"]], "start": [[35]], "entity_id": ["T6"]}}, "Effect": {"text": [["hyponatremia"]], "start": [[53]], "entity_id": ["T4"]}}]}]}
{"id": "16882112_7", "context": "Use of the Naranjo adverse drug reaction probability algorithm indicated a probable relationship between serotonin syndrome and treatment with lithium and venlafaxine.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["a probable relationship between"]], "start": [[73]], "entity_id": ["T9"]}, "Effect": {"text": [["serotonin syndrome"]], "start": [[105]], "entity_id": ["T8"]}, "Treatment": {"text": [["treatment with lithium and venlafaxine"]], "start": [[128]], "entity_id": ["T7"], "Drug": {"text": [["lithium"], ["venlafaxine"]], "start": [[143], [155]], "entity_id": ["T11", "T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[151]], "entity_id": ["T12"]}, "Drug": {"text": [["lithium"], ["venlafaxine"]], "start": [[143], [155]], "entity_id": ["T11", "T13"]}}]}, "Speculated": {"text": [["probable"]], "start": [[75]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "19203515_3", "context": "The exact mechanism of IVIG-associated acute renal failure remains unclear.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[28]], "entity_id": ["T4"]}, "Treatment": {"text": [["IVIG"]], "start": [[23]], "entity_id": ["T3"], "Drug": {"text": [["IVIG"]], "start": [[23]], "entity_id": ["T6"]}}, "Effect": {"text": [["acute renal failure"]], "start": [[39]], "entity_id": ["T5"]}, "Speculated": {"text": [["unclear"]], "start": [[67]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "1849334_2", "context": "We report on 7 patients (2 women, 5 men) with chronic renal failure, who developed under a high dosage of the new diuretic muzolimine (range 240 to 1440 mg per day) fatal neuromyeloencephalopathy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[73]], "entity_id": ["T8"]}, "Treatment": {"text": [["a high dosage of the new diuretic muzolimine (range 240 to 1440 mg per day)"]], "start": [[89]], "entity_id": ["T9"], "Drug": {"text": [["diuretic muzolimine"]], "start": [[114]], "entity_id": ["T12"]}, "Freq": {"text": [["per day"]], "start": [[156]], "entity_id": ["T14"]}, "Dosage": {"text": [["range 240 to 1440 mg"]], "start": [[135]], "entity_id": ["T13"]}}, "Effect": {"text": [["fatal neuromyeloencephalopathy"]], "start": [[165]], "entity_id": ["T10"]}, "Subject": {"text": [["7 patients (2 women, 5 men) with chronic renal failure"]], "start": [[13]], "entity_id": ["T16"], "Disorder": {"text": [["chronic renal failure"]], "start": [[46]], "entity_id": ["T7"]}, "Population": {"text": [["7"]], "start": [[13]], "entity_id": ["T11"]}}, "Severity": {"text": [["fatal"]], "start": [[165]], "entity_id": ["T15"], "value": "High"}}]}]}
{"id": "1580986_2", "context": "Two renal transplant patients developed anemia during treatment of hypertension with enalapril medication.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[30]], "entity_id": ["T8"]}, "Subject": {"text": [["Two renal transplant patients"]], "start": [[0]], "entity_id": ["T7"], "Population": {"text": [["Two"]], "start": [[0]], "entity_id": ["T12"]}, "Disorder": {"text": [["renal transplant"]], "start": [[4]], "entity_id": ["T13"]}}, "Effect": {"text": [["anemia"]], "start": [[40]], "entity_id": ["T9"]}, "Treatment": {"text": [["enalapril medication"]], "start": [[85]], "entity_id": ["T10"], "Disorder": {"text": [["hypertension"]], "start": [[67]], "entity_id": ["T11"]}, "Drug": {"text": [["enalapril"]], "start": [[85]], "entity_id": ["T14"]}}}]}]}
{"id": "7787496_1", "context": "Sotalol-induced bradycardia reversed by glucagon.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["reversed"]], "start": [[28]], "entity_id": ["T4"]}, "Treatment": {"text": [["glucagon"]], "start": [[40]], "entity_id": ["T6"], "Disorder": {"text": [["Sotalol-induced bradycardia"]], "start": [[0]], "entity_id": ["T3"]}, "Drug": {"text": [["glucagon"]], "start": [[40]], "entity_id": ["T8"]}}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[8]], "entity_id": ["T9"]}, "Treatment": {"text": [["Sotalol"]], "start": [[0]], "entity_id": ["T10"], "Drug": {"text": [["Sotalol"]], "start": [[0]], "entity_id": ["T5"]}}, "Effect": {"text": [["bradycardia"]], "start": [[16]], "entity_id": ["T11"]}}]}]}
{"id": "9892272_4", "context": "The development of cutaneous ecchymosis associated with a sudden fall in hemoglobin after the administration of alteplase should strongly suggest the possibility of diffuse subfascial hematoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["development"]], "start": [[4]], "entity_id": ["T7"]}, "Effect": {"text": [["cutaneous ecchymosis", "a sudden fall in hemoglobin", "diffuse subfascial hematoma"]], "start": [[19, 56, 165]], "entity_id": ["T8"]}, "Treatment": {"text": [["alteplase"]], "start": [[112]], "entity_id": ["T9"], "Drug": {"text": [["alteplase"]], "start": [[112]], "entity_id": ["T10"]}}, "Speculated": {"text": [["strongly sugges"]], "start": [[129]], "entity_id": ["T11"], "value": true}}]}]}
{"id": "11545487_7", "context": "We report a case of papillary necrosis in a patient treated with indinavir.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[52]], "entity_id": ["T6"]}, "Effect": {"text": [["papillary necrosis"]], "start": [[20]], "entity_id": ["T3"]}, "Treatment": {"text": [["indinavir"]], "start": [[65]], "entity_id": ["T4"], "Drug": {"text": [["indinavir"]], "start": [[65]], "entity_id": ["T7"]}}, "Subject": {"text": [["a patient"]], "start": [[42]], "entity_id": ["T5"]}}]}]}
{"id": "9247841_3", "context": "Generalized maculopapular and papular purpuric eruptions are perhaps the most common thionamide-induced reactions.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[96]], "entity_id": ["T5"]}, "Effect": {"text": [["Generalized maculopapular and papular purpuric eruptions", "reactions"]], "start": [[0, 104]], "entity_id": ["T6"]}, "Treatment": {"text": [["thionamide"]], "start": [[85]], "entity_id": ["T7"], "Drug": {"text": [["thionamide"]], "start": [[85]], "entity_id": ["T11"]}}, "Speculated": {"text": [["perhaps"]], "start": [[61]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "8276031_6", "context": "Imidazoline intoxication due to overdose or accidental ingestion but also after normal therapeutic usage is frequent in children.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[25]], "entity_id": ["T9"]}, "Subject": {"text": [["children"]], "start": [[120]], "entity_id": ["T6"], "Age": {"text": [["children"]], "start": [[120]], "entity_id": ["T10"]}}, "Treatment": {"text": [["Imidazoline", "overdose or accidental ingestion but also after normal therapeutic usage"]], "start": [[0, 32]], "entity_id": ["T7"], "Route": {"text": [["ingestion"]], "start": [[55]], "entity_id": ["T12"]}, "Dosage": {"text": [["overdose or accidental", "but also after normal therapeutic usage"]], "start": [[32, 65]], "entity_id": ["T11"]}}, "Effect": {"text": [["intoxication"]], "start": [[12]], "entity_id": ["T8"]}}]}]}
{"id": "12121061_2", "context": "A 50-year-old diabetic and hypertensive male patient is reported who had ticlopidine-induced marrow aplasia partially responsive to colony-stimulating factors and corticosteroids, but experienced complete recovery with cyclosporine.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[85]], "entity_id": ["T18"]}, "Treatment": {"text": [["ticlopidine"]], "start": [[73]], "entity_id": ["T17"], "Drug": {"text": [["ticlopidine"]], "start": [[73]], "entity_id": ["T22"]}}, "Subject": {"text": [["50-year-old diabetic and hypertensive male patient"]], "start": [[2]], "entity_id": ["T15"], "Disorder": {"text": [["diabetic and hypertensive"]], "start": [[14]], "entity_id": ["T16"]}, "Age": {"text": [["50-year-old"]], "start": [[2]], "entity_id": ["T20"]}, "Gender": {"text": [["male"]], "start": [[40]], "entity_id": ["T21"]}}, "Effect": {"text": [["marrow aplasia"]], "start": [[93]], "entity_id": ["T19"]}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["with"]], "start": [[214]], "entity_id": ["T27"]}, "Subject": {"text": [["50-year-old diabetic and hypertensive male patient"]], "start": [[2]], "entity_id": ["T15"], "Disorder": {"text": [["diabetic and hypertensive"]], "start": [[14]], "entity_id": ["T16"]}, "Age": {"text": [["50-year-old"]], "start": [[2]], "entity_id": ["T20"]}, "Gender": {"text": [["male"]], "start": [[40]], "entity_id": ["T21"]}}, "Effect": {"text": [["experienced complete recovery"]], "start": [[184]], "entity_id": ["T25"]}, "Treatment": {"text": [["cyclosporine"]], "start": [[219]], "entity_id": ["T24"], "Disorder": {"text": [["ticlopidine-induced marrow aplasia"]], "start": [[73]], "entity_id": ["T28"]}, "Drug": {"text": [["cyclosporine"]], "start": [[219]], "entity_id": ["T26"]}}}]}]}
{"id": "2378415_2", "context": "A patient with intracranial osteosarcoma that arose 16 years after radiation therapy for hereditary retinoblastoma developed fatal cerebral edema and brainstem herniation after she received a single dose of intravenous methotrexate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[115]], "entity_id": ["T7"]}, "Treatment": {"text": [["a single dose of intravenous methotrexate"]], "start": [[190]], "entity_id": ["T6"], "Disorder": {"text": [["intracranial osteosarcoma"]], "start": [[15]], "entity_id": ["T9"]}, "Freq": {"text": [["a single dose"]], "start": [[190]], "entity_id": ["T10"]}, "Route": {"text": [["intravenous"]], "start": [[207]], "entity_id": ["T11"]}, "Drug": {"text": [["methotrexate"]], "start": [[219]], "entity_id": ["T12"]}}, "Effect": {"text": [["cerebral edema and brainstem herniation"]], "start": [[131]], "entity_id": ["T8"]}, "Subject": {"text": [["A patient with intracranial osteosarcoma that arose 16 years after radiation therapy for hereditary retinoblastoma"]], "start": [[0]], "entity_id": ["T5"], "Disorder": {"text": [["hereditary retinoblastoma"]], "start": [[89]], "entity_id": ["T1"]}}, "Severity": {"text": [["fatal"]], "start": [[125]], "entity_id": ["T13"], "value": "High"}}]}]}
{"id": "8255797_2", "context": "Neutropenia is an infrequent complication following administration of the angiotensin-converting enzyme (ACE) inhibitor, captopril.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[42]], "entity_id": ["T4"]}, "Effect": {"text": [["Neutropenia"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["the angiotensin-converting enzyme (ACE) inhibitor, captopril"]], "start": [[70]], "entity_id": ["T5"], "Drug": {"text": [["captopril"]], "start": [[121]], "entity_id": ["T6"]}}}]}]}
{"id": "17522786_1", "context": "INTRODUCTION: We describe the neurointensive care (NIC) management of a patient with severe cerebral swelling and raised intracranial pressure (ICP) after severe sodium valproic acid (VPA) intoxication.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[149]], "entity_id": ["T10"]}, "Subject": {"text": [["patient"]], "start": [[72]], "entity_id": ["T7"]}, "Effect": {"text": [["severe cerebral swelling and raised intracranial pressure (ICP)", "intoxication"]], "start": [[85, 189]], "entity_id": ["T8"]}, "Treatment": {"text": [["sodium valproic acid (VPA)"]], "start": [[162]], "entity_id": ["T9"], "Drug": {"text": [["sodium valproic acid"]], "start": [[162]], "entity_id": ["T12"]}}, "Severity": {"text": [["severe"]], "start": [[155]], "entity_id": ["T11"], "value": "High"}}]}]}
{"id": "8313300_7", "context": "Lithium therapy was discontinued because of poor compliance to the medication and intolerable polyuria.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["because"]], "start": [[33]], "entity_id": ["T5"]}, "Treatment": {"text": [["Lithium"]], "start": [[0]], "entity_id": ["T3"]}, "Effect": {"text": [["polyuria"]], "start": [[94]], "entity_id": ["T4"]}}]}]}
{"id": "7594371_2", "context": "Both PAN and methotrexate have been independently demonstrated to cause sensorineural hearing loss.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[66]], "entity_id": ["T5"]}, "Effect": {"text": [["sensorineural hearing loss"]], "start": [[72]], "entity_id": ["T4"]}, "Treatment": {"text": [["PAN and methotrexate"]], "start": [[5]], "entity_id": ["T7"], "Drug": {"text": [["PAN"], ["methotrexate"]], "start": [[5], [13]], "entity_id": ["T8", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[9]], "entity_id": ["T9"]}, "Drug": {"text": [["PAN"], ["methotrexate"]], "start": [[5], [13]], "entity_id": ["T8", "T10"]}}]}}]}]}
{"id": "19667003_14", "context": "CONCLUSION: A 26-year-old man with bipolar disorder developed hyperammonemia three weeks after initiating carbamazepine therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[52]], "entity_id": ["T7"]}, "Subject": {"text": [["A 26-year-old man with bipolar disorder"]], "start": [[12]], "entity_id": ["T6"], "Age": {"text": [["26-year-old"]], "start": [[14]], "entity_id": ["T10"]}, "Gender": {"text": [["man"]], "start": [[26]], "entity_id": ["T11"]}}, "Effect": {"text": [["hyperammonemia"]], "start": [[62]], "entity_id": ["T8"]}, "Treatment": {"text": [["three weeks after initiating carbamazepine therapy"]], "start": [[77]], "entity_id": ["T9"], "Time_elapsed": {"text": [["three weeks"]], "start": [[77]], "entity_id": ["T13"]}, "Drug": {"text": [["carbamazepine"]], "start": [[106]], "entity_id": ["T14"]}, "Disorder": {"text": [["bipolar disorder"]], "start": [[35]], "entity_id": ["T15"]}}}]}]}
{"id": "11034877_2", "context": "We report two adults who received gabapentin (GBP) and subsequently developed behavioural side effects.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[68]], "entity_id": ["T8"]}, "Treatment": {"text": [["gabapentin (GBP)"]], "start": [[34]], "entity_id": ["T7"], "Drug": {"text": [["gabapentin"]], "start": [[34]], "entity_id": ["T12"]}}, "Effect": {"text": [["behavioural side effects"]], "start": [[78]], "entity_id": ["T9"]}, "Subject": {"text": [["two adults"]], "start": [[10]], "entity_id": ["T6"], "Population": {"text": [["two"]], "start": [[10]], "entity_id": ["T10"]}, "Age": {"text": [["adults"]], "start": [[14]], "entity_id": ["T11"]}}}]}]}
{"id": "4038927_1", "context": "Atrial fibrillation was induced by diltiazem in two patients and verapamil induced syncope in one patient.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[24]], "entity_id": ["T5"]}, "Treatment": {"text": [["diltiazem"]], "start": [[35]], "entity_id": ["T6"], "Drug": {"text": [["diltiazem"]], "start": [[35]], "entity_id": ["T11"]}}, "Subject": {"text": [["two patients"]], "start": [[48]], "entity_id": ["T8"], "Population": {"text": [["two"]], "start": [[48]], "entity_id": ["T9"]}}, "Effect": {"text": [["Atrial fibrillation"]], "start": [[0]], "entity_id": ["T7"]}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[75]], "entity_id": ["T14"]}, "Treatment": {"text": [["verapamil"]], "start": [[65]], "entity_id": ["T15"], "Drug": {"text": [["verapamil"]], "start": [[65]], "entity_id": ["T16"]}}, "Effect": {"text": [["syncope"]], "start": [[83]], "entity_id": ["T17"]}, "Subject": {"text": [["one patient"]], "start": [[94]], "entity_id": ["T12"], "Population": {"text": [["one"]], "start": [[94]], "entity_id": ["T13"]}}}]}]}
{"id": "21448111_6", "context": "We can conclude that in this case, as in many others, akathisia as a possible adverse effect of psychopharmacs was very hard to identify.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["adverse effect"]], "start": [[78]], "entity_id": ["T6"]}, "Treatment": {"text": [["psychopharmacs"]], "start": [[96]], "entity_id": ["T5"], "Drug": {"text": [["psychopharmacs"]], "start": [[96]], "entity_id": ["T10"]}}, "Effect": {"text": [["akathisia"]], "start": [[54]], "entity_id": ["T8"]}, "Subject": {"text": [["this case"]], "start": [[24]], "entity_id": ["T9"]}, "Speculated": {"text": [["possible"]], "start": [[69]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "18176653_12", "context": "Although HAART is very important in the treatment of HIV, its side effects are responsible for patients' non-adherence to medications.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["side effects"]], "start": [[62]], "entity_id": ["T5"]}, "Treatment": {"text": [["HAART"]], "start": [[9]], "entity_id": ["T6"], "Disorder": {"text": [["HIV"]], "start": [[53]], "entity_id": ["T7"]}, "Drug": {"text": [["HAART"]], "start": [[9]], "entity_id": ["T10"]}}, "Effect": {"text": [["non-adherence to medications"]], "start": [[105]], "entity_id": ["T8"]}, "Subject": {"text": [["patients"]], "start": [[95]], "entity_id": ["T9"]}}]}]}
{"id": "7668127_2", "context": "A case of acute subdural haematoma originating spontaneously from an angiomatous meningioma in a patient receiving prophylactic aspirin therapy is presented.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["presented"]], "start": [[147]], "entity_id": ["T9"]}, "Effect": {"text": [["acute subdural haematoma"]], "start": [[10]], "entity_id": ["T6"]}, "Subject": {"text": [["an angiomatous meningioma in a patient"]], "start": [[66]], "entity_id": ["T7"]}, "Treatment": {"text": [["aspirin"]], "start": [[128]], "entity_id": ["T8"], "Drug": {"text": [["aspirin"]], "start": [[128]], "entity_id": ["T10"]}}}]}]}
{"id": "16529136_4", "context": "Long known to psychiatrists, monoamine oxidase inhibitors (MAOIs) and complications of their use may be unfamiliar to medical and surgical practitioners who may thus unwittingly precipitate a hypertensive crisis or serotonin syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["precipitate"]], "start": [[178]], "entity_id": ["T8"]}, "Treatment": {"text": [["monoamine oxidase inhibitors (MAOIs)"]], "start": [[29]], "entity_id": ["T6"], "Drug": {"text": [["monoamine oxidase inhibitors"]], "start": [[29]], "entity_id": ["T9"]}}, "Effect": {"text": [["hypertensive crisis or serotonin syndrome"]], "start": [[192]], "entity_id": ["T7"]}}]}]}
{"id": "18294121_1", "context": "According to the Naranjo adverse drug reaction probability scale, the likelihood that temozolomide was responsible for the adverse drug reaction of fever was probable (score of 6).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["adverse drug reaction"]], "start": [[123]], "entity_id": ["T6"]}, "Treatment": {"text": [["temozolomide"]], "start": [[86]], "entity_id": ["T4"], "Drug": {"text": [["temozolomide"]], "start": [[86]], "entity_id": ["T8"]}}, "Effect": {"text": [["fever"]], "start": [[148]], "entity_id": ["T5"]}, "Speculated": {"text": [["probable"]], "start": [[158]], "entity_id": ["T3"], "value": true}}]}]}
{"id": "10891991_4", "context": "OBJECTIVE: To describe the development of valproate-related reproductive endocrine disorders in women with epilepsy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[52]], "entity_id": ["T6"]}, "Subject": {"text": [["women with epilepsy"]], "start": [[96]], "entity_id": ["T3"], "Gender": {"text": [["women"]], "start": [[96]], "entity_id": ["T7"]}}, "Effect": {"text": [["reproductive endocrine disorders"]], "start": [[60]], "entity_id": ["T4"]}, "Treatment": {"text": [["valproate"]], "start": [[42]], "entity_id": ["T5"], "Drug": {"text": [["valproate"]], "start": [[42]], "entity_id": ["T9"]}, "Disorder": {"text": [["epilepsy"]], "start": [[107]], "entity_id": ["T10"]}}}]}]}
{"id": "2857534_1", "context": "Alprazolam-induced mania: two clinical cases.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T3"]}, "Treatment": {"text": [["Alprazolam"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Alprazolam"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["mania"]], "start": [[19]], "entity_id": ["T5"]}, "Subject": {"text": [["two clinical cases"]], "start": [[26]], "entity_id": ["T6"], "Population": {"text": [["two"]], "start": [[26]], "entity_id": ["T7"]}}}]}]}
{"id": "10679548_2", "context": "Bronchiolitis obliterans organising pneumonia associated with the use of nitrofurantoin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated with"]], "start": [[46]], "entity_id": ["T4"]}, "Treatment": {"text": [["use of nitrofurantoin"]], "start": [[66]], "entity_id": ["T3"], "Drug": {"text": [["nitrofurantoin"]], "start": [[73]], "entity_id": ["T6"]}}, "Effect": {"text": [["Bronchiolitis obliterans organising pneumonia"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "6692713_3", "context": "To our knowledge, this recurrence of amiodarone pulmonary toxicity has not been reported previously.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["toxicity"]], "start": [[58]], "entity_id": ["T5"]}, "Treatment": {"text": [["amiodarone"]], "start": [[37]], "entity_id": ["T3"], "Drug": {"text": [["amiodarone"]], "start": [[37]], "entity_id": ["T8"]}}, "Effect": {"text": [["pulmonary toxicity"]], "start": [[48]], "entity_id": ["T4"]}}]}]}
{"id": "10660641_2", "context": "A patient treated with itraconazole (ITCZ) under the diagnosis of Aspergillus flavus-induced chronic hypertrophic pachymeningitis is presented.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[10]], "entity_id": ["T6"]}, "Subject": {"text": [["A patient"]], "start": [[0]], "entity_id": ["T8"]}, "Treatment": {"text": [["itraconazole (ITCZ)"]], "start": [[23]], "entity_id": ["T5"], "Drug": {"text": [["itraconazole"]], "start": [[23]], "entity_id": ["T9"]}, "Disorder": {"text": [["Aspergillus flavus-induced chronic hypertrophic pachymeningitis"]], "start": [[66]], "entity_id": ["T10"]}}}]}]}
{"id": "12802933_1", "context": "Severe autoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[35]], "entity_id": ["T4"]}, "Effect": {"text": [["Severe autoimmune hemolytic anemia"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["rituximab therapy"]], "start": [[45]], "entity_id": ["T5"], "Drug": {"text": [["rituximab"]], "start": [[45]], "entity_id": ["T8"]}, "Disorder": {"text": [["lymphoproliferative disorder"]], "start": [[83]], "entity_id": ["T9"]}}, "Subject": {"text": [["a patient with a lymphoproliferative disorder"]], "start": [[66]], "entity_id": ["T6"]}}]}]}
{"id": "11545487_6", "context": "The renal consequences of indinavir-associated nephrotoxicity are uncertain.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[36]], "entity_id": ["T4"]}, "Treatment": {"text": [["indinavir"]], "start": [[26]], "entity_id": ["T3"], "Drug": {"text": [["indinavir"]], "start": [[26]], "entity_id": ["T7"]}}, "Effect": {"text": [["nephrotoxicity"]], "start": [[47]], "entity_id": ["T5"]}, "Speculated": {"text": [["uncertain"]], "start": [[66]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "11834188_1", "context": "BACKGROUND: reports on delated cutaneous reactions to captopril have been seldom reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reported"]], "start": [[81]], "entity_id": ["T5"]}, "Treatment": {"text": [["captopril"]], "start": [[54]], "entity_id": ["T3"], "Drug": {"text": [["captopril"]], "start": [[54]], "entity_id": ["T6"]}}, "Effect": {"text": [["delated cutaneous reactions"]], "start": [[23]], "entity_id": ["T4"]}}]}]}
{"id": "24163322_7", "context": "Bismuth subsalicylate 30 mL every 4 hours was prescribed for diarrhea.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["prescribed"]], "start": [[46]], "entity_id": ["T5"]}, "Treatment": {"text": [["Bismuth subsalicylate 30 mL every 4 hours"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Bismuth subsalicylate"]], "start": [[0]], "entity_id": ["T7"]}, "Dosage": {"text": [["30 mL"]], "start": [[22]], "entity_id": ["T8"]}, "Freq": {"text": [["every 4 hours"]], "start": [[28]], "entity_id": ["T9"]}, "Disorder": {"text": [["diarrhea"]], "start": [[61]], "entity_id": ["T10"]}}}]}]}
{"id": "19382926_6", "context": "A drug interaction between the alpha(2)-adrenergic agonist medetomidine and lignocaine is suspected and highlights the potential for seizures following the subcutaneous administration of relatively large doses of lignocaine under medetomidine sedation.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[142]], "entity_id": ["T12"]}, "Effect": {"text": [["seizures"]], "start": [[133]], "entity_id": ["T11"]}, "Treatment": {"text": [["subcutaneous administration of relatively large doses of lignocaine under medetomidine sedation"]], "start": [[156]], "entity_id": ["T13"], "Drug": {"text": [["lignocaine"], ["medetomidine"]], "start": [[213], [230]], "entity_id": ["T14", "T15"]}, "Route": {"text": [["subcutaneous"]], "start": [[156]], "entity_id": ["T16"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["under"]], "start": [[224]], "entity_id": ["T17"]}, "Drug": {"text": [["medetomidine"], ["lignocaine"]], "start": [[230], [213]], "entity_id": ["T15", "T14"]}}]}, "Speculated": {"text": [["potential"]], "start": [[119]], "entity_id": ["T18"], "value": true}}]}]}
{"id": "7428724_2", "context": "Oesophageal ulceration due to emepronium bromide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due to"]], "start": [[23]], "entity_id": ["T4"]}, "Effect": {"text": [["Oesophageal ulceration"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["emepronium bromide"]], "start": [[30]], "entity_id": ["T5"], "Drug": {"text": [["emepronium bromide"]], "start": [[30]], "entity_id": ["T6"]}}}]}]}
{"id": "16432996_1", "context": "Development of sarcoidosis during interferon alpha 2b and ribavirin combination therapy for chronic hepatitis C--a case report and review of the literature.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Development"]], "start": [[0]], "entity_id": ["T8"]}, "Effect": {"text": [["sarcoidosis"]], "start": [[15]], "entity_id": ["T9"]}, "Treatment": {"text": [["interferon alpha 2b and ribavirin"]], "start": [[34]], "entity_id": ["T10"], "Drug": {"text": [["interferon alpha 2b"], ["ribavirin"]], "start": [[34], [58]], "entity_id": ["T12", "T13"]}, "Disorder": {"text": [["chronic hepatitis C"]], "start": [[92]], "entity_id": ["T15"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combination"]], "start": [[68]], "entity_id": ["T14"]}, "Drug": {"text": [["ribavirin"], ["interferon alpha 2b"]], "start": [[58], [34]], "entity_id": ["T13", "T12"]}}]}}]}]}
{"id": "9022114_2", "context": "CONCLUSION: The findings in these two patients suggest that colchicine may delay corneal wound healing.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["delay"]], "start": [[75]], "entity_id": ["T6"]}, "Effect": {"text": [["delay corneal wound healing"]], "start": [[75]], "entity_id": ["T3"]}, "Treatment": {"text": [["colchicine"]], "start": [[60]], "entity_id": ["T4"], "Drug": {"text": [["colchicine"]], "start": [[60]], "entity_id": ["T8"]}, "Disorder": {"text": [["corneal wound"]], "start": [[81]], "entity_id": ["T10"]}}, "Subject": {"text": [["two patients"]], "start": [[34]], "entity_id": ["T5"], "Population": {"text": [["two"]], "start": [[34]], "entity_id": ["T7"]}}, "Speculated": {"text": [["may"]], "start": [[71]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "12324937_3", "context": "Gemcitabine-associated hemolytic-uremic syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[12]], "entity_id": ["T3"]}, "Treatment": {"text": [["Gemcitabine"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Gemcitabine"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["hemolytic-uremic syndrome"]], "start": [[23]], "entity_id": ["T5"]}}]}]}
{"id": "9100429_1", "context": "Case study: adverse response to clonidine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["to"]], "start": [[29]], "entity_id": ["T5"]}, "Effect": {"text": [["adverse response"]], "start": [[12]], "entity_id": ["T4"]}, "Treatment": {"text": [["clonidine"]], "start": [[32]], "entity_id": ["T6"], "Drug": {"text": [["clonidine"]], "start": [[32]], "entity_id": ["T7"]}}}]}]}
{"id": "17163271_2", "context": "In this report, a patient who had undergone a renal transplantation as a result of malignant hypertension, and who was on immunosuppressive therapy consisting of cyclosporin, prednisone and azathioprine, developed thrombosis of the central retinal vein 5 years following the transplantation.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[204]], "entity_id": ["T5"]}, "Effect": {"text": [["thrombosis of the central retinal vein"]], "start": [[214]], "entity_id": ["T6"]}, "Subject": {"text": [["a patient"]], "start": [[16]], "entity_id": ["T8"], "Disorder": {"text": [["malignant hypertension"]], "start": [[83]], "entity_id": ["T4"]}}, "Treatment": {"text": [["on immunosuppressive therapy consisting of cyclosporin, prednisone and azathioprine", "undergone a renal transplantation as a result of malignant hypertension"]], "start": [[119, 34]], "entity_id": ["T1"], "Drug": {"text": [["cyclosporin"], ["prednisone"], ["azathioprine"]], "start": [[162], [175], [190]], "entity_id": ["T10", "T11", "T12"]}, "Time_elapsed": {"text": [["5 years"]], "start": [[253]], "entity_id": ["T2"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[186]], "entity_id": ["T3"]}, "Drug": {"text": [["cyclosporin"], ["prednisone"], ["azathioprine"]], "start": [[162], [175], [190]], "entity_id": ["T10", "T11", "T12"]}}]}}]}]}
{"id": "15300114_2", "context": "In each of the three reported patients, alteration of eyelid appearance with deepening of the lid sulcus was evident as the result of topical bimatoprost therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["evident"]], "start": [[109]], "entity_id": ["T5"]}, "Treatment": {"text": [["topical bimatoprost"]], "start": [[134]], "entity_id": ["T6"], "Drug": {"text": [["bimatopros"]], "start": [[142]], "entity_id": ["T10"]}}, "Subject": {"text": [["three reported patients"]], "start": [[15]], "entity_id": ["T7"], "Population": {"text": [["three"]], "start": [[15]], "entity_id": ["T9"]}}, "Effect": {"text": [["alteration of eyelid appearance with deepening of the lid sulcus"]], "start": [[40]], "entity_id": ["T8"]}}]}]}
{"id": "16629074_1", "context": "PURPOSE: To report a case of traumatic flap dehiscence and Enterobacter keratitis 34 months after LASIK.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[92]], "entity_id": ["T7"]}, "Treatment": {"text": [["34 months after LASIK"]], "start": [[82]], "entity_id": ["T5"], "Time_elapsed": {"text": [["34 months after"]], "start": [[82]], "entity_id": ["T8"]}}, "Effect": {"text": [["traumatic flap dehiscence and Enterobacter keratitis"]], "start": [[29]], "entity_id": ["T6"]}}]}]}
{"id": "9220046_2", "context": "CONCLUSIONS: The risk of drug-induced rhabdomyolysis due to the potential interaction between lovastatin and azithromycin or clarithromycin should be considered before the concomitant use of these agents.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[53]], "entity_id": ["T7"]}, "Effect": {"text": [["rhabdomyolysis"]], "start": [[38]], "entity_id": ["T5"]}, "Treatment": {"text": [["lovastatin", "azithromycin", "clarithromycin"]], "start": [[94, 109, 125]], "entity_id": ["T6"], "Drug": {"text": [["lovastatin"], ["azithromycin"], ["clarithromycin"]], "start": [[94], [109], [125]], "entity_id": ["T8", "T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[105]], "entity_id": ["T11"]}, "Drug": {"text": [["lovastatin"], ["azithromycin"], ["clarithromycin"]], "start": [[94], [109], [125]], "entity_id": ["T8", "T9", "T10"]}}]}}]}]}
{"id": "1509179_2", "context": "Ten years of behavioral data are presented to support the hypothesis that phenobarbital was exacerbating maladaptive behaviors.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["exacerbating"]], "start": [[92]], "entity_id": ["T4"]}, "Treatment": {"text": [["phenobarbital"]], "start": [[74]], "entity_id": ["T3"], "Drug": {"text": [["phenobarbital"]], "start": [[74]], "entity_id": ["T6"]}}, "Effect": {"text": [["maladaptive behaviors"]], "start": [[105]], "entity_id": ["T5"]}}]}]}
{"id": "8835752_2", "context": "Terbinafine-induced cholestatic liver disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[12]], "entity_id": ["T3"]}, "Treatment": {"text": [["Terbinafine"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Terbinafine"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["cholestatic liver disease."]], "start": [[20]], "entity_id": ["T5"]}}]}]}
{"id": "21789791_2", "context": "The proteasome inhibitor Bortezomib has been identified as a potent enhancer of TRAIL-induced apoptosis in several human cancers.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["induced"]], "start": [[86]], "entity_id": ["T8"]}, "Effect": {"text": [["apoptosis in several human cancers"]], "start": [[94]], "entity_id": ["T9"]}, "Treatment": {"text": [["proteasome inhibitor Bortezomib has been identified as a potent enhancer of TRAIL"]], "start": [[4]], "entity_id": ["T7"], "Drug": {"text": [["Bortezomib"]], "start": [[25]], "entity_id": ["T10"]}}}]}]}
{"id": "19116715_2", "context": "METHODS: A retrospective report of the first case of gemcitabine-related HUS, in a patient with metastatic pancreatic adenocarcinoma, treated with a variety of standard therapies in addition to rituximab is presented.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[65]], "entity_id": ["T4"]}, "Treatment": {"text": [["gemcitabine"]], "start": [[53]], "entity_id": ["T3"], "Drug": {"text": [["gemcitabine"]], "start": [[53]], "entity_id": ["T8"]}, "Disorder": {"text": [["metastatic pancreatic adenocarcinoma,"]], "start": [[96]], "entity_id": ["T9"]}}, "Effect": {"text": [["HUS"]], "start": [[73]], "entity_id": ["T5"]}, "Subject": {"text": [["a patient with metastatic pancreatic adenocarcinoma"]], "start": [[81]], "entity_id": ["T6"]}}]}]}
{"id": "2595431_3", "context": "Their parkinsonism improved on discontinuation of metoclopramide therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["improved"]], "start": [[19]], "entity_id": ["T5"]}, "Treatment": {"text": [["discontinuation of metoclopramide therapy"]], "start": [[31]], "entity_id": ["T4"], "Drug": {"text": [["metoclopramide"]], "start": [[50]], "entity_id": ["T7"]}, "Disorder": {"text": [["parkinsonism"]], "start": [[6]], "entity_id": ["T8"]}}, "Subject": {"text": [["Their parkinsonism"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "15304176_1", "context": "Lichen planus induced by hepatitis B vaccination: a new case and review of the literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[14]], "entity_id": ["T4"]}, "Effect": {"text": [["Lichen planus"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["hepatitis B vaccination"]], "start": [[25]], "entity_id": ["T5"], "Drug": {"text": [["hepatitis B vaccination"]], "start": [[25]], "entity_id": ["T6"]}}}]}]}
{"id": "18453852_4", "context": "A total of 40 healthy volunteers were planned to start with 600 mg rifampicin once daily from days 1-5.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["start"]], "start": [[49]], "entity_id": ["T5"]}, "Subject": {"text": [["40 healthy volunteers"]], "start": [[11]], "entity_id": ["T4"], "Population": {"text": [["40"]], "start": [[11]], "entity_id": ["T7"]}}, "Treatment": {"text": [["600 mg rifampicin once daily from days 1-5"]], "start": [[60]], "entity_id": ["T6"], "Dosage": {"text": [["600 mg"]], "start": [[60]], "entity_id": ["T8"]}, "Drug": {"text": [["rifampicin"]], "start": [[67]], "entity_id": ["T9"]}, "Freq": {"text": [["once daily"]], "start": [[78]], "entity_id": ["T10"]}}}]}]}
{"id": "9366852_1", "context": "Skin necrosis secondary to low-molecular weight heparin in a patient with antiphospholipid antibody syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["secondary to"]], "start": [[14]], "entity_id": ["T8"]}, "Subject": {"text": [["a patient with antiphospholipid antibody syndrome"]], "start": [[59]], "entity_id": ["T6"]}, "Effect": {"text": [["Skin necrosis"]], "start": [[0]], "entity_id": ["T7"]}, "Treatment": {"text": [["low-molecular weight heparin"]], "start": [[27]], "entity_id": ["T9"], "Disorder": {"text": [["antiphospholipid antibody syndrome"]], "start": [[74]], "entity_id": ["T10"]}, "Drug": {"text": [["low-molecular weight heparin"]], "start": [[27]], "entity_id": ["T11"]}}}]}]}
{"id": "20098333_1", "context": "Exacerbation of anthracycline-induced early chronic cardiomyopathy with ATRA: role of B-type natriuretic peptide as an indicator of cardiac dysfunction.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[30]], "entity_id": ["T3"]}, "Treatment": {"text": [["anthracycline", "with ATRA"]], "start": [[16, 67]], "entity_id": ["T4"], "Drug": {"text": [["anthracycline"], ["ATRA"]], "start": [[16], [72]], "entity_id": ["T7", "T8"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["with"]], "start": [[67]], "entity_id": ["T6"]}, "Drug": {"text": [["anthracycline"], ["ATRA"]], "start": [[16], [72]], "entity_id": ["T7", "T8"]}}]}, "Effect": {"text": [["early chronic cardiomyopathy"]], "start": [[38]], "entity_id": ["T5"]}}]}]}
{"id": "10395123_2", "context": "Fixed drug eruption in hands caused by omeprazole.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[29]], "entity_id": ["T4"]}, "Treatment": {"text": [["omeprazole"]], "start": [[39]], "entity_id": ["T3"], "Drug": {"text": [["omeprazole"]], "start": [[39]], "entity_id": ["T6"]}}, "Effect": {"text": [["Fixed drug eruption in hands"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "12699871_1", "context": "FK506, which began to be administered 12 days earlier, rose to a level of 44 ng/mL (normal range, 10-20 ng/mL) 1 day before neurologic abnormalities began.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["before"]], "start": [[117]], "entity_id": ["T4"]}, "Treatment": {"text": [["FK506, which began to be administered 12 days earlier, rose to a level of 44 ng/mL (normal range, 10-20 ng/mL)"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["FK506"]], "start": [[0]], "entity_id": ["T6"]}, "Time_elapsed": {"text": [["12 days earlier"]], "start": [[38]], "entity_id": ["T7"]}}, "Effect": {"text": [["neurologic abnormalities began"]], "start": [[124]], "entity_id": ["T5"]}}]}]}
{"id": "15224368_2", "context": "Sweet's syndrome is an acute febrile neutrophilic dermatosis that is a known complication of the administration of filgrastim, a drug that causes increased neutrophil proliferation and differentiation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["causes"]], "start": [[139]], "entity_id": ["T7"]}, "Treatment": {"text": [["filgrastim"]], "start": [[115]], "entity_id": ["T5"], "Drug": {"text": [["filgrastim"]], "start": [[115]], "entity_id": ["T8"]}}, "Effect": {"text": [["Sweet's syndrome is an acute febrile neutrophilic dermatosis", "increased neutrophil proliferation and differentiation"]], "start": [[0, 146]], "entity_id": ["T6"]}}]}]}
{"id": "12811715_1", "context": "Although it would be expected that, like other type IA toxicities, diphenhydramine-induced cardiotoxicity could be responsive to hypertonic sodium bicarbonate, this finding is largely unappreciated.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[83]], "entity_id": ["T3"]}, "Treatment": {"text": [["diphenhydramine"]], "start": [[67]], "entity_id": ["T5"], "Drug": {"text": [["diphenhydramine"]], "start": [[67]], "entity_id": ["T9"]}}, "Effect": {"text": [["cardiotoxicity"]], "start": [[91]], "entity_id": ["T6"]}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["responsive"]], "start": [[115]], "entity_id": ["T4"]}, "Treatment": {"text": [["hypertonic sodium bicarbonate"]], "start": [[129]], "entity_id": ["T11"], "Disorder": {"text": [["diphenhydramine-induced cardiotoxicity"]], "start": [[67]], "entity_id": ["T13"]}, "Drug": {"text": [["hypertonic sodium bicarbonate"]], "start": [[129]], "entity_id": ["T12"]}}, "Speculated": {"text": [["could"]], "start": [[106]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "2016556_1", "context": "We describe a patient who experienced chronic nausea and an episode of confusion while treated with a small, stable dose of oral morphine in the setting of mild renal insufficiency.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["experienced"]], "start": [[26]], "entity_id": ["T6"]}, "Subject": {"text": [["a patient"]], "start": [[12]], "entity_id": ["T5"], "Disorder": {"text": [["mild renal insufficiency"]], "start": [[156]], "entity_id": ["T9"]}}, "Effect": {"text": [["chronic nausea and an episode of confusion"]], "start": [[38]], "entity_id": ["T7"]}, "Treatment": {"text": [["a small, stable dose of oral morphine"]], "start": [[100]], "entity_id": ["T8"], "Dosage": {"text": [["small, stable dose"]], "start": [[102]], "entity_id": ["T10"]}, "Route": {"text": [["oral"]], "start": [[124]], "entity_id": ["T11"]}, "Drug": {"text": [["morphine"]], "start": [[129]], "entity_id": ["T12"]}}}]}]}
{"id": "2011096_1", "context": "Bulbar and pseudobulbar palsy complicating therapy with high-dose cytosine arabinoside in children with leukemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complicating"]], "start": [[30]], "entity_id": ["T10"]}, "Subject": {"text": [["children with leukemia"]], "start": [[90]], "entity_id": ["T7"], "Age": {"text": [["children"]], "start": [[90]], "entity_id": ["T11"]}}, "Effect": {"text": [["Bulbar and pseudobulbar palsy"]], "start": [[0]], "entity_id": ["T8"]}, "Treatment": {"text": [["high-dose cytosine arabinoside"]], "start": [[56]], "entity_id": ["T9"], "Drug": {"text": [["cytosine arabinoside"]], "start": [[66]], "entity_id": ["T13"]}, "Dosage": {"text": [["high-dose"]], "start": [[56]], "entity_id": ["T14"]}, "Disorder": {"text": [["leukemia"]], "start": [[104]], "entity_id": ["T15"]}}}]}]}
{"id": "1068531_2", "context": "The development of erythroid leukemia plus carcinoma in these two men suggests mutagenic change secondary to cyclophosphamide therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["suggests"]], "start": [[70]], "entity_id": ["T3"]}, "Treatment": {"text": [["cyclophosphamide therapy"]], "start": [[109]], "entity_id": ["T4"], "Drug": {"text": [["cyclophosphamide"]], "start": [[109]], "entity_id": ["T10"]}}, "Effect": {"text": [["development of erythroid leukemia plus carcinoma", "mutagenic change"]], "start": [[4, 79]], "entity_id": ["T5"]}, "Subject": {"text": [["two men"]], "start": [[62]], "entity_id": ["T6"], "Population": {"text": [["two"]], "start": [[62]], "entity_id": ["T7"]}, "Gender": {"text": [["men"]], "start": [[66]], "entity_id": ["T8"]}}}]}]}
{"id": "25538343_3", "context": "Administration of thiazide diuretics also has been the cause of hyponatremia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[55]], "entity_id": ["T5"]}, "Treatment": {"text": [["thiazide diuretics"]], "start": [[18]], "entity_id": ["T4"], "Drug": {"text": [["thiazide diuretics"]], "start": [[18]], "entity_id": ["T7"]}}, "Effect": {"text": [["hyponatremia"]], "start": [[64]], "entity_id": ["T6"]}}]}]}
{"id": "17122225_2", "context": "Serotonin syndrome is a potentially lethal adverse drug reaction that may occur in patients taking proserotoninergic medications.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occur"]], "start": [[74]], "entity_id": ["T8"]}, "Effect": {"text": [["Serotonin syndrome"]], "start": [[0]], "entity_id": ["T5"]}, "Subject": {"text": [["patients"]], "start": [[83]], "entity_id": ["T6"]}, "Treatment": {"text": [["proserotoninergic medications"]], "start": [[99]], "entity_id": ["T7"], "Drug": {"text": [["proserotoninergic"]], "start": [[99]], "entity_id": ["T9"]}, "Disorder": {"text": [["Serotonin syndrome"]], "start": [[0]], "entity_id": ["T10"]}}, "Severity": {"text": [["lethal"]], "start": [[36]], "entity_id": ["T11"], "value": "High"}, "Speculated": {"text": [["may"]], "start": [[70]], "entity_id": ["T12"], "value": true}}]}]}
{"id": "7519913_1", "context": "However, there remain questions concerning whether these drugs, especially methimazole (MMI), may be associated with aplasia cutis congenita (ACC) and how best to avoid impairment of fetal thyroid function during their use.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[101]], "entity_id": ["T8"]}, "Treatment": {"text": [["methimazole"]], "start": [[75]], "entity_id": ["T7"], "Drug": {"text": [["methimazole (MMI)"]], "start": [[75]], "entity_id": ["T11"]}}, "Effect": {"text": [["aplasia cutis congenita"]], "start": [[117]], "entity_id": ["T9"]}, "Speculated": {"text": [["questions"]], "start": [[22]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "17896898_2", "context": "An 18-year-old man with attention-deficit-hyperactivity disorder (ADHD) was prescribed varenicline for smoking cessation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["prescribed"]], "start": [[76]], "entity_id": ["T10"]}, "Subject": {"text": [["An 18-year-old man with attention-deficit-hyperactivity disorder (ADHD)"]], "start": [[0]], "entity_id": ["T7"], "Age": {"text": [["18-year-old"]], "start": [[3]], "entity_id": ["T11"]}, "Gender": {"text": [["man"]], "start": [[15]], "entity_id": ["T12"]}, "Disorder": {"text": [["attention-deficit-hyperactivity disorder (ADHD)"]], "start": [[24]], "entity_id": ["T13"]}}, "Treatment": {"text": [["varenicline"]], "start": [[87]], "entity_id": ["T8"], "Drug": {"text": [["varenicline"]], "start": [[87]], "entity_id": ["T14"]}, "Disorder": {"text": [["smoking cessation"]], "start": [[103]], "entity_id": ["T15"]}}}]}]}
{"id": "3878320_2", "context": "The condition should be suspected in patients who develop unexplained abdominal pain or collapse following vasopressin treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["develop"]], "start": [[50]], "entity_id": ["T8"]}, "Subject": {"text": [["patients"]], "start": [[37]], "entity_id": ["T5"]}, "Effect": {"text": [["unexplained abdominal pain or collapse"]], "start": [[58]], "entity_id": ["T6"]}, "Treatment": {"text": [["vasopressin"]], "start": [[107]], "entity_id": ["T7"], "Drug": {"text": [["vasopressin"]], "start": [[107]], "entity_id": ["T9"]}}, "Speculated": {"text": [["suspected"]], "start": [[24]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "10357715_3", "context": "The present observation suggests, that a batch of different testing doses, including lower testing doses may help to differentiate between an allergic type of contact dermatitis and an irritant type of reaction after treatment with calcipotriol.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after treatment"]], "start": [[211]], "entity_id": ["T4"]}, "Treatment": {"text": [["calcipotriol"]], "start": [[232]], "entity_id": ["T6"], "Drug": {"text": [["calcipotriol"]], "start": [[232]], "entity_id": ["T7"]}}, "Effect": {"text": [["an allergic type of contact dermatitis", "an irritant type of reaction"]], "start": [[139, 182]], "entity_id": ["T3"]}, "Speculated": {"text": [["may"]], "start": [[105]], "entity_id": ["T5"], "value": true}}]}]}
{"id": "1068531_1", "context": "Acute erythroid leukemia after cyclophosphamide therapy for multiple myeloma: report of two cases.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[25]], "entity_id": ["T4"]}, "Effect": {"text": [["Acute erythroid leukemia"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["cyclophosphamide therapy"]], "start": [[31]], "entity_id": ["T5"], "Drug": {"text": [["cyclophosphamide"]], "start": [[31]], "entity_id": ["T9"]}, "Disorder": {"text": [["multiple myeloma"]], "start": [[60]], "entity_id": ["T10"]}}, "Subject": {"text": [["two cases"]], "start": [[88]], "entity_id": ["T6"], "Population": {"text": [["two"]], "start": [[88]], "entity_id": ["T8"]}}}]}]}
{"id": "1642627_1", "context": "A combination of behavioural and cognitive adverse effects is illustrated in this case report of a recurrent triazolam-induced eating disorder.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[119]], "entity_id": ["T4"]}, "Treatment": {"text": [["triazolam"]], "start": [[109]], "entity_id": ["T3"], "Drug": {"text": [["triazolam"]], "start": [[109]], "entity_id": ["T6"]}}, "Effect": {"text": [["eating disorder"]], "start": [[127]], "entity_id": ["T5"]}}]}]}
{"id": "15494638_2", "context": "5-fluorouracil (5-FU)-associated peripheral neuropathy is an uncommon event.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[22]], "entity_id": ["T7"]}, "Treatment": {"text": [["5-fluorouracil"]], "start": [[0]], "entity_id": ["T6"], "Drug": {"text": [["5-fluorouracil"]], "start": [[0]], "entity_id": ["T9"]}}, "Effect": {"text": [["peripheral neuropathy"]], "start": [[33]], "entity_id": ["T8"]}}]}]}
{"id": "8908396_2", "context": "Insulin-induced lipoatrophy in type I diabetes.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[8]], "entity_id": ["T4"]}, "Treatment": {"text": [["Insulin"]], "start": [[0]], "entity_id": ["T3"], "Disorder": {"text": [["type I diabetes"]], "start": [[31]], "entity_id": ["T6"]}, "Drug": {"text": [["Insulin"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["lipoatrophy"]], "start": [[16]], "entity_id": ["T5"]}}]}]}
{"id": "2327115_4", "context": "This article describes a patient with suspected ciprofloxacin-induced interstitial nephritis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[62]], "entity_id": ["T5"]}, "Treatment": {"text": [["ciprofloxacin"]], "start": [[48]], "entity_id": ["T3"], "Drug": {"text": [["ciprofloxacin"]], "start": [[48]], "entity_id": ["T7"]}}, "Subject": {"text": [["a patient"]], "start": [[23]], "entity_id": ["T4"]}, "Effect": {"text": [["interstitial nephritis"]], "start": [[70]], "entity_id": ["T6"]}, "Speculated": {"text": [["suspected"]], "start": [[38]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "10607332_1", "context": "We report 3 cases of HIV-1 infected patients who experienced symptomatic angiolipomas shortly after starting antiretroviral therapy including the protease inhibitor indinavir.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["experienced"]], "start": [[49]], "entity_id": ["T4"]}, "Subject": {"text": [["3 cases of HIV-1 infected patients"]], "start": [[10]], "entity_id": ["T3"], "Population": {"text": [["3"]], "start": [[10]], "entity_id": ["T7"]}}, "Effect": {"text": [["symptomatic angiolipomas"]], "start": [[61]], "entity_id": ["T5"]}, "Treatment": {"text": [["antiretroviral therapy including the protease inhibitor indinavir"]], "start": [[109]], "entity_id": ["T6"], "Disorder": {"text": [["HIV-1"]], "start": [[21]], "entity_id": ["T8"]}, "Drug": {"text": [["indinavir"]], "start": [[165]], "entity_id": ["T11"]}}, "Speculated": {"text": [["shortly after"]], "start": [[86]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "11093071_1", "context": "Depressive symptoms disappeared after interferon therapy was stopped.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[32]], "entity_id": ["T4"]}, "Treatment": {"text": [["interferon therapy"]], "start": [[38]], "entity_id": ["T3"], "Drug": {"text": [["interferon"]], "start": [[38]], "entity_id": ["T6"]}}, "Effect": {"text": [["Depressive symptoms"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "12776809_2", "context": "Coumarin is reported to elevate liver function tests (LFT) values.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reported"]], "start": [[12]], "entity_id": ["T5"]}, "Treatment": {"text": [["Coumarin"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Coumarin"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["elevate liver function tests (LFT) values"]], "start": [[24]], "entity_id": ["T6"]}}]}]}
{"id": "9723127_3", "context": "Decreased plasma cortisol level during alprazolam treatment of panic disorder: a case report.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[32]], "entity_id": ["T4"]}, "Effect": {"text": [["Decreased plasma cortisol level"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["alprazolam"]], "start": [[39]], "entity_id": ["T5"], "Drug": {"text": [["alprazolam"]], "start": [[39]], "entity_id": ["T6"]}, "Disorder": {"text": [["panic disorder"]], "start": [[63]], "entity_id": ["T7"]}}}]}]}
{"id": "8181372_1", "context": "Severe diffuse interstitial pneumonitis induced by carmustine (BCNU).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[40]], "entity_id": ["T5"]}, "Effect": {"text": [["diffuse interstitial pneumonitis"]], "start": [[7]], "entity_id": ["T4"]}, "Treatment": {"text": [["carmustine (BCNU)"]], "start": [[51]], "entity_id": ["T6"], "Drug": {"text": [["carmustine"]], "start": [[51]], "entity_id": ["T7"]}}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T8"], "value": "High"}}]}]}
{"id": "2394154_1", "context": "Fever, pulmonary infiltrates, and pleural effusion following acyclovir therapy for herpes zoster ophthalmicus.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[51]], "entity_id": ["T7"]}, "Effect": {"text": [["Fever, pulmonary infiltrates, and pleural effusion"]], "start": [[0]], "entity_id": ["T10"]}, "Treatment": {"text": [["acyclovir therapy for herpes zoster ophthalmicus"]], "start": [[61]], "entity_id": ["T8"], "Disorder": {"text": [["herpes zoster ophthalmicus"]], "start": [[83]], "entity_id": ["T9"]}, "Drug": {"text": [["acyclovir"]], "start": [[61]], "entity_id": ["T11"]}}}]}]}
{"id": "1584367_2", "context": "We propose a mechanism of vancomycin-induced mast cell degranulation and subsequent release of eosinophil chemotactic factor as a cause of CSFE.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[37]], "entity_id": ["T6"]}, "Effect": {"text": [["mast cell degranulation and subsequent release of eosinophil chemotactic factor as a cause of CSFE"]], "start": [[45]], "entity_id": ["T3"]}, "Treatment": {"text": [["vancomycin"]], "start": [[26]], "entity_id": ["T5"], "Drug": {"text": [["vancomycin"]], "start": [[26]], "entity_id": ["T7"]}}, "Speculated": {"text": [["propose"]], "start": [[3]], "entity_id": ["T4"], "value": true}}]}]}
{"id": "6837655_3", "context": "Within 3 weeks of beginning continuous daily isoniazid and rifampin therapy for pulmonary tuberculosis, a patient developed acute renal failure.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[114]], "entity_id": ["T7"]}, "Treatment": {"text": [["Within 3 weeks of beginning continuous daily isoniazid and rifampin"]], "start": [[0]], "entity_id": ["T4"], "Disorder": {"text": [["pulmonary tuberculosis"]], "start": [[80]], "entity_id": ["T5"]}, "Time_elapsed": {"text": [["Within 3 weeks of beginning"]], "start": [[0]], "entity_id": ["T9"]}, "Freq": {"text": [["daily"]], "start": [[39]], "entity_id": ["T10"]}, "Drug": {"text": [["isoniazid"], ["rifampin"]], "start": [[45], [59]], "entity_id": ["T11", "T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[55]], "entity_id": ["T13"]}, "Drug": {"text": [["isoniazid"], ["rifampin"]], "start": [[45], [59]], "entity_id": ["T11", "T12"]}}]}, "Subject": {"text": [["a patient"]], "start": [[104]], "entity_id": ["T6"]}, "Effect": {"text": [["acute renal failure"]], "start": [[124]], "entity_id": ["T8"]}}]}]}
{"id": "8862924_5", "context": "We report four cases of severe corneal ulceration in methamphetamine abusers.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[50]], "entity_id": ["T6"]}, "Subject": {"text": [["four cases"]], "start": [[10]], "entity_id": ["T3"], "Population": {"text": [["four"]], "start": [[10]], "entity_id": ["T7"]}}, "Effect": {"text": [["corneal ulceration"]], "start": [[31]], "entity_id": ["T4"]}, "Treatment": {"text": [["methamphetamine"]], "start": [[53]], "entity_id": ["T5"], "Drug": {"text": [["methamphetamine"]], "start": [[53]], "entity_id": ["T8"]}}, "Severity": {"text": [["severe"]], "start": [[24]], "entity_id": ["T9"], "value": "High"}}]}]}
{"id": "7375145_1", "context": "Diagnosis: practolol induced sclerosing peritonitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[21]], "entity_id": ["T3"]}, "Treatment": {"text": [["practolol"]], "start": [[11]], "entity_id": ["T4"], "Drug": {"text": [["practolol"]], "start": [[11]], "entity_id": ["T6"]}}, "Effect": {"text": [["sclerosing peritonitis"]], "start": [[29]], "entity_id": ["T5"]}}]}]}
{"id": "19039026_2", "context": "We report the first biopsy confirmed occurrence of acute interstitial nephritis in a patient receiving treatment with Sunitinib for metastatic renal cell cancer.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurrence"]], "start": [[37]], "entity_id": ["T4"]}, "Effect": {"text": [["acute interstitial nephritis"]], "start": [[51]], "entity_id": ["T3"]}, "Subject": {"text": [["patient"]], "start": [[85]], "entity_id": ["T5"]}, "Treatment": {"text": [["Sunitinib"]], "start": [[118]], "entity_id": ["T6"], "Disorder": {"text": [["metastatic renal cell cancer"]], "start": [[132]], "entity_id": ["T7"]}, "Drug": {"text": [["Sunitinib"]], "start": [[118]], "entity_id": ["T9"]}}}]}]}
{"id": "12111771_3", "context": "Multiple pulmonary nodules: an unusual presentation of fludarabine pulmonary toxicity: case report and review of literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["presentation"]], "start": [[39]], "entity_id": ["T7"]}, "Effect": {"text": [["Multiple pulmonary nodules"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["fludarabine"]], "start": [[55]], "entity_id": ["T6"], "Drug": {"text": [["fludarabine"]], "start": [[55]], "entity_id": ["T8"]}}}]}]}
{"id": "19995222_1", "context": "Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[10]], "entity_id": ["T5"]}, "Subject": {"text": [["schizophrenic patients"]], "start": [[40]], "entity_id": ["T3"]}, "Treatment": {"text": [["Clozapine"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Clozapine"]], "start": [[0]], "entity_id": ["T8"]}, "Disorder": {"text": [["schizophrenic"]], "start": [[40]], "entity_id": ["T9"]}}, "Effect": {"text": [["tardive dyskinesia"]], "start": [[18]], "entity_id": ["T6"]}}]}]}
{"id": "9701106_4", "context": "Recently, her serum theophylline levels had increased to the toxic range (133.2 micromol/L [24 microg/mL]) shortly after the addition of zafirlukast (Accolate, Zeneca Pharmaceuticals, Wilmington, Del) to her regimen.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[115]], "entity_id": ["T7"]}, "Effect": {"text": [["theophylline levels had increased to the toxic range"]], "start": [[20]], "entity_id": ["T5"]}, "Treatment": {"text": [["zafirlukast"]], "start": [[137]], "entity_id": ["T6"], "Drug": {"text": [["zafirlukast"]], "start": [[137]], "entity_id": ["T10"]}}, "Subject": {"text": [["her"]], "start": [[10]], "entity_id": ["T8"], "Gender": {"text": [["her"]], "start": [[10]], "entity_id": ["T9"]}}}]}]}
{"id": "2738729_2", "context": "Withdrawal emergent syndrome in an infant associated with maternal haloperidol therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[42]], "entity_id": ["T5"]}, "Effect": {"text": [["Withdrawal emergent syndrome"]], "start": [[0]], "entity_id": ["T3"]}, "Subject": {"text": [["an infant"]], "start": [[32]], "entity_id": ["T4"], "Age": {"text": [["infant"]], "start": [[35]], "entity_id": ["T7"]}}, "Treatment": {"text": [["maternal haloperidol therapy"]], "start": [[58]], "entity_id": ["T6"], "Drug": {"text": [["haloperidol"]], "start": [[67]], "entity_id": ["T8"]}, "Route": {"text": [["maternal"]], "start": [[58]], "entity_id": ["T9"]}}}]}]}
{"id": "812008_1", "context": "Diphenylhydantoin apparently adversely affected both the clinical and biochemical parameters of the acute intermittent porphyria.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["affected"]], "start": [[39]], "entity_id": ["T5"]}, "Treatment": {"text": [["Diphenylhydantoin"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Diphenylhydantoin"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["adversely affected both the clinical and biochemical parameters of the acute intermittent porphyria"]], "start": [[29]], "entity_id": ["T4"]}}]}]}
{"id": "15852680_1", "context": "Successful recovery from interstitial pneumonitis, induced by bicalutamide and leuprorelin acetate given as treatment for prostate cancer.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[51]], "entity_id": ["T6"]}, "Treatment": {"text": [["bicalutamide and leuprorelin acetate"]], "start": [[62]], "entity_id": ["T4"], "Drug": {"text": [["bicalutamide"], ["leuprorelin acetate"]], "start": [[62], [79]], "entity_id": ["T10", "T11"]}, "Disorder": {"text": [["prostate cancer"]], "start": [[122]], "entity_id": ["T5"]}, "Combination": [{"event_id": "E3", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[75]], "entity_id": ["T9"]}, "Drug": {"text": [["bicalutamide"], ["leuprorelin acetate"]], "start": [[62], [79]], "entity_id": ["T10", "T11"]}}]}, "Effect": {"text": [["interstitial pneumonitis"]], "start": [[25]], "entity_id": ["T7"]}}]}]}
{"id": "3438585_1", "context": "Gold-induced pneumonitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[5]], "entity_id": ["T5"]}, "Treatment": {"text": [["Gold"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Gold"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["pneumonitis"]], "start": [[13]], "entity_id": ["T6"]}}]}]}
{"id": "12921505_4", "context": "OBJECTIVE: To report a case of significant hepatic and renal failure with the use of argatroban in a patient with heparin-induced thrombocytopenia (HIT) requiring continuous veno-veno hemodialysis (CVVHD).", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["use"]], "start": [[78]], "entity_id": ["T8"]}, "Effect": {"text": [["significant hepatic and renal failure"]], "start": [[31]], "entity_id": ["T5"]}, "Treatment": {"text": [["argatroban"]], "start": [[85]], "entity_id": ["T6"], "Drug": {"text": [["argatroban"]], "start": [[85]], "entity_id": ["T10"]}}, "Subject": {"text": [["a patient with heparin-induced thrombocytopenia (HIT) requiring continuous veno-veno hemodialysis (CVVHD)"]], "start": [[99]], "entity_id": ["T7"], "Disorder": {"text": [["heparin-induced thrombocytopenia (HIT)"]], "start": [[114]], "entity_id": ["T9"]}}, "Severity": {"text": [["significant"]], "start": [[31]], "entity_id": ["T11"], "value": "High"}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[122]], "entity_id": ["T1"]}, "Treatment": {"text": [["heparin"]], "start": [[114]], "entity_id": ["T2"], "Drug": {"text": [["heparin"]], "start": [[114]], "entity_id": ["T3"]}}, "Effect": {"text": [["thrombocytopenia"]], "start": [[130]], "entity_id": ["T4"]}}]}]}
{"id": "20378385_2", "context": "Visceral leishmaniasis and macrophagic activation syndrome in a patient with rheumatoid arthritis under treatment with adalimumab.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["under"]], "start": [[98]], "entity_id": ["T5"]}, "Treatment": {"text": [["adalimumab"]], "start": [[119]], "entity_id": ["T6"], "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[77]], "entity_id": ["T10"]}, "Drug": {"text": [["adalimumab"]], "start": [[119]], "entity_id": ["T11"]}}, "Effect": {"text": [["Visceral leishmaniasis and macrophagic activation syndrome"]], "start": [[0]], "entity_id": ["T7"]}, "Subject": {"text": [["a patient with rheumatoid arthritis"]], "start": [[62]], "entity_id": ["T8"]}}]}]}
{"id": "11215836_1", "context": "He was diagnosed with possible serotonin syndrome; his symptoms resolved after clomipramine was stopped but before clozapine was restarted eight days later.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resolved"]], "start": [[64]], "entity_id": ["T4"]}, "Effect": {"text": [["possible serotonin syndrome"]], "start": [[22]], "entity_id": ["T3"]}, "Treatment": {"text": [["clozapine"]], "start": [[115]], "entity_id": ["T5"], "Drug": {"text": [["clozapine"]], "start": [[115]], "entity_id": ["T8"]}}, "Subject": {"text": [["He"]], "start": [[0]], "entity_id": ["T6"], "Gender": {"text": [["He"]], "start": [[0]], "entity_id": ["T9"]}}}]}]}
{"id": "15878975_2", "context": "Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[94]], "entity_id": ["T8"]}, "Treatment": {"text": [["Rh(0)(D) immune globulin intravenous"]], "start": [[104]], "entity_id": ["T7"], "Drug": {"text": [["Rh(0)(D) immune globulin"]], "start": [[104]], "entity_id": ["T11"]}, "Route": {"text": [["intravenous"]], "start": [[129]], "entity_id": ["T12"]}, "Disorder": {"text": [["immune thrombocytopenic purpura"]], "start": [[160]], "entity_id": ["T13"]}}, "Effect": {"text": [["Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria"]], "start": [[0]], "entity_id": ["T9"]}}]}]}
{"id": "6484655_3", "context": "Two patients had ampicillin-associated seizures.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[28]], "entity_id": ["T4"]}, "Treatment": {"text": [["ampicillin"]], "start": [[17]], "entity_id": ["T3"], "Drug": {"text": [["ampicillin"]], "start": [[17]], "entity_id": ["T6"]}}, "Effect": {"text": [["seizures"]], "start": [[39]], "entity_id": ["T5"]}}]}]}
{"id": "15197722_1", "context": "A patient developed restless legs symptoms paralleling the course of interferon-alpha (IFN alpha) therapy for chronic hepatitis C.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[10]], "entity_id": ["T5"]}, "Subject": {"text": [["A patient"]], "start": [[0]], "entity_id": ["T4"]}, "Effect": {"text": [["restless legs symptoms"]], "start": [[20]], "entity_id": ["T6"]}, "Treatment": {"text": [["interferon-alpha (IFN alpha) therapy"]], "start": [[69]], "entity_id": ["T7"], "Drug": {"text": [["interferon-alpha"]], "start": [[69]], "entity_id": ["T9"]}, "Disorder": {"text": [["chronic hepatitis C"]], "start": [[110]], "entity_id": ["T10"]}}}]}]}
{"id": "16005413_9", "context": "While many can benefit from coadministration of serotonergic antidepressants and opioids, it appears that some individuals are at increased risk for SS.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["risk"]], "start": [[140]], "entity_id": ["T9"]}, "Effect": {"text": [["SS"]], "start": [[149]], "entity_id": ["T8"]}, "Subject": {"text": [["some individuals"]], "start": [[106]], "entity_id": ["T10"]}, "Treatment": {"text": [["coadministration of serotonergic antidepressants and opioids"]], "start": [[28]], "entity_id": ["T11"], "Drug": {"text": [["serotonergic antidepressants"], ["opioids"]], "start": [[48], [81]], "entity_id": ["T13", "T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["coadministration"]], "start": [[28]], "entity_id": ["T12"]}, "Drug": {"text": [["opioids"], ["serotonergic antidepressants"]], "start": [[81], [48]], "entity_id": ["T14", "T13"]}}]}}]}]}
{"id": "10099659_3", "context": "Stomatitis, diarrhea, dermatitis, and myelosuppression are the main toxicities of 5-FU.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["toxicities"]], "start": [[68]], "entity_id": ["T8"]}, "Treatment": {"text": [["5-FU"]], "start": [[82]], "entity_id": ["T9"], "Drug": {"text": [["5-FU"]], "start": [[82]], "entity_id": ["T11"]}}, "Effect": {"text": [["diarrhea", "dermatitis", "myelosuppression", "Stomatitis"]], "start": [[12, 22, 38, 0]], "entity_id": ["T10"]}}]}]}
{"id": "8921647_1", "context": "After treatment with cimetidine, there was a rapid deterioration with decreased oxygen saturation and arterial PO2 values.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["was"]], "start": [[39]], "entity_id": ["T4"]}, "Treatment": {"text": [["cimetidine"]], "start": [[21]], "entity_id": ["T3"], "Drug": {"text": [["cimetidine"]], "start": [[21]], "entity_id": ["T6"]}}, "Effect": {"text": [["a rapid deterioration with decreased oxygen saturation and arterial PO2 values"]], "start": [[43]], "entity_id": ["T5"]}}]}]}
{"id": "11487721_3", "context": "We describe a case of advanced ovarian carcinoma who developed difficulty walking because of marked pain in the lower extremities and loss of proprioception 25 days after treatment with weekly taxol (80 mg/m(2)x3).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[53]], "entity_id": ["T7"]}, "Effect": {"text": [["difficulty walking because of marked pain in the lower extremities and loss of proprioception"]], "start": [[63]], "entity_id": ["T8"]}, "Treatment": {"text": [["25 days after treatment with weekly taxol (80 mg/m(2)x3)"]], "start": [[157]], "entity_id": ["T9"], "Time_elapsed": {"text": [["25 days"]], "start": [[157]], "entity_id": ["T13"]}, "Drug": {"text": [["taxol"]], "start": [[193]], "entity_id": ["T14"]}, "Freq": {"text": [["weekly"]], "start": [[186]], "entity_id": ["T15"]}, "Dosage": {"text": [["80 mg/m(2)x3"]], "start": [[200]], "entity_id": ["T16"]}, "Disorder": {"text": [["advanced ovarian carcinoma"]], "start": [[22]], "entity_id": ["T17"]}}, "Subject": {"text": [["a case of advanced ovarian carcinoma"]], "start": [[12]], "entity_id": ["T10"]}, "Severity": {"text": [["marked"]], "start": [[93]], "entity_id": ["T12"], "value": "High"}}]}]}
{"id": "11722307_1", "context": "Agranulocytosis and granulocytopenia associated with quetiapine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[37]], "entity_id": ["T6"]}, "Effect": {"text": [["Agranulocytosis and granulocytopenia"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["quetiapine"]], "start": [[53]], "entity_id": ["T7"], "Drug": {"text": [["quetiapine"]], "start": [[53]], "entity_id": ["T8"]}}}]}]}
{"id": "16029707_3", "context": "The multiple comedones and ruptured epidermoid cysts are newly reported adverse effects of imiquimod therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reported"]], "start": [[63]], "entity_id": ["T7"]}, "Effect": {"text": [["multiple comedones and ruptured epidermoid cysts"]], "start": [[4]], "entity_id": ["T5"]}, "Treatment": {"text": [["imiquimod therapy"]], "start": [[91]], "entity_id": ["T6"], "Drug": {"text": [["imiquimod"]], "start": [[91]], "entity_id": ["T8"]}}}]}]}
{"id": "2305654_1", "context": "We conclude that neurosurgeons and neurologists should be aware of calcium antagonist--related ileus in patients treated with nimodipine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[87]], "entity_id": ["T4"]}, "Treatment": {"text": [["calcium antagonist", "nimodipine"]], "start": [[67, 126]], "entity_id": ["T3"], "Drug": {"text": [["nimodipine"]], "start": [[126]], "entity_id": ["T7"]}}, "Effect": {"text": [["ileus"]], "start": [[95]], "entity_id": ["T5"]}, "Subject": {"text": [["patients"]], "start": [[104]], "entity_id": ["T6"]}}]}]}
{"id": "12932249_1", "context": "Hyperpigmentation during interferon-alpha therapy for chronic hepatitis C virus infection.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[18]], "entity_id": ["T6"]}, "Effect": {"text": [["Hyperpigmentation"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["interferon-alpha therapy"]], "start": [[25]], "entity_id": ["T4"], "Drug": {"text": [["interferon-alpha"]], "start": [[25]], "entity_id": ["T7"]}, "Disorder": {"text": [["chronic hepatitis C virus infection"]], "start": [[54]], "entity_id": ["T8"]}}}]}]}
{"id": "6142995_1", "context": "Chlorambucil-induced chromosome damage to human lymphocytes is dose-dependent and cumulative.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[13]], "entity_id": ["T6"]}, "Treatment": {"text": [["Chlorambucil"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Chlorambucil"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["chromosome damage"]], "start": [[21]], "entity_id": ["T7"]}}]}]}
{"id": "17705565_1", "context": "Carbamazepine hypersensitivity syndrome is a rare, life-threatening condition.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["is"]], "start": [[40]], "entity_id": ["T5"]}, "Treatment": {"text": [["Carbamazepine"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Carbamazepine"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["hypersensitivity syndrome"]], "start": [[14]], "entity_id": ["T4"]}}]}]}
{"id": "3195622_3", "context": "Case report: dapsone hypersensitivity syndrome associated with treatment of the bite of a brown recluse spider.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[47]], "entity_id": ["T5"]}, "Treatment": {"text": [["dapsone"]], "start": [[13]], "entity_id": ["T3"], "Drug": {"text": [["dapsone"]], "start": [[13]], "entity_id": ["T6"]}}, "Effect": {"text": [["hypersensitivity syndrome"]], "start": [[21]], "entity_id": ["T4"]}}]}]}
{"id": "11706664_1", "context": "Acute asymptomatic hepatitis in a healthy normal volunteer exposed to 2 oral doses of amodiaquine and artesunate.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["exposed"]], "start": [[59]], "entity_id": ["T6"]}, "Effect": {"text": [["Acute asymptomatic hepatitis"]], "start": [[0]], "entity_id": ["T4"]}, "Subject": {"text": [["a healthy normal volunteer"]], "start": [[32]], "entity_id": ["T5"]}, "Treatment": {"text": [["2 oral doses of amodiaquine and artesunate"]], "start": [[70]], "entity_id": ["T7"], "Route": {"text": [["oral"]], "start": [[72]], "entity_id": ["T8"]}, "Dosage": {"text": [["2"]], "start": [[70]], "entity_id": ["T9"]}, "Drug": {"text": [["amodiaquine"], ["artesunate"]], "start": [[86], [102]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[98]], "entity_id": ["T12"]}, "Drug": {"text": [["artesunate"], ["amodiaquine"]], "start": [[102], [86]], "entity_id": ["T11", "T10"]}}]}}]}]}
{"id": "3753891_3", "context": "The authors report a case of focal myocardial necrosis, presenting clinically as an acute myocardial infarction during the administration of the antineoplastic drug, amsacrine, in a patient without coronary artery disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[112]], "entity_id": ["T8"]}, "Subject": {"text": [["a patient without coronary artery disease"]], "start": [[180]], "entity_id": ["T5"]}, "Treatment": {"text": [["amsacrine"]], "start": [[166]], "entity_id": ["T6"], "Drug": {"text": [["amsacrine"]], "start": [[166]], "entity_id": ["T9"]}}, "Effect": {"text": [["focal myocardial necrosis, presenting clinically as an acute myocardial infarction"]], "start": [[29]], "entity_id": ["T7"]}}]}]}
{"id": "17420198_8", "context": "Baclofen and oxazepam were prescribed secondary to right-sided hemiparesis contractures.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["prescribed"]], "start": [[27]], "entity_id": ["T7"]}, "Treatment": {"text": [["oxazepam", "Baclofen"]], "start": [[13, 0]], "entity_id": ["T6"], "Disorder": {"text": [["right-sided hemiparesis contractures"]], "start": [[51]], "entity_id": ["T8"]}, "Drug": {"text": [["Baclofen"], ["oxazepam"]], "start": [[0], [13]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[9]], "entity_id": ["T9"]}, "Drug": {"text": [["oxazepam"], ["Baclofen"]], "start": [[13], [0]], "entity_id": ["T11", "T10"]}}]}}]}]}
{"id": "11918514_2", "context": "DISCUSSION: A review of the cases of SS with implication of mirtazapine as the cause was performed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["implication of"]], "start": [[45]], "entity_id": ["T4"]}, "Treatment": {"text": [["mirtazapine"]], "start": [[60]], "entity_id": ["T3"], "Drug": {"text": [["mirtazapine"]], "start": [[60]], "entity_id": ["T6"]}}, "Effect": {"text": [["SS"]], "start": [[37]], "entity_id": ["T5"]}}]}]}
{"id": "16968538_3", "context": "A small number of oxaliplatin-related hemolytic and/or thrombocytopenic reactions have been reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[30]], "entity_id": ["T7"]}, "Treatment": {"text": [["oxaliplatin"]], "start": [[18]], "entity_id": ["T6"], "Drug": {"text": [["oxaliplatin"]], "start": [[18]], "entity_id": ["T9"]}}, "Effect": {"text": [["hemolytic and/or thrombocytopenic reactions"]], "start": [[38]], "entity_id": ["T8"]}}]}]}
{"id": "10410183_3", "context": "CASE SUMMARY: A 39-year-old white Jewish schizophrenic man treated with olanzapine developed an elevated serum CK concentration with a peak concentration of 4000 IU/L (normal < 230).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[83]], "entity_id": ["T10"]}, "Subject": {"text": [["A 39-year-old white Jewish schizophrenic man"]], "start": [[14]], "entity_id": ["T8"], "Age": {"text": [["39-year-old"]], "start": [[16]], "entity_id": ["T12"]}, "Race": {"text": [["white Jewish"]], "start": [[28]], "entity_id": ["T13"]}, "Gender": {"text": [["man"]], "start": [[55]], "entity_id": ["T15"]}}, "Effect": {"text": [["an elevated serum CK concentration"]], "start": [[93]], "entity_id": ["T9"]}, "Treatment": {"text": [["olanzapine"]], "start": [[72]], "entity_id": ["T11"], "Disorder": {"text": [["schizophrenic"]], "start": [[41]], "entity_id": ["T14"]}, "Drug": {"text": [["olanzapine"]], "start": [[72]], "entity_id": ["T16"]}}}]}]}
{"id": "23624139_1", "context": "Severe water intoxication secondary to the concomitant intake of non-steroidal anti-inflammatory drugs and desmopressin: a case report and review of the literature.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["secondary to"]], "start": [[26]], "entity_id": ["T6"]}, "Effect": {"text": [["Severe water intoxication"]], "start": [[0]], "entity_id": ["T7"]}, "Treatment": {"text": [["the concomitant intake of non-steroidal anti-inflammatory drugs and desmopressin"]], "start": [[39]], "entity_id": ["T8"], "Drug": {"text": [["non-steroidal anti-inflammatory drugs"], ["desmopressin"]], "start": [[65], [107]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["concomitant"]], "start": [[43]], "entity_id": ["T12"]}, "Drug": {"text": [["non-steroidal anti-inflammatory drugs"], ["desmopressin"]], "start": [[65], [107]], "entity_id": ["T10", "T11"]}}]}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T9"], "value": "High"}}]}]}
{"id": "17671884_3", "context": "An apparent link is described between the use of MMF with prednisone to treat pemphigus vulgaris and the development of red blood cell anemia.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["development"]], "start": [[105]], "entity_id": ["T9"]}, "Effect": {"text": [["red blood cell anemia"]], "start": [[120]], "entity_id": ["T10"]}, "Treatment": {"text": [["MMF with prednisone to treat pemphigus vulgaris"]], "start": [[49]], "entity_id": ["T8"], "Disorder": {"text": [["pemphigus vulgaris"]], "start": [[78]], "entity_id": ["T11"]}, "Drug": {"text": [["MMF"], ["prednisone"]], "start": [[49], [58]], "entity_id": ["T14", "T15"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["with"]], "start": [[53]], "entity_id": ["T16"]}, "Drug": {"text": [["MMF"], ["prednisone"]], "start": [[49], [58]], "entity_id": ["T14", "T15"]}}]}, "Speculated": {"text": [["apparent"]], "start": [[3]], "entity_id": ["T12"], "value": true}}]}]}
{"id": "9256906_3", "context": "Other potential causes of renal failure were not present in our patient and his renal function gradually recovered with the cessation of suramin treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["recovered"]], "start": [[105]], "entity_id": ["T9"]}, "Treatment": {"text": [["cessation of suramin treatmen"]], "start": [[124]], "entity_id": ["T3"], "Drug": {"text": [["suramin"]], "start": [[137]], "entity_id": ["T7"]}, "Dosage": {"text": [["cessation"]], "start": [[124]], "entity_id": ["T8"]}}, "Subject": {"text": [["our patient"]], "start": [[60]], "entity_id": ["T6"]}, "Effect": {"text": [["his renal function gradually recovered"]], "start": [[76]], "entity_id": ["T5"]}}]}]}
{"id": "11435808_2", "context": "Massive CBZ OD may produce a reversible encephalopathy that includes cortical hyperexcitability, a profound burst-suppression EEG pattern, and cranial nerve areflexia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["produce"]], "start": [[19]], "entity_id": ["T10"]}, "Treatment": {"text": [["Massive CBZ OD"]], "start": [[0]], "entity_id": ["T9"], "Dosage": {"text": [["OD"]], "start": [[12]], "entity_id": ["T12"]}, "Drug": {"text": [["CBZ"]], "start": [[8]], "entity_id": ["T13"]}}, "Effect": {"text": [["reversible encephalopathy that includes cortical hyperexcitability, a profound burst-suppression EEG pattern, and cranial nerve areflexia"]], "start": [[29]], "entity_id": ["T11"]}, "Speculated": {"text": [["may"]], "start": [[15]], "entity_id": ["T14"], "value": true}}]}]}
{"id": "10755579_3", "context": "This is the first report of a fluoxetine-related death in a child with a confirmed genetic polymorphism of the CYP2D6 gene that results in impaired drug metabolism.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[41]], "entity_id": ["T6"]}, "Treatment": {"text": [["fluoxetine"]], "start": [[30]], "entity_id": ["T3"], "Drug": {"text": [["fluoxetine"]], "start": [[30]], "entity_id": ["T9"]}}, "Effect": {"text": [["death"]], "start": [[49]], "entity_id": ["T4"]}, "Subject": {"text": [["a child with a confirmed genetic polymorphism of the CYP2D6 gene that results in impaired drug metabolism"]], "start": [[58]], "entity_id": ["T5"], "Age": {"text": [["child"]], "start": [[60]], "entity_id": ["T7"]}, "Disorder": {"text": [["genetic polymorphism of the CYP2D6 gene that results in impaired drug metabolism"]], "start": [[83]], "entity_id": ["T10"]}}}]}]}
{"id": "16025424_2", "context": "We report a case of reversible DKA and new-onset DM that developed in a demented patient who was treated with quetiapine for 14 days.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[57]], "entity_id": ["T7"]}, "Treatment": {"text": [["quetiapine for 14 days"]], "start": [[110]], "entity_id": ["T5"], "Disorder": {"text": [["demented"]], "start": [[72]], "entity_id": ["T9"]}, "Drug": {"text": [["quetiapine"]], "start": [[110]], "entity_id": ["T10"]}, "Duration": {"text": [["14 days"]], "start": [[125]], "entity_id": ["T11"]}}, "Subject": {"text": [["demented patient"]], "start": [[72]], "entity_id": ["T6"]}, "Effect": {"text": [["reversible DKA and new-onset DM"]], "start": [[20]], "entity_id": ["T8"]}}]}]}
{"id": "12811715_4", "context": "We describe 3 cases of diphenhydramine-induced cardiac toxicity that were responsive to bicarbonate.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[39]], "entity_id": ["T4"]}, "Treatment": {"text": [["diphenhydramine"]], "start": [[23]], "entity_id": ["T3"], "Drug": {"text": [["diphenhydramine"]], "start": [[23]], "entity_id": ["T7"]}}, "Effect": {"text": [["cardiac toxicity"]], "start": [[47]], "entity_id": ["T5"]}, "Subject": {"text": [["3 cases"]], "start": [[12]], "entity_id": ["T8"], "Population": {"text": [["3"]], "start": [[12]], "entity_id": ["T9"]}}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["responsive"]], "start": [[74]], "entity_id": ["T13"]}, "Subject": {"text": [["3 cases"]], "start": [[12]], "entity_id": ["T8"], "Population": {"text": [["3"]], "start": [[12]], "entity_id": ["T9"]}}, "Treatment": {"text": [["bicarbonate"]], "start": [[88]], "entity_id": ["T11"], "Disorder": {"text": [["diphenhydramine-induced cardiac toxicity"]], "start": [[23]], "entity_id": ["T10"]}, "Drug": {"text": [["bicarbonate"]], "start": [[88]], "entity_id": ["T12"]}}}]}]}
{"id": "17298107_1", "context": "The patient's arthritis flared after the second infusion of infliximab, which was discontinued.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[31]], "entity_id": ["T5"]}, "Effect": {"text": [["arthritis flared"]], "start": [[14]], "entity_id": ["T3"]}, "Subject": {"text": [["patient's"]], "start": [[4]], "entity_id": ["T4"]}, "Treatment": {"text": [["second infusion of infliximab"]], "start": [[41]], "entity_id": ["T6"], "Drug": {"text": [["infliximab"]], "start": [[60]], "entity_id": ["T8"]}, "Route": {"text": [["infusion"]], "start": [[48]], "entity_id": ["T7"]}, "Time_elapsed": {"text": [["second"]], "start": [[41]], "entity_id": ["T9"]}}}]}]}
{"id": "11077455_1", "context": "CONCLUSION: Marked visual field constriction appears to be associated with vigabatrin therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[59]], "entity_id": ["T4"]}, "Effect": {"text": [["Marked visual field constriction"]], "start": [[12]], "entity_id": ["T3"]}, "Treatment": {"text": [["vigabatrin therapy"]], "start": [[75]], "entity_id": ["T5"], "Drug": {"text": [["vigabatrin"]], "start": [[75]], "entity_id": ["T6"]}}}]}]}
{"id": "11215836_3", "context": "Possible serotonin syndrome associated with clomipramine after withdrawal of clozapine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[57]], "entity_id": ["T5"]}, "Effect": {"text": [["serotonin syndrome associated with clomipramine"]], "start": [[9]], "entity_id": ["T4"]}, "Treatment": {"text": [["withdrawal of clozapine"]], "start": [[63]], "entity_id": ["T6"], "Drug": {"text": [["clozapine"], ["clomipramine"]], "start": [[77], [44]], "entity_id": ["T8", "T9"]}}, "Speculated": {"text": [["Possible"]], "start": [[0]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "1295628_2", "context": "A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; Tegretol) used against benign Rolandic epilepsy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[21]], "entity_id": ["T19"]}, "Subject": {"text": [["A 14-year-old female"]], "start": [[0]], "entity_id": ["T16"], "Age": {"text": [["14-year-old"]], "start": [[2]], "entity_id": ["T20"]}, "Gender": {"text": [["female"]], "start": [[14]], "entity_id": ["T21"]}}, "Effect": {"text": [["systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and positive anti-nuclear antibody (ANA)"]], "start": [[31]], "entity_id": ["T17"]}, "Treatment": {"text": [["administration of carbamazepine (CBZ; Tegretol) used against benign Rolandic epilepsy"]], "start": [[162]], "entity_id": ["T18"], "Drug": {"text": [["carbamazepine"]], "start": [[180]], "entity_id": ["T22"]}, "Disorder": {"text": [["benign Rolandic epilepsy"]], "start": [[223]], "entity_id": ["T23"]}}}]}]}
{"id": "6236730_2", "context": "There was a clear relationship between restarting the Accutane and recurrence of the transient myopia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["a clear relationship"]], "start": [[10]], "entity_id": ["T3"]}, "Treatment": {"text": [["Accutane"]], "start": [[54]], "entity_id": ["T4"], "Drug": {"text": [["Accutane"]], "start": [[54]], "entity_id": ["T6"]}}, "Effect": {"text": [["recurrence of the transient myopia"]], "start": [[67]], "entity_id": ["T5"]}}]}]}
{"id": "7718983_3", "context": "Graves' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[59]], "entity_id": ["T6"]}, "Effect": {"text": [["Graves' hyperthyroidism following transient thyrotoxicosis"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["interferon therapy"]], "start": [[66]], "entity_id": ["T7"], "Drug": {"text": [["interferon therapy"]], "start": [[66]], "entity_id": ["T9"]}, "Disorder": {"text": [["chronic hepatitis type C"]], "start": [[89]], "entity_id": ["T10"]}}}]}]}
{"id": "1445134_4", "context": "Masculinization of a female fetus occurred in 5 of 39 (12.8%) exposed to norethisterone; all were cases of clitoral hypertrophy not requiring surgical treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["exposed"]], "start": [[62]], "entity_id": ["T8"]}, "Effect": {"text": [["Masculinization of a female fetus", "clitoral hypertrophy"]], "start": [[0, 107]], "entity_id": ["T5"]}, "Subject": {"text": [["5 of 39 (12.8%)"]], "start": [[46]], "entity_id": ["T6"], "Population": {"text": [["5 of 39 (12.8%)"]], "start": [[46]], "entity_id": ["T9"]}}, "Treatment": {"text": [["norethisterone"]], "start": [[73]], "entity_id": ["T7"], "Drug": {"text": [["norethisterone"]], "start": [[73]], "entity_id": ["T10"]}}, "Severity": {"text": [["not requiring surgical treatment"]], "start": [[128]], "entity_id": ["T11"], "value": "Low"}}]}]}
{"id": "9161656_16", "context": "She continued taking verapamil for 6 months, then, on her own, stopped all medications including the sustained-release verapamil, and her asthma symptoms disappeared.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["disappeared"]], "start": [[154]], "entity_id": ["T4"]}, "Subject": {"text": [["She"]], "start": [[0]], "entity_id": ["T5"], "Gender": {"text": [["She"]], "start": [[0]], "entity_id": ["T7"]}}, "Treatment": {"text": [["continued taking verapamil for 6 months, then, on her own, stopped all medications including the sustained-release verapamil"]], "start": [[4]], "entity_id": ["T6"], "Disorder": {"text": [["asthma"]], "start": [[138]], "entity_id": ["T3"]}, "Drug": {"text": [["verapamil"]], "start": [[21]], "entity_id": ["T8"]}, "Duration": {"text": [["for 6 months"]], "start": [[31]], "entity_id": ["T9"]}}}]}]}
{"id": "9311175_2", "context": "Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reactions"]], "start": [[131]], "entity_id": ["T23"]}, "Treatment": {"text": [["cisplatin", "involving intrahepatic artery infusion"]], "start": [[144, 160]], "entity_id": ["T26"], "Drug": {"text": [["cisplatin"]], "start": [[144]], "entity_id": ["T33"]}, "Disorder": {"text": [["ovarian cancer"]], "start": [[18]], "entity_id": ["T32"]}, "Route": {"text": [["intrahepatic artery infusion"]], "start": [[170]], "entity_id": ["T27"]}}, "Subject": {"text": [["one"]], "start": [[155]], "entity_id": ["T22"]}, "Effect": {"text": [["manifested general erythema, dyspnea, and hypotension"]], "start": [[200]], "entity_id": ["T24"]}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["reactions"]], "start": [[131]], "entity_id": ["T23"]}, "Subject": {"text": [["the other"]], "start": [[255]], "entity_id": ["T34"]}, "Treatment": {"text": [["cisplatin", "involving intravenous infusion"]], "start": [[144, 266]], "entity_id": ["T31"], "Drug": {"text": [["cisplatin"]], "start": [[144]], "entity_id": ["T25"]}, "Route": {"text": [["intravenous infusion"]], "start": [[276]], "entity_id": ["T28"]}}, "Effect": {"text": [["manifested abdominal pain, general erythema, and fever"]], "start": [[298]], "entity_id": ["T30"]}}]}]}
{"id": "12324937_2", "context": "CONCLUSION: There are only a few confirmed cases of gemcitabine-associated HUS despite the widespread use of the drug.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[64]], "entity_id": ["T4"]}, "Treatment": {"text": [["gemcitabine"]], "start": [[52]], "entity_id": ["T3"], "Drug": {"text": [["gemcitabine"]], "start": [[52]], "entity_id": ["T7"]}}, "Effect": {"text": [["HUS"]], "start": [[75]], "entity_id": ["T5"]}, "Speculated": {"text": [["few"]], "start": [[29]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "19365885_3", "context": "In these patients, long-acting octreotide may trigger serious hypoglycemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["trigger"]], "start": [[46]], "entity_id": ["T5"]}, "Subject": {"text": [["these patients"]], "start": [[3]], "entity_id": ["T3"]}, "Treatment": {"text": [["long-acting octreotide"]], "start": [[19]], "entity_id": ["T4"], "Drug": {"text": [["octreotide"]], "start": [[31]], "entity_id": ["T8"]}}, "Effect": {"text": [["serious hypoglycemia"]], "start": [[54]], "entity_id": ["T6"]}}]}]}
{"id": "1722991_1", "context": "Usefulness of antiplatelet drugs in the management of heparin-associated thrombocytopenia and thrombosis.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[62]], "entity_id": ["T7"]}, "Treatment": {"text": [["heparin"]], "start": [[54]], "entity_id": ["T8"], "Drug": {"text": [["heparin"]], "start": [[54]], "entity_id": ["T11"]}}, "Effect": {"text": [["thrombocytopenia and thrombosis"]], "start": [[73]], "entity_id": ["T9"]}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["Usefulness"]], "start": [[0]], "entity_id": ["T12"]}, "Treatment": {"text": [["antiplatelet drugs"]], "start": [[14]], "entity_id": ["T14"], "Disorder": {"text": [["heparin-associated thrombocytopenia and thrombosis"]], "start": [[54]], "entity_id": ["T15"]}, "Drug": {"text": [["antiplatelet drugs"]], "start": [[14]], "entity_id": ["T13"]}}}]}]}
{"id": "17039658_1", "context": "An intertrigo-like eruption from pegylated liposomal doxorubicin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["from"]], "start": [[28]], "entity_id": ["T5"]}, "Treatment": {"text": [["pegylated liposomal doxorubicin"]], "start": [[33]], "entity_id": ["T3"], "Drug": {"text": [["doxorubicin"]], "start": [[53]], "entity_id": ["T6"]}}, "Effect": {"text": [["intertrigo-like eruption"]], "start": [[3]], "entity_id": ["T4"]}}]}]}
{"id": "14514135_2", "context": "We report a case of NEH masquerading as cutaneous vasculitis in a woman receiving cyclophosphamide for lupus nephritis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[61]], "entity_id": ["T6"]}, "Treatment": {"text": [["cyclophosphamide"]], "start": [[82]], "entity_id": ["T3"], "Drug": {"text": [["cyclophosphamide"]], "start": [[82]], "entity_id": ["T9"]}, "Disorder": {"text": [["lupus nephritis."]], "start": [[103]], "entity_id": ["T10"]}}, "Effect": {"text": [["NEH masquerading as cutaneous vasculitis"]], "start": [[20]], "entity_id": ["T4"]}, "Subject": {"text": [["a woman", "for lupus nephritis"]], "start": [[64, 99]], "entity_id": ["T5"], "Gender": {"text": [["woman"]], "start": [[66]], "entity_id": ["T7"]}}}]}]}
{"id": "12621956_1", "context": "The diagnosis of hypothermia was delayed until it was apparent for several days but resolved with the discontinuation of risperidone and continuation of clozapine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["resolved"]], "start": [[84]], "entity_id": ["T3"]}, "Treatment": {"text": [["discontinuation of risperidone and continuation of clozapine"]], "start": [[102]], "entity_id": ["T4"], "Drug": {"text": [["clozapine"], ["risperidone"]], "start": [[153], [121]], "entity_id": ["T6", "T7"]}, "Disorder": {"text": [["hypothermia"]], "start": [[17]], "entity_id": ["T8"]}}}]}]}
{"id": "10048291_2", "context": "Unaccountable severe hypercalcemia in a patient treated for hypoparathyroidism with dihydrotachysterol.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[48]], "entity_id": ["T5"]}, "Treatment": {"text": [["dihydrotachysterol"]], "start": [[84]], "entity_id": ["T4"], "Disorder": {"text": [["hypoparathyroidism"]], "start": [[60]], "entity_id": ["T8"]}, "Drug": {"text": [["dihydrotachysterol"]], "start": [[84]], "entity_id": ["T9"]}}, "Effect": {"text": [["Unaccountable severe hypercalcemia"]], "start": [[0]], "entity_id": ["T6"]}, "Subject": {"text": [["patient"]], "start": [[40]], "entity_id": ["T7"]}}]}]}
{"id": "11022272_1", "context": "Anaphylaxis to calcitonin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["to"]], "start": [[12]], "entity_id": ["T4"]}, "Effect": {"text": [["Anaphylaxis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["calcitonin"]], "start": [[15]], "entity_id": ["T5"], "Drug": {"text": [["calcitonin"]], "start": [[15]], "entity_id": ["T6"]}}}]}]}
{"id": "19764104_1", "context": "However, he developed acute renal failure, hyperkalemia, and hyperuricemia 30 d after receiving the sorafenib treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[12]], "entity_id": ["T7"]}, "Subject": {"text": [["he"]], "start": [[9]], "entity_id": ["T8"], "Gender": {"text": [["he"]], "start": [[9]], "entity_id": ["T11"]}}, "Treatment": {"text": [["sorafenib"]], "start": [[100]], "entity_id": ["T10"], "Drug": {"text": [["sorafenib"]], "start": [[100]], "entity_id": ["T12"]}, "Time_elapsed": {"text": [["30 d"]], "start": [[75]], "entity_id": ["T13"]}}, "Effect": {"text": [["acute renal failure, hyperkalemia, and hyperuricemia"]], "start": [[22]], "entity_id": ["T9"]}}]}]}
{"id": "17983451_1", "context": "Mycobacterium marinum infection complicating Crohn's disease, treated with infliximab.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[62]], "entity_id": ["T3"]}, "Treatment": {"text": [["infliximab"]], "start": [[75]], "entity_id": ["T4"], "Disorder": {"text": [["Mycobacterium marinum infection complicating Crohn's disease"]], "start": [[0]], "entity_id": ["T5"]}, "Drug": {"text": [["infliximab"]], "start": [[75]], "entity_id": ["T6"]}}}]}]}
{"id": "16649344_2", "context": "Current immunosuppressive therapies are effective but can be associated with significant adverse reactions.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[61]], "entity_id": ["T5"]}, "Treatment": {"text": [["Current immunosuppressive therapies"]], "start": [[0]], "entity_id": ["T6"], "Drug": {"text": [["immunosuppressive"]], "start": [[8]], "entity_id": ["T8"]}}, "Effect": {"text": [["significant adverse reactions."]], "start": [[77]], "entity_id": ["T7"]}, "Speculated": {"text": [["can be"]], "start": [[54]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "1977935_4", "context": "This report describes the first association (exclusive of drug overdose) of symptomatic torsades de pointes occurring with the use of terfenadine in a patient who was taking the recommended prescribed dose of this drug in addition to cefaclor, ketoconazole, and medroxyprogesterone.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurring"]], "start": [[108]], "entity_id": ["T8"]}, "Treatment": {"text": [["terfenadine", "taking the recommended prescribed dose of this drug in addition to cefaclor, ketoconazole, and medroxyprogesterone"]], "start": [[134, 167]], "entity_id": ["T9"], "Drug": {"text": [["cefaclor"], ["ketoconazole"], ["medroxyprogesterone"], ["terfenadine"]], "start": [[234], [244], [262], [134]], "entity_id": ["T13", "T14", "T15", "T16"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["addition"]], "start": [[222]], "entity_id": ["T12"]}, "Drug": {"text": [["terfenadine"], ["cefaclor"], ["ketoconazole"], ["medroxyprogesterone"]], "start": [[134], [234], [244], [262]], "entity_id": ["T16", "T13", "T14", "T15"]}}]}, "Effect": {"text": [["symptomatic torsades de pointes"]], "start": [[76]], "entity_id": ["T11"]}, "Subject": {"text": [["a patient"]], "start": [[149]], "entity_id": ["T10"]}}]}]}
{"id": "9232614_2", "context": "Tamoxifen is suggested to be carcinogenic both through direct genotoxic and epigenetic mechanisms.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["suggested"]], "start": [[13]], "entity_id": ["T4"]}, "Treatment": {"text": [["Tamoxifen"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Tamoxifen"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["carcinogenic both through direct genotoxic and epigenetic mechanisms"]], "start": [[29]], "entity_id": ["T5"]}}]}]}
{"id": "14632592_3", "context": "DISCUSSION: Colchicine, the most important drug in treatment of FMF, can cause myopathy in patients with impaired renal and hepatic function.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[73]], "entity_id": ["T7"]}, "Treatment": {"text": [["Colchicine"]], "start": [[12]], "entity_id": ["T3"], "Drug": {"text": [["Colchicine"]], "start": [[12]], "entity_id": ["T9"]}, "Disorder": {"text": [["FMF"]], "start": [[64]], "entity_id": ["T4"]}}, "Effect": {"text": [["myopathy"]], "start": [[79]], "entity_id": ["T5"]}, "Subject": {"text": [["patients with impaired renal and hepatic function"]], "start": [[91]], "entity_id": ["T6"], "Disorder": {"text": [["impaired renal and hepatic function"]], "start": [[105]], "entity_id": ["T8"]}}}]}]}
{"id": "7673653_4", "context": "In the presented case fluvoxamine-induced akathisia in an OCD patient was partially resistant to the anticholinergic agent biperiden, and was successfully treated with the 5-HT2A/5-HT2C antagonist mianserin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[155]], "entity_id": ["T4"]}, "Subject": {"text": [["fluvoxamine-induced akathisia in an OCD patient"]], "start": [[22]], "entity_id": ["T3"]}, "Treatment": {"text": [["5-HT2A/5-HT2C antagonist mianserin"]], "start": [[172]], "entity_id": ["T5"], "Disorder": {"text": [["akathisia"], ["OCD"]], "start": [[42], [58]], "entity_id": ["T8", "T9"]}, "Drug": {"text": [["mianserin"]], "start": [[197]], "entity_id": ["T10"]}}}]}]}
{"id": "16225183_7", "context": "SUBSEQUENT COURSE: The nephrosis resolved almost completely once the interferon was stopped and after immunosuppressive treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["resolved"]], "start": [[33]], "entity_id": ["T7"]}, "Treatment": {"text": [["interferon was stopped and after immunosuppressive treatment"]], "start": [[69]], "entity_id": ["T6"], "Drug": {"text": [["interferon"], ["immunosuppressive"]], "start": [[69], [102]], "entity_id": ["T9", "T10"]}, "Disorder": {"text": [["nephrosis"]], "start": [[23]], "entity_id": ["T12"]}}}]}]}
{"id": "8149366_1", "context": "In two patients, apomorphine remained effective in the morning, but increased the intensity of the dyskinesias in the afternoon.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["increased"]], "start": [[68]], "entity_id": ["T5"]}, "Subject": {"text": [["In two patients"]], "start": [[0]], "entity_id": ["T3"], "Population": {"text": [["two"]], "start": [[3]], "entity_id": ["T7"]}}, "Treatment": {"text": [["apomorphine"]], "start": [[17]], "entity_id": ["T4"], "Drug": {"text": [["apomorphine"]], "start": [[17]], "entity_id": ["T8"]}}, "Effect": {"text": [["intensity of the dyskinesias in the afternoon"]], "start": [[82]], "entity_id": ["T6"]}}]}]}
{"id": "18079582_2", "context": "Transient asymptomatic bradycardia in patients on infusional 5-fluorouracil.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["on"]], "start": [[47]], "entity_id": ["T3"]}, "Treatment": {"text": [["infusional 5-fluorouracil."]], "start": [[50]], "entity_id": ["T4"], "Route": {"text": [["infusional"]], "start": [[50]], "entity_id": ["T8"]}, "Drug": {"text": [["5-fluorouracil"]], "start": [[61]], "entity_id": ["T9"]}}, "Effect": {"text": [["Transient asymptomatic bradycardia"]], "start": [[0]], "entity_id": ["T5"]}, "Subject": {"text": [["patients"]], "start": [[38]], "entity_id": ["T6"]}, "Severity": {"text": [["Transient"]], "start": [[0]], "entity_id": ["T7"], "value": "Low"}}]}]}
{"id": "25515435_6", "context": "In 2006, he was diagnosed with deep vein thrombosis and pulmonary embolism and was started on warfarin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["started"]], "start": [[83]], "entity_id": ["T8"]}, "Subject": {"text": [["he"]], "start": [[9]], "entity_id": ["T6"], "Population": {"text": [["he"]], "start": [[9]], "entity_id": ["T10"]}}, "Treatment": {"text": [["warfarin"]], "start": [[94]], "entity_id": ["T9"], "Disorder": {"text": [["deep vein thrombosis and pulmonary embolism"]], "start": [[31]], "entity_id": ["T7"]}, "Drug": {"text": [["warfarin"]], "start": [[94]], "entity_id": ["T11"]}}}]}]}
{"id": "17026827_1", "context": "Scleritis complicating zoledronic acid infusion.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complicating"]], "start": [[10]], "entity_id": ["T5"]}, "Effect": {"text": [["Scleritis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["zoledronic acid infusion"]], "start": [[23]], "entity_id": ["T4"], "Drug": {"text": [["zoledronic acid"]], "start": [[23]], "entity_id": ["T6"]}, "Route": {"text": [["infusion"]], "start": [[39]], "entity_id": ["T7"]}}}]}]}
{"id": "10467499_1", "context": "A 22-year-old black man developed fever, chills, fatigue, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting minocycline therapy for acne.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[24]], "entity_id": ["T12"]}, "Effect": {"text": [["fever, chills, fatigue, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption"]], "start": [[34]], "entity_id": ["T11"]}, "Treatment": {"text": [["minocycline therapy"]], "start": [[165]], "entity_id": ["T13"], "Disorder": {"text": [["acne"]], "start": [[189]], "entity_id": ["T18"]}, "Drug": {"text": [["minocycline"]], "start": [[165]], "entity_id": ["T19"]}, "Time_elapsed": {"text": [["3 weeks"]], "start": [[142]], "entity_id": ["T20"]}}, "Subject": {"text": [["A 22-year-old black man"]], "start": [[0]], "entity_id": ["T14"], "Age": {"text": [["22-year-old"]], "start": [[2]], "entity_id": ["T15"]}, "Race": {"text": [["black"]], "start": [[14]], "entity_id": ["T16"]}, "Gender": {"text": [["man"]], "start": [[20]], "entity_id": ["T17"]}}}]}]}
{"id": "12221670_4", "context": "Ticlopidine-induced aplastic anemia: two new case reports, review, and meta-analysis of 55 additional cases.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[12]], "entity_id": ["T4"]}, "Treatment": {"text": [["Ticlopidine"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Ticlopidine"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["aplastic anemia"]], "start": [[20]], "entity_id": ["T5"]}}]}]}
{"id": "11757641_2", "context": "This is the second report of acute lung injury and diffuse alveolar damage caused by mefloquine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[75]], "entity_id": ["T6"]}, "Effect": {"text": [["acute lung injury and diffuse alveolar damage"]], "start": [[29]], "entity_id": ["T5"]}, "Treatment": {"text": [["mefloquine"]], "start": [[85]], "entity_id": ["T7"], "Drug": {"text": [["mefloquine"]], "start": [[85]], "entity_id": ["T8"]}}}]}]}
{"id": "480917_1", "context": "A case of Erythema Multiforme Bullosum in patient of lepromatous leprosy with pulmonary tuberculosis due to Rifampicin is described.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due to"]], "start": [[101]], "entity_id": ["T6"]}, "Effect": {"text": [["Erythema Multiforme Bullosum"]], "start": [[10]], "entity_id": ["T3"]}, "Subject": {"text": [["patient of lepromatous leprosy with pulmonary tuberculosis"]], "start": [[42]], "entity_id": ["T4"]}, "Treatment": {"text": [["Rifampicin"]], "start": [[108]], "entity_id": ["T7"], "Disorder": {"text": [["pulmonary tuberculosis"], ["lepromatous leprosy"]], "start": [[78], [53]], "entity_id": ["T5", "T8"]}, "Drug": {"text": [["Rifampicin"]], "start": [[108]], "entity_id": ["T9"]}}}]}]}
{"id": "7661076_2", "context": "Life-threatening alterations in heart rate after the use of adenosine in atrial flutter.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[43]], "entity_id": ["T3"]}, "Treatment": {"text": [["adenosine"]], "start": [[60]], "entity_id": ["T4"], "Drug": {"text": [["adenosine"]], "start": [[60]], "entity_id": ["T7"]}}, "Effect": {"text": [["Life-threatening alterations in heart rate"]], "start": [[0]], "entity_id": ["T5"]}, "Severity": {"text": [["Life-threatening"]], "start": [[0]], "entity_id": ["T6"], "value": "Medium"}}]}]}
{"id": "9719245_4", "context": "We report a case of pancytopenia in a 23-year-old man with Crohn's disease who was treated with 5-aminosalicylic acid (Pentasa; Nisshin, Tokyo, Japan) 3.0 g/day.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated with"]], "start": [[83]], "entity_id": ["T6"]}, "Subject": {"text": [["a 23-year-old man with Crohn's disease"]], "start": [[36]], "entity_id": ["T4"], "Age": {"text": [["23-year-old"]], "start": [[38]], "entity_id": ["T8"]}, "Gender": {"text": [["man"]], "start": [[50]], "entity_id": ["T9"]}}, "Effect": {"text": [["pancytopenia"]], "start": [[20]], "entity_id": ["T5"]}, "Treatment": {"text": [["5-aminosalicylic acid (Pentasa; Nisshin, Tokyo, Japan) 3.0 g/day"]], "start": [[96]], "entity_id": ["T7"], "Disorder": {"text": [["Crohn's disease"]], "start": [[59]], "entity_id": ["T10"]}, "Drug": {"text": [["5-aminosalicylic acid"], ["Pentasa"]], "start": [[96], [119]], "entity_id": ["T11", "T12"]}, "Dosage": {"text": [["3.0 g/day"]], "start": [[151]], "entity_id": ["T13"]}}}]}]}
{"id": "9169264_2", "context": "The ampicillin rash occurring in cases of infectious mononucleosis is well documented.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurring"]], "start": [[20]], "entity_id": ["T3"]}, "Effect": {"text": [["The ampicillin rash"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["ampicillin"]], "start": [[4]], "entity_id": ["T5"], "Drug": {"text": [["ampicillin"]], "start": [[4]], "entity_id": ["T6"]}, "Disorder": {"text": [["infectious mononucleosis"]], "start": [[42]], "entity_id": ["T7"]}}}]}]}
{"id": "16204273_1", "context": "The major side effect of infliximab is infection.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["of"]], "start": [[22]], "entity_id": ["T5"]}, "Treatment": {"text": [["infliximab"]], "start": [[25]], "entity_id": ["T3"], "Drug": {"text": [["infliximab"]], "start": [[25]], "entity_id": ["T6"]}}, "Effect": {"text": [["infection"]], "start": [[39]], "entity_id": ["T4"]}}]}]}
{"id": "11545487_1", "context": "An asymptomatic HIV-infected woman experienced right-sided renal colicky pain during treatment with indinavir.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["experienced"]], "start": [[35]], "entity_id": ["T5"]}, "Subject": {"text": [["An asymptomatic HIV-infected woman"]], "start": [[0]], "entity_id": ["T3"], "Gender": {"text": [["woman"]], "start": [[29]], "entity_id": ["T8"]}}, "Effect": {"text": [["right-sided renal colicky pain"]], "start": [[47]], "entity_id": ["T4"]}, "Treatment": {"text": [["indinavir"]], "start": [[100]], "entity_id": ["T6"], "Drug": {"text": [["indinavir"]], "start": [[100]], "entity_id": ["T9"]}, "Disorder": {"text": [["HIV"]], "start": [[16]], "entity_id": ["T10"]}}}]}]}
{"id": "6233326_3", "context": "The case resembles two previously reported cases of optic neuropathy which occurred in patients with Wilson's disease who were receiving penicillamine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurred"]], "start": [[75]], "entity_id": ["T4"]}, "Effect": {"text": [["optic neuropathy"]], "start": [[52]], "entity_id": ["T3"]}, "Subject": {"text": [["patients with Wilson's disease"]], "start": [[87]], "entity_id": ["T5"]}, "Treatment": {"text": [["penicillamine"]], "start": [[137]], "entity_id": ["T6"], "Drug": {"text": [["penicillamine"]], "start": [[137]], "entity_id": ["T8"]}, "Disorder": {"text": [["Wilson's disease"]], "start": [[101]], "entity_id": ["T9"]}}}]}]}
{"id": "1743388_1", "context": "Cutaneous ulceration: an unusual complication of intravenous pentamidine therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[33]], "entity_id": ["T4"]}, "Effect": {"text": [["Cutaneous ulceration"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["intravenous pentamidine"]], "start": [[49]], "entity_id": ["T5"], "Drug": {"text": [["pentamidine"]], "start": [[61]], "entity_id": ["T6"]}, "Route": {"text": [["intravenous"]], "start": [[49]], "entity_id": ["T7"]}}, "Speculated": {"text": [["unusual"]], "start": [[25]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "8222875_3", "context": "Pulmonary hemorrhage is an uncommon feature in the HUS, and seems to appear especially in the HUS associated with MMC therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["appear"]], "start": [[69]], "entity_id": ["T7"]}, "Effect": {"text": [["Pulmonary hemorrhage"]], "start": [[0]], "entity_id": ["T6"]}, "Treatment": {"text": [["MMC"]], "start": [[114]], "entity_id": ["T8"], "Drug": {"text": [["MMC"]], "start": [[114]], "entity_id": ["T9"]}}}]}]}
{"id": "9017913_1", "context": "Immunosuppression elicited by the extensive administration of prednisolone was suspected for the initiation of the generalized mite infestation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["generalized"]], "start": [[115]], "entity_id": ["T4"]}, "Treatment": {"text": [["extensive administration of prednisolone"]], "start": [[34]], "entity_id": ["T3"], "Drug": {"text": [["prednisolone"]], "start": [[62]], "entity_id": ["T6"]}}, "Effect": {"text": [["mite infestation"]], "start": [[127]], "entity_id": ["T5"]}}]}]}
{"id": "6414095_4", "context": "The episode appeared to have been precipitated by toxicity due to ingestion of a large amount of phenytoin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[59]], "entity_id": ["T4"]}, "Treatment": {"text": [["a large amount of phenytoin."]], "start": [[79]], "entity_id": ["T5"], "Route": {"text": [["ingestion"]], "start": [[66]], "entity_id": ["T7"]}, "Drug": {"text": [["phenytoin"]], "start": [[97]], "entity_id": ["T8"]}, "Dosage": {"text": [["large amount"]], "start": [[81]], "entity_id": ["T9"]}}, "Effect": {"text": [["The episode appeared to have been precipitated by toxicity"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "3370103_1", "context": "Cardiopulmonary arrest following intravenous phenytoin loading.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[23]], "entity_id": ["T4"]}, "Effect": {"text": [["Cardiopulmonary arrest"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["intravenous phenytoin loading"]], "start": [[33]], "entity_id": ["T5"], "Route": {"text": [["intravenous"]], "start": [[33]], "entity_id": ["T6"]}, "Drug": {"text": [["phenytoin"]], "start": [[45]], "entity_id": ["T7"]}}}]}]}
{"id": "11487721_1", "context": "Although taxol has shown significant activity in advanced ovarian cancer, peripheral neuropathy is likely to become the major dose-limiting toxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["toxicity"]], "start": [[140]], "entity_id": ["T5"]}, "Treatment": {"text": [["taxol"]], "start": [[9]], "entity_id": ["T3"], "Drug": {"text": [["taxol"]], "start": [[9]], "entity_id": ["T6"]}}, "Effect": {"text": [["peripheral neuropathy"]], "start": [[74]], "entity_id": ["T4"]}}]}]}
{"id": "19017039_2", "context": "Syringotropic hypersensitivity reaction associated with infliximab and leflunomide combination therapy in a child with psoriatic arthritis.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[40]], "entity_id": ["T5"]}, "Effect": {"text": [["Syringotropic hypersensitivity reaction"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["infliximab and leflunomide combination therapy"]], "start": [[56]], "entity_id": ["T6"], "Drug": {"text": [["infliximab"], ["leflunomide"]], "start": [[56], [71]], "entity_id": ["T10", "T11"]}, "Disorder": {"text": [["psoriatic arthritis"]], "start": [[119]], "entity_id": ["T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combination"]], "start": [[83]], "entity_id": ["T12"]}, "Drug": {"text": [["leflunomide"], ["infliximab"]], "start": [[71], [56]], "entity_id": ["T11", "T10"]}}]}, "Subject": {"text": [["a child with psoriatic arthritis"]], "start": [[106]], "entity_id": ["T7"], "Age": {"text": [["child"]], "start": [[108]], "entity_id": ["T8"]}}}]}]}
{"id": "3438585_5", "context": "Corticosteroid therapy was continued for 8 months since there was still improvement of pulmonary function studies.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["improvement"]], "start": [[72]], "entity_id": ["T4"]}, "Treatment": {"text": [["Corticosteroid", "for 8 months"]], "start": [[0, 37]], "entity_id": ["T5"], "Disorder": {"text": [["pulmonary function"]], "start": [[87]], "entity_id": ["T6"]}, "Drug": {"text": [["Corticosteroid"]], "start": [[0]], "entity_id": ["T7"]}, "Duration": {"text": [["for 8 months"]], "start": [[37]], "entity_id": ["T9"]}}}]}]}
{"id": "19567656_3", "context": "OBJECTIVE: To describe a case of sertraline-induced rhabdomyolysis in an elderly patient with dementia and comorbidities.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[44]], "entity_id": ["T5"]}, "Treatment": {"text": [["sertraline"]], "start": [[33]], "entity_id": ["T4"], "Disorder": {"text": [["comorbidities"], ["dementia"]], "start": [[107], [94]], "entity_id": ["T9", "T11"]}, "Drug": {"text": [["sertraline"]], "start": [[33]], "entity_id": ["T10"]}}, "Effect": {"text": [["rhabdomyolysis"]], "start": [[52]], "entity_id": ["T6"]}, "Subject": {"text": [["an elderly patient with dementia and comorbidities"]], "start": [[70]], "entity_id": ["T7"], "Age": {"text": [["elderly"]], "start": [[73]], "entity_id": ["T3"]}}}]}]}
{"id": "15028964_3", "context": "Beyond the predictable pharmacokinetic drug-drug interaction requiring a significant warfarin dose reduction, the iodine-rich amiodarone affects the thyroid gland, causing overt hypothyroidism or thyrotoxicosis in 14%-18% of cases.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["causing"]], "start": [[164]], "entity_id": ["T8"]}, "Treatment": {"text": [["iodine-rich amiodarone"]], "start": [[114]], "entity_id": ["T7"], "Drug": {"text": [["iodine-rich amiodarone"]], "start": [[114]], "entity_id": ["T10"]}}, "Effect": {"text": [["overt hypothyroidism or thyrotoxicosis"]], "start": [[172]], "entity_id": ["T9"]}}]}]}
{"id": "12086549_4", "context": "Toxic epidermal necrolysis associated with interleukin-2.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[27]], "entity_id": ["T4"]}, "Effect": {"text": [["Toxic epidermal necrolysis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["interleukin-2"]], "start": [[43]], "entity_id": ["T5"], "Drug": {"text": [["interleukin-2"]], "start": [[43]], "entity_id": ["T6"]}}}]}]}
{"id": "9840249_2", "context": "The pulmonary toxicity of gold salts is an uncommon cause of life-threatening respiratory failure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[52]], "entity_id": ["T7"]}, "Effect": {"text": [["pulmonary toxicity", "life-threatening respiratory failure"]], "start": [[4, 61]], "entity_id": ["T5"]}, "Treatment": {"text": [["gold salts"]], "start": [[26]], "entity_id": ["T6"], "Drug": {"text": [["gold"]], "start": [[26]], "entity_id": ["T10"]}}}]}]}
{"id": "15383642_14", "context": "With its characteristics, tizanidine has the potential to compromise hemodynamic stability during concomitant angiotensin-converting enzyme inhibitor use.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["compromise"]], "start": [[58]], "entity_id": ["T8"]}, "Treatment": {"text": [["tizanidine", "during concomitant angiotensin-converting enzyme inhibitor use"]], "start": [[26, 91]], "entity_id": ["T7"], "Drug": {"text": [["tizanidine"], ["angiotensin-converting enzyme inhibitor"]], "start": [[26], [110]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["concomitant"]], "start": [[98]], "entity_id": ["T12"]}, "Drug": {"text": [["tizanidine"], ["angiotensin-converting enzyme inhibitor"]], "start": [[26], [110]], "entity_id": ["T10", "T11"]}}]}, "Effect": {"text": [["compromise hemodynamic stability"]], "start": [[58]], "entity_id": ["T9"]}, "Speculated": {"text": [["potential"]], "start": [[45]], "entity_id": ["T13"], "value": true}}]}]}
{"id": "17060191_1", "context": "Premature closure of the ductus arteriosus: variable response among monozygotic twins after in utero exposure to indomethacin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[86]], "entity_id": ["T6"]}, "Subject": {"text": [["monozygotic twins"]], "start": [[68]], "entity_id": ["T5"]}, "Treatment": {"text": [["in utero exposure to indomethacin"]], "start": [[92]], "entity_id": ["T7"], "Drug": {"text": [["indomethacin"]], "start": [[113]], "entity_id": ["T9"]}, "Route": {"text": [["in utero exposure"]], "start": [[92]], "entity_id": ["T10"]}}, "Effect": {"text": [["Premature closure of the ductus arteriosus"]], "start": [[0]], "entity_id": ["T8"]}}]}]}
{"id": "8239963_2", "context": "Possible mechanisms by which clonidine decreases spasticity are described, probable mechanisms of induced bradycardia are reviewed, and specific treatment recommendations for the use of clonidine in spinal cord injured patients are presented.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[98]], "entity_id": ["T5"]}, "Treatment": {"text": [["clonidine"]], "start": [[29]], "entity_id": ["T4"], "Drug": {"text": [["clonidine"]], "start": [[29]], "entity_id": ["T7"]}, "Disorder": {"text": [["spinal cord injured"]], "start": [[199]], "entity_id": ["T8"]}}, "Effect": {"text": [["bradycardia"]], "start": [[106]], "entity_id": ["T6"]}}]}]}
{"id": "10475726_3", "context": "This is the first report of a possible association between an acute cardiovascular event and venlafaxine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["association"]], "start": [[39]], "entity_id": ["T3"]}, "Effect": {"text": [["an acute cardiovascular event"]], "start": [[59]], "entity_id": ["T4"]}, "Treatment": {"text": [["venlafaxine"]], "start": [[93]], "entity_id": ["T5"], "Drug": {"text": [["venlafaxine"]], "start": [[93]], "entity_id": ["T6"]}}, "Speculated": {"text": [["possible"]], "start": [[30]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "6830388_1", "context": "Since early symptoms of the toxic effects of theophylline can mimic peptic ulcer disease, cimetidine might be prescribed for the gastrointestinal symptoms with subsequent worsening of theophylline poisoning.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["prescribed"]], "start": [[110]], "entity_id": ["T4"]}, "Treatment": {"text": [["cimetidine"]], "start": [[90]], "entity_id": ["T3"], "Disorder": {"text": [["gastrointestinal symptoms"]], "start": [[129]], "entity_id": ["T5"]}, "Drug": {"text": [["cimetidine"]], "start": [[90]], "entity_id": ["T7"]}}, "Speculated": {"text": [["might"]], "start": [[101]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "9256906_1", "context": "Acute renal failure in a patient receiving treatment with suramin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[20]], "entity_id": ["T6"]}, "Effect": {"text": [["Acute renal failure"]], "start": [[0]], "entity_id": ["T3"]}, "Subject": {"text": [["a patient"]], "start": [[23]], "entity_id": ["T4"]}, "Treatment": {"text": [["suramin"]], "start": [[58]], "entity_id": ["T5"], "Drug": {"text": [["suramin"]], "start": [[58]], "entity_id": ["T7"]}}}]}]}
{"id": "6540393_1", "context": "A further case of anaphylactoid reaction to methylprednisolone is reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["to"]], "start": [[41]], "entity_id": ["T4"]}, "Effect": {"text": [["anaphylactoid reaction"]], "start": [[18]], "entity_id": ["T3"]}, "Treatment": {"text": [["methylprednisolone"]], "start": [[44]], "entity_id": ["T5"], "Drug": {"text": [["methylprednisolone"]], "start": [[44]], "entity_id": ["T6"]}}}]}]}
{"id": "8222875_2", "context": "Pulmonary hemorrhage as a clinical manifestation of hemolytic-uremic syndrome associated with mitomycin C therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[78]], "entity_id": ["T6"]}, "Effect": {"text": [["Pulmonary hemorrhage", "hemolytic-uremic syndrome"]], "start": [[0, 52]], "entity_id": ["T5"]}, "Treatment": {"text": [["mitomycin C therapy"]], "start": [[94]], "entity_id": ["T7"], "Drug": {"text": [["mitomycin C"]], "start": [[94]], "entity_id": ["T8"]}}}]}]}
{"id": "4054170_3", "context": "EEG abnormalities were observed in two of the nine children during chlorambucil therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["observed"]], "start": [[23]], "entity_id": ["T5"]}, "Treatment": {"text": [["chlorambucil"]], "start": [[67]], "entity_id": ["T3"], "Drug": {"text": [["chlorambucil"]], "start": [[67]], "entity_id": ["T9"]}}, "Effect": {"text": [["EEG abnormalities"]], "start": [[0]], "entity_id": ["T4"]}, "Subject": {"text": [["two of the nine children"]], "start": [[35]], "entity_id": ["T6"], "Population": {"text": [["two of the nine"]], "start": [[35]], "entity_id": ["T7"]}, "Age": {"text": [["children"]], "start": [[51]], "entity_id": ["T8"]}}}]}]}
{"id": "9111724_1", "context": "Discontinuation of the itraconazole caused resolution of the drug eruption.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[36]], "entity_id": ["T4"]}, "Treatment": {"text": [["itraconazole"]], "start": [[23]], "entity_id": ["T3"], "Drug": {"text": [["itraconazole"]], "start": [[23]], "entity_id": ["T6"]}}, "Effect": {"text": [["drug eruption"]], "start": [[61]], "entity_id": ["T5"]}}]}]}
{"id": "19307676_2", "context": "The addition of intrathecal methotrexate to treatment protocols has increased survival rates in children with acute lymphoblastic leukemia but is also associated with varying degrees of neurotoxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[151]], "entity_id": ["T3"]}, "Effect": {"text": [["varying degrees of neurotoxicity"]], "start": [[167]], "entity_id": ["T4"]}, "Treatment": {"text": [["The addition of intrathecal methotrexate to treatment protocols"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["methotrexate"]], "start": [[28]], "entity_id": ["T9"]}, "Disorder": {"text": [["acute lymphoblastic leukemia"]], "start": [[110]], "entity_id": ["T10"]}}, "Subject": {"text": [["in children with acute lymphoblastic leukemia"]], "start": [[93]], "entity_id": ["T6"], "Age": {"text": [["children"]], "start": [[96]], "entity_id": ["T7"]}}}]}]}
{"id": "10473079_1", "context": "We conclude that the presence of this metabolic defect combined with topical 5-FU (a drug demonstrating a narrow therapeutic index) results in the unusual presentation of life-threatening toxicity after treatment with a topical drug.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["results in"]], "start": [[132]], "entity_id": ["T4"]}, "Effect": {"text": [["unusual presentation of life-threatening toxicity"]], "start": [[147]], "entity_id": ["T5"]}, "Treatment": {"text": [["topical 5-FU (a drug demonstrating a narrow therapeutic index)"]], "start": [[69]], "entity_id": ["T7"], "Drug": {"text": [["5-FU"]], "start": [[77]], "entity_id": ["T9"]}, "Route": {"text": [["topical"]], "start": [[69]], "entity_id": ["T10"]}}, "Subject": {"text": [["this metabolic defect"]], "start": [[33]], "entity_id": ["T3"], "Disorder": {"text": [["metabolic defect"]], "start": [[38]], "entity_id": ["T6"]}}, "Severity": {"text": [["life-threatening"]], "start": [[171]], "entity_id": ["T8"], "value": "Medium"}}]}]}
{"id": "6958210_1", "context": "Six patients with rheumatoid arthritis developed a syndrome resembling lupus erythematosus while being treated with penicillamine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[39]], "entity_id": ["T4"]}, "Subject": {"text": [["Six patients with rheumatoid arthritis"]], "start": [[0]], "entity_id": ["T3"], "Population": {"text": [["Six"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["syndrome resembling lupus erythematosus"]], "start": [[51]], "entity_id": ["T5"]}, "Treatment": {"text": [["penicillamine"]], "start": [[116]], "entity_id": ["T6"], "Drug": {"text": [["penicillamine"]], "start": [[116]], "entity_id": ["T9"]}, "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[18]], "entity_id": ["T10"]}}}]}]}
{"id": "12590235_3", "context": "This case highlights the need to monitor liver enzymes in patients treated with 6-TG and identifies the need for additional research focused on the mechanism of thiopurine-induced hepatic injury.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[172]], "entity_id": ["T4"]}, "Treatment": {"text": [["thiopurine"]], "start": [[161]], "entity_id": ["T3"], "Drug": {"text": [["thiopurine"]], "start": [[161]], "entity_id": ["T6"]}}, "Effect": {"text": [["hepatic injury"]], "start": [[180]], "entity_id": ["T5"]}, "Subject": {"text": [["patients treated with 6-TG"]], "start": [[58]], "entity_id": ["T7"]}}]}]}
{"id": "9347384_2", "context": "During clarithromycin coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[71]], "entity_id": ["T19"]}, "Subject": {"text": [["four out of the seven patients"]], "start": [[40]], "entity_id": ["T18"], "Population": {"text": [["four out of the seven"]], "start": [[40]], "entity_id": ["T21"]}}, "Treatment": {"text": [["During clarithromycin coadministration", "carbamazepine"]], "start": [[0, 118]], "entity_id": ["T17"], "Time_elapsed": {"text": [["During"]], "start": [[0]], "entity_id": ["T22"]}, "Drug": {"text": [["clarithromycin"], ["carbamazepine"]], "start": [[7], [118]], "entity_id": ["T23", "T25"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["coadministration"]], "start": [[22]], "entity_id": ["T24"]}, "Drug": {"text": [["clarithromycin"], ["carbamazepine"]], "start": [[7], [118]], "entity_id": ["T23", "T25"]}}]}, "Effect": {"text": [["moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and ataxia"]], "start": [[81]], "entity_id": ["T20"]}, "Severity": {"text": [["severe"]], "start": [[93]], "entity_id": ["T29"], "value": "Medium"}}, {"event_id": "E3", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["resolved"]], "start": [[182]], "entity_id": ["T27"]}, "Treatment": {"text": [["5 days after clarithromycin discontinuation"]], "start": [[198]], "entity_id": ["T28"], "Drug": {"text": [["clarithromycin"]], "start": [[211]], "entity_id": ["T30"]}, "Disorder": {"text": [["moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and ataxia"]], "start": [[81]], "entity_id": ["T31"]}}}]}]}
{"id": "10099659_2", "context": "5-Fluorouracil (5-FU) is an analogue of pyrimidine nucleosides that is widely used in the treatment of head and neck, breast, ovarian, and colon cancer.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["used"]], "start": [[78]], "entity_id": ["T16"]}, "Treatment": {"text": [["5-Fluorouracil (5-FU) is an analogue of pyrimidine nucleosides"]], "start": [[0]], "entity_id": ["T15"], "Drug": {"text": [["5-Fluorouracil (5-FU)"]], "start": [[0]], "entity_id": ["T17"]}, "Disorder": {"text": [["head and neck, breast, ovarian, and colon cancer"]], "start": [[103]], "entity_id": ["T18"]}}}]}]}
{"id": "19782276_1", "context": "Fulminant fatal cardiotoxicity following cyclophosphamide therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[31]], "entity_id": ["T5"]}, "Treatment": {"text": [["cyclophosphamide"]], "start": [[41]], "entity_id": ["T4"], "Drug": {"text": [["cyclophosphamide"]], "start": [[41]], "entity_id": ["T7"]}}, "Effect": {"text": [["Fulminant fatal cardiotoxicity"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "15383642_11", "context": "The reaction in our patient appeared after tizanidine initiation and improved after both lisinopril and tizanidine were discontinued.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[37]], "entity_id": ["T12"]}, "Treatment": {"text": [["tizanidine initiation"]], "start": [[43]], "entity_id": ["T17"], "Drug": {"text": [["tizanidine"]], "start": [[43]], "entity_id": ["T18"]}}, "Subject": {"text": [["patient"]], "start": [[20]], "entity_id": ["T8"]}, "Effect": {"text": [["reaction"]], "start": [[4]], "entity_id": ["T11"]}}, {"event_id": "E3", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["improved"]], "start": [[69]], "entity_id": ["T20"]}, "Subject": {"text": [["patient"]], "start": [[20]], "entity_id": ["T8"]}, "Treatment": {"text": [["both lisinopril and tizanidine"]], "start": [[84]], "entity_id": ["T9"], "Disorder": {"text": [["reaction"]], "start": [[4]], "entity_id": ["T19"]}, "Drug": {"text": [["lisinopril"], ["tizanidine"]], "start": [[89], [104]], "entity_id": ["T13", "T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["both"]], "start": [[84]], "entity_id": ["T15"]}, "Drug": {"text": [["lisinopril"], ["tizanidine"]], "start": [[89], [104]], "entity_id": ["T13", "T14"]}}]}}]}]}
{"id": "11142491_2", "context": "We describe the exceptional development of AML and lung cancer in a patient with previously diagnosed CLL in minimal residual disease status after fludarabine treatment followed by autologous peripheral blood stem-cell transplantation.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["development"]], "start": [[28]], "entity_id": ["T8"]}, "Treatment": {"text": [["fludarabine", "autologous peripheral blood stem-cell transplantation"]], "start": [[147, 181]], "entity_id": ["T7"], "Disorder": {"text": [["CLL in minimal residual disease status"]], "start": [[102]], "entity_id": ["T10"]}, "Drug": {"text": [["fludarabine"], ["autologous peripheral blood stem-cell"]], "start": [[147], [181]], "entity_id": ["T11", "T12"]}, "Route": {"text": [["transplantation"]], "start": [[219]], "entity_id": ["T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["followed by"]], "start": [[169]], "entity_id": ["T14"]}, "Drug": {"text": [["fludarabine"], ["autologous peripheral blood stem-cell"]], "start": [[147], [181]], "entity_id": ["T11", "T12"]}}]}, "Effect": {"text": [["AML", "lung cancer"]], "start": [[43, 51]], "entity_id": ["T9"]}, "Subject": {"text": [["a patient with previously diagnosed CLL in minimal residual disease status"]], "start": [[66]], "entity_id": ["T5"]}}]}]}
{"id": "12095907_2", "context": "Valproate-induced hyperammonemia as a cause of altered mental status.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[10]], "entity_id": ["T6"]}, "Treatment": {"text": [["Valproate"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Valproate"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["altered mental status", "hyperammonemia"]], "start": [[47, 18]], "entity_id": ["T7"]}}]}]}
{"id": "6353252_3", "context": "We report 5 cases of acute reversible renal failure coinciding with the onset of treatment with captopril in patients with severe drug-resistant hypertension.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["onset of treatment"]], "start": [[72]], "entity_id": ["T7"]}, "Treatment": {"text": [["captopril"]], "start": [[96]], "entity_id": ["T4"], "Drug": {"text": [["captopril"]], "start": [[96]], "entity_id": ["T8"]}, "Disorder": {"text": [["severe drug-resistant hypertension"]], "start": [[123]], "entity_id": ["T9"]}}, "Subject": {"text": [["patients with severe drug-resistant hypertension"]], "start": [[109]], "entity_id": ["T6"]}, "Effect": {"text": [["acute reversible renal failure"]], "start": [[21]], "entity_id": ["T3"]}, "Severity": {"text": [["acute"]], "start": [[21]], "entity_id": ["T11"], "value": "High"}}]}]}
{"id": "9375469_3", "context": "We report a case of contact dermatitis due to sodium bisulfite in Tathion eye drops.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[39]], "entity_id": ["T5"]}, "Effect": {"text": [["contact dermatitis"]], "start": [[20]], "entity_id": ["T3"]}, "Treatment": {"text": [["sodium bisulfite"]], "start": [[46]], "entity_id": ["T4"], "Drug": {"text": [["sodium bisulfite"]], "start": [[46]], "entity_id": ["T6"]}}}]}]}
{"id": "19815480_1", "context": "The first patient is undergoing hemodialysis and, though responding to sunitinib, is having significant fatigue and hypertension.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["having"]], "start": [[85]], "entity_id": ["T8"]}, "Treatment": {"text": [["sunitinib"]], "start": [[71]], "entity_id": ["T5"], "Drug": {"text": [["sunitinib"]], "start": [[71]], "entity_id": ["T9"]}}, "Subject": {"text": [["The first patient"]], "start": [[0]], "entity_id": ["T7"]}, "Effect": {"text": [["significant fatigue and hypertension"]], "start": [[92]], "entity_id": ["T6"]}}]}]}
{"id": "17536204_4", "context": "CCBs should be considered in the treatment of 5-FU or capecitabine-induced headaches.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatment"]], "start": [[33]], "entity_id": ["T5"]}, "Treatment": {"text": [["CCBs"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["CCBs"]], "start": [[0]], "entity_id": ["T7"]}, "Disorder": {"text": [["headaches"]], "start": [[75]], "entity_id": ["T8"]}}}]}]}
{"id": "9337441_8", "context": "Furosemide, spironolactone, allopurinol, and hydroxyurea were considered possible causes of the reaction and were discontinued.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["causes"]], "start": [[82]], "entity_id": ["T9"]}, "Treatment": {"text": [["Furosemide, spironolactone, allopurinol, and hydroxyurea"]], "start": [[0]], "entity_id": ["T7"], "Drug": {"text": [["Furosemide"], ["spironolactone"], ["allopurinol"], ["hydroxyurea"]], "start": [[0], [12], [28], [45]], "entity_id": ["T10", "T11", "T12", "T13"]}}, "Effect": {"text": [["reaction"]], "start": [[96]], "entity_id": ["T8"]}}]}]}
{"id": "11414270_5", "context": "PATIENTS: One patient with mucositis secondary to chemotherapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["secondary"]], "start": [[37]], "entity_id": ["T5"]}, "Treatment": {"text": [["chemotherapy"]], "start": [[50]], "entity_id": ["T6"], "Route": {"text": [["chemotherapy"]], "start": [[50]], "entity_id": ["T10"]}}, "Effect": {"text": [["mucositis"]], "start": [[27]], "entity_id": ["T7"]}, "Subject": {"text": [["One patient"]], "start": [[10]], "entity_id": ["T8"], "Population": {"text": [["One"]], "start": [[10]], "entity_id": ["T9"]}}}]}]}
{"id": "15266150_1", "context": "A patient with monocular open-angle glaucoma had trichiasis, a condition associated with the use of a prostaglandin analog.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["had"]], "start": [[45]], "entity_id": ["T5"]}, "Subject": {"text": [["A patient with monocular open-angle glaucoma"]], "start": [[0]], "entity_id": ["T3"]}, "Effect": {"text": [["trichiasis"]], "start": [[49]], "entity_id": ["T4"]}, "Treatment": {"text": [["a prostaglandin analog"]], "start": [[100]], "entity_id": ["T6"], "Disorder": {"text": [["monocular open-angle glaucoma"]], "start": [[15]], "entity_id": ["T7"]}, "Drug": {"text": [["prostaglandin analog"]], "start": [[102]], "entity_id": ["T8"]}}}]}]}
{"id": "21189363_3", "context": "A 53-year-old African American male with HIV was prescribed warfarin 5 mg/day for 12 months after diagnosis of idiopathic deep vein thrombosis and bilateral pulmonary emboli (target INR 2.5 [range 2.0-3.0]).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["prescribed"]], "start": [[49]], "entity_id": ["T8"]}, "Subject": {"text": [["A 53-year-old African American male with HIV"]], "start": [[0]], "entity_id": ["T7"], "Age": {"text": [["53-year-old"]], "start": [[2]], "entity_id": ["T11"]}, "Race": {"text": [["African American"]], "start": [[14]], "entity_id": ["T12"]}, "Gender": {"text": [["male"]], "start": [[31]], "entity_id": ["T13"]}, "Disorder": {"text": [["HIV"]], "start": [[41]], "entity_id": ["T14"]}}, "Treatment": {"text": [["warfarin 5 mg/day for 12 months"]], "start": [[60]], "entity_id": ["T9"], "Drug": {"text": [["warfarin"]], "start": [[60]], "entity_id": ["T15"]}, "Dosage": {"text": [["5 mg/day"]], "start": [[69]], "entity_id": ["T16"]}, "Duration": {"text": [["12 months"]], "start": [[82]], "entity_id": ["T18"]}, "Disorder": {"text": [["idiopathic deep vein thrombosis and bilateral pulmonary emboli"]], "start": [[111]], "entity_id": ["T19"]}}}]}]}
{"id": "18836269_1", "context": "After treatment with a beta-sympathomimetic drug (Partusisten) one fetus developed supraventricular tachycardia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[73]], "entity_id": ["T3"]}, "Treatment": {"text": [["a beta-sympathomimetic drug (Partusisten)"]], "start": [[21]], "entity_id": ["T4"], "Drug": {"text": [["Partusisten"]], "start": [[50]], "entity_id": ["T8"]}}, "Subject": {"text": [["one fetus"]], "start": [[63]], "entity_id": ["T5"], "Age": {"text": [["fetus"]], "start": [[67]], "entity_id": ["T7"]}}, "Effect": {"text": [["supraventricular tachycardia."]], "start": [[83]], "entity_id": ["T6"]}}]}]}
{"id": "17189581_16", "context": "Serotonin syndrome developed in a patient taking concurrent linezolid and fluoxetine.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[19]], "entity_id": ["T6"]}, "Subject": {"text": [["a patient"]], "start": [[32]], "entity_id": ["T7"]}, "Treatment": {"text": [["concurrent linezolid and fluoxetine"]], "start": [[49]], "entity_id": ["T8"], "Drug": {"text": [["linezolid"], ["fluoxetine"]], "start": [[60], [74]], "entity_id": ["T11", "T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["concurrent"]], "start": [[49]], "entity_id": ["T10"]}, "Drug": {"text": [["linezolid"], ["fluoxetine"]], "start": [[60], [74]], "entity_id": ["T11", "T12"]}}]}, "Effect": {"text": [["Serotonin syndrome"]], "start": [[0]], "entity_id": ["T9"]}}]}]}
{"id": "18533420_2", "context": "RESULTS: A male and a female patient with spasticity treated with intrathecal baclofen were recognized to have sexual dysfunction side effects from treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[53]], "entity_id": ["T7"]}, "Subject": {"text": [["A male and a female patient with spasticity"]], "start": [[9]], "entity_id": ["T3"], "Gender": {"text": [["male"], ["female"]], "start": [[11], [22]], "entity_id": ["T8", "T9"]}}, "Treatment": {"text": [["intrathecal baclofen"]], "start": [[66]], "entity_id": ["T5"], "Disorder": {"text": [["spasticity"]], "start": [[42]], "entity_id": ["T4"]}, "Drug": {"text": [["baclofen"]], "start": [[78]], "entity_id": ["T10"]}, "Route": {"text": [["intrathecal"]], "start": [[66]], "entity_id": ["T11"]}}, "Effect": {"text": [["sexual dysfunction"]], "start": [[111]], "entity_id": ["T6"]}}]}]}
{"id": "8672829_5", "context": "OBJECTIVE: To describe a patient with ifosfamide-induced nonconvulsive status epilepticus.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[49]], "entity_id": ["T5"]}, "Subject": {"text": [["patient"]], "start": [[25]], "entity_id": ["T3"]}, "Treatment": {"text": [["ifosfamide"]], "start": [[38]], "entity_id": ["T4"], "Drug": {"text": [["ifosfamide"]], "start": [[38]], "entity_id": ["T7"]}}, "Effect": {"text": [["nonconvulsive status epilepticus"]], "start": [[57]], "entity_id": ["T6"]}}]}]}
{"id": "18252776_1", "context": "Upper gastrointestinal haemorrhage is a serious complication of aspirin and clopidogrel (dual) anti-platelet therapy with a high morbidity and mortality.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[48]], "entity_id": ["T4"]}, "Effect": {"text": [["Upper gastrointestinal haemorrhage"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["aspirin and clopidogrel (dual)"]], "start": [[64]], "entity_id": ["T6"]}}]}]}
{"id": "17448102_2", "context": "Flecainide overdose can rapidly result in profound cardiovascular collapse, and is associated with a relatively high mortality.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["result"]], "start": [[32]], "entity_id": ["T8"]}, "Treatment": {"text": [["Flecainide overdose"]], "start": [[0]], "entity_id": ["T7"], "Drug": {"text": [["Flecainide"]], "start": [[0]], "entity_id": ["T10"]}, "Dosage": {"text": [["overdose"]], "start": [[11]], "entity_id": ["T11"]}}, "Effect": {"text": [["profound cardiovascular collapse, and is associated with a relatively high mortality"]], "start": [[42]], "entity_id": ["T9"]}}]}]}
{"id": "2894766_4", "context": "Sulfasalazine-induced lupus erythematosus.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[14]], "entity_id": ["T4"]}, "Treatment": {"text": [["Sulfasalazine"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Sulfasalazine"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["lupus erythematosus"]], "start": [[22]], "entity_id": ["T5"]}}]}]}
{"id": "4036917_2", "context": "Reye syndrome (RS) is believed to occur infrequently among children receiving long-term aspirin therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occur"]], "start": [[34]], "entity_id": ["T8"]}, "Effect": {"text": [["Reye syndrome (RS)"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["long-term aspirin"]], "start": [[78]], "entity_id": ["T6"], "Drug": {"text": [["aspirin"]], "start": [[88]], "entity_id": ["T11"]}}, "Subject": {"text": [["children"]], "start": [[59]], "entity_id": ["T7"], "Age": {"text": [["children"]], "start": [[59]], "entity_id": ["T10"]}}}]}]}
{"id": "14746605_2", "context": "Propecia-associated bilateral cataract.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[9]], "entity_id": ["T4"]}, "Treatment": {"text": [["Propecia"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Propecia"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["bilateral cataract"]], "start": [[20]], "entity_id": ["T5"]}}]}]}
{"id": "12921505_1", "context": "After 39 hours on argatroban, the infusion was stopped when minor bleeding was observed with a concurrent activated partial thromboplastin time (aPTT) of 100 seconds.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["After"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["argatroban"]], "start": [[18]], "entity_id": ["T3"], "Time_elapsed": {"text": [["39 hours"]], "start": [[6]], "entity_id": ["T6"]}, "Drug": {"text": [["argatroban"]], "start": [[18]], "entity_id": ["T7"]}}, "Effect": {"text": [["minor bleeding was observed with a concurrent activated partial thromboplastin time (aPTT) of 100 seconds"]], "start": [[60]], "entity_id": ["T4"]}, "Severity": {"text": [["minor"]], "start": [[60]], "entity_id": ["T8"], "value": "Low"}}]}]}
{"id": "6540393_2", "context": "Anaphylactoid reaction to methylprednisolone pulsed therapy for multiple sclerosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["to"]], "start": [[23]], "entity_id": ["T6"]}, "Treatment": {"text": [["methylprednisolone pulsed therapy"]], "start": [[26]], "entity_id": ["T3"], "Disorder": {"text": [["multiple sclerosis"]], "start": [[64]], "entity_id": ["T4"]}, "Drug": {"text": [["methylprednisolone"]], "start": [[26]], "entity_id": ["T7"]}}, "Effect": {"text": [["Anaphylactoid reaction"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "17044380_2", "context": "Warfarin-induced skin necrosis and heparin-induced thrombocytopenia following mitral valve replacement for marantic endocarditis.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[9]], "entity_id": ["T9"]}, "Treatment": {"text": [["Warfarin"]], "start": [[0]], "entity_id": ["T7"], "Drug": {"text": [["Warfarin"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["skin necrosis"]], "start": [[17]], "entity_id": ["T6"]}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[43]], "entity_id": ["T12"]}, "Treatment": {"text": [["heparin"]], "start": [[35]], "entity_id": ["T10"], "Disorder": {"text": [["marantic endocarditis"]], "start": [[107]], "entity_id": ["T14"]}, "Drug": {"text": [["heparin"]], "start": [[35]], "entity_id": ["T11"]}}, "Effect": {"text": [["thrombocytopenia"]], "start": [[51]], "entity_id": ["T13"]}}]}]}
{"id": "18020545_1", "context": "Surprisingly, we found that three patients appeared to develop tardive OGC while taking clozapine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["develop"]], "start": [[55]], "entity_id": ["T3"]}, "Effect": {"text": [["tardive OGC"]], "start": [[63]], "entity_id": ["T4"]}, "Treatment": {"text": [["clozapine"]], "start": [[88]], "entity_id": ["T5"], "Drug": {"text": [["clozapine"]], "start": [[88]], "entity_id": ["T8"]}}, "Subject": {"text": [["three patients"]], "start": [[28]], "entity_id": ["T6"], "Population": {"text": [["three"]], "start": [[28]], "entity_id": ["T7"]}}, "Speculated": {"text": [["appeared"]], "start": [[43]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "11207969_4", "context": "We report a fatal case of toxic epidermal necrolysis (TEN) resulting from a high dose of cytosine arabinoside (ARA-C).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulting from"]], "start": [[59]], "entity_id": ["T9"]}, "Effect": {"text": [["toxic epidermal necrolysis (TEN)"]], "start": [[26]], "entity_id": ["T7"]}, "Treatment": {"text": [["high dose of cytosine arabinoside (ARA-C)"]], "start": [[76]], "entity_id": ["T8"], "Drug": {"text": [["cytosine arabinoside (ARA-C)"]], "start": [[89]], "entity_id": ["T10"]}, "Dosage": {"text": [["high dose"]], "start": [[76]], "entity_id": ["T11"]}}, "Severity": {"text": [["fatal"]], "start": [[12]], "entity_id": ["T12"], "value": "High"}}]}]}
{"id": "11207969_2", "context": "On the fifth day after administration of a high dose of ARA-C (2 g/m2 intravenously every 12 hours), she developed bullous lesions on the hands and soles that disseminated, evolving to necrosis, sepsis, and death on the 22nd day.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[105]], "entity_id": ["T8"]}, "Treatment": {"text": [["high dose of ARA-C"]], "start": [[43]], "entity_id": ["T7"], "Drug": {"text": [["ARA-C"]], "start": [[56]], "entity_id": ["T10"]}, "Dosage": {"text": [["high dose"], ["2 g/m2"]], "start": [[43], [63]], "entity_id": ["T11", "T13"]}, "Time_elapsed": {"text": [["the fifth day"], ["the 22nd day"]], "start": [[3], [216]], "entity_id": ["T12", "T15"]}, "Freq": {"text": [["12 hours"]], "start": [[90]], "entity_id": ["T14"]}}, "Effect": {"text": [["bullous lesions on the hands and soles that disseminated, evolving to necrosis, sepsis, and death"]], "start": [[115]], "entity_id": ["T9"]}}]}]}
{"id": "8730143_3", "context": "We describe 2 patients with cutaneous lupus erythematosus who developed severe dapsone reaction after low dose therapy, with a fatal outcome in one.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[96]], "entity_id": ["T6"]}, "Subject": {"text": [["2 patients with cutaneous lupus erythematosus"]], "start": [[12]], "entity_id": ["T5"], "Population": {"text": [["2"]], "start": [[12]], "entity_id": ["T9"]}}, "Treatment": {"text": [["low dose therapy"]], "start": [[102]], "entity_id": ["T7"], "Disorder": {"text": [["cutaneous lupus erythematosus"]], "start": [[28]], "entity_id": ["T10"]}, "Dosage": {"text": [["low dose"]], "start": [[102]], "entity_id": ["T12"]}, "Drug": {"text": [["dapsone"]], "start": [[79]], "entity_id": ["T13"]}}, "Effect": {"text": [["severe dapsone reaction", "with a fatal outcome in one"]], "start": [[72, 120]], "entity_id": ["T8"]}, "Severity": {"text": [["fatal"]], "start": [[127]], "entity_id": ["T11"], "value": "High"}}]}]}
{"id": "1359782_1", "context": "A patient with ulcerative colitis developed skin pigmentation and diffuse pulmonary shadowing without respiratory symptomatology, while taking sulfasalazine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[34]], "entity_id": ["T6"]}, "Treatment": {"text": [["sulfasalazine"]], "start": [[143]], "entity_id": ["T8"], "Drug": {"text": [["sulfasalazine"]], "start": [[143]], "entity_id": ["T10"]}, "Disorder": {"text": [["ulcerative colitis"]], "start": [[15]], "entity_id": ["T11"]}}, "Subject": {"text": [["A patient with ulcerative colitis"]], "start": [[0]], "entity_id": ["T5"]}, "Effect": {"text": [["skin pigmentation and diffuse pulmonary shadowing without respiratory symptomatology"]], "start": [[44]], "entity_id": ["T7"]}}]}]}
{"id": "23552010_2", "context": "This is a case report involving a patient who was treated with topical 5-FU cream and subsequently developed a severe case of angioedema.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[99]], "entity_id": ["T6"]}, "Subject": {"text": [["a patient"]], "start": [[32]], "entity_id": ["T4"]}, "Treatment": {"text": [["topical 5-FU cream"]], "start": [[63]], "entity_id": ["T5"], "Route": {"text": [["topical"]], "start": [[63]], "entity_id": ["T8"]}, "Drug": {"text": [["5-FU"]], "start": [[71]], "entity_id": ["T9"]}}, "Effect": {"text": [["a severe case of angioedema"]], "start": [[109]], "entity_id": ["T7"]}}]}]}
{"id": "10555917_2", "context": "Cessation of D-Pen and the start of corticosteroid therapy were followed by recovery from bicytopenia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["followed"]], "start": [[64]], "entity_id": ["T5"]}, "Treatment": {"text": [["Cessation of D-Pen and the start of corticosteroid therapy"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["D-Pen"], ["corticosteroid"]], "start": [[13], [36]], "entity_id": ["T3", "T7"]}, "Disorder": {"text": [["bicytopenia"]], "start": [[90]], "entity_id": ["T1"]}}, "Effect": {"text": [["recovery from bicytopenia"]], "start": [[76]], "entity_id": ["T6"]}}]}]}
{"id": "21751666_3", "context": "Prevention of infection by immunization, together with early recognition and prompt antiviral treatment are critical.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["Prevention"]], "start": [[0]], "entity_id": ["T6"]}, "Treatment": {"text": [["immunization, together with early recognition and prompt antiviral treatment"]], "start": [[27]], "entity_id": ["T8"], "Disorder": {"text": [["infection"]], "start": [[14]], "entity_id": ["T7"]}}}]}]}
{"id": "10879669_1", "context": "A case of normotensive scleroderma renal crisis after high-dose methylprednisolone treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[48]], "entity_id": ["T4"]}, "Effect": {"text": [["normotensive scleroderma renal crisis"]], "start": [[10]], "entity_id": ["T3"]}, "Treatment": {"text": [["high-dose methylprednisolone treatment"]], "start": [[54]], "entity_id": ["T5"], "Dosage": {"text": [["high-dose"]], "start": [[54]], "entity_id": ["T7"]}, "Drug": {"text": [["methylprednisolone"]], "start": [[64]], "entity_id": ["T8"]}}, "Subject": {"text": [["A case"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "16411025_3", "context": "OBJECTIVES: A delayed stroke-like leukoencephalopathy has been observed in patients receiving methotrexate (MTX) for childhood leukemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["has been observed"]], "start": [[54]], "entity_id": ["T4"]}, "Effect": {"text": [["delayed stroke-like leukoencephalopathy"]], "start": [[14]], "entity_id": ["T5"]}, "Treatment": {"text": [["methotrexate (MTX)"]], "start": [[94]], "entity_id": ["T6"], "Drug": {"text": [["methotrexate"]], "start": [[94]], "entity_id": ["T9"]}, "Disorder": {"text": [["childhood leukemia"]], "start": [[117]], "entity_id": ["T10"]}}, "Subject": {"text": [["patients", "childhood leukemia"]], "start": [[75, 117]], "entity_id": ["T8"], "Age": {"text": [["childhood"]], "start": [[117]], "entity_id": ["T7"]}}}]}]}
{"id": "25538343_1", "context": "Duloxetine-induced hyponatremia in an elderly patient treated with thiazide diuretics.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T10"]}, "Treatment": {"text": [["Duloxetine"]], "start": [[0]], "entity_id": ["T9"], "Drug": {"text": [["Duloxetine"], ["thiazide diuretics"]], "start": [[0], [67]], "entity_id": ["T13", "T15"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["with"]], "start": [[62]], "entity_id": ["T12"]}, "Drug": {"text": [["thiazide diuretics"], ["Duloxetine"]], "start": [[67], [0]], "entity_id": ["T15", "T13"]}}]}, "Effect": {"text": [["hyponatremia"]], "start": [[19]], "entity_id": ["T11"]}, "Subject": {"text": [["an elderly patient treated with thiazide diuretics"]], "start": [[35]], "entity_id": ["T7"], "Age": {"text": [["elderly"]], "start": [[38]], "entity_id": ["T8"]}}}]}]}
{"id": "16623611_2", "context": "The following is a case report analysis intended to draw attention to the need for better care coordination by describing the observed relationship of olanzapine to metabolic changes manifested as uncontrolled diabetes mellitus and weight gain.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["relationship"]], "start": [[135]], "entity_id": ["T5"]}, "Treatment": {"text": [["olanzapine"]], "start": [[151]], "entity_id": ["T6"], "Drug": {"text": [["olanzapine"]], "start": [[151]], "entity_id": ["T8"]}}, "Effect": {"text": [["metabolic changes manifested as uncontrolled diabetes mellitus and weight gain"]], "start": [[165]], "entity_id": ["T7"]}}]}]}
{"id": "10466445_2", "context": "Arsenic trioxide has recently been introduced as a promising new agent to treat refractory acute promyelocytic leukemia (APL).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treat"]], "start": [[74]], "entity_id": ["T6"]}, "Treatment": {"text": [["Arsenic trioxide"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Arsenic trioxide"]], "start": [[0]], "entity_id": ["T8"]}, "Disorder": {"text": [["refractory acute promyelocytic leukemia"]], "start": [[80]], "entity_id": ["T9"]}}}]}]}
{"id": "10779995_1", "context": "Although the t-AML developed following oral etoposide therapy, the child had previously received high-dose, multiagent chemotherapy, and rearrangement of the MLL gene was not demonstrated.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[19]], "entity_id": ["T7"]}, "Subject": {"text": [["the child"]], "start": [[63]], "entity_id": ["T3"], "Age": {"text": [["child"]], "start": [[67]], "entity_id": ["T6"]}}, "Effect": {"text": [["the t-AML"]], "start": [[9]], "entity_id": ["T4"]}, "Treatment": {"text": [["oral etoposide therapy", "high-dose, multiagent chemotherapy"]], "start": [[39, 97]], "entity_id": ["T5"], "Drug": {"text": [["etoposide"], ["chemotherapy"]], "start": [[44], [119]], "entity_id": ["T8", "T11"]}, "Route": {"text": [["oral"]], "start": [[39]], "entity_id": ["T9"]}, "Dosage": {"text": [["high-dose"]], "start": [[97]], "entity_id": ["T13"]}, "Combination": [{"event_id": "E1", "event_type": "Combination", "Trigger": {"text": [["received"]], "start": [[88]], "entity_id": ["T10"]}, "Drug": {"text": [["chemotherapy"], ["etoposide"]], "start": [[119], [44]], "entity_id": ["T11", "T8"]}}]}}]}]}
{"id": "15107195_2", "context": "Heat stroke in schizophrenia during clozapine treatment: rapid recognition and management.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[29]], "entity_id": ["T3"]}, "Effect": {"text": [["Heat stroke"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["clozapine"]], "start": [[36]], "entity_id": ["T6"], "Disorder": {"text": [["schizophrenia"]], "start": [[15]], "entity_id": ["T5"]}, "Drug": {"text": [["clozapine"]], "start": [[36]], "entity_id": ["T7"]}}}]}]}
{"id": "25957434_4", "context": "The same symptoms recurred few days after taking nitrendipine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["taking"]], "start": [[42]], "entity_id": ["T5"]}, "Treatment": {"text": [["nitrendipine", "few days after"]], "start": [[49, 27]], "entity_id": ["T4"], "Time_elapsed": {"text": [["few days afte"]], "start": [[27]], "entity_id": ["T7"]}, "Drug": {"text": [["nitrendipine"]], "start": [[49]], "entity_id": ["T8"]}}, "Effect": {"text": [["same symptoms"]], "start": [[4]], "entity_id": ["T6"]}}]}]}
{"id": "16062101_3", "context": "The authors report two cases of acute dystonic reactions (ADRs) as a side effect of lamivudine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["effect"]], "start": [[74]], "entity_id": ["T8"]}, "Subject": {"text": [["two cases"]], "start": [[19]], "entity_id": ["T5"], "Population": {"text": [["two"]], "start": [[19]], "entity_id": ["T9"]}}, "Effect": {"text": [["acute dystonic reactions (ADRs)"]], "start": [[32]], "entity_id": ["T6"]}, "Treatment": {"text": [["lamivudine"]], "start": [[84]], "entity_id": ["T7"], "Drug": {"text": [["lamivudine"]], "start": [[84]], "entity_id": ["T10"]}}}]}]}
{"id": "12751276_1", "context": "Isoniazid-induced anaphylaxis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[10]], "entity_id": ["T4"]}, "Treatment": {"text": [["Isoniazid"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Isoniazid"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["anaphylaxis"]], "start": [[18]], "entity_id": ["T6"]}}]}]}
{"id": "18067642_3", "context": "Histopathology of the thyroid in amiodarone-induced hypothyroidism.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[44]], "entity_id": ["T4"]}, "Treatment": {"text": [["amiodarone"]], "start": [[33]], "entity_id": ["T3"], "Drug": {"text": [["amiodarone"]], "start": [[33]], "entity_id": ["T6"]}}, "Effect": {"text": [["hypothyroidism"]], "start": [[52]], "entity_id": ["T5"]}}]}]}
{"id": "15300114_1", "context": "Deepening of lid sulcus from topical bimatoprost therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["from"]], "start": [[24]], "entity_id": ["T4"]}, "Effect": {"text": [["Deepening of lid sulcus"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["bimatoprost"]], "start": [[37]], "entity_id": ["T5"], "Drug": {"text": [["bimatoprost"]], "start": [[37]], "entity_id": ["T6"]}}}]}]}
{"id": "2979256_2", "context": "Gastro-oesophageal reflux associated with nifedipine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[26]], "entity_id": ["T4"]}, "Effect": {"text": [["Gastro-oesophageal reflux"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["nifedipine"]], "start": [[42]], "entity_id": ["T5"], "Drug": {"text": [["nifedipine"]], "start": [[42]], "entity_id": ["T6"]}}}]}]}
{"id": "7919557_1", "context": "CASE SUMMARY: A 68-year-old woman developed a dry, irritating cough within one month of starting quinapril therapy for the treatment of essential hypertension.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["starting"]], "start": [[88]], "entity_id": ["T3"]}, "Treatment": {"text": [["quinapril therapy"]], "start": [[97]], "entity_id": ["T4"], "Time_elapsed": {"text": [["within one month"]], "start": [[68]], "entity_id": ["T9"]}, "Drug": {"text": [["quinapril"]], "start": [[97]], "entity_id": ["T10"]}, "Disorder": {"text": [["essential hypertension"]], "start": [[136]], "entity_id": ["T12"]}}, "Subject": {"text": [["A 68-year-old woman"]], "start": [[14]], "entity_id": ["T5"], "Age": {"text": [["68-year-old"]], "start": [[16]], "entity_id": ["T7"]}, "Gender": {"text": [["woman"]], "start": [[28]], "entity_id": ["T8"]}}, "Effect": {"text": [["a dry, irritating cough"]], "start": [[44]], "entity_id": ["T6"]}}]}]}
{"id": "19567656_4", "context": "Sertraline-induced rhabdomyolysis in an elderly patient with dementia and comorbidities.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T4"]}, "Treatment": {"text": [["Sertraline"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Sertraline"]], "start": [[0]], "entity_id": ["T9"]}}, "Effect": {"text": [["rhabdomyolysis"]], "start": [[19]], "entity_id": ["T5"]}, "Subject": {"text": [["an elderly patient with dementia and comorbidities"]], "start": [[37]], "entity_id": ["T6"], "Age": {"text": [["elderly"]], "start": [[40]], "entity_id": ["T7"]}, "Disorder": {"text": [["dementia"], ["comorbidities"]], "start": [[61], [74]], "entity_id": ["T8", "T1"]}}}]}]}
{"id": "11431864_1", "context": "After the dose of methylprednisolone was reduced from 40 mg to 20 mg i.v. q6h and shifted to other anti-asthma treatment by procaterol metered dose inhaler via spacer, the psychotic reaction disappeared a few hours later.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["disappeared"]], "start": [[191]], "entity_id": ["T3"]}, "Treatment": {"text": [["After the dose of methylprednisolone was reduced from 40 mg to 20 mg i.v. q6h and shifted to other anti-asthma treatment by procaterol metered dose inhaler via spacer", "a few hours later"]], "start": [[0, 203]], "entity_id": ["T5"], "Disorder": {"text": [["psychotic reaction"]], "start": [[172]], "entity_id": ["T4"]}, "Time_elapsed": {"text": [["a few hours"]], "start": [[203]], "entity_id": ["T6"]}, "Drug": {"text": [["methylprednisolone"]], "start": [[18]], "entity_id": ["T7"]}, "Dosage": {"text": [["reduced from 40 mg to 20 mg i.v. q6h"]], "start": [[41]], "entity_id": ["T8"]}, "Route": {"text": [["spacer"]], "start": [[160]], "entity_id": ["T9"]}}}]}]}
{"id": "16649344_3", "context": "Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["for"]], "start": [[88]], "entity_id": ["T9"]}, "Effect": {"text": [["increased lipid levels"]], "start": [[92]], "entity_id": ["T7"]}, "Treatment": {"text": [["Sirolimus works differently from the immunosuppressants currently available"]], "start": [[0]], "entity_id": ["T8"], "Drug": {"text": [["Sirolimus"], ["immunosuppressants"], ["sirolimus"], ["cyclosporine"], ["tacrolimus"]], "start": [[0], [37], [148], [231], [247]], "entity_id": ["T10", "T11", "T12", "T13", "T14"]}}}]}]}
{"id": "21512888_7", "context": "Patient was on warfarin for a prior deep venous thrombosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["for"]], "start": [[24]], "entity_id": ["T6"]}, "Treatment": {"text": [["warfarin"]], "start": [[15]], "entity_id": ["T5"], "Disorder": {"text": [["a prior deep venous thrombosis"]], "start": [[28]], "entity_id": ["T7"]}, "Drug": {"text": [["warfarin"]], "start": [[15]], "entity_id": ["T9"]}}}]}]}
{"id": "15729090_1", "context": "Quetiapine-induced myoclonus.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T5"]}, "Treatment": {"text": [["Quetiapine"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Quetiapine"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["myoclonus"]], "start": [[19]], "entity_id": ["T6"]}}]}]}
{"id": "3391110_1", "context": "Dyspnea possibly associated with controlled-release morphine sulfate tablets.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[17]], "entity_id": ["T4"]}, "Effect": {"text": [["Dyspnea"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["controlled-release morphine sulfate tablets"]], "start": [[33]], "entity_id": ["T5"], "Drug": {"text": [["morphine sulfate"]], "start": [[52]], "entity_id": ["T7"]}, "Route": {"text": [["tablets"]], "start": [[69]], "entity_id": ["T8"]}, "Dosage": {"text": [["controlled-release"]], "start": [[33]], "entity_id": ["T9"]}}, "Speculated": {"text": [["possibly"]], "start": [[8]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "7496198_6", "context": "The incidence of ARE suddenly exceeded 10% of the patients treated by melarsoprol during August 1992 and September 1993.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["by"]], "start": [[67]], "entity_id": ["T7"]}, "Treatment": {"text": [["melarsoprol"]], "start": [[70]], "entity_id": ["T4"], "Drug": {"text": [["melarsoprol"]], "start": [[70]], "entity_id": ["T8"]}, "Duration": {"text": [["August 1992 and September 1993"]], "start": [[89]], "entity_id": ["T9"]}}, "Subject": {"text": [["patients"]], "start": [[50]], "entity_id": ["T5"]}, "Effect": {"text": [["ARE"]], "start": [[17]], "entity_id": ["T6"]}}]}]}
{"id": "426502_1", "context": "A patient with disseminated herpes zoster developed a syndrome of inappropriate antidiuretic hormone and profound hyponatremia secondary to the administration of adenine arabinoside.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[42]], "entity_id": ["T5"]}, "Treatment": {"text": [["adenine arabinoside"]], "start": [[162]], "entity_id": ["T6"], "Drug": {"text": [["adenine arabinoside"]], "start": [[162]], "entity_id": ["T10"]}, "Disorder": {"text": [["disseminated herpes zoster"]], "start": [[15]], "entity_id": ["T11"]}}, "Effect": {"text": [["syndrome of inappropriate antidiuretic hormone and profound hyponatremia"]], "start": [[54]], "entity_id": ["T7"]}, "Subject": {"text": [["A patient with disseminated herpes zoster"]], "start": [[0]], "entity_id": ["T8"]}, "Severity": {"text": [["profound"]], "start": [[105]], "entity_id": ["T12"], "value": "High"}}]}]}
{"id": "2147700_1", "context": "One patient with systemic lupus erythematosus developed erythema multiforme after taking griseofulvin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[76]], "entity_id": ["T4"]}, "Subject": {"text": [["One patient with systemic lupus erythematosus"]], "start": [[0]], "entity_id": ["T3"], "Population": {"text": [["One"]], "start": [[0]], "entity_id": ["T7"]}, "Disorder": {"text": [["systemic lupus erythematosus"]], "start": [[17]], "entity_id": ["T8"]}}, "Effect": {"text": [["erythema multiforme"]], "start": [[56]], "entity_id": ["T5"]}, "Treatment": {"text": [["griseofulvin"]], "start": [[89]], "entity_id": ["T6"], "Drug": {"text": [["griseofulvin"]], "start": [[89]], "entity_id": ["T9"]}}}]}]}
{"id": "19949685_4", "context": "We report a rare case of colonic mucosal necrosis following Kalimate (calcium polystryrene sulfonate), an analogue of Kayexalate without sorbitol in a 34-yr-old man.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[50]], "entity_id": ["T8"]}, "Subject": {"text": [["a 34-yr-old man"]], "start": [[149]], "entity_id": ["T5"], "Age": {"text": [["34-yr-old"]], "start": [[151]], "entity_id": ["T9"]}, "Gender": {"text": [["man"]], "start": [[161]], "entity_id": ["T10"]}}, "Effect": {"text": [["colonic mucosal necrosis"]], "start": [[25]], "entity_id": ["T6"]}, "Treatment": {"text": [["Kalimate (calcium polystryrene sulfonate), an analogue of Kayexalate without sorbitol"]], "start": [[60]], "entity_id": ["T7"], "Drug": {"text": [["Kalimate"], ["(calcium polystryrene sulfonate)"], ["Kayexalate"]], "start": [[60], [69], [118]], "entity_id": ["T11", "T12", "T13"]}}}]}]}
{"id": "18379937_1", "context": "Bilateral anterior uveitis associated with clomiphene citrate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[27]], "entity_id": ["T4"]}, "Effect": {"text": [["Bilateral anterior uveitis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["clomiphene citrate"]], "start": [[43]], "entity_id": ["T5"], "Drug": {"text": [["clomiphene citrate"]], "start": [[43]], "entity_id": ["T6"]}}}]}]}
{"id": "15479299_1", "context": "Progressive anemia following combination therapy with interferon-alpha and interleukin-2 in a patient with metastatic renal cell carcinoma.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[19]], "entity_id": ["T7"]}, "Effect": {"text": [["Progressive anemia"]], "start": [[0]], "entity_id": ["T4"]}, "Subject": {"text": [["a patient with metastatic renal cell carcinoma"]], "start": [[92]], "entity_id": ["T6"]}, "Treatment": {"text": [["combination therapy with interferon-alpha and interleukin-2"]], "start": [[29]], "entity_id": ["T5"], "Disorder": {"text": [["metastatic renal cell carcinoma"]], "start": [[107]], "entity_id": ["T8"]}, "Drug": {"text": [["interferon-alpha"], ["interleukin-2"]], "start": [[54], [75]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combination"]], "start": [[29]], "entity_id": ["T11"]}, "Drug": {"text": [["interferon-alpha"], ["interleukin-2"]], "start": [[54], [75]], "entity_id": ["T9", "T10"]}}]}}]}]}
{"id": "2595431_2", "context": "Metoclopramide-induced parkinsonism.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[15]], "entity_id": ["T4"]}, "Treatment": {"text": [["Metoclopramide"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Metoclopramide"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["parkinsonism"]], "start": [[23]], "entity_id": ["T5"]}}]}]}
{"id": "8461228_1", "context": "A 12 year old patient with atrial flutter is presented, in whom intravenous adenosine was followed by acceleration of the heart rate to a potentially dangerous arrhythmia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["followed by"]], "start": [[90]], "entity_id": ["T10"]}, "Subject": {"text": [["12 year old patient with atrial flutter"]], "start": [[2]], "entity_id": ["T5"], "Age": {"text": [["12 year old"]], "start": [[2]], "entity_id": ["T11"]}}, "Treatment": {"text": [["intravenous adenosine"]], "start": [[64]], "entity_id": ["T7"], "Drug": {"text": [["adenosine"]], "start": [[76]], "entity_id": ["T12"]}, "Route": {"text": [["intravenous"]], "start": [[64]], "entity_id": ["T13"]}, "Disorder": {"text": [["atrial flutter"]], "start": [[27]], "entity_id": ["T14"]}}, "Effect": {"text": [["acceleration of the heart rate to a potentially dangerous arrhythmia"]], "start": [[102]], "entity_id": ["T9"]}, "Speculated": {"text": [["potentially"]], "start": [[138]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "17873198_3", "context": "Similar to reports in patients receiving gefitinib, those with pathologic findings of UIP on resected lung specimens or known pulmonary fibrosis may be at particular risk for erlotinib pulmonary toxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["receiving"]], "start": [[31]], "entity_id": ["T5"]}, "Treatment": {"text": [["gefitinib"]], "start": [[41]], "entity_id": ["T6"], "Drug": {"text": [["gefitinib"]], "start": [[41]], "entity_id": ["T9"]}}, "Subject": {"text": [["patients"]], "start": [[22]], "entity_id": ["T7"]}, "Effect": {"text": [["erlotinib pulmonary toxicity."]], "start": [[175]], "entity_id": ["T8"]}}]}]}
{"id": "11144696_4", "context": "Eleven days after increase of the trimipramine dosage to 100 mg/d, she was hospitalized because of seizures suggesting a secondary generalized grand-mal episode.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["hospitalized"]], "start": [[75]], "entity_id": ["T7"]}, "Treatment": {"text": [["Eleven days after increase of the trimipramine dosage to 100 mg/d"]], "start": [[0]], "entity_id": ["T5"], "Time_elapsed": {"text": [["Eleven days"]], "start": [[0]], "entity_id": ["T10"]}, "Dosage": {"text": [["100 mg/d"]], "start": [[57]], "entity_id": ["T11"]}, "Drug": {"text": [["trimipramine"]], "start": [[34]], "entity_id": ["T12"]}}, "Subject": {"text": [["she"]], "start": [[67]], "entity_id": ["T6"], "Gender": {"text": [["she"]], "start": [[67]], "entity_id": ["T9"]}}, "Effect": {"text": [["seizures suggesting a secondary generalized grand-mal episode"]], "start": [[99]], "entity_id": ["T8"]}}]}]}
{"id": "19707032_3", "context": "AIM: To report a patient with diabetic rubeosis who suffered from acute retinal ischemic change and stroke after intravitreal injection of bevacizumab.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["suffered"]], "start": [[52]], "entity_id": ["T10"]}, "Subject": {"text": [["patient with diabetic rubeosis"]], "start": [[17]], "entity_id": ["T5"]}, "Effect": {"text": [["acute retinal ischemic change and stroke"]], "start": [[66]], "entity_id": ["T7"]}, "Treatment": {"text": [["intravitreal injection of bevacizumab"]], "start": [[113]], "entity_id": ["T9"], "Disorder": {"text": [["diabetic rubeosis"]], "start": [[30]], "entity_id": ["T11"]}, "Drug": {"text": [["bevacizumab"]], "start": [[139]], "entity_id": ["T8"]}, "Route": {"text": [["intravitreal injection"]], "start": [[113]], "entity_id": ["T12"]}}, "Severity": {"text": [["acute"]], "start": [[66]], "entity_id": ["T13"], "value": "High"}}]}]}
{"id": "11174414_1", "context": "Stevens-Johnson syndrome caused by the antiretroviral drug nevirapine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused by"]], "start": [[25]], "entity_id": ["T6"]}, "Effect": {"text": [["Stevens-Johnson syndrome"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["antiretroviral drug nevirapine"]], "start": [[39]], "entity_id": ["T7"], "Drug": {"text": [["nevirapine"]], "start": [[59]], "entity_id": ["T8"]}}}]}]}
{"id": "9476721_2", "context": "From these data, acute generalized dystonia with brainstem and thalamic lesions may occur in WD patients after an initial d-penicillamine therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[105]], "entity_id": ["T5"]}, "Treatment": {"text": [["an initial d-penicillamine therapy"]], "start": [[111]], "entity_id": ["T6"], "Disorder": {"text": [["WD"]], "start": [[93]], "entity_id": ["T9"]}, "Drug": {"text": [["d-penicillamine"]], "start": [[122]], "entity_id": ["T10"]}}, "Subject": {"text": [["WD patients"]], "start": [[93]], "entity_id": ["T7"]}, "Effect": {"text": [["acute generalized dystonia with brainstem and thalamic lesions"]], "start": [[17]], "entity_id": ["T8"]}, "Speculated": {"text": [["may occur"]], "start": [[80]], "entity_id": ["T11"], "value": true}, "Severity": {"text": [["acute"]], "start": [[17]], "entity_id": ["T12"], "value": "High"}}]}]}
{"id": "20412003_2", "context": "Although this combination agent has been associated with a hypersensitivity syndrome involving cutaneous skin eruptions, pediatric cases of TMP-SMX-induced hepatotoxicity are rare.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[148]], "entity_id": ["T8"]}, "Treatment": {"text": [["TMP-SMX"]], "start": [[140]], "entity_id": ["T7"], "Drug": {"text": [["TMP-SMX"]], "start": [[140]], "entity_id": ["T13"]}}, "Effect": {"text": [["hepatotoxicity"]], "start": [[156]], "entity_id": ["T9"]}, "Subject": {"text": [["pediatric cases"]], "start": [[121]], "entity_id": ["T10"], "Age": {"text": [["pediatric"]], "start": [[121]], "entity_id": ["T12"]}}}]}]}
{"id": "21728158_4", "context": "Drug resistant tuberculosis requires more complex and longer treatment with alternative substances.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["requires"]], "start": [[28]], "entity_id": ["T5"]}, "Treatment": {"text": [["complex and longer treatment with alternative substances"]], "start": [[42]], "entity_id": ["T6"], "Disorder": {"text": [["Drug resistant tuberculosis"]], "start": [[0]], "entity_id": ["T4"]}, "Drug": {"text": [["substances"]], "start": [[88]], "entity_id": ["T7"]}, "Duration": {"text": [["complex and longer treatment"]], "start": [[42]], "entity_id": ["T8"]}}}]}]}
{"id": "7668127_1", "context": "Intracranial haemorrhage from a meningioma in a patient receiving aspirin prophylaxis: a case report.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[43]], "entity_id": ["T8"]}, "Effect": {"text": [["Intracranial haemorrhage from a meningioma"]], "start": [[0]], "entity_id": ["T5"]}, "Subject": {"text": [["a patient"]], "start": [[46]], "entity_id": ["T6"]}, "Treatment": {"text": [["aspirin"]], "start": [[66]], "entity_id": ["T9"], "Drug": {"text": [["aspirin"]], "start": [[66]], "entity_id": ["T7"]}}}]}]}
{"id": "10395123_3", "context": "The objective of this report is to describe a case of fixed drug eruption that occurred during omeprazole treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurred"]], "start": [[79]], "entity_id": ["T4"]}, "Effect": {"text": [["fixed drug eruption"]], "start": [[54]], "entity_id": ["T3"]}, "Treatment": {"text": [["during omeprazole treatment"]], "start": [[88]], "entity_id": ["T5"], "Drug": {"text": [["omeprazole"]], "start": [[95]], "entity_id": ["T6"]}}}]}]}
{"id": "10803790_2", "context": "Case 2: A 43-year-old male alcoholic remained completely abstinent with cyanamide treatment for 5 years and complained of general fatigue.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complained"]], "start": [[108]], "entity_id": ["T5"]}, "Subject": {"text": [["A 43-year-old male alcoholic"]], "start": [[8]], "entity_id": ["T3"], "Age": {"text": [["43-year-old"]], "start": [[10]], "entity_id": ["T7"]}, "Gender": {"text": [["male"]], "start": [[22]], "entity_id": ["T8"]}}, "Treatment": {"text": [["completely abstinent with cyanamide treatment for 5 years"]], "start": [[46]], "entity_id": ["T4"], "Disorder": {"text": [["alcoholic"]], "start": [[27]], "entity_id": ["T9"]}, "Drug": {"text": [["cyanamide"]], "start": [[72]], "entity_id": ["T10"]}, "Duration": {"text": [["5 years"]], "start": [[96]], "entity_id": ["T11"]}}, "Effect": {"text": [["general fatigue"]], "start": [[122]], "entity_id": ["T6"]}}]}]}
{"id": "9042097_1", "context": "Delayed hypersensitivity to flurbiprofen.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["to"]], "start": [[25]], "entity_id": ["T4"]}, "Effect": {"text": [["Delayed hypersensitivity"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["flurbiprofen"]], "start": [[28]], "entity_id": ["T5"], "Drug": {"text": [["flurbiprofen"]], "start": [[28]], "entity_id": ["T6"]}}}]}]}
{"id": "10981493_3", "context": "Propafenone-induced ataxia: report of three cases.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[12]], "entity_id": ["T5"]}, "Effect": {"text": [["ataxia"]], "start": [[20]], "entity_id": ["T3"]}, "Treatment": {"text": [["Propafenone"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Propafenone"]], "start": [[0]], "entity_id": ["T8"]}}, "Subject": {"text": [["three cases"]], "start": [[38]], "entity_id": ["T6"], "Population": {"text": [["three"]], "start": [[38]], "entity_id": ["T7"]}}}]}]}
{"id": "11225565_6", "context": "Delavirdine and efavirenz (but not nevirapine) also were strong inhibitors of CYP3A, consistent with clinical hazards of initial cotreatment with either of these drugs and substrates of CYP3A.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["consistent with"]], "start": [[85]], "entity_id": ["T12"]}, "Treatment": {"text": [["Delavirdine and efavirenz (but not nevirapine)"]], "start": [[0]], "entity_id": ["T10"], "Drug": {"text": [["Delavirdine"], ["efavirenz"]], "start": [[0], [16]], "entity_id": ["T14", "T13"]}}, "Effect": {"text": [["clinical hazards"]], "start": [[101]], "entity_id": ["T11"]}}]}]}
{"id": "10688731_2", "context": "This is the first report of UFT-induced scleroderma-like reaction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[32]], "entity_id": ["T5"]}, "Treatment": {"text": [["UFT"]], "start": [[28]], "entity_id": ["T3"], "Drug": {"text": [["UFT"]], "start": [[28]], "entity_id": ["T6"]}}, "Effect": {"text": [["scleroderma-like reaction"]], "start": [[40]], "entity_id": ["T4"]}}]}]}
{"id": "14526130_1", "context": "Can roxithromycin and betamethasone induce acute pancreatitis? A case report.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induce"]], "start": [[36]], "entity_id": ["T5"]}, "Treatment": {"text": [["roxithromycin and betamethasone"]], "start": [[4]], "entity_id": ["T4"], "Drug": {"text": [["roxithromycin"], ["betamethasone"]], "start": [[4], [22]], "entity_id": ["T8", "T9"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[18]], "entity_id": ["T10"]}, "Drug": {"text": [["roxithromycin"], ["betamethasone"]], "start": [[4], [22]], "entity_id": ["T8", "T9"]}}]}, "Effect": {"text": [["acute pancreatitis"]], "start": [[43]], "entity_id": ["T6"]}, "Speculated": {"text": [["?"]], "start": [[61]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "18362995_3", "context": "Up to four percent of patients treated with imatinib may develop hepatotoxicity, which usually resolves with discontinuation of the drug.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["develop"]], "start": [[57]], "entity_id": ["T6"]}, "Subject": {"text": [["Up to four percent of patients"]], "start": [[0]], "entity_id": ["T3"], "Population": {"text": [["Up to four percent"]], "start": [[0]], "entity_id": ["T7"]}}, "Treatment": {"text": [["imatinib"]], "start": [[44]], "entity_id": ["T4"], "Drug": {"text": [["imatinib"]], "start": [[44]], "entity_id": ["T8"]}}, "Effect": {"text": [["hepatotoxicity"]], "start": [[65]], "entity_id": ["T5"]}, "Speculated": {"text": [["may"]], "start": [[53]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "12923827_1", "context": "Schneiderian first-rank symptoms associated with fluvoxamine treatment: a case report.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[33]], "entity_id": ["T3"]}, "Treatment": {"text": [["fluvoxamine"]], "start": [[49]], "entity_id": ["T4"], "Drug": {"text": [["fluvoxamine"]], "start": [[49]], "entity_id": ["T6"]}}, "Effect": {"text": [["Schneiderian first-rank symptoms"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "17655517_5", "context": "Peripheral and optic neuropathy was usually seen after several months of linezolid therapy (median 5 mo), lactic acidosis after several weeks (median 6 wks), and serotonin syndrome after several days (median 4 days).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[49]], "entity_id": ["T11"]}, "Effect": {"text": [["Peripheral and optic neuropathy", "lactic acidosis after several weeks (median 6 wks), and serotonin syndrome after several days (median 4 days)"]], "start": [[0, 106]], "entity_id": ["T10"]}, "Treatment": {"text": [["several months of linezolid therapy (median 5 mo)"]], "start": [[55]], "entity_id": ["T12"], "Drug": {"text": [["linezolid"]], "start": [[73]], "entity_id": ["T14"]}, "Time_elapsed": {"text": [["several months"]], "start": [[55]], "entity_id": ["T15"]}}}]}]}
{"id": "1849334_1", "context": "Muzolimine-induced severe neuromyeloencephalopathy: report of seven cases.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T5"]}, "Treatment": {"text": [["Muzolimine"]], "start": [[0]], "entity_id": ["T4"], "Dosage": {"text": [["Muzolimine"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["neuromyeloencephalopathy"]], "start": [[26]], "entity_id": ["T6"]}, "Severity": {"text": [["severe"]], "start": [[19]], "entity_id": ["T8"], "value": "High"}}]}]}
{"id": "15494638_16", "context": "We conclude peripheral neuropathy with 5-FU is rare.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[34]], "entity_id": ["T6"]}, "Effect": {"text": [["peripheral neuropathy"]], "start": [[12]], "entity_id": ["T5"]}, "Treatment": {"text": [["5-FU"]], "start": [[39]], "entity_id": ["T7"], "Drug": {"text": [["5-FU"]], "start": [[39]], "entity_id": ["T8"]}}, "Speculated": {"text": [["rare"]], "start": [[47]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "7962394_2", "context": "Additionally, danazol produces hepatocellular damage in approximately 10% of women.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["produces"]], "start": [[22]], "entity_id": ["T4"]}, "Treatment": {"text": [["danazol"]], "start": [[14]], "entity_id": ["T3"], "Drug": {"text": [["danazol"]], "start": [[14]], "entity_id": ["T9"]}}, "Effect": {"text": [["hepatocellular damage"]], "start": [[31]], "entity_id": ["T5"]}, "Subject": {"text": [["10% of women"]], "start": [[70]], "entity_id": ["T6"], "Population": {"text": [["10%"]], "start": [[70]], "entity_id": ["T7"]}, "Gender": {"text": [["women"]], "start": [[77]], "entity_id": ["T8"]}}}]}]}
{"id": "17188061_1", "context": "CONCLUSIONS: We report a typical symptoms of Charles-Bonnet syndrome (CBS) in patients with severe AMD after intravitreal Avastin-injections.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[103]], "entity_id": ["T7"]}, "Effect": {"text": [["typical symptoms of Charles-Bonnet syndrome (CBS)"]], "start": [[25]], "entity_id": ["T5"]}, "Subject": {"text": [["patients with severe AMD"]], "start": [[78]], "entity_id": ["T6"]}, "Treatment": {"text": [["intravitreal Avastin-injections"]], "start": [[109]], "entity_id": ["T8"], "Drug": {"text": [["Avastin"]], "start": [[122]], "entity_id": ["T10"]}, "Route": {"text": [["intravitreal", "injections"]], "start": [[109, 130]], "entity_id": ["T11"]}, "Disorder": {"text": [["AMD"]], "start": [[99]], "entity_id": ["T12"]}}}]}]}
{"id": "11033734_3", "context": "Proconvulsive tendency of imipenem/cilastatin is one of its well-known side effects.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["side effects"]], "start": [[71]], "entity_id": ["T6"]}, "Treatment": {"text": [["imipenem/cilastatin"]], "start": [[26]], "entity_id": ["T4"], "Drug": {"text": [["cilastatin"], ["imipenem"]], "start": [[35], [26]], "entity_id": ["T7", "T8"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["/"]], "start": [[34]], "entity_id": ["T9"]}, "Drug": {"text": [["imipenem"], ["cilastatin"]], "start": [[26], [35]], "entity_id": ["T8", "T7"]}}]}, "Effect": {"text": [["Proconvulsive tendency"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "9013348_1", "context": "A 49-year-old man with Crohn's disease treated with prednisone and mesalamine (5-ASA) developed worsening respiratory distress and fever.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[86]], "entity_id": ["T10"]}, "Subject": {"text": [["49-year-old man with Crohn's disease"]], "start": [[2]], "entity_id": ["T9"], "Age": {"text": [["49-year-old"]], "start": [[2]], "entity_id": ["T13"]}, "Gender": {"text": [["man"]], "start": [[14]], "entity_id": ["T14"]}}, "Effect": {"text": [["worsening respiratory distress and fever."]], "start": [[96]], "entity_id": ["T11"]}, "Treatment": {"text": [["prednisone and mesalamine (5-ASA)"]], "start": [[52]], "entity_id": ["T12"], "Disorder": {"text": [["Crohn's disease"]], "start": [[23]], "entity_id": ["T16"]}, "Drug": {"text": [["mesalamine"], ["prednisone"]], "start": [[67], [52]], "entity_id": ["T19", "T20"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[63]], "entity_id": ["T18"]}, "Drug": {"text": [["prednisone"], ["mesalamine"]], "start": [[52], [67]], "entity_id": ["T20", "T19"]}}]}, "Severity": {"text": [["worsening"]], "start": [[96]], "entity_id": ["T17"], "value": "Medium"}}]}]}
{"id": "18721173_3", "context": "OBJECTIVE: This case report outlines a significant type of morbidity due to continued use of gabapentin during an episode of acute renal failure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["use"]], "start": [[86]], "entity_id": ["T3"]}, "Treatment": {"text": [["gabapentin"]], "start": [[93]], "entity_id": ["T4"], "Drug": {"text": [["gabapentin"]], "start": [[93]], "entity_id": ["T7"]}}, "Effect": {"text": [["a significant type of morbidity"]], "start": [[37]], "entity_id": ["T5"]}, "Subject": {"text": [["This case"]], "start": [[11]], "entity_id": ["T6"]}}]}]}
{"id": "18585545_1", "context": "Acute delirium resulting from levofloxacin therapy is an exceedingly rare complication that has been thought to occur more commonly in elderly patients.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulting"]], "start": [[15]], "entity_id": ["T4"]}, "Subject": {"text": [["elderly patients"]], "start": [[135]], "entity_id": ["T3"], "Age": {"text": [["elderly"]], "start": [[135]], "entity_id": ["T7"]}}, "Effect": {"text": [["Acute delirium"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["levofloxacin"]], "start": [[30]], "entity_id": ["T6"], "Drug": {"text": [["levofloxacin"]], "start": [[30]], "entity_id": ["T9"]}}, "Speculated": {"text": [["exceedingly rare"]], "start": [[57]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "17473493_1", "context": "Selective estrogen receptor modulator raloxifene-associated aggravation of nonalcoholic steatohepatitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[49]], "entity_id": ["T4"]}, "Treatment": {"text": [["raloxifene"]], "start": [[38]], "entity_id": ["T3"], "Drug": {"text": [["raloxifene"]], "start": [[38]], "entity_id": ["T6"]}}, "Effect": {"text": [["aggravation of nonalcoholic steatohepatitis"]], "start": [[60]], "entity_id": ["T5"]}}]}]}
{"id": "15162903_4", "context": "The day after methotrexate administration, the patient complained of severe back pain and urinary retention.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complained"]], "start": [[55]], "entity_id": ["T6"]}, "Treatment": {"text": [["The day after methotrexate administration"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["methotrexate"]], "start": [[14]], "entity_id": ["T8"]}, "Time_elapsed": {"text": [["The day after"]], "start": [[0]], "entity_id": ["T9"]}}, "Effect": {"text": [["severe back pain and urinary retention"]], "start": [[69]], "entity_id": ["T7"]}}]}]}
{"id": "11943900_1", "context": "Pulmonary toxicity secondary to procarbazine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["secondary"]], "start": [[19]], "entity_id": ["T5"]}, "Effect": {"text": [["Pulmonary toxicity"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["procarbazine"]], "start": [[32]], "entity_id": ["T4"], "Drug": {"text": [["procarbazine"]], "start": [[32]], "entity_id": ["T6"]}}}]}]}
{"id": "58443_1", "context": "In keeping with findings in the literature, the aortic wall in this case was damaged by secondary changes following irradiation and Bleomycin treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[106]], "entity_id": ["T5"]}, "Effect": {"text": [["aortic wall in this case was damaged"]], "start": [[48]], "entity_id": ["T3"]}, "Treatment": {"text": [["irradiation and Bleomycin treatment."]], "start": [[116]], "entity_id": ["T4"], "Drug": {"text": [["Bleomycin"]], "start": [[132]], "entity_id": ["T6"]}}}]}]}
{"id": "12460237_3", "context": "It has been suggested that PPE caused by cytarabine does not recur with subsequent cytarabine re-challenge.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[31]], "entity_id": ["T9"]}, "Effect": {"text": [["PPE"]], "start": [[27]], "entity_id": ["T8"]}, "Treatment": {"text": [["cytarabine"]], "start": [[41]], "entity_id": ["T10"], "Drug": {"text": [["cytarabine"]], "start": [[41]], "entity_id": ["T11"]}}, "Negated": {"text": [["not"]], "start": [[57]], "entity_id": ["T12"], "value": true}}]}]}
{"id": "9205466_3", "context": "CONCLUSIONS: The value of multihormonal therapy in breast carcinoma is not established, and the addition of progestogens to tamoxifen may not reduce of developing endometrial lesions, including carcinoma.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["may not reduce"]], "start": [[134]], "entity_id": ["T6"]}, "Effect": {"text": [["endometrial lesions"], ["carcinoma"]], "start": [[163], [194]], "entity_id": ["T7", "T8"]}, "Treatment": {"text": [["addition of progestogens to tamoxifen"]], "start": [[96]], "entity_id": ["T5"], "Drug": {"text": [["progestogens"], ["tamoxifen"]], "start": [[108], [124]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["addition"]], "start": [[96]], "entity_id": ["T12"]}, "Drug": {"text": [["progestogens"], ["tamoxifen"]], "start": [[108], [124]], "entity_id": ["T10", "T11"]}}]}, "Speculated": {"text": [["may"]], "start": [[134]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "426502_2", "context": "Inappropriate antidiuretic hormone following adenine arabinoside administration.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[35]], "entity_id": ["T4"]}, "Effect": {"text": [["Inappropriate antidiuretic hormone"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["adenine arabinoside"]], "start": [[45]], "entity_id": ["T5"], "Drug": {"text": [["adenine arabinoside"]], "start": [[45]], "entity_id": ["T6"]}}}]}]}
{"id": "6484655_2", "context": "Ampicillin-associated seizures.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[11]], "entity_id": ["T3"]}, "Treatment": {"text": [["Ampicillin"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Ampicillin"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["seizures"]], "start": [[22]], "entity_id": ["T5"]}}]}]}
{"id": "6692713_4", "context": "We describe a case of fibrosing alveolitis, diagnosed by lung biopsy, in a patient receiving amiodarone which responded to corticosteroid therapy.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["receiving"]], "start": [[83]], "entity_id": ["T7"]}, "Effect": {"text": [["fibrosing alveolitis"]], "start": [[22]], "entity_id": ["T4"]}, "Subject": {"text": [["a patient"]], "start": [[73]], "entity_id": ["T6"]}, "Treatment": {"text": [["amiodarone which responded to corticosteroid therapy"]], "start": [[93]], "entity_id": ["T8"], "Drug": {"text": [["amiodarone"], ["corticosteroid"]], "start": [[93], [123]], "entity_id": ["T5", "T9"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["responded"]], "start": [[110]], "entity_id": ["T3"]}, "Drug": {"text": [["amiodarone"], ["corticosteroid"]], "start": [[93], [123]], "entity_id": ["T5", "T9"]}}]}}]}]}
{"id": "7752014_1", "context": "Furosemide-associated fever.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[11]], "entity_id": ["T5"]}, "Treatment": {"text": [["Furosemide"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Furosemide"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["fever"]], "start": [[22]], "entity_id": ["T6"]}}]}]}
{"id": "18810448_2", "context": "Thymic enlargement in a patient with juvenile idiopathic arthritis during etanercept therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[67]], "entity_id": ["T5"]}, "Effect": {"text": [["Thymic enlargement"]], "start": [[0]], "entity_id": ["T3"]}, "Subject": {"text": [["a patient with juvenile idiopathic arthritis"]], "start": [[22]], "entity_id": ["T4"], "Age": {"text": [["juvenile"]], "start": [[37]], "entity_id": ["T2"]}}, "Treatment": {"text": [["etanercept"]], "start": [[74]], "entity_id": ["T6"], "Drug": {"text": [["etanercept"]], "start": [[74]], "entity_id": ["T8"]}, "Disorder": {"text": [["idiopathic arthritis"]], "start": [[46]], "entity_id": ["T1"]}}}]}]}
{"id": "24846936_1", "context": "Fatal methylene blue associated serotonin toxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[21]], "entity_id": ["T5"]}, "Treatment": {"text": [["methylene blue"]], "start": [[6]], "entity_id": ["T4"], "Drug": {"text": [["methylene blue"]], "start": [[6]], "entity_id": ["T7"]}}, "Effect": {"text": [["serotonin toxicity"]], "start": [[32]], "entity_id": ["T6"]}, "Severity": {"text": [["Fatal"]], "start": [[0]], "entity_id": ["T8"], "value": "High"}}]}]}
{"id": "7900744_4", "context": "Mannitol-induced ARF responds promptly to hemodialysis with rapid resolution of anuria and recovery of renal failure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[9]], "entity_id": ["T3"]}, "Effect": {"text": [["ARF", "anuria", "renal failure"]], "start": [[17, 80, 103]], "entity_id": ["T5"]}, "Treatment": {"text": [["Mannitol"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Mannitol"]], "start": [[0]], "entity_id": ["T6"]}}}]}]}
{"id": "18665833_3", "context": "We report a rare case of recurrent (stuttering) priapism in a patient with protein C deficiency while maintained on Warfarin therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["while"]], "start": [[96]], "entity_id": ["T5"]}, "Effect": {"text": [["recurrent (stuttering) priapism"]], "start": [[25]], "entity_id": ["T6"]}, "Subject": {"text": [["a patient with protein C deficiency"]], "start": [[60]], "entity_id": ["T7"]}, "Treatment": {"text": [["maintained on Warfarin therapy"]], "start": [[102]], "entity_id": ["T8"], "Disorder": {"text": [["protein C deficiency"]], "start": [[75]], "entity_id": ["T9"]}, "Drug": {"text": [["Warfarin"]], "start": [[116]], "entity_id": ["T10"]}}}]}]}
{"id": "16641839_1", "context": "Angioedema and maculopapular eruptions associated with carbamazepine administration.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[39]], "entity_id": ["T6"]}, "Effect": {"text": [["Angioedema and maculopapular eruptions"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["carbamazepine administration."]], "start": [[55]], "entity_id": ["T7"], "Drug": {"text": [["carbamazepine"]], "start": [[55]], "entity_id": ["T8"]}}}]}]}
{"id": "9195619_2", "context": "Mental nerve neuropathy as a result of hepatitis B vaccination.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["result"]], "start": [[29]], "entity_id": ["T4"]}, "Treatment": {"text": [["hepatitis B vaccination"]], "start": [[39]], "entity_id": ["T3"], "Drug": {"text": [["hepatitis B vaccination."]], "start": [[39]], "entity_id": ["T6"]}}, "Effect": {"text": [["Mental nerve neuropathy"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "12860350_2", "context": "We describe a premenopausal woman who, while having tamoxifen due to a diagnosis of in situ ductal carcinoma, developed endometriosis requiring surgery.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[110]], "entity_id": ["T5"]}, "Subject": {"text": [["a premenopausal woman"]], "start": [[12]], "entity_id": ["T3"], "Gender": {"text": [["woman"]], "start": [[28]], "entity_id": ["T9"]}, "Age": {"text": [["premenopausal"]], "start": [[14]], "entity_id": ["T10"]}}, "Treatment": {"text": [["tamoxifen"]], "start": [[52]], "entity_id": ["T6"], "Drug": {"text": [["tamoxifen"]], "start": [[52]], "entity_id": ["T12"]}, "Disorder": {"text": [["in situ ductal carcinoma"]], "start": [[84]], "entity_id": ["T13"]}}, "Effect": {"text": [["endometriosis"]], "start": [[120]], "entity_id": ["T7"]}, "Severity": {"text": [["requiring surgery"]], "start": [[134]], "entity_id": ["T8"], "value": "Medium"}}]}]}
{"id": "12773807_1", "context": "Disseminated cellulitic cryptococcosis in the setting of prednisone monotherapy for pemphigus vulgaris.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in the setting of"]], "start": [[39]], "entity_id": ["T6"]}, "Effect": {"text": [["Disseminated cellulitic cryptococcosis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["prednisone monotherapy"]], "start": [[57]], "entity_id": ["T4"], "Drug": {"text": [["prednisone"]], "start": [[57]], "entity_id": ["T7"]}, "Disorder": {"text": [["pemphigus vulgaris"]], "start": [[84]], "entity_id": ["T8"]}}}]}]}
{"id": "3417739_2", "context": "We describe a 63 year old woman with a suppurative mediastinitis, treated with continuous PI irrigation who developed an acute oliguric renal failure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[108]], "entity_id": ["T6"]}, "Subject": {"text": [["a 63 year old woman with a suppurative mediastinitis"]], "start": [[12]], "entity_id": ["T3"], "Age": {"text": [["63 year old"]], "start": [[14]], "entity_id": ["T8"]}, "Gender": {"text": [["woman"]], "start": [[26]], "entity_id": ["T9"]}}, "Treatment": {"text": [["continuous PI irrigation"]], "start": [[79]], "entity_id": ["T5"], "Drug": {"text": [["PI"]], "start": [[90]], "entity_id": ["T10"]}, "Disorder": {"text": [["suppurative mediastinitis"]], "start": [[39]], "entity_id": ["T11"]}, "Route": {"text": [["irrigation"]], "start": [[93]], "entity_id": ["T12"]}}, "Effect": {"text": [["acute oliguric renal failure"]], "start": [[121]], "entity_id": ["T7"]}}]}]}
{"id": "3128415_1", "context": "A young woman with epilepsy had tonic-clonic seizures during antineoplastic therapy with adriamycin and cisplatin.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["had"]], "start": [[28]], "entity_id": ["T4"]}, "Treatment": {"text": [["antineoplastic therapy with adriamycin and cisplatin."]], "start": [[61]], "entity_id": ["T5"], "Drug": {"text": [["adriamycin"], ["cisplatin"]], "start": [[89], [104]], "entity_id": ["T11", "T12"]}, "Disorder": {"text": [["epilepsy"]], "start": [[19]], "entity_id": ["T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[100]], "entity_id": ["T13"]}, "Drug": {"text": [["adriamycin"], ["cisplatin"]], "start": [[89], [104]], "entity_id": ["T11", "T12"]}}]}, "Subject": {"text": [["A young woman with epilepsy"]], "start": [[0]], "entity_id": ["T6"], "Age": {"text": [["young"]], "start": [[2]], "entity_id": ["T8"]}, "Gender": {"text": [["woman"]], "start": [[8]], "entity_id": ["T9"]}}, "Effect": {"text": [["tonic-clonic seizures"]], "start": [[32]], "entity_id": ["T7"]}}]}]}
{"id": "19567656_1", "context": "CONCLUSIONS: This patient's rhabdomyolysis was probably induced by sertraline therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[56]], "entity_id": ["T5"]}, "Subject": {"text": [["This patient"]], "start": [[13]], "entity_id": ["T3"]}, "Effect": {"text": [["rhabdomyolysis"]], "start": [[28]], "entity_id": ["T4"]}, "Treatment": {"text": [["sertraline"]], "start": [[67]], "entity_id": ["T6"], "Drug": {"text": [["sertraline"]], "start": [[67]], "entity_id": ["T8"]}}, "Speculated": {"text": [["probably"]], "start": [[47]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "16225183_1", "context": "Nephrotic syndrome in a multiple sclerosis patient treated with interferon beta 1a.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[51]], "entity_id": ["T11"]}, "Effect": {"text": [["Nephrotic syndrome"]], "start": [[0]], "entity_id": ["T7"]}, "Subject": {"text": [["a multiple sclerosis patient"]], "start": [[22]], "entity_id": ["T9"]}, "Treatment": {"text": [["interferon beta 1a"]], "start": [[64]], "entity_id": ["T10"], "Drug": {"text": [["interferon beta 1a"]], "start": [[64]], "entity_id": ["T12"]}, "Disorder": {"text": [["multiple sclerosis"]], "start": [[24]], "entity_id": ["T13"]}}}]}]}
{"id": "7937287_8", "context": "In our patient, DIAN possibly was related to cefuroxime, but the patient did not experience associated allergic symptoms.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related to"]], "start": [[34]], "entity_id": ["T8"]}, "Treatment": {"text": [["cefuroxime"]], "start": [[45]], "entity_id": ["T6"], "Drug": {"text": [["cefuroxime"]], "start": [[45]], "entity_id": ["T10"]}}, "Effect": {"text": [["DIAN"]], "start": [[16]], "entity_id": ["T7"]}, "Subject": {"text": [["our patient"]], "start": [[3]], "entity_id": ["T9"]}}]}]}
{"id": "9642842_2", "context": "We describe the case of a nonatopic 17-year-old girl with bronchial asthma and aspirin intolerance who developed a dramatic anaphylactic reaction to oral prednisone.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[103]], "entity_id": ["T4"]}, "Subject": {"text": [["a nonatopic 17-year-old girl with bronchial asthma and aspirin intolerance"]], "start": [[24]], "entity_id": ["T3"], "Disorder": {"text": [["nonatopic"], ["aspirin intolerance"]], "start": [[26], [79]], "entity_id": ["T7", "T11"]}, "Age": {"text": [["17-year-old"]], "start": [[36]], "entity_id": ["T8"]}, "Gender": {"text": [["girl"]], "start": [[48]], "entity_id": ["T9"]}}, "Effect": {"text": [["a dramatic anaphylactic reaction"]], "start": [[113]], "entity_id": ["T5"]}, "Treatment": {"text": [["oral prednisone"]], "start": [[149]], "entity_id": ["T6"], "Route": {"text": [["oral"]], "start": [[149]], "entity_id": ["T12"]}, "Drug": {"text": [["prednisone"]], "start": [[154]], "entity_id": ["T13"]}, "Disorder": {"text": [["bronchial asthma"]], "start": [[58]], "entity_id": ["T14"]}}}]}]}
{"id": "10772434_1", "context": "CASE SUMMARY: A 10-year-old white girl with bilateral optic glioma developed a hypersensitivity reaction to carboplatin after nine courses.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[67]], "entity_id": ["T4"]}, "Subject": {"text": [["A 10-year-old white girl with bilateral optic glioma"]], "start": [[14]], "entity_id": ["T3"], "Age": {"text": [["10-year-old"]], "start": [[16]], "entity_id": ["T7"]}, "Gender": {"text": [["girl"]], "start": [[34]], "entity_id": ["T8"]}, "Race": {"text": [["white"]], "start": [[28]], "entity_id": ["T9"]}}, "Effect": {"text": [["hypersensitivity reaction"]], "start": [[79]], "entity_id": ["T5"]}, "Treatment": {"text": [["carboplatin after nine courses"]], "start": [[108]], "entity_id": ["T6"], "Disorder": {"text": [["bilateral optic glioma"]], "start": [[44]], "entity_id": ["T10"]}, "Drug": {"text": [["carboplatin"]], "start": [[108]], "entity_id": ["T11"]}, "Duration": {"text": [["nine courses"]], "start": [[126]], "entity_id": ["T12"]}}}]}]}
{"id": "18453852_16", "context": "Liver function should be carefully monitored when rifampicin and lopinavir/ritonavir are combined in patients.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["when"]], "start": [[45]], "entity_id": ["T9"]}, "Subject": {"text": [["patients"]], "start": [[101]], "entity_id": ["T7"]}, "Effect": {"text": [["Liver function should be carefully monitored"]], "start": [[0]], "entity_id": ["T6"]}, "Treatment": {"text": [["rifampicin and lopinavir/ritonavir are combined"]], "start": [[50]], "entity_id": ["T8"], "Drug": {"text": [["rifampicin"], ["lopinavir/ritonavir"]], "start": [[50], [65]], "entity_id": ["T12", "T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[61]], "entity_id": ["T11"]}, "Drug": {"text": [["rifampicin"], ["lopinavir/ritonavir"]], "start": [[50], [65]], "entity_id": ["T12", "T13"]}}]}, "Speculated": {"text": [["monitored"]], "start": [[35]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "15504988_2", "context": "We report three patients, all of whom had preexisting diabetic dyslipidemia, who showed a profound reduction in plasma HDL cholesterol and apolipoprotein AI levels soon after the initiation of rosiglitazone therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["initiation"]], "start": [[179]], "entity_id": ["T7"]}, "Subject": {"text": [["three patients"]], "start": [[10]], "entity_id": ["T3"], "Population": {"text": [["three"]], "start": [[10]], "entity_id": ["T8"]}}, "Effect": {"text": [["profound reduction in plasma HDL cholesterol and apolipoprotein AI levels"]], "start": [[90]], "entity_id": ["T5"]}, "Treatment": {"text": [["rosiglitazone therapy"]], "start": [[193]], "entity_id": ["T6"], "Drug": {"text": [["rosiglitazone"]], "start": [[193]], "entity_id": ["T9"]}, "Time_elapsed": {"text": [["soon after"]], "start": [[164]], "entity_id": ["T10"]}, "Disorder": {"text": [["preexisting diabetic dyslipidemia"]], "start": [[42]], "entity_id": ["T11"]}}}]}]}
{"id": "12923827_4", "context": "This finding suggests that fluvoxamine can precipitate Schneiderian first-rank symptoms in some susceptible patients.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["precipitate"]], "start": [[43]], "entity_id": ["T4"]}, "Treatment": {"text": [["fluvoxamine"]], "start": [[27]], "entity_id": ["T3"], "Drug": {"text": [["fluvoxamine"]], "start": [[27]], "entity_id": ["T7"]}}, "Effect": {"text": [["Schneiderian first-rank symptoms"]], "start": [[55]], "entity_id": ["T5"]}, "Subject": {"text": [["some susceptible patients"]], "start": [[91]], "entity_id": ["T6"]}, "Speculated": {"text": [["suggests"]], "start": [[13]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "14960440_3", "context": "Warfarin-associated thoracic aortic dissection in an elderly woman.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[9]], "entity_id": ["T3"]}, "Treatment": {"text": [["Warfarin"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Warfarin"]], "start": [[0]], "entity_id": ["T9"]}}, "Effect": {"text": [["thoracic aortic dissection"]], "start": [[20]], "entity_id": ["T5"]}, "Subject": {"text": [["an elderly woman"]], "start": [[50]], "entity_id": ["T6"], "Age": {"text": [["elderly"]], "start": [[53]], "entity_id": ["T7"]}, "Gender": {"text": [["woman"]], "start": [[61]], "entity_id": ["T8"]}}}]}]}
{"id": "10774758_2", "context": "This is the first report of an adverse effect of fetal renal circulation by maternal ingestion of nimesulide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["adverse effect"]], "start": [[31]], "entity_id": ["T5"]}, "Subject": {"text": [["first report of an adverse effect of fetal renal circulation"]], "start": [[12]], "entity_id": ["T3"]}, "Treatment": {"text": [["maternal ingestion of nimesulide"], ["nimesulide"]], "start": [[76], [98]], "entity_id": ["T4", "T6"], "Drug": {"text": [["nimesulide"]], "start": [[98]], "entity_id": ["T8"]}, "Route": {"text": [["maternal ingestion"]], "start": [[76]], "entity_id": ["T9"]}}, "Effect": {"text": [["fetal renal circulation"]], "start": [[49]], "entity_id": ["T7"]}}]}]}
{"id": "11111942_1", "context": "Diarrhea-associated over-anticoagulation in a patient taking warfarin: therapeutic role of cholestyramine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["over-anticoagulation"]], "start": [[20]], "entity_id": ["T5"]}, "Treatment": {"text": [["warfarin"]], "start": [[61]], "entity_id": ["T3"], "Drug": {"text": [["warfarin"]], "start": [[61]], "entity_id": ["T7"]}}, "Effect": {"text": [["Diarrhea-associated over-anticoagulation"]], "start": [[0]], "entity_id": ["T4"]}, "Subject": {"text": [["patient"]], "start": [[46]], "entity_id": ["T6"]}}]}]}
{"id": "9876809_3", "context": "A 72-year-old white man suddenly developed combative behavior, refused to leave his room, stopped eating, and began falling to the floor 6 weeks after being given ticlopidine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[33]], "entity_id": ["T8"]}, "Subject": {"text": [["A 72-year-old white man"]], "start": [[0]], "entity_id": ["T7"], "Age": {"text": [["72-year-old"]], "start": [[2]], "entity_id": ["T11"]}, "Race": {"text": [["white"]], "start": [[14]], "entity_id": ["T12"]}, "Gender": {"text": [["man"]], "start": [[20]], "entity_id": ["T13"]}}, "Effect": {"text": [["combative behavior, refused to leave his room, stopped eating, and began falling to the floor"]], "start": [[43]], "entity_id": ["T9"]}, "Treatment": {"text": [["6 weeks after being given ticlopidine"]], "start": [[137]], "entity_id": ["T10"], "Time_elapsed": {"text": [["6 weeks"]], "start": [[137]], "entity_id": ["T14"]}, "Drug": {"text": [["ticlopidine"]], "start": [[163]], "entity_id": ["T15"]}}}]}]}
{"id": "71813_4", "context": "The case history confirms that gold treatment, even in the same patient, can give rise to a wide range of skin disturbances, which in many cases do not break out until long after the drug has been withdrawn.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["give rise"]], "start": [[77]], "entity_id": ["T4"]}, "Treatment": {"text": [["gold"]], "start": [[31]], "entity_id": ["T3"], "Drug": {"text": [["gold"]], "start": [[31]], "entity_id": ["T7"]}}, "Effect": {"text": [["wide range of skin disturbances, which in many cases do not break out until long after the drug has been withdrawn"]], "start": [[92]], "entity_id": ["T5"]}, "Subject": {"text": [["in the same patient,"]], "start": [[52]], "entity_id": ["T6"]}}]}]}
{"id": "8828999_3", "context": "Lithium neurotoxicity should be considered in Creutzfeldt-Jakob disease differential diagnosis, serial electroencephalograms being the most valuable.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["considered"]], "start": [[32]], "entity_id": ["T8"]}, "Treatment": {"text": [["Lithium"]], "start": [[0]], "entity_id": ["T5"], "Disorder": {"text": [["Creutzfeldt-Jakob disease"]], "start": [[46]], "entity_id": ["T7"]}, "Drug": {"text": [["Lithium"]], "start": [[0]], "entity_id": ["T10"]}}, "Effect": {"text": [["Lithium neurotoxicity"]], "start": [[0]], "entity_id": ["T6"]}, "Speculated": {"text": [["should"]], "start": [[22]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "7647084_1", "context": "The authors describe a case of neuroleptic malignant syndrome that occurred in a patient on amitriptyline and lithium carbonate.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurred"]], "start": [[67]], "entity_id": ["T6"]}, "Effect": {"text": [["neuroleptic malignant syndrome"]], "start": [[31]], "entity_id": ["T4"]}, "Treatment": {"text": [["amitriptyline and lithium carbonate"]], "start": [[92]], "entity_id": ["T7"], "Drug": {"text": [["amitriptyline"], ["lithium carbonate"]], "start": [[92], [110]], "entity_id": ["T8", "T9"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[106]], "entity_id": ["T10"]}, "Drug": {"text": [["amitriptyline"], ["lithium carbonate"]], "start": [[92], [110]], "entity_id": ["T8", "T9"]}}]}, "Subject": {"text": [["a patient"]], "start": [[79]], "entity_id": ["T5"]}}]}]}
{"id": "15239684_2", "context": "The findings were judged to be consistent with soft-tissue injury associated with intravenous administration of phenytoin, also termed purple glove syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[66]], "entity_id": ["T5"]}, "Treatment": {"text": [["intravenous administration of phenytoin"]], "start": [[82]], "entity_id": ["T6"], "Route": {"text": [["ntravenous administration"]], "start": [[83]], "entity_id": ["T8"]}, "Drug": {"text": [["phenytoin"]], "start": [[112]], "entity_id": ["T9"]}}, "Effect": {"text": [["soft-tissue injury"]], "start": [[47]], "entity_id": ["T7"]}}]}]}
{"id": "10749332_1", "context": "However, as illustrated by these and other cases reported to date, the onset of troglitazone-induced liver injury is insidious and temporally variable.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[93]], "entity_id": ["T3"]}, "Treatment": {"text": [["troglitazone"]], "start": [[80]], "entity_id": ["T4"], "Drug": {"text": [["troglitazone"]], "start": [[80]], "entity_id": ["T6"]}}, "Effect": {"text": [["liver injury is insidious and temporally variable"]], "start": [[101]], "entity_id": ["T5"]}}]}]}
{"id": "2887555_1", "context": "Soon after its introduction in 1952, chlorpromazine was noted to induce symptoms resembling Parkinson's disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induce"]], "start": [[65]], "entity_id": ["T4"]}, "Treatment": {"text": [["chlorpromazine"]], "start": [[37]], "entity_id": ["T3"], "Drug": {"text": [["chlorpromazine"]], "start": [[37]], "entity_id": ["T6"]}}, "Effect": {"text": [["symptoms resembling Parkinson's disease"]], "start": [[72]], "entity_id": ["T5"]}}]}]}
{"id": "9220046_4", "context": "Erythromycin is a macrolide antibiotic that may increase the risk of lovastatin-induced rhabdomyolysis.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[80]], "entity_id": ["T4"]}, "Treatment": {"text": [["Erythromycin"]], "start": [[0]], "entity_id": ["T7"], "Drug": {"text": [["Erythromycin"], ["lovastatin"]], "start": [[0], [69]], "entity_id": ["T8", "T9"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["risk"]], "start": [[61]], "entity_id": ["T10"]}, "Drug": {"text": [["lovastatin"], ["Erythromycin"]], "start": [[69], [0]], "entity_id": ["T9", "T8"]}}]}, "Effect": {"text": [["ncrease the risk of lovastatin-induced rhabdomyolysis"]], "start": [[49]], "entity_id": ["T5"]}, "Speculated": {"text": [["may"]], "start": [[44]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "17189581_3", "context": "A 23-year-old white male patient was originally admitted to receive intravenous chemotherapy for acute myelogenous leukemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["receive"]], "start": [[60]], "entity_id": ["T5"]}, "Treatment": {"text": [["intravenous chemotherapy"]], "start": [[68]], "entity_id": ["T6"], "Drug": {"text": [["chemotherapy"]], "start": [[80]], "entity_id": ["T12"]}, "Disorder": {"text": [["acute myelogenous leukemia"]], "start": [[97]], "entity_id": ["T13"]}, "Route": {"text": [["intravenous"]], "start": [[68]], "entity_id": ["T7"]}}, "Subject": {"text": [["A 23-year-old white male patient"]], "start": [[0]], "entity_id": ["T8"], "Age": {"text": [["23-year-old"]], "start": [[2]], "entity_id": ["T9"]}, "Race": {"text": [["white"]], "start": [[14]], "entity_id": ["T10"]}, "Gender": {"text": [["male"]], "start": [[20]], "entity_id": ["T11"]}}}]}]}
{"id": "2768785_2", "context": "We present two children with acute lymphocytic leukemia who developed leukoencephalopathy following administration of a combination of intravenous ara = C and methotrexate during the consolidation phase of chemotherapy.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[60]], "entity_id": ["T5"]}, "Subject": {"text": [["two children with acute lymphocytic leukemia"]], "start": [[11]], "entity_id": ["T4"], "Population": {"text": [["two"]], "start": [[11]], "entity_id": ["T8"]}, "Age": {"text": [["children"]], "start": [[15]], "entity_id": ["T9"]}}, "Effect": {"text": [["leukoencephalopathy"]], "start": [[70]], "entity_id": ["T6"]}, "Treatment": {"text": [["administration of a combination of intravenous ara = C and methotrexate during the consolidation phase of chemotherapy"]], "start": [[100]], "entity_id": ["T7"], "Disorder": {"text": [["acute lymphocytic leukemia"]], "start": [[29]], "entity_id": ["T10"]}, "Route": {"text": [["intravenous"]], "start": [[135]], "entity_id": ["T12"]}, "Drug": {"text": [["ara = C"], ["methotrexate"]], "start": [[147], [159]], "entity_id": ["T13", "T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combination"]], "start": [[120]], "entity_id": ["T11"]}, "Drug": {"text": [["ara = C"], ["methotrexate"]], "start": [[147], [159]], "entity_id": ["T13", "T14"]}}]}}]}]}
{"id": "2320800_1", "context": "Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complicating"]], "start": [[14]], "entity_id": ["T12"]}, "Subject": {"text": [["a breast cancer patient with an impaired renal function"]], "start": [[64]], "entity_id": ["T9"], "Disorder": {"text": [["an impaired renal function"]], "start": [[93]], "entity_id": ["T1"]}}, "Treatment": {"text": [["high dose ifosfamide chemotherapy"]], "start": [[27]], "entity_id": ["T10"], "Disorder": {"text": [["breast cancer"]], "start": [[66]], "entity_id": ["T13"]}, "Drug": {"text": [["ifosfamide"]], "start": [[37]], "entity_id": ["T14"]}, "Route": {"text": [["chemotherapy"]], "start": [[48]], "entity_id": ["T16"]}, "Dosage": {"text": [["high dose"]], "start": [[27]], "entity_id": ["T17"]}}, "Effect": {"text": [["anuria"]], "start": [[7]], "entity_id": ["T11"]}, "Severity": {"text": [["Lethal"]], "start": [[0]], "entity_id": ["T15"], "value": "High"}}]}]}
{"id": "15013892_2", "context": "CONCLUSIONS: Low dosages of quinacrine used for malaria prophylaxis can be associated with a delayed, severe maculopathy indistinguishable from chloroquine maculopathy in certain patients.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[75]], "entity_id": ["T6"]}, "Effect": {"text": [["a delayed, severe maculopathy"]], "start": [[91]], "entity_id": ["T8"]}, "Treatment": {"text": [["Low dosages of quinacrine used for malaria prophylaxis"]], "start": [[13]], "entity_id": ["T7"], "Time_elapsed": {"text": [["delayed"]], "start": [[93]], "entity_id": ["T10"]}, "Dosage": {"text": [["Low dosages"]], "start": [[13]], "entity_id": ["T12"]}, "Drug": {"text": [["quinacrine"]], "start": [[28]], "entity_id": ["T13"]}, "Disorder": {"text": [["malaria prophylaxis"]], "start": [[48]], "entity_id": ["T14"]}}, "Severity": {"text": [["severe"]], "start": [[102]], "entity_id": ["T9"], "value": "Medium"}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[75]], "entity_id": ["T6"]}, "Treatment": {"text": [["Low dosages of quinacrine used for malaria prophylaxis"]], "start": [[13]], "entity_id": ["T7"], "Time_elapsed": {"text": [["delayed"]], "start": [[93]], "entity_id": ["T10"]}, "Dosage": {"text": [["Low dosages"]], "start": [[13]], "entity_id": ["T12"]}, "Drug": {"text": [["quinacrine"]], "start": [[28]], "entity_id": ["T13"]}, "Disorder": {"text": [["malaria prophylaxis"]], "start": [[48]], "entity_id": ["T14"]}}, "Effect": {"text": [["chloroquine maculopathy"]], "start": [[144]], "entity_id": ["T15"]}, "Subject": {"text": [["certain patients."]], "start": [[171]], "entity_id": ["T5"]}}]}]}
{"id": "10987357_7", "context": "When pilsicainide is prescribed in patients with coronary artery disease or renal dysfunction, close attention must be paid to avoid life-threatening arrhythmias due to high plasma concentrations of the drug.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[162]], "entity_id": ["T13"]}, "Treatment": {"text": [["pilsicainide"]], "start": [[5]], "entity_id": ["T9"], "Drug": {"text": [["pilsicainide"]], "start": [[5]], "entity_id": ["T14"]}}, "Effect": {"text": [["life-threatening arrhythmias"]], "start": [[133]], "entity_id": ["T12"]}, "Subject": {"text": [["patients with coronary artery disease or renal dysfunction,"]], "start": [[35]], "entity_id": ["T10"], "Disorder": {"text": [["coronary artery disease"], ["renal dysfunction"]], "start": [[49], [76]], "entity_id": ["T11", "T1"]}}}]}]}
{"id": "19018868_3", "context": "We describe a case of severe aplastic anemia (AA) that was probably induced by lenalidomide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[68]], "entity_id": ["T5"]}, "Treatment": {"text": [["lenalidomide"]], "start": [[79]], "entity_id": ["T6"], "Drug": {"text": [["lenalidomide"]], "start": [[79]], "entity_id": ["T11"]}}, "Effect": {"text": [["severe aplastic anemia (AA)"]], "start": [[22]], "entity_id": ["T8"]}, "Subject": {"text": [["a case"]], "start": [[12]], "entity_id": ["T9"]}, "Speculated": {"text": [["probably"]], "start": [[59]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "3569037_4", "context": "We present a case report of a patient with typhoid fever who experienced a hypersensitivity reaction subsequent to the infusion of chloramphenicol sodium succinate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["subsequent to"]], "start": [[101]], "entity_id": ["T5"]}, "Subject": {"text": [["a patient with typhoid fever"]], "start": [[28]], "entity_id": ["T3"]}, "Effect": {"text": [["hypersensitivity reaction"]], "start": [[75]], "entity_id": ["T4"]}, "Treatment": {"text": [["the infusion of chloramphenicol sodium succinate"]], "start": [[115]], "entity_id": ["T6"], "Disorder": {"text": [["typhoid fever"]], "start": [[43]], "entity_id": ["T7"]}, "Drug": {"text": [["chloramphenicol sodium succinate"]], "start": [[131]], "entity_id": ["T8"]}, "Route": {"text": [["infusion"]], "start": [[119]], "entity_id": ["T9"]}}}]}]}
{"id": "3310776_3", "context": "This confirmed the history of captopril-related asthma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[40]], "entity_id": ["T4"]}, "Treatment": {"text": [["captopril"]], "start": [[30]], "entity_id": ["T3"], "Drug": {"text": [["captopril"]], "start": [[30]], "entity_id": ["T6"]}}, "Effect": {"text": [["asthma"]], "start": [[48]], "entity_id": ["T5"]}}]}]}
{"id": "9100429_3", "context": "Four cases of adverse experiences with clonidine are described.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[34]], "entity_id": ["T7"]}, "Subject": {"text": [["Four cases"]], "start": [[0]], "entity_id": ["T4"], "Population": {"text": [["Four"]], "start": [[0]], "entity_id": ["T8"]}}, "Treatment": {"text": [["clonidine"]], "start": [[39]], "entity_id": ["T5"], "Drug": {"text": [["clonidine"]], "start": [[39]], "entity_id": ["T9"]}}, "Effect": {"text": [["adverse experiences"]], "start": [[14]], "entity_id": ["T6"]}}]}]}
{"id": "9972383_2", "context": "OBJECTIVE: To report a case of reversible nonthrombocytopenic palpable purpura associated with metoclopramide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[79]], "entity_id": ["T4"]}, "Effect": {"text": [["reversible nonthrombocytopenic palpable purpura"]], "start": [[31]], "entity_id": ["T3"]}, "Treatment": {"text": [["metoclopramide"]], "start": [[95]], "entity_id": ["T5"], "Drug": {"text": [["metoclopramide"]], "start": [[95]], "entity_id": ["T6"]}}}]}]}
{"id": "424824_6", "context": "Three patients received respectively 190 mg, 175 mg, and 196 mg of methotrexate and developed bilateral pulmonary infiltrates without evidence of peripheral blood eosinophilia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[84]], "entity_id": ["T5"]}, "Subject": {"text": [["Three patients"]], "start": [[0]], "entity_id": ["T3"], "Population": {"text": [["Three"]], "start": [[0]], "entity_id": ["T7"]}}, "Treatment": {"text": [["received respectively 190 mg, 175 mg, and 196 mg of methotrexate"]], "start": [[15]], "entity_id": ["T4"], "Dosage": {"text": [["190 mg"], ["175 mg"], ["196 mg"]], "start": [[37], [45], [57]], "entity_id": ["T8", "T9", "T10"]}, "Drug": {"text": [["methotrexate"]], "start": [[67]], "entity_id": ["T11"]}}, "Effect": {"text": [["bilateral pulmonary infiltrates without evidence of peripheral blood eosinophilia"]], "start": [[94]], "entity_id": ["T6"]}}]}]}
{"id": "9876812_1", "context": "Clinicians should be aware of the possibility that vinorelbine may cause SIADH and possibly hypokalemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[67]], "entity_id": ["T8"]}, "Treatment": {"text": [["vinorelbine"]], "start": [[51]], "entity_id": ["T5"], "Drug": {"text": [["vinorelbine"]], "start": [[51]], "entity_id": ["T9"]}}, "Effect": {"text": [["SIADH and possibly hypokalemia"]], "start": [[73]], "entity_id": ["T6"]}, "Speculated": {"text": [["may"]], "start": [[63]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "19995690_4", "context": "We report a case of a 34-year-old man on carbamazepine for complex partial seizures who developed acute liver and renal failure on less than 2.5 grams a day of acetaminophen.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["on"]], "start": [[38]], "entity_id": ["T10"]}, "Treatment": {"text": [["carbamazepine", "less than 2.5 grams a day of acetaminophen"]], "start": [[41, 131]], "entity_id": ["T11"], "Drug": {"text": [["carbamazepine"], ["acetaminophen"]], "start": [[41], [160]], "entity_id": ["T16", "T20"]}, "Disorder": {"text": [["complex partial seizures"]], "start": [[59]], "entity_id": ["T17"]}, "Dosage": {"text": [["less than 2.5 grams"]], "start": [[131]], "entity_id": ["T18"]}, "Freq": {"text": [["a day"]], "start": [[151]], "entity_id": ["T19"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["on"]], "start": [[128]], "entity_id": ["T21"]}, "Drug": {"text": [["acetaminophen"], ["carbamazepine"]], "start": [[160], [41]], "entity_id": ["T20", "T16"]}}]}, "Effect": {"text": [["acute liver and renal failure"]], "start": [[98]], "entity_id": ["T12"]}, "Subject": {"text": [["a 34-year-old man"]], "start": [[20]], "entity_id": ["T13"], "Age": {"text": [["34-year-old"]], "start": [[22]], "entity_id": ["T14"]}, "Gender": {"text": [["man"]], "start": [[34]], "entity_id": ["T15"]}}}]}]}
{"id": "16935446_1", "context": "Fever and maculopapular rashes appeared at 10 days after phenytoin initiation, and then the drug was discontinued.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["appeared"]], "start": [[31]], "entity_id": ["T7"]}, "Treatment": {"text": [["phenytoin"]], "start": [[57]], "entity_id": ["T5"], "Time_elapsed": {"text": [["10 days"]], "start": [[43]], "entity_id": ["T8"]}, "Drug": {"text": [["phenytoin"]], "start": [[57]], "entity_id": ["T9"]}}, "Effect": {"text": [["Fever and maculopapular rashes"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "15628319_4", "context": "We report AZA-induced drug eruption that developed in two cases of systemic scleroderma with polymyositis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[14]], "entity_id": ["T4"]}, "Treatment": {"text": [["AZA"]], "start": [[10]], "entity_id": ["T3"], "Drug": {"text": [["AZA"]], "start": [[10]], "entity_id": ["T7"]}, "Disorder": {"text": [["systemic scleroderma with polymyositis"]], "start": [[67]], "entity_id": ["T1"]}}, "Effect": {"text": [["drug eruption"]], "start": [[22]], "entity_id": ["T5"]}, "Subject": {"text": [["two cases of systemic scleroderma with polymyositis"]], "start": [[54]], "entity_id": ["T8"], "Population": {"text": [["two"]], "start": [[54]], "entity_id": ["T2"]}}}]}]}
{"id": "12776809_1", "context": "Safety aspects of a coumarin-troxerutin combination regarding liver function in a double-blind placebo-controlled study.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Safety aspects"]], "start": [[0]], "entity_id": ["T9"]}, "Treatment": {"text": [["coumarin-troxerutin combination"]], "start": [[20]], "entity_id": ["T7"], "Drug": {"text": [["coumarin"], ["troxerutin"]], "start": [[20], [29]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combination"]], "start": [[40]], "entity_id": ["T12"]}, "Drug": {"text": [["troxerutin"], ["coumarin"]], "start": [[29], [20]], "entity_id": ["T11", "T10"]}}]}, "Effect": {"text": [["liver function"]], "start": [[62]], "entity_id": ["T8"]}}]}]}
{"id": "15580406_3", "context": "Vogt-Koyanagi-Harada disease occurring during interferon alpha therapy for chronic hepatitis C.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurring"]], "start": [[29]], "entity_id": ["T4"]}, "Effect": {"text": [["Vogt-Koyanagi-Harada disease"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["interferon alpha"]], "start": [[46]], "entity_id": ["T5"], "Drug": {"text": [["interferon alpha"]], "start": [[46]], "entity_id": ["T7"]}, "Disorder": {"text": [["chronic hepatitis C"]], "start": [[75]], "entity_id": ["T8"]}}}]}]}
{"id": "11206417_1", "context": "Glucose and insulin exert additive ocular and renal vasodilator effects on healthy humans.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["exert"]], "start": [[20]], "entity_id": ["T11"]}, "Subject": {"text": [["healthy humans"]], "start": [[75]], "entity_id": ["T9"]}, "Effect": {"text": [["additive ocular and renal vasodilator effects"]], "start": [[26]], "entity_id": ["T10"]}, "Treatment": {"text": [["Glucose and insulin"]], "start": [[0]], "entity_id": ["T12"], "Drug": {"text": [["Glucose"], ["insulin"]], "start": [[0], [12]], "entity_id": ["T13", "T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[8]], "entity_id": ["T15"]}, "Drug": {"text": [["Glucose"], ["insulin"]], "start": [[0], [12]], "entity_id": ["T13", "T14"]}}]}}]}]}
{"id": "4025011_2", "context": "Two patients with osteomyelitis who developed reversible cholestatic jaundice during treatment with oxacillin derivatives are described.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[36]], "entity_id": ["T5"]}, "Subject": {"text": [["Two patients with osteomyelitis"]], "start": [[0]], "entity_id": ["T3"], "Population": {"text": [["Two"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["reversible cholestatic jaundice"]], "start": [[46]], "entity_id": ["T4"]}, "Treatment": {"text": [["oxacillin"]], "start": [[100]], "entity_id": ["T6"], "Disorder": {"text": [["osteomyelitis"]], "start": [[18]], "entity_id": ["T8"]}, "Drug": {"text": [["oxacillin"]], "start": [[100]], "entity_id": ["T9"]}}}]}]}
{"id": "1504404_3", "context": "DATA SYNTHESIS: A 49-year-old man developed symptoms of severe psychosis concomitant with ciprofloxacin (250 mg bid) treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[34]], "entity_id": ["T5"]}, "Subject": {"text": [["A 49-year-old man"]], "start": [[16]], "entity_id": ["T3"], "Age": {"text": [["49-year-old"]], "start": [[18]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[30]], "entity_id": ["T8"]}}, "Treatment": {"text": [["ciprofloxacin"]], "start": [[90]], "entity_id": ["T4"], "Drug": {"text": [["ciprofloxacin"]], "start": [[90]], "entity_id": ["T9"]}, "Dosage": {"text": [["250 mg bid"]], "start": [[105]], "entity_id": ["T10"]}}, "Effect": {"text": [["psychosis"]], "start": [[63]], "entity_id": ["T6"]}, "Severity": {"text": [["severe"]], "start": [[56]], "entity_id": ["T11"], "value": "High"}}]}]}
{"id": "7673653_1", "context": "Beneficial effect of low-dose mianserin on fluvoxamine-induced akathisia in an obsessive-compulsive patient.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[55]], "entity_id": ["T3"]}, "Treatment": {"text": [["fluvoxamine"]], "start": [[43]], "entity_id": ["T4"], "Disorder": {"text": [["obsessive-compulsive"]], "start": [[79]], "entity_id": ["T9"]}, "Drug": {"text": [["fluvoxamine"]], "start": [[43]], "entity_id": ["T6"]}}, "Effect": {"text": [["akathisia"]], "start": [[63]], "entity_id": ["T5"]}, "Subject": {"text": [["obsessive-compulsive patient"]], "start": [[79]], "entity_id": ["T8"]}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["Beneficial"]], "start": [[0]], "entity_id": ["T11"]}, "Subject": {"text": [["obsessive-compulsive patient"]], "start": [[79]], "entity_id": ["T8"]}, "Treatment": {"text": [["low-dose mianserin"]], "start": [[21]], "entity_id": ["T12"], "Disorder": {"text": [["fluvoxamine-induced akathisia"]], "start": [[43]], "entity_id": ["T10"]}, "Dosage": {"text": [["low-dose"]], "start": [[21]], "entity_id": ["T13"]}, "Drug": {"text": [["mianserin"]], "start": [[30]], "entity_id": ["T14"]}}}]}]}
{"id": "8862924_3", "context": "Potential causes of methamphetamine-related keratitis can be divided into four categories resulting from (a) direct pharmacologic and physical effects of methamphetamine; (b) the toxic effects of diluting or \"cutting\" agents such as lidocaine and quinine; (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[36]], "entity_id": ["T9"]}, "Treatment": {"text": [["methamphetamine"]], "start": [[20]], "entity_id": ["T10"], "Drug": {"text": [["methamphetamine"]], "start": [[20]], "entity_id": ["T12"]}}, "Effect": {"text": [["keratitis"]], "start": [[44]], "entity_id": ["T11"]}}]}]}
{"id": "2028358_2", "context": "Pulmonary oedema after hexoprenaline administration in preterm labour.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[17]], "entity_id": ["T6"]}, "Effect": {"text": [["Pulmonary oedema"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["hexoprenaline"]], "start": [[23]], "entity_id": ["T4"], "Disorder": {"text": [["preterm labour"]], "start": [[55]], "entity_id": ["T5"]}, "Drug": {"text": [["hexoprenaline"]], "start": [[23]], "entity_id": ["T7"]}}}]}]}
{"id": "11144696_10", "context": "Venlafaxine-associated seizures at therapeutic doses have not been reported in the literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[12]], "entity_id": ["T6"]}, "Treatment": {"text": [["Venlafaxine"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Venlafaxine"]], "start": [[0]], "entity_id": ["T9"]}}, "Effect": {"text": [["seizures"]], "start": [[23]], "entity_id": ["T7"]}, "Negated": {"text": [["not"]], "start": [[58]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "9184269_2", "context": "Methotrexate-induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[13]], "entity_id": ["T4"]}, "Treatment": {"text": [["Methotrexate"]], "start": [[0]], "entity_id": ["T3"], "Disorder": {"text": [["rheumatoid arthritis"], ["psoriatic arthritis"]], "start": [[50], [75]], "entity_id": ["T7", "T8"]}, "Drug": {"text": [["Methotrexate"]], "start": [[0]], "entity_id": ["T9"]}}, "Effect": {"text": [["pneumonitis"]], "start": [[21]], "entity_id": ["T5"]}, "Subject": {"text": [["patients with rheumatoid arthritis and psoriatic arthritis"]], "start": [[36]], "entity_id": ["T6"]}}]}]}
{"id": "3677571_4", "context": "She was receiving phenytoin sodium 300 mg/day; carbamazepine 200 mg four times daily had been discontinued four days before admission because of leukopenia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["because"]], "start": [[134]], "entity_id": ["T9"]}, "Effect": {"text": [["leukopenia"]], "start": [[145]], "entity_id": ["T7"]}, "Treatment": {"text": [["carbamazepine 200 mg four times daily"]], "start": [[47]], "entity_id": ["T8"], "Drug": {"text": [["carbamazepine"]], "start": [[47]], "entity_id": ["T10"]}, "Dosage": {"text": [["200 mg"]], "start": [[61]], "entity_id": ["T11"]}, "Freq": {"text": [["four times daily"]], "start": [[68]], "entity_id": ["T12"]}}}]}]}
{"id": "9211543_4", "context": "Thoracoscopic biopsy to confirm metastasis revealed instead fibrotic lesions apparently attributable to bleomycin or cyclophosphamide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["attributable"]], "start": [[88]], "entity_id": ["T7"]}, "Effect": {"text": [["fibrotic lesions"]], "start": [[60]], "entity_id": ["T6"]}, "Treatment": {"text": [["bleomycin or cyclophosphamide"]], "start": [[104]], "entity_id": ["T8"], "Drug": {"text": [["bleomycin"], ["cyclophosphamide"]], "start": [[104], [117]], "entity_id": ["T9", "T10"]}}, "Speculated": {"text": [["apparently"]], "start": [[77]], "entity_id": ["T11"], "value": true}}]}]}
{"id": "16968538_4", "context": "We present a case of hemolytic-uremic syndrome that developed during the 4th cycle of combination chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[52]], "entity_id": ["T8"]}, "Effect": {"text": [["hemolytic-uremic syndrome"]], "start": [[21]], "entity_id": ["T7"]}, "Treatment": {"text": [["during the 4th cycle of combination chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin"]], "start": [[62]], "entity_id": ["T9"], "Drug": {"text": [["oxaliplatin"], ["fluorouracil"], ["leucovorin"]], "start": [[116], [131], [148]], "entity_id": ["T10", "T11", "T12"]}}}]}]}
{"id": "16632429_1", "context": "We report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with BOOP after chemotherapy with docetaxel and gemcitabine producing severe respiratory insufficiency, and simulating a progression of the tumor.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[104]], "entity_id": ["T14"]}, "Subject": {"text": [["lung cancer patient with bronquiloalveolar carcinoma (BAC)"]], "start": [[24]], "entity_id": ["T10"]}, "Effect": {"text": [["producing severe respiratory insufficiency, and simulating a progression of the tumor", "BOOP"]], "start": [[154, 99]], "entity_id": ["T11"]}, "Treatment": {"text": [["chemotherapy with docetaxel and gemcitabine"]], "start": [[110]], "entity_id": ["T12"], "Disorder": {"text": [["lung cancer"], ["bronquiloalveolar carcinoma (BAC)"]], "start": [[24], [49]], "entity_id": ["T15", "T19"]}, "Drug": {"text": [["docetaxel"], ["gemcitabine"]], "start": [[128], [142]], "entity_id": ["T16", "T17"]}, "Route": {"text": [["chemotherapy"]], "start": [[110]], "entity_id": ["T1"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[138]], "entity_id": ["T18"]}, "Drug": {"text": [["docetaxel"], ["gemcitabine"]], "start": [[128], [142]], "entity_id": ["T16", "T17"]}}]}}]}]}
{"id": "9240497_1", "context": "Relapse in the external auditory canal of acute promyelocytic leukemia after treatment with all-trans retinoic acid.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[71]], "entity_id": ["T4"]}, "Effect": {"text": [["Relapse in the external auditory canal of acute promyelocytic leukemia"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["treatment with all-trans retinoic acid"]], "start": [[77]], "entity_id": ["T5"], "Drug": {"text": [["all-trans retinoic acid"]], "start": [[92]], "entity_id": ["T6"]}}}]}]}
{"id": "10439378_1", "context": "Acute neutrophilic dermatosis induced by all-trans-retinoic acid treatment for acute promyelocytic leukemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced by"]], "start": [[30]], "entity_id": ["T3"]}, "Effect": {"text": [["Acute neutrophilic dermatosis"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["all-trans-retinoic acid"]], "start": [[41]], "entity_id": ["T6"], "Disorder": {"text": [["acute promyelocytic leukemia"]], "start": [[79]], "entity_id": ["T4"]}, "Drug": {"text": [["all-trans-retinoic acid"]], "start": [[41]], "entity_id": ["T7"]}}}]}]}
{"id": "15840734_1", "context": "Fluphenazine-induced neuroleptic malignant syndrome in a schizophrenic patient.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[13]], "entity_id": ["T7"]}, "Treatment": {"text": [["Fluphenazine"]], "start": [[0]], "entity_id": ["T6"], "Drug": {"text": [["Fluphenazine"]], "start": [[0]], "entity_id": ["T11"]}, "Disorder": {"text": [["schizophrenic"]], "start": [[57]], "entity_id": ["T12"]}}, "Effect": {"text": [["neuroleptic malignant syndrome"]], "start": [[21]], "entity_id": ["T8"]}, "Subject": {"text": [["a schizophrenic patient"]], "start": [[55]], "entity_id": ["T9"]}}]}]}
{"id": "19039026_1", "context": "Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect?", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[43]], "entity_id": ["T3"]}, "Effect": {"text": [["acute interstitial nephritis"]], "start": [[14]], "entity_id": ["T4"]}, "Treatment": {"text": [["tyrosine kinase inhibitor sunitinib"]], "start": [[63]], "entity_id": ["T5"], "Drug": {"text": [["sunitinib"]], "start": [[89]], "entity_id": ["T6"]}}}]}]}
{"id": "8222875_4", "context": "We describe two women who developed HUS after MMC therapy and presented massive pulmonary bleeding.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[40]], "entity_id": ["T7"]}, "Subject": {"text": [["two women"]], "start": [[12]], "entity_id": ["T5"], "Population": {"text": [["two"]], "start": [[12]], "entity_id": ["T9"]}, "Gender": {"text": [["women"]], "start": [[16]], "entity_id": ["T10"]}}, "Effect": {"text": [["HUS", "massive pulmonary bleeding"]], "start": [[36, 72]], "entity_id": ["T6"]}, "Treatment": {"text": [["MMC"]], "start": [[46]], "entity_id": ["T8"], "Drug": {"text": [["MMC"]], "start": [[46]], "entity_id": ["T11"]}}, "Severity": {"text": [["massive"]], "start": [[72]], "entity_id": ["T12"], "value": "High"}}]}]}
{"id": "6529939_2", "context": "Alternating sinus rhythm and intermittent sinoatrial (S-A) block was observed in a 57-year-old woman, under treatment for angina with 80 mg propranolol daily.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treatment"]], "start": [[108]], "entity_id": ["T5"]}, "Treatment": {"text": [["80 mg propranolol daily."]], "start": [[134]], "entity_id": ["T6"], "Dosage": {"text": [["80 mg"]], "start": [[134]], "entity_id": ["T11"]}, "Drug": {"text": [["propranolol"]], "start": [[140]], "entity_id": ["T12"]}, "Freq": {"text": [["daily"]], "start": [[152]], "entity_id": ["T13"]}, "Disorder": {"text": [["angina"]], "start": [[122]], "entity_id": ["T14"]}}, "Subject": {"text": [["a 57-year-old woman"]], "start": [[81]], "entity_id": ["T7"], "Age": {"text": [["57-year-old"]], "start": [[83]], "entity_id": ["T9"]}, "Gender": {"text": [["woman"]], "start": [[95]], "entity_id": ["T10"]}}, "Effect": {"text": [["Alternating sinus rhythm and intermittent sinoatrial (S-A) block"]], "start": [[0]], "entity_id": ["T8"]}}]}]}
{"id": "9399776_4", "context": "These case reports provide evidence that 5-aminosalicylic acid may induce acute pancreatitis after long term treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induce"]], "start": [[67]], "entity_id": ["T4"]}, "Treatment": {"text": [["5-aminosalicylic acid"]], "start": [[41]], "entity_id": ["T3"], "Drug": {"text": [["5-aminosalicylic acid"]], "start": [[41]], "entity_id": ["T6"]}, "Duration": {"text": [["long term"]], "start": [[99]], "entity_id": ["T7"]}}, "Effect": {"text": [["acute pancreatitis"]], "start": [[74]], "entity_id": ["T5"]}}]}]}
{"id": "17896898_4", "context": "During that time, he had also been taking amphetamine-dextroamphetamine (Adderall) on work days for his ADHD.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["taking"]], "start": [[35]], "entity_id": ["T6"]}, "Treatment": {"text": [["amphetamine-dextroamphetamine (Adderall)"]], "start": [[42]], "entity_id": ["T8"], "Disorder": {"text": [["ADHD"]], "start": [[104]], "entity_id": ["T7"]}, "Drug": {"text": [["amphetamine-dextroamphetamine"]], "start": [[42]], "entity_id": ["T11"]}}, "Subject": {"text": [["he"]], "start": [[18]], "entity_id": ["T9"], "Gender": {"text": [["he"]], "start": [[18]], "entity_id": ["T10"]}}}]}]}
{"id": "9375469_2", "context": "Therefore, we diagnosed her eruption as contact dermatitis due to sodium bisulfite.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["diagnosed"]], "start": [[14]], "entity_id": ["T7"]}, "Treatment": {"text": [["sodium bisulfite"]], "start": [[66]], "entity_id": ["T5"], "Drug": {"text": [["sodium bisulfite"]], "start": [[66]], "entity_id": ["T8"]}}, "Effect": {"text": [["r eruption as contact dermatitis"]], "start": [[26]], "entity_id": ["T6"]}}]}]}
{"id": "3485422_1", "context": "Macular infarction after endophthalmitis treated with vitrectomy and intravitreal gentamicin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[19]], "entity_id": ["T6"]}, "Effect": {"text": [["Macular infarction"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["endophthalmitis treated with vitrectomy and intravitreal gentamicin"]], "start": [[25]], "entity_id": ["T3"], "Disorder": {"text": [["endophthalmitis"]], "start": [[25]], "entity_id": ["T5"]}, "Route": {"text": [["vitrectomy and intravitreal"]], "start": [[54]], "entity_id": ["T7"]}, "Drug": {"text": [["gentamicin"]], "start": [[82]], "entity_id": ["T8"]}}}]}]}
{"id": "11876387_2", "context": "Since tamoxifen therapy can induce endometrial disorders, surveillance schemes of women taking tamoxifen have been recommended.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induce"]], "start": [[28]], "entity_id": ["T5"]}, "Treatment": {"text": [["tamoxifen therapy"]], "start": [[6]], "entity_id": ["T4"], "Drug": {"text": [["tamoxifen"]], "start": [[6]], "entity_id": ["T10"]}}, "Effect": {"text": [["endometrial disorders"]], "start": [[35]], "entity_id": ["T6"]}, "Subject": {"text": [["women"]], "start": [[82]], "entity_id": ["T7"], "Gender": {"text": [["women"]], "start": [[82]], "entity_id": ["T8"]}}}]}]}
{"id": "11837564_2", "context": "Warfarin-associated bleeding complication saved life.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[9]], "entity_id": ["T4"]}, "Treatment": {"text": [["Warfarin"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Warfarin"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["bleeding complication saved life"]], "start": [[20]], "entity_id": ["T5"]}}]}]}
{"id": "8979664_1", "context": "METHODS/RESULTS: This paper presents a new case of rifabutin uveitis and a review of the various published reports to date.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["presents"]], "start": [[28]], "entity_id": ["T5"]}, "Treatment": {"text": [["rifabutin"]], "start": [[51]], "entity_id": ["T3"], "Drug": {"text": [["rifabutin"]], "start": [[51]], "entity_id": ["T6"]}}, "Effect": {"text": [["uveitis"]], "start": [[61]], "entity_id": ["T4"]}, "Subject": {"text": [["new case"]], "start": [[39]], "entity_id": ["T7"]}}]}]}
{"id": "12860350_1", "context": "Acute abdomen due to endometriosis in a premenopausal woman taking tamoxifen.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["taking"]], "start": [[60]], "entity_id": ["T7"]}, "Effect": {"text": [["Acute abdomen due to endometriosis"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["tamoxifen"]], "start": [[67]], "entity_id": ["T6"], "Drug": {"text": [["tamoxifen"]], "start": [[67]], "entity_id": ["T8"]}}}]}]}
{"id": "18094347_3", "context": "DISCUSSION: Methotrexate-induced papular eruption is rarely reported shortly after beginning methotrexate therapy in patients with acute exacerbation of collagen vascular diseases.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[25]], "entity_id": ["T4"]}, "Treatment": {"text": [["Methotrexate"]], "start": [[12]], "entity_id": ["T3"], "Drug": {"text": [["Methotrexate"]], "start": [[12]], "entity_id": ["T9"]}, "Time_elapsed": {"text": [["shortly after"]], "start": [[69]], "entity_id": ["T11"]}}, "Effect": {"text": [["papular eruption"]], "start": [[33]], "entity_id": ["T5"]}, "Subject": {"text": [["patients with acute exacerbation of collagen vascular diseases"]], "start": [[117]], "entity_id": ["T6"], "Disorder": {"text": [["acute exacerbation of collagen vascular diseases"]], "start": [[131]], "entity_id": ["T8"]}}}]}]}
{"id": "15028964_5", "context": "We describe 3 patients on concomitant amiodarone and warfarin who developed amiodarone-induced thyrotoxicosis heralded by a significant decrease in warfarin requirements.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[66]], "entity_id": ["T12"]}, "Effect": {"text": [["amiodarone-induced thyrotoxicosis"]], "start": [[76]], "entity_id": ["T23"]}, "Subject": {"text": [["3 patients"]], "start": [[12]], "entity_id": ["T10"], "Population": {"text": [["3"]], "start": [[12]], "entity_id": ["T14"]}}, "Treatment": {"text": [["concomitant amiodarone and warfarin"]], "start": [[26]], "entity_id": ["T11"], "Drug": {"text": [["amiodarone"], ["warfarin"]], "start": [[38], [53]], "entity_id": ["T18", "T19"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["concomitant"]], "start": [[26]], "entity_id": ["T17"]}, "Drug": {"text": [["amiodarone"], ["warfarin"]], "start": [[38], [53]], "entity_id": ["T18", "T19"]}}]}}, {"event_id": "E3", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[87]], "entity_id": ["T21"]}, "Treatment": {"text": [["amiodarone"]], "start": [[76]], "entity_id": ["T13"], "Drug": {"text": [["amiodarone"]], "start": [[76]], "entity_id": ["T22"]}}, "Effect": {"text": [["thyrotoxicosis"]], "start": [[95]], "entity_id": ["T15"]}}]}]}
{"id": "25157214_3", "context": "The aim of this post-hoc analysis of data from a Phase III clinical trial (VISTA; NCT00298831) was to investigate the impact of antibiotics on recovery from rocuronium-induced NMB after administration of sugammadex for reversal, and compared the neuromuscular recovery in patients who received antibiotics preoperatively with those who did not.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[168]], "entity_id": ["T9"]}, "Treatment": {"text": [["rocuronium"]], "start": [[157]], "entity_id": ["T8"], "Drug": {"text": [["rocuronium"]], "start": [[157]], "entity_id": ["T11"]}}, "Effect": {"text": [["NMB"]], "start": [[176]], "entity_id": ["T10"]}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["recovery"]], "start": [[143]], "entity_id": ["T15"]}, "Treatment": {"text": [["antibiotics"]], "start": [[128]], "entity_id": ["T13"], "Disorder": {"text": [["rocuronium-induced NMB"]], "start": [[157]], "entity_id": ["T16"]}, "Drug": {"text": [["antibiotics"]], "start": [[128]], "entity_id": ["T14"]}}}]}]}
{"id": "14693027_1", "context": "All patients had taken phenytoin for variable time periods (range 16-80 days; mean: 40) and were on the medication when the skin lesions first appeared.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["appeared"]], "start": [[143]], "entity_id": ["T6"]}, "Treatment": {"text": [["phenytoin for variable time periods (range 16-80 days; mean: 40)"]], "start": [[23]], "entity_id": ["T3"], "Drug": {"text": [["phenytoin"]], "start": [[23]], "entity_id": ["T7"]}, "Duration": {"text": [["16-80 days;"], ["40"]], "start": [[66], [84]], "entity_id": ["T8", "T9"]}}, "Subject": {"text": [["All patients"]], "start": [[0]], "entity_id": ["T4"]}, "Effect": {"text": [["skin lesions"]], "start": [[124]], "entity_id": ["T5"]}}]}]}
{"id": "9754850_3", "context": "One should therefore be aware of possible extrapyramidal side effects with olanzapine that are reduced compared to classical neuroleptic drugs but not completely eliminated.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[70]], "entity_id": ["T4"]}, "Effect": {"text": [["extrapyramidal side effects"]], "start": [[42]], "entity_id": ["T3"]}, "Treatment": {"text": [["olanzapine"]], "start": [[75]], "entity_id": ["T5"], "Drug": {"text": [["olanzapine"]], "start": [[75]], "entity_id": ["T6"]}}, "Speculated": {"text": [["possible"]], "start": [[33]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "122410_1", "context": "A patient who had been treated with large doses of thyroid hormone for several years developed features of secondary hypothyroidism after thyroid hormone withdrawal.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[85]], "entity_id": ["T6"]}, "Subject": {"text": [["A patient"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["thyroid hormone withdrawal"]], "start": [[138]], "entity_id": ["T4"], "Drug": {"text": [["thyroid hormone"]], "start": [[138]], "entity_id": ["T7"]}}, "Effect": {"text": [["secondary hypothyroidism"]], "start": [[107]], "entity_id": ["T5"]}}]}]}
{"id": "18344455_5", "context": "This article discusses the possibility that simultaneous use of valproic acid, lamotrigine, and phenytoin could give this combination of toxicities and that concurrent viral infection may increase this risk.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["give"]], "start": [[112]], "entity_id": ["T11"]}, "Treatment": {"text": [["valproic acid, lamotrigine, and phenytoin"]], "start": [[64]], "entity_id": ["T9"], "Drug": {"text": [["valproic acid"], ["lamotrigine"], ["phenytoin"]], "start": [[64], [79], [96]], "entity_id": ["T12", "T13", "T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["simultaneous"]], "start": [[44]], "entity_id": ["T15"]}, "Drug": {"text": [["valproic acid"], ["lamotrigine"], ["phenytoin"]], "start": [[64], [79], [96]], "entity_id": ["T12", "T13", "T14"]}}]}, "Effect": {"text": [["toxicities", "concurrent viral infection"]], "start": [[137, 157]], "entity_id": ["T10"]}, "Speculated": {"text": [["possibility"]], "start": [[27]], "entity_id": ["T16"], "value": true}}]}]}
{"id": "984862_2", "context": "A second patient with a similar glucose tolerance test result showed postprandial hyperglycemia when treated similarly with betamethasone valerate cream 0.1%.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["showed"]], "start": [[62]], "entity_id": ["T3"]}, "Effect": {"text": [["postprandial hyperglycemia"]], "start": [[69]], "entity_id": ["T4"]}, "Treatment": {"text": [["betamethasone valerate cream 0.1%"]], "start": [[124]], "entity_id": ["T5"], "Drug": {"text": [["betamethasone valerate"]], "start": [[124]], "entity_id": ["T6"]}, "Route": {"text": [["cream"]], "start": [[147]], "entity_id": ["T7"]}}}]}]}
{"id": "3677571_1", "context": "Phenytoin-induced hypersensitivity reactions.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[10]], "entity_id": ["T4"]}, "Treatment": {"text": [["Phenytoin"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Phenytoin"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["hypersensitivity reactions."]], "start": [[18]], "entity_id": ["T6"]}}]}]}
{"id": "9545161_1", "context": "A 54-year-old man developed TEN 4 weeks after beginning lamotrigine for complex partial seizures related to a glioblastoma multiforme brain tumor.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[18]], "entity_id": ["T6"]}, "Subject": {"text": [["A 54-year-old man", "complex partial seizures related to a glioblastoma multiforme brain tumor"]], "start": [[0, 72]], "entity_id": ["T3"], "Age": {"text": [["54-year-old"]], "start": [[2]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[14]], "entity_id": ["T8"]}, "Disorder": {"text": [["glioblastoma multiforme brain tumor"]], "start": [[110]], "entity_id": ["T12"]}}, "Effect": {"text": [["TEN"]], "start": [[28]], "entity_id": ["T4"]}, "Treatment": {"text": [["4 weeks after beginning lamotrigine"]], "start": [[32]], "entity_id": ["T5"], "Time_elapsed": {"text": [["4 weeks"]], "start": [[32]], "entity_id": ["T9"]}, "Drug": {"text": [["lamotrigine"]], "start": [[56]], "entity_id": ["T10"]}, "Disorder": {"text": [["complex partial seizures"]], "start": [[72]], "entity_id": ["T11"]}}}]}]}
{"id": "11881322_5", "context": "The occurrence of acute hepatitis is best known for ketoconazole.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["for"]], "start": [[48]], "entity_id": ["T5"]}, "Treatment": {"text": [["ketoconazole"]], "start": [[52]], "entity_id": ["T3"], "Drug": {"text": [["ketoconazole"]], "start": [[52]], "entity_id": ["T6"]}}, "Effect": {"text": [["acute hepatitis"]], "start": [[18]], "entity_id": ["T4"]}}]}]}
{"id": "6233326_2", "context": "Optic neuropathy developed in a patient with rheumatoid arthritis who had been receiving D-penicillamine for about 1 year.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[17]], "entity_id": ["T4"]}, "Effect": {"text": [["Optic neuropathy"]], "start": [[0]], "entity_id": ["T3"]}, "Subject": {"text": [["a patient with rheumatoid arthritis"]], "start": [[30]], "entity_id": ["T5"]}, "Treatment": {"text": [["D-penicillamine for about 1 year"]], "start": [[89]], "entity_id": ["T6"], "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[45]], "entity_id": ["T7"]}, "Drug": {"text": [["D-penicillamine"]], "start": [[89]], "entity_id": ["T8"]}, "Duration": {"text": [["1 year"]], "start": [[115]], "entity_id": ["T9"]}}}]}]}
{"id": "19520277_1", "context": "Stupor and fast activity on electroencephalography in a child treated with valproate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[70]], "entity_id": ["T6"]}, "Subject": {"text": [["a child"]], "start": [[54]], "entity_id": ["T3"], "Age": {"text": [["child"]], "start": [[56]], "entity_id": ["T7"]}}, "Treatment": {"text": [["valproate"]], "start": [[75]], "entity_id": ["T4"], "Drug": {"text": [["valproate"]], "start": [[75]], "entity_id": ["T8"]}}, "Effect": {"text": [["Stupor", "fast activity on electroencephalography"]], "start": [[0, 11]], "entity_id": ["T5"]}}]}]}
{"id": "7606071_5", "context": "During her third cycle, she again received cisplatin 100 mg/m2 over 30 minutes and developed palmar pruritus, urticaria, and edema.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[83]], "entity_id": ["T11"]}, "Treatment": {"text": [["cisplatin 100 mg/m2 over 30 minutes"]], "start": [[43]], "entity_id": ["T9"], "Time_elapsed": {"text": [["30 minutes"]], "start": [[68]], "entity_id": ["T14"]}, "Dosage": {"text": [["100 mg/m2"]], "start": [[53]], "entity_id": ["T15"]}, "Drug": {"text": [["cisplatin"]], "start": [[43]], "entity_id": ["T16"]}}, "Subject": {"text": [["she"]], "start": [[24]], "entity_id": ["T10"], "Gender": {"text": [["she"]], "start": [[24]], "entity_id": ["T13"]}}, "Effect": {"text": [["palmar pruritus, urticaria, and edema"]], "start": [[93]], "entity_id": ["T12"]}}]}]}
{"id": "9169264_3", "context": "The case of a patient with infectious mononucleosis treated with cephalexin who later showed a rash is presented and the previous literature is reviewed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["showed"]], "start": [[86]], "entity_id": ["T6"]}, "Treatment": {"text": [["cephalexin"]], "start": [[65]], "entity_id": ["T3"], "Drug": {"text": [["cephalexin"]], "start": [[65]], "entity_id": ["T8"]}, "Disorder": {"text": [["infectious mononucleosis"]], "start": [[27]], "entity_id": ["T9"]}}, "Effect": {"text": [["rash"]], "start": [[95]], "entity_id": ["T4"]}, "Subject": {"text": [["a patient with infectious mononucleosis"]], "start": [[12]], "entity_id": ["T5"]}}]}]}
{"id": "9855339_1", "context": "After 1 week of nefazodone therapy the patient experienced headache, confusion, and \"gray areas\" in her vision, without abnormal ophthalmologic findings.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["experienced"]], "start": [[47]], "entity_id": ["T10"]}, "Effect": {"text": [["headache, confusion, and \"gray areas\" in her vision, without abnormal ophthalmologic findings"]], "start": [[59]], "entity_id": ["T7"]}, "Subject": {"text": [["patient", "her"]], "start": [[39, 100]], "entity_id": ["T8"], "Gender": {"text": [["her"]], "start": [[100]], "entity_id": ["T11"]}}, "Treatment": {"text": [["After 1 week of nefazodone therapy"]], "start": [[0]], "entity_id": ["T9"], "Time_elapsed": {"text": [["1 week"]], "start": [[6]], "entity_id": ["T12"]}, "Drug": {"text": [["nefazodone"]], "start": [[16]], "entity_id": ["T13"]}}}]}]}
{"id": "8771575_4", "context": "Nitrofurantoin-induced pulmonary toxicity during pregnancy: a report of a case and review of the literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[15]], "entity_id": ["T4"]}, "Treatment": {"text": [["Nitrofurantoin"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Nitrofurantoin"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["pulmonary toxicity"]], "start": [[23]], "entity_id": ["T5"]}}]}]}
{"id": "18644535_1", "context": "Methylphenidate-associated enuresis in attention deficit hyperactivity disorder.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[16]], "entity_id": ["T4"]}, "Treatment": {"text": [["Methylphenidate"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Methylphenidate"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["enuresis"]], "start": [[27]], "entity_id": ["T5"]}}]}]}
{"id": "14740795_4", "context": "To our knowledge, this is the first case report that demonstrates the occurrence of fever with low-dose amifostine therapy without the manifestation of accompanying rash or hypotension.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurrence"]], "start": [[70]], "entity_id": ["T4"]}, "Treatment": {"text": [["low-dose amifostine"]], "start": [[95]], "entity_id": ["T3"], "Dosage": {"text": [["ow-dose"]], "start": [[96]], "entity_id": ["T8"]}, "Drug": {"text": [["amifostine"]], "start": [[104]], "entity_id": ["T9"]}}, "Effect": {"text": [["fever"]], "start": [[84]], "entity_id": ["T5"]}, "Subject": {"text": [["the first case"]], "start": [[26]], "entity_id": ["T6"]}, "Speculated": {"text": [["To our knowledge"]], "start": [[0]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "3528096_1", "context": "Administration of excessive insulin induced hypoglycemia within 4 to 8 hours, followed by rebound hyperglycemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[36]], "entity_id": ["T6"]}, "Treatment": {"text": [["Administration of excessive insulin"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["insulin"]], "start": [[28]], "entity_id": ["T8"]}, "Dosage": {"text": [["excessive"]], "start": [[18]], "entity_id": ["T9"]}, "Duration": {"text": [["4 to 8 hours"]], "start": [[64]], "entity_id": ["T10"]}}, "Effect": {"text": [["hypoglycemia", "rebound hyperglycemia"]], "start": [[44, 90]], "entity_id": ["T7"]}}]}]}
{"id": "17122225_5", "context": "In both cases, symptoms of autonomic instability and severe agitation started within hours of initiation of cyclobenzaprine and fully resolved within 3 days after discontinuing the proserotoninergic drugs.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["started"]], "start": [[70]], "entity_id": ["T8"]}, "Effect": {"text": [["symptoms of autonomic instability and severe agitation"]], "start": [[15]], "entity_id": ["T6"]}, "Treatment": {"text": [["within hours of initiation of cyclobenzaprine"]], "start": [[78]], "entity_id": ["T7"], "Drug": {"text": [["cyclobenzaprine"]], "start": [[108]], "entity_id": ["T9"]}, "Time_elapsed": {"text": [["within hours of initiation"]], "start": [[78]], "entity_id": ["T10"]}}, "Severity": {"text": [["severe"]], "start": [[53]], "entity_id": ["T12"], "value": "High"}}]}]}
{"id": "10779995_2", "context": "Secondary leukemia in a child with neuroblastoma while on oral etoposide: what is the cause?", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[19]], "entity_id": ["T1"]}, "Subject": {"text": [["a child with neuroblastoma"]], "start": [[22]], "entity_id": ["T2"], "Age": {"text": [["child"]], "start": [[24]], "entity_id": ["T5"]}}, "Treatment": {"text": [["oral etoposide"]], "start": [[58]], "entity_id": ["T3"], "Disorder": {"text": [["neuroblastoma"]], "start": [[35]], "entity_id": ["T7"]}, "Route": {"text": [["oral"]], "start": [[58]], "entity_id": ["T8"]}, "Drug": {"text": [["etoposide"]], "start": [[63]], "entity_id": ["T9"]}}, "Effect": {"text": [["Secondary leukemia"]], "start": [[0]], "entity_id": ["T4"]}}]}]}
{"id": "20666169_1", "context": "Atorvastatin induced multiple organ failure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[13]], "entity_id": ["T5"]}, "Treatment": {"text": [["Atorvastatin"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Atorvastatin"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["multiple organ failure"]], "start": [[21]], "entity_id": ["T6"]}}]}]}
{"id": "19697589_3", "context": "While serotonin syndrome has become more frequent in an overdose situation and when an interacting drug is given, the toxicity of SSIRs is less than that of most other psychiatric drugs.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["toxicity"]], "start": [[118]], "entity_id": ["T6"]}, "Effect": {"text": [["serotonin syndrome"]], "start": [[6]], "entity_id": ["T4"]}, "Treatment": {"text": [["SSIRs"]], "start": [[130]], "entity_id": ["T5"], "Drug": {"text": [["SSIRs"]], "start": [[130]], "entity_id": ["T7"]}}}]}]}
{"id": "7272895_1", "context": "A 73-year-old woman with non-Hodgkin's lymphoma had two episodes of severe, bilateral, sensori-neural hearing loss after vincristine therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[115]], "entity_id": ["T5"]}, "Subject": {"text": [["A 73-year-old woman with non-Hodgkin's lymphoma"]], "start": [[0]], "entity_id": ["T3"], "Age": {"text": [["73-year-old"]], "start": [[2]], "entity_id": ["T7"]}, "Gender": {"text": [["woman"]], "start": [[14]], "entity_id": ["T8"]}}, "Effect": {"text": [["two episodes of severe, bilateral, sensori-neural hearing loss"]], "start": [[52]], "entity_id": ["T4"]}, "Treatment": {"text": [["vincristine therapy"]], "start": [[121]], "entity_id": ["T6"], "Drug": {"text": [["vincristine"]], "start": [[121]], "entity_id": ["T11"]}, "Disorder": {"text": [["non-Hodgkin's lymphoma"]], "start": [[25]], "entity_id": ["T12"]}}, "Severity": {"text": [["severe"]], "start": [[68]], "entity_id": ["T10"], "value": "High"}}]}]}
{"id": "10885900_2", "context": "Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[33]], "entity_id": ["T5"]}, "Effect": {"text": [["Severe hemolytic uremic syndrome"]], "start": [[0]], "entity_id": ["T4"]}, "Subject": {"text": [["an advanced ovarian cancer patient"]], "start": [[36]], "entity_id": ["T6"]}, "Treatment": {"text": [["carboplatin and gemcitabine"]], "start": [[84]], "entity_id": ["T7"], "Disorder": {"text": [["ovarian cancer"]], "start": [[48]], "entity_id": ["T8"]}, "Drug": {"text": [["carboplatin"], ["gemcitabine"]], "start": [[84], [100]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[96]], "entity_id": ["T12"]}, "Drug": {"text": [["carboplatin"], ["gemcitabine"]], "start": [[84], [100]], "entity_id": ["T10", "T11"]}}]}}]}]}
{"id": "2746565_2", "context": "Ulcerative proctitis in juvenile systemic lupus erythematosus after ibuprofen treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[62]], "entity_id": ["T4"]}, "Effect": {"text": [["Ulcerative proctitis in juvenile systemic lupus erythematosus"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["ibuprofen"]], "start": [[68]], "entity_id": ["T5"], "Drug": {"text": [["ibuprofen"]], "start": [[68]], "entity_id": ["T6"]}}}]}]}
{"id": "9161656_1", "context": "Acute asthma associated with sustained-release verapamil.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[13]], "entity_id": ["T4"]}, "Treatment": {"text": [["sustained-release verapamil"]], "start": [[29]], "entity_id": ["T5"], "Drug": {"text": [["sustained-release verapamil"]], "start": [[29]], "entity_id": ["T7"]}}, "Effect": {"text": [["Acute asthma"]], "start": [[0]], "entity_id": ["T6"]}, "Severity": {"text": [["Acute"]], "start": [[0]], "entity_id": ["T8"], "value": "High"}}]}]}
{"id": "8749646_3", "context": "The renal insufficiency of three patients and the timing of the seizures implicate accumulation of ofloxacin as a contributing factor.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["implicate"]], "start": [[73]], "entity_id": ["T8"]}, "Treatment": {"text": [["accumulation of ofloxacin"]], "start": [[83]], "entity_id": ["T5"], "Drug": {"text": [["ofloxacin"]], "start": [[99]], "entity_id": ["T10"]}}, "Effect": {"text": [["renal insufficiency", "seizures"]], "start": [[4, 64]], "entity_id": ["T6"]}, "Subject": {"text": [["three patients"]], "start": [[27]], "entity_id": ["T7"], "Population": {"text": [["three"]], "start": [[27]], "entity_id": ["T9"]}}}]}]}
{"id": "2413037_1", "context": "Hemolytic uremic syndrome in a patient on cis-platinum, vinblastine and bleomycin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[26]], "entity_id": ["T8"]}, "Treatment": {"text": [["cis-platinum, vinblastine and bleomycin"]], "start": [[42]], "entity_id": ["T5"], "Drug": {"text": [["cis-platinum"], ["vinblastine"], ["bleomycin"]], "start": [[42], [56], [72]], "entity_id": ["T9", "T10", "T11"]}}, "Subject": {"text": [["a patient"]], "start": [[29]], "entity_id": ["T6"]}, "Effect": {"text": [["Hemolytic uremic syndrome"]], "start": [[0]], "entity_id": ["T7"]}}]}]}
{"id": "15878975_1", "context": "A previous review described data on 15 patients who experienced acute hemoglobinemia or hemoglobinuria following anti-D IGIV administration for ITP or secondary thrombocytopenia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[103]], "entity_id": ["T7"]}, "Subject": {"text": [["15 patients"]], "start": [[36]], "entity_id": ["T5"], "Population": {"text": [["15"]], "start": [[36]], "entity_id": ["T10"]}}, "Effect": {"text": [["acute hemoglobinemia or hemoglobinuria"]], "start": [[64]], "entity_id": ["T6"]}, "Treatment": {"text": [["anti-D IGIV"]], "start": [[113]], "entity_id": ["T8"], "Disorder": {"text": [["ITP or secondary thrombocytopenia"]], "start": [[144]], "entity_id": ["T9"]}, "Drug": {"text": [["anti-D IGIV"]], "start": [[113]], "entity_id": ["T11"]}, "Route": {"text": [["administration"]], "start": [[125]], "entity_id": ["T12"]}}}]}]}
{"id": "2042691_1", "context": "Amiodarone was discontinued, and thyrotoxicosis gradually abated.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["was discontinued"]], "start": [[11]], "entity_id": ["T3"]}, "Treatment": {"text": [["Amiodarone"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Amiodarone"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["thyrotoxicosis gradually abated"]], "start": [[33]], "entity_id": ["T5"]}}]}]}
{"id": "11700998_1", "context": "De novo absence status of late onset following withdrawal of lorazepam: a case report.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[37]], "entity_id": ["T5"]}, "Effect": {"text": [["De novo absence status of late onset"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["withdrawal of lorazepam"]], "start": [[47]], "entity_id": ["T4"], "Drug": {"text": [["lorazepam"]], "start": [[61]], "entity_id": ["T6"]}}}]}]}
{"id": "19183077_1", "context": "Tenofovir-associated nephrotoxicity in two HIV-infected adolescent males.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[10]], "entity_id": ["T4"]}, "Treatment": {"text": [["Tenofovir"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Tenofovir"]], "start": [[0]], "entity_id": ["T11"]}, "Disorder": {"text": [["HIV-infected"]], "start": [[43]], "entity_id": ["T12"]}}, "Effect": {"text": [["nephrotoxicity"]], "start": [[21]], "entity_id": ["T5"]}, "Subject": {"text": [["two HIV-infected adolescent males"]], "start": [[39]], "entity_id": ["T6"], "Population": {"text": [["two"]], "start": [[39]], "entity_id": ["T8"]}, "Age": {"text": [["adolescent"]], "start": [[56]], "entity_id": ["T9"]}, "Gender": {"text": [["males"]], "start": [[67]], "entity_id": ["T10"]}}}]}]}
{"id": "17965530_1", "context": "Reports of colonic perforation as a result of the administration of calcium polystyrene sulfonate and sorbitol are rare.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["result"]], "start": [[36]], "entity_id": ["T6"]}, "Effect": {"text": [["colonic perforation"]], "start": [[11]], "entity_id": ["T4"]}, "Treatment": {"text": [["calcium polystyrene sulfonate", "sorbitol"]], "start": [[68, 102]], "entity_id": ["T5"], "Drug": {"text": [["calcium polystyrene sulfonate"], ["sorbitol"]], "start": [[68], [102]], "entity_id": ["T8", "T9"]}, "Route": {"text": [["the administration"]], "start": [[46]], "entity_id": ["T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[98]], "entity_id": ["T10"]}, "Drug": {"text": [["calcium polystyrene sulfonate"], ["sorbitol"]], "start": [[68], [102]], "entity_id": ["T8", "T9"]}}]}}]}]}
{"id": "8749646_1", "context": "Improved awareness of and further investigation into the neurotoxic effects of ofloxacin may enhance its safe use.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["of"]], "start": [[76]], "entity_id": ["T5"]}, "Treatment": {"text": [["ofloxacin"]], "start": [[79]], "entity_id": ["T3"], "Drug": {"text": [["ofloxacin"]], "start": [[79]], "entity_id": ["T6"]}}, "Effect": {"text": [["neurotoxic effects"]], "start": [[57]], "entity_id": ["T4"]}}]}]}
{"id": "12013364_2", "context": "Atypical neuroleptic malignant syndrome associated with olanzapine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[40]], "entity_id": ["T3"]}, "Treatment": {"text": [["olanzapine"]], "start": [[56]], "entity_id": ["T4"], "Drug": {"text": [["olanzapine"]], "start": [[56]], "entity_id": ["T6"]}}, "Effect": {"text": [["Atypical neuroleptic malignant syndrome"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "20118434_4", "context": "OBJECTIVE: The authors described a case of interferon-induced psychosis as a framework to review the literature and discuss the decision to pursue antiviral treatment in psychiatrically ill patients with hepatitis C.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[54]], "entity_id": ["T4"]}, "Treatment": {"text": [["interferon"]], "start": [[43]], "entity_id": ["T5"], "Drug": {"text": [["interferon"]], "start": [[43]], "entity_id": ["T9"]}, "Disorder": {"text": [["hepatitis C"]], "start": [[204]], "entity_id": ["T10"]}}, "Effect": {"text": [["psychosis"]], "start": [[62]], "entity_id": ["T6"]}, "Subject": {"text": [["psychiatrically ill patients with hepatitis C"]], "start": [[170]], "entity_id": ["T3"], "Disorder": {"text": [["psychiatrically ill"]], "start": [[170]], "entity_id": ["T7"]}}}]}]}
{"id": "1495728_4", "context": "We believe that methotrexate represents a relatively effective alternative to surgery in patients with early unruptured tubal pregnancy, but suggest that it be used with caution in view of possible systemic toxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caution"]], "start": [[170]], "entity_id": ["T12"]}, "Subject": {"text": [["patients with early unruptured tubal pregnancy"]], "start": [[89]], "entity_id": ["T9"]}, "Treatment": {"text": [["methotrexate"]], "start": [[16]], "entity_id": ["T10"], "Drug": {"text": [["methotrexate"]], "start": [[16]], "entity_id": ["T15"]}, "Disorder": {"text": [["early unruptured tubal pregnancy"]], "start": [[103]], "entity_id": ["T16"]}}, "Effect": {"text": [["systemic toxicity"]], "start": [[198]], "entity_id": ["T13"]}, "Speculated": {"text": [["suggest", "possible"]], "start": [[141, 189]], "entity_id": ["T11"], "value": true}}]}]}
{"id": "16371793_12", "context": "After intravitreal injection of triamcinolone acetonide, cataract may rapidly develop in eyes that have been intensively treated, topically and systemically, by corticosteroids for several years.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["develop"]], "start": [[78]], "entity_id": ["T9"]}, "Treatment": {"text": [["intravitreal injection of triamcinolone acetonide"]], "start": [[6]], "entity_id": ["T6"], "Route": {"text": [["intravitreal injection"]], "start": [[6]], "entity_id": ["T10"]}, "Drug": {"text": [["triamcinolone acetonide"]], "start": [[32]], "entity_id": ["T11"]}}, "Effect": {"text": [["cataract"]], "start": [[57]], "entity_id": ["T7"]}, "Speculated": {"text": [["may"]], "start": [[66]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "17277758_1", "context": "Acute endophthalmitis following intravitreal bevacizumab (Avastin) injection.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[22]], "entity_id": ["T5"]}, "Effect": {"text": [["Acute endophthalmitis"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["intravitreal bevacizumab (Avastin) injection"]], "start": [[32]], "entity_id": ["T6"], "Route": {"text": [["intravitreal"], ["injection"]], "start": [[32], [67]], "entity_id": ["T7", "T9"]}, "Drug": {"text": [["bevacizumab"]], "start": [[45]], "entity_id": ["T8"]}}}]}]}
{"id": "25957434_3", "context": "We report a case of bullous eruption, one month after starting nicardipine and lercanidipine.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[48]], "entity_id": ["T6"]}, "Treatment": {"text": [["starting nicardipine and lercanidipine."]], "start": [[54]], "entity_id": ["T7"], "Time_elapsed": {"text": [["one month"]], "start": [[38]], "entity_id": ["T9"]}, "Drug": {"text": [["nicardipine"], ["lercanidipine"]], "start": [[63], [79]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[75]], "entity_id": ["T12"]}, "Drug": {"text": [["nicardipine"], ["lercanidipine"]], "start": [[63], [79]], "entity_id": ["T10", "T11"]}}]}, "Effect": {"text": [["bullous eruption,"]], "start": [[20]], "entity_id": ["T8"]}}]}]}
{"id": "1775411_2", "context": "Pulmonary fibrosis associated with nabumetone.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[19]], "entity_id": ["T4"]}, "Treatment": {"text": [["nabumetone"]], "start": [[35]], "entity_id": ["T3"], "Drug": {"text": [["nabumetone"]], "start": [[35]], "entity_id": ["T6"]}}, "Effect": {"text": [["Pulmonary fibrosis"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "19660974_2", "context": "The ability of tumor necrosis factor (TNF)-alpha inhibitors to impair pivotal pro-inflammatory host defenses may facilitate the development of disseminated cryptococcosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["development"]], "start": [[128]], "entity_id": ["T5"]}, "Effect": {"text": [["disseminated cryptococcosis"]], "start": [[143]], "entity_id": ["T6"]}, "Treatment": {"text": [["tumor necrosis factor (TNF)-alpha inhibitors"]], "start": [[15]], "entity_id": ["T8"], "Drug": {"text": [["tumor necrosis factor (TNF)-alpha inhibitors"]], "start": [[15]], "entity_id": ["T9"]}}, "Speculated": {"text": [["may facilitate"]], "start": [[109]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "6529939_4", "context": "This was accepted as evidence for propranolol being the cause of this conduction disorder.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[56]], "entity_id": ["T3"]}, "Treatment": {"text": [["propranolol"]], "start": [[34]], "entity_id": ["T4"], "Drug": {"text": [["propranolol"]], "start": [[34]], "entity_id": ["T6"]}}, "Effect": {"text": [["conduction disorder"]], "start": [[70]], "entity_id": ["T5"]}}]}]}
{"id": "1517501_4", "context": "We report a third case of a 6-week-old infant with Escherichia coli sepsis who received ampicillin and other antibiotics and subsequently developed TEN.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[138]], "entity_id": ["T12"]}, "Subject": {"text": [["6-week-old infant with Escherichia coli sepsis"]], "start": [[28]], "entity_id": ["T8"], "Age": {"text": [["6-week-old"], ["infant"]], "start": [[28], [39]], "entity_id": ["T13", "T14"]}}, "Treatment": {"text": [["received ampicillin and other antibiotics"]], "start": [[79]], "entity_id": ["T10"], "Drug": {"text": [["ampicillin"], ["other antibiotics"]], "start": [[88], [103]], "entity_id": ["T15", "T16"]}, "Disorder": {"text": [["Escherichia coli sepsis"]], "start": [[51]], "entity_id": ["T18"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[99]], "entity_id": ["T17"]}, "Drug": {"text": [["ampicillin"], ["other antibiotics"]], "start": [[88], [103]], "entity_id": ["T15", "T16"]}}]}, "Effect": {"text": [["TEN"]], "start": [[148]], "entity_id": ["T11"]}}]}]}
{"id": "18379937_2", "context": "PURPOSE: To report a case of bilateral anterior uveitis associated with ovulation induction therapy using clomiphene citrate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[56]], "entity_id": ["T5"]}, "Subject": {"text": [["case"]], "start": [[21]], "entity_id": ["T3"]}, "Effect": {"text": [["bilateral anterior uveitis"]], "start": [[29]], "entity_id": ["T4"]}, "Treatment": {"text": [["ovulation induction therapy using clomiphene citrate"]], "start": [[72]], "entity_id": ["T6"], "Drug": {"text": [["clomiphene citrate"]], "start": [[106]], "entity_id": ["T7"]}}}]}]}
{"id": "2979256_1", "context": "A 57-year-old woman presented with a 3-week history of dysphagia for solids, 6 months after starting treatment with nifedipine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["presented"]], "start": [[20]], "entity_id": ["T5"]}, "Subject": {"text": [["A 57-year-old woman"]], "start": [[0]], "entity_id": ["T3"], "Age": {"text": [["57-year-old"]], "start": [[2]], "entity_id": ["T7"]}, "Gender": {"text": [["woman"]], "start": [[14]], "entity_id": ["T8"]}}, "Effect": {"text": [["dysphagia for solids"]], "start": [[55]], "entity_id": ["T4"]}, "Treatment": {"text": [["nifedipine"]], "start": [[116]], "entity_id": ["T6"], "Time_elapsed": {"text": [["6 months"]], "start": [[77]], "entity_id": ["T10"]}, "Drug": {"text": [["nifedipine"]], "start": [[116]], "entity_id": ["T11"]}}}]}]}
{"id": "15097937_1", "context": "Although combinations of belladonna, ergotamine, and phenobarbital have been used for medical treatment of menopausal symptoms since the 1960s, this is the first known case report of its association with anticonvulsant hypersensitivity syndrome.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["association"]], "start": [[187]], "entity_id": ["T6"]}, "Treatment": {"text": [["combinations of belladonna, ergotamine, and phenobarbital"]], "start": [[9]], "entity_id": ["T5"], "Drug": {"text": [["belladonna"], ["ergotamine"], ["phenobarbital"]], "start": [[25], [37], [53]], "entity_id": ["T9", "T10", "T11"]}, "Disorder": {"text": [["menopausal symptom"]], "start": [[107]], "entity_id": ["T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[49]], "entity_id": ["T12"]}, "Drug": {"text": [["belladonna"], ["ergotamine"], ["phenobarbital"]], "start": [[25], [37], [53]], "entity_id": ["T9", "T10", "T11"]}}]}, "Effect": {"text": [["anticonvulsant hypersensitivity syndrome"]], "start": [[204]], "entity_id": ["T7"]}}]}]}
{"id": "2728526_2", "context": "Rifampin can be associated with severe adverse effects such as hepatitis, acute renal failure, hemolytic anemia, and thrombocytopenia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[16]], "entity_id": ["T10"]}, "Treatment": {"text": [["Rifampin"]], "start": [[0]], "entity_id": ["T9"], "Drug": {"text": [["Rifampin"]], "start": [[0]], "entity_id": ["T12"]}}, "Effect": {"text": [["hepatitis, acute renal failure, hemolytic anemia, and thrombocytopenia"]], "start": [[63]], "entity_id": ["T11"]}, "Severity": {"text": [["severe"]], "start": [[32]], "entity_id": ["T13"], "value": "High"}}]}]}
{"id": "2051906_2", "context": "It is believed that this is the first reported case of reversible azathioprine-induced cholestasis associated with histological evidence of bile duct injury.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[79]], "entity_id": ["T5"]}, "Treatment": {"text": [["azathioprine"]], "start": [[66]], "entity_id": ["T3"], "Drug": {"text": [["azathioprine"]], "start": [[66]], "entity_id": ["T6"]}}, "Effect": {"text": [["cholestasis"]], "start": [[87]], "entity_id": ["T4"]}}]}]}
{"id": "9554064_4", "context": "We present a fatal case of subacute methanol toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and cerebral edema with ventricular compression.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[59]], "entity_id": ["T14"]}, "Treatment": {"text": [["methanol"]], "start": [[36]], "entity_id": ["T13"], "Drug": {"text": [["methanol"]], "start": [[36]], "entity_id": ["T16"]}}, "Effect": {"text": [["diffuse brain involvement, including bilateral putaminal necrosis and cerebral edema with ventricular compression"]], "start": [[70]], "entity_id": ["T15"]}, "Severity": {"text": [["fatal"]], "start": [[13]], "entity_id": ["T17"], "value": "High"}}]}]}
{"id": "9653495_6", "context": "Patients with inoperable or metastatic colorectal cancer were randomized to receive monthly FU 400 mg/m2/day plus LV 20 mg/m2/day as intravenous push daily for five days, or FU alone.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["receive"]], "start": [[76]], "entity_id": ["T14"]}, "Subject": {"text": [["Patients with inoperable or metastatic colorectal cancer"]], "start": [[0]], "entity_id": ["T10"]}, "Treatment": {"text": [["monthly FU 400 mg/m2/day plus LV 20 mg/m2/day as intravenous push daily for five days"]], "start": [[84]], "entity_id": ["T13"], "Disorder": {"text": [["metastatic colorectal cancer"], ["inoperable"]], "start": [[28], [14]], "entity_id": ["T12", "T24"]}, "Dosage": {"text": [["400 mg/m2/day"], ["20 mg/m2/day"]], "start": [[95], [117]], "entity_id": ["T17", "T21"]}, "Drug": {"text": [["FU"], ["LV"]], "start": [[92], [114]], "entity_id": ["T16", "T20"]}, "Route": {"text": [["intravenous push"]], "start": [[133]], "entity_id": ["T23"]}, "Freq": {"text": [["daily"], ["monthly"]], "start": [[150], [84]], "entity_id": ["T18", "T22"]}, "Duration": {"text": [["five days"]], "start": [[160]], "entity_id": ["T25"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["plus"]], "start": [[109]], "entity_id": ["T19"]}, "Drug": {"text": [["FU"], ["LV"]], "start": [[92], [114]], "entity_id": ["T16", "T20"]}}]}}]}]}
{"id": "9347384_3", "context": "The present report suggests that clarithromycin coadministration induces increased plasma carbamazepine concentrations, which may result in carbamazepine toxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induces"]], "start": [[65]], "entity_id": ["T10"]}, "Treatment": {"text": [["clarithromycin", "carbamazepine", "carbamazepine"]], "start": [[33, 90, 140]], "entity_id": ["T9"], "Drug": {"text": [["clarithromycin"]], "start": [[33]], "entity_id": ["T14"]}}, "Effect": {"text": [["increased plasma carbamazepine concentrations", "carbamazepine toxicity."]], "start": [[73, 140]], "entity_id": ["T12"]}, "Subject": {"text": [["carbamazepine"]], "start": [[90]], "entity_id": ["T15"]}, "Speculated": {"text": [["may"]], "start": [[126]], "entity_id": ["T11"], "value": true}}]}]}
{"id": "11850606_2", "context": "In this case, interferon alpha induced polymyositis and cardiomyopathy is diagnosed in a 33-yr-old male patient with history of chronic hepatitis B.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[31]], "entity_id": ["T7"]}, "Subject": {"text": [["a 33-yr-old male patient with history of chronic hepatitis B"]], "start": [[87]], "entity_id": ["T5"], "Age": {"text": [["33-yr-old"]], "start": [[89]], "entity_id": ["T9"]}, "Gender": {"text": [["male"]], "start": [[99]], "entity_id": ["T10"]}}, "Treatment": {"text": [["interferon alpha"]], "start": [[14]], "entity_id": ["T6"], "Drug": {"text": [["interferon alpha"]], "start": [[14]], "entity_id": ["T12"]}, "Disorder": {"text": [["history of chronic hepatitis B"]], "start": [[117]], "entity_id": ["T13"]}}, "Effect": {"text": [["polymyositis and cardiomyopathy"]], "start": [[39]], "entity_id": ["T8"]}}]}]}
{"id": "16005413_2", "context": "To describe the potential for interaction between opioids and serotonergic antidepressants leading to the development of serotonin syndrome (SS), mechanism of the interaction, and the spectrum of SS in elderly residents of a long-term care facility.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["leading"]], "start": [[91]], "entity_id": ["T11"]}, "Treatment": {"text": [["opioids", "serotonergic antidepressants"]], "start": [[50, 62]], "entity_id": ["T10"], "Drug": {"text": [["opioids"], ["serotonergic antidepressants"]], "start": [[50], [62]], "entity_id": ["T16", "T17"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[30]], "entity_id": ["T15"]}, "Drug": {"text": [["opioids"], ["serotonergic antidepressants"]], "start": [[50], [62]], "entity_id": ["T16", "T17"]}}]}, "Effect": {"text": [["serotonin syndrome"]], "start": [[121]], "entity_id": ["T12"]}, "Subject": {"text": [["elderly residents"]], "start": [[202]], "entity_id": ["T13"], "Age": {"text": [["elderly"]], "start": [[202]], "entity_id": ["T14"]}}}]}]}
{"id": "480917_2", "context": "Erythema multiforme bullosum due to rifampicin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[29]], "entity_id": ["T4"]}, "Effect": {"text": [["Erythema multiforme bullosum"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["rifampicin"]], "start": [[36]], "entity_id": ["T5"], "Drug": {"text": [["rifampicin"]], "start": [[36]], "entity_id": ["T6"]}}}]}]}
{"id": "2554727_4", "context": "We describe a patient with acute leukemia who developed Horner's syndrome and a severe demyelinating peripheral neuropathy leading to death after receiving high-dose cytosine arabinoside.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[46]], "entity_id": ["T7"]}, "Treatment": {"text": [["high-dose cytosine arabinoside."]], "start": [[156]], "entity_id": ["T8"], "Disorder": {"text": [["acute leukemia"]], "start": [[27]], "entity_id": ["T12"]}, "Drug": {"text": [["cytosine arabinoside"]], "start": [[166]], "entity_id": ["T14"]}, "Dosage": {"text": [["high-dose"]], "start": [[156]], "entity_id": ["T15"]}}, "Effect": {"text": [["Horner's syndrome and a severe demyelinating peripheral neuropathy leading to death"]], "start": [[56]], "entity_id": ["T9"]}, "Subject": {"text": [["a patient with acute leukemia"]], "start": [[12]], "entity_id": ["T10"]}, "Severity": {"text": [["acute"]], "start": [[27]], "entity_id": ["T13"], "value": "High"}}]}]}
{"id": "1509179_3", "context": "This profile should trigger a \"red flag\" as to the possibility of phenobarbital behavioral side effects or exacerbation of preexisting maladaptive behaviors.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["trigger"]], "start": [[20]], "entity_id": ["T7"]}, "Treatment": {"text": [["phenobarbital"]], "start": [[66]], "entity_id": ["T6"], "Drug": {"text": [["phenobarbital"]], "start": [[66]], "entity_id": ["T9"]}}, "Effect": {"text": [["behavioral side effects or exacerbation of preexisting maladaptive behaviors"]], "start": [[80]], "entity_id": ["T8"]}, "Speculated": {"text": [["possibility"]], "start": [[51]], "entity_id": ["T5"], "value": true}}]}]}
{"id": "15580406_2", "context": "Retinal abnormalities, including retinal hemorrhage and \"cotton-wool\" spots, often occur within the first 8 weeks in the course of interferon therapy in patients with chronic hepatitis C.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occur"]], "start": [[83]], "entity_id": ["T8"]}, "Effect": {"text": [["Retinal abnormalities, including retinal hemorrhage and \"cotton-wool\" spots"]], "start": [[0]], "entity_id": ["T7"]}, "Treatment": {"text": [["interferon"]], "start": [[131]], "entity_id": ["T9"], "Time_elapsed": {"text": [["8 weeks"]], "start": [[106]], "entity_id": ["T12"]}, "Drug": {"text": [["interferon"]], "start": [[131]], "entity_id": ["T13"]}, "Disorder": {"text": [["chronic hepatitis C"]], "start": [[167]], "entity_id": ["T14"]}}, "Subject": {"text": [["patients with chronic hepatitis C"]], "start": [[153]], "entity_id": ["T10"]}}]}]}
{"id": "12581772_2", "context": "Rapamycin/sirolimus-induced pneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a pulmonary infiltrate that reversed after ceasing SR therapy.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[20]], "entity_id": ["T9"]}, "Treatment": {"text": [["Rapamycin/sirolimus"]], "start": [[0]], "entity_id": ["T8"], "Drug": {"text": [["Rapamycin"], ["sirolimus"]], "start": [[0], [10]], "entity_id": ["T11", "T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["/"]], "start": [[9]], "entity_id": ["T13"]}, "Drug": {"text": [["Rapamycin"], ["sirolimus"]], "start": [[0], [10]], "entity_id": ["T11", "T12"]}}]}, "Effect": {"text": [["pneumonitis"]], "start": [[28]], "entity_id": ["T10"]}}]}]}
{"id": "19104709_1", "context": "IFNalpha-induced recurrence of Graves' disease ten years after thyroidectomy in chronic viral hepatitis C.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[9]], "entity_id": ["T6"]}, "Effect": {"text": [["recurrence of Graves' disease"]], "start": [[17]], "entity_id": ["T5"]}, "Treatment": {"text": [["IFNalpha", "ten years after thyroidectomy"]], "start": [[0, 47]], "entity_id": ["T7"], "Disorder": {"text": [["chronic viral hepatitis C"]], "start": [[80]], "entity_id": ["T3"]}, "Drug": {"text": [["IFNalpha"]], "start": [[0]], "entity_id": ["T4"]}}}]}]}
{"id": "15795553_2", "context": "Risperidone withdrawal-related respiratory dyskinesia: a case diagnosed by spirography and fibroscopy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[23]], "entity_id": ["T5"]}, "Treatment": {"text": [["Risperidone"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Risperidone"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["respiratory dyskinesia"]], "start": [[31]], "entity_id": ["T4"]}}]}]}
{"id": "17556909_2", "context": "Paralytic ileus in patients undergoing bortezomib treatment has been reported, although a definite attribution to bortezomib administration has not been established.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reported"]], "start": [[69]], "entity_id": ["T6"]}, "Effect": {"text": [["Paralytic ileus"]], "start": [[0]], "entity_id": ["T3"]}, "Subject": {"text": [["patients"]], "start": [[19]], "entity_id": ["T4"]}, "Treatment": {"text": [["bortezomib treatment"]], "start": [[39]], "entity_id": ["T5"], "Drug": {"text": [["bortezomib"]], "start": [[39]], "entity_id": ["T7"]}}}]}]}
{"id": "11918514_4", "context": "Severe serotonin syndrome induced by mirtazapine monotherapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced by"]], "start": [[26]], "entity_id": ["T4"]}, "Effect": {"text": [["serotonin syndrome"]], "start": [[7]], "entity_id": ["T3"]}, "Treatment": {"text": [["mirtazapine monotherapy"]], "start": [[37]], "entity_id": ["T5"], "Drug": {"text": [["mirtazapine"]], "start": [[37]], "entity_id": ["T6"]}}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T7"], "value": "High"}}]}]}
{"id": "21712512_6", "context": "Three days after starting fluconazole, she developed polyuria and polydipsia and was found to have severe hyperglycemia, which led to the diagnosis of Cushing syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[43]], "entity_id": ["T9"]}, "Treatment": {"text": [["Three days after starting fluconazole"]], "start": [[0]], "entity_id": ["T8"], "Drug": {"text": [["fluconazole"]], "start": [[26]], "entity_id": ["T12"]}, "Time_elapsed": {"text": [["Three days"]], "start": [[0]], "entity_id": ["T13"]}}, "Effect": {"text": [["polyuria and polydipsia and was found to have severe hyperglycemia, which led to the diagnosis of Cushing syndrome"]], "start": [[53]], "entity_id": ["T10"]}, "Severity": {"text": [["severe"]], "start": [[99]], "entity_id": ["T15"], "value": "High"}}]}]}
{"id": "10566542_1", "context": "Postoperative hypocalcemic tetany caused by fleet phospho-soda preparation in a patient taking alendronate sodium: report of a case.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[34]], "entity_id": ["T5"]}, "Effect": {"text": [["hypocalcemic tetany"]], "start": [[14]], "entity_id": ["T4"]}, "Treatment": {"text": [["fleet phospho-soda"], ["alendronate sodium"]], "start": [[44], [95]], "entity_id": ["T6", "T7"], "Drug": {"text": [["fleet phospho-soda"], ["alendronate sodium"]], "start": [[44], [95]], "entity_id": ["T10", "T9"]}}, "Subject": {"text": [["patient"]], "start": [[80]], "entity_id": ["T8"]}}]}]}
{"id": "7854541_3", "context": "Observations in our patient suggest that the leukoencephalopathy that developed in previously reported patients who received 5-fluorouracil and levamisole may have been caused at least partly by levamisole.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[169]], "entity_id": ["T6"]}, "Effect": {"text": [["leukoencephalopathy"]], "start": [[45]], "entity_id": ["T5"]}, "Subject": {"text": [["patients"]], "start": [[103]], "entity_id": ["T7"]}, "Treatment": {"text": [["levamisole"]], "start": [[195]], "entity_id": ["T8"], "Drug": {"text": [["levamisole"]], "start": [[195]], "entity_id": ["T10"]}}, "Speculated": {"text": [["may"]], "start": [[155]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "10589077_6", "context": "We describe the clinical response, as determined by increases in total Hb and decreased transfusion needs, in five patients with thalassemia intermedia treated with HU alone or in combination with SPB.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[152]], "entity_id": ["T4"]}, "Subject": {"text": [["in five patients with thalassemia intermedia"]], "start": [[107]], "entity_id": ["T5"], "Population": {"text": [["five"]], "start": [[110]], "entity_id": ["T8"]}}, "Treatment": {"text": [["HU alone or in combination with SPB"]], "start": [[165]], "entity_id": ["T6"], "Drug": {"text": [["HU"], ["SPB"]], "start": [[165], [197]], "entity_id": ["T10", "T11"]}, "Disorder": {"text": [["thalassemia intermedia"]], "start": [[129]], "entity_id": ["T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combination"]], "start": [[180]], "entity_id": ["T12"]}, "Drug": {"text": [["HU"], ["SPB"]], "start": [[165], [197]], "entity_id": ["T10", "T11"]}}]}, "Effect": {"text": [["increases in total Hb and decreased transfusion needs"]], "start": [[52]], "entity_id": ["T7"]}}]}]}
{"id": "19299370_1", "context": "According to the Naranjo et al. adverse-reaction probability scale, enoxaparin was the probable cause of hepatotoxicity in this patient.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[96]], "entity_id": ["T3"]}, "Treatment": {"text": [["enoxaparin"]], "start": [[68]], "entity_id": ["T4"], "Drug": {"text": [["enoxaparin"]], "start": [[68]], "entity_id": ["T8"]}}, "Effect": {"text": [["hepatotoxicity"]], "start": [[105]], "entity_id": ["T5"]}, "Subject": {"text": [["this patient"]], "start": [[123]], "entity_id": ["T6"]}, "Speculated": {"text": [["probable"]], "start": [[87]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "11788010_5", "context": "This is the first reported case of hepatolithiasis during octreotide therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[51]], "entity_id": ["T5"]}, "Effect": {"text": [["hepatolithiasis"]], "start": [[35]], "entity_id": ["T3"]}, "Treatment": {"text": [["octreotide"]], "start": [[58]], "entity_id": ["T4"], "Drug": {"text": [["octreotide"]], "start": [[58]], "entity_id": ["T6"]}}}]}]}
{"id": "2781955_2", "context": "Treatment of amiodarone-induced thyrotoxicosis (AIT) with thionamide, lithium or radioactive iodine is ineffective.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[24]], "entity_id": ["T4"]}, "Treatment": {"text": [["amiodarone"]], "start": [[13]], "entity_id": ["T3"], "Drug": {"text": [["amiodarone"]], "start": [[13]], "entity_id": ["T7"]}}, "Effect": {"text": [["thyrotoxicosis (AIT)"]], "start": [[32]], "entity_id": ["T5"]}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["Treatment"]], "start": [[0]], "entity_id": ["T10"]}, "Treatment": {"text": [["thionamide, lithium or radioactive iodine"]], "start": [[58]], "entity_id": ["T9"], "Disorder": {"text": [["amiodarone-induced thyrotoxicosis (AIT)"]], "start": [[13]], "entity_id": ["T11"]}}, "Negated": {"text": [["ineffective"]], "start": [[103]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "2292051_2", "context": "Six patients with no previous signs or symptoms suggestive of coronary artery disease developed acute coronary ischemia/infarction shortly after cis-diamine-dichloroplatinum II (cisplatin) -based chemotherapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[86]], "entity_id": ["T8"]}, "Treatment": {"text": [["cis-diamine-dichloroplatinum II (cisplatin) -based chemotherapy"]], "start": [[145]], "entity_id": ["T7"], "Drug": {"text": [["cis-diamine-dichloroplatinum II"]], "start": [[145]], "entity_id": ["T12"]}, "Route": {"text": [["chemotherapy"]], "start": [[196]], "entity_id": ["T13"]}}, "Subject": {"text": [["Six patients with no previous signs or symptoms suggestive of coronary artery disease"]], "start": [[0]], "entity_id": ["T9"], "Population": {"text": [["Six"]], "start": [[0]], "entity_id": ["T11"]}}, "Effect": {"text": [["acute coronary ischemia/infarction"]], "start": [[96]], "entity_id": ["T10"]}}]}]}
{"id": "10891991_6", "context": "RESULTS: Replacing valproate with lamotrigine resulted in a decrease in serum testosterone concentrations in all 3 women.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulted"]], "start": [[46]], "entity_id": ["T4"]}, "Treatment": {"text": [["Replacing valproate with lamotrigine"]], "start": [[9]], "entity_id": ["T3"], "Drug": {"text": [["lamotrigine"]], "start": [[34]], "entity_id": ["T9"]}}, "Effect": {"text": [["a decrease in serum testosterone concentrations"]], "start": [[58]], "entity_id": ["T5"]}, "Subject": {"text": [["all 3 women"]], "start": [[109]], "entity_id": ["T6"], "Population": {"text": [["3"]], "start": [[113]], "entity_id": ["T7"]}, "Gender": {"text": [["women"]], "start": [[115]], "entity_id": ["T8"]}}}]}]}
{"id": "6744146_1", "context": "A 65-year-old woman, in the intensive care unit because of septic shock and acute renal failure, had a small-bowel obstruction due to Amphojel concretions.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[127]], "entity_id": ["T4"]}, "Subject": {"text": [["A 65-year-old woman, in the intensive care unit because of septic shock and acute renal failure"]], "start": [[0]], "entity_id": ["T3"], "Disorder": {"text": [["septic shock"], ["acute renal failure"]], "start": [[59], [76]], "entity_id": ["T7", "T1"]}, "Age": {"text": [["65-year-old"]], "start": [[2]], "entity_id": ["T8"]}, "Gender": {"text": [["woman"]], "start": [[14]], "entity_id": ["T9"]}}, "Effect": {"text": [["small-bowel obstruction", "concretions"]], "start": [[103, 143]], "entity_id": ["T5"]}, "Treatment": {"text": [["Amphojel"]], "start": [[134]], "entity_id": ["T6"], "Drug": {"text": [["Amphojel"]], "start": [[134]], "entity_id": ["T10"]}}}]}]}
{"id": "1879988_3", "context": "After the first oral dose of propranolol, syncope developed together with atrioventricular block.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[50]], "entity_id": ["T7"]}, "Treatment": {"text": [["oral dose of propranolol"]], "start": [[16]], "entity_id": ["T5"], "Route": {"text": [["oral"]], "start": [[16]], "entity_id": ["T8"]}, "Drug": {"text": [["propranolol"]], "start": [[29]], "entity_id": ["T9"]}}, "Effect": {"text": [["syncope", "atrioventricular block"]], "start": [[42, 74]], "entity_id": ["T6"]}}]}]}
{"id": "19764104_2", "context": "Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[10]], "entity_id": ["T4"]}, "Treatment": {"text": [["Sorafenib"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Sorafenib"]], "start": [[0]], "entity_id": ["T8"]}, "Disorder": {"text": [["hepatocellular carcinoma"]], "start": [[54]], "entity_id": ["T9"]}}, "Subject": {"text": [["an advanced hepatocellular carcinoma patient"]], "start": [[42]], "entity_id": ["T6"]}, "Effect": {"text": [["tumor lysis syndrome"]], "start": [[18]], "entity_id": ["T5"]}}]}]}
{"id": "10660641_9", "context": "The symptoms did not recur during the 36 months of itraconazole treatment after discharge, and it was concluded that ITCZ was effective for A. flavus hypertrophic pachymeningitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["effective"]], "start": [[126]], "entity_id": ["T9"]}, "Effect": {"text": [["The symptoms did not recur"]], "start": [[0]], "entity_id": ["T11"]}, "Treatment": {"text": [["the 36 months of itraconazole treatment after discharge"]], "start": [[34]], "entity_id": ["T12"], "Disorder": {"text": [["A. flavus hypertrophic pachymeningitis"]], "start": [[140]], "entity_id": ["T10"]}, "Duration": {"text": [["36 months"]], "start": [[38]], "entity_id": ["T8"]}, "Drug": {"text": [["itraconazole"]], "start": [[51]], "entity_id": ["T13"]}}}]}]}
{"id": "14679124_3", "context": "A prospective randomized clinical trial was implemented to assess whether the concomitant or the sequential addition of tamoxifen to chemotherapy provides improved clinical benefit in the adjuvant treatment of breast cancer in postmenopausal patients.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["provides"]], "start": [[146]], "entity_id": ["T9"]}, "Treatment": {"text": [["the concomitant or the sequential addition of tamoxifen to chemotherapy"]], "start": [[74]], "entity_id": ["T8"], "Drug": {"text": [["tamoxifen"]], "start": [[120]], "entity_id": ["T13"]}, "Route": {"text": [["chemotherapy"]], "start": [[133]], "entity_id": ["T14"]}, "Disorder": {"text": [["breast cancer"]], "start": [[210]], "entity_id": ["T15"]}}, "Subject": {"text": [["postmenopausal patients"]], "start": [[227]], "entity_id": ["T10"], "Disorder": {"text": [["postmenopausal"]], "start": [[227]], "entity_id": ["T12"]}}, "Effect": {"text": [["improved clinical benefit in the adjuvant treatment"]], "start": [[155]], "entity_id": ["T1"]}, "Speculated": {"text": [["assess"]], "start": [[59]], "entity_id": ["T2"], "value": true}}]}]}
{"id": "11328247_2", "context": "Increased libido in a woman treated with fluvoxamine: a case report.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[17]], "entity_id": ["T6"]}, "Effect": {"text": [["Increased libido"]], "start": [[0]], "entity_id": ["T3"]}, "Subject": {"text": [["a woman"]], "start": [[20]], "entity_id": ["T4"], "Gender": {"text": [["woman"]], "start": [[22]], "entity_id": ["T7"]}}, "Treatment": {"text": [["fluvoxamine"]], "start": [[41]], "entity_id": ["T5"], "Drug": {"text": [["fluvoxamine"]], "start": [[41]], "entity_id": ["T8"]}}}]}]}
{"id": "2935070_3", "context": "In the following case report, a patient developed acute interstitial nephritis with renal failure and exfoliative dermatitis following ampicillin therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[40]], "entity_id": ["T7"]}, "Subject": {"text": [["patient"]], "start": [[32]], "entity_id": ["T8"]}, "Effect": {"text": [["acute interstitial nephritis with renal failure and exfoliative dermatitis"]], "start": [[50]], "entity_id": ["T9"]}, "Treatment": {"text": [["ampicillin therapy"]], "start": [[135]], "entity_id": ["T10"], "Drug": {"text": [["ampicillin"]], "start": [[135]], "entity_id": ["T11"]}}, "Severity": {"text": [["acute"]], "start": [[50]], "entity_id": ["T12"], "value": "High"}}]}]}
{"id": "21417793_10", "context": "Severe symptoms associated with serotonin toxicity were shown to be uncommon in patients receiving linezolid and selected serotonin reuptake inhibitors.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["receiving"]], "start": [[89]], "entity_id": ["T8"]}, "Treatment": {"text": [["linezolid and selected serotonin reuptake inhibitors"]], "start": [[99]], "entity_id": ["T7"], "Drug": {"text": [["serotonin"], ["linezolid"], ["serotonin reuptake inhibitors"]], "start": [[32], [99], [122]], "entity_id": ["T12", "T15", "T16"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[109]], "entity_id": ["T17"]}, "Drug": {"text": [["linezolid"], ["serotonin reuptake inhibitors"]], "start": [[99], [122]], "entity_id": ["T15", "T16"]}}]}, "Subject": {"text": [["patients"]], "start": [[80]], "entity_id": ["T9"]}, "Effect": {"text": [["Severe symptoms associated with serotonin toxicity"]], "start": [[0]], "entity_id": ["T10"]}, "Severity": {"text": [["Severe"], ["uncommon"]], "start": [[0], [68]], "entity_id": ["T11", "T14"], "value": "High"}}]}]}
{"id": "10099659_9", "context": "We describe the side effects of 5-FU in a colon cancer patient who suffered severe mucositis, desquamating dermatitis, prolonged myelosuppression, and neurologic toxicity that required admission to the intensive care unit.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["of"]], "start": [[29]], "entity_id": ["T11"]}, "Effect": {"text": [["side effects"]], "start": [[16]], "entity_id": ["T13"]}, "Subject": {"text": [["colon cancer patient who suffered severe mucositis, desquamating dermatitis, prolonged myelosuppression, and neurologic toxicity that required admission to the intensive care unit"]], "start": [[42]], "entity_id": ["T9"], "Disorder": {"text": [["mucositis"], ["desquamating dermatitis"], ["myelosuppression"], ["neurologic toxicity"]], "start": [[83], [94], [129], [151]], "entity_id": ["T14", "T15", "T16", "T17"]}}, "Treatment": {"text": [["5-FU"]], "start": [[32]], "entity_id": ["T10"], "Drug": {"text": [["5-FU"]], "start": [[32]], "entity_id": ["T18"]}, "Disorder": {"text": [["colon cancer"]], "start": [[42]], "entity_id": ["T19"]}}}]}]}
{"id": "110153_1", "context": "There have been many reports of probable lithium-induced organic brain syndromes occurring when serum lithium levels are within or close to the therapeutic range.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[49]], "entity_id": ["T4"]}, "Treatment": {"text": [["lithium", "when serum lithium levels are within or close to the therapeutic range"]], "start": [[41, 91]], "entity_id": ["T3"], "Drug": {"text": [["lithium"]], "start": [[41]], "entity_id": ["T6"]}}, "Effect": {"text": [["organic brain syndromes"]], "start": [[57]], "entity_id": ["T5"]}, "Speculated": {"text": [["probable"]], "start": [[32]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "16623611_3", "context": "The patient was enrolled in a weight-loss clinic, and his diabetes medications were adjusted.Subsequently, olanzapine was discontinued because of weight gain and uncontrolled diabetes.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["because"]], "start": [[135]], "entity_id": ["T8"]}, "Subject": {"text": [["patient"]], "start": [[4]], "entity_id": ["T5"]}, "Treatment": {"text": [["olanzapine was discontinued"]], "start": [[107]], "entity_id": ["T6"], "Drug": {"text": [["olanzapine"]], "start": [[107]], "entity_id": ["T9"]}}, "Effect": {"text": [["weight gain and uncontrolled diabetes"]], "start": [[146]], "entity_id": ["T7"]}}]}]}
{"id": "4004433_4", "context": "While most physicians are aware of heparin-induced thrombocytopenia and skin necrosis, the association of heparin and hyperkalemia is less well recognized.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[43]], "entity_id": ["T8"]}, "Treatment": {"text": [["heparin"]], "start": [[35]], "entity_id": ["T7"], "Drug": {"text": [["heparin"]], "start": [[35]], "entity_id": ["T10"]}}, "Effect": {"text": [["thrombocytopenia and skin necrosis"]], "start": [[51]], "entity_id": ["T9"]}}]}]}
{"id": "16176119_2", "context": "Gefitinib (IRESSA, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, has been approved in several countries for the treatment of advanced non-small-cell lung cancer.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatment"]], "start": [[138]], "entity_id": ["T8"]}, "Treatment": {"text": [["Gefitinib"]], "start": [[0]], "entity_id": ["T7"], "Disorder": {"text": [["advanced non-small-cell lung cancer"]], "start": [[151]], "entity_id": ["T9"]}, "Drug": {"text": [["Gefitinib"], ["IRESSA"], ["ZD1839"], ["epidermal growth factor receptor tyrosine kinase inhibitor"]], "start": [[0], [11], [19], [31]], "entity_id": ["T10", "T11", "T12", "T13"]}}}]}]}
{"id": "19520277_2", "context": "The case of a 4-year-old girl with valproate-induced stupor and electroencephalographic pattern of increased fast activity is reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[45]], "entity_id": ["T3"]}, "Treatment": {"text": [["valproate"]], "start": [[35]], "entity_id": ["T4"], "Drug": {"text": [["valproate"]], "start": [[35]], "entity_id": ["T9"]}}, "Effect": {"text": [["stupor and electroencephalographic pattern of increased fast activity"]], "start": [[53]], "entity_id": ["T5"]}, "Subject": {"text": [["a 4-year-old girl"]], "start": [[12]], "entity_id": ["T6"], "Age": {"text": [["4-year-old"]], "start": [[14]], "entity_id": ["T7"]}, "Gender": {"text": [["girl"]], "start": [[25]], "entity_id": ["T8"]}}}]}]}
{"id": "16421117_2", "context": "Prior to surgery, levodopa induced dyskinesia had improved (< or = 50%) under treatment with amantadine (400 mg/day, po) in all three patients.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["improved"]], "start": [[50]], "entity_id": ["T4"]}, "Treatment": {"text": [["treatment with amantadine (400 mg/day, po)"]], "start": [[78]], "entity_id": ["T5"], "Drug": {"text": [["amantadine"]], "start": [[93]], "entity_id": ["T8"]}, "Dosage": {"text": [["400 mg/day"]], "start": [[105]], "entity_id": ["T9"]}}, "Subject": {"text": [["all three patients"]], "start": [[124]], "entity_id": ["T6"], "Population": {"text": [["three"]], "start": [[128]], "entity_id": ["T7"]}}, "Effect": {"text": [["levodopa induced dyskinesia"]], "start": [[18]], "entity_id": ["T3"]}}]}]}
{"id": "8384030_3", "context": "Foscarnet-induced severe hypomagnesemia and other electrolyte disorders.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[10]], "entity_id": ["T6"]}, "Treatment": {"text": [["Foscarnet"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Foscarnet"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["hypomagnesemia and other electrolyte disorders"]], "start": [[25]], "entity_id": ["T7"]}, "Severity": {"text": [["severe"]], "start": [[18]], "entity_id": ["T9"], "value": "High"}}]}]}
{"id": "667809_1", "context": "A case is reported of a child with fatal pulmonary fibrosis following BCNU therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[60]], "entity_id": ["T6"]}, "Subject": {"text": [["child with fatal pulmonary fibrosis"]], "start": [[24]], "entity_id": ["T3"], "Age": {"text": [["child"]], "start": [[24]], "entity_id": ["T7"]}}, "Effect": {"text": [["fatal pulmonary fibrosis"]], "start": [[35]], "entity_id": ["T4"]}, "Treatment": {"text": [["BCNU therapy"]], "start": [[70]], "entity_id": ["T5"], "Drug": {"text": [["BCNU"]], "start": [[70]], "entity_id": ["T8"]}}, "Severity": {"text": [["fatal"]], "start": [[35]], "entity_id": ["T9"], "value": "High"}}]}]}
{"id": "15729090_3", "context": "A 64-year-old man with schizophrenia developed myoclonic jerks when given higher doses of quetiapine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[37]], "entity_id": ["T8"]}, "Subject": {"text": [["A 64-year-old man with schizophrenia"]], "start": [[0]], "entity_id": ["T6"], "Age": {"text": [["64-year-old"]], "start": [[2]], "entity_id": ["T11"]}, "Gender": {"text": [["man"]], "start": [[14]], "entity_id": ["T12"]}}, "Effect": {"text": [["myoclonic jerks"]], "start": [[47]], "entity_id": ["T9"]}, "Treatment": {"text": [["higher doses of quetiapine"]], "start": [[74]], "entity_id": ["T10"], "Disorder": {"text": [["schizophrenia"]], "start": [[23]], "entity_id": ["T13"]}, "Drug": {"text": [["quetiapine"]], "start": [[90]], "entity_id": ["T14"]}, "Dosage": {"text": [["higher doses"]], "start": [[74]], "entity_id": ["T15"]}}}]}]}
{"id": "15494638_18", "context": "The etiology of neurotoxicity in our two patients remains unclear; however, as CAP is rapidly metabolized to 5-FU in patients with normal liver function, it is likely that 5-FU or its active metabolites (fluoro-beta-alanine) were contributing factors.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["contributing"]], "start": [[230]], "entity_id": ["T12"]}, "Subject": {"text": [["two patients"]], "start": [[37]], "entity_id": ["T10"], "Population": {"text": [["two"]], "start": [[37]], "entity_id": ["T14"]}}, "Treatment": {"text": [["5-FU or its active metabolites (fluoro-beta-alanine)"]], "start": [[172]], "entity_id": ["T11"], "Drug": {"text": [["5-FU"], ["fluoro-beta-alanine"]], "start": [[172], [204]], "entity_id": ["T15", "T16"]}}, "Effect": {"text": [["neurotoxicity"]], "start": [[16]], "entity_id": ["T13"]}, "Speculated": {"text": [["it is likely"]], "start": [[154]], "entity_id": ["T17"], "value": true}}]}]}
{"id": "19034138_2", "context": "CONCLUSIONS: Amantadine can cause reversible corneal edema but can irreversibly reduce the density of endothelial cells.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[28]], "entity_id": ["T4"]}, "Treatment": {"text": [["Amantadine"]], "start": [[13]], "entity_id": ["T3"], "Drug": {"text": [["Amantadine"]], "start": [[13]], "entity_id": ["T6"]}}, "Effect": {"text": [["reversible corneal edema"]], "start": [[34]], "entity_id": ["T5"]}, "Severity": {"text": [["irreversibly"]], "start": [[67]], "entity_id": ["T7"], "value": "High"}}]}]}
{"id": "1635565_1", "context": "After gastric-outlet obstruction was recognized in several infants who received prostaglandin E1, we studied the association between the drug and this complication.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["received"]], "start": [[71]], "entity_id": ["T6"]}, "Subject": {"text": [["several infants"]], "start": [[51]], "entity_id": ["T3"], "Age": {"text": [["infants"]], "start": [[59]], "entity_id": ["T7"]}}, "Treatment": {"text": [["prostaglandin E1"]], "start": [[80]], "entity_id": ["T4"], "Drug": {"text": [["prostaglandin E1"]], "start": [[80]], "entity_id": ["T8"]}}, "Effect": {"text": [["gastric-outlet obstruction"]], "start": [[6]], "entity_id": ["T5"]}}]}]}
{"id": "10981493_2", "context": "A wide variety of adverse central nervous system effects have been reported in association with propafenone; dizziness is the most common.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["association"]], "start": [[79]], "entity_id": ["T9"]}, "Treatment": {"text": [["propafenone"]], "start": [[96]], "entity_id": ["T5"], "Drug": {"text": [["propafenone"]], "start": [[96]], "entity_id": ["T10"]}}, "Effect": {"text": [["adverse central nervous system effects", "dizziness"]], "start": [[18, 109]], "entity_id": ["T7"]}, "Speculated": {"text": [["most common"]], "start": [[126]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "21712512_10", "context": "Iatrogenic Cushing syndrome has been reported in patients with CF treated concomitantly, and for extended duration, with inhaled corticosteroids and CYP3A4 inhibitors.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reported"]], "start": [[37]], "entity_id": ["T9"]}, "Treatment": {"text": [["inhaled corticosteroids and CYP3A4 inhibitors"]], "start": [[121]], "entity_id": ["T8"], "Route": {"text": [["inhaled"]], "start": [[121]], "entity_id": ["T14"]}, "Drug": {"text": [["corticosteroids"], ["CYP3A4 inhibitors"]], "start": [[129], [149]], "entity_id": ["T15", "T16"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[145]], "entity_id": ["T13"]}, "Drug": {"text": [["corticosteroids"], ["CYP3A4 inhibitors"]], "start": [[129], [149]], "entity_id": ["T15", "T16"]}}]}, "Effect": {"text": [["Iatrogenic Cushing syndrome"]], "start": [[0]], "entity_id": ["T10"]}, "Subject": {"text": [["patients with CF"]], "start": [[49]], "entity_id": ["T11"], "Disorder": {"text": [["CF"]], "start": [[63]], "entity_id": ["T12"]}}}]}]}
{"id": "17671884_1", "context": "Red blood cell anemia in a patient with pemphigus vulgaris induced by the use of mycophenolate mofetil and prednisone.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[59]], "entity_id": ["T10"]}, "Effect": {"text": [["Red blood cell anemia"]], "start": [[0]], "entity_id": ["T8"]}, "Subject": {"text": [["a patient with pemphigus vulgaris"]], "start": [[25]], "entity_id": ["T9"]}, "Treatment": {"text": [["mycophenolate mofetil and prednisone"]], "start": [[81]], "entity_id": ["T11"], "Disorder": {"text": [["pemphigus vulgaris"]], "start": [[40]], "entity_id": ["T12"]}, "Drug": {"text": [["mycophenolate mofetil"], ["prednisone"]], "start": [[81], [107]], "entity_id": ["T13", "T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[103]], "entity_id": ["T15"]}, "Drug": {"text": [["mycophenolate mofetil"], ["prednisone"]], "start": [[81], [107]], "entity_id": ["T13", "T14"]}}]}}]}]}
{"id": "1765991_1", "context": "Induction of systemic lupus erythematosus by interferon-gamma in a patient with rheumatoid arthritis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["by"]], "start": [[42]], "entity_id": ["T10"]}, "Treatment": {"text": [["interferon-gamma"]], "start": [[45]], "entity_id": ["T8"], "Drug": {"text": [["interferon-gamma"]], "start": [[45]], "entity_id": ["T11"]}, "Disorder": {"text": [["rheumatoid arthritis."]], "start": [[80]], "entity_id": ["T12"]}}, "Effect": {"text": [["systemic lupus erythematosus"]], "start": [[13]], "entity_id": ["T9"]}, "Subject": {"text": [["a patient with rheumatoid arthritis"]], "start": [[65]], "entity_id": ["T6"]}}]}]}
{"id": "16997047_2", "context": "In this case, unlike those previously reported, hyponatremia recurred 5 months after switching from citalopram to mirtazapine, which is believed to be a safe antidepressant.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[79]], "entity_id": ["T4"]}, "Treatment": {"text": [["switching from citalopram to mirtazapine"]], "start": [[85]], "entity_id": ["T5"], "Drug": {"text": [["citalopram"], ["mirtazapine"]], "start": [[100], [114]], "entity_id": ["T7", "T8"]}, "Time_elapsed": {"text": [["5 months"]], "start": [[70]], "entity_id": ["T9"]}}, "Effect": {"text": [["hyponatremia"]], "start": [[48]], "entity_id": ["T6"]}}]}]}
{"id": "16945058_2", "context": "This report describes a case of acute compromise of renal function associated with hypotension in a 7-year-old boy treated with the ACE inhibitor lisinopril and the ARB losartan.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[67]], "entity_id": ["T7"]}, "Effect": {"text": [["acute compromise of renal function", "hypotension"]], "start": [[32, 83]], "entity_id": ["T4"]}, "Subject": {"text": [["a 7-year-old boy"]], "start": [[98]], "entity_id": ["T5"], "Age": {"text": [["7-year-old"]], "start": [[100]], "entity_id": ["T8"]}, "Gender": {"text": [["boy"]], "start": [[111]], "entity_id": ["T9"]}}, "Treatment": {"text": [["ACE inhibitor lisinopril and the ARB losartan"]], "start": [[132]], "entity_id": ["T6"], "Drug": {"text": [["lisinopril"], ["losartan"]], "start": [[146], [169]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[157]], "entity_id": ["T12"]}, "Drug": {"text": [["lisinopril"], ["losartan"]], "start": [[146], [169]], "entity_id": ["T10", "T11"]}}]}}]}]}
{"id": "9302445_4", "context": "We report a male patient with advanced AIDS who developed hypercalcemia 2 weeks after institution of rhGH therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[48]], "entity_id": ["T4"]}, "Subject": {"text": [["a male patient with advanced AIDS"]], "start": [[10]], "entity_id": ["T3"], "Gender": {"text": [["male"]], "start": [[12]], "entity_id": ["T7"]}}, "Effect": {"text": [["hypercalcemia"]], "start": [[58]], "entity_id": ["T5"]}, "Treatment": {"text": [["2 weeks after institution of rhGH therapy"]], "start": [[72]], "entity_id": ["T6"], "Disorder": {"text": [["advanced AIDS"]], "start": [[30]], "entity_id": ["T9"]}, "Drug": {"text": [["rhGH"]], "start": [[101]], "entity_id": ["T10"]}, "Time_elapsed": {"text": [["2 weeks"]], "start": [[72]], "entity_id": ["T11"]}}}]}]}
{"id": "1592841_2", "context": "RESULTS: Both patients experienced a previously unreported side effect--falling backward--associated with bupropion use.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[90]], "entity_id": ["T3"]}, "Treatment": {"text": [["bupropion"]], "start": [[106]], "entity_id": ["T4"], "Drug": {"text": [["bupropion"]], "start": [[106]], "entity_id": ["T8"]}}, "Subject": {"text": [["Both patients"]], "start": [[9]], "entity_id": ["T5"], "Population": {"text": [["Both"]], "start": [[9]], "entity_id": ["T7"]}}, "Effect": {"text": [["falling backward"]], "start": [[72]], "entity_id": ["T6"]}}]}]}
{"id": "150825_2", "context": "A second episode of jaundice followed the intravaginal administration of a mixture of furazolidone and nifuroxime.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["followed"]], "start": [[29]], "entity_id": ["T6"]}, "Effect": {"text": [["jaundice"]], "start": [[20]], "entity_id": ["T4"]}, "Treatment": {"text": [["intravaginal administration of a mixture of furazolidone and nifuroxime"]], "start": [[42]], "entity_id": ["T5"], "Drug": {"text": [["furazolidone"], ["nifuroxime"]], "start": [[86], [103]], "entity_id": ["T7", "T8"]}, "Route": {"text": [["intravaginal"]], "start": [[42]], "entity_id": ["T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["mixture"]], "start": [[75]], "entity_id": ["T9"]}, "Drug": {"text": [["furazolidone"], ["nifuroxime"]], "start": [[86], [103]], "entity_id": ["T7", "T8"]}}]}}]}]}
{"id": "18294121_2", "context": "Clinicians should be aware that an erythematous and exfoliative rash may be induced by temozolomide, and be familiar with the pharmacologic and supportive measures necessary for its treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[76]], "entity_id": ["T4"]}, "Effect": {"text": [["an erythematous and exfoliative rash"]], "start": [[32]], "entity_id": ["T3"]}, "Treatment": {"text": [["temozolomide"]], "start": [[87]], "entity_id": ["T5"], "Drug": {"text": [["temozolomide"]], "start": [[87]], "entity_id": ["T6"]}}, "Speculated": {"text": [["may"]], "start": [[69]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "8255797_1", "context": "Captopril-induced bone marrow suppression in two cardiac patients with trisomy 21.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[10]], "entity_id": ["T4"]}, "Treatment": {"text": [["Captopril"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Captopril"]], "start": [[0]], "entity_id": ["T10"]}}, "Effect": {"text": [["bone marrow suppression"]], "start": [[18]], "entity_id": ["T5"]}, "Subject": {"text": [["two cardiac patients with trisomy 21"]], "start": [[45]], "entity_id": ["T6"], "Population": {"text": [["two"]], "start": [[45]], "entity_id": ["T8"]}, "Disorder": {"text": [["cardiac"], ["trisomy 21"]], "start": [[49], [71]], "entity_id": ["T7", "T1"]}}}]}]}
{"id": "9796135_1", "context": "A 65-year-old woman with angina pectoris presented with syncope after sublingual ingestion of isosorbide dinitrate (5 mg).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["presented"]], "start": [[41]], "entity_id": ["T5"]}, "Treatment": {"text": [["sublingual ingestion of isosorbide dinitrate (5 mg)"]], "start": [[70]], "entity_id": ["T3"], "Disorder": {"text": [["angina pectoris"]], "start": [[25]], "entity_id": ["T7"]}, "Route": {"text": [["sublingual ingestion"]], "start": [[70]], "entity_id": ["T10"]}, "Drug": {"text": [["isosorbide dinitrate"]], "start": [[94]], "entity_id": ["T11"]}, "Dosage": {"text": [["5 mg"]], "start": [[116]], "entity_id": ["T12"]}}, "Effect": {"text": [["syncope"]], "start": [[56]], "entity_id": ["T4"]}, "Subject": {"text": [["A 65-year-old woman with angina pectoris"]], "start": [[0]], "entity_id": ["T6"], "Age": {"text": [["65-year-old"]], "start": [[2]], "entity_id": ["T8"]}, "Gender": {"text": [["woman"]], "start": [[14]], "entity_id": ["T9"]}}}]}]}
{"id": "1860779_1", "context": "The authors present a case study of a mentally healthy man who repeatedly experienced short-lived, obsessional-like suicidal ideas and images after ingestion of the anti-fungal drug ketoconazole.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["experienced"]], "start": [[74]], "entity_id": ["T4"]}, "Subject": {"text": [["a mentally healthy man"]], "start": [[36]], "entity_id": ["T3"], "Gender": {"text": [["man"]], "start": [[55]], "entity_id": ["T7"]}}, "Effect": {"text": [["short-lived, obsessional-like suicidal ideas and images"]], "start": [[86]], "entity_id": ["T5"]}, "Treatment": {"text": [["ingestion of the anti-fungal drug ketoconazole"]], "start": [[148]], "entity_id": ["T6"], "Route": {"text": [["ingestion"]], "start": [[148]], "entity_id": ["T8"]}, "Drug": {"text": [["ketoconazole"]], "start": [[182]], "entity_id": ["T9"]}}}]}]}
{"id": "1356045_2", "context": "Flaccid quadriparesis was noted after discontinuation of vecuronium.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["noted"]], "start": [[26]], "entity_id": ["T5"]}, "Effect": {"text": [["Flaccid quadriparesis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["vecuronium"]], "start": [[57]], "entity_id": ["T4"], "Drug": {"text": [["vecuronium"]], "start": [[57]], "entity_id": ["T6"]}}}]}]}
{"id": "17444802_2", "context": "AIMS: The aim of this study was to report on the effectiveness and tumor side effects of topical interferon (INF) alpha 2-beta in a case of conjunctiva-cornea intraepithelial neoplasia (CIN) of a patient that rejected any surgical procedure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["side effects"]], "start": [[73]], "entity_id": ["T10"]}, "Subject": {"text": [["conjunctiva-cornea intraepithelial neoplasia (CIN) of a patient that rejected any surgical procedure"]], "start": [[140]], "entity_id": ["T7"]}, "Treatment": {"text": [["topical interferon (INF) alpha 2-beta"]], "start": [[89]], "entity_id": ["T8"], "Route": {"text": [["topical"]], "start": [[89]], "entity_id": ["T12"]}, "Drug": {"text": [["interferon", "alpha 2-beta"]], "start": [[97, 114]], "entity_id": ["T13"]}, "Disorder": {"text": [["conjunctiva-cornea intraepithelial neoplasia"]], "start": [[140]], "entity_id": ["T14"]}}, "Effect": {"text": [["tumor side effects"]], "start": [[67]], "entity_id": ["T9"]}}]}]}
{"id": "17044380_1", "context": "Herein is reported an unusual case of coexistent warfarin-induced skin necrosis and heparin-induced thrombocytopenia following mitral valve replacement for thromboembolic phenomena associated with marantic endocarditis and bronchial adenocarcinoma.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[58]], "entity_id": ["T6"]}, "Treatment": {"text": [["warfarin"]], "start": [[49]], "entity_id": ["T7"], "Drug": {"text": [["warfarin"]], "start": [[49]], "entity_id": ["T8"]}}, "Effect": {"text": [["skin necrosis"]], "start": [[66]], "entity_id": ["T9"]}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[92]], "entity_id": ["T11"]}, "Treatment": {"text": [["heparin"]], "start": [[84]], "entity_id": ["T10"], "Drug": {"text": [["heparin"]], "start": [[84]], "entity_id": ["T13"]}}, "Effect": {"text": [["thrombocytopenia"]], "start": [[100]], "entity_id": ["T12"]}}]}]}
{"id": "17026827_2", "context": "We present a case of severe unilateral posterior scleritis associated with zoledronic acid administration that was recognized and treated in a timely manner.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[59]], "entity_id": ["T4"]}, "Effect": {"text": [["severe unilateral posterior scleritis"]], "start": [[21]], "entity_id": ["T3"]}, "Treatment": {"text": [["zoledronic acid"]], "start": [[75]], "entity_id": ["T5"], "Drug": {"text": [["zoledronic acid"]], "start": [[75]], "entity_id": ["T6"]}}}]}]}
{"id": "19567656_5", "context": "The patient's other comorbidities and medications have not been suggested as possible interactions with sertraline that can cause rhabdomyolysis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[124]], "entity_id": ["T4"]}, "Treatment": {"text": [["sertraline"]], "start": [[104]], "entity_id": ["T3"], "Drug": {"text": [["sertraline"]], "start": [[104]], "entity_id": ["T6"]}}, "Effect": {"text": [["rhabdomyolysis"]], "start": [[130]], "entity_id": ["T5"]}, "Negated": {"text": [["not"]], "start": [[55]], "entity_id": ["T7"], "value": true}, "Speculated": {"text": [["possible"]], "start": [[77]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "11030530_1", "context": "L-asparaginase-provoked seizures as singular expression of central nervous toxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["provoked"]], "start": [[15]], "entity_id": ["T6"]}, "Effect": {"text": [["seizures as singular expression of central nervous toxicity"]], "start": [[24]], "entity_id": ["T5"]}, "Treatment": {"text": [["L-asparaginase"]], "start": [[0]], "entity_id": ["T7"], "Drug": {"text": [["L-asparaginase"]], "start": [[0]], "entity_id": ["T8"]}}}]}]}
{"id": "7351000_1", "context": "Acute non-lymphocytic leukemia in patients with ovarian carcinoma following long-term treatment with Treosulfan (= dihydroxybusulfan).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[66]], "entity_id": ["T6"]}, "Effect": {"text": [["Acute non-lymphocytic leukemia"]], "start": [[0]], "entity_id": ["T4"]}, "Subject": {"text": [["patients with ovarian carcinoma"]], "start": [[34]], "entity_id": ["T5"]}, "Treatment": {"text": [["long-term treatment with Treosulfan (= dihydroxybusulfan)"]], "start": [[76]], "entity_id": ["T7"], "Drug": {"text": [["Treosulfan"]], "start": [[101]], "entity_id": ["T9"]}, "Disorder": {"text": [["ovarian carcinoma"]], "start": [[48]], "entity_id": ["T10"]}}}]}]}
{"id": "15694139_7", "context": "Children treated with thalidomide should undergo regular neurophysiologic studies in order to detect presymptomatic or progressive peripheral neuropathy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["detect"]], "start": [[94]], "entity_id": ["T12"]}, "Subject": {"text": [["Children"]], "start": [[0]], "entity_id": ["T9"], "Age": {"text": [["Children"]], "start": [[0]], "entity_id": ["T13"]}}, "Treatment": {"text": [["thalidomide"]], "start": [[22]], "entity_id": ["T10"], "Drug": {"text": [["thalidomide"]], "start": [[22]], "entity_id": ["T14"]}}, "Effect": {"text": [["presymptomatic or progressive peripheral neuropathy"]], "start": [[101]], "entity_id": ["T11"]}}]}]}
{"id": "11174414_2", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor widely used in combination with other antiretroviral agents for the treatment of HIV infection.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatment"]], "start": [[131]], "entity_id": ["T7"]}, "Treatment": {"text": [["Nevirapine is a non-nucleoside reverse transcriptase inhibitor widely used in combination with other antiretroviral agents"]], "start": [[0]], "entity_id": ["T6"], "Drug": {"text": [["Nevirapine"], ["other antiretroviral agents"]], "start": [[0], [95]], "entity_id": ["T9", "T11"]}, "Disorder": {"text": [["HIV infection"]], "start": [[144]], "entity_id": ["T8"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combination"]], "start": [[78]], "entity_id": ["T10"]}, "Drug": {"text": [["Nevirapine"], ["other antiretroviral agents"]], "start": [[0], [95]], "entity_id": ["T9", "T11"]}}]}}]}]}
{"id": "17260498_4", "context": "The case is presented of a 72-year-old man with hormone-refractory prostate cancer and weekly administration of 30 mg/m2 docetaxel who developed subacute interstitial pneumonitis-related pulmonary fibrosis after seven doses and died despite mechanical ventilation and high-dose corticosteroid treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[135]], "entity_id": ["T15"]}, "Treatment": {"text": [["weekly administration of 30 mg/m2 docetaxel", "seven doses", "despite mechanical ventilation and high-dose corticosteroid treatment"]], "start": [[87, 212, 233]], "entity_id": ["T14"], "Freq": {"text": [["weekly"]], "start": [[87]], "entity_id": ["T19"]}, "Route": {"text": [["administration"]], "start": [[94]], "entity_id": ["T20"]}, "Dosage": {"text": [["30 mg/m2"], ["seven doses"], ["high-dose"]], "start": [[112], [212], [268]], "entity_id": ["T21", "T23", "T30"]}, "Drug": {"text": [["docetaxel"], ["corticosteroid"]], "start": [[121], [278]], "entity_id": ["T22", "T24"]}, "Disorder": {"text": [["hormone-refractory prostate cancer"]], "start": [[48]], "entity_id": ["T25"]}}, "Effect": {"text": [["subacute interstitial pneumonitis-related pulmonary fibrosis", "and died"]], "start": [[145, 224]], "entity_id": ["T16"]}, "Subject": {"text": [["a 72-year-old man with hormone-refractory prostate cancer"]], "start": [[25]], "entity_id": ["T12"], "Age": {"text": [["72-year-old"]], "start": [[27]], "entity_id": ["T17"]}, "Gender": {"text": [["man"]], "start": [[39]], "entity_id": ["T18"]}}, "Severity": {"text": [["died"]], "start": [[228]], "entity_id": ["T27"], "value": "Medium"}}]}]}
{"id": "10732843_5", "context": "In this case, it was suspected that a combination of cigarette smoking, pulmonary fibrosis, and low-dose methotrexate therapy might have promoted the development of lung cancer.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["promoted"]], "start": [[137]], "entity_id": ["T9"]}, "Treatment": {"text": [["low-dose methotrexate therapy"]], "start": [[96]], "entity_id": ["T6"], "Dosage": {"text": [["low-dose"]], "start": [[96]], "entity_id": ["T10"]}, "Drug": {"text": [["methotrexate"]], "start": [[105]], "entity_id": ["T11"]}}, "Effect": {"text": [["the development of lung cancer"]], "start": [[146]], "entity_id": ["T7"]}, "Subject": {"text": [["pulmonary fibrosis"]], "start": [[72]], "entity_id": ["T8"], "Disorder": {"text": [["pulmonary fibrosis"]], "start": [[72]], "entity_id": ["T12"]}}}]}]}
{"id": "21712512_1", "context": "Rapid onset of iatrogenic adrenal insufficiency in a patient with cystic fibrosis-related liver disease treated with inhaled corticosteroids and a moderate CYP3A4 inhibitor.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["onset"]], "start": [[6]], "entity_id": ["T14"]}, "Effect": {"text": [["iatrogenic adrenal insufficiency"]], "start": [[15]], "entity_id": ["T10"]}, "Treatment": {"text": [["inhaled corticosteroids and a moderate CYP3A4 inhibitor"]], "start": [[117]], "entity_id": ["T13"], "Drug": {"text": [["inhaled corticosteroids"], ["CYP3A4 inhibitor."]], "start": [[117], [156]], "entity_id": ["T15", "T16"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[141]], "entity_id": ["T17"]}, "Drug": {"text": [["inhaled corticosteroids"], ["CYP3A4 inhibitor."]], "start": [[117], [156]], "entity_id": ["T15", "T16"]}}]}, "Subject": {"text": [["a patient with cystic fibrosis-related liver disease"]], "start": [[51]], "entity_id": ["T11"], "Disorder": {"text": [["cystic fibrosis-related liver disease"]], "start": [[66]], "entity_id": ["T12"]}}}]}]}
{"id": "1722991_2", "context": "Heparin-associated thrombocytopenia and thrombosis is a severe complication of systemic heparin therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[8]], "entity_id": ["T9"]}, "Treatment": {"text": [["Heparin"]], "start": [[0]], "entity_id": ["T8"], "Drug": {"text": [["Heparin"], ["heparin"]], "start": [[0], [88]], "entity_id": ["T11", "T12"]}}, "Effect": {"text": [["thrombocytopenia and thrombosis"]], "start": [[19]], "entity_id": ["T10"]}}]}]}
{"id": "10891991_7", "context": "The polycystic changes disappeared from the ovaries in 2 of the women after valproate therapy was discontinued, and the 2 women who had gained weight and developed amenorrhea while being treated with valproate lost weight and resumed menstruating after the change in medication.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["disappeared"]], "start": [[23]], "entity_id": ["T11"]}, "Effect": {"text": [["polycystic changes disappeared from the ovaries", "lost weight and resumed menstruating"]], "start": [[4, 210]], "entity_id": ["T10"]}, "Subject": {"text": [["2 of the women"]], "start": [[55]], "entity_id": ["T8"], "Population": {"text": [["2"]], "start": [[55]], "entity_id": ["T12"]}, "Gender": {"text": [["women"]], "start": [[64]], "entity_id": ["T13"]}}, "Treatment": {"text": [["after valproate therapy was discontinued"]], "start": [[70]], "entity_id": ["T9"], "Drug": {"text": [["valproate"]], "start": [[76]], "entity_id": ["T14"]}}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["while"]], "start": [[175]], "entity_id": ["T21"]}, "Subject": {"text": [["2 women"]], "start": [[120]], "entity_id": ["T15"], "Population": {"text": [["2"]], "start": [[120]], "entity_id": ["T19"]}, "Gender": {"text": [["women"]], "start": [[122]], "entity_id": ["T20"]}}, "Effect": {"text": [["gained weight and developed amenorrhea"]], "start": [[136]], "entity_id": ["T18"]}, "Treatment": {"text": [["valproate"]], "start": [[200]], "entity_id": ["T16"], "Drug": {"text": [["valproate"]], "start": [[200]], "entity_id": ["T17"]}}}]}]}
{"id": "11225532_2", "context": "The cause of his bleeding was a severe thrombocytopoaenia, induced by chronic ingestion of quinine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[59]], "entity_id": ["T5"]}, "Treatment": {"text": [["chronic ingestion of quinine"]], "start": [[70]], "entity_id": ["T3"], "Route": {"text": [["ingestion"]], "start": [[78]], "entity_id": ["T6"]}, "Drug": {"text": [["quinine"]], "start": [[91]], "entity_id": ["T7"]}}, "Effect": {"text": [["thrombocytopoaenia"]], "start": [[39]], "entity_id": ["T4"]}, "Severity": {"text": [["severe"]], "start": [[32]], "entity_id": ["T8"], "value": "High"}}]}]}
{"id": "16882112_3", "context": "The concomitant use of antidepressant drugs associated with lithium as a co-adjuvant seems to increase the risk of this adverse reaction.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["increase"]], "start": [[94]], "entity_id": ["T8"]}, "Treatment": {"text": [["concomitant use of antidepressant drugs associated with lithium as a co-adjuvant"]], "start": [[4]], "entity_id": ["T7"], "Drug": {"text": [["antidepressant drugs"], ["lithium"]], "start": [[23], [60]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["associated"]], "start": [[44]], "entity_id": ["T12"]}, "Drug": {"text": [["antidepressant drugs"], ["lithium"]], "start": [[23], [60]], "entity_id": ["T10", "T11"]}}]}, "Effect": {"text": [["adverse reaction"]], "start": [[120]], "entity_id": ["T9"]}}]}]}
{"id": "2554727_3", "context": "Peripheral nervous system disturbances caused by cytosine arabinoside have rarely been reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[39]], "entity_id": ["T6"]}, "Effect": {"text": [["Peripheral nervous system disturbances"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["cytosine arabinoside"]], "start": [[49]], "entity_id": ["T7"], "Drug": {"text": [["cytosine arabinoside"]], "start": [[49]], "entity_id": ["T8"]}}}]}]}
{"id": "9315405_1", "context": "We report an unusually short lived and asymptomatic episode of severe cisplatin-induced renal tubular salt wasting in a fit 41-year-old patient with malignant teratoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[80]], "entity_id": ["T5"]}, "Subject": {"text": [["a fit 41-year-old patient with malignant teratoma"]], "start": [[118]], "entity_id": ["T3"], "Age": {"text": [["41-year-old"]], "start": [[124]], "entity_id": ["T7"]}}, "Treatment": {"text": [["cisplatin"]], "start": [[70]], "entity_id": ["T4"], "Disorder": {"text": [["malignant teratoma"]], "start": [[149]], "entity_id": ["T8"]}, "Drug": {"text": [["cisplatin"]], "start": [[70]], "entity_id": ["T9"]}}, "Effect": {"text": [["renal tubular salt wasting"]], "start": [[88]], "entity_id": ["T6"]}}]}]}
{"id": "10102531_1", "context": "This case suggests that BH-AC, a derivative of cytosine arabinoside (1-beta-D-arabinofuranosylcytosine) could be a cause of reversible encephalopathy syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[115]], "entity_id": ["T5"]}, "Treatment": {"text": [["BH-AC, a derivative of cytosine arabinoside (1-beta-D-arabinofuranosylcytosine)"]], "start": [[24]], "entity_id": ["T3"], "Drug": {"text": [["BH-AC"]], "start": [[24]], "entity_id": ["T7"]}}, "Effect": {"text": [["reversible encephalopathy syndrome"]], "start": [[124]], "entity_id": ["T4"]}, "Subject": {"text": [["This case"]], "start": [[0]], "entity_id": ["T6"]}, "Speculated": {"text": [["could be"]], "start": [[104]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "11816261_5", "context": "She was administered metoclopramide because of nausea and, within 2 hours, developed agitation, dysarthria, diaphoresis, and a movement disorder.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[75]], "entity_id": ["T11"]}, "Treatment": {"text": [["metoclopramide"]], "start": [[21]], "entity_id": ["T9"], "Drug": {"text": [["metoclopramide"]], "start": [[21]], "entity_id": ["T13"]}, "Disorder": {"text": [["nausea"]], "start": [[47]], "entity_id": ["T14"]}, "Time_elapsed": {"text": [["within 2 hours"]], "start": [[59]], "entity_id": ["T15"]}}, "Effect": {"text": [["agitation, dysarthria, diaphoresis, and a movement disorder"]], "start": [[85]], "entity_id": ["T12"]}}]}]}
{"id": "448845_4", "context": "This article describes two cases of aplastic anemia, at least one of which was almost certainly induced by the use of methazolamide, and one case of agranulocytosis related to the use of methazolamide.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[96]], "entity_id": ["T10"]}, "Subject": {"text": [["two cases"]], "start": [[23]], "entity_id": ["T13"]}, "Effect": {"text": [["aplastic anemia"]], "start": [[36]], "entity_id": ["T9"]}, "Treatment": {"text": [["methazolamide"]], "start": [[118]], "entity_id": ["T18"], "Drug": {"text": [["methazolamide"]], "start": [[118]], "entity_id": ["T11"]}}, "Speculated": {"text": [["almost certainly"]], "start": [[79]], "entity_id": ["T14"], "value": true}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[165]], "entity_id": ["T15"]}, "Effect": {"text": [["agranulocytosis"]], "start": [[149]], "entity_id": ["T16"]}, "Treatment": {"text": [["methazolamide"]], "start": [[187]], "entity_id": ["T17"], "Drug": {"text": [["methazolamide"]], "start": [[187]], "entity_id": ["T12"]}}}]}]}
{"id": "12584153_3", "context": "Amprenavir is a human immunodeficiency virus-1 (HIV-1) protease inhibitor intended to be used to treat HIV-infected children.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treat"]], "start": [[97]], "entity_id": ["T9"]}, "Treatment": {"text": [["Amprenavir"]], "start": [[0]], "entity_id": ["T8"], "Disorder": {"text": [["HIV-infected"]], "start": [[103]], "entity_id": ["T13"]}, "Drug": {"text": [["Amprenavir"]], "start": [[0]], "entity_id": ["T14"]}}, "Subject": {"text": [["children"]], "start": [[116]], "entity_id": ["T11"], "Age": {"text": [["children"]], "start": [[116]], "entity_id": ["T12"]}}}]}]}
{"id": "18094347_4", "context": "Methotrexate-induced papular eruption following treatment of psoriasis has not been previously reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[13]], "entity_id": ["T4"]}, "Treatment": {"text": [["Methotrexate"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Methotrexate"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["papular eruption"]], "start": [[21]], "entity_id": ["T5"]}}]}]}
{"id": "19733945_2", "context": "On day 7 of linezolid treatment, the patient developed severe pruritus, macular rash, facial edema, eosinophilia, marked increase in serum creatinine level, and mild hepatitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[45]], "entity_id": ["T16"]}, "Treatment": {"text": [["linezolid"]], "start": [[12]], "entity_id": ["T13"], "Drug": {"text": [["linezolid"]], "start": [[12]], "entity_id": ["T17"]}}, "Subject": {"text": [["the patient"]], "start": [[33]], "entity_id": ["T14"]}, "Effect": {"text": [["pruritus, macular rash, facial edema, eosinophilia, marked increase in serum creatinine level", "hepatitis"]], "start": [[62, 166]], "entity_id": ["T15"]}, "Severity": {"text": [["severe"], ["mild"]], "start": [[55], [161]], "entity_id": ["T18", "T19"], "value": "Medium"}}]}]}
{"id": "8181372_2", "context": "We report a fatal case of acute interstitial pneumonitis in a patient treated with carmustine (BCNU) for a brain tumor.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated with"]], "start": [[70]], "entity_id": ["T6"]}, "Effect": {"text": [["acute interstitial pneumonitis"]], "start": [[26]], "entity_id": ["T4"]}, "Subject": {"text": [["a patient", "for a brain tumor"]], "start": [[60, 101]], "entity_id": ["T5"]}, "Treatment": {"text": [["carmustine (BCNU)"]], "start": [[83]], "entity_id": ["T7"], "Drug": {"text": [["carmustine (BCNU)"]], "start": [[83]], "entity_id": ["T9"]}, "Disorder": {"text": [["a brain tumor"]], "start": [[105]], "entity_id": ["T10"]}}, "Severity": {"text": [["fatal"]], "start": [[12]], "entity_id": ["T11"], "value": "High"}}]}]}
{"id": "10749332_4", "context": "The three reported cases demonstrate that troglitazone is an idiosyncratic hepatotoxin that can lead to irreversible liver injury.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["lead"]], "start": [[96]], "entity_id": ["T5"]}, "Subject": {"text": [["three reported cases"]], "start": [[4]], "entity_id": ["T3"], "Population": {"text": [["three"]], "start": [[4]], "entity_id": ["T7"]}}, "Effect": {"text": [["irreversible liver injury"]], "start": [[104]], "entity_id": ["T4"]}, "Treatment": {"text": [["troglitazone"]], "start": [[42]], "entity_id": ["T6"], "Drug": {"text": [["troglitazone"]], "start": [[42]], "entity_id": ["T8"]}}, "Severity": {"text": [["irreversible"]], "start": [[104]], "entity_id": ["T9"], "value": "High"}}]}]}
{"id": "7814182_1", "context": "High-grade atrioventricular block during dipyridamole stress testing.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[34]], "entity_id": ["T4"]}, "Treatment": {"text": [["dipyridamole stress testing"]], "start": [[41]], "entity_id": ["T3"], "Drug": {"text": [["dipyridamole"]], "start": [[41]], "entity_id": ["T6"]}}, "Effect": {"text": [["High-grade atrioventricular block"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "16453964_1", "context": "We describe a case of intraoperative gelatine-induced anaphylaxis whose diagnosis was delayed as the use of gelatine during surgical procedures was omitted for two times in patient's medical records.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[46]], "entity_id": ["T5"]}, "Treatment": {"text": [["intraoperative gelatine"]], "start": [[22]], "entity_id": ["T4"], "Drug": {"text": [["gelatine"]], "start": [[37]], "entity_id": ["T7"]}, "Route": {"text": [["intraoperative"]], "start": [[22]], "entity_id": ["T8"]}}, "Effect": {"text": [["anaphylaxis"]], "start": [[54]], "entity_id": ["T6"]}}]}]}
{"id": "2406680_3", "context": "The case of a 29-year-old man suffering from falciparum malaria disease who got a reversible hearing loss from quinine therapy is presented.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["got"]], "start": [[76]], "entity_id": ["T7"]}, "Subject": {"text": [["a 29-year-old man suffering from falciparum malaria disease"]], "start": [[12]], "entity_id": ["T3"], "Age": {"text": [["29-year-old"]], "start": [[14]], "entity_id": ["T8"]}, "Gender": {"text": [["man"]], "start": [[26]], "entity_id": ["T9"]}}, "Effect": {"text": [["reversible hearing loss"]], "start": [[82]], "entity_id": ["T5"]}, "Treatment": {"text": [["quinine"]], "start": [[111]], "entity_id": ["T6"], "Disorder": {"text": [["falciparum malaria disease"]], "start": [[45]], "entity_id": ["T11"]}, "Drug": {"text": [["quinine"]], "start": [[111]], "entity_id": ["T12"]}}, "Severity": {"text": [["reversible"]], "start": [[82]], "entity_id": ["T10"], "value": "Medium"}}]}]}
{"id": "7893301_3", "context": "The cases of two asthmatic patients who became hypokalemic after inhalation of normal doses of albuterol are presented.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[59]], "entity_id": ["T4"]}, "Subject": {"text": [["two asthmatic patients"]], "start": [[13]], "entity_id": ["T3"], "Population": {"text": [["two"]], "start": [[13]], "entity_id": ["T7"]}}, "Effect": {"text": [["hypokalemic"]], "start": [[47]], "entity_id": ["T5"]}, "Treatment": {"text": [["inhalation of normal doses of albutero"]], "start": [[65]], "entity_id": ["T6"], "Disorder": {"text": [["asthmatic"]], "start": [[17]], "entity_id": ["T8"]}, "Route": {"text": [["inhalation"]], "start": [[65]], "entity_id": ["T9"]}, "Dosage": {"text": [["normal doses"]], "start": [[79]], "entity_id": ["T10"]}, "Drug": {"text": [["albuterol"]], "start": [[95]], "entity_id": ["T11"]}}}]}]}
{"id": "19537383_4", "context": "This article presents a case of an atypical localized cutaneous eruption with an unusual course and protracted resolution time associated with sorafenib therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated with"]], "start": [[127]], "entity_id": ["T4"]}, "Treatment": {"text": [["sorafenib therapy"]], "start": [[143]], "entity_id": ["T5"], "Drug": {"text": [["sorafenib"]], "start": [[143]], "entity_id": ["T7"]}}, "Effect": {"text": [["an atypical localized cutaneous eruption with an unusual course and protracted resolution time"]], "start": [[32]], "entity_id": ["T6"]}}]}]}
{"id": "16480245_1", "context": "METHOD: We describe two patients who presented with diabetic ketoacidosis after treatment with quetiapine and risperidone, respectively.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E3", "event_type": "Adverse_event", "Trigger": {"text": [["presented"]], "start": [[37]], "entity_id": ["T12"]}, "Subject": {"text": [["two patients"]], "start": [[20]], "entity_id": ["T4"], "Population": {"text": [["two"]], "start": [[20]], "entity_id": ["T8"]}}, "Treatment": {"text": [["quetiapine and risperidone"]], "start": [[95]], "entity_id": ["T6"], "Drug": {"text": [["quetiapine"], ["risperidone"]], "start": [[95], [110]], "entity_id": ["T9", "T10"]}}, "Effect": {"text": [["diabetic ketoacidosis"]], "start": [[52]], "entity_id": ["T7"]}}]}]}
{"id": "9855339_4", "context": "We suspect that nefazodone inhibits metabolism of tacrolimus.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["inhibits"]], "start": [[27]], "entity_id": ["T5"]}, "Treatment": {"text": [["nefazodone"]], "start": [[16]], "entity_id": ["T4"], "Drug": {"text": [["nefazodone"]], "start": [[16]], "entity_id": ["T8"]}}, "Effect": {"text": [["metabolism of tacrolimus"]], "start": [[36]], "entity_id": ["T6"]}, "Speculated": {"text": [["suspect"]], "start": [[3]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "9184269_4", "context": "Our review of 194 RA patients and 38 PsA patients receiving MTX has identified four RA patients and one PsA patient with MTX-induced pneumonitis, giving a prevalence of 2.1% and 0.03%, respectively.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[125]], "entity_id": ["T4"]}, "Treatment": {"text": [["MTX"]], "start": [[121]], "entity_id": ["T3"], "Disorder": {"text": [["RA"], ["PsA"]], "start": [[84], [104]], "entity_id": ["T12", "T13"]}, "Drug": {"text": [["MTX"]], "start": [[121]], "entity_id": ["T14"]}}, "Effect": {"text": [["pneumonitis"]], "start": [[133]], "entity_id": ["T5"]}, "Subject": {"text": [["194 RA patients and 38 PsA patients receiving MTX has identified four RA patients and one PsA patient"]], "start": [[14]], "entity_id": ["T6"], "Population": {"text": [["four"], ["one"]], "start": [[79], [100]], "entity_id": ["T7", "T8"]}}}]}]}
{"id": "12862258_1", "context": "A case report of fatal dapsone-induced agranulocytosis in an Indian mid-borderline leprosy patient.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[31]], "entity_id": ["T4"]}, "Treatment": {"text": [["dapsone"]], "start": [[23]], "entity_id": ["T3"], "Drug": {"text": [["dapsone"]], "start": [[23]], "entity_id": ["T10"]}}, "Effect": {"text": [["agranulocytosis"]], "start": [[39]], "entity_id": ["T5"]}, "Subject": {"text": [["an Indian mid-borderline leprosy patient"]], "start": [[58]], "entity_id": ["T6"], "Race": {"text": [["Indian"]], "start": [[61]], "entity_id": ["T7"]}, "Disorder": {"text": [["mid-borderline leprosy"]], "start": [[68]], "entity_id": ["T8"]}}, "Severity": {"text": [["fatal"]], "start": [[17]], "entity_id": ["T9"], "value": "Medium"}}]}]}
{"id": "16498048_1", "context": "Autoimmune thyroid disease is a common side-effect of interferon-alpha (IFN-alpha) treatment of viral hepatitis C.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["side-effect"]], "start": [[39]], "entity_id": ["T7"]}, "Effect": {"text": [["Autoimmune thyroid disease"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["interferon-alpha (IFN-alpha)"]], "start": [[54]], "entity_id": ["T5"], "Drug": {"text": [["interferon-alpha"]], "start": [[54]], "entity_id": ["T9"]}, "Disorder": {"text": [["viral hepatitis C"]], "start": [[96]], "entity_id": ["T10"]}}}]}]}
{"id": "15866658_4", "context": "The side effects of MMF, such as bone marrow toxicity, have been reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reported"]], "start": [[65]], "entity_id": ["T5"]}, "Treatment": {"text": [["MMF"]], "start": [[20]], "entity_id": ["T3"], "Drug": {"text": [["MMF"]], "start": [[20]], "entity_id": ["T6"]}}, "Effect": {"text": [["bone marrow toxicity"]], "start": [[33]], "entity_id": ["T4"]}}]}]}
{"id": "15727358_1", "context": "He developed a late secondary infection in some sites treated with imiquimod.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[3]], "entity_id": ["T3"]}, "Effect": {"text": [["late secondary infection"]], "start": [[15]], "entity_id": ["T4"]}, "Treatment": {"text": [["imiquimod"]], "start": [[67]], "entity_id": ["T5"], "Drug": {"text": [["imiquimod"]], "start": [[67]], "entity_id": ["T8"]}}, "Subject": {"text": [["He"]], "start": [[0]], "entity_id": ["T6"], "Gender": {"text": [["He"]], "start": [[0]], "entity_id": ["T7"]}}}]}]}
{"id": "19104709_3", "context": "We report the case of a 51-year-old man in whom IFN-alpha treatment was followed by recurrence of Graves' disease 10 years after thyroidectomy was performed and the patient was declared cured.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["followed"]], "start": [[72]], "entity_id": ["T6"]}, "Subject": {"text": [["a 51-year-old man"]], "start": [[22]], "entity_id": ["T3"], "Age": {"text": [["51-year-old"]], "start": [[24]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[36]], "entity_id": ["T8"]}}, "Treatment": {"text": [["IFN-alpha treatment", "10 years after thyroidectomy"]], "start": [[48, 114]], "entity_id": ["T4"], "Drug": {"text": [["IFN-alpha"]], "start": [[48]], "entity_id": ["T9"]}}, "Effect": {"text": [["recurrence of Graves' disease"]], "start": [[84]], "entity_id": ["T5"]}}]}]}
{"id": "9407188_2", "context": "We report 2 cases of maculopapular eruption and fever in patients infected with human immunodeficiency virus (HIV) on the 2nd day of first administration of ritonavir, a protease inhibitor.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["infected"]], "start": [[66]], "entity_id": ["T13"]}, "Treatment": {"text": [["ritonavir"]], "start": [[157]], "entity_id": ["T9"], "Disorder": {"text": [["human immunodeficiency virus"]], "start": [[80]], "entity_id": ["T12"]}, "Drug": {"text": [["ritonavir"]], "start": [[157]], "entity_id": ["T14"]}, "Time_elapsed": {"text": [["2nd day of first administration"]], "start": [[122]], "entity_id": ["T15"]}}, "Effect": {"text": [["maculopapular eruption and fever"]], "start": [[21]], "entity_id": ["T10"]}, "Subject": {"text": [["patients"]], "start": [[57]], "entity_id": ["T11"]}}]}]}
{"id": "18344734_2", "context": "We report the case of a woman who developed photo-onycholysis on multiple nails after uptake of olanzapine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[34]], "entity_id": ["T4"]}, "Subject": {"text": [["a woman"]], "start": [[22]], "entity_id": ["T3"], "Gender": {"text": [["woman"]], "start": [[24]], "entity_id": ["T7"]}}, "Effect": {"text": [["photo-onycholysis on multiple nails"]], "start": [[44]], "entity_id": ["T5"]}, "Treatment": {"text": [["uptake of olanzapine"]], "start": [[86]], "entity_id": ["T6"], "Drug": {"text": [["olanzapine"]], "start": [[96]], "entity_id": ["T8"]}, "Time_elapsed": {"text": [["after uptake"]], "start": [[80]], "entity_id": ["T9"]}}}]}]}
{"id": "6733633_2", "context": "Cimetidine is a rare cause of drug-induced fever.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[21]], "entity_id": ["T4"]}, "Treatment": {"text": [["Cimetidine"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Cimetidine"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["fever"]], "start": [[43]], "entity_id": ["T5"]}}]}]}
{"id": "19745701_2", "context": "Reversible methotrexate-associated lymphoproliferative disorder resembling advanced gastric cancer in a patient with rheumatoid arthritis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[24]], "entity_id": ["T4"]}, "Treatment": {"text": [["methotrexate"]], "start": [[11]], "entity_id": ["T3"], "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[117]], "entity_id": ["T7"]}, "Drug": {"text": [["methotrexate"]], "start": [[11]], "entity_id": ["T8"]}}, "Effect": {"text": [["lymphoproliferative disorder"]], "start": [[35]], "entity_id": ["T5"]}, "Subject": {"text": [["a patient with rheumatoid arthritis"]], "start": [[102]], "entity_id": ["T6"]}}]}]}
{"id": "11077455_5", "context": "The field defects and some electrophysiological abnormalities persist when vigabatrin therapy is withdrawn.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["persist"]], "start": [[62]], "entity_id": ["T5"]}, "Effect": {"text": [["field defects and some electrophysiological abnormalities persist"]], "start": [[4]], "entity_id": ["T3"]}, "Treatment": {"text": [["vigabatrin therapy is withdrawn"]], "start": [[75]], "entity_id": ["T4"], "Drug": {"text": [["vigabatrin"]], "start": [[75]], "entity_id": ["T6"]}}}]}]}
{"id": "9177620_1", "context": "A possible case of carbamazepine induced pancreatitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[33]], "entity_id": ["T4"]}, "Treatment": {"text": [["carbamazepine"]], "start": [[19]], "entity_id": ["T3"], "Drug": {"text": [["carbamazepine"]], "start": [[19]], "entity_id": ["T7"]}}, "Effect": {"text": [["pancreatitis"]], "start": [[41]], "entity_id": ["T5"]}, "Subject": {"text": [["A possible case"]], "start": [[0]], "entity_id": ["T8"]}, "Speculated": {"text": [["possible"]], "start": [[2]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "24791374_4", "context": "Subsequent to the first dose of mirtazapine the patient experienced seizures, bradycardia and prolonged QRS as well as QTc intervals on EKG.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Subsequent"]], "start": [[0]], "entity_id": ["T10"]}, "Treatment": {"text": [["mirtazapine"]], "start": [[32]], "entity_id": ["T9"], "Drug": {"text": [["mirtazapine"]], "start": [[32]], "entity_id": ["T13"]}}, "Subject": {"text": [["the patient"]], "start": [[44]], "entity_id": ["T11"]}, "Effect": {"text": [["seizures, bradycardia and prolonged QRS as well as QTc intervals on EKG"]], "start": [[68]], "entity_id": ["T12"]}}]}]}
{"id": "18665833_1", "context": "Stuttering priapism complicating warfarin therapy in a patient with protein C deficiency.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[50]], "entity_id": ["T6"]}, "Subject": {"text": [["a patient with protein C deficiency"]], "start": [[53]], "entity_id": ["T3"]}, "Effect": {"text": [["Stuttering priapism"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["warfarin"]], "start": [[33]], "entity_id": ["T5"], "Disorder": {"text": [["protein C deficiency"]], "start": [[68]], "entity_id": ["T8"]}, "Drug": {"text": [["warfarin"]], "start": [[33]], "entity_id": ["T9"]}}}]}]}
{"id": "12187348_6", "context": "She had been on a combined treatment of steroid and lobenzarit disodium for the first 3 years, and then continued with a combined treatment of steroid and bucillamine for the following years until she was found to have pulmonary tuberculosis, at which time the steroid was suspended 10 months before she visited the authors' clinic.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatment"]], "start": [[27]], "entity_id": ["T15"]}, "Effect": {"text": [["pulmonary tuberculosis"]], "start": [[219]], "entity_id": ["T12"]}, "Treatment": {"text": [["steroid and lobenzarit disodium for the first 3 years, and then continued with a combined treatment of steroid and bucillamine for the following years"]], "start": [[40]], "entity_id": ["T14"], "Drug": {"text": [["steroid"], ["bucillamine"], ["lobenzarit disodium"], ["steroid"]], "start": [[143], [155], [52], [40]], "entity_id": ["T13", "T16", "T17", "T18"]}, "Time_elapsed": {"text": [["3 years"]], "start": [[86]], "entity_id": ["T20"]}, "Duration": {"text": [["for the following years"]], "start": [[167]], "entity_id": ["T21"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combined"]], "start": [[121]], "entity_id": ["T19"]}, "Drug": {"text": [["steroid"], ["bucillamine"], ["lobenzarit disodium"], ["steroid"]], "start": [[143], [155], [52], [40]], "entity_id": ["T13", "T16", "T17", "T18"]}}]}}]}]}
{"id": "24791374_2", "context": "We describe a rare case of severe drug-drug interaction between propafenone and mirtazapine leading to propafenone toxicity.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["leading"]], "start": [[92]], "entity_id": ["T8"]}, "Subject": {"text": [["a rare case"]], "start": [[12]], "entity_id": ["T6"]}, "Treatment": {"text": [["propafenone and mirtazapine"]], "start": [[64]], "entity_id": ["T7"], "Drug": {"text": [["propafenone"], ["mirtazapine"]], "start": [[64], [80]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[44]], "entity_id": ["T12"]}, "Drug": {"text": [["propafenone"], ["mirtazapine"]], "start": [[64], [80]], "entity_id": ["T10", "T11"]}}]}, "Effect": {"text": [["propafenone toxicity"]], "start": [[103]], "entity_id": ["T9"]}, "Severity": {"text": [["severe"]], "start": [[27]], "entity_id": ["T13"], "value": "High"}}]}]}
{"id": "9512187_1", "context": "Because the combination of bleomycin and vinca alkaloids is commonly used for the treatment of AIDS-related Kaposi's sarcoma, clinicians should be aware of the risk of provoking acral necrosis in patients who develop Raynaud's phenomenon under chemotherapy.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["provoking"]], "start": [[168]], "entity_id": ["T7"]}, "Effect": {"text": [["acral necrosis", "Raynaud's phenomenon"]], "start": [[178, 217]], "entity_id": ["T5"]}, "Treatment": {"text": [["bleomycin", "vinca alkaloids"]], "start": [[27, 41]], "entity_id": ["T6"], "Drug": {"text": [["bleomycin"], ["vinca alkaloids"]], "start": [[27], [41]], "entity_id": ["T8", "T9"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[37]], "entity_id": ["T10"]}, "Drug": {"text": [["bleomycin"], ["vinca alkaloids"]], "start": [[27], [41]], "entity_id": ["T8", "T9"]}}]}}]}]}
{"id": "12875956_3", "context": "The psychotic behavior resolved completely soon after the discontinuation of levetiracetam.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["resolved"]], "start": [[23]], "entity_id": ["T5"]}, "Treatment": {"text": [["discontinuation of levetiracetam"]], "start": [[58]], "entity_id": ["T4"], "Disorder": {"text": [["psychotic behavior"]], "start": [[4]], "entity_id": ["T3"]}, "Time_elapsed": {"text": [["soon after"]], "start": [[43]], "entity_id": ["T6"]}, "Drug": {"text": [["levetiracetam"]], "start": [[77]], "entity_id": ["T7"]}}}]}]}
{"id": "15034704_3", "context": "Male volunteers ( n=12) participated in a randomised, two-period, crossover trial evaluating the effect of multiple doses of 600 mg rifampicin once daily for 7 days on repaglinide metabolism.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["on"]], "start": [[165]], "entity_id": ["T9"]}, "Subject": {"text": [["Male volunteers ( n=12)"]], "start": [[0]], "entity_id": ["T7"], "Gender": {"text": [["Male"]], "start": [[0]], "entity_id": ["T11"]}, "Population": {"text": [["n=12"]], "start": [[18]], "entity_id": ["T12"]}}, "Treatment": {"text": [["multiple doses of 600 mg rifampicin once daily for 7 days"]], "start": [[107]], "entity_id": ["T8"], "Dosage": {"text": [["multiple doses of 600 mg"]], "start": [[107]], "entity_id": ["T13"]}, "Drug": {"text": [["rifampicin"]], "start": [[132]], "entity_id": ["T14"]}, "Freq": {"text": [["once daily"]], "start": [[143]], "entity_id": ["T15"]}, "Duration": {"text": [["7 days"]], "start": [[158]], "entity_id": ["T16"]}}, "Effect": {"text": [["repaglinide metabolism"]], "start": [[168]], "entity_id": ["T10"]}}]}]}
{"id": "17671884_9", "context": "This report suggests that anemia can occur due to MMF, in particular when it is given with prednisone, a side effect well documented in the transplantation literature when the triple combination of MMF, cyclosporine and prednisone is used.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[43]], "entity_id": ["T15"]}, "Effect": {"text": [["anemia"]], "start": [[26]], "entity_id": ["T14"]}, "Treatment": {"text": [["MMF", "prednisone"]], "start": [[50, 91]], "entity_id": ["T16"], "Drug": {"text": [["MMF"], ["prednisone"]], "start": [[50], [91]], "entity_id": ["T18", "T19"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["with"]], "start": [[86]], "entity_id": ["T20"]}, "Drug": {"text": [["MMF"], ["prednisone"]], "start": [[50], [91]], "entity_id": ["T18", "T19"]}}]}, "Speculated": {"text": [["can"]], "start": [[33]], "entity_id": ["T17"], "value": true}}]}]}
{"id": "24163322_4", "context": "Warfarin was initiated for deep vein thrombosis prophylaxis due to the patient's inability to ambulate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["prophylaxis"]], "start": [[48]], "entity_id": ["T6"]}, "Subject": {"text": [["patient's inability to ambulate"]], "start": [[71]], "entity_id": ["T7"], "Disorder": {"text": [["inability to ambulate"]], "start": [[81]], "entity_id": ["T8"]}}, "Treatment": {"text": [["Warfarin was initiated for deep vein thrombosis"]], "start": [[0]], "entity_id": ["T4"], "Disorder": {"text": [["deep vein thrombosis"]], "start": [[27]], "entity_id": ["T5"]}, "Drug": {"text": [["a"]], "start": [[4]], "entity_id": ["T9"]}}}]}]}
{"id": "16432996_4", "context": "We report a case with chronic hepatitis C (CHC) who developed sarcoidosis after the treatment by interferon alpha and ribavirin.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[52]], "entity_id": ["T10"]}, "Effect": {"text": [["sarcoidosis"]], "start": [[62]], "entity_id": ["T11"]}, "Treatment": {"text": [["treatment by interferon alpha and ribavirin"]], "start": [[84]], "entity_id": ["T12"], "Disorder": {"text": [["chronic hepatitis C (CHC)"]], "start": [[22]], "entity_id": ["T9"]}, "Drug": {"text": [["interferon alpha"], ["ribavirin"]], "start": [[97], [118]], "entity_id": ["T13", "T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[114]], "entity_id": ["T15"]}, "Drug": {"text": [["interferon alpha"], ["ribavirin"]], "start": [[97], [118]], "entity_id": ["T13", "T14"]}}]}}]}]}
{"id": "15785053_2", "context": "The relation between tacrolimus treatment and staining was suggested by the appearance of pigmentation during topical tacrolimus treatment and its clinical disappearance when treatment was stopped.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[103]], "entity_id": ["T6"]}, "Treatment": {"text": [["topical tacrolimus"]], "start": [[110]], "entity_id": ["T4"], "Drug": {"text": [["tacrolimus"]], "start": [[118]], "entity_id": ["T7"]}, "Route": {"text": [["topical"]], "start": [[110]], "entity_id": ["T8"]}}, "Effect": {"text": [["appearance of pigmentation"]], "start": [[76]], "entity_id": ["T5"]}}]}]}
{"id": "8239963_3", "context": "Though hypotension, dry mouth, and constipation are well-documented possible adverse effects, the possibility of clonidine-induced bradycardia is less well recognized and is rare.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[123]], "entity_id": ["T10"]}, "Treatment": {"text": [["clonidine"]], "start": [[113]], "entity_id": ["T9"], "Drug": {"text": [["clonidine"]], "start": [[113]], "entity_id": ["T13"]}}, "Effect": {"text": [["bradycardia"]], "start": [[131]], "entity_id": ["T11"]}, "Speculated": {"text": [["possibility"]], "start": [[98]], "entity_id": ["T12"], "value": true}}]}]}
{"id": "16540070_3", "context": "Several hypersensitivity reactions to cloxacillin have been reported, although IgE-mediated allergic reactions to the drug are rare and there is little information about possible tolerance to other semisynthetic penicillins or cephalosporins in patients with cloxacillin allergy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reactions to"]], "start": [[25]], "entity_id": ["T6"]}, "Effect": {"text": [["hypersensitivity"]], "start": [[8]], "entity_id": ["T5"]}, "Treatment": {"text": [["cloxacillin"]], "start": [[38]], "entity_id": ["T7"], "Drug": {"text": [["cloxacillin"]], "start": [[38]], "entity_id": ["T8"]}}}]}]}
{"id": "17547624_1", "context": "Brugada type electrocardiographic changes induced by concomitant use of lithium and propafenone in patient with Wolff-Parkinson-White syndrome.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[42]], "entity_id": ["T5"]}, "Effect": {"text": [["Brugada type electrocardiographic changes"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["concomitant use of lithium and propafenone"]], "start": [[53]], "entity_id": ["T6"], "Disorder": {"text": [["Wolff-Parkinson-White syndrome"]], "start": [[112]], "entity_id": ["T8"]}, "Drug": {"text": [["lithium"], ["propafenone"]], "start": [[72], [84]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["concomitant"]], "start": [[53]], "entity_id": ["T11"]}, "Drug": {"text": [["lithium"], ["propafenone"]], "start": [[72], [84]], "entity_id": ["T9", "T10"]}}]}, "Subject": {"text": [["patient with Wolff-Parkinson-White syndrome"]], "start": [[99]], "entity_id": ["T7"]}}]}]}
{"id": "17404582_2", "context": "Docetaxel-induced Meibomian duct inflammation and blockage leading to chalazion formation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[10]], "entity_id": ["T5"]}, "Effect": {"text": [["Meibomian duct inflammation and blockage leading to chalazion formation"]], "start": [[18]], "entity_id": ["T6"]}, "Treatment": {"text": [["Docetaxel"]], "start": [[0]], "entity_id": ["T7"], "Drug": {"text": [["Docetaxel"]], "start": [[0]], "entity_id": ["T8"]}}}]}]}
{"id": "15628319_1", "context": "Allergic side effects of AZA are rare, and reported allergic skin eruptions from AZA are very limited in Japan.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["from"]], "start": [[76]], "entity_id": ["T5"]}, "Effect": {"text": [["allergic skin eruptions"]], "start": [[52]], "entity_id": ["T4"]}, "Treatment": {"text": [["AZA"]], "start": [[81]], "entity_id": ["T6"], "Drug": {"text": [["AZA"]], "start": [[81]], "entity_id": ["T7"]}}}]}]}
{"id": "11212595_1", "context": "Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[101]], "entity_id": ["T9"]}, "Effect": {"text": [["obsessive-compulsive symptoms (OCS)"], ["OCS"]], "start": [[15], [109]], "entity_id": ["T7", "T6"]}, "Treatment": {"text": [["antipsychotic"]], "start": [[87]], "entity_id": ["T8"], "Drug": {"text": [["antipsychotic"]], "start": [[87]], "entity_id": ["T11"]}}}]}]}
{"id": "17852449_1", "context": "Outcome of pregnancy in women treated with all-trans retinoic acid; a case report and review of literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[30]], "entity_id": ["T4"]}, "Treatment": {"text": [["all-trans retinoic acid"]], "start": [[43]], "entity_id": ["T5"], "Drug": {"text": [["all-trans retinoic acid"]], "start": [[43]], "entity_id": ["T9"]}, "Disorder": {"text": [["pregnancy"]], "start": [[11]], "entity_id": ["T10"]}}, "Subject": {"text": [["pregnancy in women"]], "start": [[11]], "entity_id": ["T6"], "Gender": {"text": [["women"]], "start": [[24]], "entity_id": ["T8"]}}}]}]}
{"id": "19687711_6", "context": "The potential development of SJS/TEN, a severe life-threatening illness, emphasizes the need for judicious use of TMP-Sx and close monitoring and follow-up for patients who were given TMP-Sx for SSTIs.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["development"]], "start": [[14]], "entity_id": ["T12"]}, "Effect": {"text": [["SJS/TEN, a severe life-threatening illness"]], "start": [[29]], "entity_id": ["T13"]}, "Subject": {"text": [["patients"]], "start": [[160]], "entity_id": ["T14"]}, "Treatment": {"text": [["TMP-Sx"]], "start": [[184]], "entity_id": ["T15"], "Disorder": {"text": [["SSTIs"]], "start": [[195]], "entity_id": ["T16"]}, "Drug": {"text": [["TMP"], ["Sx"]], "start": [[184], [188]], "entity_id": ["T21", "T22"]}, "Combination": [{"event_id": "E3", "event_type": "Combination", "Trigger": {"text": [["-"]], "start": [[187]], "entity_id": ["T20"]}, "Drug": {"text": [["TMP"], ["Sx"]], "start": [[184], [188]], "entity_id": ["T21", "T22"]}}]}}]}]}
{"id": "665845_1", "context": "A case history of a 15-year-old boy who developed incapacitating tardive dyskinesia that resolved during treatment with deanol is presented.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["resolved"]], "start": [[89]], "entity_id": ["T5"]}, "Subject": {"text": [["a 15-year-old boy"]], "start": [[18]], "entity_id": ["T3"], "Age": {"text": [["15-year-old"]], "start": [[20]], "entity_id": ["T7"]}, "Gender": {"text": [["boy"]], "start": [[32]], "entity_id": ["T8"]}}, "Effect": {"text": [["incapacitating tardive dyskinesia"]], "start": [[50]], "entity_id": ["T4"]}, "Treatment": {"text": [["deanol"]], "start": [[120]], "entity_id": ["T6"], "Drug": {"text": [["deanol"]], "start": [[120]], "entity_id": ["T9"]}}}]}]}
{"id": "12187348_2", "context": "Drug-induced mammary hyperplasias have been reported as rare complications of D-penicillamine and Neothetazone.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[5]], "entity_id": ["T8"]}, "Effect": {"text": [["mammary hyperplasias"]], "start": [[13]], "entity_id": ["T6"]}, "Treatment": {"text": [["Drug", "D-penicillamine and Neothetazone"]], "start": [[0, 78]], "entity_id": ["T7"], "Drug": {"text": [["Drug"], ["Neothetazone"], ["D-penicillamine"]], "start": [[0], [98], [78]], "entity_id": ["T9", "T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[94]], "entity_id": ["T12"]}, "Drug": {"text": [["D-penicillamine"], ["Neothetazone"]], "start": [[78], [98]], "entity_id": ["T11", "T10"]}}]}}]}]}
{"id": "10482872_2", "context": "The purpose of this report is to document a new case of in utero CP exposure with multiple congenital anomalies and to establish an apparent CP embryopathy phenotype.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["exposure"]], "start": [[68]], "entity_id": ["T9"]}, "Treatment": {"text": [["CP"]], "start": [[65]], "entity_id": ["T5"], "Drug": {"text": [["CP"]], "start": [[65]], "entity_id": ["T7"]}}, "Effect": {"text": [["multiple congenital anomalies", "CP embryopathy"]], "start": [[82, 141]], "entity_id": ["T6"]}}]}]}
{"id": "18176653_2", "context": "AIM: The aim of this article is to present the clinical characteristics and management of an oral adverse effect stemming from the use of the antiretroviral medication Nevirapine (NVP).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["from"]], "start": [[122]], "entity_id": ["T6"]}, "Effect": {"text": [["adverse effect"]], "start": [[98]], "entity_id": ["T5"]}, "Treatment": {"text": [["antiretroviral medication Nevirapine (NVP)"]], "start": [[142]], "entity_id": ["T7"], "Drug": {"text": [["Nevirapine"]], "start": [[168]], "entity_id": ["T8"]}}}]}]}
{"id": "16484748_1", "context": "A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (SMX) treatment.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["receiving"]], "start": [[249]], "entity_id": ["T31"]}, "Treatment": {"text": [["trimethoprim (TMP)-sulfamethoxazole (SMX)"]], "start": [[259]], "entity_id": ["T32"], "Drug": {"text": [["trimethoprim"], ["sulfamethoxazole"]], "start": [[259], [278]], "entity_id": ["T38", "T39"]}, "Time_elapsed": {"text": [["two weeks after"]], "start": [[233]], "entity_id": ["T41"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["-"]], "start": [[277]], "entity_id": ["T40"]}, "Drug": {"text": [["sulfamethoxazole"], ["trimethoprim"]], "start": [[278], [259]], "entity_id": ["T39", "T38"]}}]}, "Effect": {"text": [["fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia"]], "start": [[123]], "entity_id": ["T33"]}, "Subject": {"text": [["A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia"]], "start": [[0]], "entity_id": ["T34"], "Age": {"text": [["27-year-old"]], "start": [[2]], "entity_id": ["T35"]}, "Gender": {"text": [["man"]], "start": [[14]], "entity_id": ["T36"]}, "Disorder": {"text": [["bronchial asthma"], ["eosinophilic enteritis"], ["eosinophilic pneumonia"]], "start": [[39], [57], [85]], "entity_id": ["T37", "T44", "T45"]}}}]}]}
{"id": "14674674_4", "context": "Treatment with infliximab is known to produce an increase of autoantibodies (antinuclear antibodies, anti-double-stranded DNA), but not clinical disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["produce"]], "start": [[38]], "entity_id": ["T8"]}, "Treatment": {"text": [["Treatment with infliximab"]], "start": [[0]], "entity_id": ["T7"], "Drug": {"text": [["infliximab"]], "start": [[15]], "entity_id": ["T10"]}}, "Effect": {"text": [["increase of autoantibodies (antinuclear antibodies, anti-double-stranded DNA), but not clinical disease"]], "start": [[49]], "entity_id": ["T9"]}}]}]}
{"id": "16882112_2", "context": "Serotonin syndrome, which occurs as a result of enhanced serotonin concentration in the central nervous system, is a well-known adverse effect of serotonin-active medications.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurs"]], "start": [[26]], "entity_id": ["T6"]}, "Effect": {"text": [["Serotonin syndrome,"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["serotonin-active medications"]], "start": [[146]], "entity_id": ["T7"]}}]}]}
{"id": "11424102_5", "context": "Despite the risk of needle-track seeding, PEI remains useful in the treatment of HCC.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["remains"]], "start": [[46]], "entity_id": ["T8"]}, "Treatment": {"text": [["PEI"]], "start": [[42]], "entity_id": ["T7"], "Drug": {"text": [["PEI"]], "start": [[42]], "entity_id": ["T11"]}, "Disorder": {"text": [["HCC"]], "start": [[81]], "entity_id": ["T12"]}}, "Speculated": {"text": [["risk"]], "start": [[12]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "20412003_4", "context": "Trimethoprim-sulfamethoxazole-induced hepatotoxicity in a pediatric patient.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[30]], "entity_id": ["T5"]}, "Subject": {"text": [["a pediatric patient"]], "start": [[56]], "entity_id": ["T3"], "Age": {"text": [["pediatric"]], "start": [[58]], "entity_id": ["T7"]}}, "Treatment": {"text": [["Trimethoprim-sulfamethoxazole"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Trimethoprim"], ["sulfamethoxazole"]], "start": [[0], [13]], "entity_id": ["T2", "T8"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["-"]], "start": [[12]], "entity_id": ["T1"]}, "Drug": {"text": [["Trimethoprim"], ["sulfamethoxazole"]], "start": [[0], [13]], "entity_id": ["T2", "T8"]}}]}, "Effect": {"text": [["hepatotoxicity"]], "start": [[38]], "entity_id": ["T6"]}}]}]}
{"id": "10589077_3", "context": "Prolonged responses were achieved with low doses of HU (3-10 mg/kg/day) and higher doses were associated with mild reversible hematologic or hepatic toxicity and no further increases in Hb.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[94]], "entity_id": ["T7"]}, "Treatment": {"text": [["HU (3-10 mg/kg/day) and higher doses"]], "start": [[52]], "entity_id": ["T13"], "Drug": {"text": [["HU"]], "start": [[52]], "entity_id": ["T15"]}, "Dosage": {"text": [["higher doses"]], "start": [[76]], "entity_id": ["T14"]}}, "Effect": {"text": [["mild reversible hematologic or hepatic toxicity and no further increases in Hb"]], "start": [[110]], "entity_id": ["T6"]}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["achieved"]], "start": [[25]], "entity_id": ["T9"]}, "Treatment": {"text": [["low doses of HU"]], "start": [[39]], "entity_id": ["T10"], "Dosage": {"text": [["low doses"]], "start": [[39]], "entity_id": ["T12"]}, "Drug": {"text": [["HU"]], "start": [[52]], "entity_id": ["T11"]}}, "Effect": {"text": [["Prolonged responses"]], "start": [[0]], "entity_id": ["T8"]}}]}]}
{"id": "8276031_1", "context": "Imidazoline intoxication in children.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["intoxication"]], "start": [[12]], "entity_id": ["T6"]}, "Subject": {"text": [["children"]], "start": [[28]], "entity_id": ["T5"], "Age": {"text": [["children"]], "start": [[28]], "entity_id": ["T9"]}}, "Treatment": {"text": [["Imidazoline"]], "start": [[0]], "entity_id": ["T7"], "Drug": {"text": [["Imidazoline"]], "start": [[0]], "entity_id": ["T10"]}}, "Effect": {"text": [["Imidazoline intoxication"]], "start": [[0]], "entity_id": ["T8"]}}]}]}
{"id": "19782276_10", "context": "Concomitant administration of cytarabine might have affected his liver function and there might have been interaction between the drugs.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["affected"]], "start": [[52]], "entity_id": ["T8"]}, "Treatment": {"text": [["cytarabine"]], "start": [[30]], "entity_id": ["T7"], "Drug": {"text": [["cytarabine"]], "start": [[30]], "entity_id": ["T10"]}}, "Effect": {"text": [["liver function"]], "start": [[65]], "entity_id": ["T9"]}, "Speculated": {"text": [["might"]], "start": [[41]], "entity_id": ["T11"], "value": true}}]}]}
{"id": "7351000_4", "context": "The probability of developing acute leukemia in this study was not significantly correlated to the total cumulative dosage of Treosulfan.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["developing"]], "start": [[19]], "entity_id": ["T7"]}, "Treatment": {"text": [["the total cumulative dosage of Treosulfan"]], "start": [[95]], "entity_id": ["T3"], "Drug": {"text": [["Treosulfan"]], "start": [[126]], "entity_id": ["T6"]}}, "Effect": {"text": [["acute leukemia"]], "start": [[30]], "entity_id": ["T5"]}, "Negated": {"text": [["not"]], "start": [[63]], "entity_id": ["T4"], "value": true}}]}]}
{"id": "1584367_1", "context": "Intraventricular vancomycin-induced cerebrospinal fluid eosinophilia: report of two patients.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[28]], "entity_id": ["T3"]}, "Treatment": {"text": [["Intraventricular vancomycin"]], "start": [[0]], "entity_id": ["T4"], "Route": {"text": [["Intraventricular"]], "start": [[0]], "entity_id": ["T8"]}, "Drug": {"text": [["vancomycin"]], "start": [[17]], "entity_id": ["T9"]}}, "Effect": {"text": [["cerebrospinal fluid eosinophilia"]], "start": [[36]], "entity_id": ["T5"]}, "Subject": {"text": [["two patients."]], "start": [[80]], "entity_id": ["T6"], "Population": {"text": [["two"]], "start": [[80]], "entity_id": ["T7"]}}}]}]}
{"id": "3438585_6", "context": "This case supports the view that in gold-induced pneumonitis a prolonged treatment with corticosteroids may be necessary, as lung function continued to improve.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["as"]], "start": [[122]], "entity_id": ["T9"]}, "Treatment": {"text": [["a prolonged treatment with corticosteroids"]], "start": [[61]], "entity_id": ["T6"], "Disorder": {"text": [["in gold-induced pneumonitis"]], "start": [[33]], "entity_id": ["T7"]}, "Drug": {"text": [["gold"], ["corticosteroids"]], "start": [[36], [88]], "entity_id": ["T10", "T11"]}}}]}]}
{"id": "11443640_1", "context": "Massive plasmocytosis due to methimazole-induced bone marrow toxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[41]], "entity_id": ["T6"]}, "Effect": {"text": [["bone marrow toxicity", "Massive plasmocytosis"]], "start": [[49, 0]], "entity_id": ["T5"]}, "Treatment": {"text": [["methimazole"]], "start": [[29]], "entity_id": ["T7"], "Drug": {"text": [["methimazole"]], "start": [[29]], "entity_id": ["T8"]}}}]}]}
{"id": "15331204_4", "context": "RESULTS: After 4- to 14-month period of therapy with the combination of indapamide (2.5 mg/day) and fosinopril (10 mg/day) in three patients and 6-month period of monotherapy with indapamide (2.5 mg/day) in one patient, glucose levels of all patients increased and achieve criteria of diabetes diagnoses.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["achieve"]], "start": [[265]], "entity_id": ["T14"]}, "Treatment": {"text": [["6-month period of monotherapy with indapamide (2.5 mg/day)"]], "start": [[145]], "entity_id": ["T27"], "Duration": {"text": [["6-month"]], "start": [[145]], "entity_id": ["T28"]}, "Drug": {"text": [["indapamide"]], "start": [[180]], "entity_id": ["T29"]}, "Dosage": {"text": [["2.5 mg/day"]], "start": [[192]], "entity_id": ["T30"]}}, "Subject": {"text": [["one patient"]], "start": [[207]], "entity_id": ["T25"], "Population": {"text": [["one"]], "start": [[207]], "entity_id": ["T26"]}}, "Effect": {"text": [["glucose levels of all patients increased and achieve criteria of diabetes diagnoses"]], "start": [[220]], "entity_id": ["T13"]}}, {"event_id": "E3", "event_type": "Adverse_event", "Trigger": {"text": [["achieve"]], "start": [[265]], "entity_id": ["T14"]}, "Effect": {"text": [["glucose levels of all patients increased and achieve criteria of diabetes diagnoses"]], "start": [[220]], "entity_id": ["T13"]}, "Treatment": {"text": [["After 4- to 14-month period of therapy with the combination of indapamide (2.5 mg/day) and fosinopril (10 mg/day)"]], "start": [[9]], "entity_id": ["T12"], "Time_elapsed": {"text": [["4- to 14-month"]], "start": [[15]], "entity_id": ["T17"]}, "Drug": {"text": [["indapamide"], ["fosinopril"]], "start": [[72], [100]], "entity_id": ["T19", "T20"]}, "Dosage": {"text": [["2.5 mg/day"], ["10 mg/day"]], "start": [[84], [112]], "entity_id": ["T21", "T22"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combination"]], "start": [[57]], "entity_id": ["T18"]}, "Drug": {"text": [["indapamide"], ["fosinopril"]], "start": [[72], [100]], "entity_id": ["T19", "T20"]}}]}, "Subject": {"text": [["three patients"]], "start": [[126]], "entity_id": ["T23"], "Population": {"text": [["three"]], "start": [[126]], "entity_id": ["T24"]}}}]}]}
{"id": "6453500_1", "context": "A reversible toxic liver damage was observed in a non-alcoholic woman treated with disulfiram.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["damage"]], "start": [[25]], "entity_id": ["T10"]}, "Subject": {"text": [["a non-alcoholic woman"]], "start": [[48]], "entity_id": ["T3"], "Disorder": {"text": [["non-alcoholic"]], "start": [[50]], "entity_id": ["T7"]}, "Gender": {"text": [["woman"]], "start": [[64]], "entity_id": ["T8"]}}, "Treatment": {"text": [["disulfiram"]], "start": [[83]], "entity_id": ["T4"], "Drug": {"text": [["disulfiram"]], "start": [[83]], "entity_id": ["T9"]}}, "Effect": {"text": [["reversible toxic liver damage"]], "start": [[2]], "entity_id": ["T5"]}}]}]}
{"id": "10904571_1", "context": "A 60 year-old woman with chronic renal failure developed acute proximal muscle weakness after receiving a regular dosage of colchicine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[47]], "entity_id": ["T4"]}, "Subject": {"text": [["A 60 year-old woman with chronic renal failure"]], "start": [[0]], "entity_id": ["T3"], "Age": {"text": [["60 year-old"]], "start": [[2]], "entity_id": ["T7"]}, "Gender": {"text": [["woman"]], "start": [[14]], "entity_id": ["T8"]}}, "Effect": {"text": [["acute proximal muscle weakness"]], "start": [[57]], "entity_id": ["T5"]}, "Treatment": {"text": [["regular dosage of colchicine"]], "start": [[106]], "entity_id": ["T6"], "Disorder": {"text": [["chronic renal failure"]], "start": [[25]], "entity_id": ["T10"]}, "Drug": {"text": [["colchicine"]], "start": [[124]], "entity_id": ["T11"]}, "Dosage": {"text": [["regular dosage"]], "start": [[106]], "entity_id": ["T12"]}}}]}]}
{"id": "9824032_2", "context": "The cause of these previously unreported side effects of niacin therapy is uncertain but may be related to prostaglandin-mediated vasodilatation, hyperalgesia of sensory nerve receptors, and potentiation of inflammation in the gingiva with referral of pain to the teeth.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[96]], "entity_id": ["T11"]}, "Treatment": {"text": [["niacin"]], "start": [[57]], "entity_id": ["T9"], "Drug": {"text": [["niacin"]], "start": [[57]], "entity_id": ["T13"]}}, "Effect": {"text": [["prostaglandin-mediated vasodilatation, hyperalgesia of sensory nerve receptors, and potentiation of inflammation in the gingiva with referral of pain to the teeth"]], "start": [[107]], "entity_id": ["T10"]}, "Speculated": {"text": [["uncertain"]], "start": [[75]], "entity_id": ["T12"], "value": true}}]}]}
{"id": "16404563_4", "context": "Nocardia is an important opportunistic infectious agent in immunocompromised hosts, i.e. in patients taking corticosteroids.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["infectious agent"]], "start": [[39]], "entity_id": ["T8"]}, "Treatment": {"text": [["corticosteroids"]], "start": [[108]], "entity_id": ["T5"], "Drug": {"text": [["corticosteroids"]], "start": [[108]], "entity_id": ["T10"]}}, "Subject": {"text": [["immunocompromised hosts"]], "start": [[59]], "entity_id": ["T6"], "Disorder": {"text": [["immunocompromised"]], "start": [[59]], "entity_id": ["T9"]}}, "Effect": {"text": [["Nocardia"]], "start": [[0]], "entity_id": ["T7"]}}]}]}
{"id": "8835752_1", "context": "Hepatobiliary disorders associated with orally administered terbinafine have rarely been reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[24]], "entity_id": ["T5"]}, "Effect": {"text": [["Hepatobiliary disorders"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["orally administered terbinafine"]], "start": [[40]], "entity_id": ["T6"], "Drug": {"text": [["terbinafine"]], "start": [[60]], "entity_id": ["T7"]}, "Route": {"text": [["orally"]], "start": [[40]], "entity_id": ["T8"]}}}]}]}
{"id": "3790438_2", "context": "We report a patient in whom the anti-depressant trazodone hydrochloride (Molipaxin, Roussel), a serotonin antagonist, provoked generalized pustular psoriasis (GPP).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["provoked"]], "start": [[118]], "entity_id": ["T8"]}, "Treatment": {"text": [["trazodone hydrochloride (Molipaxin, Roussel)"]], "start": [[48]], "entity_id": ["T7"], "Drug": {"text": [["trazodone hydrochloride"]], "start": [[48]], "entity_id": ["T11"]}}, "Effect": {"text": [["generalized pustular psoriasis (GPP)"]], "start": [[127]], "entity_id": ["T9"]}, "Subject": {"text": [["a patient"]], "start": [[10]], "entity_id": ["T10"]}}]}]}
{"id": "11703329_1", "context": "Early recognition of hereditary motor and sensory neuropathy type 1 can avoid life-threatening vincristine neurotoxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["can"]], "start": [[68]], "entity_id": ["T5"]}, "Treatment": {"text": [["Early recognition of hereditary motor and sensory neuropathy type 1"]], "start": [[0]], "entity_id": ["T4"]}, "Severity": {"text": [["life-threatening"]], "start": [[78]], "entity_id": ["T6"], "value": "High"}}]}]}
{"id": "19299370_3", "context": "Probable enoxaparin-induced hepatotoxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[20]], "entity_id": ["T4"]}, "Treatment": {"text": [["enoxaparin"]], "start": [[9]], "entity_id": ["T3"], "Drug": {"text": [["enoxaparin"]], "start": [[9]], "entity_id": ["T6"]}}, "Effect": {"text": [["hepatotoxicity"]], "start": [[28]], "entity_id": ["T5"]}}]}]}
{"id": "12581772_1", "context": "Interstitial pneumonitis associated with sirolimus: a dilemma for lung transplantation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[25]], "entity_id": ["T4"]}, "Effect": {"text": [["Interstitial pneumonitis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["sirolimus"]], "start": [[41]], "entity_id": ["T5"], "Drug": {"text": [["sirolimus"]], "start": [[41]], "entity_id": ["T6"]}}}]}]}
{"id": "19667003_15", "context": "He had also developed elevated serum ammonia levels while on valproic acid.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[12]], "entity_id": ["T4"]}, "Subject": {"text": [["He"]], "start": [[0]], "entity_id": ["T3"], "Gender": {"text": [["He"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["elevated serum ammonia levels"]], "start": [[22]], "entity_id": ["T5"]}, "Treatment": {"text": [["valproic acid"]], "start": [[61]], "entity_id": ["T6"], "Drug": {"text": [["valproic acid"]], "start": [[61]], "entity_id": ["T8"]}}}]}]}
{"id": "16641839_4", "context": "Cutaneous rashes and eruptions can be caused by many medications, including carbamazepine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[38]], "entity_id": ["T6"]}, "Effect": {"text": [["Cutaneous rashes and eruptions"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["carbamazepine"]], "start": [[76]], "entity_id": ["T7"], "Drug": {"text": [["carbamazepine"]], "start": [[76]], "entity_id": ["T8"]}}}]}]}
{"id": "8140860_5", "context": "In this case, the increase in the INR value with associated bruising after the addition of amoxycillin suggests a drug interaction between acenocoumarol and amoxycillin, other possible causes having been eliminated.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[69]], "entity_id": ["T9"]}, "Effect": {"text": [["the increase in the INR value with associated bruising"]], "start": [[14]], "entity_id": ["T8"]}, "Treatment": {"text": [["amoxycillin"]], "start": [[91]], "entity_id": ["T10"], "Drug": {"text": [["amoxycillin"], ["acenocoumarol"], ["amoxycillin"]], "start": [[91], [139], [157]], "entity_id": ["T11", "T13", "T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[119]], "entity_id": ["T12"]}, "Drug": {"text": [["acenocoumarol"], ["amoxycillin"]], "start": [[139], [157]], "entity_id": ["T13", "T14"]}}]}, "Speculated": {"text": [["suggests"]], "start": [[103]], "entity_id": ["T15"], "value": true}}]}]}
{"id": "19897274_4", "context": "Oncologists supervising future clinical trials for lung cancer should be alert to the fact that sorafenib can potentially induce serious interstitial lung disease, although this might depend on racial differences.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induce"]], "start": [[122]], "entity_id": ["T4"]}, "Treatment": {"text": [["sorafenib"]], "start": [[96]], "entity_id": ["T3"], "Drug": {"text": [["sorafenib"]], "start": [[96]], "entity_id": ["T6"]}, "Disorder": {"text": [["lung cancer"]], "start": [[51]], "entity_id": ["T7"]}}, "Effect": {"text": [["serious interstitial lung disease"]], "start": [[129]], "entity_id": ["T5"]}, "Speculated": {"text": [["potentially"]], "start": [[110]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "19667003_3", "context": "SUMMARY: A 26-year-old man with bipolar disorder, seizures, and mild mental retardation secondary to a traumatic brain injury began treatment with carbamazepine for aggression and seizure control.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatment"]], "start": [[132]], "entity_id": ["T13"]}, "Treatment": {"text": [["carbamazepine"]], "start": [[147]], "entity_id": ["T12"], "Drug": {"text": [["carbamazepine"]], "start": [[147]], "entity_id": ["T16"]}, "Disorder": {"text": [["aggression"], ["seizure"]], "start": [[165], [180]], "entity_id": ["T17", "T18"]}}, "Subject": {"text": [["A 26-year-old man with bipolar disorder, seizures, and mild mental retardation secondary to a traumatic brain injury"]], "start": [[9]], "entity_id": ["T10"], "Disorder": {"text": [["bipolar disorder", "seizures", "mild mental retardation secondary to a traumatic brain injury"]], "start": [[32, 50, 64]], "entity_id": ["T11"]}, "Age": {"text": [["26-year-old"]], "start": [[11]], "entity_id": ["T14"]}, "Gender": {"text": [["man"]], "start": [[23]], "entity_id": ["T15"]}}}]}]}
{"id": "18676387_3", "context": "Serotonin toxicity precipitated by fentanyl is unusual and has not previously been described in combination with SSRIs in the perioperative setting.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["precipitated"]], "start": [[19]], "entity_id": ["T9"]}, "Effect": {"text": [["Serotonin toxicity"]], "start": [[0]], "entity_id": ["T8"]}, "Treatment": {"text": [["fentanyl"]], "start": [[35]], "entity_id": ["T10"], "Drug": {"text": [["fentanyl"], ["SSRIs"]], "start": [[35], [113]], "entity_id": ["T12", "T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combination"]], "start": [[96]], "entity_id": ["T14"]}, "Drug": {"text": [["fentanyl"], ["SSRIs"]], "start": [[35], [113]], "entity_id": ["T12", "T13"]}}]}, "Speculated": {"text": [["unusual"]], "start": [[47]], "entity_id": ["T11"], "value": true}}]}]}
{"id": "16889287_1", "context": "It may cause a severe adverse drug reaction with multiorgan involvement known as dapsone hypersensitivity syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[7]], "entity_id": ["T6"]}, "Treatment": {"text": [["dapsone"]], "start": [[81]], "entity_id": ["T3"], "Drug": {"text": [["dapsone"]], "start": [[81]], "entity_id": ["T8"]}}, "Effect": {"text": [["hypersensitivity syndrome"], ["a severe adverse drug reaction"]], "start": [[89], [13]], "entity_id": ["T4", "T5"]}, "Speculated": {"text": [["may"]], "start": [[3]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "15806568_3", "context": "Visual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[65]], "entity_id": ["T6"]}, "Effect": {"text": [["Visual system side effects caused by parasympathetic dysfunction"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["botulinum toxin type B injections"]], "start": [[71]], "entity_id": ["T7"], "Drug": {"text": [["botulinum toxin type B"]], "start": [[71]], "entity_id": ["T8"]}, "Route": {"text": [["injections"]], "start": [[94]], "entity_id": ["T9"]}}}]}]}
{"id": "1124417_2", "context": "Renal failure associated with acetazolamide therapy for glaucoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[14]], "entity_id": ["T4"]}, "Effect": {"text": [["Renal failure"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["acetazolamide therapy"]], "start": [[30]], "entity_id": ["T5"], "Drug": {"text": [["acetazolamide"]], "start": [[30]], "entity_id": ["T7"]}, "Disorder": {"text": [["glaucoma"]], "start": [[56]], "entity_id": ["T8"]}}}]}]}
{"id": "12424571_1", "context": "Acute onset of nephrotic syndrome during interferon-alpha retreatment for chronic active hepatitis C.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[34]], "entity_id": ["T6"]}, "Effect": {"text": [["Acute onset of nephrotic syndrome"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["interferon-alpha retreatment"]], "start": [[41]], "entity_id": ["T4"], "Drug": {"text": [["interferon-alpha"]], "start": [[41]], "entity_id": ["T7"]}, "Disorder": {"text": [["chronic active hepatitis C"]], "start": [[74]], "entity_id": ["T8"]}}}]}]}
{"id": "12587815_1", "context": "A 16-year-old boy developed fever, generalized rigidity, leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and lithium.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["while"]], "start": [[131]], "entity_id": ["T16"]}, "Subject": {"text": [["A 16-year-old boy"]], "start": [[0]], "entity_id": ["T13"], "Age": {"text": [["16-year-old"]], "start": [[2]], "entity_id": ["T17"]}, "Gender": {"text": [["boy"]], "start": [[14]], "entity_id": ["T18"]}}, "Treatment": {"text": [["olanzapine and lithium"]], "start": [[162]], "entity_id": ["T14"], "Drug": {"text": [["olanzapine"], ["lithium"]], "start": [[162], [177]], "entity_id": ["T19", "T21"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[173]], "entity_id": ["T20"]}, "Drug": {"text": [["olanzapine"], ["lithium"]], "start": [[162], [177]], "entity_id": ["T19", "T21"]}}]}, "Effect": {"text": [["fever, generalized rigidity, leukocytosis, and increased serum transaminase and creatine kinase levels"]], "start": [[28]], "entity_id": ["T15"]}}]}]}
{"id": "17526968_4", "context": "The hyperpigmentation was diffuse scattered, flagellate like and linear streaking which was thought to be mainly related to the skin toxicity of bleomycin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["toxicity"]], "start": [[133]], "entity_id": ["T5"]}, "Treatment": {"text": [["bleomycin"]], "start": [[145]], "entity_id": ["T6"], "Drug": {"text": [["bleomycin"]], "start": [[145]], "entity_id": ["T9"]}}, "Effect": {"text": [["hyperpigmentation was diffuse scattered, flagellate like and linear streaking"]], "start": [[4]], "entity_id": ["T7"]}, "Speculated": {"text": [["mainly"]], "start": [[106]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "11243427_5", "context": "Exacerbation of 5-FU dermatologic toxicities in patients with preexisting conditions suggests the importance of aggressive ocular prophylaxis, using frequent ocular lubrication and topical steroid preparations with concurrent medical management of pre-existing dermatologic conditions.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["toxicities"]], "start": [[34]], "entity_id": ["T6"]}, "Effect": {"text": [["dermatologic toxicities"]], "start": [[21]], "entity_id": ["T5"]}, "Treatment": {"text": [["5-FU"]], "start": [[16]], "entity_id": ["T7"], "Drug": {"text": [["5-FU"]], "start": [[16]], "entity_id": ["T4"]}}}]}]}
{"id": "2295443_1", "context": "Bowel perforation associated with intraperitoneal chromic phosphate instillation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[18]], "entity_id": ["T3"]}, "Treatment": {"text": [["intraperitoneal chromic phosphate instillation"]], "start": [[34]], "entity_id": ["T4"], "Route": {"text": [["intraperitoneal", "instillation"]], "start": [[34, 68]], "entity_id": ["T6"]}, "Drug": {"text": [["chromic phosphate"]], "start": [[50]], "entity_id": ["T7"]}}, "Effect": {"text": [["Bowel perforation"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "2224786_1", "context": "A 62-year-old woman who was being treated for squamous cell carcinoma of the head and neck developed a chemotherapy-related hemolytic-uremic syndrome during the second cycle of neoadjuvant chemotherapy consisting of cisplatin, bleomycin, and methotrexate.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[91]], "entity_id": ["T7"]}, "Treatment": {"text": [["the second cycle of neoadjuvant chemotherapy consisting of cisplatin, bleomycin, and methotrexate"]], "start": [[157]], "entity_id": ["T5"], "Disorder": {"text": [["squamous cell carcinoma of the head and neck"]], "start": [[46]], "entity_id": ["T12"]}, "Dosage": {"text": [["second cycle"]], "start": [[161]], "entity_id": ["T13"]}, "Drug": {"text": [["cisplatin"], ["bleomycin"], ["methotrexate"]], "start": [[216], [227], [242]], "entity_id": ["T14", "T15", "T16"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["consisting of"]], "start": [[202]], "entity_id": ["T17"]}, "Drug": {"text": [["cisplatin"], ["bleomycin"], ["methotrexate"]], "start": [[216], [227], [242]], "entity_id": ["T14", "T15", "T16"]}}]}, "Effect": {"text": [["a chemotherapy-related hemolytic-uremic syndrome"]], "start": [[101]], "entity_id": ["T6"]}, "Subject": {"text": [["A 62-year-old woman who was being treated for squamous cell carcinoma of the head and neck"]], "start": [[0]], "entity_id": ["T8"], "Age": {"text": [["62-year-old"]], "start": [[2]], "entity_id": ["T9"]}, "Gender": {"text": [["woman"]], "start": [[14]], "entity_id": ["T10"]}}}]}]}
{"id": "10466445_7", "context": "These data confirm the therapeutic value of arsenic trioxide in relapsed/resistant APL.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["therapeutic value"]], "start": [[23]], "entity_id": ["T6"]}, "Treatment": {"text": [["arsenic trioxide"]], "start": [[44]], "entity_id": ["T4"], "Disorder": {"text": [["relapsed/resistant APL"]], "start": [[64]], "entity_id": ["T5"]}}}]}]}
{"id": "11373877_1", "context": "Avascular necrosis of the femoral head in patients with prostate cancer treated with cyproterone acetate and radiotherapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[39]], "entity_id": ["T6"]}, "Effect": {"text": [["Avascular necrosis of the femoral head"]], "start": [[0]], "entity_id": ["T3"]}, "Subject": {"text": [["patients with prostate cancer"]], "start": [[42]], "entity_id": ["T4"]}, "Treatment": {"text": [["cyproterone acetate and radiotherapy"]], "start": [[85]], "entity_id": ["T5"], "Disorder": {"text": [["prostate cancer"]], "start": [[56]], "entity_id": ["T8"]}, "Drug": {"text": [["cyproterone acetate"]], "start": [[85]], "entity_id": ["T9"]}}}]}]}
{"id": "11243427_4", "context": "Ectropion secondary to bolus injection of 5-fluorouracil.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["secondary"]], "start": [[10]], "entity_id": ["T3"]}, "Effect": {"text": [["Ectropion"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["bolus injection of 5-fluorouracil"]], "start": [[23]], "entity_id": ["T5"], "Route": {"text": [["bolus injection"]], "start": [[23]], "entity_id": ["T6"]}, "Drug": {"text": [["5-fluorouracil"]], "start": [[42]], "entity_id": ["T7"]}}}]}]}
{"id": "2595431_1", "context": "Metoclopramide-induced parkinsonism is not rare, and appropriate dose reduction in patients with renal failure will help reduce the incidence of this morbidity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[15]], "entity_id": ["T4"]}, "Treatment": {"text": [["Metoclopramide"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Metoclopramide"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["parkinsonism"]], "start": [[23]], "entity_id": ["T5"]}, "Subject": {"text": [["patients with renal failure"]], "start": [[83]], "entity_id": ["T6"], "Disorder": {"text": [["renal failure"]], "start": [[97]], "entity_id": ["T7"]}}}]}]}
{"id": "19307676_1", "context": "Posterior reversible encephalopathy syndrome associated with methotrexate neurotoxicity: conventional magnetic resonance and diffusion-weighted imaging findings.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[45]], "entity_id": ["T4"]}, "Effect": {"text": [["Posterior reversible encephalopathy syndrome"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["methotrexate neurotoxicity"]], "start": [[61]], "entity_id": ["T5"], "Drug": {"text": [["methotrexate"]], "start": [[61]], "entity_id": ["T6"]}}}]}]}
{"id": "25407257_4", "context": "A 6-year-old boy (weight: 16 kg, at the start of treatment) began sodium valproate (valproate syrup 5%) treatment for epilepsy in February 2012.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatment"]], "start": [[104]], "entity_id": ["T6"]}, "Subject": {"text": [["A 6-year-old boy (weight: 16 kg, at the start of treatment)"]], "start": [[0]], "entity_id": ["T8"], "Age": {"text": [["6-year-old"]], "start": [[2]], "entity_id": ["T10"]}, "Gender": {"text": [["boy"]], "start": [[13]], "entity_id": ["T11"]}}, "Treatment": {"text": [["sodium valproate (valproate syrup 5%)"]], "start": [[66]], "entity_id": ["T9"], "Disorder": {"text": [["epilepsy"]], "start": [[118]], "entity_id": ["T7"]}, "Drug": {"text": [["sodium valproate"]], "start": [[66]], "entity_id": ["T12"]}}}]}]}
{"id": "3465489_1", "context": "Pharmacokinetic determinants of 6-mercaptopurine myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[87]], "entity_id": ["T6"]}, "Treatment": {"text": [["6-mercaptopurine"]], "start": [[32]], "entity_id": ["T3"], "Drug": {"text": [["6-mercaptopurine"]], "start": [[32]], "entity_id": ["T9"]}, "Disorder": {"text": [["acute lymphoblastic leukemia"]], "start": [[104]], "entity_id": ["T10"]}}, "Effect": {"text": [["myelotoxicity and therapeutic failure"]], "start": [[49]], "entity_id": ["T4"]}, "Subject": {"text": [["children with acute lymphoblastic leukemia"]], "start": [[90]], "entity_id": ["T5"], "Age": {"text": [["children"]], "start": [[90]], "entity_id": ["T7"]}}}]}]}
{"id": "8816294_2", "context": "We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by, in the first case intrathecally administered methotrexate and, in the second by intrathecally administered methotrexate and cranial irradiation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[146]], "entity_id": ["T8"]}, "Subject": {"text": [["identical twin brothers"]], "start": [[32]], "entity_id": ["T7"], "Gender": {"text": [["brothers"]], "start": [[47]], "entity_id": ["T11"]}}, "Effect": {"text": [["leukoencephalopathy and hydrocephalus"]], "start": [[156]], "entity_id": ["T9"]}, "Treatment": {"text": [["intrathecally administered methotrexate", "intrathecally administered methotrexate and cranial irradiation"]], "start": [[262, 324]], "entity_id": ["T10"], "Drug": {"text": [["methotrexate"], ["methotrexate"]], "start": [[289], [351]], "entity_id": ["T12", "T15"]}, "Route": {"text": [["intrathecally"], ["intrathecally"]], "start": [[262], [324]], "entity_id": ["T13", "T14"]}}}]}]}
{"id": "15735923_8", "context": "Considering the increasing use of TMZ, which is regarded as a drug with moderate toxicity, careful follow-up with routine blood testing is vital.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[67]], "entity_id": ["T6"]}, "Effect": {"text": [["moderate toxicity"]], "start": [[72]], "entity_id": ["T4"]}, "Treatment": {"text": [["TMZ"]], "start": [[34]], "entity_id": ["T5"], "Drug": {"text": [["TMZ"]], "start": [[34]], "entity_id": ["T7"]}}}]}]}
{"id": "11093071_3", "context": "While for ribavirin antidepressant effects are not known, we suppose that antidepressants may prevent changes in serotonergic or noradrenergic neurotransmission caused by IFN-alpha.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["prevent"]], "start": [[94]], "entity_id": ["T4"]}, "Treatment": {"text": [["antidepressants"]], "start": [[74]], "entity_id": ["T3"], "Disorder": {"text": [["changes in serotonergic or noradrenergic neurotransmission caused by IFN-alpha"]], "start": [[102]], "entity_id": ["T5"]}, "Drug": {"text": [["antidepressants"]], "start": [[74]], "entity_id": ["T6"]}}, "Speculated": {"text": [["may"]], "start": [[90]], "entity_id": ["T7"], "value": true}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[161]], "entity_id": ["T9"]}, "Treatment": {"text": [["IFN-alpha"]], "start": [[171]], "entity_id": ["T10"], "Drug": {"text": [["IFN-alpha"]], "start": [[171]], "entity_id": ["T11"]}}, "Effect": {"text": [["changes in serotonergic or noradrenergic neurotransmission"]], "start": [[102]], "entity_id": ["T12"]}}]}]}
{"id": "17381671_2", "context": "To report a case of serotonin syndrome associated with interaction between fentanyl and citalopram, as evidenced by medication history, clinical features and reversal following discontinuation of fentanyl.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[39]], "entity_id": ["T10"]}, "Effect": {"text": [["serotonin syndrome"]], "start": [[20]], "entity_id": ["T7"]}, "Treatment": {"text": [["nteraction between fentanyl and citalopram"]], "start": [[56]], "entity_id": ["T9"], "Drug": {"text": [["fentanyl"], ["citalopram"]], "start": [[75], [88]], "entity_id": ["T8", "T11"]}, "Combination": [{"event_id": "E1", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[55]], "entity_id": ["T12"]}, "Drug": {"text": [["fentanyl"], ["citalopram"]], "start": [[75], [88]], "entity_id": ["T8", "T11"]}}]}, "Subject": {"text": [["a case"]], "start": [[10]], "entity_id": ["T13"]}}]}]}
{"id": "2586773_2", "context": "We report a case of ibuprofen-induced meningitis in an otherwise healthy individual.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[30]], "entity_id": ["T3"]}, "Treatment": {"text": [["ibuprofen"]], "start": [[20]], "entity_id": ["T4"], "Drug": {"text": [["ibuprofen"]], "start": [[20]], "entity_id": ["T7"]}}, "Effect": {"text": [["meningitis"]], "start": [[38]], "entity_id": ["T5"]}, "Subject": {"text": [["an otherwise healthy individual"]], "start": [[52]], "entity_id": ["T6"]}}]}]}
{"id": "10482872_3", "context": "The reported cases of in utero exposure to cyclosposphamide shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["shared"]], "start": [[60]], "entity_id": ["T15"]}, "Effect": {"text": [["growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly"]], "start": [[114]], "entity_id": ["T16"]}, "Treatment": {"text": [["in utero exposure to cyclosposphamide"]], "start": [[22]], "entity_id": ["T17"], "Drug": {"text": [["cyclosposphamide"]], "start": [[43]], "entity_id": ["T19"]}}, "Subject": {"text": [["patient"]], "start": [[105]], "entity_id": ["T18"]}}]}]}
{"id": "2931445_1", "context": "L-Thyroxine-induced leukopenia in a patient with Hashimoto's disease: involvement of suppressor-cytotoxic T cells.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[12]], "entity_id": ["T7"]}, "Treatment": {"text": [["L-Thyroxine"]], "start": [[0]], "entity_id": ["T6"], "Drug": {"text": [["L-Thyroxine"]], "start": [[0]], "entity_id": ["T10"]}, "Disorder": {"text": [["Hashimoto's disease"]], "start": [[49]], "entity_id": ["T11"]}}, "Effect": {"text": [["leukopenia"]], "start": [[20]], "entity_id": ["T8"]}, "Subject": {"text": [["a patient with Hashimoto's disease"]], "start": [[34]], "entity_id": ["T9"]}}]}]}
{"id": "1295628_1", "context": "Carbamazepine-induced systemic lupus erythematosus-like disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[14]], "entity_id": ["T4"]}, "Treatment": {"text": [["Carbamazepine"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Carbamazepine"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["systemic lupus erythematosus-like disease"]], "start": [[22]], "entity_id": ["T6"]}}]}]}
{"id": "8038468_1", "context": "CONCLUSIONS: This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of warfarin alone.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[76]], "entity_id": ["T8"]}, "Effect": {"text": [["increase of INR"]], "start": [[60]], "entity_id": ["T5"]}, "Subject": {"text": [["an elderly patient"]], "start": [[79]], "entity_id": ["T6"], "Age": {"text": [["elderly"]], "start": [[82]], "entity_id": ["T9"]}}, "Treatment": {"text": [["levamisole and 5-FU", "warfarin"]], "start": [[137, 182]], "entity_id": ["T7"], "Drug": {"text": [["levamisole"], ["5-FU"], ["warfarin"]], "start": [[137], [152], [182]], "entity_id": ["T12", "T14", "T15"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[148]], "entity_id": ["T13"]}, "Drug": {"text": [["levamisole"], ["5-FU"], ["warfarin"]], "start": [[137], [152], [182]], "entity_id": ["T12", "T14", "T15"]}}]}, "Severity": {"text": [["significant"]], "start": [[48]], "entity_id": ["T11"], "value": "Medium"}}]}]}
{"id": "7653281_8", "context": "These results suggest that the hepatoxicity of ethanol in alcoholic beverages is enhanced by interaction with its congeners and acetaldehyde; they also suggest that alcoholic beverages are not equivalent in their potential to cause liver damage.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["enhanced"]], "start": [[81]], "entity_id": ["T10"]}, "Effect": {"text": [["hepatoxicity"]], "start": [[31]], "entity_id": ["T8"]}, "Treatment": {"text": [["alcoholic"]], "start": [[58]], "entity_id": ["T9"], "Drug": {"text": [["alcoholic"]], "start": [[58]], "entity_id": ["T12"]}}, "Speculated": {"text": [["potential"]], "start": [[213]], "entity_id": ["T11"], "value": true}}]}]}
{"id": "17671884_8", "context": "The dermatology literature heretofore has not noted that anemia is a side effect of patients taking MMF to treat pemphigus.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["is"]], "start": [[64]], "entity_id": ["T13"]}, "Effect": {"text": [["anemia"]], "start": [[57]], "entity_id": ["T9"]}, "Subject": {"text": [["patients"]], "start": [[84]], "entity_id": ["T10"]}, "Treatment": {"text": [["MMF"]], "start": [[100]], "entity_id": ["T11"], "Disorder": {"text": [["pemphigus"]], "start": [[113]], "entity_id": ["T14"]}}, "Negated": {"text": [["not"]], "start": [[42]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "3430507_4", "context": "The 9 other reported cases of D-penicillamine induced rapidly progressive glomerulonephritis have been reviewed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[46]], "entity_id": ["T6"]}, "Treatment": {"text": [["D-penicillamine"]], "start": [[30]], "entity_id": ["T5"], "Drug": {"text": [["D-penicillamine"]], "start": [[30]], "entity_id": ["T8"]}}, "Effect": {"text": [["rapidly progressive glomerulonephritis"]], "start": [[54]], "entity_id": ["T7"]}}]}]}
{"id": "15203443_2", "context": "We describe a heroin abuser in whom clinical and laboratory manifestations of acute hepatitis B and C appeared a few days after the insertion of a subcutaneous naltrexone implant.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[122]], "entity_id": ["T3"]}, "Treatment": {"text": [["subcutaneous naltrexone implant"]], "start": [[147]], "entity_id": ["T4"], "Disorder": {"text": [["heroin abuser"]], "start": [[14]], "entity_id": ["T7"]}, "Route": {"text": [["subcutaneous"]], "start": [[147]], "entity_id": ["T8"]}, "Drug": {"text": [["naltrexone"]], "start": [[160]], "entity_id": ["T9"]}}, "Effect": {"text": [["acute hepatitis B and C"]], "start": [[78]], "entity_id": ["T5"]}, "Subject": {"text": [["a heroin abuser"]], "start": [[12]], "entity_id": ["T6"]}}]}]}
{"id": "1504404_2", "context": "Ciprofloxacin-induced psychosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[14]], "entity_id": ["T4"]}, "Treatment": {"text": [["Ciprofloxacin"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Ciprofloxacin"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["psychosis"]], "start": [[22]], "entity_id": ["T5"]}}]}]}
{"id": "15694139_2", "context": "Thalidomide was withdrawn from world markets in 1961 following recognition of its teratogenic effects.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[53]], "entity_id": ["T4"]}, "Effect": {"text": [["teratogenic effects"]], "start": [[82]], "entity_id": ["T5"]}, "Treatment": {"text": [["Thalidomide"]], "start": [[0]], "entity_id": ["T6"], "Drug": {"text": [["Thalidomide"]], "start": [[0]], "entity_id": ["T7"]}}}]}]}
{"id": "24318743_1", "context": "Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["in"]], "start": [[24]], "entity_id": ["T9"]}, "Treatment": {"text": [["Weekly AUC2 carboplatin", "with or without oral phenoxodiol"]], "start": [[0, 70]], "entity_id": ["T8"], "Freq": {"text": [["Weekly"]], "start": [[0]], "entity_id": ["T10"]}, "Drug": {"text": [["AUC2 carboplatin"], ["phenoxodiol"]], "start": [[7], [91]], "entity_id": ["T11", "T13"]}, "Disorder": {"text": [["platinum-resistant ovarian cancer"]], "start": [[36]], "entity_id": ["T12"]}, "Route": {"text": [["oral"]], "start": [[86]], "entity_id": ["T7"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["with or without"]], "start": [[70]], "entity_id": ["T14"]}, "Drug": {"text": [["phenoxodiol"], ["AUC2 carboplatin"]], "start": [[91], [7]], "entity_id": ["T13", "T11"]}}]}}]}]}
{"id": "1688693_5", "context": "We suggest the use of esmolol for treatment of dysrhythmias secondary to caffeine toxicity; to the best of our knowledge, the use of esmolol has not been reported for this purpose.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatment"]], "start": [[34]], "entity_id": ["T9"]}, "Treatment": {"text": [["esmolol"]], "start": [[22]], "entity_id": ["T8"], "Drug": {"text": [["esmolol"], ["caffeine"], ["esmolol"]], "start": [[22], [73], [133]], "entity_id": ["T11", "T13", "T14"]}, "Disorder": {"text": [["dysrhythmias"]], "start": [[47]], "entity_id": ["T12"]}}}]}]}
{"id": "15806568_2", "context": "To date, there have been few reports of visual disturbances associated with BTX-B use.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[60]], "entity_id": ["T6"]}, "Treatment": {"text": [["BTX-B"]], "start": [[76]], "entity_id": ["T3"], "Drug": {"text": [["BTX-B"]], "start": [[76]], "entity_id": ["T8"]}}, "Effect": {"text": [["visual disturbances"]], "start": [[40]], "entity_id": ["T5"]}}]}]}
{"id": "19116715_1", "context": "Gemcitabine is a known risk factor for hemolytic uremic syndrome (HUS), which can often have a rapidly fatal clinical course despite intervention with steroids, plasmapheresis and hemodialysis.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["risk"]], "start": [[23]], "entity_id": ["T6"]}, "Treatment": {"text": [["Gemcitabine"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Gemcitabine"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["hemolytic uremic syndrome"]], "start": [[39]], "entity_id": ["T7"]}, "Severity": {"text": [["fatal"]], "start": [[103]], "entity_id": ["T10"], "value": "High"}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["intervention"]], "start": [[133]], "entity_id": ["T16"]}, "Treatment": {"text": [["with steroids, plasmapheresis and hemodialysis"]], "start": [[146]], "entity_id": ["T11"], "Drug": {"text": [["steroids"], ["plasmapheresis"], ["hemodialysis"]], "start": [[151], [161], [180]], "entity_id": ["T12", "T13", "T14"]}, "Disorder": {"text": [["a rapidly fatal"]], "start": [[93]], "entity_id": ["T15"]}}}]}]}
{"id": "16411025_4", "context": "Our objective is to present a retrospective analysis of the DWI findings in four patients who suffered subacute neurotoxicity after intrathecal MTX.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[126]], "entity_id": ["T3"]}, "Treatment": {"text": [["intrathecal MTX"]], "start": [[132]], "entity_id": ["T4"], "Drug": {"text": [["intrathecal MTX"]], "start": [[132]], "entity_id": ["T8"]}}, "Effect": {"text": [["subacute neurotoxicity"]], "start": [[103]], "entity_id": ["T5"]}, "Subject": {"text": [["four patients"]], "start": [[76]], "entity_id": ["T6"], "Population": {"text": [["four"]], "start": [[76]], "entity_id": ["T7"]}}}]}]}
{"id": "17547624_2", "context": "We report a case of ST elevation in right precordial leads compatible with type 1 Brugada syndrome following administration of propafenone in a patient with Wolff-Parkinson-White syndrome who was receiving lithium at concentrations within therapeutic levels.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[99]], "entity_id": ["T8"]}, "Treatment": {"text": [["administration of propafenone", "receiving lithium at concentrations within therapeutic levels"]], "start": [[109, 196]], "entity_id": ["T6"], "Drug": {"text": [["propafenone"], ["lithium"]], "start": [[127], [206]], "entity_id": ["T10", "T3"]}, "Disorder": {"text": [["Wolff-Parkinson-White syndrome"]], "start": [[157]], "entity_id": ["T1"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["administration"]], "start": [[109]], "entity_id": ["T2"]}, "Drug": {"text": [["propafenone"], ["lithium"]], "start": [[127], [206]], "entity_id": ["T10", "T3"]}}]}, "Effect": {"text": [["ST elevation in right precordial leads compatible with type 1 Brugada syndrome"]], "start": [[20]], "entity_id": ["T7"]}, "Subject": {"text": [["a patient with Wolff-Parkinson-White syndrome"]], "start": [[142]], "entity_id": ["T5"]}}]}]}
{"id": "25957434_2", "context": "The spectrum of cutaneous eruptions associated with dihydropyridines is extensive, varying from exanthemas to severe adverse events.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[36]], "entity_id": ["T6"]}, "Treatment": {"text": [["dihydropyridines"]], "start": [[52]], "entity_id": ["T7"], "Drug": {"text": [["dihydropyridines"]], "start": [[52]], "entity_id": ["T9"]}}, "Effect": {"text": [["cutaneous eruptions", "exanthemas"]], "start": [[16, 96]], "entity_id": ["T8"]}}]}]}
{"id": "3365032_2", "context": "Polymyositis after propylthiouracil treatment for hyperthyroidism.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[13]], "entity_id": ["T4"]}, "Effect": {"text": [["Polymyositis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["propylthiouracil"]], "start": [[19]], "entity_id": ["T5"], "Drug": {"text": [["propylthiouracil"]], "start": [[19]], "entity_id": ["T7"]}, "Disorder": {"text": [["hyperthyroidism"]], "start": [[50]], "entity_id": ["T8"]}}}]}]}
{"id": "8862924_2", "context": "Methamphetamine's extensive physiologic effects, inconsistent street purity, and multiple routes of administration offer many possibilities for injury to the cornea.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["offer"]], "start": [[115]], "entity_id": ["T5"]}, "Treatment": {"text": [["Methamphetamine's"]], "start": [[0]], "entity_id": ["T3"], "Disorder": {"text": [["injury to the cornea"]], "start": [[144]], "entity_id": ["T4"]}, "Drug": {"text": [["Methamphetamine's"]], "start": [[0]], "entity_id": ["T6"]}}}]}]}
{"id": "2956288_4", "context": "Since ethambutol is actively excreted via the renal system, compromise of renal function such as due to renal tuberculosis may lead to serum concentration elevations of ethambutol sufficient to produce optic neuropathy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["lead"]], "start": [[127]], "entity_id": ["T4"]}, "Treatment": {"text": [["ethambutol"]], "start": [[6]], "entity_id": ["T3"], "Drug": {"text": [["ethambutol"]], "start": [[6]], "entity_id": ["T6"]}}, "Effect": {"text": [["serum concentration elevations of ethambutol sufficient to produce optic neuropathy"]], "start": [[135]], "entity_id": ["T5"]}, "Speculated": {"text": [["may"]], "start": [[123]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "788666_3", "context": "Renal failure appeared 8 to 17 days after beginning gentamicin therapy and was characterized by creatinine clearances 4 to 10 ml/min, urine to plasma creatinine ratios less than 20, urinary sodium concentrations 16 to 60 mEq/liter, proteinuria, and cylindruria.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["beginning"]], "start": [[42]], "entity_id": ["T4"]}, "Treatment": {"text": [["gentamicin therapy"]], "start": [[52]], "entity_id": ["T3"], "Time_elapsed": {"text": [["8 to 17 days"]], "start": [[23]], "entity_id": ["T6"]}, "Drug": {"text": [["gentamicin"]], "start": [[52]], "entity_id": ["T7"]}}, "Effect": {"text": [["Renal failure", "creatinine clearances 4 to 10 ml/min, urine to plasma creatinine ratios less than 20, urinary sodium concentrations 16 to 60 mEq/liter, proteinuria, and cylindruria"]], "start": [[0, 96]], "entity_id": ["T5"]}}]}]}
{"id": "8749646_2", "context": "Seizures associated with ofloxacin therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[9]], "entity_id": ["T4"]}, "Effect": {"text": [["Seizures"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["ofloxacin"]], "start": [[25]], "entity_id": ["T5"], "Drug": {"text": [["ofloxacin"]], "start": [[25]], "entity_id": ["T6"]}}}]}]}
{"id": "11424102_1", "context": "Cutaneous seeding after ultrasound-guided percutaneous ethanol injection for treatment of hepatocellular carcinoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[18]], "entity_id": ["T6"]}, "Effect": {"text": [["Cutaneous seeding"]], "start": [[0]], "entity_id": ["T7"]}, "Treatment": {"text": [["ultrasound-guided percutaneous ethanol injection"]], "start": [[24]], "entity_id": ["T8"], "Route": {"text": [["injection"]], "start": [[63]], "entity_id": ["T10"]}, "Drug": {"text": [["ethanol"]], "start": [[55]], "entity_id": ["T11"]}, "Disorder": {"text": [["hepatocellular carcinoma"]], "start": [[90]], "entity_id": ["T12"]}}}]}]}
{"id": "19145124_3", "context": "Two patients who developed decreased visual acuity after several months of ethambutol treatment for Mycobacterium avium-intracellulare infection had bitemporal visual field defects that suggested optic chiasm damage.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[51]], "entity_id": ["T7"]}, "Subject": {"text": [["Two patients", "Mycobacterium avium-intracellulare infection"]], "start": [[0, 100]], "entity_id": ["T5"], "Population": {"text": [["Two"]], "start": [[0]], "entity_id": ["T10"]}}, "Effect": {"text": [["decreased visual acuity", "bitemporal visual field defects", "optic chiasm damage"]], "start": [[27, 149, 196]], "entity_id": ["T6"]}, "Treatment": {"text": [["ethambutol"]], "start": [[75]], "entity_id": ["T8"], "Disorder": {"text": [["Mycobacterium avium-intracellulare infection"]], "start": [[100]], "entity_id": ["T9"]}, "Drug": {"text": [["ethambutol"]], "start": [[75]], "entity_id": ["T13"]}}}]}]}
{"id": "9972383_1", "context": "CONCLUSIONS: Metoclopramide may cause reversible nonthrombocytopenic vascular-type palpable purpura.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[32]], "entity_id": ["T6"]}, "Treatment": {"text": [["Metoclopramide"]], "start": [[13]], "entity_id": ["T3"], "Drug": {"text": [["Metoclopramide"]], "start": [[13]], "entity_id": ["T7"]}}, "Effect": {"text": [["reversible nonthrombocytopenic vascular-type palpable purpura"]], "start": [[38]], "entity_id": ["T4"]}, "Speculated": {"text": [["may"]], "start": [[28]], "entity_id": ["T5"], "value": true}}]}]}
{"id": "18784429_2", "context": "CONCLUSIONS: Life-threatening adrenal suppression, requiring hydrocortisone supplementation and intensive therapy, was observed and successfully treated in a newborn, whose mother had received high-dose methylprednisolone in late pregnancy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["requiring"]], "start": [[51]], "entity_id": ["T5"]}, "Treatment": {"text": [["hydrocortisone supplementation and intensive therapy"]], "start": [[61]], "entity_id": ["T3"], "Drug": {"text": [["hydrocortisone"]], "start": [[61]], "entity_id": ["T8"]}}, "Effect": {"text": [["successfully treated"]], "start": [[132]], "entity_id": ["T4"]}, "Subject": {"text": [["a newborn, whose mother had received high-dose methylprednisolone in late pregnancy"]], "start": [[156]], "entity_id": ["T6"], "Age": {"text": [["newborn"]], "start": [[158]], "entity_id": ["T7"]}}}]}]}
{"id": "17420198_2", "context": "A case of extrapyramidal symptoms (EPS) following administration of aripiprazole to a man with developmental disabilities who had never received antipsychotic medications and had no history of movement disorders is presented.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[40]], "entity_id": ["T11"]}, "Effect": {"text": [["extrapyramidal symptoms (EPS)"]], "start": [[10]], "entity_id": ["T10"]}, "Treatment": {"text": [["aripiprazole"]], "start": [[68]], "entity_id": ["T12"], "Drug": {"text": [["aripiprazole"]], "start": [[68]], "entity_id": ["T16"]}}, "Subject": {"text": [["a man with developmental disabilities who had never received antipsychotic medications and had no history of movement disorders is presented"]], "start": [[84]], "entity_id": ["T13"], "Gender": {"text": [["man"]], "start": [[86]], "entity_id": ["T14"]}, "Disorder": {"text": [["developmental disabilities"]], "start": [[95]], "entity_id": ["T15"]}}}]}]}
{"id": "2378415_1", "context": "Although high-dose methotrexate has been shown to be useful in the treatment of primary osteogenic sarcoma, the tumoricidal effects of therapy appear to have caused a fatal rise in intracranial pressure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[158]], "entity_id": ["T5"]}, "Treatment": {"text": [["high-dose methotrexate"]], "start": [[9]], "entity_id": ["T4"], "Disorder": {"text": [["primary osteogenic sarcoma"]], "start": [[80]], "entity_id": ["T6"]}, "Dosage": {"text": [["high-dose"]], "start": [[9]], "entity_id": ["T8"]}, "Drug": {"text": [["methotrexate"]], "start": [[19]], "entity_id": ["T9"]}}, "Effect": {"text": [["a fatal rise in intracranial pressure"]], "start": [[165]], "entity_id": ["T7"]}, "Severity": {"text": [["fatal"]], "start": [[167]], "entity_id": ["T10"], "value": "High"}}]}]}
{"id": "20298401_11", "context": "This case had radiation fibrosis, so we suggest that radiation fibrosis may be another contributor of the occurrence of ILD in patients taking erlotinib.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["of"]], "start": [[99]], "entity_id": ["T10"]}, "Treatment": {"text": [["taking erlotinib"]], "start": [[136]], "entity_id": ["T7"], "Drug": {"text": [["erlotinib"]], "start": [[143]], "entity_id": ["T11"]}}, "Subject": {"text": [["patients"]], "start": [[127]], "entity_id": ["T8"]}, "Effect": {"text": [["occurrence of ILD"]], "start": [[106]], "entity_id": ["T9"]}}]}]}
{"id": "16156485_1", "context": "Since recent studies have reported no negative interactions with concurrent use, we here report three cases (one case of a prolonged seizure, a serotonin syndrome and a focal seizure) of severe lithium-induced side effects while patients underwent ECT without complications and lithium serum levels were still subtherapeutic.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[202]], "entity_id": ["T8"]}, "Effect": {"text": [["a prolonged seizure"]], "start": [[121]], "entity_id": ["T12"]}, "Treatment": {"text": [["lithium"]], "start": [[194]], "entity_id": ["T7"], "Drug": {"text": [["lithium"]], "start": [[194]], "entity_id": ["T10"]}}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[202]], "entity_id": ["T8"]}, "Treatment": {"text": [["lithium"]], "start": [[194]], "entity_id": ["T7"], "Drug": {"text": [["lithium"]], "start": [[194]], "entity_id": ["T10"]}}, "Effect": {"text": [["a serotonin syndrome"]], "start": [[142]], "entity_id": ["T13"]}}, {"event_id": "E3", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[202]], "entity_id": ["T8"]}, "Treatment": {"text": [["lithium"]], "start": [[194]], "entity_id": ["T7"], "Drug": {"text": [["lithium"]], "start": [[194]], "entity_id": ["T10"]}}, "Effect": {"text": [["a focal seizure"]], "start": [[167]], "entity_id": ["T14"]}, "Severity": {"text": [["severe"]], "start": [[187]], "entity_id": ["T15"], "value": "High"}}, {"event_id": "E4", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["underwent"]], "start": [[238]], "entity_id": ["T17"]}, "Treatment": {"text": [["ECT"]], "start": [[248]], "entity_id": ["T18"], "Disorder": {"text": [["lithium-induced side effects"]], "start": [[194]], "entity_id": ["T16"]}, "Drug": {"text": [["ECT"]], "start": [[248]], "entity_id": ["T19"]}}, "Effect": {"text": [["without complications and lithium serum levels were still subtherapeutic"]], "start": [[252]], "entity_id": ["T20"]}}]}]}
{"id": "8363533_3", "context": "Lithium-associated transient thyrotoxicosis in 4 Chinese women with autoimmune thyroiditis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[8]], "entity_id": ["T5"]}, "Subject": {"text": [["4 Chinese women with autoimmune thyroiditis"]], "start": [[47]], "entity_id": ["T3"], "Population": {"text": [["4"]], "start": [[47]], "entity_id": ["T7"]}, "Race": {"text": [["Chinese"]], "start": [[49]], "entity_id": ["T8"]}, "Gender": {"text": [["women"]], "start": [[57]], "entity_id": ["T9"]}, "Disorder": {"text": [["autoimmune thyroiditis"]], "start": [[68]], "entity_id": ["T10"]}}, "Treatment": {"text": [["Lithium"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Lithium"]], "start": [[0]], "entity_id": ["T11"]}}, "Effect": {"text": [["transient thyrotoxicosis"]], "start": [[19]], "entity_id": ["T6"]}}]}]}
{"id": "2006943_2", "context": "A patient, while on intravenous ritodrine therapy for preterm labor, experienced an episode of acute chest pain.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["on"]], "start": [[17]], "entity_id": ["T7"]}, "Treatment": {"text": [["intravenous ritodrine therapy"]], "start": [[20]], "entity_id": ["T8"], "Route": {"text": [["intravenous"]], "start": [[20]], "entity_id": ["T11"]}, "Drug": {"text": [["ritodrine"]], "start": [[32]], "entity_id": ["T12"]}}, "Effect": {"text": [["an episode of acute chest pain"]], "start": [[81]], "entity_id": ["T9"]}, "Subject": {"text": [["A patient"]], "start": [[0]], "entity_id": ["T10"]}}]}]}
{"id": "4095247_2", "context": "Subsequent in vivo/vitro studies clearly demonstrated that the neurological effects were due to a synergistic action of desferrioxamine and prochlorperazine, probably resulting in exceptional fluxes of intra/extra cellular iron/copper disturbing noradrenergic and serotonergic systems.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[89]], "entity_id": ["T6"]}, "Treatment": {"text": [["desferrioxamine and prochlorperazine"]], "start": [[120]], "entity_id": ["T4"], "Drug": {"text": [["desferrioxamine"], ["prochlorperazine"]], "start": [[120], [140]], "entity_id": ["T7", "T8"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["synergistic"]], "start": [[98]], "entity_id": ["T9"]}, "Drug": {"text": [["desferrioxamine"], ["prochlorperazine"]], "start": [[120], [140]], "entity_id": ["T7", "T8"]}}]}, "Effect": {"text": [["neurological effects"]], "start": [[63]], "entity_id": ["T5"]}, "Speculated": {"text": [["probably"]], "start": [[158]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "19725909_1", "context": "Favorable outcome of de novo hepatitis B infection after liver transplantation with lamivudine and adefovir therapy.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["outcome"]], "start": [[10]], "entity_id": ["T6"]}, "Treatment": {"text": [["after liver transplantation with lamivudine and adefovir therapy"]], "start": [[51]], "entity_id": ["T5"], "Drug": {"text": [["lamivudine"], ["adefovir"]], "start": [[84], [99]], "entity_id": ["T8", "T9"]}, "Disorder": {"text": [["hepatitis B infection"]], "start": [[29]], "entity_id": ["T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[95]], "entity_id": ["T10"]}, "Drug": {"text": [["lamivudine"], ["adefovir"]], "start": [[84], [99]], "entity_id": ["T8", "T9"]}}]}}]}]}
{"id": "6498095_3", "context": "Pemphigus foliaceus was seen in a patient with pulmonary tuberculosis during rifampicin therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["seen"]], "start": [[24]], "entity_id": ["T5"]}, "Effect": {"text": [["Pemphigus foliaceus"]], "start": [[0]], "entity_id": ["T3"]}, "Subject": {"text": [["a patient with pulmonary tuberculosis"]], "start": [[32]], "entity_id": ["T4"]}, "Treatment": {"text": [["rifampicin"]], "start": [[77]], "entity_id": ["T6"], "Disorder": {"text": [["pulmonary tuberculosis"]], "start": [[47]], "entity_id": ["T7"]}, "Drug": {"text": [["rifampicin"]], "start": [[77]], "entity_id": ["T8"]}}}]}]}
{"id": "11816261_2", "context": "CONCLUSIONS: Clinicians should be aware of a risk of serotonin syndrome with serious extrapyramidal reactions in patients receiving sertraline or venlafaxine when metoclopramide is coadministered even in a single, conventional dose.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["receiving"]], "start": [[122]], "entity_id": ["T10"]}, "Subject": {"text": [["patients"]], "start": [[113]], "entity_id": ["T9"]}, "Treatment": {"text": [["sertraline or venlafaxine when metoclopramide is coadministered even in a single, conventional dose"]], "start": [[132]], "entity_id": ["T11"], "Drug": {"text": [["sertraline"], ["venlafaxine"], ["metoclopramide"]], "start": [[132], [146], [163]], "entity_id": ["T14", "T15", "T16"]}, "Dosage": {"text": [["single, conventional dose"]], "start": [[206]], "entity_id": ["T19"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["coadministered"]], "start": [[181]], "entity_id": ["T17"]}, "Drug": {"text": [["metoclopramide"], ["venlafaxine"], ["sertraline"]], "start": [[163], [146], [132]], "entity_id": ["T16", "T15", "T14"]}}]}, "Effect": {"text": [["serotonin syndrome with serious extrapyramidal reactions"]], "start": [[53]], "entity_id": ["T12"]}, "Speculated": {"text": [["risk"]], "start": [[45]], "entity_id": ["T13"], "value": true}}]}]}
{"id": "9260733_2", "context": "We report the case of a patient who developed polyserositis (pericardial effusion, pleural effusion, and pericarditis) after being started on clozapine, and whose symptoms remitted upon discontinuation of clozapine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[119]], "entity_id": ["T14"]}, "Treatment": {"text": [["started on clozapine"]], "start": [[131]], "entity_id": ["T13"], "Drug": {"text": [["clozapine"]], "start": [[142]], "entity_id": ["T17"]}}, "Effect": {"text": [["polyserositis (pericardial effusion, pleural effusion, and pericarditis)"]], "start": [[46]], "entity_id": ["T15"]}, "Subject": {"text": [["a patient"]], "start": [[22]], "entity_id": ["T16"]}}]}]}
{"id": "8053440_5", "context": "Three years later, treatment with ampicillin caused another episode of cholestatic hepatitis with cholestasis and duct paucity on rebiopsy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[45]], "entity_id": ["T9"]}, "Treatment": {"text": [["ampicillin"]], "start": [[34]], "entity_id": ["T7"], "Drug": {"text": [["ampicillin"]], "start": [[34]], "entity_id": ["T10"]}, "Time_elapsed": {"text": [["Three years later"]], "start": [[0]], "entity_id": ["T11"]}}, "Effect": {"text": [["cholestatic hepatitis with cholestasis and duct paucity on rebiopsy"]], "start": [[71]], "entity_id": ["T8"]}}]}]}
{"id": "8071504_5", "context": "METHODS: A patient who developed dramatic, permanent vision loss after a 9-month course of treatment with ethambutol and isoniazid for pulmonary tuberculosis is presented.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[65]], "entity_id": ["T11"]}, "Subject": {"text": [["A patient"]], "start": [[9]], "entity_id": ["T7"]}, "Treatment": {"text": [["9-month course of treatment with ethambutol and isoniazid"]], "start": [[73]], "entity_id": ["T9"], "Disorder": {"text": [["pulmonary tuberculosis"]], "start": [[135]], "entity_id": ["T10"]}, "Time_elapsed": {"text": [["9-month"]], "start": [[73]], "entity_id": ["T13"]}, "Drug": {"text": [["ethambutol"], ["isoniazid"]], "start": [[106], [121]], "entity_id": ["T14", "T15"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[117]], "entity_id": ["T16"]}, "Drug": {"text": [["ethambutol"], ["isoniazid"]], "start": [[106], [121]], "entity_id": ["T14", "T15"]}}]}, "Effect": {"text": [["permanent vision loss"]], "start": [[43]], "entity_id": ["T8"]}}]}]}
{"id": "16239768_2", "context": "The authors report a case of urinary incontinence (UI) that occurred in a woman after administration of venlafaxine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurred"]], "start": [[60]], "entity_id": ["T7"]}, "Subject": {"text": [["a woman"]], "start": [[72]], "entity_id": ["T5"], "Gender": {"text": [["woman"]], "start": [[74]], "entity_id": ["T9"]}}, "Effect": {"text": [["urinary incontinence (UI)"]], "start": [[29]], "entity_id": ["T6"]}, "Treatment": {"text": [["venlafaxine"]], "start": [[104]], "entity_id": ["T8"], "Drug": {"text": [["venlafaxine"]], "start": [[104]], "entity_id": ["T10"]}}}]}]}
{"id": "8651254_3", "context": "The possibility can be raised that M-CSF accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus, leading to the development of nephrotic syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["accelerated"]], "start": [[41]], "entity_id": ["T6"]}, "Treatment": {"text": [["M-CSF"]], "start": [[35]], "entity_id": ["T5"], "Drug": {"text": [["M-CSF"]], "start": [[35]], "entity_id": ["T9"]}}, "Effect": {"text": [["underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus, leading to the development of nephrotic syndrome"]], "start": [[57]], "entity_id": ["T7"]}, "Speculated": {"text": [["possibility"]], "start": [[4]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "14996269_2", "context": "We describe two ELBW infants affected by hyperkalaemia, treated with Kayexalate, who developed serious hypernatraemia, that has never been reported before in preterm infants.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[85]], "entity_id": ["T4"]}, "Treatment": {"text": [["Kayexalate"]], "start": [[69]], "entity_id": ["T6"], "Disorder": {"text": [["hyperkalaemia"]], "start": [[41]], "entity_id": ["T8"]}, "Drug": {"text": [["Kayexalate"]], "start": [[69]], "entity_id": ["T11"]}}, "Subject": {"text": [["two ELBW infants affected by hyperkalaemia"]], "start": [[12]], "entity_id": ["T3"], "Population": {"text": [["two"]], "start": [[12]], "entity_id": ["T7"]}, "Age": {"text": [["infants"]], "start": [[21]], "entity_id": ["T9"]}, "Disorder": {"text": [["ELBW"]], "start": [[16]], "entity_id": ["T10"]}}, "Effect": {"text": [["serious hypernatraemia"]], "start": [[95]], "entity_id": ["T5"]}, "Severity": {"text": [["serious"]], "start": [[95]], "entity_id": ["T12"], "value": "High"}}]}]}
{"id": "8384030_2", "context": "DISCUSSION: Electrolyte disorders associated with foscarnet are reviewed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[34]], "entity_id": ["T4"]}, "Effect": {"text": [["Electrolyte disorders"]], "start": [[12]], "entity_id": ["T3"]}, "Treatment": {"text": [["foscarnet"]], "start": [[50]], "entity_id": ["T5"], "Drug": {"text": [["foscarnet"]], "start": [[50]], "entity_id": ["T6"]}}}]}]}
{"id": "9232614_3", "context": "We report two cases that developed acute myeloid leukaemia (AML) during tamoxifen therapy for breast cancer.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[25]], "entity_id": ["T5"]}, "Effect": {"text": [["acute myeloid leukaemia (AML)"]], "start": [[35]], "entity_id": ["T6"]}, "Treatment": {"text": [["tamoxifen therapy for breast cancer"]], "start": [[72]], "entity_id": ["T7"], "Disorder": {"text": [["breast cancer"]], "start": [[94]], "entity_id": ["T8"]}, "Drug": {"text": [["tamoxifen"]], "start": [[72]], "entity_id": ["T11"]}}, "Subject": {"text": [["two cases"]], "start": [[10]], "entity_id": ["T9"], "Population": {"text": [["two"]], "start": [[10]], "entity_id": ["T10"]}}}]}]}
{"id": "15261876_1", "context": "Our patient was a 72-year-old man with advanced Parkinson's disease (PD) who received levodopa and anti-cholinergic drugs and whose head had become almost completely bald.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["become"]], "start": [[141]], "entity_id": ["T6"]}, "Subject": {"text": [["a 72-year-old man with advanced Parkinson's disease (PD)"]], "start": [[16]], "entity_id": ["T3"], "Age": {"text": [["72-year-old"]], "start": [[18]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[30]], "entity_id": ["T8"]}}, "Treatment": {"text": [["levodopa and anti-cholinergic drugs"]], "start": [[86]], "entity_id": ["T4"], "Disorder": {"text": [["advanced Parkinson's disease (PD)"]], "start": [[39]], "entity_id": ["T9"]}, "Drug": {"text": [["levodopa"], ["anti-cholinergic drugs"]], "start": [[86], [99]], "entity_id": ["T10", "T11"]}}, "Effect": {"text": [["completely bald"]], "start": [[155]], "entity_id": ["T5"]}}]}]}
{"id": "18633310_2", "context": "The patient experienced hallucinations, agitation, vomiting, tachycardia and seizures after ingestion of 1050 (48 mg/kg) of extended-release bupropion.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["experienced"]], "start": [[12]], "entity_id": ["T11"]}, "Effect": {"text": [["hallucinations, agitation, vomiting, tachycardia and seizures"]], "start": [[24]], "entity_id": ["T12"]}, "Treatment": {"text": [["ingestion of 1050 (48 mg/kg) of extended-release bupropion"]], "start": [[92]], "entity_id": ["T13"], "Route": {"text": [["ingestion"]], "start": [[92]], "entity_id": ["T14"]}, "Dosage": {"text": [["1050 (48 mg/kg)"]], "start": [[105]], "entity_id": ["T15"]}, "Drug": {"text": [["bupropion"]], "start": [[141]], "entity_id": ["T16"]}}}]}]}
{"id": "1440123_1", "context": "This case report describes a 38-year-old male in whom SIADH was strongly suspected secondary to Tegretol therapy to control a seizure disorder.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["suspected"]], "start": [[73]], "entity_id": ["T6"]}, "Subject": {"text": [["38-year-old male", "a seizure disorder"]], "start": [[29, 124]], "entity_id": ["T3"], "Age": {"text": [["38-year-old"]], "start": [[29]], "entity_id": ["T9"]}, "Gender": {"text": [["male"]], "start": [[41]], "entity_id": ["T10"]}}, "Treatment": {"text": [["Tegretol"]], "start": [[96]], "entity_id": ["T5"], "Drug": {"text": [["Tegretol"]], "start": [[96]], "entity_id": ["T11"]}, "Disorder": {"text": [["seizure"]], "start": [[126]], "entity_id": ["T12"]}}, "Effect": {"text": [["SIADH"]], "start": [[54]], "entity_id": ["T7"]}}]}]}
{"id": "17199845_1", "context": "However, cyclosporine dependency is associated with the risk of nephrotoxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[36]], "entity_id": ["T4"]}, "Treatment": {"text": [["cyclosporine dependency"]], "start": [[9]], "entity_id": ["T3"], "Drug": {"text": [["cyclosporine"]], "start": [[9]], "entity_id": ["T6"]}}, "Effect": {"text": [["nephrotoxicity"]], "start": [[64]], "entity_id": ["T5"]}}]}]}
{"id": "3335488_1", "context": "The observations suggest that testicular swelling and pain are side effects of desipramine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["side effects"]], "start": [[63]], "entity_id": ["T7"]}, "Effect": {"text": [["testicular swelling and pain"]], "start": [[30]], "entity_id": ["T5"]}, "Treatment": {"text": [["desipramine"]], "start": [[79]], "entity_id": ["T6"], "Drug": {"text": [["desipramine"]], "start": [[79]], "entity_id": ["T8"]}}}]}]}
{"id": "11722307_3", "context": "METHOD: We describe three case-reports concerning haematological adverse effects of quetiapine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["adverse effects"]], "start": [[65]], "entity_id": ["T5"]}, "Effect": {"text": [["haematological adverse effects"]], "start": [[50]], "entity_id": ["T3"]}, "Treatment": {"text": [["quetiapine"]], "start": [[84]], "entity_id": ["T4"], "Drug": {"text": [["quetiapine"]], "start": [[84]], "entity_id": ["T6"]}}}]}]}
{"id": "1575118_1", "context": "Typically, drug-induced neutropenia occurs in a patient receiving a semisynthetic penicillin for two weeks or more.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurs"]], "start": [[36]], "entity_id": ["T4"]}, "Effect": {"text": [["drug-induced neutropenia"]], "start": [[11]], "entity_id": ["T3"]}, "Subject": {"text": [["a patient"]], "start": [[46]], "entity_id": ["T5"]}, "Treatment": {"text": [["a semisynthetic penicillin for two weeks or more"]], "start": [[66]], "entity_id": ["T6"], "Drug": {"text": [["semisynthetic penicillin"]], "start": [[68]], "entity_id": ["T7"]}, "Duration": {"text": [["two weeks"]], "start": [[97]], "entity_id": ["T8"]}}}]}]}
{"id": "2554727_5", "context": "Peripheral nerve dysfunction is a potentially serious complication of high-dose cytosine arabinoside.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["of"]], "start": [[67]], "entity_id": ["T6"]}, "Effect": {"text": [["Peripheral nerve dysfunction"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["cytosine arabinoside"]], "start": [[80]], "entity_id": ["T7"], "Drug": {"text": [["cytosine arabinoside"]], "start": [[80]], "entity_id": ["T9"]}, "Dosage": {"text": [["high-dose"]], "start": [[70]], "entity_id": ["T10"]}}, "Speculated": {"text": [["potentially"]], "start": [[34]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "17444802_1", "context": "Tumor-volume increase at beginning of primary treatment with topical interferon alpha 2-beta in a case of conjunctiva-cornea intraepithelial neoplasia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["increase"]], "start": [[13]], "entity_id": ["T9"]}, "Effect": {"text": [["Tumor-volume increase"]], "start": [[0]], "entity_id": ["T6"]}, "Treatment": {"text": [["primary treatment with topical interferon alpha 2-beta"]], "start": [[38]], "entity_id": ["T7"], "Drug": {"text": [["interferon alpha 2-beta"]], "start": [[69]], "entity_id": ["T11"]}, "Route": {"text": [["topical"]], "start": [[61]], "entity_id": ["T12"]}, "Time_elapsed": {"text": [["beginning"]], "start": [[25]], "entity_id": ["T13"]}, "Disorder": {"text": [["conjunctiva-cornea intraepithelial neoplasia"]], "start": [[106]], "entity_id": ["T14"]}}, "Subject": {"text": [["a case of conjunctiva-cornea intraepithelial neoplasia"]], "start": [[96]], "entity_id": ["T8"]}}]}]}
{"id": "18504683_1", "context": "L-asparaginase-induced posterior reversible encephalopathy syndrome during acute lymphoblastic leukemia treatment in children.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[15]], "entity_id": ["T4"]}, "Treatment": {"text": [["L-asparaginase"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["L-asparaginase"]], "start": [[0]], "entity_id": ["T7"]}, "Disorder": {"text": [["acute lymphoblastic leukemia"]], "start": [[75]], "entity_id": ["T8"]}}, "Effect": {"text": [["posterior reversible encephalopathy syndrome"]], "start": [[23]], "entity_id": ["T5"]}, "Subject": {"text": [["children"]], "start": [[117]], "entity_id": ["T9"], "Age": {"text": [["children"]], "start": [[117]], "entity_id": ["T10"]}}}]}]}
{"id": "9184269_3", "context": "On the other hand, MTX-induced pneumonitis seems to be very rare in psoriatic arthritis (PsA).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[23]], "entity_id": ["T4"]}, "Treatment": {"text": [["MTX"]], "start": [[19]], "entity_id": ["T3"], "Drug": {"text": [["MTX"]], "start": [[19]], "entity_id": ["T7"]}}, "Effect": {"text": [["pneumonitis"]], "start": [[31]], "entity_id": ["T5"]}, "Speculated": {"text": [["seems"]], "start": [[43]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "3899068_1", "context": "Ototoxicity as a result of cis-platinum administration is well documented.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["result"]], "start": [[17]], "entity_id": ["T5"]}, "Effect": {"text": [["Ototoxicity"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["cis-platinum administration"]], "start": [[27]], "entity_id": ["T4"], "Drug": {"text": [["cis-platinum"]], "start": [[27]], "entity_id": ["T6"]}}}]}]}
{"id": "9892272_1", "context": "Massive subfascial hematoma after alteplase therapy for acute myocardial infarction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[28]], "entity_id": ["T4"]}, "Effect": {"text": [["Massive subfascial hematoma"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["alteplase therapy"]], "start": [[34]], "entity_id": ["T5"], "Drug": {"text": [["alteplase"]], "start": [[34]], "entity_id": ["T7"]}, "Disorder": {"text": [["acute myocardial infarction"]], "start": [[56]], "entity_id": ["T8"]}}}]}]}
{"id": "11881322_7", "context": "We suggest that itraconazole should be added to the list of drugs that may be responsible for a drug-induced vanishing bile duct syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["responsible"]], "start": [[78]], "entity_id": ["T4"]}, "Treatment": {"text": [["itraconazole"]], "start": [[16]], "entity_id": ["T3"], "Drug": {"text": [["itraconazole"]], "start": [[16]], "entity_id": ["T6"]}}, "Effect": {"text": [["drug-induced vanishing bile duct syndrome"]], "start": [[96]], "entity_id": ["T5"]}, "Speculated": {"text": [["may"]], "start": [[71]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "14998226_2", "context": "A 67-year-old man receiving a stable maintenance dosage of warfarin experienced an increased international normalized ratio (INR) without bleeding when his atorvastatin therapy was switched to fluvastatin.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["experienced"]], "start": [[68]], "entity_id": ["T11"]}, "Treatment": {"text": [["warfarin"]], "start": [[59]], "entity_id": ["T10"], "Drug": {"text": [["warfarin"]], "start": [[59]], "entity_id": ["T15"]}}, "Effect": {"text": [["increased international normalized ratio (INR)"]], "start": [[83]], "entity_id": ["T12"]}, "Subject": {"text": [["A 67-year-old man"]], "start": [[0]], "entity_id": ["T9"], "Age": {"text": [["67-year-old"]], "start": [[2]], "entity_id": ["T13"]}, "Gender": {"text": [["man"]], "start": [[14]], "entity_id": ["T14"]}}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["switched"]], "start": [[181]], "entity_id": ["T21"]}, "Treatment": {"text": [["atorvastatin therapy was switched to fluvastatin"]], "start": [[156]], "entity_id": ["T22"], "Drug": {"text": [["fluvastatin"], ["atorvastatin"]], "start": [[193], [156]], "entity_id": ["T17", "T16"]}, "Disorder": {"text": [["bleeding"]], "start": [[138]], "entity_id": ["T19"]}}}]}]}
{"id": "1295628_4", "context": "The cases of CBZ-induced SLE reported in the literature were reviewed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[17]], "entity_id": ["T5"]}, "Treatment": {"text": [["CBZ"]], "start": [[13]], "entity_id": ["T4"], "Drug": {"text": [["CBZ"]], "start": [[13]], "entity_id": ["T7"]}}, "Effect": {"text": [["SLE"]], "start": [[25]], "entity_id": ["T6"]}}]}]}
{"id": "19892516_1", "context": "Ciprofloxacin-induced hemorrhagic vasculitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[14]], "entity_id": ["T4"]}, "Treatment": {"text": [["Ciprofloxacin"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Ciprofloxacin"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["hemorrhagic vasculitis"]], "start": [[22]], "entity_id": ["T5"]}}]}]}
{"id": "8691927_4", "context": "INTERPRETATION: When high doses of fluticasone propionate are used, growth may be retarded and adrenal suppression may occur.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occur"]], "start": [[119]], "entity_id": ["T7"]}, "Treatment": {"text": [["high doses of fluticasone propionate"]], "start": [[21]], "entity_id": ["T5"], "Dosage": {"text": [["high doses"]], "start": [[21]], "entity_id": ["T8"]}, "Drug": {"text": [["fluticasone propionate"]], "start": [[35]], "entity_id": ["T9"]}}, "Effect": {"text": [["growth may be retarded and adrenal suppression"]], "start": [[68]], "entity_id": ["T6"]}}]}]}
{"id": "10614572_2", "context": "To our knowledge, this is the first report of significant hypotension associated with intravenous valproate in the treatment of status epilepticus in the pediatric population.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[70]], "entity_id": ["T5"]}, "Effect": {"text": [["hypotension"]], "start": [[58]], "entity_id": ["T3"]}, "Treatment": {"text": [["intravenous valproate"]], "start": [[86]], "entity_id": ["T4"], "Drug": {"text": [["valproate"]], "start": [[98]], "entity_id": ["T9"]}, "Route": {"text": [["intravenous"]], "start": [[86]], "entity_id": ["T10"]}, "Disorder": {"text": [["status epilepticus"]], "start": [[128]], "entity_id": ["T11"]}}, "Subject": {"text": [["pediatric population"]], "start": [[154]], "entity_id": ["T6"], "Age": {"text": [["pediatric"]], "start": [[154]], "entity_id": ["T8"]}}}]}]}
{"id": "8678015_3", "context": "While undergoing treatment with albendazole, he developed worsening diarrhea with abdominal pain and fever.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[48]], "entity_id": ["T9"]}, "Treatment": {"text": [["albendazole"]], "start": [[32]], "entity_id": ["T7"], "Drug": {"text": [["albendazole"]], "start": [[32]], "entity_id": ["T12"]}}, "Subject": {"text": [["he"]], "start": [[45]], "entity_id": ["T8"], "Gender": {"text": [["he"]], "start": [[45]], "entity_id": ["T11"]}}, "Effect": {"text": [["worsening diarrhea with abdominal pain and fever"]], "start": [[58]], "entity_id": ["T10"]}}]}]}
{"id": "17655517_1", "context": "Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[10]], "entity_id": ["T7"]}, "Treatment": {"text": [["Linezolid"]], "start": [[0]], "entity_id": ["T8"], "Drug": {"text": [["Linezolid"]], "start": [[0]], "entity_id": ["T10"]}}, "Effect": {"text": [["peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome."]], "start": [[21]], "entity_id": ["T9"]}}]}]}
{"id": "7538828_1", "context": "Bone marrow aplasia and severe skin rash after a single low dose of methotrexate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[41]], "entity_id": ["T6"]}, "Effect": {"text": [["Bone marrow aplasia and severe skin rash"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["a single low dose of methotrexate"]], "start": [[47]], "entity_id": ["T7"], "Drug": {"text": [["methotrexate"]], "start": [[68]], "entity_id": ["T8"]}, "Dosage": {"text": [["single low dose"]], "start": [[49]], "entity_id": ["T9"]}}, "Severity": {"text": [["severe"]], "start": [[24]], "entity_id": ["T11"], "value": "High"}}]}]}
{"id": "3124393_1", "context": "A woman 38-year-old, suffering for about ten years from multiple sclerosis and treated with repeated therapy cycles of intrathecal Depo-Medrol, developed a spastic paraparesis at the lower limbs.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[144]], "entity_id": ["T5"]}, "Subject": {"text": [["A woman 38-year-old, suffering for about ten years from multiple sclerosis"]], "start": [[0]], "entity_id": ["T3"], "Gender": {"text": [["woman"]], "start": [[2]], "entity_id": ["T7"]}, "Age": {"text": [["38-year-old"]], "start": [[8]], "entity_id": ["T8"]}}, "Treatment": {"text": [["repeated therapy cycles of intrathecal Depo-Medrol"]], "start": [[92]], "entity_id": ["T4"], "Drug": {"text": [["Depo-Medrol"]], "start": [[131]], "entity_id": ["T10"]}, "Disorder": {"text": [["multiple sclerosis"]], "start": [[56]], "entity_id": ["T11"]}, "Route": {"text": [["intrathecal"]], "start": [[119]], "entity_id": ["T12"]}, "Freq": {"text": [["repeated"]], "start": [[92]], "entity_id": ["T13"]}}, "Effect": {"text": [["a spastic paraparesis at the lower limbs"]], "start": [[154]], "entity_id": ["T6"]}}]}]}
{"id": "8513656_10", "context": "The efficacy of single-dose disulfiram as an inhibitor of human P450 2E1 suggests that this modality for manipulating clinical P450 2E1 activity may provide a useful probe for delineating P450 2E1 participation in human drug biotransformation or for the treatment of poisoning by P450 2E1-activated toxins.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["by"]], "start": [[277]], "entity_id": ["T8"]}, "Effect": {"text": [["poisoning"]], "start": [[267]], "entity_id": ["T7"]}, "Treatment": {"text": [["P450 2E1-activated toxins"]], "start": [[280]], "entity_id": ["T10"], "Drug": {"text": [["disulfiram"], ["P450 2E1-activated toxins"]], "start": [[28], [280]], "entity_id": ["T11", "T9"]}, "Dosage": {"text": [["single-dose"]], "start": [[16]], "entity_id": ["T12"]}}}]}]}
{"id": "3579660_2", "context": "To develop information on the relative rarity or frequency of neurologic worsening with the initiation of penicillamine therapy, we conducted a retrospective survey of 25 additional patients with Wilson's disease who met the criteria of presenting with neurologic disease and having been treated with penicillamine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["presenting"]], "start": [[237]], "entity_id": ["T8"]}, "Subject": {"text": [["25 additional patients with Wilson's disease"]], "start": [[168]], "entity_id": ["T7"], "Population": {"text": [["25"]], "start": [[168]], "entity_id": ["T5"]}}, "Effect": {"text": [["neurologic disease"]], "start": [[253]], "entity_id": ["T9"]}, "Treatment": {"text": [["penicillamine"]], "start": [[301]], "entity_id": ["T10"], "Drug": {"text": [["penicillamine"]], "start": [[301]], "entity_id": ["T11"]}, "Disorder": {"text": [["Wilson's disease"]], "start": [[196]], "entity_id": ["T12"]}}}]}]}
{"id": "10779995_3", "context": "The authors present a case of t-AML that developed in a child with metastatic neuroblastoma 18 months after he received oral etoposide, given for palliation purpose.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[102]], "entity_id": ["T4"]}, "Treatment": {"text": [["oral etoposide"]], "start": [[120]], "entity_id": ["T3"], "Time_elapsed": {"text": [["18 months"]], "start": [[92]], "entity_id": ["T9"]}, "Route": {"text": [["oral"]], "start": [[120]], "entity_id": ["T10"]}, "Drug": {"text": [["etoposide"]], "start": [[125]], "entity_id": ["T11"]}, "Disorder": {"text": [["metastatic neuroblastoma"]], "start": [[67]], "entity_id": ["T12"]}}, "Effect": {"text": [["t-AML"]], "start": [[30]], "entity_id": ["T5"]}, "Subject": {"text": [["a child with metastatic neuroblastoma"]], "start": [[54]], "entity_id": ["T6"], "Age": {"text": [["child"]], "start": [[56]], "entity_id": ["T7"]}}}]}]}
{"id": "7781845_10", "context": "Mechanisms and triggering factors of hypoglycaemia induced by mefloquine and some other anti-malarial quinine analogues are discussed.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[51]], "entity_id": ["T6"]}, "Effect": {"text": [["hypoglycaemia"]], "start": [[37]], "entity_id": ["T5"]}, "Treatment": {"text": [["mefloquine and some other anti-malarial quinine analogues"]], "start": [[62]], "entity_id": ["T7"], "Drug": {"text": [["mefloquine"], ["quinine analogues"]], "start": [[62], [102]], "entity_id": ["T8", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[73]], "entity_id": ["T9"]}, "Drug": {"text": [["mefloquine"], ["quinine analogues"]], "start": [[62], [102]], "entity_id": ["T8", "T10"]}}]}}]}]}
{"id": "11414270_15", "context": "Only nondepolarizing muscle relaxants should be used in patients who are at risk for mucositis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["used"]], "start": [[48]], "entity_id": ["T9"]}, "Treatment": {"text": [["nondepolarizing muscle relaxants"]], "start": [[5]], "entity_id": ["T6"], "Drug": {"text": [["nondepolarizing muscle relaxants"]], "start": [[5]], "entity_id": ["T11"]}}, "Subject": {"text": [["patients who are at risk for mucositis"]], "start": [[56]], "entity_id": ["T8"], "Disorder": {"text": [["mucositis"]], "start": [[85]], "entity_id": ["T12"]}}, "Speculated": {"text": [["should"]], "start": [[38]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "15685264_11", "context": "CONCLUSION: A possible pharmacokinetic interaction between Dantrolene and Oxybutynin should be borne in mind when considering Carbamazepine medication for a patient with a spinal cord lesion.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["medication"]], "start": [[140]], "entity_id": ["T15"]}, "Subject": {"text": [["a patient"]], "start": [[155]], "entity_id": ["T10"]}, "Treatment": {"text": [["Carbamazepine medication"]], "start": [[126]], "entity_id": ["T12"], "Disorder": {"text": [["a spinal cord lesion"]], "start": [[170]], "entity_id": ["T14"]}, "Drug": {"text": [["Dantrolene"], ["Oxybutynin"], ["Carbamazepine"]], "start": [[59], [74], [126]], "entity_id": ["T16", "T17", "T18"]}, "Combination": [{"event_id": "E1", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[39]], "entity_id": ["T13"]}, "Drug": {"text": [["Dantrolene"], ["Oxybutynin"]], "start": [[59], [74]], "entity_id": ["T16", "T17"]}}]}}]}]}
{"id": "19307676_3", "context": "We describe a 15-year-old female patient diagnosed with acute lymphoblastic leukemia presenting with status epilepticus after receiving intrathecal methotrexate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[120]], "entity_id": ["T5"]}, "Subject": {"text": [["a 15-year-old female patient diagnosed with acute lymphoblastic leukemia"]], "start": [[12]], "entity_id": ["T3"], "Age": {"text": [["15-year-old"]], "start": [[14]], "entity_id": ["T7"]}, "Gender": {"text": [["female"]], "start": [[26]], "entity_id": ["T8"]}}, "Effect": {"text": [["presenting with status epilepticus"]], "start": [[85]], "entity_id": ["T4"]}, "Treatment": {"text": [["receiving intrathecal methotrexate"]], "start": [[126]], "entity_id": ["T6"], "Route": {"text": [["intrathecal"]], "start": [[136]], "entity_id": ["T10"]}, "Drug": {"text": [["methotrexate"]], "start": [[148]], "entity_id": ["T11"]}, "Disorder": {"text": [["acute lymphoblastic leukemia"]], "start": [[56]], "entity_id": ["T12"]}}}]}]}
{"id": "3767790_1", "context": "Duodenal ulceration: a complication of tolazoline therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[23]], "entity_id": ["T4"]}, "Treatment": {"text": [["tolazoline"]], "start": [[39]], "entity_id": ["T3"], "Drug": {"text": [["tolazoline"]], "start": [[39]], "entity_id": ["T6"]}}, "Effect": {"text": [["Duodenal ulceration"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "1747495_1", "context": "Hepatic damage after danazol treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[15]], "entity_id": ["T6"]}, "Effect": {"text": [["Hepatic damage"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["danazol"]], "start": [[21]], "entity_id": ["T5"], "Drug": {"text": [["danazol"]], "start": [[21]], "entity_id": ["T7"]}}}]}]}
{"id": "10461415_2", "context": "Hepato-biliary abnormalities secondary to ceftriaxone use: a case report.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["secondary to"]], "start": [[29]], "entity_id": ["T4"]}, "Effect": {"text": [["Hepato-biliary abnormalities"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["ceftriaxone use"]], "start": [[42]], "entity_id": ["T5"], "Drug": {"text": [["ceftriaxone"]], "start": [[42]], "entity_id": ["T6"]}}}]}]}
{"id": "12243603_1", "context": "Rhabdomyolysis with concurrent atorvastatin and diltiazem.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[15]], "entity_id": ["T7"]}, "Effect": {"text": [["Rhabdomyolysis"]], "start": [[0]], "entity_id": ["T6"]}, "Treatment": {"text": [["diltiazem", "atorvastatin"]], "start": [[48, 31]], "entity_id": ["T8"], "Drug": {"text": [["atorvastatin"], ["diltiazem"]], "start": [[31], [48]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["concurrent"]], "start": [[20]], "entity_id": ["T9"]}, "Drug": {"text": [["atorvastatin"], ["diltiazem"]], "start": [[31], [48]], "entity_id": ["T10", "T11"]}}]}}]}]}
{"id": "7900744_1", "context": "Case report: mannitol nephrotoxicity syndrome: role of hemodialysis and postulate of mechanisms.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["syndrome"]], "start": [[37]], "entity_id": ["T5"]}, "Treatment": {"text": [["mannitol"]], "start": [[13]], "entity_id": ["T3"], "Drug": {"text": [["mannitol"]], "start": [[13]], "entity_id": ["T7"]}}, "Effect": {"text": [["nephrotoxicity"]], "start": [[22]], "entity_id": ["T4"]}}]}]}
{"id": "8710040_1", "context": "Uveitis during treatment of disseminated Mycobacterium avium-intracellulare complex infection with the combination of rifabutin, clarithromycin and ethambutol.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[8]], "entity_id": ["T6"]}, "Effect": {"text": [["Uveitis"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["combination of rifabutin, clarithromycin and ethambutol"]], "start": [[103]], "entity_id": ["T8"], "Disorder": {"text": [["disseminated Mycobacterium avium-intracellulare complex infection"]], "start": [[28]], "entity_id": ["T7"]}, "Drug": {"text": [["rifabutin"], ["clarithromycin"], ["ethambutol"]], "start": [[118], [129], [148]], "entity_id": ["T10", "T11", "T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combination"]], "start": [[103]], "entity_id": ["T9"]}, "Drug": {"text": [["rifabutin"], ["clarithromycin"], ["ethambutol"]], "start": [[118], [129], [148]], "entity_id": ["T10", "T11", "T12"]}}]}}]}]}
{"id": "16527771_2", "context": "The visual loss in this patient seems to result from phenol neurotoxicity rather than mechanical compression of the intraorbital optic nerve.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["result"]], "start": [[41]], "entity_id": ["T8"]}, "Effect": {"text": [["visual loss", "neurotoxicity"]], "start": [[4, 60]], "entity_id": ["T5"]}, "Subject": {"text": [["patient"]], "start": [[24]], "entity_id": ["T6"]}, "Treatment": {"text": [["phenol"]], "start": [[53]], "entity_id": ["T7"], "Drug": {"text": [["phenol"]], "start": [[53]], "entity_id": ["T9"]}}}]}]}
{"id": "16200540_1", "context": "Polysomnographic and pharmacokinetic findings in levodopa-induced augmentation of restless legs syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[58]], "entity_id": ["T5"]}, "Effect": {"text": [["augmentation of restless legs syndrome"]], "start": [[66]], "entity_id": ["T3"]}, "Treatment": {"text": [["levodopa"]], "start": [[49]], "entity_id": ["T4"], "Drug": {"text": [["levodopa"]], "start": [[49]], "entity_id": ["T6"]}}}]}]}
{"id": "15752306_6", "context": "These cases highlight the occurrence of livedo reticularis as an uncommon side-effect of interferon alpha treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["side-effect"]], "start": [[74]], "entity_id": ["T7"]}, "Subject": {"text": [["These cases"]], "start": [[0]], "entity_id": ["T6"]}, "Effect": {"text": [["livedo reticularis"]], "start": [[40]], "entity_id": ["T5"]}, "Treatment": {"text": [["interferon alpha"]], "start": [[89]], "entity_id": ["T8"], "Drug": {"text": [["interferon alpha"]], "start": [[89]], "entity_id": ["T9"]}}}]}]}
{"id": "11399735_1", "context": "So far, few cases of pulmonary side effects caused by ticlopidine have been reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[44]], "entity_id": ["T4"]}, "Effect": {"text": [["pulmonary side effects"]], "start": [[21]], "entity_id": ["T3"]}, "Treatment": {"text": [["ticlopidine"]], "start": [[54]], "entity_id": ["T5"], "Drug": {"text": [["ticlopidine"]], "start": [[54]], "entity_id": ["T7"]}}, "Speculated": {"text": [["few cases"]], "start": [[8]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "21104646_1", "context": "Abnormal dexamethasone suppression tests in a rifampicin-treated patient with suspected Cushing's syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Abnormal"]], "start": [[0]], "entity_id": ["T5"]}, "Effect": {"text": [["Abnormal dexamethasone suppression tests"]], "start": [[0]], "entity_id": ["T6"]}, "Treatment": {"text": [["rifampicin"]], "start": [[46]], "entity_id": ["T7"], "Disorder": {"text": [["Cushing's syndrome"]], "start": [[88]], "entity_id": ["T11"]}, "Drug": {"text": [["rifampicin"]], "start": [[46]], "entity_id": ["T12"]}}, "Subject": {"text": [["patient with suspected Cushing's syndrome"]], "start": [[65]], "entity_id": ["T8"]}, "Speculated": {"text": [["suspected"]], "start": [[78]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "16109609_2", "context": "Gemcitabine therapy has been associated with radiation recall reactions when used in the treatment of carcinoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[29]], "entity_id": ["T4"]}, "Treatment": {"text": [["Gemcitabine"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Gemcitabine"]], "start": [[0]], "entity_id": ["T7"]}, "Disorder": {"text": [["carcinoma"]], "start": [[102]], "entity_id": ["T8"]}}, "Effect": {"text": [["radiation recall reactions"]], "start": [[45]], "entity_id": ["T5"]}}]}]}
{"id": "15266150_2", "context": "Increased lash length, thickness, and pigmentation are well-documented side effects of prostaglandin analog glaucoma drops.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["are"]], "start": [[51]], "entity_id": ["T7"]}, "Effect": {"text": [["Increased lash length, thickness, and pigmentation"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["prostaglandin analog glaucoma drops"]], "start": [[87]], "entity_id": ["T6"], "Route": {"text": [["drops"]], "start": [[117]], "entity_id": ["T8"]}, "Drug": {"text": [["prostaglandin analog"]], "start": [[87]], "entity_id": ["T9"]}, "Disorder": {"text": [["glaucoma"]], "start": [[108]], "entity_id": ["T10"]}}}]}]}
{"id": "25957434_1", "context": "Bullous Eruption Associated With Dihydropyridines With Cross Reactivity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Associated"]], "start": [[17]], "entity_id": ["T4"]}, "Treatment": {"text": [["Dihydropyridines"]], "start": [[33]], "entity_id": ["T5"], "Drug": {"text": [["Dihydropyridines"]], "start": [[33]], "entity_id": ["T7"]}}, "Effect": {"text": [["Bullous Eruption"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "11020127_3", "context": "Ritonavir acted as a CYP3A4 inhibitor, diminishing carbamazepine metabolism and provoking an increase in serum levels and clinical toxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["acted"]], "start": [[10]], "entity_id": ["T8"]}, "Treatment": {"text": [["Ritonavir"]], "start": [[0]], "entity_id": ["T7"], "Drug": {"text": [["Ritonavir"]], "start": [[0]], "entity_id": ["T10"]}}, "Effect": {"text": [["CYP3A4 inhibitor, diminishing carbamazepine metabolism and provoking an increase in serum levels and clinical toxicity"]], "start": [[21]], "entity_id": ["T9"]}}]}]}
{"id": "17083900_1", "context": "Acute generalized exanthematous pustulosis induced by nimesulide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[43]], "entity_id": ["T4"]}, "Effect": {"text": [["Acute generalized exanthematous pustulosis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["nimesulide"]], "start": [[54]], "entity_id": ["T5"], "Drug": {"text": [["nimesulide"]], "start": [[54]], "entity_id": ["T6"]}}}]}]}
{"id": "11225532_1", "context": "Quinine induced coagulopathy--a near fatal experience.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[8]], "entity_id": ["T4"]}, "Treatment": {"text": [["Quinine"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Quinine"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["coagulopathy--a near fatal experience"]], "start": [[16]], "entity_id": ["T5"]}, "Severity": {"text": [["fatal"]], "start": [[37]], "entity_id": ["T7"], "value": "High"}}]}]}
{"id": "71813_1", "context": "A 58-year-old man with rheumatoid arthritis developed lichen planus during treatment with gold.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[44]], "entity_id": ["T4"]}, "Treatment": {"text": [["treatment with gold"]], "start": [[75]], "entity_id": ["T3"], "Drug": {"text": [["gold"]], "start": [[90]], "entity_id": ["T10"]}, "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[23]], "entity_id": ["T11"]}}, "Effect": {"text": [["lichen planus during"]], "start": [[54]], "entity_id": ["T5"]}, "Subject": {"text": [["A 58-year-old man with rheumatoid arthritis"]], "start": [[0]], "entity_id": ["T6"], "Age": {"text": [["58-year-old"]], "start": [[2]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[14]], "entity_id": ["T8"]}}}]}]}
{"id": "2347102_1", "context": "Atenolol-induced pseudolymphoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[9]], "entity_id": ["T5"]}, "Treatment": {"text": [["Atenolol"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Atenolol"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["pseudolymphoma"]], "start": [[17]], "entity_id": ["T6"]}}]}]}
{"id": "25407257_1", "context": "First case report of suspected onset of convulsive seizures due to co-administration of valproic acid and tebipenem.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[60]], "entity_id": ["T7"]}, "Effect": {"text": [["convulsive seizures"]], "start": [[40]], "entity_id": ["T6"]}, "Treatment": {"text": [["co-administration of valproic acid and tebipenem"]], "start": [[67]], "entity_id": ["T8"], "Drug": {"text": [["valproic acid"], ["tebipenem"]], "start": [[88], [106]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["co-administration"]], "start": [[67]], "entity_id": ["T11"]}, "Drug": {"text": [["valproic acid"], ["tebipenem"]], "start": [[88], [106]], "entity_id": ["T9", "T10"]}}]}}]}]}
{"id": "10755579_1", "context": "Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[11]], "entity_id": ["T6"]}, "Treatment": {"text": [["Fluoxetine"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Fluoxetine"]], "start": [[0]], "entity_id": ["T9"]}}, "Subject": {"text": [["child with cytochrome P-450 2D6 genetic deficiency"]], "start": [[30]], "entity_id": ["T5"], "Age": {"text": [["child"]], "start": [[30]], "entity_id": ["T7"]}, "Disorder": {"text": [["cytochrome P-450 2D6 genetic deficiency"]], "start": [[41]], "entity_id": ["T8"]}}, "Effect": {"text": [["death"]], "start": [[19]], "entity_id": ["T3"]}}]}]}
{"id": "448845_1", "context": "Aplastic anemia and agranulocytosis in patients using methazolamide for glaucoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[36]], "entity_id": ["T11"]}, "Effect": {"text": [["Aplastic anemia and agranulocytosis"]], "start": [[0]], "entity_id": ["T7"]}, "Subject": {"text": [["patients", "glaucoma"]], "start": [[39, 72]], "entity_id": ["T8"]}, "Treatment": {"text": [["methazolamide"]], "start": [[54]], "entity_id": ["T9"], "Drug": {"text": [["methazolamide"]], "start": [[54]], "entity_id": ["T12"]}, "Disorder": {"text": [["glaucoma"]], "start": [[72]], "entity_id": ["T13"]}}}]}]}
{"id": "15735923_3", "context": "We report a 44-year-old woman with t-MDS (refractory anemia with excess blasts) following treatment of recurrent anaplastic astrocytoma with temozolomide (TMZ).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[80]], "entity_id": ["T10"]}, "Subject": {"text": [["a 44-year-old woman"]], "start": [[10]], "entity_id": ["T9"], "Age": {"text": [["44-year-old"]], "start": [[12]], "entity_id": ["T13"]}, "Gender": {"text": [["woman"]], "start": [[24]], "entity_id": ["T14"]}, "Population": {"text": [["a"]], "start": [[10]], "entity_id": ["T1"]}}, "Effect": {"text": [["t-MDS (refractory anemia with excess blasts)"]], "start": [[35]], "entity_id": ["T15"]}, "Treatment": {"text": [["treatment of recurrent anaplastic astrocytoma with temozolomide (TMZ)"]], "start": [[90]], "entity_id": ["T11"], "Disorder": {"text": [["recurrent anaplastic astrocytoma"]], "start": [[103]], "entity_id": ["T12"]}, "Drug": {"text": [["temozolomide"]], "start": [[141]], "entity_id": ["T16"]}}}]}]}
{"id": "11332679_1", "context": "An infant who developed pancreatitis during meglumine antimoniate treatment for visceral leishmaniasis and who was successfully treated with a combination of allopurinol and ketoconazole is reported.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[128]], "entity_id": ["T3"]}, "Treatment": {"text": [["a combination of allopurinol and ketoconazole"]], "start": [[141]], "entity_id": ["T4"], "Drug": {"text": [["allopurinol"], ["ketoconazole"]], "start": [[158], [174]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combination"]], "start": [[143]], "entity_id": ["T8"]}, "Drug": {"text": [["allopurinol"], ["ketoconazole"]], "start": [[158], [174]], "entity_id": ["T9", "T10"]}}]}, "Effect": {"text": [["pancreatitis"]], "start": [[24]], "entity_id": ["T5"]}, "Subject": {"text": [["An infant"]], "start": [[0]], "entity_id": ["T6"], "Age": {"text": [["infant"]], "start": [[3]], "entity_id": ["T7"]}}}]}]}
{"id": "8345435_2", "context": "L-Carnitine supplementation has been recommended to prevent the fatal hepatotoxic effects associated with valproic acid.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[90]], "entity_id": ["T8"]}, "Treatment": {"text": [["valproic acid"]], "start": [[106]], "entity_id": ["T12"], "Drug": {"text": [["valproic acid"]], "start": [[106]], "entity_id": ["T9"]}}, "Effect": {"text": [["hepatotoxic effects"]], "start": [[70]], "entity_id": ["T5"]}, "Severity": {"text": [["fatal"]], "start": [[64]], "entity_id": ["T3"], "value": "High"}}, {"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["recommended"]], "start": [[37]], "entity_id": ["T4"]}, "Treatment": {"text": [["L-Carnitine"]], "start": [[0]], "entity_id": ["T6"], "Drug": {"text": [["L-Carnitine"]], "start": [[0]], "entity_id": ["T10"]}, "Disorder": {"text": [["fatal hepatotoxic effects"]], "start": [[64]], "entity_id": ["T11"]}}}]}]}
{"id": "8641617_6", "context": "The purpose of this study was to examine the incidence and cause of Clostridium difficile colitis occurring after cisplatin-based combination chemotherapy in ovarian cancer patients.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurring"]], "start": [[98]], "entity_id": ["T4"]}, "Effect": {"text": [["Clostridium difficile colitis"]], "start": [[68]], "entity_id": ["T3"]}, "Treatment": {"text": [["cisplatin-based combination chemotherapy"]], "start": [[114]], "entity_id": ["T5"], "Route": {"text": [["chemotherapy"]], "start": [[142]], "entity_id": ["T8"]}, "Drug": {"text": [["cisplatin"]], "start": [[114]], "entity_id": ["T9"]}, "Disorder": {"text": [["ovarian cancer"]], "start": [[158]], "entity_id": ["T10"]}}, "Subject": {"text": [["ovarian cancer patients"]], "start": [[158]], "entity_id": ["T6"]}}]}]}
{"id": "7854541_1", "context": "Cerebral demyelinating disease developed in a patient during adjuvant therapy with levamisole for malignant melanoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[54]], "entity_id": ["T3"]}, "Treatment": {"text": [["adjuvant therapy with levamisole"]], "start": [[61]], "entity_id": ["T4"], "Drug": {"text": [["levamisole"]], "start": [[83]], "entity_id": ["T7"]}, "Disorder": {"text": [["malignant melanoma"]], "start": [[98]], "entity_id": ["T8"]}}, "Subject": {"text": [["a patient"]], "start": [[44]], "entity_id": ["T5"]}, "Effect": {"text": [["Cerebral demyelinating disease"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "3558331_1", "context": "Amoxapine-induced cognitive impairment in two patients.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[10]], "entity_id": ["T3"]}, "Treatment": {"text": [["Amoxapine"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Amoxapine"]], "start": [[0]], "entity_id": ["T8"]}}, "Subject": {"text": [["two patients"]], "start": [[42]], "entity_id": ["T5"], "Population": {"text": [["two"]], "start": [[42]], "entity_id": ["T7"]}}, "Effect": {"text": [["cognitive impairment"]], "start": [[18]], "entity_id": ["T6"]}}]}]}
{"id": "21881031_5", "context": "Granisetron hydrochloride (3 mg on days 1, 8, and 15) and dexamethasone (13.2 mg on day 1 and 6.6 mg on days 2, 3, 8, and 15) were used prior to irinotecan administration in both patients.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["used"]], "start": [[131]], "entity_id": ["T9"]}, "Treatment": {"text": [["Granisetron hydrochloride (3 mg on days 1, 8, and 15) and dexamethasone (13.2 mg on day 1 and 6.6 mg on days 2, 3, 8, and 15)", "irinotecan"]], "start": [[0, 145]], "entity_id": ["T8"], "Drug": {"text": [["Granisetron hydrochloride"], ["dexamethasone"]], "start": [[0], [58]], "entity_id": ["T11", "T15"]}, "Dosage": {"text": [["3 mg"], ["13.2 mg"], ["6.6 mg"]], "start": [[27], [73], [94]], "entity_id": ["T12", "T16", "T18"]}, "Freq": {"text": [["on day 1"], ["on days 1, 8, and 15"], ["on days 2, 3, 8, and 15"]], "start": [[81], [32], [101]], "entity_id": ["T17", "T13", "T19"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[54]], "entity_id": ["T14"]}, "Drug": {"text": [["dexamethasone"], ["Granisetron hydrochloride"]], "start": [[58], [0]], "entity_id": ["T15", "T11"]}}]}, "Subject": {"text": [["both patients"]], "start": [[174]], "entity_id": ["T10"]}}]}]}
{"id": "6245286_3", "context": "Visceral herpesvirus infections in leukemic patients receiving cytarabine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[32]], "entity_id": ["T6"]}, "Effect": {"text": [["Visceral herpesvirus infections"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["cytarabine"]], "start": [[63]], "entity_id": ["T5"], "Drug": {"text": [["cytarabine."]], "start": [[63]], "entity_id": ["T8"]}, "Disorder": {"text": [["leukemic"]], "start": [[35]], "entity_id": ["T9"]}}, "Subject": {"text": [["leukemic patients"]], "start": [[35]], "entity_id": ["T4"]}}]}]}
{"id": "8678015_2", "context": "Although a few case reports link metronidazole with the development of pseudomembranous colitis, albendazole has not been associated with the development of this condition.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["development"]], "start": [[56]], "entity_id": ["T4"]}, "Treatment": {"text": [["metronidazole"]], "start": [[33]], "entity_id": ["T3"], "Drug": {"text": [["metronidazole"]], "start": [[33]], "entity_id": ["T6"]}}, "Effect": {"text": [["pseudomembranous colitis"]], "start": [[71]], "entity_id": ["T5"]}}]}]}
{"id": "11414270_13", "context": "CONCLUSION: Oral mucositis is a frequent and potentially severe complication of cancer chemotherapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[64]], "entity_id": ["T8"]}, "Effect": {"text": [["Oral mucositis"]], "start": [[12]], "entity_id": ["T6"]}, "Treatment": {"text": [["cancer chemotherapy"]], "start": [[80]], "entity_id": ["T7"], "Route": {"text": [["chemotherapy"]], "start": [[87]], "entity_id": ["T11"]}, "Disorder": {"text": [["cancer"]], "start": [[80]], "entity_id": ["T12"]}}, "Speculated": {"text": [["potentially"]], "start": [[45]], "entity_id": ["T9"], "value": true}, "Severity": {"text": [["severe"]], "start": [[57]], "entity_id": ["T10"], "value": "Medium"}}]}]}
{"id": "10431414_1", "context": "One case of priapism occurred during heparin therapy for a previous surgical operation to the knee is reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurred"]], "start": [[21]], "entity_id": ["T4"]}, "Treatment": {"text": [["during heparin therapy"]], "start": [[30]], "entity_id": ["T5"], "Drug": {"text": [["heparin"]], "start": [[37]], "entity_id": ["T8"]}, "Disorder": {"text": [["surgical operation to the knee"]], "start": [[68]], "entity_id": ["T9"]}}, "Effect": {"text": [["priapism"]], "start": [[12]], "entity_id": ["T7"]}, "Subject": {"text": [["One case"]], "start": [[0]], "entity_id": ["T3"]}}]}]}
{"id": "12365708_5", "context": "While both amiodarone and digoxin can cause permanent visual changes, the ocular effects are often reversible.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[38]], "entity_id": ["T8"]}, "Treatment": {"text": [["amiodarone and digoxin"]], "start": [[11]], "entity_id": ["T7"], "Drug": {"text": [["amiodarone"], ["digoxin"]], "start": [[11], [26]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[22]], "entity_id": ["T12"]}, "Drug": {"text": [["amiodarone"], ["digoxin"]], "start": [[11], [26]], "entity_id": ["T10", "T11"]}}]}, "Effect": {"text": [["permanent visual changes"]], "start": [[44]], "entity_id": ["T9"]}}]}]}
{"id": "15543388_1", "context": "AIM: Report of a case of a woman patient who developed celiac disease after pegylated interferon alpha-2a and ribavirin use for chronic hepatitis C.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[45]], "entity_id": ["T5"]}, "Subject": {"text": [["a woman patient"]], "start": [[25]], "entity_id": ["T4"], "Gender": {"text": [["woman"]], "start": [[27]], "entity_id": ["T8"]}}, "Effect": {"text": [["celiac disease"]], "start": [[55]], "entity_id": ["T6"]}, "Treatment": {"text": [["pegylated interferon alpha-2a and ribavirin use for chronic hepatitis C"]], "start": [[76]], "entity_id": ["T7"], "Drug": {"text": [["pegylated interferon alpha-2a"], ["ribavirin"]], "start": [[76], [110]], "entity_id": ["T9", "T11"]}, "Disorder": {"text": [["chronic hepatitis C"]], "start": [[128]], "entity_id": ["T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[106]], "entity_id": ["T10"]}, "Drug": {"text": [["ribavirin"], ["pegylated interferon alpha-2a"]], "start": [[110], [76]], "entity_id": ["T11", "T9"]}}]}}]}]}
{"id": "11243427_2", "context": "Differential diagnoses included ocular rosacea with cicatrizing conjunctivitis and 5-FU-induced ectropion.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[88]], "entity_id": ["T4"]}, "Treatment": {"text": [["5-FU"]], "start": [[83]], "entity_id": ["T3"], "Drug": {"text": [["5-FU"]], "start": [[83]], "entity_id": ["T6"]}}, "Effect": {"text": [["ectropion"]], "start": [[96]], "entity_id": ["T5"]}}]}]}
{"id": "9660541_1", "context": "In rare cases mitomycin C (MMC) may induce cancer-associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, thrombocytopenia and progressive renal failure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induce"]], "start": [[36]], "entity_id": ["T14"]}, "Treatment": {"text": [["mitomycin C (MMC)"]], "start": [[14]], "entity_id": ["T13"], "Drug": {"text": [["mitomycin C"]], "start": [[14]], "entity_id": ["T17"]}}, "Effect": {"text": [["cancer-associated hemolytic uremic syndrome", "hemolytic anemia, thrombocytopenia and progressive renal failure"]], "start": [[43, 114]], "entity_id": ["T15"]}, "Subject": {"text": [["In rare cases"]], "start": [[0]], "entity_id": ["T18"]}, "Speculated": {"text": [["may"]], "start": [[32]], "entity_id": ["T16"], "value": true}}]}]}
{"id": "16968538_1", "context": "Hemolytic uremic syndrome following the infusion of oxaliplatin: case report.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[26]], "entity_id": ["T6"]}, "Treatment": {"text": [["oxaliplatin"]], "start": [[52]], "entity_id": ["T4"], "Drug": {"text": [["oxaliplatin"]], "start": [[52]], "entity_id": ["T7"]}}, "Effect": {"text": [["Hemolytic uremic syndrome"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "12699871_4", "context": "Tacrolimus (FK506)-induced mutism after liver transplant.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[19]], "entity_id": ["T5"]}, "Treatment": {"text": [["Tacrolimus (FK506"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Tacrolimus"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["mutism"]], "start": [[27]], "entity_id": ["T6"]}}]}]}
{"id": "17009081_4", "context": "Though proteinuria and nephrotic syndrome is a rare adverse effect of IFN-beta-1b therapy, physicians treating MS patients with this agent should pay careful attention to new clinical symptoms and laboratory findings.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["adverse effect"]], "start": [[52]], "entity_id": ["T7"]}, "Effect": {"text": [["proteinuria and nephrotic syndrome"]], "start": [[7]], "entity_id": ["T5"]}, "Treatment": {"text": [["IFN-beta-1b"]], "start": [[70]], "entity_id": ["T8"], "Drug": {"text": [["IFN-beta-1b"]], "start": [[70]], "entity_id": ["T11"]}, "Disorder": {"text": [["MS"]], "start": [[111]], "entity_id": ["T12"]}}, "Subject": {"text": [["MS patients"]], "start": [[111]], "entity_id": ["T9"]}}]}]}
{"id": "2894766_1", "context": "It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[51]], "entity_id": ["T8"]}, "Treatment": {"text": [["sulfasalazine"]], "start": [[37]], "entity_id": ["T7"], "Drug": {"text": [["sulfasalazine"]], "start": [[37]], "entity_id": ["T10"]}}, "Effect": {"text": [["lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms"]], "start": [[59]], "entity_id": ["T9"]}}]}]}
{"id": "1310879_2", "context": "By means of the in vitro heparin-induced platelet activation (HIPA) assay it was shown that standard heparin and the LMW heparins Fragmin and Fraxiparin (Sanofi Labaz, Munich, FRG), as well as the enoxaparine Clexane (Nattermann, Cologne, FRG), all induced platelet activation with the patient's serum.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[249]], "entity_id": ["T8"]}, "Effect": {"text": [["platelet activation"]], "start": [[257]], "entity_id": ["T6"]}, "Treatment": {"text": [["standard heparin and the LMW heparins Fragmin and Fraxiparin (Sanofi Labaz, Munich, FRG), as well as the enoxaparine Clexane (Nattermann, Cologne, FRG)"]], "start": [[92]], "entity_id": ["T7"], "Drug": {"text": [["Fragmin"], ["Fraxiparin"], ["Clexane"]], "start": [[130], [142], [209]], "entity_id": ["T9", "T10", "T11"]}}}]}]}
{"id": "19357764_2", "context": "DISCUSSION: This case shows that switching to zidovudine potentially can lead to a hyperlactatemia relapse.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["lead"]], "start": [[73]], "entity_id": ["T4"]}, "Effect": {"text": [["hyperlactatemia relapse"]], "start": [[83]], "entity_id": ["T3"]}, "Subject": {"text": [["This case"]], "start": [[12]], "entity_id": ["T5"]}, "Treatment": {"text": [["zidovudine"]], "start": [[46]], "entity_id": ["T7"], "Drug": {"text": [["zidovudine"]], "start": [[46]], "entity_id": ["T9"]}}, "Speculated": {"text": [["potentially"]], "start": [[57]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "9232614_1", "context": "Acute leukaemia during tamoxifen therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[16]], "entity_id": ["T5"]}, "Effect": {"text": [["Acute leukaemia"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["tamoxifen therapy"]], "start": [[23]], "entity_id": ["T4"], "Drug": {"text": [["tamoxifen"]], "start": [[23]], "entity_id": ["T6"]}}}]}]}
{"id": "1310879_3", "context": "Heparin-associated thrombocytopenia: successful therapy with the heparinoid Org 10172 in a patient showing cross-reaction to LMW heparins.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[8]], "entity_id": ["T4"]}, "Treatment": {"text": [["Heparin"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Heparin"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["thrombocytopenia"]], "start": [[19]], "entity_id": ["T5"]}, "Subject": {"text": [["a patient"]], "start": [[89]], "entity_id": ["T6"]}}]}]}
{"id": "3970339_1", "context": "A patient presented with a painful, oedematous, cyanosed hand having injected a solution of diamorphine and methylphenidate into his radial artery.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["presented"]], "start": [[10]], "entity_id": ["T7"]}, "Subject": {"text": [["A patient"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["injected a solution of diamorphine and methylphenidate into his radial artery"]], "start": [[69]], "entity_id": ["T5"], "Route": {"text": [["injected", "into his radial artery"]], "start": [[69, 124]], "entity_id": ["T8"]}, "Drug": {"text": [["diamorphine"], ["methylphenidate"]], "start": [[92], [108]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[104]], "entity_id": ["T11"]}, "Drug": {"text": [["diamorphine"], ["methylphenidate"]], "start": [[92], [108]], "entity_id": ["T9", "T10"]}}]}, "Effect": {"text": [["painful, oedematous, cyanosed hand"]], "start": [[27]], "entity_id": ["T6"]}}]}]}
{"id": "9509511_2", "context": "We conclude that vincristine and actinomycin D were the cause of this rare from of hepatotoxicity and that chemotherapy for the underlying malignant disease could be given safely after clinical recovery.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[56]], "entity_id": ["T6"]}, "Treatment": {"text": [["vincristine and actinomycin D"]], "start": [[17]], "entity_id": ["T4"], "Drug": {"text": [["vincristine"], ["actinomycin D"]], "start": [[17], [33]], "entity_id": ["T7", "T8"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[29]], "entity_id": ["T9"]}, "Drug": {"text": [["vincristine"], ["actinomycin D"]], "start": [[17], [33]], "entity_id": ["T7", "T8"]}}]}, "Effect": {"text": [["hepatotoxicity"]], "start": [[83]], "entity_id": ["T5"]}}]}]}
{"id": "6702890_2", "context": "Pure red cell aplasia associated with fenoprofen.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[22]], "entity_id": ["T4"]}, "Effect": {"text": [["Pure red cell aplasia"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["fenoprofen"]], "start": [[38]], "entity_id": ["T5"], "Drug": {"text": [["fenoprofen"]], "start": [[38]], "entity_id": ["T6"]}}}]}]}
{"id": "16239768_1", "context": "A 56-year-old white woman with a diagnosis of reactive depression developed severe UI after a 30 days' treatment with venlafaxine 75 mg/day.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[86]], "entity_id": ["T6"]}, "Subject": {"text": [["A 56-year-old white woman with a diagnosis of reactive depression"]], "start": [[0]], "entity_id": ["T3"], "Age": {"text": [["56-year-old"]], "start": [[2]], "entity_id": ["T7"]}, "Race": {"text": [["white"]], "start": [[14]], "entity_id": ["T8"]}, "Gender": {"text": [["woman"]], "start": [[20]], "entity_id": ["T9"]}}, "Effect": {"text": [["severe UI"]], "start": [[76]], "entity_id": ["T4"]}, "Treatment": {"text": [["30 days' treatment with venlafaxine 75 mg/day."]], "start": [[94]], "entity_id": ["T5"], "Disorder": {"text": [["reactive depression"]], "start": [[46]], "entity_id": ["T10"]}, "Time_elapsed": {"text": [["30 days"]], "start": [[94]], "entity_id": ["T12"]}, "Drug": {"text": [["venlafaxine"]], "start": [[118]], "entity_id": ["T13"]}, "Dosage": {"text": [["75 mg/day"]], "start": [[130]], "entity_id": ["T14"]}}}]}]}
{"id": "10891991_5", "context": "PATIENTS: Three patients developed a reproductive endocrine disorder during treatment with valproate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[25]], "entity_id": ["T9"]}, "Subject": {"text": [["Three patients"]], "start": [[10]], "entity_id": ["T3"], "Population": {"text": [["Three"]], "start": [[10]], "entity_id": ["T7"]}}, "Effect": {"text": [["reproductive endocrine disorder"]], "start": [[37]], "entity_id": ["T5"]}, "Treatment": {"text": [["valproate"]], "start": [[91]], "entity_id": ["T6"], "Drug": {"text": [["valproate"]], "start": [[91]], "entity_id": ["T8"]}}}]}]}
{"id": "10410183_2", "context": "OBJECTIVE: To report a case of marked elevation of serum creatine kinase (CK) associated with olanzapine therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[78]], "entity_id": ["T4"]}, "Treatment": {"text": [["olanzapine"]], "start": [[94]], "entity_id": ["T5"], "Drug": {"text": [["olanzapine"]], "start": [[94]], "entity_id": ["T7"]}}, "Effect": {"text": [["marked elevation of serum creatine kinase"]], "start": [[31]], "entity_id": ["T6"]}}]}]}
{"id": "8641617_5", "context": "Severe C. difficile colitis occurred in 2 patients (6.1%) after receiving cisplatin-based combination chemotherapy for ovarian malignancies.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurred"]], "start": [[28]], "entity_id": ["T4"]}, "Effect": {"text": [["Severe C. difficile colitis"]], "start": [[0]], "entity_id": ["T3"]}, "Subject": {"text": [["2 patients (6.1%)"]], "start": [[40]], "entity_id": ["T5"], "Population": {"text": [["2"], ["(6.1%)"]], "start": [[40], [51]], "entity_id": ["T8", "T9"]}}, "Treatment": {"text": [["cisplatin-based combination chemotherapy"]], "start": [[74]], "entity_id": ["T6"], "Drug": {"text": [["cisplatin"]], "start": [[74]], "entity_id": ["T10"]}, "Disorder": {"text": [["ovarian malignancies"]], "start": [[119]], "entity_id": ["T11"]}, "Route": {"text": [["chemotherapy"]], "start": [[102]], "entity_id": ["T7"]}}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T12"], "value": "High"}}]}]}
{"id": "3430507_6", "context": "A 56-year-old woman with scleroderma developed rapidly progressive glomerulonephritis with epithelial crescents associated with hemoptysis after 27 months of D-penicillamine therapy and a cumulative dose of 1,200 g.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[37]], "entity_id": ["T8"]}, "Subject": {"text": [["A 56-year-old woman with scleroderma"]], "start": [[0]], "entity_id": ["T7"], "Age": {"text": [["56-year-old"]], "start": [[2]], "entity_id": ["T11"]}, "Gender": {"text": [["woman"]], "start": [[14]], "entity_id": ["T12"]}}, "Effect": {"text": [["rapidly progressive glomerulonephritis with epithelial crescents associated with hemoptysis"]], "start": [[47]], "entity_id": ["T9"]}, "Treatment": {"text": [["27 months of D-penicillamine therapy and a cumulative dose of 1,200 g"]], "start": [[145]], "entity_id": ["T10"], "Disorder": {"text": [["scleroderma"]], "start": [[25]], "entity_id": ["T13"]}, "Time_elapsed": {"text": [["27 months"]], "start": [[145]], "entity_id": ["T14"]}, "Drug": {"text": [["D-penicillamine"]], "start": [[158]], "entity_id": ["T15"]}, "Dosage": {"text": [["1,200 g"]], "start": [[207]], "entity_id": ["T16"]}}}]}]}
{"id": "9831311_2", "context": "High-dose phosphate treatment leads to hypokalemia in hypophosphatemic osteomalacia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["leads"]], "start": [[30]], "entity_id": ["T4"]}, "Treatment": {"text": [["High-dose phosphate"]], "start": [[0]], "entity_id": ["T3"], "Disorder": {"text": [["hypophosphatemic osteomalacia"]], "start": [[54]], "entity_id": ["T6"]}, "Drug": {"text": [["phosphate"]], "start": [[10]], "entity_id": ["T7"]}, "Dosage": {"text": [["High-dose"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["hypokalemia"]], "start": [[39]], "entity_id": ["T5"]}}]}]}
{"id": "2212262_2", "context": "We report a patient who developed heparin associated thrombocytopenia during continuous arteriovenous haemofiltration and discuss its implications and alternative anticoagulant treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[70]], "entity_id": ["T3"]}, "Treatment": {"text": [["heparin", "continuous arteriovenous haemofiltration"]], "start": [[34, 77]], "entity_id": ["T4"], "Drug": {"text": [["heparin"]], "start": [[34]], "entity_id": ["T7"]}}, "Subject": {"text": [["a patient"]], "start": [[10]], "entity_id": ["T5"]}, "Effect": {"text": [["heparin associated thrombocytopenia"]], "start": [[34]], "entity_id": ["T6"]}}]}]}
{"id": "17133571_2", "context": "We describe a detailed case of fulminant hepatitis induced by nevirapine (Viramune) and treated by liver transplantation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[51]], "entity_id": ["T5"]}, "Effect": {"text": [["fulminant hepatitis"]], "start": [[31]], "entity_id": ["T4"]}, "Treatment": {"text": [["nevirapine"]], "start": [[62]], "entity_id": ["T6"], "Drug": {"text": [["nevirapine"]], "start": [[62]], "entity_id": ["T7"]}}}]}]}
{"id": "7900744_5", "context": "The literature is also reviewed for ARF associated with mannitol infusion in patients who received dialysis and those who did not receive dialysis; and the possible mechanism(s) of mannitol nephrotoxicity are discussed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[40]], "entity_id": ["T6"]}, "Effect": {"text": [["ARF"]], "start": [[36]], "entity_id": ["T5"]}, "Treatment": {"text": [["mannitol infusion"]], "start": [[56]], "entity_id": ["T7"], "Drug": {"text": [["mannitol"]], "start": [[56]], "entity_id": ["T9"]}, "Route": {"text": [["infusion"]], "start": [[65]], "entity_id": ["T10"]}}, "Subject": {"text": [["patients"]], "start": [[77]], "entity_id": ["T8"]}}]}]}
{"id": "15190230_2", "context": "In this case report, we present clinical and laboratory findings of a case with chronic hepatitis B that developed acute dystonia soon after the first dose of pegylated interferon alpha.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[135]], "entity_id": ["T3"]}, "Treatment": {"text": [["the first dose of pegylated interferon alpha."]], "start": [[141]], "entity_id": ["T4"], "Disorder": {"text": [["chronic hepatitis B"]], "start": [[80]], "entity_id": ["T6"]}, "Dosage": {"text": [["first dose"]], "start": [[145]], "entity_id": ["T10"]}, "Drug": {"text": [["pegylated interferon alpha"]], "start": [[159]], "entity_id": ["T11"]}}, "Effect": {"text": [["acute dystonia"]], "start": [[115]], "entity_id": ["T5"]}, "Subject": {"text": [["a case with chronic hepatitis B"]], "start": [[68]], "entity_id": ["T8"], "Population": {"text": [["a"]], "start": [[68]], "entity_id": ["T9"]}}, "Severity": {"text": [["acute"]], "start": [[115]], "entity_id": ["T12"], "value": "High"}}]}]}
{"id": "15266150_3", "context": "Trichiasis associated with prostaglandin analog use.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[11]], "entity_id": ["T5"]}, "Effect": {"text": [["Trichiasis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["prostaglandin analog"]], "start": [[27]], "entity_id": ["T4"], "Drug": {"text": [["prostaglandin analog"]], "start": [[27]], "entity_id": ["T6"]}}}]}]}
{"id": "2937155_2", "context": "The possible development of a drug-induced vasculitis or lupus-like syndrome should be added to the list of rare toxic effects of vancomycin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["development"]], "start": [[13]], "entity_id": ["T6"]}, "Treatment": {"text": [["vancomycin"]], "start": [[130]], "entity_id": ["T7"], "Drug": {"text": [["vancomycin"]], "start": [[130]], "entity_id": ["T9"]}}, "Effect": {"text": [["drug-induced vasculitis or lupus-like syndrome"]], "start": [[30]], "entity_id": ["T8"]}, "Speculated": {"text": [["possible"]], "start": [[4]], "entity_id": ["T5"], "value": true}}]}]}
{"id": "17381671_8", "context": "Healthcare professionals should be aware of the possible development of serotonin syndrome as a complication of initiation of fentanyl and other phenylpiperidine opioids in patients treated with SSRIs.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["development"]], "start": [[57]], "entity_id": ["T10"]}, "Treatment": {"text": [["fentanyl and other phenylpiperidine opioids", "treated with SSRIs"]], "start": [[126, 182]], "entity_id": ["T8"], "Drug": {"text": [["fentanyl"], ["phenylpiperidine opioids"], ["SSRIs"]], "start": [[126], [145], [195]], "entity_id": ["T13", "T14", "T15"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["treated"]], "start": [[182]], "entity_id": ["T16"]}, "Drug": {"text": [["phenylpiperidine opioids"], ["fentanyl"], ["SSRIs"]], "start": [[145], [126], [195]], "entity_id": ["T14", "T13", "T15"]}}]}, "Subject": {"text": [["patients"]], "start": [[173]], "entity_id": ["T9"]}, "Effect": {"text": [["serotonin syndrome"]], "start": [[72]], "entity_id": ["T11"]}, "Speculated": {"text": [["possible"]], "start": [[48]], "entity_id": ["T12"], "value": true}}]}]}
{"id": "16196187_1", "context": "Acute myocardial ischemia following accidental intravenous administration of epinephrine in high concentration.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[26]], "entity_id": ["T4"]}, "Effect": {"text": [["Acute myocardial ischemia"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["accidental intravenous administration of epinephrine in high concentration"]], "start": [[36]], "entity_id": ["T5"], "Route": {"text": [["intravenous administration"]], "start": [[47]], "entity_id": ["T6"]}, "Drug": {"text": [["epinephrine"]], "start": [[77]], "entity_id": ["T7"]}, "Dosage": {"text": [["high concentration"]], "start": [[92]], "entity_id": ["T8"]}}}]}]}
{"id": "2299784_2", "context": "Bromide intoxication secondary to pyridostigmine bromide therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["secondary"]], "start": [[21]], "entity_id": ["T4"]}, "Effect": {"text": [["Bromide intoxication"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["pyridostigmine bromide"]], "start": [[34]], "entity_id": ["T5"], "Drug": {"text": [["pyridostigmine bromide"]], "start": [[34]], "entity_id": ["T6"]}}}]}]}
{"id": "11886466_3", "context": "We have recently encountered a patient with acquired haemophilia who developed a thrombotic left middle cerebral artery distribution stroke while being treated with pFVIII.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[152]], "entity_id": ["T9"]}, "Treatment": {"text": [["pFVIII"]], "start": [[165]], "entity_id": ["T10"], "Disorder": {"text": [["acquired haemophilia"]], "start": [[44]], "entity_id": ["T8"]}, "Drug": {"text": [["pFVIII"]], "start": [[165]], "entity_id": ["T12"]}}, "Subject": {"text": [["patient with acquired haemophilia who developed a thrombotic left middle cerebral artery distribution stroke"]], "start": [[31]], "entity_id": ["T7"]}, "Effect": {"text": [["thrombotic left middle cerebral artery distribution stroke"]], "start": [[81]], "entity_id": ["T11"]}}]}]}
{"id": "22735246_4", "context": "We present a case of serotonin syndrome, which was precipitated by this medicine in a patient who had been predisposed by long-term treatment with sertraline, a selective serotonin reuptake inhibitor.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["precipitated"]], "start": [[51]], "entity_id": ["T10"]}, "Effect": {"text": [["serotonin syndrome"]], "start": [[21]], "entity_id": ["T7"]}, "Subject": {"text": [["a patient"]], "start": [[84]], "entity_id": ["T8"]}, "Treatment": {"text": [["long-term treatment with sertraline"]], "start": [[122]], "entity_id": ["T9"], "Drug": {"text": [["sertraline"]], "start": [[147]], "entity_id": ["T11"]}, "Time_elapsed": {"text": [["long-term"]], "start": [[122]], "entity_id": ["T12"]}}}]}]}
{"id": "19789372_6", "context": "Of the 15 patients treated with tizanidine and mexiletine, 4 suffered tizanidine-induced adverse effects such as drowsiness and dry mouth in the retrospective survey.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[81]], "entity_id": ["T14"]}, "Treatment": {"text": [["tizanidine and mexiletine"]], "start": [[32]], "entity_id": ["T13"], "Drug": {"text": [["tizanidine"], ["mexiletine"], ["tizanidine"]], "start": [[32], [47], [70]], "entity_id": ["T17", "T18", "T21"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[43]], "entity_id": ["T19"]}, "Drug": {"text": [["tizanidine"], ["mexiletine"]], "start": [[32], [47]], "entity_id": ["T17", "T18"]}}]}, "Effect": {"text": [["drowsiness and dry mouth"]], "start": [[113]], "entity_id": ["T15"]}, "Subject": {"text": [["15 patients"], ["4"]], "start": [[7], [59]], "entity_id": ["T12", "T20"], "Population": {"text": [["15"]], "start": [[7]], "entity_id": ["T16"]}}}]}]}
{"id": "2006943_1", "context": "Type I second-degree AV block (Mobitz type I, Wenckebach AV block) during ritodrine therapy for preterm labor.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[67]], "entity_id": ["T8"]}, "Effect": {"text": [["Type I second-degree AV block (Mobitz type I, Wenckebach AV block)"]], "start": [[0]], "entity_id": ["T7"]}, "Treatment": {"text": [["ritodrine"]], "start": [[74]], "entity_id": ["T9"], "Disorder": {"text": [["preterm labor"]], "start": [[96]], "entity_id": ["T10"]}, "Drug": {"text": [["ritodrine"]], "start": [[74]], "entity_id": ["T11"]}}}]}]}
{"id": "20412003_1", "context": "After other potential causes of liver toxicity were excluded, TMP-SMX was determined to be the cause of his acute liver toxicity.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["determined"]], "start": [[74]], "entity_id": ["T6"]}, "Treatment": {"text": [["TMP-SMX"]], "start": [[62]], "entity_id": ["T5"], "Drug": {"text": [["TMP"], ["SMX"]], "start": [[62], [66]], "entity_id": ["T8", "T9"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["-"]], "start": [[65]], "entity_id": ["T10"]}, "Drug": {"text": [["TMP"], ["SMX"]], "start": [[62], [66]], "entity_id": ["T8", "T9"]}}]}, "Effect": {"text": [["acute liver toxicity"]], "start": [[108]], "entity_id": ["T7"]}}]}]}
{"id": "6149250_3", "context": "One of the patients had a dexamethasone dependent brain metastatic condition.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["had"]], "start": [[20]], "entity_id": ["T10"]}, "Subject": {"text": [["One of the patients"]], "start": [[0]], "entity_id": ["T4"], "Population": {"text": [["One"]], "start": [[0]], "entity_id": ["T8"]}}, "Treatment": {"text": [["dexamethasone"]], "start": [[26]], "entity_id": ["T6"], "Drug": {"text": [["dexamethasone"]], "start": [[26]], "entity_id": ["T9"]}, "Disorder": {"text": [["brain metastatic condition"]], "start": [[50]], "entity_id": ["T5"]}}, "Effect": {"text": [["brain metastatic condition"]], "start": [[50]], "entity_id": ["T7"]}}]}]}
{"id": "12365708_2", "context": "Biomicroscopy revealed amiodarone corneal deposits.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["revealed"]], "start": [[14]], "entity_id": ["T4"]}, "Treatment": {"text": [["Biomicroscopy"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Biomicroscopy"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["amiodarone corneal deposits"]], "start": [[23]], "entity_id": ["T5"]}}]}]}
{"id": "14601701_5", "context": "This case and a review of the literature show the severe and unpredictable nature of ethambutol toxicity and its potential for irreversible vision loss despite careful ophthalmologic monitoring.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["unpredictable"]], "start": [[61]], "entity_id": ["T10"]}, "Treatment": {"text": [["ethambutol"]], "start": [[85]], "entity_id": ["T11"], "Drug": {"text": [["ethambutol"]], "start": [[85]], "entity_id": ["T13"]}}, "Effect": {"text": [["irreversible vision loss"]], "start": [[127]], "entity_id": ["T9"]}, "Speculated": {"text": [["potential"]], "start": [[113]], "entity_id": ["T12"], "value": true}, "Severity": {"text": [["severe"]], "start": [[50]], "entity_id": ["T14"], "value": "High"}}]}]}
{"id": "15790469_4", "context": "Recently, some studies have also reported association between patients with juvenile rheumatoid arthritis (JRA) treated with Methotrexate (MTX) and malignant lymphoma developing.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["association"]], "start": [[42]], "entity_id": ["T9"]}, "Treatment": {"text": [["Methotrexate (MTX)"]], "start": [[125]], "entity_id": ["T10"], "Drug": {"text": [["Methotrexate"]], "start": [[125]], "entity_id": ["T16"]}, "Disorder": {"text": [["juvenile rheumatoid arthritis"]], "start": [[76]], "entity_id": ["T6"]}}, "Effect": {"text": [["malignant lymphoma"]], "start": [[148]], "entity_id": ["T11"]}, "Subject": {"text": [["patients with juvenile rheumatoid arthritis (JRA"]], "start": [[62]], "entity_id": ["T12"]}}]}]}
{"id": "10679548_6", "context": "The two middle aged women presented with respiratory symptoms after prolonged treatment with nitrofurantoin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["presented"]], "start": [[26]], "entity_id": ["T5"]}, "Subject": {"text": [["The two middle aged women"]], "start": [[0]], "entity_id": ["T3"], "Population": {"text": [["two"]], "start": [[4]], "entity_id": ["T7"]}, "Age": {"text": [["middle aged"]], "start": [[8]], "entity_id": ["T8"]}, "Gender": {"text": [["women"]], "start": [[20]], "entity_id": ["T9"]}}, "Effect": {"text": [["respiratory symptoms"]], "start": [[41]], "entity_id": ["T4"]}, "Treatment": {"text": [["prolonged treatment with nitrofurantoin"]], "start": [[68]], "entity_id": ["T6"], "Freq": {"text": [["prolonged treatment"]], "start": [[68]], "entity_id": ["T10"]}, "Drug": {"text": [["nitrofurantoin"]], "start": [[93]], "entity_id": ["T11"]}}}]}]}
{"id": "20378385_1", "context": "OBJECTIVE: 1) To describe a patient with rheumatoid arthritis receiving adalimumab who developed fever, pancytopenia, splenomegaly, and extreme hyperferritinemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[87]], "entity_id": ["T9"]}, "Effect": {"text": [["fever, pancytopenia, splenomegaly, and extreme hyperferritinemia"]], "start": [[97]], "entity_id": ["T10"]}, "Subject": {"text": [["a patient with rheumatoid arthritis"]], "start": [[26]], "entity_id": ["T11"], "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[41]], "entity_id": ["T13"]}}, "Treatment": {"text": [["adalimumab"]], "start": [[72]], "entity_id": ["T12"], "Drug": {"text": [["adalimumab"]], "start": [[72]], "entity_id": ["T14"]}}}]}]}
{"id": "12523465_2", "context": "Visual hallucinations associated with zonisamide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated with"]], "start": [[22]], "entity_id": ["T4"]}, "Effect": {"text": [["Visual hallucinations"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["zonisamide"]], "start": [[38]], "entity_id": ["T5"], "Drug": {"text": [["zonisamide"]], "start": [[38]], "entity_id": ["T6"]}}}]}]}
{"id": "8667442_1", "context": "Milk-alkali syndrome induced by 1,25(OH)2D in a patient with hypoparathyroidism.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[21]], "entity_id": ["T3"]}, "Effect": {"text": [["Milk-alkali syndrome"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["1,25(OH)2D"]], "start": [[32]], "entity_id": ["T5"], "Drug": {"text": [["1,25(OH)2D"]], "start": [[32]], "entity_id": ["T8"]}, "Disorder": {"text": [["hypoparathyroidism"]], "start": [[61]], "entity_id": ["T9"]}}, "Subject": {"text": [["a patient with hypoparathyroidism."]], "start": [[46]], "entity_id": ["T6"]}}]}]}
{"id": "10494874_1", "context": "We report the case of a female acromegalic patient in whom multiple hepatic adenomas appeared soon after danazol treatment for uterine fibromatosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["appeared"]], "start": [[85]], "entity_id": ["T6"]}, "Subject": {"text": [["a female acromegalic patient"]], "start": [[22]], "entity_id": ["T3"], "Disorder": {"text": [["acromegalic"]], "start": [[31]], "entity_id": ["T4"]}, "Gender": {"text": [["female"]], "start": [[24]], "entity_id": ["T8"]}}, "Effect": {"text": [["hepatic adenomas"]], "start": [[68]], "entity_id": ["T5"]}, "Treatment": {"text": [["danazol treatment"]], "start": [[105]], "entity_id": ["T7"], "Disorder": {"text": [["uterine fibromatosis."]], "start": [[127]], "entity_id": ["T10"]}, "Drug": {"text": [["danazol"]], "start": [[105]], "entity_id": ["T9"]}}}]}]}
{"id": "9347384_1", "context": "Carbamazepine toxicity induced by clarithromycin coadministration in psychiatric patients.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[23]], "entity_id": ["T6"]}, "Subject": {"text": [["psychiatric patients"]], "start": [[69]], "entity_id": ["T4"], "Disorder": {"text": [["psychiatric"]], "start": [[69]], "entity_id": ["T5"]}}, "Effect": {"text": [["Carbamazepine toxicity"]], "start": [[0]], "entity_id": ["T7"]}, "Treatment": {"text": [["clarithromycin"]], "start": [[34]], "entity_id": ["T8"], "Drug": {"text": [["clarithromycin"], ["Carbamazepine"]], "start": [[34], [0]], "entity_id": ["T9", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["coadministration"]], "start": [[49]], "entity_id": ["T10"]}, "Drug": {"text": [["clarithromycin"], ["Carbamazepine"]], "start": [[34], [0]], "entity_id": ["T9", "T11"]}}]}}]}]}
{"id": "2116935_2", "context": "Thrombolytic therapy with tissue plasminogen activator (tPA) for acute myocardial infarction may result in major bleeding complications such as gastrointestinal or intracranial bleeding.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["result"]], "start": [[97]], "entity_id": ["T12"]}, "Treatment": {"text": [["tissue plasminogen activator"]], "start": [[26]], "entity_id": ["T10"], "Disorder": {"text": [["acute myocardial infarction"]], "start": [[65]], "entity_id": ["T11"]}, "Drug": {"text": [["tissue plasminogen activator"]], "start": [[26]], "entity_id": ["T15"]}}, "Effect": {"text": [["gastrointestinal or intracranial bleeding"]], "start": [[144]], "entity_id": ["T14"]}, "Speculated": {"text": [["may"]], "start": [[93]], "entity_id": ["T13"], "value": true}}]}]}
{"id": "16968538_8", "context": "CONCLUSION: The hemolytic-uremic syndrome may be a rare complication of oxaliplatin-based chemotherapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[56]], "entity_id": ["T7"]}, "Effect": {"text": [["hemolytic-uremic syndrome"]], "start": [[16]], "entity_id": ["T6"]}, "Treatment": {"text": [["oxaliplatin-based chemotherapy"]], "start": [[72]], "entity_id": ["T8"], "Drug": {"text": [["oxaliplatin"]], "start": [[72]], "entity_id": ["T10"]}, "Route": {"text": [["chemotherapy"]], "start": [[90]], "entity_id": ["T11"]}}, "Speculated": {"text": [["may"]], "start": [[42]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "10897389_1", "context": "However, recurrent staphylococcus aureus sepsis developed during CyA therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[48]], "entity_id": ["T3"]}, "Treatment": {"text": [["CyA therapy"]], "start": [[65]], "entity_id": ["T4"], "Drug": {"text": [["CyA"]], "start": [[65]], "entity_id": ["T6"]}}, "Effect": {"text": [["staphylococcus aureus sepsis"]], "start": [[19]], "entity_id": ["T5"]}}]}]}
{"id": "8570441_1", "context": "Nabumetone-associated interstitial nephritis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[11]], "entity_id": ["T4"]}, "Treatment": {"text": [["Nabumetone"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Nabumetone"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["interstitial nephritis"]], "start": [[22]], "entity_id": ["T5"]}}]}]}
{"id": "18362995_1", "context": "A short review on imatinib-related hepatotoxicity is also presented.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[27]], "entity_id": ["T4"]}, "Treatment": {"text": [["imatinib"]], "start": [[18]], "entity_id": ["T3"], "Drug": {"text": [["imatinib"]], "start": [[18]], "entity_id": ["T6"]}}, "Effect": {"text": [["hepatotoxicity"]], "start": [[35]], "entity_id": ["T5"]}}]}]}
{"id": "17260498_1", "context": "Fatal interstitial pneumonitis associated with docetaxel administration in a patient with hormone-refractory prostate cancer.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[31]], "entity_id": ["T6"]}, "Effect": {"text": [["Fatal interstitial pneumonitis"]], "start": [[0]], "entity_id": ["T7"]}, "Treatment": {"text": [["docetaxel"]], "start": [[47]], "entity_id": ["T8"], "Drug": {"text": [["docetaxel"]], "start": [[47]], "entity_id": ["T12"]}, "Disorder": {"text": [["hormone-refractory prostate cancer"]], "start": [[90]], "entity_id": ["T13"]}}, "Subject": {"text": [["a patient with hormone-refractory prostate cancer"]], "start": [[75]], "entity_id": ["T9"]}, "Severity": {"text": [["Fatal"]], "start": [[0]], "entity_id": ["T11"], "value": "High"}}]}]}
{"id": "17364199_2", "context": "BACKGROUND: Etanercept is a tumor necrosis factor (TNF) inhibitor that has been licensed in the United States for the treatment of adult and juvenile rheumatoid arthritis as well as psoriatic arthritis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["licensed"]], "start": [[80]], "entity_id": ["T10"]}, "Treatment": {"text": [["Etanercept", "a tumor necrosis factor (TNF) inhibitor"]], "start": [[12, 26]], "entity_id": ["T8"], "Drug": {"text": [["Etanercept"]], "start": [[12]], "entity_id": ["T15"]}, "Disorder": {"text": [["adult and juvenile rheumatoid arthritis"], ["psoriatic arthritis"]], "start": [[131], [182]], "entity_id": ["T16", "T17"]}}, "Subject": {"text": [["adult and juvenile rheumatoid arthritis as well as psoriatic arthritis"]], "start": [[131]], "entity_id": ["T9"], "Age": {"text": [["adult"], ["juvenile"]], "start": [[131], [141]], "entity_id": ["T11", "T12"]}}}]}]}
{"id": "3379435_2", "context": "Reye-like syndrome following treatment with the pantothenic acid antagonist, calcium hopantenate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[19]], "entity_id": ["T4"]}, "Effect": {"text": [["Reye-like syndrome"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["calcium hopantenate"]], "start": [[77]], "entity_id": ["T5"], "Drug": {"text": [["calcium hopantenate"]], "start": [[77]], "entity_id": ["T6"]}}}]}]}
{"id": "834512_1", "context": "Sudden death in an infant from methemoglobinemia after administration of \"sweet spirits of nitre\".", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[49]], "entity_id": ["T6"]}, "Effect": {"text": [["Sudden death", "methemoglobinemia"]], "start": [[0, 31]], "entity_id": ["T3"]}, "Subject": {"text": [["an infant"]], "start": [[16]], "entity_id": ["T4"], "Age": {"text": [["infant"]], "start": [[19]], "entity_id": ["T7"]}}, "Treatment": {"text": [["sweet spirits of nitre"]], "start": [[74]], "entity_id": ["T5"], "Drug": {"text": [["sweet spirits of nitre"]], "start": [[74]], "entity_id": ["T8"]}}}]}]}
{"id": "8691927_2", "context": "FINDINGS: Six children with growth retardation noted after treatment with high-dose fluticasone propionate were found to have adrenal suppression.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["have"]], "start": [[121]], "entity_id": ["T8"]}, "Subject": {"text": [["Six children with growth retardation"]], "start": [[10]], "entity_id": ["T5"], "Population": {"text": [["Six"]], "start": [[10]], "entity_id": ["T10"]}, "Age": {"text": [["children"]], "start": [[14]], "entity_id": ["T11"]}}, "Treatment": {"text": [["high-dose fluticasone propionate"]], "start": [[74]], "entity_id": ["T7"], "Dosage": {"text": [["high-dose"]], "start": [[74]], "entity_id": ["T12"]}, "Drug": {"text": [["fluticasone propionate"]], "start": [[84]], "entity_id": ["T13"]}, "Disorder": {"text": [["growth retardation"]], "start": [[28]], "entity_id": ["T14"]}}, "Effect": {"text": [["adrenal suppression"]], "start": [[126]], "entity_id": ["T9"]}}]}]}
{"id": "16326413_3", "context": "Methotrexate-associated nephropathy is a rare complication in pediatric oncology, and a review of the literature suggests that exposure to nephrotoxic agents may be a significant but perhaps underrecognized risk factor for its development.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[13]], "entity_id": ["T4"]}, "Treatment": {"text": [["Methotrexate"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Methotrexate"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["nephropathy"]], "start": [[24]], "entity_id": ["T5"]}, "Speculated": {"text": [["may"], ["rare"]], "start": [[158], [41]], "entity_id": ["T7", "T8"], "value": true}}]}]}
{"id": "7428724_1", "context": "Four cases of oesophageal damage associated with ingestion of the urinary anti-spasmodic agent emepronium bromide are described.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[33]], "entity_id": ["T5"]}, "Subject": {"text": [["Four cases"]], "start": [[0]], "entity_id": ["T3"], "Population": {"text": [["Four"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["oesophageal damage"]], "start": [[14]], "entity_id": ["T4"]}, "Treatment": {"text": [["ingestion of the urinary anti-spasmodic agent emepronium bromide"]], "start": [[49]], "entity_id": ["T6"], "Route": {"text": [["ingestion"]], "start": [[49]], "entity_id": ["T8"]}, "Drug": {"text": [["emepronium bromide"]], "start": [[95]], "entity_id": ["T9"]}}}]}]}
{"id": "10555917_1", "context": "A 66-year-old Japanese woman with severe scleroderma developed anemia and thrombocytopenia due to D-penicillamine (D-Pen) treatment, although the leukopenia was not markedly severe.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[53]], "entity_id": ["T8"]}, "Subject": {"text": [["A 66-year-old Japanese woman with severe scleroderma"]], "start": [[0]], "entity_id": ["T7"], "Age": {"text": [["66-year-old"]], "start": [[2]], "entity_id": ["T11"]}, "Race": {"text": [["Japanese"]], "start": [[14]], "entity_id": ["T12"]}, "Gender": {"text": [["woman"]], "start": [[23]], "entity_id": ["T13"]}}, "Effect": {"text": [["anemia and thrombocytopenia"]], "start": [[63]], "entity_id": ["T9"]}, "Treatment": {"text": [["D-penicillamine (D-Pen) treatment"]], "start": [[98]], "entity_id": ["T10"], "Disorder": {"text": [["severe scleroderma"]], "start": [[34]], "entity_id": ["T14"]}, "Drug": {"text": [["D-penicillamine"]], "start": [[98]], "entity_id": ["T15"]}}}]}]}
{"id": "20456080_4", "context": "Corticosteroid injections are commonly used as effective treatments for a variety of pain disorders.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatments"]], "start": [[57]], "entity_id": ["T5"]}, "Treatment": {"text": [["Corticosteroid injections"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Corticosteroid"]], "start": [[0]], "entity_id": ["T7"]}, "Route": {"text": [["injections"]], "start": [[15]], "entity_id": ["T8"]}, "Disorder": {"text": [["pain disorders"]], "start": [[85]], "entity_id": ["T9"]}}}]}]}
{"id": "15549981_1", "context": "We present two cases of anaphylaxis under anaesthesia where return of spontaneous circulation was refractory to epinephrine, but occurred following the administration of the alpha-agonist metaraminol.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["occurred"]], "start": [[129]], "entity_id": ["T9"]}, "Treatment": {"text": [["epinephrine", "administration of the alpha-agonist metaraminol"]], "start": [[112, 152]], "entity_id": ["T4"], "Disorder": {"text": [["anaphylaxis under anaesthesia"]], "start": [[24]], "entity_id": ["T3"]}, "Drug": {"text": [["metaraminol"], ["epinephrine"]], "start": [[188], [112]], "entity_id": ["T6", "T7"]}, "Combination": [{"event_id": "E1", "event_type": "Combination", "Trigger": {"text": [["administration"]], "start": [[152]], "entity_id": ["T5"]}, "Drug": {"text": [["epinephrine"], ["metaraminol"]], "start": [[112], [188]], "entity_id": ["T7", "T6"]}}]}, "Effect": {"text": [["return of spontaneous circulation"]], "start": [[60]], "entity_id": ["T8"]}}]}]}
{"id": "3310776_1", "context": "A 51-yr-old nonsmoking male patient without any history of previous allergies, asthma, hay fever, or urticaria developed attacks of asthma when captopril was added to the nadolol and dyazide treatment for his high blood pressure.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[111]], "entity_id": ["T6"]}, "Subject": {"text": [["A 51-yr-old nonsmoking male patient without any history of previous allergies, asthma, hay fever, or urticaria"]], "start": [[0]], "entity_id": ["T5"], "Age": {"text": [["51-yr-old"]], "start": [[2]], "entity_id": ["T10"]}, "Gender": {"text": [["male"]], "start": [[23]], "entity_id": ["T11"]}}, "Effect": {"text": [["attacks of asthma"]], "start": [[121]], "entity_id": ["T7"]}, "Treatment": {"text": [["captopril was added to the nadolol and dyazide"]], "start": [[144]], "entity_id": ["T8"], "Disorder": {"text": [["high blood pressure"]], "start": [[209]], "entity_id": ["T9"]}, "Drug": {"text": [["captopril"], ["nadolol"], ["dyazide"]], "start": [[144], [171], [183]], "entity_id": ["T13", "T14", "T15"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["added"]], "start": [[158]], "entity_id": ["T12"]}, "Drug": {"text": [["captopril"], ["nadolol"], ["dyazide"]], "start": [[144], [171], [183]], "entity_id": ["T13", "T14", "T15"]}}]}}]}]}
{"id": "9876809_5", "context": "After ticlopidine was discontinued, the patient was rechallenged with the same dose of phenytoin without symptoms of toxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["toxicity"]], "start": [[117]], "entity_id": ["T8"]}, "Effect": {"text": [["toxicity"]], "start": [[117]], "entity_id": ["T7"]}, "Treatment": {"text": [["After ticlopidine was discontinued", "rechallenged with the same dose of phenytoin"]], "start": [[0, 52]], "entity_id": ["T9"], "Drug": {"text": [["ticlopidine"], ["phenytoin"]], "start": [[6], [87]], "entity_id": ["T6", "T11"]}}, "Negated": {"text": [["without"]], "start": [[97]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "19151423_1", "context": "Rhabdomyolysis due to an uncommon interaction of ciprofloxacin with simvastatin.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[15]], "entity_id": ["T7"]}, "Effect": {"text": [["Rhabdomyolysis"]], "start": [[0]], "entity_id": ["T6"]}, "Treatment": {"text": [["interaction of ciprofloxacin with simvastatin"]], "start": [[34]], "entity_id": ["T8"], "Drug": {"text": [["ciprofloxacin"], ["simvastatin"]], "start": [[49], [68]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[34]], "entity_id": ["T12"]}, "Drug": {"text": [["ciprofloxacin"], ["simvastatin"]], "start": [[49], [68]], "entity_id": ["T10", "T11"]}}]}}]}]}
{"id": "8672829_1", "context": "After receiving 3 doses of ifosfamide/mesna, she was found to be unresponsive.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["found"]], "start": [[53]], "entity_id": ["T5"]}, "Treatment": {"text": [["ifosfamide/mesna"]], "start": [[27]], "entity_id": ["T4"], "Drug": {"text": [["ifosfamide"], ["mesna"]], "start": [[27], [38]], "entity_id": ["T7", "T8"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["/"]], "start": [[37]], "entity_id": ["T11"]}, "Drug": {"text": [["ifosfamide"], ["mesna"]], "start": [[27], [38]], "entity_id": ["T7", "T8"]}}]}, "Effect": {"text": [["unresponsive"]], "start": [[65]], "entity_id": ["T6"]}, "Subject": {"text": [["she"]], "start": [[45]], "entity_id": ["T9"], "Gender": {"text": [["she"]], "start": [[45]], "entity_id": ["T10"]}}}]}]}
{"id": "2316232_2", "context": "Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["secondary to"]], "start": [[25]], "entity_id": ["T6"]}, "Effect": {"text": [["Symptomatic hypoglycemia"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["glipizide-trimethoprim/sulfamethoxazole drug interaction"]], "start": [[40]], "entity_id": ["T7"], "Drug": {"text": [["glipizide"], ["trimethoprim"], ["sulfamethoxazole"]], "start": [[40], [50], [63]], "entity_id": ["T8", "T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[85]], "entity_id": ["T11"]}, "Drug": {"text": [["glipizide"], ["trimethoprim"], ["sulfamethoxazole"]], "start": [[40], [50], [63]], "entity_id": ["T8", "T9", "T10"]}}]}}]}]}
{"id": "18421192_1", "context": "A 51-year-old man developed type 1 diabetes mellitus following 24 weeks of treatment with recombinant alpha-2b peginterferon plus ribavirin for chronic hepatitis C.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[18]], "entity_id": ["T5"]}, "Subject": {"text": [["A 51-year-old man"]], "start": [[0]], "entity_id": ["T4"], "Age": {"text": [["51-year-old"]], "start": [[2]], "entity_id": ["T9"]}, "Gender": {"text": [["man"]], "start": [[14]], "entity_id": ["T10"]}}, "Effect": {"text": [["type 1 diabetes mellitus"]], "start": [[28]], "entity_id": ["T6"]}, "Treatment": {"text": [["24 weeks of treatment with recombinant alpha-2b peginterferon plus ribavirin"]], "start": [[63]], "entity_id": ["T7"], "Time_elapsed": {"text": [["24 weeks"]], "start": [[63]], "entity_id": ["T8"]}, "Drug": {"text": [["recombinant alpha-2b peginterferon"], ["ribavirin"]], "start": [[90], [130]], "entity_id": ["T11", "T12"]}, "Disorder": {"text": [["chronic hepatitis C"]], "start": [[144]], "entity_id": ["T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["plus"]], "start": [[125]], "entity_id": ["T13"]}, "Drug": {"text": [["recombinant alpha-2b peginterferon"], ["ribavirin"]], "start": [[90], [130]], "entity_id": ["T11", "T12"]}}]}}]}]}
{"id": "8832451_1", "context": "A noninvasive method in the differential diagnosis of vecuronium-induced and magnesium-induced protracted neuromuscular block in a severely preeclamptic patient.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[65]], "entity_id": ["T4"]}, "Treatment": {"text": [["vecuronium"]], "start": [[54]], "entity_id": ["T1"], "Drug": {"text": [["vecuronium"]], "start": [[54]], "entity_id": ["T10"]}}, "Effect": {"text": [["protracted neuromuscular block"]], "start": [[95]], "entity_id": ["T6"]}, "Subject": {"text": [["severely preeclamptic patient"]], "start": [[131]], "entity_id": ["T7"], "Disorder": {"text": [["severely preeclamptic"]], "start": [[131]], "entity_id": ["T8"]}}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[87]], "entity_id": ["T3"]}, "Effect": {"text": [["protracted neuromuscular block"]], "start": [[95]], "entity_id": ["T6"]}, "Subject": {"text": [["severely preeclamptic patient"]], "start": [[131]], "entity_id": ["T7"], "Disorder": {"text": [["severely preeclamptic"]], "start": [[131]], "entity_id": ["T8"]}}, "Treatment": {"text": [["magnesium"]], "start": [[77]], "entity_id": ["T2"], "Drug": {"text": [["magnesium"]], "start": [[77]], "entity_id": ["T11"]}}}]}]}
{"id": "3725284_1", "context": "Paroxysmal supraventricular tachycardia during treatment with cisplatin and etoposide combination.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[40]], "entity_id": ["T4"]}, "Effect": {"text": [["Paroxysmal supraventricular tachycardia"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["cisplatin and etoposide combination"]], "start": [[62]], "entity_id": ["T6"], "Drug": {"text": [["cisplatin"], ["etoposide"]], "start": [[62], [76]], "entity_id": ["T7", "T8"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combination"]], "start": [[86]], "entity_id": ["T9"]}, "Drug": {"text": [["etoposide"], ["cisplatin"]], "start": [[76], [62]], "entity_id": ["T8", "T7"]}}]}}]}]}
{"id": "424824_1", "context": "Conversely, diffuse interstitial pulmonary fibrosis should be considered in the differential diagnosis of patients receiving methotrexate who develop bilateral pulmonary infiltrates seen on chest roentgenograms.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["develop"]], "start": [[142]], "entity_id": ["T7"]}, "Treatment": {"text": [["methotrexate"]], "start": [[125]], "entity_id": ["T6"], "Drug": {"text": [["methotrexate"]], "start": [[125]], "entity_id": ["T10"]}}, "Effect": {"text": [["diffuse interstitial pulmonary fibrosis", "bilateral pulmonary infiltrates"]], "start": [[12, 150]], "entity_id": ["T5"]}, "Subject": {"text": [["patients"]], "start": [[106]], "entity_id": ["T8"]}, "Speculated": {"text": [["should be considered"]], "start": [[52]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "2316232_1", "context": "An 83-year-old man receiving glipizide 10 mg bid developed symptomatic hypoglycemia within three days of adding trimethoprim/sulfamethoxazole (TMP/SMX) to his regimen.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[49]], "entity_id": ["T9"]}, "Effect": {"text": [["symptomatic hypoglycemia"]], "start": [[59]], "entity_id": ["T10"]}, "Treatment": {"text": [["receiving glipizide 10 mg", "three days of adding trimethoprim/sulfamethoxazole (TMP/SMX)"]], "start": [[19, 91]], "entity_id": ["T11"], "Time_elapsed": {"text": [["three days"]], "start": [[91]], "entity_id": ["T13"]}, "Drug": {"text": [["trimethoprim"], ["sulfamethoxazole"], ["glipizide"]], "start": [[112], [125], [29]], "entity_id": ["T14", "T15", "T16"]}, "Dosage": {"text": [["10 mg"]], "start": [[39]], "entity_id": ["T17"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["receiving"]], "start": [[19]], "entity_id": ["T18"]}, "Drug": {"text": [["glipizide"], ["trimethoprim"], ["sulfamethoxazole"]], "start": [[29], [112], [125]], "entity_id": ["T16", "T14", "T15"]}}]}, "Subject": {"text": [["An 83-year-old man"]], "start": [[0]], "entity_id": ["T8"], "Age": {"text": [["83-year-old"]], "start": [[3]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[15]], "entity_id": ["T12"]}}}]}]}
{"id": "16268429_1", "context": "In this case senna was likely the cause of a subacute cholestatic hepatitis exemplifying again the potential role of herbal related liver injury.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[34]], "entity_id": ["T6"]}, "Treatment": {"text": [["senna"]], "start": [[13]], "entity_id": ["T5"], "Drug": {"text": [["senna"]], "start": [[13]], "entity_id": ["T8"]}}, "Effect": {"text": [["a subacute cholestatic hepatitis", "herbal related liver injury"]], "start": [[43, 117]], "entity_id": ["T7"]}, "Speculated": {"text": [["likely"]], "start": [[23]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "12598508_4", "context": "Early peritoneal dialysis has not previously been reported for lisinopril induced multiorgan failure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[74]], "entity_id": ["T5"]}, "Treatment": {"text": [["lisinopril"]], "start": [[63]], "entity_id": ["T4"], "Drug": {"text": [["lisinopril"]], "start": [[63]], "entity_id": ["T7"]}}, "Effect": {"text": [["multiorgan failure"]], "start": [[82]], "entity_id": ["T6"]}}]}]}
{"id": "12862258_3", "context": "Various case reports concerning dapsone-induced agranulocytosis are reviewed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[40]], "entity_id": ["T5"]}, "Treatment": {"text": [["dapsone"]], "start": [[32]], "entity_id": ["T3"], "Drug": {"text": [["dapsone"]], "start": [[32]], "entity_id": ["T6"]}}, "Effect": {"text": [["agranulocytosis"]], "start": [[48]], "entity_id": ["T4"]}}]}]}
{"id": "18717612_3", "context": "We report the first case of a 54-year-old Turkish woman who presented with ceftriaxone-induced FDE.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[87]], "entity_id": ["T5"]}, "Subject": {"text": [["a 54-year-old Turkish woman"]], "start": [[28]], "entity_id": ["T3"], "Age": {"text": [["54-year-old"]], "start": [[30]], "entity_id": ["T7"]}, "Race": {"text": [["Turkish"]], "start": [[42]], "entity_id": ["T8"]}, "Gender": {"text": [["woman"]], "start": [[50]], "entity_id": ["T9"]}}, "Treatment": {"text": [["ceftriaxone"]], "start": [[75]], "entity_id": ["T4"], "Drug": {"text": [["ceftriaxone"]], "start": [[75]], "entity_id": ["T10"]}}, "Effect": {"text": [["FDE"]], "start": [[95]], "entity_id": ["T6"]}}]}]}
{"id": "10487084_1", "context": "In all cases, seizures were controlled by withdrawal of phenytoin and reduction of drug levels.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["controlled"]], "start": [[28]], "entity_id": ["T3"]}, "Treatment": {"text": [["withdrawal of phenytoin and reduction of drug levels"]], "start": [[42]], "entity_id": ["T4"], "Drug": {"text": [["phenytoin"]], "start": [[56]], "entity_id": ["T6"]}}, "Effect": {"text": [["seizures"]], "start": [[14]], "entity_id": ["T5"]}}]}]}
{"id": "15379082_3", "context": "This case describes fulminant hepatic failure in a patient taking disulfiram with no previous liver disease and report of being compliant with alcohol abstinence.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[46]], "entity_id": ["T6"]}, "Effect": {"text": [["fulminant hepatic failure"]], "start": [[20]], "entity_id": ["T3"]}, "Subject": {"text": [["a patient"]], "start": [[49]], "entity_id": ["T4"]}, "Treatment": {"text": [["disulfiram"]], "start": [[66]], "entity_id": ["T5"], "Drug": {"text": [["disulfiram"]], "start": [[66]], "entity_id": ["T7"]}}}]}]}
{"id": "15373932_2", "context": "Fungal infection is a significant comorbidity in patients with diabetes mellitus, and ketoconazole, an antifungal agent, causes a number of drug interactions with coadministered drugs.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["causes"]], "start": [[121]], "entity_id": ["T10"]}, "Subject": {"text": [["patients with diabetes mellitus"]], "start": [[49]], "entity_id": ["T6"], "Disorder": {"text": [["diabetes mellitus"]], "start": [[63]], "entity_id": ["T7"]}}, "Treatment": {"text": [["ketoconazole"]], "start": [[86]], "entity_id": ["T8"], "Drug": {"text": [["ketoconazole"]], "start": [[86]], "entity_id": ["T11"]}, "Disorder": {"text": [["Fungal infection"]], "start": [[0]], "entity_id": ["T15"]}}, "Effect": {"text": [["a number of drug interactions with coadministered drugs"]], "start": [[128]], "entity_id": ["T9"]}}]}]}
{"id": "15289139_1", "context": "Dorzolamide-induced choroidal detachment in a surgically untreated eye.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[12]], "entity_id": ["T4"]}, "Treatment": {"text": [["Dorzolamide"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Dorzolamide"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["choroidal detachment"]], "start": [[20]], "entity_id": ["T5"]}, "Subject": {"text": [["a surgically untreated eye"]], "start": [[44]], "entity_id": ["T8"]}}]}]}
{"id": "8438851_2", "context": "Idiosyncratic factors involving vasopressin receptor affinity and distribution, vasopressin-associated vasodilation in some vascular beds, and the effect of vasopressin on the renin-angiotensin system may further contribute to impaired tissue perfusion.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["contribute"]], "start": [[213]], "entity_id": ["T7"]}, "Treatment": {"text": [["vasopressin"]], "start": [[32]], "entity_id": ["T5"], "Drug": {"text": [["vasopressin"]], "start": [[32]], "entity_id": ["T8"]}}, "Effect": {"text": [["impaired tissue perfusion"]], "start": [[227]], "entity_id": ["T6"]}}]}]}
{"id": "16765687_2", "context": "Rapid resolution of topiramate-induced angle-closure glaucoma with methylprednisolone and mannitol.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["resolution"]], "start": [[6]], "entity_id": ["T6"]}, "Treatment": {"text": [["methylprednisolone and mannitol"]], "start": [[67]], "entity_id": ["T5"], "Disorder": {"text": [["topiramate-induced angle-closure glaucoma"]], "start": [[20]], "entity_id": ["T7"]}, "Drug": {"text": [["methylprednisolone"], ["mannitol"]], "start": [[67], [90]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[86]], "entity_id": ["T8"]}, "Drug": {"text": [["methylprednisolone"], ["mannitol"]], "start": [[67], [90]], "entity_id": ["T9", "T10"]}}]}}, {"event_id": "E3", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[31]], "entity_id": ["T11"]}, "Treatment": {"text": [["topiramate"]], "start": [[20]], "entity_id": ["T12"], "Drug": {"text": [["topiramate"]], "start": [[20]], "entity_id": ["T13"]}}, "Effect": {"text": [["angle-closure glaucoma"]], "start": [[39]], "entity_id": ["T14"]}}]}]}
{"id": "7098384_1", "context": "A 66-year-old mand suffering from severe coronary heart disease took digoxin with suicidal intent an was treated for the ensuing complete atrioventricular block with digoxin-specific antibody fragments.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["took"]], "start": [[64]], "entity_id": ["T6"]}, "Subject": {"text": [["A 66-year-old mand suffering from severe coronary heart disease"]], "start": [[0]], "entity_id": ["T3"], "Age": {"text": [["66-year-old"]], "start": [[2]], "entity_id": ["T7"]}, "Gender": {"text": [["mand"]], "start": [[14]], "entity_id": ["T8"]}, "Disorder": {"text": [["coronary heart diseas"]], "start": [[41]], "entity_id": ["T9"]}}, "Treatment": {"text": [["digoxin"]], "start": [[69]], "entity_id": ["T4"], "Drug": {"text": [["digoxin"]], "start": [[69]], "entity_id": ["T10"]}}, "Effect": {"text": [["complete atrioventricular block"]], "start": [[129]], "entity_id": ["T5"]}}]}]}
{"id": "16116136_1", "context": "A patient with generalized MG was effectively managed with MM but developed CNS lymphoma after 3 years of treatment.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["managed"]], "start": [[46]], "entity_id": ["T6"]}, "Treatment": {"text": [["MM"]], "start": [[59]], "entity_id": ["T5"], "Disorder": {"text": [["generalized MG"]], "start": [[15]], "entity_id": ["T12"]}, "Drug": {"text": [["MM"]], "start": [[59]], "entity_id": ["T7"]}}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[66]], "entity_id": ["T9"]}, "Subject": {"text": [["A patient with generalized MG"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["MM"]], "start": [[59]], "entity_id": ["T13"], "Duration": {"text": [["3 years"]], "start": [[95]], "entity_id": ["T11"]}}, "Effect": {"text": [["CNS lymphoma"]], "start": [[76]], "entity_id": ["T10"]}}]}]}
{"id": "12114387_1", "context": "Epoprostenol may be associated rarely with severe erythroderma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[20]], "entity_id": ["T7"]}, "Treatment": {"text": [["Epoprostenol"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Epoprostenol"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["severe erythroderma."]], "start": [[43]], "entity_id": ["T6"]}, "Speculated": {"text": [["may"]], "start": [[13]], "entity_id": ["T4"], "value": true}, "Severity": {"text": [["severe"]], "start": [[43]], "entity_id": ["T9"], "value": "High"}}]}]}
{"id": "15533031_2", "context": "We report the case of a patient with increased cerebral cortical excitability following intoxication with flupirtine, a centrally acting analgesic and antispastic drug.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[78]], "entity_id": ["T5"]}, "Subject": {"text": [["a patient"]], "start": [[22]], "entity_id": ["T3"]}, "Effect": {"text": [["increased cerebral cortical excitability"]], "start": [[37]], "entity_id": ["T4"]}, "Treatment": {"text": [["flupirtine"]], "start": [[106]], "entity_id": ["T6"], "Drug": {"text": [["flupirtine"]], "start": [[106]], "entity_id": ["T7"]}}}]}]}
{"id": "6702890_3", "context": "This case represents the third example of erythroid aplasia associated with an anti-inflammatory agent and the first instance due to fenoprofen.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[60]], "entity_id": ["T4"]}, "Treatment": {"text": [["fenoprofen"]], "start": [[133]], "entity_id": ["T3"], "Drug": {"text": [["fenoprofen"]], "start": [[133]], "entity_id": ["T6"]}}, "Effect": {"text": [["erythroid aplasia"]], "start": [[42]], "entity_id": ["T5"]}}]}]}
{"id": "11568758_1", "context": "Lichenoid drug eruption to salsalate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["eruption"]], "start": [[15]], "entity_id": ["T4"]}, "Effect": {"text": [["Lichenoid drug eruption"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["salsalate"]], "start": [[27]], "entity_id": ["T5"], "Drug": {"text": [["salsalate"]], "start": [[27]], "entity_id": ["T6"]}}}]}]}
{"id": "9211543_2", "context": "Two pediatric oncology patients with Ewing's sarcoma and one with mixed germ cell tumor were treated with drug regimens that included bleomycin or cyclophosphamide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated with"]], "start": [[93]], "entity_id": ["T9"]}, "Treatment": {"text": [["drug regimens that included bleomycin or cyclophosphamide"]], "start": [[106]], "entity_id": ["T7"], "Drug": {"text": [["bleomycin"], ["cyclophosphamide"]], "start": [[134], [147]], "entity_id": ["T12", "T13"]}, "Disorder": {"text": [["Ewing's sarcoma"], ["mixed germ cell tumor"]], "start": [[37], [66]], "entity_id": ["T2", "T4"]}}, "Subject": {"text": [["Two pediatric oncology patients with Ewing's sarcoma and one with mixed germ cell tumor"]], "start": [[0]], "entity_id": ["T8"], "Population": {"text": [["Two"], ["one"]], "start": [[0], [57]], "entity_id": ["T10", "T3"]}, "Age": {"text": [["pediatric"]], "start": [[4]], "entity_id": ["T1"]}}}]}]}
{"id": "8375752_1", "context": "Although retinoic acid is well tolerated by the majority of patients with this disease, a potentially fatal complication of this kind of treatment has been reported: \"the retinoic acid syndrome\".", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[108]], "entity_id": ["T8"]}, "Treatment": {"text": [["retinoic acid"]], "start": [[9]], "entity_id": ["T5"], "Drug": {"text": [["retinoic acid"]], "start": [[9]], "entity_id": ["T10"]}}, "Effect": {"text": [["fatal complication"]], "start": [[102]], "entity_id": ["T7"]}, "Speculated": {"text": [["potentially"]], "start": [[90]], "entity_id": ["T6"], "value": true}, "Severity": {"text": [["fatal"]], "start": [[102]], "entity_id": ["T9"], "value": "Medium"}}]}]}
{"id": "2011096_2", "context": "Three of 38 children given high-dose cytosine arabinoside therapy developed a previously undescribed complication.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[66]], "entity_id": ["T7"]}, "Subject": {"text": [["38 children"]], "start": [[9]], "entity_id": ["T5"], "Population": {"text": [["38"]], "start": [[9]], "entity_id": ["T9"]}, "Age": {"text": [["children"]], "start": [[12]], "entity_id": ["T10"]}}, "Treatment": {"text": [["high-dose cytosine arabinoside"]], "start": [[27]], "entity_id": ["T6"], "Dosage": {"text": [["high-dose"]], "start": [[27]], "entity_id": ["T11"]}, "Drug": {"text": [["cytosine arabinoside"]], "start": [[37]], "entity_id": ["T12"]}}, "Effect": {"text": [["complication"]], "start": [[101]], "entity_id": ["T8"]}}]}]}
{"id": "20178709_1", "context": "A case of aseptic pleuropericarditis in a patient with chronic plaque psoriasis under methotrexate therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[37]], "entity_id": ["T5"]}, "Subject": {"text": [["a patient with chronic plaque psoriasis"]], "start": [[40]], "entity_id": ["T3"]}, "Treatment": {"text": [["methotrexate therapy"]], "start": [[86]], "entity_id": ["T4"], "Drug": {"text": [["methotrexate"]], "start": [[86]], "entity_id": ["T8"]}, "Disorder": {"text": [["chronic plaque psoriasis"]], "start": [[55]], "entity_id": ["T9"]}}, "Effect": {"text": [["aseptic pleuropericarditis"]], "start": [[10]], "entity_id": ["T6"]}}]}]}
{"id": "16207263_1", "context": "Linezolid-induced dyserythropoiesis: chloramphenicol toxicity revisited.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[10]], "entity_id": ["T4"]}, "Treatment": {"text": [["Linezolid"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Linezolid"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["dyserythropoiesis"]], "start": [[18]], "entity_id": ["T5"]}}]}]}
{"id": "11328247_1", "context": "CONCLUSION: The present findings suggest that fluvoxamine can cause increased libido in some patients.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[62]], "entity_id": ["T6"]}, "Effect": {"text": [["increased libido"]], "start": [[68]], "entity_id": ["T3"]}, "Subject": {"text": [["some patients"]], "start": [[88]], "entity_id": ["T4"]}, "Treatment": {"text": [["fluvoxamine"]], "start": [[46]], "entity_id": ["T5"], "Drug": {"text": [["fluvoxamine"]], "start": [[46]], "entity_id": ["T9"]}}}]}]}
{"id": "2144305_1", "context": "A unique case of a transient, nonpigmenting fixed drug eruption caused by the radiopaque contrast medium iothalamate is reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[64]], "entity_id": ["T5"]}, "Treatment": {"text": [["iothalamate"]], "start": [[105]], "entity_id": ["T3"], "Drug": {"text": [["iothalamate"]], "start": [[105]], "entity_id": ["T6"]}}, "Effect": {"text": [["a transient, nonpigmenting fixed drug eruption"]], "start": [[17]], "entity_id": ["T4"]}}]}]}
{"id": "15785053_1", "context": "Mucosal pigmentation after oral lichen planus treatment with topical tacrolimus.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treatment"]], "start": [[46]], "entity_id": ["T3"]}, "Effect": {"text": [["Mucosal pigmentation"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["topical tacrolimus"]], "start": [[61]], "entity_id": ["T5"], "Disorder": {"text": [["oral lichen planus"]], "start": [[27]], "entity_id": ["T6"]}, "Drug": {"text": [["tacrolimus"]], "start": [[69]], "entity_id": ["T7"]}, "Route": {"text": [["topical"]], "start": [[61]], "entity_id": ["T8"]}}}]}]}
{"id": "10473079_2", "context": "We now report the first known cancer patient who developed life-threatening complications after treatment with topical 5-FU and was shown subsequently to have profound DPD deficiency.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[49]], "entity_id": ["T10"]}, "Subject": {"text": [["cancer patient"]], "start": [[30]], "entity_id": ["T3"]}, "Effect": {"text": [["life-threatening complications", "have profound DPD deficiency"]], "start": [[59, 154]], "entity_id": ["T4"]}, "Treatment": {"text": [["topical 5-FU"]], "start": [[111]], "entity_id": ["T5"], "Disorder": {"text": [["cancer"]], "start": [[30]], "entity_id": ["T6"]}, "Drug": {"text": [["5-FU"]], "start": [[119]], "entity_id": ["T8"]}, "Route": {"text": [["topical"]], "start": [[111]], "entity_id": ["T12"]}}, "Severity": {"text": [["life-threatening"]], "start": [[59]], "entity_id": ["T9"], "value": "High"}}]}]}
{"id": "110153_2", "context": "When the acute manic state is characterized by marked psychotic symptoms and intense anxiety, it may be associated with increased vulnerability to the development of severe lithium neurotoxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated with"]], "start": [[104]], "entity_id": ["T8"]}, "Treatment": {"text": [["lithium"]], "start": [[173]], "entity_id": ["T7"], "Drug": {"text": [["lithium"]], "start": [[173]], "entity_id": ["T10"]}}, "Effect": {"text": [["acute manic state is characterized by marked psychotic symptoms and intense anxiety"]], "start": [[9]], "entity_id": ["T9"]}, "Speculated": {"text": [["may"]], "start": [[97]], "entity_id": ["T11"], "value": true}}]}]}
{"id": "7781845_11", "context": "Clinicians who manage cachectic patients, particularly those with protracted diarrhoea and/or receiving anti-malarial drugs including mefloquine, should be aware of the risk of severe hypoglycaemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["risk"]], "start": [[169]], "entity_id": ["T13"]}, "Subject": {"text": [["cachectic patients", "with protracted diarrhoea"]], "start": [[22, 61]], "entity_id": ["T10"]}, "Treatment": {"text": [["anti-malarial drugs including mefloquine"]], "start": [[104]], "entity_id": ["T12"], "Drug": {"text": [["mefloquine"]], "start": [[134]], "entity_id": ["T18"]}, "Disorder": {"text": [["cachectic"], ["protracted diarrhoea"]], "start": [[22], [66]], "entity_id": ["T19", "T20"]}}, "Effect": {"text": [["severe hypoglycaemia"]], "start": [[177]], "entity_id": ["T14"]}, "Speculated": {"text": [["risk"]], "start": [[169]], "entity_id": ["T16"], "value": true}, "Severity": {"text": [["severe"]], "start": [[177]], "entity_id": ["T17"], "value": "Medium"}}]}]}
{"id": "7696938_1", "context": "Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[50]], "entity_id": ["T5"]}, "Treatment": {"text": [["amphotericin B administration"]], "start": [[57]], "entity_id": ["T6"], "Drug": {"text": [["amphotericin B"]], "start": [[57]], "entity_id": ["T8"]}}, "Effect": {"text": [["Arrhythmias and cardiac arrest"]], "start": [[0]], "entity_id": ["T7"]}}]}]}
{"id": "15383642_15", "context": "Based upon the literature review, the hypotension in this patient was possibly due to the interaction between tizanidine and lisinopril.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[79]], "entity_id": ["T9"]}, "Effect": {"text": [["the hypotension"]], "start": [[34]], "entity_id": ["T8"]}, "Treatment": {"text": [["the interaction between tizanidine and lisinopril"]], "start": [[86]], "entity_id": ["T10"], "Drug": {"text": [["tizanidine"], ["lisinopril"]], "start": [[110], [125]], "entity_id": ["T12", "T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[90]], "entity_id": ["T14"]}, "Drug": {"text": [["tizanidine"], ["lisinopril"]], "start": [[110], [125]], "entity_id": ["T12", "T13"]}}]}, "Subject": {"text": [["this patient"]], "start": [[53]], "entity_id": ["T15"]}, "Speculated": {"text": [["possibly"]], "start": [[70]], "entity_id": ["T11"], "value": true}}]}]}
{"id": "16119501_1", "context": "Baclofen withdrawal: a cause of prolonged fever in the intensive care unit.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[23]], "entity_id": ["T3"]}, "Treatment": {"text": [["Baclofen withdrawal"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Baclofen"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["prolonged fever"]], "start": [[32]], "entity_id": ["T5"]}}]}]}
{"id": "17596682_1", "context": "Interstitial pneumonitis and alveolar hemorrhage complicating use of rituximab: case report and review of the literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complicating"]], "start": [[49]], "entity_id": ["T6"]}, "Effect": {"text": [["Interstitial pneumonitis and alveolar hemorrhage"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["rituximab"]], "start": [[69]], "entity_id": ["T8"], "Drug": {"text": [["rituximab"]], "start": [[69]], "entity_id": ["T7"]}}}]}]}
{"id": "11022272_4", "context": "We introduce a case of a sixty years old woman with several previous episodes of rhinitis, conjunctivitis and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration (Calsynar).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[135]], "entity_id": ["T12"]}, "Effect": {"text": [["several previous episodes of rhinitis, conjunctivitis and perspiration immediately"]], "start": [[52]], "entity_id": ["T11"]}, "Treatment": {"text": [["salmon calcitonin with nasal spray or intramuscular administration (Calsynar)"]], "start": [[163]], "entity_id": ["T10"], "Route": {"text": [["nasal spray"], ["intramuscular"]], "start": [[186], [201]], "entity_id": ["T16", "T18"]}, "Drug": {"text": [["salmon calcitonin"]], "start": [[163]], "entity_id": ["T19"]}}, "Subject": {"text": [["a sixty years old woman"]], "start": [[23]], "entity_id": ["T13"], "Age": {"text": [["sixty years old"]], "start": [[25]], "entity_id": ["T14"]}, "Gender": {"text": [["woman"]], "start": [[41]], "entity_id": ["T15"]}}}]}]}
{"id": "15554737_1", "context": "In this article, we describe another case of subcutaneous changes following repeated glatiramer acetate injection, presented as localized panniculitis in the area around the injection sites, in a 46-year-old female patient who was treated with glatiramer acetate for 18 months.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[66]], "entity_id": ["T9"]}, "Effect": {"text": [["subcutaneous changes", "presented as localized panniculitis in the area around the injection sites"]], "start": [[45, 115]], "entity_id": ["T7"]}, "Treatment": {"text": [["repeated glatiramer acetate injection"]], "start": [[76]], "entity_id": ["T8"], "Drug": {"text": [["glatiramer acetate"]], "start": [[85]], "entity_id": ["T12"]}, "Route": {"text": [["injection"]], "start": [[104]], "entity_id": ["T13"]}}, "Subject": {"text": [["a 46-year-old female patient"]], "start": [[194]], "entity_id": ["T6"], "Age": {"text": [["46-year-old"]], "start": [[196]], "entity_id": ["T10"]}, "Gender": {"text": [["female"]], "start": [[208]], "entity_id": ["T11"]}}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[231]], "entity_id": ["T17"]}, "Subject": {"text": [["a 46-year-old female patient"]], "start": [[194]], "entity_id": ["T6"], "Age": {"text": [["46-year-old"]], "start": [[196]], "entity_id": ["T10"]}, "Gender": {"text": [["female"]], "start": [[208]], "entity_id": ["T11"]}}, "Treatment": {"text": [["glatiramer acetate for 18 months"]], "start": [[244]], "entity_id": ["T18"], "Drug": {"text": [["glatiramer acetate"]], "start": [[244]], "entity_id": ["T15"]}, "Time_elapsed": {"text": [["18 months."]], "start": [[267]], "entity_id": ["T14"]}}}]}]}
{"id": "11033734_1", "context": "Eighty-two patients with various malignancies who received imipenem/cilastatin 143 times for neutropenic fever between March 1994 and October 1999 in Department of Pediatric Oncology, Gazi University, were identified.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["received"]], "start": [[50]], "entity_id": ["T7"]}, "Subject": {"text": [["Eighty-two patients with various malignancies"]], "start": [[0]], "entity_id": ["T4"], "Population": {"text": [["Eighty-two"]], "start": [[0]], "entity_id": ["T8"]}, "Disorder": {"text": [["various malignancies"]], "start": [[25]], "entity_id": ["T9"]}}, "Treatment": {"text": [["imipenem/cilastatin 143 times for neutropenic fever"]], "start": [[59]], "entity_id": ["T5"], "Drug": {"text": [["imipenem"], ["cilastatin"]], "start": [[59], [68]], "entity_id": ["T10", "T11"]}, "Disorder": {"text": [["neutropenic fever"]], "start": [[93]], "entity_id": ["T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["/"]], "start": [[67]], "entity_id": ["T6"]}, "Drug": {"text": [["imipenem"], ["cilastatin"]], "start": [[59], [68]], "entity_id": ["T10", "T11"]}}]}}]}]}
{"id": "23624139_9", "context": "The present report first highlights the potentially life-threatening side effects associated with over-the-counter NSAIDs during DDAVP replacement therapy for central DI.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated with"]], "start": [[82]], "entity_id": ["T9"]}, "Treatment": {"text": [["NSAIDs"]], "start": [[115]], "entity_id": ["T8"], "Drug": {"text": [["NSAIDs"], ["DDAVP"]], "start": [[115], [129]], "entity_id": ["T11", "T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["during"]], "start": [[122]], "entity_id": ["T13"]}, "Drug": {"text": [["NSAIDs"], ["DDAVP"]], "start": [[115], [129]], "entity_id": ["T11", "T12"]}}]}, "Effect": {"text": [["potentially life-threatening side effects"]], "start": [[40]], "entity_id": ["T10"]}}]}]}
{"id": "16623611_1", "context": "Case report: lack of control of diabetes and weight gain in a patient on initiation and rechallenge of therapy with olanzapine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["initiation and rechallenge"]], "start": [[73]], "entity_id": ["T9"]}, "Subject": {"text": [["a patient"]], "start": [[60]], "entity_id": ["T5"]}, "Effect": {"text": [["diabetes"], ["weight gain"]], "start": [[32], [45]], "entity_id": ["T6", "T7"]}, "Treatment": {"text": [["olanzapine"]], "start": [[116]], "entity_id": ["T8"], "Drug": {"text": [["olanzapine"]], "start": [[116]], "entity_id": ["T10"]}}}]}]}
{"id": "10030778_1", "context": "Intravenous azithromycin-induced ototoxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[25]], "entity_id": ["T4"]}, "Treatment": {"text": [["azithromycin"]], "start": [[12]], "entity_id": ["T3"], "Drug": {"text": [["azithromycin"]], "start": [[12]], "entity_id": ["T6"]}}, "Effect": {"text": [["ototoxicity"]], "start": [[33]], "entity_id": ["T5"]}}]}]}
{"id": "24318743_14", "context": "Orally delivered PXD showed no evidence of clinical activity, when combined with weekly AUC2-carboplatin in PROC.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["clinical activity"]], "start": [[43]], "entity_id": ["T10"]}, "Treatment": {"text": [["Orally delivered PXD", "weekly AUC2-carboplatin"]], "start": [[0, 81]], "entity_id": ["T7"], "Disorder": {"text": [["PROC"]], "start": [[108]], "entity_id": ["T8"]}, "Route": {"text": [["Orally"]], "start": [[0]], "entity_id": ["T11"]}, "Drug": {"text": [["PXD"], ["AUC2-carboplatin"]], "start": [[17], [88]], "entity_id": ["T12", "T14"]}, "Freq": {"text": [["weekly"]], "start": [[81]], "entity_id": ["T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combined"]], "start": [[67]], "entity_id": ["T15"]}, "Drug": {"text": [["PXD"], ["AUC2-carboplatin"]], "start": [[17], [88]], "entity_id": ["T12", "T14"]}}]}, "Negated": {"text": [["no"]], "start": [[28]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "18079582_3", "context": "We report such a series of patients who had transient asymptomatic bradycardia after being treated with continuous infusion 5-FU.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[79]], "entity_id": ["T4"]}, "Effect": {"text": [["transient asymptomatic bradycardia"]], "start": [[44]], "entity_id": ["T3"]}, "Treatment": {"text": [["continuous infusion 5-FU"]], "start": [[104]], "entity_id": ["T5"], "Freq": {"text": [["continuous"]], "start": [[104]], "entity_id": ["T8"]}, "Drug": {"text": [["5-FU"]], "start": [[124]], "entity_id": ["T9"]}, "Route": {"text": [["infusion"]], "start": [[115]], "entity_id": ["T10"]}}, "Subject": {"text": [["a series of patients"]], "start": [[15]], "entity_id": ["T6"], "Population": {"text": [["a series"]], "start": [[15]], "entity_id": ["T7"]}}}]}]}
{"id": "18854289_1", "context": "Consolidation therapy with bortezomib/lenalidomide/ dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen in patients with multiple myeloma: a randomized phase III trial.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["in"]], "start": [[144]], "entity_id": ["T11"]}, "Subject": {"text": [["patients with multiple myeloma"]], "start": [[147]], "entity_id": ["T12"]}, "Treatment": {"text": [["Consolidation therapy with bortezomib/lenalidomide/ dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen"]], "start": [[0]], "entity_id": ["T13"], "Disorder": {"text": [["multiple myeloma"]], "start": [[161]], "entity_id": ["T15"]}, "Drug": {"text": [["bortezomib"], ["lenalidomide"], ["dexamethasone"], ["bortezomib"], ["dexamethasone"]], "start": [[27], [38], [52], [73], [84]], "entity_id": ["T16", "T17", "T18", "T19", "T20"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["/"]], "start": [[37]], "entity_id": ["T21"]}, "Drug": {"text": [["bortezomib"], ["lenalidomide"], ["dexamethasone"]], "start": [[27], [38], [52]], "entity_id": ["T16", "T17", "T18"]}}, {"event_id": "E3", "event_type": "Combination", "Trigger": {"text": [["/"]], "start": [[83]], "entity_id": ["T22"]}, "Drug": {"text": [["bortezomib"], ["dexamethasone"]], "start": [[73], [84]], "entity_id": ["T19", "T20"]}}]}}]}]}
{"id": "24318743_3", "context": "Based on prior data suggesting that scheduling alterations of platinum would increase activity, the aim of the present study was to assess the potential therapeutic benefit of phenoxodiol (PXD), a novel biomodulator shown to have chemoresistance reversing potential, when combined with weekly AUC2-carboplatin in PROC patients.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["assess"]], "start": [[132]], "entity_id": ["T12"]}, "Treatment": {"text": [["phenoxodiol (PXD), a novel biomodulator shown to have chemoresistance reversing potential, when combined with weekly AUC2-carboplatin"]], "start": [[176]], "entity_id": ["T10"], "Drug": {"text": [["phenoxodiol"], ["carboplatin"]], "start": [[176], [298]], "entity_id": ["T15", "T19"]}, "Disorder": {"text": [["PROC"]], "start": [[313]], "entity_id": ["T16"]}, "Freq": {"text": [["weekly"]], "start": [[286]], "entity_id": ["T18"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combined"]], "start": [[272]], "entity_id": ["T17"]}, "Drug": {"text": [["carboplatin"], ["phenoxodiol"]], "start": [[298], [176]], "entity_id": ["T19", "T15"]}}]}, "Effect": {"text": [["potential therapeutic benefit"]], "start": [[143]], "entity_id": ["T11"]}, "Subject": {"text": [["PROC patients"]], "start": [[313]], "entity_id": ["T13"]}}]}]}
{"id": "8832451_3", "context": "We also describe a new, noninvasive method to assess magnesium-induced neuromuscular block when curariform muscle relaxant was given simultaneously.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[63]], "entity_id": ["T3"]}, "Treatment": {"text": [["curariform muscle relaxant was given simultaneously"]], "start": [[96]], "entity_id": ["T5"], "Drug": {"text": [["magnesium"], ["curariform muscle relaxant"]], "start": [[53], [96]], "entity_id": ["T6", "T7"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["simultaneously"]], "start": [[133]], "entity_id": ["T8"]}, "Drug": {"text": [["magnesium"], ["curariform muscle relaxant"]], "start": [[53], [96]], "entity_id": ["T6", "T7"]}}]}, "Effect": {"text": [["neuromuscular block"]], "start": [[71]], "entity_id": ["T4"]}}]}]}
{"id": "1378497_2", "context": "Our series of 3 patients supports a causal connection between bleomycin and scleroderma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["supports"]], "start": [[25]], "entity_id": ["T6"]}, "Subject": {"text": [["3 patients"]], "start": [[14]], "entity_id": ["T3"], "Population": {"text": [["3"]], "start": [[14]], "entity_id": ["T7"]}}, "Treatment": {"text": [["bleomycin"]], "start": [[62]], "entity_id": ["T4"], "Drug": {"text": [["bleomycin"]], "start": [[62]], "entity_id": ["T8"]}}, "Effect": {"text": [["scleroderma"]], "start": [[76]], "entity_id": ["T5"]}}]}]}
{"id": "16404563_6", "context": "In this paper, we report a patient with primary anti-phospholipid syndrome treated by corticosteroid, who developed disseminated nocardiosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[106]], "entity_id": ["T9"]}, "Subject": {"text": [["a patient"]], "start": [[25]], "entity_id": ["T7"]}, "Treatment": {"text": [["corticosteroid"]], "start": [[86]], "entity_id": ["T8"], "Drug": {"text": [["corticosteroid"]], "start": [[86]], "entity_id": ["T11"]}, "Disorder": {"text": [["anti-phospholipid syndrome"]], "start": [[48]], "entity_id": ["T12"]}}, "Effect": {"text": [["disseminated nocardiosis"]], "start": [[116]], "entity_id": ["T10"]}}]}]}
{"id": "9052919_1", "context": "Eye movement disorders in bone marrow transplant patients on cyclosporin and ganciclovir.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["on"]], "start": [[58]], "entity_id": ["T7"]}, "Effect": {"text": [["Eye movement disorders"]], "start": [[0]], "entity_id": ["T4"]}, "Subject": {"text": [["bone marrow transplant patients"]], "start": [[26]], "entity_id": ["T5"], "Disorder": {"text": [["bone marrow transplant"]], "start": [[26]], "entity_id": ["T8"]}}, "Treatment": {"text": [["cyclosporin and ganciclovir"]], "start": [[61]], "entity_id": ["T6"], "Drug": {"text": [["cyclosporin"], ["ganciclovir"]], "start": [[61], [77]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[73]], "entity_id": ["T11"]}, "Drug": {"text": [["cyclosporin"], ["ganciclovir"]], "start": [[61], [77]], "entity_id": ["T9", "T10"]}}]}}]}]}
{"id": "4025011_1", "context": "Prolonged severe cholestasis induced by oxacillin derivatives.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[29]], "entity_id": ["T4"]}, "Effect": {"text": [["Prolonged severe cholestasis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["oxacillin derivatives"]], "start": [[40]], "entity_id": ["T5"], "Drug": {"text": [["oxacillin"]], "start": [[40]], "entity_id": ["T6"]}}, "Severity": {"text": [["severe"]], "start": [[10]], "entity_id": ["T7"], "value": "High"}}]}]}
{"id": "21881031_11", "context": "Cisplatin was the common drug in the cases presented and therefore could be related to the INR elevations.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[76]], "entity_id": ["T8"]}, "Treatment": {"text": [["Cisplatin"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Cisplatin"]], "start": [[0]], "entity_id": ["T10"]}}, "Subject": {"text": [["the cases"]], "start": [[33]], "entity_id": ["T6"]}, "Effect": {"text": [["INR elevations"]], "start": [[91]], "entity_id": ["T7"]}, "Speculated": {"text": [["could"]], "start": [[67]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "17624096_1", "context": "5-Fluorouracil cardiotoxicity complicating treatment of stage IIB cervical cancer--case report.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complicating"]], "start": [[30]], "entity_id": ["T8"]}, "Treatment": {"text": [["5-Fluorouracil"]], "start": [[0]], "entity_id": ["T6"], "Drug": {"text": [["5-Fluorouracil"]], "start": [[0]], "entity_id": ["T9"]}, "Disorder": {"text": [["cervical cancer"]], "start": [[66]], "entity_id": ["T10"]}}, "Effect": {"text": [["cardiotoxicity"]], "start": [[15]], "entity_id": ["T7"]}}]}]}
{"id": "17241588_1", "context": "RESULTS: A clinical diagnosis of fixed drug eruption owing to use of the PDE5 inhibitor tadalafil (Cialis) was made.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["owing"]], "start": [[53]], "entity_id": ["T5"]}, "Effect": {"text": [["fixed drug eruption"]], "start": [[33]], "entity_id": ["T4"]}, "Treatment": {"text": [["PDE5 inhibitor tadalafil (Cialis)"]], "start": [[73]], "entity_id": ["T6"], "Drug": {"text": [["tadalafil"]], "start": [[88]], "entity_id": ["T7"]}}}]}]}
{"id": "9719245_3", "context": "Pancytopenia associated with 5-aminosalicylic acid use in a patient with Crohn's disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[13]], "entity_id": ["T4"]}, "Effect": {"text": [["Pancytopenia"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["5-aminosalicylic acid"]], "start": [[29]], "entity_id": ["T5"], "Disorder": {"text": [["Crohn's disease"]], "start": [[73]], "entity_id": ["T7"]}, "Drug": {"text": [["5-aminosalicylic acid"]], "start": [[29]], "entity_id": ["T8"]}}, "Subject": {"text": [["a patient with Crohn's disease"]], "start": [[58]], "entity_id": ["T6"]}}]}]}
{"id": "12111771_2", "context": "Fludarabine induced lung toxicity must be considered in all patients who develop unexplained lung disease while receiving fludarabine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["receiving"]], "start": [[112]], "entity_id": ["T8"]}, "Subject": {"text": [["all patients who develop unexplained lung disease"]], "start": [[56]], "entity_id": ["T6"], "Disorder": {"text": [["lung disease"]], "start": [[93]], "entity_id": ["T10"]}}, "Effect": {"text": [["Fludarabine induced lung toxicity"]], "start": [[0]], "entity_id": ["T7"]}, "Treatment": {"text": [["fludarabine"]], "start": [[122]], "entity_id": ["T9"], "Drug": {"text": [["fludarabine"]], "start": [[122]], "entity_id": ["T11"]}}}]}]}
{"id": "8007037_1", "context": "Although other nitrites induce methemoglobinemia, exposure to methyl nitrite during phenylpropanolamine production appears to be a new cause of occupational methemoglobinemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[135]], "entity_id": ["T5"]}, "Treatment": {"text": [["methyl nitrite"]], "start": [[62]], "entity_id": ["T4"], "Drug": {"text": [["methyl nitrite"]], "start": [[62]], "entity_id": ["T7"]}}, "Effect": {"text": [["occupational methemoglobinemia"]], "start": [[144]], "entity_id": ["T6"]}, "Speculated": {"text": [["appears to be"]], "start": [[115]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "15694139_5", "context": "We report four cases of sensorimotor axonal neuropathy in children aged 10-15 years, treated with thalidomide for myxopapillary ependymoma, Crohn's disease and recurrent giant aphthous ulceration.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[85]], "entity_id": ["T11"]}, "Subject": {"text": [["four cases", "children aged 10-15 years", "myxopapillary ependymoma, Crohn's disease and recurrent giant aphthous ulceration"]], "start": [[10, 58, 114]], "entity_id": ["T9"], "Population": {"text": [["four"]], "start": [[10]], "entity_id": ["T16"]}, "Age": {"text": [["10-15 years"]], "start": [[72]], "entity_id": ["T21"]}}, "Effect": {"text": [["sensorimotor axonal neuropathy"]], "start": [[24]], "entity_id": ["T10"]}, "Treatment": {"text": [["thalidomide"]], "start": [[98]], "entity_id": ["T12"], "Drug": {"text": [["thalidomide"]], "start": [[98]], "entity_id": ["T17"]}, "Disorder": {"text": [["myxopapillary ependymoma"], ["Crohn's disease"], ["ecurrent giant aphthous ulceration"]], "start": [[114], [140], [161]], "entity_id": ["T18", "T19", "T20"]}}}]}]}
{"id": "20298401_9", "context": "The patient died of respiratory failure after 8 days of steroid infusion and erlotinib discontinuation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[40]], "entity_id": ["T8"]}, "Subject": {"text": [["The patient"], ["The"]], "start": [[0], [0]], "entity_id": ["T6", "T15"]}, "Effect": {"text": [["died of respiratory failure"]], "start": [[12]], "entity_id": ["T7"]}, "Treatment": {"text": [["8 days of steroid infusion and erlotinib discontinuation."]], "start": [[46]], "entity_id": ["T9"], "Time_elapsed": {"text": [["after 8 days"]], "start": [[40]], "entity_id": ["T11"]}, "Drug": {"text": [["steroid"], ["erlotinib"]], "start": [[56], [77]], "entity_id": ["T12", "T14"]}, "Route": {"text": [["infusion"]], "start": [[64]], "entity_id": ["T13"]}}, "Severity": {"text": [["died"]], "start": [[12]], "entity_id": ["T10"], "value": "High"}}]}]}
{"id": "7962394_3", "context": "Hypo-oestrogenic and anabolic/androgenic side-effects of danazol are well known by the gynaecologist and some of them are present in > 50% of patients being treated for endometriosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["side-effects"]], "start": [[41]], "entity_id": ["T5"]}, "Effect": {"text": [["Hypo-oestrogenic and anabolic/androgenic"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["danazol"]], "start": [[57]], "entity_id": ["T4"], "Drug": {"text": [["danazol"]], "start": [[57]], "entity_id": ["T6"]}, "Disorder": {"text": [["endometriosis"]], "start": [[169]], "entity_id": ["T8"]}}}]}]}
{"id": "10656221_9", "context": "We believe that this is the first description of acute hepatitis caused by an idiosyncratic adverse reaction to gliclazide or to one of its metabolites.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["idiosyncratic adverse reaction"]], "start": [[78]], "entity_id": ["T5"]}, "Effect": {"text": [["acute hepatitis"]], "start": [[49]], "entity_id": ["T6"]}, "Treatment": {"text": [["gliclazide"]], "start": [[112]], "entity_id": ["T4"], "Drug": {"text": [["gliclazide"]], "start": [[112]], "entity_id": ["T7"]}}}]}]}
{"id": "15482394_4", "context": "In view of our experience in the present case, it should be stressed that close monitoring of coagulation capacity is necessary in critically ill patients in order to avoid fatal haemorrhage after initiating warfarin therapy regardless of the dosage.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[191]], "entity_id": ["T5"]}, "Treatment": {"text": [["initiating warfarin therapy regardless of the dosage"]], "start": [[197]], "entity_id": ["T3"], "Drug": {"text": [["warfarin"]], "start": [[208]], "entity_id": ["T6"]}}, "Effect": {"text": [["haemorrhage"]], "start": [[179]], "entity_id": ["T4"]}, "Severity": {"text": [["fatal"]], "start": [[173]], "entity_id": ["T7"], "value": "High"}}]}]}
{"id": "17352036_4", "context": "We report a patient who developed acute pancreatitis during amiodarone therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[53]], "entity_id": ["T3"]}, "Treatment": {"text": [["amiodarone"]], "start": [[60]], "entity_id": ["T4"], "Drug": {"text": [["amiodarone"]], "start": [[60]], "entity_id": ["T7"]}}, "Effect": {"text": [["acute pancreatitis"]], "start": [[34]], "entity_id": ["T5"]}, "Subject": {"text": [["a patient"]], "start": [[10]], "entity_id": ["T6"]}}]}]}
{"id": "9602881_1", "context": "We report a 76-year-old man who developed an acute blistering eruption following high-dose penicillin treatment for pneumococcal septicaemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[32]], "entity_id": ["T4"]}, "Subject": {"text": [["76-year-old man"]], "start": [[12]], "entity_id": ["T3"], "Age": {"text": [["76-year-old"]], "start": [[12]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[24]], "entity_id": ["T8"]}}, "Effect": {"text": [["acute blistering eruption"]], "start": [[45]], "entity_id": ["T5"]}, "Treatment": {"text": [["high-dose penicillin treatment"]], "start": [[81]], "entity_id": ["T6"], "Drug": {"text": [["penicillin"]], "start": [[91]], "entity_id": ["T9"]}, "Dosage": {"text": [["high-dose"]], "start": [[81]], "entity_id": ["T10"]}, "Disorder": {"text": [["pneumococcal septicaemia"]], "start": [[116]], "entity_id": ["T11"]}}, "Severity": {"text": [["acute"]], "start": [[45]], "entity_id": ["T12"], "value": "High"}}]}]}
{"id": "14632592_5", "context": "OBJECTIVE: To report a case of colchicine-induced myopathy in a teenager with familial Mediterranean fever (FMF).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[42]], "entity_id": ["T3"]}, "Effect": {"text": [["myopathy"]], "start": [[50]], "entity_id": ["T4"]}, "Subject": {"text": [["a teenager with familial Mediterranean fever (FMF)"]], "start": [[62]], "entity_id": ["T5"], "Age": {"text": [["teenager"]], "start": [[64]], "entity_id": ["T7"]}}, "Treatment": {"text": [["colchicine"]], "start": [[31]], "entity_id": ["T6"], "Disorder": {"text": [["familial Mediterranean fever"]], "start": [[78]], "entity_id": ["T8"]}, "Drug": {"text": [["colchicine"]], "start": [[31]], "entity_id": ["T9"]}}}]}]}
{"id": "11414270_14", "context": "We believe that mucositis was a contributing factor to this case of fatal hyperkalemia after administration of succinylcholine, with a mechanism similar to that reported with thermal injury.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[87]], "entity_id": ["T7"]}, "Treatment": {"text": [["succinylcholine"]], "start": [[111]], "entity_id": ["T6"], "Drug": {"text": [["succinylcholine"]], "start": [[111]], "entity_id": ["T11"]}}, "Effect": {"text": [["fatal hyperkalemia"]], "start": [[68]], "entity_id": ["T8"]}, "Subject": {"text": [["mucositis"]], "start": [[16]], "entity_id": ["T12"], "Disorder": {"text": [["mucositis"]], "start": [[16]], "entity_id": ["T9"]}}, "Severity": {"text": [["fatal"]], "start": [[68]], "entity_id": ["T10"], "value": "High"}}]}]}
{"id": "10928688_1", "context": "Our experience supports hemodialysis for ESRF patients with atenolol toxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["for"]], "start": [[37]], "entity_id": ["T3"]}, "Subject": {"text": [["ESRF patients with atenolol toxicity"]], "start": [[41]], "entity_id": ["T5"], "Disorder": {"text": [["ESRF"]], "start": [[41]], "entity_id": ["T4"]}}, "Treatment": {"text": [["hemodialysis"]], "start": [[24]], "entity_id": ["T7"], "Drug": {"text": [["hemodialysis"]], "start": [[24]], "entity_id": ["T8"]}, "Disorder": {"text": [["atenolol toxicity"]], "start": [[60]], "entity_id": ["T9"]}}}]}]}
{"id": "14679124_1", "context": "Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["administered"]], "start": [[65]], "entity_id": ["T11"]}, "Treatment": {"text": [["Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently"]], "start": [[0]], "entity_id": ["T9"], "Drug": {"text": [["tamoxifen"], ["Epirubicin-cyclophosphamide"]], "start": [[55], [0]], "entity_id": ["T13", "T15"]}, "Disorder": {"text": [["node-positive breast cancer"]], "start": [[157]], "entity_id": ["T16"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["plus"]], "start": [[50]], "entity_id": ["T14"]}, "Drug": {"text": [["tamoxifen"], ["Epirubicin-cyclophosphamide"]], "start": [[55], [0]], "entity_id": ["T13", "T15"]}}]}, "Subject": {"text": [["postmenopausal node-positive breast cancer patients"]], "start": [[142]], "entity_id": ["T10"]}}]}]}
{"id": "3628148_1", "context": "Rupture of a cerebral aneurysm associated with nifedipine treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[31]], "entity_id": ["T5"]}, "Treatment": {"text": [["nifedipine"]], "start": [[47]], "entity_id": ["T3"], "Drug": {"text": [["nifedipine"]], "start": [[47]], "entity_id": ["T6"]}}, "Effect": {"text": [["Rupture of a cerebral aneurysm"]], "start": [[0]], "entity_id": ["T4"]}}]}]}
{"id": "15157248_1", "context": "An immediate hemolytic reaction induced by repeated administration of oxaliplatin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[32]], "entity_id": ["T4"]}, "Effect": {"text": [["immediate hemolytic reaction"]], "start": [[3]], "entity_id": ["T3"]}, "Treatment": {"text": [["repeated administration of oxaliplatin"]], "start": [[43]], "entity_id": ["T5"], "Freq": {"text": [["repeated"]], "start": [[43]], "entity_id": ["T6"]}, "Drug": {"text": [["oxaliplatin"]], "start": [[70]], "entity_id": ["T7"]}}}]}]}
{"id": "15494638_8", "context": "Patient B developed perioral and upper extremity paresthesias during the fourth cycle of CAP alone (2500 mg/m2).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[10]], "entity_id": ["T7"]}, "Subject": {"text": [["Patient B"]], "start": [[0]], "entity_id": ["T5"]}, "Effect": {"text": [["perioral and upper extremity paresthesias"]], "start": [[20]], "entity_id": ["T6"]}, "Treatment": {"text": [["the fourth cycle of CAP alone (2500 mg/m2)"]], "start": [[69]], "entity_id": ["T8"], "Drug": {"text": [["CAP"]], "start": [[89]], "entity_id": ["T9"]}, "Freq": {"text": [["the fourth cycle"]], "start": [[69]], "entity_id": ["T10"]}, "Dosage": {"text": [["2500 mg/m2"]], "start": [[100]], "entity_id": ["T11"]}}}]}]}
{"id": "8749646_4", "context": "We describe four patients who had seizures while receiving ofloxacin; no other causes were evident.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["receiving"]], "start": [[49]], "entity_id": ["T4"]}, "Treatment": {"text": [["ofloxacin"]], "start": [[59]], "entity_id": ["T3"], "Drug": {"text": [["ofloxacin"]], "start": [[59]], "entity_id": ["T8"]}}, "Effect": {"text": [["seizures"]], "start": [[34]], "entity_id": ["T5"]}, "Subject": {"text": [["four patients"]], "start": [[12]], "entity_id": ["T6"], "Population": {"text": [["four"]], "start": [[12]], "entity_id": ["T7"]}}}]}]}
{"id": "14607011_2", "context": "The case history and toxicological findings of an infant fatality involving pseudoephedrine, brompheniramine, and dextromethorphan are presented.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["involving"]], "start": [[66]], "entity_id": ["T9"]}, "Treatment": {"text": [["pseudoephedrine, brompheniramine, and dextromethorphan"]], "start": [[76]], "entity_id": ["T7"], "Drug": {"text": [["pseudoephedrine"], ["brompheniramine"], ["dextromethorphan"]], "start": [[76], [93], [114]], "entity_id": ["T10", "T11", "T12"]}}, "Effect": {"text": [["infant fatality"]], "start": [[50]], "entity_id": ["T8"]}, "Subject": {"text": [["an infant"]], "start": [[47]], "entity_id": ["T13"], "Age": {"text": [["infant"]], "start": [[50]], "entity_id": ["T14"]}}}]}]}
{"id": "9701106_1", "context": "A drug interaction between zafirlukast and theophylline.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["between"]], "start": [[19]], "entity_id": ["T5"]}, "Effect": {"text": [["drug interaction"]], "start": [[2]], "entity_id": ["T4"]}, "Treatment": {"text": [["zafirlukast and theophylline"]], "start": [[27]], "entity_id": ["T6"], "Drug": {"text": [["zafirlukast"], ["theophylline"]], "start": [[27], [43]], "entity_id": ["T7", "T8"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[39]], "entity_id": ["T9"]}, "Drug": {"text": [["zafirlukast"], ["theophylline"]], "start": [[27], [43]], "entity_id": ["T7", "T8"]}}]}}]}]}
{"id": "16503727_1", "context": "Dipyrone, also known as metamizole, is an analgesic and antipyretic drug that was banned by the United States Food and Drug Administration because of its association with agranulocytosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["association"]], "start": [[154]], "entity_id": ["T6"]}, "Effect": {"text": [["agranulocytosis"]], "start": [[171]], "entity_id": ["T4"]}, "Treatment": {"text": [["Dipyrone, also known as metamizole"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Dipyrone"]], "start": [[0]], "entity_id": ["T7"]}}}]}]}
{"id": "990658_1", "context": "A fatal case of pancytopenia due to levomepromazine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[29]], "entity_id": ["T4"]}, "Effect": {"text": [["pancytopenia"]], "start": [[16]], "entity_id": ["T3"]}, "Treatment": {"text": [["levomepromazine"]], "start": [[36]], "entity_id": ["T5"], "Drug": {"text": [["levomepromazine"]], "start": [[36]], "entity_id": ["T7"]}}, "Subject": {"text": [["A fatal case"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "20130478_2", "context": "Reversible heart failure in a patient receiving etanercept for ankylosing spondylitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[25]], "entity_id": ["T7"]}, "Effect": {"text": [["Reversible heart failure"]], "start": [[0]], "entity_id": ["T3"]}, "Subject": {"text": [["a patient"]], "start": [[28]], "entity_id": ["T4"]}, "Treatment": {"text": [["etanercept"]], "start": [[48]], "entity_id": ["T5"], "Drug": {"text": [["etanercept"]], "start": [[48]], "entity_id": ["T6"]}, "Disorder": {"text": [["ankylosing spondylitis"]], "start": [[63]], "entity_id": ["T8"]}}}]}]}
{"id": "12503933_7", "context": "The most likely cause of liver failure in this patient was, therefore, clarithromycin, which undergoes hepatic metabolism and has been reported to cause fulminant hepatic failure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[16]], "entity_id": ["T6"]}, "Effect": {"text": [["liver failure"]], "start": [[25]], "entity_id": ["T5"]}, "Treatment": {"text": [["clarithromycin"]], "start": [[71]], "entity_id": ["T7"], "Drug": {"text": [["clarithromycin"]], "start": [[71]], "entity_id": ["T8"]}}, "Speculated": {"text": [["likely"]], "start": [[9]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "15554737_2", "context": "Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[50]], "entity_id": ["T9"]}, "Effect": {"text": [["Localized panniculitis and subsequent lipoatrophy"]], "start": [[0]], "entity_id": ["T7"]}, "Treatment": {"text": [["subcutaneous glatiramer acetate (Copaxone) injection"]], "start": [[55]], "entity_id": ["T8"], "Drug": {"text": [["glatiramer acetate (Copaxone)"]], "start": [[68]], "entity_id": ["T11"]}, "Route": {"text": [["injection"]], "start": [[98]], "entity_id": ["T12"]}, "Disorder": {"text": [["multiple sclerosis"]], "start": [[129]], "entity_id": ["T13"]}}}]}]}
{"id": "19224802_6", "context": "glycopyrrolate (5.0 microg/kg) not only resulting in resolution of bradycardia but also resulting in an exaggerated increase of arterial blood pressure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulting"]], "start": [[40]], "entity_id": ["T7"]}, "Treatment": {"text": [["glycopyrrolate (5.0 microg/kg)"]], "start": [[0]], "entity_id": ["T8"], "Drug": {"text": [["glycopyrrolate"]], "start": [[0]], "entity_id": ["T10"]}, "Dosage": {"text": [["5.0 microg/kg"]], "start": [[16]], "entity_id": ["T11"]}}, "Effect": {"text": [["resolution of bradycardia", "an exaggerated increase of arterial blood pressure"]], "start": [[53, 101]], "entity_id": ["T9"]}}]}]}
{"id": "16511396_3", "context": "This case underscores problems in clinical management with sulfadiazine hypersensitivity, potential immunosuppression from corticosteroids and selection of medications for recurrences of toxoplasmic chorioretinitis.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["hypersensitivity"]], "start": [[72]], "entity_id": ["T7"]}, "Treatment": {"text": [["sulfadiazine"]], "start": [[59]], "entity_id": ["T4"], "Drug": {"text": [["sulfadiazine"]], "start": [[59]], "entity_id": ["T5"]}}, "Effect": {"text": [["hypersensitivity"]], "start": [[72]], "entity_id": ["T6"]}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["from"]], "start": [[118]], "entity_id": ["T8"]}, "Effect": {"text": [["immunosuppression"]], "start": [[100]], "entity_id": ["T11"]}, "Treatment": {"text": [["corticosteroids"]], "start": [[123]], "entity_id": ["T9"], "Drug": {"text": [["corticosteroids"]], "start": [[123]], "entity_id": ["T10"]}}, "Speculated": {"text": [["potential"]], "start": [[90]], "entity_id": ["T12"], "value": true}}]}]}
{"id": "10084639_2", "context": "CONCLUSION: The results suggest that olanzapine may be useful in treating patients with clozapine-induced granulocytopenia without the risk of recurrence of hematologic side effects.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treating"]], "start": [[65]], "entity_id": ["T6"]}, "Treatment": {"text": [["olanzapine"]], "start": [[37]], "entity_id": ["T3"], "Drug": {"text": [["olanzapine"]], "start": [[37]], "entity_id": ["T8"]}}, "Effect": {"text": [["without the risk of recurrence of hematologic side effects"]], "start": [[123]], "entity_id": ["T4"]}, "Subject": {"text": [["patients with clozapine-induced granulocytopenia"]], "start": [[74]], "entity_id": ["T5"]}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[98]], "entity_id": ["T12"]}, "Treatment": {"text": [["clozapine"]], "start": [[88]], "entity_id": ["T13"], "Disorder": {"text": [["clozapine-induced granulocytopenia"]], "start": [[88]], "entity_id": ["T10"]}, "Drug": {"text": [["clozapine"]], "start": [[88]], "entity_id": ["T15"]}}, "Effect": {"text": [["granulocytopenia"]], "start": [[106]], "entity_id": ["T14"]}}]}]}
{"id": "10452772_1", "context": "CONCLUSION: Patients with insulin allergy may not have complete resolution of their symptoms after standard desensitization, particularly those patients with concomitant protamine allergy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["resolution"]], "start": [[64]], "entity_id": ["T3"]}, "Treatment": {"text": [["standard desensitization"]], "start": [[99]], "entity_id": ["T4"]}, "Subject": {"text": [["Patients with insulin allergy", "concomitant protamine allergy"]], "start": [[12, 158]], "entity_id": ["T5"], "Disorder": {"text": [["insulin allergy"], ["protamine allergy"]], "start": [[26], [170]], "entity_id": ["T7", "T10"]}}, "Negated": {"text": [["not"]], "start": [[46]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "2394154_4", "context": "To our knowledge, the syndrome of fever, pulmonary infiltrates, and pleural effusion following use of acyclovir has not been previously reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[85]], "entity_id": ["T8"]}, "Effect": {"text": [["fever, pulmonary infiltrates, and pleural effusion"]], "start": [[34]], "entity_id": ["T7"]}, "Treatment": {"text": [["acyclovir"]], "start": [[102]], "entity_id": ["T9"], "Drug": {"text": [["acyclovir"]], "start": [[102]], "entity_id": ["T11"]}}, "Negated": {"text": [["not"]], "start": [[116]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "3485422_2", "context": "We are concerned that the macular lesion was a retinal toxic effect of gentamicin because of the recent description of similar lesions occurring after the inadvertent intraocular injection of massive doses of this drug.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["of"]], "start": [[68]], "entity_id": ["T5"]}, "Effect": {"text": [["macular lesion"]], "start": [[26]], "entity_id": ["T3"]}, "Treatment": {"text": [["gentamicin"]], "start": [[71]], "entity_id": ["T4"], "Drug": {"text": [["gentamicin"]], "start": [[71]], "entity_id": ["T7"]}}, "Speculated": {"text": [["concerned"]], "start": [[7]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "16791713_1", "context": "Acute myocardial infarction during high-dose methylprednisolone therapy for Graves' ophthalmopathy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[28]], "entity_id": ["T3"]}, "Treatment": {"text": [["high-dose methylprednisolone therapy"]], "start": [[35]], "entity_id": ["T4"], "Drug": {"text": [["methylprednisolone"]], "start": [[45]], "entity_id": ["T6"]}, "Disorder": {"text": [["Graves' ophthalmopathy"]], "start": [[76]], "entity_id": ["T7"]}, "Dosage": {"text": [["high-dose"]], "start": [[35]], "entity_id": ["T8"]}}, "Effect": {"text": [["Acute myocardial infarction"]], "start": [[0]], "entity_id": ["T5"]}, "Severity": {"text": [["Acute"]], "start": [[0]], "entity_id": ["T9"], "value": "High"}}]}]}
{"id": "11881322_8", "context": "With itraconazole, hepatotoxic reactions have only very rarely been reported, and histologic data are lacking.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reported"]], "start": [[68]], "entity_id": ["T4"]}, "Treatment": {"text": [["itraconazole"]], "start": [[5]], "entity_id": ["T3"], "Drug": {"text": [["itraconazole"]], "start": [[5]], "entity_id": ["T6"]}}, "Effect": {"text": [["hepatotoxic"]], "start": [[19]], "entity_id": ["T5"]}}]}]}
{"id": "17675030_4", "context": "We describe in detail the first U.S. case report, of a 4(1/2)-year-old boy who experienced angioedema during treatment with oxcarbazepine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treatment"]], "start": [[109]], "entity_id": ["T3"]}, "Treatment": {"text": [["oxcarbazepine"]], "start": [[124]], "entity_id": ["T4"], "Drug": {"text": [["oxcarbazepine"]], "start": [[124]], "entity_id": ["T9"]}}, "Effect": {"text": [["angioedema"]], "start": [[91]], "entity_id": ["T5"]}, "Subject": {"text": [["a 4(1/2)-year-old boy"]], "start": [[53]], "entity_id": ["T6"], "Age": {"text": [["4(1/2)-year-old"]], "start": [[55]], "entity_id": ["T7"]}, "Gender": {"text": [["boy"]], "start": [[71]], "entity_id": ["T8"]}}}]}]}
{"id": "21045170_11", "context": "Caution should be used when coadministering enfuvirtide and niacin to HIV-infected patients.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["used"]], "start": [[18]], "entity_id": ["T9"]}, "Effect": {"text": [["Caution"]], "start": [[0]], "entity_id": ["T8"]}, "Subject": {"text": [["HIV-infected patients"]], "start": [[70]], "entity_id": ["T11"]}, "Treatment": {"text": [["coadministering enfuvirtide and niacin"]], "start": [[28]], "entity_id": ["T10"], "Drug": {"text": [["enfuvirtide"], ["niacin"]], "start": [[44], [60]], "entity_id": ["T13", "T14"]}, "Disorder": {"text": [["HIV"]], "start": [[70]], "entity_id": ["T1"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["coadministering"]], "start": [[28]], "entity_id": ["T15"]}, "Drug": {"text": [["enfuvirtide"], ["niacin"]], "start": [[44], [60]], "entity_id": ["T13", "T14"]}}]}}]}]}
{"id": "448845_3", "context": "Several case reports of aplastic anemia with use of acetazolamide, and two cases with use of methazolamide, have appeared in the literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reports"]], "start": [[13]], "entity_id": ["T8"]}, "Effect": {"text": [["aplastic anemia"]], "start": [[24]], "entity_id": ["T6"]}, "Treatment": {"text": [["acetazolamide"]], "start": [[52]], "entity_id": ["T7"], "Drug": {"text": [["acetazolamide"]], "start": [[52]], "entity_id": ["T11"]}}, "Subject": {"text": [["Several case"]], "start": [[0]], "entity_id": ["T9"], "Population": {"text": [["Several"]], "start": [[0]], "entity_id": ["T10"]}}}]}]}
{"id": "17381671_7", "context": "SSRIs and fentanyl are commonly co-administered, especially in the setting of chronic or malignant pain, as underlying depression may contribute to the pathogenesis of pain.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["in"]], "start": [[60]], "entity_id": ["T13"]}, "Treatment": {"text": [["SSRIs and fentanyl are commonly co-administered"]], "start": [[0]], "entity_id": ["T12"], "Disorder": {"text": [["chronic or malignant pain", "underlying depression"]], "start": [[78, 108]], "entity_id": ["T11"]}, "Drug": {"text": [["SSRIs"], ["fentanyl"]], "start": [[0], [10]], "entity_id": ["T14", "T15"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[6]], "entity_id": ["T16"]}, "Drug": {"text": [["SSRIs"], ["fentanyl"]], "start": [[0], [10]], "entity_id": ["T14", "T15"]}}]}}]}]}
{"id": "1420650_2", "context": "In this report we present four patients treated with a combination of different psychotropic drugs, in whom asterixis was triggered either by adding carbamazepine (CBZ) to a treatment regimen, or by increasing its dosage.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["triggered"]], "start": [[122]], "entity_id": ["T6"]}, "Subject": {"text": [["four patients"]], "start": [[26]], "entity_id": ["T4"], "Population": {"text": [["four"]], "start": [[26]], "entity_id": ["T8"]}}, "Effect": {"text": [["asterixis"]], "start": [[108]], "entity_id": ["T5"]}, "Treatment": {"text": [["carbamazepine"]], "start": [[149]], "entity_id": ["T7"], "Drug": {"text": [["carbamazepine"]], "start": [[149]], "entity_id": ["T9"]}}}]}]}
{"id": "458006_1", "context": "Squamous-cell carcinoma arising in a basal-cell epithelioma treated with 5-fluorouracil.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[60]], "entity_id": ["T3"]}, "Treatment": {"text": [["5-fluorouracil"]], "start": [[73]], "entity_id": ["T4"], "Drug": {"text": [["5-fluorouracil"]], "start": [[73]], "entity_id": ["T6"]}}, "Effect": {"text": [["Squamous-cell carcinoma arising"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "8313300_2", "context": "The case of a bipolar patient who developed thyrotoxicosis with severe exophthalmos while on lithium therapy is described.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["on"]], "start": [[90]], "entity_id": ["T8"]}, "Treatment": {"text": [["lithium"]], "start": [[93]], "entity_id": ["T9"], "Drug": {"text": [["lithium"]], "start": [[93]], "entity_id": ["T14"]}, "Disorder": {"text": [["bipolar"]], "start": [[14]], "entity_id": ["T15"]}}, "Subject": {"text": [["The case of a bipolar patient"]], "start": [[0]], "entity_id": ["T10"]}, "Effect": {"text": [["thyrotoxicosis with severe exophthalmos"]], "start": [[44]], "entity_id": ["T11"]}, "Severity": {"text": [["severe"]], "start": [[64]], "entity_id": ["T13"], "value": "High"}}]}]}
{"id": "1267457_2", "context": "The patient received only the ophthalmic sulfonamide, and it was used for one day, but he developed Stevens-Johnson syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[90]], "entity_id": ["T5"]}, "Treatment": {"text": [["ophthalmic sulfonamide, and it was used for one day"]], "start": [[30]], "entity_id": ["T3"], "Route": {"text": [["ophthalmic"]], "start": [[30]], "entity_id": ["T8"]}, "Drug": {"text": [["sulfonamide"]], "start": [[41]], "entity_id": ["T9"]}, "Duration": {"text": [["one day"]], "start": [[74]], "entity_id": ["T10"]}}, "Subject": {"text": [["The patient", "he"]], "start": [[0, 87]], "entity_id": ["T4"], "Gender": {"text": [["he"]], "start": [[87]], "entity_id": ["T7"]}}, "Effect": {"text": [["Stevens-Johnson syndrome"]], "start": [[100]], "entity_id": ["T6"]}}]}]}
{"id": "11545487_3", "context": "Papillary necrosis associated with the HIV protease inhibitor indinavir.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[19]], "entity_id": ["T5"]}, "Treatment": {"text": [["indinavir"]], "start": [[62]], "entity_id": ["T3"], "Drug": {"text": [["indinavir"]], "start": [[62]], "entity_id": ["T7"]}, "Disorder": {"text": [["HIV"]], "start": [[39]], "entity_id": ["T1"]}}, "Effect": {"text": [["Papillary necrosis"]], "start": [[0]], "entity_id": ["T4"]}}]}]}
{"id": "8360712_1", "context": "A case is reported of a 40 year old woman treated with intraventricular IL-2 for leptomeningeal disease who developed progressive cognitive dysfunction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[108]], "entity_id": ["T7"]}, "Subject": {"text": [["a 40 year old woman"]], "start": [[22]], "entity_id": ["T3"], "Age": {"text": [["40 year old"]], "start": [[24]], "entity_id": ["T8"]}, "Gender": {"text": [["woman"]], "start": [[36]], "entity_id": ["T9"]}}, "Treatment": {"text": [["intraventricular IL-2"]], "start": [[55]], "entity_id": ["T5"], "Disorder": {"text": [["leptomeningeal disease"]], "start": [[81]], "entity_id": ["T4"]}, "Drug": {"text": [["IL-2"]], "start": [[72]], "entity_id": ["T10"]}, "Route": {"text": [["intraventricular"]], "start": [[55]], "entity_id": ["T1"]}}, "Effect": {"text": [["progressive cognitive dysfunction"]], "start": [[118]], "entity_id": ["T6"]}}]}]}
{"id": "15289139_3", "context": "We document the abrupt development of an extensive choroidal detachment after initiation of dorzolamide therapy in a surgically untreated eye with primary open-angle glaucoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["development"]], "start": [[23]], "entity_id": ["T7"]}, "Effect": {"text": [["extensive choroidal detachment"]], "start": [[41]], "entity_id": ["T3"]}, "Treatment": {"text": [["dorzolamide therapy"]], "start": [[92]], "entity_id": ["T4"], "Drug": {"text": [["dorzolamide"]], "start": [[92]], "entity_id": ["T9"]}, "Disorder": {"text": [["surgically untreated eye with primary open-angle glaucoma"]], "start": [[117]], "entity_id": ["T10"]}}, "Subject": {"text": [["surgically untreated eye with primary open-angle glaucoma"]], "start": [[117]], "entity_id": ["T6"]}, "Severity": {"text": [["abrupt"], ["extensive"]], "start": [[16], [41]], "entity_id": ["T8", "T11"], "value": "High"}}]}]}
{"id": "19226083_1", "context": "Serotonin toxicity as a consequence of linezolid use in revision hip arthroplasty.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["consequence"]], "start": [[24]], "entity_id": ["T4"]}, "Effect": {"text": [["Serotonin toxicity"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["linezolid use in revision hip arthroplasty", "Serotonin"]], "start": [[39, 0]], "entity_id": ["T6"], "Drug": {"text": [["Serotonin"], ["linezolid"]], "start": [[0], [39]], "entity_id": ["T7", "T8"]}}}]}]}
{"id": "11788010_2", "context": "Gallstones and bile sludge are common side effects of octreotide therapy but rarely become symptomatic or require treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["side effects of"]], "start": [[38]], "entity_id": ["T6"]}, "Effect": {"text": [["Gallstones and bile sludge"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["octreotide therapy"]], "start": [[54]], "entity_id": ["T7"], "Drug": {"text": [["octreotide"]], "start": [[54]], "entity_id": ["T8"]}}}]}]}
{"id": "14557583_3", "context": "The authors' results suggest that L-dopa may cause daytime somnolence in some patients with Parkinson's disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[45]], "entity_id": ["T5"]}, "Subject": {"text": [["some patients with Parkinson's disease"]], "start": [[73]], "entity_id": ["T3"]}, "Effect": {"text": [["daytime somnolence"]], "start": [[51]], "entity_id": ["T4"]}, "Treatment": {"text": [["L-dopa"]], "start": [[34]], "entity_id": ["T6"], "Drug": {"text": [["L-dopa"]], "start": [[34]], "entity_id": ["T8"]}, "Disorder": {"text": [["Parkinson's disease"]], "start": [[92]], "entity_id": ["T9"]}}}]}]}
{"id": "8597009_2", "context": "Seventy-four per cent of patients with epileptogenic disorders seen at the Emergency Unit at Groote Schuur Hospital were on phenytoin and 11.6% of these had blood levels in the toxic range.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["had"]], "start": [[153]], "entity_id": ["T5"]}, "Effect": {"text": [["blood levels in the toxic range"]], "start": [[157]], "entity_id": ["T3"]}, "Treatment": {"text": [["phenytoin"]], "start": [[124]], "entity_id": ["T4"], "Drug": {"text": [["phenytoin"]], "start": [[124]], "entity_id": ["T10"]}, "Disorder": {"text": [["epileptogenic"]], "start": [[39]], "entity_id": ["T12"]}}, "Subject": {"text": [["Seventy-four per cent of patients with epileptogenic disorders", "11.6% of these"]], "start": [[0, 138]], "entity_id": ["T6"], "Population": {"text": [["Seventy-four per cent"], ["11.6%"]], "start": [[0], [138]], "entity_id": ["T7", "T9"]}}}]}]}
{"id": "16284443_1", "context": "Based on the history and clinical features, a diagnosis of insulin-induced lipohypertrophy was made.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[67]], "entity_id": ["T4"]}, "Treatment": {"text": [["insulin"]], "start": [[59]], "entity_id": ["T3"], "Drug": {"text": [["insulin"]], "start": [[59]], "entity_id": ["T6"]}}, "Effect": {"text": [["lipohypertrophy"]], "start": [[75]], "entity_id": ["T5"]}}]}]}
{"id": "16637972_2", "context": "An unusual presentation of spontaneous sub-conjunctival haematoma in a patient receiving warfarin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[66]], "entity_id": ["T6"]}, "Effect": {"text": [["spontaneous sub-conjunctival haematoma"]], "start": [[27]], "entity_id": ["T3"]}, "Subject": {"text": [["a patient"]], "start": [[69]], "entity_id": ["T4"]}, "Treatment": {"text": [["warfarin"]], "start": [[89]], "entity_id": ["T5"], "Drug": {"text": [["warfarin"]], "start": [[89]], "entity_id": ["T7"]}}}]}]}
{"id": "19782276_4", "context": "He developed congestive heart failure 5 days after administration of cyclophosphamide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[3]], "entity_id": ["T7"]}, "Effect": {"text": [["congestive heart failure"]], "start": [[13]], "entity_id": ["T5"]}, "Treatment": {"text": [["5 days after administration of cyclophosphamide"]], "start": [[38]], "entity_id": ["T6"], "Time_elapsed": {"text": [["5 days"]], "start": [[38]], "entity_id": ["T8"]}, "Drug": {"text": [["cyclophosphamide"]], "start": [[69]], "entity_id": ["T9"]}}}]}]}
{"id": "12503933_5", "context": "Fulminant liver failure associated with clarithromycin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[24]], "entity_id": ["T5"]}, "Effect": {"text": [["Fulminant liver failure"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["clarithromycin"]], "start": [[40]], "entity_id": ["T4"], "Drug": {"text": [["clarithromycin"]], "start": [[40]], "entity_id": ["T6"]}}}]}]}
{"id": "2979256_3", "context": "Nifedipine may induce, or aggravate, pre-existing, gastro-oesophageal reflux.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induce, or aggravate"]], "start": [[15]], "entity_id": ["T4"]}, "Treatment": {"text": [["Nifedipine"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Nifedipine"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["gastro-oesophageal reflux"]], "start": [[51]], "entity_id": ["T5"]}}]}]}
{"id": "2728526_1", "context": "Rifampin-associated thrombocytopenia secondary to poor compliance.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[9]], "entity_id": ["T5"]}, "Treatment": {"text": [["Rifampin"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Rifampin"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["thrombocytopenia secondary to poor compliance"]], "start": [[20]], "entity_id": ["T6"]}}]}]}
{"id": "8672829_2", "context": "CONCLUSIONS: There was a temporal relationship between the onset of nonconvulsive status epilepticus and initiation of ifosfamide infusion.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["relationship"]], "start": [[34]], "entity_id": ["T5"]}, "Effect": {"text": [["onset of nonconvulsive status epilepticus"]], "start": [[59]], "entity_id": ["T3"]}, "Treatment": {"text": [["initiation of ifosfamide infusion"]], "start": [[105]], "entity_id": ["T4"], "Drug": {"text": [["ifosfamide"]], "start": [[119]], "entity_id": ["T7"]}, "Route": {"text": [["infusion"]], "start": [[130]], "entity_id": ["T8"]}}}]}]}
{"id": "16109609_1", "context": "Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[12]], "entity_id": ["T5"]}, "Treatment": {"text": [["Gemcitabine"]], "start": [[0]], "entity_id": ["T6"], "Drug": {"text": [["Gemcitabine"]], "start": [[0]], "entity_id": ["T8"]}, "Disorder": {"text": [["unblocked cardiac irradiation"]], "start": [[61]], "entity_id": ["T9"]}}, "Effect": {"text": [["pericardial effusion and tamponade"]], "start": [[20]], "entity_id": ["T7"]}}]}]}
{"id": "7416268_3", "context": "Although useful in the management of chronic alcoholism, disulfiram is being increasingly associated with a wide spectrum of side effects and untoward medical sequelae, which now include catatonia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[90]], "entity_id": ["T8"]}, "Treatment": {"text": [["disulfiram"]], "start": [[57]], "entity_id": ["T7"], "Drug": {"text": [["disulfiram"]], "start": [[57]], "entity_id": ["T11"]}, "Disorder": {"text": [["chronic alcoholism"]], "start": [[37]], "entity_id": ["T14"]}}, "Effect": {"text": [["a wide spectrum of side effects and untoward medical sequelae, which now include catatonia"]], "start": [[106]], "entity_id": ["T9"]}}]}]}
{"id": "19567656_2", "context": "DISCUSSION: The Naranjo probability scale indicated a probable relationship between sertraline treatment and the onset of rhabdomyolysis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["relationship"]], "start": [[63]], "entity_id": ["T6"]}, "Treatment": {"text": [["sertraline"]], "start": [[84]], "entity_id": ["T4"], "Drug": {"text": [["sertraline"]], "start": [[84]], "entity_id": ["T7"]}}, "Effect": {"text": [["rhabdomyolysis"]], "start": [[122]], "entity_id": ["T5"]}, "Speculated": {"text": [["probable"]], "start": [[54]], "entity_id": ["T3"], "value": true}}]}]}
{"id": "14677199_1", "context": "Severe Raynaud's phenomenon with yohimbine therapy for erectile dysfunction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[28]], "entity_id": ["T6"]}, "Effect": {"text": [["Raynaud's phenomenon"]], "start": [[7]], "entity_id": ["T3"]}, "Treatment": {"text": [["yohimbine"]], "start": [[33]], "entity_id": ["T4"], "Drug": {"text": [["yohimbine"]], "start": [[33]], "entity_id": ["T7"]}, "Disorder": {"text": [["erectile dysfunction"]], "start": [[55]], "entity_id": ["T8"]}}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T9"], "value": "High"}}]}]}
{"id": "10323129_1", "context": "Possible theophylline toxicity during anesthesia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[31]], "entity_id": ["T5"]}, "Treatment": {"text": [["anesthesia"]], "start": [[38]], "entity_id": ["T7"], "Drug": {"text": [["anesthesia"]], "start": [[38]], "entity_id": ["T10"]}}, "Effect": {"text": [["theophylline toxicity"]], "start": [[9]], "entity_id": ["T6"]}, "Speculated": {"text": [["Possible"]], "start": [[0]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "3124393_2", "context": "Calcification and ossification of the spinal arachnoid after intrathecal administration of Depo-Medrol.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[55]], "entity_id": ["T6"]}, "Effect": {"text": [["Calcification and ossification of the spinal arachnoid"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["intrathecal administration of Depo-Medrol"]], "start": [[61]], "entity_id": ["T7"], "Route": {"text": [["intrathecal"]], "start": [[61]], "entity_id": ["T8"]}, "Drug": {"text": [["Depo-Medrol"]], "start": [[91]], "entity_id": ["T9"]}}}]}]}
{"id": "921427_2", "context": "Circulating anticoagulant in the procainamide-induced lupus syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[46]], "entity_id": ["T4"]}, "Treatment": {"text": [["procainamide"]], "start": [[33]], "entity_id": ["T3"], "Drug": {"text": [["procainamide"]], "start": [[33]], "entity_id": ["T6"]}}, "Effect": {"text": [["lupus syndrome"]], "start": [[54]], "entity_id": ["T5"]}}]}]}
{"id": "16405935_3", "context": "This report describes a case of bilateral ptosis induced by chloroquine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[49]], "entity_id": ["T5"]}, "Subject": {"text": [["a case"]], "start": [[22]], "entity_id": ["T3"]}, "Effect": {"text": [["bilateral ptosis"]], "start": [[32]], "entity_id": ["T4"]}, "Treatment": {"text": [["chloroquine"]], "start": [[60]], "entity_id": ["T6"], "Drug": {"text": [["chloroquine"]], "start": [[60]], "entity_id": ["T7"]}}}]}]}
{"id": "12221670_5", "context": "When the data of the 57 patients are evaluated, a reversible direct cytotoxic effect of ticlopidine on the pluripotent/bipotent hematopoietic progenitor stem cell is proposed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["proposed"]], "start": [[166]], "entity_id": ["T6"]}, "Subject": {"text": [["57 patients"]], "start": [[21]], "entity_id": ["T3"], "Population": {"text": [["57"]], "start": [[21]], "entity_id": ["T7"]}}, "Effect": {"text": [["cytotoxic effect"]], "start": [[68]], "entity_id": ["T4"]}, "Treatment": {"text": [["ticlopidine"]], "start": [[88]], "entity_id": ["T5"], "Drug": {"text": [["ticlopidine"]], "start": [[88]], "entity_id": ["T8"]}}}]}]}
{"id": "17526968_3", "context": "We report a child with yolk sac tumor who developed localized pigmentation after the first course of chemotherapy regimen that included cisplatin, etoposide and bleomycin.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[75]], "entity_id": ["T12"]}, "Subject": {"text": [["a child with yolk sac tumor"]], "start": [[10]], "entity_id": ["T9"], "Age": {"text": [["child"]], "start": [[12]], "entity_id": ["T13"]}}, "Effect": {"text": [["localized pigmentation"]], "start": [[52]], "entity_id": ["T10"]}, "Treatment": {"text": [["the first course of chemotherapy regimen that included cisplatin, etoposide and bleomycin"]], "start": [[81]], "entity_id": ["T11"], "Duration": {"text": [["the first course"]], "start": [[81]], "entity_id": ["T15"]}, "Drug": {"text": [["cisplatin"], ["etoposide"], ["bleomycin"]], "start": [[136], [147], [161]], "entity_id": ["T17", "T18", "T19"]}, "Disorder": {"text": [["yolk sac tumor"]], "start": [[23]], "entity_id": ["T20"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["included"]], "start": [[127]], "entity_id": ["T16"]}, "Drug": {"text": [["cisplatin"], ["etoposide"], ["bleomycin"]], "start": [[136], [147], [161]], "entity_id": ["T17", "T18", "T19"]}}]}}]}]}
{"id": "16791713_2", "context": "Except hypothyroidism after radioiodine treatment (euthyroid under substitutional therapy), she suffered from no other diseases.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[22]], "entity_id": ["T6"]}, "Effect": {"text": [["hypothyroidism"]], "start": [[7]], "entity_id": ["T3"]}, "Treatment": {"text": [["radioiodine treatment (euthyroid under substitutional therapy)"]], "start": [[28]], "entity_id": ["T4"], "Drug": {"text": [["radioiodine"]], "start": [[28]], "entity_id": ["T8"]}}, "Subject": {"text": [["she"]], "start": [[92]], "entity_id": ["T5"], "Gender": {"text": [["she"]], "start": [[92]], "entity_id": ["T7"]}}}]}]}
{"id": "17034541_1", "context": "Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[43]], "entity_id": ["T3"]}, "Treatment": {"text": [["rituximab"]], "start": [[49]], "entity_id": ["T4"], "Disorder": {"text": [["low-grade cutaneous B-cell lymphoma"]], "start": [[72]], "entity_id": ["T5"]}, "Drug": {"text": [["rituximab"]], "start": [[49]], "entity_id": ["T7"]}}, "Effect": {"text": [["Late lethal hepatitis B virus reactivation"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "15482394_3", "context": "Despite the low dosage of warfarin, international normalized ratio (INR) was markedly elevated from 1.15 to 11.28 for only 4 days, and bleeding symptoms concurrently developed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[166]], "entity_id": ["T5"]}, "Treatment": {"text": [["low dosage of warfarin"]], "start": [[12]], "entity_id": ["T3"], "Drug": {"text": [["warfarin"]], "start": [[26]], "entity_id": ["T6"]}, "Dosage": {"text": [["low dosage"], ["1.15"], ["11.28"]], "start": [[12], [100], [108]], "entity_id": ["T7", "T8", "T9"]}, "Duration": {"text": [["4 days"]], "start": [[123]], "entity_id": ["T10"]}}, "Effect": {"text": [["international normalized ratio (INR) was markedly elevated", "bleeding symptoms"]], "start": [[36, 135]], "entity_id": ["T4"]}}]}]}
{"id": "3815268_2", "context": "The possible role of interferon beta in the pathogenesis of sarcoidosis in this patient is discussed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["role"]], "start": [[13]], "entity_id": ["T7"]}, "Subject": {"text": [["this patient"]], "start": [[75]], "entity_id": ["T4"]}, "Treatment": {"text": [["interferon beta"]], "start": [[21]], "entity_id": ["T5"], "Drug": {"text": [["interferon beta"]], "start": [[21]], "entity_id": ["T9"]}}, "Effect": {"text": [["sarcoidosis"]], "start": [[60]], "entity_id": ["T3"]}, "Speculated": {"text": [["possible"]], "start": [[4]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "11144696_11", "context": "We hypothesize that a pharmacodynamic or pharmacokinetic drug interaction between venlafaxine and trimipramine involving the CYP2D6 isoenzyme may have played a role in inducing the seizures.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["inducing"]], "start": [[168]], "entity_id": ["T7"]}, "Effect": {"text": [["seizures"]], "start": [[181]], "entity_id": ["T8"]}, "Treatment": {"text": [["venlafaxine and trimipramine"]], "start": [[82]], "entity_id": ["T9"], "Drug": {"text": [["venlafaxine"], ["trimipramine"]], "start": [[82], [98]], "entity_id": ["T13", "T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[94]], "entity_id": ["T15"]}, "Drug": {"text": [["venlafaxine"], ["trimipramine"]], "start": [[82], [98]], "entity_id": ["T13", "T14"]}}]}, "Speculated": {"text": [["may"], ["hypothesize"]], "start": [[142], [3]], "entity_id": ["T10", "T11"], "value": true}}]}]}
{"id": "2116935_3", "context": "A case is described of severe splenic hemorrhage and rupture which developed 3 h after completion of tPA infusion for suspected acute myocardial infarction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[67]], "entity_id": ["T8"]}, "Effect": {"text": [["severe splenic hemorrhage and rupture"]], "start": [[23]], "entity_id": ["T7"]}, "Treatment": {"text": [["3 h after completion of tPA infusion"]], "start": [[77]], "entity_id": ["T9"], "Disorder": {"text": [["suspected acute myocardial infarction"]], "start": [[118]], "entity_id": ["T10"]}, "Time_elapsed": {"text": [["3 h"]], "start": [[77]], "entity_id": ["T12"]}, "Drug": {"text": [["tPA"]], "start": [[101]], "entity_id": ["T13"]}, "Route": {"text": [["infusion"]], "start": [[105]], "entity_id": ["T14"]}}, "Severity": {"text": [["severe"]], "start": [[23]], "entity_id": ["T11"], "value": "High"}}]}]}
{"id": "15383642_6", "context": "Three weeks later, the decerebrate rigidity and high BP remained, and tizanidine was initiated to see whether the decrease in muscle tone could facilitate hypertension control and motor recovery.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["initiated"]], "start": [[85]], "entity_id": ["T12"]}, "Subject": {"text": [["decerebrate rigidity and high BP"]], "start": [[23]], "entity_id": ["T9"]}, "Treatment": {"text": [["tizanidine"]], "start": [[70]], "entity_id": ["T10"], "Drug": {"text": [["tizanidine"]], "start": [[70]], "entity_id": ["T16"]}, "Disorder": {"text": [["decerebrate rigidity and high BP"]], "start": [[23]], "entity_id": ["T17"]}}, "Effect": {"text": [["hypertension control and motor recovery"]], "start": [[155]], "entity_id": ["T13"]}, "Speculated": {"text": [["to see whether"]], "start": [[95]], "entity_id": ["T15"], "value": true}}]}]}
{"id": "1635565_2", "context": "CONCLUSIONS: The administration of prostaglandin E1 to neonates can cause gastric-outlet obstruction due to antral hyperplasia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[68]], "entity_id": ["T7"]}, "Treatment": {"text": [["prostaglandin E1"]], "start": [[35]], "entity_id": ["T5"], "Drug": {"text": [["prostaglandin E1"]], "start": [[35]], "entity_id": ["T10"]}}, "Subject": {"text": [["neonates"]], "start": [[55]], "entity_id": ["T6"], "Age": {"text": [["neonates"]], "start": [[55]], "entity_id": ["T9"]}}, "Effect": {"text": [["gastric-outlet obstruction due to antral hyperplasia"]], "start": [[74]], "entity_id": ["T8"]}}]}]}
{"id": "8013261_1", "context": "During and after IFN therapy we should consider the possibility of occurrence of IDDM as well as other autoimmune diseases and observe the clinical course carefully.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurrence"]], "start": [[67]], "entity_id": ["T4"]}, "Treatment": {"text": [["IFN therapy"]], "start": [[17]], "entity_id": ["T3"], "Drug": {"text": [["IFN therapy"]], "start": [[17]], "entity_id": ["T6"]}, "Time_elapsed": {"text": [["During and after"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["IDDM as well as other autoimmune diseases"]], "start": [[81]], "entity_id": ["T5"]}}]}]}
{"id": "9754850_1", "context": "In two of these cases akathisia resolved after withdrawal of olanzapine and substitution by a classical or an atypical neuroleptic agent, respectively.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resolved"]], "start": [[32]], "entity_id": ["T3"]}, "Treatment": {"text": [["withdrawal of olanzapine and substitution by a classical", "neuroleptic agent"]], "start": [[47, 119]], "entity_id": ["T4"], "Drug": {"text": [["olanzapine"], ["neuroleptic agent"]], "start": [[61], [119]], "entity_id": ["T6", "T7"]}}, "Effect": {"text": [["akathisia"]], "start": [[22]], "entity_id": ["T5"]}, "Subject": {"text": [["two of these cases"]], "start": [[3]], "entity_id": ["T9"], "Population": {"text": [["two"]], "start": [[3]], "entity_id": ["T10"]}}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["resolved"]], "start": [[32]], "entity_id": ["T3"]}, "Effect": {"text": [["akathisia"]], "start": [[22]], "entity_id": ["T5"]}, "Treatment": {"text": [["withdrawal of olanzapine and substitution by", "an atypical neuroleptic agent"]], "start": [[47, 107]], "entity_id": ["T8"]}}]}]}
{"id": "3310776_2", "context": "Captopril-related (and -induced?) asthma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[10]], "entity_id": ["T3"]}, "Treatment": {"text": [["Captopril"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Captopril"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["asthma"]], "start": [[34]], "entity_id": ["T5"]}}]}]}
{"id": "15671134_3", "context": "These findings suggest that clozapine-induced seizures can be successfully treated, that gradual dose titration can reduce the likelihood of further episodes of seizures and that concomitant use of a suitable mood stabilizer/anti-epileptic medication can improve the outcome of treatment-resistant schizophrenia.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[38]], "entity_id": ["T4"]}, "Treatment": {"text": [["clozapine"]], "start": [[28]], "entity_id": ["T3"], "Drug": {"text": [["clozapine"]], "start": [[28]], "entity_id": ["T6"]}}, "Effect": {"text": [["seizures"]], "start": [[46]], "entity_id": ["T5"]}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[75]], "entity_id": ["T9"]}, "Treatment": {"text": [["gradual dose titration", "concomitant use of a suitable mood stabilizer/anti-epileptic medication"]], "start": [[89, 179]], "entity_id": ["T8"], "Disorder": {"text": [["clozapine-induced seizures"]], "start": [[28]], "entity_id": ["T11"]}}, "Effect": {"text": [["the likelihood of further episodes of seizures", "improve the outcome of treatment-resistant schizophrenia"]], "start": [[123, 255]], "entity_id": ["T10"]}}]}]}
{"id": "18094347_1", "context": "According to the Naranjo probability scale, the papular eruption was probably caused by methotrexate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[78]], "entity_id": ["T5"]}, "Effect": {"text": [["papular eruption"]], "start": [[48]], "entity_id": ["T3"]}, "Treatment": {"text": [["methotrexate"]], "start": [[88]], "entity_id": ["T4"], "Drug": {"text": [["methotrexate"]], "start": [[88]], "entity_id": ["T6"]}}, "Speculated": {"text": [["probably"]], "start": [[69]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "3688031_3", "context": "The patient's defects may be due to methimazole teratogenicity or could represent a previously undescribed syndrome affecting ectodermal structures.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[29]], "entity_id": ["T5"]}, "Treatment": {"text": [["methimazole"]], "start": [[36]], "entity_id": ["T3"], "Drug": {"text": [["methimazole"]], "start": [[36]], "entity_id": ["T6"]}}, "Effect": {"text": [["teratogenicity"]], "start": [[48]], "entity_id": ["T4"]}, "Speculated": {"text": [["may"]], "start": [[22]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "11881322_2", "context": "CONCLUSIONS: Itraconazole-induced liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to ductopenia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[26]], "entity_id": ["T10"]}, "Treatment": {"text": [["Itraconazole"]], "start": [[13]], "entity_id": ["T9"], "Drug": {"text": [["Itraconazole"]], "start": [[13]], "entity_id": ["T12"]}}, "Effect": {"text": [["liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to ductopenia"]], "start": [[34]], "entity_id": ["T11"]}}]}]}
{"id": "12243603_8", "context": "Rhabdomyolysis resulting from the drug interaction between diltiazem and other HMG-CoA reductase inhibitors has been described in the literature.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulting"]], "start": [[15]], "entity_id": ["T7"]}, "Effect": {"text": [["Rhabdomyolysis"]], "start": [[0]], "entity_id": ["T6"]}, "Treatment": {"text": [["diltiazem and other HMG-CoA reductase inhibitors"]], "start": [[59]], "entity_id": ["T8"], "Drug": {"text": [["diltiazem"], ["HMG-CoA reductase inhibitors"]], "start": [[59], [79]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[39]], "entity_id": ["T9"]}, "Drug": {"text": [["diltiazem"], ["HMG-CoA reductase inhibitors"]], "start": [[59], [79]], "entity_id": ["T10", "T11"]}}]}}]}]}
{"id": "23552010_1", "context": "Acute angioedema response to topical 5-fluorouracil therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["response"]], "start": [[17]], "entity_id": ["T5"]}, "Effect": {"text": [["angioedema"]], "start": [[6]], "entity_id": ["T4"]}, "Treatment": {"text": [["5-fluorouracil"]], "start": [[37]], "entity_id": ["T6"], "Drug": {"text": [["5-fluorouracil"]], "start": [[37]], "entity_id": ["T7"]}}}]}]}
{"id": "3569037_3", "context": "Hypersensitivity reactions due to chloramphenicol are rarely reported in the literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[27]], "entity_id": ["T4"]}, "Effect": {"text": [["Hypersensitivity reactions"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["chloramphenicol"]], "start": [[34]], "entity_id": ["T5"], "Drug": {"text": [["chloramphenicol"]], "start": [[34]], "entity_id": ["T6"]}}}]}]}
{"id": "18515982_3", "context": "Diagnosis of sclerosing glomerulonephritis occurred in this patient during anastrozole use, suggesting a newly defined side effect of anastrozole.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[68]], "entity_id": ["T4"]}, "Effect": {"text": [["sclerosing glomerulonephritis"]], "start": [[13]], "entity_id": ["T3"]}, "Subject": {"text": [["patient"]], "start": [[60]], "entity_id": ["T5"]}, "Treatment": {"text": [["anastrozole"]], "start": [[75]], "entity_id": ["T6"], "Drug": {"text": [["anastrozole"]], "start": [[75]], "entity_id": ["T8"]}}, "Speculated": {"text": [["suggesting"]], "start": [[92]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "582099_1", "context": "A patient with coccidioidal meningitis was treated with intrathecally administered amphotericin B, and an acute toxic delirium with EEG abnormalities developed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated with"]], "start": [[43]], "entity_id": ["T5"]}, "Treatment": {"text": [["intrathecally administered amphotericin B"]], "start": [[56]], "entity_id": ["T6"], "Disorder": {"text": [["coccidioidal meningitis"]], "start": [[15]], "entity_id": ["T9"]}, "Drug": {"text": [["amphotericin B"]], "start": [[83]], "entity_id": ["T10"]}, "Route": {"text": [["intrathecally"]], "start": [[56]], "entity_id": ["T11"]}}, "Effect": {"text": [["an acute toxic delirium with EEG abnormalities"]], "start": [[103]], "entity_id": ["T7"]}, "Subject": {"text": [["A patient with coccidioidal meningitis"]], "start": [[0]], "entity_id": ["T8"]}}]}]}
{"id": "18801826_5", "context": "This case raises important questions about non-ketotic, hyperosmolar diabetic coma with antipsychotics, the possible association between hyperglycaemia and hyperthermia, and the direction of causality in this, the recognition of either syndrome when they co-exist and management issues in such patients.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["association"]], "start": [[117]], "entity_id": ["T8"]}, "Effect": {"text": [["non-ketotic, hyperosmolar diabetic coma", "hyperglycaemia and hyperthermia"]], "start": [[43, 137]], "entity_id": ["T7"]}, "Treatment": {"text": [["antipsychotics"]], "start": [[88]], "entity_id": ["T9"], "Drug": {"text": [["antipsychotics"]], "start": [[88]], "entity_id": ["T12"]}}, "Speculated": {"text": [["possible"]], "start": [[108]], "entity_id": ["T13"], "value": true}}]}]}
{"id": "10203437_8", "context": "CONCLUSIONS: Reversible lupus-like syndrome appears to be a rare but significant side effect of 5-ASA compounds.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["side effect"]], "start": [[81]], "entity_id": ["T6"]}, "Treatment": {"text": [["5-ASA"]], "start": [[96]], "entity_id": ["T7"], "Drug": {"text": [["5-ASA"]], "start": [[96]], "entity_id": ["T9"]}}, "Effect": {"text": [["Reversible lupus-like syndrome"]], "start": [[13]], "entity_id": ["T8"]}, "Speculated": {"text": [["appears"]], "start": [[44]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "267281_1", "context": "A patient with chronic myeloid leukaemia treated with busulphan for 4-5 years, developed signs of busulphan toxicity and portal hypertension with ascites, oesophageal varices and jaundice.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[79]], "entity_id": ["T12"]}, "Subject": {"text": [["A patient with chronic myeloid leukaemia"]], "start": [[0]], "entity_id": ["T9"]}, "Treatment": {"text": [["busulphan for 4-5 years"]], "start": [[54]], "entity_id": ["T11"], "Duration": {"text": [["4-5 years"]], "start": [[68]], "entity_id": ["T14"]}, "Drug": {"text": [["busulphan"]], "start": [[54]], "entity_id": ["T15"]}, "Disorder": {"text": [["chronic myeloid leukaemia"]], "start": [[15]], "entity_id": ["T16"]}}, "Effect": {"text": [["busulphan toxicity and portal hypertension with ascites, oesophageal varices and jaundice"]], "start": [[98]], "entity_id": ["T13"]}}]}]}
{"id": "8828999_4", "context": "Several cases of lithium-induced Creutzfeldt-Jakob syndrome have been reported to date; all of them were elderly patients and a half had \"therapeutic\" lithium serum levels.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[25]], "entity_id": ["T5"]}, "Treatment": {"text": [["lithium", "\"therapeutic\" lithium serum levels"]], "start": [[17, 137]], "entity_id": ["T6"], "Drug": {"text": [["lithium"], ["lithium"]], "start": [[17], [151]], "entity_id": ["T9", "T10"]}}, "Effect": {"text": [["Creutzfeldt-Jakob syndrome"]], "start": [[33]], "entity_id": ["T7"]}, "Subject": {"text": [["elderly patients"]], "start": [[105]], "entity_id": ["T4"], "Age": {"text": [["elderly"]], "start": [[105]], "entity_id": ["T8"]}}}]}]}
{"id": "11206417_3", "context": "There is, however, currently no data on the effect of combined hyperglycaemia and hyperinsulinaemia on the renal and ocular blood flow seen in diabetic patients on insulin therapy.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["on"]], "start": [[161]], "entity_id": ["T11"]}, "Effect": {"text": [["renal and ocular blood flow"]], "start": [[107]], "entity_id": ["T9"]}, "Subject": {"text": [["combined hyperglycaemia and hyperinsulinaemia", "diabetic patients"]], "start": [[54, 143]], "entity_id": ["T10"]}, "Treatment": {"text": [["insulin therapy"]], "start": [[164]], "entity_id": ["T8"], "Drug": {"text": [["hyperglycaemia"], ["hyperinsulinaemia"]], "start": [[63], [82]], "entity_id": ["T14", "T15"]}, "Disorder": {"text": [["diabetic"]], "start": [[143]], "entity_id": ["T16"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combined"]], "start": [[54]], "entity_id": ["T13"]}, "Drug": {"text": [["hyperglycaemia"], ["hyperinsulinaemia"]], "start": [[63], [82]], "entity_id": ["T14", "T15"]}}]}, "Negated": {"text": [["no data"]], "start": [[29]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "8445549_2", "context": "Pemphigus vulgaris precipitated by glibenclamide therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["precipitated"]], "start": [[19]], "entity_id": ["T4"]}, "Effect": {"text": [["Pemphigus vulgaris"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["glibenclamide"]], "start": [[35]], "entity_id": ["T5"], "Drug": {"text": [["glibenclamide"]], "start": [[35]], "entity_id": ["T6"]}}}]}]}
{"id": "3804181_1", "context": "Methimazole-associated cholestatic liver injury: case report and brief literature review.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[12]], "entity_id": ["T4"]}, "Treatment": {"text": [["Methimazole"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Methimazole"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["cholestatic liver injury"]], "start": [[23]], "entity_id": ["T5"]}}]}]}
{"id": "2452936_2", "context": "The most likely cause of such hyponatremic episode is vinblastine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["is"]], "start": [[51]], "entity_id": ["T3"]}, "Treatment": {"text": [["vinblastine"]], "start": [[54]], "entity_id": ["T4"], "Drug": {"text": [["vinblastine"]], "start": [[54]], "entity_id": ["T6"]}}, "Effect": {"text": [["hyponatremic episode"]], "start": [[30]], "entity_id": ["T5"]}, "Speculated": {"text": [["most likely"]], "start": [[4]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "15770343_1", "context": "Anti-tuberculous drugs had been stopped on the 2nd day of therapy due to development of optic neuritis secondary to ethambutol administration at another hospital.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["to"]], "start": [[113]], "entity_id": ["T6"]}, "Effect": {"text": [["optic neuritis secondary"]], "start": [[88]], "entity_id": ["T4"]}, "Treatment": {"text": [["ethambutol"]], "start": [[116]], "entity_id": ["T5"], "Drug": {"text": [["ethambutol"]], "start": [[116]], "entity_id": ["T3"]}}}]}]}
{"id": "21751692_5", "context": "Based on this experience, we suggest that low-dose ketamine added to propofol may be associated with prevention of EA in children with a history of EA with propofol TIVA.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["prevention"]], "start": [[101]], "entity_id": ["T12"]}, "Subject": {"text": [["children with a history of EA with propofol TIVA"]], "start": [[121]], "entity_id": ["T10"], "Disorder": {"text": [["EA with propofol TIVA"]], "start": [[148]], "entity_id": ["T14"]}, "Age": {"text": [["children"]], "start": [[121]], "entity_id": ["T15"]}}, "Treatment": {"text": [["low-dose ketamine added to propofol"]], "start": [[42]], "entity_id": ["T13"], "Disorder": {"text": [["EA"]], "start": [[115]], "entity_id": ["T11"]}, "Drug": {"text": [["ketamine"], ["propofol"]], "start": [[51], [69]], "entity_id": ["T18", "T19"]}, "Dosage": {"text": [["low-dose"]], "start": [[42]], "entity_id": ["T20"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["added"]], "start": [[60]], "entity_id": ["T17"]}, "Drug": {"text": [["ketamine"], ["propofol"]], "start": [[51], [69]], "entity_id": ["T18", "T19"]}}]}, "Speculated": {"text": [["may"]], "start": [[78]], "entity_id": ["T16"], "value": true}}]}]}
{"id": "8903300_2", "context": "Tetany in a child with AIDS receiving intravenous tobramycin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[7]], "entity_id": ["T5"]}, "Effect": {"text": [["Tetany"]], "start": [[0]], "entity_id": ["T3"]}, "Subject": {"text": [["a child with AIDS"]], "start": [[10]], "entity_id": ["T4"], "Age": {"text": [["child"]], "start": [[12]], "entity_id": ["T7"]}, "Disorder": {"text": [["AIDS"]], "start": [[23]], "entity_id": ["T8"]}}, "Treatment": {"text": [["intravenous tobramycin"]], "start": [[38]], "entity_id": ["T6"], "Drug": {"text": [["tobramycin"]], "start": [[50]], "entity_id": ["T9"]}, "Route": {"text": [["intravenous"]], "start": [[38]], "entity_id": ["T10"]}}}]}]}
{"id": "15454180_3", "context": "Sideroblastic anemia due to linezolid in a patient with a left ventricular assist device.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[21]], "entity_id": ["T7"]}, "Effect": {"text": [["Sideroblastic anemia"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["linezolid"]], "start": [[28]], "entity_id": ["T4"], "Drug": {"text": [["linezolid"]], "start": [[28]], "entity_id": ["T8"]}, "Disorder": {"text": [["left ventricular assist device"]], "start": [[58]], "entity_id": ["T9"]}}, "Subject": {"text": [["patient with a left ventricular assist device"]], "start": [[43]], "entity_id": ["T6"]}}]}]}
{"id": "17655376_2", "context": "Oral dapsone has been available for over 60 years and has been used to treat severe acne vulgaris; however, the oral formulation is known to cause dose-dependent haematological reactions and is currently indicated only for diseases such as dermatitis herpetiformis and Hansen's disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[141]], "entity_id": ["T10"]}, "Treatment": {"text": [["Oral dapsone"]], "start": [[0]], "entity_id": ["T9"], "Drug": {"text": [["dapsone"]], "start": [[5]], "entity_id": ["T13"]}, "Route": {"text": [["Oral"]], "start": [[0]], "entity_id": ["T14"]}, "Disorder": {"text": [["dermatitis herpetiformis"], ["Hansen's disease"]], "start": [[240], [269]], "entity_id": ["T15", "T16"]}}, "Effect": {"text": [["dose-dependent haematological reactions"]], "start": [[147]], "entity_id": ["T11"]}}]}]}
{"id": "1580986_1", "context": "Enalapril-induced anemia in two kidney transplant recipients.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[10]], "entity_id": ["T6"]}, "Treatment": {"text": [["Enalapril"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Enalapril"]], "start": [[0]], "entity_id": ["T9"]}, "Disorder": {"text": [["kidney transplant"]], "start": [[32]], "entity_id": ["T10"]}}, "Subject": {"text": [["two kidney transplant recipients"]], "start": [[28]], "entity_id": ["T8"]}, "Effect": {"text": [["anemia"]], "start": [[18]], "entity_id": ["T7"]}}]}]}
{"id": "10458196_5", "context": "PURPOSE: To report two cases in which topical brimonidine resulted in apparent central nervous system depression and unresponsiveness in an infant.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulted"]], "start": [[58]], "entity_id": ["T6"]}, "Treatment": {"text": [["topical brimonidine"]], "start": [[38]], "entity_id": ["T3"], "Route": {"text": [["topical"]], "start": [[38]], "entity_id": ["T8"]}, "Drug": {"text": [["brimonidine"]], "start": [[46]], "entity_id": ["T9"]}}, "Effect": {"text": [["apparent central nervous system depression and unresponsiveness"]], "start": [[70]], "entity_id": ["T4"]}, "Subject": {"text": [["an infant"]], "start": [[137]], "entity_id": ["T5"], "Age": {"text": [["infant"]], "start": [[140]], "entity_id": ["T7"]}}}]}]}
{"id": "16225183_2", "context": "BACKGROUND: Interferon beta has become standard therapy for reducing relapse frequency in relapsing/remitting Multiple Sclerosis (RRMS).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["standard therapy"]], "start": [[39]], "entity_id": ["T11"]}, "Treatment": {"text": [["Interferon beta"]], "start": [[12]], "entity_id": ["T5"], "Drug": {"text": [["Interferon beta"]], "start": [[12]], "entity_id": ["T9"]}, "Disorder": {"text": [["relapsing/remitting Multiple Sclerosis"]], "start": [[90]], "entity_id": ["T10"]}}}]}]}
{"id": "14566215_1", "context": "In this article lithium is not discussed, although there are a number of concerns about lithium's potential teratogenicity, and it has been implicated in Epstein's anomaly, a congenital heart defect among infants born to women taking lithium; as with other medications, however, the data have specific limitations.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["implicated"]], "start": [[140]], "entity_id": ["T9"]}, "Treatment": {"text": [["lithium"]], "start": [[234]], "entity_id": ["T7"], "Drug": {"text": [["lithium"]], "start": [[234]], "entity_id": ["T10"]}}, "Effect": {"text": [["Epstein's anomaly"]], "start": [[154]], "entity_id": ["T8"]}}]}]}
{"id": "21751542_5", "context": "The risk of gastrointestinal bleeding during the treatment with antiagregants and anticoagulants, the risk of bradycardia in beta-blockade, possible interactions with other medications lowering the heart rate are discussed.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[38]], "entity_id": ["T11"]}, "Effect": {"text": [["gastrointestinal bleeding"]], "start": [[12]], "entity_id": ["T10"]}, "Treatment": {"text": [["antiagregants and anticoagulants"]], "start": [[64]], "entity_id": ["T12"], "Drug": {"text": [["antiagregants"], ["anticoagulants"]], "start": [[64], [82]], "entity_id": ["T15", "T16"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[78]], "entity_id": ["T14"]}, "Drug": {"text": [["antiagregants"], ["anticoagulants"]], "start": [[64], [82]], "entity_id": ["T15", "T16"]}}]}, "Speculated": {"text": [["risk"]], "start": [[4]], "entity_id": ["T17"], "value": true}}, {"event_id": "E3", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[122]], "entity_id": ["T20"]}, "Effect": {"text": [["bradycardia"]], "start": [[110]], "entity_id": ["T19"]}, "Treatment": {"text": [["beta-blockade"]], "start": [[125]], "entity_id": ["T21"], "Drug": {"text": [["beta-blockade"]], "start": [[125]], "entity_id": ["T22"]}}, "Speculated": {"text": [["risk"]], "start": [[102]], "entity_id": ["T18"], "value": true}}]}]}
{"id": "847572_1", "context": "Hepatotoxicity of paracetamol enhanced by ingestion of alcohol: report of two cases.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["enhanced"]], "start": [[30]], "entity_id": ["T4"]}, "Effect": {"text": [["Hepatotoxicity"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["paracetamol", "ingestion of alcohol"]], "start": [[18, 42]], "entity_id": ["T5"], "Drug": {"text": [["paracetamol"], ["alcohol"]], "start": [[18], [55]], "entity_id": ["T8", "T10"]}, "Route": {"text": [["ingestion"]], "start": [[42]], "entity_id": ["T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["enhanced"]], "start": [[30]], "entity_id": ["T9"]}, "Drug": {"text": [["alcohol"], ["paracetamol"]], "start": [[55], [18]], "entity_id": ["T10", "T8"]}}]}, "Subject": {"text": [["two cases."]], "start": [[74]], "entity_id": ["T6"], "Population": {"text": [["two"]], "start": [[74]], "entity_id": ["T7"]}}}]}]}
{"id": "10099659_7", "context": "Cancer patients who are receiving 5-FU treatment and are DPD deficient can develop severe side effects.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["develop"]], "start": [[75]], "entity_id": ["T13"]}, "Subject": {"text": [["Cancer patients", "are DPD deficient"]], "start": [[0, 53]], "entity_id": ["T9"], "Disorder": {"text": [["DPD deficient"]], "start": [[57]], "entity_id": ["T11"]}}, "Treatment": {"text": [["receiving 5-FU"]], "start": [[24]], "entity_id": ["T10"], "Drug": {"text": [["5-FU"]], "start": [[34]], "entity_id": ["T14"]}, "Disorder": {"text": [["Cancer"]], "start": [[0]], "entity_id": ["T18"]}}, "Effect": {"text": [["severe side effects"]], "start": [[83]], "entity_id": ["T12"]}, "Speculated": {"text": [["can"]], "start": [[71]], "entity_id": ["T15"], "value": true}, "Severity": {"text": [["severe"]], "start": [[83]], "entity_id": ["T16"], "value": "Medium"}}]}]}
{"id": "876914_1", "context": "A patient is described who developed a poorly differentiated sarcoma after cyclophosphamide was used to treat his rheumatoid arthritis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[27]], "entity_id": ["T4"]}, "Subject": {"text": [["A patient", "his rheumatoid arthritis"]], "start": [[0, 110]], "entity_id": ["T3"], "Gender": {"text": [["his"]], "start": [[110]], "entity_id": ["T10"]}}, "Effect": {"text": [["poorly differentiated sarcoma"]], "start": [[39]], "entity_id": ["T5"]}, "Treatment": {"text": [["cyclophosphamide"]], "start": [[75]], "entity_id": ["T6"], "Drug": {"text": [["cyclophosphamide"]], "start": [[75]], "entity_id": ["T8"]}, "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[114]], "entity_id": ["T9"]}}}]}]}
{"id": "18344734_1", "context": "Photo-onycholysis caused by olanzapine and aripiprazole.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[18]], "entity_id": ["T5"]}, "Effect": {"text": [["Photo-onycholysis"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["olanzapine and aripiprazole"]], "start": [[28]], "entity_id": ["T6"], "Drug": {"text": [["olanzapine"], ["aripiprazole"]], "start": [[28], [43]], "entity_id": ["T7", "T8"]}}}]}]}
{"id": "7606071_7", "context": "We observed 5 reactions in 3 patients that appear to be related to a high dose-infusion time ratio, indicating that dose and rate of infusion may be important factors in precipitating anaphylactoid reactions with cisplatin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["precipitating"]], "start": [[170]], "entity_id": ["T4"]}, "Treatment": {"text": [["high dose-infusion time ratio", "cisplatin"]], "start": [[69, 213]], "entity_id": ["T3"], "Dosage": {"text": [["high dose"]], "start": [[69]], "entity_id": ["T8"]}, "Drug": {"text": [["cisplatin"]], "start": [[213]], "entity_id": ["T9"]}}, "Effect": {"text": [["anaphylactoid reactions"]], "start": [[184]], "entity_id": ["T5"]}, "Subject": {"text": [["3 patients"]], "start": [[27]], "entity_id": ["T6"], "Population": {"text": [["3"]], "start": [[27]], "entity_id": ["T7"]}}}]}]}
{"id": "10395123_1", "context": "CONCLUSION: Fixed drug eruption is associated with many drugs but this is the first such report with omeprazole.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[35]], "entity_id": ["T5"]}, "Effect": {"text": [["Fixed drug eruption"]], "start": [[12]], "entity_id": ["T4"]}, "Treatment": {"text": [["omeprazole"]], "start": [[101]], "entity_id": ["T6"], "Drug": {"text": [["omeprazole"]], "start": [[101]], "entity_id": ["T3"]}}}]}]}
{"id": "6460590_1", "context": "One type of SMON is associated with acrodermatitis enteropathica which has a very high frequency of occurrence in association with administration of clioquinol.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["association"]], "start": [[114]], "entity_id": ["T6"]}, "Effect": {"text": [["SMON", "acrodermatitis enteropathica"]], "start": [[12, 36]], "entity_id": ["T5"]}, "Treatment": {"text": [["clioquinol"]], "start": [[149]], "entity_id": ["T7"], "Drug": {"text": [["clioquinol"]], "start": [[149]], "entity_id": ["T8"]}}, "Speculated": {"text": [["a very high frequency"]], "start": [[75]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "8949576_3", "context": "We report a case of amiodarone-induced thyrotoxicosis of protracted duration, unresponsive to conventional thionamide therapy, with therapy limited by severe adverse drug reactions.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[31]], "entity_id": ["T4"]}, "Treatment": {"text": [["amiodarone"]], "start": [[20]], "entity_id": ["T3"], "Drug": {"text": [["amiodarone"]], "start": [[20]], "entity_id": ["T7"]}}, "Effect": {"text": [["thyrotoxicosis"]], "start": [[39]], "entity_id": ["T5"]}, "Subject": {"text": [["a case"]], "start": [[10]], "entity_id": ["T6"]}}]}]}
{"id": "19151423_3", "context": "The addition of ciprofloxacin to chronic simvastatin therapy led to the development of rhabdomyolysis.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["led"]], "start": [[61]], "entity_id": ["T7"]}, "Treatment": {"text": [["ciprofloxacin", "chronic simvastatin"]], "start": [[16, 33]], "entity_id": ["T6"], "Drug": {"text": [["ciprofloxacin"], ["chronic simvastatin"]], "start": [[16], [33]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["addition"]], "start": [[4]], "entity_id": ["T11"]}, "Drug": {"text": [["ciprofloxacin"], ["chronic simvastatin"]], "start": [[16], [33]], "entity_id": ["T9", "T10"]}}]}, "Effect": {"text": [["rhabdomyolysis"]], "start": [[87]], "entity_id": ["T8"]}}]}]}
{"id": "941054_1", "context": "Nephropathy caused by methicillin therapy for staphylococcal septicemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[12]], "entity_id": ["T4"]}, "Effect": {"text": [["Nephropathy"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["methicillin therapy for staphylococcal septicemia"]], "start": [[22]], "entity_id": ["T5"], "Disorder": {"text": [["staphylococcal septicemia"]], "start": [[46]], "entity_id": ["T6"]}, "Drug": {"text": [["methicillin"]], "start": [[22]], "entity_id": ["T7"]}}}]}]}
{"id": "2028358_1", "context": "Four patients in whom pulmonary oedema developed during tocolysis with hexoprenaline are described and the aetiological factors and pathogenesis of this potentially lethal complication discussed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[39]], "entity_id": ["T6"]}, "Subject": {"text": [["Four patients"]], "start": [[0]], "entity_id": ["T3"], "Population": {"text": [["Four"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["pulmonary oedema"]], "start": [[22]], "entity_id": ["T4"]}, "Treatment": {"text": [["tocolysis with hexoprenaline"]], "start": [[56]], "entity_id": ["T1"], "Drug": {"text": [["hexoprenaline"]], "start": [[71]], "entity_id": ["T8"]}}}]}]}
{"id": "7379406_2", "context": "A case of skeletal fluorosis induced by prolonged treatment with niflumic acid, a fast-acting non-steroid antiinflammatory agent, is reported in a 35-year-old woman suffering from rheumatoid arthritis and treated, in addition, with corticosteroids.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[29]], "entity_id": ["T9"]}, "Treatment": {"text": [["niflumic acid", "in addition, with corticosteroids"]], "start": [[65, 214]], "entity_id": ["T10"], "Drug": {"text": [["niflumic acid"], ["corticosteroids"]], "start": [[65], [232]], "entity_id": ["T16", "T17"]}, "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[180]], "entity_id": ["T19"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["addition"]], "start": [[217]], "entity_id": ["T18"]}, "Drug": {"text": [["corticosteroids"], ["niflumic acid"]], "start": [[232], [65]], "entity_id": ["T17", "T16"]}}]}, "Effect": {"text": [["skeletal fluorosis"]], "start": [[10]], "entity_id": ["T11"]}, "Subject": {"text": [["a 35-year-old woman suffering from rheumatoid arthritis"]], "start": [[145]], "entity_id": ["T12"], "Age": {"text": [["35-year-old"]], "start": [[147]], "entity_id": ["T13"]}, "Gender": {"text": [["woman"]], "start": [[159]], "entity_id": ["T14"]}}}]}]}
{"id": "16637972_1", "context": "A 65-year-old man on warfarin therapy with a sudden spontaneous onset of sub-conjunctival haematoma associated with bloody tears was assessed in the clinic following a referral from an optometrist.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[38]], "entity_id": ["T8"]}, "Effect": {"text": [["a sudden spontaneous onset of sub-conjunctival haematoma associated with bloody tears"]], "start": [[43]], "entity_id": ["T5"]}, "Subject": {"text": [["A 65-year-old man"]], "start": [[0]], "entity_id": ["T6"], "Age": {"text": [["65-year-old"]], "start": [[2]], "entity_id": ["T9"]}, "Gender": {"text": [["man"]], "start": [[14]], "entity_id": ["T10"]}}, "Treatment": {"text": [["warfarin therapy"]], "start": [[21]], "entity_id": ["T7"], "Drug": {"text": [["warfarin"]], "start": [[21]], "entity_id": ["T11"]}}}]}]}
{"id": "11749112_2", "context": "This case report describes the development of asymptomatic visual field defects (VFDs) in a psychiatric patient with bipolar disorder receiving adjunctive tiagabine treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["development"]], "start": [[31]], "entity_id": ["T12"]}, "Treatment": {"text": [["tiagabine"]], "start": [[155]], "entity_id": ["T9"], "Disorder": {"text": [["bipolar disorder"]], "start": [[117]], "entity_id": ["T11"]}, "Drug": {"text": [["tiagabine"]], "start": [[155]], "entity_id": ["T14"]}}, "Subject": {"text": [["patient"]], "start": [[104]], "entity_id": ["T10"]}, "Effect": {"text": [["asymptomatic visual field defects"]], "start": [[46]], "entity_id": ["T13"]}}]}]}
{"id": "7436161_1", "context": "Cardiorespiratory toxicity due to miconazole.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due to"]], "start": [[27]], "entity_id": ["T6"]}, "Effect": {"text": [["Cardiorespiratory toxicity"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["miconazole"]], "start": [[34]], "entity_id": ["T5"], "Drug": {"text": [["miconazole"]], "start": [[34]], "entity_id": ["T7"]}}}]}]}
{"id": "9220046_5", "context": "Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T6"]}, "Treatment": {"text": [["clarithromycin", "azithromycin", "Lovastatin"]], "start": [[59, 78, 0]], "entity_id": ["T5"], "Drug": {"text": [["clarithromycin"], ["azithromycin"], ["Lovastatin"]], "start": [[59], [78], [0]], "entity_id": ["T8", "T9", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[74]], "entity_id": ["T10"]}, "Drug": {"text": [["clarithromycin"], ["azithromycin"]], "start": [[59], [78]], "entity_id": ["T8", "T9"]}}]}, "Effect": {"text": [["rhabdomyolysis"]], "start": [[19]], "entity_id": ["T7"]}, "Speculated": {"text": [["possibly"]], "start": [[34]], "entity_id": ["T12"], "value": true}}]}]}
{"id": "10490907_14", "context": "For prevention of CYP2E1-mediated bioactivation, depending on protoxicant disposition, a second DSF dose might be necessary to completely prevent toxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["to"]], "start": [[124]], "entity_id": ["T10"]}, "Treatment": {"text": [["a second DSF dose"]], "start": [[87]], "entity_id": ["T8"], "Drug": {"text": [["protoxicant"], ["DSF"]], "start": [[62], [96]], "entity_id": ["T9", "T11"]}, "Dosage": {"text": [["a second DSF dose"]], "start": [[87]], "entity_id": ["T12"]}}}]}]}
{"id": "3438585_3", "context": "We describe a patient with rheumatoid arthritis treated with gold salts, who developed bilateral interstitial pulmonary abnormalities and showed a dramatic response on corticosteroid therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated with"]], "start": [[48]], "entity_id": ["T10"]}, "Treatment": {"text": [["gold salts"]], "start": [[61]], "entity_id": ["T7"], "Drug": {"text": [["gold salts"], ["corticosteroid"]], "start": [[61], [168]], "entity_id": ["T12", "T13"]}, "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[27]], "entity_id": ["T14"]}}, "Effect": {"text": [["bilateral interstitial pulmonary abnormalities"]], "start": [[87]], "entity_id": ["T8"]}, "Subject": {"text": [["a patient with rheumatoid arthritis"]], "start": [[12]], "entity_id": ["T9"]}}]}]}
{"id": "9184269_5", "context": "Pneumonitis is emerging as one of the most unpredictable and potentially serious, adverse effects of treatment with MTX.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[111]], "entity_id": ["T3"]}, "Treatment": {"text": [["MTX"]], "start": [[116]], "entity_id": ["T4"], "Drug": {"text": [["MTX"]], "start": [[116]], "entity_id": ["T7"]}}, "Effect": {"text": [["Pneumonitis"]], "start": [[0]], "entity_id": ["T5"]}, "Speculated": {"text": [["potentially"]], "start": [[61]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "8771575_1", "context": "A chronic reaction associated with long-term treatment with nitrofurantoin has also been reported and causes irreversible pulmonary fibrosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["causes"]], "start": [[102]], "entity_id": ["T4"]}, "Treatment": {"text": [["long-term treatment with nitrofurantoin"]], "start": [[35]], "entity_id": ["T3"], "Dosage": {"text": [["long-term treatment"]], "start": [[35]], "entity_id": ["T6"]}, "Drug": {"text": [["nitrofurantoin"]], "start": [[60]], "entity_id": ["T7"]}}, "Effect": {"text": [["irreversible pulmonary fibrosis"]], "start": [[109]], "entity_id": ["T5"]}}]}]}
{"id": "19789166_2", "context": "Nitrofurantoin-induced acute liver damage in pregnancy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[15]], "entity_id": ["T4"]}, "Treatment": {"text": [["Nitrofurantoin"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Nitrofurantoin"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["acute liver damage"]], "start": [[23]], "entity_id": ["T5"]}, "Subject": {"text": [["pregnancy"]], "start": [[45]], "entity_id": ["T6"]}}]}]}
{"id": "12656748_1", "context": "A 58-yr-old male patient with essential thrombocythaemia (ET) developed chronic myeloid leukaemia (CML) after continuous uneventful treatment with hydroxyurea for 18 yr.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[62]], "entity_id": ["T6"]}, "Subject": {"text": [["A 58-yr-old male patient with essential thrombocythaemia (ET)"]], "start": [[0]], "entity_id": ["T5"], "Age": {"text": [["58-yr-old"]], "start": [[2]], "entity_id": ["T9"]}, "Gender": {"text": [["male"]], "start": [[12]], "entity_id": ["T10"]}}, "Effect": {"text": [["chronic myeloid leukaemia (CML)"]], "start": [[72]], "entity_id": ["T7"]}, "Treatment": {"text": [["continuous uneventful treatment with hydroxyurea for 18 yr"]], "start": [[110]], "entity_id": ["T8"], "Disorder": {"text": [["essential thrombocythaemia (ET)"]], "start": [[30]], "entity_id": ["T11"]}, "Drug": {"text": [["hydroxyurea"]], "start": [[147]], "entity_id": ["T12"]}, "Duration": {"text": [["18 yr"]], "start": [[163]], "entity_id": ["T13"]}}}]}]}
{"id": "7538828_2", "context": "A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed severe skin rash and bone marrow aplasia 4 and 7 days, respectively, following a single dose of 40 mg/m2 methotrexate (MTX).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[89]], "entity_id": ["T11"]}, "Effect": {"text": [["skin rash and bone marrow aplasia"]], "start": [[106]], "entity_id": ["T12"]}, "Treatment": {"text": [["a single dose of 40 mg/m2 methotrexate (MTX)"]], "start": [[178]], "entity_id": ["T14"], "Disorder": {"text": [["recurrent metastatic squamous cell carcinoma of the head and neck"]], "start": [[23]], "entity_id": ["T10"]}, "Dosage": {"text": [["40 mg/m2"]], "start": [[195]], "entity_id": ["T16"]}, "Drug": {"text": [["methotrexate"]], "start": [[204]], "entity_id": ["T17"]}, "Freq": {"text": [["a single dose"]], "start": [[178]], "entity_id": ["T19"]}, "Time_elapsed": {"text": [["4 and 7 days"]], "start": [[140]], "entity_id": ["T18"]}}, "Subject": {"text": [["A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck"]], "start": [[0]], "entity_id": ["T15"], "Age": {"text": [["64 year old"]], "start": [[2]], "entity_id": ["T9"]}, "Gender": {"text": [["man"]], "start": [[14]], "entity_id": ["T13"]}}, "Severity": {"text": [["severe"]], "start": [[99]], "entity_id": ["T20"], "value": "High"}}]}]}
{"id": "4004433_3", "context": "We present four cases in which the use of heparin was associated with hyperkalemia and discuss the pathophysiology.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[54]], "entity_id": ["T5"]}, "Subject": {"text": [["four cases"]], "start": [[11]], "entity_id": ["T3"], "Population": {"text": [["four"]], "start": [[11]], "entity_id": ["T7"]}}, "Treatment": {"text": [["heparin"]], "start": [[42]], "entity_id": ["T4"], "Drug": {"text": [["heparin"]], "start": [[42]], "entity_id": ["T8"]}}, "Effect": {"text": [["hyperkalemia"]], "start": [[70]], "entity_id": ["T6"]}}]}]}
{"id": "16968538_6", "context": "Three cycles of chemotherapy had been administered without complications when, at the beginning of the fourth cycle, the patient developed clinical and laboratory abnormalities consistent with the development of the hemolytic-uremic syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[129]], "entity_id": ["T4"]}, "Effect": {"text": [["hemolytic-uremic syndrome."]], "start": [[216]], "entity_id": ["T5"]}, "Treatment": {"text": [["chemotherapy", "at the beginning of the fourth cycle"]], "start": [[16, 79]], "entity_id": ["T6"], "Drug": {"text": [["chemotherapy"]], "start": [[16]], "entity_id": ["T8"]}, "Duration": {"text": [["fourth cycle"]], "start": [[103]], "entity_id": ["T9"]}}, "Subject": {"text": [["the patient"]], "start": [[117]], "entity_id": ["T7"]}}]}]}
{"id": "8862924_1", "context": "Keratitis in methamphetamine abusers.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[10]], "entity_id": ["T4"]}, "Effect": {"text": [["Keratitis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["methamphetamine abusers"]], "start": [[13]], "entity_id": ["T5"], "Drug": {"text": [["methamphetamine"]], "start": [[13]], "entity_id": ["T6"]}}}]}]}
{"id": "9399776_3", "context": "A rechallenge, performed in both patients, confirmed the diagnosis of mesalamine-induced pancreatitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[81]], "entity_id": ["T4"]}, "Treatment": {"text": [["mesalamine"]], "start": [[70]], "entity_id": ["T3"], "Drug": {"text": [["mesalamine"]], "start": [[70]], "entity_id": ["T7"]}}, "Effect": {"text": [["pancreatitis"]], "start": [[89]], "entity_id": ["T5"]}, "Subject": {"text": [["both patients"]], "start": [[28]], "entity_id": ["T6"]}}]}]}
{"id": "8197046_1", "context": "Central nervous system toxicity associated with meperidine use in hepatic disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[32]], "entity_id": ["T4"]}, "Effect": {"text": [["Central nervous system toxicity"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["meperidine"]], "start": [[48]], "entity_id": ["T5"], "Disorder": {"text": [["hepatic disease"]], "start": [[66]], "entity_id": ["T6"]}, "Drug": {"text": [["meperidine"]], "start": [[48]], "entity_id": ["T7"]}}}]}]}
{"id": "12066972_2", "context": "To our knowledge, this case is the first published report of levofloxacin-induced TEN.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[74]], "entity_id": ["T5"]}, "Treatment": {"text": [["levofloxacin"]], "start": [[61]], "entity_id": ["T3"], "Drug": {"text": [["levofloxacin"]], "start": [[61]], "entity_id": ["T6"]}}, "Effect": {"text": [["TEN"]], "start": [[82]], "entity_id": ["T4"]}}]}]}
{"id": "7282702_3", "context": "On the second day of hospitalization, it was noted that the patient's dyspnea and sinus bradycardia could be related to a recent increase in his timolol dosage.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[109]], "entity_id": ["T7"]}, "Effect": {"text": [["dyspnea and sinus bradycardia"]], "start": [[70]], "entity_id": ["T5"]}, "Subject": {"text": [["patient"]], "start": [[60]], "entity_id": ["T6"]}, "Treatment": {"text": [["a recent increase in his timolol dosage"]], "start": [[120]], "entity_id": ["T9"], "Drug": {"text": [["timolol"]], "start": [[145]], "entity_id": ["T11"]}}, "Speculated": {"text": [["could"]], "start": [[100]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "10870485_1", "context": "Three months following splenectomy, multiple abscesses occurred in the muscles of both thighs while the patient was receiving the third course of the CHOP regimen.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["while"]], "start": [[94]], "entity_id": ["T6"]}, "Effect": {"text": [["multiple abscesses occurred in the muscles of both thighs"]], "start": [[36]], "entity_id": ["T3"]}, "Subject": {"text": [["the patient"]], "start": [[100]], "entity_id": ["T4"]}, "Treatment": {"text": [["Three months following splenectomy", "third course of the CHOP regimen"]], "start": [[0, 130]], "entity_id": ["T5"], "Duration": {"text": [["Three months"]], "start": [[0]], "entity_id": ["T7"]}, "Drug": {"text": [["splenectomy"], ["CHOP"]], "start": [[23], [150]], "entity_id": ["T8", "T10"]}, "Dosage": {"text": [["third course"]], "start": [[130]], "entity_id": ["T9"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["receiving"]], "start": [[116]], "entity_id": ["T11"]}, "Drug": {"text": [["CHOP"], ["splenectomy"]], "start": [[150], [23]], "entity_id": ["T10", "T8"]}}]}}]}]}
{"id": "19423610_9", "context": "Methylene blue is used in a variety of surgical settings as well as for treatment of various types of hypotensive shock and methemoglobinaemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatment"]], "start": [[72]], "entity_id": ["T6"]}, "Treatment": {"text": [["Methylene blue"]], "start": [[0]], "entity_id": ["T5"], "Disorder": {"text": [["hypotensive shock"], ["methemoglobinaemia"]], "start": [[102], [124]], "entity_id": ["T8", "T9"]}, "Drug": {"text": [["Methylene blue"]], "start": [[0]], "entity_id": ["T7"]}}}]}]}
{"id": "9554064_1", "context": "Methanol toxicity can cause severe central nervous system insult in which a characteristic pattern of bilateral putaminal injury is noted on brain imaging studies.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[22]], "entity_id": ["T8"]}, "Effect": {"text": [["central nervous system insult"]], "start": [[35]], "entity_id": ["T7"]}, "Treatment": {"text": [["Methanol toxicity"]], "start": [[0]], "entity_id": ["T9"], "Drug": {"text": [["Methanol"]], "start": [[0]], "entity_id": ["T10"]}}, "Severity": {"text": [["severe"]], "start": [[28]], "entity_id": ["T11"], "value": "High"}}]}]}
{"id": "11737689_5", "context": "We believe that these skin eruptions belong to a spectrum of neutrophilic dermatoses that can be induced or aggravated by G-CSF therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[97]], "entity_id": ["T6"]}, "Effect": {"text": [["skin eruptions"]], "start": [[22]], "entity_id": ["T5"]}, "Treatment": {"text": [["G-CSF"]], "start": [[122]], "entity_id": ["T7"], "Drug": {"text": [["G-CSF"]], "start": [[122]], "entity_id": ["T9"]}}, "Speculated": {"text": [["believe"]], "start": [[3]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "3892171_4", "context": "Although adverse reactions to protamine are reported infrequently and are usually mild, we recently observed the first fatal case of type I anaphylaxis resulting from protamine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulting"]], "start": [[152]], "entity_id": ["T6"]}, "Treatment": {"text": [["protamine"]], "start": [[167]], "entity_id": ["T7"], "Drug": {"text": [["protamine"]], "start": [[167]], "entity_id": ["T9"]}}, "Effect": {"text": [["fatal case of type I anaphylaxis"]], "start": [[119]], "entity_id": ["T8"]}, "Severity": {"text": [["fatal"]], "start": [[119]], "entity_id": ["T10"], "value": "High"}}]}]}
{"id": "2595431_4", "context": "We have reported six cases of metoclopramide-induced parkinsonism seen in consultation over a two-year period.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[45]], "entity_id": ["T5"]}, "Subject": {"text": [["six cases"]], "start": [[17]], "entity_id": ["T3"], "Population": {"text": [["six"]], "start": [[17]], "entity_id": ["T7"]}}, "Treatment": {"text": [["metoclopramide"]], "start": [[30]], "entity_id": ["T4"], "Drug": {"text": [["metoclopramide"]], "start": [[30]], "entity_id": ["T8"]}}, "Effect": {"text": [["parkinsonism"]], "start": [[53]], "entity_id": ["T6"]}}]}]}
{"id": "14514135_1", "context": "Neutrophilic eccrine hidradenitis mimicking cutaneous vasculitis in a lupus patient: a complication of cyclophosphamide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[87]], "entity_id": ["T3"]}, "Treatment": {"text": [["cyclophosphamide"]], "start": [[103]], "entity_id": ["T4"], "Disorder": {"text": [["lupus"]], "start": [[70]], "entity_id": ["T7"]}, "Drug": {"text": [["cyclophosphamide"]], "start": [[103]], "entity_id": ["T8"]}}, "Effect": {"text": [["Neutrophilic eccrine hidradenitis"]], "start": [[0]], "entity_id": ["T5"]}, "Subject": {"text": [["a lupus patient"]], "start": [[68]], "entity_id": ["T6"]}}]}]}
{"id": "10656221_1", "context": "Gliclazide-induced acute hepatitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T5"]}, "Treatment": {"text": [["Gliclazide"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Gliclazide"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["acute hepatitis"]], "start": [[19]], "entity_id": ["T6"]}}]}]}
{"id": "8435665_1", "context": "A 16-year-old white male with acute biphenotypic leukemia developed evidence of the eosinophilia myalgia syndrome associated with total parenteral nutritional support with solutions containing tryptophan, which were given during his initial induction chemotherapy and also after autologous marrow transplantation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[58]], "entity_id": ["T4"]}, "Subject": {"text": [["A 16-year-old white male with acute biphenotypic leukemia"]], "start": [[0]], "entity_id": ["T3"], "Age": {"text": [["16-year-old"]], "start": [[2]], "entity_id": ["T7"]}, "Race": {"text": [["white"]], "start": [[14]], "entity_id": ["T8"]}, "Gender": {"text": [["male"]], "start": [[20]], "entity_id": ["T9"]}, "Disorder": {"text": [["acute biphenotypic leukemia"]], "start": [[30]], "entity_id": ["T10"]}}, "Effect": {"text": [["eosinophilia myalgia syndrome"]], "start": [[84]], "entity_id": ["T5"]}, "Treatment": {"text": [["total parenteral nutritional support with solutions containing tryptophan, which were given during his initial induction chemotherapy and also after autologous marrow transplantation"]], "start": [[130]], "entity_id": ["T6"], "Drug": {"text": [["tryptophan"]], "start": [[193]], "entity_id": ["T11"]}, "Route": {"text": [["parenteral"]], "start": [[136]], "entity_id": ["T12"]}}}]}]}
{"id": "16268429_2", "context": "Subacute cholestatic hepatitis likely related to the use of senna for chronic constipation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related to"]], "start": [[38]], "entity_id": ["T4"]}, "Effect": {"text": [["Subacute cholestatic hepatitis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["use of senna"]], "start": [[53]], "entity_id": ["T5"], "Drug": {"text": [["senna"]], "start": [[60]], "entity_id": ["T7"]}, "Disorder": {"text": [["chronic constipation."]], "start": [[70]], "entity_id": ["T8"]}}}]}]}
{"id": "12460237_2", "context": "Palmar-plantar erythrodysaesthesia (PPE) is an uncommon cutaneous complication of cytotoxic chemotherapy which generally presents as a painful erythema involving the palms and soles.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[66]], "entity_id": ["T8"]}, "Effect": {"text": [["Palmar-plantar erythrodysaesthesia (PPE)", "an uncommon cutaneous complication", "a painful erythema involving the palms and soles"]], "start": [[0, 44, 133]], "entity_id": ["T6"]}, "Treatment": {"text": [["cytotoxic chemotherapy"]], "start": [[82]], "entity_id": ["T7"], "Drug": {"text": [["cytotoxic"]], "start": [[82]], "entity_id": ["T9"]}, "Route": {"text": [["chemotherapy"]], "start": [[92]], "entity_id": ["T10"]}}}]}]}
{"id": "19363904_2", "context": "We report a case of an 11-year-old boy who experienced an anaphylactic reaction after administration of bacitracin ointment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["experienced"]], "start": [[43]], "entity_id": ["T5"]}, "Subject": {"text": [["an 11-year-old boy"]], "start": [[20]], "entity_id": ["T3"], "Age": {"text": [["11-year-old"]], "start": [[23]], "entity_id": ["T7"]}, "Gender": {"text": [["boy"]], "start": [[35]], "entity_id": ["T8"]}}, "Effect": {"text": [["an anaphylactic reaction"]], "start": [[55]], "entity_id": ["T4"]}, "Treatment": {"text": [["after administration of bacitracin ointment"]], "start": [[80]], "entity_id": ["T6"], "Drug": {"text": [["bacitracin"]], "start": [[104]], "entity_id": ["T9"]}}}]}]}
{"id": "15661067_2", "context": "The patient was found to have no motile sperm with a normal sperm count, while taking a dose of 400 mg/day of carbamazepine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["found"]], "start": [[16]], "entity_id": ["T6"]}, "Subject": {"text": [["The patient"]], "start": [[0]], "entity_id": ["T3"]}, "Effect": {"text": [["no motile sperm with a normal sperm count"]], "start": [[30]], "entity_id": ["T4"]}, "Treatment": {"text": [["400 mg/day of carbamazepine"]], "start": [[96]], "entity_id": ["T5"], "Dosage": {"text": [["400 mg/day"]], "start": [[96]], "entity_id": ["T8"]}, "Drug": {"text": [["carbamazepine"]], "start": [[110]], "entity_id": ["T9"]}}}]}]}
{"id": "990658_2", "context": "A fatal pancytopenia occurred in a patient with an history of depression with hypomanic rebounds, admitted for a manic episode and treated with levomepromazine, diazepam and lithium carbonate.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurred"]], "start": [[21]], "entity_id": ["T6"]}, "Effect": {"text": [["A fatal pancytopenia"]], "start": [[0]], "entity_id": ["T5"]}, "Subject": {"text": [["a patient with an history of depression with hypomanic rebounds"]], "start": [[33]], "entity_id": ["T7"], "Disorder": {"text": [["depression"], ["hypomanic rebounds"]], "start": [[62], [78]], "entity_id": ["T10", "T12"]}}, "Treatment": {"text": [["treated with levomepromazine, diazepam and lithium carbonate"]], "start": [[131]], "entity_id": ["T9"], "Disorder": {"text": [["a manic episode"]], "start": [[111]], "entity_id": ["T8"]}, "Drug": {"text": [["levomepromazine"], ["diazepam"], ["lithium carbonate"]], "start": [[144], [161], [174]], "entity_id": ["T13", "T15", "T16"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[170]], "entity_id": ["T14"]}, "Drug": {"text": [["levomepromazine"], ["diazepam"], ["lithium carbonate"]], "start": [[144], [161], [174]], "entity_id": ["T13", "T15", "T16"]}}]}, "Severity": {"text": [["fatal"]], "start": [[2]], "entity_id": ["T11"], "value": "High"}}]}]}
{"id": "15133245_2", "context": "Oxatomide is an antiallergic drug used for the treatment of diseases mediated by type I allergy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["used"]], "start": [[34]], "entity_id": ["T7"]}, "Treatment": {"text": [["Oxatomide"]], "start": [[0]], "entity_id": ["T8"], "Disorder": {"text": [["diseases mediated by type I allergy"]], "start": [[60]], "entity_id": ["T6"]}, "Drug": {"text": [["Oxatomide"]], "start": [[0]], "entity_id": ["T9"]}}}]}]}
{"id": "6453500_2", "context": "Toxic hepatitis induced by disulfiram in a non-alcoholic.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[16]], "entity_id": ["T4"]}, "Effect": {"text": [["Toxic hepatitis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["disulfiram"]], "start": [[27]], "entity_id": ["T6"], "Drug": {"text": [["disulfiram"]], "start": [[27]], "entity_id": ["T5"]}}, "Subject": {"text": [["a non-alcoholic"]], "start": [[41]], "entity_id": ["T7"]}}]}]}
{"id": "3143551_1", "context": "Accordingly, camptocormia is a dose-dependent side effect of valproate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["effect"]], "start": [[51]], "entity_id": ["T4"]}, "Effect": {"text": [["camptocormia"]], "start": [[13]], "entity_id": ["T3"]}, "Treatment": {"text": [["valproate"]], "start": [[61]], "entity_id": ["T5"], "Drug": {"text": [["valproate"]], "start": [[61]], "entity_id": ["T6"]}}}]}]}
{"id": "19390192_2", "context": "The uncomplicated long-term use of adequately-dosed AZA and stable non-toxic metabolite levels could not acknowledge TPMT deficiency as a primary cause of the leukopenia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[146]], "entity_id": ["T3"]}, "Effect": {"text": [["leukopenia"]], "start": [[159]], "entity_id": ["T5"]}, "Treatment": {"text": [["long-term use of adequately-dosed AZA and stable non-toxic metabolite levels could not acknowledge TPMT deficiency"]], "start": [[18]], "entity_id": ["T4"], "Duration": {"text": [["ong-term"]], "start": [[19]], "entity_id": ["T8"]}, "Dosage": {"text": [["adequately-dosed"]], "start": [[35]], "entity_id": ["T9"]}, "Drug": {"text": [["AZA"]], "start": [[52]], "entity_id": ["T10"]}}}]}]}
{"id": "17381671_9", "context": "CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[122]], "entity_id": ["T31"]}, "Subject": {"text": [["65-year-old patient"]], "start": [[16]], "entity_id": ["T29"], "Age": {"text": [["65-year-old"]], "start": [[16]], "entity_id": ["T30"]}}, "Effect": {"text": [["confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome"]], "start": [[132]], "entity_id": ["T6"]}, "Treatment": {"text": [["chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram", "following initiation of fentanyl"]], "start": [[36, 247]], "entity_id": ["T4"], "Drug": {"text": [["fentanyl"], ["citalopram"]], "start": [[271], [111]], "entity_id": ["T33", "T8"]}, "Duration": {"text": [["chronically"]], "start": [[36]], "entity_id": ["T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["following"]], "start": [[247]], "entity_id": ["T7"]}, "Drug": {"text": [["fentanyl"], ["citalopram"]], "start": [[271], [111]], "entity_id": ["T33", "T8"]}}]}}]}]}
{"id": "3941210_2", "context": "Such a case induced by hypothyroidism complicating long-term therapy with amiodarone in a 45 year old woman with pre-excitation is presented.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["complicating"]], "start": [[38]], "entity_id": ["T12"]}, "Subject": {"text": [["a 45 year old woman with pre-excitation"]], "start": [[88]], "entity_id": ["T3"], "Age": {"text": [["45 year old"]], "start": [[90]], "entity_id": ["T7"]}, "Gender": {"text": [["woman"]], "start": [[102]], "entity_id": ["T8"]}}, "Effect": {"text": [["hypothyroidism"]], "start": [[23]], "entity_id": ["T4"]}, "Treatment": {"text": [["long-term therapy with amiodarone"]], "start": [[51]], "entity_id": ["T5"], "Drug": {"text": [["amiodarone"]], "start": [[74]], "entity_id": ["T10"]}, "Duration": {"text": [["long-term"]], "start": [[51]], "entity_id": ["T6"]}, "Disorder": {"text": [["pre-excitation"]], "start": [[113]], "entity_id": ["T13"]}}}]}]}
{"id": "2935070_4", "context": "The diagnosis was based on the rapid onset of renal failure, presence of eosinophilia, skin rash, and characteristic renal biopsy finding, following the administration of ampicillin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[139]], "entity_id": ["T7"]}, "Treatment": {"text": [["ampicillin"]], "start": [[171]], "entity_id": ["T8"], "Drug": {"text": [["ampicillin"]], "start": [[171]], "entity_id": ["T10"]}}, "Effect": {"text": [["rapid onset of renal failure, presence of eosinophilia, skin rash, and characteristic renal biopsy"]], "start": [[31]], "entity_id": ["T9"]}}]}]}
{"id": "16008658_1", "context": "46-year-old woman developed painful ulcers over her lower abdomen in the form of reticulate erythema after injecting interferon beta-1b subcutaneously for multiple sclerosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[18]], "entity_id": ["T6"]}, "Subject": {"text": [["46-year-old woman"]], "start": [[0]], "entity_id": ["T5"], "Age": {"text": [["46-year-old"]], "start": [[0]], "entity_id": ["T10"]}, "Gender": {"text": [["woman"]], "start": [[12]], "entity_id": ["T11"]}}, "Effect": {"text": [["painful ulcers over her lower abdomen in the form of reticulate erythema"]], "start": [[28]], "entity_id": ["T7"]}, "Treatment": {"text": [["injecting interferon beta-1b subcutaneously"]], "start": [[107]], "entity_id": ["T8"], "Drug": {"text": [["interferon beta-1b"]], "start": [[117]], "entity_id": ["T12"]}, "Route": {"text": [["injecting"]], "start": [[107]], "entity_id": ["T13"]}, "Disorder": {"text": [["multiple sclerosis"]], "start": [[155]], "entity_id": ["T14"]}}}]}]}
{"id": "10203437_1", "context": "Lupus-like syndrome caused by 5-aminosalicylic acid in patients with inflammatory bowel disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[20]], "entity_id": ["T6"]}, "Effect": {"text": [["Lupus-like syndrome"]], "start": [[0]], "entity_id": ["T7"]}, "Treatment": {"text": [["5-aminosalicylic acid"]], "start": [[30]], "entity_id": ["T8"], "Disorder": {"text": [["inflammatory bowel disease"]], "start": [[69]], "entity_id": ["T10"]}, "Drug": {"text": [["5-aminosalicylic acid"]], "start": [[30]], "entity_id": ["T12"]}}, "Subject": {"text": [["patients with inflammatory bowel disease"]], "start": [[55]], "entity_id": ["T9"]}}]}]}
{"id": "566977_1", "context": "Fatal acute tubular necrosis occurred in 1 patient in whom intravesical formalin was used to control massive persistent hemorrhage from radiation cystitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurred"]], "start": [[29]], "entity_id": ["T5"]}, "Effect": {"text": [["acute tubular necrosis"]], "start": [[6]], "entity_id": ["T3"]}, "Subject": {"text": [["1 patient"]], "start": [[41]], "entity_id": ["T4"], "Population": {"text": [["1"]], "start": [[41]], "entity_id": ["T8"]}}, "Treatment": {"text": [["intravesical formalin"]], "start": [[59]], "entity_id": ["T6"], "Disorder": {"text": [["massive persistent hemorrhage from radiation cystitis"]], "start": [[101]], "entity_id": ["T7"]}, "Route": {"text": [["intravesical"]], "start": [[59]], "entity_id": ["T9"]}, "Drug": {"text": [["formalin"]], "start": [[72]], "entity_id": ["T10"]}}, "Severity": {"text": [["Fatal"]], "start": [[0]], "entity_id": ["T12"], "value": "High"}}]}]}
{"id": "9302445_3", "context": "The hypercalcemia responded to discontinuation of rhGH and a single dose of intravenous pamidronate disodium and has not recurred in 8 months of follow-up.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["responded"]], "start": [[18]], "entity_id": ["T4"]}, "Treatment": {"text": [["discontinuation of rhGH and a single dose of intravenous pamidronate disodium"]], "start": [[31]], "entity_id": ["T5"], "Disorder": {"text": [["hypercalcemia"]], "start": [[4]], "entity_id": ["T3"]}, "Drug": {"text": [["rhGH"], ["pamidronate disodium"]], "start": [[50], [88]], "entity_id": ["T7", "T9"]}, "Route": {"text": [["intravenous"]], "start": [[76]], "entity_id": ["T8"]}}, "Effect": {"text": [["has not recurred in 8 months of follow-up"]], "start": [[113]], "entity_id": ["T6"]}}]}]}
{"id": "834512_2", "context": "The administration of \"sweet spirits of nitre\" (4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["followed"]], "start": [[101]], "entity_id": ["T13"]}, "Treatment": {"text": [["\"sweet spirits of nitre\" (4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol)"]], "start": [[22]], "entity_id": ["T16"], "Drug": {"text": [["sweet spirits of nitre"]], "start": [[23]], "entity_id": ["T19"]}}, "Effect": {"text": [["acute methemoglobinemia and severe anoxic metabolic acidosis"]], "start": [[113]], "entity_id": ["T14"]}, "Subject": {"text": [["infant twins"]], "start": [[177]], "entity_id": ["T15"], "Age": {"text": [["infant"]], "start": [[177]], "entity_id": ["T17"]}}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["reversed"]], "start": [[221]], "entity_id": ["T22"]}, "Subject": {"text": [["infant twins"]], "start": [[177]], "entity_id": ["T15"], "Age": {"text": [["infant"]], "start": [[177]], "entity_id": ["T17"]}}, "Treatment": {"text": [["Methylene blue"]], "start": [[191]], "entity_id": ["T20"], "Disorder": {"text": [["methemoglobinemia"]], "start": [[230]], "entity_id": ["T23"]}, "Drug": {"text": [["Methylene blue"]], "start": [[191]], "entity_id": ["T21"]}}}, {"event_id": "E3", "event_type": "Adverse_event", "Trigger": {"text": [["died"]], "start": [[270]], "entity_id": ["T26"]}, "Treatment": {"text": [["\"sweet spirits of nitre\" (4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol)"]], "start": [[22]], "entity_id": ["T16"], "Drug": {"text": [["sweet spirits of nitre"]], "start": [[23]], "entity_id": ["T19"]}}, "Subject": {"text": [["one twin"]], "start": [[261]], "entity_id": ["T24"]}, "Effect": {"text": [["died from the consequences of hypoxemia"]], "start": [[270]], "entity_id": ["T25"]}, "Severity": {"text": [["died"]], "start": [[270]], "entity_id": ["T27"], "value": "High"}}]}]}
{"id": "12196666_1", "context": "The authors describe three families in whom the occurrence of FVS in all the siblings strongly suggests hereditary susceptibility to valproic acid-induced adverse outcome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["susceptibility"]], "start": [[115]], "entity_id": ["T3"]}, "Treatment": {"text": [["valproic acid-induced"]], "start": [[133]], "entity_id": ["T4"], "Drug": {"text": [["valproic acid"]], "start": [[133]], "entity_id": ["T8"]}}, "Subject": {"text": [["three families", "all the siblings"]], "start": [[21, 69]], "entity_id": ["T5"], "Population": {"text": [["three"]], "start": [[21]], "entity_id": ["T7"]}}, "Effect": {"text": [["FVS"]], "start": [[62]], "entity_id": ["T6"]}}]}]}
{"id": "17536204_6", "context": "We hypothesize that capecitabine-induced headache is vascular in nature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[33]], "entity_id": ["T4"]}, "Treatment": {"text": [["capecitabine"]], "start": [[20]], "entity_id": ["T3"], "Drug": {"text": [["capecitabine"]], "start": [[20]], "entity_id": ["T6"]}}, "Effect": {"text": [["headache"]], "start": [[41]], "entity_id": ["T5"]}}]}]}
{"id": "12792223_2", "context": "A lupus-like syndrome associated with infliximab therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[22]], "entity_id": ["T3"]}, "Treatment": {"text": [["infliximab"]], "start": [[38]], "entity_id": ["T4"], "Drug": {"text": [["infliximab"]], "start": [[38]], "entity_id": ["T6"]}}, "Effect": {"text": [["A lupus-like syndrome"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "2669373_1", "context": "A case report of a patient with probable cisplatin and bleomycin-induced TMA is presented.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[65]], "entity_id": ["T7"]}, "Subject": {"text": [["a patient with probable cisplatin"]], "start": [[17]], "entity_id": ["T4"]}, "Treatment": {"text": [["bleomycin"]], "start": [[55]], "entity_id": ["T6"], "Drug": {"text": [["bleomycin"]], "start": [[55]], "entity_id": ["T9"]}, "Disorder": {"text": [["probable cisplatin"]], "start": [[32]], "entity_id": ["T10"]}}, "Effect": {"text": [["TMA"]], "start": [[73]], "entity_id": ["T8"]}}]}]}
{"id": "11250985_3", "context": "In some cases this seems to happen because spironolactone causes diarrhoea.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["causes"]], "start": [[58]], "entity_id": ["T4"]}, "Treatment": {"text": [["spironolactone"]], "start": [[43]], "entity_id": ["T3"], "Drug": {"text": [["spironolactone"]], "start": [[43]], "entity_id": ["T6"]}}, "Effect": {"text": [["diarrhoea"]], "start": [[65]], "entity_id": ["T5"]}, "Speculated": {"text": [["seems"]], "start": [[19]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "11737689_4", "context": "Painful neutrophilic skin lesions were observed in two children receiving granulocyte colony-stimulating factor (G-CSF) for treatment of idiopathic neutropenia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["observed"]], "start": [[39]], "entity_id": ["T11"]}, "Subject": {"text": [["two children"]], "start": [[51]], "entity_id": ["T7"], "Population": {"text": [["two"]], "start": [[51]], "entity_id": ["T12"]}, "Age": {"text": [["children"]], "start": [[55]], "entity_id": ["T13"]}}, "Treatment": {"text": [["granulocyte colony-stimulating factor (G-CSF)"]], "start": [[74]], "entity_id": ["T9"], "Drug": {"text": [["granulocyte colony-stimulating factor"]], "start": [[74]], "entity_id": ["T14"]}, "Disorder": {"text": [["idiopathic neutropenia"]], "start": [[137]], "entity_id": ["T15"]}}, "Effect": {"text": [["Painful neutrophilic skin lesions"]], "start": [[0]], "entity_id": ["T10"]}}]}]}
{"id": "10458196_3", "context": "Apparent central nervous system depression in infants after the use of topical brimonidine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[54]], "entity_id": ["T6"]}, "Effect": {"text": [["Apparent central nervous system depression"]], "start": [[0]], "entity_id": ["T3"]}, "Subject": {"text": [["infants"]], "start": [[46]], "entity_id": ["T4"], "Age": {"text": [["infants"]], "start": [[46]], "entity_id": ["T9"]}}, "Treatment": {"text": [["topical brimonidine"]], "start": [[71]], "entity_id": ["T5"], "Drug": {"text": [["brimonidine"]], "start": [[79]], "entity_id": ["T7"]}, "Route": {"text": [["topical"]], "start": [[71]], "entity_id": ["T8"]}}}]}]}
{"id": "16284443_4", "context": "To our knowledge, this is the first report of insulin-induced lipohypertrophy with detailed histological examinations.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[54]], "entity_id": ["T4"]}, "Treatment": {"text": [["insulin"]], "start": [[46]], "entity_id": ["T3"], "Drug": {"text": [["insulin"]], "start": [[46]], "entity_id": ["T6"]}}, "Effect": {"text": [["lipohypertrophy"]], "start": [[62]], "entity_id": ["T5"]}}]}]}
{"id": "19540093_4", "context": "Tigecycline-induced acute pancreatitis: case report and literature review.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[12]], "entity_id": ["T3"]}, "Effect": {"text": [["acute pancreatitis"]], "start": [[20]], "entity_id": ["T4"]}, "Treatment": {"text": [["Tigecycline"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Tigecycline"]], "start": [[0]], "entity_id": ["T6"]}}}]}]}
{"id": "11850606_3", "context": "Polymyositis is a rare complication of interferon alpha treatment as a result of immune-modulating role of the drug itself.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication of"]], "start": [[23]], "entity_id": ["T5"]}, "Treatment": {"text": [["interferon alpha treatment"]], "start": [[39]], "entity_id": ["T3"], "Drug": {"text": [["interferon alpha"]], "start": [[39]], "entity_id": ["T6"]}}, "Effect": {"text": [["Polymyositis"]], "start": [[0]], "entity_id": ["T4"]}}]}]}
{"id": "4038510_3", "context": "Sodium thiosulfate is a neutralizing agent for cisplatin that protects against renal damage.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["protects"]], "start": [[62]], "entity_id": ["T7"]}, "Treatment": {"text": [["Sodium thiosulfate is a neutralizing agent for cisplatin"]], "start": [[0]], "entity_id": ["T6"], "Drug": {"text": [["cisplatin"], ["Sodium thiosulfate"]], "start": [[47], [0]], "entity_id": ["T10", "T11"]}, "Disorder": {"text": [["renal damage"]], "start": [[79]], "entity_id": ["T9"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["neutralizing agent"]], "start": [[24]], "entity_id": ["T12"]}, "Drug": {"text": [["Sodium thiosulfate"], ["cisplatin"]], "start": [[0], [47]], "entity_id": ["T11", "T10"]}}]}, "Effect": {"text": [["protects against renal damage"]], "start": [[62]], "entity_id": ["T8"]}}]}]}
{"id": "19363904_1", "context": "Anaphylactic reaction to bacitracin ointment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reaction"]], "start": [[13]], "entity_id": ["T3"]}, "Treatment": {"text": [["bacitracin ointment"]], "start": [[25]], "entity_id": ["T4"], "Drug": {"text": [["bacitracin"]], "start": [[25]], "entity_id": ["T6"]}}, "Effect": {"text": [["Anaphylactic"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "7679525_1", "context": "Severe bleomycin lung toxicity: reversal with high dose corticosteroids.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["toxicity"]], "start": [[22]], "entity_id": ["T7"]}, "Treatment": {"text": [["bleomycin"]], "start": [[7]], "entity_id": ["T6"], "Drug": {"text": [["bleomycin"]], "start": [[7]], "entity_id": ["T10"]}}, "Effect": {"text": [["Severe bleomycin lung toxicity"]], "start": [[0]], "entity_id": ["T8"]}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T9"], "value": "Medium"}}]}]}
{"id": "11918514_1", "context": "CONCLUSIONS: Although mirtazapine offers clinicians a combination of strong efficacy and good safety, we suggest bearing SS in mind when prescribing this drug, especially in frail, elderly patients with underlying chronic conditions.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["bearing"]], "start": [[113]], "entity_id": ["T6"]}, "Effect": {"text": [["SS"]], "start": [[121]], "entity_id": ["T3"]}, "Subject": {"text": [["frail, elderly patients with underlying chronic conditions"]], "start": [[174]], "entity_id": ["T4"], "Age": {"text": [["elderly"]], "start": [[181]], "entity_id": ["T7"]}, "Disorder": {"text": [["underlying chronic conditions"]], "start": [[203]], "entity_id": ["T8"]}}, "Treatment": {"text": [["mirtazapine"]], "start": [[22]], "entity_id": ["T5"], "Drug": {"text": [["mirtazapine"]], "start": [[22]], "entity_id": ["T9"]}}}]}]}
{"id": "536461_1", "context": "Five cases of clindamycin-associated pseudomembranous colitis in leukaemic patients are reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[26]], "entity_id": ["T4"]}, "Treatment": {"text": [["clindamycin"]], "start": [[14]], "entity_id": ["T3"], "Drug": {"text": [["clindamycin"]], "start": [[14]], "entity_id": ["T8"]}}, "Effect": {"text": [["pseudomembranous colitis"]], "start": [[37]], "entity_id": ["T5"]}, "Subject": {"text": [["leukaemic patients"]], "start": [[65]], "entity_id": ["T6"], "Disorder": {"text": [["leukaemic"]], "start": [[65]], "entity_id": ["T7"]}}}]}]}
{"id": "19707032_6", "context": "Three days after receiving intravitreal injection of bevacizumab (1.25 mg in 0.1 ml), he developed acute vision loss and change of consciousness.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[89]], "entity_id": ["T6"]}, "Treatment": {"text": [["intravitreal injection of bevacizumab (1.25 mg in 0.1 ml),"]], "start": [[27]], "entity_id": ["T5"], "Route": {"text": [["intravitreal injection"]], "start": [[27]], "entity_id": ["T10"]}, "Drug": {"text": [["bevacizumab"]], "start": [[53]], "entity_id": ["T11"]}, "Dosage": {"text": [["1.25 mg in 0.1 ml"]], "start": [[66]], "entity_id": ["T12"]}}, "Effect": {"text": [["acute vision loss and change of consciousness"]], "start": [[99]], "entity_id": ["T7"]}, "Subject": {"text": [["he"]], "start": [[86]], "entity_id": ["T8"], "Gender": {"text": [["he"]], "start": [[86]], "entity_id": ["T9"]}}}]}]}
{"id": "23868369_7", "context": "The proposed cause of the nausea and anorexia was digoxin toxicity secondary to a drug-drug interaction with ciprofloxacin.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["secondary"]], "start": [[67]], "entity_id": ["T8"]}, "Effect": {"text": [["nausea and anorexia was digoxin toxicity"]], "start": [[26]], "entity_id": ["T7"]}, "Treatment": {"text": [["ciprofloxacin"]], "start": [[109]], "entity_id": ["T9"], "Drug": {"text": [["ciprofloxacin"], ["digoxin"]], "start": [[109], [50]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[92]], "entity_id": ["T12"]}, "Drug": {"text": [["digoxin"], ["ciprofloxacin"]], "start": [[50], [109]], "entity_id": ["T11", "T10"]}}]}, "Speculated": {"text": [["proposed cause"]], "start": [[4]], "entity_id": ["T13"], "value": true}}]}]}
{"id": "8222875_1", "context": "Mitomycin C (MMC) is an alkylating agent that has been recently associated with the hemolytic-uremic syndrome (HUS).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[64]], "entity_id": ["T8"]}, "Treatment": {"text": [["Mitomycin C (MMC)"]], "start": [[0]], "entity_id": ["T7"], "Drug": {"text": [["Mitomycin C"]], "start": [[0]], "entity_id": ["T10"]}}, "Effect": {"text": [["the hemolytic-uremic syndrome (HUS)"]], "start": [[80]], "entity_id": ["T9"]}}]}]}
{"id": "10904571_3", "context": "Muscle biopsy revealed variation in muscle fiber size and few vacuolated fibers which were features of colchicine-induced myopathy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[114]], "entity_id": ["T9"]}, "Treatment": {"text": [["colchicine"]], "start": [[103]], "entity_id": ["T10"], "Drug": {"text": [["colchicine"]], "start": [[103]], "entity_id": ["T11"]}}, "Effect": {"text": [["variation in muscle fiber size and few vacuolated fibers", "myopathy"]], "start": [[23, 122]], "entity_id": ["T7"]}}]}]}
{"id": "1467295_1", "context": "We describe a patient who developed NEH on three separate occasions provoked by two different chemotherapeutic agents--cytarabine and mitoxantrone.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["provoked"]], "start": [[68]], "entity_id": ["T4"]}, "Treatment": {"text": [["cytarabine and mitoxantrone"]], "start": [[119]], "entity_id": ["T5"], "Drug": {"text": [["cytarabine"], ["mitoxantrone"]], "start": [[119], [134]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[130]], "entity_id": ["T8"]}, "Drug": {"text": [["cytarabine"], ["mitoxantrone"]], "start": [[119], [134]], "entity_id": ["T9", "T10"]}}]}, "Effect": {"text": [["NEH"]], "start": [[36]], "entity_id": ["T6"]}, "Subject": {"text": [["a patient"]], "start": [[12]], "entity_id": ["T7"]}}]}]}
{"id": "22791547_4", "context": "Orofacial dyskinesia appeared 5 hours after methylphenidate administration, persisted for 10 hours, and had completely resolved within 2 days.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["appeared"]], "start": [[21]], "entity_id": ["T6"]}, "Effect": {"text": [["Orofacial dyskinesia"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["5 hours after methylphenidate"]], "start": [[30]], "entity_id": ["T5"], "Drug": {"text": [["methylphenidate"]], "start": [[44]], "entity_id": ["T7"]}, "Time_elapsed": {"text": [["5 hours after"]], "start": [[30]], "entity_id": ["T8"]}}}]}]}
{"id": "19789372_7", "context": "Present results suggested that coadministration of mexiletine increased blood tizanidine concentrations and enhanced tizanidine pharmacodynamics in terms of reduction in blood pressure and adverse symptoms.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["enhanced"]], "start": [[108]], "entity_id": ["T10"]}, "Effect": {"text": [["tizanidine pharmacodynamics in terms of reduction in blood pressure and adverse symptoms"]], "start": [[117]], "entity_id": ["T11"]}, "Treatment": {"text": [["coadministration of mexiletine increased blood tizanidine concentrations"]], "start": [[31]], "entity_id": ["T8"], "Drug": {"text": [["mexiletine"], ["tizanidine"]], "start": [[51], [78]], "entity_id": ["T13", "T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["increased"]], "start": [[62]], "entity_id": ["T15"]}, "Drug": {"text": [["mexiletine"], ["tizanidine"]], "start": [[51], [78]], "entity_id": ["T13", "T14"]}}]}, "Speculated": {"text": [["suggested"]], "start": [[16]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "7272895_3", "context": "Bilateral acoustic (VIII) nerve palsy in this patient was most likely a manifestation of vincristine neurotoxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["most likely"]], "start": [[58]], "entity_id": ["T7"]}, "Effect": {"text": [["Bilateral acoustic (VIII) nerve palsy", "neurotoxicity"]], "start": [[0, 101]], "entity_id": ["T5"]}, "Subject": {"text": [["this patient"]], "start": [[41]], "entity_id": ["T6"]}, "Treatment": {"text": [["vincristine"]], "start": [[89]], "entity_id": ["T8"], "Drug": {"text": [["vincristine"]], "start": [[89]], "entity_id": ["T9"]}}}]}]}
{"id": "633424_1", "context": "Acute leukopenia associated with silver sulfadiazine therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[17]], "entity_id": ["T4"]}, "Effect": {"text": [["Acute leukopenia"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["silver sulfadiazine"]], "start": [[33]], "entity_id": ["T5"], "Drug": {"text": [["silver sulfadiazine"]], "start": [[33]], "entity_id": ["T6"]}}}]}]}
{"id": "12135176_3", "context": "We describe two cases of PSVT that changed to non-sustained polymorphic ventricular tachycardia after administration of verapamil.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["changed"]], "start": [[35]], "entity_id": ["T4"]}, "Effect": {"text": [["non-sustained polymorphic ventricular tachycardia"]], "start": [[46]], "entity_id": ["T5"]}, "Treatment": {"text": [["administration of verapamil."]], "start": [[102]], "entity_id": ["T6"], "Drug": {"text": [["verapamil"]], "start": [[120]], "entity_id": ["T9"]}, "Disorder": {"text": [["PSVT"]], "start": [[25]], "entity_id": ["T10"]}}, "Subject": {"text": [["two cases of PSVT"]], "start": [[12]], "entity_id": ["T3"], "Population": {"text": [["two"]], "start": [[12]], "entity_id": ["T7"]}}}]}]}
{"id": "8301877_4", "context": "We described the occurrence of L-dopa-induced myoclonus and seizures in a case of parkinsonism with its SEPs findings.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[38]], "entity_id": ["T6"]}, "Treatment": {"text": [["L-dopa"]], "start": [[31]], "entity_id": ["T5"], "Drug": {"text": [["L-dopa"]], "start": [[31]], "entity_id": ["T10"]}, "Disorder": {"text": [["parkinsonism"]], "start": [[82]], "entity_id": ["T11"]}}, "Effect": {"text": [["myoclonus and seizures"]], "start": [[46]], "entity_id": ["T7"]}, "Subject": {"text": [["case of parkinsonism"]], "start": [[74]], "entity_id": ["T9"]}}]}]}
{"id": "12187348_8", "context": "Retrospectively, bucillamine was believed to be the cause of the giant hypertrophy because of its structural similarity to D-penicillamine, which was the subject of an abundance of reports of mammary hyperplasia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause of"]], "start": [[52]], "entity_id": ["T10"]}, "Treatment": {"text": [["bucillamine"]], "start": [[17]], "entity_id": ["T8"], "Drug": {"text": [["bucillamine"], ["D-penicillamine"]], "start": [[17], [123]], "entity_id": ["T11", "T12"]}}, "Effect": {"text": [["giant hypertrophy"]], "start": [[65]], "entity_id": ["T9"]}}]}]}
{"id": "11886466_5", "context": "We speculate that platelet activation induced by pFVIII may have contributed to thrombosis and suggest that pFVIII be used with caution in elderly patients with pre-existing cardiovascular risk factors.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["contributed"]], "start": [[65]], "entity_id": ["T11"]}, "Treatment": {"text": [["pFVIII"]], "start": [[49]], "entity_id": ["T10"], "Drug": {"text": [["pFVIII"]], "start": [[49]], "entity_id": ["T14"]}, "Disorder": {"text": [["cardiovascular"]], "start": [[174]], "entity_id": ["T15"]}}, "Effect": {"text": [["thrombosis"]], "start": [[80]], "entity_id": ["T12"]}, "Speculated": {"text": [["may"]], "start": [[56]], "entity_id": ["T13"], "value": true}}]}]}
{"id": "11181395_1", "context": "Restoration of vancomycin susceptibility in Enterococcus faecalis by antiresistance determinant gene transfer.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["by"]], "start": [[66]], "entity_id": ["T6"]}, "Effect": {"text": [["Restoration of vancomycin susceptibility in Enterococcus faecalis"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["antiresistance determinant gene transfer"]], "start": [[69]], "entity_id": ["T7"], "Drug": {"text": [["vancomycin"]], "start": [[15]], "entity_id": ["T8"]}}}]}]}
{"id": "9824032_1", "context": "Dental and gingival pain as side effects of niacin therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["side effects"]], "start": [[28]], "entity_id": ["T4"]}, "Effect": {"text": [["Dental and gingival pain"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["niacin"]], "start": [[44]], "entity_id": ["T5"], "Drug": {"text": [["niacin"]], "start": [[44]], "entity_id": ["T6"]}}}]}]}
{"id": "12590235_5", "context": "We describe a case of significant elevation of serum transaminases in a patient treated with 6-TG for a flare of Crohn's disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["elevation"]], "start": [[34]], "entity_id": ["T7"]}, "Effect": {"text": [["significant elevation of serum transaminases"]], "start": [[22]], "entity_id": ["T3"]}, "Subject": {"text": [["a patient"]], "start": [[70]], "entity_id": ["T4"]}, "Treatment": {"text": [["6-TG"]], "start": [[93]], "entity_id": ["T6"], "Disorder": {"text": [["Crohn's disease"]], "start": [[113]], "entity_id": ["T5"]}, "Drug": {"text": [["6-TG"]], "start": [[93]], "entity_id": ["T8"]}}}]}]}
{"id": "6236730_1", "context": "A patient developed transient, acute myopia while on isotretinoin (Accutane) therapy for acne.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[10]], "entity_id": ["T5"]}, "Subject": {"text": [["acne", "A patient"]], "start": [[89, 0]], "entity_id": ["T4"]}, "Effect": {"text": [["transient, acute myopia"]], "start": [[20]], "entity_id": ["T6"]}, "Treatment": {"text": [["isotretinoin (Accutane)"]], "start": [[53]], "entity_id": ["T7"], "Disorder": {"text": [["acne"]], "start": [[89]], "entity_id": ["T8"]}, "Drug": {"text": [["isotretinoin"]], "start": [[53]], "entity_id": ["T10"]}}}]}]}
{"id": "18094347_2", "context": "CONCLUSIONS: The pathogenesis of methotrexate-induced papular eruption in collagen vascular diseases may suggest cutaneous small-vessel vasculitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[46]], "entity_id": ["T3"]}, "Effect": {"text": [["papular eruption"]], "start": [[54]], "entity_id": ["T4"]}, "Treatment": {"text": [["methotrexate"]], "start": [[33]], "entity_id": ["T6"], "Disorder": {"text": [["collagen vascular diseases"]], "start": [[74]], "entity_id": ["T5"]}, "Drug": {"text": [["methotrexate"]], "start": [[33]], "entity_id": ["T8"]}}, "Speculated": {"text": [["may"]], "start": [[101]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "1536494_1", "context": "Aminophylline hypersensitivity apparently due to ethylenediamine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[42]], "entity_id": ["T7"]}, "Effect": {"text": [["Aminophylline hypersensitivity"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["ethylenediamine"]], "start": [[49]], "entity_id": ["T5"], "Drug": {"text": [["ethylenediamine"]], "start": [[49]], "entity_id": ["T8"]}}, "Speculated": {"text": [["apparently"]], "start": [[31]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "3804181_3", "context": "The main clinical features of this 58-year-old female patient were laboratory evidence of leucopenia and cholestasis, and biopsy features of fatty liver parenchyma degeneration with granulocytic portal infiltration and bile stasis, demonstrated 20 days after the initiation of antithyroid therapy with 20 mg methimazole daily.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["demonstrated"]], "start": [[232]], "entity_id": ["T11"]}, "Treatment": {"text": [["antithyroid therapy with 20 mg methimazole daily"]], "start": [[277]], "entity_id": ["T12"], "Time_elapsed": {"text": [["20 days after"]], "start": [[245]], "entity_id": ["T17"]}, "Drug": {"text": [["methimazole"]], "start": [[308]], "entity_id": ["T18"]}, "Dosage": {"text": [["20 mg"]], "start": [[302]], "entity_id": ["T19"]}, "Freq": {"text": [["daily"]], "start": [[320]], "entity_id": ["T20"]}}, "Subject": {"text": [["this 58-year-old female"]], "start": [[30]], "entity_id": ["T13"], "Age": {"text": [["58-year-old"]], "start": [[35]], "entity_id": ["T15"]}, "Gender": {"text": [["female"]], "start": [[47]], "entity_id": ["T16"]}}, "Effect": {"text": [["leucopenia and cholestasis, and biopsy features of fatty liver parenchyma degeneration with granulocytic portal infiltration and bile stasis"]], "start": [[90]], "entity_id": ["T14"]}}]}]}
{"id": "19892516_4", "context": "In one patient the vasculitis resolved after termination of the ciprofloxacin therapy; in the other patient the ciprofloxacin-induced hemorrhagic vasculitis was superimposed on a severe forefoot infection, leading to progressive gangrene and a below-knee amputation.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[126]], "entity_id": ["T12"]}, "Treatment": {"text": [["ciprofloxacin"]], "start": [[112]], "entity_id": ["T13"], "Drug": {"text": [["ciprofloxacin"]], "start": [[112]], "entity_id": ["T15"]}}, "Effect": {"text": [["hemorrhagic vasculitis was superimposed on a severe forefoot infection, leading to progressive gangrene and a below-knee amputation"]], "start": [[134]], "entity_id": ["T14"]}, "Subject": {"text": [["patient"]], "start": [[100]], "entity_id": ["T11"]}, "Severity": {"text": [["severe"]], "start": [[179]], "entity_id": ["T24"], "value": "Medium"}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["resolved"]], "start": [[30]], "entity_id": ["T20"]}, "Subject": {"text": [["one patient the vasculitis"]], "start": [[3]], "entity_id": ["T17"], "Population": {"text": [["one"]], "start": [[3]], "entity_id": ["T18"]}}, "Treatment": {"text": [["termination of the ciprofloxacin therapy"]], "start": [[45]], "entity_id": ["T21"], "Drug": {"text": [["ciprofloxacin"]], "start": [[64]], "entity_id": ["T22"]}, "Disorder": {"text": [["vasculitis"]], "start": [[19]], "entity_id": ["T23"]}}}]}]}
{"id": "9719245_1", "context": "Excluding other causes, Pentasa-associated pancytopenia was considered.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[32]], "entity_id": ["T4"]}, "Treatment": {"text": [["Pentasa"]], "start": [[24]], "entity_id": ["T3"], "Drug": {"text": [["Pentasa"]], "start": [[24]], "entity_id": ["T6"]}}, "Effect": {"text": [["pancytopenia"]], "start": [[43]], "entity_id": ["T5"]}}]}]}
{"id": "15013892_3", "context": "RESULTS: A patient developed a bilaterally symmetric bull's-eye maculopathy 45 years after taking quinacrine for 18 months as prophylaxis against malaria.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[19]], "entity_id": ["T7"]}, "Effect": {"text": [["A patient"], ["bilaterally symmetric bull's-eye maculopathy"]], "start": [[9], [31]], "entity_id": ["T3", "T4"]}, "Treatment": {"text": [["45 years after taking quinacrine for 18 months"]], "start": [[76]], "entity_id": ["T5"], "Time_elapsed": {"text": [["45 years after"], ["18 months"]], "start": [[76], [113]], "entity_id": ["T8", "T10"]}, "Drug": {"text": [["quinacrine"]], "start": [[98]], "entity_id": ["T9"]}, "Disorder": {"text": [["malaria"]], "start": [[146]], "entity_id": ["T12"]}}}]}]}
{"id": "23868369_1", "context": "Possible digoxin toxicity associated with concomitant ciprofloxacin therapy.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[26]], "entity_id": ["T7"]}, "Effect": {"text": [["digoxin toxicity"]], "start": [[9]], "entity_id": ["T6"]}, "Treatment": {"text": [["ciprofloxacin", "digoxin"]], "start": [[54, 9]], "entity_id": ["T8"], "Drug": {"text": [["ciprofloxacin"], ["digoxin"]], "start": [[54], [9]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["concomitant"]], "start": [[42]], "entity_id": ["T11"]}, "Drug": {"text": [["ciprofloxacin"], ["digoxin"]], "start": [[54], [9]], "entity_id": ["T9", "T10"]}}]}, "Speculated": {"text": [["Possible"]], "start": [[0]], "entity_id": ["T5"], "value": true}}]}]}
{"id": "8313300_9", "context": "The exophthalmos improved dramatically within 72 hours of the withdrawal of lithium.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["improved"]], "start": [[17]], "entity_id": ["T7"]}, "Treatment": {"text": [["within 72 hours of the withdrawal of lithium"]], "start": [[39]], "entity_id": ["T4"], "Disorder": {"text": [["exophthalmos"]], "start": [[4]], "entity_id": ["T5"]}, "Drug": {"text": [["lithium"]], "start": [[76]], "entity_id": ["T6"]}, "Time_elapsed": {"text": [["within 72 hours"]], "start": [[39]], "entity_id": ["T8"]}}}]}]}
{"id": "8255797_3", "context": "We report two cases of neutropenia following captopril use in cardiac patients with trisomy 21.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[35]], "entity_id": ["T5"]}, "Subject": {"text": [["two cases of", "cardiac patients with trisomy 21"]], "start": [[10, 62]], "entity_id": ["T3"], "Population": {"text": [["two"]], "start": [[10]], "entity_id": ["T7"]}, "Disorder": {"text": [["cardiac"], ["trisomy 21"]], "start": [[62], [84]], "entity_id": ["T8", "T1"]}}, "Effect": {"text": [["neutropenia"]], "start": [[23]], "entity_id": ["T4"]}, "Treatment": {"text": [["captopril use"]], "start": [[45]], "entity_id": ["T6"], "Drug": {"text": [["captopril"]], "start": [[45]], "entity_id": ["T9"]}}}]}]}
{"id": "1433432_2", "context": "We report a case of hyponatremia associated with a grand mal seizure in a 28 month-old child after intra-nasal desmopressin administration for high fluid intake with nocturnal enuresis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[93]], "entity_id": ["T12"]}, "Effect": {"text": [["hyponatremia associated with a grand mal seizure"]], "start": [[20]], "entity_id": ["T8"]}, "Subject": {"text": [["a 28 month-old child"]], "start": [[72]], "entity_id": ["T9"], "Age": {"text": [["28 month-old child"]], "start": [[74]], "entity_id": ["T13"]}}, "Treatment": {"text": [["intra-nasal desmopressin administration"]], "start": [[99]], "entity_id": ["T10"], "Disorder": {"text": [["high fluid intake with nocturnal enuresis"]], "start": [[143]], "entity_id": ["T11"]}, "Drug": {"text": [["desmopressin"]], "start": [[111]], "entity_id": ["T15"]}, "Route": {"text": [["intra-nasal"]], "start": [[99]], "entity_id": ["T16"]}}}]}]}
{"id": "9719245_2", "context": "He developed fever, nausea, diarrhea, and malaise and stopped taking on the third day after commencing Pentasa.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[3]], "entity_id": ["T10"]}, "Treatment": {"text": [["Pentasa"]], "start": [[103]], "entity_id": ["T9"], "Drug": {"text": [["Pentasa"]], "start": [[103]], "entity_id": ["T14"]}, "Time_elapsed": {"text": [["third day"]], "start": [[76]], "entity_id": ["T15"]}}, "Effect": {"text": [["fever, nausea, diarrhea, and malaise"]], "start": [[13]], "entity_id": ["T11"]}, "Subject": {"text": [["He"]], "start": [[0]], "entity_id": ["T12"], "Gender": {"text": [["He"]], "start": [[0]], "entity_id": ["T13"]}}}]}]}
{"id": "15752306_1", "context": "Livedo reticularis associated with interferon alpha therapy in two melanoma patients.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[19]], "entity_id": ["T11"]}, "Subject": {"text": [["two melanoma patients"]], "start": [[63]], "entity_id": ["T8"], "Population": {"text": [["two"]], "start": [[63]], "entity_id": ["T13"]}}, "Treatment": {"text": [["interferon alpha therapy"]], "start": [[35]], "entity_id": ["T9"], "Disorder": {"text": [["melanoma"]], "start": [[67]], "entity_id": ["T15"]}, "Drug": {"text": [["interferon alpha"]], "start": [[35]], "entity_id": ["T14"]}}, "Effect": {"text": [["Livedo reticularis"]], "start": [[0]], "entity_id": ["T10"]}}]}]}
{"id": "10656221_4", "context": "A 60-year-old woman with diabetes mellitus (type 2) developed an acute icteric hepatitis-like illness 6 weeks after the initiation of gliclazide therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[52]], "entity_id": ["T9"]}, "Subject": {"text": [["A 60-year-old woman with diabetes mellitus (type 2)"]], "start": [[0]], "entity_id": ["T6"], "Age": {"text": [["60-year-old"]], "start": [[2]], "entity_id": ["T10"]}, "Gender": {"text": [["woman"]], "start": [[14]], "entity_id": ["T11"]}}, "Treatment": {"text": [["6 weeks after the initiation of gliclazide therapy"]], "start": [[102]], "entity_id": ["T7"], "Time_elapsed": {"text": [["6 weeks"]], "start": [[102]], "entity_id": ["T13"]}, "Drug": {"text": [["gliclazide"]], "start": [[134]], "entity_id": ["T14"]}, "Disorder": {"text": [["diabetes mellitus (type 2)"]], "start": [[25]], "entity_id": ["T15"]}}, "Effect": {"text": [["an acute icteric hepatitis-like illness"]], "start": [[62]], "entity_id": ["T8"]}}]}]}
{"id": "1348483_3", "context": "Thus cabergoline may cause similar pleuropulmonary abnormalities to bromocriptine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[21]], "entity_id": ["T4"]}, "Treatment": {"text": [["bromocriptine", "cabergoline"]], "start": [[68, 5]], "entity_id": ["T5"], "Drug": {"text": [["cabergoline"], ["bromocriptine"]], "start": [[5], [68]], "entity_id": ["T10", "T11"]}}, "Effect": {"text": [["pleuropulmonary abnormalities"]], "start": [[35]], "entity_id": ["T7"]}, "Speculated": {"text": [["may"]], "start": [[17]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "7067510_1", "context": "Although the existence of an acute pericarditis or an acute myocarditis as possible causes of the ST elevation cannot be fully ruled out, the sudden onset, prominent magnitude, and brief duration of the ST elevation are perhaps more indicative of an acute ischemic event, possibly related to a transient coronary vasoconstriction induced by the dopamine infusion.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[330]], "entity_id": ["T4"]}, "Effect": {"text": [["transient coronary vasoconstriction"]], "start": [[294]], "entity_id": ["T3"]}, "Treatment": {"text": [["dopamine"]], "start": [[345]], "entity_id": ["T5"], "Drug": {"text": [["dopamine"]], "start": [[345]], "entity_id": ["T6"]}}}]}]}
{"id": "7594371_1", "context": "Acute sensorineural hearing loss following intravenous ketoralac administration.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[33]], "entity_id": ["T3"]}, "Effect": {"text": [["Acute sensorineural hearing loss"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["intravenous ketoralac"]], "start": [[43]], "entity_id": ["T5"], "Drug": {"text": [["ketoralac"]], "start": [[55]], "entity_id": ["T6"]}, "Route": {"text": [["intravenous"]], "start": [[43]], "entity_id": ["T7"]}}}]}]}
{"id": "16484748_3", "context": "Trimethoprim-sulfamethoxazole-induced hypersensitivity syndrome associated with reactivation of human herpesvirus-6.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[30]], "entity_id": ["T3"]}, "Treatment": {"text": [["Trimethoprim-sulfamethoxazole"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Trimethoprim-sulfamethoxazole"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["hypersensitivity syndrome associated with reactivation of human herpesvirus-6"]], "start": [[38]], "entity_id": ["T5"]}}]}]}
{"id": "1775411_1", "context": "A patient is described who developed a rapid onset of pulmonary fibrosis following treatment with a new non-steroidal anti-inflammatory drug, nabumetone.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[27]], "entity_id": ["T4"]}, "Subject": {"text": [["A patient"]], "start": [[0]], "entity_id": ["T3"]}, "Effect": {"text": [["pulmonary fibrosis"]], "start": [[54]], "entity_id": ["T5"]}, "Treatment": {"text": [["nabumetone"]], "start": [[142]], "entity_id": ["T6"], "Drug": {"text": [["nabumetone"]], "start": [[142]], "entity_id": ["T7"]}}}]}]}
{"id": "11675845_2", "context": "To report a case of increased international normalized ratio (INR) in a geriatric patient receiving warfarin and ropinirole.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["case"]], "start": [[12]], "entity_id": ["T11"]}, "Treatment": {"text": [["warfarin and ropinirole"]], "start": [[100]], "entity_id": ["T9"], "Drug": {"text": [["warfarin"], ["ropinirole"]], "start": [[100], [113]], "entity_id": ["T13", "T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[109]], "entity_id": ["T15"]}, "Drug": {"text": [["ropinirole"], ["warfarin"]], "start": [[113], [100]], "entity_id": ["T14", "T13"]}}]}, "Subject": {"text": [["a geriatric patient"]], "start": [[70]], "entity_id": ["T8"], "Age": {"text": [["geriatric"]], "start": [[72]], "entity_id": ["T12"]}}, "Effect": {"text": [["increased international normalized ratio (INR)"]], "start": [[20]], "entity_id": ["T10"]}}]}]}
{"id": "8071504_8", "context": "There is documentation of ocular toxicity with ethambutol when administered at dosages generally pronounced as being safe.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[42]], "entity_id": ["T6"]}, "Effect": {"text": [["ocular toxicity"]], "start": [[26]], "entity_id": ["T4"]}, "Treatment": {"text": [["ethambutol"]], "start": [[47]], "entity_id": ["T5"], "Drug": {"text": [["ethambutol"]], "start": [[47]], "entity_id": ["T7"]}}}]}]}
{"id": "6329575_1", "context": "k bipolar manic-depressive patient, developed while on lithium prophylaxis, akathisia at therapeutic serum lithium levels and subsequently bucco-linguo-masticatory dyskinesia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[36]], "entity_id": ["T6"]}, "Treatment": {"text": [["lithium", "at therapeutic serum lithium levels"]], "start": [[55, 86]], "entity_id": ["T5"], "Disorder": {"text": [["k bipolar manic-depressive"]], "start": [[0]], "entity_id": ["T9"]}, "Drug": {"text": [["lithium"]], "start": [[55]], "entity_id": ["T10"]}}, "Subject": {"text": [["k bipolar manic-depressive patient"]], "start": [[0]], "entity_id": ["T8"]}, "Effect": {"text": [["bucco-linguo-masticatory dyskinesia", "akathisia"]], "start": [[139, 76]], "entity_id": ["T1"]}}]}]}
{"id": "11712064_2", "context": "We describe a patient who had a systemic allergic contact dermatitis to 8-MOP develop during her second course of PUVA treatment for psoriasis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["develop"]], "start": [[78]], "entity_id": ["T7"]}, "Subject": {"text": [["a patient"]], "start": [[12]], "entity_id": ["T3"]}, "Effect": {"text": [["systemic allergic contact dermatitis to 8-MOP"]], "start": [[32]], "entity_id": ["T4"]}, "Treatment": {"text": [["PUVA"]], "start": [[114]], "entity_id": ["T5"], "Disorder": {"text": [["psoriasis"]], "start": [[133]], "entity_id": ["T6"]}, "Drug": {"text": [["PUVA"]], "start": [[114]], "entity_id": ["T8"]}}}]}]}
{"id": "3677571_8", "context": "Seizures were treated with diazepam.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[14]], "entity_id": ["T4"]}, "Treatment": {"text": [["diazepam"]], "start": [[27]], "entity_id": ["T5"], "Disorder": {"text": [["Seizures"]], "start": [[0]], "entity_id": ["T6"]}, "Drug": {"text": [["diazepam"]], "start": [[27]], "entity_id": ["T7"]}}}]}]}
{"id": "10487084_2", "context": "Paradoxical seizures in phenytoin toxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["seizures"]], "start": [[12]], "entity_id": ["T5"]}, "Effect": {"text": [["Paradoxical seizures"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["phenytoin toxicity"]], "start": [[24]], "entity_id": ["T4"], "Drug": {"text": [["phenytoin"]], "start": [[24]], "entity_id": ["T6"]}}}]}]}
{"id": "1477441_1", "context": "CASE SUMMARY: Two children with attention deficit disorder treated with methylphenidate as a simple drug developed fixed drug eruption of the scrotum.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[105]], "entity_id": ["T6"]}, "Effect": {"text": [["fixed drug eruption of the scrotum"]], "start": [[115]], "entity_id": ["T7"]}, "Subject": {"text": [["Two children with attention deficit disorder"]], "start": [[14]], "entity_id": ["T3"], "Population": {"text": [["Two"]], "start": [[14]], "entity_id": ["T5"]}, "Age": {"text": [["children"]], "start": [[18]], "entity_id": ["T8"]}}, "Treatment": {"text": [["methylphenidate as a simple drug"]], "start": [[72]], "entity_id": ["T4"], "Drug": {"text": [["methylphenidate"]], "start": [[72]], "entity_id": ["T10"]}, "Disorder": {"text": [["attention deficit disorder"]], "start": [[32]], "entity_id": ["T11"]}}}]}]}
{"id": "24477376_5", "context": "While the patient was receiving both drugs, platelet aggregation studies revealed less platelet inhibition than would be expected in a patient not taking a concomitant inducer of ticagrelor metabolism.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["revealed"]], "start": [[73]], "entity_id": ["T7"]}, "Effect": {"text": [["less platelet inhibition than would be expected"]], "start": [[82]], "entity_id": ["T8"]}, "Subject": {"text": [["a patient"]], "start": [[133]], "entity_id": ["T9"]}, "Treatment": {"text": [["taking a concomitant inducer of ticagrelor metabolism."]], "start": [[147]], "entity_id": ["T6"], "Drug": {"text": [["ticagrelor"], ["inducer of ticagrelor metabolism"]], "start": [[179], [168]], "entity_id": ["T10", "T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["concomitant"]], "start": [[156]], "entity_id": ["T13"]}, "Drug": {"text": [["inducer of ticagrelor metabolism"], ["ticagrelor"]], "start": [[168], [179]], "entity_id": ["T12", "T10"]}}]}}]}]}
{"id": "17667216_2", "context": "Metformin-associated lactic acidosis precipitated by diarrhea.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[10]], "entity_id": ["T4"]}, "Treatment": {"text": [["Metformin"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Metformin"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["lactic acidosis"]], "start": [[21]], "entity_id": ["T5"]}}]}]}
{"id": "9846036_6", "context": "To date, only 1 death attributable to risperidone overdose has been reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["attributable"]], "start": [[22]], "entity_id": ["T5"]}, "Effect": {"text": [["death"]], "start": [[16]], "entity_id": ["T4"]}, "Treatment": {"text": [["risperidone overdose"]], "start": [[38]], "entity_id": ["T6"], "Drug": {"text": [["risperidone"]], "start": [[38]], "entity_id": ["T9"]}, "Dosage": {"text": [["overdose"]], "start": [[50]], "entity_id": ["T10"]}}, "Subject": {"text": [["1"]], "start": [[14]], "entity_id": ["T7"], "Population": {"text": [["1"]], "start": [[14]], "entity_id": ["T8"]}}}]}]}
{"id": "11712064_1", "context": "Systemic allergic contact dermatitis to 8-methoxypsoralen (8-MOP).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["to"]], "start": [[37]], "entity_id": ["T4"]}, "Treatment": {"text": [["8-methoxypsoralen (8-MOP)"]], "start": [[40]], "entity_id": ["T5"], "Drug": {"text": [["8-methoxypsoralen"]], "start": [[40]], "entity_id": ["T7"]}}, "Effect": {"text": [["Systemic allergic contact dermatitis"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "3301251_1", "context": "A case of a 21-year-old woman who had developed mild hepatotoxicity while receiving choline magnesium trisalicylate therapy is described.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["receiving"]], "start": [[74]], "entity_id": ["T4"]}, "Subject": {"text": [["a 21-year-old woman"]], "start": [[10]], "entity_id": ["T3"], "Age": {"text": [["21-year-old"]], "start": [[12]], "entity_id": ["T7"]}, "Gender": {"text": [["woman"]], "start": [[24]], "entity_id": ["T8"]}}, "Effect": {"text": [["mild hepatotoxicity"]], "start": [[48]], "entity_id": ["T5"]}, "Treatment": {"text": [["choline magnesium trisalicylate"]], "start": [[84]], "entity_id": ["T6"], "Drug": {"text": [["choline magnesium trisalicylate"]], "start": [[84]], "entity_id": ["T9"]}}}]}]}
{"id": "9407188_1", "context": "Early ritonavir-induced maculopapular eruption.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[16]], "entity_id": ["T5"]}, "Treatment": {"text": [["ritonavir"]], "start": [[6]], "entity_id": ["T4"], "Drug": {"text": [["ritonavir"]], "start": [[6]], "entity_id": ["T7"]}}, "Effect": {"text": [["maculopapular eruption"]], "start": [[24]], "entity_id": ["T6"]}}]}]}
{"id": "14632592_4", "context": "In our patient, an objective causality scale showed that therapeutic doses of colchicine for FMF were the definite cause of myopathy, even though his renal and hepatic function were normal.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[115]], "entity_id": ["T7"]}, "Treatment": {"text": [["therapeutic doses of colchicine for FMF"]], "start": [[57]], "entity_id": ["T3"], "Drug": {"text": [["colchicine"]], "start": [[78]], "entity_id": ["T10"]}, "Disorder": {"text": [["FMF"]], "start": [[93]], "entity_id": ["T11"]}, "Dosage": {"text": [["therapeutic doses"]], "start": [[57]], "entity_id": ["T1"]}}, "Subject": {"text": [["our patient", "his renal and hepatic function were normal"]], "start": [[3, 146]], "entity_id": ["T5"], "Gender": {"text": [["his"]], "start": [[146]], "entity_id": ["T9"]}}, "Effect": {"text": [["myopathy"]], "start": [[124]], "entity_id": ["T6"]}}]}]}
{"id": "20367573_3", "context": "Thrombocytosis induced by enoxaparin has been reported as a rare adverse effect of this medication in adults.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[15]], "entity_id": ["T4"]}, "Effect": {"text": [["Thrombocytosis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["enoxaparin"]], "start": [[26]], "entity_id": ["T5"], "Drug": {"text": [["enoxaparin"]], "start": [[26]], "entity_id": ["T6"]}}}]}]}
{"id": "3493797_1", "context": "A woman with a 20-year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs, developed a B-cell lymphoma of the lip following 4 1/2 years of treatment with razoxane.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[135]], "entity_id": ["T4"]}, "Subject": {"text": [["A woman with a 20-year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs"]], "start": [[0]], "entity_id": ["T3"], "Gender": {"text": [["woman"]], "start": [[2]], "entity_id": ["T7"]}}, "Effect": {"text": [["a B-cell lymphoma of the lip"]], "start": [[145]], "entity_id": ["T5"]}, "Treatment": {"text": [["4 1/2 years of treatment with razoxane"]], "start": [[184]], "entity_id": ["T6"], "Duration": {"text": [["following 4 1/2 years"]], "start": [[174]], "entity_id": ["T9"]}, "Drug": {"text": [["razoxane"]], "start": [[214]], "entity_id": ["T10"]}, "Disorder": {"text": [["acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs"]], "start": [[34]], "entity_id": ["T11"]}}}]}]}
{"id": "9177620_3", "context": "The evidence of high plasmatic levels of CBZ and the absence of other aetiologic factors lead the authors to conclude that the overdose of CBZ could have represented the precipitating of the episode of acute pancreatitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["precipitating"]], "start": [[170]], "entity_id": ["T5"]}, "Treatment": {"text": [["overdose of CBZ"]], "start": [[127]], "entity_id": ["T4"], "Drug": {"text": [["CBZ"]], "start": [[41]], "entity_id": ["T7"]}}, "Effect": {"text": [["acute pancreatitis"]], "start": [[202]], "entity_id": ["T6"]}}]}]}
{"id": "19904536_3", "context": "In this report, we describe a fatal gemcitabine-induced pulmonary toxicity in a patient with gallbladder metastatic adenocarcinoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[48]], "entity_id": ["T6"]}, "Treatment": {"text": [["gemcitabine"]], "start": [[36]], "entity_id": ["T7"], "Disorder": {"text": [["gallbladder metastatic adenocarcinoma"]], "start": [[93]], "entity_id": ["T10"]}, "Drug": {"text": [["gemcitabine"]], "start": [[36]], "entity_id": ["T12"]}}, "Effect": {"text": [["pulmonary toxicity"]], "start": [[56]], "entity_id": ["T8"]}, "Subject": {"text": [["a patient with gallbladder metastatic adenocarcinoma"]], "start": [[78]], "entity_id": ["T9"]}, "Severity": {"text": [["fatal"]], "start": [[30]], "entity_id": ["T1"], "value": "High"}}]}]}
{"id": "736591_2", "context": "Progressive interstitial fibrosis with roentgenographic honeycombing developed in the case of a psoriatic patient who had been on a regimen of methotrexate for 18 years.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[69]], "entity_id": ["T4"]}, "Effect": {"text": [["Progressive interstitial fibrosis with roentgenographic honeycombing"]], "start": [[0]], "entity_id": ["T3"]}, "Subject": {"text": [["a psoriatic patient"]], "start": [[94]], "entity_id": ["T5"]}, "Treatment": {"text": [["a regimen of methotrexate for 18 years"]], "start": [[130]], "entity_id": ["T6"], "Drug": {"text": [["methotrexate"]], "start": [[143]], "entity_id": ["T8"]}, "Duration": {"text": [["18 years"]], "start": [[160]], "entity_id": ["T9"]}, "Disorder": {"text": [["psoriatic"]], "start": [[96]], "entity_id": ["T10"]}}}]}]}
{"id": "9512187_2", "context": "In this report, one patient who developed gangrene after bleomycin and vincristine/vinblastine chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of severe Raynaud's phenomenon related to the same regimen are presented.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[32]], "entity_id": ["T10"]}, "Subject": {"text": [["one patient"]], "start": [[16]], "entity_id": ["T9"], "Population": {"text": [["one"]], "start": [[16]], "entity_id": ["T13"]}}, "Effect": {"text": [["gangrene"]], "start": [[42]], "entity_id": ["T11"]}, "Treatment": {"text": [["bleomycin and vincristine/vinblastine"]], "start": [[57]], "entity_id": ["T12"], "Drug": {"text": [["bleomycin"], ["vincristine"], ["vinblastine"]], "start": [[57], [71], [83]], "entity_id": ["T14", "T15", "T16"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[67]], "entity_id": ["T18"]}, "Drug": {"text": [["bleomycin"], ["vincristine"], ["vinblastine"]], "start": [[57], [71], [83]], "entity_id": ["T14", "T15", "T16"]}}]}, "Severity": {"text": [["severe"]], "start": [[201]], "entity_id": ["T17"], "value": "High"}}]}]}
{"id": "8438851_4", "context": "These multiple overlapping factors probably lead to rhabdomyolysis in a minority of patients receiving vasopressin infusion.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["lead"]], "start": [[44]], "entity_id": ["T6"]}, "Effect": {"text": [["rhabdomyolysis"]], "start": [[52]], "entity_id": ["T3"]}, "Subject": {"text": [["patients"]], "start": [[84]], "entity_id": ["T4"]}, "Treatment": {"text": [["vasopressin"]], "start": [[103]], "entity_id": ["T5"], "Drug": {"text": [["vasopressin"]], "start": [[103]], "entity_id": ["T7"]}, "Route": {"text": [["infusion"]], "start": [[115]], "entity_id": ["T8"]}}}]}]}
{"id": "20412003_3", "context": "Due to the increasing use of TMP-SMX in children, clinicians should be aware of this potentially life-threatening, immunemediated hypersensitivity reaction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reaction"]], "start": [[147]], "entity_id": ["T7"]}, "Subject": {"text": [["children"]], "start": [[40]], "entity_id": ["T3"], "Age": {"text": [["children"]], "start": [[40]], "entity_id": ["T8"]}}, "Treatment": {"text": [["TMP-SMX"]], "start": [[29]], "entity_id": ["T4"], "Drug": {"text": [["TMP-SMX"]], "start": [[29]], "entity_id": ["T9"]}}, "Effect": {"text": [["life-threatening, immunemediated hypersensitivity"]], "start": [[97]], "entity_id": ["T6"]}, "Speculated": {"text": [["potentially"]], "start": [[85]], "entity_id": ["T5"], "value": true}, "Severity": {"text": [["life-threatening"]], "start": [[97]], "entity_id": ["T10"], "value": "High"}}]}]}
{"id": "19789166_1", "context": "Given that discontinuation of nitrofurantoin and introduction of methylprednisolon therapy significantly lowered liver enzyme levels, restoring most of them to normal, we concluded that this was probably the case of toxic liver damage caused by nitrofurantoin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[235]], "entity_id": ["T4"]}, "Effect": {"text": [["toxic liver damage"]], "start": [[216]], "entity_id": ["T3"]}, "Treatment": {"text": [["nitrofurantoin"]], "start": [[245]], "entity_id": ["T5"], "Drug": {"text": [["nitrofurantoin"]], "start": [[245]], "entity_id": ["T6"]}}, "Speculated": {"text": [["probably"]], "start": [[195]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "8597009_3", "context": "Slow acetylators, who comprise roughly 50% of the South African population, are likely to develop clinical and biochemical features of phenytoin toxicity when this drug is given together with antituberculosis therapy.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["develop"]], "start": [[90]], "entity_id": ["T6"]}, "Treatment": {"text": [["phenytoin", "together with antituberculosis"]], "start": [[135, 178]], "entity_id": ["T3"], "Drug": {"text": [["antituberculosis"], ["phenytoin"]], "start": [[192], [135]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["together"]], "start": [[178]], "entity_id": ["T9"]}, "Drug": {"text": [["phenytoin"], ["antituberculosis"]], "start": [[135], [192]], "entity_id": ["T11", "T10"]}}]}, "Subject": {"text": [["Slow acetylators"]], "start": [[0]], "entity_id": ["T4"], "Disorder": {"text": [["Slow acetylators"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["clinical and biochemical features of phenytoin toxicity"]], "start": [[98]], "entity_id": ["T5"]}, "Speculated": {"text": [["likely"]], "start": [[80]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "12235444_3", "context": "Therefore there is the potential for significant concentration-related adverse effects when phenytoin is coadministered with other CYP2C9 substrates.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["potentia"]], "start": [[23]], "entity_id": ["T9"]}, "Effect": {"text": [["significant concentration-related adverse effects"]], "start": [[37]], "entity_id": ["T7"]}, "Treatment": {"text": [["phenytoin", "other CYP2C9 substrates"]], "start": [[92, 125]], "entity_id": ["T8"], "Drug": {"text": [["phenytoin"], ["other CYP2C9 substrates"]], "start": [[92], [125]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["coadministered"]], "start": [[105]], "entity_id": ["T12"]}, "Drug": {"text": [["phenytoin"], ["other CYP2C9 substrates"]], "start": [[92], [125]], "entity_id": ["T10", "T11"]}}]}}]}]}
{"id": "9554064_2", "context": "Putaminal infarct in methanol intoxication: case report and role of brain imaging studies.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["intoxication"]], "start": [[30]], "entity_id": ["T7"]}, "Treatment": {"text": [["methanol"]], "start": [[21]], "entity_id": ["T5"], "Drug": {"text": [["methanol"]], "start": [[21]], "entity_id": ["T8"]}}, "Effect": {"text": [["Putaminal infarct in methanol intoxication"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "736591_3", "context": "Progressive interstitial lung disease from prolonged methotrexate therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["from"]], "start": [[38]], "entity_id": ["T5"]}, "Effect": {"text": [["Progressive interstitial lung disease"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["prolonged methotrexate therapy"]], "start": [[43]], "entity_id": ["T4"], "Duration": {"text": [["prolonged"]], "start": [[43]], "entity_id": ["T6"]}, "Drug": {"text": [["methotrexate"]], "start": [[53]], "entity_id": ["T7"]}}}]}]}
{"id": "16044093_2", "context": "The case reported here is of a child given a large dose of intravenous iron sucrose (16 mg/kg) over 3 hours, who subsequently developed features of systemic iron toxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[126]], "entity_id": ["T4"]}, "Treatment": {"text": [["a large dose of intravenous iron sucrose"]], "start": [[43]], "entity_id": ["T3"], "Drug": {"text": [["iron sucrose"]], "start": [[71]], "entity_id": ["T8"]}, "Dosage": {"text": [["16 mg/kg"]], "start": [[85]], "entity_id": ["T9"]}, "Duration": {"text": [["3 hours"]], "start": [[100]], "entity_id": ["T10"]}}, "Effect": {"text": [["systemic iron toxicity"]], "start": [[148]], "entity_id": ["T5"]}, "Subject": {"text": [["a child"]], "start": [[29]], "entity_id": ["T6"], "Age": {"text": [["child"]], "start": [[31]], "entity_id": ["T7"]}}}]}]}
{"id": "11292139_1", "context": "We report a patient with advanced colonic carcinoma who was treated with concomitant chemoirradiation with oxaliplatin and developed a peculiar dermnatitis in the irradiated field after being exposed to subsequent chemotherapy with oxaliplatin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[123]], "entity_id": ["T4"]}, "Subject": {"text": [["a patient with advanced colonic carcinoma who was treated with concomitant chemoirradiation with oxaliplatin"]], "start": [[10]], "entity_id": ["T3"]}, "Treatment": {"text": [["exposed to subsequent chemotherapy with oxaliplatin"]], "start": [[192]], "entity_id": ["T5"], "Disorder": {"text": [["advanced colonic carcinoma"]], "start": [[25]], "entity_id": ["T8"]}, "Drug": {"text": [["concomitant chemoirradiation"], ["oxaliplatin"], ["oxaliplatin"]], "start": [[73], [107], [232]], "entity_id": ["T9", "T10", "T11"]}}, "Effect": {"text": [["a peculiar dermnatitis in the irradiated field"]], "start": [[133]], "entity_id": ["T6"]}}]}]}
{"id": "1751354_2", "context": "Recombinant human interferon-alpha has been used in the treatment of several cancers, but there have been several reports that it may exacerbate psoriasis or trigger off its onset.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["trigger"]], "start": [[158]], "entity_id": ["T5"]}, "Treatment": {"text": [["Recombinant human interferon-alpha"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Recombinant human interferon-alpha"]], "start": [[0]], "entity_id": ["T7"]}, "Disorder": {"text": [["cancers"]], "start": [[77]], "entity_id": ["T8"]}}, "Effect": {"text": [["exacerbate psoriasis"]], "start": [[134]], "entity_id": ["T6"]}, "Speculated": {"text": [["may"]], "start": [[130]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "17034541_3", "context": "This is the first case of HBV reactivation occurring during the year following rituximab monotherapy in the absence of any other immunosuppressive factor.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurring"]], "start": [[43]], "entity_id": ["T4"]}, "Effect": {"text": [["HBV reactivation"]], "start": [[26]], "entity_id": ["T3"]}, "Treatment": {"text": [["the year following rituximab monotherapy in the absence of any other immunosuppressive factor"]], "start": [[60]], "entity_id": ["T5"], "Drug": {"text": [["rituximab"]], "start": [[79]], "entity_id": ["T6"]}, "Time_elapsed": {"text": [["year following"]], "start": [[64]], "entity_id": ["T7"]}}}]}]}
{"id": "6958210_2", "context": "Systemic lupus erythematosus during penicillamine therapy for rheumatoid arthritis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[29]], "entity_id": ["T4"]}, "Effect": {"text": [["Systemic lupus erythematosus"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["penicillamine therapy"]], "start": [[36]], "entity_id": ["T5"], "Drug": {"text": [["penicillamine"]], "start": [[36]], "entity_id": ["T7"]}, "Disorder": {"text": [["rheumatoid arthritis."]], "start": [[62]], "entity_id": ["T8"]}}}]}]}
{"id": "7538828_7", "context": "In the absence of mucositis or diarrhea, severe dermatologic toxicity following a single low dose of the drug suggests an 'allergic' or acute hypersensitivity reaction to MTX in this patient.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[70]], "entity_id": ["T14"]}, "Effect": {"text": [["dermatologic toxicity", "an 'allergic' or acute hypersensitivity reaction"]], "start": [[48, 119]], "entity_id": ["T13"]}, "Treatment": {"text": [["a single low dose of the drug", "MTX"]], "start": [[80, 171]], "entity_id": ["T15"], "Drug": {"text": [["MTX"]], "start": [[171]], "entity_id": ["T17"]}, "Dosage": {"text": [["single low dose"]], "start": [[82]], "entity_id": ["T19"]}}, "Subject": {"text": [["this patient"]], "start": [[178]], "entity_id": ["T16"]}, "Severity": {"text": [["severe"]], "start": [[41]], "entity_id": ["T20"], "value": "High"}}]}]}
{"id": "3346128_2", "context": "Erosion of psoriatic plaques after chronic methotrexate administration.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[29]], "entity_id": ["T4"]}, "Effect": {"text": [["Erosion of psoriatic plaques"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["methotrexate"]], "start": [[43]], "entity_id": ["T5"], "Drug": {"text": [["methotrexate"]], "start": [[43]], "entity_id": ["T6"]}}}]}]}
{"id": "3982906_1", "context": "Cardiac decompensation following verapamil therapy in infants with supraventricular tachycardia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[23]], "entity_id": ["T5"]}, "Subject": {"text": [["infants with supraventricular tachycardia"]], "start": [[54]], "entity_id": ["T3"], "Age": {"text": [["infants"]], "start": [[54]], "entity_id": ["T7"]}}, "Effect": {"text": [["Cardiac decompensation"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["verapamil therapy"]], "start": [[33]], "entity_id": ["T6"], "Disorder": {"text": [["supraventricular tachycardia"]], "start": [[67]], "entity_id": ["T8"]}, "Drug": {"text": [["verapamil"]], "start": [[33]], "entity_id": ["T1"]}}}]}]}
{"id": "19183077_3", "context": "We report two cases of tenofovir (TDF)-associated nephrotoxicity in perinatally HIV-infected adolescents.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[39]], "entity_id": ["T5"]}, "Treatment": {"text": [["tenofovir (TDF)"]], "start": [[23]], "entity_id": ["T4"], "Drug": {"text": [["tenofovir"]], "start": [[23]], "entity_id": ["T10"]}, "Disorder": {"text": [["HIV"]], "start": [[80]], "entity_id": ["T8"]}}, "Effect": {"text": [["nephrotoxicity"]], "start": [[50]], "entity_id": ["T6"]}, "Subject": {"text": [["perinatally HIV-infected adolescents"]], "start": [[68]], "entity_id": ["T7"], "Age": {"text": [["adolescents"]], "start": [[93]], "entity_id": ["T9"]}}}]}]}
{"id": "12324937_6", "context": "RESULTS: Including our own patient, a total of 26 cases of gemcitabine-associated HUS were identified.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[71]], "entity_id": ["T5"]}, "Treatment": {"text": [["gemcitabine"]], "start": [[59]], "entity_id": ["T4"], "Drug": {"text": [["gemcitabine"]], "start": [[59]], "entity_id": ["T3"]}}, "Effect": {"text": [["HUS"]], "start": [[82]], "entity_id": ["T6"]}}]}]}
{"id": "17260498_5", "context": "Even though only a few cases of this adverse event have been reported in the literature, severe docetaxel-induced pulmonary toxicity needs to be considered in the differential diagnosis when such patients present with respiratory symptoms.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[106]], "entity_id": ["T6"]}, "Treatment": {"text": [["docetaxel"]], "start": [[96]], "entity_id": ["T7"], "Drug": {"text": [["docetaxel"]], "start": [[96]], "entity_id": ["T12"]}}, "Effect": {"text": [["pulmonary toxicity", "respiratory symptoms"]], "start": [[114, 218]], "entity_id": ["T8"]}, "Severity": {"text": [["severe"]], "start": [[89]], "entity_id": ["T11"], "value": "Medium"}}]}]}
{"id": "22791547_3", "context": "In this article, the authors report a 7-year-old male patient who presented with orofacial and limb dyskinesia after his first dose of methylphenidate treatment for a diagnosis of attention-deficit/hyperactivity disorder; he was also receiving sodium valproate treatment for epilepsy.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[111]], "entity_id": ["T10"]}, "Subject": {"text": [["a 7-year-old male patient"]], "start": [[36]], "entity_id": ["T9"], "Age": {"text": [["7-year-old"]], "start": [[38]], "entity_id": ["T14"]}, "Gender": {"text": [["male"]], "start": [[49]], "entity_id": ["T15"]}}, "Effect": {"text": [["orofacial and limb dyskinesia"]], "start": [[81]], "entity_id": ["T13"]}, "Treatment": {"text": [["first dose of methylphenidate"]], "start": [[121]], "entity_id": ["T11"], "Disorder": {"text": [["attention-deficit/hyperactivity disorder"]], "start": [[180]], "entity_id": ["T12"]}, "Time_elapsed": {"text": [["first dose"]], "start": [[121]], "entity_id": ["T16"]}, "Drug": {"text": [["methylphenidate"]], "start": [[135]], "entity_id": ["T17"]}}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["receiving"]], "start": [[234]], "entity_id": ["T22"]}, "Subject": {"text": [["a 7-year-old male patient"]], "start": [[36]], "entity_id": ["T9"], "Age": {"text": [["7-year-old"]], "start": [[38]], "entity_id": ["T14"]}, "Gender": {"text": [["male"]], "start": [[49]], "entity_id": ["T15"]}}, "Treatment": {"text": [["sodium valproate"]], "start": [[244]], "entity_id": ["T20"], "Disorder": {"text": [["epilepsy"]], "start": [[275]], "entity_id": ["T19"]}, "Drug": {"text": [["sodium valproate"]], "start": [[244]], "entity_id": ["T21"]}}}]}]}
{"id": "12221670_1", "context": "The first case concerns a 70-year-old man who developed severe aplastic anemia 7 weeks after treatment with 500 mg of ticlopidine daily.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[46]], "entity_id": ["T6"]}, "Subject": {"text": [["70-year-old man"]], "start": [[26]], "entity_id": ["T3"], "Age": {"text": [["70-year-old"]], "start": [[26]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[38]], "entity_id": ["T8"]}}, "Effect": {"text": [["severe aplastic anemia"]], "start": [[56]], "entity_id": ["T4"]}, "Treatment": {"text": [["7 weeks after treatment with 500 mg of ticlopidine daily"]], "start": [[79]], "entity_id": ["T5"], "Time_elapsed": {"text": [["7 weeks"]], "start": [[79]], "entity_id": ["T10"]}, "Dosage": {"text": [["500 mg"]], "start": [[108]], "entity_id": ["T11"]}, "Drug": {"text": [["ticlopidine"]], "start": [[118]], "entity_id": ["T12"]}, "Freq": {"text": [["daily"]], "start": [[130]], "entity_id": ["T13"]}}}]}]}
{"id": "17931455_1", "context": "CASE REPORT: A six-year-old boy with transfusion-dependent beta-thalassaemia developed a unilateral hearing loss shortly after commencing desferrioxamine therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[77]], "entity_id": ["T4"]}, "Subject": {"text": [["A six-year-old boy with transfusion-dependent beta-thalassaemia"]], "start": [[13]], "entity_id": ["T3"], "Age": {"text": [["six-year-old"]], "start": [[15]], "entity_id": ["T7"]}, "Gender": {"text": [["boy"]], "start": [[28]], "entity_id": ["T8"]}}, "Effect": {"text": [["a unilateral hearing loss"]], "start": [[87]], "entity_id": ["T5"]}, "Treatment": {"text": [["commencing desferrioxamine therapy"]], "start": [[127]], "entity_id": ["T6"], "Disorder": {"text": [["transfusion-dependent beta-thalassaemia"]], "start": [[37]], "entity_id": ["T9"]}, "Time_elapsed": {"text": [["shortly after"]], "start": [[113]], "entity_id": ["T10"]}, "Drug": {"text": [["desferrioxamine"]], "start": [[138]], "entity_id": ["T11"]}}}]}]}
{"id": "9796135_4", "context": "Syncope in a 65-year-old woman after nitrate ingestion.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[31]], "entity_id": ["T5"]}, "Effect": {"text": [["Syncope"]], "start": [[0]], "entity_id": ["T3"]}, "Subject": {"text": [["a 65-year-old woman"]], "start": [[11]], "entity_id": ["T4"], "Age": {"text": [["65-year-old"]], "start": [[13]], "entity_id": ["T7"]}, "Gender": {"text": [["woman"]], "start": [[25]], "entity_id": ["T8"]}}, "Treatment": {"text": [["nitrate ingestion"]], "start": [[37]], "entity_id": ["T6"], "Drug": {"text": [["nitrate"]], "start": [[37]], "entity_id": ["T9"]}, "Route": {"text": [["ingestion"]], "start": [[45]], "entity_id": ["T10"]}}}]}]}
{"id": "18691992_3", "context": "Both the longitudinal melanonychia and the multiple skin cancers first appeared after approximately 6 months of hydroxyurea treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["appeared"]], "start": [[71]], "entity_id": ["T6"]}, "Effect": {"text": [["longitudinal melanonychia and the multiple skin cancers"]], "start": [[9]], "entity_id": ["T5"]}, "Treatment": {"text": [["approximately 6 months of hydroxyurea treatment"]], "start": [[86]], "entity_id": ["T7"], "Duration": {"text": [["6 months"]], "start": [[100]], "entity_id": ["T8"]}, "Drug": {"text": [["hydroxyurea"]], "start": [[112]], "entity_id": ["T9"]}}}]}]}
{"id": "7854541_2", "context": "Multifocal inflammatory leukoencephalopathy associated with levamisole therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated with"]], "start": [[44]], "entity_id": ["T4"]}, "Effect": {"text": [["Multifocal inflammatory leukoencephalopathy"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["levamisole therapy"]], "start": [[60]], "entity_id": ["T5"], "Drug": {"text": [["levamisole"]], "start": [[60]], "entity_id": ["T6"]}}}]}]}
{"id": "9247841_5", "context": "The observation of cutaneous vasculitis during administration of propylthiouracil suggested that clinical awareness of this complication should be of considerable importance.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[40]], "entity_id": ["T6"]}, "Effect": {"text": [["cutaneous vasculitis"]], "start": [[19]], "entity_id": ["T4"]}, "Treatment": {"text": [["propylthiouracil"]], "start": [[65]], "entity_id": ["T5"], "Drug": {"text": [["propylthiouracil"]], "start": [[65]], "entity_id": ["T7"]}}}]}]}
{"id": "16109609_3", "context": "Physicians should be aware of the potential for developing a gemcitabine-induced radiation recall reaction resulting in hemodynamically significant pericardial effusion.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[73]], "entity_id": ["T6"]}, "Treatment": {"text": [["gemcitabine"]], "start": [[61]], "entity_id": ["T5"], "Drug": {"text": [["gemcitabine"]], "start": [[61]], "entity_id": ["T8"]}}, "Effect": {"text": [["radiation recall reaction resulting in hemodynamically significant pericardial effusion"]], "start": [[81]], "entity_id": ["T7"]}}]}]}
{"id": "18648015_3", "context": "OBJECTIVE: To describe a case of cefazolin-induced leukopenia in a critically ill patient who developed this adverse reaction upon rechallenge with cefoxitin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[43]], "entity_id": ["T4"]}, "Treatment": {"text": [["cefazolin"]], "start": [[33]], "entity_id": ["T3"], "Drug": {"text": [["cefazolin"]], "start": [[33]], "entity_id": ["T8"]}}, "Effect": {"text": [["leukopenia"]], "start": [[51]], "entity_id": ["T5"]}, "Subject": {"text": [["a critically ill patient"]], "start": [[65]], "entity_id": ["T6"], "Disorder": {"text": [["critically ill"]], "start": [[67]], "entity_id": ["T7"]}}}]}]}
{"id": "6149250_4", "context": "The second patient suffered from high blood pressure, which was controlled with beta-blocker drugs.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["controlled"]], "start": [[64]], "entity_id": ["T6"]}, "Subject": {"text": [["The second patient suffered from high blood pressure"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["beta-blocker drugs"]], "start": [[80]], "entity_id": ["T7"], "Disorder": {"text": [["high blood pressure"]], "start": [[33]], "entity_id": ["T9"]}, "Drug": {"text": [["beta-blocker drugs"]], "start": [[80]], "entity_id": ["T10"]}}}]}]}
{"id": "11999915_3", "context": "The female patient received clozapine in a daily dose of 400 mg, which induced agranulocytosis after 2 months.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[71]], "entity_id": ["T4"]}, "Subject": {"text": [["The female patient"]], "start": [[0]], "entity_id": ["T3"], "Gender": {"text": [["female"]], "start": [[4]], "entity_id": ["T7"]}}, "Effect": {"text": [["agranulocytosis"]], "start": [[79]], "entity_id": ["T5"]}, "Treatment": {"text": [["clozapine in a daily dose of 400 mg", "after 2 months"]], "start": [[28, 95]], "entity_id": ["T6"], "Duration": {"text": [["2 months"]], "start": [[101]], "entity_id": ["T8"]}, "Dosage": {"text": [["400 mg"]], "start": [[57]], "entity_id": ["T9"]}, "Freq": {"text": [["daily"]], "start": [[43]], "entity_id": ["T10"]}, "Drug": {"text": [["clozapine"]], "start": [[28]], "entity_id": ["T11"]}}}]}]}
{"id": "11399735_4", "context": "We report a case of interstitial pulmonary disease that occurred together with lymphocytic colitis during treatment with ticlopidine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[99]], "entity_id": ["T6"]}, "Effect": {"text": [["interstitial pulmonary disease", "lymphocytic colitis"]], "start": [[20, 79]], "entity_id": ["T5"]}, "Treatment": {"text": [["ticlopidine"]], "start": [[121]], "entity_id": ["T7"], "Drug": {"text": [["ticlopidine"]], "start": [[121]], "entity_id": ["T8"]}}, "Subject": {"text": [["a case"]], "start": [[10]], "entity_id": ["T9"]}}]}]}
{"id": "9579301_1", "context": "Increased ocular pressure in two patients with narrow angle glaucoma treated with venlafaxine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[26]], "entity_id": ["T7"]}, "Treatment": {"text": [["venlafaxine"]], "start": [[82]], "entity_id": ["T3"], "Drug": {"text": [["venlafaxine"]], "start": [[82]], "entity_id": ["T9"]}}, "Effect": {"text": [["Increased ocular pressure"]], "start": [[0]], "entity_id": ["T6"]}, "Subject": {"text": [["two patients with narrow angle glaucoma"]], "start": [[29]], "entity_id": ["T5"], "Disorder": {"text": [["narrow angle glaucoma"]], "start": [[47]], "entity_id": ["T4"]}, "Population": {"text": [["two"]], "start": [[29]], "entity_id": ["T8"]}}}]}]}
{"id": "6484655_1", "context": "Although they had complex medical problems, the high serum concentrations of ampicillin at the time of seizures without their recurrence after discontinuing the antibiotic suggest that the seizures were related to the ampicillin therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[203]], "entity_id": ["T5"]}, "Effect": {"text": [["seizures"]], "start": [[189]], "entity_id": ["T4"]}, "Treatment": {"text": [["ampicillin therapy"]], "start": [[218]], "entity_id": ["T6"], "Drug": {"text": [["ampicillin"]], "start": [[218]], "entity_id": ["T7"]}}}]}]}
{"id": "2250853_1", "context": "Glaucoma secondary to epithelial downgrowth and 5-fluorouracil.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["secondary"]], "start": [[9]], "entity_id": ["T4"]}, "Effect": {"text": [["Glaucoma"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["5-fluorouracil"]], "start": [[48]], "entity_id": ["T5"], "Drug": {"text": [["5-fluorouracil"]], "start": [[48]], "entity_id": ["T6"]}}}]}]}
{"id": "17319250_1", "context": "Of particular interest in this patient is the fluctuation of the QT interval at a stable dose of methadone, suggesting that a single normal electrocardiogram (ECG) does not guarantee that the patient is not at risk of ventricular arrhythmias.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["at"]], "start": [[77]], "entity_id": ["T4"]}, "Effect": {"text": [["fluctuation of the QT interval"]], "start": [[46]], "entity_id": ["T3"]}, "Subject": {"text": [["this patient"]], "start": [[26]], "entity_id": ["T5"]}, "Treatment": {"text": [["a stable dose of methadone"]], "start": [[80]], "entity_id": ["T6"], "Drug": {"text": [["methadone"]], "start": [[97]], "entity_id": ["T7"]}, "Dosage": {"text": [["a stable dose"]], "start": [[80]], "entity_id": ["T8"]}}}]}]}
{"id": "20190474_4", "context": "This is the first report of acute kidney injury due to zonisamide-induced DRESS/DIHS.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[66]], "entity_id": ["T9"]}, "Treatment": {"text": [["zonisamide"]], "start": [[55]], "entity_id": ["T8"], "Drug": {"text": [["zonisamide"]], "start": [[55]], "entity_id": ["T10"]}}, "Effect": {"text": [["acute kidney injury due to", "DRESS/DIHS"]], "start": [[28, 74]], "entity_id": ["T7"]}}]}]}
{"id": "1393348_2", "context": "Although both the spontaneous occurrence of SLE and the psychosis as a sign of CNS involvement of SLE cannot be excluded, SLE could be considered as an adverse effect of carbamazepine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["considered"]], "start": [[135]], "entity_id": ["T6"]}, "Effect": {"text": [["SLE"]], "start": [[122]], "entity_id": ["T5"]}, "Treatment": {"text": [["carbamazepine"]], "start": [[170]], "entity_id": ["T7"], "Drug": {"text": [["carbamazepine"]], "start": [[170]], "entity_id": ["T9"]}}, "Speculated": {"text": [["could"]], "start": [[126]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "10803790_1", "context": "BACKGROUND: Cyanamide, an aversive agent widely used in Japan, is known to induce various degrees of hepatic lesion with ground-glass inclusion bodies.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induce"]], "start": [[75]], "entity_id": ["T3"]}, "Effect": {"text": [["various degrees of hepatic lesion with ground-glass inclusion bodies"]], "start": [[82]], "entity_id": ["T4"]}, "Treatment": {"text": [["Cyanamide"]], "start": [[12]], "entity_id": ["T5"], "Drug": {"text": [["Cyanamide"]], "start": [[12]], "entity_id": ["T6"]}}}]}]}
{"id": "17675030_3", "context": "Oxcarbazepine-associated angioedema manifested by swelling of the face, eyes, lips, or tongue or difficulty swallowing or breathing (or both) is a rare but potentially life-threatening reaction for which early recognition and management are vital.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[14]], "entity_id": ["T4"]}, "Treatment": {"text": [["Oxcarbazepine"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Oxcarbazepine"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["angioedema manifested by swelling of the face, eyes, lips, or tongue or difficulty swallowing or breathing (or both)"]], "start": [[25]], "entity_id": ["T5"]}}]}]}
{"id": "16432996_5", "context": "The combination therapy of interferon alpha and ribavirin was given to a 50-year-old female with CHC who had not responded to a previous treatment by interferon alpha.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["given"]], "start": [[62]], "entity_id": ["T10"]}, "Subject": {"text": [["a 50-year-old female with CHC who had not responded to a previous treatment by interferon alpha"]], "start": [[71]], "entity_id": ["T9"], "Age": {"text": [["50-year-old"]], "start": [[73]], "entity_id": ["T11"]}, "Gender": {"text": [["female"]], "start": [[85]], "entity_id": ["T12"]}}, "Treatment": {"text": [["combination therapy of interferon alpha and ribavirin"]], "start": [[4]], "entity_id": ["T8"], "Disorder": {"text": [["CHC"]], "start": [[97]], "entity_id": ["T13"]}, "Drug": {"text": [["interferon alpha"], ["ribavirin"]], "start": [[27], [48]], "entity_id": ["T15", "T16"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combination"]], "start": [[4]], "entity_id": ["T14"]}, "Drug": {"text": [["interferon alpha"], ["ribavirin"]], "start": [[27], [48]], "entity_id": ["T15", "T16"]}}]}}]}]}
{"id": "15494638_1", "context": "Peripheral neuropathy associated with capecitabine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[22]], "entity_id": ["T5"]}, "Effect": {"text": [["Peripheral neuropathy"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["capecitabine."]], "start": [[38]], "entity_id": ["T6"], "Drug": {"text": [["capecitabine"]], "start": [[38]], "entity_id": ["T7"]}}}]}]}
{"id": "16411025_1", "context": "DESIGN: We reviewed the medical records of four patients, who were seen by us between July 2000 and February 2004 for sudden onset of a central neurological syndrome within days of intrathecal MTX.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["intrathecal"]], "start": [[181]], "entity_id": ["T3"]}, "Treatment": {"text": [["MTX"]], "start": [[193]], "entity_id": ["T4"], "Drug": {"text": [["MTX"]], "start": [[193]], "entity_id": ["T8"]}, "Time_elapsed": {"text": [["within days"]], "start": [[166]], "entity_id": ["T9"]}}, "Effect": {"text": [["a central neurological syndrome"]], "start": [[134]], "entity_id": ["T5"]}, "Subject": {"text": [["medical records of four patients"]], "start": [[24]], "entity_id": ["T6"], "Population": {"text": [["four"]], "start": [[43]], "entity_id": ["T7"]}}}]}]}
{"id": "9497597_1", "context": "Prothipendylhydrochloride-induced priapism: case report.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[26]], "entity_id": ["T4"]}, "Treatment": {"text": [["Prothipendylhydrochloride"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Prothipendylhydrochloride"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["priapism"]], "start": [[34]], "entity_id": ["T5"]}}]}]}
{"id": "19897274_2", "context": "Interstitial pneumonia probably associated with sorafenib treatment: An alert of an adverse event.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[32]], "entity_id": ["T3"]}, "Treatment": {"text": [["sorafenib treatment:"]], "start": [[48]], "entity_id": ["T4"], "Drug": {"text": [["sorafenib"]], "start": [[48]], "entity_id": ["T7"]}}, "Effect": {"text": [["Interstitial pneumonia"]], "start": [[0]], "entity_id": ["T5"]}, "Speculated": {"text": [["probably"]], "start": [[23]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "19915794_1", "context": "He had hypokalemia (K 2.3 mmol/L) induced by licorice and also had received disopyramide for arrhythmia, bicalutamide for prostate cancer, and silodosin for prostate hypertrophy.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[34]], "entity_id": ["T4"]}, "Effect": {"text": [["hypokalemia (K 2.3 mmol/L)"]], "start": [[7]], "entity_id": ["T3"]}, "Treatment": {"text": [["licorice and also had received disopyramide for arrhythmia, bicalutamide for prostate cancer, and silodosin for prostate hypertrophy"]], "start": [[45]], "entity_id": ["T5"], "Drug": {"text": [["licorice"], ["disopyramide"], ["bicalutamide"], ["silodosin"]], "start": [[45], [76], [105], [143]], "entity_id": ["T6", "T7", "T8", "T9"]}, "Disorder": {"text": [["prostate hypertrophy"], ["prostate cancer"], ["arrhythmia"]], "start": [[157], [122], [93]], "entity_id": ["T10", "T11", "T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[54]], "entity_id": ["T13"]}, "Drug": {"text": [["disopyramide"], ["bicalutamide"], ["silodosin"], ["licorice"]], "start": [[76], [105], [143], [45]], "entity_id": ["T7", "T8", "T9", "T6"]}}]}}]}]}
{"id": "20412003_5", "context": "Use of the Naranjo adverse drug reaction probability scale indicated a probable relationship (score of 5) between the patient's development of hepatotoxicity and the TMP-SMX therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["development"]], "start": [[128]], "entity_id": ["T4"]}, "Treatment": {"text": [["TMP-SMX therapy"]], "start": [[166]], "entity_id": ["T3"], "Drug": {"text": [["TMP-SMX"]], "start": [[166]], "entity_id": ["T7"]}}, "Effect": {"text": [["hepatotoxicity"]], "start": [[143]], "entity_id": ["T5"]}, "Subject": {"text": [["patient's"]], "start": [[118]], "entity_id": ["T6"]}, "Speculated": {"text": [["probable"]], "start": [[71]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "24429012_9", "context": "Since its introduction in 2012, vismodegib has been implicated as a possible factor in seven reports of patient deaths.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["implicated"]], "start": [[52]], "entity_id": ["T7"]}, "Treatment": {"text": [["vismodegib"]], "start": [[32]], "entity_id": ["T6"], "Drug": {"text": [["vismodegib"]], "start": [[32]], "entity_id": ["T11"]}}, "Effect": {"text": [["deaths"]], "start": [[112]], "entity_id": ["T8"]}, "Subject": {"text": [["seven reports of patient"]], "start": [[87]], "entity_id": ["T9"], "Population": {"text": [["seven"]], "start": [[87]], "entity_id": ["T10"]}}, "Speculated": {"text": [["possible"]], "start": [[68]], "entity_id": ["T12"], "value": true}}]}]}
{"id": "8461228_2", "context": "Acceleration of ventricular response to atrial flutter after intravenous adenosine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[55]], "entity_id": ["T3"]}, "Treatment": {"text": [["intravenous adenosine."]], "start": [[61]], "entity_id": ["T4"], "Drug": {"text": [["adenosine"]], "start": [[73]], "entity_id": ["T6"]}, "Route": {"text": [["intravenous"]], "start": [[61]], "entity_id": ["T7"]}, "Disorder": {"text": [["atrial flutter"]], "start": [[40]], "entity_id": ["T9"]}}, "Effect": {"text": [["Acceleration of ventricular response"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "15331204_1", "context": "Possible induction of diabetes by treatment of hypertension with indapamide (with four case reports).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induction"]], "start": [[9]], "entity_id": ["T8"]}, "Effect": {"text": [["diabetes"]], "start": [[22]], "entity_id": ["T7"]}, "Treatment": {"text": [["indapamide"]], "start": [[65]], "entity_id": ["T10"], "Disorder": {"text": [["hypertension"]], "start": [[47]], "entity_id": ["T9"]}, "Drug": {"text": [["indapamide"]], "start": [[65]], "entity_id": ["T12"]}}, "Speculated": {"text": [["Possible"]], "start": [[0]], "entity_id": ["T11"], "value": true}}]}]}
{"id": "4036917_1", "context": "Physicians should be aware of the potential for the development of RS among children who are receiving long-term aspirin therapy for the treatment of systemic inflammatory illnesses.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["development"]], "start": [[52]], "entity_id": ["T7"]}, "Effect": {"text": [["RS"]], "start": [[67]], "entity_id": ["T3"]}, "Subject": {"text": [["children"]], "start": [[76]], "entity_id": ["T4"], "Age": {"text": [["children"]], "start": [[76]], "entity_id": ["T8"]}}, "Treatment": {"text": [["long-term aspirin therapy"]], "start": [[103]], "entity_id": ["T6"], "Disorder": {"text": [["systemic inflammatory illnesses"]], "start": [[150]], "entity_id": ["T5"]}, "Drug": {"text": [["aspirin"]], "start": [[113]], "entity_id": ["T9"]}}, "Speculated": {"text": [["potential"]], "start": [[34]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "889156_7", "context": "While a lower systemic steroid dosage may have been the provoking factor, we feel that an adverse reaction to oleic acid, a dispersing agent in the aerosol freon vehicle, is a strong possibility.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["to"]], "start": [[107]], "entity_id": ["T8"]}, "Treatment": {"text": [["oleic acid"]], "start": [[110]], "entity_id": ["T6"], "Drug": {"text": [["oleic acid"]], "start": [[110]], "entity_id": ["T10"]}}, "Effect": {"text": [["adverse reaction"]], "start": [[90]], "entity_id": ["T7"]}, "Speculated": {"text": [["strong possibility"]], "start": [[176]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "16119501_2", "context": "Baclofen withdrawal syndrome resulting from underdosing of oral baclofen should be considered as a potential source of prolonged fever in the intensive care unit.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulting"]], "start": [[29]], "entity_id": ["T6"]}, "Effect": {"text": [["Baclofen withdrawal syndrome", "prolonged fever in the intensive care unit"]], "start": [[0, 119]], "entity_id": ["T4"]}, "Treatment": {"text": [["underdosing of oral baclofen"]], "start": [[44]], "entity_id": ["T5"], "Route": {"text": [["oral"]], "start": [[59]], "entity_id": ["T9"]}, "Drug": {"text": [["baclofen"]], "start": [[64]], "entity_id": ["T10"]}}, "Speculated": {"text": [["potential source"]], "start": [[99]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "7787496_2", "context": "We present a case of sotalol-induced bradycardia reversed by glucagon.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[29]], "entity_id": ["T4"]}, "Treatment": {"text": [["sotalol"]], "start": [[21]], "entity_id": ["T3"], "Drug": {"text": [["sotalol"]], "start": [[21]], "entity_id": ["T7"]}}, "Effect": {"text": [["bradycardia"]], "start": [[37]], "entity_id": ["T5"]}, "Subject": {"text": [["a case"]], "start": [[11]], "entity_id": ["T6"]}}]}]}
{"id": "8192712_2", "context": "Hyperammonemia has been described as a complication of valproic acid therapy but may often be overlooked as a cause of lethargy in the postictal patient who presents to the emergency department.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[39]], "entity_id": ["T6"]}, "Effect": {"text": [["Hyperammonemia"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["valproic acid therapy"]], "start": [[55]], "entity_id": ["T7"], "Drug": {"text": [["valproic acid"]], "start": [[55]], "entity_id": ["T8"]}}}]}]}
{"id": "19423610_7", "context": "Methylene blue has been found to be a potent inhibitor of monoamine oxidase (MAO), and several cases of serotonin toxicity have been reported recently following its administration.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[151]], "entity_id": ["T9"]}, "Treatment": {"text": [["Methylene blue"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Methylene blue"]], "start": [[0]], "entity_id": ["T11"]}}, "Effect": {"text": [["serotonin toxicity"]], "start": [[104]], "entity_id": ["T6"]}, "Subject": {"text": [["several cases"]], "start": [[87]], "entity_id": ["T8"]}}]}]}
{"id": "8903300_1", "context": "She had just finished a 3-week course of intravenous tobramycin for bronchiectasis and had an elevated serum tobramycin trough level 1 week before the onset of tetany.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["had"]], "start": [[87]], "entity_id": ["T5"]}, "Treatment": {"text": [["a 3-week course of intravenous tobramycin"]], "start": [[22]], "entity_id": ["T3"], "Drug": {"text": [["tobramycin"]], "start": [[53]], "entity_id": ["T7"]}, "Duration": {"text": [["3-week course"]], "start": [[24]], "entity_id": ["T8"]}, "Route": {"text": [["intravenous"]], "start": [[41]], "entity_id": ["T9"]}, "Disorder": {"text": [["bronchiectasis"]], "start": [[68]], "entity_id": ["T10"]}}, "Effect": {"text": [["elevated serum tobramycin trough level 1 week before the onset of tetany"]], "start": [[94]], "entity_id": ["T6"]}}]}]}
{"id": "9796135_3", "context": "In a postural challenge test after administration of isosorbide dinitrate (5 mg), blood pressure decreased from 120/67 to 65/35 mmHg, followed by syncope with a sudden decrease in pulse rate from 85 to 60 beats/min.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[29]], "entity_id": ["T11"]}, "Treatment": {"text": [["administration of isosorbide dinitrate (5 mg)"]], "start": [[35]], "entity_id": ["T7"], "Drug": {"text": [["isosorbide dinitrate"]], "start": [[53]], "entity_id": ["T12"]}, "Dosage": {"text": [["5 mg"]], "start": [[75]], "entity_id": ["T13"]}}, "Effect": {"text": [["blood pressure decreased"], ["syncope"], ["a sudden decrease in pulse rate"]], "start": [[82], [146], [159]], "entity_id": ["T8", "T9", "T10"]}}]}]}
{"id": "19122478_7", "context": "The condition improved slowly after stopping medication and systemic steroids.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["stopping"]], "start": [[36]], "entity_id": ["T5"]}, "Treatment": {"text": [["steroids"]], "start": [[69]], "entity_id": ["T6"], "Drug": {"text": [["steroids"]], "start": [[69]], "entity_id": ["T7"]}}, "Effect": {"text": [["condition improved"]], "start": [[4]], "entity_id": ["T4"]}}]}]}
{"id": "19995690_2", "context": "Acetaminophen is a widely used analgesic that can cause acute liver failure when consumed above a maximum daily dose.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[50]], "entity_id": ["T7"]}, "Treatment": {"text": [["Acetaminophen"]], "start": [[0]], "entity_id": ["T6"], "Drug": {"text": [["Acetaminophen"]], "start": [[0]], "entity_id": ["T9"]}}, "Effect": {"text": [["acute liver failure"]], "start": [[56]], "entity_id": ["T8"]}}]}]}
{"id": "10203437_9", "context": "Patients treated with 5-ASA compounds who experience acute inflammatory symptoms or clinical deterioration not related to their gastrointestinal disease should be screened to rule out a lupus-like reaction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["experience"]], "start": [[42]], "entity_id": ["T11"]}, "Subject": {"text": [["Patients", "who experience acute inflammatory symptoms or clinical deterioration not related to their gastrointestinal disease"]], "start": [[0, 38]], "entity_id": ["T9"]}, "Treatment": {"text": [["5-ASA compounds"]], "start": [[22]], "entity_id": ["T10"], "Drug": {"text": [["5-ASA"]], "start": [[22]], "entity_id": ["T14"]}, "Disorder": {"text": [["gastrointestinal disease"]], "start": [[128]], "entity_id": ["T15"]}}, "Effect": {"text": [["lupus-like reaction"]], "start": [[186]], "entity_id": ["T16"]}, "Speculated": {"text": [["rule out"]], "start": [[175]], "entity_id": ["T13"], "value": true}}]}]}
{"id": "10466445_1", "context": "Successful treatment with arsenic trioxide of a patient with ATRA-resistant relapse of acute promyelocytic leukemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatment"]], "start": [[11]], "entity_id": ["T6"]}, "Subject": {"text": [["a patient with ATRA-resistant relapse of acute promyelocytic leukemia"]], "start": [[46]], "entity_id": ["T5"]}, "Treatment": {"text": [["arsenic trioxide"]], "start": [[26]], "entity_id": ["T7"], "Drug": {"text": [["arsenic trioxide"]], "start": [[26]], "entity_id": ["T9"]}, "Disorder": {"text": [["ATRA-resistant relapse of acute promyelocytic leukemia"]], "start": [[61]], "entity_id": ["T10"]}}}]}]}
{"id": "19122478_1", "context": "Drug rash with eosinophilia and systemic symptoms after chlorambucil treatment in chronic lymphocytic leukaemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[50]], "entity_id": ["T7"]}, "Effect": {"text": [["Drug rash with eosinophilia and systemic symptoms"]], "start": [[0]], "entity_id": ["T6"]}, "Treatment": {"text": [["chlorambucil"]], "start": [[56]], "entity_id": ["T8"], "Drug": {"text": [["chlorambucil"]], "start": [[56]], "entity_id": ["T10"]}, "Disorder": {"text": [["chronic lymphocytic leukaemia"]], "start": [[82]], "entity_id": ["T11"]}}}]}]}
{"id": "1688693_3", "context": "She manifested all the clinical symptoms and signs of caffeine toxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["manifested"]], "start": [[4]], "entity_id": ["T9"]}, "Subject": {"text": [["She"]], "start": [[0]], "entity_id": ["T6"], "Gender": {"text": [["She"]], "start": [[0]], "entity_id": ["T5"]}}, "Treatment": {"text": [["caffeine"]], "start": [[54]], "entity_id": ["T7"], "Drug": {"text": [["caffeine"]], "start": [[54]], "entity_id": ["T10"]}}, "Effect": {"text": [["all the clinical symptoms and signs of caffeine toxicity."]], "start": [[15]], "entity_id": ["T8"]}}]}]}
{"id": "2406680_1", "context": "Quinine-induced hearing loss.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[8]], "entity_id": ["T4"]}, "Treatment": {"text": [["Quinine"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Quinine"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["hearing loss"]], "start": [[16]], "entity_id": ["T5"]}}]}]}
{"id": "17458405_1", "context": "Ezetimibe-induced acute pancreatitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[10]], "entity_id": ["T4"]}, "Treatment": {"text": [["Ezetimibe"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Ezetimibe"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["acute pancreatitis"]], "start": [[18]], "entity_id": ["T5"]}}]}]}
{"id": "1569260_2", "context": "We report a case of drug-induced pemphigus caused by an angiotensin-converting enzyme inhibitor, captopril.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[25]], "entity_id": ["T3"]}, "Effect": {"text": [["pemphigus"]], "start": [[33]], "entity_id": ["T4"]}, "Treatment": {"text": [["captopril"]], "start": [[97]], "entity_id": ["T5"], "Drug": {"text": [["captopril"]], "start": [[97]], "entity_id": ["T7"]}}, "Subject": {"text": [["a case"]], "start": [[10]], "entity_id": ["T6"]}}]}]}
{"id": "10589077_5", "context": "We conclude that low-dose HU therapy in patients with thalassemia intermedia may increase total Hb levels sufficiently to eliminate the need for transfusions.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["therapy"]], "start": [[29]], "entity_id": ["T5"]}, "Subject": {"text": [["in patients with thalassemia intermedia"]], "start": [[37]], "entity_id": ["T3"]}, "Treatment": {"text": [["low-dose HU therapy"]], "start": [[17]], "entity_id": ["T4"], "Disorder": {"text": [["thalassemia intermedia"]], "start": [[54]], "entity_id": ["T7"]}, "Drug": {"text": [["HU"]], "start": [[26]], "entity_id": ["T8"]}, "Dosage": {"text": [["low-dose"]], "start": [[17]], "entity_id": ["T9"]}}, "Effect": {"text": [["increase total Hb levels"]], "start": [[81]], "entity_id": ["T6"]}, "Speculated": {"text": [["may"]], "start": [[77]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "1115340_6", "context": "There is the risk of convulsions occurring in susceptible patients following the use of the new anaesthetic agents which are capable of inducing CNS excitability.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurring"]], "start": [[33]], "entity_id": ["T8"]}, "Effect": {"text": [["convulsions"]], "start": [[21]], "entity_id": ["T7"]}, "Subject": {"text": [["susceptible patients"]], "start": [[46]], "entity_id": ["T9"]}, "Treatment": {"text": [["the use of the new anaesthetic agents which are capable of inducing CNS excitability"]], "start": [[77]], "entity_id": ["T10"], "Drug": {"text": [["anaesthetic"]], "start": [[96]], "entity_id": ["T1"]}}}]}]}
{"id": "984862_1", "context": "A patient with psoriasis is described who had an abnormal response to the glucose tolerance test without other evidence of diabetes and then developed postprandial hyperglycemia and glycosuria during a period of topical administration of a corticosteroid cream, halcinonide cream 0.1%, under occlusion.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[141]], "entity_id": ["T7"]}, "Effect": {"text": [["postprandial hyperglycemia and glycosuria"]], "start": [[151]], "entity_id": ["T8"]}, "Treatment": {"text": [["a period of topical administration of a corticosteroid cream, halcinonide cream 0.1%, under occlusion"]], "start": [[200]], "entity_id": ["T9"], "Disorder": {"text": [["psoriasis"]], "start": [[15]], "entity_id": ["T6"]}, "Drug": {"text": [["halcinonide"]], "start": [[262]], "entity_id": ["T10"]}, "Route": {"text": [["cream"]], "start": [[274]], "entity_id": ["T11"]}}, "Subject": {"text": [["A patient with psoriasis is described who had an abnormal response to the glucose tolerance test without other evidence of diabetes"]], "start": [[0]], "entity_id": ["T5"], "Disorder": {"text": [["an abnormal response to the glucose tolerance test without other evidence of diabetes"]], "start": [[46]], "entity_id": ["T1"]}}}]}]}
{"id": "8503421_1", "context": "Although there is one case report of cholesterol crystal embolization following t-PA therapy with only extrarenal manifestations (N Engl J Med 321:1270, 1989), this is the first reported case of atheroembolic acute renal failure following t-PA therapy.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[229]], "entity_id": ["T10"]}, "Treatment": {"text": [["t-PA therapy"]], "start": [[239]], "entity_id": ["T9"], "Drug": {"text": [["t-PA"]], "start": [[239]], "entity_id": ["T11"]}}, "Effect": {"text": [["atheroembolic acute renal failure"]], "start": [[195]], "entity_id": ["T8"]}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[70]], "entity_id": ["T16"]}, "Treatment": {"text": [["t-PA"]], "start": [[80]], "entity_id": ["T15"], "Drug": {"text": [["t-PA"]], "start": [[80]], "entity_id": ["T14"]}}, "Effect": {"text": [["cholesterol crystal embolization", "with only extrarenal manifestations"]], "start": [[37, 93]], "entity_id": ["T13"]}}]}]}
{"id": "573779_3", "context": "A young woman developed galactorrhea during treatment with a new dibenzoxazepine antidepressant, amoxapine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[14]], "entity_id": ["T8"]}, "Subject": {"text": [["A young woman"]], "start": [[0]], "entity_id": ["T7"], "Age": {"text": [["young"]], "start": [[2]], "entity_id": ["T11"]}, "Gender": {"text": [["woman"]], "start": [[8]], "entity_id": ["T12"]}}, "Effect": {"text": [["galactorrhea"]], "start": [[24]], "entity_id": ["T9"]}, "Treatment": {"text": [["during treatment with a new dibenzoxazepine antidepressant, amoxapine"]], "start": [[37]], "entity_id": ["T10"], "Drug": {"text": [["amoxapine"]], "start": [[97]], "entity_id": ["T13"]}}}]}]}
{"id": "7379406_7", "context": "After ruling out a hydrotelluric source of fluorine, the patient's fluorosis was linked to chronic use of niflumic acid, following the publication in 1978 of the 2 previously reported cases affected by this drug.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["linked to"]], "start": [[81]], "entity_id": ["T8"]}, "Effect": {"text": [["fluorosis"]], "start": [[67]], "entity_id": ["T6"]}, "Subject": {"text": [["the patient's"]], "start": [[53]], "entity_id": ["T7"]}, "Treatment": {"text": [["chronic use of niflumic acid"]], "start": [[91]], "entity_id": ["T9"], "Drug": {"text": [["niflumic acid"]], "start": [[106]], "entity_id": ["T10"]}, "Duration": {"text": [["chronic"]], "start": [[91]], "entity_id": ["T11"]}}}]}]}
{"id": "20203465_2", "context": "The hospital course of the acute renal failure is presented with a review of the literature on cases of acute renal failure after IVIG.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[124]], "entity_id": ["T4"]}, "Effect": {"text": [["acute renal failure"]], "start": [[104]], "entity_id": ["T3"]}, "Treatment": {"text": [["IVIG"]], "start": [[130]], "entity_id": ["T5"], "Drug": {"text": [["IVIG"]], "start": [[130]], "entity_id": ["T6"]}}}]}]}
{"id": "18504683_3", "context": "We report 3 cases of children with acute lymphoblastic leukemia who developed seizures and altered sensorium after L-asparaginase therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[109]], "entity_id": ["T8"]}, "Subject": {"text": [["3 cases of children with acute lymphoblastic leukemia"]], "start": [[10]], "entity_id": ["T5"], "Population": {"text": [["3"]], "start": [[10]], "entity_id": ["T9"]}, "Age": {"text": [["children"]], "start": [[21]], "entity_id": ["T1"]}}, "Effect": {"text": [["seizures and altered sensorium"]], "start": [[78]], "entity_id": ["T6"]}, "Treatment": {"text": [["L-asparaginase"]], "start": [[115]], "entity_id": ["T7"], "Disorder": {"text": [["acute lymphoblastic leukemia"]], "start": [[35]], "entity_id": ["T10"]}, "Drug": {"text": [["L-asparaginase"]], "start": [[115]], "entity_id": ["T11"]}}}]}]}
{"id": "8921647_2", "context": "Caution with use of cimetidine in tolazoline induced upper gastrointestinal bleeding.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[45]], "entity_id": ["T5"]}, "Treatment": {"text": [["tolazoline"]], "start": [[34]], "entity_id": ["T4"], "Drug": {"text": [["tolazoline"]], "start": [[34]], "entity_id": ["T8"]}}, "Effect": {"text": [["upper gastrointestinal bleeding"]], "start": [[53]], "entity_id": ["T6"]}}]}]}
{"id": "10749332_3", "context": "Other thiazolidinediones currently in clinical trials may be able to provide the therapeutic benefits of troglitazone without significant hepatotoxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["provide"]], "start": [[69]], "entity_id": ["T4"]}, "Treatment": {"text": [["thiazolidinediones"]], "start": [[6]], "entity_id": ["T3"], "Drug": {"text": [["thiazolidinediones"]], "start": [[6]], "entity_id": ["T6"]}}}]}]}
{"id": "15840734_2", "context": "OBJECTIVE: To report a case of neuroleptic malignant syndrome (NMS) associated with fluphenazine in a schizophrenic patient and review the literature related to this condition.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[68]], "entity_id": ["T7"]}, "Effect": {"text": [["a case of neuroleptic malignant syndrome (NMS)"]], "start": [[21]], "entity_id": ["T8"]}, "Treatment": {"text": [["fluphenazine"]], "start": [[84]], "entity_id": ["T9"], "Disorder": {"text": [["schizophrenic"]], "start": [[102]], "entity_id": ["T11"]}, "Drug": {"text": [["fluphenazine"]], "start": [[84]], "entity_id": ["T12"]}}, "Subject": {"text": [["schizophrenic patient"]], "start": [[102]], "entity_id": ["T10"]}}]}]}
{"id": "9876812_2", "context": "CONCLUSIONS: Because of its structural similarity to the other vinca alkaloids, vinorelbine is believed to be responsible for SIADH in our patient.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["responsible"]], "start": [[110]], "entity_id": ["T4"]}, "Treatment": {"text": [["vinorelbine"]], "start": [[80]], "entity_id": ["T3"], "Drug": {"text": [["vinorelbine"]], "start": [[80]], "entity_id": ["T6"]}}, "Effect": {"text": [["SIADH"]], "start": [[126]], "entity_id": ["T5"]}}]}]}
{"id": "2940999_1", "context": "Abnormal retinal function associated with isotretinoin therapy for acne.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[26]], "entity_id": ["T3"]}, "Effect": {"text": [["Abnormal retinal function"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["isotretinoin"]], "start": [[42]], "entity_id": ["T5"], "Disorder": {"text": [["acne"]], "start": [[67]], "entity_id": ["T6"]}, "Drug": {"text": [["isotretinoin"]], "start": [[42]], "entity_id": ["T7"]}}}]}]}
{"id": "2299784_3", "context": "To our knowledge , this is the first reported case of bromide intoxication due to pyridostigmine bromide administration.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[75]], "entity_id": ["T5"]}, "Subject": {"text": [["first reported case"]], "start": [[31]], "entity_id": ["T3"], "Population": {"text": [["first"]], "start": [[31]], "entity_id": ["T7"]}}, "Effect": {"text": [["bromide intoxication"]], "start": [[54]], "entity_id": ["T4"]}, "Treatment": {"text": [["pyridostigmine bromide"]], "start": [[82]], "entity_id": ["T6"], "Drug": {"text": [["pyridostigmine bromide"]], "start": [[82]], "entity_id": ["T8"]}}}]}]}
{"id": "15920338_3", "context": "In deciding if tamoxifen therapy is warranted, all potentially life-threatening adverse events associated with tamoxifen should be considered, including endometrial adenocarcinoma or uterine sarcoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated with"]], "start": [[95]], "entity_id": ["T7"]}, "Treatment": {"text": [["tamoxifen"]], "start": [[111]], "entity_id": ["T8"], "Drug": {"text": [["x"], ["tamoxifen"], ["tamoxifen"]], "start": [[19], [111], [15]], "entity_id": ["T10", "T11", "T12"]}}, "Effect": {"text": [["potentially life-threatening adverse events", "including endometrial adenocarcinoma or uterine sarcoma"]], "start": [[51, 143]], "entity_id": ["T9"]}}]}]}
{"id": "8891729_4", "context": "We report the case of a patient with chronic lymphocytic leukemia (CLL) who developed fatal intravascular autoimmune hemolytic anemia (AIHA) after fludarabine treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[141]], "entity_id": ["T6"]}, "Subject": {"text": [["a patient with chronic lymphocytic leukemia (CLL)"]], "start": [[22]], "entity_id": ["T5"]}, "Effect": {"text": [["fatal intravascular autoimmune hemolytic anemia (AIHA)"]], "start": [[86]], "entity_id": ["T7"]}, "Treatment": {"text": [["fludarabine treatment"]], "start": [[147]], "entity_id": ["T8"], "Drug": {"text": [["fludarabine"]], "start": [[147]], "entity_id": ["T10"]}, "Disorder": {"text": [["chronic lymphocytic leukemia"]], "start": [[37]], "entity_id": ["T11"]}}}]}]}
{"id": "2299784_1", "context": "A 59-year-old woman with myasthenia gravis who received a large dose of pyridostigmine bromide developed postoperative psychosis and was diagnosed as having bromide intoxication.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[95]], "entity_id": ["T5"]}, "Treatment": {"text": [["a large dose of pyridostigmine bromide"]], "start": [[56]], "entity_id": ["T6"], "Drug": {"text": [["pyridostigmine bromide"]], "start": [[72]], "entity_id": ["T12"]}, "Disorder": {"text": [["myasthenia gravis"]], "start": [[25]], "entity_id": ["T13"]}, "Dosage": {"text": [["a large dose"]], "start": [[56]], "entity_id": ["T14"]}}, "Effect": {"text": [["postoperative psychosis and was diagnosed as having bromide intoxication."]], "start": [[105]], "entity_id": ["T7"]}, "Subject": {"text": [["A 59-year-old woman with myasthenia gravis"]], "start": [[0]], "entity_id": ["T8"], "Age": {"text": [["59-year-old"]], "start": [[2]], "entity_id": ["T9"]}, "Gender": {"text": [["woman"]], "start": [[14]], "entity_id": ["T10"]}}}]}]}
{"id": "1743388_2", "context": "This is a report of a renal transplant patient with Pneumocystis pneumonia who developed chemical cellulitis and ulceration following the extravasation of intravenous pentamidine into the soft tissues of the left hand and forearm.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[79]], "entity_id": ["T5"]}, "Effect": {"text": [["chemical cellulitis and ulceration"]], "start": [[89]], "entity_id": ["T6"]}, "Subject": {"text": [["a renal transplant patient with Pneumocystis pneumonia"]], "start": [[20]], "entity_id": ["T9"], "Disorder": {"text": [["renal transplant"]], "start": [[22]], "entity_id": ["T11"]}}, "Treatment": {"text": [["intravenous pentamidine into the soft tissues of the left hand and forearm"]], "start": [[155]], "entity_id": ["T7"], "Disorder": {"text": [["Pneumocystis pneumonia"]], "start": [[52]], "entity_id": ["T10"]}, "Route": {"text": [["intravenous"]], "start": [[155]], "entity_id": ["T12"]}, "Drug": {"text": [["pentamidine"]], "start": [[167]], "entity_id": ["T13"]}}}]}]}
{"id": "9701106_2", "context": "Attempts were made to stop and then restart the theophylline therapy at progressively lower doses; however, with each attempt, the patient's reaction to the drug became more toxic, with serum theophylline levels ranging between 99.9 and 149.9 micromol/L (18 and 27 microg/mL).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["became"]], "start": [[162]], "entity_id": ["T7"]}, "Treatment": {"text": [["theophylline therapy"]], "start": [[48]], "entity_id": ["T4"], "Drug": {"text": [["theophylline"]], "start": [[48]], "entity_id": ["T8"]}, "Dosage": {"text": [["99.9 and 149.9 micromol/L"], ["18 and 27 microg/mL"]], "start": [[228], [255]], "entity_id": ["T9", "T10"]}}, "Subject": {"text": [["patient"]], "start": [[131]], "entity_id": ["T5"]}, "Effect": {"text": [["reaction to the drug became more toxic"]], "start": [[141]], "entity_id": ["T6"]}}]}]}
{"id": "16298824_4", "context": "Dyspnea, hypoxemia, and pleuritic chest pain occurred within 24 hours of rituximab administration, and there was no other apparent explanation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurred"]], "start": [[45]], "entity_id": ["T9"]}, "Effect": {"text": [["Dyspnea, hypoxemia, and pleuritic chest pain"]], "start": [[0]], "entity_id": ["T7"]}, "Treatment": {"text": [["rituximab administration"]], "start": [[73]], "entity_id": ["T8"], "Time_elapsed": {"text": [["24 hours"]], "start": [[61]], "entity_id": ["T10"]}, "Drug": {"text": [["rituximab"]], "start": [[73]], "entity_id": ["T11"]}}}]}]}
{"id": "11834188_3", "context": "Dermatitis to captopril.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["to"]], "start": [[11]], "entity_id": ["T4"]}, "Treatment": {"text": [["captopril"]], "start": [[14]], "entity_id": ["T5"], "Drug": {"text": [["captopril"]], "start": [[14]], "entity_id": ["T6"]}, "Disorder": {"text": [["Dermatitis"]], "start": [[0]], "entity_id": ["T7"]}}}]}]}
{"id": "3067748_2", "context": "Histological examination of the dacryolith suggested its derivation from breakdown products of adrenaline.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["from"]], "start": [[68]], "entity_id": ["T5"]}, "Effect": {"text": [["dacryolith"]], "start": [[32]], "entity_id": ["T3"]}, "Treatment": {"text": [["breakdown products of adrenaline"]], "start": [[73]], "entity_id": ["T6"], "Drug": {"text": [["adrenaline"]], "start": [[95]], "entity_id": ["T8"]}}, "Speculated": {"text": [["suggested"]], "start": [[43]], "entity_id": ["T4"], "value": true}}]}]}
{"id": "515777_2", "context": "Two patients developed diabetic coma when taking a combination of a thiazide diuretic and propranolol.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[13]], "entity_id": ["T5"]}, "Subject": {"text": [["Two patients"]], "start": [[0]], "entity_id": ["T4"], "Population": {"text": [["Two"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["diabetic coma"]], "start": [[23]], "entity_id": ["T6"]}, "Treatment": {"text": [["a combination of a thiazide diuretic and propranolol"]], "start": [[49]], "entity_id": ["T7"], "Drug": {"text": [["thiazide"], ["propranolol"]], "start": [[68], [90]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combination"]], "start": [[51]], "entity_id": ["T11"]}, "Drug": {"text": [["thiazide"], ["propranolol"]], "start": [[68], [90]], "entity_id": ["T9", "T10"]}}]}}]}]}
{"id": "24318743_2", "context": "Platinum-resistant ovarian cancer (PROC) constitutes a therapeutic dilemma with limited efficacy from traditional cytotoxic agents.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["from"]], "start": [[97]], "entity_id": ["T8"]}, "Treatment": {"text": [["traditional cytotoxic agents"]], "start": [[102]], "entity_id": ["T9"], "Disorder": {"text": [["Platinum-resistant ovarian cancer (PROC)"]], "start": [[0]], "entity_id": ["T6"]}, "Drug": {"text": [["traditional cytotoxic agents"]], "start": [[102]], "entity_id": ["T11"]}}, "Effect": {"text": [["limited efficacy"]], "start": [[80]], "entity_id": ["T10"]}}]}]}
{"id": "1310879_1", "context": "A patient suffering from heparin-associated thrombocytopenia (HAT), recurrent arteriothromboses, and acute renal failure after treatment with standard heparin is described.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[121]], "entity_id": ["T13"]}, "Treatment": {"text": [["standard heparin"]], "start": [[142]], "entity_id": ["T14"], "Drug": {"text": [["heparin"]], "start": [[151]], "entity_id": ["T17"]}}, "Effect": {"text": [["thrombocytopenia (HAT), recurrent arteriothromboses, and acute renal failure"]], "start": [[44]], "entity_id": ["T15"]}, "Subject": {"text": [["A patient"]], "start": [[0]], "entity_id": ["T16"]}}]}]}
{"id": "16116136_2", "context": "Despite minimal short-term side effects and apparent efficacy, chronic treatment of MG with MM may be associated with increased risk of lymphoproliferative disorders.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[102]], "entity_id": ["T6"]}, "Treatment": {"text": [["MG with MM"]], "start": [[84]], "entity_id": ["T3"], "Disorder": {"text": [["MG"]], "start": [[84]], "entity_id": ["T9"]}, "Drug": {"text": [["MM"]], "start": [[92]], "entity_id": ["T4"]}}, "Effect": {"text": [["increased risk of lymphoproliferative"]], "start": [[118]], "entity_id": ["T7"]}, "Speculated": {"text": [["may be"]], "start": [[95]], "entity_id": ["T5"], "value": true}}]}]}
{"id": "2616440_2", "context": "We report the case of a patient with multiple myeloma who developed acute life-threatening water intoxication following treatment with oral indomethacin and low dose intravenous cyclophosphamide.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[58]], "entity_id": ["T6"]}, "Effect": {"text": [["acute life-threatening water intoxication"]], "start": [[68]], "entity_id": ["T7"]}, "Treatment": {"text": [["oral indomethacin and low dose intravenous cyclophosphamide"]], "start": [[135]], "entity_id": ["T8"], "Disorder": {"text": [["multiple myeloma"]], "start": [[37]], "entity_id": ["T5"]}, "Route": {"text": [["oral"], ["intravenous"]], "start": [[135], [166]], "entity_id": ["T9", "T12"]}, "Drug": {"text": [["indomethacin"], ["cyclophosphamide"]], "start": [[140], [178]], "entity_id": ["T10", "T13"]}, "Dosage": {"text": [["low dose"]], "start": [[157]], "entity_id": ["T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[153]], "entity_id": ["T14"]}, "Drug": {"text": [["indomethacin"], ["cyclophosphamide"]], "start": [[140], [178]], "entity_id": ["T10", "T13"]}}]}, "Subject": {"text": [["a patient with multiple myeloma"]], "start": [[22]], "entity_id": ["T4"]}, "Severity": {"text": [["life-threatening"]], "start": [[74]], "entity_id": ["T15"], "value": "High"}}]}]}
{"id": "19145124_1", "context": "Multifocal electroretinographic abnormalities in ethambutol-induced visual loss.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[60]], "entity_id": ["T4"]}, "Treatment": {"text": [["ethambutol"]], "start": [[49]], "entity_id": ["T3"], "Drug": {"text": [["ethambutol"]], "start": [[49]], "entity_id": ["T6"]}}, "Effect": {"text": [["visual loss"]], "start": [[68]], "entity_id": ["T5"]}}]}]}
{"id": "17364199_7", "context": "She was on etanercept and methotrexate for rheumatoid arthritis.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["for"]], "start": [[39]], "entity_id": ["T8"]}, "Subject": {"text": [["She"]], "start": [[0]], "entity_id": ["T6"], "Gender": {"text": [["She"]], "start": [[0]], "entity_id": ["T10"]}}, "Treatment": {"text": [["etanercept and methotrexate"]], "start": [[11]], "entity_id": ["T7"], "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[43]], "entity_id": ["T9"]}, "Drug": {"text": [["etanercept"], ["methotrexate"]], "start": [[11], [26]], "entity_id": ["T11", "T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[22]], "entity_id": ["T13"]}, "Drug": {"text": [["etanercept"], ["methotrexate"]], "start": [[11], [26]], "entity_id": ["T11", "T12"]}}]}}]}]}
{"id": "1504404_1", "context": "Central nervous system effects secondary to ciprofloxacin treatment are uncommon and usually consist only of minor dizziness or mild headache, although rare occurrences of seizures and hallucinations have been reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["consist"]], "start": [[93]], "entity_id": ["T10"]}, "Treatment": {"text": [["secondary to ciprofloxacin treatment"]], "start": [[31]], "entity_id": ["T9"], "Drug": {"text": [["ciprofloxacin"]], "start": [[44]], "entity_id": ["T12"]}}, "Effect": {"text": [["minor dizziness or mild headache, although rare occurrences of seizures and hallucinations"]], "start": [[109]], "entity_id": ["T11"]}}]}]}
{"id": "14585456_1", "context": "We present a case of a 20-year-old woman who ingested 900 mg of glyburide causing refractory hypoglycemia resistant to treatment with intravenous dextrose, glucagon, and diazoxide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["ingested"]], "start": [[45]], "entity_id": ["T6"]}, "Subject": {"text": [["a 20-year-old woman"]], "start": [[21]], "entity_id": ["T3"], "Age": {"text": [["20-year-old"]], "start": [[23]], "entity_id": ["T7"]}, "Gender": {"text": [["woman"]], "start": [[35]], "entity_id": ["T8"]}}, "Treatment": {"text": [["900 mg of glyburide"]], "start": [[54]], "entity_id": ["T4"], "Dosage": {"text": [["900 mg"]], "start": [[54]], "entity_id": ["T9"]}, "Drug": {"text": [["glyburide"]], "start": [[64]], "entity_id": ["T10"]}}, "Effect": {"text": [["refractory hypoglycemia"]], "start": [[82]], "entity_id": ["T5"]}}]}]}
{"id": "7619765_1", "context": "Etoposide-related myocardial infarction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[10]], "entity_id": ["T4"]}, "Treatment": {"text": [["Etoposide"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Etoposide"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["myocardial infarction"]], "start": [[18]], "entity_id": ["T5"]}}]}]}
{"id": "12460237_5", "context": "Contrary to previous recommendations, our experience cautions against the further use of high-dose cytarabine in patients who develop PPE, and is a timely reminder of the potential toxicity of this agent, which is now increasingly being used as first-line treatment in the management of haematologic malignancies.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["toxicity"]], "start": [[181]], "entity_id": ["T11"]}, "Treatment": {"text": [["high-dose cytarabine"]], "start": [[89]], "entity_id": ["T12"], "Dosage": {"text": [["high-dose"]], "start": [[89]], "entity_id": ["T16"]}, "Drug": {"text": [["cytarabine"]], "start": [[99]], "entity_id": ["T17"]}, "Disorder": {"text": [["haematologic malignancies"]], "start": [[287]], "entity_id": ["T1"]}}, "Effect": {"text": [["PPE"]], "start": [[134]], "entity_id": ["T14"]}, "Speculated": {"text": [["potential"]], "start": [[171]], "entity_id": ["T18"], "value": true}}]}]}
{"id": "18607107_4", "context": "She had been on Copaxone 20 mg/day treatment for 2 years when she first exhibited gastrointestinal symptoms.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["exhibited"]], "start": [[72]], "entity_id": ["T5"]}, "Treatment": {"text": [["Copaxone 20 mg/day treatment for 2 years"]], "start": [[16]], "entity_id": ["T3"], "Drug": {"text": [["Copaxone"]], "start": [[16]], "entity_id": ["T8"]}, "Dosage": {"text": [["20 mg/day"]], "start": [[25]], "entity_id": ["T9"]}, "Duration": {"text": [["2 years"]], "start": [[49]], "entity_id": ["T11"]}}, "Subject": {"text": [["she"]], "start": [[62]], "entity_id": ["T4"], "Gender": {"text": [["she"]], "start": [[62]], "entity_id": ["T7"]}}, "Effect": {"text": [["gastrointestinal symptoms"]], "start": [[82]], "entity_id": ["T6"]}}]}]}
{"id": "15795553_3", "context": "The authors present an elderly patient with mixed dementia who developed TD at multiple sites, (including respiratory dyskinesia [RD], limb dyskinesia, and orofacial dyskinesia) following abrupt withdrawal of risperidone therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[63]], "entity_id": ["T13"]}, "Subject": {"text": [["elderly patient with mixed dementia"]], "start": [[23]], "entity_id": ["T11"], "Age": {"text": [["elderly"]], "start": [[23]], "entity_id": ["T17"]}}, "Effect": {"text": [["TD at multiple sites, (including respiratory dyskinesia [RD], limb dyskinesia, and orofacial dyskinesia)"]], "start": [[73]], "entity_id": ["T15"]}, "Treatment": {"text": [["abrupt withdrawal of risperidone therapy"]], "start": [[188]], "entity_id": ["T16"], "Drug": {"text": [["risperidone"]], "start": [[209]], "entity_id": ["T14"]}, "Disorder": {"text": [["mixed dementia"]], "start": [[44]], "entity_id": ["T18"]}}}]}]}
{"id": "20118434_1", "context": "Interferon-based treatments have the potential to decrease the burden of disease, but are complicated by side effects, including neuropsychiatric symptoms.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complicated"]], "start": [[90]], "entity_id": ["T4"]}, "Treatment": {"text": [["Interferon"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Interferon"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["neuropsychiatric symptoms"]], "start": [[129]], "entity_id": ["T5"]}, "Speculated": {"text": [["potential"]], "start": [[37]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "21416219_1", "context": "Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["efficacy"]], "start": [[10]], "entity_id": ["T9"]}, "Subject": {"text": [["patients with persistent elevated triglycerides"]], "start": [[80]], "entity_id": ["T7"]}, "Treatment": {"text": [["adding fenofibric acid to moderate-dose statin therapy"]], "start": [[22]], "entity_id": ["T8"], "Disorder": {"text": [["persistent elevated triglycerides"]], "start": [[94]], "entity_id": ["T10"]}, "Drug": {"text": [["fenofibric acid"], ["statin"]], "start": [[29], [62]], "entity_id": ["T11", "T12"]}, "Dosage": {"text": [["moderate-dose"]], "start": [[48]], "entity_id": ["T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["adding"]], "start": [[22]], "entity_id": ["T14"]}, "Drug": {"text": [["fenofibric acid"], ["statin"]], "start": [[29], [62]], "entity_id": ["T11", "T12"]}}]}}]}]}
{"id": "18421192_3", "context": "Type 1 diabetes mellitus provoked by peginterferon alpha-2b plus ribavirin treatment for chronic hepatitis C.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["provoked"]], "start": [[25]], "entity_id": ["T4"]}, "Treatment": {"text": [["peginterferon alpha-2b plus ribavirin treatment"]], "start": [[37]], "entity_id": ["T5"], "Drug": {"text": [["peginterferon alpha-2b"], ["ribavirin"]], "start": [[37], [65]], "entity_id": ["T7", "T8"]}, "Disorder": {"text": [["chronic hepatitis C"]], "start": [[89]], "entity_id": ["T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["plus"]], "start": [[60]], "entity_id": ["T9"]}, "Drug": {"text": [["ribavirin"], ["peginterferon alpha-2b"]], "start": [[65], [37]], "entity_id": ["T8", "T7"]}}]}, "Effect": {"text": [["Type 1 diabetes mellitus"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "17519584_1", "context": "A 61-year-old man with early diffuse cutaneous scleroderma with myositis and progressive interstitial pneumonia developed generalized erythema with high fever 3 weeks after taking sulfamethoxazole/trimethoprim.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["taking"]], "start": [[173]], "entity_id": ["T5"]}, "Subject": {"text": [["A 61-year-old man with early diffuse cutaneous scleroderma with myositis and progressive interstitial pneumonia"]], "start": [[0]], "entity_id": ["T4"], "Age": {"text": [["61-year-old"]], "start": [[2]], "entity_id": ["T8"]}, "Gender": {"text": [["man"]], "start": [[14]], "entity_id": ["T9"]}, "Disorder": {"text": [["early diffuse cutaneous scleroderma with myositis"], ["progressive interstitial pneumonia"]], "start": [[23], [77]], "entity_id": ["T10", "T11"]}}, "Treatment": {"text": [["sulfamethoxazole/trimethoprim"]], "start": [[180]], "entity_id": ["T6"], "Drug": {"text": [["sulfamethoxazole"], ["trimethoprim"]], "start": [[180], [197]], "entity_id": ["T12", "T13"]}, "Time_elapsed": {"text": [["3 weeks after"]], "start": [[159]], "entity_id": ["T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["/"]], "start": [[196]], "entity_id": ["T15"]}, "Drug": {"text": [["trimethoprim"], ["sulfamethoxazole"]], "start": [[197], [180]], "entity_id": ["T13", "T12"]}}]}, "Effect": {"text": [["generalized erythema with high fever"]], "start": [[122]], "entity_id": ["T7"]}}]}]}
{"id": "18676387_1", "context": "Serotonin toxicity caused by an interaction between fentanyl and paroxetine.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[19]], "entity_id": ["T7"]}, "Effect": {"text": [["Serotonin toxicity"]], "start": [[0]], "entity_id": ["T6"]}, "Treatment": {"text": [["an interaction between fentanyl and paroxetine"]], "start": [[29]], "entity_id": ["T8"], "Drug": {"text": [["fentanyl"], ["paroxetine"]], "start": [[52], [65]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[32]], "entity_id": ["T9"]}, "Drug": {"text": [["fentanyl"], ["paroxetine"]], "start": [[52], [65]], "entity_id": ["T10", "T11"]}}]}}]}]}
{"id": "16637972_4", "context": "The sub-conjunctival haematoma in a patient receiving warfarin can pose a significant management challenge.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["receiving"]], "start": [[44]], "entity_id": ["T5"]}, "Effect": {"text": [["sub-conjunctival haematoma"]], "start": [[4]], "entity_id": ["T3"]}, "Treatment": {"text": [["warfarin"]], "start": [[54]], "entity_id": ["T4"], "Drug": {"text": [["warfarin"]], "start": [[54]], "entity_id": ["T6"]}}}]}]}
{"id": "8071504_1", "context": "Toxic optic neuropathy associated with ethambutol: implications for current therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[23]], "entity_id": ["T4"]}, "Treatment": {"text": [["ethambutol"]], "start": [[39]], "entity_id": ["T5"], "Drug": {"text": [["ethambutol"]], "start": [[39]], "entity_id": ["T7"]}}, "Effect": {"text": [["Toxic optic neuropathy"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "15316423_3", "context": "The site of thrombosis and the chronological relationship with the IIR implicates a hypersensitivity to infliximab in the causation of the venous thrombosis in this case.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["causation"]], "start": [[122]], "entity_id": ["T7"]}, "Effect": {"text": [["venous thrombosis"]], "start": [[139]], "entity_id": ["T8"]}, "Treatment": {"text": [["infliximab"]], "start": [[104]], "entity_id": ["T9"], "Drug": {"text": [["infliximab"]], "start": [[104]], "entity_id": ["T10"]}}}]}]}
{"id": "19875411_1", "context": "One week after the initial-dose of adalimumab (160 mg), which was initiated due to an acute exacerbation of Crohn's disease, the patient developed a fulminant cardiomyopathy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[137]], "entity_id": ["T4"]}, "Treatment": {"text": [["One week after the initial-dose of adalimumab (160 mg)"]], "start": [[0]], "entity_id": ["T3"], "Disorder": {"text": [["Crohn's disease"]], "start": [[108]], "entity_id": ["T8"]}, "Drug": {"text": [["adalimumab"]], "start": [[35]], "entity_id": ["T9"]}, "Dosage": {"text": [["160 mg"]], "start": [[47]], "entity_id": ["T10"]}, "Time_elapsed": {"text": [["One week"]], "start": [[0]], "entity_id": ["T1"]}}, "Effect": {"text": [["fulminant cardiomyopathy"]], "start": [[149]], "entity_id": ["T5"]}, "Subject": {"text": [["an acute exacerbation of Crohn's disease, the patient"]], "start": [[83]], "entity_id": ["T6"]}}]}]}
{"id": "8071504_7", "context": "RESULTS: Ethambutol, and to a lesser extent isoniazid, are both implicated in the development of visually related side effects.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["development"]], "start": [[82]], "entity_id": ["T7"]}, "Treatment": {"text": [["Ethambutol", "isoniazid"]], "start": [[9, 44]], "entity_id": ["T6"], "Drug": {"text": [["isoniazid"], ["Ethambutol"]], "start": [[44], [9]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[21]], "entity_id": ["T11"]}, "Drug": {"text": [["Ethambutol"], ["isoniazid"]], "start": [[9], [44]], "entity_id": ["T10", "T9"]}}]}, "Effect": {"text": [["visually related side effects"]], "start": [[97]], "entity_id": ["T8"]}}]}]}
{"id": "24163322_2", "context": "We report a case of an inadvertent increase in the international normalized ratio (INR) after the addition of bismuth subsalicylate for the treatment of diarrhea in an enterally fed patient receiving warfarin therapy.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[88]], "entity_id": ["T9"]}, "Treatment": {"text": [["addition of bismuth subsalicylate", "warfarin therapy"]], "start": [[98, 200]], "entity_id": ["T10"], "Disorder": {"text": [["diarrhea"]], "start": [[153]], "entity_id": ["T11"]}, "Drug": {"text": [["bismuth subsalicylate"], ["warfarin"]], "start": [[110], [200]], "entity_id": ["T15", "T16"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["addition"]], "start": [[98]], "entity_id": ["T14"]}, "Drug": {"text": [["bismuth subsalicylate"], ["warfarin"]], "start": [[110], [200]], "entity_id": ["T15", "T16"]}}]}, "Subject": {"text": [["an enterally fed patient"]], "start": [[165]], "entity_id": ["T12"]}, "Effect": {"text": [["inadvertent increase in the international normalized ratio (INR)"]], "start": [[23]], "entity_id": ["T13"]}}]}]}
{"id": "7995001_1", "context": "Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["to"]], "start": [[40]], "entity_id": ["T11"]}, "Treatment": {"text": [["triazolam"]], "start": [[5]], "entity_id": ["T8"], "Drug": {"text": [["triazolam"], ["ketoconazole"], ["itraconazole"]], "start": [[5], [84], [100]], "entity_id": ["T13", "T15", "T16"]}, "Route": {"text": [["Oral"]], "start": [[0]], "entity_id": ["T14"]}}, "Effect": {"text": [["hazardous"]], "start": [[30]], "entity_id": ["T9"]}, "Subject": {"text": [["patients"]], "start": [[43]], "entity_id": ["T10"]}, "Speculated": {"text": [["potentially"]], "start": [[18]], "entity_id": ["T12"], "value": true}}]}]}
{"id": "12776809_17", "context": "LFT elevation is transient and the low risk of the SB-LOT therapy to increase LFT value can be limited when risk factors are considered.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["the low risk"]], "start": [[31]], "entity_id": ["T8"]}, "Treatment": {"text": [["SB-LOT"]], "start": [[51]], "entity_id": ["T6"], "Disorder": {"text": [["increase LFT value"]], "start": [[69]], "entity_id": ["T7"]}, "Drug": {"text": [["SB-LOT"]], "start": [[51]], "entity_id": ["T10"]}}, "Speculated": {"text": [["risk"]], "start": [[39]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "16012330_9", "context": "Nineteen cases of unusual enhanced vincristine neurotoxicity related to itraconazole have been reported in children.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[61]], "entity_id": ["T10"]}, "Subject": {"text": [["Nineteen cases", "children"]], "start": [[0, 107]], "entity_id": ["T7"], "Population": {"text": [["Nineteen"]], "start": [[0]], "entity_id": ["T11"]}, "Age": {"text": [["children"]], "start": [[107]], "entity_id": ["T12"]}}, "Effect": {"text": [["unusual enhanced vincristine neurotoxicity"]], "start": [[18]], "entity_id": ["T8"]}, "Treatment": {"text": [["itraconazole"]], "start": [[72]], "entity_id": ["T9"], "Drug": {"text": [["itraconazole"]], "start": [[72]], "entity_id": ["T13"]}}}]}]}
{"id": "16718947_3", "context": "Extended-release tolterodine 4 mg/day was then prescribed to manage overactive bladder.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["prescribed"]], "start": [[47]], "entity_id": ["T6"]}, "Treatment": {"text": [["Extended-release tolterodine 4 mg/day"]], "start": [[0]], "entity_id": ["T4"], "Disorder": {"text": [["overactive bladder"]], "start": [[68]], "entity_id": ["T7"]}, "Drug": {"text": [["Extended-release tolterodine"]], "start": [[0]], "entity_id": ["T8"]}, "Dosage": {"text": [["4 mg/day"]], "start": [[29]], "entity_id": ["T9"]}}}]}]}
{"id": "18067642_1", "context": "Although it is difficult to be certain of the direct link of amiodarone on the basis of a single case, it is reasonable to presume that this histopathology is associated with amiodarone-induced hypothyroidism and that involution changes represent the hypofunctional status of this drug-induced disorder.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[186]], "entity_id": ["T3"]}, "Treatment": {"text": [["amiodarone"]], "start": [[175]], "entity_id": ["T4"], "Drug": {"text": [["amiodarone"], ["amiodarone"]], "start": [[175], [61]], "entity_id": ["T8", "T9"]}}, "Effect": {"text": [["hypothyroidism"]], "start": [[194]], "entity_id": ["T5"]}, "Subject": {"text": [["a single case"]], "start": [[88]], "entity_id": ["T6"], "Population": {"text": [["single"]], "start": [[90]], "entity_id": ["T7"]}}}]}]}
{"id": "7962394_4", "context": "The present report describes the first case of acute pancreatitis associated with danazol treatment of endometriosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[66]], "entity_id": ["T5"]}, "Subject": {"text": [["the first case"]], "start": [[29]], "entity_id": ["T3"]}, "Effect": {"text": [["acute pancreatitis"]], "start": [[47]], "entity_id": ["T4"]}, "Treatment": {"text": [["danazol treatment of endometriosis"]], "start": [[82]], "entity_id": ["T6"], "Disorder": {"text": [["endometriosis"]], "start": [[103]], "entity_id": ["T7"]}, "Drug": {"text": [["danazol"]], "start": [[82]], "entity_id": ["T8"]}}}]}]}
{"id": "2229534_1", "context": "Awareness of this route of intoxication might be important in patients in whom neurologic or psychiatric symptoms develop while large amounts of lidocaine cream are being used.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["develop"]], "start": [[114]], "entity_id": ["T5"]}, "Effect": {"text": [["neurologic or psychiatric symptoms"]], "start": [[79]], "entity_id": ["T4"]}, "Treatment": {"text": [["large amounts of lidocaine cream are being used"]], "start": [[128]], "entity_id": ["T3"], "Drug": {"text": [["lidocaine"]], "start": [[145]], "entity_id": ["T6"]}, "Route": {"text": [["cream"]], "start": [[155]], "entity_id": ["T7"]}, "Dosage": {"text": [["large amounts"]], "start": [[128]], "entity_id": ["T8"]}}}]}]}
{"id": "18648015_1", "context": "Cephalosporin-induced leukopenia following rechallenge with cefoxitin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[14]], "entity_id": ["T4"]}, "Treatment": {"text": [["cefoxitin", "Cephalosporin"]], "start": [[60, 0]], "entity_id": ["T3"], "Drug": {"text": [["Cephalosporin"], ["cefoxitin"]], "start": [[0], [60]], "entity_id": ["T6", "T7"]}}, "Effect": {"text": [["leukopenia"]], "start": [[22]], "entity_id": ["T5"]}}]}]}
{"id": "17266059_2", "context": "Thrombotic thrombocytopenic purpura induced by trimethoprim-sulfamethoxazole in a Jehovah's Witness.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[36]], "entity_id": ["T5"]}, "Effect": {"text": [["Thrombotic thrombocytopenic purpura"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["trimethoprim-sulfamethoxazole"]], "start": [[47]], "entity_id": ["T6"], "Drug": {"text": [["trimethoprim-sulfamethoxazole"]], "start": [[47]], "entity_id": ["T8"]}}, "Subject": {"text": [["a Jehovah's Witness"]], "start": [[80]], "entity_id": ["T7"]}}]}]}
{"id": "17039658_2", "context": "This eruption appears to be a distinct cutaneous toxicity of PLD.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["of"]], "start": [[58]], "entity_id": ["T5"]}, "Effect": {"text": [["eruption", "distinct cutaneous toxicity"]], "start": [[5, 30]], "entity_id": ["T3"]}, "Treatment": {"text": [["PLD"]], "start": [[61]], "entity_id": ["T4"], "Drug": {"text": [["PLD"]], "start": [[61]], "entity_id": ["T7"]}}, "Speculated": {"text": [["appears"]], "start": [[14]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "11999915_2", "context": "Granulocytopenia and agranulocytosis are considered among the most dangerous adverse effects of clozapine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["among"]], "start": [[52]], "entity_id": ["T7"]}, "Effect": {"text": [["Granulocytopenia and agranulocytosis"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["clozapine"]], "start": [[96]], "entity_id": ["T6"], "Drug": {"text": [["clozapine"]], "start": [[96]], "entity_id": ["T8"]}}}]}]}
{"id": "20298401_5", "context": "RESULTS: We recently experienced a case of fatal erlotinib-induced ILD, diagnosed based on clinical and radiologic findings, which occurred in a patient with radiation fibrosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[59]], "entity_id": ["T7"]}, "Treatment": {"text": [["erlotinib"]], "start": [[49]], "entity_id": ["T6"], "Drug": {"text": [["erlotinib"]], "start": [[49]], "entity_id": ["T11"]}}, "Effect": {"text": [["ILD"]], "start": [[67]], "entity_id": ["T8"]}, "Subject": {"text": [["a patient with radiation fibrosis"]], "start": [[143]], "entity_id": ["T9"], "Disorder": {"text": [["radiation fibrosis"]], "start": [[158]], "entity_id": ["T10"]}}, "Severity": {"text": [["fatal"]], "start": [[43]], "entity_id": ["T1"], "value": "High"}}]}]}
{"id": "15482394_5", "context": "Unusual hypersensitivity to warfarin in a critically ill patient.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["to"]], "start": [[25]], "entity_id": ["T4"]}, "Treatment": {"text": [["warfarin"]], "start": [[28]], "entity_id": ["T5"], "Drug": {"text": [["warfarin"]], "start": [[28]], "entity_id": ["T8"]}}, "Subject": {"text": [["a critically ill patient"]], "start": [[40]], "entity_id": ["T6"], "Disorder": {"text": [["critically ill"]], "start": [[42]], "entity_id": ["T7"]}}, "Effect": {"text": [["Unusual hypersensitivity"]], "start": [[0]], "entity_id": ["T3"]}}]}]}
{"id": "7914463_1", "context": "Flumazenil reversal of benzodiazepine-induced sedation for a patient with severe pre-ECT anxiety.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[38]], "entity_id": ["T7"]}, "Treatment": {"text": [["benzodiazepine"]], "start": [[23]], "entity_id": ["T11"], "Drug": {"text": [["benzodiazepine"]], "start": [[23]], "entity_id": ["T13"]}}, "Effect": {"text": [["sedation"]], "start": [[46]], "entity_id": ["T8"]}, "Subject": {"text": [["a patient with severe pre-ECT anxiety"]], "start": [[59]], "entity_id": ["T9"], "Disorder": {"text": [["severe pre-ECT anxiety"]], "start": [[74]], "entity_id": ["T10"]}}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["reversal"]], "start": [[11]], "entity_id": ["T15"]}, "Subject": {"text": [["a patient with severe pre-ECT anxiety"]], "start": [[59]], "entity_id": ["T9"], "Disorder": {"text": [["severe pre-ECT anxiety"]], "start": [[74]], "entity_id": ["T10"]}}, "Treatment": {"text": [["Flumazenil"]], "start": [[0]], "entity_id": ["T17"], "Disorder": {"text": [["benzodiazepine-induced sedation"]], "start": [[23]], "entity_id": ["T14"]}, "Drug": {"text": [["Flumazenil"]], "start": [[0]], "entity_id": ["T16"]}}}]}]}
{"id": "11030530_3", "context": "We report a case of seizure associated with L-asparaginase therapy but no evidence of hemorrhagic or thrombotic cerebrovascular events.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[28]], "entity_id": ["T4"]}, "Effect": {"text": [["seizure"]], "start": [[20]], "entity_id": ["T3"]}, "Treatment": {"text": [["L-asparaginase therapy"]], "start": [[44]], "entity_id": ["T5"], "Drug": {"text": [["L-asparaginase"]], "start": [[44]], "entity_id": ["T6"]}}}]}]}
{"id": "15316423_2", "context": "Here we describe a patient with Crohn's disease who developed a severe infliximab infusion reaction (IIR), complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of infliximab infusion.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[52]], "entity_id": ["T10"]}, "Subject": {"text": [["a patient with Crohn's disease"]], "start": [[17]], "entity_id": ["T11"]}, "Treatment": {"text": [["infliximab infusion"]], "start": [[201]], "entity_id": ["T13"], "Drug": {"text": [["infliximab"]], "start": [[201]], "entity_id": ["T18"]}, "Route": {"text": [["infusion"]], "start": [[212]], "entity_id": ["T19"]}, "Disorder": {"text": [["Crohn's disease"]], "start": [[32]], "entity_id": ["T20"]}}, "Effect": {"text": [["severe infliximab infusion reaction (IIR), complicated 1 day later by severe swelling of the forearm and hand ipsilateral"]], "start": [[64]], "entity_id": ["T12"]}}]}]}
{"id": "16167682_1", "context": "She died within six weeks of developing congestive heart failure coupled with liver failure due to haemosiderosis despite regular use of desferrioxamine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["despite"]], "start": [[114]], "entity_id": ["T7"]}, "Treatment": {"text": [["regular use of desferrioxamine"]], "start": [[122]], "entity_id": ["T9"], "Drug": {"text": [["desferrioxamine"]], "start": [[137]], "entity_id": ["T12"]}, "Disorder": {"text": [["haemosiderosis"]], "start": [[99]], "entity_id": ["T13"]}}, "Effect": {"text": [["died within six weeks of developing congestive heart failure coupled with liver failure"]], "start": [[4]], "entity_id": ["T8"]}, "Negated": {"text": [["died"]], "start": [[4]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "14740795_1", "context": "A 56-year-old Caucasian man who received concomitant chemotherapy and radiation for head and neck cancer developed fever concurrent with the administration of amifostine.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[105]], "entity_id": ["T6"]}, "Subject": {"text": [["A 56-year-old Caucasian man"]], "start": [[0]], "entity_id": ["T3"], "Age": {"text": [["56-year-old"]], "start": [[2]], "entity_id": ["T8"]}, "Race": {"text": [["Caucasian"]], "start": [[14]], "entity_id": ["T9"]}, "Gender": {"text": [["man"]], "start": [[24]], "entity_id": ["T10"]}}, "Effect": {"text": [["fever"]], "start": [[115]], "entity_id": ["T7"]}, "Treatment": {"text": [["concomitant chemotherapy and radiation for head and neck cancer", "concurrent with the administration of amifostine"]], "start": [[41, 121]], "entity_id": ["T4"], "Disorder": {"text": [["head and neck cancer"]], "start": [[84]], "entity_id": ["T5"]}, "Drug": {"text": [["amifostine"], ["radiation"], ["chemotherapy"]], "start": [[159], [70], [53]], "entity_id": ["T11", "T12", "T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["concurrent"]], "start": [[121]], "entity_id": ["T14"]}, "Drug": {"text": [["amifostine"], ["radiation"], ["chemotherapy"]], "start": [[159], [70], [53]], "entity_id": ["T11", "T12", "T13"]}}]}}]}]}
{"id": "15806568_1", "context": "In this study, we report on three individual patients who received BTX-B and who subsequently developed parasympathetic dysfunction of the visual system after injections of BTX-B at remote sites.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[94]], "entity_id": ["T7"]}, "Subject": {"text": [["three individual patients"]], "start": [[28]], "entity_id": ["T4"], "Population": {"text": [["three"]], "start": [[28]], "entity_id": ["T8"]}}, "Treatment": {"text": [["BTX-B", "BTX-B"]], "start": [[67, 173]], "entity_id": ["T5"], "Drug": {"text": [["BTX-B"], ["BTX-B"]], "start": [[67], [173]], "entity_id": ["T9", "T10"]}}, "Effect": {"text": [["parasympathetic dysfunction of the visual system"]], "start": [[104]], "entity_id": ["T6"]}}]}]}
{"id": "11026106_2", "context": "Minocycline-induced autoimmune hepatitis is usually identical to sporadic autoimmune hepatitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[12]], "entity_id": ["T4"]}, "Treatment": {"text": [["Minocycline"]], "start": [[0]], "entity_id": ["T3"], "Disorder": {"text": [["sporadic autoimmune hepatitis"]], "start": [[65]], "entity_id": ["T6"]}, "Drug": {"text": [["Minocycline"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["autoimmune hepatitis"]], "start": [[20]], "entity_id": ["T5"]}}]}]}
{"id": "10891991_2", "context": "BACKGROUND: Reproductive endocrine disorders characterized by menstrual disorders, polycystic ovaries, and hyperandrogenism seem to be common among women treated with sodium valproate for epilepsy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[154]], "entity_id": ["T12"]}, "Subject": {"text": [["women"]], "start": [[148]], "entity_id": ["T10"], "Gender": {"text": [["women"]], "start": [[148]], "entity_id": ["T13"]}}, "Effect": {"text": [["Reproductive endocrine disorders characterized by menstrual disorders, polycystic ovaries, and hyperandrogenism"]], "start": [[12]], "entity_id": ["T11"]}, "Treatment": {"text": [["sodium valproate for epilepsy"]], "start": [[167]], "entity_id": ["T9"], "Drug": {"text": [["sodium valproate"]], "start": [[167]], "entity_id": ["T15"]}, "Disorder": {"text": [["epilepsy"]], "start": [[188]], "entity_id": ["T16"]}}, "Speculated": {"text": [["seem"]], "start": [[124]], "entity_id": ["T14"], "value": true}}]}]}
{"id": "2621382_3", "context": "Two cases of lepromatous leprosy with erythema nodosum leprosum who were on high doses of clofazimine, showed discoloration of nail plate, subungual hyperkeratosis and onycholysis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["showed"]], "start": [[103]], "entity_id": ["T9"]}, "Subject": {"text": [["Two cases of lepromatous leprosy with erythema nodosum leprosum"]], "start": [[0]], "entity_id": ["T7"], "Population": {"text": [["Two"]], "start": [[0]], "entity_id": ["T11"]}}, "Treatment": {"text": [["high doses of clofazimine"]], "start": [[76]], "entity_id": ["T8"], "Disorder": {"text": [["lepromatous leprosy with erythema nodosum leprosum"]], "start": [[13]], "entity_id": ["T12"]}, "Drug": {"text": [["clofazimine"]], "start": [[90]], "entity_id": ["T13"]}, "Dosage": {"text": [["high doses"]], "start": [[76]], "entity_id": ["T14"]}}, "Effect": {"text": [["discoloration of nail plate, subungual hyperkeratosis and onycholysis"]], "start": [[110]], "entity_id": ["T10"]}}]}]}
{"id": "14711147_1", "context": "Doxycycline-induced photo-onycholysis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[12]], "entity_id": ["T5"]}, "Treatment": {"text": [["Doxycycline"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Doxycycline"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["photo-onycholysis"]], "start": [[20]], "entity_id": ["T6"]}}]}]}
{"id": "20203465_1", "context": "Case report: acute renal failure after administering intravenous immunoglobulin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[33]], "entity_id": ["T5"]}, "Effect": {"text": [["acute renal failure"]], "start": [[13]], "entity_id": ["T3"]}, "Treatment": {"text": [["administering intravenous immunoglobulin"]], "start": [[39]], "entity_id": ["T4"], "Drug": {"text": [["immunoglobulin"]], "start": [[65]], "entity_id": ["T6"]}, "Route": {"text": [["intravenous"]], "start": [[53]], "entity_id": ["T7"]}}}]}]}
{"id": "15224368_1", "context": "Sweet's syndrome associated with sargramostim (granulocyte-macrophage colony stimulating factor) treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[17]], "entity_id": ["T4"]}, "Treatment": {"text": [["sargramostim (granulocyte-macrophage colony stimulating factor) treatment"]], "start": [[33]], "entity_id": ["T3"], "Drug": {"text": [["sargramostim"]], "start": [[33]], "entity_id": ["T6"]}}, "Effect": {"text": [["Sweet's syndrome"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "16416684_1", "context": "This is a rare case of ARDS associated with lithium intoxication.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[28]], "entity_id": ["T4"]}, "Effect": {"text": [["ARDS"]], "start": [[23]], "entity_id": ["T3"]}, "Treatment": {"text": [["lithium"]], "start": [[44]], "entity_id": ["T5"], "Drug": {"text": [["lithium"]], "start": [[44]], "entity_id": ["T6"]}}, "Speculated": {"text": [["rare case"]], "start": [[10]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "8520081_1", "context": "Intravenous haloperidol is generally well tolerated, but multiform ventricular tachycardia has been reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reported"]], "start": [[100]], "entity_id": ["T5"]}, "Treatment": {"text": [["Intravenous haloperidol"]], "start": [[0]], "entity_id": ["T3"]}, "Effect": {"text": [["multiform ventricular tachycardia"]], "start": [[57]], "entity_id": ["T4"]}}]}]}
{"id": "12243603_2", "context": "To report a case of rhabdomyolysis and acute hepatitis associated with the coadministration of atorvastatin and diltiazem.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[55]], "entity_id": ["T8"]}, "Treatment": {"text": [["coadministration of atorvastatin and diltiazem"]], "start": [[75]], "entity_id": ["T9"], "Drug": {"text": [["atorvastatin"], ["diltiazem"]], "start": [[95], [112]], "entity_id": ["T11", "T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["coadministration"]], "start": [[75]], "entity_id": ["T13"]}, "Drug": {"text": [["atorvastatin"], ["diltiazem"]], "start": [[95], [112]], "entity_id": ["T11", "T12"]}}]}, "Effect": {"text": [["rhabdomyolysis and acute hepatitis"]], "start": [[20]], "entity_id": ["T10"]}}]}]}
{"id": "18094347_8", "context": "Ten hours after the second methotrexate injection, the patient experienced a diffuse pruritic papular eruption located mainly on the limbs.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["experienced"]], "start": [[63]], "entity_id": ["T5"]}, "Effect": {"text": [["diffuse pruritic papular eruption located mainly on the limbs"]], "start": [[77]], "entity_id": ["T3"]}, "Subject": {"text": [["the patient"]], "start": [[51]], "entity_id": ["T4"]}, "Treatment": {"text": [["Ten hours after the second methotrexate injection"]], "start": [[0]], "entity_id": ["T6"], "Drug": {"text": [["methotrexate"]], "start": [[27]], "entity_id": ["T7"]}, "Route": {"text": [["injection"]], "start": [[40]], "entity_id": ["T8"]}, "Time_elapsed": {"text": [["Ten hours"], ["second"]], "start": [[0], [20]], "entity_id": ["T9", "T10"]}}}]}]}
{"id": "19531695_10", "context": "Flecainide and pharmacologically similar agents that interact with sodium channels may cause delirium in susceptible patients.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[87]], "entity_id": ["T9"]}, "Subject": {"text": [["susceptible patients"]], "start": [[105]], "entity_id": ["T6"]}, "Effect": {"text": [["delirium"]], "start": [[93]], "entity_id": ["T7"]}, "Treatment": {"text": [["Flecainide and pharmacologically similar agents that interact with sodium channels"]], "start": [[0]], "entity_id": ["T8"], "Drug": {"text": [["Flecainide"]], "start": [[0]], "entity_id": ["T10"]}}, "Speculated": {"text": [["may"]], "start": [[83]], "entity_id": ["T11"], "value": true}}]}]}
{"id": "921427_1", "context": "An elderly man with procainamide hydrochloride-induced lupus syndrome had a circulating anticoagulant against factor XI and a biologic false-positive (BFP) test result for syphilis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[47]], "entity_id": ["T3"]}, "Treatment": {"text": [["procainamide hydrochloride"]], "start": [[20]], "entity_id": ["T4"], "Drug": {"text": [["procainamide hydrochloride"]], "start": [[20]], "entity_id": ["T9"]}}, "Effect": {"text": [["lupus"]], "start": [[55]], "entity_id": ["T5"]}, "Subject": {"text": [["An elderly man"]], "start": [[0]], "entity_id": ["T6"], "Age": {"text": [["elderly"]], "start": [[3]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[11]], "entity_id": ["T8"]}}}]}]}
{"id": "7151655_1", "context": "In one patient, treatment with DCA was associated with a decrease in blood lactate levels from 11.2 mM before treatment to 0.8 mM 16 h later.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[39]], "entity_id": ["T5"]}, "Subject": {"text": [["one patient"]], "start": [[3]], "entity_id": ["T3"], "Population": {"text": [["one"]], "start": [[3]], "entity_id": ["T7"]}}, "Treatment": {"text": [["DCA"]], "start": [[31]], "entity_id": ["T4"], "Drug": {"text": [["DCA"]], "start": [[31]], "entity_id": ["T8"]}, "Time_elapsed": {"text": [["16 h later"]], "start": [[130]], "entity_id": ["T9"]}}, "Effect": {"text": [["decrease in blood lactate levels"]], "start": [[57]], "entity_id": ["T6"]}}]}]}
{"id": "7865488_3", "context": "We report a case of noncardiogenic pulmonary edema developed after therapeutic trial of EO as sclerosing agent for esophageal varix.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[51]], "entity_id": ["T6"]}, "Effect": {"text": [["noncardiogenic pulmonary edema"]], "start": [[20]], "entity_id": ["T4"]}, "Treatment": {"text": [["EO"]], "start": [[88]], "entity_id": ["T5"], "Drug": {"text": [["EO"]], "start": [[88]], "entity_id": ["T8"]}, "Disorder": {"text": [["esophageal varix"]], "start": [[115]], "entity_id": ["T9"]}}}]}]}
{"id": "15878975_3", "context": "That review suggested that patients receiving anti-D IGIV be monitored for those and other potential complications of hemoglobinemia, particularly disseminated intravascular coagulation (DIC).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complications"]], "start": [[101]], "entity_id": ["T11"]}, "Subject": {"text": [["patients"]], "start": [[27]], "entity_id": ["T7"]}, "Treatment": {"text": [["receiving anti-D IGIV"]], "start": [[36]], "entity_id": ["T8"], "Drug": {"text": [["anti-D IGIV"]], "start": [[46]], "entity_id": ["T12"]}}, "Effect": {"text": [["hemoglobinemia, particularly disseminated intravascular coagulation (DIC)"]], "start": [[118]], "entity_id": ["T9"]}, "Speculated": {"text": [["potential"]], "start": [[91]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "11144696_1", "context": "Seizures associated with therapeutic doses of venlafaxine and trimipramine.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[9]], "entity_id": ["T5"]}, "Treatment": {"text": [["therapeutic doses of venlafaxine and trimipramine"]], "start": [[25]], "entity_id": ["T6"], "Drug": {"text": [["venlafaxine"], ["trimipramine"]], "start": [[46], [62]], "entity_id": ["T8", "T10"]}, "Dosage": {"text": [["therapeutic doses"]], "start": [[25]], "entity_id": ["T9"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[58]], "entity_id": ["T11"]}, "Drug": {"text": [["venlafaxine"], ["trimipramine"]], "start": [[46], [62]], "entity_id": ["T8", "T10"]}}]}, "Effect": {"text": [["Seizures"]], "start": [[0]], "entity_id": ["T7"]}}]}]}
{"id": "14960440_1", "context": "BACKGROUND: The risk/benefit ratio of warfarin therapy changes in the over 75s, when haemorrhagic side-effects become more common.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["become"]], "start": [[111]], "entity_id": ["T5"]}, "Treatment": {"text": [["warfarin therapy"]], "start": [[38]], "entity_id": ["T3"], "Drug": {"text": [["warfarin"]], "start": [[38]], "entity_id": ["T6"]}}, "Effect": {"text": [["haemorrhagic side-effects"]], "start": [[85]], "entity_id": ["T4"]}, "Subject": {"text": [["over 75s"]], "start": [[70]], "entity_id": ["T8"], "Age": {"text": [["over 75s"]], "start": [[70]], "entity_id": ["T7"]}}}]}]}
{"id": "1445134_5", "context": "Norethisterone in these 69 pregnancies accounted for 33.3% (5 of 15) cases of clitoral hypertrophy diagnosed in 100,756 consecutive births.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["accounted"]], "start": [[39]], "entity_id": ["T5"]}, "Treatment": {"text": [["Norethisterone"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Norethisterone"]], "start": [[0]], "entity_id": ["T8"]}}, "Subject": {"text": [["69 pregnancies"]], "start": [[24]], "entity_id": ["T4"], "Population": {"text": [["69"]], "start": [[24]], "entity_id": ["T7"]}}, "Effect": {"text": [["clitoral hypertrophy"]], "start": [[78]], "entity_id": ["T6"]}}]}]}
{"id": "736591_1", "context": "Interstitial fibrosis of the lung is a potential complication of methotrexate therapy for psoriasis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[49]], "entity_id": ["T6"]}, "Effect": {"text": [["Interstitial fibrosis of the lung"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["methotrexate"]], "start": [[65]], "entity_id": ["T4"], "Drug": {"text": [["methotrexate"]], "start": [[65]], "entity_id": ["T7"]}, "Disorder": {"text": [["psoriasis"]], "start": [[90]], "entity_id": ["T8"]}}}]}]}
{"id": "22735246_5", "context": "This is the first reported fatality due to this drug interaction and only the second case of serotonin syndrome reported with oxcarbazepine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reported"]], "start": [[112]], "entity_id": ["T5"]}, "Effect": {"text": [["serotonin syndrome"]], "start": [[93]], "entity_id": ["T4"]}, "Treatment": {"text": [["oxcarbazepine"]], "start": [[126]], "entity_id": ["T6"], "Drug": {"text": [["oxcarbazepine"]], "start": [[126]], "entity_id": ["T7"]}}}]}]}
{"id": "15239684_1", "context": "Purple glove syndrome, named for its distinctive purple discoloration and swelling of the hands in the distribution of a glove, is an uncommon complication of intravenous phenytoin administration through small dorsal veins of the hands.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[143]], "entity_id": ["T7"]}, "Effect": {"text": [["Purple glove syndrome", "purple discoloration and swelling of the hands in the distribution of a glove"]], "start": [[0, 49]], "entity_id": ["T8"]}, "Treatment": {"text": [["intravenous phenytoin administration through small dorsal veins of the hands"]], "start": [[159]], "entity_id": ["T9"], "Route": {"text": [["intravenous"]], "start": [[159]], "entity_id": ["T11"]}, "Drug": {"text": [["phenytoin"]], "start": [[171]], "entity_id": ["T12"]}}}]}]}
{"id": "11483161_1", "context": "Possible linkage of amprenavir with intracranial bleeding in an HIV-infected hemophiliac.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["linkage"]], "start": [[9]], "entity_id": ["T6"]}, "Subject": {"text": [["an HIV-infected hemophiliac"]], "start": [[61]], "entity_id": ["T3"]}, "Treatment": {"text": [["amprenavir"]], "start": [[20]], "entity_id": ["T4"], "Drug": {"text": [["amprenavir"]], "start": [[20]], "entity_id": ["T9"]}, "Disorder": {"text": [["HIV"]], "start": [[64]], "entity_id": ["T10"]}}, "Effect": {"text": [["intracranial bleeding"]], "start": [[36]], "entity_id": ["T5"]}, "Speculated": {"text": [["Possible"]], "start": [[0]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "8098286_2", "context": "Inadvertent subsequent rechallenge with celiprolol led to recurrence of the pneumonitis, 10 weeks after drug readministration.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["led to"]], "start": [[51]], "entity_id": ["T3"]}, "Treatment": {"text": [["Inadvertent subsequent rechallenge with celiprolol", "10 weeks after drug readministration"]], "start": [[0, 89]], "entity_id": ["T4"], "Drug": {"text": [["celiprolol"]], "start": [[40]], "entity_id": ["T6"]}, "Time_elapsed": {"text": [["10 weeks"]], "start": [[89]], "entity_id": ["T7"]}}, "Effect": {"text": [["recurrence of the pneumonitis"]], "start": [[58]], "entity_id": ["T5"]}}]}]}
{"id": "19531695_5", "context": "Flecainide had been started 2 weeks prior for atrial fibrillation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["for"]], "start": [[42]], "entity_id": ["T5"]}, "Treatment": {"text": [["Flecainide"]], "start": [[0]], "entity_id": ["T4"], "Disorder": {"text": [["atrial fibrillation"]], "start": [[46]], "entity_id": ["T6"]}, "Drug": {"text": [["Flecainide"]], "start": [[0]], "entity_id": ["T7"]}}}]}]}
{"id": "18396749_4", "context": "In the absence of evidence of a potential role for concomitant medication i.e. hydroxychloroquine sulfate to play a role in the clinical, biochemical and morphological picture, an interaction between the herbal preparation and tibolone was suspected as the likely cause of liver damage.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["suspected"]], "start": [[240]], "entity_id": ["T8"]}, "Treatment": {"text": [["an interaction between the herbal preparation and tibolone"]], "start": [[177]], "entity_id": ["T9"], "Drug": {"text": [["herbal preparation"], ["tibolone"]], "start": [[204], [227]], "entity_id": ["T13", "T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[180]], "entity_id": ["T12"]}, "Drug": {"text": [["herbal preparation"], ["tibolone"]], "start": [[204], [227]], "entity_id": ["T13", "T14"]}}]}, "Effect": {"text": [["liver damage"]], "start": [[273]], "entity_id": ["T10"]}, "Speculated": {"text": [["suspected"]], "start": [[240]], "entity_id": ["T11"], "value": true}}]}]}
{"id": "9128433_1", "context": "Its overall toxicity is considerably less compared to standard induction chemotherapy; however, it is associated with a high incidence of a potentially fatal symptom complex referred to as \"retinoic acid syndrome.\" This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[260]], "entity_id": ["T8"]}, "Subject": {"text": [["a patient with APL"]], "start": [[237]], "entity_id": ["T7"]}, "Effect": {"text": [["symptom complex referred to as \"retinoic acid syndrome.\""]], "start": [[158]], "entity_id": ["T9"]}, "Treatment": {"text": [["a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis"]], "start": [[283]], "entity_id": ["T10"], "Drug": {"text": [["ATRA"]], "start": [[335]], "entity_id": ["T13"]}, "Time_elapsed": {"text": [["a few weeks"]], "start": [[283]], "entity_id": ["T14"]}, "Disorder": {"text": [["APL"]], "start": [[252]], "entity_id": ["T15"]}}, "Severity": {"text": [["fatal"]], "start": [[152]], "entity_id": ["T16"], "value": "High"}}]}]}
{"id": "18609153_2", "context": "During intravenous treatment with terlipressin for recurrent gastrointestinal (GI) bleeding, a 50-year-old male with no history of heart disease developed a newly prolonged QT interval and torsade de pointes.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[145]], "entity_id": ["T10"]}, "Subject": {"text": [["a 50-year-old male with no history of heart disease"]], "start": [[93]], "entity_id": ["T9"], "Age": {"text": [["50-year-old"]], "start": [[95]], "entity_id": ["T13"]}, "Gender": {"text": [["male"]], "start": [[107]], "entity_id": ["T14"]}}, "Effect": {"text": [["a newly prolonged QT interval and torsade de pointes"]], "start": [[155]], "entity_id": ["T11"]}, "Treatment": {"text": [["During intravenous treatment with terlipressin for recurrent gastrointestinal (GI) bleeding"]], "start": [[0]], "entity_id": ["T12"], "Route": {"text": [["intravenous"]], "start": [[7]], "entity_id": ["T15"]}, "Drug": {"text": [["terlipressin"]], "start": [[34]], "entity_id": ["T16"]}, "Disorder": {"text": [["recurrent gastrointestinal"]], "start": [[51]], "entity_id": ["T17"]}}}]}]}
{"id": "1109248_9", "context": "It is concluded that chloral hydrate and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caution"]], "start": [[100]], "entity_id": ["T9"]}, "Treatment": {"text": [["chloral hydrate and methaqualone", "during oral anticoagulant therapy"]], "start": [[21, 139]], "entity_id": ["T8"], "Drug": {"text": [["chloral hydrate"], ["methaqualone"], ["anticoagulant"]], "start": [[21], [41], [151]], "entity_id": ["T13", "T14", "T15"]}, "Route": {"text": [["oral"]], "start": [[146]], "entity_id": ["T16"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[37]], "entity_id": ["T17"]}, "Drug": {"text": [["chloral hydrate"], ["methaqualone"], ["anticoagulant"]], "start": [[21], [41], [151]], "entity_id": ["T13", "T14", "T15"]}}]}, "Speculated": {"text": [["may be"]], "start": [[54]], "entity_id": ["T7"], "value": true}, "Negated": {"text": [["without"]], "start": [[81]], "entity_id": ["T12"], "value": true}}]}]}
{"id": "6692713_1", "context": "Amiodarone hydrochloride, a new antiarrhythmic agent, has been associated with pulmonary toxicity characterized by cough, dyspnea and diffuse pulmonary infiltrates.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[63]], "entity_id": ["T9"]}, "Treatment": {"text": [["Amiodarone hydrochloride"]], "start": [[0]], "entity_id": ["T10"], "Drug": {"text": [["Amiodarone hydrochloride"]], "start": [[0]], "entity_id": ["T12"]}}, "Effect": {"text": [["pulmonary toxicity characterized by cough, dyspnea and diffuse pulmonary infiltrates"]], "start": [[79]], "entity_id": ["T11"]}}]}]}
{"id": "9831311_1", "context": "Although major hazards of treatment of hypophosphatemic osteomalacia with phosphate and calcitriol are secondary hyperparathyroidism and vitamin D intoxication, potassium loss also should be kept in mind.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["major hazards"]], "start": [[9]], "entity_id": ["T11"]}, "Treatment": {"text": [["hypophosphatemic osteomalacia with phosphate and calcitriol"]], "start": [[39]], "entity_id": ["T10"], "Drug": {"text": [["phosphate"], ["calcitriol"]], "start": [[74], [88]], "entity_id": ["T13", "T14"]}, "Disorder": {"text": [["hypophosphatemic osteomalacia"]], "start": [[39]], "entity_id": ["T15"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[84]], "entity_id": ["T16"]}, "Drug": {"text": [["phosphate"], ["calcitriol"]], "start": [[74], [88]], "entity_id": ["T13", "T14"]}}]}, "Effect": {"text": [["secondary hyperparathyroidism and vitamin D intoxication, potassium loss"]], "start": [[103]], "entity_id": ["T12"]}}]}]}
{"id": "19579947_1", "context": "He had priapism following the use of olanzapine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[16]], "entity_id": ["T4"]}, "Effect": {"text": [["priapism"]], "start": [[7]], "entity_id": ["T3"]}, "Treatment": {"text": [["olanzapine"]], "start": [[37]], "entity_id": ["T5"], "Drug": {"text": [["olanzapine"]], "start": [[37]], "entity_id": ["T6"]}}}]}]}
{"id": "20298401_10", "context": "CONCLUSION: Our case shows a fatal side effect of erlotinib.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["of"]], "start": [[47]], "entity_id": ["T4"]}, "Effect": {"text": [["side effect"]], "start": [[35]], "entity_id": ["T3"]}, "Treatment": {"text": [["erlotinib"]], "start": [[50]], "entity_id": ["T5"], "Drug": {"text": [["erlotinib"]], "start": [[50]], "entity_id": ["T6"]}}, "Severity": {"text": [["fatal"]], "start": [[29]], "entity_id": ["T7"], "value": "High"}}]}]}
{"id": "2161782_1", "context": "Data have been published regarding the possibility that tamoxifen may be responsible for the subsequent development of carcinoma of the corpus uteri in these patients.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["responsible"]], "start": [[73]], "entity_id": ["T6"]}, "Treatment": {"text": [["tamoxifen"]], "start": [[56]], "entity_id": ["T3"], "Drug": {"text": [["tamoxifen"]], "start": [[56]], "entity_id": ["T8"]}}, "Effect": {"text": [["subsequent development of carcinoma of the corpus uteri"]], "start": [[93]], "entity_id": ["T4"]}, "Subject": {"text": [["these patients"]], "start": [[152]], "entity_id": ["T5"]}, "Speculated": {"text": [["may"]], "start": [[66]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "16404563_3", "context": "Corticosteroids may be useful for therapy of some features of this syndrome, such as thrombocytopenia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["be useful"]], "start": [[20]], "entity_id": ["T6"]}, "Treatment": {"text": [["Corticosteroids"]], "start": [[0]], "entity_id": ["T7"], "Drug": {"text": [["Corticosteroids"]], "start": [[0]], "entity_id": ["T10"]}, "Disorder": {"text": [["thrombocytopenia"]], "start": [[85]], "entity_id": ["T11"]}}, "Speculated": {"text": [["may"]], "start": [[16]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "15183980_1", "context": "Eosinophilic cystitis after bladder instillation with dimethyl sulfoxide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[22]], "entity_id": ["T4"]}, "Treatment": {"text": [["bladder instillation with dimethyl sulfoxide"]], "start": [[28]], "entity_id": ["T3"], "Drug": {"text": [["dimethyl sulfoxide"]], "start": [[54]], "entity_id": ["T6"]}, "Route": {"text": [["bladder instillation"]], "start": [[28]], "entity_id": ["T7"]}}, "Effect": {"text": [["Eosinophilic cystitis"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "11881322_1", "context": "Beginning ductopenia was present in two, suggesting that itraconazole might be responsible for the occurrence of prolonged drug-induced cholangiopathy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["responsible"]], "start": [[79]], "entity_id": ["T7"]}, "Effect": {"text": [["ductopenia"]], "start": [[10]], "entity_id": ["T5"]}, "Treatment": {"text": [["itraconazole"]], "start": [[57]], "entity_id": ["T6"], "Disorder": {"text": [["prolonged drug-induced cholangiopathy"]], "start": [[113]], "entity_id": ["T8"]}, "Drug": {"text": [["itraconazole"]], "start": [[57]], "entity_id": ["T9"]}}, "Subject": {"text": [["two"]], "start": [[36]], "entity_id": ["T11"]}, "Speculated": {"text": [["might be"]], "start": [[70]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "576675_1", "context": "A 15-kg weight gain developed in a patient during the third week of ibuprofen therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[20]], "entity_id": ["T4"]}, "Effect": {"text": [["A 15-kg weight gain"]], "start": [[0]], "entity_id": ["T3"]}, "Subject": {"text": [["a patient"]], "start": [[33]], "entity_id": ["T5"]}, "Treatment": {"text": [["ibuprofen"]], "start": [[68]], "entity_id": ["T6"], "Drug": {"text": [["ibuprofen"]], "start": [[68]], "entity_id": ["T7"]}, "Time_elapsed": {"text": [["the third week"]], "start": [[50]], "entity_id": ["T8"]}}}]}]}
{"id": "7019786_1", "context": "Cefoxitin-associated renal failure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[10]], "entity_id": ["T4"]}, "Treatment": {"text": [["Cefoxitin"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Cefoxitin"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["renal failure"]], "start": [[21]], "entity_id": ["T5"]}}]}]}
{"id": "9169264_4", "context": "The rash seen in this patient, who was treated with cephalexin, may be similar to the rash seen with ampicillin treatment of patients with infectious mononucleosis.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["seen"]], "start": [[9]], "entity_id": ["T7"]}, "Subject": {"text": [["patient"]], "start": [[22]], "entity_id": ["T5"]}, "Treatment": {"text": [["cephalexin"]], "start": [[52]], "entity_id": ["T6"], "Drug": {"text": [["cephalexin"]], "start": [[52]], "entity_id": ["T8"]}}, "Effect": {"text": [["rash"]], "start": [[4]], "entity_id": ["T4"]}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["seen"]], "start": [[91]], "entity_id": ["T14"]}, "Treatment": {"text": [["ampicillin treatment"]], "start": [[101]], "entity_id": ["T10"], "Drug": {"text": [["ampicillin"]], "start": [[101]], "entity_id": ["T11"]}}, "Subject": {"text": [["patients"]], "start": [[125]], "entity_id": ["T12"]}, "Effect": {"text": [["infectious mononucleosis"]], "start": [[139]], "entity_id": ["T13"]}}]}]}
{"id": "15644988_2", "context": "Two of our patients developed TD after 23 months and 34 months of ziprasidone monotherapy, respectively.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[20]], "entity_id": ["T6"]}, "Subject": {"text": [["Two of our patients"]], "start": [[0]], "entity_id": ["T3"], "Population": {"text": [["Two"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["TD"]], "start": [[30]], "entity_id": ["T4"]}, "Treatment": {"text": [["ziprasidone"]], "start": [[66]], "entity_id": ["T5"], "Drug": {"text": [["ziprasidone"]], "start": [[66]], "entity_id": ["T8"]}, "Time_elapsed": {"text": [["23 months"], ["34 months"]], "start": [[39], [53]], "entity_id": ["T9", "T10"]}}}]}]}
{"id": "12932249_3", "context": "We describe two dark-skinned patients who developed hyperpigmented skin and tongue lesions during combination therapy with IFN and ribavirin.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[91]], "entity_id": ["T7"]}, "Treatment": {"text": [["combination therapy with IFN and ribavirin."]], "start": [[98]], "entity_id": ["T8"], "Drug": {"text": [["IFN"], ["ribavirin"]], "start": [[123], [131]], "entity_id": ["T13", "T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combination"]], "start": [[98]], "entity_id": ["T15"]}, "Drug": {"text": [["IFN"], ["ribavirin"]], "start": [[123], [131]], "entity_id": ["T13", "T14"]}}]}, "Subject": {"text": [["two dark-skinned patients"]], "start": [[12]], "entity_id": ["T9"], "Population": {"text": [["two"]], "start": [[12]], "entity_id": ["T11"]}, "Race": {"text": [["dark-skinned"]], "start": [[16]], "entity_id": ["T12"]}}, "Effect": {"text": [["hyperpigmented skin and tongue lesions"]], "start": [[52]], "entity_id": ["T10"]}}]}]}
{"id": "2643458_1", "context": "Attenuation of asparaginase-induced hyperglycemia after substitution of the Erwinia carotovora for the Escherichia coli enzyme preparation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["after"]], "start": [[50]], "entity_id": ["T4"]}, "Treatment": {"text": [["substitution of the Erwinia carotovora for the Escherichia coli enzyme preparation"]], "start": [[56]], "entity_id": ["T3"], "Drug": {"text": [["Erwinia carotovora"], ["Escherichia coli enzyme preparation"]], "start": [[76], [103]], "entity_id": ["T6", "T7"]}}, "Effect": {"text": [["Attenuation of asparaginase-induced hyperglycemia"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "10749332_2", "context": "It remains to be seen whether the hepatotoxicity associated with troglitazone is a drug-class effect or specific to troglitazone.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[49]], "entity_id": ["T5"]}, "Effect": {"text": [["hepatotoxicity"]], "start": [[34]], "entity_id": ["T4"]}, "Treatment": {"text": [["troglitazone"]], "start": [[65]], "entity_id": ["T6"], "Drug": {"text": [["troglitazone"]], "start": [[65]], "entity_id": ["T7"]}}, "Speculated": {"text": [["whether"]], "start": [[22]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "2935070_1", "context": "Ampicillin-induced interstitial nephritis with generalised exfoliative dermatitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T6"]}, "Treatment": {"text": [["Ampicillin"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Ampicillin"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["interstitial nephritis with generalised exfoliative dermatitis"]], "start": [[19]], "entity_id": ["T7"]}}]}]}
{"id": "7900744_3", "context": "High-dose intravenous mannitol infusion in various clinical settings may result in acute renal failure (ARF).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["result"]], "start": [[73]], "entity_id": ["T6"]}, "Treatment": {"text": [["High-dose intravenous mannitol infusion"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["mannitol"]], "start": [[22]], "entity_id": ["T8"]}, "Route": {"text": [["intravenous", "infusion"]], "start": [[10, 31]], "entity_id": ["T10"]}, "Dosage": {"text": [["High-dose"]], "start": [[0]], "entity_id": ["T11"]}}, "Effect": {"text": [["acute renal failure"]], "start": [[83]], "entity_id": ["T7"]}, "Speculated": {"text": [["may"]], "start": [[69]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "6416845_1", "context": "A 7-year-old boy developed a severe unilateral grand mal seizure at the age of 5 years (phenobarbitone therapy); 1.5 years later valproate (2-propylpentanoic acid, VPA) was added to the therapy.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["therapy"]], "start": [[186]], "entity_id": ["T7"]}, "Subject": {"text": [["A 7-year-old boy developed a severe unilateral grand mal seizure"]], "start": [[0]], "entity_id": ["T6"], "Age": {"text": [["7-year-old"]], "start": [[2]], "entity_id": ["T8"]}, "Gender": {"text": [["boy"]], "start": [[13]], "entity_id": ["T10"]}, "Disorder": {"text": [["a severe unilateral grand mal seizure"]], "start": [[27]], "entity_id": ["T11"]}}, "Treatment": {"text": [["at the age of 5 years (phenobarbitone therapy); 1.5 years later valproate (2-propylpentanoic acid, VPA) was added to the therapy."]], "start": [[65]], "entity_id": ["T9"], "Drug": {"text": [["phenobarbitone"], ["valproate"]], "start": [[88], [129]], "entity_id": ["T12", "T13"]}, "Time_elapsed": {"text": [["1.5 years later"]], "start": [[113]], "entity_id": ["T15"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["added"]], "start": [[173]], "entity_id": ["T16"]}, "Drug": {"text": [["valproate"], ["phenobarbitone"]], "start": [[129], [88]], "entity_id": ["T13", "T12"]}}]}}]}]}
{"id": "19474653_2", "context": "We report the first case of rhabdomyolysis related to the administration of clarithromycin without concurrent use of other medications.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related to"]], "start": [[43]], "entity_id": ["T4"]}, "Effect": {"text": [["rhabdomyolysis"]], "start": [[28]], "entity_id": ["T3"]}, "Treatment": {"text": [["administration of clarithromycin without concurrent use of other medications"]], "start": [[58]], "entity_id": ["T5"], "Drug": {"text": [["clarithromycin"]], "start": [[76]], "entity_id": ["T6"]}}}]}]}
{"id": "3804181_2", "context": "The authors report a further case of methimazole-associated liver damage and present a brief review of eleven previous cases found in the literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[49]], "entity_id": ["T4"]}, "Treatment": {"text": [["methimazole"]], "start": [[37]], "entity_id": ["T3"], "Drug": {"text": [["methimazole"]], "start": [[37]], "entity_id": ["T6"]}}, "Effect": {"text": [["liver damage"]], "start": [[60]], "entity_id": ["T5"]}, "Subject": {"text": [["a further case", "eleven previous cases"]], "start": [[19, 103]], "entity_id": ["T7"], "Population": {"text": [["eleven"]], "start": [[103]], "entity_id": ["T8"]}}}]}]}
{"id": "2051906_1", "context": "A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[97]], "entity_id": ["T3"]}, "Subject": {"text": [["A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease"]], "start": [[0]], "entity_id": ["T4"], "Age": {"text": [["67-year-old"]], "start": [[2]], "entity_id": ["T1"]}}, "Treatment": {"text": [["3 months after initiation of azathioprine"]], "start": [[163]], "entity_id": ["T5"], "Drug": {"text": [["azathioprine"]], "start": [[192]], "entity_id": ["T7"]}, "Time_elapsed": {"text": [["3 months"]], "start": [[163]], "entity_id": ["T8"]}, "Disorder": {"text": [["primary polymyositis"]], "start": [[28]], "entity_id": ["T9"]}}, "Effect": {"text": [["cholestasis"]], "start": [[151]], "entity_id": ["T6"]}, "Severity": {"text": [["severe"]], "start": [[144]], "entity_id": ["T10"], "value": "High"}}]}]}
{"id": "3569037_2", "context": "Hypersensitivity reaction following chloramphenicol administration in a patient with typhoid fever.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[26]], "entity_id": ["T5"]}, "Subject": {"text": [["a patient with typhoid fever"]], "start": [[70]], "entity_id": ["T3"]}, "Effect": {"text": [["Hypersensitivity reaction"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["chloramphenicol"]], "start": [[36]], "entity_id": ["T6"], "Drug": {"text": [["chloramphenicol"]], "start": [[36]], "entity_id": ["T8"]}, "Disorder": {"text": [["typhoid fever"]], "start": [[85]], "entity_id": ["T9"]}}}]}]}
{"id": "10357715_1", "context": "Allergic and irritant contact dermatitis to calcipotriol.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["to"]], "start": [[41]], "entity_id": ["T4"]}, "Effect": {"text": [["contact dermatitis"]], "start": [[22]], "entity_id": ["T3"]}, "Treatment": {"text": [["calcipotriol"]], "start": [[44]], "entity_id": ["T5"], "Drug": {"text": [["calcipotriol"]], "start": [[44]], "entity_id": ["T6"]}}, "Severity": {"text": [["Allergic and irritant"]], "start": [[0]], "entity_id": ["T7"], "value": "Medium"}}]}]}
{"id": "3565435_1", "context": "A 23-year-old woman with systemic lupus erythematosus had a severe hypersensitivity reaction to the drug ibuprofen.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["had"]], "start": [[54]], "entity_id": ["T7"]}, "Effect": {"text": [["hypersensitivity reaction"]], "start": [[67]], "entity_id": ["T5"]}, "Treatment": {"text": [["ibuprofen"]], "start": [[105]], "entity_id": ["T6"], "Disorder": {"text": [["systemic lupus erythematosus"]], "start": [[25]], "entity_id": ["T10"]}, "Drug": {"text": [["ibuprofen"]], "start": [[105]], "entity_id": ["T11"]}}, "Subject": {"text": [["A 23-year-old woman with systemic lupus erythematosus"]], "start": [[0]], "entity_id": ["T9"], "Age": {"text": [["23-year-old"]], "start": [[2]], "entity_id": ["T3"]}, "Gender": {"text": [["woman"]], "start": [[14]], "entity_id": ["T8"]}}, "Severity": {"text": [["severe"]], "start": [[60]], "entity_id": ["T12"], "value": "High"}}]}]}
{"id": "2738729_1", "context": "We present the first case of WES in an infant born to a mother taking haloperidol during her pregnancy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["case"]], "start": [[21]], "entity_id": ["T6"]}, "Effect": {"text": [["WES"]], "start": [[29]], "entity_id": ["T3"]}, "Treatment": {"text": [["haloperidol"]], "start": [[70]], "entity_id": ["T5"], "Drug": {"text": [["haloperidol"]], "start": [[70]], "entity_id": ["T8"]}}, "Subject": {"text": [["an infant born to a mother"]], "start": [[36]], "entity_id": ["T7"], "Age": {"text": [["infant"]], "start": [[39]], "entity_id": ["T4"]}}}]}]}
{"id": "17189581_7", "context": "Despite treatment with levofloxacin, acyclovir, and voriconazole, the patient developed high fevers.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[78]], "entity_id": ["T9"]}, "Treatment": {"text": [["levofloxacin, acyclovir, and voriconazole"]], "start": [[23]], "entity_id": ["T8"], "Drug": {"text": [["levofloxacin"], ["acyclovir"], ["voriconazole"]], "start": [[23], [37], [52]], "entity_id": ["T12", "T13", "T14"]}}, "Effect": {"text": [["high fevers"]], "start": [[88]], "entity_id": ["T10"]}, "Subject": {"text": [["patient"]], "start": [[70]], "entity_id": ["T11"]}}]}]}
{"id": "6353252_2", "context": "The 5 patients had severe renovascular disease which might thus represent a significant risk factor in the development of captopril-induced acute renal failure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[132]], "entity_id": ["T5"]}, "Subject": {"text": [["The 5 patients had severe renovascular disease"]], "start": [[0]], "entity_id": ["T4"], "Population": {"text": [["5"]], "start": [[4]], "entity_id": ["T8"]}, "Disorder": {"text": [["renovascular disease"]], "start": [[26]], "entity_id": ["T9"]}}, "Treatment": {"text": [["captopril"]], "start": [[122]], "entity_id": ["T6"], "Drug": {"text": [["captopril"]], "start": [[122]], "entity_id": ["T11"]}}, "Effect": {"text": [["acute renal failure"]], "start": [[140]], "entity_id": ["T7"]}, "Speculated": {"text": [["might"]], "start": [[53]], "entity_id": ["T3"], "value": true}}]}]}
{"id": "8691927_5", "context": "METHODS: Growth retardation was observed in six severely asthmatic children after introduction of high-dose fluticasone propionate treatment (dry powder).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[76]], "entity_id": ["T5"]}, "Subject": {"text": [["six severely asthmatic children"]], "start": [[44]], "entity_id": ["T3"], "Population": {"text": [["six"]], "start": [[44]], "entity_id": ["T7"]}, "Age": {"text": [["children"]], "start": [[67]], "entity_id": ["T9"]}}, "Effect": {"text": [["Growth retardation"]], "start": [[9]], "entity_id": ["T4"]}, "Treatment": {"text": [["introduction of high-dose fluticasone propionate treatment (dry powder)"]], "start": [[82]], "entity_id": ["T6"], "Disorder": {"text": [["severely asthmatic"]], "start": [[48]], "entity_id": ["T8"]}, "Dosage": {"text": [["high-dose"]], "start": [[98]], "entity_id": ["T10"]}, "Drug": {"text": [["fluticasone propionate"]], "start": [[108]], "entity_id": ["T11"]}, "Route": {"text": [["dry powder"]], "start": [[142]], "entity_id": ["T1"]}}}]}]}
{"id": "433855_1", "context": "The toxic effects of methotrexate included elevated liver transaminases (3/4), nausea (2/4), abdominal pain (2/4), bone pain (2/4), mild neutropenia (1/4), and mild pruritus (1/4).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["of"]], "start": [[18]], "entity_id": ["T13"]}, "Treatment": {"text": [["methotrexate"]], "start": [[21]], "entity_id": ["T14"], "Drug": {"text": [["methotrexate"]], "start": [[21]], "entity_id": ["T17"]}}, "Effect": {"text": [["toxic effects", "elevated liver transaminases (3/4), nausea (2/4), abdominal pain (2/4), bone pain (2/4), mild neutropenia (1/4), and mild pruritus (1/4)"]], "start": [[4, 43]], "entity_id": ["T15"]}, "Severity": {"text": [["mild"]], "start": [[132]], "entity_id": ["T16"], "value": "Low"}}]}]}
{"id": "20120657_1", "context": "CONCLUSION: Zidovudine is well a known cause of anaemia and thus should be used with caution in the initiation of antiretroviral therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[39]], "entity_id": ["T5"]}, "Treatment": {"text": [["Zidovudine"]], "start": [[12]], "entity_id": ["T3"], "Drug": {"text": [["Zidovudine"]], "start": [[12]], "entity_id": ["T6"]}}, "Effect": {"text": [["anaemia"]], "start": [[48]], "entity_id": ["T4"]}}]}]}
{"id": "18676387_4", "context": "A 60-yr-old woman, established on paroxetine for depression, underwent excision of a chest wall myxofibrosarcoma and chest wall reconstruction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["established"]], "start": [[19]], "entity_id": ["T7"]}, "Subject": {"text": [["A 60-yr-old woman", "depression"]], "start": [[0, 49]], "entity_id": ["T6"], "Age": {"text": [["60-yr-old"]], "start": [[2]], "entity_id": ["T10"]}, "Gender": {"text": [["woman"]], "start": [[12]], "entity_id": ["T11"]}}, "Treatment": {"text": [["paroxetine", "underwent excision of a chest wall myxofibrosarcoma and chest wall reconstruction"]], "start": [[34, 61]], "entity_id": ["T8"], "Drug": {"text": [["paroxetine"]], "start": [[34]], "entity_id": ["T12"]}, "Disorder": {"text": [["depression"], ["myxofibrosarcoma"]], "start": [[49], [96]], "entity_id": ["T13", "T14"]}}}]}]}
{"id": "7397053_2", "context": "Papilloedema and hepatic dysfunction apparently induced by perhexiline maleate (Pexid).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[48]], "entity_id": ["T8"]}, "Effect": {"text": [["Papilloedema and hepatic dysfunction"]], "start": [[0]], "entity_id": ["T7"]}, "Treatment": {"text": [["perhexiline maleate (Pexid)"]], "start": [[59]], "entity_id": ["T9"], "Drug": {"text": [["perhexiline maleate"]], "start": [[59]], "entity_id": ["T10"]}}}]}]}
{"id": "9103523_2", "context": "The volatile anesthetic halothane undergoes substantial biotransformation generating metabolites that mediate hepatotoxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["mediate"]], "start": [[102]], "entity_id": ["T6"]}, "Treatment": {"text": [["volatile anesthetic halothane"]], "start": [[4]], "entity_id": ["T5"], "Drug": {"text": [["halothane"]], "start": [[24]], "entity_id": ["T8"]}, "Route": {"text": [["volatile"]], "start": [[4]], "entity_id": ["T9"]}}, "Effect": {"text": [["hepatotoxicity"]], "start": [[110]], "entity_id": ["T7"]}}]}]}
{"id": "10803790_4", "context": "Case 4: A 61-year-old male alcoholic who remained completely abstinent while taking cyanamide for 3 years showed slight elevation of serum transaminases.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["taking"]], "start": [[77]], "entity_id": ["T3"]}, "Effect": {"text": [["elevation of serum transaminases"]], "start": [[120]], "entity_id": ["T5"]}, "Subject": {"text": [["61-year-old male alcoholic who remained completely abstinent"]], "start": [[10]], "entity_id": ["T6"], "Age": {"text": [["61-year-old"]], "start": [[10]], "entity_id": ["T7"]}, "Gender": {"text": [["male"]], "start": [[22]], "entity_id": ["T8"]}}, "Treatment": {"text": [["cyanamide for 3 years"]], "start": [[84]], "entity_id": ["T4"], "Drug": {"text": [["cyanamide"]], "start": [[84]], "entity_id": ["T11"]}, "Duration": {"text": [["3 years"]], "start": [[98]], "entity_id": ["T12"]}, "Disorder": {"text": [["alcoholic"]], "start": [[27]], "entity_id": ["T1"]}}}]}]}
{"id": "1261772_3", "context": "These observations indicate that submassive hepatic necrosis may result from treatment with propylthiouracil and are consistent with the notion that sensitization mechanisms may be responsible for the hepatic injury induced by this drug.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["result"]], "start": [[65]], "entity_id": ["T7"]}, "Effect": {"text": [["submassive hepatic necrosis"]], "start": [[33]], "entity_id": ["T5"]}, "Treatment": {"text": [["propylthiouracil"]], "start": [[92]], "entity_id": ["T6"], "Drug": {"text": [["propylthiouracil"]], "start": [[92]], "entity_id": ["T9"]}}}]}]}
{"id": "6197014_2", "context": "Two children with rheumatic fever developed anicteric hepatitis while on high-dose aspirin therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[34]], "entity_id": ["T6"]}, "Subject": {"text": [["Two children with rheumatic fever"]], "start": [[0]], "entity_id": ["T3"], "Population": {"text": [["Two"]], "start": [[0]], "entity_id": ["T7"]}, "Age": {"text": [["children"]], "start": [[4]], "entity_id": ["T8"]}}, "Effect": {"text": [["anicteric hepatitis"]], "start": [[44]], "entity_id": ["T4"]}, "Treatment": {"text": [["high-dose aspirin"]], "start": [[73]], "entity_id": ["T5"], "Disorder": {"text": [["rheumatic fever"]], "start": [[18]], "entity_id": ["T9"]}, "Drug": {"text": [["aspirin"]], "start": [[83]], "entity_id": ["T10"]}, "Dosage": {"text": [["high-dose"]], "start": [[73]], "entity_id": ["T11"]}}}]}]}
{"id": "12095907_1", "context": "The authors describe valproate-induced hyperammonemia and mental status changes in an 88-year-old man, the first known reported case in an elderly patient.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[31]], "entity_id": ["T7"]}, "Subject": {"text": [["an 88-year-old man"]], "start": [[83]], "entity_id": ["T5"], "Age": {"text": [["88-year-old"]], "start": [[86]], "entity_id": ["T9"]}, "Gender": {"text": [["man"]], "start": [[98]], "entity_id": ["T10"]}}, "Treatment": {"text": [["valproate"]], "start": [[21]], "entity_id": ["T6"], "Drug": {"text": [["valproate"]], "start": [[21]], "entity_id": ["T11"]}}, "Effect": {"text": [["hyperammonemia and mental status changes"]], "start": [[39]], "entity_id": ["T8"]}}]}]}
{"id": "9831311_5", "context": "The mechanism of the decrease in plasma potassium induced by phosphate treatment was investigated in a 24-year-old hypertensive patient with hypophosphatemic osteomalacia, who was the youngest of four patients, belonging to a 23 number kindred of five generations.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[50]], "entity_id": ["T4"]}, "Effect": {"text": [["decrease in plasma potassium"]], "start": [[21]], "entity_id": ["T3"]}, "Treatment": {"text": [["phosphate treatment"]], "start": [[61]], "entity_id": ["T5"], "Drug": {"text": [["phosphate"]], "start": [[61]], "entity_id": ["T10"]}, "Disorder": {"text": [["hypophosphatemic osteomalacia"]], "start": [[141]], "entity_id": ["T11"]}}, "Subject": {"text": [["a 24-year-old hypertensive patient with hypophosphatemic osteomalacia, who was the youngest of four patients, belonging to a 23 number kindred of five generations"]], "start": [[101]], "entity_id": ["T6"], "Age": {"text": [["24-year-old"]], "start": [[103]], "entity_id": ["T7"]}, "Disorder": {"text": [["hypertensive"]], "start": [[115]], "entity_id": ["T8"]}}}]}]}
{"id": "1722991_6", "context": "In the two cases, a combination of iloprost, a stable prostacyclin analogue (1 to 2 ng/kg/mn) with aspirin and dipyridamole was shown to inhibit ex vivo the heparin-induced platelet aggregation.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["inhibit ex vivo"]], "start": [[137]], "entity_id": ["T12"]}, "Subject": {"text": [["two cases"]], "start": [[7]], "entity_id": ["T11"], "Population": {"text": [["two"]], "start": [[7]], "entity_id": ["T14"]}}, "Treatment": {"text": [["iloprost, a stable prostacyclin analogue (1 to 2 ng/kg/mn) with aspirin and dipyridamole"]], "start": [[35]], "entity_id": ["T10"], "Disorder": {"text": [["heparin-induced platelet aggregation"]], "start": [[157]], "entity_id": ["T13"]}, "Dosage": {"text": [["1 to 2 ng/kg/mn"]], "start": [[77]], "entity_id": ["T16"]}, "Drug": {"text": [["iloprost"], ["aspirin"], ["dipyridamole"]], "start": [[35], [99], [111]], "entity_id": ["T15", "T17", "T18"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["with"]], "start": [[94]], "entity_id": ["T19"]}, "Drug": {"text": [["iloprost"], ["aspirin"], ["dipyridamole"]], "start": [[35], [99], [111]], "entity_id": ["T15", "T17", "T18"]}}]}}, {"event_id": "E3", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[165]], "entity_id": ["T1"]}, "Treatment": {"text": [["heparin"]], "start": [[157]], "entity_id": ["T2"], "Drug": {"text": [["heparin"]], "start": [[157]], "entity_id": ["T3"]}}, "Effect": {"text": [["platelet aggregation"]], "start": [[173]], "entity_id": ["T4"]}}]}]}
{"id": "3067748_1", "context": "Adrenaline dacryolith: detection by ultrasound examination of the nasolacrimal duct.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Adrenaline dacryolith"]], "start": [[0]], "entity_id": ["T5"]}, "Effect": {"text": [["dacryolith"]], "start": [[11]], "entity_id": ["T3"]}, "Treatment": {"text": [["Adrenaline"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Adrenaline"]], "start": [[0]], "entity_id": ["T6"]}, "Route": {"text": [["nasolacrimal duct"]], "start": [[66]], "entity_id": ["T7"]}}}]}]}
{"id": "16012330_7", "context": "Ten days after itraconazole was started, he developed paralytic ileus, neurogenic bladder, mild left ptosis, and absence of deep reflexes, with severe paralysis of the lower extremities and mild weakness of the upper extremities.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[44]], "entity_id": ["T9"]}, "Treatment": {"text": [["itraconazole"]], "start": [[15]], "entity_id": ["T8"], "Drug": {"text": [["itraconazole"]], "start": [[15]], "entity_id": ["T11"]}}, "Effect": {"text": [["paralytic ileus, neurogenic bladder, mild left ptosis, and absence of deep reflexes, with severe paralysis of the lower extremities and mild weakness of the upper extremities"]], "start": [[54]], "entity_id": ["T10"]}, "Severity": {"text": [["severe"], ["mild"], ["mild"]], "start": [[144], [190], [91]], "entity_id": ["T12", "T13", "T14"], "value": "Medium"}}]}]}
{"id": "11328247_3", "context": "OBJECTIVE: The aim of this paper is to describe a case of increased libido during fluvoxamine therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[75]], "entity_id": ["T3"]}, "Treatment": {"text": [["fluvoxamine therapy."]], "start": [[82]], "entity_id": ["T4"], "Drug": {"text": [["fluvoxamine"]], "start": [[82]], "entity_id": ["T6"]}}, "Effect": {"text": [["increased libido"]], "start": [[58]], "entity_id": ["T5"]}, "Subject": {"text": [["a case"]], "start": [[48]], "entity_id": ["T7"]}}]}]}
{"id": "11131346_3", "context": "An 8-year-old child with familial Mediterranean fever exhibited signs of colchicine intoxication while receiving prophylactic doses of the drug.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["exhibited"]], "start": [[54]], "entity_id": ["T10"]}, "Subject": {"text": [["An 8-year-old child"]], "start": [[0]], "entity_id": ["T6"], "Age": {"text": [["8-year-old"], ["child"]], "start": [[3], [14]], "entity_id": ["T11", "T12"]}}, "Effect": {"text": [["colchicine intoxication"]], "start": [[73]], "entity_id": ["T7"]}, "Treatment": {"text": [["prophylactic doses of the drug"]], "start": [[113]], "entity_id": ["T9"], "Dosage": {"text": [["prophylactic doses"]], "start": [[113]], "entity_id": ["T13"]}, "Disorder": {"text": [["familial Mediterranean fever"]], "start": [[25]], "entity_id": ["T14"]}, "Drug": {"text": [["colchicine"]], "start": [[73]], "entity_id": ["T8"]}}}]}]}
{"id": "11675845_9", "context": "Furthermore, the warfarin dose was again increased after discontinuation of ropinirole due to common gastrointestinal adverse effects.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["due to"]], "start": [[87]], "entity_id": ["T8"]}, "Treatment": {"text": [["the warfarin dose was again increased after discontinuation of ropinirole"]], "start": [[13]], "entity_id": ["T7"], "Disorder": {"text": [["gastrointestinal adverse effects"]], "start": [[101]], "entity_id": ["T6"]}, "Drug": {"text": [["warfarin"]], "start": [[17]], "entity_id": ["T9"]}}}]}]}
{"id": "25671244_1", "context": "Serotonin syndrome following metaxalone overdose and therapeutic use of a selective serotonin reuptake inhibitor.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[19]], "entity_id": ["T7"]}, "Effect": {"text": [["Serotonin syndrome"]], "start": [[0]], "entity_id": ["T6"]}, "Treatment": {"text": [["metaxalone overdose"]], "start": [[29]], "entity_id": ["T8"], "Drug": {"text": [["metaxalone"], ["selective serotonin reuptake inhibitor"]], "start": [[29], [74]], "entity_id": ["T9", "T11"]}, "Dosage": {"text": [["overdose"]], "start": [[40]], "entity_id": ["T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[49]], "entity_id": ["T12"]}, "Drug": {"text": [["metaxalone"], ["selective serotonin reuptake inhibitor"]], "start": [[29], [74]], "entity_id": ["T9", "T11"]}}]}}]}]}
{"id": "11700998_2", "context": "The aim of this report is to describe the clinical and electroencephalographic findings seen in an elderly woman without previous history of seizures who developed a nonconvulsive generalized status epilepticus following acute withdrawal of lorazepam.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[211]], "entity_id": ["T6"]}, "Subject": {"text": [["an elderly woman"]], "start": [[96]], "entity_id": ["T3"], "Age": {"text": [["elderly"]], "start": [[99]], "entity_id": ["T7"]}, "Gender": {"text": [["woman"]], "start": [[107]], "entity_id": ["T8"]}}, "Effect": {"text": [["nonconvulsive generalized status epilepticus"]], "start": [[166]], "entity_id": ["T4"]}, "Treatment": {"text": [["acute withdrawal of lorazepam"]], "start": [[221]], "entity_id": ["T5"], "Drug": {"text": [["lorazepam"]], "start": [[241]], "entity_id": ["T9"]}}}]}]}
{"id": "9634122_4", "context": "We describe a patient with androgen-independent prostate cancer in whom PSA continued to decrease for a period of 15 months after flutamide withdrawal.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[124]], "entity_id": ["T6"]}, "Subject": {"text": [["a patient with androgen-independent prostate cancer"]], "start": [[12]], "entity_id": ["T3"]}, "Effect": {"text": [["PSA continued to decrease for a period of 15 months"]], "start": [[72]], "entity_id": ["T4"]}, "Treatment": {"text": [["flutamide withdrawal"]], "start": [[130]], "entity_id": ["T5"], "Drug": {"text": [["flutamide"]], "start": [[130]], "entity_id": ["T8"]}, "Disorder": {"text": [["androgen-independent prostate cancer"]], "start": [[27]], "entity_id": ["T9"]}}}]}]}
{"id": "19203515_1", "context": "Acute renal failure following intravenous immunoglobulin therapy in a HIV-infected patient.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[20]], "entity_id": ["T5"]}, "Subject": {"text": [["a HIV-infected patient"]], "start": [[68]], "entity_id": ["T3"], "Disorder": {"text": [["HIV"]], "start": [[70]], "entity_id": ["T7"]}}, "Treatment": {"text": [["intravenous immunoglobulin therapy"]], "start": [[30]], "entity_id": ["T4"], "Drug": {"text": [["immunoglobulin"]], "start": [[42]], "entity_id": ["T8"]}, "Route": {"text": [["intravenous"]], "start": [[30]], "entity_id": ["T1"]}}, "Effect": {"text": [["Acute renal failure"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "17189581_11", "context": "After a total of four doses of linezolid, the patient reported further discomfort.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reported"]], "start": [[54]], "entity_id": ["T7"]}, "Treatment": {"text": [["a total of four doses of linezolid"]], "start": [[6]], "entity_id": ["T5"], "Drug": {"text": [["linezolid"]], "start": [[31]], "entity_id": ["T9"]}, "Dosage": {"text": [["four doses"]], "start": [[17]], "entity_id": ["T10"]}}, "Subject": {"text": [["the patient"]], "start": [[42]], "entity_id": ["T6"]}, "Effect": {"text": [["further discomfort"]], "start": [[63]], "entity_id": ["T8"]}}]}]}
{"id": "19018868_2", "context": "Although moderate myelosuppression is not uncommonly seen in patients treated with lenalidomide, aplastic anemia has not previously been reported to be associated with this agent.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[152]], "entity_id": ["T3"]}, "Treatment": {"text": [["lenalidomide"]], "start": [[83]], "entity_id": ["T5"], "Drug": {"text": [["lenalidomide"]], "start": [[83]], "entity_id": ["T6"]}}, "Effect": {"text": [["aplastic anemia"]], "start": [[97]], "entity_id": ["T4"]}, "Negated": {"text": [["not"]], "start": [[117]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "18176653_11", "context": "This paper contributed to the identification of possible reactions in the oral cavity due to antiretroviral medication.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[86]], "entity_id": ["T6"]}, "Treatment": {"text": [["antiretroviral medication"]], "start": [[93]], "entity_id": ["T5"], "Drug": {"text": [["antiretroviral medication"]], "start": [[93]], "entity_id": ["T8"]}}, "Effect": {"text": [["reactions in the oral cavity"]], "start": [[57]], "entity_id": ["T7"]}, "Speculated": {"text": [["possible"]], "start": [[48]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "2076372_1", "context": "Persistent light reactivity from systemic quinine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["from"]], "start": [[28]], "entity_id": ["T5"]}, "Effect": {"text": [["Persistent light reactivity"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["systemic quinine"]], "start": [[33]], "entity_id": ["T4"], "Drug": {"text": [["quinine"]], "start": [[42]], "entity_id": ["T6"]}}}]}]}
{"id": "15482394_2", "context": "Based on the clinical status of the patient, it was suspected that several conditions contributed to the abnormal hypersensitivity to warfarin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["to"]], "start": [[131]], "entity_id": ["T5"]}, "Effect": {"text": [["abnormal hypersensitivity"]], "start": [[105]], "entity_id": ["T3"]}, "Treatment": {"text": [["warfarin"]], "start": [[134]], "entity_id": ["T4"], "Drug": {"text": [["warfarin"]], "start": [[134]], "entity_id": ["T9"]}}, "Subject": {"text": [["the patient"]], "start": [[32]], "entity_id": ["T6"]}, "Speculated": {"text": [["suspected"]], "start": [[52]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "17852449_3", "context": "Treatment of APL in pregnancy is controversial as the use of ATRA has been questioned due to the teratogenic effect of retinoids.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[86]], "entity_id": ["T7"]}, "Treatment": {"text": [["retinoids"]], "start": [[119]], "entity_id": ["T8"], "Drug": {"text": [["retinoids"]], "start": [[119]], "entity_id": ["T11"]}}, "Effect": {"text": [["teratogenic effect"]], "start": [[97]], "entity_id": ["T9"]}, "Speculated": {"text": [["questioned"]], "start": [[75]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "2302898_1", "context": "Diazepam use by pregnant women can be associated with a later presentation of withdrawal symptoms in the neonate than that induced by the use of other drugs.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[38]], "entity_id": ["T6"]}, "Effect": {"text": [["later presentation of withdrawal symptoms in the neonate"]], "start": [[56]], "entity_id": ["T3"]}, "Subject": {"text": [["neonate"]], "start": [[105]], "entity_id": ["T4"], "Age": {"text": [["neonate"]], "start": [[105]], "entity_id": ["T7"]}}, "Treatment": {"text": [["Diazepam"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Diazepam"]], "start": [[0]], "entity_id": ["T8"]}}}]}]}
{"id": "17381671_3", "context": "A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[108]], "entity_id": ["T20"]}, "Subject": {"text": [["A 65-year-old patient"]], "start": [[0]], "entity_id": ["T17"], "Age": {"text": [["65-year-old"]], "start": [[2]], "entity_id": ["T21"]}}, "Treatment": {"text": [["chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram", "following initiation of fentanyl"]], "start": [[22, 233]], "entity_id": ["T18"], "Drug": {"text": [["citalopram"], ["fentanyl"]], "start": [[97], [257]], "entity_id": ["T22", "T25"]}, "Time_elapsed": {"text": [["chronically"]], "start": [[22]], "entity_id": ["T26"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["following"]], "start": [[233]], "entity_id": ["T24"]}, "Drug": {"text": [["citalopram"], ["fentanyl"]], "start": [[97], [257]], "entity_id": ["T22", "T25"]}}]}, "Effect": {"text": [["confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome"]], "start": [[118]], "entity_id": ["T19"]}}]}]}
{"id": "21712512_11", "context": "This case highlights rapid onset of adrenal insufficiency in a patient with CF-related liver disease treated briefly with a moderate CYP3A4 inhibitor.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["onset"]], "start": [[27]], "entity_id": ["T12"]}, "Subject": {"text": [["a patient with CF-related liver disease"]], "start": [[61]], "entity_id": ["T9"]}, "Treatment": {"text": [["briefly with a moderate CYP3A4 inhibitor"]], "start": [[109]], "entity_id": ["T10"], "Drug": {"text": [["CYP3A4 inhibitor"]], "start": [[133]], "entity_id": ["T14"]}, "Disorder": {"text": [["CF-related liver disease"]], "start": [[76]], "entity_id": ["T15"]}}, "Effect": {"text": [["rapid onset of adrenal insufficiency"]], "start": [[21]], "entity_id": ["T11"]}}]}]}
{"id": "847572_2", "context": "The biochemistry of paracetamol hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of paracetamol is remarked upon.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["remarked"]], "start": [[159]], "entity_id": ["T10"]}, "Subject": {"text": [["alcoholic patients"]], "start": [[95]], "entity_id": ["T7"]}, "Effect": {"text": [["hepatotoxic effects"]], "start": [[121]], "entity_id": ["T8"]}, "Treatment": {"text": [["paracetamol"]], "start": [[144]], "entity_id": ["T9"], "Drug": {"text": [["paracetamol"]], "start": [[144]], "entity_id": ["T5"]}}}]}]}
{"id": "12951892_2", "context": "The newborn manifested a four day course of lethargy with unexplained high lithium levels in the adult toxic range.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["manifested"]], "start": [[12]], "entity_id": ["T5"]}, "Effect": {"text": [["four day course of lethargy with unexplained high lithium levels"]], "start": [[25]], "entity_id": ["T3"]}, "Treatment": {"text": [["lithium"]], "start": [[75]], "entity_id": ["T4"], "Drug": {"text": [["lithium"]], "start": [[75]], "entity_id": ["T7"]}}, "Subject": {"text": [["newborn"]], "start": [[4]], "entity_id": ["T6"], "Age": {"text": [["newborn"]], "start": [[4]], "entity_id": ["T8"]}}}]}]}
{"id": "8891729_3", "context": "The occurrence of severe AIHA in CLL patients treated with fludarabine has been reported by several authors.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[46]], "entity_id": ["T3"]}, "Treatment": {"text": [["fludarabine"]], "start": [[59]], "entity_id": ["T4"], "Disorder": {"text": [["CLL"]], "start": [[33]], "entity_id": ["T7"]}, "Drug": {"text": [["fludarabine"]], "start": [[59]], "entity_id": ["T9"]}}, "Effect": {"text": [["severe AIHA"]], "start": [[18]], "entity_id": ["T5"]}, "Subject": {"text": [["CLL patients"]], "start": [[33]], "entity_id": ["T6"]}, "Severity": {"text": [["severe"]], "start": [[18]], "entity_id": ["T8"], "value": "High"}}]}]}
{"id": "19034138_4", "context": "Corneal endothelial dysfunction associated with amantadine toxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[32]], "entity_id": ["T4"]}, "Effect": {"text": [["Corneal endothelial dysfunction"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["amantadine"]], "start": [[48]], "entity_id": ["T5"], "Drug": {"text": [["amantadine"]], "start": [[48]], "entity_id": ["T6"]}}}]}]}
{"id": "1378497_4", "context": "We describe the development of cutaneous scleroderma in 3 patients coincident with the use of bleomycin in low cumulative doses of less than 100 U.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["development"]], "start": [[16]], "entity_id": ["T3"]}, "Effect": {"text": [["cutaneous scleroderma"]], "start": [[31]], "entity_id": ["T4"]}, "Subject": {"text": [["3 patients"]], "start": [[56]], "entity_id": ["T5"], "Population": {"text": [["3"]], "start": [[56]], "entity_id": ["T7"]}}, "Treatment": {"text": [["the use of bleomycin in low cumulative doses of less than 100 U"]], "start": [[83]], "entity_id": ["T6"], "Drug": {"text": [["bleomycin"]], "start": [[94]], "entity_id": ["T8"]}, "Dosage": {"text": [["less than 100 U"]], "start": [[131]], "entity_id": ["T9"]}}}]}]}
{"id": "10367184_3", "context": "This case suggests that sarcoidosis and pravastatin, two entities not frequently associated with myotonia, may interact in a synergistic manner to produce severe clinical myotonia in humans.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["interact"]], "start": [[111]], "entity_id": ["T4"]}, "Subject": {"text": [["humans."]], "start": [[183]], "entity_id": ["T6"]}, "Effect": {"text": [["severe clinical myotonia"]], "start": [[155]], "entity_id": ["T3"]}, "Treatment": {"text": [["pravastatin"]], "start": [[40]], "entity_id": ["T5"], "Drug": {"text": [["pravastatin"]], "start": [[40]], "entity_id": ["T10"]}}, "Speculated": {"text": [["may"]], "start": [[107]], "entity_id": ["T8"], "value": true}, "Severity": {"text": [["severe"]], "start": [[155]], "entity_id": ["T9"], "value": "Medium"}}]}]}
{"id": "7226916_2", "context": "Disopyramide-induced heart block.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[13]], "entity_id": ["T3"]}, "Treatment": {"text": [["Disopyramide"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Disopyramide"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["heart block"]], "start": [[21]], "entity_id": ["T5"]}}]}]}
{"id": "578255_2", "context": "Telescoped digits of the hands and feet developed in a 69-year-old male with severe chronic tophaceous gout during allopurinol treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[40]], "entity_id": ["T5"]}, "Subject": {"text": [["a 69-year-old male with severe chronic tophaceous gout"]], "start": [[53]], "entity_id": ["T3"], "Age": {"text": [["69-year-old"]], "start": [[55]], "entity_id": ["T7"]}, "Gender": {"text": [["male"]], "start": [[67]], "entity_id": ["T8"]}}, "Effect": {"text": [["Telescoped digits of the hands and feet"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["allopurinol treatment"]], "start": [[115]], "entity_id": ["T6"], "Disorder": {"text": [["severe chronic tophaceous gout"]], "start": [[77]], "entity_id": ["T10"]}, "Drug": {"text": [["allopurinol"]], "start": [[115]], "entity_id": ["T11"]}}}]}]}
{"id": "8742573_2", "context": "CONCLUSIONS: Jet-injection devices might constitute a helpful method to treat those patients affected by severe human insulin-induced lipoatrophy.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treat"]], "start": [[72]], "entity_id": ["T6"]}, "Treatment": {"text": [["Jet-injection devices"]], "start": [[13]], "entity_id": ["T5"], "Disorder": {"text": [["insulin-induced lipoatrophy"]], "start": [[118]], "entity_id": ["T10"]}, "Route": {"text": [["Jet-injection"]], "start": [[13]], "entity_id": ["T9"]}}, "Subject": {"text": [["patients"]], "start": [[84]], "entity_id": ["T8"]}, "Speculated": {"text": [["might"]], "start": [[35]], "entity_id": ["T7"], "value": true}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[126]], "entity_id": ["T13"]}, "Effect": {"text": [["lipoatrophy"]], "start": [[134]], "entity_id": ["T14"]}, "Treatment": {"text": [["insulin"]], "start": [[118]], "entity_id": ["T4"], "Drug": {"text": [["insulin"]], "start": [[118]], "entity_id": ["T12"]}}, "Severity": {"text": [["severe"]], "start": [[105]], "entity_id": ["T11"], "value": "High"}}]}]}
{"id": "20412003_6", "context": "We describe a relatively healthy, 9-year-old boy who developed a CA-MRSA skin and soft tissue infection and was treated with TMP-SMX.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[112]], "entity_id": ["T3"]}, "Treatment": {"text": [["TMP-SMX"]], "start": [[125]], "entity_id": ["T4"], "Disorder": {"text": [["CA-MRSA skin and soft tissue infection"]], "start": [[65]], "entity_id": ["T6"]}, "Drug": {"text": [["TMP-SMX"]], "start": [[125]], "entity_id": ["T9"]}}, "Subject": {"text": [["a relatively healthy, 9-year-old boy"]], "start": [[12]], "entity_id": ["T5"], "Age": {"text": [["9-year-old"]], "start": [[34]], "entity_id": ["T7"]}, "Gender": {"text": [["boy"]], "start": [[45]], "entity_id": ["T8"]}}}]}]}
{"id": "10897389_2", "context": "Recurrent septicemia with lethal outcome during and after cyclosporine therapy in severe ulcerative colitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[52]], "entity_id": ["T8"]}, "Treatment": {"text": [["cyclosporine"]], "start": [[58]], "entity_id": ["T6"], "Disorder": {"text": [["severe ulcerative colitis"]], "start": [[82]], "entity_id": ["T5"]}, "Drug": {"text": [["cyclosporine"]], "start": [[58]], "entity_id": ["T10"]}}, "Effect": {"text": [["Recurrent septicemia with lethal outcome"]], "start": [[0]], "entity_id": ["T7"]}, "Severity": {"text": [["lethal"]], "start": [[26]], "entity_id": ["T9"], "value": "High"}}]}]}
{"id": "14740795_2", "context": "Amifostine-induced fever: case report and review of the literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T4"]}, "Treatment": {"text": [["Amifostine"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Amifostine"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["fever"]], "start": [[19]], "entity_id": ["T5"]}}]}]}
{"id": "16767537_3", "context": "We report a patient who developed spontaneous splenic infarction after the use of sumatriptan for the treatment of migraine headache.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[24]], "entity_id": ["T4"]}, "Effect": {"text": [["spontaneous splenic infarction"]], "start": [[34]], "entity_id": ["T3"]}, "Subject": {"text": [["a patient"]], "start": [[10]], "entity_id": ["T5"]}, "Treatment": {"text": [["sumatriptan"]], "start": [[82]], "entity_id": ["T6"], "Disorder": {"text": [["migraine headache"]], "start": [[115]], "entity_id": ["T7"]}, "Drug": {"text": [["sumatriptan"]], "start": [[82]], "entity_id": ["T8"]}}}]}]}
{"id": "12590235_2", "context": "Hepatotoxicity associated with 6-thioguanine therapy for Crohn's disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[15]], "entity_id": ["T6"]}, "Effect": {"text": [["Hepatotoxicity"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["6-thioguanine"]], "start": [[31]], "entity_id": ["T4"], "Drug": {"text": [["6-thioguanine"]], "start": [[31]], "entity_id": ["T7"]}, "Disorder": {"text": [["Crohn's disease"]], "start": [[57]], "entity_id": ["T8"]}}}]}]}
{"id": "15694139_4", "context": "Neuropathy is a significant side effect of thalidomide therapy, which may limit its clinical use.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["side effect"]], "start": [[28]], "entity_id": ["T6"]}, "Effect": {"text": [["Neuropathy"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["thalidomide"]], "start": [[43]], "entity_id": ["T7"], "Drug": {"text": [["thalidomide"]], "start": [[43]], "entity_id": ["T8"]}}, "Severity": {"text": [["significant"]], "start": [[16]], "entity_id": ["T9"], "value": "High"}}]}]}
{"id": "6414095_5", "context": "A possible mechanism for focal neurological deficit in brain-damaged patients on phenytoin therapy is discussed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["mechanism"]], "start": [[11]], "entity_id": ["T10"]}, "Treatment": {"text": [["phenytoin therapy"]], "start": [[81]], "entity_id": ["T8"], "Drug": {"text": [["phenytoin"]], "start": [[81]], "entity_id": ["T12"]}, "Disorder": {"text": [["brain-damaged"]], "start": [[55]], "entity_id": ["T13"]}}, "Effect": {"text": [["focal neurological deficit"]], "start": [[25]], "entity_id": ["T9"]}, "Subject": {"text": [["brain-damaged patients"]], "start": [[55]], "entity_id": ["T1"]}, "Speculated": {"text": [["possible"]], "start": [[2]], "entity_id": ["T14"], "value": true}}]}]}
{"id": "11757641_1", "context": "Pulmonary toxicity with mefloquine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[19]], "entity_id": ["T5"]}, "Effect": {"text": [["Pulmonary toxicity"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["mefloquine"]], "start": [[24]], "entity_id": ["T4"], "Drug": {"text": [["mefloquine"]], "start": [[24]], "entity_id": ["T6"]}}}]}]}
{"id": "2327115_1", "context": "Ciprofloxacin is one drug that has been reported to cause interstitial nephritis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[52]], "entity_id": ["T4"]}, "Treatment": {"text": [["Ciprofloxacin"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Ciprofloxacin"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["interstitial nephritis"]], "start": [[58]], "entity_id": ["T5"]}}]}]}
{"id": "16945058_1", "context": "Acute renal failure during lisinopril and losartan therapy for proteinuria.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[20]], "entity_id": ["T5"]}, "Effect": {"text": [["Acute renal failure"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["lisinopril and losartan"]], "start": [[27]], "entity_id": ["T6"], "Disorder": {"text": [["proteinuria"]], "start": [[63]], "entity_id": ["T7"]}, "Drug": {"text": [["lisinopril"], ["losartan"]], "start": [[27], [42]], "entity_id": ["T8", "T9"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[38]], "entity_id": ["T10"]}, "Drug": {"text": [["lisinopril"], ["losartan"]], "start": [[27], [42]], "entity_id": ["T8", "T9"]}}]}}]}]}
{"id": "9497597_2", "context": "We present the first case of a patient with priapism after oral intake of the phenothiazine prothipendylhydrochloride.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[53]], "entity_id": ["T6"]}, "Subject": {"text": [["a patient"]], "start": [[29]], "entity_id": ["T3"]}, "Effect": {"text": [["priapism"]], "start": [[44]], "entity_id": ["T4"]}, "Treatment": {"text": [["oral intake of the phenothiazine prothipendylhydrochloride"]], "start": [[59]], "entity_id": ["T5"], "Drug": {"text": [["prothipendylhydrochloride"]], "start": [[92]], "entity_id": ["T7"]}, "Route": {"text": [["oral"]], "start": [[59]], "entity_id": ["T8"]}}}]}]}
{"id": "12811715_3", "context": "However, because diphenhydramine also exhibits type IA sodium channel blockade, cardiac toxicity is also possible.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["because"]], "start": [[9]], "entity_id": ["T5"]}, "Treatment": {"text": [["diphenhydramine"]], "start": [[17]], "entity_id": ["T3"], "Drug": {"text": [["diphenhydramine"]], "start": [[17]], "entity_id": ["T7"]}}, "Effect": {"text": [["also exhibits type IA sodium channel blockade, cardiac toxicity"]], "start": [[33]], "entity_id": ["T4"]}, "Speculated": {"text": [["also possible"]], "start": [[100]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "11399735_3", "context": "Ticlopidine-induced interstitial pulmonary disease: a case report.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[12]], "entity_id": ["T4"]}, "Treatment": {"text": [["Ticlopidine"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Ticlopidine"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["interstitial pulmonary disease"]], "start": [[20]], "entity_id": ["T5"]}}]}]}
{"id": "19226083_16", "context": "Linezolid is a popular choice of antibiotic, especially for the treatment of orthopedic-related MRSA infections.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatment"]], "start": [[64]], "entity_id": ["T6"]}, "Treatment": {"text": [["Linezolid"]], "start": [[0]], "entity_id": ["T5"], "Disorder": {"text": [["orthopedic-related MRSA infections"]], "start": [[77]], "entity_id": ["T7"]}, "Drug": {"text": [["Linezolid"]], "start": [[0]], "entity_id": ["T8"]}}}]}]}
{"id": "14711147_4", "context": "We present a case of photo-onycholysis in a patient treated with doxycycline for acne vulgaris.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[52]], "entity_id": ["T8"]}, "Treatment": {"text": [["doxycycline"]], "start": [[65]], "entity_id": ["T9"], "Drug": {"text": [["doxycycline"]], "start": [[65]], "entity_id": ["T11"]}, "Disorder": {"text": [["acne vulgaris"]], "start": [[81]], "entity_id": ["T12"]}}, "Subject": {"text": [["a patient"]], "start": [[42]], "entity_id": ["T7"]}, "Effect": {"text": [["photo-onycholysis"]], "start": [[21]], "entity_id": ["T10"]}}]}]}
{"id": "15097937_2", "context": "Anticonvulsant hypersensitivity syndrome associated with Bellamine S, a therapy for menopausal symptoms.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[41]], "entity_id": ["T4"]}, "Effect": {"text": [["Anticonvulsant hypersensitivity syndrome"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["Bellamine S, a therapy for menopausal symptoms"]], "start": [[57]], "entity_id": ["T5"], "Disorder": {"text": [["menopausal symptoms."]], "start": [[84]], "entity_id": ["T6"]}, "Drug": {"text": [["Bellamine S"]], "start": [[57]], "entity_id": ["T7"]}}}]}]}
{"id": "9161656_3", "context": "CASE SUMMARY: A 66-year-old white woman with a 10-year history of hypertension and bronchial asthma was switched from immediate-release verapamil hydrocloride 40 mg tid to sustained-release verapamil 240 mg/d po for better hypertension control.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["control"]], "start": [[236]], "entity_id": ["T9"]}, "Subject": {"text": [["A 66-year-old white woman with a 10-year history of hypertension and bronchial asthma"]], "start": [[14]], "entity_id": ["T8"], "Age": {"text": [["66-year-old"]], "start": [[16]], "entity_id": ["T12"]}, "Race": {"text": [["white"]], "start": [[28]], "entity_id": ["T13"]}, "Gender": {"text": [["woman"]], "start": [[34]], "entity_id": ["T14"]}, "Disorder": {"text": [["bronchial asthma"]], "start": [[83]], "entity_id": ["T16"]}}, "Treatment": {"text": [["switched from immediate-release verapamil hydrocloride 40 mg tid to sustained-release verapamil 240 mg/d po"]], "start": [[104]], "entity_id": ["T10"], "Disorder": {"text": [["hypertension"], ["hypertension"]], "start": [[66], [223]], "entity_id": ["T15", "T1"]}, "Drug": {"text": [["immediate-release verapamil hydrocloride"], ["sustained-release verapamil"]], "start": [[118], [172]], "entity_id": ["T11", "T17"]}, "Dosage": {"text": [["240 mg/d"], ["40 mg tid"]], "start": [[200], [159]], "entity_id": ["T18", "T19"]}, "Route": {"text": [["po"]], "start": [[209]], "entity_id": ["T22"]}}}]}]}
{"id": "18294121_3", "context": "Due to the severity of the rash, temozolomide was permanently discontinued.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Due"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["temozolomide"]], "start": [[33]], "entity_id": ["T3"], "Drug": {"text": [["temozolomide"]], "start": [[33]], "entity_id": ["T6"]}}, "Effect": {"text": [["rash"]], "start": [[27]], "entity_id": ["T5"]}, "Severity": {"text": [["severity"]], "start": [[11]], "entity_id": ["T7"], "value": "High"}}]}]}
{"id": "7835785_1", "context": "Ovarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy: a case report and review of the literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[102]], "entity_id": ["T6"]}, "Effect": {"text": [["Ovarian endometrioid carcinoma and endometriosis"]], "start": [[0]], "entity_id": ["T5"]}, "Subject": {"text": [["a postmenopausal breast cancer patient"]], "start": [[63]], "entity_id": ["T7"], "Disorder": {"text": [["postmenopausal"]], "start": [[65]], "entity_id": ["T9"]}}, "Treatment": {"text": [["tamoxifen therapy"]], "start": [[109]], "entity_id": ["T8"], "Drug": {"text": [["tamoxifen"]], "start": [[109]], "entity_id": ["T11"]}, "Disorder": {"text": [["breast cancer"]], "start": [[80]], "entity_id": ["T12"]}}}]}]}
{"id": "18585545_2", "context": "CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and insomnia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[197]], "entity_id": ["T22"]}, "Effect": {"text": [["central nervous system-related adverse effects, including headache, dizziness and insomnia"]], "start": [[203]], "entity_id": ["T23"]}, "Treatment": {"text": [["The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors"]], "start": [[12]], "entity_id": ["T24"], "Drug": {"text": [["levofloxacin"], ["sparfloxacin"], ["grepafloxacin"], ["trovafloxacin"], ["gatifloxacin"], ["moxifloxacin"]], "start": [[43], [57], [71], [86], [101], [118]], "entity_id": ["T25", "T26", "T27", "T28", "T29", "T30"]}}}]}]}
{"id": "18609153_1", "context": "Terlipressin-induced ventricular arrhythmia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[13]], "entity_id": ["T5"]}, "Treatment": {"text": [["Terlipressin"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Terlipressin"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["ventricular arrhythmia"]], "start": [[21]], "entity_id": ["T6"]}}]}]}
{"id": "17228132_4", "context": "CASE REPORT: We report a case of acute severe hepatitis resulting from erlotinib monotherapy in a patient with locally advanced pancreatic cancer.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulting"]], "start": [[56]], "entity_id": ["T7"]}, "Effect": {"text": [["acute severe hepatitis"]], "start": [[33]], "entity_id": ["T6"]}, "Treatment": {"text": [["erlotinib monotherapy"]], "start": [[71]], "entity_id": ["T8"], "Drug": {"text": [["erlotinib"]], "start": [[71]], "entity_id": ["T12"]}, "Disorder": {"text": [["locally advanced pancreatic cancer"]], "start": [[111]], "entity_id": ["T13"]}}, "Subject": {"text": [["a patient with locally advanced pancreatic cancer"]], "start": [[96]], "entity_id": ["T9"]}, "Severity": {"text": [["severe"]], "start": [[39]], "entity_id": ["T11"], "value": "High"}}]}]}
{"id": "16914372_1", "context": "We highlight two instances of systemic allergic reaction, and discuss the potential side effects of local aprotinin injections in the orthopaedic setting as well as the evidence base for its use.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["of"]], "start": [[97]], "entity_id": ["T5"]}, "Subject": {"text": [["two instances"]], "start": [[13]], "entity_id": ["T3"], "Population": {"text": [["two"]], "start": [[13]], "entity_id": ["T7"]}}, "Effect": {"text": [["systemic allergic reaction", "potential side effects"]], "start": [[30, 74]], "entity_id": ["T4"]}, "Treatment": {"text": [["aprotinin"]], "start": [[106]], "entity_id": ["T6"], "Drug": {"text": [["aprotinin"]], "start": [[106]], "entity_id": ["T9"]}, "Route": {"text": [["injections"]], "start": [[116]], "entity_id": ["T10"]}}, "Speculated": {"text": [["potential"]], "start": [[74]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "7962394_1", "context": "Acute pancreatitis associated with danazol treatment for endometriosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[19]], "entity_id": ["T3"]}, "Effect": {"text": [["Acute pancreatitis"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["danazol treatment"]], "start": [[35]], "entity_id": ["T5"], "Drug": {"text": [["danazol"]], "start": [[35]], "entity_id": ["T6"]}, "Disorder": {"text": [["endometriosis"]], "start": [[57]], "entity_id": ["T7"]}}, "Severity": {"text": [["Acute"]], "start": [[0]], "entity_id": ["T8"], "value": "High"}}]}]}
{"id": "14526130_2", "context": "CASE REPORT: We report the case of a 58 year old patient who, after 2 days of treatment with roxithromycin and betamethasone, manifested acute pancreatitis.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["manifested"]], "start": [[126]], "entity_id": ["T6"]}, "Subject": {"text": [["a 58 year old patient"]], "start": [[35]], "entity_id": ["T4"], "Age": {"text": [["58 year old"]], "start": [[37]], "entity_id": ["T8"]}}, "Treatment": {"text": [["after 2 days of treatment with roxithromycin", "betamethasone"]], "start": [[62, 111]], "entity_id": ["T5"], "Drug": {"text": [["roxithromycin"], ["betamethasone"]], "start": [[93], [111]], "entity_id": ["T9", "T10"]}, "Time_elapsed": {"text": [["2 days"]], "start": [[68]], "entity_id": ["T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[107]], "entity_id": ["T11"]}, "Drug": {"text": [["roxithromycin"], ["betamethasone"]], "start": [[93], [111]], "entity_id": ["T9", "T10"]}}]}, "Effect": {"text": [["acute pancreatitis"]], "start": [[137]], "entity_id": ["T7"]}}]}]}
{"id": "576675_3", "context": "It should be recognized that ibuprofen may be associated with salt and water retention in the same fashion as previously described with phenylbutazone and indomethacin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[46]], "entity_id": ["T6"]}, "Effect": {"text": [["salt and water retention"]], "start": [[62]], "entity_id": ["T5"]}, "Treatment": {"text": [["ibuprofen"]], "start": [[29]], "entity_id": ["T7"], "Drug": {"text": [["ibuprofen"], ["phenylbutazone"], ["indomethacin"]], "start": [[29], [136], [155]], "entity_id": ["T8", "T9", "T10"]}}, "Speculated": {"text": [["may"]], "start": [[39]], "entity_id": ["T11"], "value": true}}]}]}
{"id": "18459568_1", "context": "Gastric tumor, endometrial carcinoma and cervical adenocarcinoma in situ were detected after treatment with tamoxifen for breast cancer.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["detected"]], "start": [[78]], "entity_id": ["T10"]}, "Treatment": {"text": [["tamoxifen"]], "start": [[108]], "entity_id": ["T9"], "Disorder": {"text": [["breast cancer"]], "start": [[122]], "entity_id": ["T8"]}, "Drug": {"text": [["tamoxifen"]], "start": [[108]], "entity_id": ["T11"]}}, "Effect": {"text": [["Gastric tumor, endometrial carcinoma and cervical adenocarcinoma in situ"]], "start": [[0]], "entity_id": ["T7"]}}]}]}
{"id": "18665833_2", "context": "This therapy was also complicated by Warfarin-induced skin necrosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[46]], "entity_id": ["T4"]}, "Treatment": {"text": [["Warfarin"]], "start": [[37]], "entity_id": ["T3"], "Drug": {"text": [["Warfarin"]], "start": [[37]], "entity_id": ["T6"]}}, "Effect": {"text": [["skin necrosis"]], "start": [[54]], "entity_id": ["T5"]}}]}]}
{"id": "10048291_1", "context": "Immobilization, while Paget's bone disease was present, and perhaps enhanced activation of dihydrotachysterol by rifampicin, could have led to increased calcium-release into the circulation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["led"]], "start": [[136]], "entity_id": ["T5"]}, "Treatment": {"text": [["dihydrotachysterol"]], "start": [[91]], "entity_id": ["T4"], "Drug": {"text": [["dihydrotachysterol"]], "start": [[91]], "entity_id": ["T6"]}}, "Effect": {"text": [["increased calcium-release"]], "start": [[143]], "entity_id": ["T3"]}, "Speculated": {"text": [["enhanced"]], "start": [[68]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "8949576_2", "context": "Failure of plasmapheresis, corticosteroids and thionamides to ameliorate a case of protracted amiodarone-induced thyroiditis.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[105]], "entity_id": ["T3"]}, "Treatment": {"text": [["amiodarone"]], "start": [[94]], "entity_id": ["T4"], "Drug": {"text": [["amiodarone"]], "start": [[94]], "entity_id": ["T6"]}}, "Effect": {"text": [["thyroiditis"]], "start": [[113]], "entity_id": ["T5"]}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["ameliorate"]], "start": [[62]], "entity_id": ["T8"]}, "Treatment": {"text": [["plasmapheresis, corticosteroids and thionamides"]], "start": [[11]], "entity_id": ["T10"], "Disorder": {"text": [["amiodarone-induced thyroiditis"]], "start": [[94]], "entity_id": ["T13"]}, "Drug": {"text": [["corticosteroids"], ["thionamides"]], "start": [[27], [47]], "entity_id": ["T11", "T12"]}}, "Negated": {"text": [["Failure"]], "start": [[0]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "15162903_1", "context": "Although neurotoxicity is a frequent complication of methotrexate therapy, fatal acute neurotoxicity is extremely uncommon, especially in adults.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[37]], "entity_id": ["T6"]}, "Effect": {"text": [["neurotoxicity"]], "start": [[9]], "entity_id": ["T5"]}, "Treatment": {"text": [["methotrexate therapy"]], "start": [[53]], "entity_id": ["T7"], "Drug": {"text": [["methotrexate"]], "start": [[53]], "entity_id": ["T8"]}}}]}]}
{"id": "566977_3", "context": "Intravenous sodium bicarbonate appears to be indicated prophylactically in combating the associated metabolic acidosis due to absorbed formic acid.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[119]], "entity_id": ["T4"]}, "Effect": {"text": [["metabolic acidosis"]], "start": [[100]], "entity_id": ["T3"]}, "Treatment": {"text": [["absorbed formic acid"]], "start": [[126]], "entity_id": ["T5"], "Drug": {"text": [["formic acid"]], "start": [[135]], "entity_id": ["T7"]}}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["combating"]], "start": [[75]], "entity_id": ["T10"]}, "Treatment": {"text": [["Intravenous sodium bicarbonate"]], "start": [[0]], "entity_id": ["T9"], "Disorder": {"text": [["metabolic acidosis due to absorbed formic acid"]], "start": [[100]], "entity_id": ["T11"]}, "Route": {"text": [["Intravenous"]], "start": [[0]], "entity_id": ["T12"]}, "Drug": {"text": [["sodium bicarbonate"]], "start": [[12]], "entity_id": ["T13"]}}, "Speculated": {"text": [["appears to"]], "start": [[31]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "578255_1", "context": "Allopurinol-associated hand and foot deformities in chronic tophaceous gout.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[12]], "entity_id": ["T4"]}, "Treatment": {"text": [["Allopurinol"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Allopurinol"]], "start": [[0]], "entity_id": ["T7"]}, "Disorder": {"text": [["chronic tophaceous gout"]], "start": [[52]], "entity_id": ["T8"]}}, "Effect": {"text": [["hand and foot deformities"]], "start": [[23]], "entity_id": ["T5"]}}]}]}
{"id": "11022272_3", "context": "The intramuscular challenge test with 25 UI of Miacalcic was positive with an immediate anaphylactic reaction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reaction"]], "start": [[101]], "entity_id": ["T5"]}, "Treatment": {"text": [["25 UI of Miacalcic", "immediate"]], "start": [[38, 78]], "entity_id": ["T3"], "Drug": {"text": [["Miacalcic"]], "start": [[47]], "entity_id": ["T6"]}, "Dosage": {"text": [["25 UI"]], "start": [[38]], "entity_id": ["T7"]}, "Time_elapsed": {"text": [["immediate"]], "start": [[78]], "entity_id": ["T8"]}}, "Effect": {"text": [["anaphylactic reaction"]], "start": [[88]], "entity_id": ["T4"]}}]}]}
{"id": "19226083_4", "context": "There are several documented case reports of serotonin toxicity when used with selective serotonin reuptake inhibitors.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reports"]], "start": [[34]], "entity_id": ["T6"]}, "Treatment": {"text": [["selective serotonin reuptake inhibitors"]], "start": [[79]], "entity_id": ["T4"], "Drug": {"text": [["selective serotonin reuptake inhibitors"], ["serotonin"]], "start": [[79], [45]], "entity_id": ["T7", "T8"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["with"]], "start": [[74]], "entity_id": ["T9"]}, "Drug": {"text": [["selective serotonin reuptake inhibitors"], ["serotonin"]], "start": [[79], [45]], "entity_id": ["T7", "T8"]}}]}, "Effect": {"text": [["serotonin toxicity"]], "start": [[45]], "entity_id": ["T5"]}, "Subject": {"text": [["several documented case"]], "start": [[10]], "entity_id": ["T10"], "Population": {"text": [["several"]], "start": [[10]], "entity_id": ["T11"]}}}]}]}
{"id": "4082283_6", "context": "A literature review revealed 83 other reported cases of rifampicin-induced renal insufficiency.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[67]], "entity_id": ["T4"]}, "Treatment": {"text": [["rifampicin"]], "start": [[56]], "entity_id": ["T5"], "Drug": {"text": [["rifampicin"]], "start": [[56]], "entity_id": ["T9"]}}, "Effect": {"text": [["renal insufficiency"]], "start": [[75]], "entity_id": ["T6"]}, "Subject": {"text": [["83 other reported cases"]], "start": [[29]], "entity_id": ["T7"], "Population": {"text": [["83"]], "start": [[29]], "entity_id": ["T8"]}}}]}]}
{"id": "8485005_1", "context": "Complete regression of iatrogenic Kaposi's sarcoma due to corticosteroid treatment in a patient with tubercular pericarditis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["regression"]], "start": [[9]], "entity_id": ["T10"]}, "Treatment": {"text": [["corticosteroid"]], "start": [[58]], "entity_id": ["T9"], "Disorder": {"text": [["Kaposi's sarcoma"]], "start": [[34]], "entity_id": ["T12"]}, "Drug": {"text": [["corticosteroid"]], "start": [[58]], "entity_id": ["T11"]}}, "Subject": {"text": [["a patient with tubercular pericarditis"]], "start": [[86]], "entity_id": ["T7"], "Disorder": {"text": [["tubercular pericarditis"]], "start": [[101]], "entity_id": ["T8"]}}}]}]}
{"id": "16757971_1", "context": "DIAGNOSIS: Severe temozolomide-induced immunosuppression, exacerbated by corticosteroids, with profound T-cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[31]], "entity_id": ["T12"]}, "Treatment": {"text": [["temozolomide", "exacerbated by corticosteroids"]], "start": [[18, 58]], "entity_id": ["T11"], "Drug": {"text": [["temozolomide"], ["corticosteroids"]], "start": [[18], [73]], "entity_id": ["T18", "T19"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["exacerbated"]], "start": [[58]], "entity_id": ["T20"]}, "Drug": {"text": [["corticosteroids"], ["temozolomide"]], "start": [[73], [18]], "entity_id": ["T19", "T18"]}}]}, "Effect": {"text": [["immunosuppression"], ["T-cell lymphocytopenia"], ["Pneumocystis jiroveci pneumonia"], ["brain abscess with Listeria monocytogenes"], ["cutaneous Kaposi's sarcoma"]], "start": [[39], [104], [174], [207], [254]], "entity_id": ["T13", "T14", "T15", "T16", "T17"]}, "Severity": {"text": [["Severe"]], "start": [[11]], "entity_id": ["T21"], "value": "High"}}]}]}
{"id": "17163271_3", "context": "The use of cyclosporin has been associated with the development of cholelithiasis in transplant recipients.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["development"]], "start": [[52]], "entity_id": ["T3"]}, "Effect": {"text": [["cholelithiasis"]], "start": [[67]], "entity_id": ["T4"]}, "Subject": {"text": [["transplant recipients"]], "start": [[85]], "entity_id": ["T5"], "Disorder": {"text": [["transplant"]], "start": [[85]], "entity_id": ["T7"]}}, "Treatment": {"text": [["cyclosporin"]], "start": [[11]], "entity_id": ["T6"], "Drug": {"text": [["cyclosporin"]], "start": [[11]], "entity_id": ["T8"]}}}]}]}
{"id": "3200786_1", "context": "Rifampicin-induced adrenal insufficiency in the acquired immunodeficiency syndrome: difficulties in diagnosis and treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T6"]}, "Treatment": {"text": [["Rifampicin"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Rifampicin"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["adrenal insufficiency"]], "start": [[19]], "entity_id": ["T7"]}}]}]}
{"id": "19235747_2", "context": "Bisphosphonate-related osteonecrosis of the skull base.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[15]], "entity_id": ["T5"]}, "Treatment": {"text": [["Bisphosphonate"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Bisphosphonate"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["osteonecrosis of the skull base"]], "start": [[23]], "entity_id": ["T3"]}}]}]}
{"id": "14641354_1", "context": "Angioedema and dysphagia caused by contact allergy to inhaled budesonide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["inhaled"]], "start": [[54]], "entity_id": ["T7"]}, "Effect": {"text": [["contact allergy", "Angioedema and dysphagia"]], "start": [[35, 0]], "entity_id": ["T5"]}, "Treatment": {"text": [["budesonide"]], "start": [[62]], "entity_id": ["T6"], "Drug": {"text": [["budesonide"]], "start": [[62]], "entity_id": ["T8"]}}}]}]}
{"id": "12656748_2", "context": "Emergence of Philadelphia positive chronic myeloid leukaemia during treatment with hydroxyurea for Philadelphia negative essential thrombocythaemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treatment"]], "start": [[68]], "entity_id": ["T4"]}, "Effect": {"text": [["Emergence of Philadelphia positive chronic myeloid leukaemia"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["hydroxyurea"]], "start": [[83]], "entity_id": ["T5"], "Drug": {"text": [["hydroxyurea"]], "start": [[83]], "entity_id": ["T7"]}, "Disorder": {"text": [["Philadelphia negative essential thrombocythaemia"]], "start": [[99]], "entity_id": ["T8"]}}}]}]}
{"id": "15592331_1", "context": "Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["increases"]], "start": [[22]], "entity_id": ["T8"]}, "Treatment": {"text": [["Ciprofloxacin"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Ciprofloxacin"], ["tizanidine"]], "start": [[0], [73]], "entity_id": ["T9", "T10"]}}, "Effect": {"text": [["concentrations and hypotensive effect of tizanidine"]], "start": [[32]], "entity_id": ["T6"]}}]}]}
{"id": "10426918_1", "context": "2-CdA induces lymphocytopenia, which may explain the improvement in this patient's psoriasis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["induces"]], "start": [[6]], "entity_id": ["T4"]}, "Subject": {"text": [["patient's psoriasis"]], "start": [[73]], "entity_id": ["T3"]}, "Treatment": {"text": [["2-CdA"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["2-CdA"]], "start": [[0]], "entity_id": ["T7"]}, "Disorder": {"text": [["psoriasis"]], "start": [[83]], "entity_id": ["T10"]}}, "Effect": {"text": [["lymphocytopenia"]], "start": [[14]], "entity_id": ["T8"]}, "Speculated": {"text": [["may"]], "start": [[37]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "7831179_2", "context": "There is a dose-effect relationship between doxorubicin and the incidence of symptomatic cardiac failure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["relationship"]], "start": [[23]], "entity_id": ["T5"]}, "Treatment": {"text": [["doxorubicin"]], "start": [[44]], "entity_id": ["T3"], "Drug": {"text": [["doxorubicin"]], "start": [[44]], "entity_id": ["T6"]}}, "Effect": {"text": [["symptomatic cardiac failure"]], "start": [[77]], "entity_id": ["T4"]}}]}]}
{"id": "19145124_2", "context": "These are the first reported patients to show mfERG abnormalities that correspond to bitemporal visual field defects and add to the growing evidence that ethambutol damages the retina.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["evidence"]], "start": [[140]], "entity_id": ["T7"]}, "Treatment": {"text": [["ethambutol"]], "start": [[154]], "entity_id": ["T5"], "Drug": {"text": [["ethambutol"]], "start": [[154]], "entity_id": ["T8"]}}, "Effect": {"text": [["damages the retina"]], "start": [[165]], "entity_id": ["T6"]}}]}]}
{"id": "19949685_3", "context": "Two days after administration of Kalimate enema, he had profuse hematochezia, and a sigmoidoscopy showed diffuse colonic mucosal necrosis in the rectum and sigmoid colon.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[9]], "entity_id": ["T5"]}, "Treatment": {"text": [["Two days after administration of Kalimate enema"]], "start": [[0]], "entity_id": ["T6"], "Route": {"text": [["enema"]], "start": [[42]], "entity_id": ["T10"]}, "Drug": {"text": [["Kalimate"]], "start": [[33]], "entity_id": ["T11"]}, "Time_elapsed": {"text": [["Two days"]], "start": [[0]], "entity_id": ["T12"]}}, "Subject": {"text": [["he"]], "start": [[49]], "entity_id": ["T7"], "Gender": {"text": [["he"]], "start": [[49]], "entity_id": ["T9"]}}, "Effect": {"text": [["profuse hematochezia", "diffuse colonic mucosal necrosis in the rectum"]], "start": [[56, 105]], "entity_id": ["T8"]}}]}]}
{"id": "18191947_1", "context": "Conventional and diffusion-weighted MRI findings of methotrexate related sub-acute neurotoxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[65]], "entity_id": ["T4"]}, "Treatment": {"text": [["methotrexate"]], "start": [[52]], "entity_id": ["T3"], "Drug": {"text": [["methotrexate"]], "start": [[52]], "entity_id": ["T6"]}}, "Effect": {"text": [["sub-acute neurotoxicity"]], "start": [[73]], "entity_id": ["T5"]}}]}]}
{"id": "14760958_1", "context": "Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["on"]], "start": [[78]], "entity_id": ["T5"]}, "Treatment": {"text": [["interferon beta-1a"]], "start": [[81]], "entity_id": ["T3"], "Drug": {"text": [["interferon beta-1a"]], "start": [[81]], "entity_id": ["T9"]}, "Disorder": {"text": [["multiple sclerosis"]], "start": [[33]], "entity_id": ["T10"]}}, "Effect": {"text": [["Scleromyxedema"]], "start": [[0]], "entity_id": ["T4"]}, "Subject": {"text": [["a patient with multiple sclerosis and monoclonal gammopathy"]], "start": [[18]], "entity_id": ["T6"], "Disorder": {"text": [["monoclonal gammopathy"]], "start": [[56]], "entity_id": ["T8"]}}}]}]}
{"id": "9494448_8", "context": "The literature search revealed 22 cases of hypersensitivity reaction to cyclosporine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["to"]], "start": [[69]], "entity_id": ["T6"]}, "Subject": {"text": [["22 cases"]], "start": [[31]], "entity_id": ["T3"], "Population": {"text": [["22"]], "start": [[31]], "entity_id": ["T7"]}}, "Effect": {"text": [["hypersensitivity reaction"]], "start": [[43]], "entity_id": ["T4"]}, "Treatment": {"text": [["cyclosporine"]], "start": [[72]], "entity_id": ["T5"], "Drug": {"text": [["cyclosporine"]], "start": [[72]], "entity_id": ["T8"]}}}]}]}
{"id": "9184269_6", "context": "The presence of a lymphocyte alveolitis with a predominance of CD4+ T cells in 3 RA patients and CD8+ T cells with a concomitant increase in neutrophils in another case suggests that immunologically mediated reactions may be one damage mechanism in MTX-induced pneumonitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[253]], "entity_id": ["T4"]}, "Treatment": {"text": [["MTX"]], "start": [[249]], "entity_id": ["T3"], "Disorder": {"text": [["RA"]], "start": [[81]], "entity_id": ["T7"]}, "Drug": {"text": [["MTX"]], "start": [[249]], "entity_id": ["T9"]}}, "Effect": {"text": [["a lymphocyte alveolitis with a predominance of CD4+ T cells", "pneumonitis", "CD8+ T cells with a concomitant increase in neutrophils"]], "start": [[16, 261, 97]], "entity_id": ["T6"]}, "Subject": {"text": [["3 RA patients"]], "start": [[79]], "entity_id": ["T8"], "Population": {"text": [["3"]], "start": [[79]], "entity_id": ["T5"]}}}]}]}
{"id": "11972105_1", "context": "The authors report two cases of delayed elimination of methotrexate in patients receiving ciprofloxacin, with severe toxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["of"]], "start": [[52]], "entity_id": ["T9"]}, "Effect": {"text": [["delayed elimination"]], "start": [[32]], "entity_id": ["T6"]}, "Treatment": {"text": [["methotrexate"]], "start": [[55]], "entity_id": ["T7"], "Drug": {"text": [["methotrexate"]], "start": [[55]], "entity_id": ["T10"]}}, "Subject": {"text": [["patients receiving ciprofloxacin"]], "start": [[71]], "entity_id": ["T8"]}, "Severity": {"text": [["severe"]], "start": [[110]], "entity_id": ["T11"], "value": "High"}}]}]}
{"id": "2329972_2", "context": "Severe acute encephalopathy following inadvertent intrathecal doxorubicin administration.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[28]], "entity_id": ["T3"]}, "Effect": {"text": [["Severe acute encephalopathy"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["intrathecal doxorubicin administration"]], "start": [[50]], "entity_id": ["T5"], "Route": {"text": [["intrathecal"]], "start": [[50]], "entity_id": ["T7"]}, "Drug": {"text": [["doxorubicin"]], "start": [[62]], "entity_id": ["T8"]}}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T6"], "value": "High"}}]}]}
{"id": "11886466_2", "context": "Porcine factor VIII (pFVIII), which is used to control bleeding in patients with congenital or acquired haemophilia who have high-titre neutralizing antibodies to human FVIII, is not known to increase the risk of arterial or venous thrombosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["increase"]], "start": [[192]], "entity_id": ["T15"]}, "Effect": {"text": [["risk of arterial or venous thrombosis."]], "start": [[205]], "entity_id": ["T16"]}, "Treatment": {"text": [["Porcine factor VIII (pFVIII)"]], "start": [[0]], "entity_id": ["T17"], "Disorder": {"text": [["high-titre neutralizing antibodies to human FVIII"], ["bleeding"], ["congenital or acquired haemophilia"]], "start": [[125], [55], [81]], "entity_id": ["T21", "T28", "T19"]}, "Drug": {"text": [["Porcine factor VIII"]], "start": [[0]], "entity_id": ["T24"]}}, "Subject": {"text": [["patients with congenital or acquired haemophilia who have high-titre neutralizing antibodies to human FVIII"]], "start": [[67]], "entity_id": ["T18"]}, "Speculated": {"text": [["risk"]], "start": [[205]], "entity_id": ["T23"], "value": true}, "Negated": {"text": [["not"]], "start": [[179]], "entity_id": ["T22"], "value": true}}]}]}
{"id": "4031907_1", "context": "In all the patients, pellagra symptoms appeared during isoniazid therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["appeared"]], "start": [[39]], "entity_id": ["T5"]}, "Subject": {"text": [["all the patients"]], "start": [[3]], "entity_id": ["T3"]}, "Effect": {"text": [["pellagra symptoms"]], "start": [[21]], "entity_id": ["T4"]}, "Treatment": {"text": [["isoniazid therapy"]], "start": [[55]], "entity_id": ["T6"], "Drug": {"text": [["isoniazid"]], "start": [[55]], "entity_id": ["T7"]}}}]}]}
{"id": "19904536_1", "context": "Fatal gemcitabine-induced pulmonary toxicity in metastatic gallbladder adenocarcinoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[18]], "entity_id": ["T7"]}, "Treatment": {"text": [["gemcitabine"]], "start": [[6]], "entity_id": ["T6"], "Drug": {"text": [["gemcitabine"]], "start": [[6]], "entity_id": ["T9"]}, "Disorder": {"text": [["metastatic gallbladder adenocarcinoma"]], "start": [[48]], "entity_id": ["T11"]}}, "Effect": {"text": [["pulmonary toxicity"]], "start": [[26]], "entity_id": ["T10"]}, "Severity": {"text": [["Fatal"]], "start": [[0]], "entity_id": ["T12"], "value": "High"}}]}]}
{"id": "18801826_1", "context": "Olanzapine-induced hyperglycaemic coma and neuroleptic malignant syndrome: case report and review of literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T6"]}, "Treatment": {"text": [["Olanzapine"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Olanzapine"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["hyperglycaemic coma and neuroleptic malignant syndrome"]], "start": [[19]], "entity_id": ["T7"]}}]}]}
{"id": "15494638_20", "context": "Neurologic symptoms resolved after stopping CAP for 4 weeks in Patient A, with no recurrence after reinitiating CAP alone at 2000 mg/m2.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["after"]], "start": [[29]], "entity_id": ["T5"]}, "Effect": {"text": [["Neurologic symptoms resolved"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["stopping CAP for 4 weeks"]], "start": [[35]], "entity_id": ["T6"], "Drug": {"text": [["CAP"]], "start": [[44]], "entity_id": ["T7"]}, "Time_elapsed": {"text": [["4 weeks"]], "start": [[52]], "entity_id": ["T8"]}}}]}]}
{"id": "17381671_11", "context": "OBJECTIVE: To report a case of serotonin syndrome associated with interaction between fentanyl and citalopram, as evidenced by medication history, clinical features and reversal following discontinuation of fentanyl.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["interaction"]], "start": [[66]], "entity_id": ["T7"]}, "Subject": {"text": [["a case"]], "start": [[21]], "entity_id": ["T5"]}, "Effect": {"text": [["serotonin syndrome"]], "start": [[31]], "entity_id": ["T6"]}, "Treatment": {"text": [["fentanyl and citalopram"]], "start": [[86]], "entity_id": ["T8"], "Drug": {"text": [["fentanyl"], ["citalopram"]], "start": [[86], [99]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[95]], "entity_id": ["T11"]}, "Drug": {"text": [["fentanyl"], ["citalopram"]], "start": [[86], [99]], "entity_id": ["T9", "T10"]}}]}}]}]}
{"id": "17968817_2", "context": "We report (to our knowledge, for the first time in a child) the emergence of psychosis in a 12-year old white girl with an increased efavirenz concentration and heterozygous gene polymorphism of the CYP2B6-G516T.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["emergence"]], "start": [[64]], "entity_id": ["T4"]}, "Effect": {"text": [["psychosis"]], "start": [[77]], "entity_id": ["T3"]}, "Subject": {"text": [["a 12-year old white girl", "heterozygous gene polymorphism of the CYP2B6-G516T"]], "start": [[90, 161]], "entity_id": ["T5"], "Age": {"text": [["12-year old"]], "start": [[92]], "entity_id": ["T7"]}, "Race": {"text": [["white"]], "start": [[104]], "entity_id": ["T8"]}, "Gender": {"text": [["girl"]], "start": [[110]], "entity_id": ["T9"]}}, "Treatment": {"text": [["increased efavirenz concentration"]], "start": [[123]], "entity_id": ["T6"], "Drug": {"text": [["efavirenz"]], "start": [[133]], "entity_id": ["T10"]}}}]}]}
{"id": "12114387_2", "context": "Severe erythroderma as a complication of continuous epoprostenol therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[25]], "entity_id": ["T5"]}, "Effect": {"text": [["Severe erythroderma"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["continuous epoprostenol"]], "start": [[41]], "entity_id": ["T4"], "Drug": {"text": [["epoprostenol"]], "start": [[52]], "entity_id": ["T7"]}, "Freq": {"text": [["continuous"]], "start": [[41]], "entity_id": ["T8"]}}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T6"], "value": "Medium"}}]}]}
{"id": "18717612_2", "context": "FDE from cephalosporins has been rarely reported, and to the best of our knowledge there is no published report of ceftriaxone-induced FDE in the literature.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["from"]], "start": [[4]], "entity_id": ["T5"]}, "Effect": {"text": [["FDE"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["cephalosporins"]], "start": [[9]], "entity_id": ["T6"], "Drug": {"text": [["cephalosporins"]], "start": [[9]], "entity_id": ["T8"]}}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[127]], "entity_id": ["T10"]}, "Treatment": {"text": [["ceftriaxone"]], "start": [[115]], "entity_id": ["T12"], "Drug": {"text": [["ceftriaxone"]], "start": [[115]], "entity_id": ["T9"]}}, "Effect": {"text": [["FDE"]], "start": [[135]], "entity_id": ["T11"]}}]}]}
{"id": "12503933_3", "context": "CASE SUMMARY: A 58-year-old white woman developed fulminant liver failure while being treated with the macrolide antibiotic clarithromycin for pneumonia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[40]], "entity_id": ["T5"]}, "Subject": {"text": [["A 58-year-old white woman"]], "start": [[14]], "entity_id": ["T3"], "Age": {"text": [["58-year-old"]], "start": [[16]], "entity_id": ["T8"]}, "Race": {"text": [["white"]], "start": [[28]], "entity_id": ["T9"]}, "Gender": {"text": [["woman"]], "start": [[34]], "entity_id": ["T10"]}}, "Effect": {"text": [["fulminant liver failure"]], "start": [[50]], "entity_id": ["T4"]}, "Treatment": {"text": [["macrolide antibiotic clarithromycin for pneumonia"]], "start": [[103]], "entity_id": ["T6"], "Disorder": {"text": [["pneumonia"]], "start": [[143]], "entity_id": ["T11"]}, "Drug": {"text": [["clarithromycin"]], "start": [[124]], "entity_id": ["T7"]}}}]}]}
{"id": "10410183_10", "context": "CONCLUSIONS: Marked elevation of serum CK may be a possible complication of olanzapine therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[60]], "entity_id": ["T7"]}, "Effect": {"text": [["Marked elevation of serum CK"]], "start": [[13]], "entity_id": ["T5"]}, "Treatment": {"text": [["olanzapine therapy"]], "start": [[76]], "entity_id": ["T6"], "Drug": {"text": [["olanzapine"]], "start": [[76]], "entity_id": ["T8"]}}}]}]}
{"id": "12163813_2", "context": "OBJECTIVE: To describe a case of severe skin necrosis resulting from peripheral intravenous administration of low-dose vasopressin in a patient with catecholamine-resistant septic shock.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulting"]], "start": [[54]], "entity_id": ["T3"]}, "Subject": {"text": [["a patient with catecholamine-resistant septic shock"]], "start": [[134]], "entity_id": ["T4"]}, "Effect": {"text": [["skin necrosis"]], "start": [[40]], "entity_id": ["T5"]}, "Treatment": {"text": [["peripheral intravenous administration of low-dose vasopressin"]], "start": [[69]], "entity_id": ["T6"], "Route": {"text": [["peripheral intravenous administration"]], "start": [[69]], "entity_id": ["T9"]}, "Dosage": {"text": [["low-dose"]], "start": [[110]], "entity_id": ["T10"]}, "Drug": {"text": [["vasopressin"]], "start": [[119]], "entity_id": ["T11"]}, "Disorder": {"text": [["catecholamine-resistant septic shock"]], "start": [[149]], "entity_id": ["T12"]}}, "Severity": {"text": [["severe"]], "start": [[33]], "entity_id": ["T8"], "value": "High"}}]}]}
{"id": "8445549_1", "context": "Although the essential cause of PV is unclear, its onset has occasionally been associated with drug therapy, in particular penicillamine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[79]], "entity_id": ["T3"]}, "Treatment": {"text": [["penicillamine"]], "start": [[123]], "entity_id": ["T4"], "Drug": {"text": [["penicillamine"]], "start": [[123]], "entity_id": ["T8"]}}, "Effect": {"text": [["PV"]], "start": [[32]], "entity_id": ["T5"]}}]}]}
{"id": "8031432_1", "context": "Recurrent hypotension immediately after seizures in nortriptyline overdose.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[49]], "entity_id": ["T7"]}, "Effect": {"text": [["Recurrent hypotension immediately after seizures"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["nortriptyline overdose"]], "start": [[52]], "entity_id": ["T6"], "Drug": {"text": [["nortriptyline"]], "start": [[52]], "entity_id": ["T8"]}, "Dosage": {"text": [["overdose"]], "start": [[66]], "entity_id": ["T9"]}}}]}]}
{"id": "12460237_4", "context": "We report a patient with recurrent, increasingly severe episodes of PPE, ultimately complicated by a severe bullous eruption, following successive cycles of high-dose cytarabine for the treatment of acute lymphoblastic leukaemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[126]], "entity_id": ["T9"]}, "Subject": {"text": [["a patient"]], "start": [[10]], "entity_id": ["T8"]}, "Effect": {"text": [["recurrent, increasingly severe episodes of PPE, ultimately complicated by a severe bullous eruption"]], "start": [[25]], "entity_id": ["T12"]}, "Treatment": {"text": [["cycles of high-dose cytarabine for the treatment of acute lymphoblastic leukaemia"]], "start": [[147]], "entity_id": ["T10"], "Disorder": {"text": [["acute lymphoblastic leukaemia"]], "start": [[199]], "entity_id": ["T11"]}, "Dosage": {"text": [["high-dose"]], "start": [[157]], "entity_id": ["T14"]}, "Drug": {"text": [["cytarabine"]], "start": [[167]], "entity_id": ["T15"]}}, "Severity": {"text": [["severe"]], "start": [[101]], "entity_id": ["T13"], "value": "Medium"}}]}]}
{"id": "6408978_1", "context": "Intravenous diazepam exacerbated the seizures.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["exacerbated"]], "start": [[21]], "entity_id": ["T3"]}, "Effect": {"text": [["seizures"]], "start": [[37]], "entity_id": ["T4"]}, "Treatment": {"text": [["Intravenous diazepam"]], "start": [[0]], "entity_id": ["T5"], "Route": {"text": [["Intravenous"]], "start": [[0]], "entity_id": ["T6"]}, "Drug": {"text": [["diazepam"]], "start": [[12]], "entity_id": ["T7"]}}}]}]}
{"id": "12494253_1", "context": "After nine previous uncomplicated cycles she developed severe anaphylaxis to cisplatin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[45]], "entity_id": ["T4"]}, "Subject": {"text": [["she"]], "start": [[41]], "entity_id": ["T3"], "Gender": {"text": [["she"]], "start": [[41]], "entity_id": ["T7"]}}, "Effect": {"text": [["severe anaphylaxis"]], "start": [[55]], "entity_id": ["T5"]}, "Treatment": {"text": [["cisplatin"]], "start": [[77]], "entity_id": ["T6"], "Drug": {"text": [["cisplatin"]], "start": [[77]], "entity_id": ["T8"]}}}]}]}
{"id": "7937287_1", "context": "Cefuroxime-induced acute renal failure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T5"]}, "Treatment": {"text": [["Cefuroxime"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Cefuroxime"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["acute renal failure"]], "start": [[19]], "entity_id": ["T6"]}}]}]}
{"id": "11026106_3", "context": "We describe the clinical and liver biopsy morphologic features for 4 patients with minocycline-induced autoimmune hepatitis (group 1).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[95]], "entity_id": ["T5"]}, "Subject": {"text": [["4 patients"]], "start": [[67]], "entity_id": ["T3"], "Population": {"text": [["4"]], "start": [[67]], "entity_id": ["T7"]}}, "Treatment": {"text": [["minocycline"]], "start": [[83]], "entity_id": ["T4"], "Drug": {"text": [["minocycline"]], "start": [[83]], "entity_id": ["T8"]}}, "Effect": {"text": [["autoimmune hepatitis"]], "start": [[103]], "entity_id": ["T6"]}}]}]}
{"id": "16371793_1", "context": "Intravitreal triamcinolone acetonide for persisting cystoid macular edema after penetrating keratoplasty.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["for"]], "start": [[37]], "entity_id": ["T5"]}, "Treatment": {"text": [["ntravitreal triamcinolone acetonide"]], "start": [[1]], "entity_id": ["T6"], "Disorder": {"text": [["persisting cystoid macular edema"]], "start": [[41]], "entity_id": ["T9"]}, "Drug": {"text": [["triamcinolone acetonide"]], "start": [[13]], "entity_id": ["T7"]}, "Route": {"text": [["Intravitreal"]], "start": [[0]], "entity_id": ["T8"]}}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[74]], "entity_id": ["T12"]}, "Treatment": {"text": [["penetrating keratoplasty"]], "start": [[80]], "entity_id": ["T13"]}, "Effect": {"text": [["persisting cystoid macular edema"]], "start": [[41]], "entity_id": ["T4"]}, "Severity": {"text": [["persisting"]], "start": [[41]], "entity_id": ["T11"], "value": "High"}}]}]}
{"id": "24661191_4", "context": "We report a case of a 29-year-old liver transplant patient who suffered liver injury most likely induced by drug interaction between capecitabine and warfarin.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[97]], "entity_id": ["T9"]}, "Subject": {"text": [["a 29-year-old liver transplant patient"]], "start": [[20]], "entity_id": ["T8"], "Age": {"text": [["29-year-old"]], "start": [[22]], "entity_id": ["T13"]}, "Disorder": {"text": [["liver transplant"]], "start": [[34]], "entity_id": ["T14"]}}, "Effect": {"text": [["liver injury"]], "start": [[72]], "entity_id": ["T12"]}, "Treatment": {"text": [["drug interaction between capecitabine and warfarin"]], "start": [[108]], "entity_id": ["T10"], "Drug": {"text": [["capecitabine"], ["warfarin"]], "start": [[133], [150]], "entity_id": ["T15", "T16"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[113]], "entity_id": ["T17"]}, "Drug": {"text": [["capecitabine"], ["warfarin"]], "start": [[133], [150]], "entity_id": ["T15", "T16"]}}]}, "Speculated": {"text": [["most likely"]], "start": [[85]], "entity_id": ["T11"], "value": true}}]}]}
{"id": "11243427_3", "context": "DISCUSSION: Patients with 5-FU-induced ectropion experience tender, red, scaled lids, making contact lens wear difficult.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[31]], "entity_id": ["T6"]}, "Treatment": {"text": [["5-FU"]], "start": [[26]], "entity_id": ["T5"], "Drug": {"text": [["5-FU"]], "start": [[26]], "entity_id": ["T10"]}}, "Effect": {"text": [["ectropion"], ["tender, red, scaled lids"]], "start": [[39], [60]], "entity_id": ["T7", "T9"]}, "Subject": {"text": [["Patients with 5-FU-induced ectropion"]], "start": [[12]], "entity_id": ["T8"]}}]}]}
{"id": "15197722_3", "context": "Restless legs syndrome may thus be an adverse effect of IFN alpha treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["adverse effect"]], "start": [[38]], "entity_id": ["T3"]}, "Treatment": {"text": [["IFN alpha treatment."]], "start": [[56]], "entity_id": ["T4"], "Drug": {"text": [["IFN alpha"]], "start": [[56]], "entity_id": ["T7"]}}, "Effect": {"text": [["Restless legs syndrome"]], "start": [[0]], "entity_id": ["T5"]}, "Speculated": {"text": [["may"]], "start": [[23]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "11093071_2", "context": "Treatment of chronic hepatitis C with interferon alpha (IFN-alpha) is relatively contraindicated in patients with psychiatric disorders because of possible severe psychiatric side effects.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["contraindicated"]], "start": [[81]], "entity_id": ["T8"]}, "Treatment": {"text": [["interferon alpha (IFN-alpha)"]], "start": [[38]], "entity_id": ["T4"], "Disorder": {"text": [["chronic hepatitis C"]], "start": [[13]], "entity_id": ["T10"]}, "Drug": {"text": [["interferon alpha"]], "start": [[38]], "entity_id": ["T13"]}}, "Subject": {"text": [["patients with psychiatric disorders"]], "start": [[100]], "entity_id": ["T5"], "Disorder": {"text": [["psychiatric disorders"]], "start": [[114]], "entity_id": ["T9"]}}, "Effect": {"text": [["possible severe psychiatric side effects"]], "start": [[147]], "entity_id": ["T7"]}}]}]}
{"id": "9494448_6", "context": "METHODS: We report a patient who had an anaphylactic reaction during the intravenous infusion of cyclosporine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[62]], "entity_id": ["T6"]}, "Subject": {"text": [["a patient"]], "start": [[19]], "entity_id": ["T3"]}, "Effect": {"text": [["anaphylactic reaction"]], "start": [[40]], "entity_id": ["T4"]}, "Treatment": {"text": [["intravenous infusion of cyclosporine"]], "start": [[73]], "entity_id": ["T5"], "Drug": {"text": [["cyclosporine"]], "start": [[97]], "entity_id": ["T7"]}, "Route": {"text": [["intravenous infusion"]], "start": [[73]], "entity_id": ["T8"]}}}]}]}
{"id": "18721173_2", "context": "Gabapentin toxicity in renal failure: the importance of dose adjustment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["toxicity"]], "start": [[11]], "entity_id": ["T5"]}, "Treatment": {"text": [["Gabapentin"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Gabapentin"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["renal failure"]], "start": [[23]], "entity_id": ["T4"]}}]}]}
{"id": "16854757_1", "context": "We describe a case of a man treated with an EGFR-inhibitor (erlotinib) for a cell lung cancer who developed skin manifestations localized in an uncommon area and with an atypical evolution.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[98]], "entity_id": ["T3"]}, "Subject": {"text": [["a man"]], "start": [[22]], "entity_id": ["T4"], "Gender": {"text": [["man"]], "start": [[24]], "entity_id": ["T8"]}}, "Treatment": {"text": [["EGFR-inhibitor (erlotinib)"]], "start": [[44]], "entity_id": ["T5"], "Disorder": {"text": [["cell lung cancer"]], "start": [[77]], "entity_id": ["T6"]}, "Drug": {"text": [["EGFR-inhibitor"]], "start": [[44]], "entity_id": ["T9"]}}, "Effect": {"text": [["skin manifestations localized in an uncommon area and with an atypical evolution"]], "start": [[108]], "entity_id": ["T7"]}}]}]}
{"id": "15671134_4", "context": "We describe a case of clozapine-induced seizures in a patient with treatment-resistant schizophrenia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[32]], "entity_id": ["T4"]}, "Treatment": {"text": [["clozapine"]], "start": [[22]], "entity_id": ["T3"], "Drug": {"text": [["clozapine"]], "start": [[22]], "entity_id": ["T8"]}, "Disorder": {"text": [["treatment-resistant schizophrenia"]], "start": [[67]], "entity_id": ["T9"]}}, "Effect": {"text": [["seizures"]], "start": [[40]], "entity_id": ["T5"]}, "Subject": {"text": [["a patient with treatment-resistant schizophrenia"]], "start": [[52]], "entity_id": ["T6"]}}]}]}
{"id": "847572_3", "context": "Two fatal cases of poisoning by paracetamol are described.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["by"]], "start": [[29]], "entity_id": ["T3"]}, "Treatment": {"text": [["paracetamol"]], "start": [[32]], "entity_id": ["T4"], "Drug": {"text": [["paracetamol"]], "start": [[32]], "entity_id": ["T8"]}}, "Subject": {"text": [["Two fatal cases"]], "start": [[0]], "entity_id": ["T5"], "Population": {"text": [["Two"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["poisoning"]], "start": [[19]], "entity_id": ["T6"]}, "Severity": {"text": [["fatal"]], "start": [[4]], "entity_id": ["T9"], "value": "High"}}]}]}
{"id": "3470173_4", "context": "The neurotoxicity seen with HDARAC is dose-related and has occurred in up to 60 percent of treated patients.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[43]], "entity_id": ["T5"]}, "Effect": {"text": [["neurotoxicity"]], "start": [[4]], "entity_id": ["T3"]}, "Treatment": {"text": [["HDARAC"]], "start": [[28]], "entity_id": ["T4"], "Drug": {"text": [["HDARAC"]], "start": [[28]], "entity_id": ["T8"]}}, "Subject": {"text": [["60 percent of treated patients"]], "start": [[77]], "entity_id": ["T6"], "Population": {"text": [["60 percent"]], "start": [[77]], "entity_id": ["T7"]}}}]}]}
{"id": "11545487_5", "context": "The HIV protease inhibitor indinavir may cause nephrolithiasis and interstitial nephritis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[41]], "entity_id": ["T6"]}, "Treatment": {"text": [["HIV protease inhibitor indinavir"]], "start": [[4]], "entity_id": ["T5"], "Drug": {"text": [["indinavir"]], "start": [[27]], "entity_id": ["T8"]}}, "Effect": {"text": [["nephrolithiasis and interstitial nephritis"]], "start": [[47]], "entity_id": ["T7"]}, "Speculated": {"text": [["may"]], "start": [[37]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "9022114_1", "context": "BACKGROUND: Colchicine has a known adverse effect on wound healing through its inhibitory effect on tubulin-dependent cell functions and through collagenase activation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["adverse effect"]], "start": [[35]], "entity_id": ["T6"]}, "Treatment": {"text": [["Colchicine"]], "start": [[12]], "entity_id": ["T5"], "Drug": {"text": [["Colchicine"]], "start": [[12]], "entity_id": ["T8"]}}, "Effect": {"text": [["wound healing"]], "start": [[53]], "entity_id": ["T7"]}}]}]}
{"id": "1792646_1", "context": "Pneumocystis carinii pneumonia as a complication of methotrexate treatment of asthma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[36]], "entity_id": ["T4"]}, "Effect": {"text": [["Pneumocystis carinii pneumonia"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["methotrexate"]], "start": [[52]], "entity_id": ["T5"], "Drug": {"text": [["methotrexate"]], "start": [[52]], "entity_id": ["T6"]}, "Disorder": {"text": [["asthma"]], "start": [[78]], "entity_id": ["T7"]}}}]}]}
{"id": "14690166_5", "context": "2-CdA typically causes a long-lasting state of immunodeficiency and the profound influence of this drug on the immune system has raised questions concerning the emergence of secondary neoplasms after its use.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["causes"]], "start": [[16]], "entity_id": ["T10"]}, "Treatment": {"text": [["2-CdA"]], "start": [[0]], "entity_id": ["T9"], "Drug": {"text": [["2-CdA"]], "start": [[0]], "entity_id": ["T12"]}}, "Effect": {"text": [["a long-lasting state of immunodeficiency", "emergence of secondary neoplasms after its use"]], "start": [[23, 161]], "entity_id": ["T11"]}, "Speculated": {"text": [["questions"]], "start": [[136]], "entity_id": ["T13"], "value": true}}]}]}
{"id": "14700673_1", "context": "CONCLUSIONS: Topiramate may be associated with ciliochoroidal effusion with forward displacement of the lens-iris diaphragm and anterior chamber shallowing, resulting in acute myopia and angle-closure glaucoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulting"]], "start": [[157]], "entity_id": ["T12"]}, "Treatment": {"text": [["Topiramate"]], "start": [[13]], "entity_id": ["T11"], "Drug": {"text": [["Topiramate"]], "start": [[13]], "entity_id": ["T15"]}}, "Effect": {"text": [["acute myopia and angle-closure glaucoma"]], "start": [[170]], "entity_id": ["T13"]}}]}]}
{"id": "19745701_1", "context": "Increased awareness is needed on the possible occurrence of LPD resembling gastric cancer in rheumatoid arthritis patients treated with MTX.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurrence"]], "start": [[46]], "entity_id": ["T6"]}, "Effect": {"text": [["LPD"]], "start": [[60]], "entity_id": ["T3"]}, "Subject": {"text": [["rheumatoid arthritis patients"]], "start": [[93]], "entity_id": ["T4"]}, "Treatment": {"text": [["MTX"]], "start": [[136]], "entity_id": ["T5"], "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[93]], "entity_id": ["T7"]}, "Drug": {"text": [["MTX"]], "start": [[136]], "entity_id": ["T8"]}}}]}]}
{"id": "3195622_2", "context": "A dapsone hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[187]], "entity_id": ["T24"]}, "Treatment": {"text": [["dapsone"]], "start": [[2]], "entity_id": ["T21"], "Drug": {"text": [["dapsone"]], "start": [[2]], "entity_id": ["T25"]}, "Disorder": {"text": [["leprosy"]], "start": [[213]], "entity_id": ["T26"]}}, "Effect": {"text": [["hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis"]], "start": [[10]], "entity_id": ["T23"]}, "Subject": {"text": [["patients"]], "start": [[178]], "entity_id": ["T22"]}}]}]}
{"id": "16371793_11", "context": "CONCLUSIONS: Intravitreal injection of triamcinolone acetonide may be an additional tool in the treatment of therapy-resistant cystoid macular edema after penetrating keratoplasty.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatment"]], "start": [[96]], "entity_id": ["T6"]}, "Treatment": {"text": [["Intravitreal injection of triamcinolone acetonide"]], "start": [[13]], "entity_id": ["T4"], "Route": {"text": [["Intravitreal injection"]], "start": [[13]], "entity_id": ["T7"]}, "Drug": {"text": [["triamcinolone acetonide"]], "start": [[39]], "entity_id": ["T8"]}, "Disorder": {"text": [["therapy-resistant cystoid macular edema"]], "start": [[109]], "entity_id": ["T9"]}}}]}]}
{"id": "17458405_2", "context": "Since its FDA approval in 2002, there are no known citations of ezetimibe-induced pancreatitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[74]], "entity_id": ["T4"]}, "Treatment": {"text": [["ezetimibe"]], "start": [[64]], "entity_id": ["T3"], "Drug": {"text": [["ezetimibe"]], "start": [[64]], "entity_id": ["T6"]}}, "Effect": {"text": [["pancreatitis"]], "start": [[82]], "entity_id": ["T5"]}, "Negated": {"text": [["no"]], "start": [[42]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "7272895_2", "context": "Acute acoustic nerve palsy associated with vincristine therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[27]], "entity_id": ["T4"]}, "Treatment": {"text": [["vincristine therapy"]], "start": [[43]], "entity_id": ["T3"], "Drug": {"text": [["vincristine"]], "start": [[43]], "entity_id": ["T6"]}}, "Effect": {"text": [["Acute acoustic nerve palsy"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "17852449_6", "context": "Review of all reported cases of the use of ATRA in pregnancy revealed no serious adverse outcomes or congenital anomalies although only very few cases had exposure in the first trimester.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["revealed"]], "start": [[61]], "entity_id": ["T9"]}, "Treatment": {"text": [["ATRA"]], "start": [[43]], "entity_id": ["T7"], "Drug": {"text": [["ATRA"]], "start": [[43]], "entity_id": ["T13"]}}, "Subject": {"text": [["in pregnancy"]], "start": [[48]], "entity_id": ["T8"], "Disorder": {"text": [["pregnancy"]], "start": [[51]], "entity_id": ["T12"]}}, "Effect": {"text": [["adverse outcomes or congenital anomalies"]], "start": [[81]], "entity_id": ["T10"]}, "Negated": {"text": [["no"]], "start": [[70]], "entity_id": ["T14"], "value": true}}]}]}
{"id": "19857154_5", "context": "The first patient was a 57-year-old man with HIV and bipolar disease who developed rapid and severe weight gain when quetiapine was added to a stable atazanavir-ritonavir-based antiretroviral regimen.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[73]], "entity_id": ["T11"]}, "Subject": {"text": [["a 57-year-old man with HIV and bipolar disease"]], "start": [[22]], "entity_id": ["T10"], "Age": {"text": [["57-year-old"]], "start": [[24]], "entity_id": ["T14"]}, "Gender": {"text": [["man"]], "start": [[36]], "entity_id": ["T15"]}}, "Effect": {"text": [["rapid and severe weight gain"]], "start": [[83]], "entity_id": ["T12"]}, "Treatment": {"text": [["quetiapine was added to a stable atazanavir-ritonavir-based antiretroviral regimen"]], "start": [[117]], "entity_id": ["T13"], "Disorder": {"text": [["HIV"], ["bipolar disease"]], "start": [[45], [53]], "entity_id": ["T1", "T2"]}, "Drug": {"text": [["atazanavir"], ["ritonavir"], ["quetiapine"]], "start": [[150], [161], [117]], "entity_id": ["T4", "T5", "T6"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["added"]], "start": [[132]], "entity_id": ["T3"]}, "Drug": {"text": [["quetiapine"], ["atazanavir"], ["ritonavir"]], "start": [[117], [150], [161]], "entity_id": ["T6", "T4", "T5"]}}]}}]}]}
{"id": "17009081_1", "context": "A 43-year-old woman with multiple sclerosis (MS) had nephrotic syndrome 21 months after starting treatment with interferon (IFN)-beta-1b (subcutaneous administration).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["had"]], "start": [[49]], "entity_id": ["T6"]}, "Subject": {"text": [["A 43-year-old woman with multiple sclerosis (MS)"]], "start": [[0]], "entity_id": ["T3"], "Age": {"text": [["43-year-old"]], "start": [[2]], "entity_id": ["T7"]}, "Gender": {"text": [["woman"]], "start": [[14]], "entity_id": ["T8"]}}, "Effect": {"text": [["nephrotic syndrome"]], "start": [[53]], "entity_id": ["T4"]}, "Treatment": {"text": [["21 months after starting treatment with interferon (IFN)-beta-1b (subcutaneous administration)"]], "start": [[72]], "entity_id": ["T5"], "Disorder": {"text": [["multiple sclerosis"]], "start": [[25]], "entity_id": ["T9"]}, "Drug": {"text": [["interferon (IFN)-beta-1b"]], "start": [[112]], "entity_id": ["T10"]}, "Time_elapsed": {"text": [["21 months"]], "start": [[72]], "entity_id": ["T1"]}}}]}]}
{"id": "17444802_4", "context": "RESULTS: An 81-year-old man with a history of neoplasies of the colon and prostate and anticoagulant treatment was referred for treatment of an ocular surface neoplasia on his left eye.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["referred"]], "start": [[115]], "entity_id": ["T10"]}, "Treatment": {"text": [["anticoagulant"]], "start": [[87]], "entity_id": ["T8"], "Drug": {"text": [["anticoagulant"]], "start": [[87]], "entity_id": ["T13"]}, "Disorder": {"text": [["neoplasies of the colon and prostate"]], "start": [[46]], "entity_id": ["T7"]}}, "Effect": {"text": [["an ocular surface neoplasia on his left eye"]], "start": [[141]], "entity_id": ["T9"]}, "Subject": {"text": [["An 81-year-old man with a history of neoplasies of the colon and prostate"]], "start": [[9]], "entity_id": ["T6"], "Age": {"text": [["81-year-old"]], "start": [[12]], "entity_id": ["T11"]}, "Gender": {"text": [["man"]], "start": [[24]], "entity_id": ["T12"]}}}]}]}
{"id": "16421117_1", "context": "CONCLUSION: The present findings suggest that: (i) amantadine probably exerts its anti-dyskinetic effect by acting on the \"indirect\" pathway; (ii) the pathophysiological mechanisms of subthalamotomy induced dyskinesias may differ from those involved in L-dopa induced dyskinesias; (iii) dyskinesias induced by STN surgery resolve spontaneously as compensatory mechanisms develop.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["exerts"]], "start": [[71]], "entity_id": ["T4"]}, "Treatment": {"text": [["amantadine"]], "start": [[51]], "entity_id": ["T3"], "Drug": {"text": [["amantadine"]], "start": [[51]], "entity_id": ["T7"]}}, "Effect": {"text": [["anti-dyskinetic effect"]], "start": [[82]], "entity_id": ["T5"]}, "Speculated": {"text": [["probably"]], "start": [[62]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "15097937_3", "context": "We report a case of a previously healthy, postmenopausal woman who developed anticonvulsant hypersensitivity syndrome while taking Bellamine S (belladonna alkaloids; ergotamine; phenobarbital) for hot flashes.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[67]], "entity_id": ["T7"]}, "Subject": {"text": [["a previously healthy, postmenopausal woman"]], "start": [[20]], "entity_id": ["T6"], "Gender": {"text": [["woman"]], "start": [[57]], "entity_id": ["T11"]}}, "Effect": {"text": [["anticonvulsant hypersensitivity syndrome"]], "start": [[77]], "entity_id": ["T8"]}, "Treatment": {"text": [["Bellamine S (belladonna alkaloids; ergotamine; phenobarbital)"]], "start": [[131]], "entity_id": ["T9"], "Disorder": {"text": [["hot flashes"]], "start": [[197]], "entity_id": ["T12"]}, "Drug": {"text": [["Bellamine S"], ["belladonna alkaloids"], ["ergotamine"], ["phenobarbital"]], "start": [[131], [144], [166], [178]], "entity_id": ["T13", "T14", "T15", "T16"]}}}]}]}
{"id": "2332596_3", "context": "Skin rash began after 2 weeks of treatment, and signs of hepatocellular failure developed 3 weeks after phenobarbital had been started.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[80]], "entity_id": ["T6"]}, "Effect": {"text": [["Skin rash", "hepatocellular failure"]], "start": [[0, 57]], "entity_id": ["T5"]}, "Treatment": {"text": [["phenobarbital"]], "start": [[104]], "entity_id": ["T7"], "Time_elapsed": {"text": [["3 weeks"], ["2 weeks"]], "start": [[90], [22]], "entity_id": ["T8", "T9"]}, "Drug": {"text": [["phenobarbital"]], "start": [[104]], "entity_id": ["T10"]}}}]}]}
{"id": "10461415_1", "context": "Ceftriaxone was approved in 1997 for the treatment of otitis media despite previous studies that documented an association of ceftriaxone with elevated hepato-biliary enzymes and transient biliary stasis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["association of"]], "start": [[111]], "entity_id": ["T5"]}, "Effect": {"text": [["elevated hepato-biliary enzymes and transient biliary stasis"]], "start": [[143]], "entity_id": ["T7"]}, "Treatment": {"text": [["ceftriaxone"]], "start": [[126]], "entity_id": ["T6"], "Disorder": {"text": [["otitis media"]], "start": [[54]], "entity_id": ["T8"]}, "Drug": {"text": [["ceftriaxone"]], "start": [[126]], "entity_id": ["T9"]}}}]}]}
{"id": "11487721_2", "context": "A rare case of advanced ovarian carcinoma who developed difficulty walking 25 days after treatment with weekly paclitaxel.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[46]], "entity_id": ["T5"]}, "Effect": {"text": [["difficulty walking"]], "start": [[56]], "entity_id": ["T4"]}, "Treatment": {"text": [["25 days after treatment with weekly paclitaxel"]], "start": [[75]], "entity_id": ["T6"], "Disorder": {"text": [["advanced ovarian carcinoma"]], "start": [[15]], "entity_id": ["T3"]}, "Time_elapsed": {"text": [["25 days"]], "start": [[75]], "entity_id": ["T7"]}, "Freq": {"text": [["weekly"]], "start": [[104]], "entity_id": ["T8"]}, "Drug": {"text": [["paclitaxel"]], "start": [[111]], "entity_id": ["T9"]}}, "Subject": {"text": [["A rare case of advanced ovarian carcinoma"]], "start": [[0]], "entity_id": ["T10"]}}]}]}
{"id": "7919557_5", "context": "We report a case of cough following the administration of quinapril, with complete resolution after changing to the alternative ACE inhibitor fosinopril in a patient with essential hypertension.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[26]], "entity_id": ["T4"]}, "Effect": {"text": [["cough"]], "start": [[20]], "entity_id": ["T3"]}, "Treatment": {"text": [["the administration of quinapril"]], "start": [[36]], "entity_id": ["T5"], "Drug": {"text": [["quinapril"]], "start": [[58]], "entity_id": ["T7"]}, "Disorder": {"text": [["hypertension"]], "start": [[181]], "entity_id": ["T9"]}}, "Subject": {"text": [["patient with essential hypertension"]], "start": [[158]], "entity_id": ["T8"]}}]}]}
{"id": "7321956_1", "context": "Liver disease induced by perhexiline maleate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced by"]], "start": [[14]], "entity_id": ["T4"]}, "Effect": {"text": [["Liver disease"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["perhexiline maleate"]], "start": [[25]], "entity_id": ["T5"], "Drug": {"text": [["perhexiline maleate"]], "start": [[25]], "entity_id": ["T6"]}}}]}]}
{"id": "7606071_6", "context": "OBJECTIVE: To report the occurrence of anaphylactoid reactions to intraperitoneal cisplatin in 3 patients.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["to"]], "start": [[63]], "entity_id": ["T3"]}, "Treatment": {"text": [["intraperitoneal cisplatin"]], "start": [[66]], "entity_id": ["T4"], "Drug": {"text": [["cisplatin"]], "start": [[82]], "entity_id": ["T8"]}, "Route": {"text": [["intraperitoneal"]], "start": [[66]], "entity_id": ["T9"]}}, "Subject": {"text": [["3 patients."]], "start": [[95]], "entity_id": ["T5"], "Population": {"text": [["3"]], "start": [[95]], "entity_id": ["T7"]}}, "Effect": {"text": [["anaphylactoid reactions"]], "start": [[39]], "entity_id": ["T6"]}}]}]}
{"id": "2329972_1", "context": "In a female with acute lymphoblastic leukemia, inadvertent doxorubicin administration intrathecally caused severe, life-threatening, acute encephalopathy with high-pressure hydrocephalus.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[100]], "entity_id": ["T7"]}, "Subject": {"text": [["female with acute lymphoblastic leukemia"]], "start": [[5]], "entity_id": ["T5"], "Gender": {"text": [["female"]], "start": [[5]], "entity_id": ["T10"]}}, "Effect": {"text": [["severe, life-threatening, acute encephalopathy with high-pressure hydrocephalus"]], "start": [[107]], "entity_id": ["T8"]}, "Treatment": {"text": [["inadvertent doxorubicin administration intrathecally"]], "start": [[47]], "entity_id": ["T11"], "Drug": {"text": [["doxorubicin"]], "start": [[59]], "entity_id": ["T12"]}, "Disorder": {"text": [["acute lymphoblastic leukemia"]], "start": [[17]], "entity_id": ["T13"]}, "Route": {"text": [["intrathecally"]], "start": [[86]], "entity_id": ["T14"]}}, "Severity": {"text": [["severe, life-threatening, acute"]], "start": [[107]], "entity_id": ["T15"], "value": "High"}}]}]}
{"id": "12932249_2", "context": "These skin lesions may be induced or worsened during antiviral therapy with interferon-alpha (IFN).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[26]], "entity_id": ["T6"]}, "Effect": {"text": [["skin lesions"]], "start": [[6]], "entity_id": ["T4"]}, "Treatment": {"text": [["antiviral therapy with interferon-alpha (IFN)"]], "start": [[53]], "entity_id": ["T5"], "Drug": {"text": [["interferon-alpha (IFN)."]], "start": [[76]], "entity_id": ["T7"]}}, "Speculated": {"text": [["may"]], "start": [[19]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "11144696_12", "context": "Clinicians should be aware of the proepileptogenic effect of venlafaxine and trimipramine at therapeutic doses and that this combination may eventually increase the risk of seizures.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["eventually"]], "start": [[141]], "entity_id": ["T12"]}, "Effect": {"text": [["increase the risk of seizures"]], "start": [[152]], "entity_id": ["T10"]}, "Treatment": {"text": [["venlafaxine and trimipramine at therapeutic doses"]], "start": [[61]], "entity_id": ["T11"], "Drug": {"text": [["venlafaxine"], ["trimipramine"]], "start": [[61], [77]], "entity_id": ["T13", "T14"]}, "Dosage": {"text": [["therapeutic doses"]], "start": [[93]], "entity_id": ["T17"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[73]], "entity_id": ["T15"]}, "Drug": {"text": [["venlafaxine"], ["trimipramine"]], "start": [[61], [77]], "entity_id": ["T13", "T14"]}}]}, "Speculated": {"text": [["may"]], "start": [[137]], "entity_id": ["T18"], "value": true}}]}]}
{"id": "16298824_6", "context": "We report the case of a 43-year-old man with ITP refractory to steroids and intravenous immunoglobulin who developed acute respiratory distress syndrome (ARDS) after a single infusion of rituximab.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[107]], "entity_id": ["T6"]}, "Treatment": {"text": [["single infusion of rituximab"]], "start": [[168]], "entity_id": ["T5"], "Route": {"text": [["infusion"]], "start": [[175]], "entity_id": ["T12"]}, "Drug": {"text": [["rituximab"]], "start": [[187]], "entity_id": ["T13"]}, "Disorder": {"text": [["ITP"]], "start": [[45]], "entity_id": ["T1"]}}, "Effect": {"text": [["acute respiratory distress syndrome (ARDS)"]], "start": [[117]], "entity_id": ["T7"]}, "Subject": {"text": [["the case of a 43-year-old man with ITP refractory to steroids and intravenous immunoglobulin"]], "start": [[10]], "entity_id": ["T8"], "Age": {"text": [["43-year-old"]], "start": [[24]], "entity_id": ["T9"]}, "Gender": {"text": [["man"]], "start": [[36]], "entity_id": ["T10"]}, "Disorder": {"text": [["refractory to steroids and intravenous immunoglobulin"]], "start": [[49]], "entity_id": ["T11"]}}}]}]}
{"id": "16573370_6", "context": "She had been prescribed two mood stabilizers and suffered from anticholinergic adverse effects and the movement disorder tardive dyskinesia (TD).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["suffered from"]], "start": [[49]], "entity_id": ["T10"]}, "Treatment": {"text": [["prescribed two mood stabilizers"]], "start": [[13]], "entity_id": ["T8"], "Drug": {"text": [["mood stabilizers"]], "start": [[28]], "entity_id": ["T11"]}}, "Effect": {"text": [["anticholinergic adverse effects and the movement disorder tardive dyskinesia (TD)"]], "start": [[63]], "entity_id": ["T9"]}}]}]}
{"id": "19357764_1", "context": "CASE REPORT: We describe here a case of a 60 year old female that experienced a relapse of symptomatic hyperlactatemia after being switched from stavudine to zidovudine and how the case was managed at the Infectious Diseases Institute, Kampala, Uganda.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[119]], "entity_id": ["T8"]}, "Subject": {"text": [["a case of a 60 year old female"]], "start": [[30]], "entity_id": ["T4"], "Age": {"text": [["60 year old"]], "start": [[42]], "entity_id": ["T5"]}, "Gender": {"text": [["female"]], "start": [[54]], "entity_id": ["T9"]}}, "Effect": {"text": [["relapse of symptomatic hyperlactatemia"]], "start": [[80]], "entity_id": ["T6"]}, "Treatment": {"text": [["switched from stavudine to zidovudine"]], "start": [[131]], "entity_id": ["T7"], "Drug": {"text": [["stavudine"], ["zidovudine"]], "start": [[145], [158]], "entity_id": ["T10", "T11"]}}}]}]}
{"id": "2743258_1", "context": "This report describes two patients who developed acute myelocytic leukemia only after exposure to cyclophosphamide, methotrexate, and 5-fluorouracil adjuvant therapy.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[39]], "entity_id": ["T6"]}, "Subject": {"text": [["two patients"]], "start": [[22]], "entity_id": ["T5"], "Population": {"text": [["two"]], "start": [[22]], "entity_id": ["T9"]}}, "Effect": {"text": [["acute myelocytic leukemia"]], "start": [[49]], "entity_id": ["T7"]}, "Treatment": {"text": [["exposure to cyclophosphamide, methotrexate, and 5-fluorouracil adjuvant therapy"]], "start": [[86]], "entity_id": ["T8"], "Drug": {"text": [["cyclophosphamide"], ["methotrexate"], ["5-fluorouracil"]], "start": [[98], [116], [134]], "entity_id": ["T10", "T11", "T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[130]], "entity_id": ["T13"]}, "Drug": {"text": [["5-fluorouracil"], ["cyclophosphamide"], ["methotrexate"]], "start": [[134], [98], [116]], "entity_id": ["T12", "T10", "T11"]}}]}}]}]}
{"id": "1694575_1", "context": "Reversible corneal keratinization following trabeculectomy and treatment with 5-fluorouracil.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[34]], "entity_id": ["T4"]}, "Effect": {"text": [["Reversible corneal keratinization"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["5-fluorouracil"]], "start": [[78]], "entity_id": ["T5"], "Drug": {"text": [["5-fluorouracil."]], "start": [[78]], "entity_id": ["T6"]}}}]}]}
{"id": "8742573_1", "context": "CASE: We report a case of a woman with severe human insulin-induced lipoatrophy who has been treated exclusively with recombinant DNA human insulin since the onset of IDDM.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[93]], "entity_id": ["T7"]}, "Treatment": {"text": [["recombinant DNA human insulin"]], "start": [[118]], "entity_id": ["T4"], "Drug": {"text": [["recombinant DNA human insulin"]], "start": [[118]], "entity_id": ["T11"]}}, "Subject": {"text": [["woman"]], "start": [[28]], "entity_id": ["T5"], "Gender": {"text": [["woman"]], "start": [[28]], "entity_id": ["T8"]}}, "Effect": {"text": [["severe human insulin-induced lipoatrophy"]], "start": [[39]], "entity_id": ["T6"]}, "Severity": {"text": [["severe"]], "start": [[39]], "entity_id": ["T9"], "value": "High"}}]}]}
{"id": "16923659_6", "context": "METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, divalproex sodium, risperidone, and carbamazepine) presenting with mixed SS/NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["presenting"]], "start": [[123]], "entity_id": ["T15"]}, "Treatment": {"text": [["a poly-drug overdose (venlafaxine, topiramate, divalproex sodium, risperidone, and carbamazepine)"]], "start": [[25]], "entity_id": ["T13"], "Drug": {"text": [["venlafaxine"], ["topiramate"], ["divalproex sodium"], ["risperidone"], ["carbamazepine"]], "start": [[47], [60], [72], [91], [108]], "entity_id": ["T16", "T17", "T18", "T19", "T20"]}, "Dosage": {"text": [["overdose"]], "start": [[37]], "entity_id": ["T21"]}}, "Effect": {"text": [["mixed SS/NMS features"]], "start": [[139]], "entity_id": ["T14"]}}]}]}
{"id": "17526968_2", "context": "Hyperpigmentation is one of the cutaneous side effects of chemotherapautic agents, but it is usually accepted as a cosmetic problem.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["of"]], "start": [[55]], "entity_id": ["T6"]}, "Effect": {"text": [["Hyperpigmentation"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["chemotherapautic agents"]], "start": [[58]], "entity_id": ["T5"], "Drug": {"text": [["chemotherapautic agents"]], "start": [[58]], "entity_id": ["T7"]}}}]}]}
{"id": "17352036_2", "context": "Pancreatitis is a very rare adverse effect associated with the use of amiodarone, and only four cases of amiodarone-induced pancreatitis have been reported in literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[116]], "entity_id": ["T5"]}, "Effect": {"text": [["pancreatitis"]], "start": [[124]], "entity_id": ["T6"]}, "Treatment": {"text": [["amiodarone"]], "start": [[105]], "entity_id": ["T7"], "Drug": {"text": [["amiodarone"]], "start": [[105]], "entity_id": ["T10"]}}, "Subject": {"text": [["four cases"]], "start": [[91]], "entity_id": ["T8"], "Population": {"text": [["four"]], "start": [[91]], "entity_id": ["T9"]}}}]}]}
{"id": "3773837_1", "context": "The latter form (Macrodantin) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form--liver damage, acute and chronic pulmonary reactions, peripheral neuropathy, blood dyscrasias and allergic reactions--and does so just as rapidly and floridly; one such case is reported here.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["adverse effects"]], "start": [[116]], "entity_id": ["T13"]}, "Treatment": {"text": [["Macrodantin"]], "start": [[17]], "entity_id": ["T11"], "Drug": {"text": [["Macrodantin"]], "start": [[17]], "entity_id": ["T18"]}}, "Effect": {"text": [["less gastrointestinal intolerance", "liver damage, acute and chronic pulmonary reactions, peripheral neuropathy, blood dyscrasias and allergic reactions"]], "start": [[54, 158]], "entity_id": ["T12"]}, "Subject": {"text": [["one such case"]], "start": [[317]], "entity_id": ["T14"], "Population": {"text": [["one"]], "start": [[317]], "entity_id": ["T15"]}}, "Speculated": {"text": [["can"]], "start": [[95]], "entity_id": ["T17"], "value": true}}]}]}
{"id": "18176653_4", "context": "CASE REPORT: A 29-year-old black man, HIV-infected since 1996, began highly active antiretroviral therapy (HAART) with zidovudine, lamivudine, and indinavir.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["began"]], "start": [[63]], "entity_id": ["T11"]}, "Subject": {"text": [["A 29-year-old black man, HIV-infected since 1996"]], "start": [[13]], "entity_id": ["T10"], "Age": {"text": [["29-year-old"]], "start": [[15]], "entity_id": ["T13"]}, "Race": {"text": [["black"]], "start": [[27]], "entity_id": ["T14"]}, "Gender": {"text": [["man"]], "start": [[33]], "entity_id": ["T15"]}}, "Treatment": {"text": [["highly active antiretroviral therapy (HAART) with zidovudine, lamivudine, and indinavir"]], "start": [[69]], "entity_id": ["T12"], "Drug": {"text": [["zidovudine"], ["lamivudine"], ["indinavir"]], "start": [[119], [131], [147]], "entity_id": ["T17", "T18", "T19"]}, "Disorder": {"text": [["HIV"]], "start": [[38]], "entity_id": ["T1"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[143]], "entity_id": ["T20"]}, "Drug": {"text": [["zidovudine"], ["lamivudine"], ["indinavir"]], "start": [[119], [131], [147]], "entity_id": ["T17", "T18", "T19"]}}]}}]}]}
{"id": "20118434_3", "context": "METHOD: The authors followed a patient with chronic HCV who received interferon and ribavirin and who developed hallucinations ultimately requiring psychiatric hospitalization.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[102]], "entity_id": ["T7"]}, "Subject": {"text": [["a patient with chronic HCV"]], "start": [[29]], "entity_id": ["T4"]}, "Treatment": {"text": [["interferon and ribavirin"]], "start": [[69]], "entity_id": ["T5"], "Drug": {"text": [["interferon"], ["ribavirin"]], "start": [[69], [84]], "entity_id": ["T9", "T11"]}, "Disorder": {"text": [["chronic HCV"]], "start": [[44]], "entity_id": ["T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[80]], "entity_id": ["T10"]}, "Drug": {"text": [["interferon"], ["ribavirin"]], "start": [[69], [84]], "entity_id": ["T9", "T11"]}}]}, "Effect": {"text": [["hallucinations"]], "start": [[112]], "entity_id": ["T6"]}}]}]}
{"id": "19733945_3", "context": "This case of linezolid-associated acute interstitial nephritis within the context of a drug rash with eosinophilia and systemic symptoms (DRESS) syndrome in a patient treated with linezolid raises concerns about the presumed renal safety of this drug.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[23]], "entity_id": ["T13"]}, "Effect": {"text": [["acute interstitial nephritis within the context of a drug rash with eosinophilia and systemic symptoms (DRESS) syndrome"]], "start": [[34]], "entity_id": ["T10"]}, "Treatment": {"text": [["linezolid"]], "start": [[13]], "entity_id": ["T1"], "Drug": {"text": [["linezolid"]], "start": [[13]], "entity_id": ["T15"]}}}]}]}
{"id": "15359206_1", "context": "Easily reversible hypoxemia and hypotension induced by nimodipine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[44]], "entity_id": ["T6"]}, "Effect": {"text": [["hypoxemia and hypotension"]], "start": [[18]], "entity_id": ["T5"]}, "Treatment": {"text": [["nimodipine"]], "start": [[55]], "entity_id": ["T7"], "Drug": {"text": [["nimodipine"]], "start": [[55]], "entity_id": ["T8"]}}, "Severity": {"text": [["Easily reversible"]], "start": [[0]], "entity_id": ["T9"], "value": "Low"}}]}]}
{"id": "17352036_1", "context": "Adverse effects of amiodarone including pulmonary toxicity, hepatotoxicity, aggravation of arrhythmia, and thyroid diseases are well understood.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["including"]], "start": [[30]], "entity_id": ["T10"]}, "Treatment": {"text": [["amiodarone"]], "start": [[19]], "entity_id": ["T9"], "Drug": {"text": [["amiodarone"]], "start": [[19]], "entity_id": ["T12"]}}, "Effect": {"text": [["pulmonary toxicity, hepatotoxicity, aggravation of arrhythmia, and thyroid diseases"]], "start": [[40]], "entity_id": ["T11"]}}]}]}
{"id": "3977377_1", "context": "Chronic photosensitivity associated with hydrochlorothiazide ingestion occurred in four patients.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[25]], "entity_id": ["T6"]}, "Effect": {"text": [["Chronic photosensitivity"]], "start": [[0]], "entity_id": ["T3"]}, "Subject": {"text": [["four patients"]], "start": [[83]], "entity_id": ["T4"], "Population": {"text": [["four"]], "start": [[83]], "entity_id": ["T7"]}}, "Treatment": {"text": [["hydrochlorothiazide ingestion"]], "start": [[41]], "entity_id": ["T5"], "Drug": {"text": [["hydrochlorothiazide"]], "start": [[41]], "entity_id": ["T8"]}, "Route": {"text": [["ingestion"]], "start": [[61]], "entity_id": ["T9"]}}}]}]}
{"id": "4054170_2", "context": "Chlorambucil central nervous toxicity: a significant side effect of chlorambucil therapy in childhood nephrotic syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["side effect"]], "start": [[53]], "entity_id": ["T6"]}, "Treatment": {"text": [["Chlorambucil"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Chlorambucil"]], "start": [[0]], "entity_id": ["T7"]}, "Disorder": {"text": [["childhood nephrotic syndrome"]], "start": [[92]], "entity_id": ["T8"]}}, "Effect": {"text": [["central nervous toxicity"]], "start": [[13]], "entity_id": ["T4"]}}]}]}
{"id": "25671244_3", "context": "The mechanism of action of this centrally acting muscle relaxant is unknown; however, the observation of serotonin syndrome in patients with metaxalone overdose suggests a role in the serotonergic pathway.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[124]], "entity_id": ["T8"]}, "Treatment": {"text": [["centrally acting muscle relaxant", "metaxalone overdose"]], "start": [[32, 141]], "entity_id": ["T5"], "Drug": {"text": [["centrally acting muscle relaxant"], ["metaxalone"]], "start": [[32], [141]], "entity_id": ["T9", "T10"]}, "Dosage": {"text": [["overdose"]], "start": [[152]], "entity_id": ["T11"]}}, "Effect": {"text": [["serotonin syndrome"]], "start": [[105]], "entity_id": ["T6"]}, "Subject": {"text": [["patients"]], "start": [[127]], "entity_id": ["T7"]}}]}]}
{"id": "12598508_2", "context": "In general, angiotensin converting enzyme (ACE) inhibitors should be discontinued in pregnancy, as they can induce an ACE fetopathy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induce"]], "start": [[108]], "entity_id": ["T6"]}, "Effect": {"text": [["ACE fetopathy"]], "start": [[118]], "entity_id": ["T5"]}, "Treatment": {"text": [["angiotensin converting enzyme (ACE) inhibitors"]], "start": [[12]], "entity_id": ["T7"], "Drug": {"text": [["angiotensin converting enzyme (ACE) inhibitors"]], "start": [[12]], "entity_id": ["T11"]}}, "Subject": {"text": [["pregnancy"]], "start": [[85]], "entity_id": ["T12"], "Disorder": {"text": [["pregnancy"]], "start": [[85]], "entity_id": ["T8"]}}, "Speculated": {"text": [["can"]], "start": [[104]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "1993143_1", "context": "Of 371 patients treated with 8MOP, three (0.8%) developed an acute dermatitis in the PUVA-treated areas.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[48]], "entity_id": ["T5"]}, "Effect": {"text": [["acute dermatitis"]], "start": [[61]], "entity_id": ["T3"]}, "Subject": {"text": [["Of 371 patients", "three (0.8%)"]], "start": [[0, 35]], "entity_id": ["T4"], "Population": {"text": [["371", "three (0.8%)"]], "start": [[3, 35]], "entity_id": ["T7"]}}, "Treatment": {"text": [["treated with 8MOP"]], "start": [[16]], "entity_id": ["T6"], "Drug": {"text": [["8MOP"]], "start": [[29]], "entity_id": ["T8"]}}}]}]}
{"id": "1174301_1", "context": "There is a putative role of liothyronine administration in precipitating or activating hyperthyroidism.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["precipitating or activating"]], "start": [[59]], "entity_id": ["T4"]}, "Effect": {"text": [["hyperthyroidism"]], "start": [[87]], "entity_id": ["T3"]}, "Treatment": {"text": [["liothyronine"]], "start": [[28]], "entity_id": ["T5"], "Drug": {"text": [["liothyronine"]], "start": [[28]], "entity_id": ["T6"]}}}]}]}
{"id": "16436462_1", "context": "Neutropenic colitis during standard dose combination chemotherapy with nedaplatin and irinotecan for testicular cancer.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[20]], "entity_id": ["T5"]}, "Effect": {"text": [["Neutropenic colitis"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["standard dose combination chemotherapy with nedaplatin and irinotecan for testicular cancer"]], "start": [[27]], "entity_id": ["T7"], "Disorder": {"text": [["testicular cancer"]], "start": [[101]], "entity_id": ["T6"]}, "Dosage": {"text": [["standard dose"]], "start": [[27]], "entity_id": ["T8"]}, "Drug": {"text": [["nedaplatin"], ["irinotecan"]], "start": [[71], [86]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combination"]], "start": [[41]], "entity_id": ["T9"]}, "Drug": {"text": [["nedaplatin"], ["irinotecan"]], "start": [[71], [86]], "entity_id": ["T10", "T11"]}}]}}]}]}
{"id": "17383767_2", "context": "Brain metastases are a frequent finding in patients with advanced non-small cell lung cancer and concomitant administration of antiepileptic and chemotherapeutic drugs or epidermal growth factor receptor (EGFR) inhibitor is necessary in many cases.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["necessary"]], "start": [[224]], "entity_id": ["T9"]}, "Treatment": {"text": [["concomitant administration of antiepileptic and chemotherapeutic drugs or epidermal growth factor receptor (EGFR) inhibitor"]], "start": [[97]], "entity_id": ["T15"], "Drug": {"text": [["antiepileptic"], ["chemotherapeutic"], ["epidermal growth factor receptor (EGFR) inhibitor"]], "start": [[127], [145], [171]], "entity_id": ["T11", "T12", "T13"]}, "Disorder": {"text": [["Brain metastases"]], "start": [[0]], "entity_id": ["T18"]}, "Combination": [{"event_id": "E1", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[141]], "entity_id": ["T14"]}, "Drug": {"text": [["antiepileptic"], ["chemotherapeutic"]], "start": [[127], [145]], "entity_id": ["T11", "T12"]}}]}, "Subject": {"text": [["patients with advanced non-small cell lung cancer"]], "start": [[43]], "entity_id": ["T16"], "Disorder": {"text": [["advanced non-small cell lung cancer"]], "start": [[57]], "entity_id": ["T17"]}}}]}]}
{"id": "18343993_2", "context": "A female patient with HER2 positive, metastatic breast cancer presented with pulmonary infiltrates, and a plural effusion dyspnoea after several months of trastuzumab treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["presented"]], "start": [[62]], "entity_id": ["T6"]}, "Subject": {"text": [["A female patient with HER2 positive, metastatic breast cancer"]], "start": [[0]], "entity_id": ["T5"], "Gender": {"text": [["female"]], "start": [[2]], "entity_id": ["T9"]}}, "Treatment": {"text": [["trastuzumab"]], "start": [[155]], "entity_id": ["T8"], "Disorder": {"text": [["HER2 positive, metastatic breast cancer"]], "start": [[22]], "entity_id": ["T10"]}, "Drug": {"text": [["trastuzumab"]], "start": [[155]], "entity_id": ["T11"]}, "Time_elapsed": {"text": [["several months"]], "start": [[137]], "entity_id": ["T12"]}}, "Effect": {"text": [["pulmonary infiltrates, and a plural effusion dyspnoea"]], "start": [[77]], "entity_id": ["T7"]}}]}]}
{"id": "12944250_3", "context": "Thrombocytosis under ciprofloxacin and tazobactam/piperacillin.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["under"]], "start": [[15]], "entity_id": ["T6"]}, "Effect": {"text": [["Thrombocytosis"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["ciprofloxacin and tazobactam/piperacillin"]], "start": [[21]], "entity_id": ["T9"], "Drug": {"text": [["ciprofloxacin"], ["tazobactam"], ["piperacillin"]], "start": [[21], [39], [50]], "entity_id": ["T11", "T12", "T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[35]], "entity_id": ["T10"]}, "Drug": {"text": [["ciprofloxacin"], ["tazobactam"], ["piperacillin"]], "start": [[21], [39], [50]], "entity_id": ["T11", "T12", "T13"]}}]}}]}]}
{"id": "7781845_2", "context": "Quinine and its isomer quinidine are well-known causes of iatrogenic hypoglycaemia, due to excessive insulin secretion.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["causes"]], "start": [[48]], "entity_id": ["T8"]}, "Treatment": {"text": [["Quinine and its isomer quinidine"]], "start": [[0]], "entity_id": ["T6"], "Drug": {"text": [["Quinine"]], "start": [[0]], "entity_id": ["T10"]}}, "Effect": {"text": [["iatrogenic hypoglycaemia, due to excessive insulin secretion"]], "start": [[58]], "entity_id": ["T9"]}}]}]}
{"id": "14690166_6", "context": "Therefore, it is reasonable to conclude that: 1) 2-CdA can induce durable complete remission in MCD patients but unfortunately it cannot cure the disease; 2) the possibility that 2-CdA may accelerate the transformation of MCD to NHL cannot be ruled out.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["induce"]], "start": [[59]], "entity_id": ["T18"]}, "Effect": {"text": [["durable complete remission"]], "start": [[66]], "entity_id": ["T19"]}, "Treatment": {"text": [["2-CdA"]], "start": [[49]], "entity_id": ["T15"], "Disorder": {"text": [["MCD"]], "start": [[96]], "entity_id": ["T14"]}, "Drug": {"text": [["2-CdA"]], "start": [[49]], "entity_id": ["T16"]}}, "Speculated": {"text": [["can"]], "start": [[55]], "entity_id": ["T17"], "value": true}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["accelerate"]], "start": [[189]], "entity_id": ["T20"]}, "Treatment": {"text": [["2-CdA"]], "start": [[179]], "entity_id": ["T22"], "Drug": {"text": [["2-CdA"]], "start": [[179]], "entity_id": ["T23"]}}, "Effect": {"text": [["the transformation of MCD to NHL"]], "start": [[200]], "entity_id": ["T24"]}, "Speculated": {"text": [["possibility"]], "start": [[162]], "entity_id": ["T21"], "value": true}}]}]}
{"id": "8192712_3", "context": "Hyperammonemia secondary to valproic acid as a cause of lethargy in a postictal patient.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[47]], "entity_id": ["T6"]}, "Effect": {"text": [["Hyperammonemia"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["valproic acid"]], "start": [[28]], "entity_id": ["T7"], "Drug": {"text": [["valproic acid"]], "start": [[28]], "entity_id": ["T9"]}}, "Subject": {"text": [["a postictal patient"]], "start": [[68]], "entity_id": ["T8"]}}]}]}
{"id": "11215836_2", "context": "OBJECTIVE: To report on the possible development of serotonin syndrome in a patient receiving clomipramine after clozapine was withdrawn from the treatment regimen.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["receiving"]], "start": [[84]], "entity_id": ["T5"]}, "Treatment": {"text": [["clomipramine"]], "start": [[94]], "entity_id": ["T4"], "Drug": {"text": [["clomipramine"], ["clozapine"]], "start": [[94], [113]], "entity_id": ["T8", "T9"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["after"]], "start": [[107]], "entity_id": ["T10"]}, "Drug": {"text": [["clomipramine"], ["clozapine"]], "start": [[94], [113]], "entity_id": ["T8", "T9"]}}]}, "Effect": {"text": [["serotonin syndrome"]], "start": [[52]], "entity_id": ["T6"]}, "Subject": {"text": [["patient"]], "start": [[76]], "entity_id": ["T7"]}, "Speculated": {"text": [["possible"]], "start": [[28]], "entity_id": ["T11"], "value": true}}]}]}
{"id": "7295427_1", "context": "Fatal ventricular fibrillation after treatment with digoxin in a 27-year-old man with mitral leaflet prolapse syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[31]], "entity_id": ["T3"]}, "Treatment": {"text": [["digoxin"]], "start": [[52]], "entity_id": ["T4"], "Drug": {"text": [["digoxin"]], "start": [[52]], "entity_id": ["T11"]}, "Disorder": {"text": [["mitral leaflet prolapse syndrome"]], "start": [[86]], "entity_id": ["T12"]}}, "Subject": {"text": [["a 27-year-old man with mitral leaflet prolapse syndrome"]], "start": [[63]], "entity_id": ["T5"], "Age": {"text": [["27-year-old"]], "start": [[65]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[77]], "entity_id": ["T8"]}}, "Effect": {"text": [["Fatal ventricular fibrillation"]], "start": [[0]], "entity_id": ["T6"]}, "Severity": {"text": [["Fatal"]], "start": [[0]], "entity_id": ["T10"], "value": "Medium"}}]}]}
{"id": "8641617_4", "context": "Clostridium difficile colitis associated with cisplatin-based chemotherapy in ovarian cancer patients.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[30]], "entity_id": ["T3"]}, "Effect": {"text": [["Clostridium difficile colitis"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["cisplatin-based chemotherapy"]], "start": [[46]], "entity_id": ["T5"], "Drug": {"text": [["cisplatin"]], "start": [[46]], "entity_id": ["T8"]}, "Disorder": {"text": [["ovarian cancer"]], "start": [[78]], "entity_id": ["T9"]}, "Route": {"text": [["chemotherapy"]], "start": [[62]], "entity_id": ["T10"]}}, "Subject": {"text": [["ovarian cancer patients."]], "start": [[78]], "entity_id": ["T6"]}}]}]}
{"id": "8828999_2", "context": "Lithium-induced Creutzfeldt-Jakob syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[8]], "entity_id": ["T4"]}, "Treatment": {"text": [["Lithium"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Lithium"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["Creutzfeldt-Jakob syndrome"]], "start": [[16]], "entity_id": ["T5"]}}]}]}
{"id": "12944250_1", "context": "It is concluded that simultaneous administration of ciprofloxacin and tazobactam/piperacillin may cause marked thrombocytosis.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[98]], "entity_id": ["T5"]}, "Treatment": {"text": [["simultaneous administration of ciprofloxacin and tazobactam/piperacillin"]], "start": [[21]], "entity_id": ["T7"], "Drug": {"text": [["ciprofloxacin"], ["tazobactam/piperacillin"]], "start": [[52], [70]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[66]], "entity_id": ["T11"]}, "Drug": {"text": [["ciprofloxacin"], ["tazobactam/piperacillin"]], "start": [[52], [70]], "entity_id": ["T9", "T10"]}}]}, "Effect": {"text": [["marked thrombocytosis"]], "start": [[104]], "entity_id": ["T8"]}, "Speculated": {"text": [["may"]], "start": [[94]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "12121061_6", "context": "Alone or in combination with corticosteroids, cyclosporine is an effective drug of choice for the resistant patients.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["is"]], "start": [[59]], "entity_id": ["T9"]}, "Treatment": {"text": [["Alone or in combination with corticosteroids, cyclosporine"]], "start": [[0]], "entity_id": ["T6"], "Drug": {"text": [["corticosteroids"], ["cyclosporine"]], "start": [[29], [46]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combination"]], "start": [[12]], "entity_id": ["T12"]}, "Drug": {"text": [["corticosteroids"], ["cyclosporine"]], "start": [[29], [46]], "entity_id": ["T10", "T11"]}}]}, "Subject": {"text": [["resistant patients"]], "start": [[98]], "entity_id": ["T8"]}}]}]}
{"id": "15013892_1", "context": "Bull's-eye maculopathy associated with quinacrine therapy for malaria.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[23]], "entity_id": ["T4"]}, "Effect": {"text": [["Bull's-eye maculopathy"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["quinacrine"]], "start": [[39]], "entity_id": ["T5"], "Drug": {"text": [["quinacrine"]], "start": [[39]], "entity_id": ["T7"]}, "Disorder": {"text": [["malaria"]], "start": [[62]], "entity_id": ["T8"]}}}]}]}
{"id": "11545487_4", "context": "Physicians should be aware that indinavir nephrolithiasis may cause papillary necrosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[62]], "entity_id": ["T6"]}, "Treatment": {"text": [["indinavir nephrolithiasis"]], "start": [[32]], "entity_id": ["T5"], "Drug": {"text": [["indinavir"]], "start": [[32]], "entity_id": ["T9"]}}, "Effect": {"text": [["papillary necrosis"]], "start": [[68]], "entity_id": ["T7"]}, "Speculated": {"text": [["may"]], "start": [[58]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "2394154_2", "context": "Following the institution of intravenous therapy with acyclovir, the patient developed fever, hemoptysis, and a pleural friction rub.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[77]], "entity_id": ["T9"]}, "Treatment": {"text": [["acyclovir"]], "start": [[54]], "entity_id": ["T7"], "Drug": {"text": [["acyclovir"]], "start": [[54]], "entity_id": ["T11"]}}, "Subject": {"text": [["the patient"]], "start": [[65]], "entity_id": ["T8"]}, "Effect": {"text": [["fever, hemoptysis, and a pleural friction rub"]], "start": [[87]], "entity_id": ["T10"]}}]}]}
{"id": "16637972_3", "context": "Due to discomfort, diplopia and lagophthalmos, the haematoma necessitated suspension of warfarin therapy and a surgical evacuation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Due to"]], "start": [[0]], "entity_id": ["T11"]}, "Effect": {"text": [["discomfort, diplopia and lagophthalmos, the haematoma"]], "start": [[7]], "entity_id": ["T9"]}, "Treatment": {"text": [["warfarin therapy and a surgical evacuation"]], "start": [[88]], "entity_id": ["T10"], "Drug": {"text": [["warfarin"]], "start": [[88]], "entity_id": ["T12"]}}}]}]}
{"id": "9476721_1", "context": "Acute dystonia with thalamic and brainstem lesions after initial penicillamine treatment in Wilson's disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[51]], "entity_id": ["T6"]}, "Effect": {"text": [["Acute dystonia with thalamic and brainstem lesions"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["penicillamine"]], "start": [[65]], "entity_id": ["T7"], "Drug": {"text": [["penicillamine"]], "start": [[65]], "entity_id": ["T9"]}, "Disorder": {"text": [["Wilson's disease"]], "start": [[92]], "entity_id": ["T10"]}}}]}]}
{"id": "12862258_2", "context": "Fatal agranulocytosis in an Indian male receiving 100mg of dapsone daily, hospitalized for mid-borderline leprosy in type I reaction with triple nerve paralysis is reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["receiving"]], "start": [[40]], "entity_id": ["T7"]}, "Subject": {"text": [["mid-borderline leprosy in type I reaction with triple nerve paralysis"]], "start": [[91]], "entity_id": ["T3"], "Race": {"text": [["Indian"]], "start": [[28]], "entity_id": ["T8"]}, "Gender": {"text": [["male"]], "start": [[35]], "entity_id": ["T9"]}}, "Effect": {"text": [["Fatal agranulocytosis"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["100mg of dapsone daily"]], "start": [[50]], "entity_id": ["T5"], "Dosage": {"text": [["100mg"]], "start": [[50]], "entity_id": ["T10"]}, "Drug": {"text": [["dapsone"]], "start": [[59]], "entity_id": ["T11"]}, "Freq": {"text": [["daily"]], "start": [[67]], "entity_id": ["T12"]}, "Disorder": {"text": [["mid-borderline leprosy in type I reaction with triple nerve paralysis"]], "start": [[91]], "entity_id": ["T13"]}}, "Severity": {"text": [["Fatal"]], "start": [[0]], "entity_id": ["T14"], "value": "High"}}]}]}
{"id": "17285101_2", "context": "The authors presented a case of pulmonary hypertension during lithium therapy, while she has been on lithium for 6 years.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[55]], "entity_id": ["T5"]}, "Effect": {"text": [["pulmonary hypertension"]], "start": [[32]], "entity_id": ["T3"]}, "Treatment": {"text": [["lithium therapy"]], "start": [[62]], "entity_id": ["T4"], "Drug": {"text": [["lithium"]], "start": [[62]], "entity_id": ["T9"]}, "Duration": {"text": [["6 years"]], "start": [[113]], "entity_id": ["T1"]}}, "Subject": {"text": [["she"]], "start": [[85]], "entity_id": ["T6"], "Gender": {"text": [["she"]], "start": [[85]], "entity_id": ["T7"]}}}]}]}
{"id": "16968538_2", "context": "BACKGROUND: Oxaliplatin is a platinum derivative, which is used in the treatment of colorectal cancer.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatment"]], "start": [[71]], "entity_id": ["T7"]}, "Treatment": {"text": [["Oxaliplatin is a platinum derivative"]], "start": [[12]], "entity_id": ["T5"], "Drug": {"text": [["Oxaliplatin"], ["platinum derivative"]], "start": [[12], [29]], "entity_id": ["T8", "T9"]}, "Disorder": {"text": [["colorectal cancer"]], "start": [[84]], "entity_id": ["T10"]}}}]}]}
{"id": "17406804_2", "context": "After having received gemcitabine on day 1 of the second course, the patient developed dry cough, subfebrile temperatures and dyspnea within 48 h.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[77]], "entity_id": ["T9"]}, "Treatment": {"text": [["received gemcitabine on day 1 of the second course"]], "start": [[13]], "entity_id": ["T7"], "Drug": {"text": [["gemcitabine"]], "start": [[22]], "entity_id": ["T11"]}, "Time_elapsed": {"text": [["within 48 h"]], "start": [[134]], "entity_id": ["T13"]}}, "Subject": {"text": [["the patient"]], "start": [[65]], "entity_id": ["T8"]}, "Effect": {"text": [["dry cough, subfebrile temperatures and dyspnea within 48 h"]], "start": [[87]], "entity_id": ["T10"]}}]}]}
{"id": "15454180_2", "context": "As linezolid has been shown to have hematologic side effects, blood count monitoring is recommended in patients receiving this drug for long-term therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["have"]], "start": [[31]], "entity_id": ["T4"]}, "Treatment": {"text": [["linezolid"]], "start": [[3]], "entity_id": ["T3"], "Drug": {"text": [["linezolid"]], "start": [[3]], "entity_id": ["T6"]}, "Duration": {"text": [["long-term"]], "start": [[136]], "entity_id": ["T7"]}}, "Effect": {"text": [["hematologic side effects"]], "start": [[36]], "entity_id": ["T5"]}}]}]}
{"id": "189279_3", "context": "The role of Adriamycin in the production of cardiotoxicity is reviewed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["production"]], "start": [[30]], "entity_id": ["T5"]}, "Treatment": {"text": [["Adriamycin"]], "start": [[12]], "entity_id": ["T3"], "Drug": {"text": [["Adriamycin"]], "start": [[12]], "entity_id": ["T6"]}}, "Effect": {"text": [["cardiotoxicity"]], "start": [[44]], "entity_id": ["T4"]}}]}]}
{"id": "7663030_5", "context": "He began taking propafenone only 6 days prior to admission because of uncontrolled atrial fibrillation and symptoms of fatigue.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["taking"]], "start": [[9]], "entity_id": ["T9"]}, "Treatment": {"text": [["propafenone"]], "start": [[16]], "entity_id": ["T5"], "Drug": {"text": [["propafenone"]], "start": [[16]], "entity_id": ["T7"]}, "Disorder": {"text": [["atrial fibrillation"], ["fatigue"]], "start": [[83], [119]], "entity_id": ["T8", "T10"]}}}]}]}
{"id": "12013364_1", "context": "A 53-year-old man developed NMS without rigidity while taking olanzapine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[18]], "entity_id": ["T4"]}, "Subject": {"text": [["A 53-year-old man"]], "start": [[0]], "entity_id": ["T3"], "Age": {"text": [["53-year-old"]], "start": [[2]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[14]], "entity_id": ["T8"]}}, "Effect": {"text": [["NMS without rigidity"]], "start": [[28]], "entity_id": ["T5"]}, "Treatment": {"text": [["olanzapine"]], "start": [[62]], "entity_id": ["T6"], "Drug": {"text": [["olanzapine"]], "start": [[62]], "entity_id": ["T9"]}}}]}]}
{"id": "10650865_2", "context": "We report on a 14-year-old boy with severe haemophilia A who developed a portal vein thrombosis during continuous infusion of F VIII.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[61]], "entity_id": ["T4"]}, "Subject": {"text": [["a 14-year-old boy with severe haemophilia A"]], "start": [[13]], "entity_id": ["T3"], "Age": {"text": [["14-year-old"]], "start": [[15]], "entity_id": ["T7"]}, "Gender": {"text": [["boy"]], "start": [[27]], "entity_id": ["T8"]}}, "Effect": {"text": [["a portal vein thrombosis"]], "start": [[71]], "entity_id": ["T5"]}, "Treatment": {"text": [["continuous infusion of F VIII"]], "start": [[103]], "entity_id": ["T6"], "Freq": {"text": [["continuous"]], "start": [[103]], "entity_id": ["T10"]}, "Route": {"text": [["infusion"]], "start": [[114]], "entity_id": ["T11"]}, "Drug": {"text": [["F VIII"]], "start": [[126]], "entity_id": ["T12"]}, "Disorder": {"text": [["haemophilia A"]], "start": [[43]], "entity_id": ["T13"]}}}]}]}
{"id": "961329_2", "context": "Suxamethonium apnoea terminated with commercial serumcholinesterase.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["terminated"]], "start": [[21]], "entity_id": ["T4"]}, "Effect": {"text": [["Suxamethonium apnoea"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["commercial serumcholinesterase"]], "start": [[37]], "entity_id": ["T5"], "Drug": {"text": [["commercial serumcholinesterase"]], "start": [[37]], "entity_id": ["T6"]}}}]}]}
{"id": "9788533_1", "context": "Fatal multiple drug intoxication following acute sertraline use.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[33]], "entity_id": ["T5"]}, "Effect": {"text": [["multiple drug intoxication"]], "start": [[6]], "entity_id": ["T4"]}, "Treatment": {"text": [["acute sertraline use"]], "start": [[43]], "entity_id": ["T6"], "Drug": {"text": [["sertraline"]], "start": [[49]], "entity_id": ["T8"]}}, "Severity": {"text": [["Fatal"]], "start": [[0]], "entity_id": ["T9"], "value": "High"}}]}]}
{"id": "15611427_1", "context": "OBSERVATIONS: We observed aggravation and spreading of a psoriatic plaque when treated topically with the toll-like receptor (TLR) 7 agonist imiquimod.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["observed"]], "start": [[17]], "entity_id": ["T5"]}, "Effect": {"text": [["aggravation and spreading of a psoriatic plaque"]], "start": [[26]], "entity_id": ["T3"]}, "Treatment": {"text": [["the toll-like receptor (TLR) 7 agonist imiquimod"]], "start": [[102]], "entity_id": ["T4"], "Drug": {"text": [["imiquimod"]], "start": [[141]], "entity_id": ["T6"]}, "Route": {"text": [["topically"]], "start": [[87]], "entity_id": ["T7"]}}}]}]}
{"id": "9302445_2", "context": "Hypercalcemia in an AIDS patient treated with growth hormone.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[41]], "entity_id": ["T6"]}, "Effect": {"text": [["Hypercalcemia"]], "start": [[0]], "entity_id": ["T3"]}, "Subject": {"text": [["an AIDS patient"]], "start": [[17]], "entity_id": ["T4"]}, "Treatment": {"text": [["growth hormone"]], "start": [[46]], "entity_id": ["T5"], "Disorder": {"text": [["AIDS"]], "start": [[20]], "entity_id": ["T7"]}, "Drug": {"text": [["growth hormone"]], "start": [[46]], "entity_id": ["T8"]}}}]}]}
{"id": "17383767_1", "context": "Significant drug interaction: phenytoin toxicity due to erlotinib.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[49]], "entity_id": ["T7"]}, "Effect": {"text": [["phenytoin toxicity"]], "start": [[30]], "entity_id": ["T6"]}, "Treatment": {"text": [["erlotinib"]], "start": [[56]], "entity_id": ["T8"], "Drug": {"text": [["erlotinib"]], "start": [[56]], "entity_id": ["T9"]}}}]}]}
{"id": "10599932_2", "context": "A pharmacokinetic interaction between the selective serotonin reuptake inhibitor citalopram and a tricyclic antidepressant, clomipramine, was noted in a patient treated for major depression and obsessive-compulsive disorder.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["interaction"]], "start": [[18]], "entity_id": ["T13"]}, "Effect": {"text": [["A pharmacokinetic interaction"]], "start": [[0]], "entity_id": ["T10"]}, "Treatment": {"text": [["the selective serotonin reuptake inhibitor citalopram and a tricyclic antidepressant, clomipramine"]], "start": [[38]], "entity_id": ["T11"], "Drug": {"text": [["citalopram"], ["clomipramine"]], "start": [[81], [124]], "entity_id": ["T16", "T17"]}, "Disorder": {"text": [["depression"], ["obsessive-compulsive disorder"]], "start": [[179], [194]], "entity_id": ["T18", "T19"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[18]], "entity_id": ["T15"]}, "Drug": {"text": [["citalopram"], ["clomipramine"]], "start": [[81], [124]], "entity_id": ["T16", "T17"]}}]}, "Subject": {"text": [["a patient treated for major depression and obsessive-compulsive disorder"]], "start": [[151]], "entity_id": ["T12"]}}]}]}
{"id": "3301251_4", "context": "They continued to rise for five more days before salicylate hepatotoxicity was suspected.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["suspected"]], "start": [[79]], "entity_id": ["T5"]}, "Treatment": {"text": [["salicylate"]], "start": [[49]], "entity_id": ["T3"], "Drug": {"text": [["salicylate"]], "start": [[49]], "entity_id": ["T6"]}}, "Effect": {"text": [["hepatotoxicity"]], "start": [[60]], "entity_id": ["T4"]}, "Speculated": {"text": [["suspected"]], "start": [[79]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "8832451_2", "context": "The occurrence of neuromuscular blockade and the resulting potentiation of muscle relaxants during magnesium sulfate (MgSO4) administration is well known.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[92]], "entity_id": ["T9"]}, "Effect": {"text": [["neuromuscular blockade", "potentiation of muscle relaxants"]], "start": [[18, 59]], "entity_id": ["T7"]}, "Treatment": {"text": [["magnesium sulfate"]], "start": [[99]], "entity_id": ["T8"], "Drug": {"text": [["magnesium sulfate (MgSO4)"]], "start": [[99]], "entity_id": ["T10"]}}}]}]}
{"id": "12680486_1", "context": "Based on these findings, the patient was diagnosed with diabetes insipidus secondary to lithium therapy and was treated successfully with amiloride.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["diagnosed"]], "start": [[41]], "entity_id": ["T4"]}, "Effect": {"text": [["diabetes insipidus"]], "start": [[56]], "entity_id": ["T13"]}, "Treatment": {"text": [["lithium"]], "start": [[88]], "entity_id": ["T6"], "Drug": {"text": [["lithium"]], "start": [[88]], "entity_id": ["T7"]}}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[112]], "entity_id": ["T5"]}, "Effect": {"text": [["successfully"]], "start": [[120]], "entity_id": ["T9"]}, "Treatment": {"text": [["amiloride"]], "start": [[138]], "entity_id": ["T11"], "Disorder": {"text": [["diabetes insipidus secondary to lithium therapy"]], "start": [[56]], "entity_id": ["T3"]}, "Drug": {"text": [["amiloride"]], "start": [[138]], "entity_id": ["T12"]}}}]}]}
{"id": "11034877_1", "context": "Gabapentin-induced mood changes with hypomanic features in adults.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T9"]}, "Subject": {"text": [["adults"]], "start": [[59]], "entity_id": ["T6"], "Age": {"text": [["adults"]], "start": [[59]], "entity_id": ["T10"]}}, "Effect": {"text": [["mood changes with hypomanic features"]], "start": [[19]], "entity_id": ["T7"]}, "Treatment": {"text": [["Gabapentin"]], "start": [[0]], "entity_id": ["T8"], "Drug": {"text": [["Gabapentin"]], "start": [[0]], "entity_id": ["T11"]}}}]}]}
{"id": "1954704_1", "context": "Drug induced polymyositis secondary to leuprolide acetate (Lupron) therapy for prostate carcinoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["secondary to"]], "start": [[26]], "entity_id": ["T7"]}, "Treatment": {"text": [["leuprolide acetate (Lupron) therapy"]], "start": [[39]], "entity_id": ["T4"], "Disorder": {"text": [["prostate carcinoma"]], "start": [[79]], "entity_id": ["T5"]}, "Drug": {"text": [["leuprolide acetate (Lupron)"]], "start": [[39]], "entity_id": ["T8"]}}, "Effect": {"text": [["Drug induced polymyositis"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "18465737_1", "context": "Incomplete posterior hyaloid detachment after intravitreal pegaptanib injection in diabetic macular edema.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[40]], "entity_id": ["T6"]}, "Effect": {"text": [["Incomplete posterior hyaloid detachment"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["ntravitreal pegaptanib injection in diabetic macular edema"]], "start": [[47]], "entity_id": ["T4"], "Disorder": {"text": [["diabetic macular edema"]], "start": [[83]], "entity_id": ["T5"]}, "Drug": {"text": [["pegaptanib"]], "start": [[59]], "entity_id": ["T7"]}, "Route": {"text": [["intravitreal", "injection"]], "start": [[46, 70]], "entity_id": ["T8"]}}}]}]}
{"id": "7321956_2", "context": "This paper reports a case of fatal perhexiline maleate liver injury.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["a case of"]], "start": [[19]], "entity_id": ["T5"]}, "Treatment": {"text": [["perhexiline maleate"]], "start": [[35]], "entity_id": ["T3"], "Drug": {"text": [["perhexiline maleate"]], "start": [[35]], "entity_id": ["T6"]}}, "Effect": {"text": [["liver injury"]], "start": [[55]], "entity_id": ["T4"]}, "Severity": {"text": [["fatal"]], "start": [[29]], "entity_id": ["T7"], "value": "High"}}]}]}
{"id": "21448111_5", "context": "During the second hospitalization it is possible that antipsychotic treatment combined with an antidepressant caused akathisia or there were symptoms of agitated depression and akathisia present at the same time, which is very difficult to determine in everyday clinical practice.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[110]], "entity_id": ["T11"]}, "Treatment": {"text": [["antipsychotic treatment combined with an antidepressant"]], "start": [[54]], "entity_id": ["T8"], "Drug": {"text": [["antipsychotic"], ["antidepressant"]], "start": [[54], [95]], "entity_id": ["T12", "T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combined"]], "start": [[78]], "entity_id": ["T14"]}, "Drug": {"text": [["antidepressant"], ["antipsychotic"]], "start": [[95], [54]], "entity_id": ["T13", "T12"]}}]}, "Effect": {"text": [["akathisia"]], "start": [[117]], "entity_id": ["T9"]}, "Speculated": {"text": [["possible"]], "start": [[40]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "7724306_5", "context": "OBJECTIVES: To describe the presentation and treatment of acute isoniazid (INH) neurotoxicity appearing at an inner-city municipal hospital.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["neurotoxicity"]], "start": [[80]], "entity_id": ["T5"]}, "Effect": {"text": [["isoniazid (INH) neurotoxicity"]], "start": [[64]], "entity_id": ["T4"]}, "Treatment": {"text": [["isoniazid (INH)"]], "start": [[64]], "entity_id": ["T6"], "Drug": {"text": [["isoniazid"]], "start": [[64]], "entity_id": ["T7"]}}}]}]}
{"id": "9846036_4", "context": "Clozapine, an atypical antipsychotic, can be toxic at doses 4 times a moderate dose.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["be"]], "start": [[42]], "entity_id": ["T8"]}, "Treatment": {"text": [["doses 4 times a moderate dose", "Clozapine"]], "start": [[54, 0]], "entity_id": ["T6"], "Dosage": {"text": [["4 times a moderate dose"]], "start": [[60]], "entity_id": ["T5"]}, "Drug": {"text": [["Clozapine"]], "start": [[0]], "entity_id": ["T9"]}}, "Effect": {"text": [["toxic"]], "start": [[45]], "entity_id": ["T7"]}}]}]}
{"id": "18344455_3", "context": "This article presents a 3(1/2)-year-old child on valproic acid, lamotrigine, and phenytoin who developed simultaneous hepatotoxicity and bone marrow toxicity during a parainfluenza virus type 3 infection.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[95]], "entity_id": ["T13"]}, "Subject": {"text": [["a 3(1/2)-year-old child"]], "start": [[22]], "entity_id": ["T11"], "Age": {"text": [["3(1/2)-year-old"], ["child"]], "start": [[24], [40]], "entity_id": ["T15", "T16"]}}, "Treatment": {"text": [["valproic acid, lamotrigine, and phenytoin"]], "start": [[49]], "entity_id": ["T12"], "Drug": {"text": [["valproic acid"], ["lamotrigine"], ["phenytoin"]], "start": [[49], [64], [81]], "entity_id": ["T17", "T18", "T20"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[77]], "entity_id": ["T19"]}, "Drug": {"text": [["phenytoin"], ["lamotrigine"], ["valproic acid"]], "start": [[81], [64], [49]], "entity_id": ["T20", "T18", "T17"]}}]}, "Effect": {"text": [["simultaneous hepatotoxicity and bone marrow toxicity"]], "start": [[105]], "entity_id": ["T14"]}}]}]}
{"id": "2051906_3", "context": "Reversible cholestasis with bile duct injury following azathioprine therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[45]], "entity_id": ["T6"]}, "Effect": {"text": [["Reversible cholestasis with bile duct injury"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["azathioprine"]], "start": [[55]], "entity_id": ["T7"], "Drug": {"text": [["azathioprine"]], "start": [[55]], "entity_id": ["T8"]}}}]}]}
{"id": "20185472_1", "context": "The authors report five cases of tremor related to itraconazole therapy, which occurred within 1-12 months of initiating treatment and resolved gradually following itraconazole withdrawal.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[40]], "entity_id": ["T6"]}, "Effect": {"text": [["tremor"]], "start": [[33]], "entity_id": ["T4"]}, "Treatment": {"text": [["itraconazole therapy,"]], "start": [[51]], "entity_id": ["T5"], "Drug": {"text": [["itraconazole"]], "start": [[51]], "entity_id": ["T7"]}, "Time_elapsed": {"text": [["within 1-12 months"]], "start": [[88]], "entity_id": ["T8"]}}}]}]}
{"id": "9337441_2", "context": "OBJECTIVE: To report a case of phenolphthalein-induced toxic epidermal necrolysis (TEN) in a patient maintained on several other medications more commonly known to be associated with TEN.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[47]], "entity_id": ["T8"]}, "Effect": {"text": [["toxic epidermal necrolysis (TEN)"]], "start": [[55]], "entity_id": ["T5"]}, "Subject": {"text": [["a case of", "a patient"]], "start": [[21, 91]], "entity_id": ["T6"]}, "Treatment": {"text": [["phenolphthalein", "maintained on several other medications more commonly known to be associated with TEN"]], "start": [[31, 101]], "entity_id": ["T7"], "Drug": {"text": [["phenolphthalein"]], "start": [[31]], "entity_id": ["T9"]}}}]}]}
{"id": "1295628_3", "context": "Clinical symptoms and leukopenia normalized after discontinuation of CBZ and administration of prednisolone at 40 mg.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["normalized"]], "start": [[33]], "entity_id": ["T8"]}, "Effect": {"text": [["Clinical symptoms and leukopenia normalized"]], "start": [[0]], "entity_id": ["T7"]}, "Treatment": {"text": [["discontinuation of CBZ and administration of prednisolone at 40 mg"]], "start": [[50]], "entity_id": ["T9"], "Drug": {"text": [["CBZ"], ["prednisolone"]], "start": [[69], [95]], "entity_id": ["T11", "T12"]}, "Dosage": {"text": [["40 mg"]], "start": [[111]], "entity_id": ["T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[73]], "entity_id": ["T14"]}, "Drug": {"text": [["CBZ"], ["prednisolone"]], "start": [[69], [95]], "entity_id": ["T11", "T12"]}}]}}]}]}
{"id": "6766717_1", "context": "A patient with alcoholic cerebellar degeneration had periodic alternating nystagmus during a period of phenytoin intoxication.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[84]], "entity_id": ["T4"]}, "Subject": {"text": [["A patient with alcoholic cerebellar degeneration"]], "start": [[0]], "entity_id": ["T3"], "Disorder": {"text": [["alcoholic cerebellar degeneration"]], "start": [[15]], "entity_id": ["T7"]}}, "Treatment": {"text": [["phenytoin"]], "start": [[103]], "entity_id": ["T5"], "Drug": {"text": [["phenytoin"]], "start": [[103]], "entity_id": ["T8"]}}, "Effect": {"text": [["periodic alternating nystagmus"]], "start": [[53]], "entity_id": ["T6"]}}]}]}
{"id": "15316423_1", "context": "Extensive forearm deep venous thrombosis following a severe infliximab infusion reaction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[41]], "entity_id": ["T4"]}, "Effect": {"text": [["Extensive forearm deep venous thrombosis"], ["nfusion reaction"]], "start": [[0], [72]], "entity_id": ["T3", "T6"]}, "Treatment": {"text": [["infliximab"]], "start": [[60]], "entity_id": ["T5"], "Drug": {"text": [["infliximab"]], "start": [[60]], "entity_id": ["T8"]}}, "Severity": {"text": [["severe"]], "start": [[53]], "entity_id": ["T7"], "value": "Medium"}}]}]}
{"id": "527355_2", "context": "Severe acidosis from acetazolamide in a diabetic patient.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["from"]], "start": [[16]], "entity_id": ["T5"]}, "Subject": {"text": [["a diabetic patient"]], "start": [[38]], "entity_id": ["T3"], "Disorder": {"text": [["diabetic"]], "start": [[40]], "entity_id": ["T7"]}}, "Effect": {"text": [["Severe acidosis"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["acetazolamide"]], "start": [[21]], "entity_id": ["T6"], "Drug": {"text": [["acetazolamide"]], "start": [[21]], "entity_id": ["T9"]}}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T8"], "value": "Medium"}}]}]}
{"id": "18607107_1", "context": "CONCLUSIONS: Clinicians should be aware that Crohn's disease is a potential novel adverse drug effect of Copaxone.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["effect"]], "start": [[95]], "entity_id": ["T6"]}, "Effect": {"text": [["Crohn's disease"]], "start": [[45]], "entity_id": ["T3"]}, "Treatment": {"text": [["Copaxone"]], "start": [[105]], "entity_id": ["T4"], "Drug": {"text": [["Copaxone"]], "start": [[105]], "entity_id": ["T7"]}}, "Speculated": {"text": [["potential"]], "start": [[66]], "entity_id": ["T5"], "value": true}}]}]}
{"id": "16062101_2", "context": "ADR induced by drug treatment can be a side effect of treatment with antipsychotic drugs and other drugs; however, there have been no reports of lamivudine-induced ADR in the English literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[156]], "entity_id": ["T5"]}, "Treatment": {"text": [["lamivudine"]], "start": [[145]], "entity_id": ["T4"], "Drug": {"text": [["lamivudine"]], "start": [[145]], "entity_id": ["T7"]}}, "Effect": {"text": [["ADR"]], "start": [[164]], "entity_id": ["T6"]}, "Negated": {"text": [["no"]], "start": [[131]], "entity_id": ["T3"], "value": true}}]}]}
{"id": "17324248_2", "context": "CONCLUSIONS: The piloerection observed after the replacement of fluvoxamine with milnacipran in this patient appears to have been due to an increase in the alpha(1)-adrenoceptor occupancy by endogenous norepinephrine induced by milnacipran.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[217]], "entity_id": ["T5"]}, "Treatment": {"text": [["milnacipran"]], "start": [[228]], "entity_id": ["T6"], "Drug": {"text": [["milnacipran"]], "start": [[228]], "entity_id": ["T8"]}}, "Effect": {"text": [["an increase in the alpha(1)-adrenoceptor occupancy by endogenous norepinephrine"]], "start": [[137]], "entity_id": ["T7"]}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["observed"]], "start": [[30]], "entity_id": ["T13"]}, "Effect": {"text": [["piloerection"]], "start": [[17]], "entity_id": ["T12"]}, "Subject": {"text": [["this patient"]], "start": [[96]], "entity_id": ["T4"]}, "Treatment": {"text": [["milnacipran"]], "start": [[81]], "entity_id": ["T10"], "Drug": {"text": [["milnacipran"]], "start": [[81]], "entity_id": ["T11"]}}}]}]}
{"id": "17122225_1", "context": "Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["from"]], "start": [[19]], "entity_id": ["T8"]}, "Effect": {"text": [["Serotonin syndrome"]], "start": [[0]], "entity_id": ["T6"]}, "Treatment": {"text": [["interaction of cyclobenzaprine with other serotoninergic drugs"]], "start": [[28]], "entity_id": ["T7"], "Drug": {"text": [["cyclobenzaprine"], ["serotoninergic drugs"]], "start": [[43], [70]], "entity_id": ["T9", "T10"]}}}]}]}
{"id": "19897274_1", "context": "However, a recent post-marketing survey in Japan revealed that interstitial pneumonia occurred in 4 among approximately 2 000 Japanese patients treated with sorafenib.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurred"]], "start": [[86]], "entity_id": ["T6"]}, "Subject": {"text": [["4 among approximately 2 000 Japanese patients"]], "start": [[98]], "entity_id": ["T3"], "Race": {"text": [["Japanese"]], "start": [[126]], "entity_id": ["T8"]}, "Population": {"text": [["4 among approximately 2 000"]], "start": [[98]], "entity_id": ["T7"]}}, "Treatment": {"text": [["sorafenib"]], "start": [[157]], "entity_id": ["T4"], "Drug": {"text": [["sorafenib"]], "start": [[157]], "entity_id": ["T9"]}}, "Effect": {"text": [["interstitial pneumonia"]], "start": [[63]], "entity_id": ["T5"]}}]}]}
{"id": "20338114_2", "context": "The other patient developed transient intraoperative hypertension immediately after inadvertent submucosal injection of concentrated epinephrine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[18]], "entity_id": ["T3"]}, "Effect": {"text": [["transient intraoperative hypertension immediately"]], "start": [[28]], "entity_id": ["T4"]}, "Treatment": {"text": [["inadvertent submucosal injection of concentrated epinephrine"]], "start": [[84]], "entity_id": ["T6"], "Drug": {"text": [["epinephrine"]], "start": [[133]], "entity_id": ["T5"]}, "Route": {"text": [["injection"]], "start": [[107]], "entity_id": ["T7"]}}, "Subject": {"text": [["The other patient"]], "start": [[0]], "entity_id": ["T8"]}}]}]}
{"id": "1722991_9", "context": "This experience supports the hypothesis that heparin can be readministered early to patients with heparin-associated thrombocytopenia and thrombosis, provided antiplatelet therapy is given.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["readministered"]], "start": [[60]], "entity_id": ["T13"]}, "Treatment": {"text": [["heparin", "antiplatelet therapy is given"]], "start": [[45, 159]], "entity_id": ["T10"], "Disorder": {"text": [["heparin-associated thrombocytopenia"]], "start": [[98]], "entity_id": ["T17"]}, "Drug": {"text": [["heparin"], ["antiplatelet"]], "start": [[45], [159]], "entity_id": ["T14", "T18"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["given"]], "start": [[183]], "entity_id": ["T19"]}, "Drug": {"text": [["antiplatelet"], ["heparin"]], "start": [[159], [45]], "entity_id": ["T18", "T14"]}}]}, "Speculated": {"text": [["hypothesis"]], "start": [[29]], "entity_id": ["T20"], "value": true}}, {"event_id": "E3", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[106]], "entity_id": ["T21"]}, "Treatment": {"text": [["heparin"]], "start": [[98]], "entity_id": ["T24"], "Drug": {"text": [["heparin"]], "start": [[98]], "entity_id": ["T22"]}}, "Effect": {"text": [["thrombocytopenia and thrombosis"]], "start": [[117]], "entity_id": ["T23"]}}]}]}
{"id": "3997294_1", "context": "Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[65]], "entity_id": ["T8"]}, "Effect": {"text": [["Pneumonitis with pleural and pericardial effusion and neuropathy"]], "start": [[0]], "entity_id": ["T7"]}, "Treatment": {"text": [["amiodarone therapy"]], "start": [[72]], "entity_id": ["T9"], "Drug": {"text": [["amiodarone"]], "start": [[72]], "entity_id": ["T10"]}}}]}]}
{"id": "15852680_2", "context": "We report a case of interstitial pneumonitis induced by bicalutamide and/or leuprorelin acetate given as therapy for prostate cancer, in which the pneumonitis was successfully managed by steroid treatment.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[45]], "entity_id": ["T5"]}, "Effect": {"text": [["interstitial pneumonitis"]], "start": [[20]], "entity_id": ["T4"]}, "Subject": {"text": [["a case"]], "start": [[10]], "entity_id": ["T8"]}, "Treatment": {"text": [["bicalutamide and/or leuprorelin acetate given as therapy for prostate cancer"]], "start": [[56]], "entity_id": ["T6"], "Disorder": {"text": [["prostate cancer"]], "start": [[117]], "entity_id": ["T7"]}, "Drug": {"text": [["bicalutamide"], ["leuprorelin acetate"]], "start": [[56], [76]], "entity_id": ["T9", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[69]], "entity_id": ["T10"]}, "Drug": {"text": [["bicalutamide"], ["leuprorelin acetate"]], "start": [[56], [76]], "entity_id": ["T9", "T11"]}}]}}]}]}
{"id": "10410183_9", "context": "For those patients with a history of NMS, or even of isolated serum CK elevation during antipsychotic therapy, follow-up should be stricter.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[81]], "entity_id": ["T10"]}, "Subject": {"text": [["patients with a history of NMS"]], "start": [[10]], "entity_id": ["T8"], "Disorder": {"text": [["a history of NMS"]], "start": [[24]], "entity_id": ["T12"]}}, "Effect": {"text": [["isolated serum CK elevation"]], "start": [[53]], "entity_id": ["T9"]}, "Treatment": {"text": [["antipsychotic therapy"]], "start": [[88]], "entity_id": ["T11"]}}]}]}
{"id": "8292513_2", "context": "Children with acute lymphoblastic leukemia (ALL), treated with L-asparaginase are at risk for cerebral thrombosis or hemorrhage because of coagulation protein deficiencies.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["risk"]], "start": [[85]], "entity_id": ["T9"]}, "Treatment": {"text": [["L-asparaginase"]], "start": [[63]], "entity_id": ["T7"], "Drug": {"text": [["L-asparaginase"]], "start": [[63]], "entity_id": ["T13"]}, "Disorder": {"text": [["acute lymphoblastic leukemia (ALL)"]], "start": [[14]], "entity_id": ["T14"]}}, "Subject": {"text": [["Children with acute lymphoblastic leukemia (ALL)"]], "start": [[0]], "entity_id": ["T8"], "Age": {"text": [["Children"]], "start": [[0]], "entity_id": ["T11"]}}, "Effect": {"text": [["cerebral thrombosis or hemorrhage", "coagulation protein deficiencies"]], "start": [[94, 139]], "entity_id": ["T10"]}}]}]}
{"id": "8530331_6", "context": "Two of the five patients who worsened motorically also developed encephalopathy during risperidone treatment; the encephalopathy resolved when the patients were switched to clozapine treatment.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[55]], "entity_id": ["T9"]}, "Subject": {"text": [["Two of the five patients who worsened motorically"]], "start": [[0]], "entity_id": ["T8"], "Population": {"text": [["Two of the five"]], "start": [[0]], "entity_id": ["T12"]}, "Disorder": {"text": [["worsened motorically"]], "start": [[29]], "entity_id": ["T13"]}}, "Effect": {"text": [["encephalopathy"]], "start": [[65]], "entity_id": ["T10"]}, "Treatment": {"text": [["risperidone treatment"]], "start": [[87]], "entity_id": ["T11"], "Drug": {"text": [["risperidone"]], "start": [[87]], "entity_id": ["T14"]}}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["resolved"]], "start": [[129]], "entity_id": ["T1"]}, "Subject": {"text": [["Two of the five patients who worsened motorically"]], "start": [[0]], "entity_id": ["T8"], "Population": {"text": [["Two of the five"]], "start": [[0]], "entity_id": ["T12"]}, "Disorder": {"text": [["worsened motorically"]], "start": [[29]], "entity_id": ["T13"]}}, "Treatment": {"text": [["switched to clozapine treatment"]], "start": [[161]], "entity_id": ["T3"], "Disorder": {"text": [["encephalopathy"]], "start": [[114]], "entity_id": ["T2"]}, "Drug": {"text": [["clozapine"]], "start": [[173]], "entity_id": ["T4"]}}}]}]}
{"id": "25157214_2", "context": "The effectiveness of sugammadex in reversing rocuronium-induced neuromuscular blockade (NMB) in the presence of drugs that may potentiate NMB remains to be fully established.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[56]], "entity_id": ["T8"]}, "Treatment": {"text": [["rocuronium"]], "start": [[45]], "entity_id": ["T9"], "Drug": {"text": [["rocuronium"]], "start": [[45]], "entity_id": ["T12"]}}, "Effect": {"text": [["neuromuscular blockade (NMB)"]], "start": [[64]], "entity_id": ["T10"]}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["reversing"]], "start": [[35]], "entity_id": ["T15"]}, "Treatment": {"text": [["sugammadex", "in the presence of drugs that may potentiate NMB"]], "start": [[21, 93]], "entity_id": ["T13"], "Disorder": {"text": [["rocuronium-induced neuromuscular blockade (NMB)"]], "start": [[45]], "entity_id": ["T16"]}, "Drug": {"text": [["sugammadex"]], "start": [[21]], "entity_id": ["T14"]}}, "Speculated": {"text": [["remains to be fully established"]], "start": [[142]], "entity_id": ["T11"], "value": true}}]}]}
{"id": "2781955_1", "context": "Dexamethasone treatment of amiodarone-induced thyrotoxicosis (AIT) with or without persistent administration of the drug.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[38]], "entity_id": ["T3"]}, "Treatment": {"text": [["amiodarone"]], "start": [[27]], "entity_id": ["T4"], "Drug": {"text": [["amiodarone"]], "start": [[27]], "entity_id": ["T6"]}}, "Effect": {"text": [["thyrotoxicosis (AIT)"]], "start": [[46]], "entity_id": ["T5"]}}]}]}
{"id": "7973922_1", "context": "Acyclovir neurotoxicity: clinical experience and review of the literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["experience"]], "start": [[34]], "entity_id": ["T5"]}, "Treatment": {"text": [["Acyclovir"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Acyclovir"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["neurotoxicity"]], "start": [[10]], "entity_id": ["T4"]}}]}]}
{"id": "24163322_1", "context": "Inadvertent exaggerated anticoagulation following use of bismuth subsalicylate in an enterally fed patient receiving warfarin therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[40]], "entity_id": ["T8"]}, "Effect": {"text": [["Inadvertent exaggerated anticoagulation"]], "start": [[0]], "entity_id": ["T7"]}, "Treatment": {"text": [["bismuth subsalicylate", "warfarin therapy"]], "start": [[57, 117]], "entity_id": ["T9"], "Drug": {"text": [["warfarin"], ["bismuth subsalicylate"]], "start": [[117], [57]], "entity_id": ["T11", "T12"]}}, "Subject": {"text": [["an enterally fed patient"]], "start": [[82]], "entity_id": ["T10"]}}]}]}
{"id": "9230324_1", "context": "We report the specifics of 12 cases of severe hypertension after the intraoperative use of topical phenylephrine, submucosal epinephrine, or both.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[59]], "entity_id": ["T5"]}, "Subject": {"text": [["12 cases"]], "start": [[27]], "entity_id": ["T4"], "Population": {"text": [["12"]], "start": [[27]], "entity_id": ["T8"]}}, "Treatment": {"text": [["intraoperative use of topical phenylephrine, submucosal epinephrine, or both"]], "start": [[69]], "entity_id": ["T6"], "Drug": {"text": [["phenylephrine"], ["epinephrine"]], "start": [[99], [125]], "entity_id": ["T9", "T10"]}, "Route": {"text": [["topical"], ["submucosal"]], "start": [[91], [114]], "entity_id": ["T11", "T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["or both"]], "start": [[138]], "entity_id": ["T14"]}, "Drug": {"text": [["epinephrine"], ["phenylephrine"]], "start": [[125], [99]], "entity_id": ["T10", "T9"]}}]}, "Effect": {"text": [["hypertension"]], "start": [[46]], "entity_id": ["T7"]}, "Severity": {"text": [["severe"]], "start": [[39]], "entity_id": ["T12"], "value": "High"}}]}]}
{"id": "8384030_5", "context": "The patient experienced muscle twitches, tremulousness, and anxiety on day 17 of foscarnet therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["experienced"]], "start": [[12]], "entity_id": ["T10"]}, "Effect": {"text": [["muscle twitches, tremulousness, and anxiet"]], "start": [[24]], "entity_id": ["T7"]}, "Treatment": {"text": [["foscarnet therapy"]], "start": [[81]], "entity_id": ["T8"], "Drug": {"text": [["foscarnet"]], "start": [[81]], "entity_id": ["T11"]}, "Time_elapsed": {"text": [["on day 17"]], "start": [[68]], "entity_id": ["T12"]}}, "Subject": {"text": [["patient"]], "start": [[4]], "entity_id": ["T9"]}}]}]}
{"id": "7282702_1", "context": "A case of timolol-associated heart failure in a 73-year old white man is reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[18]], "entity_id": ["T5"]}, "Subject": {"text": [["a 73-year old white man"]], "start": [[46]], "entity_id": ["T3"], "Age": {"text": [["73-year old"]], "start": [[48]], "entity_id": ["T7"]}, "Race": {"text": [["white"]], "start": [[60]], "entity_id": ["T8"]}, "Gender": {"text": [["man"]], "start": [[66]], "entity_id": ["T9"]}}, "Treatment": {"text": [["timolol"]], "start": [[10]], "entity_id": ["T4"], "Drug": {"text": [["timolol"]], "start": [[10]], "entity_id": ["T10"]}}, "Effect": {"text": [["heart failure"]], "start": [[29]], "entity_id": ["T6"]}}]}]}
{"id": "25407257_6", "context": "In December, he was prescribed 160 mg/day tebipenem pivoxil by an otolaryngologist for inflammation of the tympanic membrane.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["for"]], "start": [[83]], "entity_id": ["T5"]}, "Treatment": {"text": [["160 mg/day tebipenem pivoxil"]], "start": [[31]], "entity_id": ["T7"], "Disorder": {"text": [["inflammation of the tympanic membrane"]], "start": [[87]], "entity_id": ["T6"]}, "Dosage": {"text": [["160 mg/day"]], "start": [[31]], "entity_id": ["T10"]}, "Drug": {"text": [["tebipenem pivoxil"]], "start": [[42]], "entity_id": ["T11"]}}, "Subject": {"text": [["he"]], "start": [[13]], "entity_id": ["T8"], "Gender": {"text": [["he"]], "start": [[13]], "entity_id": ["T9"]}}}]}]}
{"id": "19669617_1", "context": "A 65-year-old female patient presented with jaundice followed 2 days later by severe dyspnea and tachypnea which worsened when patient was lying flat, 1 week after the fourth dose of adalimumab.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["presented"]], "start": [[29]], "entity_id": ["T8"]}, "Treatment": {"text": [["1 week after the fourth dose of adalimumab"]], "start": [[151]], "entity_id": ["T7"], "Drug": {"text": [["adalimumab"]], "start": [[183]], "entity_id": ["T13"]}, "Time_elapsed": {"text": [["1 week after"]], "start": [[151]], "entity_id": ["T14"]}, "Dosage": {"text": [["fourth dose"]], "start": [[168]], "entity_id": ["T15"]}}, "Effect": {"text": [["jaundice followed 2 days later by severe dyspnea and tachypnea which worsened when patient was lying flat"]], "start": [[44]], "entity_id": ["T9"]}, "Subject": {"text": [["A 65-year-old female patient"]], "start": [[0]], "entity_id": ["T10"], "Age": {"text": [["65-year-old"]], "start": [[2]], "entity_id": ["T11"]}, "Gender": {"text": [["female"]], "start": [[14]], "entity_id": ["T12"]}}}]}]}
{"id": "4082283_2", "context": "Renal failure is a rare complication associated with the use of rifampicin for the treatment of tuberculosis, usually occurring well into the course of therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[37]], "entity_id": ["T7"]}, "Effect": {"text": [["Renal failure"]], "start": [[0]], "entity_id": ["T6"]}, "Treatment": {"text": [["rifampicin"]], "start": [[64]], "entity_id": ["T8"], "Drug": {"text": [["rifampicin"]], "start": [[64]], "entity_id": ["T10"]}, "Disorder": {"text": [["tuberculosis"]], "start": [[96]], "entity_id": ["T11"]}}}]}]}
{"id": "21887897_1", "context": "An autopsy case of multiple psychotropic drug poisoning.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["poisoning"]], "start": [[46]], "entity_id": ["T5"]}, "Effect": {"text": [["poisoning"]], "start": [[46]], "entity_id": ["T4"]}, "Treatment": {"text": [["multiple psychotropic drug"]], "start": [[19]], "entity_id": ["T6"], "Drug": {"text": [["psychotropic"]], "start": [[28]], "entity_id": ["T9"]}}, "Subject": {"text": [["An autopsy case"]], "start": [[0]], "entity_id": ["T7"]}}]}]}
{"id": "2212262_1", "context": "Severe heparin associated thrombocytopenia is a rare complication of heparin therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[15]], "entity_id": ["T5"]}, "Treatment": {"text": [["heparin"]], "start": [[7]], "entity_id": ["T4"], "Drug": {"text": [["heparin"]], "start": [[7]], "entity_id": ["T7"]}}, "Effect": {"text": [["thrombocytopenia"]], "start": [[26]], "entity_id": ["T6"]}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T8"], "value": "High"}}]}]}
{"id": "10546851_5", "context": "Six patients at steady state in treatment with indinavir participated in the study.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatment"]], "start": [[32]], "entity_id": ["T6"]}, "Subject": {"text": [["Six patients"]], "start": [[0]], "entity_id": ["T4"], "Population": {"text": [["Six"]], "start": [[0]], "entity_id": ["T7"]}}, "Treatment": {"text": [["indinavir"]], "start": [[47]], "entity_id": ["T5"], "Drug": {"text": [["indinavir"]], "start": [[47]], "entity_id": ["T8"]}}}]}]}
{"id": "19034138_6", "context": "RESULTS: A 52-year-old woman with Parkinson disease who had taken amantadine for 6 years had bilateral corneal edema for 2 months at baseline.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["had"]], "start": [[89]], "entity_id": ["T6"]}, "Subject": {"text": [["A 52-year-old woman with Parkinson disease"]], "start": [[9]], "entity_id": ["T3"], "Age": {"text": [["52-year-old"]], "start": [[11]], "entity_id": ["T7"]}, "Gender": {"text": [["woman"]], "start": [[23]], "entity_id": ["T8"]}}, "Effect": {"text": [["bilateral corneal edema for 2 months at baseline"]], "start": [[93]], "entity_id": ["T4"]}, "Treatment": {"text": [["taken amantadine for 6 years"]], "start": [[60]], "entity_id": ["T5"], "Disorder": {"text": [["Parkinson disease"]], "start": [[34]], "entity_id": ["T9"]}, "Drug": {"text": [["amantadine"]], "start": [[66]], "entity_id": ["T10"]}, "Duration": {"text": [["6 years"]], "start": [[81]], "entity_id": ["T11"]}}}]}]}
{"id": "12114387_3", "context": "We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with epoprostenol, presented with rapidly progressive erythema, scaling, nausea and vomiting, and fever.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["presented"]], "start": [[157]], "entity_id": ["T12"]}, "Treatment": {"text": [["2 months of treatment with epoprostenol"]], "start": [[116]], "entity_id": ["T11"], "Drug": {"text": [["epoprostenol"]], "start": [[143]], "entity_id": ["T17"]}, "Time_elapsed": {"text": [["after 2 months"]], "start": [[110]], "entity_id": ["T18"]}, "Disorder": {"text": [["pulmonary hypertension"], ["undifferentiated connective tissue disease"]], "start": [[35], [62]], "entity_id": ["T19", "T20"]}}, "Effect": {"text": [["rapidly progressive erythema, scaling, nausea and vomiting, and fever"]], "start": [[172]], "entity_id": ["T13"]}, "Subject": {"text": [["a patient with pulmonary hypertension and undifferentiated connective tissue disease"]], "start": [[20]], "entity_id": ["T14"]}}]}]}
{"id": "12587815_3", "context": "Neuroleptic malignant syndrome in an adolescent receiving olanzapine-lithium combination therapy.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["receiving"]], "start": [[48]], "entity_id": ["T7"]}, "Effect": {"text": [["Neuroleptic malignant syndrome"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["olanzapine-lithium combination therapy"]], "start": [[58]], "entity_id": ["T6"], "Drug": {"text": [["olanzapine"], ["lithium"]], "start": [[58], [69]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combination"]], "start": [[77]], "entity_id": ["T5"]}, "Drug": {"text": [["lithium"], ["olanzapine"]], "start": [[69], [58]], "entity_id": ["T10", "T9"]}}]}, "Subject": {"text": [["adolescent"]], "start": [[37]], "entity_id": ["T8"]}}]}]}
{"id": "3878320_1", "context": "A lethal complication of peripheral vein vasopressin infusion.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[9]], "entity_id": ["T4"]}, "Effect": {"text": [["complication"]], "start": [[9]], "entity_id": ["T3"]}, "Treatment": {"text": [["peripheral vein vasopressin infusion"]], "start": [[25]], "entity_id": ["T5"], "Route": {"text": [["peripheral vein"]], "start": [[25]], "entity_id": ["T6"]}, "Drug": {"text": [["vasopressin"]], "start": [[41]], "entity_id": ["T7"]}}, "Severity": {"text": [["lethal"]], "start": [[2]], "entity_id": ["T8"], "value": "High"}}]}]}
{"id": "16641839_3", "context": "Cutaneous eruptions occur in 3% of individuals administered carbamazepine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occur"]], "start": [[20]], "entity_id": ["T4"]}, "Effect": {"text": [["Cutaneous eruptions"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["carbamazepine"]], "start": [[60]], "entity_id": ["T5"], "Drug": {"text": [["carbamazepine"]], "start": [[60]], "entity_id": ["T6"]}}, "Speculated": {"text": [["3% of individuals"]], "start": [[29]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "23868369_2", "context": "A 27 year old female with a complex history of congenital heart disease, cardiac surgery, heart failure, and arrhythmias was admitted for a Pseudomonas aeruginosa sternal wound infection and treated with intravenous antibiotics.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[191]], "entity_id": ["T11"]}, "Subject": {"text": [["A 27 year old female with a complex history of congenital heart disease, cardiac surgery, heart failure, and arrhythmias"]], "start": [[0]], "entity_id": ["T8"], "Age": {"text": [["27 year old"]], "start": [[2]], "entity_id": ["T12"]}, "Gender": {"text": [["female"]], "start": [[14]], "entity_id": ["T13"]}, "Disorder": {"text": [["congenital heart disease"], ["cardiac surgery"], ["heart failure"], ["arrhythmias"]], "start": [[47], [73], [90], [109]], "entity_id": ["T14", "T15", "T16", "T17"]}}, "Treatment": {"text": [["intravenous antibiotics"]], "start": [[204]], "entity_id": ["T10"], "Drug": {"text": [["antibiotics"]], "start": [[216]], "entity_id": ["T18"]}, "Route": {"text": [["intravenous"]], "start": [[204]], "entity_id": ["T19"]}, "Disorder": {"text": [["a Pseudomonas aeruginosa sternal wound infection"]], "start": [[138]], "entity_id": ["T20"]}}}]}]}
{"id": "8244201_2", "context": "Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole-trimethoprim (co-trimoxazole) is described in 2 elderly Japanese patients with lymphoid malignancy, who developed Pneumocystis carinii pneumonia and improved.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["described"]], "start": [[114]], "entity_id": ["T10"]}, "Treatment": {"text": [["oral therapy of sulfamethoxazole-trimethoprim (co-trimoxazole)"]], "start": [[48]], "entity_id": ["T8"], "Route": {"text": [["oral"]], "start": [[48]], "entity_id": ["T15"]}, "Drug": {"text": [["sulfamethoxazole-trimethoprim"]], "start": [[64]], "entity_id": ["T16"]}, "Disorder": {"text": [["Pneumocystis carinii pneumonia"]], "start": [[195]], "entity_id": ["T1"]}}, "Subject": {"text": [["2 elderly Japanese patients with lymphoid malignancy"]], "start": [[127]], "entity_id": ["T9"], "Population": {"text": [["2"]], "start": [[127]], "entity_id": ["T11"]}, "Age": {"text": [["elderly"]], "start": [[129]], "entity_id": ["T12"]}, "Race": {"text": [["Japanese"]], "start": [[137]], "entity_id": ["T13"]}, "Disorder": {"text": [["lymphoid malignancy"]], "start": [[160]], "entity_id": ["T14"]}}, "Effect": {"text": [["Hyperkalaemia with renal tubular dysfunction"]], "start": [[0]], "entity_id": ["T2"]}}]}]}
{"id": "18067642_4", "context": "This is the first report on the histopathological findings of thyroid tissue from a patient with amiodarone-induced hypothyroidism.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[108]], "entity_id": ["T3"]}, "Effect": {"text": [["hypothyroidism"]], "start": [[116]], "entity_id": ["T4"]}, "Treatment": {"text": [["amiodarone"]], "start": [[97]], "entity_id": ["T5"], "Drug": {"text": [["amiodarone"]], "start": [[97]], "entity_id": ["T7"]}}}]}]}
{"id": "8771575_2", "context": "Acute pulmonary reactions to nitrofurantoin are an uncommon side effect of therapy and can cause minor or life-threatening pulmonary dysfunction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["are"]], "start": [[44]], "entity_id": ["T7"]}, "Effect": {"text": [["Acute pulmonary reactions", "can cause minor or life-threatening pulmonary dysfunction"]], "start": [[0, 87]], "entity_id": ["T5"]}, "Treatment": {"text": [["nitrofurantoin"]], "start": [[29]], "entity_id": ["T6"], "Drug": {"text": [["nitrofurantoin"]], "start": [[29]], "entity_id": ["T10"]}}, "Speculated": {"text": [["can"]], "start": [[87]], "entity_id": ["T8"], "value": true}, "Severity": {"text": [["minor or life-threatening"]], "start": [[97]], "entity_id": ["T9"], "value": "Medium"}}]}]}
{"id": "2554727_2", "context": "High-dose cytosine arabinoside may benefit patients with refractory acute leukemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["benefit"]], "start": [[35]], "entity_id": ["T7"]}, "Treatment": {"text": [["High-dose cytosine arabinoside"]], "start": [[0]], "entity_id": ["T6"], "Disorder": {"text": [["refractory acute leukemia"]], "start": [[57]], "entity_id": ["T9"]}, "Dosage": {"text": [["High-dose"]], "start": [[0]], "entity_id": ["T11"]}, "Drug": {"text": [["cytosine arabinoside"]], "start": [[10]], "entity_id": ["T12"]}}, "Subject": {"text": [["patients with refractory acute leukemia"]], "start": [[43]], "entity_id": ["T8"]}, "Speculated": {"text": [["may"]], "start": [[31]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "2452936_1", "context": "Life-threatening hyponatremia caused by vinblastine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[30]], "entity_id": ["T4"]}, "Effect": {"text": [["hyponatremia"]], "start": [[17]], "entity_id": ["T3"]}, "Treatment": {"text": [["vinblastine"]], "start": [[40]], "entity_id": ["T5"], "Drug": {"text": [["vinblastine"]], "start": [[40]], "entity_id": ["T6"]}}}]}]}
{"id": "17556909_3", "context": "We report a myeloma patient who developed severe paralytic ileus during bortezomib therapy, which presented in the context of progressive constipation without other known causes and which regressed promptly with medical management after drug cessation, suggesting a direct causal relationship.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[32]], "entity_id": ["T6"]}, "Subject": {"text": [["a myeloma patient"]], "start": [[10]], "entity_id": ["T3"]}, "Effect": {"text": [["paralytic ileus", "presented in the context of progressive constipation without other known causes and which regressed promptly with medical management after drug cessation"]], "start": [[49, 98]], "entity_id": ["T4"]}, "Treatment": {"text": [["bortezomib therapy"]], "start": [[72]], "entity_id": ["T5"], "Disorder": {"text": [["myeloma"]], "start": [[12]], "entity_id": ["T7"]}, "Drug": {"text": [["bortezomib"]], "start": [[72]], "entity_id": ["T8"]}}, "Severity": {"text": [["severe"]], "start": [[42]], "entity_id": ["T9"], "value": "High"}}]}]}
{"id": "12776809_4", "context": "Here, we report on the drug safety of coumarin with special respect to liver reaction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["respect"]], "start": [[60]], "entity_id": ["T7"]}, "Treatment": {"text": [["coumarin"]], "start": [[38]], "entity_id": ["T4"], "Drug": {"text": [["coumarin"]], "start": [[38]], "entity_id": ["T10"]}}, "Effect": {"text": [["liver reaction"]], "start": [[71]], "entity_id": ["T5"]}, "Speculated": {"text": [["report"]], "start": [[9]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "7865488_2", "context": "However, EO-induced noncardiogenic pulmonary edema has not been reported in human.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[12]], "entity_id": ["T4"]}, "Treatment": {"text": [["EO"]], "start": [[9]], "entity_id": ["T3"], "Drug": {"text": [["EO"]], "start": [[9]], "entity_id": ["T8"]}}, "Effect": {"text": [["noncardiogenic pulmonary edema"]], "start": [[20]], "entity_id": ["T5"]}, "Subject": {"text": [["human"]], "start": [[76]], "entity_id": ["T7"]}, "Negated": {"text": [["not"]], "start": [[55]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "12944250_2", "context": "Since the thrombocyte count started to increase immediately after initiation and dropped immediately after discontinuation of ciprofloxacin and tazobactam/piperacillin and all other drugs were discontinued already before or were started after the nadir of the thrombocyte count, these two antibiotics were regarded causative.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Since"]], "start": [[0]], "entity_id": ["T7"]}, "Treatment": {"text": [["discontinuation of ciprofloxacin and tazobactam/piperacillin"]], "start": [[107]], "entity_id": ["T5"], "Drug": {"text": [["ciprofloxacin"], ["tazobactam/piperacillin"]], "start": [[126], [144]], "entity_id": ["T8", "T9"]}, "Dosage": {"text": [["discontinuation"]], "start": [[107]], "entity_id": ["T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[140]], "entity_id": ["T11"]}, "Drug": {"text": [["tazobactam/piperacillin"], ["ciprofloxacin"]], "start": [[144], [126]], "entity_id": ["T9", "T8"]}}]}, "Effect": {"text": [["the thrombocyte count started to increase immediately after initiation and dropped immediately"]], "start": [[6]], "entity_id": ["T6"]}}]}]}
{"id": "8586895_1", "context": "However, in 1993, a clinical study involving 400 patients on the Thai-Burmese border revealed cardiac effects of antimalarial treatment with halofantrine, including one sudden death after the treatment.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["effects"]], "start": [[102]], "entity_id": ["T5"]}, "Treatment": {"text": [["halofantrine"]], "start": [[141]], "entity_id": ["T6"], "Drug": {"text": [["halofantrine"], ["antimalarial treatment"]], "start": [[141], [113]], "entity_id": ["T11", "T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["with"]], "start": [[136]], "entity_id": ["T12"]}, "Drug": {"text": [["halofantrine"], ["antimalarial treatment"]], "start": [[141], [113]], "entity_id": ["T11", "T13"]}}]}, "Subject": {"text": [["400 patients on the Thai-Burmese border"]], "start": [[45]], "entity_id": ["T7"], "Population": {"text": [["400"]], "start": [[45]], "entity_id": ["T10"]}}, "Effect": {"text": [["cardiac effects", "sudden death"]], "start": [[94, 169]], "entity_id": ["T8"]}}]}]}
{"id": "10723699_1", "context": "Tetracycline-induced benign intracranial hypertension.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[13]], "entity_id": ["T4"]}, "Treatment": {"text": [["Tetracycline"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["a"]], "start": [[4]], "entity_id": ["T7"]}}, "Effect": {"text": [["benign intracranial hypertension"]], "start": [[21]], "entity_id": ["T6"]}}]}]}
{"id": "12889716_2", "context": "Only one case of a generalized maculopapular rash with enoxaparin has been reported in Europe.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[50]], "entity_id": ["T6"]}, "Subject": {"text": [["one case"]], "start": [[5]], "entity_id": ["T3"], "Population": {"text": [["one"]], "start": [[5]], "entity_id": ["T7"]}}, "Effect": {"text": [["generalized maculopapular rash"]], "start": [[19]], "entity_id": ["T4"]}, "Treatment": {"text": [["enoxaparin"]], "start": [[55]], "entity_id": ["T5"], "Drug": {"text": [["enoxaparin"]], "start": [[55]], "entity_id": ["T8"]}}}]}]}
{"id": "15331204_7", "context": "After 3- to 13-month period of therapy without indapamide, glucose levels of all patients decreased and diabetes disappeared.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["After"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["3- to 13-month period of therapy without indapamide"]], "start": [[6]], "entity_id": ["T4"], "Drug": {"text": [["indapamide"]], "start": [[47]], "entity_id": ["T6"]}, "Time_elapsed": {"text": [["3- to 13-month"]], "start": [[6]], "entity_id": ["T7"]}}, "Effect": {"text": [["glucose levels of all patients decreased and diabetes disappeared"]], "start": [[59]], "entity_id": ["T5"]}}]}]}
{"id": "10679548_4", "context": "The favourable outcome in these two patients contrasts with the fatal outcome of the two other reported cases of nitrofurantoin induced BOOP.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[128]], "entity_id": ["T7"]}, "Treatment": {"text": [["nitrofurantoin"]], "start": [[113]], "entity_id": ["T6"], "Drug": {"text": [["nitrofurantoin"]], "start": [[113]], "entity_id": ["T10"]}}, "Effect": {"text": [["BOOP"]], "start": [[136]], "entity_id": ["T8"]}, "Subject": {"text": [["two patients"]], "start": [[32]], "entity_id": ["T5"], "Population": {"text": [["two"]], "start": [[32]], "entity_id": ["T9"]}}}]}]}
{"id": "12163813_3", "context": "Skin necrosis after extravasation of low-dose vasopressin administered for septic shock.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["extravasation"]], "start": [[20]], "entity_id": ["T5"]}, "Treatment": {"text": [["vasopressin"]], "start": [[46]], "entity_id": ["T3"], "Drug": {"text": [["vasopressin"]], "start": [[46]], "entity_id": ["T6"]}, "Disorder": {"text": [["septic shock"]], "start": [[75]], "entity_id": ["T7"]}}, "Effect": {"text": [["Skin necrosis"]], "start": [[0]], "entity_id": ["T4"]}}]}]}
{"id": "24477376_4", "context": "The patient was previously on phenytoin and was initiated on ticagrelor for antiplatelet therapy following stent placement.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["for"]], "start": [[72]], "entity_id": ["T8"]}, "Subject": {"text": [["The patient"]], "start": [[0]], "entity_id": ["T6"]}, "Treatment": {"text": [["previously on phenytoin", "initiated on ticagrelor", "following stent placement"]], "start": [[16, 48, 97]], "entity_id": ["T9"], "Disorder": {"text": [["antiplatelet therapy"]], "start": [[76]], "entity_id": ["T7"]}, "Drug": {"text": [["phenytoin"], ["ticagrelor"]], "start": [[30], [61]], "entity_id": ["T10", "T11"]}}}]}]}
{"id": "8239963_1", "context": "Clonidine-induced bradycardia in patients with spinal cord injury.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[10]], "entity_id": ["T4"]}, "Treatment": {"text": [["Clonidine"]], "start": [[0]], "entity_id": ["T3"], "Disorder": {"text": [["spinal cord injury"]], "start": [[47]], "entity_id": ["T7"]}, "Drug": {"text": [["Clonidine"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["bradycardia"]], "start": [[18]], "entity_id": ["T5"]}, "Subject": {"text": [["patients with spinal cord injury"]], "start": [[33]], "entity_id": ["T6"]}}]}]}
{"id": "11122162_1", "context": "MI related to the use of activated and non-activated PCCs predominantly affects young patients who often have no preceding history of, or risk factors for, MI and tends to be associated with large cumulative doses of concentrate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[3]], "entity_id": ["T4"]}, "Effect": {"text": [["MI"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["activated and non-activated PCCs", "large cumulative doses of concentrate"]], "start": [[25, 191]], "entity_id": ["T5"], "Drug": {"text": [["non-activated PCCs"], ["activated", "PCCs"]], "start": [[39], [25, 53]], "entity_id": ["T8", "T10"]}, "Dosage": {"text": [["large cumulative doses"]], "start": [[191]], "entity_id": ["T9"]}}, "Subject": {"text": [["young patients who often have no preceding history of, or risk factors for, MI"]], "start": [[80]], "entity_id": ["T6"], "Age": {"text": [["young"]], "start": [[80]], "entity_id": ["T7"]}}}]}]}
{"id": "6093724_3", "context": "To our knowledge, we describe the first reported case of isolated paresthesia and peripheral neuropathy, without systemic involvement, secondary to sulindac administration.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["secondary"]], "start": [[135]], "entity_id": ["T7"]}, "Effect": {"text": [["isolated paresthesia and peripheral neuropathy"]], "start": [[57]], "entity_id": ["T5"]}, "Treatment": {"text": [["sulindac administration"]], "start": [[148]], "entity_id": ["T6"], "Drug": {"text": [["sulindac"]], "start": [[148]], "entity_id": ["T9"]}}, "Speculated": {"text": [["To our knowledge"]], "start": [[0]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "9876809_2", "context": "To report a probable case of ticlopidine-induced phenytoin toxicity.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[41]], "entity_id": ["T4"]}, "Treatment": {"text": [["phenytoin", "ticlopidine"]], "start": [[49, 29]], "entity_id": ["T5"], "Drug": {"text": [["ticlopidine"], ["phenytoin"]], "start": [[29], [49]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["induced"]], "start": [[41]], "entity_id": ["T12"]}, "Drug": {"text": [["ticlopidine"], ["phenytoin"]], "start": [[29], [49]], "entity_id": ["T10", "T11"]}}]}, "Subject": {"text": [["a probable case"]], "start": [[10]], "entity_id": ["T6"]}, "Effect": {"text": [["phenytoin toxicity"]], "start": [[49]], "entity_id": ["T8"]}, "Speculated": {"text": [["probable"]], "start": [[12]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "3558331_2", "context": "Two patients are described in whom subtle cognitive impairments are associated with therapeutic doses of amoxapine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[68]], "entity_id": ["T3"]}, "Treatment": {"text": [["therapeutic doses of amoxapine"]], "start": [[84]], "entity_id": ["T4"], "Dosage": {"text": [["therapeutic doses"]], "start": [[84]], "entity_id": ["T8"]}, "Drug": {"text": [["amoxapine"]], "start": [[105]], "entity_id": ["T9"]}}, "Effect": {"text": [["subtle cognitive impairments"]], "start": [[35]], "entity_id": ["T5"]}, "Subject": {"text": [["Two patients"]], "start": [[0]], "entity_id": ["T6"], "Population": {"text": [["Two"]], "start": [[0]], "entity_id": ["T7"]}}, "Severity": {"text": [["subtle"]], "start": [[35]], "entity_id": ["T10"], "value": "Low"}}]}]}
{"id": "16012330_2", "context": "Itraconazole is particularly attractive in fungal prophylaxis for cancer patients due to its broad spectrum, including Candida and Aspergillus.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["prophylaxis"]], "start": [[50]], "entity_id": ["T9"]}, "Treatment": {"text": [["Itraconazole"]], "start": [[0]], "entity_id": ["T8"], "Disorder": {"text": [["fungal"]], "start": [[43]], "entity_id": ["T12"]}, "Drug": {"text": [["Itraconazole"]], "start": [[0]], "entity_id": ["T15"]}}, "Subject": {"text": [["cancer patients"]], "start": [[66]], "entity_id": ["T11"], "Disorder": {"text": [["cancer"]], "start": [[66]], "entity_id": ["T13"]}}, "Speculated": {"text": [["attractive"]], "start": [[29]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "16062101_4", "context": "The authors think that although lamivudine is widely used and well tolerated, it can cause ADRs, which are reversible after drug withdrawal.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[85]], "entity_id": ["T5"]}, "Effect": {"text": [["ADRs"]], "start": [[91]], "entity_id": ["T3"]}, "Treatment": {"text": [["lamivudine"]], "start": [[32]], "entity_id": ["T4"], "Drug": {"text": [["lamivudine"]], "start": [[32]], "entity_id": ["T6"]}}}]}]}
{"id": "1751354_1", "context": "Psoriasis induced by interferon-alpha.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[10]], "entity_id": ["T3"]}, "Effect": {"text": [["Psoriasis"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["interferon-alpha"]], "start": [[21]], "entity_id": ["T5"], "Drug": {"text": [["interferon-alpha"]], "start": [[21]], "entity_id": ["T6"]}}}]}]}
{"id": "12915840_2", "context": "We report the first case of IHA associated with cefuroxime administration.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[32]], "entity_id": ["T4"]}, "Effect": {"text": [["IHA"]], "start": [[28]], "entity_id": ["T3"]}, "Treatment": {"text": [["cefuroxime"]], "start": [[48]], "entity_id": ["T5"], "Drug": {"text": [["cefuroxime"]], "start": [[48]], "entity_id": ["T6"]}}, "Subject": {"text": [["the first case"]], "start": [[10]], "entity_id": ["T7"]}}]}]}
{"id": "7577414_3", "context": "We report a 16-year-old male who developed nephrotic syndrome related to membranous glomerulopathy with clinical and serological evidence of systemic lupus erythematosus after treatment with griseofulvin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[170]], "entity_id": ["T6"]}, "Subject": {"text": [["a 16-year-old male"]], "start": [[10]], "entity_id": ["T5"], "Age": {"text": [["16-year-old"]], "start": [[12]], "entity_id": ["T9"]}, "Gender": {"text": [["male"]], "start": [[24]], "entity_id": ["T10"]}}, "Treatment": {"text": [["treatment with griseofulvin"]], "start": [[176]], "entity_id": ["T8"], "Drug": {"text": [["griseofulvin"]], "start": [[191]], "entity_id": ["T11"]}}, "Effect": {"text": [["nephrotic syndrome related to membranous glomerulopathy with clinical and serological evidence of systemic lupus erythematosus"]], "start": [[43]], "entity_id": ["T7"]}}]}]}
{"id": "10803790_5", "context": "CONCLUSION: In some abstainers who take cyanamide for several years, thin septum-like liver fibrosis progresses along with the emergence of ground-glass hepatocytes.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["In"]], "start": [[12]], "entity_id": ["T8"]}, "Subject": {"text": [["some abstainers"]], "start": [[15]], "entity_id": ["T5"]}, "Treatment": {"text": [["take cyanamide for several years"]], "start": [[35]], "entity_id": ["T6"], "Drug": {"text": [["cyanamide"]], "start": [[40]], "entity_id": ["T9"]}, "Freq": {"text": [["several years"]], "start": [[54]], "entity_id": ["T10"]}}, "Effect": {"text": [["thin septum-like liver fibrosis progresses along with the emergence of ground-glass hepatocytes"]], "start": [[69]], "entity_id": ["T7"]}}]}]}
{"id": "1814986_1", "context": "Metabolic acidosis induced by acetazolamide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[19]], "entity_id": ["T3"]}, "Treatment": {"text": [["acetazolamide"]], "start": [[30]], "entity_id": ["T4"], "Drug": {"text": [["acetazolamide"]], "start": [[30]], "entity_id": ["T6"]}}, "Effect": {"text": [["Metabolic acidosis"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "15359206_2", "context": "In this paper we report a case of nimodipine overdosage resulting in prolonged hypotension and hypoxemia, which was successfully treated with calcium gluconate.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulting"]], "start": [[56]], "entity_id": ["T5"]}, "Treatment": {"text": [["nimodipine overdosage"]], "start": [[34]], "entity_id": ["T6"], "Dosage": {"text": [["overdosage"]], "start": [[45]], "entity_id": ["T8"]}, "Drug": {"text": [["nimodipine"]], "start": [[34]], "entity_id": ["T9"]}}, "Effect": {"text": [["prolonged hypotension and hypoxemia"]], "start": [[69]], "entity_id": ["T7"]}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[129]], "entity_id": ["T12"]}, "Treatment": {"text": [["calcium gluconate"]], "start": [[142]], "entity_id": ["T13"], "Disorder": {"text": [["prolonged hypotension and hypoxemia"]], "start": [[69]], "entity_id": ["T11"]}, "Drug": {"text": [["calcium gluconate"]], "start": [[142]], "entity_id": ["T14"]}}}]}]}
{"id": "21512888_4", "context": "Valproic acid also displaces warfarin from the protein binding sites resulting in significant INR changes but this type of drug interaction is less well known.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulting"]], "start": [[69]], "entity_id": ["T9"]}, "Treatment": {"text": [["Valproic acid also displaces warfarin from the protein binding sites"]], "start": [[0]], "entity_id": ["T7"], "Drug": {"text": [["Valproic acid"], ["warfarin"]], "start": [[0], [29]], "entity_id": ["T12", "T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["displaces"]], "start": [[19]], "entity_id": ["T11"]}, "Drug": {"text": [["Valproic acid"], ["warfarin"]], "start": [[0], [29]], "entity_id": ["T12", "T13"]}}]}, "Effect": {"text": [["significant INR changes"]], "start": [[82]], "entity_id": ["T8"]}, "Speculated": {"text": [["less well known"]], "start": [[143]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "15190230_3", "context": "Therapy with IFN-alpha may be associated with a number of neuropsychiatric symptoms, such as Parkinsonism, akathisia, seizure, and depressive disorders.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated with"]], "start": [[30]], "entity_id": ["T12"]}, "Effect": {"text": [["neuropsychiatric symptoms, such as Parkinsonism, akathisia, seizure, and depressive disorders"]], "start": [[58]], "entity_id": ["T11"]}, "Treatment": {"text": [["Therapy with IFN-alpha"]], "start": [[0]], "entity_id": ["T13"], "Drug": {"text": [["IFN-alpha"]], "start": [[13]], "entity_id": ["T14"]}}}]}]}
{"id": "18805724_1", "context": "DISCUSSION: The main adverse effects of leflunomide consist of diarrhea, nausea, liver enzyme elevation, hypertension, alopecia, and allergic skin reactions.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["effects"]], "start": [[29]], "entity_id": ["T15"]}, "Treatment": {"text": [["leflunomide"]], "start": [[40]], "entity_id": ["T13"], "Drug": {"text": [["leflunomide"]], "start": [[40]], "entity_id": ["T16"]}}, "Effect": {"text": [["diarrhea, nausea, liver enzyme elevation, hypertension, alopecia, and allergic skin reactions"]], "start": [[63]], "entity_id": ["T14"]}}]}]}
{"id": "1445134_3", "context": "In a single practice during the 21 years 1971-1991, the incidence of gestational diabetes in pregnancies in which norethisterone was prescribed was 32.4% (22 of 69) in comparison with 7.1% in pregnancies in which the women did not take norethisterone (137 of 1,684) (p < 0.001).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["incidence"]], "start": [[56]], "entity_id": ["T4"]}, "Effect": {"text": [["gestational diabetes"]], "start": [[69]], "entity_id": ["T3"]}, "Subject": {"text": [["pregnancies"]], "start": [[93]], "entity_id": ["T5"]}, "Treatment": {"text": [["norethisterone"]], "start": [[114]], "entity_id": ["T6"], "Drug": {"text": [["norethisterone"]], "start": [[114]], "entity_id": ["T7"]}}}]}]}
{"id": "1765991_2", "context": "The development of systemic lupus erythematosus (SLE) after 38 months of therapy with recombinant human interferon gamma (rIFN-gamma) was observed in a patient with rheumatoid arthritis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["development"]], "start": [[4]], "entity_id": ["T13"]}, "Treatment": {"text": [["after 38 months", "recombinant human interferon gamma"]], "start": [[54, 86]], "entity_id": ["T11"], "Time_elapsed": {"text": [["after 38 months"]], "start": [[54]], "entity_id": ["T14"]}, "Drug": {"text": [["recombinant human interferon gamma"]], "start": [[86]], "entity_id": ["T15"]}, "Disorder": {"text": [["rheumatoid arthritis."]], "start": [[165]], "entity_id": ["T16"]}}, "Effect": {"text": [["systemic lupus erythematosus"]], "start": [[19]], "entity_id": ["T12"]}, "Subject": {"text": [["a patient with rheumatoid arthritis."]], "start": [[150]], "entity_id": ["T9"]}}]}]}
{"id": "7668127_3", "context": "To the best of our knowledge no comparable case and no discussion of possible complications of aspirin prophylaxis in patients with brain tumours have been published.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complications"]], "start": [[78]], "entity_id": ["T9"]}, "Subject": {"text": [["patients with brain tumours"]], "start": [[118]], "entity_id": ["T7"], "Disorder": {"text": [["brain tumours"]], "start": [[132]], "entity_id": ["T11"]}}, "Treatment": {"text": [["aspirin prophylaxis"]], "start": [[95]], "entity_id": ["T8"], "Drug": {"text": [["aspirin"]], "start": [[95]], "entity_id": ["T12"]}}, "Negated": {"text": [["no"]], "start": [[52]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "16225183_6", "context": "CASE REPORT: We present a case of a 28-yr-old male who developed a severe case of nephrotic syndrome while being treated for relapsing/remitting Multiple Sclerosis (RRMS) with weekly injections of interferon beta 1a.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[55]], "entity_id": ["T12"]}, "Subject": {"text": [["28-yr-old male", "relapsing/remitting Multiple Sclerosis (RRMS)"]], "start": [[36, 125]], "entity_id": ["T8"], "Age": {"text": [["28-yr-old"]], "start": [[36]], "entity_id": ["T14"]}, "Gender": {"text": [["male"]], "start": [[46]], "entity_id": ["T15"]}}, "Effect": {"text": [["nephrotic syndrome"]], "start": [[82]], "entity_id": ["T9"]}, "Treatment": {"text": [["weekly injections of interferon beta 1a"]], "start": [[176]], "entity_id": ["T11"], "Freq": {"text": [["weekly"]], "start": [[176]], "entity_id": ["T16"]}, "Route": {"text": [["injections"]], "start": [[183]], "entity_id": ["T17"]}, "Drug": {"text": [["interferon beta 1a"]], "start": [[197]], "entity_id": ["T18"]}, "Disorder": {"text": [["relapsing/remitting Multiple Sclerosis"]], "start": [[125]], "entity_id": ["T19"]}}, "Severity": {"text": [["severe case"]], "start": [[67]], "entity_id": ["T13"], "value": "High"}}]}]}
{"id": "2369419_3", "context": "This is the third report of reversible hepatic decompensation associated with prolonged MTX therapy in patients with rheumatoid arthritis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[62]], "entity_id": ["T4"]}, "Effect": {"text": [["reversible hepatic decompensation"]], "start": [[28]], "entity_id": ["T3"]}, "Treatment": {"text": [["MTX"]], "start": [[88]], "entity_id": ["T5"], "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[117]], "entity_id": ["T7"]}, "Drug": {"text": [["MTX"]], "start": [[88]], "entity_id": ["T8"]}}, "Subject": {"text": [["patients with rheumatoid arthritis"]], "start": [[103]], "entity_id": ["T6"]}}]}]}
{"id": "17228132_6", "context": "CONCLUSIONS: Acute severe hepatitis though rare is occasionally observed with EGFR inhibitors gefitinib or erlotinib.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["observed"]], "start": [[64]], "entity_id": ["T6"]}, "Treatment": {"text": [["EGFR inhibitors gefitinib or erlotinib"]], "start": [[78]], "entity_id": ["T7"], "Drug": {"text": [["gefitinib"], ["erlotinib"]], "start": [[94], [107]], "entity_id": ["T10", "T11"]}}, "Effect": {"text": [["Acute severe hepatitis"]], "start": [[13]], "entity_id": ["T8"]}, "Severity": {"text": [["severe"]], "start": [[19]], "entity_id": ["T9"], "value": "High"}}]}]}
{"id": "24791374_6", "context": "Propafenone is an established class IC antiarrhythmic drug commonly used in the treatment of atrial fibrillation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatment"]], "start": [[80]], "entity_id": ["T5"]}, "Treatment": {"text": [["Propafenone"]], "start": [[0]], "entity_id": ["T7"], "Disorder": {"text": [["atrial fibrillation"]], "start": [[93]], "entity_id": ["T6"]}, "Drug": {"text": [["Propafenone"]], "start": [[0]], "entity_id": ["T8"]}}}]}]}
{"id": "9972383_3", "context": "Reversible nonthrombocytopenic palpable purpura associated with metoclopramide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[48]], "entity_id": ["T3"]}, "Treatment": {"text": [["metoclopramide"]], "start": [[64]], "entity_id": ["T4"], "Drug": {"text": [["metoclopramide"]], "start": [[64]], "entity_id": ["T6"]}}, "Effect": {"text": [["Reversible nonthrombocytopenic palpable purpura"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "2894766_2", "context": "Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-induced lupus syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[129]], "entity_id": ["T6"]}, "Treatment": {"text": [["sulfasalazine", "sulfasalazine"]], "start": [[19, 115]], "entity_id": ["T3"], "Drug": {"text": [["sulfasalazine"], ["sulfasalazine"]], "start": [[19], [115]], "entity_id": ["T7", "T9"]}, "Disorder": {"text": [["inflammatory bowel disease"]], "start": [[56]], "entity_id": ["T8"]}}, "Effect": {"text": [["lupus syndrome"]], "start": [[137]], "entity_id": ["T4"]}}]}]}
{"id": "6414095_1", "context": "Transient hemiparesis caused by phenytoin toxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[22]], "entity_id": ["T5"]}, "Effect": {"text": [["Transient hemiparesis"]], "start": [[0]], "entity_id": ["T6"]}, "Treatment": {"text": [["phenytoin toxicity"]], "start": [[32]], "entity_id": ["T7"], "Drug": {"text": [["phenytoin"]], "start": [[32]], "entity_id": ["T8"]}}}]}]}
{"id": "2406680_2", "context": "Sensorineural hearing loss due to quinine therapy for malaria has frequently been mentioned in the literature but has not been a subject of research during the last decades.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[27]], "entity_id": ["T3"]}, "Treatment": {"text": [["quinine"]], "start": [[34]], "entity_id": ["T4"], "Disorder": {"text": [["malaria"]], "start": [[54]], "entity_id": ["T5"]}, "Drug": {"text": [["quinine"]], "start": [[34]], "entity_id": ["T8"]}}, "Effect": {"text": [["Sensorineural hearing loss"]], "start": [[0]], "entity_id": ["T6"]}, "Speculated": {"text": [["frequently been mentioned"]], "start": [[66]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "16527771_3", "context": "We report a 78-year-old man who had acute unilateral total visual loss after retrogasserian phenol injection for the treatment of trigeminal neuralgia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[71]], "entity_id": ["T3"]}, "Treatment": {"text": [["retrogasserian phenol injection"]], "start": [[77]], "entity_id": ["T4"], "Disorder": {"text": [["trigeminal neuralgia"]], "start": [[130]], "entity_id": ["T5"]}, "Route": {"text": [["injection"]], "start": [[99]], "entity_id": ["T10"]}, "Drug": {"text": [["phenol"]], "start": [[92]], "entity_id": ["T11"]}}, "Subject": {"text": [["a 78-year-old man"]], "start": [[10]], "entity_id": ["T6"], "Age": {"text": [["78-year-old"]], "start": [[12]], "entity_id": ["T8"]}, "Gender": {"text": [["man"]], "start": [[24]], "entity_id": ["T9"]}}, "Effect": {"text": [["acute unilateral total visual loss"]], "start": [[36]], "entity_id": ["T7"]}}]}]}
{"id": "18983414_1", "context": "Four months after receiving an orthotopic liver transplant, a 51-year-old man was admitted for progressive liver failure and severe hepatocellular necrosis thought to be due to tacrolimus.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due to"]], "start": [[170]], "entity_id": ["T8"]}, "Treatment": {"text": [["tacrolimus"]], "start": [[177]], "entity_id": ["T5"], "Drug": {"text": [["tacrolimus"]], "start": [[177]], "entity_id": ["T10"]}, "Time_elapsed": {"text": [["Four months"]], "start": [[0]], "entity_id": ["T11"]}}, "Effect": {"text": [["progressive liver failure and severe hepatocellular necrosis"]], "start": [[95]], "entity_id": ["T6"]}, "Subject": {"text": [["Four months after receiving an orthotopic liver transplant, a 51-year-old man"]], "start": [[0]], "entity_id": ["T7"], "Age": {"text": [["a 51-year-old"]], "start": [[60]], "entity_id": ["T9"]}}}]}]}
{"id": "10452772_4", "context": "Patients receiving neutral protamine Hagedorn (NPH) insulin are at increased risk for the development of protamine hypersensitivity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["development"]], "start": [[90]], "entity_id": ["T5"]}, "Effect": {"text": [["protamine hypersensitivity"]], "start": [[105]], "entity_id": ["T4"]}, "Subject": {"text": [["Patients"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["neutral protamine Hagedorn (NPH) insulin"]], "start": [[19]], "entity_id": ["T6"], "Drug": {"text": [["neutral protamine Hagedorn (NPH) insulin"]], "start": [[19]], "entity_id": ["T7"]}}, "Severity": {"text": [["increased risk"]], "start": [[67]], "entity_id": ["T8"], "value": "Medium"}}]}]}
{"id": "8053440_3", "context": "The second patient, who developed cholestasis after receiving trimethoprim-sulfamethoxazole, had marked duct paucity in the liver biopsy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[24]], "entity_id": ["T6"]}, "Subject": {"text": [["The second patient"]], "start": [[0]], "entity_id": ["T5"]}, "Effect": {"text": [["cholestasis", "duct paucity"]], "start": [[34, 104]], "entity_id": ["T7"]}, "Treatment": {"text": [["trimethoprim-sulfamethoxazole"]], "start": [[62]], "entity_id": ["T8"], "Drug": {"text": [["trimethoprim-sulfamethoxazole"]], "start": [[62]], "entity_id": ["T9"]}}}]}]}
{"id": "9191742_2", "context": "We describe a patient who became hypothyroid while taking ferrous sulfate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["became"]], "start": [[26]], "entity_id": ["T5"]}, "Effect": {"text": [["hypothyroid"]], "start": [[33]], "entity_id": ["T3"]}, "Treatment": {"text": [["ferrous sulfate"]], "start": [[58]], "entity_id": ["T4"], "Drug": {"text": [["ferrous sulfate"]], "start": [[58]], "entity_id": ["T7"]}}, "Subject": {"text": [["a patient"]], "start": [[12]], "entity_id": ["T6"]}}]}]}
{"id": "16540070_2", "context": "Allergy to cloxacillin with normal tolerance to amoxicillin and cefuroxime.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["to"]], "start": [[8]], "entity_id": ["T4"]}, "Effect": {"text": [["Allergy"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["cloxacillin"]], "start": [[11]], "entity_id": ["T5"], "Drug": {"text": [["cloxacillin"], ["amoxicillin"], ["cefuroxime"]], "start": [[11], [48], [64]], "entity_id": ["T6", "T7", "T8"]}}}]}]}
{"id": "1642627_2", "context": "Triazolam-induced nocturnal bingeing with amnesia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[10]], "entity_id": ["T6"]}, "Treatment": {"text": [["Triazolam"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Triazolam"]], "start": [[0]], "entity_id": ["T9"]}}, "Effect": {"text": [["nocturnal bingeing with amnesia"]], "start": [[18]], "entity_id": ["T7"]}}]}]}
{"id": "12221670_3", "context": "Ticlopidine-induced aplastic anemia (TIAA) is considered very uncommon.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[12]], "entity_id": ["T6"]}, "Treatment": {"text": [["Ticlopidine"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Ticlopidine"]], "start": [[0]], "entity_id": ["T9"]}}, "Effect": {"text": [["aplastic anemia (TIAA)"]], "start": [[20]], "entity_id": ["T7"]}, "Speculated": {"text": [["uncommon"]], "start": [[62]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "14998226_9", "context": "One case report describes an interaction between simvastatin and the anticoagulant acenocoumarol, which resulted in an elevated INR.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulted"]], "start": [[104]], "entity_id": ["T7"]}, "Treatment": {"text": [["simvastatin and the anticoagulant acenocoumarol"]], "start": [[49]], "entity_id": ["T6"], "Drug": {"text": [["simvastatin"], ["anticoagulant acenocoumarol"]], "start": [[49], [69]], "entity_id": ["T11", "T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[61]], "entity_id": ["T13"]}, "Drug": {"text": [["simvastatin"], ["anticoagulant acenocoumarol"]], "start": [[49], [69]], "entity_id": ["T11", "T12"]}}]}, "Effect": {"text": [["elevated INR"]], "start": [[119]], "entity_id": ["T8"]}, "Subject": {"text": [["One case"]], "start": [[0]], "entity_id": ["T9"], "Population": {"text": [["One"]], "start": [[0]], "entity_id": ["T10"]}}}]}]}
{"id": "16884425_1", "context": "A 35-year-old woman presented with neurotoxicity correlated to an i.v. regimen of 5-fluorouracil as episodes of acute confusional state and abnormalities of symmetrically restricted diffusion in the periventricular white matter and corpus callosum.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["correlated"]], "start": [[49]], "entity_id": ["T5"]}, "Treatment": {"text": [["an i.v. regimen of 5-fluorouracil"]], "start": [[63]], "entity_id": ["T6"], "Drug": {"text": [["5-fluorouracil"]], "start": [[82]], "entity_id": ["T11"]}, "Route": {"text": [["i.v."]], "start": [[66]], "entity_id": ["T12"]}}, "Effect": {"text": [["neurotoxicity", "acute confusional state and abnormalities of symmetrically restricted diffusion in the periventricular white matter and corpus callosum"]], "start": [[35, 112]], "entity_id": ["T7"]}, "Subject": {"text": [["A 35-year-old woman"]], "start": [[0]], "entity_id": ["T8"], "Age": {"text": [["35-year-old"]], "start": [[2]], "entity_id": ["T9"]}, "Gender": {"text": [["woman"]], "start": [[14]], "entity_id": ["T10"]}}}]}]}
{"id": "3947272_2", "context": "Ampicillin may aggravate clinical and experimental myasthenia gravis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["aggravate"]], "start": [[15]], "entity_id": ["T4"]}, "Treatment": {"text": [["Ampicillin"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Ampicillin"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["myasthenia gravis"]], "start": [[51]], "entity_id": ["T5"]}, "Speculated": {"text": [["may"]], "start": [[11]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "8586895_2", "context": "In the present paper, we discuss the first Japanese vivax malaria patient whose QT interval was prolonged after treatment with halofantrine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[106]], "entity_id": ["T6"]}, "Subject": {"text": [["Japanese vivax malaria patient"]], "start": [[43]], "entity_id": ["T3"], "Race": {"text": [["Japanese"]], "start": [[43]], "entity_id": ["T7"]}}, "Treatment": {"text": [["halofantrine"]], "start": [[127]], "entity_id": ["T4"], "Disorder": {"text": [["vivax malaria"]], "start": [[52]], "entity_id": ["T8"]}, "Drug": {"text": [["halofantrine"]], "start": [[127]], "entity_id": ["T9"]}}, "Effect": {"text": [["QT interval was prolonged"]], "start": [[80]], "entity_id": ["T5"]}}]}]}
{"id": "1772299_2", "context": "The Center for Disease Control has received numerous reports of an eosinophilia-myalgia syndrome related to products containing L-tryptophan.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[97]], "entity_id": ["T5"]}, "Treatment": {"text": [["products containing L-tryptophan"]], "start": [[108]], "entity_id": ["T3"], "Drug": {"text": [["L-tryptophan"]], "start": [[128]], "entity_id": ["T6"]}}, "Effect": {"text": [["eosinophilia-myalgia syndrome"]], "start": [[67]], "entity_id": ["T4"]}}]}]}
{"id": "6998294_2", "context": "Disopyramide (Norpace)-induced hypoglycemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[23]], "entity_id": ["T5"]}, "Treatment": {"text": [["Disopyramide (Norpace)"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Disopyramide"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["hypoglycemia"]], "start": [[31]], "entity_id": ["T6"]}}]}]}
{"id": "3195622_1", "context": "A case report of the hypersensitivity syndrome occurring in a patient being treated with dapsone for a brown recluse spider bite is presented.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[76]], "entity_id": ["T3"]}, "Treatment": {"text": [["dapsone"]], "start": [[89]], "entity_id": ["T4"], "Drug": {"text": [["dapsone"]], "start": [[89]], "entity_id": ["T7"]}, "Disorder": {"text": [["brown recluse spider bite"]], "start": [[103]], "entity_id": ["T8"]}}, "Effect": {"text": [["hypersensitivity syndrome"]], "start": [[21]], "entity_id": ["T5"]}, "Subject": {"text": [["a patient"]], "start": [[60]], "entity_id": ["T6"]}}]}]}
{"id": "17324248_1", "context": "AIMS: To present a case of piloerection after replacing fluvoxamine maleate with milnacipran hydrochloride, and to analyse this effect based on receptor occupancy theory.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[40]], "entity_id": ["T6"]}, "Effect": {"text": [["piloerection"]], "start": [[27]], "entity_id": ["T4"]}, "Treatment": {"text": [["fluvoxamine maleate"]], "start": [[56]], "entity_id": ["T5"], "Drug": {"text": [["fluvoxamine maleate"], ["milnacipran hydrochloride"]], "start": [[56], [81]], "entity_id": ["T7", "T8"]}}}]}]}
{"id": "18171260_4", "context": "Serotonin syndrome after concomitant linezolid and meperidine therapy has not been described.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[19]], "entity_id": ["T7"]}, "Effect": {"text": [["Serotonin syndrome"]], "start": [[0]], "entity_id": ["T6"]}, "Treatment": {"text": [["linezolid and meperidine"]], "start": [[37]], "entity_id": ["T8"], "Drug": {"text": [["linezolid"], ["meperidine"]], "start": [[37], [51]], "entity_id": ["T9", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["concomitant"]], "start": [[25]], "entity_id": ["T10"]}, "Drug": {"text": [["linezolid"], ["meperidine"]], "start": [[37], [51]], "entity_id": ["T9", "T11"]}}]}, "Negated": {"text": [["not"]], "start": [[74]], "entity_id": ["T12"], "value": true}}]}]}
{"id": "23868369_4", "context": "She presented to clinic with nausea and anorexia within a few days of addition of ciprofloxacin to her current regimen of medications, which included digoxin.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["presented"]], "start": [[4]], "entity_id": ["T8"]}, "Treatment": {"text": [["addition of ciprofloxacin to her current regimen of medications, which included digoxin"]], "start": [[70]], "entity_id": ["T9"], "Time_elapsed": {"text": [["within a few days"]], "start": [[49]], "entity_id": ["T13"]}, "Drug": {"text": [["ciprofloxacin"], ["digoxin"]], "start": [[82], [150]], "entity_id": ["T14", "T15"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["addition"]], "start": [[70]], "entity_id": ["T16"]}, "Drug": {"text": [["ciprofloxacin"], ["digoxin"]], "start": [[82], [150]], "entity_id": ["T14", "T15"]}}]}, "Effect": {"text": [["nausea and anorexia"]], "start": [[29]], "entity_id": ["T10"]}, "Subject": {"text": [["She"]], "start": [[0]], "entity_id": ["T11"], "Gender": {"text": [["She"]], "start": [[0]], "entity_id": ["T12"]}}}]}]}
{"id": "15379082_1", "context": "Disulfiram-induced fulminant hepatic failure in an active duty soldier.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T5"]}, "Subject": {"text": [["an active duty soldier"]], "start": [[48]], "entity_id": ["T3"]}, "Treatment": {"text": [["Disulfiram"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Disulfiram"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["fulminant hepatic failure"]], "start": [[19]], "entity_id": ["T6"]}}]}]}
{"id": "8530331_2", "context": "BACKGROUND: We report six cases of psychosis in patients with akinetic-rigid syndromes who were treated with risperidone.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[96]], "entity_id": ["T9"]}, "Subject": {"text": [["six cases", "patients with akinetic-rigid syndromes"]], "start": [[22, 48]], "entity_id": ["T7"], "Population": {"text": [["six"]], "start": [[22]], "entity_id": ["T11"]}, "Disorder": {"text": [["akinetic-rigid syndromes"]], "start": [[62]], "entity_id": ["T12"]}}, "Treatment": {"text": [["risperidone"]], "start": [[109]], "entity_id": ["T10"], "Disorder": {"text": [["psychosis"]], "start": [[35]], "entity_id": ["T8"]}, "Drug": {"text": [["risperidone"]], "start": [[109]], "entity_id": ["T13"]}}}]}]}
{"id": "19949685_2", "context": "Colonic necrosis is known as a rare complication following the administration of Kayexalate (sodium polystryrene sulfonate) in sorbitol.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[49]], "entity_id": ["T6"]}, "Effect": {"text": [["Colonic necrosis"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["Kayexalate (sodium polystryrene sulfonate) in sorbitol"]], "start": [[81]], "entity_id": ["T5"], "Drug": {"text": [["Kayexalate"], ["sorbitol"]], "start": [[81], [127]], "entity_id": ["T7", "T8"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["in"]], "start": [[124]], "entity_id": ["T9"]}, "Drug": {"text": [["sorbitol"], ["Kayexalate"]], "start": [[127], [81]], "entity_id": ["T8", "T7"]}}]}}]}]}
{"id": "12494253_3", "context": "Anaphylaxis to cisplatin is an infrequent life-threatening complication which may occur even in patients who have received prior treatment with cisplatin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occur"]], "start": [[82]], "entity_id": ["T6"]}, "Effect": {"text": [["Anaphylaxis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["cisplatin"]], "start": [[15]], "entity_id": ["T4"], "Drug": {"text": [["cisplatin"]], "start": [[15]], "entity_id": ["T7"]}}, "Subject": {"text": [["patients"]], "start": [[96]], "entity_id": ["T5"]}, "Severity": {"text": [["life-threatening"]], "start": [[42]], "entity_id": ["T8"], "value": "High"}}]}]}
{"id": "17324248_3", "context": "Piloerection induced by replacing fluvoxamine with milnacipran.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[13]], "entity_id": ["T5"]}, "Effect": {"text": [["Piloerection"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["replacing fluvoxamine with milnacipran"]], "start": [[24]], "entity_id": ["T6"], "Drug": {"text": [["milnacipran"], ["fluvoxamine"]], "start": [[51], [34]], "entity_id": ["T7", "T8"]}}}]}]}
{"id": "14601701_2", "context": "Ethambutol is an antimicrobial agent used frequently to treat tuberculosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treat"]], "start": [[56]], "entity_id": ["T5"]}, "Treatment": {"text": [["Ethambutol"]], "start": [[0]], "entity_id": ["T7"], "Disorder": {"text": [["tuberculosis"]], "start": [[62]], "entity_id": ["T6"]}, "Drug": {"text": [["Ethambutol"]], "start": [[0]], "entity_id": ["T9"]}}, "Speculated": {"text": [["frequently"]], "start": [[42]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "15878975_4", "context": "The purpose of this review is to increase awareness among physicians and other health care professionals that DIC may be a rare but potentially severe complication of anti-D IGIV treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[151]], "entity_id": ["T5"]}, "Effect": {"text": [["DIC"]], "start": [[110]], "entity_id": ["T3"]}, "Treatment": {"text": [["anti-D IGIV"]], "start": [[167]], "entity_id": ["T4"], "Drug": {"text": [["anti-D IGIV"]], "start": [[167]], "entity_id": ["T6"]}}}]}]}
{"id": "8363533_2", "context": "Four Chinese female patients who suffered from manic-depressive disorder and underlying autoimmune thyroiditis developed transient episodes of thyrotoxicosis during maintenance lithium therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[158]], "entity_id": ["T6"]}, "Effect": {"text": [["transient episodes of thyrotoxicosis"]], "start": [[121]], "entity_id": ["T3"]}, "Subject": {"text": [["Four Chinese female patients who suffered from manic-depressive disorder and underlying autoimmune thyroiditis"]], "start": [[0]], "entity_id": ["T5"], "Population": {"text": [["Four"]], "start": [[0]], "entity_id": ["T8"]}, "Race": {"text": [["Chinese"]], "start": [[5]], "entity_id": ["T9"]}, "Gender": {"text": [["female"]], "start": [[13]], "entity_id": ["T10"]}, "Disorder": {"text": [["underlying autoimmune thyroiditis"]], "start": [[77]], "entity_id": ["T1"]}}, "Treatment": {"text": [["maintenance lithium therapy"]], "start": [[165]], "entity_id": ["T7"], "Disorder": {"text": [["manic-depressive disorder"]], "start": [[47]], "entity_id": ["T11"]}, "Drug": {"text": [["lithium"]], "start": [[177]], "entity_id": ["T12"]}}}]}]}
{"id": "17522786_2", "context": "Neurointensive care management of raised intracranial pressure caused by severe valproic acid intoxication.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[63]], "entity_id": ["T4"]}, "Effect": {"text": [["raised intracranial pressure"]], "start": [[34]], "entity_id": ["T3"]}, "Treatment": {"text": [["valproic acid"]], "start": [[80]], "entity_id": ["T5"], "Drug": {"text": [["valproic acid"]], "start": [[80]], "entity_id": ["T6"]}}}]}]}
{"id": "15790469_1", "context": "Primary ovarian large B-cell lymphoma in patient with juvenile rheumatoid arthritis treated with low dose Methotrexate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[38]], "entity_id": ["T1"]}, "Subject": {"text": [["patient with juvenile rheumatoid arthritis"]], "start": [[41]], "entity_id": ["T7"]}, "Treatment": {"text": [["low dose Methotrexate"]], "start": [[97]], "entity_id": ["T9"], "Disorder": {"text": [["juvenile rheumatoid arthritis"]], "start": [[54]], "entity_id": ["T11"]}, "Drug": {"text": [["Methotrexate"]], "start": [[106]], "entity_id": ["T12"]}, "Dosage": {"text": [["low dose"]], "start": [[97]], "entity_id": ["T2"]}}, "Effect": {"text": [["Primary ovarian large B-cell lymphoma"]], "start": [[0]], "entity_id": ["T10"]}}]}]}
{"id": "1420650_1", "context": "Asterixis induced by carbamazepine therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[10]], "entity_id": ["T3"]}, "Treatment": {"text": [["carbamazepine"]], "start": [[21]], "entity_id": ["T4"], "Drug": {"text": [["carbamazepine"]], "start": [[21]], "entity_id": ["T6"]}}, "Effect": {"text": [["Asterixis"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "2320800_6", "context": "Ifosfamide is a known nephrotoxic drug with demonstrated tubulopathies.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[39]], "entity_id": ["T5"]}, "Effect": {"text": [["tubulopathies"]], "start": [[57]], "entity_id": ["T6"]}, "Treatment": {"text": [["Ifosfamide"]], "start": [[0]], "entity_id": ["T7"], "Drug": {"text": [["Ifosfamide"]], "start": [[0]], "entity_id": ["T8"]}}}]}]}
{"id": "7865488_1", "context": "A case of noncardiogenic pulmonary edema by ethanolamine oleate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["by"]], "start": [[41]], "entity_id": ["T3"]}, "Treatment": {"text": [["ethanolamine oleate"]], "start": [[44]], "entity_id": ["T4"], "Drug": {"text": [["ethanolamine oleate"]], "start": [[44]], "entity_id": ["T7"]}}, "Effect": {"text": [["noncardiogenic pulmonary edema"]], "start": [[10]], "entity_id": ["T5"]}, "Subject": {"text": [["A case"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "11737689_1", "context": "A boy with chronic neutropenia and recurrent inflammatory skin lesions developed multiple erythematous nodules following administration of G-CSF.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[71]], "entity_id": ["T4"]}, "Subject": {"text": [["A boy with chronic neutropenia and recurrent inflammatory skin lesions"]], "start": [[0]], "entity_id": ["T3"], "Gender": {"text": [["boy"]], "start": [[2]], "entity_id": ["T7"]}}, "Effect": {"text": [["multiple erythematous nodules"]], "start": [[81]], "entity_id": ["T5"]}, "Treatment": {"text": [["G-CSF"]], "start": [[139]], "entity_id": ["T6"], "Disorder": {"text": [["chronic neutropenia and recurrent inflammatory skin lesions"]], "start": [[11]], "entity_id": ["T9"]}, "Drug": {"text": [["G-CSF"]], "start": [[139]], "entity_id": ["T10"]}}}]}]}
{"id": "1261772_2", "context": "Fulminant hepatitis and lymphocyte sensitization due to propylthiouracil.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[49]], "entity_id": ["T6"]}, "Treatment": {"text": [["propylthiouracil"]], "start": [[56]], "entity_id": ["T3"], "Drug": {"text": [["propylthiouracil"]], "start": [[56]], "entity_id": ["T7"]}}, "Effect": {"text": [["Fulminant hepatitis"], ["lymphocyte sensitization"]], "start": [[0], [24]], "entity_id": ["T4", "T5"]}, "Severity": {"text": [["Fulminant"]], "start": [[0]], "entity_id": ["T8"], "value": "High"}}]}]}
{"id": "9754850_5", "context": "We report on three patients with acute schizophrenia, who developed severe akathisia during treatment with olanzapine (20-25 mg/d).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[102]], "entity_id": ["T5"]}, "Subject": {"text": [["three patients with acute schizophrenia"]], "start": [[13]], "entity_id": ["T3"], "Population": {"text": [["three"]], "start": [[13]], "entity_id": ["T7"]}}, "Effect": {"text": [["akathisia"]], "start": [[75]], "entity_id": ["T4"]}, "Treatment": {"text": [["olanzapine (20-25 mg/d)"]], "start": [[107]], "entity_id": ["T6"], "Disorder": {"text": [["acute schizophrenia"]], "start": [[33]], "entity_id": ["T8"]}, "Drug": {"text": [["olanzapine"]], "start": [[107]], "entity_id": ["T9"]}, "Dosage": {"text": [["20-25 mg/d"]], "start": [[119]], "entity_id": ["T10"]}}, "Severity": {"text": [["severe"]], "start": [[68]], "entity_id": ["T12"], "value": "High"}}]}]}
{"id": "11206417_2", "context": "AIMS/HYPOTHESIS: There is evidence that insulin and glucose cause renal and ocular vasodilation.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[60]], "entity_id": ["T10"]}, "Treatment": {"text": [["insulin and glucose"]], "start": [[40]], "entity_id": ["T9"], "Drug": {"text": [["glucose"], ["insulin"]], "start": [[52], [40]], "entity_id": ["T13", "T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[48]], "entity_id": ["T12"]}, "Drug": {"text": [["insulin"], ["glucose"]], "start": [[40], [52]], "entity_id": ["T14", "T13"]}}]}, "Effect": {"text": [["renal and ocular vasodilation"]], "start": [[66]], "entity_id": ["T11"]}}]}]}
{"id": "17536204_1", "context": "A cause-effect relationship to capecitabine was suggested due to resolution of headache with capecitabine withdrawal and reappearance with capecitabine rechallenge.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["relationship to"]], "start": [[15]], "entity_id": ["T5"]}, "Treatment": {"text": [["capecitabine"]], "start": [[31]], "entity_id": ["T4"], "Drug": {"text": [["capecitabine"]], "start": [[31]], "entity_id": ["T6"]}}, "Effect": {"text": [["headache"]], "start": [[79]], "entity_id": ["T3"]}}]}]}
{"id": "7900744_6", "context": "This is a report of a case of anuric ARF after high-dose mannitol infusion for treatment of narrow-angle glaucoma that readily responded to acute hemodialysis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[41]], "entity_id": ["T7"]}, "Subject": {"text": [["a case"]], "start": [[20]], "entity_id": ["T3"]}, "Effect": {"text": [["anuric ARF"]], "start": [[30]], "entity_id": ["T4"]}, "Treatment": {"text": [["high-dose mannitol infusion"]], "start": [[47]], "entity_id": ["T5"], "Drug": {"text": [["mannitol"]], "start": [[57]], "entity_id": ["T8"]}, "Route": {"text": [["infusion"]], "start": [[66]], "entity_id": ["T9"]}, "Dosage": {"text": [["high-dose"]], "start": [[47]], "entity_id": ["T10"]}, "Disorder": {"text": [["narrow-angle glaucoma"]], "start": [[92]], "entity_id": ["T11"]}}, "Speculated": {"text": [["readily"]], "start": [[119]], "entity_id": ["T12"], "value": true}}]}]}
{"id": "23673446_6", "context": "She was treated with sorafenib at 400 mg daily.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[8]], "entity_id": ["T5"]}, "Subject": {"text": [["She"]], "start": [[0]], "entity_id": ["T4"], "Gender": {"text": [["She"]], "start": [[0]], "entity_id": ["T7"]}}, "Treatment": {"text": [["sorafenib at 400 mg daily"]], "start": [[21]], "entity_id": ["T6"], "Drug": {"text": [["sorafenib"]], "start": [[21]], "entity_id": ["T8"]}, "Dosage": {"text": [["400 mg"]], "start": [[34]], "entity_id": ["T9"]}, "Freq": {"text": [["daily"]], "start": [[41]], "entity_id": ["T10"]}}}]}]}
{"id": "18421192_2", "context": "The clinical course suggested that recombinant alpha-2b peginterferon plus ribavirin provoked type 1 diabetes mellitus, therefore, in patients who are candidates for interferon therapy the presence of pancreatic autoantibodies and the fasting plasma glucose level should be investigated before and during treatment.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["provoked"]], "start": [[85]], "entity_id": ["T5"]}, "Treatment": {"text": [["recombinant alpha-2b peginterferon plus ribavirin"]], "start": [[35]], "entity_id": ["T4"], "Drug": {"text": [["recombinant alpha-2b peginterferon"], ["ribavirin"]], "start": [[35], [75]], "entity_id": ["T7", "T9"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["plus"]], "start": [[70]], "entity_id": ["T8"]}, "Drug": {"text": [["ribavirin"], ["recombinant alpha-2b peginterferon"]], "start": [[75], [35]], "entity_id": ["T9", "T7"]}}]}, "Effect": {"text": [["type 1 diabetes mellitus"]], "start": [[94]], "entity_id": ["T6"]}}]}]}
{"id": "19474653_1", "context": "Rhabdomyolysis following clarithromycin monotherapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[15]], "entity_id": ["T3"]}, "Effect": {"text": [["Rhabdomyolysis"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["clarithromycin monotherapy"]], "start": [[25]], "entity_id": ["T5"], "Drug": {"text": [["clarithromycin"]], "start": [[25]], "entity_id": ["T6"]}}}]}]}
{"id": "11788010_4", "context": "In addition to its known effect on gallbladder stasis, octreotide alters bile acid composition and may thus hasten intrahepatic sludge and stone formation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["effect on"]], "start": [[25]], "entity_id": ["T11"]}, "Effect": {"text": [["gallbladder stasis", "alters bile acid composition and may thus hasten intrahepatic sludge and stone formation"]], "start": [[35, 66]], "entity_id": ["T9"]}, "Treatment": {"text": [["octreotide"]], "start": [[55]], "entity_id": ["T10"], "Drug": {"text": [["octreotide"]], "start": [[55]], "entity_id": ["T12"]}}}]}]}
{"id": "16326413_1", "context": "A 17-year-old boy with acute lymphoblastic leukemia developed acute renal failure within 48 h of an intravenous high-dose methotrexate (5 g/m2) infusion.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[52]], "entity_id": ["T5"]}, "Subject": {"text": [["17-year-old boy with acute lymphoblastic leukemia"]], "start": [[2]], "entity_id": ["T3"], "Age": {"text": [["17-year-old"]], "start": [[2]], "entity_id": ["T8"]}, "Gender": {"text": [["boy"]], "start": [[14]], "entity_id": ["T9"]}}, "Effect": {"text": [["acute renal failure"]], "start": [[62]], "entity_id": ["T6"]}, "Treatment": {"text": [["intravenous high-dose methotrexate (5 g/m2) infusion"]], "start": [[100]], "entity_id": ["T7"], "Route": {"text": [["intravenous"]], "start": [[100]], "entity_id": ["T10"]}, "Drug": {"text": [["methotrexate"]], "start": [[122]], "entity_id": ["T11"]}, "Dosage": {"text": [["5 g/m2"]], "start": [[136]], "entity_id": ["T12"]}, "Time_elapsed": {"text": [["within 48 h"]], "start": [[82]], "entity_id": ["T13"]}, "Disorder": {"text": [["acute lymphoblastic leukemia"]], "start": [[23]], "entity_id": ["T14"]}}}]}]}
{"id": "2116935_1", "context": "Splenic hemorrhage: a complication of tissue plasminogen activator treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication of"]], "start": [[22]], "entity_id": ["T5"]}, "Effect": {"text": [["Splenic hemorrhage"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["tissue plasminogen activator treatment"]], "start": [[38]], "entity_id": ["T6"], "Drug": {"text": [["tissue plasminogen activator"]], "start": [[38]], "entity_id": ["T7"]}}}]}]}
{"id": "18648015_2", "context": "CONCLUSIONS: Cefazolin was a probable cause of this patient's leukopenia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[38]], "entity_id": ["T5"]}, "Treatment": {"text": [["Cefazolin"]], "start": [[13]], "entity_id": ["T3"], "Drug": {"text": [["Cefazolin"]], "start": [[13]], "entity_id": ["T8"]}}, "Subject": {"text": [["patient"]], "start": [[52]], "entity_id": ["T6"]}, "Effect": {"text": [["leukopenia"]], "start": [[62]], "entity_id": ["T7"]}, "Speculated": {"text": [["probable"]], "start": [[29]], "entity_id": ["T4"], "value": true}}]}]}
{"id": "15533031_1", "context": "Paradoxical cerebral cortical hyperexcitability following flupirtine overdose.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[48]], "entity_id": ["T4"]}, "Effect": {"text": [["Paradoxical cerebral cortical hyperexcitability"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["flupirtine overdose"]], "start": [[58]], "entity_id": ["T5"], "Drug": {"text": [["flupirtine"]], "start": [[58]], "entity_id": ["T6"]}, "Dosage": {"text": [["overdose"]], "start": [[69]], "entity_id": ["T7"]}}}]}]}
{"id": "6245286_1", "context": "Autopsy evidence of herpesvirus infection was found in visceral organs of four leukemic patients who had received large doses of cytarabine (cytosine arabinoside; Ara-C) shortly before their death.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["found"]], "start": [[46]], "entity_id": ["T8"]}, "Effect": {"text": [["herpesvirus infection"]], "start": [[20]], "entity_id": ["T5"]}, "Subject": {"text": [["four leukemic patients"]], "start": [[74]], "entity_id": ["T6"], "Population": {"text": [["four"]], "start": [[74]], "entity_id": ["T10"]}}, "Treatment": {"text": [["large doses of cytarabine"]], "start": [[114]], "entity_id": ["T7"], "Drug": {"text": [["cytarabine (cytosine arabinoside; Ara-C)"]], "start": [[129]], "entity_id": ["T11"]}, "Disorder": {"text": [["leukemic"]], "start": [[79]], "entity_id": ["T12"]}}}]}]}
{"id": "4004433_1", "context": "Heparin-induced hyperkalemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[8]], "entity_id": ["T4"]}, "Treatment": {"text": [["Heparin"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Heparin"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["hyperkalemia"]], "start": [[16]], "entity_id": ["T5"]}}]}]}
{"id": "6608139_1", "context": "Although myelosuppression is mild, immunosuppression and superinfection are potential hazards of treatment with DCF.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["hazards"]], "start": [[86]], "entity_id": ["T7"]}, "Treatment": {"text": [["DCF"]], "start": [[112]], "entity_id": ["T5"], "Drug": {"text": [["DCF"]], "start": [[112]], "entity_id": ["T8"]}}, "Effect": {"text": [["myelosuppression", "immunosuppression and superinfection"]], "start": [[9, 35]], "entity_id": ["T6"]}, "Severity": {"text": [["mild"]], "start": [[29]], "entity_id": ["T9"], "value": "Low"}, "Speculated": {"text": [["potential"]], "start": [[76]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "2076372_2", "context": "The photosensitivity is still present 3 years after the withdrawal of quinine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[46]], "entity_id": ["T3"]}, "Treatment": {"text": [["withdrawal of quinine"]], "start": [[56]], "entity_id": ["T4"], "Drug": {"text": [["quinine"]], "start": [[70]], "entity_id": ["T6"]}}, "Effect": {"text": [["photosensitivity is still present 3 years"]], "start": [[4]], "entity_id": ["T5"]}}]}]}
{"id": "8396491_1", "context": "Interference with the cortisol axis by the microtubule antagonist, CPH82.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["by"]], "start": [[36]], "entity_id": ["T3"]}, "Effect": {"text": [["Interference with the cortisol axis"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["CPH82"]], "start": [[67]], "entity_id": ["T5"], "Drug": {"text": [["CPH82"]], "start": [[67]], "entity_id": ["T6"]}}}]}]}
{"id": "9892272_2", "context": "Physicians should be aware of the possible association between the use of alteplase and the development of subfascial hemorrhage.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["development"]], "start": [[92]], "entity_id": ["T3"]}, "Effect": {"text": [["subfascial hemorrhage"]], "start": [[107]], "entity_id": ["T4"]}, "Treatment": {"text": [["alteplase"]], "start": [[74]], "entity_id": ["T5"], "Drug": {"text": [["alteplase"]], "start": [[74]], "entity_id": ["T8"]}}, "Speculated": {"text": [["possible"]], "start": [[34]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "3763264_5", "context": "The clinical findings and laboratory studies suggested an autoimmune cell-mediated hypersensitivity reaction triggered by phenobarbital.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["triggered"]], "start": [[109]], "entity_id": ["T4"]}, "Treatment": {"text": [["phenobarbital"]], "start": [[122]], "entity_id": ["T5"], "Drug": {"text": [["phenobarbital"]], "start": [[122]], "entity_id": ["T7"]}}, "Effect": {"text": [["an autoimmune cell-mediated hypersensitivity reaction"]], "start": [[55]], "entity_id": ["T6"]}}]}]}
{"id": "9642842_1", "context": "Anaphylactic reaction to oral prednisone: a case report and review of the literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["to"]], "start": [[22]], "entity_id": ["T4"]}, "Effect": {"text": [["Anaphylactic reaction"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["oral prednisone"]], "start": [[25]], "entity_id": ["T5"], "Drug": {"text": [["prednisone"]], "start": [[30]], "entity_id": ["T6"]}, "Route": {"text": [["oral"]], "start": [[25]], "entity_id": ["T7"]}}, "Subject": {"text": [["a case"]], "start": [[42]], "entity_id": ["T8"]}}]}]}
{"id": "9634122_2", "context": "Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[45]], "entity_id": ["T7"]}, "Treatment": {"text": [["flutamide"]], "start": [[48]], "entity_id": ["T5"], "Drug": {"text": [["flutamide"]], "start": [[48]], "entity_id": ["T8"]}}, "Effect": {"text": [["Prolonged prostate-specific antigen response"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "7436161_4", "context": "None of them had a history of cardiac disease, and with the possible exception of one case of cardiac arrest, where the patient received doxorubicin, no predisposing factors could be found.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["received"]], "start": [[128]], "entity_id": ["T8"]}, "Effect": {"text": [["cardiac arrest"]], "start": [[94]], "entity_id": ["T6"]}, "Treatment": {"text": [["doxorubicin"]], "start": [[137]], "entity_id": ["T7"], "Drug": {"text": [["doxorubicin"]], "start": [[137]], "entity_id": ["T9"]}}, "Subject": {"text": [["the patient"]], "start": [[116]], "entity_id": ["T5"]}}]}]}
{"id": "8013261_4", "context": "We report a case of IDDM which occurred during interferon therapy for chronic hepatitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurred"]], "start": [[31]], "entity_id": ["T4"]}, "Effect": {"text": [["IDDM"]], "start": [[20]], "entity_id": ["T3"]}, "Treatment": {"text": [["interferon therapy"]], "start": [[47]], "entity_id": ["T5"], "Drug": {"text": [["interferon"]], "start": [[47]], "entity_id": ["T7"]}, "Disorder": {"text": [["chronic hepatitis."]], "start": [[70]], "entity_id": ["T8"]}}, "Subject": {"text": [["a case"]], "start": [[10]], "entity_id": ["T9"]}}]}]}
{"id": "11174414_4", "context": "Though physicians treating large populations of patients with HIV are well aware of this complication, only one other report of nevirapine-associated SJS has been documented in the dermatology literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[139]], "entity_id": ["T9"]}, "Treatment": {"text": [["nevirapine"]], "start": [[128]], "entity_id": ["T8"], "Drug": {"text": [["nevirapine"]], "start": [[128]], "entity_id": ["T13"]}, "Disorder": {"text": [["HIV"]], "start": [[62]], "entity_id": ["T14"]}}, "Effect": {"text": [["SJS"]], "start": [[150]], "entity_id": ["T10"]}, "Subject": {"text": [["patients with HIV"]], "start": [[48]], "entity_id": ["T11"]}}]}]}
{"id": "16119501_4", "context": "We report a case of baclofen withdrawal syndrome resulting from oral baclofen underdosing.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulting"]], "start": [[49]], "entity_id": ["T5"]}, "Effect": {"text": [["baclofen withdrawal syndrome"]], "start": [[20]], "entity_id": ["T4"]}, "Treatment": {"text": [["oral baclofen underdosing"]], "start": [[64]], "entity_id": ["T6"], "Route": {"text": [["oral"]], "start": [[64]], "entity_id": ["T7"]}, "Drug": {"text": [["baclofen"]], "start": [[69]], "entity_id": ["T8"]}, "Dosage": {"text": [["underdosing"]], "start": [[78]], "entity_id": ["T9"]}}}]}]}
{"id": "9403220_1", "context": "A 35-year-old nephrotic man developed acute renal failure with serum creatinine to 1543 micromol/l after a month of therapy with enalapril.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[99]], "entity_id": ["T3"]}, "Treatment": {"text": [["a month of therapy with enalapril"]], "start": [[105]], "entity_id": ["T4"], "Disorder": {"text": [["nephrotic"]], "start": [[14]], "entity_id": ["T8"]}, "Duration": {"text": [["a month"]], "start": [[105]], "entity_id": ["T10"]}, "Drug": {"text": [["enalapril"]], "start": [[129]], "entity_id": ["T11"]}}, "Effect": {"text": [["acute renal failure with serum creatinine to 1543 micromol/l"]], "start": [[38]], "entity_id": ["T5"]}, "Subject": {"text": [["A 35-year-old nephrotic man"]], "start": [[0]], "entity_id": ["T6"], "Age": {"text": [["35-year-old"]], "start": [[2]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[24]], "entity_id": ["T9"]}}, "Severity": {"text": [["acute"]], "start": [[38]], "entity_id": ["T12"], "value": "High"}}]}]}
{"id": "7663030_14", "context": "Comparable adverse effects, such as disorientation and temporary amnesia, have been reported in patients in the analogous agent, propranolol.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["been reported"]], "start": [[79]], "entity_id": ["T7"]}, "Treatment": {"text": [["propranolol"]], "start": [[129]], "entity_id": ["T5"], "Drug": {"text": [["propranolol"]], "start": [[129]], "entity_id": ["T9"]}}, "Effect": {"text": [["disorientation and temporary amnesia"]], "start": [[36]], "entity_id": ["T6"]}, "Subject": {"text": [["patients"]], "start": [[96]], "entity_id": ["T8"]}}]}]}
{"id": "18821094_2", "context": "This is an image and brief case report of a 13-year-old boy who presented with severe rash and systemic symptoms after starting oxcarbazepine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[113]], "entity_id": ["T3"]}, "Treatment": {"text": [["oxcarbazepine"]], "start": [[128]], "entity_id": ["T4"], "Drug": {"text": [["oxcarbazepine"]], "start": [[128]], "entity_id": ["T10"]}}, "Effect": {"text": [["severe rash and systemic symptoms"]], "start": [[79]], "entity_id": ["T5"]}, "Subject": {"text": [["a 13-year-old boy"]], "start": [[42]], "entity_id": ["T6"], "Age": {"text": [["13-year-old"]], "start": [[44]], "entity_id": ["T7"]}, "Gender": {"text": [["boy"]], "start": [[56]], "entity_id": ["T8"]}}, "Severity": {"text": [["severe"]], "start": [[79]], "entity_id": ["T9"], "value": "Medium"}}]}]}
{"id": "489527_1", "context": "Renal damage associated with long term use of lithium carbonate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[13]], "entity_id": ["T4"]}, "Effect": {"text": [["Renal damage"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["lithium carbonate"]], "start": [[46]], "entity_id": ["T5"], "Drug": {"text": [["lithium carbonate."]], "start": [[46]], "entity_id": ["T6"]}}}]}]}
{"id": "20456080_1", "context": "Triamcinolone acetonide induced secondary adrenal insufficiency related to impaired CYP3A4 metabolism by coadministration of nefazodone.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[24]], "entity_id": ["T7"]}, "Treatment": {"text": [["Triamcinolone acetonide", "coadministration of nefazodone"]], "start": [[0, 105]], "entity_id": ["T6"], "Drug": {"text": [["Triamcinolone acetonide"], ["nefazodone"]], "start": [[0], [125]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["coadministration"]], "start": [[105]], "entity_id": ["T11"]}, "Drug": {"text": [["nefazodone"], ["Triamcinolone acetonide"]], "start": [[125], [0]], "entity_id": ["T10", "T9"]}}]}, "Effect": {"text": [["secondary adrenal insufficiency"]], "start": [[32]], "entity_id": ["T8"]}}]}]}
{"id": "16044093_1", "context": "Hepatocellular damage following therapeutic intravenous iron sucrose infusion in a child.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[22]], "entity_id": ["T5"]}, "Subject": {"text": [["a child"]], "start": [[81]], "entity_id": ["T3"], "Age": {"text": [["child"]], "start": [[83]], "entity_id": ["T7"]}}, "Effect": {"text": [["Hepatocellular damage"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["intravenous iron sucrose infusion"]], "start": [[44]], "entity_id": ["T6"], "Drug": {"text": [["iron sucrose"]], "start": [[56]], "entity_id": ["T8"]}, "Route": {"text": [["intravenous", "infusion"]], "start": [[44, 69]], "entity_id": ["T9"]}}}]}]}
{"id": "14641354_2", "context": "We report a 43-year-old woman who developed sore throat, swelling of the lips and oral cavity and dysphagia, 2 weeks after the use of budesonide spray (Budefat) for treatment of bronchial asthma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[34]], "entity_id": ["T11"]}, "Subject": {"text": [["a 43-year-old woman"]], "start": [[10]], "entity_id": ["T10"], "Age": {"text": [["43-year-old"]], "start": [[12]], "entity_id": ["T15"]}, "Gender": {"text": [["woman"]], "start": [[24]], "entity_id": ["T16"]}}, "Effect": {"text": [["sore throat, swelling of the lips and oral cavity and dysphagia"]], "start": [[44]], "entity_id": ["T12"]}, "Treatment": {"text": [["2 weeks after the use of budesonide spray (Budefat)"]], "start": [[109]], "entity_id": ["T13"], "Time_elapsed": {"text": [["2 weeks after"]], "start": [[109]], "entity_id": ["T17"]}, "Drug": {"text": [["budesonide"], ["Budefat"]], "start": [[134], [152]], "entity_id": ["T18", "T19"]}, "Disorder": {"text": [["bronchial asthma."]], "start": [[178]], "entity_id": ["T20"]}, "Route": {"text": [["spray"]], "start": [[145]], "entity_id": ["T21"]}}}]}]}
{"id": "7496198_9", "context": "Among the risk factors studied, two appear to increase the risk of ARE: the prescription of thiabendazole to treat strongyloidiasis during the melarsoprol cure and the bad general clinical conditions of patients.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["appear to"]], "start": [[36]], "entity_id": ["T12"]}, "Treatment": {"text": [["prescription of thiabendazole", "during the melarsoprol cure"]], "start": [[76, 132]], "entity_id": ["T9"], "Drug": {"text": [["thiabendazole"], ["melarsoprol"]], "start": [[92], [143]], "entity_id": ["T13", "T15"]}, "Disorder": {"text": [["strongyloidiasis"]], "start": [[115]], "entity_id": ["T14"]}}, "Effect": {"text": [["increase the risk of ARE"]], "start": [[46]], "entity_id": ["T10"]}, "Speculated": {"text": [["appear to"]], "start": [[36]], "entity_id": ["T16"], "value": true}}]}]}
{"id": "3997294_2", "context": "Review of this and previously reported cases indicates the need for early diagnosis of amiodarone pneumonitis, immediate withdrawal of amiodarone, and prompt but continued steroid therapy to ensure full recovery.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["of"]], "start": [[84]], "entity_id": ["T5"]}, "Treatment": {"text": [["amiodarone"]], "start": [[87]], "entity_id": ["T3"], "Drug": {"text": [["amiodarone"]], "start": [[87]], "entity_id": ["T6"]}}, "Effect": {"text": [["pneumonitis"]], "start": [[98]], "entity_id": ["T4"]}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["recovery"]], "start": [[203]], "entity_id": ["T12"]}, "Treatment": {"text": [["immediate withdrawal of amiodarone, and prompt but continued steroid therapy"]], "start": [[111]], "entity_id": ["T9"], "Disorder": {"text": [["pneumonitis"]], "start": [[98]], "entity_id": ["T8"]}, "Drug": {"text": [["steroid"], ["amiodarone"]], "start": [[172], [135]], "entity_id": ["T10", "T11"]}}}]}]}
{"id": "12503933_2", "context": "A second possibility is an interaction between clarithromycin and isradipine, potentially increasing the hepatic toxicity of isradipine.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["increasing"]], "start": [[90]], "entity_id": ["T6"]}, "Effect": {"text": [["hepatic toxicity"]], "start": [[105]], "entity_id": ["T7"]}, "Treatment": {"text": [["interaction between clarithromycin and isradipine"]], "start": [[27]], "entity_id": ["T5"], "Drug": {"text": [["clarithromycin"], ["isradipine"]], "start": [[47], [66]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[27]], "entity_id": ["T9"]}, "Drug": {"text": [["clarithromycin"], ["isradipine"]], "start": [[47], [66]], "entity_id": ["T10", "T11"]}}]}, "Speculated": {"text": [["potentially"]], "start": [[78]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "1584367_3", "context": "We report two cases of cerebrospinal fluid eosinophilia (CSFE) secondary to the intraventricular administration of vancomycin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["secondary"]], "start": [[63]], "entity_id": ["T5"]}, "Treatment": {"text": [["intraventricular administration of vancomycin"]], "start": [[80]], "entity_id": ["T6"], "Route": {"text": [["intraventricular"]], "start": [[80]], "entity_id": ["T10"]}, "Drug": {"text": [["vancomycin"]], "start": [[115]], "entity_id": ["T11"]}}, "Effect": {"text": [["cerebrospinal fluid eosinophilia (CSFE)"]], "start": [[23]], "entity_id": ["T9"]}, "Subject": {"text": [["two cases"]], "start": [[10]], "entity_id": ["T1"], "Population": {"text": [["two"]], "start": [[10]], "entity_id": ["T8"]}}}]}]}
{"id": "19857154_4", "context": "We describe two patients who experienced serious quetiapine adverse effects potentially mediated through an interaction with ritonavir-boosted atazanavir.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["experienced"]], "start": [[29]], "entity_id": ["T10"]}, "Subject": {"text": [["two patients"]], "start": [[12]], "entity_id": ["T8"], "Population": {"text": [["two"]], "start": [[12]], "entity_id": ["T13"]}}, "Effect": {"text": [["serious quetiapine adverse effects"]], "start": [[41]], "entity_id": ["T11"]}, "Treatment": {"text": [["ritonavir-boosted atazanavir"]], "start": [[125]], "entity_id": ["T12"], "Drug": {"text": [["ritonavir"], ["atazanavir"]], "start": [[125], [143]], "entity_id": ["T14", "T16"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[108]], "entity_id": ["T15"]}, "Drug": {"text": [["ritonavir"], ["atazanavir"]], "start": [[125], [143]], "entity_id": ["T14", "T16"]}}]}, "Speculated": {"text": [["potentially"]], "start": [[76]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "11020127_4", "context": "The patient was diagnosed with carbamazepine toxicity related to the introduction of ritonavir.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[54]], "entity_id": ["T7"]}, "Treatment": {"text": [["ritonavir"]], "start": [[85]], "entity_id": ["T4"], "Drug": {"text": [["ritonavir"]], "start": [[85]], "entity_id": ["T8"]}}, "Subject": {"text": [["patient"]], "start": [[4]], "entity_id": ["T5"]}, "Effect": {"text": [["carbamazepine toxicity"]], "start": [[31]], "entity_id": ["T6"]}}]}]}
{"id": "17987285_12", "context": "Caution should be exercised, especially in patients who are given voriconazole or fluconazole during long-lasting fentanyl treatment, because insidiously elevated fentanyl concentration may lead to respiratory depression.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["lead"]], "start": [[190]], "entity_id": ["T10"]}, "Subject": {"text": [["patients"]], "start": [[43]], "entity_id": ["T8"]}, "Treatment": {"text": [["fentanyl"]], "start": [[114]], "entity_id": ["T9"], "Drug": {"text": [["voriconazole"], ["fluconazole"], ["fentanyl"]], "start": [[66], [82], [163]], "entity_id": ["T12", "T13", "T15"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["during"]], "start": [[94]], "entity_id": ["T14"]}, "Drug": {"text": [["voriconazole"], ["fluconazole"]], "start": [[66], [82]], "entity_id": ["T12", "T13"]}}]}, "Effect": {"text": [["respiratory depression"]], "start": [[198]], "entity_id": ["T11"]}}]}]}
{"id": "15878975_5", "context": "This review presents the first case series of DIC associated with acute hemoglobinemia or hemoglobinuria following anti-D IGIV administration for ITP.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[105]], "entity_id": ["T9"]}, "Effect": {"text": [["DIC associated with acute hemoglobinemia or hemoglobinuria"]], "start": [[46]], "entity_id": ["T8"]}, "Treatment": {"text": [["anti-D IGIV administration"]], "start": [[115]], "entity_id": ["T10"], "Route": {"text": [["IV administration"]], "start": [[124]], "entity_id": ["T7"]}, "Drug": {"text": [["anti-D"]], "start": [[115]], "entity_id": ["T12"]}, "Disorder": {"text": [["ITP"]], "start": [[146]], "entity_id": ["T13"]}}}]}]}
{"id": "15795553_1", "context": "Risperidone is a frequently used member of a new class of atypical antipsychotics-the serotonin-dopamine antagonists (SDAs)-due to its comparatively high efficacy and low D2/5HT2 binding ratio, which results in a low incidence of extrapyramidal side effects including tardive dyskinesia (TD).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["results"]], "start": [[200]], "entity_id": ["T6"]}, "Treatment": {"text": [["Risperidone"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Risperidone"]], "start": [[0]], "entity_id": ["T9"]}}, "Effect": {"text": [["tardive dyskinesia"]], "start": [[268]], "entity_id": ["T8"]}}]}]}
{"id": "10458196_1", "context": "A 5-month-old infant became lethargic and poorly responsive after receiving 1 drop of brimonidine in each eye.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["became"]], "start": [[21]], "entity_id": ["T8"]}, "Subject": {"text": [["A 5-month-old infant"]], "start": [[0]], "entity_id": ["T5"], "Age": {"text": [["5-month-old"], ["infant"]], "start": [[2], [14]], "entity_id": ["T11", "T12"]}}, "Effect": {"text": [["lethargic and poorly responsive"]], "start": [[28]], "entity_id": ["T6"]}, "Treatment": {"text": [["receiving 1 drop of brimonidine in each eye"]], "start": [[66]], "entity_id": ["T7"], "Drug": {"text": [["brimonidine"]], "start": [[86]], "entity_id": ["T9"]}, "Dosage": {"text": [["1 drop"]], "start": [[76]], "entity_id": ["T10"]}, "Route": {"text": [["in each eye"]], "start": [[98]], "entity_id": ["T13"]}}}]}]}
{"id": "489527_2", "context": "The authors report 2 cases of renal damage associated with lithium carbonate treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[43]], "entity_id": ["T4"]}, "Effect": {"text": [["renal damage"]], "start": [[30]], "entity_id": ["T3"]}, "Treatment": {"text": [["lithium carbonate treatment"]], "start": [[59]], "entity_id": ["T5"], "Drug": {"text": [["lithium carbonate"]], "start": [[59]], "entity_id": ["T8"]}}, "Subject": {"text": [["2 cases"]], "start": [[19]], "entity_id": ["T6"], "Population": {"text": [["2"]], "start": [[19]], "entity_id": ["T7"]}}}]}]}
{"id": "9545161_4", "context": "It was hypothesized that valproic acid may interfere with glucuronidation of lamotrigine, leading to increased serum lamotrigine levels, or perhaps alter the drug's metabolism, resulting in accumulation of a toxic intermediate metabolite.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["leading"]], "start": [[90]], "entity_id": ["T10"]}, "Treatment": {"text": [["valproic acid may interfere with glucuronidation of lamotrigine"]], "start": [[25]], "entity_id": ["T8"], "Drug": {"text": [["valproic acid"], ["lamotrigine"]], "start": [[25], [77]], "entity_id": ["T12", "T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interfere"]], "start": [[43]], "entity_id": ["T11"]}, "Drug": {"text": [["valproic acid"], ["lamotrigine"]], "start": [[25], [77]], "entity_id": ["T12", "T13"]}}]}, "Effect": {"text": [["increased serum lamotrigine levels, or perhaps alter the drug's metabolism, resulting in accumulation of a toxic intermediate metabolite"]], "start": [[101]], "entity_id": ["T9"]}, "Speculated": {"text": [["hypothesized"]], "start": [[7]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "10650865_1", "context": "Portal vein thrombosis in a patient with severe haemophilia A and F V G1691A mutation during continuous infusion of F VIII after intramural jejunal bleeding--successful thrombolysis under heparin therapy.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[86]], "entity_id": ["T7"]}, "Treatment": {"text": [["continuous infusion of F VIII"]], "start": [[93]], "entity_id": ["T5"], "Disorder": {"text": [["intramural jejunal bleeding"]], "start": [[129]], "entity_id": ["T11"]}, "Route": {"text": [["continuous infusion"]], "start": [[93]], "entity_id": ["T9"]}, "Drug": {"text": [["F VIII"]], "start": [[116]], "entity_id": ["T10"]}}, "Subject": {"text": [["a patient with severe haemophilia A and F V G1691A mutation"]], "start": [[26]], "entity_id": ["T4"], "Disorder": {"text": [["haemophilia A and F V G1691A mutation"]], "start": [[48]], "entity_id": ["T8"]}}, "Effect": {"text": [["Portal vein thrombosis"]], "start": [[0]], "entity_id": ["T3"]}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["therapy"]], "start": [[196]], "entity_id": ["T1"]}, "Treatment": {"text": [["heparin"]], "start": [[188]], "entity_id": ["T2"], "Disorder": {"text": [["Portal vein thrombosis"]], "start": [[0]], "entity_id": ["T12"]}, "Drug": {"text": [["heparin"]], "start": [[188]], "entity_id": ["T6"]}}, "Effect": {"text": [["successful thrombolysis"]], "start": [[158]], "entity_id": ["T13"]}}]}]}
{"id": "6093724_1", "context": "A healthy, 30-year-old man, exposed to sulindac on two separate occasions, had an incapacitating isolated idential sensory neuropathy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["exposed"]], "start": [[28]], "entity_id": ["T6"]}, "Effect": {"text": [["incapacitating isolated idential sensory neuropathy"]], "start": [[82]], "entity_id": ["T3"]}, "Subject": {"text": [["A healthy, 30-year-old man"]], "start": [[0]], "entity_id": ["T4"], "Age": {"text": [["30-year-old"]], "start": [[11]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[23]], "entity_id": ["T8"]}}, "Treatment": {"text": [["sulindac"]], "start": [[39]], "entity_id": ["T5"], "Drug": {"text": [["sulindac"]], "start": [[39]], "entity_id": ["T9"]}}}]}]}
{"id": "7439122_1", "context": "Clofibrate-induced myopathy in patients with diabetes insipidus.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T4"]}, "Treatment": {"text": [["Clofibrate"]], "start": [[0]], "entity_id": ["T3"], "Disorder": {"text": [["diabetes insipidus"]], "start": [[45]], "entity_id": ["T7"]}, "Drug": {"text": [["Clofibrate"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["myopathy"]], "start": [[19]], "entity_id": ["T5"]}, "Subject": {"text": [["patients with diabetes insipidus"]], "start": [[31]], "entity_id": ["T6"]}}]}]}
{"id": "17473493_2", "context": "This is the first histologically confirmed case of NASH that was aggravated by raloxifene.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["aggravated"]], "start": [[65]], "entity_id": ["T4"]}, "Effect": {"text": [["NASH"]], "start": [[51]], "entity_id": ["T3"]}, "Treatment": {"text": [["raloxifene"]], "start": [[79]], "entity_id": ["T5"], "Drug": {"text": [["raloxifene"]], "start": [[79]], "entity_id": ["T6"]}}, "Subject": {"text": [["the first histologically confirmed case"]], "start": [[8]], "entity_id": ["T7"]}}]}]}
{"id": "9545161_5", "context": "To date, eight cases of TEN and one of SJS related to lamotrigine administration have been reported in the literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[43]], "entity_id": ["T7"]}, "Treatment": {"text": [["lamotrigine"]], "start": [[54]], "entity_id": ["T5"], "Drug": {"text": [["lamotrigine"]], "start": [[54]], "entity_id": ["T8"]}}, "Effect": {"text": [["TEN", "SJS"]], "start": [[24, 39]], "entity_id": ["T6"]}}]}]}
{"id": "11207969_1", "context": "ARA-C is frequently associated with dermatologic toxicity, but this is only the second case of toxic epidermal necrolysis described in connection with this drug.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[20]], "entity_id": ["T6"]}, "Treatment": {"text": [["ARA-C"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["ARA-C"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["dermatologic toxicity"]], "start": [[36]], "entity_id": ["T7"]}}]}]}
{"id": "515777_1", "context": "Hyperglycemia and diabetic coma: possible relationship to diuretic-propranolol therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["to"]], "start": [[55]], "entity_id": ["T7"]}, "Effect": {"text": [["Hyperglycemia and diabetic coma"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["propranolol"]], "start": [[67]], "entity_id": ["T6"], "Drug": {"text": [["propranolol"]], "start": [[67]], "entity_id": ["T8"]}}}]}]}
{"id": "15977922_1", "context": "Potential mechanisms involved in the occurrence of ischemic colitis in patients receiving tegaserod are also discussed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurrence"]], "start": [[37]], "entity_id": ["T4"]}, "Effect": {"text": [["ischemic colitis"]], "start": [[51]], "entity_id": ["T3"]}, "Treatment": {"text": [["tegaserod"]], "start": [[90]], "entity_id": ["T5"], "Drug": {"text": [["tegaserod"]], "start": [[90]], "entity_id": ["T7"]}}, "Subject": {"text": [["patients"]], "start": [[71]], "entity_id": ["T6"]}}]}]}
{"id": "9494448_2", "context": "Anaphylaxis to intravenous cyclosporine and tolerance to oral cyclosporine: case report and review.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["to"]], "start": [[12]], "entity_id": ["T5"]}, "Effect": {"text": [["Anaphylaxis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["intravenous cyclosporine"]], "start": [[15]], "entity_id": ["T4"], "Drug": {"text": [["cyclosporine"]], "start": [[27]], "entity_id": ["T6"]}, "Route": {"text": [["intravenous"]], "start": [[15]], "entity_id": ["T7"]}}, "Subject": {"text": [["case"]], "start": [[76]], "entity_id": ["T8"]}}]}]}
{"id": "14960440_2", "context": "CASE REPORT: A woman of 80 years, on long-term warfarin therapy presented with an acute dissecting thoracic aortic aneurysm; on investigation the only precipitating factor found was an international normalised ratio of 4.8.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["presented"]], "start": [[64]], "entity_id": ["T5"]}, "Subject": {"text": [["A woman of 80 years"]], "start": [[13]], "entity_id": ["T3"], "Gender": {"text": [["woman"]], "start": [[15]], "entity_id": ["T7"]}, "Age": {"text": [["80 years"]], "start": [[24]], "entity_id": ["T8"]}}, "Treatment": {"text": [["on long-term warfarin"]], "start": [[34]], "entity_id": ["T4"], "Duration": {"text": [["long-term"]], "start": [[37]], "entity_id": ["T9"]}, "Drug": {"text": [["warfarin"]], "start": [[47]], "entity_id": ["T10"]}}, "Effect": {"text": [["acute dissecting thoracic aortic aneurysm"]], "start": [[82]], "entity_id": ["T6"]}}]}]}
{"id": "10808214_1", "context": "A patient with an allergy to a macrolide antibiotic was given tacrolimus and developed a sudden cutaneous reaction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[77]], "entity_id": ["T6"]}, "Effect": {"text": [["sudden cutaneous reaction"]], "start": [[89]], "entity_id": ["T7"]}, "Subject": {"text": [["A patient with an allergy to a macrolide antibiotic"]], "start": [[0]], "entity_id": ["T3"], "Disorder": {"text": [["allergy to a macrolide antibiotic"]], "start": [[18]], "entity_id": ["T8"]}}, "Treatment": {"text": [["given tacrolimus"]], "start": [[56]], "entity_id": ["T4"], "Drug": {"text": [["tacrolimus"]], "start": [[62]], "entity_id": ["T9"]}}}]}]}
{"id": "9240497_2", "context": "This case suggests the importance of careful observation for extramedullary relapse in patients who are treated with ATRA.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[104]], "entity_id": ["T6"]}, "Effect": {"text": [["extramedullary relapse"]], "start": [[61]], "entity_id": ["T3"]}, "Subject": {"text": [["patients"]], "start": [[87]], "entity_id": ["T4"]}, "Treatment": {"text": [["ATRA"]], "start": [[117]], "entity_id": ["T5"], "Drug": {"text": [["ATRA"]], "start": [[117]], "entity_id": ["T9"]}}, "Speculated": {"text": [["suggests"]], "start": [[10]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "16863495_1", "context": "Olanzapine-associated neuroleptic malignant syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[11]], "entity_id": ["T4"]}, "Treatment": {"text": [["Olanzapine"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Olanzapine"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["neuroleptic malignant syndrome"]], "start": [[22]], "entity_id": ["T5"]}}]}]}
{"id": "16062101_1", "context": "Acute dystonia induced by lamivudine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[15]], "entity_id": ["T4"]}, "Effect": {"text": [["Acute dystonia"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["lamivudine"]], "start": [[26]], "entity_id": ["T5"], "Drug": {"text": [["lamivudine"]], "start": [[26]], "entity_id": ["T6"]}}}]}]}
{"id": "12792223_4", "context": "We report in detail an unusual adverse reaction to infliximab therapy, a drug-induced lupus-like clinical syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[78]], "entity_id": ["T4"]}, "Treatment": {"text": [["infliximab"]], "start": [[51]], "entity_id": ["T3"], "Drug": {"text": [["infliximab"]], "start": [[51]], "entity_id": ["T6"]}}, "Effect": {"text": [["lupus-like clinical syndrome"]], "start": [[86]], "entity_id": ["T5"]}}]}]}
{"id": "11722307_4", "context": "RESULTS: Quetiapine was associated with leucopenia in two patients and clinically apparent agranulocytosis in one patient.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[24]], "entity_id": ["T5"]}, "Treatment": {"text": [["Quetiapine"]], "start": [[9]], "entity_id": ["T6"], "Drug": {"text": [["Quetiapine"]], "start": [[9]], "entity_id": ["T12"]}}, "Effect": {"text": [["leucopenia"]], "start": [[40]], "entity_id": ["T7"]}, "Subject": {"text": [["two patients"]], "start": [[54]], "entity_id": ["T8"], "Population": {"text": [["two"]], "start": [[54]], "entity_id": ["T9"]}}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[24]], "entity_id": ["T5"]}, "Treatment": {"text": [["Quetiapine"]], "start": [[9]], "entity_id": ["T6"], "Drug": {"text": [["Quetiapine"]], "start": [[9]], "entity_id": ["T12"]}}, "Effect": {"text": [["clinically apparent agranulocytosis"]], "start": [[71]], "entity_id": ["T13"]}, "Subject": {"text": [["one patient"]], "start": [[110]], "entity_id": ["T14"], "Population": {"text": [["one"]], "start": [[110]], "entity_id": ["T10"]}}}]}]}
{"id": "11180704_1", "context": "Oral intake and acarbose were withheld and the ileus spontaneously resolved after 2 days.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[76]], "entity_id": ["T5"]}, "Treatment": {"text": [["Oral intake and acarbose"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["acarbose"]], "start": [[16]], "entity_id": ["T7"]}, "Route": {"text": [["Oral intake"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["the ileus spontaneously resolved"]], "start": [[43]], "entity_id": ["T4"]}}]}]}
{"id": "8260059_2", "context": "No explanation for this delay was found, other than the possibility that magnesium sulfate treatment impeded lactogenesis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["impeded"]], "start": [[101]], "entity_id": ["T4"]}, "Treatment": {"text": [["magnesium sulfate"]], "start": [[73]], "entity_id": ["T3"], "Drug": {"text": [["magnesium sulfate"]], "start": [[73]], "entity_id": ["T6"]}}, "Effect": {"text": [["lactogenesis"]], "start": [[109]], "entity_id": ["T5"]}}]}]}
{"id": "9205466_1", "context": "Although its side effects are few, tamoxifen increases the incidence of proliferative lesions of the endometrium, which theoretically should be preventable with progestational agents.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["increases"]], "start": [[45]], "entity_id": ["T5"]}, "Treatment": {"text": [["tamoxifen"]], "start": [[35]], "entity_id": ["T3"], "Drug": {"text": [["tamoxifen"]], "start": [[35]], "entity_id": ["T6"]}}, "Effect": {"text": [["incidence of proliferative lesions of the endometrium"]], "start": [[59]], "entity_id": ["T4"]}}]}]}
{"id": "3379435_3", "context": "Three senile patients developed fatal acute encephalopathy while receiving calcium hopantenate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[22]], "entity_id": ["T4"]}, "Subject": {"text": [["Three senile patients"]], "start": [[0]], "entity_id": ["T3"], "Population": {"text": [["Three"]], "start": [[0]], "entity_id": ["T7"]}, "Age": {"text": [["senile"]], "start": [[6]], "entity_id": ["T8"]}}, "Effect": {"text": [["encephalopathy"]], "start": [[44]], "entity_id": ["T5"]}, "Treatment": {"text": [["calcium hopantenate"]], "start": [[75]], "entity_id": ["T6"], "Drug": {"text": [["calcium hopantenate"]], "start": [[75]], "entity_id": ["T10"]}}, "Severity": {"text": [["fatal"]], "start": [[32]], "entity_id": ["T9"], "value": "Medium"}}]}]}
{"id": "18515982_4", "context": "Renal injury due to anastrozole has not been published in the English literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[13]], "entity_id": ["T4"]}, "Effect": {"text": [["Renal injury"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["anastrozole"]], "start": [[20]], "entity_id": ["T5"], "Drug": {"text": [["anastrozole"]], "start": [[20]], "entity_id": ["T6"]}}, "Negated": {"text": [["not"]], "start": [[36]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "17420198_10", "context": "Facial, tongue, and arm movements were first reported approximately five weeks after the initiation of aripiprazole.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[79]], "entity_id": ["T9"]}, "Treatment": {"text": [["initiation of aripiprazole"]], "start": [[89]], "entity_id": ["T10"], "Time_elapsed": {"text": [["five weeks"]], "start": [[68]], "entity_id": ["T11"]}, "Drug": {"text": [["aripiprazole"]], "start": [[103]], "entity_id": ["T12"]}}, "Effect": {"text": [["Facial, tongue, and arm movements"]], "start": [[0]], "entity_id": ["T8"]}}]}]}
{"id": "15197722_2", "context": "Restless legs syndrome due to interferon-alpha.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[23]], "entity_id": ["T5"]}, "Effect": {"text": [["Restless legs syndrome"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["interferon-alpha"]], "start": [[30]], "entity_id": ["T4"], "Drug": {"text": [["interferon-alpha"]], "start": [[30]], "entity_id": ["T6"]}}}]}]}
{"id": "10885900_1", "context": "HUS has been reported after several anticancer chemotherapies and most often after mitomycin C-based chemotherapy regimens.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reported"]], "start": [[13]], "entity_id": ["T3"]}, "Effect": {"text": [["HUS"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["several anticancer chemotherapies and most often after mitomycin C-based chemotherapy regimens"]], "start": [[28]], "entity_id": ["T5"], "Drug": {"text": [["mitomycin C"]], "start": [[83]], "entity_id": ["T7"]}}}]}]}
{"id": "19687711_3", "context": "Although the association between SJS/TEN and the sulfonamide class of antibiotics is well established, the increasing prevalence of CA-MRSA has left practitioners with limited regimens to effectively treat skin and soft tissue infections (SSTIs) in the outpatient setting.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["association"]], "start": [[13]], "entity_id": ["T11"]}, "Treatment": {"text": [["sulfonamide class of antibiotics"]], "start": [[49]], "entity_id": ["T10"], "Drug": {"text": [["sulfonamide class of antibiotics"]], "start": [[49]], "entity_id": ["T12"]}, "Disorder": {"text": [["skin and soft tissue infections (SSTIs)"]], "start": [[206]], "entity_id": ["T13"]}}, "Effect": {"text": [["SJS/TEN"]], "start": [[33]], "entity_id": ["T9"]}, "Subject": {"text": [["CA-MRSA"]], "start": [[132]], "entity_id": ["T15"], "Disorder": {"text": [["CA-MRSA"]], "start": [[132]], "entity_id": ["T14"]}}}]}]}
{"id": "7351000_2", "context": "Acute non-lymphocytic leukemia occurred in eight women following long-term treatment with Treosulfan (= dihydroxybusulfan) for ovarian carcinoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurred"]], "start": [[31]], "entity_id": ["T5"]}, "Effect": {"text": [["Acute non-lymphocytic leukemia"]], "start": [[0]], "entity_id": ["T4"]}, "Subject": {"text": [["eight women"]], "start": [[43]], "entity_id": ["T6"], "Population": {"text": [["eight"]], "start": [[43]], "entity_id": ["T9"]}, "Gender": {"text": [["women"]], "start": [[49]], "entity_id": ["T10"]}}, "Treatment": {"text": [["Treosulfan (= dihydroxybusulfan)"]], "start": [[90]], "entity_id": ["T7"], "Drug": {"text": [["Treosulfan"], ["dihydroxybusulfan"]], "start": [[90], [104]], "entity_id": ["T11", "T12"]}, "Disorder": {"text": [["ovarian carcinoma"]], "start": [[127]], "entity_id": ["T13"]}}}]}]}
{"id": "9796135_2", "context": "Elderly patients for whom nitrate has been prescribed should be warned of the occurrence of hypotension, leading to unconsciousness.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurrence"]], "start": [[78]], "entity_id": ["T8"]}, "Subject": {"text": [["Elderly patients"]], "start": [[0]], "entity_id": ["T5"], "Age": {"text": [["Elderly"]], "start": [[0]], "entity_id": ["T9"]}}, "Treatment": {"text": [["nitrate"]], "start": [[26]], "entity_id": ["T6"], "Drug": {"text": [["nitrate"]], "start": [[26]], "entity_id": ["T10"]}}, "Effect": {"text": [["hypotension", "unconsciousness"]], "start": [[92, 116]], "entity_id": ["T7"]}}]}]}
{"id": "2937155_1", "context": "A patient receiving vancomycin for a serious staphylococcal infection had a lupus-like syndrome characterized by a malar rash, pain and erythema of the cartilage of both ears, and tender erythematous and hemorrhagic lesions of the finger tips.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["had"]], "start": [[70]], "entity_id": ["T17"]}, "Treatment": {"text": [["vancomycin"]], "start": [[20]], "entity_id": ["T13"], "Drug": {"text": [["vancomycin"]], "start": [[20]], "entity_id": ["T18"]}, "Disorder": {"text": [["serious staphylococcal infection"]], "start": [[37]], "entity_id": ["T19"]}}, "Effect": {"text": [["a lupus-like syndrome characterized by a malar rash, pain and erythema of the cartilage of both ears, and tender erythematous and hemorrhagic lesions of the finger tips"]], "start": [[74]], "entity_id": ["T16"]}, "Severity": {"text": [["serious"]], "start": [[37]], "entity_id": ["T20"], "value": "High"}}]}]}
{"id": "7436161_2", "context": "Seven patients with hematologic malignancies who were treated with miconazole for either suspected or proven fungal infections developed eight episodes of major adverse cardiorespiratory and anaphylactic reactions.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[127]], "entity_id": ["T12"]}, "Subject": {"text": [["Seven patients with hematologic malignancies"]], "start": [[0]], "entity_id": ["T9"], "Population": {"text": [["Seven"]], "start": [[0]], "entity_id": ["T14"]}, "Disorder": {"text": [["hematologic malignancies"]], "start": [[20]], "entity_id": ["T15"]}}, "Treatment": {"text": [["miconazole"]], "start": [[67]], "entity_id": ["T10"], "Drug": {"text": [["miconazole"]], "start": [[67]], "entity_id": ["T17"]}, "Disorder": {"text": [["fungal infections"]], "start": [[109]], "entity_id": ["T18"]}}, "Effect": {"text": [["eight episodes of major adverse cardiorespiratory and anaphylactic reactions"]], "start": [[137]], "entity_id": ["T13"]}}]}]}
{"id": "12802933_3", "context": "We report the first case, to our knowledge, of rituximab-related autoimmune hemolytic anemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[57]], "entity_id": ["T4"]}, "Treatment": {"text": [["rituximab"]], "start": [[47]], "entity_id": ["T3"], "Drug": {"text": [["rituximab"]], "start": [[47]], "entity_id": ["T7"]}}, "Effect": {"text": [["autoimmune hemolytic anemia"]], "start": [[65]], "entity_id": ["T5"]}, "Speculated": {"text": [["first"]], "start": [[14]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "7606071_1", "context": "Anaphylactoid reactions with intraperitoneal cisplatin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[24]], "entity_id": ["T5"]}, "Treatment": {"text": [["intraperitoneal cisplatin"]], "start": [[29]], "entity_id": ["T3"], "Route": {"text": [["intraperitoneal"]], "start": [[29]], "entity_id": ["T6"]}, "Drug": {"text": [["cisplatin"]], "start": [[45]], "entity_id": ["T7"]}}, "Effect": {"text": [["Anaphylactoid reactions"]], "start": [[0]], "entity_id": ["T4"]}}]}]}
{"id": "20185472_2", "context": "Tremor: a newly described adverse event with long-term itraconazole therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[40]], "entity_id": ["T3"]}, "Treatment": {"text": [["long-term itraconazole therapy"]], "start": [[45]], "entity_id": ["T4"], "Drug": {"text": [["itraconazole"]], "start": [[55]], "entity_id": ["T6"]}, "Duration": {"text": [["long-term"]], "start": [[45]], "entity_id": ["T7"]}}, "Effect": {"text": [["Tremor"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "15735923_1", "context": "Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[43]], "entity_id": ["T7"]}, "Effect": {"text": [["myelodysplastic syndrome"]], "start": [[18]], "entity_id": ["T6"]}, "Treatment": {"text": [["temozolomide"]], "start": [[49]], "entity_id": ["T8"], "Drug": {"text": [["temozolomide"]], "start": [[49]], "entity_id": ["T10"]}, "Disorder": {"text": [["recurrent high-grade glioma"]], "start": [[66]], "entity_id": ["T11"]}}}]}]}
{"id": "9366852_3", "context": "It occasionally accompanies the heparin-associated thrombocytopenia and thrombosis syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[40]], "entity_id": ["T6"]}, "Treatment": {"text": [["heparin"]], "start": [[32]], "entity_id": ["T5"], "Drug": {"text": [["heparin"]], "start": [[32]], "entity_id": ["T8"]}}, "Effect": {"text": [["thrombocytopenia and thrombosis syndrome"]], "start": [[51]], "entity_id": ["T7"]}}]}]}
{"id": "16035204_1", "context": "We report an unusual case of massive fluoxetine ingestion resulting in neurological and cardiovascular toxicity resulting in death.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulting in"]], "start": [[58]], "entity_id": ["T6"]}, "Treatment": {"text": [["massive fluoxetine ingestion"]], "start": [[29]], "entity_id": ["T5"], "Drug": {"text": [["fluoxetine"]], "start": [[37]], "entity_id": ["T8"]}, "Dosage": {"text": [["massive"]], "start": [[29]], "entity_id": ["T9"]}, "Route": {"text": [["ingestion"]], "start": [[48]], "entity_id": ["T11"]}}, "Effect": {"text": [["neurological and cardiovascular toxicity resulting in death"]], "start": [[71]], "entity_id": ["T7"]}, "Subject": {"text": [["an unusual case"]], "start": [[10]], "entity_id": ["T10"]}}]}]}
{"id": "9161656_14", "context": "Although dyspnea associated with verapamil administration has been reported, this is the first report of an elderly asymptomatic asthmatic patient with hypertension who developed an acute asthma attack following sustained-release verapamil administration.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[169]], "entity_id": ["T13"]}, "Subject": {"text": [["an elderly asymptomatic asthmatic patient with hypertension"]], "start": [[105]], "entity_id": ["T12"], "Age": {"text": [["elderly"]], "start": [[108]], "entity_id": ["T9"]}, "Disorder": {"text": [["asymptomatic asthmatic"]], "start": [[116]], "entity_id": ["T10"]}}, "Effect": {"text": [["an acute asthma attack"]], "start": [[179]], "entity_id": ["T14"]}, "Treatment": {"text": [["sustained-release verapamil administration"]], "start": [[212]], "entity_id": ["T15"], "Drug": {"text": [["sustained-release verapamil"]], "start": [[212]], "entity_id": ["T16"]}, "Disorder": {"text": [["hypertension"]], "start": [[152]], "entity_id": ["T17"]}}}]}]}
{"id": "11483161_2", "context": "The bleeding resolved on discontinuation of APV.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["resolved"]], "start": [[13]], "entity_id": ["T5"]}, "Treatment": {"text": [["discontinuation of APV"]], "start": [[25]], "entity_id": ["T4"], "Disorder": {"text": [["The bleeding"]], "start": [[0]], "entity_id": ["T3"]}, "Drug": {"text": [["APV"]], "start": [[44]], "entity_id": ["T6"]}}}]}]}
{"id": "16249064_1", "context": "We describe a case of infection with Mycobacterium abscessus in a 67-year-old woman receiving infliximab as a component of her therapy for RA.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["receiving"]], "start": [[84]], "entity_id": ["T6"]}, "Subject": {"text": [["a 67-year-old woman", "RA"]], "start": [[64, 139]], "entity_id": ["T4"], "Age": {"text": [["67-year-old"]], "start": [[66]], "entity_id": ["T8"]}, "Gender": {"text": [["woman"]], "start": [[78]], "entity_id": ["T9"]}}, "Effect": {"text": [["infection with Mycobacterium abscessus"]], "start": [[22]], "entity_id": ["T3"]}, "Treatment": {"text": [["infliximab as a component of her therapy"]], "start": [[94]], "entity_id": ["T5"], "Drug": {"text": [["infliximab"]], "start": [[94]], "entity_id": ["T10"]}, "Disorder": {"text": [["RA"]], "start": [[139]], "entity_id": ["T11"]}}}]}]}
{"id": "2327115_2", "context": "Renal toxicities have been reported in less than one percent of the patients receiving ciprofloxacin therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reported"]], "start": [[27]], "entity_id": ["T5"]}, "Effect": {"text": [["Renal toxicities"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["ciprofloxacin therapy."]], "start": [[87]], "entity_id": ["T4"], "Drug": {"text": [["ciprofloxacin"]], "start": [[87]], "entity_id": ["T8"]}}, "Subject": {"text": [["less than one percent of the patients"]], "start": [[39]], "entity_id": ["T6"], "Population": {"text": [["less than one percent"]], "start": [[39]], "entity_id": ["T7"]}}}]}]}
{"id": "10513720_1", "context": "Taxane-induced glaucoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[7]], "entity_id": ["T4"]}, "Treatment": {"text": [["Taxane"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Taxane"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["glaucoma"]], "start": [[15]], "entity_id": ["T5"]}}]}]}
{"id": "14735388_1", "context": "Ciprofloxacin-induced toxic epidermal necrolysis in a patient with systemic lupus erythematosus.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["nduced"]], "start": [[15]], "entity_id": ["T4"]}, "Treatment": {"text": [["Ciprofloxacin"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Ciprofloxacin"]], "start": [[0]], "entity_id": ["T8"]}, "Disorder": {"text": [["systemic lupus erythematosus"]], "start": [[67]], "entity_id": ["T9"]}}, "Effect": {"text": [["toxic epidermal necrolysis"]], "start": [[22]], "entity_id": ["T5"]}, "Subject": {"text": [["a patient with systemic lupus erythematosus."]], "start": [[52]], "entity_id": ["T6"]}}]}]}
{"id": "15383642_1", "context": "Hypotension due to interaction between lisinopril and tizanidine.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due to"]], "start": [[12]], "entity_id": ["T6"]}, "Treatment": {"text": [["interaction between lisinopril and tizanidine"]], "start": [[19]], "entity_id": ["T7"], "Drug": {"text": [["tizanidine"], ["lisinopril"]], "start": [[54], [39]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[19]], "entity_id": ["T9"]}, "Drug": {"text": [["lisinopril"], ["tizanidine"]], "start": [[39], [54]], "entity_id": ["T11", "T10"]}}]}, "Effect": {"text": [["Hypotension"]], "start": [[0]], "entity_id": ["T8"]}}]}]}
{"id": "7538828_8", "context": "Development of an extensive skin rash following a single dose of MTX may be an early warning sign for life-threatening bone marrow aplasia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[38]], "entity_id": ["T6"]}, "Effect": {"text": [["extensive skin rash"]], "start": [[18]], "entity_id": ["T5"]}, "Treatment": {"text": [["MTX"]], "start": [[65]], "entity_id": ["T7"], "Drug": {"text": [["MTX"]], "start": [[65]], "entity_id": ["T8"]}}}]}]}
{"id": "6159523_1", "context": "Anaphylactoid reaction to 50% solution of dextrose.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["to"]], "start": [[23]], "entity_id": ["T5"]}, "Effect": {"text": [["Anaphylactoid reaction"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["50% solution of dextrose"]], "start": [[26]], "entity_id": ["T6"], "Drug": {"text": [["dextrose"]], "start": [[42]], "entity_id": ["T7"]}}}]}]}
{"id": "7893301_2", "context": "Hypokalemia after normal doses of neubulized albuterol (salbutamol).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[12]], "entity_id": ["T6"]}, "Effect": {"text": [["Hypokalemia"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["normal doses of neubulized albuterol (salbutamol)"]], "start": [[18]], "entity_id": ["T5"], "Drug": {"text": [["albuterol"], ["salbutamol"]], "start": [[45], [56]], "entity_id": ["T7", "T8"]}, "Dosage": {"text": [["normal doses"]], "start": [[18]], "entity_id": ["T9"]}}}]}]}
{"id": "9770151_1", "context": "Although praziquantel administration may have been effective in killing the parasite in both patients, we are concerned about the production of marked inflammation as a result of treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["production"]], "start": [[130]], "entity_id": ["T5"]}, "Effect": {"text": [["marked inflammation"]], "start": [[144]], "entity_id": ["T3"]}, "Treatment": {"text": [["praziquantel"]], "start": [[9]], "entity_id": ["T4"], "Drug": {"text": [["praziquantel"]], "start": [[9]], "entity_id": ["T11"]}, "Disorder": {"text": [["parasite"]], "start": [[76]], "entity_id": ["T12"]}}, "Subject": {"text": [["parasite in both patients"]], "start": [[76]], "entity_id": ["T7"], "Population": {"text": [["both"]], "start": [[88]], "entity_id": ["T9"]}}, "Speculated": {"text": [["may"]], "start": [[37]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "16503727_3", "context": "We describe a patient who developed granulocytopenia and fever after taking dipyrone and discuss the available literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[26]], "entity_id": ["T4"]}, "Subject": {"text": [["a patient"]], "start": [[12]], "entity_id": ["T3"]}, "Effect": {"text": [["granulocytopenia and fever"]], "start": [[36]], "entity_id": ["T5"]}, "Treatment": {"text": [["taking dipyrone"]], "start": [[69]], "entity_id": ["T6"], "Drug": {"text": [["dipyrone"]], "start": [[76]], "entity_id": ["T7"]}}}]}]}
{"id": "20126479_3", "context": "Spectral-domain optical coherence tomography and adaptive optics may detect hydroxychloroquine retinal toxicity before symptomatic vision loss.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["before"]], "start": [[112]], "entity_id": ["T5"]}, "Treatment": {"text": [["hydroxychloroquine"]], "start": [[76]], "entity_id": ["T3"], "Drug": {"text": [["hydroxychloroquine"]], "start": [[76]], "entity_id": ["T6"]}}, "Effect": {"text": [["symptomatic vision loss"]], "start": [[119]], "entity_id": ["T4"]}}]}]}
{"id": "11961411_1", "context": "A 64-year-old man presented with proteinuria during postoperative interferon (IFN)-beta therapy against malignant melanoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[45]], "entity_id": ["T6"]}, "Effect": {"text": [["proteinuria"]], "start": [[33]], "entity_id": ["T3"]}, "Treatment": {"text": [["postoperative interferon (IFN)-beta therapy"]], "start": [[52]], "entity_id": ["T5"], "Drug": {"text": [["interferon (IFN)-beta"]], "start": [[66]], "entity_id": ["T9"]}, "Disorder": {"text": [["malignant melanoma"]], "start": [[104]], "entity_id": ["T10"]}}, "Subject": {"text": [["A 64-year-old man"]], "start": [[0]], "entity_id": ["T4"], "Age": {"text": [["64-year-old"]], "start": [[2]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[14]], "entity_id": ["T8"]}}}]}]}
{"id": "17509184_2", "context": "Ethambutol toxicity manifesting as acute onset psychosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["toxicity"]], "start": [[11]], "entity_id": ["T4"]}, "Treatment": {"text": [["Ethambutol"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Ethambutol"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["acute onset psychosis"]], "start": [[35]], "entity_id": ["T5"]}}]}]}
{"id": "8503421_2", "context": "Cholesterol crystal embolization-associated renal failure after therapy with recombinant tissue-type plasminogen activator.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[58]], "entity_id": ["T1"]}, "Treatment": {"text": [["therapy with recombinant tissue-type plasminogen activator"]], "start": [[64]], "entity_id": ["T2"], "Drug": {"text": [["plasminogen activator"]], "start": [[101]], "entity_id": ["T4"]}}, "Effect": {"text": [["Cholesterol crystal embolization-associated renal failure"]], "start": [[0]], "entity_id": ["T3"]}}]}]}
{"id": "15289139_2", "context": "METHODS: A 76-year-old woman with primary open-angle glaucoma and no history of ocular surgery developed a choroidal detachment 12 hours after initiation of therapy with dorzolamide eye drops.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[95]], "entity_id": ["T4"]}, "Subject": {"text": [["A 76-year-old woman with primary open-angle glaucoma and no history of ocular surgery"]], "start": [[9]], "entity_id": ["T3"], "Age": {"text": [["76-year-old"]], "start": [[11]], "entity_id": ["T7"]}, "Gender": {"text": [["woman"]], "start": [[23]], "entity_id": ["T8"]}}, "Effect": {"text": [["choroidal detachment"]], "start": [[107]], "entity_id": ["T5"]}, "Treatment": {"text": [["12 hours after initiation of therapy with dorzolamide eye drops"]], "start": [[128]], "entity_id": ["T6"], "Time_elapsed": {"text": [["12 hours"]], "start": [[128]], "entity_id": ["T10"]}, "Drug": {"text": [["dorzolamide"]], "start": [[170]], "entity_id": ["T11"]}, "Disorder": {"text": [["open-angle glaucoma"]], "start": [[42]], "entity_id": ["T12"]}, "Route": {"text": [["eye drops"]], "start": [[182]], "entity_id": ["T13"]}}}]}]}
{"id": "717931_1", "context": "Life-threatening hyperkalemia induced by arginine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[30]], "entity_id": ["T4"]}, "Effect": {"text": [["hyperkalemia"]], "start": [[17]], "entity_id": ["T3"]}, "Treatment": {"text": [["arginine"]], "start": [[41]], "entity_id": ["T5"], "Drug": {"text": [["arginine"]], "start": [[41]], "entity_id": ["T6"]}}, "Severity": {"text": [["Life-threatening"]], "start": [[0]], "entity_id": ["T7"], "value": "High"}}]}]}
{"id": "11881322_6", "context": "We report on three patients who developed acute liver damage during therapy with itraconazole, and in whom liver biopsy specimens were obtained.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[32]], "entity_id": ["T6"]}, "Subject": {"text": [["three patients"]], "start": [[13]], "entity_id": ["T3"], "Population": {"text": [["three"]], "start": [[13]], "entity_id": ["T7"]}}, "Effect": {"text": [["acute liver damage"]], "start": [[42]], "entity_id": ["T4"]}, "Treatment": {"text": [["itraconazole"]], "start": [[81]], "entity_id": ["T5"], "Drug": {"text": [["itraconazole"]], "start": [[81]], "entity_id": ["T8"]}}}]}]}
{"id": "15126179_2", "context": "METHODS: A 68-year-old man developed intense conjunctival hyperemia and cystoid macula edema after switching from latanoprost to bimatoprost 9 months after cataract surgery in an eye at low-risk for this cystoid macular edema.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[27]], "entity_id": ["T11"]}, "Subject": {"text": [["A 68-year-old man"]], "start": [[9]], "entity_id": ["T10"], "Age": {"text": [["68-year-old"]], "start": [[11]], "entity_id": ["T15"]}, "Gender": {"text": [["man"]], "start": [[23]], "entity_id": ["T16"]}}, "Effect": {"text": [["intense conjunctival hyperemia and cystoid macula edema"]], "start": [[37]], "entity_id": ["T12"]}, "Treatment": {"text": [["bimatoprost"]], "start": [[129]], "entity_id": ["T14"], "Disorder": {"text": [["cataract surgery"]], "start": [[156]], "entity_id": ["T13"]}, "Drug": {"text": [["bimatoprost"]], "start": [[129]], "entity_id": ["T17"]}}}]}]}
{"id": "12699871_3", "context": "Tacrolimus (FK506), an immunosuppressant, has been associated with mutism in adults after liver transplant.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated with"]], "start": [[51]], "entity_id": ["T5"]}, "Treatment": {"text": [["Tacrolimus (FK506), an immunosuppressant"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Tacrolimus"]], "start": [[0]], "entity_id": ["T10"]}}, "Effect": {"text": [["mutism"]], "start": [[67]], "entity_id": ["T6"]}, "Subject": {"text": [["adults after liver transplant"]], "start": [[77]], "entity_id": ["T7"], "Age": {"text": [["adults"]], "start": [[77]], "entity_id": ["T8"]}, "Disorder": {"text": [["liver transplant."]], "start": [[90]], "entity_id": ["T9"]}}}]}]}
{"id": "19904536_13", "context": "Gemcitabine-induced pulmonary toxicity is usually a dramatic condition.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[12]], "entity_id": ["T5"]}, "Treatment": {"text": [["Gemcitabine"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Gemcitabine"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["pulmonary toxicity"]], "start": [[20]], "entity_id": ["T6"]}, "Severity": {"text": [["dramatic"]], "start": [[52]], "entity_id": ["T7"], "value": "High"}}]}]}
{"id": "6987607_1", "context": "However, the amount of prednisone required to maintain normotension resulted in Cushingoid features and has been discontinued.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulted in"]], "start": [[68]], "entity_id": ["T4"]}, "Effect": {"text": [["Cushingoid features"]], "start": [[80]], "entity_id": ["T3"]}, "Treatment": {"text": [["prednisone", "to maintain normotension"]], "start": [[23, 43]], "entity_id": ["T5"], "Drug": {"text": [["prednisone"]], "start": [[23]], "entity_id": ["T6"]}}}]}]}
{"id": "8140860_2", "context": "We present the case of a woman undergoing treatment with acenocoumarol for deep vein thrombosis, who maintained an international normalized ratio (INR) of between 2.5 and 4 for 2 months.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatment"]], "start": [[42]], "entity_id": ["T6"]}, "Subject": {"text": [["a woman"]], "start": [[23]], "entity_id": ["T5"], "Gender": {"text": [["woman"]], "start": [[25]], "entity_id": ["T8"]}}, "Treatment": {"text": [["acenocoumarol"]], "start": [[57]], "entity_id": ["T7"], "Drug": {"text": [["acenocoumarol"]], "start": [[57]], "entity_id": ["T10"]}, "Disorder": {"text": [["deep vein thrombosis"]], "start": [[75]], "entity_id": ["T1"]}}}]}]}
{"id": "18408649_1", "context": "Development of tics in a thirteen-year-old male following atomoxetine use.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[48]], "entity_id": ["T3"]}, "Treatment": {"text": [["atomoxetine"]], "start": [[58]], "entity_id": ["T4"], "Drug": {"text": [["atomoxetine"]], "start": [[58]], "entity_id": ["T9"]}}, "Effect": {"text": [["Development of tics"]], "start": [[0]], "entity_id": ["T5"]}, "Subject": {"text": [["a thirteen-year-old male"]], "start": [[23]], "entity_id": ["T6"], "Age": {"text": [["thirteen-year-old"]], "start": [[25]], "entity_id": ["T7"]}, "Gender": {"text": [["male"]], "start": [[43]], "entity_id": ["T8"]}}}]}]}
{"id": "7919557_3", "context": "OBJECTIVE: To report a case of chronic, nonproductive cough secondary to the angiotensin-converting enzyme (ACE) inhibitor quinapril, with complete resolution after switching to another ACE inhibitor, fosinopril.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["resolution"]], "start": [[148]], "entity_id": ["T4"]}, "Effect": {"text": [["chronic, nonproductive cough secondary to the angiotensin-converting enzyme (ACE) inhibitor quinapril"]], "start": [[31]], "entity_id": ["T3"]}, "Treatment": {"text": [["switching to another ACE inhibitor, fosinopril"]], "start": [[165]], "entity_id": ["T5"], "Drug": {"text": [["fosinopril"]], "start": [[201]], "entity_id": ["T6"]}}}]}]}
{"id": "17163271_1", "context": "Cholelithiasis and thrombosis of the central retinal vein in a renal transplant recipient treated with cyclosporin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[58]], "entity_id": ["T8"]}, "Subject": {"text": [["a renal transplant recipient"]], "start": [[61]], "entity_id": ["T5"], "Disorder": {"text": [["renal transplant"]], "start": [[63]], "entity_id": ["T9"]}}, "Treatment": {"text": [["cyclosporin"]], "start": [[103]], "entity_id": ["T6"], "Drug": {"text": [["cyclosporin"]], "start": [[103]], "entity_id": ["T10"]}}, "Effect": {"text": [["Cholelithiasis and thrombosis of the central retinal vein"]], "start": [[0]], "entity_id": ["T7"]}}]}]}
{"id": "11788010_6", "context": "We report a case of hepatolithiasis (intrahepatic stone) complicated by gram-negative sepsis in a 37 year old male with acromegaly being treated with octreotide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[93]], "entity_id": ["T6"]}, "Effect": {"text": [["hepatolithiasis (intrahepatic stone) complicated by gram-negative sepsis"]], "start": [[20]], "entity_id": ["T3"]}, "Subject": {"text": [["a 37 year old male with acromegaly"]], "start": [[96]], "entity_id": ["T4"], "Age": {"text": [["37 year old"]], "start": [[98]], "entity_id": ["T7"]}, "Gender": {"text": [["male"]], "start": [[110]], "entity_id": ["T8"]}}, "Treatment": {"text": [["octreotide"]], "start": [[150]], "entity_id": ["T5"], "Drug": {"text": [["octreotide"]], "start": [[150]], "entity_id": ["T10"]}, "Disorder": {"text": [["acromegaly"]], "start": [[120]], "entity_id": ["T11"]}}}]}]}
{"id": "1288290_1", "context": "Proliferation of abnormal bone marrow histiocytes, an undesired effect of granulocyte macrophage-colony-stimulating factor therapy in a patient with Hurler's syndrome undergoing bone marrow transplantation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["undesired effect"]], "start": [[54]], "entity_id": ["T6"]}, "Effect": {"text": [["Proliferation of abnormal bone marrow histiocytes"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["granulocyte macrophage-colony-stimulating factor"]], "start": [[74]], "entity_id": ["T5"], "Drug": {"text": [["granulocyte macrophage-colony-stimulating factor"]], "start": [[74]], "entity_id": ["T8"]}, "Disorder": {"text": [["Hurler's syndrome"]], "start": [[149]], "entity_id": ["T9"]}}, "Subject": {"text": [["a patient with Hurler's syndrome"]], "start": [[134]], "entity_id": ["T3"]}}]}]}
{"id": "18431096_2", "context": "We report 4 patients, 2 on methylphenidate and 2 on dextroamphetamine who presented with acral cyanosis, livedo reticularis, or Raynaud phenomenon.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["presented"]], "start": [[74]], "entity_id": ["T12"]}, "Treatment": {"text": [["dextroamphetamine"]], "start": [[52]], "entity_id": ["T18"], "Drug": {"text": [["dextroamphetamine"]], "start": [[52]], "entity_id": ["T14"]}}, "Subject": {"text": [["2"]], "start": [[47]], "entity_id": ["T17"]}, "Effect": {"text": [["acral cyanosis, livedo reticularis, or Raynaud phenomenon"]], "start": [[89]], "entity_id": ["T10"]}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["presented"]], "start": [[74]], "entity_id": ["T12"]}, "Effect": {"text": [["acral cyanosis, livedo reticularis, or Raynaud phenomenon"]], "start": [[89]], "entity_id": ["T10"]}, "Treatment": {"text": [["methylphenidate"]], "start": [[27]], "entity_id": ["T11"], "Drug": {"text": [["methylphenidate"]], "start": [[27]], "entity_id": ["T13"]}}, "Subject": {"text": [["4 patients, 2 on"]], "start": [[10]], "entity_id": ["T15"]}}]}]}
{"id": "10575189_1", "context": "Described here are 2 patients who developed thrombotic microangiopathy of the kidneys after receiving high cumulative doses of the new anticancer drug gemcitabine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["receiving"]], "start": [[92]], "entity_id": ["T4"]}, "Effect": {"text": [["thrombotic microangiopathy of the kidneys"]], "start": [[44]], "entity_id": ["T3"]}, "Treatment": {"text": [["gemcitabine"]], "start": [[151]], "entity_id": ["T5"], "Dosage": {"text": [["high cumulative doses"]], "start": [[102]], "entity_id": ["T8"]}, "Drug": {"text": [["gemcitabine"]], "start": [[151]], "entity_id": ["T9"]}}, "Subject": {"text": [["2 patients"]], "start": [[19]], "entity_id": ["T6"], "Population": {"text": [["2"]], "start": [[19]], "entity_id": ["T7"]}}}]}]}
{"id": "15840734_11", "context": "CONCLUSIONS: An objective causality assessment revealed that fluphenazine was the probable cause of NMS in this patient.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[91]], "entity_id": ["T7"]}, "Treatment": {"text": [["fluphenazine"]], "start": [[61]], "entity_id": ["T5"], "Drug": {"text": [["fluphenazine"]], "start": [[61]], "entity_id": ["T9"]}}, "Effect": {"text": [["NMS"]], "start": [[100]], "entity_id": ["T6"]}, "Subject": {"text": [["patient"]], "start": [[112]], "entity_id": ["T8"]}}]}]}
{"id": "9754850_2", "context": "Like other atypical neuroleptics olanzapine is considered to show a reduced prevalence of extrapyramidal side effects when compared to classical neuroleptic drugs.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["show"]], "start": [[61]], "entity_id": ["T6"]}, "Effect": {"text": [["reduced prevalence of extrapyramidal side effects"]], "start": [[68]], "entity_id": ["T3"]}, "Treatment": {"text": [["olanzapine"]], "start": [[33]], "entity_id": ["T5"], "Drug": {"text": [["olanzapine"], ["neuroleptic drugs."]], "start": [[33], [145]], "entity_id": ["T7", "T8"]}}}]}]}
{"id": "8192712_1", "context": "Based on our experience and on previously published data, serum ammonia levels appear to be indicated in all ED patients on valproic acid therapy who present with altered mental status.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["present"]], "start": [[150]], "entity_id": ["T6"]}, "Treatment": {"text": [["valproic acid therapy"]], "start": [[124]], "entity_id": ["T3"], "Disorder": {"text": [["ED"]], "start": [[109]], "entity_id": ["T7"]}, "Drug": {"text": [["valproic acid"]], "start": [[124]], "entity_id": ["T8"]}}, "Subject": {"text": [["all ED patients"]], "start": [[105]], "entity_id": ["T4"]}, "Effect": {"text": [["altered mental status"]], "start": [[163]], "entity_id": ["T5"]}, "Speculated": {"text": [["appear to be"]], "start": [[79]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "12581772_3", "context": "Rapamycin/sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and infection.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[118]], "entity_id": ["T22"]}, "Treatment": {"text": [["Rapamycin/sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia)"]], "start": [[0]], "entity_id": ["T21"], "Drug": {"text": [["Rapamycin/sirolimus"]], "start": [[0]], "entity_id": ["T29"]}}, "Effect": {"text": [["myelosuppression, hypertension, hyperlipidemia, and infection"]], "start": [[134]], "entity_id": ["T1"]}}]}]}
{"id": "12889716_1", "context": "Enoxaparin-induced generalized exanthem.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T4"]}, "Effect": {"text": [["generalized exanthem"]], "start": [[19]], "entity_id": ["T3"]}, "Treatment": {"text": [["Enoxaparin"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Enoxaparin"]], "start": [[0]], "entity_id": ["T6"]}}}]}]}
{"id": "7776854_1", "context": "Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far, and comprise the first cases of (sub)fulminant hepatitis and cirrhosis related to benzarone.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["of"]], "start": [[43]], "entity_id": ["T11"]}, "Treatment": {"text": [["benzarone"]], "start": [[46]], "entity_id": ["T9"], "Drug": {"text": [["benzarone"], ["benzarone"]], "start": [[46], [170]], "entity_id": ["T12", "T13"]}}, "Effect": {"text": [["hepatotoxicity", "(sub)fulminant hepatitis and cirrhosis"]], "start": [[56, 120]], "entity_id": ["T10"]}}]}]}
{"id": "24163322_8", "context": "Within 3 days after starting bismuth subsalicylate therapy, the patient's INR increased from 2.56 to 3.54 and minor bleeding was noted from the patient's tracheostomy site.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["noted"]], "start": [[129]], "entity_id": ["T7"]}, "Treatment": {"text": [["Within 3 days after starting bismuth subsalicylate therapy"]], "start": [[0]], "entity_id": ["T4"], "Duration": {"text": [["3 days"]], "start": [[7]], "entity_id": ["T9"]}, "Drug": {"text": [["bismuth subsalicylate"]], "start": [[29]], "entity_id": ["T10"]}}, "Subject": {"text": [["the patient"]], "start": [[60]], "entity_id": ["T5"]}, "Effect": {"text": [["INR increased from 2.56 to 3.54 and minor bleeding was noted from the patient's tracheostomy site"]], "start": [[74]], "entity_id": ["T6"]}, "Severity": {"text": [["minor"]], "start": [[110]], "entity_id": ["T8"], "value": "Low"}}]}]}
{"id": "19667003_4", "context": "After three weeks of carbamazepine therapy, the patient arrived at the emergency department (ED) with severe agitation and aggressive behavior.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["After"]], "start": [[0]], "entity_id": ["T8"]}, "Subject": {"text": [["patient"]], "start": [[48]], "entity_id": ["T5"]}, "Effect": {"text": [["severe agitation and aggressive behavior"]], "start": [[102]], "entity_id": ["T6"]}, "Treatment": {"text": [["After three weeks of carbamazepine therapy"]], "start": [[0]], "entity_id": ["T7"], "Duration": {"text": [["three weeks"]], "start": [[6]], "entity_id": ["T10"]}, "Drug": {"text": [["carbamazepine"]], "start": [[21]], "entity_id": ["T11"]}}, "Severity": {"text": [["severe"]], "start": [[102]], "entity_id": ["T9"], "value": "Medium"}}]}]}
{"id": "1504404_4", "context": "OBJECTIVE: To report a case of ciprofloxacin-induced psychosis and to discuss occurrence rates, risk factors, possible etiologies, preventive measures, and treatment courses for this adverse reaction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[45]], "entity_id": ["T4"]}, "Treatment": {"text": [["ciprofloxacin"]], "start": [[31]], "entity_id": ["T3"], "Drug": {"text": [["ciprofloxacin"]], "start": [[31]], "entity_id": ["T6"]}}, "Effect": {"text": [["psychosis"]], "start": [[53]], "entity_id": ["T5"]}}]}]}
{"id": "12126225_3", "context": "A 77-year-old man developed ankle, hand, and facial swelling 2 weeks after starting rosiglitazone.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[18]], "entity_id": ["T4"]}, "Subject": {"text": [["A 77-year-old man"]], "start": [[0]], "entity_id": ["T3"], "Age": {"text": [["77-year-old"]], "start": [[2]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[14]], "entity_id": ["T8"]}}, "Effect": {"text": [["ankle, hand, and facial swelling"]], "start": [[28]], "entity_id": ["T5"]}, "Treatment": {"text": [["2 weeks after starting rosiglitazone"]], "start": [[61]], "entity_id": ["T6"], "Time_elapsed": {"text": [["2 weeks"]], "start": [[61]], "entity_id": ["T9"]}, "Drug": {"text": [["rosiglitazone"]], "start": [[84]], "entity_id": ["T10"]}}}]}]}
{"id": "3659584_5", "context": "Although rare, massive pulmonary embolus must be considered to be a major risk of thrombolytic therapy for deep venous thrombosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["risk"]], "start": [[74]], "entity_id": ["T8"]}, "Effect": {"text": [["massive pulmonary embolus"]], "start": [[15]], "entity_id": ["T7"]}, "Treatment": {"text": [["thrombolytic"]], "start": [[82]], "entity_id": ["T9"], "Drug": {"text": [["thrombolytic"]], "start": [[82]], "entity_id": ["T10"]}}}]}]}
{"id": "7781845_5", "context": "We report a case of hypoglycaemia after mefloquine therapy (1,500 mg over two days) for severe gastrointestinal cryptosporidiasis in a cachectic AIDS patient with protracted diarrhoea.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[34]], "entity_id": ["T10"]}, "Effect": {"text": [["hypoglycaemia"]], "start": [[20]], "entity_id": ["T9"]}, "Treatment": {"text": [["mefloquine therapy (1,500 mg over two days)"]], "start": [[40]], "entity_id": ["T11"], "Disorder": {"text": [["severe gastrointestinal cryptosporidiasis"]], "start": [[88]], "entity_id": ["T12"]}, "Drug": {"text": [["mefloquine"]], "start": [[40]], "entity_id": ["T17"]}, "Dosage": {"text": [["1,500 mg"]], "start": [[60]], "entity_id": ["T18"]}}, "Subject": {"text": [["a cachectic AIDS patient with protracted diarrhoea"]], "start": [[133]], "entity_id": ["T13"], "Disorder": {"text": [["cachectic AIDS"], ["protracted diarrhoea"]], "start": [[135], [163]], "entity_id": ["T15", "T16"]}}}]}]}
{"id": "9876812_3", "context": "OBJECTIVE: To describe onset of syndrome of inappropriate antidiuretic hormone (SIADH) associated with vinorelbine therapy for advanced breast cancer.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated with"]], "start": [[87]], "entity_id": ["T6"]}, "Effect": {"text": [["syndrome of inappropriate antidiuretic hormone (SIADH)"]], "start": [[32]], "entity_id": ["T5"]}, "Treatment": {"text": [["vinorelbine"]], "start": [[103]], "entity_id": ["T7"], "Drug": {"text": [["vinorelbine"]], "start": [[103]], "entity_id": ["T9"]}, "Disorder": {"text": [["advanced breast cancer"]], "start": [[127]], "entity_id": ["T10"]}}}]}]}
{"id": "11160777_9", "context": "The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are \"insulin sensitizers\" and exert direct effects on the mechanisms of insulin resistance.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["exert"]], "start": [[128]], "entity_id": ["T9"]}, "Treatment": {"text": [["thiazolidinediones"]], "start": [[4]], "entity_id": ["T8"], "Disorder": {"text": [["insulin resistance"]], "start": [[170]], "entity_id": ["T10"]}}}]}]}
{"id": "15611427_4", "context": "The exacerbation of psoriasis was accompanied by a massive induction of lesional type I interferon activity, detected by MxA expression after imiquimod therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["detected"]], "start": [[109]], "entity_id": ["T5"]}, "Treatment": {"text": [["imiquimod"]], "start": [[142]], "entity_id": ["T3"], "Drug": {"text": [["imiquimod"]], "start": [[142]], "entity_id": ["T6"]}}, "Effect": {"text": [["exacerbation of psoriasis", "a massive induction of lesional type I interferon activity"]], "start": [[4, 49]], "entity_id": ["T4"]}}]}]}
{"id": "2857534_3", "context": "Two patients treated with alprazolam had histories suggestive of a bipolar disorder and developed lithium-responsive manic episodes.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[88]], "entity_id": ["T6"]}, "Subject": {"text": [["Two patients"]], "start": [[0]], "entity_id": ["T3"], "Population": {"text": [["Two"]], "start": [[0]], "entity_id": ["T8"]}, "Disorder": {"text": [["a bipolar disorder"]], "start": [[65]], "entity_id": ["T10"]}}, "Treatment": {"text": [["alprazolam"]], "start": [[26]], "entity_id": ["T4"], "Drug": {"text": [["alprazolam"]], "start": [[26]], "entity_id": ["T9"]}}, "Effect": {"text": [["lithium-responsive manic episodes"]], "start": [[98]], "entity_id": ["T7"]}}]}]}
{"id": "8292513_1", "context": "Cerebrovascular complications of L-asparaginase therapy in children with leukemia: aphasia and other neuropsychological deficits.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complications"]], "start": [[16]], "entity_id": ["T10"]}, "Effect": {"text": [["Cerebrovascular complications", "aphasia and other neuropsychological deficits"]], "start": [[0, 83]], "entity_id": ["T7"]}, "Treatment": {"text": [["L-asparaginase"]], "start": [[33]], "entity_id": ["T8"], "Drug": {"text": [["L-asparaginase"]], "start": [[33]], "entity_id": ["T13"]}, "Disorder": {"text": [["leukemia"]], "start": [[73]], "entity_id": ["T14"]}}, "Subject": {"text": [["children with leukemia"]], "start": [[59]], "entity_id": ["T9"], "Age": {"text": [["children"]], "start": [[59]], "entity_id": ["T11"]}}}]}]}
{"id": "15752306_2", "context": "We report two patients who developed intense livedo reticularis clearly related to the administration of interferon alpha 2b as an adjuvant therapy for melanoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[72]], "entity_id": ["T8"]}, "Subject": {"text": [["two patients"]], "start": [[10]], "entity_id": ["T7"], "Population": {"text": [["two"]], "start": [[10]], "entity_id": ["T10"]}}, "Treatment": {"text": [["interferon alpha 2b as an adjuvant therapy for melanoma"]], "start": [[105]], "entity_id": ["T9"], "Drug": {"text": [["interferon alpha 2b"]], "start": [[105]], "entity_id": ["T12"]}, "Disorder": {"text": [["melanoma"]], "start": [[152]], "entity_id": ["T13"]}}, "Effect": {"text": [["intense livedo reticularis"]], "start": [[37]], "entity_id": ["T11"]}}]}]}
{"id": "6833205_1", "context": "A case of SIADH associated with desipramine treatment in an elderly depressed woman is described.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[16]], "entity_id": ["T4"]}, "Effect": {"text": [["SIADH"]], "start": [[10]], "entity_id": ["T3"]}, "Treatment": {"text": [["desipramine treatment"]], "start": [[32]], "entity_id": ["T5"], "Disorder": {"text": [["depressed"]], "start": [[68]], "entity_id": ["T8"]}, "Drug": {"text": [["desipramine"]], "start": [[32]], "entity_id": ["T10"]}}, "Subject": {"text": [["an elderly depressed woman"]], "start": [[57]], "entity_id": ["T6"], "Age": {"text": [["elderly"]], "start": [[60]], "entity_id": ["T7"]}, "Gender": {"text": [["woman"]], "start": [[78]], "entity_id": ["T9"]}}}]}]}
{"id": "7379406_1", "context": "Niflumic acid-induced skeletal fluorosis: iatrogenic disease or therapeutic perspective for osteoporosis?", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[14]], "entity_id": ["T7"]}, "Treatment": {"text": [["Niflumic acid"]], "start": [[0]], "entity_id": ["T6"], "Drug": {"text": [["Niflumic acid"]], "start": [[0]], "entity_id": ["T10"]}}, "Effect": {"text": [["skeletal fluorosis"]], "start": [[22]], "entity_id": ["T8"]}, "Speculated": {"text": [["?"]], "start": [[104]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "6149250_5", "context": "Both patients developed severe complications when treated with aminoglutethimide as a cancer hormonal therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[14]], "entity_id": ["T10"]}, "Treatment": {"text": [["aminoglutethimide"]], "start": [[63]], "entity_id": ["T7"], "Disorder": {"text": [["cancer"]], "start": [[86]], "entity_id": ["T9"]}, "Drug": {"text": [["aminoglutethimide"]], "start": [[63]], "entity_id": ["T13"]}}, "Subject": {"text": [["Both patients"]], "start": [[0]], "entity_id": ["T8"]}, "Effect": {"text": [["severe complications"]], "start": [[24]], "entity_id": ["T11"]}, "Severity": {"text": [["severe"]], "start": [[24]], "entity_id": ["T12"], "value": "High"}}]}]}
{"id": "10458196_2", "context": "An 11-day-old infant became lethargic and apneic after a single drop of brimonidine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["became"]], "start": [[21]], "entity_id": ["T8"]}, "Subject": {"text": [["An 11-day-old infant"]], "start": [[0]], "entity_id": ["T5"], "Age": {"text": [["11-day-old"], ["infant"]], "start": [[3], [14]], "entity_id": ["T11", "T12"]}}, "Effect": {"text": [["lethargic and apneic"]], "start": [[28]], "entity_id": ["T6"]}, "Treatment": {"text": [["a single drop of brimonidine"]], "start": [[55]], "entity_id": ["T7"], "Dosage": {"text": [["single drop"]], "start": [[57]], "entity_id": ["T9"]}, "Drug": {"text": [["brimonidine"]], "start": [[72]], "entity_id": ["T10"]}}}]}]}
{"id": "6159523_3", "context": "Investigations suggested that the dextrose, rather than any additives, was responsible for the reaction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["responsible"]], "start": [[75]], "entity_id": ["T5"]}, "Treatment": {"text": [["dextrose"]], "start": [[34]], "entity_id": ["T4"], "Drug": {"text": [["dextrose"]], "start": [[34]], "entity_id": ["T7"]}}, "Effect": {"text": [["the reaction"]], "start": [[91]], "entity_id": ["T6"]}}]}]}
{"id": "10660641_8", "context": "Since renal insufficiency was induced by AMPH and the other antifungal drugs were ineffective, daily administration of 200 mg of ITCZ was initiated, and the inflammatory signs and symptoms gradually subsided.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["initiated"]], "start": [[138]], "entity_id": ["T10"]}, "Treatment": {"text": [["daily administration of 200 mg of ITCZ"]], "start": [[95]], "entity_id": ["T9"], "Disorder": {"text": [["renal insufficiency"]], "start": [[6]], "entity_id": ["T15"]}, "Dosage": {"text": [["200 mg"]], "start": [[119]], "entity_id": ["T12"]}, "Freq": {"text": [["daily administration"]], "start": [[95]], "entity_id": ["T13"]}, "Drug": {"text": [["ITCZ"]], "start": [[129]], "entity_id": ["T14"]}}, "Effect": {"text": [["the inflammatory signs and symptoms gradually subsided."]], "start": [[153]], "entity_id": ["T11"]}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[30]], "entity_id": ["T17"]}, "Effect": {"text": [["renal insufficiency"]], "start": [[6]], "entity_id": ["T19"]}, "Treatment": {"text": [["AMPH"]], "start": [[41]], "entity_id": ["T20"], "Drug": {"text": [["AMPH"]], "start": [[41]], "entity_id": ["T18"]}}}]}]}
{"id": "7696938_2", "context": "Correction of serum electrolyte imbalance prevents cardiac arrhythmia during amphotericin B administration.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[70]], "entity_id": ["T4"]}, "Effect": {"text": [["cardiac arrhythmia"]], "start": [[51]], "entity_id": ["T3"]}, "Treatment": {"text": [["amphotericin B administration"]], "start": [[77]], "entity_id": ["T5"], "Drug": {"text": [["amphotericin B"]], "start": [[77]], "entity_id": ["T6"]}}}]}]}
{"id": "1356045_1", "context": "Acute myopathy with selective degeneration of myosin filaments following status asthmaticus treated with methylprednisolone and vecuronium.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[63]], "entity_id": ["T8"]}, "Effect": {"text": [["Acute myopathy with selective degeneration of myosin filaments"]], "start": [[0]], "entity_id": ["T7"]}, "Treatment": {"text": [["methylprednisolone", "vecuronium"]], "start": [[105, 128]], "entity_id": ["T10"], "Disorder": {"text": [["asthmaticus"]], "start": [[80]], "entity_id": ["T9"]}, "Drug": {"text": [["methylprednisolone"], ["vecuronium"]], "start": [[105], [128]], "entity_id": ["T11", "T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[124]], "entity_id": ["T13"]}, "Drug": {"text": [["vecuronium"], ["methylprednisolone"]], "start": [[128], [105]], "entity_id": ["T12", "T11"]}}]}}]}]}
{"id": "1124417_1", "context": "Presented is a case of acute renal failure induced by acetazolamide therapy for glaucoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[43]], "entity_id": ["T4"]}, "Effect": {"text": [["acute renal failure"]], "start": [[23]], "entity_id": ["T3"]}, "Treatment": {"text": [["acetazolamide therapy for glaucoma"]], "start": [[54]], "entity_id": ["T5"], "Drug": {"text": [["acetazolamide"]], "start": [[54]], "entity_id": ["T6"]}, "Disorder": {"text": [["glaucoma"]], "start": [[80]], "entity_id": ["T7"]}}}]}]}
{"id": "10803790_6", "context": "Cyanamide-induced liver dysfunction after abstinence in alcoholics: a long-term follow-up study on four cases.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[10]], "entity_id": ["T4"]}, "Treatment": {"text": [["Cyanamide"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Cyanamide"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["liver dysfunction"]], "start": [[18]], "entity_id": ["T5"]}, "Subject": {"text": [["abstinence in alcoholics"]], "start": [[42]], "entity_id": ["T8"]}}]}]}
{"id": "16680561_10", "context": "Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reported"]], "start": [[206]], "entity_id": ["T14"]}, "Treatment": {"text": [["desipramine or cinacalcet"]], "start": [[248]], "entity_id": ["T13"], "Drug": {"text": [["desipramine"], ["cinacalcet"], ["desipramine"], ["desipramine"], ["cinacalcet"]], "start": [[248], [263], [64], [102], [119]], "entity_id": ["T15", "T16", "T17", "T18", "T19"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["with"]], "start": [[114]], "entity_id": ["T20"]}, "Drug": {"text": [["desipramine"], ["cinacalcet"]], "start": [[102], [119]], "entity_id": ["T18", "T19"]}}]}, "Effect": {"text": [["nausea and headache"]], "start": [[175]], "entity_id": ["T12"]}, "Subject": {"text": [["patients"]], "start": [[219]], "entity_id": ["T22"]}}]}]}
{"id": "412488_2", "context": "Three patients developed proteinuria following gold therapy for rheumatoid arthritis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[37]], "entity_id": ["T8"]}, "Subject": {"text": [["Three patients"]], "start": [[0]], "entity_id": ["T7"], "Population": {"text": [["Three"]], "start": [[0]], "entity_id": ["T12"]}}, "Treatment": {"text": [["gold"]], "start": [[47]], "entity_id": ["T9"], "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[64]], "entity_id": ["T10"]}, "Drug": {"text": [["gold"]], "start": [[47]], "entity_id": ["T13"]}}, "Effect": {"text": [["proteinuria"]], "start": [[25]], "entity_id": ["T11"]}}]}]}
{"id": "9892272_3", "context": "The authors report a case of a patient who received alteplase for acute myocardial infarction and developed spontaneous subfascial hematoma without any evidence of direct trauma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[98]], "entity_id": ["T6"]}, "Subject": {"text": [["a case of a patient"]], "start": [[19]], "entity_id": ["T3"]}, "Treatment": {"text": [["alteplase"]], "start": [[52]], "entity_id": ["T5"], "Disorder": {"text": [["acute myocardial infarction"]], "start": [[66]], "entity_id": ["T4"]}, "Drug": {"text": [["alteplase"]], "start": [[52]], "entity_id": ["T8"]}}, "Effect": {"text": [["spontaneous subfascial hematoma without any evidence of direct trauma"]], "start": [[108]], "entity_id": ["T7"]}}]}]}
{"id": "12121061_1", "context": "Ticlopidine-induced marrow aplasia treated with cyclosporine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[12]], "entity_id": ["T7"]}, "Treatment": {"text": [["Ticlopidine"]], "start": [[0]], "entity_id": ["T6"], "Drug": {"text": [["Ticlopidine"]], "start": [[0]], "entity_id": ["T9"]}}, "Effect": {"text": [["marrow aplasia"]], "start": [[20]], "entity_id": ["T8"]}}]}]}
{"id": "6947095_1", "context": "Dural sinus thrombosis developed in two children with acute lymphoblastic leukemia during induction treatment with vincristine sulfate, prednisone, and asparaginase.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[23]], "entity_id": ["T8"]}, "Effect": {"text": [["Dural sinus thrombosis"]], "start": [[0]], "entity_id": ["T5"]}, "Subject": {"text": [["two children with acute lymphoblastic leukemia"]], "start": [[36]], "entity_id": ["T6"], "Population": {"text": [["two"]], "start": [[36]], "entity_id": ["T9"]}, "Age": {"text": [["children"]], "start": [[40]], "entity_id": ["T10"]}}, "Treatment": {"text": [["induction treatment with vincristine sulfate, prednisone, and asparaginase"]], "start": [[90]], "entity_id": ["T14"], "Drug": {"text": [["vincristine sulfate"], ["prednisone"], ["asparaginase"]], "start": [[115], [136], [152]], "entity_id": ["T11", "T12", "T13"]}, "Disorder": {"text": [["acute lymphoblastic leukemia"]], "start": [[54]], "entity_id": ["T15"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[148]], "entity_id": ["T16"]}, "Drug": {"text": [["vincristine sulfate"], ["prednisone"], ["asparaginase"]], "start": [[115], [136], [152]], "entity_id": ["T11", "T12", "T13"]}}]}}]}]}
{"id": "8926752_1", "context": "Zolpidem (Ambien), a relatively new nonbenzodiazepine sedative-hypnotic, was involved in the death of a 39-year-old obese male who was being treated for depression and insomnia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["involved"]], "start": [[77]], "entity_id": ["T4"]}, "Effect": {"text": [["death"]], "start": [[93]], "entity_id": ["T5"]}, "Subject": {"text": [["a 39-year-old obese male"]], "start": [[102]], "entity_id": ["T6"], "Age": {"text": [["39-year-old"]], "start": [[104]], "entity_id": ["T9"]}, "Disorder": {"text": [["obese"]], "start": [[116]], "entity_id": ["T10"]}, "Gender": {"text": [["male"]], "start": [[122]], "entity_id": ["T11"]}}, "Treatment": {"text": [["Zolpidem (Ambien)"]], "start": [[0]], "entity_id": ["T8"], "Disorder": {"text": [["depression and insomnia"]], "start": [[153]], "entity_id": ["T7"]}, "Drug": {"text": [["Zolpidem"]], "start": [[0]], "entity_id": ["T13"]}}, "Severity": {"text": [["death"]], "start": [[93]], "entity_id": ["T12"], "value": "High"}}]}]}
{"id": "9494448_1", "context": "A MEDLINE search identified all the reported cases of hypersensitivity reactions to cyclosporine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reactions"]], "start": [[71]], "entity_id": ["T4"]}, "Effect": {"text": [["hypersensitivity reactions"]], "start": [[54]], "entity_id": ["T3"]}, "Treatment": {"text": [["cyclosporine"]], "start": [[84]], "entity_id": ["T5"], "Drug": {"text": [["cyclosporine"]], "start": [[84]], "entity_id": ["T6"]}}}]}]}
{"id": "16029707_2", "context": "METHODS: A 79-year-old woman being treated with imiquimod 5 days per week for a nodular basal cell developed a verrucous plaque over the treatment area after 7 weeks of therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[99]], "entity_id": ["T7"]}, "Subject": {"text": [["A 79-year-old woman"]], "start": [[9]], "entity_id": ["T3"], "Age": {"text": [["79-year-old"]], "start": [[11]], "entity_id": ["T8"]}, "Gender": {"text": [["woman"]], "start": [[23]], "entity_id": ["T9"]}}, "Treatment": {"text": [["imiquimod 5 days per week", "after 7 weeks"]], "start": [[48, 152]], "entity_id": ["T4"], "Disorder": {"text": [["nodular basal cell"]], "start": [[80]], "entity_id": ["T5"]}, "Drug": {"text": [["imiquimod"]], "start": [[48]], "entity_id": ["T10"]}, "Freq": {"text": [["5 days per week"]], "start": [[58]], "entity_id": ["T11"]}, "Time_elapsed": {"text": [["7 weeks"]], "start": [[158]], "entity_id": ["T12"]}}, "Effect": {"text": [["verrucous plaque"]], "start": [[111]], "entity_id": ["T6"]}}]}]}
{"id": "22735246_2", "context": "Oxcarbazepine, a metabolite of carbamazepine, is used as an antiepileptic, analgesic for neuropathic pain and in the treatment of affective disorders.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["used"]], "start": [[49]], "entity_id": ["T9"]}, "Treatment": {"text": [["Oxcarbazepine"]], "start": [[0]], "entity_id": ["T8"], "Disorder": {"text": [["neuropathic pain"], ["affective disorder"]], "start": [[89], [130]], "entity_id": ["T11", "T12"]}, "Drug": {"text": [["Oxcarbazepine"]], "start": [[0]], "entity_id": ["T13"]}}, "Effect": {"text": [["antiepileptic, analgesic"]], "start": [[60]], "entity_id": ["T10"]}}]}]}
{"id": "15543388_3", "context": "PATIENT AND METHOD: A 34-year-old woman with chronic hepatitis C, genotype 3, receiving pegylated interferon alpha-2a and ribavirin for 6 months, developed progressive malaise and anemia 6 months after the end of treatment.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[146]], "entity_id": ["T7"]}, "Subject": {"text": [["A 34-year-old woman with chronic hepatitis C, genotype 3"]], "start": [[20]], "entity_id": ["T8"], "Age": {"text": [["34-year-old"]], "start": [[22]], "entity_id": ["T11"]}, "Gender": {"text": [["woman"]], "start": [[34]], "entity_id": ["T12"]}, "Disorder": {"text": [["genotype 3"]], "start": [[66]], "entity_id": ["T13"]}}, "Treatment": {"text": [["pegylated interferon alpha-2a and ribavirin for 6 months"]], "start": [[88]], "entity_id": ["T9"], "Duration": {"text": [["6 months"]], "start": [[136]], "entity_id": ["T14"]}, "Drug": {"text": [["pegylated interferon alpha-2a"], ["ribavirin"]], "start": [[88], [122]], "entity_id": ["T16", "T17"]}, "Time_elapsed": {"text": [["6 months"]], "start": [[187]], "entity_id": ["T1"]}, "Disorder": {"text": [["chronic hepatitis C"]], "start": [[45]], "entity_id": ["T2"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[118]], "entity_id": ["T15"]}, "Drug": {"text": [["ribavirin"], ["pegylated interferon alpha-2a"]], "start": [[122], [88]], "entity_id": ["T17", "T16"]}}]}, "Effect": {"text": [["progressive malaise and anemia"]], "start": [[156]], "entity_id": ["T10"]}}]}]}
{"id": "19224802_5", "context": "We report on three cases wherein treatment of dexmedetomidine-induced bradycardia with i.v.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[62]], "entity_id": ["T6"]}, "Treatment": {"text": [["treatment of dexmedetomidine"]], "start": [[33]], "entity_id": ["T5"], "Drug": {"text": [["dexmedetomidine"]], "start": [[46]], "entity_id": ["T8"]}}, "Effect": {"text": [["bradycardia with i.v"]], "start": [[70]], "entity_id": ["T7"]}}]}]}
{"id": "1688693_4", "context": "Esmolol, an ultrashort-acting beta 1-selective antagonist, controlled her multiple dysrhythmias and symptoms of sympathetic nervous system hyperstimulation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["controlled"]], "start": [[59]], "entity_id": ["T7"]}, "Treatment": {"text": [["Esmolol, an ultrashort-acting beta 1-selective antagonist"]], "start": [[0]], "entity_id": ["T6"], "Disorder": {"text": [["multiple dysrhythmias and symptoms of sympathetic nervous system hyperstimulation"]], "start": [[74]], "entity_id": ["T8"]}, "Drug": {"text": [["Esmolol"]], "start": [[0]], "entity_id": ["T10"]}}, "Subject": {"text": [["her"]], "start": [[70]], "entity_id": ["T9"]}}]}]}
{"id": "25671244_4", "context": "(Case 1) A 29-year-old woman with overdose of metaxalone presented to the emergency department with altered mental status, seizure-like activity, hyperthermia, rigidity in the lower extremities, myoclonus, and hyperreflexia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["presented"]], "start": [[57]], "entity_id": ["T12"]}, "Subject": {"text": [["A 29-year-old woman"]], "start": [[9]], "entity_id": ["T10"], "Age": {"text": [["29-year-old"]], "start": [[11]], "entity_id": ["T14"]}, "Gender": {"text": [["woman"]], "start": [[23]], "entity_id": ["T15"]}}, "Treatment": {"text": [["metaxalone"]], "start": [[46]], "entity_id": ["T11"], "Drug": {"text": [["metaxalone"]], "start": [[46]], "entity_id": ["T16"]}, "Dosage": {"text": [["overdose"]], "start": [[34]], "entity_id": ["T17"]}}, "Effect": {"text": [["altered mental status, seizure-like activity, hyperthermia, rigidity in the lower extremities, myoclonus, and hyperreflexia"]], "start": [[100]], "entity_id": ["T13"]}}]}]}
{"id": "25515435_1", "context": "Warfarin and boceprevir interaction causing subtherapeutic international normalized ratio: a case report.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["causing"]], "start": [[36]], "entity_id": ["T7"]}, "Treatment": {"text": [["Warfarin", "boceprevir"]], "start": [[0, 13]], "entity_id": ["T6"], "Drug": {"text": [["Warfarin"], ["boceprevir"]], "start": [[0], [13]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[24]], "entity_id": ["T11"]}, "Drug": {"text": [["Warfarin"], ["boceprevir"]], "start": [[0], [13]], "entity_id": ["T9", "T10"]}}]}, "Effect": {"text": [["subtherapeutic international normalized ratio"]], "start": [[44]], "entity_id": ["T8"]}}]}]}
{"id": "3569037_1", "context": "A brief review of reported cases of chloramphenicol hypersensitivity in the English-language literature, as well as possible alternative explanations in this case, are provided.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["of"]], "start": [[33]], "entity_id": ["T5"]}, "Treatment": {"text": [["chloramphenicol"]], "start": [[36]], "entity_id": ["T3"], "Drug": {"text": [["chloramphenicol"]], "start": [[36]], "entity_id": ["T6"]}}, "Effect": {"text": [["hypersensitivity"]], "start": [[52]], "entity_id": ["T4"]}}]}]}
{"id": "6692713_2", "context": "Possible recurrence of amiodarone pulmonary toxicity following corticosteroid therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[53]], "entity_id": ["T4"]}, "Effect": {"text": [["amiodarone pulmonary toxicity"]], "start": [[23]], "entity_id": ["T3"]}, "Treatment": {"text": [["corticosteroid"]], "start": [[63]], "entity_id": ["T5"], "Drug": {"text": [["amiodarone"], ["corticosteroid"]], "start": [[23], [63]], "entity_id": ["T6", "T7"]}}, "Speculated": {"text": [["Possible"]], "start": [[0]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "10466445_3", "context": "In the present study, arsenic trioxide was given intravenously for 42 days to a 56-year-old female patient suffering from chemotherapy/ATRA-resistant APL, with 43% APL blasts in the bone marrow and elevated D-dimers.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["given"]], "start": [[43]], "entity_id": ["T9"]}, "Subject": {"text": [["56-year-old female patient"]], "start": [[80]], "entity_id": ["T7"], "Age": {"text": [["56-year-old"]], "start": [[80]], "entity_id": ["T11"]}, "Gender": {"text": [["female"]], "start": [[92]], "entity_id": ["T12"]}}, "Treatment": {"text": [["arsenic trioxide"]], "start": [[22]], "entity_id": ["T10"], "Drug": {"text": [["arsenic trioxide"]], "start": [[22]], "entity_id": ["T13"]}, "Disorder": {"text": [["chemotherapy/ATRA-resistant APL"]], "start": [[122]], "entity_id": ["T15"]}, "Duration": {"text": [["42 days"]], "start": [[67]], "entity_id": ["T14"]}}}]}]}
{"id": "1765991_4", "context": "We assume that rIFN-gamma induced the de novo development of SLE in our patient.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[26]], "entity_id": ["T6"]}, "Treatment": {"text": [["rIFN-gamma"]], "start": [[15]], "entity_id": ["T5"], "Drug": {"text": [["rIFN-gamma"]], "start": [[15]], "entity_id": ["T9"]}}, "Effect": {"text": [["the de novo development of SLE"]], "start": [[34]], "entity_id": ["T7"]}, "Subject": {"text": [["our patient"]], "start": [[68]], "entity_id": ["T8"]}, "Speculated": {"text": [["assume"]], "start": [[3]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "6519218_2", "context": "Interstitial pneumopathy and low-dosage amiodarone.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["and"]], "start": [[25]], "entity_id": ["T3"]}, "Treatment": {"text": [["low-dosage amiodarone"]], "start": [[29]], "entity_id": ["T4"], "Drug": {"text": [["amiodarone"]], "start": [[40]], "entity_id": ["T6"]}, "Dosage": {"text": [["low-dosage"]], "start": [[29]], "entity_id": ["T7"]}}, "Effect": {"text": [["Interstitial pneumopathy"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "19995222_2", "context": "CONCLUSIONS: These results suggest that clozapine may cause TD; however, the prevalence is low and the severity is relatively mild, with no or mild self-reported discomfort.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[54]], "entity_id": ["T5"]}, "Effect": {"text": [["TD"]], "start": [[60]], "entity_id": ["T7"]}, "Treatment": {"text": [["clozapine"]], "start": [[40]], "entity_id": ["T8"], "Drug": {"text": [["clozapine"]], "start": [[40]], "entity_id": ["T10"]}}, "Speculated": {"text": [["may"]], "start": [[50]], "entity_id": ["T6"], "value": true}, "Severity": {"text": [["mild"]], "start": [[126]], "entity_id": ["T9"], "value": "Low"}}]}]}
{"id": "17228132_8", "context": "Hepatotoxicity resolved once erlotinib was discontinued and serum transaminases returned to baseline normal values.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["discontinued"]], "start": [[43]], "entity_id": ["T5"]}, "Effect": {"text": [["Hepatotoxicity"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["erlotinib"]], "start": [[29]], "entity_id": ["T4"], "Disorder": {"text": [["Hepatotoxicity"]], "start": [[0]], "entity_id": ["T6"]}, "Drug": {"text": [["erlotinib"]], "start": [[29]], "entity_id": ["T7"]}}}]}]}
{"id": "9161656_15", "context": "CONCLUSIONS: Sustained-release verapamil is thought to be the cause of the asthma attack in this patient because she was not taking any other preparations; the symptoms started with the administration of sustained-release verapamil and were relieved after its discontinuation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[62]], "entity_id": ["T9"]}, "Treatment": {"text": [["Sustained-release verapamil"]], "start": [[13]], "entity_id": ["T8"], "Drug": {"text": [["verapamil"]], "start": [[31]], "entity_id": ["T11"]}}, "Effect": {"text": [["asthma attack"]], "start": [[75]], "entity_id": ["T10"]}}]}]}
{"id": "150825_1", "context": "A patient developed cholestatic hepatitis while being treated with nitrofurantoin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[10]], "entity_id": ["T5"]}, "Effect": {"text": [["cholestatic hepatitis"]], "start": [[20]], "entity_id": ["T3"]}, "Treatment": {"text": [["nitrofurantoin"]], "start": [[67]], "entity_id": ["T4"], "Drug": {"text": [["nitrofurantoin"]], "start": [[67]], "entity_id": ["T6"]}}}]}]}
{"id": "19826099_2", "context": "Severe apnea in an infant exposed to lamotrigine in breast milk.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[13]], "entity_id": ["T6"]}, "Effect": {"text": [["apnea"]], "start": [[7]], "entity_id": ["T3"]}, "Treatment": {"text": [["lamotrigine"]], "start": [[37]], "entity_id": ["T4"], "Drug": {"text": [["lamotrigine"]], "start": [[37]], "entity_id": ["T8"]}, "Route": {"text": [["breast milk"]], "start": [[52]], "entity_id": ["T9"]}}, "Subject": {"text": [["an infant"]], "start": [[16]], "entity_id": ["T5"], "Age": {"text": [["infant"]], "start": [[19]], "entity_id": ["T7"]}}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T10"], "value": "High"}}]}]}
{"id": "2894766_3", "context": "Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[119]], "entity_id": ["T13"]}, "Subject": {"text": [["a 43-year-old man"]], "start": [[132]], "entity_id": ["T9"], "Age": {"text": [["43-year-old"]], "start": [[134]], "entity_id": ["T14"]}, "Gender": {"text": [["man"]], "start": [[146]], "entity_id": ["T15"]}}, "Treatment": {"text": [["long-term sulfasalazine"]], "start": [[169]], "entity_id": ["T11"], "Disorder": {"text": [["chronic ulcerative colitis"]], "start": [[205]], "entity_id": ["T10"]}, "Drug": {"text": [["sulfasalazine"]], "start": [[179]], "entity_id": ["T16"]}}, "Effect": {"text": [["Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies"]], "start": [[0]], "entity_id": ["T12"]}}]}]}
{"id": "3166573_1", "context": "Bone formation induced in an infant by systemic prostaglandin-E2 administration.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["induced"]], "start": [[15]], "entity_id": ["T4"]}, "Effect": {"text": [["Bone formation"]], "start": [[0]], "entity_id": ["T3"]}, "Subject": {"text": [["an infant"]], "start": [[26]], "entity_id": ["T5"], "Age": {"text": [["infant"]], "start": [[29]], "entity_id": ["T7"]}}, "Treatment": {"text": [["systemic prostaglandin-E2 administration"]], "start": [[39]], "entity_id": ["T6"], "Drug": {"text": [["prostaglandin-E2"]], "start": [[48]], "entity_id": ["T8"]}, "Route": {"text": [["systemic", "administration"]], "start": [[39, 65]], "entity_id": ["T9"]}}}]}]}
{"id": "8244201_1", "context": "A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea, and increased urinary N-acetyl glucosaminase after several days of the drug administration in these patients; one patient became unconscious.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[29]], "entity_id": ["T9"]}, "Treatment": {"text": [["A high dose of cotrimoxazole", "after several days of the drug administration"]], "start": [[0, 151]], "entity_id": ["T10"], "Dosage": {"text": [["high dose"]], "start": [[2]], "entity_id": ["T14"]}, "Drug": {"text": [["cotrimoxazole"]], "start": [[15]], "entity_id": ["T15"]}, "Time_elapsed": {"text": [["several days"]], "start": [[157]], "entity_id": ["T16"]}}, "Effect": {"text": [["hyperkalaemia with the elevation of serum creatinine and blood urea, and increased urinary N-acetyl glucosaminase"]], "start": [[37]], "entity_id": ["T11"]}, "Subject": {"text": [["these patients"]], "start": [[200]], "entity_id": ["T17"]}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["became"]], "start": [[228]], "entity_id": ["T19"]}, "Treatment": {"text": [["A high dose of cotrimoxazole", "after several days of the drug administration"]], "start": [[0, 151]], "entity_id": ["T10"], "Dosage": {"text": [["high dose"]], "start": [[2]], "entity_id": ["T14"]}, "Drug": {"text": [["cotrimoxazole"]], "start": [[15]], "entity_id": ["T15"]}, "Time_elapsed": {"text": [["several days"]], "start": [[157]], "entity_id": ["T16"]}}, "Subject": {"text": [["one patient"]], "start": [[216]], "entity_id": ["T12"], "Population": {"text": [["one"]], "start": [[216]], "entity_id": ["T18"]}}, "Effect": {"text": [["unconscious"]], "start": [[235]], "entity_id": ["T20"]}}]}]}
{"id": "16641839_2", "context": "Angioedema, a rare side effect of carbamazepine, involves vascular leakage in dermis and subcutis mediated by immunoglobulin E and/or bradykinins.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["of"]], "start": [[31]], "entity_id": ["T5"]}, "Effect": {"text": [["Angioedema", "involves vascular leakage in dermis and subcutis mediated by immunoglobulin E and/or bradykinins"]], "start": [[0, 49]], "entity_id": ["T3"]}, "Treatment": {"text": [["carbamazepine"]], "start": [[34]], "entity_id": ["T4"], "Drug": {"text": [["carbamazepine"]], "start": [[34]], "entity_id": ["T6"]}}}]}]}
{"id": "18343993_1", "context": "A diagnosis of trastuzumab-induced pneumonitis was made.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[27]], "entity_id": ["T4"]}, "Treatment": {"text": [["trastuzumab"]], "start": [[15]], "entity_id": ["T3"], "Drug": {"text": [["trastuzumab"]], "start": [[15]], "entity_id": ["T6"]}}, "Effect": {"text": [["pneumonitis"]], "start": [[35]], "entity_id": ["T5"]}}]}]}
{"id": "10885900_3", "context": "We present a case of HUS in an advanced ovarian cancer patient treated with carboplatin and gemcitabine, and described its favorable outcome after chemotherapy interruption and supportive care with a 1 year follow-up.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[63]], "entity_id": ["T5"]}, "Effect": {"text": [["HUS"]], "start": [[21]], "entity_id": ["T16"]}, "Treatment": {"text": [["carboplatin and gemcitabine"]], "start": [[76]], "entity_id": ["T10"], "Disorder": {"text": [["advanced ovarian cancer"]], "start": [[31]], "entity_id": ["T15"]}, "Drug": {"text": [["carboplatin"], ["gemcitabine"]], "start": [[76], [92]], "entity_id": ["T11", "T12"]}, "Combination": [{"event_id": "E3", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[88]], "entity_id": ["T13"]}, "Drug": {"text": [["carboplatin"], ["gemcitabine"]], "start": [[76], [92]], "entity_id": ["T11", "T12"]}}]}}, {"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["after"]], "start": [[141]], "entity_id": ["T7"]}, "Effect": {"text": [["favorable outcome"]], "start": [[123]], "entity_id": ["T4"]}, "Treatment": {"text": [["chemotherapy interruption and supportive care with a 1 year follow-up"]], "start": [[147]], "entity_id": ["T6"], "Disorder": {"text": [["HUS"]], "start": [[21]], "entity_id": ["T17"]}}, "Subject": {"text": [["an advanced ovarian cancer patient"]], "start": [[28]], "entity_id": ["T8"]}}]}]}
{"id": "17034541_2", "context": "Several such HBV reactivations were reported after combined rituximab and multiagent chemotherapy for B-cell lymphomas.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[45]], "entity_id": ["T4"]}, "Effect": {"text": [["Several such HBV reactivations"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["combined rituximab and multiagent chemotherapy"]], "start": [[51]], "entity_id": ["T5"], "Drug": {"text": [["rituximab"]], "start": [[60]], "entity_id": ["T7"]}, "Disorder": {"text": [["B-cell lymphomas"]], "start": [[102]], "entity_id": ["T10"]}, "Route": {"text": [["chemotherapy"]], "start": [[85]], "entity_id": ["T8"]}}}]}]}
{"id": "8435665_3", "context": "Thus, the eosinophilia myalgia syndrome can be associated with parenteral tryptophan administration.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[47]], "entity_id": ["T4"]}, "Effect": {"text": [["eosinophilia myalgia syndrome"]], "start": [[10]], "entity_id": ["T3"]}, "Treatment": {"text": [["parenteral tryptophan"]], "start": [[63]], "entity_id": ["T5"], "Drug": {"text": [["tryptophan"]], "start": [[74]], "entity_id": ["T6"]}, "Route": {"text": [["parenteral"]], "start": [[63]], "entity_id": ["T7"]}}, "Speculated": {"text": [["can be"]], "start": [[40]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "3790438_1", "context": "Generalized pustular psoriasis precipitated by trazodone in the treatment of depression.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["precipitated"]], "start": [[31]], "entity_id": ["T5"]}, "Treatment": {"text": [["trazodone"]], "start": [[47]], "entity_id": ["T4"], "Disorder": {"text": [["depression"]], "start": [[77]], "entity_id": ["T3"]}, "Drug": {"text": [["trazodone"]], "start": [[47]], "entity_id": ["T7"]}}, "Effect": {"text": [["Generalized pustular psoriasis"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "15224368_3", "context": "We report a case of Sweet's syndrome in association with sargramostim treatment following chemotherapy for acute myelogenous leukemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["association"]], "start": [[40]], "entity_id": ["T4"]}, "Treatment": {"text": [["sargramostim treatment following chemotherapy"]], "start": [[57]], "entity_id": ["T5"], "Drug": {"text": [["sargramostim"]], "start": [[57]], "entity_id": ["T7"]}, "Route": {"text": [["chemotherapy"]], "start": [[90]], "entity_id": ["T8"]}, "Disorder": {"text": [["acute myelogenous leukemia"]], "start": [[107]], "entity_id": ["T9"]}}, "Effect": {"text": [["Sweet's syndrome"]], "start": [[20]], "entity_id": ["T3"]}}]}]}
{"id": "10772434_2", "context": "This regimen could prove useful for other patients who develop hypersensitivity reactions to carboplatin and allow therapy to continue.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["develop"]], "start": [[55]], "entity_id": ["T3"]}, "Effect": {"text": [["hypersensitivity reactions"]], "start": [[63]], "entity_id": ["T4"]}, "Treatment": {"text": [["carboplatin"]], "start": [[93]], "entity_id": ["T5"], "Drug": {"text": [["carboplatin"]], "start": [[93]], "entity_id": ["T8"]}}, "Subject": {"text": [["patients"]], "start": [[42]], "entity_id": ["T7"]}, "Speculated": {"text": [["could"]], "start": [[13]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "12150593_2", "context": "We present a neonate with a seizure disorder who acutely developed pupillary mydriasis secondary to lidocaine overdose.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[57]], "entity_id": ["T6"]}, "Subject": {"text": [["a neonate with a seizure disorde"]], "start": [[11]], "entity_id": ["T3"], "Age": {"text": [["neonate"]], "start": [[13]], "entity_id": ["T9"]}}, "Effect": {"text": [["pupillary mydriasis"]], "start": [[67]], "entity_id": ["T7"]}, "Treatment": {"text": [["lidocaine overdose"]], "start": [[100]], "entity_id": ["T8"], "Drug": {"text": [["lidocaine"]], "start": [[100]], "entity_id": ["T10"]}, "Dosage": {"text": [["overdose"]], "start": [[110]], "entity_id": ["T11"]}, "Disorder": {"text": [["seizure disorder"]], "start": [[28]], "entity_id": ["T12"]}}, "Severity": {"text": [["acutely"]], "start": [[49]], "entity_id": ["T5"], "value": "High"}}]}]}
{"id": "18691992_2", "context": "Based on the Naranjo algorithm, the adverse reaction observed was probably related to the hydroxyurea treatment (score = 6); however, the hydroxyurea chemotherapy could not be discontinued because of the myeloproliferative disorder.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[75]], "entity_id": ["T9"]}, "Treatment": {"text": [["hydroxyurea chemotherapy"]], "start": [[138]], "entity_id": ["T3"], "Drug": {"text": [["hydroxyurea"], ["hydroxyurea"]], "start": [[90], [138]], "entity_id": ["T6", "T7"]}, "Route": {"text": [["chemotherapy"]], "start": [[150]], "entity_id": ["T4"]}}, "Effect": {"text": [["myeloproliferative disorder"]], "start": [[204]], "entity_id": ["T5"]}, "Speculated": {"text": [["probably"]], "start": [[66]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "7673653_2", "context": "Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors (SSRIs), i.e. fluoxetine and sertraline, have been previously reported in patients with depression and obsessive-compulsive disorder (OCD).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced by"]], "start": [[28]], "entity_id": ["T5"]}, "Effect": {"text": [["Extrapyramidal side effects"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["some selective serotonin reuptake inhibitors (SSRIs), i.e. fluoxetine and sertraline"]], "start": [[39]], "entity_id": ["T6"], "Disorder": {"text": [["depression"], ["obsessive-compulsive disorder (OCD)"]], "start": [[172], [187]], "entity_id": ["T8", "T9"]}, "Drug": {"text": [["fluoxetine"], ["sertraline"], ["serotonin reuptake inhibitors"]], "start": [[98], [113], [54]], "entity_id": ["T10", "T11", "T12"]}}, "Subject": {"text": [["patients with depression and obsessive-compulsive disorder (OCD)"]], "start": [[158]], "entity_id": ["T7"]}}]}]}
{"id": "9291634_6", "context": "Ten-17 days after receiving chemotherapy, five patients (4 males and 1 female) with acute lymphoblastic leukemia developed incapacitating myalgias in neck, thighs and arms.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[113]], "entity_id": ["T7"]}, "Subject": {"text": [["five patients (4 males and 1 female) with acute lymphoblastic leukemia"]], "start": [[42]], "entity_id": ["T8"], "Population": {"text": [["five"]], "start": [[42]], "entity_id": ["T12"]}, "Gender": {"text": [["4 males and 1 female"]], "start": [[57]], "entity_id": ["T13"]}}, "Effect": {"text": [["incapacitating myalgias in neck, thighs and arms"]], "start": [[123]], "entity_id": ["T9"]}, "Treatment": {"text": [["Ten-17 days after receiving chemotherapy"]], "start": [[0]], "entity_id": ["T10"], "Disorder": {"text": [["acute lymphoblastic leukemia"]], "start": [[84]], "entity_id": ["T14"]}, "Time_elapsed": {"text": [["Ten-17 days"]], "start": [[0]], "entity_id": ["T15"]}, "Route": {"text": [["chemotherapy"]], "start": [[28]], "entity_id": ["T16"]}}}]}]}
{"id": "21597286_2", "context": "We report a case of a potential drug-drug interaction in a woman treated by a first injection of high-dose methotrexate for a T-lymphoblastic lymphoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[65]], "entity_id": ["T5"]}, "Subject": {"text": [["a woman"]], "start": [[57]], "entity_id": ["T6"], "Gender": {"text": [["woman"]], "start": [[59]], "entity_id": ["T9"]}}, "Treatment": {"text": [["a first injection of high-dose methotrexate"]], "start": [[76]], "entity_id": ["T7"], "Disorder": {"text": [["a T-lymphoblastic lymphoma"]], "start": [[124]], "entity_id": ["T8"]}, "Route": {"text": [["injection"]], "start": [[84]], "entity_id": ["T11"]}, "Dosage": {"text": [["high-dose"]], "start": [[97]], "entity_id": ["T12"]}, "Drug": {"text": [["methotrexate"]], "start": [[107]], "entity_id": ["T13"]}}, "Speculated": {"text": [["potential"]], "start": [[22]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "16791713_4", "context": "We conclude that myocardial infarction may develop in patients treated with high-dose glucocorticoids for Graves' ophthalmopathy, and increased blood pressure may herald this complication.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["develop"]], "start": [[43]], "entity_id": ["T7"]}, "Effect": {"text": [["myocardial infarction"], ["increased blood pressure"]], "start": [[17], [134]], "entity_id": ["T3", "T6"]}, "Subject": {"text": [["patients"]], "start": [[54]], "entity_id": ["T4"]}, "Treatment": {"text": [["high-dose glucocorticoids"]], "start": [[76]], "entity_id": ["T5"], "Drug": {"text": [["glucocorticoids"]], "start": [[86]], "entity_id": ["T8"]}, "Dosage": {"text": [["high-dose"]], "start": [[76]], "entity_id": ["T9"]}, "Disorder": {"text": [["Graves' ophthalmopathy"]], "start": [[106]], "entity_id": ["T10"]}}, "Speculated": {"text": [["may"]], "start": [[39]], "entity_id": ["T11"], "value": true}}]}]}
{"id": "19798640_1", "context": "A 40-year-old man with relapsing-remitting multiple sclerosis (MS) developed primary central nervous system lymphoma (PCNSL) after having received 21 doses of natalizumab monotherapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[67]], "entity_id": ["T7"]}, "Effect": {"text": [["primary central nervous system lymphoma (PCNSL)"]], "start": [[77]], "entity_id": ["T8"]}, "Treatment": {"text": [["21 doses of natalizumab monotherapy"]], "start": [[147]], "entity_id": ["T9"], "Disorder": {"text": [["relapsing-remitting multiple sclerosis (MS)"]], "start": [[23]], "entity_id": ["T6"]}, "Dosage": {"text": [["21 doses"]], "start": [[147]], "entity_id": ["T12"]}, "Drug": {"text": [["natalizumab"]], "start": [[159]], "entity_id": ["T13"]}}, "Subject": {"text": [["40-year-old man with relapsing-remitting multiple sclerosis (MS)"]], "start": [[2]], "entity_id": ["T5"], "Age": {"text": [["40-year-old"]], "start": [[2]], "entity_id": ["T10"]}, "Gender": {"text": [["man"]], "start": [[14]], "entity_id": ["T11"]}}}]}]}
{"id": "11816261_4", "context": "Serotonin syndrome caused by selective serotonin reuptake-inhibitors-metoclopramide interaction.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[19]], "entity_id": ["T3"]}, "Treatment": {"text": [["selective serotonin reuptake-inhibitors-metoclopramide interaction"]], "start": [[29]], "entity_id": ["T4"], "Drug": {"text": [["metoclopramide"], ["selective serotonin reuptake-inhibitors"]], "start": [[69], [29]], "entity_id": ["T7", "T8"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[84]], "entity_id": ["T6"]}, "Drug": {"text": [["metoclopramide"], ["selective serotonin reuptake-inhibitors"]], "start": [[69], [29]], "entity_id": ["T7", "T8"]}}]}, "Effect": {"text": [["Serotonin syndrome"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "7937287_10", "context": "This is the first reported case of suspected DIAN due to cefuroxime.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due to"]], "start": [[50]], "entity_id": ["T6"]}, "Effect": {"text": [["DIAN"]], "start": [[45]], "entity_id": ["T5"]}, "Treatment": {"text": [["cefuroxime"]], "start": [[57]], "entity_id": ["T7"], "Drug": {"text": [["cefuroxime"]], "start": [[57]], "entity_id": ["T9"]}}, "Subject": {"text": [["first reported case"]], "start": [[12]], "entity_id": ["T10"]}, "Speculated": {"text": [["suspected"]], "start": [[35]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "7995508_2", "context": "We report a cae of paranoid psychosis following use of a decongestant containing PPA and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[38]], "entity_id": ["T6"]}, "Subject": {"text": [["a cae"]], "start": [[10]], "entity_id": ["T5"]}, "Treatment": {"text": [["decongestant containing PPA"]], "start": [[57]], "entity_id": ["T7"], "Drug": {"text": [["PPA"]], "start": [[81]], "entity_id": ["T9"]}}, "Effect": {"text": [["paranoid psychosis"]], "start": [[19]], "entity_id": ["T8"]}}]}]}
{"id": "17133571_1", "context": "Liver transplantation for fulminant hepatitis related to nevirapine therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[46]], "entity_id": ["T4"]}, "Effect": {"text": [["Liver transplantation for fulminant hepatitis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["nevirapine therapy"]], "start": [[57]], "entity_id": ["T5"], "Drug": {"text": [["nevirapine"]], "start": [[57]], "entity_id": ["T6"]}}}]}]}
{"id": "11414270_2", "context": "OBJECTIVE: To report a case of fatal hyperkalemia owing to succinylcholine administration in a patient with mucositis secondary to chemotherapy.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["owing"]], "start": [[50]], "entity_id": ["T10"]}, "Subject": {"text": [["a patient with mucositis secondary to chemotherapy"]], "start": [[93]], "entity_id": ["T12"]}, "Treatment": {"text": [["succinylcholine administration"]], "start": [[59]], "entity_id": ["T11"], "Disorder": {"text": [["mucositis"]], "start": [[108]], "entity_id": ["T16"]}, "Drug": {"text": [["succinylcholine"]], "start": [[59]], "entity_id": ["T15"]}}, "Effect": {"text": [["hyperkalemia"]], "start": [[37]], "entity_id": ["T9"]}, "Severity": {"text": [["fatal"]], "start": [[31]], "entity_id": ["T14"], "value": "High"}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["secondary"]], "start": [[118]], "entity_id": ["T18"]}, "Treatment": {"text": [["chemotherapy"]], "start": [[131]], "entity_id": ["T22"], "Drug": {"text": [["chemotherapy"]], "start": [[131]], "entity_id": ["T19"]}}, "Effect": {"text": [["mucositis"]], "start": [[108]], "entity_id": ["T21"]}, "Subject": {"text": [["a patient"]], "start": [[93]], "entity_id": ["T20"]}}]}]}
{"id": "8835752_3", "context": "We describe a case of prolonged terbinafine-induced cholestatic liver disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[44]], "entity_id": ["T4"]}, "Treatment": {"text": [["prolonged terbinafine"]], "start": [[22]], "entity_id": ["T3"], "Drug": {"text": [["terbinafine"]], "start": [[32]], "entity_id": ["T7"]}}, "Subject": {"text": [["a case"]], "start": [[12]], "entity_id": ["T5"]}, "Effect": {"text": [["cholestatic liver disease"]], "start": [[52]], "entity_id": ["T6"]}}]}]}
{"id": "10707759_3", "context": "We describe a case of interstitial hypoxaemiant pneumonitis probably related to flecainide in a patient with the LEOPARD syndrome, a rare congenital disorder.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[69]], "entity_id": ["T7"]}, "Effect": {"text": [["interstitial hypoxaemiant pneumonitis"]], "start": [[22]], "entity_id": ["T5"]}, "Treatment": {"text": [["flecainide"]], "start": [[80]], "entity_id": ["T6"], "Drug": {"text": [["flecainide"]], "start": [[80]], "entity_id": ["T8"]}, "Disorder": {"text": [["LEOPARD syndrome"]], "start": [[113]], "entity_id": ["T9"]}}, "Subject": {"text": [["a patient with the LEOPARD syndrome"]], "start": [[94]], "entity_id": ["T4"]}, "Speculated": {"text": [["probably"]], "start": [[60]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "7718983_4", "context": "This case showed sequential manifestation from transient thyrotoxicosis to the appearance of TSH-receptor autoantibodies, and then the occurrence of Graves' hyperthyroidism during IFN therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurrence"]], "start": [[135]], "entity_id": ["T5"]}, "Effect": {"text": [["Graves' hyperthyroidism"]], "start": [[149]], "entity_id": ["T3"]}, "Treatment": {"text": [["IFN therapy"]], "start": [[180]], "entity_id": ["T4"], "Drug": {"text": [["IFN"]], "start": [[180]], "entity_id": ["T6"]}}, "Subject": {"text": [["This case"]], "start": [[0]], "entity_id": ["T7"]}}]}]}
{"id": "3405528_2", "context": "Halothane hepatitis and prompt resolution with methionine therapy: case report.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["resolution"]], "start": [[31]], "entity_id": ["T3"]}, "Treatment": {"text": [["methionine"]], "start": [[47]], "entity_id": ["T4"], "Disorder": {"text": [["Halothane hepatitis"]], "start": [[0]], "entity_id": ["T5"]}, "Drug": {"text": [["methionine"]], "start": [[47]], "entity_id": ["T6"]}}, "Subject": {"text": [["case"]], "start": [[67]], "entity_id": ["T7"]}}]}]}
{"id": "11706664_2", "context": "This report describes an unexpected drug-induced hepatitis in a previously healthy young woman exposed to 2 doses of amodiaquine and artesunate.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["exposed"]], "start": [[95]], "entity_id": ["T7"]}, "Effect": {"text": [["hepatitis"]], "start": [[49]], "entity_id": ["T4"]}, "Subject": {"text": [["a previously healthy young woman"]], "start": [[62]], "entity_id": ["T5"], "Gender": {"text": [["young"], ["woman"]], "start": [[83], [89]], "entity_id": ["T9", "T10"]}}, "Treatment": {"text": [["2 doses of amodiaquine and artesunate"]], "start": [[106]], "entity_id": ["T6"], "Dosage": {"text": [["2 doses"]], "start": [[106]], "entity_id": ["T11"]}, "Drug": {"text": [["amodiaquine"], ["artesunate"]], "start": [[117], [133]], "entity_id": ["T12", "T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[129]], "entity_id": ["T14"]}, "Drug": {"text": [["amodiaquine"], ["artesunate"]], "start": [[117], [133]], "entity_id": ["T12", "T13"]}}]}, "Speculated": {"text": [["unexpected"]], "start": [[25]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "3680913_1", "context": "It was restarted 6 weeks later, and 10 weeks after that, the patient presented with fulminant hepatic failure, which resolved rapidly after cessation of nicotinic acid therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["presented"]], "start": [[69]], "entity_id": ["T6"]}, "Effect": {"text": [["fulminant hepatic failure"]], "start": [[84]], "entity_id": ["T3"]}, "Treatment": {"text": [["10 weeks after", "nicotinic acid"]], "start": [[36, 153]], "entity_id": ["T4"], "Time_elapsed": {"text": [["10 weeks after"]], "start": [[36]], "entity_id": ["T7"]}, "Drug": {"text": [["nicotinic acid"]], "start": [[153]], "entity_id": ["T8"]}}, "Subject": {"text": [["the patient"]], "start": [[57]], "entity_id": ["T5"]}}]}]}
{"id": "9366852_4", "context": "We describe a patient with the antiphospholipid syndrome who had skin necrosis develop from low-molecular weight heparin therapy at sites distant from injection sites.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["develop"]], "start": [[79]], "entity_id": ["T9"]}, "Effect": {"text": [["skin necrosis"]], "start": [[65]], "entity_id": ["T8"]}, "Treatment": {"text": [["low-molecular weight heparin therapy at sites distant from injection sites"]], "start": [[92]], "entity_id": ["T10"], "Disorder": {"text": [["antiphospholipid syndrome"]], "start": [[31]], "entity_id": ["T7"]}, "Drug": {"text": [["low-molecular weight heparin"]], "start": [[92]], "entity_id": ["T11"]}, "Route": {"text": [["injection"]], "start": [[151]], "entity_id": ["T12"]}}, "Subject": {"text": [["a patient with the antiphospholipid syndrome"]], "start": [[12]], "entity_id": ["T6"]}}]}]}
{"id": "18022748_11", "context": "While CYP form induction by Pyrethrins, Phenobarbital and related compounds can be associated with liver and thyroid gland tumour formation in rodents, epidemiological data for Phenobarbital suggests that such effects do not occur in humans.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induction"]], "start": [[15]], "entity_id": ["T13"]}, "Treatment": {"text": [["Pyrethrins, Phenobarbital and related compounds"]], "start": [[28]], "entity_id": ["T14"], "Drug": {"text": [["Pyrethrins"], ["Phenobarbital"], ["related compounds"]], "start": [[28], [40], [58]], "entity_id": ["T16", "T17", "T18"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[54]], "entity_id": ["T19"]}, "Drug": {"text": [["related compounds"], ["Phenobarbital"], ["Pyrethrins"]], "start": [[58], [40], [28]], "entity_id": ["T18", "T17", "T16"]}}]}, "Effect": {"text": [["liver and thyroid gland tumour formation in rodents"]], "start": [[99]], "entity_id": ["T15"]}, "Negated": {"text": [["do not occur"]], "start": [[218]], "entity_id": ["T20"], "value": true}}]}]}
{"id": "7416268_1", "context": "Disulfiram encephalopathy as a cause of the catatonia syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[31]], "entity_id": ["T9"]}, "Treatment": {"text": [["Disulfiram"]], "start": [[0]], "entity_id": ["T7"], "Drug": {"text": [["Disulfiram"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["catatonia syndrome", "encephalopathy"]], "start": [[44, 11]], "entity_id": ["T8"]}}]}]}
{"id": "7653281_2", "context": "Little has been studied of the adverse effects of the exposure of the liver to the interaction of ethanol with its congeners and acetaldehyde, coexisting in the contents of alcoholic beverages.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["interaction"]], "start": [[83]], "entity_id": ["T8"]}, "Effect": {"text": [["adverse effects of the exposure of the liver"]], "start": [[31]], "entity_id": ["T6"]}, "Treatment": {"text": [["ethanol with its congeners and acetaldehyde"]], "start": [[98]], "entity_id": ["T7"], "Drug": {"text": [["acetaldehyde"], ["ethanol"]], "start": [[129], [98]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[83]], "entity_id": ["T11"]}, "Drug": {"text": [["ethanol"], ["acetaldehyde"]], "start": [[98], [129]], "entity_id": ["T10", "T9"]}}]}}]}]}
{"id": "22735246_1", "context": "Fatal serotonin syndrome precipitated by oxcarbazepine in a patient using an selective serotonin reuptake inhibitor.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["precipitated"]], "start": [[25]], "entity_id": ["T7"]}, "Effect": {"text": [["serotonin syndrome"]], "start": [[6]], "entity_id": ["T6"]}, "Treatment": {"text": [["oxcarbazepine"]], "start": [[41]], "entity_id": ["T8"], "Drug": {"text": [["oxcarbazepine"]], "start": [[41]], "entity_id": ["T11"]}}, "Subject": {"text": [["a patient"]], "start": [[58]], "entity_id": ["T9"]}, "Severity": {"text": [["Fatal"]], "start": [[0]], "entity_id": ["T10"], "value": "Medium"}}]}]}
{"id": "11568758_2", "context": "This eruption emerged after 1 month of therapy with salsalate, persisted for as long as salsalate was administered, and cleared within 3 weeks of discontinuing the medication.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["emerged"]], "start": [[14]], "entity_id": ["T4"]}, "Effect": {"text": [["eruption"]], "start": [[5]], "entity_id": ["T3"]}, "Treatment": {"text": [["after 1 month of therapy with salsalate"]], "start": [[22]], "entity_id": ["T5"], "Time_elapsed": {"text": [["1 month"]], "start": [[28]], "entity_id": ["T7"]}, "Drug": {"text": [["salsalate"]], "start": [[52]], "entity_id": ["T8"]}}}]}]}
{"id": "8969033_1", "context": "A case report is presented concerning the administration of ketanserin in the treatment of pulmonary vasoconstriction and right ventricular failure following the infusion of protamine in a patient undergoing coronary artery bypass surgery and mitral valve replacement.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[148]], "entity_id": ["T8"]}, "Treatment": {"text": [["infusion of protamine", "undergoing coronary artery bypass surgery and mitral valve replacement"]], "start": [[162, 197]], "entity_id": ["T5"], "Drug": {"text": [["protamine"]], "start": [[174]], "entity_id": ["T9"]}, "Route": {"text": [["infusion"]], "start": [[162]], "entity_id": ["T10"]}}, "Subject": {"text": [["a patient"]], "start": [[187]], "entity_id": ["T6"]}, "Effect": {"text": [["pulmonary vasoconstriction and right ventricular failure"]], "start": [[91]], "entity_id": ["T7"]}}]}]}
{"id": "10803790_7", "context": "When cyanamide-treated alcoholics relapse into drinking, more severe inflammation develops in the liver.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["develops"]], "start": [[82]], "entity_id": ["T5"]}, "Treatment": {"text": [["cyanamide"]], "start": [[5]], "entity_id": ["T3"], "Drug": {"text": [["cyanamide"]], "start": [[5]], "entity_id": ["T8"]}, "Disorder": {"text": [["alcoholics"]], "start": [[23]], "entity_id": ["T9"]}}, "Effect": {"text": [["inflammation"]], "start": [[69]], "entity_id": ["T4"]}, "Subject": {"text": [["cyanamide-treated alcoholics"]], "start": [[5]], "entity_id": ["T6"]}, "Severity": {"text": [["severe"]], "start": [[62]], "entity_id": ["T10"], "value": "High"}}]}]}
{"id": "9256906_2", "context": "Acute renal failure should be recognized as a potential complication of suramin treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[56]], "entity_id": ["T4"]}, "Effect": {"text": [["Acute renal failure"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["suramin treatment"]], "start": [[72]], "entity_id": ["T5"], "Drug": {"text": [["suramin"]], "start": [[72]], "entity_id": ["T7"]}}, "Speculated": {"text": [["potential"]], "start": [[46]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "8936932_2", "context": "After induction of general anesthesia and administration of a standard dose of intravenous esmolol hydrochloride, her cardiac rhythm progressed to asystole.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["After"]], "start": [[0]], "entity_id": ["T6"]}, "Treatment": {"text": [["induction of general anesthesia and administration of a standard dose of intravenous esmolol hydrochloride"]], "start": [[6]], "entity_id": ["T3"], "Route": {"text": [["intravenous"]], "start": [[79]], "entity_id": ["T8"]}, "Drug": {"text": [["esmolol hydrochloride"], ["general anesthesia"]], "start": [[91], [19]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[38]], "entity_id": ["T11"]}, "Drug": {"text": [["general anesthesia"], ["esmolol hydrochloride"]], "start": [[19], [91]], "entity_id": ["T10", "T9"]}}]}, "Subject": {"text": [["her"]], "start": [[114]], "entity_id": ["T4"], "Gender": {"text": [["her"]], "start": [[114]], "entity_id": ["T7"]}}, "Effect": {"text": [["asystole"]], "start": [[147]], "entity_id": ["T5"]}}]}]}
{"id": "2875665_1", "context": "Exacerbation of schizophrenia associated with amantadine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[30]], "entity_id": ["T4"]}, "Treatment": {"text": [["amantadine"]], "start": [[46]], "entity_id": ["T5"], "Drug": {"text": [["amantadine"]], "start": [[46]], "entity_id": ["T7"]}}, "Effect": {"text": [["Exacerbation of schizophrenia"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "10431414_2", "context": "Priapism as a complication of heparin therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[14]], "entity_id": ["T5"]}, "Effect": {"text": [["Priapism"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["heparin"]], "start": [[30]], "entity_id": ["T3"], "Drug": {"text": [["heparin"]], "start": [[30]], "entity_id": ["T6"]}}}]}]}
{"id": "1977935_1", "context": "Torsades de pointes occurring in association with terfenadine use.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["association"]], "start": [[33]], "entity_id": ["T4"]}, "Effect": {"text": [["Torsades de pointes"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["terfenadine"]], "start": [[50]], "entity_id": ["T6"], "Drug": {"text": [["terfenadine"]], "start": [[50]], "entity_id": ["T7"]}}}]}]}
{"id": "10452772_5", "context": "Protamine allergy as a complication of insulin hypersensitivity: A case report.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[23]], "entity_id": ["T5"]}, "Treatment": {"text": [["insulin"]], "start": [[39]], "entity_id": ["T7"], "Drug": {"text": [["insulin"]], "start": [[39]], "entity_id": ["T6"]}}, "Effect": {"text": [["hypersensitivity", "Protamine allergy"]], "start": [[47, 0]], "entity_id": ["T3"]}}]}]}
{"id": "10524732_2", "context": "We report a case of recurrent torsades de pointes following treatment with pentavalent antimonial drugs and amiodarone.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treatment with"]], "start": [[60]], "entity_id": ["T4"]}, "Treatment": {"text": [["pentavalent antimonial drugs and amiodarone"]], "start": [[75]], "entity_id": ["T3"], "Drug": {"text": [["amiodarone"], ["pentavalent antimonial drugs"]], "start": [[108], [75]], "entity_id": ["T6", "T7"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[104]], "entity_id": ["T8"]}, "Drug": {"text": [["pentavalent antimonial drugs"], ["amiodarone"]], "start": [[75], [108]], "entity_id": ["T7", "T6"]}}]}, "Effect": {"text": [["recurrent torsades de pointes"]], "start": [[20]], "entity_id": ["T5"]}}]}]}
{"id": "2038845_1", "context": "This case presentation is of a patient who had the clinical appearance of epiglottitis, but actually had an oro-pharyngeal dystonic reaction to prochlorperazine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["had"]], "start": [[101]], "entity_id": ["T8"]}, "Subject": {"text": [["a patient"]], "start": [[29]], "entity_id": ["T5"]}, "Treatment": {"text": [["prochlorperazine"]], "start": [[144]], "entity_id": ["T7"], "Drug": {"text": [["prochlorperazine"]], "start": [[144]], "entity_id": ["T9"]}}, "Effect": {"text": [["clinical appearance of epiglottitis", "actually had an oro-pharyngeal dystonic reaction"]], "start": [[51, 92]], "entity_id": ["T6"]}}]}]}
{"id": "19537383_1", "context": "Localized dyskeratotic plaque with milia associated with sorafenib.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[41]], "entity_id": ["T4"]}, "Treatment": {"text": [["sorafenib"]], "start": [[57]], "entity_id": ["T5"], "Drug": {"text": [["sorafenib"]], "start": [[57]], "entity_id": ["T7"]}}, "Effect": {"text": [["Localized dyskeratotic plaque with milia"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "7416268_2", "context": "The authors describe a case of the catatonia syndrome associated with disulfiram therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[54]], "entity_id": ["T5"]}, "Effect": {"text": [["catatonia syndrome"]], "start": [[35]], "entity_id": ["T4"]}, "Treatment": {"text": [["disulfiram therapy"]], "start": [[70]], "entity_id": ["T6"], "Drug": {"text": [["disulfiram"]], "start": [[70]], "entity_id": ["T7"]}}}]}]}
{"id": "23624139_2", "context": "Most of the clinical data on the safety profile of desmopressin (DDAVP), which is an effective treatment for both polyuric conditions and bleeding disorders, originate from studies on the tailoring of drug treatment, whereas few reports exist describing severe side effects secondary to drug-drug interaction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatment"]], "start": [[95]], "entity_id": ["T10"]}, "Treatment": {"text": [["desmopressin (DDAVP)"]], "start": [[51]], "entity_id": ["T8"], "Drug": {"text": [["desmopressin"]], "start": [[51]], "entity_id": ["T13"]}, "Disorder": {"text": [["polyuric conditions"], ["bleeding disorders"]], "start": [[114], [138]], "entity_id": ["T14", "T15"]}}, "Subject": {"text": [["both polyuric conditions and bleeding disorders"]], "start": [[109]], "entity_id": ["T9"]}}]}]}
{"id": "7663030_12", "context": "Propafenone's distribution, clearance, and structural similarity to propranolol contribute to its central nervous system effects.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["contribute"]], "start": [[80]], "entity_id": ["T5"]}, "Treatment": {"text": [["Propafenone"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["propranolol"], ["Propafenone"]], "start": [[68], [0]], "entity_id": ["T8", "T7"]}}, "Effect": {"text": [["central nervous system effects"]], "start": [[98]], "entity_id": ["T6"]}}]}]}
{"id": "19423610_1", "context": "Risk of severe serotonin toxicity following co-administration of methylene blue and serotonin reuptake inhibitors: an update on a case report of post-operative delirium.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[34]], "entity_id": ["T11"]}, "Effect": {"text": [["serotonin toxicity", "post-operative delirium"]], "start": [[15, 145]], "entity_id": ["T8"]}, "Treatment": {"text": [["co-administration of methylene blue and serotonin reuptake inhibitors"]], "start": [[44]], "entity_id": ["T10"], "Drug": {"text": [["methylene blue"], ["serotonin reuptake inhibitors"]], "start": [[65], [84]], "entity_id": ["T9", "T12"]}, "Combination": [{"event_id": "E1", "event_type": "Combination", "Trigger": {"text": [["co-administration"]], "start": [[44]], "entity_id": ["T13"]}, "Drug": {"text": [["methylene blue"], ["serotonin reuptake inhibitors"]], "start": [[65], [84]], "entity_id": ["T9", "T12"]}}]}}]}]}
{"id": "19782276_9", "context": "Cyclophosphamide-induced cardiotoxicity occurred, even though the patient had both shown normal cardiac function before high-dose chemotherapy and had received a lower dose of cyclophosphamide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[17]], "entity_id": ["T6"]}, "Treatment": {"text": [["Cyclophosphamide", "high-dose chemotherapy and had received a lower dose of cyclophosphamide"]], "start": [[0, 120]], "entity_id": ["T5"], "Drug": {"text": [["Cyclophosphamide"]], "start": [[0]], "entity_id": ["T9"]}, "Dosage": {"text": [["lower dose"]], "start": [[162]], "entity_id": ["T10"]}}, "Effect": {"text": [["cardiotoxicity"]], "start": [[25]], "entity_id": ["T7"]}, "Subject": {"text": [["the patient had both shown normal cardiac function"]], "start": [[62]], "entity_id": ["T8"]}}]}]}
{"id": "18707772_1", "context": "A 64 year old woman with previous history of coronary stenting five days before was admitted in our institution for intracranial bleeding while receiving aspirin and clopidogrel.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["receiving"]], "start": [[144]], "entity_id": ["T7"]}, "Subject": {"text": [["A 64 year old woman with previous history of coronary stenting"]], "start": [[0]], "entity_id": ["T4"], "Age": {"text": [["64 year old"]], "start": [[2]], "entity_id": ["T8"]}, "Gender": {"text": [["woman"]], "start": [[14]], "entity_id": ["T9"]}}, "Effect": {"text": [["intracranial bleeding"]], "start": [[116]], "entity_id": ["T5"]}, "Treatment": {"text": [["five days before", "aspirin and clopidogrel"]], "start": [[63, 154]], "entity_id": ["T6"], "Drug": {"text": [["clopidogrel"], ["aspirin"]], "start": [[166], [154]], "entity_id": ["T11", "T12"]}, "Disorder": {"text": [["coronary stenting"]], "start": [[45]], "entity_id": ["T14"]}, "Time_elapsed": {"text": [["five days"]], "start": [[63]], "entity_id": ["T15"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[162]], "entity_id": ["T13"]}, "Drug": {"text": [["aspirin"], ["clopidogrel"]], "start": [[154], [166]], "entity_id": ["T12", "T11"]}}]}}]}]}
{"id": "12324937_5", "context": "METHODS: A case is presented of a 45-year-old woman on prolonged gemcitabine treatment for ovarian cancer who developed HUS and recovered after drug discontinuation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[110]], "entity_id": ["T6"]}, "Subject": {"text": [["a 45-year-old woman"]], "start": [[32]], "entity_id": ["T3"], "Age": {"text": [["45-year-old"]], "start": [[34]], "entity_id": ["T8"]}, "Gender": {"text": [["woman"]], "start": [[46]], "entity_id": ["T9"]}}, "Treatment": {"text": [["prolonged gemcitabine treatment"]], "start": [[55]], "entity_id": ["T4"], "Drug": {"text": [["gemcitabine"]], "start": [[65]], "entity_id": ["T10"]}, "Duration": {"text": [["prolonged"]], "start": [[55]], "entity_id": ["T11"]}, "Disorder": {"text": [["ovarian cance"]], "start": [[91]], "entity_id": ["T12"]}}, "Effect": {"text": [["HUS"]], "start": [[120]], "entity_id": ["T7"]}}]}]}
{"id": "889156_4", "context": "A more serious development of adrenal insufficiency may occur upon the improper replacement of systemic steroids.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["replacement"]], "start": [[80]], "entity_id": ["T6"]}, "Effect": {"text": [["development of adrenal insufficiency"]], "start": [[15]], "entity_id": ["T5"]}, "Treatment": {"text": [["systemic steroids"]], "start": [[95]], "entity_id": ["T7"], "Drug": {"text": [["steroids"]], "start": [[104]], "entity_id": ["T9"]}}, "Speculated": {"text": [["may"]], "start": [[52]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "1495728_2", "context": "We describe a case of pneumonitis following local administration of methotrexate for nonsurgical termination of an ectopic pregnancy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[34]], "entity_id": ["T8"]}, "Subject": {"text": [["a case"]], "start": [[12]], "entity_id": ["T6"]}, "Effect": {"text": [["pneumonitis"]], "start": [[22]], "entity_id": ["T7"]}, "Treatment": {"text": [["local administration of methotrexate"]], "start": [[44]], "entity_id": ["T9"], "Drug": {"text": [["methotrexate"]], "start": [[68]], "entity_id": ["T11"]}, "Disorder": {"text": [["ectopic pregnancy"]], "start": [[115]], "entity_id": ["T12"]}}}]}]}
{"id": "14690166_2", "context": "There is currently no consensus on the best treatment for unresectable hyaline-vascular variant or for multicentric Castleman's disease (MCD), because none of the reported regimens have consistently produced complete response or durable remission in the majority of patients In the present study, we report on the use of 2-CdA (2-chloro-deoxyadenosine) in three patients, two of them with MCD and one with unresectable hyaline-vascular type disease.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["use"]], "start": [[314]], "entity_id": ["T14"]}, "Subject": {"text": [["one"]], "start": [[397]], "entity_id": ["T19"], "Population": {"text": [["one"]], "start": [[397]], "entity_id": ["T13"]}}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["use"]], "start": [[314]], "entity_id": ["T14"]}, "Treatment": {"text": [["2-CdA (2-chloro-deoxyadenosine)"], ["2-CdA (2-chloro-deoxyadenosine)"]], "start": [[321], [321]], "entity_id": ["T12", "T23"], "Drug": {"text": [["2-CdA"], ["2-CdA"]], "start": [[321], [321]], "entity_id": ["T24", "T20"]}, "Disorder": {"text": [["MCD"], ["unresectable hyaline-vascular type disease"]], "start": [[389], [406]], "entity_id": ["T17", "T22"]}}, "Subject": {"text": [["two"]], "start": [[372]], "entity_id": ["T21"], "Population": {"text": [["two"]], "start": [[372]], "entity_id": ["T16"]}}}]}]}
{"id": "19667003_1", "context": "Carbamazepine-induced hyperammonemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[14]], "entity_id": ["T5"]}, "Treatment": {"text": [["Carbamazepine"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Carbamazepine"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["hyperammonemia"]], "start": [[22]], "entity_id": ["T6"]}}]}]}
{"id": "10803790_3", "context": "Case 3: A 29-year-old female alcoholic complained of general fatigue and a slight fever after 1.5 years of abstinence with cyanamide treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complained"]], "start": [[39]], "entity_id": ["T8"]}, "Subject": {"text": [["A 29-year-old female alcoholic"]], "start": [[8]], "entity_id": ["T5"], "Age": {"text": [["29-year-old"]], "start": [[10]], "entity_id": ["T9"]}, "Gender": {"text": [["female"]], "start": [[22]], "entity_id": ["T10"]}}, "Effect": {"text": [["general fatigue and a slight fever"]], "start": [[53]], "entity_id": ["T6"]}, "Treatment": {"text": [["after 1.5 years of abstinence with cyanamide"]], "start": [[88]], "entity_id": ["T7"], "Disorder": {"text": [["alcoholic"]], "start": [[29]], "entity_id": ["T11"]}, "Duration": {"text": [["1.5 years"]], "start": [[94]], "entity_id": ["T13"]}, "Drug": {"text": [["cyanamide"]], "start": [[123]], "entity_id": ["T15"]}}, "Severity": {"text": [["slight"]], "start": [[75]], "entity_id": ["T12"], "value": "Medium"}}]}]}
{"id": "10667036_1", "context": "Caution is, therefore, needed to prevent undesired accumulation of TCA that may lead to protracted Cushing's syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["lead to"]], "start": [[80]], "entity_id": ["T4"]}, "Treatment": {"text": [["TCA"]], "start": [[67]], "entity_id": ["T3"], "Drug": {"text": [["TCA"]], "start": [[67]], "entity_id": ["T6"]}}, "Effect": {"text": [["protracted Cushing's syndrome"]], "start": [[88]], "entity_id": ["T5"]}}]}]}
{"id": "7408538_2", "context": "Unusual pigmentary changes associated with 5-fluorouracil therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[27]], "entity_id": ["T4"]}, "Effect": {"text": [["Unusual pigmentary changes"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["5-fluorouracil"]], "start": [[43]], "entity_id": ["T5"], "Drug": {"text": [["5-fluorouracil"]], "start": [[43]], "entity_id": ["T6"]}}}]}]}
{"id": "9876812_4", "context": "Syndrome of inappropriate antidiuretic hormone associated with vinorelbine therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[47]], "entity_id": ["T4"]}, "Effect": {"text": [["Syndrome of inappropriate antidiuretic hormone"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["vinorelbine"]], "start": [[63]], "entity_id": ["T5"], "Drug": {"text": [["vinorelbine"]], "start": [[63]], "entity_id": ["T6"]}}}]}]}
{"id": "18453852_14", "context": "The study showed a high incidence of adverse events when a higher than standard dose of the new lopinavir/ritonavir tablets was combined with rifampicin.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["when"]], "start": [[52]], "entity_id": ["T8"]}, "Treatment": {"text": [["higher than standard dose of the new lopinavir/ritonavir tablets was combined with rifampicin"]], "start": [[59]], "entity_id": ["T6"], "Dosage": {"text": [["higher than standard dose"]], "start": [[59]], "entity_id": ["T10"]}, "Drug": {"text": [["rifampicin"], ["lopinavir"], ["ritonavir"]], "start": [[142], [96], [106]], "entity_id": ["T11", "T12", "T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combined"]], "start": [[128]], "entity_id": ["T9"]}, "Drug": {"text": [["ritonavir"], ["lopinavir"], ["rifampicin"]], "start": [[106], [96], [142]], "entity_id": ["T13", "T12", "T11"]}}]}, "Effect": {"text": [["adverse events"]], "start": [[37]], "entity_id": ["T7"]}}]}]}
{"id": "19499966_3", "context": "Onset of male gynaecomastia in a patient treated with sunitinib for metastatic renal cell carcinoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Onset"]], "start": [[0]], "entity_id": ["T7"]}, "Effect": {"text": [["gynaecomastia"]], "start": [[14]], "entity_id": ["T3"]}, "Subject": {"text": [["male", "a patient"]], "start": [[9, 31]], "entity_id": ["T4"], "Gender": {"text": [["male"]], "start": [[9]], "entity_id": ["T9"]}}, "Treatment": {"text": [["sunitinib for metastatic renal cell carcinoma"]], "start": [[54]], "entity_id": ["T5"], "Disorder": {"text": [["metastatic renal cell carcinoma"]], "start": [[68]], "entity_id": ["T6"]}, "Drug": {"text": [["sunitinib"]], "start": [[54]], "entity_id": ["T8"]}}}]}]}
{"id": "7973922_3", "context": "Systemic disease, most commonly renal dysfunction, preceded all 30 reported cases of acyclovir neurotoxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["preceded"]], "start": [[51]], "entity_id": ["T5"]}, "Treatment": {"text": [["acyclovir"]], "start": [[85]], "entity_id": ["T3"], "Drug": {"text": [["acyclovir"]], "start": [[85]], "entity_id": ["T8"]}}, "Effect": {"text": [["Systemic disease, most commonly renal dysfunction", "neurotoxicity"]], "start": [[0, 95]], "entity_id": ["T4"]}, "Subject": {"text": [["30 reported cases"]], "start": [[64]], "entity_id": ["T6"], "Population": {"text": [["30"]], "start": [[64]], "entity_id": ["T7"]}}}]}]}
{"id": "4082283_1", "context": "Rifampicin-induced renal failure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T5"]}, "Treatment": {"text": [["Rifampicin"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Rifampicin"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["renal failure"]], "start": [[19]], "entity_id": ["T6"]}}]}]}
{"id": "15920338_1", "context": "A case of high-grade endometrial stromal sarcoma, confined into an intrauterine polypoid growth, in a woman with a history of breast cancer who was treated with adjuvant tamoxifen.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[148]], "entity_id": ["T8"]}, "Treatment": {"text": [["adjuvant tamoxifen"]], "start": [[161]], "entity_id": ["T7"], "Drug": {"text": [["tamoxifen"]], "start": [[170]], "entity_id": ["T12"]}, "Disorder": {"text": [["high-grade endometrial stromal sarcoma, confined into an intrauterine polypoid growth"]], "start": [[10]], "entity_id": ["T13"]}}, "Subject": {"text": [["A case of high-grade endometrial stromal sarcoma, confined into an intrauterine polypoid growth, in a woman with a history of breast cancer"]], "start": [[0]], "entity_id": ["T5"], "Gender": {"text": [["woman"]], "start": [[102]], "entity_id": ["T6"]}, "Disorder": {"text": [["breast cancer"]], "start": [[126]], "entity_id": ["T9"]}, "Population": {"text": [["A"]], "start": [[0]], "entity_id": ["T14"]}}}]}]}
{"id": "8880251_1", "context": "After therapy for diabetic coma with insulin (containing the preservative cresol) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and respiratory and metabolic acidosis and lost consciousness.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["After"]], "start": [[0]], "entity_id": ["T14"]}, "Subject": {"text": [["the patient"]], "start": [[121]], "entity_id": ["T13"]}, "Treatment": {"text": [["therapy for diabetic coma with insulin (containing the preservative cresol) and electrolyte solutions"]], "start": [[6]], "entity_id": ["T15"], "Disorder": {"text": [["diabetic coma"]], "start": [[18]], "entity_id": ["T17"]}, "Drug": {"text": [["insulin"], ["preservative cresol"], ["electrolyte solutions"]], "start": [[37], [61], [86]], "entity_id": ["T18", "T19", "T20"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[82]], "entity_id": ["T21"]}, "Drug": {"text": [["electrolyte solutions"], ["preservative cresol"], ["insulin"]], "start": [[86], [61], [37]], "entity_id": ["T20", "T19", "T18"]}}]}, "Effect": {"text": [["increasing myalgia, developed a high fever and respiratory and metabolic acidosis and lost consciousness"]], "start": [[147]], "entity_id": ["T16"]}}]}]}
{"id": "19018868_1", "context": "A case of severe aplastic anemia secondary to treatment with lenalidomide for multiple myeloma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["secondary"]], "start": [[33]], "entity_id": ["T6"]}, "Effect": {"text": [["severe aplastic anemia"]], "start": [[10]], "entity_id": ["T5"]}, "Subject": {"text": [["A case"]], "start": [[0]], "entity_id": ["T7"]}, "Treatment": {"text": [["lenalidomide for multiple myeloma"]], "start": [[61]], "entity_id": ["T4"], "Disorder": {"text": [["multiple myeloma"]], "start": [[78]], "entity_id": ["T3"]}, "Drug": {"text": [["lenalidomide"]], "start": [[61]], "entity_id": ["T9"]}}, "Severity": {"text": [["severe"]], "start": [[10]], "entity_id": ["T8"], "value": "Medium"}}]}]}
{"id": "21712512_5", "context": "Seven weeks after the initiation of inhaled fluticasone, she developed vaginal candidiasis and was prescribed fluconazole 100 mg/day, a CYP3A4 inhibitor.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[61]], "entity_id": ["T8"]}, "Treatment": {"text": [["Seven weeks after the initiation of inhaled fluticasone"]], "start": [[0]], "entity_id": ["T10"], "Route": {"text": [["inhaled"]], "start": [[36]], "entity_id": ["T11"]}, "Drug": {"text": [["fluticasone"]], "start": [[44]], "entity_id": ["T12"]}, "Time_elapsed": {"text": [["Seven weeks"]], "start": [[0]], "entity_id": ["T18"]}}, "Effect": {"text": [["vaginal candidiasis"]], "start": [[71]], "entity_id": ["T9"]}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["prescribed"]], "start": [[99]], "entity_id": ["T20"]}, "Treatment": {"text": [["fluconazole 100 mg/day, a CYP3A4 inhibitor"]], "start": [[110]], "entity_id": ["T21"], "Disorder": {"text": [["vaginal candidiasis"]], "start": [[71]], "entity_id": ["T19"]}, "Drug": {"text": [["fluconazole"]], "start": [[110]], "entity_id": ["T13"]}, "Dosage": {"text": [["100 mg/day"]], "start": [[122]], "entity_id": ["T14"]}}}]}]}
{"id": "7393795_4", "context": "The introduction of para-aminosalicylic acid (PAS) led to hypoglycaemic coma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["led to"]], "start": [[51]], "entity_id": ["T5"]}, "Treatment": {"text": [["The introduction of para-aminosalicylic acid (PAS)"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["para-aminosalicylic acid"]], "start": [[20]], "entity_id": ["T7"]}}, "Effect": {"text": [["hypoglycaemic coma"]], "start": [[58]], "entity_id": ["T6"]}}]}]}
{"id": "19434733_2", "context": "The risk of developing sAML is estimated to be between 1% and 5%, 2-20 years after exposure to etoposide but may also be related to cumulative drug doses, treatment schedules, host factors and co-administration of other antineoplastic agents.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[77]], "entity_id": ["T4"]}, "Effect": {"text": [["sAML"]], "start": [[23]], "entity_id": ["T3"]}, "Treatment": {"text": [["2-20 years after exposure to etoposide"]], "start": [[66]], "entity_id": ["T5"], "Drug": {"text": [["etoposide"]], "start": [[95]], "entity_id": ["T7"]}, "Time_elapsed": {"text": [["2-20 years"]], "start": [[66]], "entity_id": ["T8"]}}, "Speculated": {"text": [["may"]], "start": [[109]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "3688031_1", "context": "An infant girl with choanal atresia, athelia, minor anomalies, and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with methimazole and propranolol.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[172]], "entity_id": ["T12"]}, "Treatment": {"text": [["methimazole and propranolo"]], "start": [[177]], "entity_id": ["T13"], "Drug": {"text": [["methimazole"], ["propranolol"]], "start": [[177], [193]], "entity_id": ["T16", "T18"]}, "Disorder": {"text": [["hyperthyroidism"]], "start": [[135]], "entity_id": ["T17"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[189]], "entity_id": ["T19"]}, "Drug": {"text": [["methimazole"], ["propranolol"]], "start": [[177], [193]], "entity_id": ["T16", "T18"]}}]}, "Effect": {"text": [["An infant girl with choanal atresia, athelia, minor anomalies, and mild to moderate mental retardation"]], "start": [[0]], "entity_id": ["T10"]}, "Subject": {"text": [["a woman"]], "start": [[115]], "entity_id": ["T1"], "Gender": {"text": [["woman"]], "start": [[117]], "entity_id": ["T2"]}}}]}]}
{"id": "2956288_1", "context": "Ethambutol is frequently used in the treatment of tuberculosis, and, although optic neuropathies have been reported with the use of ethambutol, this adverse side effect has been considered to be rare and generally reversible with discontinuation of the medication.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["used"]], "start": [[25]], "entity_id": ["T5"]}, "Treatment": {"text": [["Ethambutol"]], "start": [[0]], "entity_id": ["T3"], "Disorder": {"text": [["tuberculosis"]], "start": [[50]], "entity_id": ["T4"]}, "Drug": {"text": [["Ethambutol"]], "start": [[0]], "entity_id": ["T6"]}}}]}]}
{"id": "10923593_1", "context": "Skin manifestations of a case of phenylbutazone-induced serum sickness-like reactions.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[48]], "entity_id": ["T6"]}, "Treatment": {"text": [["phenylbutazone"]], "start": [[33]], "entity_id": ["T5"], "Drug": {"text": [["phenylbutazone"]], "start": [[33]], "entity_id": ["T8"]}}, "Effect": {"text": [["serum sickness-like reactions"]], "start": [[56]], "entity_id": ["T7"]}}]}]}
{"id": "18607107_2", "context": "Development of Crohn's disease in a patient with multiple sclerosis treated with copaxone.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Development"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["copaxone"]], "start": [[81]], "entity_id": ["T3"], "Disorder": {"text": [["multiple sclerosis"]], "start": [[49]], "entity_id": ["T7"]}, "Drug": {"text": [["copaxone"]], "start": [[81]], "entity_id": ["T8"]}}, "Effect": {"text": [["Crohn's disease"]], "start": [[15]], "entity_id": ["T4"]}, "Subject": {"text": [["a patient with multiple sclerosis"]], "start": [[34]], "entity_id": ["T6"]}}]}]}
{"id": "19281746_1", "context": "Aliskiren-associated acute renal failure with hyperkalemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[10]], "entity_id": ["T3"]}, "Treatment": {"text": [["Aliskiren"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Aliskiren"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["acute renal failure"]], "start": [[21]], "entity_id": ["T5"]}}]}]}
{"id": "7752014_3", "context": "Fever caused by the use of furosemide was proved; the fever resolved after discontinuation of this medication and recurred after its reintroduction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[6]], "entity_id": ["T8"]}, "Effect": {"text": [["Fever"]], "start": [[0]], "entity_id": ["T7"]}, "Treatment": {"text": [["furosemide"]], "start": [[27]], "entity_id": ["T9"], "Drug": {"text": [["furosemide"]], "start": [[27]], "entity_id": ["T10"]}}}]}]}
{"id": "8034807_1", "context": "The use of methotrexate (MTX) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and accelerate HIV disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["accelerate"]], "start": [[217]], "entity_id": ["T6"]}, "Treatment": {"text": [["MTX"]], "start": [[161]], "entity_id": ["T5"], "Drug": {"text": [["methotrexate (MTX)"], ["MTX"]], "start": [[11], [161]], "entity_id": ["T8", "T9"]}}, "Effect": {"text": [["HIV disease"]], "start": [[228]], "entity_id": ["T7"]}}]}]}
{"id": "17655376_1", "context": "Pharmacokinetics of dapsone gel, 5% for the treatment of acne vulgaris.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatment"]], "start": [[44]], "entity_id": ["T6"]}, "Treatment": {"text": [["dapsone gel, 5%"]], "start": [[20]], "entity_id": ["T5"], "Drug": {"text": [["dapsone"]], "start": [[20]], "entity_id": ["T7"]}, "Disorder": {"text": [["acne vulgaris"]], "start": [[57]], "entity_id": ["T8"]}}}]}]}
{"id": "19183077_2", "context": "To our knowledge, these cases represent the first reports of TDF-associated irreversible renal failure and rickets in pediatric patients.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[65]], "entity_id": ["T6"]}, "Treatment": {"text": [["TDF"]], "start": [[61]], "entity_id": ["T5"], "Drug": {"text": [["TDF"]], "start": [[61]], "entity_id": ["T10"]}}, "Effect": {"text": [["irreversible renal failure and rickets"]], "start": [[76]], "entity_id": ["T7"]}, "Subject": {"text": [["pediatric patients"]], "start": [[118]], "entity_id": ["T8"], "Age": {"text": [["pediatric"]], "start": [[118]], "entity_id": ["T9"]}}}]}]}
{"id": "7781845_4", "context": "In particular, this adverse effect has never been described with mefloquine (Lariam).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["described"]], "start": [[50]], "entity_id": ["T8"]}, "Treatment": {"text": [["mefloquine (Lariam)"]], "start": [[65]], "entity_id": ["T6"], "Drug": {"text": [["mefloquine"]], "start": [[65]], "entity_id": ["T9"]}}, "Effect": {"text": [["adverse effect"]], "start": [[20]], "entity_id": ["T7"]}, "Negated": {"text": [["never"]], "start": [[39]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "8949576_1", "context": "A potential role for renal and hepatic impairment in the observed protracted course of amiodarone-induced thyrotoxicosis is suggested.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[98]], "entity_id": ["T4"]}, "Treatment": {"text": [["amiodarone"]], "start": [[87]], "entity_id": ["T3"], "Drug": {"text": [["amiodarone"]], "start": [[87]], "entity_id": ["T6"]}}, "Effect": {"text": [["thyrotoxicosis"]], "start": [[106]], "entity_id": ["T5"]}, "Speculated": {"text": [["potential"]], "start": [[2]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "18691992_7", "context": "The patient completed a 10-month follow-up, maintaining a complete resolution of the treated skin lesions; however, the development of a painful hand ulcer, possibly associated with the hydroxyurea, and new skin cancers were observed at the last follow-up visit.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[166]], "entity_id": ["T7"]}, "Subject": {"text": [["The patient"]], "start": [[0]], "entity_id": ["T5"]}, "Effect": {"text": [["a painful hand ulcer", "new skin cancers"]], "start": [[135, 203]], "entity_id": ["T8"]}, "Treatment": {"text": [["hydroxyurea"]], "start": [[186]], "entity_id": ["T9"], "Disorder": {"text": [["skin lesions"]], "start": [[93]], "entity_id": ["T6"]}, "Duration": {"text": [["10-month"]], "start": [[24]], "entity_id": ["T10"]}, "Drug": {"text": [["hydroxyurea"]], "start": [[186]], "entity_id": ["T11"]}}, "Speculated": {"text": [["possibly"]], "start": [[157]], "entity_id": ["T12"], "value": true}}]}]}
{"id": "17420198_1", "context": "Potential aripiprazole-mediated extrapyramidal symptoms in an adult with developmental disabilities.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["mediated"]], "start": [[23]], "entity_id": ["T10"]}, "Treatment": {"text": [["aripiprazole"]], "start": [[10]], "entity_id": ["T9"], "Drug": {"text": [["aripiprazole"]], "start": [[10]], "entity_id": ["T13"]}, "Disorder": {"text": [["developmental disabilities"]], "start": [[73]], "entity_id": ["T14"]}}, "Effect": {"text": [["extrapyramidal symptoms"]], "start": [[32]], "entity_id": ["T11"]}, "Subject": {"text": [["an adult with developmental disabilities"]], "start": [[59]], "entity_id": ["T7"], "Age": {"text": [["adult"]], "start": [[62]], "entity_id": ["T12"]}}}]}]}
{"id": "12823045_1", "context": "We describe a patient with extranodal non-Hodgkin lymphoma who developed systemic candidiasis after treatment with a cyclophosphamide-based chemotherapy regimen.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treatment"]], "start": [[100]], "entity_id": ["T5"]}, "Subject": {"text": [["a patient with extranodal non-Hodgkin lymphoma"]], "start": [[12]], "entity_id": ["T3"]}, "Effect": {"text": [["systemic candidiasis"]], "start": [[73]], "entity_id": ["T4"]}, "Treatment": {"text": [["a cyclophosphamide-based chemotherapy regimen."]], "start": [[115]], "entity_id": ["T6"], "Disorder": {"text": [["extranodal non-Hodgkin lymphoma"]], "start": [[27]], "entity_id": ["T8"]}, "Drug": {"text": [["cyclophosphamide-based chemotherapy"]], "start": [[117]], "entity_id": ["T9"]}}}]}]}
{"id": "2663536_2", "context": "We describe the first case of de novo asthma following treatment with the angiotensin converting enzyme (ACE) inhibitor captopril.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treatment with"]], "start": [[55]], "entity_id": ["T4"]}, "Effect": {"text": [["de novo asthma"]], "start": [[30]], "entity_id": ["T3"]}, "Treatment": {"text": [["the angiotensin converting enzyme (ACE) inhibitor captopril"]], "start": [[70]], "entity_id": ["T5"], "Drug": {"text": [["captopril"]], "start": [[120]], "entity_id": ["T6"]}}}]}]}
{"id": "8120934_1", "context": "A 53-year-old male, without any prior history of psychosis, developed schizophrenia 4 days after starting low-dose bromocriptine therapy for a macroprolactinoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[60]], "entity_id": ["T4"]}, "Subject": {"text": [["A 53-year-old male, without any prior history of psychosis", "macroprolactinoma"]], "start": [[0, 143]], "entity_id": ["T3"], "Age": {"text": [["53-year-old"]], "start": [[2]], "entity_id": ["T8"]}, "Gender": {"text": [["male"]], "start": [[14]], "entity_id": ["T9"]}}, "Effect": {"text": [["schizophrenia"]], "start": [[70]], "entity_id": ["T5"]}, "Treatment": {"text": [["4 days after starting low-dose bromocriptine therapy"]], "start": [[84]], "entity_id": ["T6"], "Drug": {"text": [["bromocriptine"]], "start": [[115]], "entity_id": ["T10"]}, "Disorder": {"text": [["macroprolactinoma"]], "start": [[143]], "entity_id": ["T11"]}, "Time_elapsed": {"text": [["4 days after"]], "start": [[84]], "entity_id": ["T12"]}, "Dosage": {"text": [["low-dose"]], "start": [[106]], "entity_id": ["T13"]}}}]}]}
{"id": "20298401_7", "context": "Six days after taking erlotinib, a chest radiograph showed rapid progression of reticular infiltration in both lung fields.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[9]], "entity_id": ["T6"]}, "Effect": {"text": [["rapid progression of reticular infiltration in both lung fields"]], "start": [[59]], "entity_id": ["T4"]}, "Treatment": {"text": [["Six days", "erlotinib"]], "start": [[0, 22]], "entity_id": ["T5"], "Time_elapsed": {"text": [["Six days"]], "start": [[0]], "entity_id": ["T7"]}, "Drug": {"text": [["erlotinib"]], "start": [[22]], "entity_id": ["T8"]}}}]}]}
{"id": "11144696_6", "context": "Because of suspected drug-induced seizures, both antidepressants were stopped.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["stopped"]], "start": [[70]], "entity_id": ["T5"]}, "Treatment": {"text": [["antidepressants"]], "start": [[49]], "entity_id": ["T7"], "Drug": {"text": [["antidepressants"]], "start": [[49]], "entity_id": ["T9"]}}, "Effect": {"text": [["seizures"]], "start": [[34]], "entity_id": ["T6"]}, "Speculated": {"text": [["suspected"]], "start": [[11]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "17381671_4", "context": "Based on the Naranjo probability scale, serotonin syndrome was a probable adverse reaction associated with co-administration of citalopram and fentanyl.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[91]], "entity_id": ["T9"]}, "Effect": {"text": [["serotonin syndrome"]], "start": [[40]], "entity_id": ["T7"]}, "Treatment": {"text": [["co-administration of citalopram and fentanyl"]], "start": [[107]], "entity_id": ["T8"], "Drug": {"text": [["citalopram"], ["fentanyl"]], "start": [[128], [143]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["co-administration"]], "start": [[107]], "entity_id": ["T12"]}, "Drug": {"text": [["citalopram"], ["fentanyl"]], "start": [[128], [143]], "entity_id": ["T10", "T11"]}}]}, "Speculated": {"text": [["probable"]], "start": [[65]], "entity_id": ["T13"], "value": true}}]}]}
{"id": "18034202_1", "context": "We report a case of a patient with rheumatoid arthritis treated with low-dose methotrexate (15 mg/week) who developed infection with both M. tuberculosis and M. chelonae after the revision of a prosthetic hip.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[108]], "entity_id": ["T6"]}, "Subject": {"text": [["patient with rheumatoid arthritis"]], "start": [[22]], "entity_id": ["T3"]}, "Treatment": {"text": [["low-dose methotrexate (15 mg/week)"]], "start": [[69]], "entity_id": ["T5"], "Dosage": {"text": [["15 mg/week"]], "start": [[92]], "entity_id": ["T8"]}, "Drug": {"text": [["methotrexate"]], "start": [[78]], "entity_id": ["T10"]}, "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[35]], "entity_id": ["T11"]}}, "Effect": {"text": [["nfection with both M. tuberculosis and M. chelonae"]], "start": [[119]], "entity_id": ["T7"]}}]}]}
{"id": "10575189_2", "context": "Thrombotic microangiopathy with renal failure in two patients undergoing gemcitabine chemotherapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["undergoing"]], "start": [[62]], "entity_id": ["T5"]}, "Treatment": {"text": [["gemcitabine chemotherapy"]], "start": [[73]], "entity_id": ["T6"], "Drug": {"text": [["gemcitabine"]], "start": [[73]], "entity_id": ["T10"]}, "Route": {"text": [["chemotherapy"]], "start": [[85]], "entity_id": ["T11"]}}, "Effect": {"text": [["Thrombotic microangiopathy with renal failure"]], "start": [[0]], "entity_id": ["T7"]}, "Subject": {"text": [["two patients"]], "start": [[49]], "entity_id": ["T8"], "Population": {"text": [["two"]], "start": [[49]], "entity_id": ["T9"]}}}]}]}
{"id": "8771575_3", "context": "Despite the known pulmonary side effects of nitrofurantoin, there is no report of this toxicity occurring in pregnant patients.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["of"]], "start": [[41]], "entity_id": ["T5"]}, "Effect": {"text": [["pulmonary side effects"]], "start": [[18]], "entity_id": ["T3"]}, "Treatment": {"text": [["nitrofurantoin"]], "start": [[44]], "entity_id": ["T4"], "Drug": {"text": [["nitrofurantoin"]], "start": [[44]], "entity_id": ["T6"]}}, "Negated": {"text": [["no"]], "start": [[69]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "19995222_3", "context": "However, several case reports have suggested that clozapine could also cause TD.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[71]], "entity_id": ["T4"]}, "Effect": {"text": [["TD"]], "start": [[77]], "entity_id": ["T3"]}, "Treatment": {"text": [["clozapine"]], "start": [[50]], "entity_id": ["T5"], "Drug": {"text": [["clozapine"]], "start": [[50]], "entity_id": ["T6"]}}}]}]}
{"id": "2862137_1", "context": "A case is presented in which a 68-year-old man became delirious after being withdrawn from a low dosage of alprazolam.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[64]], "entity_id": ["T6"]}, "Subject": {"text": [["68-year-old man"]], "start": [[31]], "entity_id": ["T3"], "Age": {"text": [["68-year-old"]], "start": [[31]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[43]], "entity_id": ["T8"]}}, "Treatment": {"text": [["withdrawn from a low dosage of alprazolam"]], "start": [[76]], "entity_id": ["T4"], "Drug": {"text": [["alprazolam"]], "start": [[107]], "entity_id": ["T9"]}, "Dosage": {"text": [["low dosage"]], "start": [[93]], "entity_id": ["T10"]}}, "Effect": {"text": [["delirious"]], "start": [[54]], "entity_id": ["T5"]}}]}]}
{"id": "19499966_2", "context": "However, re-initiation of sunitinib treatment was followed by bilateral breast enlargement again.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["followed"]], "start": [[50]], "entity_id": ["T4"]}, "Treatment": {"text": [["sunitinib"]], "start": [[26]], "entity_id": ["T3"], "Drug": {"text": [["sunitinib"]], "start": [[26]], "entity_id": ["T6"]}}, "Effect": {"text": [["bilateral breast enlargement"]], "start": [[62]], "entity_id": ["T5"]}}]}]}
{"id": "18691992_1", "context": "BACKGROUND: Hydroxyurea is a cytostatic agent used to treat myeloproliferative disorders and long-term treatment is associated with mucocutaneous adverse events and nail hyperpigmentation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[116]], "entity_id": ["T7"]}, "Treatment": {"text": [["Hydroxyurea is a cytostatic agen"]], "start": [[12]], "entity_id": ["T5"], "Drug": {"text": [["Hydroxyurea"]], "start": [[12]], "entity_id": ["T9"]}, "Disorder": {"text": [["myeloproliferative disorders"]], "start": [[60]], "entity_id": ["T10"]}}, "Effect": {"text": [["mucocutaneous adverse events and nail hyperpigmentation"]], "start": [[132]], "entity_id": ["T8"]}}]}]}
{"id": "6353252_1", "context": "Captopril-induced acute reversible renal failure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[10]], "entity_id": ["T4"]}, "Treatment": {"text": [["Captopril"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Captopril"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["acute reversible renal failure"]], "start": [[18]], "entity_id": ["T5"]}}]}]}
{"id": "16498048_3", "context": "Hence, hyperthyroidism induced by IFN-alpha could correspond to the first phase of silent thyroiditis, to Graves' disease or to the succession of both.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[23]], "entity_id": ["T4"]}, "Treatment": {"text": [["IFN-alpha"]], "start": [[34]], "entity_id": ["T3"], "Drug": {"text": [["IFN-alpha"]], "start": [[34]], "entity_id": ["T6"]}}, "Effect": {"text": [["hyperthyroidism"]], "start": [[7]], "entity_id": ["T5"]}}]}]}
{"id": "12107858_1", "context": "The epivodes of NMS occured under treatment with clozapine, risperidone, and amisulpride.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occured"]], "start": [[20]], "entity_id": ["T5"]}, "Effect": {"text": [["NMS"]], "start": [[16]], "entity_id": ["T6"]}, "Treatment": {"text": [["clozapine, risperidone, and amisulpride"]], "start": [[49]], "entity_id": ["T7"], "Drug": {"text": [["clozapine"], ["risperidone"], ["amisulpride"]], "start": [[49], [60], [77]], "entity_id": ["T8", "T9", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[73]], "entity_id": ["T10"]}, "Drug": {"text": [["clozapine"], ["risperidone"], ["amisulpride"]], "start": [[49], [60], [77]], "entity_id": ["T8", "T9", "T11"]}}]}}]}]}
{"id": "10466445_8", "context": "During the first days of arsenic trioxide treatment a rapid decrease in the D-dimers was seen (normal values reached until day 7), together with a slight decrease in peripheral blood leukocytes.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["During"]], "start": [[0]], "entity_id": ["T7"]}, "Treatment": {"text": [["the first days of arsenic trioxide treatment"]], "start": [[7]], "entity_id": ["T5"], "Drug": {"text": [["arsenic trioxide"]], "start": [[25]], "entity_id": ["T8"]}, "Duration": {"text": [["the first days"]], "start": [[7]], "entity_id": ["T9"]}}, "Effect": {"text": [["a rapid decrease in the D-dimers was seen (normal values reached until day 7), together with a slight decrease in peripheral blood leukocytes"]], "start": [[52]], "entity_id": ["T6"]}}]}]}
{"id": "19104709_2", "context": "In contrast to chronic or subacute thyroiditis, Graves' disease rarely complicates IFN-alpha therapy for chronic viral C hepatitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["for"]], "start": [[101]], "entity_id": ["T5"]}, "Treatment": {"text": [["IFN-alpha"]], "start": [[83]], "entity_id": ["T6"], "Disorder": {"text": [["chronic viral C hepatitis"]], "start": [[105]], "entity_id": ["T7"]}, "Drug": {"text": [["IFN-alpha"]], "start": [[83]], "entity_id": ["T12"]}}, "Subject": {"text": [["Graves' disease"]], "start": [[48]], "entity_id": ["T11"], "Disorder": {"text": [["Graves' disease"]], "start": [[48]], "entity_id": ["T10"]}}}]}]}
{"id": "17551408_1", "context": "We postulate that gastritis caused by dexamethasone, mucositis caused by doxorubicin, and the unique anatomic nature of a Meckel diverticulum may have contributed to this extremely unlikely and previously unreported event.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[28]], "entity_id": ["T7"]}, "Effect": {"text": [["gastritis"]], "start": [[18]], "entity_id": ["T5"]}, "Treatment": {"text": [["dexamethasone"]], "start": [[38]], "entity_id": ["T6"], "Drug": {"text": [["dexamethasone"]], "start": [[38]], "entity_id": ["T9"]}}, "Speculated": {"text": [["may"]], "start": [[142]], "entity_id": ["T8"], "value": true}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[63]], "entity_id": ["T12"]}, "Effect": {"text": [["mucositis"]], "start": [[53]], "entity_id": ["T11"]}, "Treatment": {"text": [["doxorubicin"]], "start": [[73]], "entity_id": ["T13"], "Drug": {"text": [["doxorubicin"]], "start": [[73]], "entity_id": ["T14"]}}}]}]}
{"id": "9013348_3", "context": "Mesalamine may cause hypersensitivity pneumonitis in patients with Crohn's disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[15]], "entity_id": ["T7"]}, "Treatment": {"text": [["Mesalamine"]], "start": [[0]], "entity_id": ["T3"], "Disorder": {"text": [["Crohn's disease"]], "start": [[67]], "entity_id": ["T8"]}, "Drug": {"text": [["Mesalamine"]], "start": [[0]], "entity_id": ["T10"]}}, "Effect": {"text": [["hypersensitivity pneumonitis"]], "start": [[21]], "entity_id": ["T5"]}, "Subject": {"text": [["patients with Crohn's disease"]], "start": [[53]], "entity_id": ["T6"]}, "Speculated": {"text": [["may"]], "start": [[11]], "entity_id": ["T4"], "value": true}}]}]}
{"id": "7814182_2", "context": "We present a case in which dipyridamole induced high-grade atrioventricular (AV) block that responded promptly to intravenous aminophylline but not to atropine.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[40]], "entity_id": ["T4"]}, "Treatment": {"text": [["dipyridamole"]], "start": [[27]], "entity_id": ["T3"], "Drug": {"text": [["dipyridamole"]], "start": [[27]], "entity_id": ["T6"]}}, "Effect": {"text": [["high-grade atrioventricular (AV) block"]], "start": [[48]], "entity_id": ["T5"]}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["responded"]], "start": [[92]], "entity_id": ["T9"]}, "Treatment": {"text": [["intravenous aminophylline but not to atropine"]], "start": [[114]], "entity_id": ["T10"], "Drug": {"text": [["intravenous aminophylline"], ["atropine"]], "start": [[114], [151]], "entity_id": ["T11", "T12"]}, "Disorder": {"text": [["dipyridamole induced high-grade atrioventricular (AV) block"]], "start": [[27]], "entity_id": ["T8"]}}}]}]}
{"id": "2442958_3", "context": "This paper reports an autopsy case of a 78-year-old male with multiple nodules in the liver developed after long-termed administration of phosphate diethylstilbestrol (PDES) for prostatic cancer.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[92]], "entity_id": ["T6"]}, "Subject": {"text": [["an autopsy case of a 78-year-old male", "prostatic cancer"]], "start": [[19, 178]], "entity_id": ["T4"], "Age": {"text": [["78-year-old"]], "start": [[40]], "entity_id": ["T9"]}, "Gender": {"text": [["male"]], "start": [[52]], "entity_id": ["T10"]}}, "Effect": {"text": [["multiple nodules in the liver"]], "start": [[62]], "entity_id": ["T5"]}, "Treatment": {"text": [["phosphate diethylstilbestrol (PDES)"]], "start": [[138]], "entity_id": ["T7"], "Disorder": {"text": [["prostatic cancer"]], "start": [[178]], "entity_id": ["T8"]}, "Drug": {"text": [["phosphate diethylstilbestrol"]], "start": [[138]], "entity_id": ["T12"]}}}]}]}
{"id": "7933665_1", "context": "Fracture of the femoral neck occurred in one patient during PSL therapy, although the relationship between the fracture and PSL therapy was uncertain.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurred"]], "start": [[29]], "entity_id": ["T4"]}, "Effect": {"text": [["Fracture of the femoral neck"]], "start": [[0]], "entity_id": ["T3"]}, "Subject": {"text": [["one patient"]], "start": [[41]], "entity_id": ["T5"], "Population": {"text": [["one"]], "start": [[41]], "entity_id": ["T7"]}}, "Treatment": {"text": [["PSL therapy"]], "start": [[60]], "entity_id": ["T6"], "Drug": {"text": [["PSL"]], "start": [[60]], "entity_id": ["T9"]}}, "Speculated": {"text": [["uncertain"]], "start": [[140]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "2796025_2", "context": "This panic anxiety was not relieved by taking etizolam and flunitrazepam again, but subsided rapidly by the re-administration of mianserin 30 mg/day, and because of that the depressive symptom also disappeared.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["subsided"]], "start": [[84]], "entity_id": ["T12"]}, "Treatment": {"text": [["etizolam and flunitrazepam", "mianserin 30 mg/day"]], "start": [[46, 129]], "entity_id": ["T4"], "Disorder": {"text": [["panic anxiety"], ["depressive symptom"]], "start": [[5], [174]], "entity_id": ["T6", "T13"]}, "Drug": {"text": [["flunitrazepam"], ["etizolam"], ["mianserin"]], "start": [[59], [46], [129]], "entity_id": ["T7", "T8", "T9"]}, "Dosage": {"text": [["30 mg/day"]], "start": [[139]], "entity_id": ["T10"]}, "Combination": [{"event_id": "E1", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[55]], "entity_id": ["T3"]}, "Drug": {"text": [["etizolam"], ["flunitrazepam"], ["mianserin"]], "start": [[46], [59], [129]], "entity_id": ["T8", "T7", "T9"]}}]}, "Effect": {"text": [["because of that the depressive symptom also disappeared"]], "start": [[154]], "entity_id": ["T5"]}}]}]}
{"id": "3101617_2", "context": "When co-trimoxazole was stopped the red cell aplasia resolved.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["stopped"]], "start": [[24]], "entity_id": ["T3"]}, "Treatment": {"text": [["co-trimoxazole"]], "start": [[5]], "entity_id": ["T5"], "Drug": {"text": [["co-trimoxazole"]], "start": [[5]], "entity_id": ["T6"]}}, "Effect": {"text": [["red cell aplasia resolved"]], "start": [[36]], "entity_id": ["T4"]}}]}]}
{"id": "10546851_1", "context": "Interaction of sildenafil and indinavir when co-administered to HIV-positive patients.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["co-administered"]], "start": [[45]], "entity_id": ["T11"]}, "Subject": {"text": [["HIV-positive patients"]], "start": [[64]], "entity_id": ["T9"]}, "Treatment": {"text": [["Interaction of sildenafil and indinavir"]], "start": [[0]], "entity_id": ["T10"], "Disorder": {"text": [["HIV-positive"]], "start": [[64]], "entity_id": ["T8"]}, "Drug": {"text": [["sildenafil"], ["indinavir"]], "start": [[15], [30]], "entity_id": ["T13", "T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["Interaction"]], "start": [[0]], "entity_id": ["T12"]}, "Drug": {"text": [["sildenafil"], ["indinavir"]], "start": [[15], [30]], "entity_id": ["T13", "T14"]}}]}}]}]}
{"id": "4095247_1", "context": "Cerebral and ocular toxicity induced by desferrioxamine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[29]], "entity_id": ["T4"]}, "Effect": {"text": [["Cerebral and ocular toxicity"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["desferrioxamine"]], "start": [[40]], "entity_id": ["T5"], "Drug": {"text": [["desferrioxamine"]], "start": [[40]], "entity_id": ["T6"]}}}]}]}
{"id": "7397053_1", "context": "A patient developed papilloedema and hepatic dysfunction while being treated with perhexiline maleate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["while"]], "start": [[57]], "entity_id": ["T8"]}, "Treatment": {"text": [["perhexiline maleate"]], "start": [[82]], "entity_id": ["T5"], "Drug": {"text": [["perhexiline maleate"]], "start": [[82]], "entity_id": ["T9"]}}, "Subject": {"text": [["A patient"]], "start": [[0]], "entity_id": ["T6"]}, "Effect": {"text": [["papilloedema and hepatic dysfunction"]], "start": [[20]], "entity_id": ["T7"]}}]}]}
{"id": "11868077_2", "context": "We describe a case of subcutaneous metastasis along the needle track after percutaneous ethanol injection (PEI) for treatment of hepatocellular carcinoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[69]], "entity_id": ["T6"]}, "Effect": {"text": [["subcutaneous metastasis"]], "start": [[22]], "entity_id": ["T3"]}, "Treatment": {"text": [["percutaneous ethanol injection (PEI)"]], "start": [[75]], "entity_id": ["T4"], "Drug": {"text": [["ethanol"]], "start": [[88]], "entity_id": ["T8"]}, "Route": {"text": [["injection"]], "start": [[96]], "entity_id": ["T9"]}, "Disorder": {"text": [["hepatocellular carcinoma"]], "start": [[129]], "entity_id": ["T10"]}}, "Subject": {"text": [["a case"]], "start": [[12]], "entity_id": ["T7"]}}]}]}
{"id": "17420198_5", "context": "He developed episodic movements possibly consistent with EPS secondary to aripiprazole usage.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[3]], "entity_id": ["T6"]}, "Effect": {"text": [["episodic movements possibly consistent with EPS"]], "start": [[13]], "entity_id": ["T7"]}, "Treatment": {"text": [["secondary to aripiprazole usage"]], "start": [[61]], "entity_id": ["T8"], "Drug": {"text": [["aripiprazole"]], "start": [[74]], "entity_id": ["T10"]}}}]}]}
{"id": "15133245_3", "context": "Recently, it has been reported that terfenadine and astemizole, which have antiallergic actions similar to those of oxatomide, show side effects on the cardiovascular system, such as QT prolongation, ventricular arrhythmia and cardiac arrest.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["show"]], "start": [[127]], "entity_id": ["T10"]}, "Treatment": {"text": [["terfenadine and astemizole"]], "start": [[36]], "entity_id": ["T8"], "Drug": {"text": [["terfenadine"], ["astemizole"]], "start": [[36], [52]], "entity_id": ["T11", "T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[48]], "entity_id": ["T13"]}, "Drug": {"text": [["terfenadine"], ["astemizole"]], "start": [[36], [52]], "entity_id": ["T11", "T12"]}}]}, "Effect": {"text": [["side effects on the cardiovascular system, such as QT prolongation, ventricular arrhythmia and cardiac arrest"]], "start": [[132]], "entity_id": ["T9"]}}]}]}
{"id": "9476721_3", "context": "We reported 3 patients who developed acute generalized dystonia and akinetic rigid syndrome following an initial therapy with d-penicillamine 125-500 mg daily.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[92]], "entity_id": ["T5"]}, "Treatment": {"text": [["d-penicillamine 125-500 mg daily"]], "start": [[126]], "entity_id": ["T6"], "Drug": {"text": [["d-penicillamine"]], "start": [[126]], "entity_id": ["T10"]}, "Dosage": {"text": [["125-500 mg daily"]], "start": [[142]], "entity_id": ["T11"]}}, "Subject": {"text": [["3 patients"]], "start": [[12]], "entity_id": ["T7"], "Population": {"text": [["3"]], "start": [[12]], "entity_id": ["T9"]}}, "Effect": {"text": [["acute generalized dystonia and akinetic rigid syndrome"]], "start": [[37]], "entity_id": ["T8"]}}]}]}
{"id": "19579947_2", "context": "Priapism associated with olanzapine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[9]], "entity_id": ["T3"]}, "Effect": {"text": [["Priapism"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["olanzapine"]], "start": [[25]], "entity_id": ["T5"], "Drug": {"text": [["olanzapine"]], "start": [[25]], "entity_id": ["T6"]}}}]}]}
{"id": "9883483_2", "context": "Thus, an immunological mechanism might be involved in the mechanism of pirmenol-induced QT prolongation and T wave inversion on the electrocardiogram.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[80]], "entity_id": ["T6"]}, "Treatment": {"text": [["pirmenol"]], "start": [[71]], "entity_id": ["T5"], "Drug": {"text": [["pirmenol"]], "start": [[71]], "entity_id": ["T9"]}}, "Effect": {"text": [["QT prolongation and T wave inversion"]], "start": [[88]], "entity_id": ["T7"]}, "Speculated": {"text": [["might be involved"]], "start": [[33]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "16997047_1", "context": "Five months after initiating mirtazapine therapy, she developed symptomatic hyponatremia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[54]], "entity_id": ["T3"]}, "Effect": {"text": [["symptomatic hyponatremia"]], "start": [[64]], "entity_id": ["T4"]}, "Treatment": {"text": [["Five months after initiating mirtazapine"]], "start": [[0]], "entity_id": ["T5"], "Time_elapsed": {"text": [["Five months"]], "start": [[0]], "entity_id": ["T8"]}, "Drug": {"text": [["mirtazapine"]], "start": [[29]], "entity_id": ["T9"]}}, "Subject": {"text": [["she"]], "start": [[50]], "entity_id": ["T6"], "Gender": {"text": [["she"]], "start": [[50]], "entity_id": ["T7"]}}}]}]}
{"id": "3797173_1", "context": "Intravenous verapamil therapy in babies may cause apnea, hypotension, and bradycardia; continued episodes of atrial flutter in a child may cause sudden death; quinidine may be related to the death; children with \"familial seizure disorders\" may in fact have the long QT interval syndrome.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[44]], "entity_id": ["T23"]}, "Treatment": {"text": [["Intravenous verapamil"]], "start": [[0]], "entity_id": ["T20"], "Route": {"text": [["Intravenous"]], "start": [[0]], "entity_id": ["T21"]}, "Drug": {"text": [["verapamil"]], "start": [[12]], "entity_id": ["T22"]}}, "Subject": {"text": [["babies"]], "start": [[33]], "entity_id": ["T18"], "Age": {"text": [["babies"]], "start": [[33]], "entity_id": ["T19"]}}, "Effect": {"text": [["apnea, hypotension, and bradycardia"]], "start": [[50]], "entity_id": ["T17"]}, "Speculated": {"text": [["may"]], "start": [[40]], "entity_id": ["T29"], "value": true}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[176]], "entity_id": ["T26"]}, "Treatment": {"text": [["quinidine"]], "start": [[159]], "entity_id": ["T24"], "Drug": {"text": [["quinidine"]], "start": [[159]], "entity_id": ["T25"]}}, "Effect": {"text": [["death"]], "start": [[191]], "entity_id": ["T27"]}, "Speculated": {"text": [["may"]], "start": [[169]], "entity_id": ["T28"], "value": true}}]}]}
{"id": "12796597_4", "context": "The renal biopsy showed focal segmental glomerulosclerosis, which has only been previously reported in two cases of CML treated with IFNalpha.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reported"]], "start": [[91]], "entity_id": ["T4"]}, "Effect": {"text": [["The renal biopsy showed focal segmental glomerulosclerosis"]], "start": [[0]], "entity_id": ["T3"]}, "Subject": {"text": [["two cases"]], "start": [[103]], "entity_id": ["T5"], "Population": {"text": [["two"]], "start": [[103]], "entity_id": ["T7"]}}, "Treatment": {"text": [["IFNalpha"]], "start": [[133]], "entity_id": ["T6"], "Disorder": {"text": [["CML"]], "start": [[116]], "entity_id": ["T8"]}, "Drug": {"text": [["IFNalpha"]], "start": [[133]], "entity_id": ["T9"]}}}]}]}
{"id": "6093724_2", "context": "Sulindac (Clinoril), a nonsteroidal anti-inflammatory agent, has few reported neurologic toxic effects, all of which have been associated with systemic disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["reported"]], "start": [[69]], "entity_id": ["T8"]}, "Effect": {"text": [["neurologic toxic effects"]], "start": [[78]], "entity_id": ["T4"]}, "Treatment": {"text": [["Sulindac (Clinoril)"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Sulindac"]], "start": [[0]], "entity_id": ["T10"]}}}]}]}
{"id": "19857154_7", "context": "The second patient was a 32-year-old woman with HIV, anxiety disorder, and a history of intravenous drug abuse who developed increased sedation and mental confusion when an atazanavir-ritonavir-based antiretroviral regimen was added to her stable antianxiety drug regimen, which included quetiapine.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[115]], "entity_id": ["T14"]}, "Subject": {"text": [["a 32-year-old woman with HIV, anxiety disorder, and a history of intravenous drug abuse"]], "start": [[23]], "entity_id": ["T13"], "Age": {"text": [["32-year-old"]], "start": [[25]], "entity_id": ["T17"]}, "Gender": {"text": [["woman"]], "start": [[37]], "entity_id": ["T18"]}, "Disorder": {"text": [["intravenous drug abuse"]], "start": [[88]], "entity_id": ["T21"]}}, "Effect": {"text": [["increased sedation and mental confusion"]], "start": [[125]], "entity_id": ["T15"]}, "Treatment": {"text": [["atazanavir-ritonavir-based antiretroviral regimen was added to her stable antianxiety drug regimen, which included quetiapine"]], "start": [[173]], "entity_id": ["T16"], "Drug": {"text": [["quetiapine"], ["atazanavir"], ["ritonavir"]], "start": [[288], [173], [184]], "entity_id": ["T22", "T23", "T24"]}, "Disorder": {"text": [["HIV"], ["anxiety disorder"]], "start": [[48], [53]], "entity_id": ["T26", "T27"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["added"]], "start": [[227]], "entity_id": ["T25"]}, "Drug": {"text": [["ritonavir"], ["atazanavir"], ["quetiapine"]], "start": [[184], [173], [288]], "entity_id": ["T24", "T23", "T22"]}}]}}]}]}
{"id": "6860059_1", "context": "Fulminant hepatitis associated with disulfiram.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[20]], "entity_id": ["T3"]}, "Treatment": {"text": [["disulfiram"]], "start": [[36]], "entity_id": ["T4"], "Drug": {"text": [["disulfiram"]], "start": [[36]], "entity_id": ["T6"]}}, "Effect": {"text": [["Fulminant hepatitis"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "3397227_1", "context": "Anhedonic ejaculation with desipramine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[22]], "entity_id": ["T4"]}, "Effect": {"text": [["Anhedonic ejaculation"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["desipramine"]], "start": [[27]], "entity_id": ["T5"], "Drug": {"text": [["desipramine"]], "start": [[27]], "entity_id": ["T6"]}}}]}]}
{"id": "9674820_1", "context": "Serotonin syndrome induced by transitioning from phenelzine to venlafaxine: four patient reports.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[19]], "entity_id": ["T5"]}, "Effect": {"text": [["Serotonin syndrome"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["phenelzine to venlafaxine"]], "start": [[49]], "entity_id": ["T6"], "Drug": {"text": [["phenelzine"], ["venlafaxine"]], "start": [[49], [63]], "entity_id": ["T7", "T8"]}}, "Subject": {"text": [["four patient"]], "start": [[76]], "entity_id": ["T9"]}}]}]}
{"id": "16960880_2", "context": "Lower extremity arterial thrombosis following sonographically guided thrombin injection of a femoral pseudoaneurysm.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[36]], "entity_id": ["T4"]}, "Effect": {"text": [["Lower extremity arterial thrombosis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["thrombin injection of a femoral pseudoaneurysm"]], "start": [[69]], "entity_id": ["T5"], "Drug": {"text": [["thrombin"]], "start": [[69]], "entity_id": ["T6"]}, "Route": {"text": [["injection"]], "start": [[78]], "entity_id": ["T7"]}, "Disorder": {"text": [["femoral pseudoaneurysm"]], "start": [[93]], "entity_id": ["T8"]}}}]}]}
{"id": "8313300_6", "context": "A severe form of exophthalmos resulting from lithium therapy has not been described in the literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulting"]], "start": [[30]], "entity_id": ["T5"]}, "Effect": {"text": [["exophthalmos"]], "start": [[17]], "entity_id": ["T4"]}, "Treatment": {"text": [["lithium"]], "start": [[45]], "entity_id": ["T6"], "Drug": {"text": [["lithium"]], "start": [[45]], "entity_id": ["T8"]}}, "Severity": {"text": [["severe"]], "start": [[2]], "entity_id": ["T9"], "value": "High"}}]}]}
{"id": "8604715_2", "context": "No cases of renal acidosis, and only one case of nephrogenic diabetes insipidus, has been previously reported as a complication of foscarnet treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reported"]], "start": [[101]], "entity_id": ["T4"]}, "Effect": {"text": [["nephrogenic diabetes insipidus"]], "start": [[49]], "entity_id": ["T3"]}, "Treatment": {"text": [["foscarnet treatment"]], "start": [[131]], "entity_id": ["T5"], "Drug": {"text": [["foscarnet"]], "start": [[131]], "entity_id": ["T6"]}}}]}]}
{"id": "7919557_2", "context": "Cough induced by quinapril with resolution after changing to fosinopril.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["resolution"]], "start": [[32]], "entity_id": ["T4"]}, "Effect": {"text": [["Cough"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["fosinopril"]], "start": [[61]], "entity_id": ["T5"], "Drug": {"text": [["quinapril"], ["fosinopril"]], "start": [[17], [61]], "entity_id": ["T6", "T7"]}}}]}]}
{"id": "20298401_2", "context": "INTRODUCTION: Although gefitinib used for the treatment of non-small-cell lung cancer is a well-known cause of interstitial lung disease (ILD), few case reports on erlotinib-induced ILD have been issued.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[102]], "entity_id": ["T16"]}, "Treatment": {"text": [["gefitinib"]], "start": [[23]], "entity_id": ["T12"], "Disorder": {"text": [["non-small-cell lung cancer"]], "start": [[59]], "entity_id": ["T14"]}, "Drug": {"text": [["gefitinib"]], "start": [[23]], "entity_id": ["T13"]}}, "Effect": {"text": [["interstitial lung disease (ILD)"]], "start": [[111]], "entity_id": ["T15"]}}, {"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[174]], "entity_id": ["T11"]}, "Treatment": {"text": [["erlotinib"]], "start": [[164]], "entity_id": ["T17"], "Drug": {"text": [["erlotinib"]], "start": [[164]], "entity_id": ["T18"]}}, "Effect": {"text": [["ILD"]], "start": [[182]], "entity_id": ["T19"]}}]}]}
{"id": "17383767_4", "context": "We report a case in which a potential drug interaction resulted in elevated phenytoin levels after initiation of erlotinib therapy in a patient who was receiving phenytoin.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulted in"]], "start": [[55]], "entity_id": ["T9"]}, "Treatment": {"text": [["a potential drug interaction", "initiation of erlotinib therapy", "receiving phenytoin"]], "start": [[26, 99, 152]], "entity_id": ["T8"], "Drug": {"text": [["phenytoin"], ["erlotinib"]], "start": [[162], [113]], "entity_id": ["T16", "T17"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[43]], "entity_id": ["T14"]}, "Drug": {"text": [["erlotinib"], ["phenytoin"]], "start": [[113], [162]], "entity_id": ["T17", "T16"]}}]}, "Effect": {"text": [["elevated phenytoin levels"]], "start": [[67]], "entity_id": ["T10"]}, "Subject": {"text": [["a patient"]], "start": [[134]], "entity_id": ["T12"]}, "Speculated": {"text": [["potential"]], "start": [[28]], "entity_id": ["T13"], "value": true}}]}]}
{"id": "18515982_1", "context": "Anastrozole-associated sclerosing glomerulonephritis in a patient with breast cancer.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[12]], "entity_id": ["T4"]}, "Subject": {"text": [["a patient with breast cancer."]], "start": [[56]], "entity_id": ["T3"]}, "Treatment": {"text": [["Anastrozole"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Anastrozole"]], "start": [[0]], "entity_id": ["T8"]}, "Disorder": {"text": [["breast cancer"]], "start": [[71]], "entity_id": ["T9"]}}, "Effect": {"text": [["sclerosing glomerulonephritis"]], "start": [[23]], "entity_id": ["T6"]}}]}]}
{"id": "12324937_1", "context": "BACKGROUND: Gemcitabine has mild renal toxicity, but cases of gemcitabine-associated hemolytic-uremic syndrome (HUS) have been reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[74]], "entity_id": ["T12"]}, "Treatment": {"text": [["gemcitabine"]], "start": [[62]], "entity_id": ["T10"], "Drug": {"text": [["gemcitabine"]], "start": [[62]], "entity_id": ["T9"]}}, "Effect": {"text": [["hemolytic-uremic syndrome (HUS)"], ["renal toxicity"]], "start": [[85], [33]], "entity_id": ["T11", "T14"]}, "Subject": {"text": [["cases"]], "start": [[53]], "entity_id": ["T13"]}, "Severity": {"text": [["mild"]], "start": [[28]], "entity_id": ["T15"], "value": "High"}}]}]}
{"id": "12460237_1", "context": "Recurrent palmar-plantar erythrodysaesthesia following high-dose cytarabine treatment for acute lymphoblastic leukemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatment"]], "start": [[76]], "entity_id": ["T9"]}, "Effect": {"text": [["palmar-plantar erythrodysaesthesia"]], "start": [[10]], "entity_id": ["T6"]}, "Treatment": {"text": [["high-dose cytarabine"]], "start": [[55]], "entity_id": ["T7"], "Drug": {"text": [["cytarabine"]], "start": [[65]], "entity_id": ["T10"]}, "Dosage": {"text": [["high-dose"]], "start": [[55]], "entity_id": ["T11"]}, "Disorder": {"text": [["acute lymphoblastic leukemia"]], "start": [[90]], "entity_id": ["T12"]}}}]}]}
{"id": "12163813_1", "context": "CONCLUSIONS: Peripheral administration of low-dose vasopressin for septic shock should be discouraged because of the risk of ischemic skin complications.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["risk"]], "start": [[117]], "entity_id": ["T3"]}, "Effect": {"text": [["ischemic skin complications"]], "start": [[125]], "entity_id": ["T4"]}, "Treatment": {"text": [["Peripheral administration of low-dose vasopressin"]], "start": [[13]], "entity_id": ["T5"], "Disorder": {"text": [["septic shock"]], "start": [[67]], "entity_id": ["T6"]}, "Drug": {"text": [["vasopressin"]], "start": [[51]], "entity_id": ["T8"]}, "Dosage": {"text": [["low-dose"]], "start": [[42]], "entity_id": ["T9"]}, "Route": {"text": [["Peripheral administration"]], "start": [[13]], "entity_id": ["T10"]}}, "Speculated": {"text": [["risk"]], "start": [[117]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "21448111_3", "context": "Many types of medicaments can cause akathisia as an adverse event of their use and they include: antipsychotics, antidepressants, antiemetics, antihistamines, and psychoactive substances.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["adverse event"]], "start": [[52]], "entity_id": ["T10"]}, "Treatment": {"text": [["antipsychotics, antidepressants, antiemetics, antihistamines, and psychoactive substances"]], "start": [[97]], "entity_id": ["T9"], "Drug": {"text": [["antipsychotics"], ["antidepressants"], ["antiemetics"], ["antihistamines"], ["psychoactive substances."]], "start": [[97], [113], [130], [143], [163]], "entity_id": ["T12", "T13", "T14", "T15", "T16"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[159]], "entity_id": ["T17"]}, "Drug": {"text": [["antipsychotics"], ["antidepressants"], ["antiemetics"], ["antihistamines"], ["psychoactive substances."]], "start": [[97], [113], [130], [143], [163]], "entity_id": ["T12", "T13", "T14", "T15", "T16"]}}]}, "Effect": {"text": [["akathisia"]], "start": [[36]], "entity_id": ["T11"]}}]}]}
{"id": "17039658_3", "context": "We report the case of a 60-year-old woman who developed erythema and erosions in the axilla and groin while on PLD for breast cancer.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[46]], "entity_id": ["T6"]}, "Subject": {"text": [["a 60-year-old woman", "breast cancer"]], "start": [[22, 119]], "entity_id": ["T5"], "Age": {"text": [["60-year-old"]], "start": [[24]], "entity_id": ["T11"]}, "Gender": {"text": [["woman"]], "start": [[36]], "entity_id": ["T12"]}}, "Effect": {"text": [["erythema"], ["erosions in the axilla and groin"]], "start": [[56], [69]], "entity_id": ["T7", "T8"]}, "Treatment": {"text": [["PLD"]], "start": [[111]], "entity_id": ["T9"], "Drug": {"text": [["PLD"]], "start": [[111]], "entity_id": ["T13"]}, "Disorder": {"text": [["breast cancer"]], "start": [[119]], "entity_id": ["T14"]}}}]}]}
{"id": "18171260_2", "context": "Serotonin syndrome has been reported with administration of linezolid and serotonin reuptake inhibitors.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reported with"]], "start": [[28]], "entity_id": ["T7"]}, "Treatment": {"text": [["administration of linezolid and serotonin reuptake inhibitors"]], "start": [[42]], "entity_id": ["T6"], "Drug": {"text": [["linezolid"], ["serotonin reuptake inhibitors"]], "start": [[60], [74]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[70]], "entity_id": ["T11"]}, "Drug": {"text": [["linezolid"], ["serotonin reuptake inhibitors"]], "start": [[60], [74]], "entity_id": ["T9", "T10"]}}]}, "Effect": {"text": [["Serotonin syndrome"]], "start": [[0]], "entity_id": ["T8"]}}]}]}
{"id": "6159523_6", "context": "We suggest that the treatment of hypoglycaemia with 50% solution of dextrose is associated with a significant risk factor in those diabetic individuals who are either allergic or are receiving beta-adrenoreceptor blocking drugs.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[80]], "entity_id": ["T14"]}, "Treatment": {"text": [["50% solution of dextrose"]], "start": [[52]], "entity_id": ["T13"], "Disorder": {"text": [["hypoglycaemia"]], "start": [[33]], "entity_id": ["T18"]}, "Drug": {"text": [["dextrose"]], "start": [[68]], "entity_id": ["T12"]}, "Route": {"text": [["50% solution"]], "start": [[52]], "entity_id": ["T19"]}}, "Subject": {"text": [["diabetic individuals who are either allergic or are receiving beta-adrenoreceptor blocking drugs"]], "start": [[131]], "entity_id": ["T15"], "Disorder": {"text": [["diabetic"]], "start": [[131]], "entity_id": ["T17"]}}, "Effect": {"text": [["a significant risk factor"]], "start": [[96]], "entity_id": ["T16"]}}]}]}
{"id": "1509179_1", "context": "A case of phenobarbital exacerbation of a preexisting maladaptive behavior partially suppressed by chlorpromazine and misinterpreted as chlorpromazine efficacy.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["exacerbation"]], "start": [[24]], "entity_id": ["T6"]}, "Treatment": {"text": [["phenobarbital", "partially suppressed by chlorpromazine"]], "start": [[10, 75]], "entity_id": ["T4"], "Drug": {"text": [["phenobarbital"], ["chlorpromazine"]], "start": [[10], [99]], "entity_id": ["T8", "T9"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["suppressed"]], "start": [[85]], "entity_id": ["T3"]}, "Drug": {"text": [["phenobarbital"], ["chlorpromazine"]], "start": [[10], [99]], "entity_id": ["T8", "T9"]}}]}, "Effect": {"text": [["exacerbation of a preexisting maladaptive behavior"]], "start": [[24]], "entity_id": ["T5"]}, "Subject": {"text": [["preexisting maladaptive behavior"]], "start": [[42]], "entity_id": ["T7"], "Disorder": {"text": [["preexisting maladaptive behavior"]], "start": [[42]], "entity_id": ["T10"]}}}]}]}
{"id": "14632592_1", "context": "Colchicine-induced myopathy in a teenager with familial Mediterranean fever.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T3"]}, "Treatment": {"text": [["Colchicine"]], "start": [[0]], "entity_id": ["T4"], "Disorder": {"text": [["Mediterranean fever"]], "start": [[56]], "entity_id": ["T8"]}, "Drug": {"text": [["Colchicine"]], "start": [[0]], "entity_id": ["T9"]}}, "Effect": {"text": [["myopathy"]], "start": [[19]], "entity_id": ["T5"]}, "Subject": {"text": [["a teenager with familial Mediterranean fever"]], "start": [[31]], "entity_id": ["T6"], "Age": {"text": [["teenager"]], "start": [[33]], "entity_id": ["T7"]}}}]}]}
{"id": "18585545_4", "context": "Levofloxacin-induced delirium with psychotic features.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[13]], "entity_id": ["T3"]}, "Effect": {"text": [["delirium with psychotic features"]], "start": [[21]], "entity_id": ["T4"]}, "Treatment": {"text": [["Levofloxacin"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Levofloxacin"]], "start": [[0]], "entity_id": ["T6"]}}}]}]}
{"id": "8007037_2", "context": "Methemoglobinemia: an occupational hazard of phenylpropanolamine production.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["production"]], "start": [[65]], "entity_id": ["T5"]}, "Effect": {"text": [["Methemoglobinemia"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["phenylpropanolamine"]], "start": [[45]], "entity_id": ["T4"], "Drug": {"text": [["phenylpropanolamine"]], "start": [[45]], "entity_id": ["T6"]}}}]}]}
{"id": "16498048_2", "context": "Destructive thyrotoxicosis appeared 4-6 months after starting IFN-alpha, followed by Graves' hyperthyroidism within 8 to 11 months.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[47]], "entity_id": ["T7"]}, "Effect": {"text": [["Destructive thyrotoxicosis", "Graves' hyperthyroidism"]], "start": [[0, 85]], "entity_id": ["T5"]}, "Treatment": {"text": [["IFN-alpha"]], "start": [[62]], "entity_id": ["T6"], "Drug": {"text": [["IFN-alpha"]], "start": [[62]], "entity_id": ["T8"]}, "Time_elapsed": {"text": [["4-6 months"]], "start": [[36]], "entity_id": ["T9"]}}}]}]}
{"id": "9220046_1", "context": "CASE SUMMARIES: In each case, the patients were treated over 5 years with lovastatin and developed rhabdomyolysis that coincided with the completion of a prescribed regimen of a newer macrolide antibiotic.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[89]], "entity_id": ["T5"]}, "Subject": {"text": [["patients"]], "start": [[34]], "entity_id": ["T3"]}, "Treatment": {"text": [["5 years with lovastatin", "a newer macrolide antibiotic"]], "start": [[61, 176]], "entity_id": ["T4"], "Duration": {"text": [["5 years"]], "start": [[61]], "entity_id": ["T7"]}, "Drug": {"text": [["lovastatin"], ["macrolide antibiotic"]], "start": [[74], [184]], "entity_id": ["T8", "T9"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["coincided"]], "start": [[119]], "entity_id": ["T10"]}, "Drug": {"text": [["lovastatin"], ["macrolide antibiotic"]], "start": [[74], [184]], "entity_id": ["T8", "T9"]}}]}, "Effect": {"text": [["rhabdomyolysis"]], "start": [[99]], "entity_id": ["T6"]}}]}]}
{"id": "11886466_1", "context": "Thrombotic stroke associated with the use of porcine factor VIII in a patient with acquired haemophilia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[18]], "entity_id": ["T8"]}, "Subject": {"text": [["patient with acquired haemophilia"]], "start": [[70]], "entity_id": ["T7"]}, "Effect": {"text": [["Thrombotic stroke"]], "start": [[0]], "entity_id": ["T9"]}, "Treatment": {"text": [["porcine factor VIII"]], "start": [[45]], "entity_id": ["T10"], "Drug": {"text": [["porcine factor VIII"]], "start": [[45]], "entity_id": ["T12"]}, "Disorder": {"text": [["acquired haemophilia"]], "start": [[83]], "entity_id": ["T13"]}}}]}]}
{"id": "16371793_2", "context": "PURPOSE: The intravitreal application of triamcinolone acetonide as treatment of long-standing, therapy-resistant cystoid macular edema after penetrating keratoplasty is reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatment"]], "start": [[68]], "entity_id": ["T5"]}, "Treatment": {"text": [["The intravitreal application of triamcinolone acetonide"]], "start": [[9]], "entity_id": ["T4"], "Route": {"text": [["intravitreal"]], "start": [[13]], "entity_id": ["T7"]}, "Drug": {"text": [["triamcinolone acetonide"]], "start": [[41]], "entity_id": ["T8"]}, "Disorder": {"text": [["cystoid macular edema"]], "start": [[114]], "entity_id": ["T9"]}}}]}]}
{"id": "23868369_8", "context": "Patients receiving ciprofloxacin and digoxin should be monitored closely for the risk of digoxin toxicity.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["the risk"]], "start": [[77]], "entity_id": ["T11"]}, "Subject": {"text": [["Patients"]], "start": [[0]], "entity_id": ["T7"]}, "Treatment": {"text": [["ciprofloxacin and digoxin"]], "start": [[19]], "entity_id": ["T8"], "Drug": {"text": [["ciprofloxacin"], ["digoxin"]], "start": [[19], [37]], "entity_id": ["T12", "T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[33]], "entity_id": ["T14"]}, "Drug": {"text": [["digoxin"], ["ciprofloxacin"]], "start": [[37], [19]], "entity_id": ["T13", "T12"]}}]}, "Effect": {"text": [["digoxin toxicity"]], "start": [[89]], "entity_id": ["T10"]}, "Speculated": {"text": [["should"]], "start": [[45]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "11443640_2", "context": "To our knowledge this is the first report of pancytopenia due to MMI, where the usual hypoplasia found is replaced by massive plasmocytosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[58]], "entity_id": ["T7"]}, "Effect": {"text": [["pancytopenia"]], "start": [[45]], "entity_id": ["T5"]}, "Treatment": {"text": [["MMI"]], "start": [[65]], "entity_id": ["T6"], "Drug": {"text": [["MMI"]], "start": [[65]], "entity_id": ["T8"]}}}]}]}
{"id": "4082283_3", "context": "The following is a report of 2 cases of rifampicin-induced renal insufficiency.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[51]], "entity_id": ["T5"]}, "Treatment": {"text": [["rifampicin"]], "start": [[40]], "entity_id": ["T4"], "Drug": {"text": [["rifampicin"]], "start": [[40]], "entity_id": ["T7"]}}, "Effect": {"text": [["renal insufficiency"]], "start": [[59]], "entity_id": ["T6"]}}]}]}
{"id": "8435665_2", "context": "Fatal eosinophilia myalgia syndrome in a marrow transplant patient attributed to total parenteral nutrition with a solution containing tryptophan.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["attributed"]], "start": [[67]], "entity_id": ["T6"]}, "Effect": {"text": [["Fatal eosinophilia myalgia syndrome"]], "start": [[0]], "entity_id": ["T3"]}, "Subject": {"text": [["marrow transplant patient"]], "start": [[41]], "entity_id": ["T4"]}, "Treatment": {"text": [["total parenteral nutrition with a solution containing tryptophan"]], "start": [[81]], "entity_id": ["T5"], "Drug": {"text": [["tryptophan"]], "start": [[135]], "entity_id": ["T7"]}, "Route": {"text": [["parenteral"]], "start": [[87]], "entity_id": ["T8"]}}}]}]}
{"id": "14601701_4", "context": "We describe a 43-year-old man who developed signs and symptoms of bilateral optic neuropathy during treatment with ethambutol.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[34]], "entity_id": ["T7"]}, "Subject": {"text": [["43-year-old man"]], "start": [[14]], "entity_id": ["T6"], "Age": {"text": [["43-year-old"]], "start": [[14]], "entity_id": ["T10"]}, "Gender": {"text": [["man"]], "start": [[26]], "entity_id": ["T11"]}}, "Effect": {"text": [["bilateral optic neuropathy"]], "start": [[66]], "entity_id": ["T8"]}, "Treatment": {"text": [["ethambutol"]], "start": [[115]], "entity_id": ["T9"], "Drug": {"text": [["ethambutol"]], "start": [[115]], "entity_id": ["T12"]}}}]}]}
{"id": "8445549_3", "context": "The patient described in this paper was a 78-year-old diabetic man who developed oral lesions of PV following institution of glibenclamide therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[100]], "entity_id": ["T5"]}, "Treatment": {"text": [["institution of glibenclamide"]], "start": [[110]], "entity_id": ["T3"], "Drug": {"text": [["glibenclamide"]], "start": [[125]], "entity_id": ["T10"]}, "Disorder": {"text": [["diabetic"]], "start": [[54]], "entity_id": ["T11"]}}, "Subject": {"text": [["The patient described in this paper was a 78-year-old diabetic man"]], "start": [[0]], "entity_id": ["T4"], "Age": {"text": [["78-year-old"]], "start": [[42]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[63]], "entity_id": ["T9"]}}, "Effect": {"text": [["oral lesions of PV"]], "start": [[81]], "entity_id": ["T6"]}}]}]}
{"id": "16146480_2", "context": "Since elevated cortisol levels in Cushing's disease poses a threat for pancreatitis, there is a possibility that patients with Cushing's disease might be more prone to acute pancreatitis following propofol administration.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[187]], "entity_id": ["T4"]}, "Effect": {"text": [["acute pancreatitis"]], "start": [[168]], "entity_id": ["T3"]}, "Treatment": {"text": [["propofol"]], "start": [[197]], "entity_id": ["T5"], "Drug": {"text": [["propofol"]], "start": [[197]], "entity_id": ["T12"]}, "Disorder": {"text": [["Cushing's disease"]], "start": [[127]], "entity_id": ["T13"]}}, "Subject": {"text": [["patients with Cushing's disease"]], "start": [[113]], "entity_id": ["T6"]}, "Speculated": {"text": [["might"]], "start": [[145]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "9433539_3", "context": "Ticlopidine is an oral antiplatelet agent frequently utilized in the treatment of cerebrovascular disease and is rarely associated with severe bone marrow suppression, typically aplastic anemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[120]], "entity_id": ["T8"]}, "Treatment": {"text": [["Ticlopidine is an oral antiplatelet agent"]], "start": [[0]], "entity_id": ["T6"], "Disorder": {"text": [["cerebrovascular disease"]], "start": [[82]], "entity_id": ["T5"]}, "Drug": {"text": [["Ticlopidine"]], "start": [[0]], "entity_id": ["T10"]}, "Route": {"text": [["oral"]], "start": [[18]], "entity_id": ["T11"]}}, "Effect": {"text": [["severe bone marrow suppression, typically aplastic anemia"]], "start": [[136]], "entity_id": ["T9"]}, "Speculated": {"text": [["rarely"]], "start": [[113]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "21715267_2", "context": "Moxifloxacin and lomefloxacin are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treating"]], "start": [[70]], "entity_id": ["T9"]}, "Treatment": {"text": [["Moxifloxacin and lomefloxacin", "fluoroquinolone antibiotics"]], "start": [[0, 34]], "entity_id": ["T8"], "Drug": {"text": [["Moxifloxacin"], ["lomefloxacin"], ["fluoroquinolone antibiotics"]], "start": [[0], [17], [34]], "entity_id": ["T11", "T12", "T13"]}, "Disorder": {"text": [["urinary and respiratory tract infections"]], "start": [[79]], "entity_id": ["T14"]}}}]}]}
{"id": "9337441_14", "context": "To our knowledge, this case report represents only the third description of laxative-induced TEN.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[85]], "entity_id": ["T4"]}, "Treatment": {"text": [["laxative"]], "start": [[76]], "entity_id": ["T5"], "Drug": {"text": [["laxative"]], "start": [[76]], "entity_id": ["T7"]}}, "Effect": {"text": [["TEN"]], "start": [[93]], "entity_id": ["T6"]}}]}]}
{"id": "21417793_2", "context": "Prompted by the advent of potentially life-threatening neuromuscular symptoms following initiation of linezolid therapy in two patients receiving treatment with a serotonin reuptake inhibitor antidepressant, an evaluation was conducted to determine the incidence and characteristics of symptomatic serotonin toxicity among hospitalized patients receiving combined treatment with these medications.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[78]], "entity_id": ["T17"]}, "Treatment": {"text": [["linezolid", "with a serotonin reuptake inhibitor antidepressant"]], "start": [[102, 156]], "entity_id": ["T15"], "Drug": {"text": [["serotonin reuptake inhibitor antidepressant"], ["linezolid"]], "start": [[163], [102]], "entity_id": ["T20", "T21"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["with"]], "start": [[156]], "entity_id": ["T22"]}, "Drug": {"text": [["linezolid"], ["serotonin reuptake inhibitor antidepressant"]], "start": [[102], [163]], "entity_id": ["T21", "T20"]}}]}, "Effect": {"text": [["life-threatening neuromuscular symptoms"]], "start": [[38]], "entity_id": ["T16"]}, "Subject": {"text": [["two patients"]], "start": [[123]], "entity_id": ["T14"], "Population": {"text": [["two"]], "start": [[123]], "entity_id": ["T18"]}}, "Severity": {"text": [["life-threatening"]], "start": [[38]], "entity_id": ["T19"], "value": "High"}}]}]}
{"id": "15543388_2", "context": "Celiac disease onset after pegylated interferon and ribavirin treatment of chronic hepatitis C.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["onset"]], "start": [[15]], "entity_id": ["T6"]}, "Treatment": {"text": [["pegylated interferon and ribavirin treatment of chronic hepatitis C"]], "start": [[27]], "entity_id": ["T5"], "Drug": {"text": [["pegylated interferon"], ["ribavirin treatment"]], "start": [[27], [52]], "entity_id": ["T7", "T9"]}, "Disorder": {"text": [["chronic hepatitis C"]], "start": [[75]], "entity_id": ["T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[48]], "entity_id": ["T8"]}, "Drug": {"text": [["pegylated interferon"], ["ribavirin treatment"]], "start": [[27], [52]], "entity_id": ["T7", "T9"]}}]}, "Effect": {"text": [["Celiac disease"]], "start": [[0]], "entity_id": ["T4"]}}]}]}
{"id": "8244201_3", "context": "Hyperkalaemia with renal tubular dysfunction by sulfamethoxazole-trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["by"]], "start": [[45]], "entity_id": ["T8"]}, "Subject": {"text": [["patients with lymphoid malignancy"]], "start": [[116]], "entity_id": ["T7"], "Disorder": {"text": [["lymphoid malignancy"]], "start": [[130]], "entity_id": ["T10"]}}, "Effect": {"text": [["Hyperkalaemia with renal tubular dysfunction"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["sulfamethoxazole-trimethoprim for Pneumocystis carinii pneumonia"]], "start": [[48]], "entity_id": ["T6"], "Disorder": {"text": [["Pneumocystis carinii pneumonia"]], "start": [[82]], "entity_id": ["T9"]}, "Drug": {"text": [["sulfamethoxazole-trimethoprim"]], "start": [[48]], "entity_id": ["T11"]}}}]}]}
{"id": "19540093_2", "context": "Following 7 days of tigecycline she developed severe abdominal pain and elevated pancreatic enzymes suggesting acute pancreatitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[36]], "entity_id": ["T8"]}, "Treatment": {"text": [["7 days of tigecycline"]], "start": [[10]], "entity_id": ["T7"], "Time_elapsed": {"text": [["7 days"]], "start": [[10]], "entity_id": ["T10"]}, "Drug": {"text": [["tigecycline"]], "start": [[20]], "entity_id": ["T11"]}}, "Effect": {"text": [["abdominal pain and elevated pancreatic enzymes"]], "start": [[53]], "entity_id": ["T9"]}, "Subject": {"text": [["she"]], "start": [[32]], "entity_id": ["T12"]}, "Severity": {"text": [["severe"]], "start": [[46]], "entity_id": ["T13"], "value": "High"}}]}]}
{"id": "11850606_4", "context": "To treat hepatitis B, interferon alpha was administered until the proximal muscle weakness developed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[91]], "entity_id": ["T6"]}, "Treatment": {"text": [["interferon alpha"]], "start": [[22]], "entity_id": ["T4"], "Disorder": {"text": [["hepatitis B"]], "start": [[9]], "entity_id": ["T7"]}, "Drug": {"text": [["interferon alpha"]], "start": [[22]], "entity_id": ["T8"]}}, "Effect": {"text": [["proximal muscle weakness"]], "start": [[66]], "entity_id": ["T5"]}}]}]}
{"id": "16882112_4", "context": "We report a case of the serotonin syndrome during treatment with lithium and venlafaxine, an antidepressant with a dual selective re-uptake inhibition mechanism, and review the literature for similar cases.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[43]], "entity_id": ["T10"]}, "Effect": {"text": [["serotonin syndrome"]], "start": [[24]], "entity_id": ["T7"]}, "Treatment": {"text": [["lithium and venlafaxine"]], "start": [[65]], "entity_id": ["T8"], "Drug": {"text": [["lithium"], ["venlafaxine"]], "start": [[65], [77]], "entity_id": ["T11", "T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[73]], "entity_id": ["T13"]}, "Drug": {"text": [["lithium"], ["venlafaxine"]], "start": [[65], [77]], "entity_id": ["T11", "T12"]}}]}, "Subject": {"text": [["a case"]], "start": [[10]], "entity_id": ["T9"]}}]}]}
{"id": "19531695_13", "context": "Supratherapeutic flecainide plasma concentrations may cause delirium.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[54]], "entity_id": ["T7"]}, "Effect": {"text": [["delirium"]], "start": [[60]], "entity_id": ["T5"]}, "Treatment": {"text": [["Supratherapeutic flecainide plasma concentrations"]], "start": [[0]], "entity_id": ["T6"], "Drug": {"text": [["flecainide"]], "start": [[17]], "entity_id": ["T8"]}}}]}]}
{"id": "19499966_1", "context": "At the end of his fifth cycle of sunitinib therapy, the patient complained of the development of abnormally large mammary glands associated with pain and peri-areolar erythema.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["development"]], "start": [[82]], "entity_id": ["T10"]}, "Treatment": {"text": [["fifth cycle of sunitinib therapy"]], "start": [[18]], "entity_id": ["T7"], "Drug": {"text": [["sunitinib"]], "start": [[33]], "entity_id": ["T11"]}, "Freq": {"text": [["fifth cycle"]], "start": [[18]], "entity_id": ["T12"]}}, "Subject": {"text": [["the patient"]], "start": [[52]], "entity_id": ["T8"]}, "Effect": {"text": [["abnormally large mammary glands associated with pain and peri-areolar erythema"]], "start": [[97]], "entity_id": ["T9"]}}]}]}
{"id": "18644535_2", "context": "This is a case report of possible association of methylphenidate and enuresis in an 11-year-old boy with attention deficit hyperactivity disorder.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["association"]], "start": [[34]], "entity_id": ["T6"]}, "Treatment": {"text": [["methylphenidate"]], "start": [[49]], "entity_id": ["T3"], "Drug": {"text": [["methylphenidate"]], "start": [[49]], "entity_id": ["T11"]}, "Disorder": {"text": [["attention deficit hyperactivity disorder"]], "start": [[105]], "entity_id": ["T12"]}}, "Effect": {"text": [["enuresis"]], "start": [[69]], "entity_id": ["T4"]}, "Subject": {"text": [["an 11-year-old boy with attention deficit hyperactivity disorder"]], "start": [[81]], "entity_id": ["T5"], "Age": {"text": [["11-year-old"]], "start": [[84]], "entity_id": ["T7"]}, "Gender": {"text": [["boy"]], "start": [[96]], "entity_id": ["T8"]}}, "Speculated": {"text": [["possible"]], "start": [[25]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "19331262_4", "context": "This report describes a case of neuroleptic malignant syndrome due to risperidone in a child with Joubert syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due to"]], "start": [[63]], "entity_id": ["T8"]}, "Subject": {"text": [["a child with Joubert syndrome"]], "start": [[85]], "entity_id": ["T6"], "Age": {"text": [["child"]], "start": [[87]], "entity_id": ["T10"]}}, "Treatment": {"text": [["risperidone"]], "start": [[70]], "entity_id": ["T7"], "Disorder": {"text": [["Joubert syndrome"]], "start": [[98]], "entity_id": ["T12"]}, "Drug": {"text": [["risperidone"]], "start": [[70]], "entity_id": ["T13"]}}, "Effect": {"text": [["neuroleptic malignant syndrome"]], "start": [[32]], "entity_id": ["T9"]}}]}]}
{"id": "21045170_3", "context": "A 47-year-old HIV-infected man with dilated cardiomyopathy and prolonged QT syndrome with an automatic implantable cardiovascular defibrillator device was prescribed subcutaneous enfuvirtide 90 mg twice daily as part of his antiretroviral regimen and oral extended-release niacin 500 mg/day for a high-density lipoprotein level of 8 mg/dL. After 1 week of concomitant therapy, the patient began experiencing extreme redness, edema, and swelling at the injection site that corresponded with the flushing sensation due to niacin.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["experiencing"]], "start": [[395]], "entity_id": ["T20"]}, "Subject": {"text": [["A 47-year-old HIV-infected man with dilated cardiomyopathy and prolonged QT syndrome with an automatic implantable cardiovascular defibrillator device"]], "start": [[0]], "entity_id": ["T17"], "Disorder": {"text": [["dilated cardiomyopathy"], ["prolonged QT syndrome"]], "start": [[36], [63]], "entity_id": ["T18", "T1"]}, "Age": {"text": [["47-year-old"]], "start": [[2]], "entity_id": ["T22"]}, "Gender": {"text": [["man"]], "start": [[27]], "entity_id": ["T24"]}}, "Treatment": {"text": [["subcutaneous enfuvirtide 90 mg twice daily as part of his antiretroviral regimen and oral extended-release niacin 500 mg/day for a high-density lipoprotein level of 8 mg/dL"]], "start": [[166]], "entity_id": ["T19"], "Disorder": {"text": [["HIV-infected"]], "start": [[14]], "entity_id": ["T23"]}, "Dosage": {"text": [["90 mg"], ["500 mg"]], "start": [[191], [280]], "entity_id": ["T25", "T31"]}, "Freq": {"text": [["twice daily"], ["day"]], "start": [[197], [287]], "entity_id": ["T26", "T32"]}, "Drug": {"text": [["enfuvirtide"], ["niacin"]], "start": [[179], [273]], "entity_id": ["T27", "T30"]}, "Route": {"text": [["subcutaneous"], ["oral"]], "start": [[166], [251]], "entity_id": ["T28", "T29"]}, "Time_elapsed": {"text": [["1 week"]], "start": [[346]], "entity_id": ["T3"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[247]], "entity_id": ["T2"]}, "Drug": {"text": [["niacin"], ["enfuvirtide"]], "start": [[273], [179]], "entity_id": ["T30", "T27"]}}]}, "Effect": {"text": [["extreme redness, edema, and swelling at the injection site that corresponded with the flushing sensation due to niacin"]], "start": [[408]], "entity_id": ["T21"]}}]}]}
{"id": "7724306_1", "context": "Acute INH neurotoxicity was not suspected on the first admission; however, when readmitted 4 weeks later with another seizure, the diagnosis of acute INH neurotoxicity was made.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["diagnosis"]], "start": [[131]], "entity_id": ["T4"]}, "Treatment": {"text": [["INH"]], "start": [[150]], "entity_id": ["T5"], "Drug": {"text": [["INH"]], "start": [[150]], "entity_id": ["T10"]}}, "Effect": {"text": [["seizure"], ["acute INH neurotoxicity"]], "start": [[118], [144]], "entity_id": ["T8", "T9"]}}]}]}
{"id": "12066972_1", "context": "Levofloxacin-induced toxic epidermal necrolysis in an elderly patient.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[13]], "entity_id": ["T5"]}, "Subject": {"text": [["an elderly patient."]], "start": [[51]], "entity_id": ["T3"], "Age": {"text": [["elderly"]], "start": [[54]], "entity_id": ["T7"]}}, "Treatment": {"text": [["Levofloxacin"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Levofloxacin"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["toxic epidermal necrolysis"]], "start": [[21]], "entity_id": ["T6"]}}]}]}
{"id": "18079582_1", "context": "The incidence of 5-fluorouracil (5-FU)-related cardiotoxicity seems to be dosage and schedule dependent.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[39]], "entity_id": ["T5"]}, "Treatment": {"text": [["5-fluorouracil", "dosage", "schedule"]], "start": [[17, 74, 85]], "entity_id": ["T4"], "Drug": {"text": [["5-fluorouracil (5-FU)"]], "start": [[17]], "entity_id": ["T7"]}}, "Effect": {"text": [["cardiotoxicity"]], "start": [[47]], "entity_id": ["T6"]}, "Speculated": {"text": [["seems"]], "start": [[62]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "19915794_3", "context": "Torsades de Pointes induced by a combination of garenoxacin and disopyramide and other cytochrome P450, family 3, subfamily A polypeptide-4-influencing drugs during hypokalemia due to licorice.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[20]], "entity_id": ["T4"]}, "Effect": {"text": [["Torsades de Pointes"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["a combination of garenoxacin and disopyramide and other cytochrome P450, family 3, subfamily A polypeptide-4-influencing drugs"]], "start": [[31]], "entity_id": ["T6"], "Drug": {"text": [["garenoxacin"], ["disopyramide"], ["cytochrome P450, family 3, subfamily A polypeptide-4-influencing drugs"]], "start": [[48], [64], [87]], "entity_id": ["T7", "T8", "T9"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combination"]], "start": [[33]], "entity_id": ["T10"]}, "Drug": {"text": [["garenoxacin"], ["disopyramide"], ["cytochrome P450, family 3, subfamily A polypeptide-4-influencing drugs"]], "start": [[48], [64], [87]], "entity_id": ["T7", "T8", "T9"]}}]}}]}]}
{"id": "10981493_1", "context": "Ataxia caused by propafenone has been reported to the pharmaceutical companies and drug monitoring agencies, but has not been well described or emphasized in the medical literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[7]], "entity_id": ["T3"]}, "Treatment": {"text": [["propafenone"]], "start": [[17]], "entity_id": ["T4"], "Drug": {"text": [["propafenone"]], "start": [[17]], "entity_id": ["T6"]}}, "Effect": {"text": [["Ataxia"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "7582710_2", "context": "The first patient developed mild nitritoid symptoms and pain in a band-like distribution, corresponding to T10-T12 dermatomes, shortly after gold sodium thiomalate (GSTM) injection.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[18]], "entity_id": ["T12"]}, "Treatment": {"text": [["gold sodium thiomalate (GSTM) injection"]], "start": [[141]], "entity_id": ["T10"], "Drug": {"text": [["gold sodium thiomalate"]], "start": [[141]], "entity_id": ["T15"]}, "Route": {"text": [["injection"]], "start": [[171]], "entity_id": ["T16"]}}, "Subject": {"text": [["The first patient"]], "start": [[0]], "entity_id": ["T11"]}, "Effect": {"text": [["mild nitritoid symptoms and pain in a band-like distribution"]], "start": [[28]], "entity_id": ["T13"]}, "Severity": {"text": [["mild"]], "start": [[28]], "entity_id": ["T14"], "value": "Medium"}}]}]}
{"id": "9433539_1", "context": "A case is reported of an elderly woman who developed febrile agranulocytosis several weeks after commencing ticlopidine but who had a favorable outcome after cessation of that drug and treatment with filgastrim.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[43]], "entity_id": ["T7"]}, "Subject": {"text": [["an elderly woman"]], "start": [[22]], "entity_id": ["T4"], "Age": {"text": [["elderly"]], "start": [[25]], "entity_id": ["T5"]}, "Gender": {"text": [["woman"]], "start": [[33]], "entity_id": ["T6"]}}, "Effect": {"text": [["febrile agranulocytosis"]], "start": [[53]], "entity_id": ["T8"]}, "Treatment": {"text": [["several weeks after commencing ticlopidine"]], "start": [[77]], "entity_id": ["T9"], "Time_elapsed": {"text": [["several weeks"]], "start": [[77]], "entity_id": ["T10"]}, "Drug": {"text": [["ticlopidine"]], "start": [[108]], "entity_id": ["T11"]}}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["after"]], "start": [[152]], "entity_id": ["T13"]}, "Subject": {"text": [["an elderly woman"]], "start": [[22]], "entity_id": ["T4"], "Age": {"text": [["elderly"]], "start": [[25]], "entity_id": ["T5"]}, "Gender": {"text": [["woman"]], "start": [[33]], "entity_id": ["T6"]}}, "Effect": {"text": [["a favorable outcome"]], "start": [[132]], "entity_id": ["T12"]}, "Treatment": {"text": [["cessation of that drug and treatment with filgastrim"]], "start": [[158]], "entity_id": ["T14"], "Disorder": {"text": [["febrile agranulocytosis"]], "start": [[53]], "entity_id": ["T16"]}, "Drug": {"text": [["filgastrim"]], "start": [[200]], "entity_id": ["T15"]}}}]}]}
{"id": "9824032_3", "context": "Two 65-year-old white men with coronary heart disease, given niacin therapy for dyslipidemia for 5 months, developed intense dental and gingival pain that was associated with increases in dose and that was relieved with discontinuance of niacin treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[107]], "entity_id": ["T8"]}, "Treatment": {"text": [["niacin therapy for dyslipidemia for 5 months", "increases in dose"]], "start": [[61, 175]], "entity_id": ["T7"], "Disorder": {"text": [["dyslipidemia"]], "start": [[80]], "entity_id": ["T6"]}, "Drug": {"text": [["niacin"]], "start": [[61]], "entity_id": ["T14"]}, "Dosage": {"text": [["ncreases in dose"]], "start": [[176]], "entity_id": ["T15"]}, "Duration": {"text": [["5 months"]], "start": [[97]], "entity_id": ["T16"]}}, "Effect": {"text": [["intense dental and gingival pain"]], "start": [[117]], "entity_id": ["T9"]}, "Subject": {"text": [["Two 65-year-old white men with coronary heart disease"]], "start": [[0]], "entity_id": ["T4"], "Disorder": {"text": [["coronary heart disease"]], "start": [[31]], "entity_id": ["T5"]}, "Population": {"text": [["Two"]], "start": [[0]], "entity_id": ["T10"]}, "Age": {"text": [["65-year-old"]], "start": [[4]], "entity_id": ["T11"]}, "Race": {"text": [["white"]], "start": [[16]], "entity_id": ["T12"]}, "Gender": {"text": [["men"]], "start": [[22]], "entity_id": ["T13"]}}}]}]}
{"id": "3335488_2", "context": "Two patients are described who developed testicular swelling and pain during treatment with desipramine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[70]], "entity_id": ["T5"]}, "Treatment": {"text": [["desipramine"]], "start": [[92]], "entity_id": ["T6"], "Drug": {"text": [["desipramine"]], "start": [[92]], "entity_id": ["T10"]}}, "Subject": {"text": [["Two patients"]], "start": [[0]], "entity_id": ["T7"], "Population": {"text": [["Two"]], "start": [[0]], "entity_id": ["T9"]}}, "Effect": {"text": [["testicular swelling and pain"]], "start": [[41]], "entity_id": ["T8"]}}]}]}
{"id": "6635723_1", "context": "Metabolic balance studies and rechallenge with hydrochlorothiazide were undertaken to investigate the mechanism of the thiazide-induced hyponatremia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[128]], "entity_id": ["T4"]}, "Effect": {"text": [["hyponatremia"]], "start": [[136]], "entity_id": ["T3"]}, "Treatment": {"text": [["thiazide"]], "start": [[119]], "entity_id": ["T5"], "Drug": {"text": [["hydrochlorothiazide"], ["thiazide"]], "start": [[47], [119]], "entity_id": ["T6", "T7"]}}}]}]}
{"id": "3926849_2", "context": "Paradoxical pulmonary vasoconstriction induced by nitroglycerin in idiopathic pulmonary hypertension.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[39]], "entity_id": ["T4"]}, "Effect": {"text": [["Paradoxical pulmonary vasoconstriction"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["nitroglycerin"]], "start": [[50]], "entity_id": ["T5"], "Drug": {"text": [["nitroglycerin"]], "start": [[50]], "entity_id": ["T6"]}, "Disorder": {"text": [["idiopathic pulmonary hypertension"]], "start": [[67]], "entity_id": ["T7"]}}}]}]}
{"id": "12523465_1", "context": "Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and altered mental status after zonisamide treatment was begun or its dosage increased.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[189]], "entity_id": ["T7"]}, "Treatment": {"text": [["zonisamide"]], "start": [[195]], "entity_id": ["T5"], "Drug": {"text": [["zonisamide"]], "start": [[195]], "entity_id": ["T8"]}}, "Effect": {"text": [["complex visual hallucinations and altered mental status"]], "start": [[133]], "entity_id": ["T6"]}}]}]}
{"id": "17675030_2", "context": "Clinical profile of oxcarbazepine-related angioneurotic edema: case report and review.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[34]], "entity_id": ["T3"]}, "Treatment": {"text": [["oxcarbazepine"]], "start": [[20]], "entity_id": ["T4"], "Drug": {"text": [["oxcarbazepine"]], "start": [[20]], "entity_id": ["T6"]}}, "Effect": {"text": [["angioneurotic edema"]], "start": [[42]], "entity_id": ["T5"]}, "Subject": {"text": [["case"]], "start": [[63]], "entity_id": ["T7"]}}]}]}
{"id": "11788010_1", "context": "Extra caution should be taken in using octreotide or its long-acting analog in patients otherwise predisposed to intrahepatic bile stasis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["predisposed"]], "start": [[98]], "entity_id": ["T6"]}, "Treatment": {"text": [["octreotide or its long-acting analog"]], "start": [[39]], "entity_id": ["T3"], "Drug": {"text": [["octreotide"], ["long-acting analog"]], "start": [[39], [57]], "entity_id": ["T7", "T8"]}}, "Effect": {"text": [["intrahepatic bile stasis"]], "start": [[113]], "entity_id": ["T5"]}, "Subject": {"text": [["patients"]], "start": [[79]], "entity_id": ["T4"]}}]}]}
{"id": "8253700_1", "context": "BACKGROUND: Fluoxetine, a highly specific serotonin reuptake inhibitor, has been reported to cause sexual dysfunction in a minority of patients.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[93]], "entity_id": ["T3"]}, "Effect": {"text": [["sexual dysfunction"]], "start": [[99]], "entity_id": ["T4"]}, "Treatment": {"text": [["Fluoxetine"]], "start": [[12]], "entity_id": ["T5"], "Drug": {"text": [["Fluoxetine"]], "start": [[12]], "entity_id": ["T6"]}}, "Subject": {"text": [["minority of patients"]], "start": [[123]], "entity_id": ["T7"]}}]}]}
{"id": "18362995_4", "context": "We report a 45-year-old Chinese man with CML and chronic hepatitis B virus infection, on imatinib treatment, presenting with herpetic rash and acute liver failure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["presenting"]], "start": [[109]], "entity_id": ["T8"]}, "Subject": {"text": [["a 45-year-old Chinese man with CML and chronic hepatitis B virus infection"]], "start": [[10]], "entity_id": ["T5"], "Age": {"text": [["45-year-old"]], "start": [[12]], "entity_id": ["T9"]}, "Race": {"text": [["Chinese"]], "start": [[24]], "entity_id": ["T10"]}, "Gender": {"text": [["man"]], "start": [[32]], "entity_id": ["T11"]}}, "Treatment": {"text": [["on imatinib treatment"]], "start": [[86]], "entity_id": ["T6"], "Drug": {"text": [["imatinib"]], "start": [[89]], "entity_id": ["T13"]}, "Disorder": {"text": [["CML and chronic hepatitis B"]], "start": [[41]], "entity_id": ["T14"]}}, "Effect": {"text": [["herpetic rash and acute liver failure"]], "start": [[125]], "entity_id": ["T7"]}}]}]}
{"id": "3947272_4", "context": "One patient had severe temporary weakness after an ampicillin sodium challenge.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[42]], "entity_id": ["T5"]}, "Subject": {"text": [["One patient"]], "start": [[0]], "entity_id": ["T3"], "Population": {"text": [["One"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["temporary weakness"]], "start": [[23]], "entity_id": ["T4"]}, "Treatment": {"text": [["an ampicillin sodium challenge"]], "start": [[48]], "entity_id": ["T6"], "Drug": {"text": [["ampicillin sodium"]], "start": [[51]], "entity_id": ["T8"]}}, "Severity": {"text": [["severe"]], "start": [[16]], "entity_id": ["T9"], "value": "High"}}]}]}
{"id": "11142491_1", "context": "Acute myeloid leukemia and lung cancer occurring in a chronic lymphocytic leukemia patient treated with fludarabine and autologous peripheral blood stem-cell transplantation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurring"]], "start": [[39]], "entity_id": ["T6"]}, "Effect": {"text": [["Acute myeloid leukemia and lung cancer"]], "start": [[0]], "entity_id": ["T5"]}, "Subject": {"text": [["a chronic lymphocytic leukemia patient"]], "start": [[52]], "entity_id": ["T7"]}, "Treatment": {"text": [["fludarabine and autologous peripheral blood stem-cell transplantation"]], "start": [[104]], "entity_id": ["T8"], "Drug": {"text": [["fludarabine"]], "start": [[104]], "entity_id": ["T10"]}, "Disorder": {"text": [["chronic lymphocytic leukemia"]], "start": [[54]], "entity_id": ["T11"]}}}]}]}
{"id": "16960880_1", "context": "Despite a very low complication rate, several severe arterial thrombotic events have been reported following thrombin injection of pseudoaneurysms.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[99]], "entity_id": ["T6"]}, "Effect": {"text": [["arterial thrombotic"]], "start": [[53]], "entity_id": ["T3"]}, "Treatment": {"text": [["thrombin injection"]], "start": [[109]], "entity_id": ["T4"], "Drug": {"text": [["thrombin"]], "start": [[109]], "entity_id": ["T7"]}, "Route": {"text": [["injection"]], "start": [[118]], "entity_id": ["T8"]}, "Disorder": {"text": [["pseudoaneurysms"]], "start": [[131]], "entity_id": ["T9"]}}, "Severity": {"text": [["severe"]], "start": [[46]], "entity_id": ["T10"], "value": "High"}}]}]}
{"id": "8396491_2", "context": "The results clearly demonstrate that CPH82 was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[47]], "entity_id": ["T5"]}, "Treatment": {"text": [["CPH82"]], "start": [[37]], "entity_id": ["T6"], "Drug": {"text": [["CPH82"]], "start": [[37]], "entity_id": ["T10"]}}, "Effect": {"text": [["suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism"]], "start": [[63]], "entity_id": ["T7"]}}]}]}
{"id": "17060191_2", "context": "Exposure of the fetus to indomethacin by administration of the drug to the mother may cause many side effects, including premature closure of the ductus arteriosus.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["side effects"]], "start": [[97]], "entity_id": ["T10"]}, "Subject": {"text": [["fetus"]], "start": [[16]], "entity_id": ["T8"], "Age": {"text": [["fetus"]], "start": [[16]], "entity_id": ["T12"]}}, "Treatment": {"text": [["indomethacin"]], "start": [[25]], "entity_id": ["T9"], "Drug": {"text": [["indomethacin"]], "start": [[25]], "entity_id": ["T13"]}}, "Effect": {"text": [["premature closure of the ductus arteriosus"]], "start": [[121]], "entity_id": ["T11"]}, "Speculated": {"text": [["may"]], "start": [[82]], "entity_id": ["T14"], "value": true}}]}]}
{"id": "19745701_3", "context": "She was diagnosed with Epstein-Barr virus-associated polymorphic lymphoproliferative disorder (LPD) due to immunodeficiency caused by MTX administration.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[100]], "entity_id": ["T8"]}, "Effect": {"text": [["Epstein-Barr virus-associated polymorphic lymphoproliferative disorder (LPD)"]], "start": [[23]], "entity_id": ["T7"]}, "Treatment": {"text": [["immunodeficiency caused by MTX administration"]], "start": [[107]], "entity_id": ["T9"], "Drug": {"text": [["MTX"]], "start": [[134]], "entity_id": ["T10"]}}, "Subject": {"text": [["She"]], "start": [[0]], "entity_id": ["T11"], "Gender": {"text": [["She"]], "start": [[0]], "entity_id": ["T12"]}}}]}]}
{"id": "17285101_1", "context": "Pulmonary hypertension during lithium therapy: clinical case study.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[23]], "entity_id": ["T3"]}, "Treatment": {"text": [["lithium therapy"]], "start": [[30]], "entity_id": ["T4"], "Drug": {"text": [["lithium"]], "start": [[30]], "entity_id": ["T6"]}}, "Effect": {"text": [["Pulmonary hypertension"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "18682542_1", "context": "CONCLUSIONS: Clinicians should be aware of this adverse reaction when facing similar complex neurologic symptoms in patients who are receiving the antibiotic treatment described here, especially vancomycin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["adverse reaction"]], "start": [[48]], "entity_id": ["T5"]}, "Treatment": {"text": [["vancomycin"]], "start": [[195]], "entity_id": ["T3"], "Drug": {"text": [["vancomycin"]], "start": [[195]], "entity_id": ["T7"]}}, "Subject": {"text": [["patients"]], "start": [[116]], "entity_id": ["T4"]}, "Effect": {"text": [["neurologic symptoms"]], "start": [[93]], "entity_id": ["T6"]}}]}]}
{"id": "19034138_3", "context": "Corneal edema recurred when the administration of amantadine was resumed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["when"]], "start": [[23]], "entity_id": ["T4"]}, "Effect": {"text": [["Corneal edema"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["the administration of amantadine was resumed"]], "start": [[28]], "entity_id": ["T5"], "Drug": {"text": [["amantadine"]], "start": [[50]], "entity_id": ["T6"]}}}]}]}
{"id": "24661191_5", "context": "Vitamin K1 caused skin rash possibly because of the distribution and metabolism characteristic of the drug in this patient.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[11]], "entity_id": ["T5"]}, "Treatment": {"text": [["Vitamin K1"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Vitamin K1"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["skin rash"]], "start": [[18]], "entity_id": ["T6"]}}]}]}
{"id": "15311565_1", "context": "Initial treatment with heparin was substituted with thrombolysis, which resulted in clinical improvement and dissolution of right heart thrombus but was followed by fatal intracerebral haemorrhage.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulted"]], "start": [[72]], "entity_id": ["T4"]}, "Treatment": {"text": [["thrombolysis"]], "start": [[52]], "entity_id": ["T3"], "Drug": {"text": [["thrombolysis"]], "start": [[52]], "entity_id": ["T6"]}}, "Effect": {"text": [["fatal intracerebral haemorrhage"]], "start": [[165]], "entity_id": ["T5"]}, "Severity": {"text": [["fatal"]], "start": [[165]], "entity_id": ["T7"], "value": "High"}}]}]}
{"id": "14601701_3", "context": "The most commonly recognized toxic effect of ethambutol is optic neuropathy, which generally is considered uncommon and reversible in medical literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["effect"]], "start": [[35]], "entity_id": ["T6"]}, "Treatment": {"text": [["ethambutol"]], "start": [[45]], "entity_id": ["T4"], "Drug": {"text": [["ethambutol"]], "start": [[45]], "entity_id": ["T7"]}}, "Effect": {"text": [["optic neuropathy"]], "start": [[59]], "entity_id": ["T5"]}}]}]}
{"id": "189279_1", "context": "A case of congestive heart failure in a child with Wilms' tumor treated Adriamycin is presented and discussed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[35]], "entity_id": ["T6"]}, "Effect": {"text": [["congestive heart failure"]], "start": [[10]], "entity_id": ["T3"]}, "Subject": {"text": [["a child with Wilms' tumor"]], "start": [[38]], "entity_id": ["T4"], "Age": {"text": [["child"]], "start": [[40]], "entity_id": ["T7"]}}, "Treatment": {"text": [["Adriamycin"]], "start": [[72]], "entity_id": ["T5"], "Drug": {"text": [["Adriamycin"]], "start": [[72]], "entity_id": ["T9"]}, "Disorder": {"text": [["Wilms' tumor"]], "start": [[51]], "entity_id": ["T10"]}}}]}]}
{"id": "9494448_3", "context": "BACKGROUND: Hypersensitivity reactions to cyclosporine are rare.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["to"]], "start": [[39]], "entity_id": ["T4"]}, "Effect": {"text": [["Hypersensitivity reactions"]], "start": [[12]], "entity_id": ["T3"]}, "Treatment": {"text": [["cyclosporine"]], "start": [[42]], "entity_id": ["T5"], "Drug": {"text": [["cyclosporine"]], "start": [[42]], "entity_id": ["T7"]}}}]}]}
{"id": "16484748_2", "context": "This is the first case of TMP-SMX-induced hypersensitivity syndrome associated with the reactivation of a latent viral infection.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[34]], "entity_id": ["T4"]}, "Treatment": {"text": [["TMP-SMX"]], "start": [[26]], "entity_id": ["T3"], "Drug": {"text": [["TMP"], ["SMX"]], "start": [[26], [30]], "entity_id": ["T7", "T8"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["-"]], "start": [[29]], "entity_id": ["T9"]}, "Drug": {"text": [["SMX"], ["TMP"]], "start": [[30], [26]], "entity_id": ["T8", "T7"]}}]}, "Effect": {"text": [["hypersensitivity syndrome", "reactivation of a latent viral infection"]], "start": [[42, 88]], "entity_id": ["T5"]}, "Subject": {"text": [["first case"]], "start": [[12]], "entity_id": ["T6"]}}]}]}
{"id": "24318743_15", "context": "In addition, single-agent weekly AUC2-carboplatin appeared to be inactive by response criteria in a homogenously defined population of PROC.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["inactive"]], "start": [[65]], "entity_id": ["T6"]}, "Treatment": {"text": [["single-agent weekly AUC2-carboplatin"]], "start": [[13]], "entity_id": ["T5"], "Disorder": {"text": [["PROC"]], "start": [[135]], "entity_id": ["T8"]}, "Freq": {"text": [["weekly"]], "start": [[26]], "entity_id": ["T9"]}, "Drug": {"text": [["AUC2-carboplatin"]], "start": [[33]], "entity_id": ["T10"]}}, "Subject": {"text": [["a homogenously defined population of PROC"]], "start": [[98]], "entity_id": ["T7"]}, "Negated": {"text": [["inactive"]], "start": [[65]], "entity_id": ["T1"], "value": true}}]}]}
{"id": "18533420_1", "context": "CONCLUSIONS: Intrathecal baclofen can impair sexual function and ejaculation in some patients.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["impair"]], "start": [[38]], "entity_id": ["T4"]}, "Treatment": {"text": [["Intrathecal baclofen"]], "start": [[13]], "entity_id": ["T3"], "Route": {"text": [["Intrathecal"]], "start": [[13]], "entity_id": ["T9"]}, "Drug": {"text": [["baclofen"]], "start": [[25]], "entity_id": ["T10"]}}, "Effect": {"text": [["impair sexual function and ejaculation"]], "start": [[38]], "entity_id": ["T5"]}, "Subject": {"text": [["some patients"]], "start": [[80]], "entity_id": ["T6"]}}]}]}
{"id": "15671134_1", "context": "A case of clozapine-induced tonic-clonic seizures managed with valproate: implications for clinical care.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[20]], "entity_id": ["T4"]}, "Treatment": {"text": [["clozapine"]], "start": [[10]], "entity_id": ["T3"], "Drug": {"text": [["clozapine"]], "start": [[10]], "entity_id": ["T6"]}}, "Effect": {"text": [["tonic-clonic seizures"]], "start": [[28]], "entity_id": ["T5"]}, "Subject": {"text": [["A case"]], "start": [[0]], "entity_id": ["T9"]}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["managed"]], "start": [[50]], "entity_id": ["T12"]}, "Subject": {"text": [["A case"]], "start": [[0]], "entity_id": ["T9"]}, "Treatment": {"text": [["valproate"]], "start": [[63]], "entity_id": ["T10"], "Drug": {"text": [["valproate"]], "start": [[63]], "entity_id": ["T11"]}, "Disorder": {"text": [["clozapine-induced tonic-clonic seizures"]], "start": [[10]], "entity_id": ["T8"]}}}]}]}
{"id": "10923593_2", "context": "Serum sickness consists of a systemic reaction resulting from the formation of soluble circulating immunocomplexes after the introduction of a foreign substance into the body We studied a 38-year-old woman diagnosed with anxiety, depression and right sacroileitis who was treated with phenylbutazone, ranitidine, clomipramine and levomepromazine.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E3", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[272]], "entity_id": ["T24"]}, "Subject": {"text": [["a 38-year-old woman diagnosed with anxiety, depression and right sacroileitis"]], "start": [[186]], "entity_id": ["T13"], "Age": {"text": [["38-year-old"]], "start": [[188]], "entity_id": ["T17"]}, "Gender": {"text": [["woman"]], "start": [[200]], "entity_id": ["T18"]}}, "Treatment": {"text": [["phenylbutazone, ranitidine, clomipramine and levomepromazin"]], "start": [[285]], "entity_id": ["T16"], "Drug": {"text": [["phenylbutazone"], ["clomipramine"], ["levomepromazine"], ["ranitidine"]], "start": [[285], [313], [330], [301]], "entity_id": ["T19", "T20", "T21", "T22"]}, "Disorder": {"text": [["anxiety, depression and right sacroileitis"]], "start": [[221]], "entity_id": ["T25"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[326]], "entity_id": ["T23"]}, "Drug": {"text": [["levomepromazine"], ["clomipramine"], ["ranitidine"], ["phenylbutazone"]], "start": [[330], [313], [301], [285]], "entity_id": ["T21", "T20", "T22", "T19"]}}]}}]}]}
{"id": "8276031_5", "context": "The symptomatology of 18 other paediatric cases of naphthylimidazoline exposure reported to the Belgian National Poison Centre, is also discussed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["symptomatology"]], "start": [[4]], "entity_id": ["T8"]}, "Subject": {"text": [["18 other paediatric cases"]], "start": [[22]], "entity_id": ["T5"], "Population": {"text": [["18"]], "start": [[22]], "entity_id": ["T9"]}, "Age": {"text": [["paediatric"]], "start": [[31]], "entity_id": ["T10"]}}, "Effect": {"text": [["naphthylimidazoline exposure"]], "start": [[51]], "entity_id": ["T6"]}, "Treatment": {"text": [["naphthylimidazoline"]], "start": [[51]], "entity_id": ["T7"], "Drug": {"text": [["naphthylimidazoline"]], "start": [[51]], "entity_id": ["T11"]}}}]}]}
{"id": "85289_1", "context": "Anterior spinal artery syndrome--a complication of cervical intrathecal phenol injection.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[35]], "entity_id": ["T4"]}, "Effect": {"text": [["Anterior spinal artery syndrome"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["cervical intrathecal phenol injection"]], "start": [[51]], "entity_id": ["T5"], "Drug": {"text": [["phenol"]], "start": [[72]], "entity_id": ["T6"]}, "Route": {"text": [["injection"]], "start": [[79]], "entity_id": ["T7"]}}}]}]}
{"id": "3677571_16", "context": "Phenytoin was discontinued after admission; however, phenytoin 1 g i.v. was given for a tonic-clonic seizure two days after admission, after which swelling of the face and legs and pruritus developed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[190]], "entity_id": ["T7"]}, "Effect": {"text": [["swelling of the face and legs and pruritus"]], "start": [[147]], "entity_id": ["T6"]}, "Treatment": {"text": [["phenytoin 1 g i.v."]], "start": [[53]], "entity_id": ["T5"], "Disorder": {"text": [["a tonic-clonic seizure"]], "start": [[86]], "entity_id": ["T8"]}, "Drug": {"text": [["phenytoin"]], "start": [[53]], "entity_id": ["T10"]}, "Dosage": {"text": [["1 g"]], "start": [[63]], "entity_id": ["T11"]}, "Route": {"text": [["i.v."]], "start": [[67]], "entity_id": ["T12"]}}}]}]}
{"id": "11961411_3", "context": "To our knowledge this is the first report that demonstrates histological abnormalities of the glomerulus associated with postoperative IFN-beta therapy for the malignant melanoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[105]], "entity_id": ["T4"]}, "Effect": {"text": [["histological abnormalities of the glomerulus"]], "start": [[60]], "entity_id": ["T3"]}, "Treatment": {"text": [["postoperative IFN-beta therapy"]], "start": [[121]], "entity_id": ["T5"], "Drug": {"text": [["IFN-beta"]], "start": [[135]], "entity_id": ["T7"]}, "Disorder": {"text": [["malignant melanoma"]], "start": [[160]], "entity_id": ["T8"]}}}]}]}
{"id": "11020127_1", "context": "Protease inhibitor-induced carbamazepine toxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[19]], "entity_id": ["T4"]}, "Treatment": {"text": [["Protease inhibitor"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Protease inhibitor"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["carbamazepine toxicity"]], "start": [[27]], "entity_id": ["T5"]}}]}]}
{"id": "11452688_1", "context": "This report details a case of bilateral avascular necrosis of the femoral heads in a patient receiving 'standard' doses of dexamethasone as part of the antiemetic regimen used in cisplatin-based combination chemotherapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["receiving"]], "start": [[93]], "entity_id": ["T6"]}, "Effect": {"text": [["bilateral avascular necrosis of the femoral heads"]], "start": [[30]], "entity_id": ["T3"]}, "Subject": {"text": [["a patient"]], "start": [[83]], "entity_id": ["T4"]}, "Treatment": {"text": [["'standard' doses of dexamethasone"]], "start": [[103]], "entity_id": ["T5"], "Dosage": {"text": [["'standard' doses"]], "start": [[103]], "entity_id": ["T7"]}, "Drug": {"text": [["dexamethasone"]], "start": [[123]], "entity_id": ["T8"]}}}]}]}
{"id": "7679525_3", "context": "He recovered successfully after treatment with very high doses of corticosteroids and azathioprine.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["recovered"]], "start": [[3]], "entity_id": ["T7"]}, "Treatment": {"text": [["very high doses of corticosteroids and azathioprine"]], "start": [[47]], "entity_id": ["T6"], "Dosage": {"text": [["very high doses"]], "start": [[47]], "entity_id": ["T11"]}, "Drug": {"text": [["corticosteroids"], ["azathioprine"]], "start": [[66], [86]], "entity_id": ["T12", "T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[82]], "entity_id": ["T14"]}, "Drug": {"text": [["corticosteroids"], ["azathioprine"]], "start": [[66], [86]], "entity_id": ["T12", "T13"]}}]}, "Subject": {"text": [["He"]], "start": [[0]], "entity_id": ["T8"], "Gender": {"text": [["He"]], "start": [[0]], "entity_id": ["T10"]}}}]}]}
{"id": "717931_2", "context": "Marked hyperkalemia was observed during and immediately after an infusion of arginine monohydrochloride in two patients with severe hepatic disease and moderate renal insufficiency.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["observed"]], "start": [[24]], "entity_id": ["T4"]}, "Effect": {"text": [["Marked hyperkalemia"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["during and immediately after an infusion of arginine monohydrochloride"]], "start": [[33]], "entity_id": ["T5"], "Drug": {"text": [["arginine monohydrochloride"]], "start": [[77]], "entity_id": ["T10"]}, "Route": {"text": [["infusion"]], "start": [[65]], "entity_id": ["T11"]}, "Time_elapsed": {"text": [["immediately"]], "start": [[44]], "entity_id": ["T12"]}, "Disorder": {"text": [["hepatic disease"]], "start": [[132]], "entity_id": ["T13"]}}, "Subject": {"text": [["two patients with severe hepatic disease and moderate renal insufficiency"]], "start": [[107]], "entity_id": ["T6"], "Population": {"text": [["two"]], "start": [[107]], "entity_id": ["T7"]}, "Disorder": {"text": [["moderate renal insufficiency"]], "start": [[152]], "entity_id": ["T14"]}}, "Severity": {"text": [["severe"]], "start": [[125]], "entity_id": ["T15"], "value": "High"}}]}]}
{"id": "937377_1", "context": "Finally, reserpine toxicity, in particular central nervous system (CNS) disturbances, was reported more frequently in patients also receiving barbiturates, suggesting additive CNS effects.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reported"]], "start": [[90]], "entity_id": ["T4"]}, "Effect": {"text": [["reserpine toxicity, in particular central nervous system (CNS) disturbances", "additive CNS effects"]], "start": [[9, 167]], "entity_id": ["T3"]}, "Treatment": {"text": [["reserpine", "also receiving barbiturates,"]], "start": [[9, 127]], "entity_id": ["T5"], "Drug": {"text": [["barbiturates"], ["reserpine"]], "start": [[142], [9]], "entity_id": ["T6", "T7"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["also"]], "start": [[127]], "entity_id": ["T8"]}, "Drug": {"text": [["barbiturates"], ["reserpine"]], "start": [[142], [9]], "entity_id": ["T6", "T7"]}}]}}]}]}
{"id": "14740795_3", "context": "Patients receiving amifostine who develop only fever should be evaluated for an adverse drug reaction, as well as for sepsis and fevers of neutropenia, and it may be necessary to discontinue the drug.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["develop"]], "start": [[34]], "entity_id": ["T9"]}, "Treatment": {"text": [["amifostine"]], "start": [[19]], "entity_id": ["T7"], "Drug": {"text": [["amifostine"]], "start": [[19]], "entity_id": ["T10"]}}, "Effect": {"text": [["fever"], ["sepsis and fevers of neutropenia"]], "start": [[47], [118]], "entity_id": ["T8", "T11"]}}]}]}
{"id": "9215418_1", "context": "Clinical signs of hypermagnesemia are an uncommon complication following oral administration of magnesium sulfate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[50]], "entity_id": ["T4"]}, "Effect": {"text": [["hypermagnesemia"]], "start": [[18]], "entity_id": ["T3"]}, "Treatment": {"text": [["oral administration of magnesium sulfate"]], "start": [[73]], "entity_id": ["T5"], "Drug": {"text": [["magnesium sulfate"]], "start": [[96]], "entity_id": ["T6"]}, "Route": {"text": [["oral"]], "start": [[73]], "entity_id": ["T7"]}}}]}]}
{"id": "7408538_1", "context": "Markedly increased pigmementation of skin immediately overlying veins used for multiple 5-fluorouracil infusions was noted.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["noted"]], "start": [[117]], "entity_id": ["T4"]}, "Effect": {"text": [["Markedly increased pigmementation of skin immediately overlying veins"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["multiple 5-fluorouracil infusions"]], "start": [[79]], "entity_id": ["T5"], "Drug": {"text": [["5-fluorouracil"]], "start": [[88]], "entity_id": ["T6"]}, "Route": {"text": [["infusions"]], "start": [[103]], "entity_id": ["T7"]}}}]}]}
{"id": "2140997_3", "context": "Severe hepatitis caused by cyproterone acetate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[17]], "entity_id": ["T4"]}, "Effect": {"text": [["Severe hepatitis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["cyproterone acetate"]], "start": [[27]], "entity_id": ["T5"], "Drug": {"text": [["cyproterone acetate"]], "start": [[27]], "entity_id": ["T7"]}}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T6"], "value": "High"}}]}]}
{"id": "14693027_2", "context": "Erythema multiforme associated with phenytoin and cranial radiation therapy: a report of three patients and review of the literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[20]], "entity_id": ["T6"]}, "Effect": {"text": [["Erythema multiforme"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["phenytoin and cranial radiation therapy"]], "start": [[36]], "entity_id": ["T4"], "Drug": {"text": [["phenytoin"]], "start": [[36]], "entity_id": ["T8"]}}, "Subject": {"text": [["three patients"]], "start": [[89]], "entity_id": ["T5"], "Population": {"text": [["three"]], "start": [[89]], "entity_id": ["T7"]}}}]}]}
{"id": "12967198_2", "context": "Chloroquine has been used for many decades in the prophylaxis and treatment of malaria.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["of"]], "start": [[76]], "entity_id": ["T8"]}, "Treatment": {"text": [["Chloroquine"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Chloroquine"]], "start": [[0]], "entity_id": ["T9"]}, "Disorder": {"text": [["malaria"]], "start": [[79]], "entity_id": ["T10"]}}, "Effect": {"text": [["prophylaxis and treatment"]], "start": [[50]], "entity_id": ["T7"]}}]}]}
{"id": "11414270_7", "context": "Before ICU admission, the patient had suffered from painful mucositis causing severe dysphagia and bleeding, which was thought to be the result of chemotherapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["result"]], "start": [[137]], "entity_id": ["T9"]}, "Treatment": {"text": [["chemotherapy"]], "start": [[147]], "entity_id": ["T8"], "Route": {"text": [["chemotherapy"]], "start": [[147]], "entity_id": ["T13"]}}, "Effect": {"text": [["severe dysphagia and bleeding"]], "start": [[78]], "entity_id": ["T11"]}, "Subject": {"text": [["the patient had suffered from painful mucositis"]], "start": [[22]], "entity_id": ["T10"], "Disorder": {"text": [["mucositis"]], "start": [[60]], "entity_id": ["T12"]}}}]}]}
{"id": "3200786_3", "context": "We report the case of a patient with the acquired immunodeficiency syndrome treated with rifampicin who had a 'normal' screening test for adrenal insufficiency, yet had clinical evidence of adrenal failure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["had"]], "start": [[165]], "entity_id": ["T10"]}, "Subject": {"text": [["a patient with the acquired immunodeficiency syndrome"]], "start": [[22]], "entity_id": ["T7"]}, "Treatment": {"text": [["rifampicin"]], "start": [[89]], "entity_id": ["T8"], "Drug": {"text": [["rifampicin"]], "start": [[89]], "entity_id": ["T12"]}, "Disorder": {"text": [["acquired immunodeficiency syndrome"]], "start": [[41]], "entity_id": ["T13"]}}, "Effect": {"text": [["adrenal failure"]], "start": [[190]], "entity_id": ["T9"]}}]}]}
{"id": "9052919_3", "context": "We postulate that cyclosporin, possibly together with ganciclovir, can produce transient brain stem or neuromuscular dysfunction with eye movement abnormality in occasional patients.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["produce"]], "start": [[71]], "entity_id": ["T8"]}, "Treatment": {"text": [["cyclosporin", "together with ganciclovir"]], "start": [[18, 40]], "entity_id": ["T7"], "Drug": {"text": [["ganciclovir"], ["cyclosporin"]], "start": [[54], [18]], "entity_id": ["T13", "T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["together"]], "start": [[40]], "entity_id": ["T12"]}, "Drug": {"text": [["cyclosporin"], ["ganciclovir"]], "start": [[18], [54]], "entity_id": ["T14", "T13"]}}]}, "Subject": {"text": [["occasional patients"]], "start": [[162]], "entity_id": ["T10"]}, "Effect": {"text": [["transient brain stem or neuromuscular dysfunction with eye movement abnormality"]], "start": [[79]], "entity_id": ["T9"]}, "Speculated": {"text": [["postulate"]], "start": [[3]], "entity_id": ["T11"], "value": true}}]}]}
{"id": "313865_1", "context": "Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulted"]], "start": [[123]], "entity_id": ["T28"]}, "Subject": {"text": [["Three patients"]], "start": [[0]], "entity_id": ["T25"], "Population": {"text": [["Three"]], "start": [[0]], "entity_id": ["T29"]}}, "Effect": {"text": [["'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment)"]], "start": [[139]], "entity_id": ["T26"]}, "Treatment": {"text": [["cytotoxic treatment, including high dose methotrexate with folinic acid rescue"]], "start": [[43]], "entity_id": ["T27"], "Disorder": {"text": [["tumour"]], "start": [[24]], "entity_id": ["T30"]}, "Drug": {"text": [["cytotoxic"], ["methotrexate"], ["folinic acid rescue"]], "start": [[43], [84], [102]], "entity_id": ["T31", "T32", "T33"]}, "Dosage": {"text": [["high dose"]], "start": [[74]], "entity_id": ["T35"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["with"]], "start": [[97]], "entity_id": ["T34"]}, "Drug": {"text": [["folinic acid rescue"], ["methotrexate"], ["cytotoxic"]], "start": [[102], [84], [43]], "entity_id": ["T33", "T32", "T31"]}}]}}]}]}
{"id": "24846936_3", "context": "Methylene blue-associated serotonin toxicity has been described before but usually as mild toxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[15]], "entity_id": ["T6"]}, "Treatment": {"text": [["Methylene blue"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Methylene blue"]], "start": [[0]], "entity_id": ["T10"]}}, "Effect": {"text": [["serotonin toxicity"]], "start": [[26]], "entity_id": ["T7"]}, "Severity": {"text": [["mild"]], "start": [[86]], "entity_id": ["T9"], "value": "Medium"}}]}]}
{"id": "12221670_2", "context": "The second was an 82-year-old man receiving ticlopidine for 2 years when, during a febrile episode, he was found neutropenic with marrow aplasia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["found"]], "start": [[107]], "entity_id": ["T7"]}, "Effect": {"text": [["neutropenic with marrow aplasia."]], "start": [[113]], "entity_id": ["T6"]}, "Treatment": {"text": [["receiving ticlopidine for 2 years"]], "start": [[34]], "entity_id": ["T8"], "Duration": {"text": [["2 years"]], "start": [[60]], "entity_id": ["T11"]}, "Drug": {"text": [["ticlopidine"]], "start": [[44]], "entity_id": ["T12"]}}, "Subject": {"text": [["82-year-old man"]], "start": [[18]], "entity_id": ["T5"], "Age": {"text": [["82-year-old"]], "start": [[18]], "entity_id": ["T9"]}, "Gender": {"text": [["man"]], "start": [[30]], "entity_id": ["T10"]}}}]}]}
{"id": "19357764_3", "context": "INTRODUCTION: In resource limited settings patients on antiretroviral treatment who develop stavudine induced hyperlactatemia are often switched to zidovudine on the basis of published studies that demonstrate that this agent can be a safe alternative.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[102]], "entity_id": ["T4"]}, "Treatment": {"text": [["stavudine"]], "start": [[92]], "entity_id": ["T9"], "Drug": {"text": [["stavudine"]], "start": [[92]], "entity_id": ["T7"]}}, "Effect": {"text": [["hyperlactatemia"]], "start": [[110]], "entity_id": ["T5"]}, "Subject": {"text": [["patients on antiretroviral treatment"]], "start": [[43]], "entity_id": ["T6"]}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["switched"]], "start": [[136]], "entity_id": ["T13"]}, "Subject": {"text": [["patients on antiretroviral treatment"]], "start": [[43]], "entity_id": ["T6"]}, "Treatment": {"text": [["zidovudine"]], "start": [[148]], "entity_id": ["T10"], "Drug": {"text": [["zidovudine"]], "start": [[148]], "entity_id": ["T11"]}, "Disorder": {"text": [["stavudine induced hyperlactatemia"]], "start": [[92]], "entity_id": ["T12"]}}}]}]}
{"id": "18633310_3", "context": "We report a case of pediatric bupropion ingestion resulting in multiple seizures.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulting"]], "start": [[50]], "entity_id": ["T5"]}, "Subject": {"text": [["pediatric"]], "start": [[20]], "entity_id": ["T3"], "Age": {"text": [["pediatric"]], "start": [[20]], "entity_id": ["T9"]}}, "Treatment": {"text": [["bupropion ingestion"]], "start": [[30]], "entity_id": ["T4"], "Drug": {"text": [["bupropion"]], "start": [[30]], "entity_id": ["T7"]}, "Route": {"text": [["ingestion"]], "start": [[40]], "entity_id": ["T8"]}}, "Effect": {"text": [["multiple seizures"]], "start": [[63]], "entity_id": ["T6"]}}]}]}
{"id": "18676387_8", "context": "The co-administration of SSRIs and fentanyl may precipitate serotonin toxicity.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["precipitate"]], "start": [[48]], "entity_id": ["T7"]}, "Effect": {"text": [["serotonin toxicity"]], "start": [[60]], "entity_id": ["T9"]}, "Treatment": {"text": [["co-administration of SSRIs and fentanyl"]], "start": [[4]], "entity_id": ["T10"], "Drug": {"text": [["SSRIs"], ["fentanyl"]], "start": [[25], [35]], "entity_id": ["T11", "T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["co-administration"]], "start": [[4]], "entity_id": ["T13"]}, "Drug": {"text": [["SSRIs"], ["fentanyl"]], "start": [[25], [35]], "entity_id": ["T11", "T12"]}}]}, "Speculated": {"text": [["may"]], "start": [[44]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "19707032_5", "context": "Three days after intravitreal injection of bevacizumab, acute ocular ischemic syndrome occurred.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurred"]], "start": [[87]], "entity_id": ["T5"]}, "Treatment": {"text": [["Three days after intravitreal injection of bevacizumab"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["bevacizumab"]], "start": [[43]], "entity_id": ["T6"]}, "Route": {"text": [["intravitreal injection"]], "start": [[17]], "entity_id": ["T7"]}, "Time_elapsed": {"text": [["Three days"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["acute ocular ischemic syndrome"]], "start": [[56]], "entity_id": ["T4"]}}]}]}
{"id": "18453852_10", "context": "After addition of lopinavir/ritonavir, eight volunteers suffered from both nausea and vomiting, one from nausea only, and one from vomiting only.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["After"]], "start": [[0]], "entity_id": ["T14"]}, "Treatment": {"text": [["lopinavir/ritonavir"]], "start": [[18]], "entity_id": ["T12"], "Drug": {"text": [["lopinavir"], ["ritonavir"]], "start": [[18], [28]], "entity_id": ["T18", "T19"]}, "Combination": [{"event_id": "E1", "event_type": "Combination", "Trigger": {"text": [["/"]], "start": [[27]], "entity_id": ["T20"]}, "Drug": {"text": [["lopinavir"], ["ritonavir"]], "start": [[18], [28]], "entity_id": ["T18", "T19"]}}]}, "Subject": {"text": [["eight volunteers"]], "start": [[39]], "entity_id": ["T13"], "Population": {"text": [["eight"]], "start": [[39]], "entity_id": ["T16"]}}, "Effect": {"text": [["nausea and vomiting"]], "start": [[75]], "entity_id": ["T15"]}}, {"event_id": "E3", "event_type": "Adverse_event", "Trigger": {"text": [["After"]], "start": [[0]], "entity_id": ["T14"]}, "Treatment": {"text": [["lopinavir/ritonavir"]], "start": [[18]], "entity_id": ["T12"], "Drug": {"text": [["lopinavir"], ["ritonavir"]], "start": [[18], [28]], "entity_id": ["T18", "T19"]}}, "Subject": {"text": [["one"]], "start": [[122]], "entity_id": ["T23"], "Population": {"text": [["one"]], "start": [[122]], "entity_id": ["T24"]}}, "Effect": {"text": [["vomiting"]], "start": [[131]], "entity_id": ["T26"]}}, {"event_id": "E4", "event_type": "Adverse_event", "Trigger": {"text": [["After"]], "start": [[0]], "entity_id": ["T14"]}, "Treatment": {"text": [["lopinavir/ritonavir"]], "start": [[18]], "entity_id": ["T12"], "Drug": {"text": [["lopinavir"], ["ritonavir"]], "start": [[18], [28]], "entity_id": ["T18", "T19"]}}, "Subject": {"text": [["one"]], "start": [[96]], "entity_id": ["T21"], "Population": {"text": [["one"]], "start": [[96]], "entity_id": ["T22"]}}, "Effect": {"text": [["nausea"]], "start": [[105]], "entity_id": ["T25"]}}]}]}
{"id": "10357715_2", "context": "Calcipotriol (Daivonex R; Leo Pharmaceuticals, Zurich, Switzerland) may cause irritation of the skin, whereas allergic reactions are less common.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[72]], "entity_id": ["T6"]}, "Effect": {"text": [["irritation of the skin"]], "start": [[78]], "entity_id": ["T5"]}, "Treatment": {"text": [["Calcipotriol"]], "start": [[0]], "entity_id": ["T7"], "Drug": {"text": [["Calcipotriol"]], "start": [[0]], "entity_id": ["T9"]}}, "Speculated": {"text": [["may"]], "start": [[68]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "2309833_1", "context": "After discontinuation of danazol the diabetes completely resolved.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["resolved"]], "start": [[57]], "entity_id": ["T5"]}, "Treatment": {"text": [["discontinuation of danazo"]], "start": [[6]], "entity_id": ["T3"], "Disorder": {"text": [["diabetes"]], "start": [[37]], "entity_id": ["T4"]}, "Drug": {"text": [["danazol"]], "start": [[25]], "entity_id": ["T6"]}}}]}]}
{"id": "15977922_3", "context": "We describe the development of ischemic colitis in a woman who was treated with tegaserod and review the relationship among ischemic colitis, tegaserod use, and irritable bowel syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["development"]], "start": [[16]], "entity_id": ["T10"]}, "Subject": {"text": [["woman"]], "start": [[53]], "entity_id": ["T9"], "Gender": {"text": [["woman"]], "start": [[53]], "entity_id": ["T13"]}}, "Effect": {"text": [["ischemic colitis"]], "start": [[31]], "entity_id": ["T11"]}, "Treatment": {"text": [["tegaserod"]], "start": [[80]], "entity_id": ["T12"], "Drug": {"text": [["tegaserod"]], "start": [[80]], "entity_id": ["T14"]}}}]}]}
{"id": "11834188_4", "context": "We presented the case of a patient who developed a cutaneous reaction induced by captopril with positive patch test.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[70]], "entity_id": ["T5"]}, "Subject": {"text": [["a patient"]], "start": [[25]], "entity_id": ["T3"]}, "Effect": {"text": [["cutaneous reaction"]], "start": [[51]], "entity_id": ["T4"]}, "Treatment": {"text": [["captopril"]], "start": [[81]], "entity_id": ["T6"], "Drug": {"text": [["captopril"]], "start": [[81]], "entity_id": ["T7"]}}}]}]}
{"id": "11033734_4", "context": "Three of these patients had convulsions attributed to imipenem/cilastatin; 3.6% of the patients had seizure, or 2% of imipenem/cilastatin administrations was followed by a seizure attack.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["attributed"]], "start": [[40]], "entity_id": ["T11"]}, "Subject": {"text": [["Three of these patients"]], "start": [[0]], "entity_id": ["T9"], "Population": {"text": [["Three"]], "start": [[0]], "entity_id": ["T14"]}}, "Treatment": {"text": [["imipenem/cilastatin"]], "start": [[54]], "entity_id": ["T12"], "Drug": {"text": [["imipenem"], ["cilastatin"]], "start": [[54], [63]], "entity_id": ["T15", "T16"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["/"]], "start": [[62]], "entity_id": ["T17"]}, "Drug": {"text": [["imipenem"], ["cilastatin"]], "start": [[54], [63]], "entity_id": ["T15", "T16"]}}]}, "Effect": {"text": [["convulsions"]], "start": [[28]], "entity_id": ["T10"]}}, {"event_id": "E4", "event_type": "Adverse_event", "Trigger": {"text": [["followed"]], "start": [[158]], "entity_id": ["T24"]}, "Subject": {"text": [["2%"]], "start": [[112]], "entity_id": ["T18"], "Population": {"text": [["2%"]], "start": [[112]], "entity_id": ["T19"]}}, "Treatment": {"text": [["imipenem/cilastatin"]], "start": [[118]], "entity_id": ["T20"], "Drug": {"text": [["imipenem"], ["cilastatin"]], "start": [[118], [127]], "entity_id": ["T22", "T23"]}, "Combination": [{"event_id": "E3", "event_type": "Combination", "Trigger": {"text": [["/"]], "start": [[126]], "entity_id": ["T21"]}, "Drug": {"text": [["imipenem"], ["cilastatin"]], "start": [[118], [127]], "entity_id": ["T22", "T23"]}}]}, "Effect": {"text": [["seizure"]], "start": [[172]], "entity_id": ["T25"]}}]}]}
{"id": "16225183_10", "context": "This latest (third) report suggests that the safety profile should be reexamined and at least raises the question of potential renal toxicity of interferons in MS.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["raises"]], "start": [[94]], "entity_id": ["T11"]}, "Effect": {"text": [["potential renal toxicity"]], "start": [[117]], "entity_id": ["T7"]}, "Treatment": {"text": [["interferons"]], "start": [[145]], "entity_id": ["T8"], "Drug": {"text": [["interferons"]], "start": [[145]], "entity_id": ["T9"]}, "Disorder": {"text": [["MS"]], "start": [[160]], "entity_id": ["T12"]}}, "Speculated": {"text": [["potential"]], "start": [[117]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "3101617_1", "context": "Co-trimoxazole red cell aplasia in leukaemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[32]], "entity_id": ["T6"]}, "Treatment": {"text": [["Co-trimoxazole"]], "start": [[0]], "entity_id": ["T4"], "Disorder": {"text": [["leukaemia"]], "start": [[35]], "entity_id": ["T3"]}, "Drug": {"text": [["Co-trimoxazole"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["red cell aplasia"]], "start": [[15]], "entity_id": ["T5"]}}]}]}
{"id": "12639299_1", "context": "Interferon-alpha (IFN-alpha) may precipitate or exacerbate the occurrence of MPGN.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurrence"]], "start": [[63]], "entity_id": ["T5"]}, "Treatment": {"text": [["Interferon-alpha (IFN-alpha)"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Interferon-alpha (IFN-alpha)"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["MPGN"]], "start": [[77]], "entity_id": ["T6"]}, "Speculated": {"text": [["may"]], "start": [[29]], "entity_id": ["T8"], "value": true}, "Severity": {"text": [["precipitate or exacerbate"]], "start": [[33]], "entity_id": ["T9"], "value": "Medium"}}]}]}
{"id": "11207969_3", "context": "Toxic epidermal necrolysis after the use of high-dose cytosine arabinoside.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[27]], "entity_id": ["T5"]}, "Treatment": {"text": [["high-dose cytosine arabinoside"]], "start": [[44]], "entity_id": ["T3"], "Drug": {"text": [["cytosine arabinoside"]], "start": [[54]], "entity_id": ["T6"]}}, "Effect": {"text": [["Toxic epidermal necrolysis"]], "start": [[0]], "entity_id": ["T4"]}}]}]}
{"id": "10981493_4", "context": "We describe 3 elderly patients with moderate to severe ataxia that occurred while they were taking propafenone.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurred"]], "start": [[67]], "entity_id": ["T6"]}, "Effect": {"text": [["moderate to severe ataxia"]], "start": [[36]], "entity_id": ["T3"]}, "Treatment": {"text": [["taking propafenone"]], "start": [[92]], "entity_id": ["T4"], "Drug": {"text": [["propafenone"]], "start": [[99]], "entity_id": ["T9"]}}, "Subject": {"text": [["3 elderly patients"]], "start": [[12]], "entity_id": ["T5"], "Age": {"text": [["elderly"]], "start": [[14]], "entity_id": ["T7"]}, "Population": {"text": [["3"]], "start": [[12]], "entity_id": ["T8"]}}}]}]}
{"id": "1445134_1", "context": "Gestational diabetes was no less severe (degree of hyperglycaemia, need for insulin therapy) when associated with norethisterone.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[98]], "entity_id": ["T5"]}, "Effect": {"text": [["Gestational diabetes"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["norethisterone"]], "start": [[114]], "entity_id": ["T4"], "Drug": {"text": [["norethisterone"]], "start": [[114]], "entity_id": ["T6"]}}, "Severity": {"text": [["no less severe"]], "start": [[25]], "entity_id": ["T7"], "value": "Medium"}}]}]}
{"id": "1445134_2", "context": "However, follow-up revealed that gestational diabetes when associated with norethisterone had a lesser risk of emerging diabetes mellitus and impaired glucose tolerance.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["emerging"]], "start": [[111]], "entity_id": ["T7"]}, "Effect": {"text": [["diabetes mellitus and impaired glucose tolerance"]], "start": [[120]], "entity_id": ["T8"]}, "Treatment": {"text": [["norethisterone"]], "start": [[75]], "entity_id": ["T9"], "Drug": {"text": [["norethisterone"]], "start": [[75]], "entity_id": ["T10"]}}, "Severity": {"text": [["lesser risk"]], "start": [[96]], "entity_id": ["T11"], "value": "Low"}}]}]}
{"id": "3470173_1", "context": "Because the cerebellar toxicity may be worsened by continuation of therapy after initial onset of symptoms, prompt termination of HDARAC is recommended.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["of"]], "start": [[127]], "entity_id": ["T5"]}, "Effect": {"text": [["cerebellar toxicity"]], "start": [[12]], "entity_id": ["T3"]}, "Treatment": {"text": [["HDARAC"]], "start": [[130]], "entity_id": ["T4"], "Drug": {"text": [["HDARAC"]], "start": [[130]], "entity_id": ["T6"]}}}]}]}
{"id": "2746565_3", "context": "We describe a case of ulcerative proctitis after ibuprofen treatment in a girl with juvenile systemic lupus erythematosus.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[43]], "entity_id": ["T3"]}, "Treatment": {"text": [["ibuprofen treatment"]], "start": [[49]], "entity_id": ["T4"], "Drug": {"text": [["ibuprofen"]], "start": [[49]], "entity_id": ["T9"]}, "Disorder": {"text": [["juvenile systemic lupus erythematosus"]], "start": [[84]], "entity_id": ["T10"]}}, "Effect": {"text": [["ulcerative proctitis"]], "start": [[22]], "entity_id": ["T5"]}, "Subject": {"text": [["a girl with juvenile systemic lupus erythematosus"]], "start": [[72]], "entity_id": ["T6"], "Gender": {"text": [["girl"]], "start": [[74]], "entity_id": ["T7"]}}}]}]}
{"id": "9337441_18", "context": "Clinicians should include phenolphthalein in their list of possible causes of drug-induced TEN.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[83]], "entity_id": ["T6"]}, "Treatment": {"text": [["phenolphthalein"]], "start": [[26]], "entity_id": ["T7"], "Drug": {"text": [["phenolphthalein"]], "start": [[26]], "entity_id": ["T9"]}}, "Effect": {"text": [["TEN"]], "start": [[91]], "entity_id": ["T8"]}, "Speculated": {"text": [["possible"]], "start": [[59]], "entity_id": ["T5"], "value": true}}]}]}
{"id": "424824_4", "context": "Methotrexate-induced diffuse interstitial pulmonary fibrosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[13]], "entity_id": ["T4"]}, "Treatment": {"text": [["Methotrexate"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Methotrexate"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["diffuse interstitial pulmonary fibrosis"]], "start": [[21]], "entity_id": ["T5"]}}]}]}
{"id": "16008658_2", "context": "Abdominal wall ulceration and mucinosis secondary to recombinant human interferon-beta-1b.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["secondary"]], "start": [[40]], "entity_id": ["T5"]}, "Effect": {"text": [["Abdominal wall ulceration and mucinosis"]], "start": [[0]], "entity_id": ["T6"]}, "Treatment": {"text": [["recombinant human interferon-beta-1b"]], "start": [[53]], "entity_id": ["T7"], "Drug": {"text": [["recombinant human interferon-beta-1b"]], "start": [[53]], "entity_id": ["T8"]}}}]}]}
{"id": "15661067_1", "context": "Asthenozoospermia: possible association with long-term exposure to an anti-epileptic drug of carbamazepine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["association"]], "start": [[28]], "entity_id": ["T3"]}, "Effect": {"text": [["Asthenozoospermia"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["long-term exposure to an anti-epileptic drug of carbamazepine"]], "start": [[45]], "entity_id": ["T6"], "Drug": {"text": [["carbamazepine"]], "start": [[93]], "entity_id": ["T8"]}, "Duration": {"text": [["long-term"]], "start": [[45]], "entity_id": ["T9"]}}, "Speculated": {"text": [["possible"]], "start": [[19]], "entity_id": ["T4"], "value": true}}]}]}
{"id": "15611427_2", "context": "Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["triggered"]], "start": [[10]], "entity_id": ["T5"]}, "Effect": {"text": [["Psoriasis"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["imiquimod"]], "start": [[52]], "entity_id": ["T6"], "Disorder": {"text": [["dermal plasmacytoid dendritic cell precursors"]], "start": [[81]], "entity_id": ["T3"]}, "Drug": {"text": [["imiquimod"]], "start": [[52]], "entity_id": ["T7"]}}}]}]}
{"id": "6414095_3", "context": "A 52-year-old Black woman on phenytoin therapy for post-traumatic epilepsy developed transient hemiparesis contralateral to the injury.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[75]], "entity_id": ["T7"]}, "Effect": {"text": [["transient hemiparesis contralateral to the injury"]], "start": [[85]], "entity_id": ["T8"]}, "Treatment": {"text": [["phenytoin"]], "start": [[29]], "entity_id": ["T9"], "Disorder": {"text": [["post-traumatic epilepsy"]], "start": [[51]], "entity_id": ["T10"]}, "Drug": {"text": [["phenytoin"]], "start": [[29]], "entity_id": ["T16"]}}, "Subject": {"text": [["A 52-year-old Black woman"]], "start": [[0]], "entity_id": ["T11"], "Age": {"text": [["52-year-old"]], "start": [[2]], "entity_id": ["T12"]}, "Race": {"text": [["Black"]], "start": [[14]], "entity_id": ["T13"]}, "Gender": {"text": [["woman"]], "start": [[20]], "entity_id": ["T14"]}}, "Severity": {"text": [["transient"]], "start": [[85]], "entity_id": ["T15"], "value": "Low"}}]}]}
{"id": "18648015_4", "context": "Use of the Naranjo probability scale determined the association between cephalosporin use and leukopenia to be probable.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["use"]], "start": [[86]], "entity_id": ["T3"]}, "Treatment": {"text": [["cephalosporin"]], "start": [[72]], "entity_id": ["T4"], "Drug": {"text": [["cephalosporin"]], "start": [[72]], "entity_id": ["T6"]}}, "Effect": {"text": [["leukopenia"]], "start": [[94]], "entity_id": ["T5"]}, "Speculated": {"text": [["probable"]], "start": [[111]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "6142995_2", "context": "Sister chromatid exchanges (SCEs), a sensitive measure of chromosome damage, were counted in peripheral-blood lymphocytes from 10 patients with Behcet's syndrome receiving chlorambucil.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["receiving"]], "start": [[162]], "entity_id": ["T10"]}, "Subject": {"text": [["10 patients with Behcet's syndrome"]], "start": [[127]], "entity_id": ["T8"], "Population": {"text": [["10"]], "start": [[127]], "entity_id": ["T12"]}}, "Treatment": {"text": [["chlorambucil"]], "start": [[172]], "entity_id": ["T9"], "Disorder": {"text": [["Behcet's syndrome"]], "start": [[144]], "entity_id": ["T13"]}, "Drug": {"text": [["chlorambucil"]], "start": [[172]], "entity_id": ["T14"]}}, "Effect": {"text": [["chromosome damage"]], "start": [[58]], "entity_id": ["T11"]}}]}]}
{"id": "876914_2", "context": "Sarcoma complicating therapy with cyclophosphamide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complicating"]], "start": [[8]], "entity_id": ["T5"]}, "Effect": {"text": [["Sarcoma"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["cyclophosphamide"]], "start": [[34]], "entity_id": ["T4"], "Drug": {"text": [["cyclophosphamide"]], "start": [[34]], "entity_id": ["T6"]}}}]}]}
{"id": "9260733_1", "context": "Clozapine induced polyserositis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[10]], "entity_id": ["T4"]}, "Treatment": {"text": [["Clozapine"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Clozapine"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["polyserositis"]], "start": [[18]], "entity_id": ["T5"]}}]}]}
{"id": "20298401_1", "context": "Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[32]], "entity_id": ["T8"]}, "Effect": {"text": [["interstitial lung disease"]], "start": [[6]], "entity_id": ["T7"]}, "Treatment": {"text": [["erlotinib"]], "start": [[38]], "entity_id": ["T9"], "Drug": {"text": [["erlotinib"]], "start": [[38]], "entity_id": ["T13"]}}, "Subject": {"text": [["a patient with radiation fibrosis"]], "start": [[66]], "entity_id": ["T10"], "Disorder": {"text": [["radiation fibrosis"]], "start": [[81]], "entity_id": ["T11"]}}, "Severity": {"text": [["Fatal"]], "start": [[0]], "entity_id": ["T12"], "value": "Medium"}}]}]}
{"id": "8586895_4", "context": "The pharmaceutical company producing Halfan has reported 8 cardiac arrests, leading to 6 deaths, when a higher dose than recommended was used, there was recent or concomitant treatment with mefloquine, there was pre-existing prolongation of the QT interval or the patient had a thiamine deficiency.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reported"]], "start": [[48]], "entity_id": ["T8"]}, "Treatment": {"text": [["Halfan", "when a higher dose than recommended was used"]], "start": [[37, 97]], "entity_id": ["T9"], "Drug": {"text": [["Halfan"], ["mefloquine"]], "start": [[37], [190]], "entity_id": ["T10", "T12"]}, "Dosage": {"text": [["a higher dose than recommended"]], "start": [[102]], "entity_id": ["T11"]}}, "Effect": {"text": [["8 cardiac arrests", "6 deaths"]], "start": [[57, 87]], "entity_id": ["T7"]}}]}]}
{"id": "1477441_2", "context": "CONCLUSIONS: Fixed drug rash induced by methylphenidate is a possible but rare phenomenon.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[29]], "entity_id": ["T4"]}, "Effect": {"text": [["Fixed drug rash"]], "start": [[13]], "entity_id": ["T3"]}, "Treatment": {"text": [["methylphenidate"]], "start": [[40]], "entity_id": ["T5"], "Drug": {"text": [["methylphenidate"]], "start": [[40]], "entity_id": ["T6"]}}}]}]}
{"id": "11399735_2", "context": "Special care should be taken when pulmonary symptoms appear in association with ticlopidine treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["appear"]], "start": [[53]], "entity_id": ["T4"]}, "Effect": {"text": [["pulmonary symptoms"]], "start": [[34]], "entity_id": ["T3"]}, "Treatment": {"text": [["ticlopidine treatment"]], "start": [[80]], "entity_id": ["T5"], "Drug": {"text": [["ticlopidine"]], "start": [[80]], "entity_id": ["T6"]}}}]}]}
{"id": "11722307_2", "context": "CONCLUSION: Although a definite association has not been proven, clinicians should be aware of the possibility of agranulocytosis while using quetiapine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["using"]], "start": [[136]], "entity_id": ["T6"]}, "Treatment": {"text": [["quetiapine"]], "start": [[142]], "entity_id": ["T3"], "Drug": {"text": [["quetiapine"]], "start": [[142]], "entity_id": ["T7"]}}, "Effect": {"text": [["agranulocytosis"]], "start": [[114]], "entity_id": ["T4"]}, "Speculated": {"text": [["possibility"]], "start": [[99]], "entity_id": ["T5"], "value": true}}]}]}
{"id": "19203515_2", "context": "Acute renal failure is a rare complication following the administration of intravenous immunoglobulin (IVIG).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[30]], "entity_id": ["T4"]}, "Effect": {"text": [["Acute renal failure"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["intravenous immunoglobulin (IVIG)"]], "start": [[75]], "entity_id": ["T5"], "Route": {"text": [["intravenous"]], "start": [[75]], "entity_id": ["T6"]}, "Drug": {"text": [["immunoglobulin"]], "start": [[87]], "entity_id": ["T7"]}}}]}]}
{"id": "1751354_3", "context": "We report four patients, three of whom first developed psoriasis and one who had an aggravation of the condition during treatment with interferon-alpha.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[130]], "entity_id": ["T5"]}, "Subject": {"text": [["one"]], "start": [[69]], "entity_id": ["T6"], "Population": {"text": [["one"]], "start": [[69]], "entity_id": ["T7"]}}, "Effect": {"text": [["had an aggravation of the condition"]], "start": [[77]], "entity_id": ["T12"]}, "Treatment": {"text": [["interferon-alpha"]], "start": [[135]], "entity_id": ["T4"], "Drug": {"text": [["interferon-alpha"]], "start": [[135]], "entity_id": ["T8"]}}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[45]], "entity_id": ["T11"]}, "Treatment": {"text": [["interferon-alpha"]], "start": [[135]], "entity_id": ["T4"], "Drug": {"text": [["interferon-alpha"]], "start": [[135]], "entity_id": ["T8"]}}, "Subject": {"text": [["three"]], "start": [[25]], "entity_id": ["T9"], "Population": {"text": [["three"]], "start": [[25]], "entity_id": ["T10"]}}, "Effect": {"text": [["psoriasis"]], "start": [[55]], "entity_id": ["T3"]}}]}]}
{"id": "1661260_1", "context": "Reactivation of cytomegalovirus probably followed the treatment of Wegener's granulomatosis with corticosteroids and azathioprine.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["followed"]], "start": [[41]], "entity_id": ["T3"]}, "Effect": {"text": [["Reactivation of cytomegalovirus"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["corticosteroids and azathioprine"]], "start": [[97]], "entity_id": ["T5"], "Disorder": {"text": [["Wegener's granulomatosis"]], "start": [[67]], "entity_id": ["T6"]}, "Drug": {"text": [["corticosteroids"], ["azathioprine"]], "start": [[97], [117]], "entity_id": ["T7", "T8"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[113]], "entity_id": ["T9"]}, "Drug": {"text": [["corticosteroids"], ["azathioprine"]], "start": [[97], [117]], "entity_id": ["T7", "T8"]}}]}, "Speculated": {"text": [["probably"]], "start": [[32]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "8771575_5", "context": "We present a case of respiratory failure occurring in a woman at 16 weeks' gestation who was being treated with nitrofurantoin for a urinary tract infection.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurring"]], "start": [[41]], "entity_id": ["T4"]}, "Effect": {"text": [["respiratory failure"]], "start": [[21]], "entity_id": ["T3"]}, "Subject": {"text": [["a woman at 16 weeks' gestation"]], "start": [[54]], "entity_id": ["T5"], "Gender": {"text": [["woman"]], "start": [[56]], "entity_id": ["T7"]}, "Disorder": {"text": [["16 weeks' gestation"]], "start": [[65]], "entity_id": ["T8"]}}, "Treatment": {"text": [["being treated with nitrofurantoin for a urinary tract infection"]], "start": [[93]], "entity_id": ["T6"], "Drug": {"text": [["nitrofurantoin"]], "start": [[112]], "entity_id": ["T9"]}, "Disorder": {"text": [["urinary tract infection"]], "start": [[133]], "entity_id": ["T10"]}}}]}]}
{"id": "10963515_2", "context": "We describe a case of EGE manifested as an allergy to gemfibrozil.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["manifested"]], "start": [[26]], "entity_id": ["T6"]}, "Subject": {"text": [["a case of EGE"]], "start": [[12]], "entity_id": ["T3"], "Disorder": {"text": [["EGE"]], "start": [[22]], "entity_id": ["T4"]}}, "Treatment": {"text": [["gemfibrozil"]], "start": [[54]], "entity_id": ["T5"], "Drug": {"text": [["gemfibrozil"]], "start": [[54]], "entity_id": ["T8"]}}, "Effect": {"text": [["allergy"]], "start": [[43]], "entity_id": ["T7"]}}]}]}
{"id": "7724306_7", "context": "RESULTS: At our institution, no children appeared with acute INH neurotoxicity in the period 1985 through 1990, whereas seven patients were treated from 1991 through 1993.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["appeared with"]], "start": [[41]], "entity_id": ["T5"]}, "Treatment": {"text": [["INH"]], "start": [[61]], "entity_id": ["T3"], "Drug": {"text": [["INH"]], "start": [[61]], "entity_id": ["T9"]}}, "Effect": {"text": [["neurotoxicity"]], "start": [[65]], "entity_id": ["T4"]}, "Subject": {"text": [["children"]], "start": [[32]], "entity_id": ["T6"], "Age": {"text": [["children"]], "start": [[32]], "entity_id": ["T8"]}}}]}]}
{"id": "7249424_3", "context": "Two patients on long-term lithium therapy developed the nephrotic syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[42]], "entity_id": ["T5"]}, "Subject": {"text": [["Two patients"]], "start": [[0]], "entity_id": ["T3"], "Population": {"text": [["Two"]], "start": [[0]], "entity_id": ["T7"]}}, "Treatment": {"text": [["long-term lithium therapy"]], "start": [[16]], "entity_id": ["T4"], "Drug": {"text": [["lithium"]], "start": [[26]], "entity_id": ["T8"]}}, "Effect": {"text": [["nephrotic syndrome"]], "start": [[56]], "entity_id": ["T6"]}}]}]}
{"id": "12875956_1", "context": "Acute psychosis associated with levetiracetam.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[16]], "entity_id": ["T4"]}, "Effect": {"text": [["Acute psychosis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["levetiracetam"]], "start": [[32]], "entity_id": ["T5"], "Drug": {"text": [["levetiracetam"]], "start": [[32]], "entity_id": ["T6"]}}}]}]}
{"id": "19365885_2", "context": "Hypoglycemia induced by long-acting somatostatin analogues in a patient with nonfunctional neuroendocrine tumor.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[13]], "entity_id": ["T4"]}, "Subject": {"text": [["a patient with nonfunctional neuroendocrine tumor"]], "start": [[62]], "entity_id": ["T3"]}, "Effect": {"text": [["Hypoglycemia"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["long-acting somatostatin analogues"]], "start": [[24]], "entity_id": ["T6"], "Disorder": {"text": [["nonfunctional neuroendocrine tumor"]], "start": [[77]], "entity_id": ["T7"]}, "Drug": {"text": [["long-acting somatostatin analogues"]], "start": [[24]], "entity_id": ["T8"]}}}]}]}
{"id": "15157248_2", "context": "CASE REPORT: We report a patient who developed a DAT-positive hemolytic episode after a red cell (RBC) transfusion was delivered during the infusion of her 17th cycle of oxaliplatin.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[80]], "entity_id": ["T6"]}, "Subject": {"text": [["a patient"]], "start": [[23]], "entity_id": ["T3"]}, "Effect": {"text": [["developed a DAT-positive hemolytic episode"]], "start": [[37]], "entity_id": ["T4"]}, "Treatment": {"text": [["a red cell (RBC) transfusion was delivered during the infusion of her 17th cycle of oxaliplatin"]], "start": [[86]], "entity_id": ["T5"], "Drug": {"text": [["oxaliplatin"], ["a red cell"]], "start": [[170], [86]], "entity_id": ["T7", "T11"]}, "Route": {"text": [["infusion"], ["transfusion"]], "start": [[140], [103]], "entity_id": ["T9", "T10"]}, "Duration": {"text": [["17th cycle"]], "start": [[156]], "entity_id": ["T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["during"]], "start": [[129]], "entity_id": ["T8"]}, "Drug": {"text": [["oxaliplatin"], ["a red cell"]], "start": [[170], [86]], "entity_id": ["T7", "T11"]}}]}}]}]}
{"id": "8313300_8", "context": "Regression of thyrotoxic ophthalmopathy following lithium withdrawal.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["Regression"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["lithium withdrawal"]], "start": [[50]], "entity_id": ["T5"], "Drug": {"text": [["lithium"]], "start": [[50]], "entity_id": ["T8"]}, "Disorder": {"text": [["thyrotoxic ophthalmopathy"]], "start": [[14]], "entity_id": ["T4"]}}}]}]}
{"id": "14700673_2", "context": "Mechanism of topiramate-induced acute-onset myopia and angle closure glaucoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[24]], "entity_id": ["T6"]}, "Treatment": {"text": [["topiramate"]], "start": [[13]], "entity_id": ["T5"], "Drug": {"text": [["topiramate"]], "start": [[13]], "entity_id": ["T8"]}}, "Effect": {"text": [["acute-onset myopia and angle closure glaucoma"]], "start": [[32]], "entity_id": ["T7"]}}]}]}
{"id": "17610180_1", "context": "The clinical symptoms of gastric mucosa foveolar hyperplasia due to long-term PGE1 therapy simulate hypertrophic pyloric stenosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[61]], "entity_id": ["T5"]}, "Effect": {"text": [["gastric mucosa foveolar hyperplasia", "simulate hypertrophic pyloric stenosis"]], "start": [[25, 91]], "entity_id": ["T3"]}, "Treatment": {"text": [["long-term PGE1 therapy"]], "start": [[68]], "entity_id": ["T4"], "Drug": {"text": [["PGE1"]], "start": [[78]], "entity_id": ["T6"]}, "Duration": {"text": [["long-term"]], "start": [[68]], "entity_id": ["T7"]}}}]}]}
{"id": "7831179_1", "context": "Aggressive management of doxorubicin-induced cardiomyopathy associated with 'low' doses of doxorubicin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[37]], "entity_id": ["T5"]}, "Treatment": {"text": [["doxorubicin", "'low' doses"]], "start": [[25, 76]], "entity_id": ["T4"], "Drug": {"text": [["doxorubicin"]], "start": [[25]], "entity_id": ["T7"]}, "Dosage": {"text": [["'low' doses"]], "start": [[76]], "entity_id": ["T8"]}}, "Effect": {"text": [["cardiomyopathy"]], "start": [[45]], "entity_id": ["T6"]}}]}]}
{"id": "8157823_1", "context": "Generalized argyria after habitual use of AgNO3.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[20]], "entity_id": ["T4"]}, "Treatment": {"text": [["habitual use of AgNO3"]], "start": [[26]], "entity_id": ["T3"], "Drug": {"text": [["AgNO3"]], "start": [[42]], "entity_id": ["T6"]}}, "Effect": {"text": [["Generalized argyria"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "12187348_3", "context": "The authors report the first case of bucillamine-induced giant mammary hyperplasia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[49]], "entity_id": ["T5"]}, "Treatment": {"text": [["bucillamine"]], "start": [[37]], "entity_id": ["T4"], "Drug": {"text": [["bucillamine"]], "start": [[37]], "entity_id": ["T8"]}}, "Effect": {"text": [["giant mammary hyperplasia"]], "start": [[57]], "entity_id": ["T6"]}, "Speculated": {"text": [["first"]], "start": [[23]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "10589077_1", "context": "Hydroxyurea (HU) and sodium phenylbutyrate (SPB) have been shown to increase fetal hemoglobin (Hb F) levels in patients with thalassemia intermedia.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["increase"]], "start": [[68]], "entity_id": ["T7"]}, "Treatment": {"text": [["Hydroxyurea (HU) and sodium phenylbutyrate (SPB)"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Hydroxyurea"], ["sodium phenylbutyrate"]], "start": [[0], [21]], "entity_id": ["T9", "T10"]}, "Disorder": {"text": [["thalassemia intermedia"]], "start": [[125]], "entity_id": ["T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[17]], "entity_id": ["T11"]}, "Drug": {"text": [["Hydroxyurea"], ["sodium phenylbutyrate"]], "start": [[0], [21]], "entity_id": ["T9", "T10"]}}]}, "Effect": {"text": [["hemoglobin (Hb F) levels"]], "start": [[83]], "entity_id": ["T5"]}, "Subject": {"text": [["patients with thalassemia intermedia"]], "start": [[111]], "entity_id": ["T6"]}, "Severity": {"text": [["fetal"]], "start": [[77]], "entity_id": ["T13"], "value": "High"}}]}]}
{"id": "1954704_2", "context": "We report a case of biopsy proven myositis whose symptoms began within 10 days of receiving leuprolide acetate therapy for prostate cancer.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["symptoms began"]], "start": [[49]], "entity_id": ["T5"]}, "Effect": {"text": [["myositis"]], "start": [[34]], "entity_id": ["T3"]}, "Treatment": {"text": [["within 10 days of receiving leuprolide acetate therapy"]], "start": [[64]], "entity_id": ["T4"], "Drug": {"text": [["leuprolide acetate"]], "start": [[92]], "entity_id": ["T8"]}, "Time_elapsed": {"text": [["10 days"]], "start": [[71]], "entity_id": ["T9"]}, "Disorder": {"text": [["prostate cancer"]], "start": [[123]], "entity_id": ["T10"]}}, "Subject": {"text": [["a case"]], "start": [[10]], "entity_id": ["T7"]}}]}]}
{"id": "16239768_3", "context": "Venlafaxine-induced urinary incontinence resolved after switching to sertraline.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[12]], "entity_id": ["T4"]}, "Treatment": {"text": [["Venlafaxine"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Venlafaxine"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["urinary incontinence"]], "start": [[20]], "entity_id": ["T5"]}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["resolved"]], "start": [[41]], "entity_id": ["T8"]}, "Treatment": {"text": [["sertraline"]], "start": [[69]], "entity_id": ["T9"], "Disorder": {"text": [["Venlafaxine-induced urinary incontinence"]], "start": [[0]], "entity_id": ["T11"]}, "Drug": {"text": [["sertraline"]], "start": [[69]], "entity_id": ["T10"]}}}]}]}
{"id": "17122225_4", "context": "We report two cases of severe serotonin syndrome induced by the administration of cyclobenzaprine in postoperative patients already receiving another proserotoninergic drug (phenelzine in one case and duloxetine in the other).", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[49]], "entity_id": ["T12"]}, "Effect": {"text": [["serotonin syndrome"]], "start": [[30]], "entity_id": ["T11"]}, "Treatment": {"text": [["cyclobenzaprine", "duloxetine"]], "start": [[82, 201]], "entity_id": ["T13"], "Drug": {"text": [["duloxetine"]], "start": [[201]], "entity_id": ["T18"]}, "Combination": [{"event_id": "E3", "event_type": "Combination", "Trigger": {"text": [["administration"]], "start": [[64]], "entity_id": ["T20"]}, "Drug": {"text": [["cyclobenzaprine"], ["duloxetine"]], "start": [[82], [201]], "entity_id": ["T15", "T18"]}}]}, "Subject": {"text": [["postoperative patients"]], "start": [[101]], "entity_id": ["T10"], "Disorder": {"text": [["postoperative"]], "start": [[101]], "entity_id": ["T14"]}}, "Severity": {"text": [["severe"]], "start": [[23]], "entity_id": ["T19"], "value": "High"}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[49]], "entity_id": ["T12"]}, "Effect": {"text": [["serotonin syndrome"]], "start": [[30]], "entity_id": ["T11"]}, "Subject": {"text": [["postoperative patients"]], "start": [[101]], "entity_id": ["T10"], "Disorder": {"text": [["postoperative"]], "start": [[101]], "entity_id": ["T14"]}}, "Treatment": {"text": [["cyclobenzaprine", "phenelzine"]], "start": [[82, 174]], "entity_id": ["T16"], "Drug": {"text": [["cyclobenzaprine"], ["phenelzine"]], "start": [[82], [174]], "entity_id": ["T15", "T17"]}, "Combination": [{"event_id": "E4", "event_type": "Combination", "Trigger": {"text": [["administration"]], "start": [[64]], "entity_id": ["T20"]}, "Drug": {"text": [["cyclobenzaprine"], ["phenelzine"]], "start": [[82], [174]], "entity_id": ["T15", "T17"]}}]}}]}]}
{"id": "11816261_3", "context": "OBJECTIVE: To report 2 cases of serotonin syndrome with serious extrapyramidal movement disorders occurring when metoclopramide was coadministered with sertraline or venlafaxine.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurring"]], "start": [[98]], "entity_id": ["T9"]}, "Treatment": {"text": [["metoclopramide was coadministered with sertraline or venlafaxine"]], "start": [[113]], "entity_id": ["T10"], "Drug": {"text": [["metoclopramide"], ["sertraline"], ["venlafaxine"]], "start": [[113], [152], [166]], "entity_id": ["T15", "T16", "T17"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["coadministered"]], "start": [[132]], "entity_id": ["T14"]}, "Drug": {"text": [["metoclopramide"], ["sertraline"], ["venlafaxine"]], "start": [[113], [152], [166]], "entity_id": ["T15", "T16", "T17"]}}, {"event_id": "E3", "event_type": "Combination", "Trigger": {"text": [["coadministered"]], "start": [[132]], "entity_id": ["T14"]}, "Drug": {"text": [["metoclopramide"]], "start": [[113]], "entity_id": ["T15"]}}]}, "Effect": {"text": [["serotonin syndrome with serious extrapyramidal movement disorders"]], "start": [[32]], "entity_id": ["T11"]}, "Subject": {"text": [["2 cases"]], "start": [[21]], "entity_id": ["T12"], "Population": {"text": [["2"]], "start": [[21]], "entity_id": ["T13"]}}}]}]}
{"id": "11703329_4", "context": "We report a 31-year-old women with recurrent Hodgkin's lymphoma and unrecognized HMSN-1 who developed severe motor neuropathy 3 weeks after the first cycle of treatment including 2 mg of vincristine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[92]], "entity_id": ["T4"]}, "Subject": {"text": [["a 31-year-old women with recurrent Hodgkin's lymphoma and unrecognized HMSN-1"]], "start": [[10]], "entity_id": ["T3"], "Age": {"text": [["31-year-old"]], "start": [[12]], "entity_id": ["T7"]}, "Gender": {"text": [["women"]], "start": [[24]], "entity_id": ["T8"]}, "Disorder": {"text": [["unrecognized HMSN-1"]], "start": [[68]], "entity_id": ["T1"]}}, "Effect": {"text": [["severe motor neuropathy"]], "start": [[102]], "entity_id": ["T5"]}, "Treatment": {"text": [["3 weeks after the first cycle of treatment including 2 mg of vincristine"]], "start": [[126]], "entity_id": ["T6"], "Disorder": {"text": [["recurrent Hodgkin's lymphoma"]], "start": [[35]], "entity_id": ["T9"]}, "Time_elapsed": {"text": [["3 weeks"]], "start": [[126]], "entity_id": ["T11"]}, "Dosage": {"text": [["2 mg"]], "start": [[179]], "entity_id": ["T12"]}, "Drug": {"text": [["vincristine"]], "start": [[187]], "entity_id": ["T13"]}}, "Severity": {"text": [["severe"]], "start": [[102]], "entity_id": ["T10"], "value": "High"}}]}]}
{"id": "8891729_5", "context": "When the patient was treated again with fludarabine nine months later, the DAT became positive with anti-IgG and anti-C3d antiglobulins after the second course of treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[21]], "entity_id": ["T3"]}, "Subject": {"text": [["the patient"]], "start": [[5]], "entity_id": ["T4"]}, "Treatment": {"text": [["fludarabine", "second course of treatment"]], "start": [[40, 146]], "entity_id": ["T5"], "Drug": {"text": [["fludarabine"]], "start": [[40]], "entity_id": ["T7"]}, "Time_elapsed": {"text": [["nine months later"]], "start": [[52]], "entity_id": ["T8"]}}, "Effect": {"text": [["the DAT became positive with anti-IgG and anti-C3d antiglobulins"]], "start": [[71]], "entity_id": ["T6"]}}]}]}
{"id": "10566542_2", "context": "This case report describes a patient who was previously prescribed alendronate (Fosamax) and presented with postoperative hypophosphatemia and hypocalcemic tetany after bowel preparation with Fleet Phospho-Soda.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["presented"]], "start": [[93]], "entity_id": ["T9"]}, "Subject": {"text": [["patient"]], "start": [[29]], "entity_id": ["T10"]}, "Effect": {"text": [["postoperative hypophosphatemia and hypocalcemic tetany"]], "start": [[108]], "entity_id": ["T11"]}, "Treatment": {"text": [["alendronate (Fosamax)", "after bowel preparation with Fleet Phospho-Soda"]], "start": [[67, 163]], "entity_id": ["T12"], "Drug": {"text": [["alendronate"], ["Fleet Phospho-Soda"]], "start": [[67], [192]], "entity_id": ["T13", "T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["with"]], "start": [[187]], "entity_id": ["T15"]}, "Drug": {"text": [["alendronate"], ["Fleet Phospho-Soda"]], "start": [[67], [192]], "entity_id": ["T13", "T14"]}}]}}]}]}
{"id": "8496127_1", "context": "Acute dystonic reaction with low-dose pimozide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[24]], "entity_id": ["T4"]}, "Treatment": {"text": [["low-dose pimozide"]], "start": [[29]], "entity_id": ["T3"], "Dosage": {"text": [["low-dose"]], "start": [[29]], "entity_id": ["T6"]}, "Drug": {"text": [["pimozide"]], "start": [[38]], "entity_id": ["T7"]}}, "Effect": {"text": [["Acute dystonic reaction"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "18408649_2", "context": "There are, however, case studies describing patients experiencing recurrences of tics following treatment with atomoxetine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[86]], "entity_id": ["T4"]}, "Effect": {"text": [["recurrences of tics"]], "start": [[66]], "entity_id": ["T3"]}, "Treatment": {"text": [["treatment with atomoxetine"]], "start": [[96]], "entity_id": ["T5"], "Drug": {"text": [["atomoxetine"]], "start": [[111]], "entity_id": ["T6"]}}}]}]}
{"id": "3680913_2", "context": "Nicotinic acid-induced fulminant hepatic failure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[15]], "entity_id": ["T4"]}, "Treatment": {"text": [["Nicotinic acid"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Nicotinic acid"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["fulminant hepatic failure"]], "start": [[23]], "entity_id": ["T5"]}}]}]}
{"id": "8969033_2", "context": "Ketanserin in the treatment of protamine-induced pulmonary hypertension.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[41]], "entity_id": ["T3"]}, "Treatment": {"text": [["protamine"]], "start": [[31]], "entity_id": ["T4"], "Drug": {"text": [["protamine"]], "start": [[31]], "entity_id": ["T6"]}}, "Effect": {"text": [["pulmonary hypertension."]], "start": [[49]], "entity_id": ["T5"]}}]}]}
{"id": "11122162_3", "context": "We have safely used recombinant factor VIIa to treat bleeding in the immediate and long-term period following PCC-related MI.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treat"]], "start": [[47]], "entity_id": ["T3"]}, "Treatment": {"text": [["recombinant factor VIIa"]], "start": [[20]], "entity_id": ["T7"], "Disorder": {"text": [["bleeding"]], "start": [[53]], "entity_id": ["T5"]}, "Time_elapsed": {"text": [["immediate and long-term period"]], "start": [[69]], "entity_id": ["T10"]}, "Drug": {"text": [["recombinant factor VIIa"]], "start": [[20]], "entity_id": ["T8"]}}, "Subject": {"text": [["PCC-related MI"]], "start": [[110]], "entity_id": ["T11"], "Disorder": {"text": [["PCC-related MI"]], "start": [[110]], "entity_id": ["T4"]}}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[114]], "entity_id": ["T12"]}, "Treatment": {"text": [["PCC"]], "start": [[110]], "entity_id": ["T6"], "Drug": {"text": [["PCC"]], "start": [[110]], "entity_id": ["T13"]}}, "Effect": {"text": [["MI"]], "start": [[122]], "entity_id": ["T14"]}}]}]}
{"id": "16882112_1", "context": "Lithium and venlafaxine interaction: a case of serotonin syndrome.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["case"]], "start": [[39]], "entity_id": ["T8"]}, "Effect": {"text": [["serotonin syndrome"]], "start": [[47]], "entity_id": ["T7"]}, "Treatment": {"text": [["Lithium and venlafaxine interaction"]], "start": [[0]], "entity_id": ["T6"], "Drug": {"text": [["Lithium"], ["venlafaxine"]], "start": [[0], [12]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[24]], "entity_id": ["T9"]}, "Drug": {"text": [["Lithium"], ["venlafaxine"]], "start": [[0], [12]], "entity_id": ["T10", "T11"]}}]}}]}]}
{"id": "25407257_3", "context": "The seizures were suspected to be caused by a reduced concentration of VPA in the blood.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[34]], "entity_id": ["T5"]}, "Treatment": {"text": [["reduced concentration of VPA in the blood"]], "start": [[46]], "entity_id": ["T6"], "Dosage": {"text": [["reduced concentration"]], "start": [[46]], "entity_id": ["T9"]}, "Drug": {"text": [["VPA"]], "start": [[71]], "entity_id": ["T10"]}}, "Effect": {"text": [["seizures"]], "start": [[4]], "entity_id": ["T7"]}, "Speculated": {"text": [["suspected"]], "start": [[18]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "3430507_1", "context": "D-penicillamine induced crescentic glomerulonephritis: report and review of the literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[16]], "entity_id": ["T5"]}, "Treatment": {"text": [["D-penicillamine"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["D-penicillamine"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["crescentic glomerulonephritis"]], "start": [[24]], "entity_id": ["T6"]}}]}]}
{"id": "19423610_4", "context": "We offered several tentative explanations for this event, including an adverse interaction between paroxetine and other agent(s) used in the course of the anaesthesia.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["between"]], "start": [[91]], "entity_id": ["T8"]}, "Effect": {"text": [["adverse interaction"]], "start": [[71]], "entity_id": ["T6"]}, "Treatment": {"text": [["paroxetine and other agent(s)"]], "start": [[99]], "entity_id": ["T7"], "Drug": {"text": [["paroxetine"], ["anaesthesia"]], "start": [[99], [155]], "entity_id": ["T10", "T9"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["course"]], "start": [[141]], "entity_id": ["T11"]}, "Drug": {"text": [["anaesthesia"], ["paroxetine"]], "start": [[155], [99]], "entity_id": ["T9", "T10"]}}]}}]}]}
{"id": "19331262_3", "context": "Neuroleptic malignant syndrome is an uncommon and potentially fatal idiosynchratic reaction of antipsychotic drugs, in which the clinical scenario encompass muscular rigidity, hyperthermia, autonomic dysfunction, altered consciousness, high creatinine phosphokinase levels, and leukocytosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reaction"]], "start": [[83]], "entity_id": ["T15"]}, "Effect": {"text": [["Neuroleptic malignant syndrome", "muscular rigidity, hyperthermia, autonomic dysfunction, altered consciousness, high creatinine phosphokinase levels, and leukocytosis"]], "start": [[0, 157]], "entity_id": ["T11"]}, "Treatment": {"text": [["antipsychotic drugs"]], "start": [[95]], "entity_id": ["T12"], "Drug": {"text": [["antipsychotic"]], "start": [[95]], "entity_id": ["T16"]}}, "Speculated": {"text": [["potentially"]], "start": [[50]], "entity_id": ["T13"], "value": true}, "Severity": {"text": [["fatal"]], "start": [[62]], "entity_id": ["T17"], "value": "High"}}]}]}
{"id": "11545487_2", "context": "Indinavir-associated nephrolithiasis and chronic interstitial nephritis were the only possible causes identified in this patient.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[10]], "entity_id": ["T6"]}, "Treatment": {"text": [["Indinavir"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Indinavir"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["nephrolithiasis and chronic interstitial nephritis"]], "start": [[21]], "entity_id": ["T7"]}}]}]}
{"id": "19904536_2", "context": "Gemcitabine is a chemotherapy agent that may cause unpredictable side effects.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[45]], "entity_id": ["T7"]}, "Treatment": {"text": [["Gemcitabine"]], "start": [[0]], "entity_id": ["T6"], "Drug": {"text": [["Gemcitabine"]], "start": [[0]], "entity_id": ["T10"]}}, "Effect": {"text": [["unpredictable side effects"]], "start": [[51]], "entity_id": ["T8"]}, "Speculated": {"text": [["may"]], "start": [[41]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "8678015_1", "context": "Albendazole-induced pseudomembranous colitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[12]], "entity_id": ["T4"]}, "Treatment": {"text": [["Albendazole"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Albendazole"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["pseudomembranous colitis"]], "start": [[20]], "entity_id": ["T5"]}}]}]}
{"id": "17364199_1", "context": "Tuberculous uveitis after treatment with etanercept.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[20]], "entity_id": ["T6"]}, "Effect": {"text": [["Tuberculous uveitis"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["etanercept"]], "start": [[41]], "entity_id": ["T5"], "Drug": {"text": [["etanercept"]], "start": [[41]], "entity_id": ["T7"]}}}]}]}
{"id": "3301251_3", "context": "Salicylate-induced hepatotoxicity is reviewed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T4"]}, "Treatment": {"text": [["Salicylate"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Salicylate"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["hepatotoxicity"]], "start": [[19]], "entity_id": ["T5"]}}]}]}
{"id": "19531695_2", "context": "To describe a case of flecainide-induced delirium associated with a pharmacokinetic drug interaction with paroxetine.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[33]], "entity_id": ["T7"]}, "Treatment": {"text": [["flecainide", "interaction with paroxetine"]], "start": [[22, 89]], "entity_id": ["T8"], "Drug": {"text": [["flecainide"], ["paroxetine"]], "start": [[22], [106]], "entity_id": ["T11", "T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[89]], "entity_id": ["T13"]}, "Drug": {"text": [["paroxetine"], ["flecainide"]], "start": [[106], [22]], "entity_id": ["T12", "T11"]}}]}, "Effect": {"text": [["delirium"]], "start": [[41]], "entity_id": ["T9"]}, "Subject": {"text": [["a case"]], "start": [[12]], "entity_id": ["T10"]}}]}]}
{"id": "8098286_3", "context": "We report on a patient who developed hypersensitivity pneumonitis during treatment with the beta-blocker, celiprolol.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[27]], "entity_id": ["T4"]}, "Subject": {"text": [["a patient"]], "start": [[13]], "entity_id": ["T3"]}, "Effect": {"text": [["hypersensitivity pneumonitis"]], "start": [[37]], "entity_id": ["T5"]}, "Treatment": {"text": [["celiprolol"]], "start": [[106]], "entity_id": ["T6"], "Drug": {"text": [["celiprolol"]], "start": [[106]], "entity_id": ["T7"]}}}]}]}
{"id": "19224802_3", "context": "dexmedetomidine is used to provide sedation for pediatric patients undergoing nonpainful radiological imaging studies.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["used to"]], "start": [[19]], "entity_id": ["T6"]}, "Effect": {"text": [["provide sedation"]], "start": [[27]], "entity_id": ["T5"]}, "Treatment": {"text": [["dexmedetomidine"]], "start": [[0]], "entity_id": ["T7"], "Drug": {"text": [["dexmedetomidine"]], "start": [[0]], "entity_id": ["T10"]}}, "Subject": {"text": [["pediatric patients undergoing nonpainful radiological imaging studies"]], "start": [[48]], "entity_id": ["T8"], "Age": {"text": [["pediatric"]], "start": [[48]], "entity_id": ["T9"]}}}]}]}
{"id": "16882112_5", "context": "A 71-year-old woman developed serotonin syndrome while receiving treatment with moderate doses of lithium and venlafaxine for refractory depression.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[20]], "entity_id": ["T9"]}, "Subject": {"text": [["A 71-year-old woman"]], "start": [[0]], "entity_id": ["T10"], "Age": {"text": [["71-year-old"]], "start": [[2]], "entity_id": ["T14"]}, "Gender": {"text": [["woman"]], "start": [[14]], "entity_id": ["T15"]}}, "Effect": {"text": [["serotonin syndrome"]], "start": [[30]], "entity_id": ["T11"]}, "Treatment": {"text": [["moderate doses of lithium and venlafaxine"]], "start": [[80]], "entity_id": ["T12"], "Disorder": {"text": [["refractory depression"]], "start": [[126]], "entity_id": ["T13"]}, "Dosage": {"text": [["moderate doses"]], "start": [[80]], "entity_id": ["T16"]}, "Drug": {"text": [["lithium"], ["venlafaxine"]], "start": [[98], [110]], "entity_id": ["T18", "T19"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[106]], "entity_id": ["T17"]}, "Drug": {"text": [["lithium"], ["venlafaxine"]], "start": [[98], [110]], "entity_id": ["T18", "T19"]}}]}}]}]}
{"id": "8013261_2", "context": "Four years after the beginning of IFN therapy, he acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody, and then 28 units/day of insulin injection was started.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[58]], "entity_id": ["T8"]}, "Treatment": {"text": [["Four years after the beginning of IFN therapy"]], "start": [[0]], "entity_id": ["T5"], "Time_elapsed": {"text": [["Four years after"]], "start": [[0]], "entity_id": ["T10"]}, "Drug": {"text": [["IFN"]], "start": [[34]], "entity_id": ["T11"]}}, "Subject": {"text": [["he"]], "start": [[47]], "entity_id": ["T6"], "Gender": {"text": [["he"]], "start": [[47]], "entity_id": ["T9"]}}, "Effect": {"text": [["acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody"]], "start": [[50]], "entity_id": ["T7"]}}]}]}
{"id": "15644988_1", "context": "Tardive dyskinesia in 2 patients treated with ziprasidone.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[19]], "entity_id": ["T6"]}, "Effect": {"text": [["Tardive dyskinesia"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["ziprasidone"]], "start": [[46]], "entity_id": ["T4"], "Drug": {"text": [["ziprasidone"]], "start": [[46]], "entity_id": ["T8"]}}, "Subject": {"text": [["2 patients"]], "start": [[22]], "entity_id": ["T5"], "Population": {"text": [["2"]], "start": [[22]], "entity_id": ["T7"]}}}]}]}
{"id": "15866658_3", "context": "The mean time from starting MMF to the development of neutropenia was 4 months.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["development"]], "start": [[39]], "entity_id": ["T3"]}, "Treatment": {"text": [["MMF"]], "start": [[28]], "entity_id": ["T4"], "Drug": {"text": [["MMF"]], "start": [[28]], "entity_id": ["T6"]}}, "Effect": {"text": [["neutropenia"]], "start": [[54]], "entity_id": ["T5"]}}]}]}
{"id": "9037299_1", "context": "Fulminant hepatic failure associated with bicalutamide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[26]], "entity_id": ["T4"]}, "Effect": {"text": [["Fulminant hepatic failure"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["bicalutamide"]], "start": [[42]], "entity_id": ["T5"], "Drug": {"text": [["bicalutamide"]], "start": [[42]], "entity_id": ["T6"]}}}]}]}
{"id": "17366681_1", "context": "A complex pattern of melanonychia and onycholysis after treatment with pemetrexed for lung cancer.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treatment"]], "start": [[56]], "entity_id": ["T5"]}, "Effect": {"text": [["melanonychia and onycholysis"]], "start": [[21]], "entity_id": ["T6"]}, "Treatment": {"text": [["pemetrexed for lung cancer"]], "start": [[71]], "entity_id": ["T7"], "Disorder": {"text": [["lung cancer"]], "start": [[86]], "entity_id": ["T8"]}, "Drug": {"text": [["pemetrexed"]], "start": [[71]], "entity_id": ["T9"]}}}]}]}
{"id": "14996269_1", "context": "Hypernatraemia induced by sodium polystyrene sulphonate (Kayexalate) in two extremely low birth weight newborns.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced by"]], "start": [[15]], "entity_id": ["T5"]}, "Effect": {"text": [["Hypernatraemia"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["sodium polystyrene sulphonate (Kayexalate)"]], "start": [[26]], "entity_id": ["T6"], "Drug": {"text": [["sodium polystyrene sulphonate (Kayexalate"]], "start": [[26]], "entity_id": ["T10"]}}, "Subject": {"text": [["two extremely low birth weight newborns"]], "start": [[72]], "entity_id": ["T7"], "Population": {"text": [["two"]], "start": [[72]], "entity_id": ["T8"]}, "Age": {"text": [["newborns"]], "start": [[103]], "entity_id": ["T9"]}}}]}]}
{"id": "17060191_3", "context": "Hypoxia is a predisposing factor for premature ductal closure and often occurs after maternal indomethacin therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[79]], "entity_id": ["T5"]}, "Treatment": {"text": [["maternal indomethacin therapy"]], "start": [[85]], "entity_id": ["T6"], "Drug": {"text": [["indomethacin"]], "start": [[94]], "entity_id": ["T8"]}, "Route": {"text": [["maternal"]], "start": [[85]], "entity_id": ["T9"]}}, "Effect": {"text": [["premature ductal closure"]], "start": [[37]], "entity_id": ["T7"]}}]}]}
{"id": "640344_2", "context": "Severe histological osteomalacia developed in a woman with Crohn's disease 2 years after ileal resection and the start of cholestyramine therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[33]], "entity_id": ["T4"]}, "Subject": {"text": [["a woman with Crohn's disease"]], "start": [[46]], "entity_id": ["T3"], "Gender": {"text": [["woman"]], "start": [[48]], "entity_id": ["T7"]}}, "Effect": {"text": [["histological osteomalacia"]], "start": [[7]], "entity_id": ["T5"]}, "Treatment": {"text": [["2 years after ileal resection and the start of cholestyramine"]], "start": [[75]], "entity_id": ["T6"], "Drug": {"text": [["cholestyramine"]], "start": [[122]], "entity_id": ["T9"]}, "Time_elapsed": {"text": [["start"]], "start": [[113]], "entity_id": ["T10"]}, "Disorder": {"text": [["Crohn's disease"]], "start": [[59]], "entity_id": ["T11"]}}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T12"], "value": "High"}}]}]}
{"id": "16923659_2", "context": "Serotonin syndrome (SS) and neuroleptic malignant syndrome (NMS) are medical emergencies associated with psychotropic administration.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[89]], "entity_id": ["T8"]}, "Effect": {"text": [["Serotonin syndrome (SS) and neuroleptic malignant syndrome (NMS)"]], "start": [[0]], "entity_id": ["T7"]}, "Treatment": {"text": [["psychotropic administration"]], "start": [[105]], "entity_id": ["T9"], "Drug": {"text": [["psychotropic"]], "start": [[105]], "entity_id": ["T10"]}}}]}]}
{"id": "15628319_3", "context": "Drug eruption caused by azathioprine: value of using the drug-induced lymphocytes stimulation test for diagnosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[14]], "entity_id": ["T5"]}, "Treatment": {"text": [["azathioprine"]], "start": [[24]], "entity_id": ["T3"], "Drug": {"text": [["azathioprine"]], "start": [[24]], "entity_id": ["T6"]}}, "Effect": {"text": [["Drug eruption"]], "start": [[0]], "entity_id": ["T4"]}}]}]}
{"id": "11435808_1", "context": "Continuous EEG monitoring is helpful in managing seizures that occur as a complication of CBZ OD, after the course of recovery or worsening, and in providing assistance with prognosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occur"]], "start": [[63]], "entity_id": ["T4"]}, "Effect": {"text": [["seizures"]], "start": [[49]], "entity_id": ["T3"]}, "Treatment": {"text": [["a complication of CBZ OD"]], "start": [[72]], "entity_id": ["T5"], "Drug": {"text": [["CBZ OD"]], "start": [[90]], "entity_id": ["T6"]}}}]}]}
{"id": "7379406_8", "context": "The fluorine contained in niflumic acid induced a marked densification of trabecular bone in all 3 cases.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[40]], "entity_id": ["T6"]}, "Treatment": {"text": [["fluorine", "niflumic acid"]], "start": [[4, 26]], "entity_id": ["T5"], "Drug": {"text": [["fluorine"], ["niflumic acid"]], "start": [[4], [26]], "entity_id": ["T10", "T11"]}}, "Effect": {"text": [["marked densification of trabecular bone"]], "start": [[50]], "entity_id": ["T7"]}, "Subject": {"text": [["all 3 cases"]], "start": [[93]], "entity_id": ["T8"], "Population": {"text": [["3"]], "start": [[97]], "entity_id": ["T9"]}}}]}]}
{"id": "19017039_1", "context": "A 17-year-old boy with refractory psoriatic arthritis and alpha-1 antitrypsin deficiency who developed a syringotropic hypersensitivity reaction after 9 months of therapy with infliximab and leflunomide is described.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[93]], "entity_id": ["T5"]}, "Subject": {"text": [["A 17-year-old boy with refractory psoriatic arthritis and alpha-1 antitrypsin deficiency"]], "start": [[0]], "entity_id": ["T4"], "Age": {"text": [["17-year-old"]], "start": [[2]], "entity_id": ["T8"]}, "Gender": {"text": [["boy"]], "start": [[14]], "entity_id": ["T9"]}, "Disorder": {"text": [["alpha-1 antitrypsin deficiency"]], "start": [[58]], "entity_id": ["T11"]}}, "Effect": {"text": [["syringotropic hypersensitivity reaction"]], "start": [[105]], "entity_id": ["T6"]}, "Treatment": {"text": [["9 months of therapy with infliximab and leflunomide"]], "start": [[151]], "entity_id": ["T7"], "Disorder": {"text": [["refractory psoriatic arthritis"]], "start": [[23]], "entity_id": ["T10"]}, "Drug": {"text": [["infliximab"], ["leflunomide"]], "start": [[176], [191]], "entity_id": ["T12", "T13"]}, "Duration": {"text": [["9 months"]], "start": [[151]], "entity_id": ["T1"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[187]], "entity_id": ["T14"]}, "Drug": {"text": [["infliximab"], ["leflunomide"]], "start": [[176], [191]], "entity_id": ["T12", "T13"]}}]}}]}]}
{"id": "17448102_1", "context": "Managing cardiovascular collapse in severe flecainide overdose without recourse to extracorporeal therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[33]], "entity_id": ["T5"]}, "Effect": {"text": [["cardiovascular collapse"]], "start": [[9]], "entity_id": ["T4"]}, "Treatment": {"text": [["severe flecainide overdose"]], "start": [[36]], "entity_id": ["T6"], "Drug": {"text": [["flecainide"]], "start": [[43]], "entity_id": ["T7"]}, "Dosage": {"text": [["overdose"]], "start": [[54]], "entity_id": ["T8"]}}}]}]}
{"id": "9788533_2", "context": "A 53-year-old Caucasian male victim of suicide was suspected of overdose with sertraline and alprazolam after death-scene investigation.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[73]], "entity_id": ["T11"]}, "Subject": {"text": [["53-year-old Caucasian male victim of suicide"]], "start": [[2]], "entity_id": ["T8"], "Age": {"text": [["53-year-old"]], "start": [[2]], "entity_id": ["T12"]}, "Race": {"text": [["Caucasian"]], "start": [[14]], "entity_id": ["T13"]}, "Gender": {"text": [["male"]], "start": [[24]], "entity_id": ["T14"]}}, "Treatment": {"text": [["overdose", "sertraline and alprazolam"]], "start": [[64, 78]], "entity_id": ["T10"], "Dosage": {"text": [["overdose"]], "start": [[64]], "entity_id": ["T15"]}, "Drug": {"text": [["sertraline"], ["alprazolam"]], "start": [[78], [93]], "entity_id": ["T16", "T18"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[89]], "entity_id": ["T17"]}, "Drug": {"text": [["sertraline"], ["alprazolam"]], "start": [[78], [93]], "entity_id": ["T16", "T18"]}}]}}]}]}
{"id": "12792223_3", "context": "Infliximab therapy may cause a lupus-like syndrome that is reversible upon discontinuing this agent.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[23]], "entity_id": ["T4"]}, "Treatment": {"text": [["Infliximab therapy"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Infliximab"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["lupus-like syndrome"]], "start": [[31]], "entity_id": ["T5"]}, "Speculated": {"text": [["may"]], "start": [[19]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "16511396_1", "context": "A 7-year-old with congenital toxoplasmosis who took pyrimethamine and sulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[115]], "entity_id": ["T20"]}, "Subject": {"text": [["A 7-year-old with congenital toxoplasmosis"]], "start": [[0]], "entity_id": ["T16"], "Age": {"text": [["7-year-old"]], "start": [[2]], "entity_id": ["T22"]}}, "Effect": {"text": [["fever, severe cutaneous involvement, swelling, abdominal pain and transaminitis"]], "start": [[125]], "entity_id": ["T21"]}, "Treatment": {"text": [["pyrimethamine and sulfadiazine for reactivated chorioretinitis"]], "start": [[52]], "entity_id": ["T18"], "Disorder": {"text": [["reactivated chorioretinitis"], ["congenital toxoplasmosis"]], "start": [[87], [18]], "entity_id": ["T19", "T27"]}, "Drug": {"text": [["pyrimethamine"], ["sulfadiazine"]], "start": [[52], [70]], "entity_id": ["T24", "T25"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[66]], "entity_id": ["T26"]}, "Drug": {"text": [["pyrimethamine"], ["sulfadiazine"]], "start": [[52], [70]], "entity_id": ["T24", "T25"]}}]}, "Severity": {"text": [["severe"]], "start": [[132]], "entity_id": ["T23"], "value": "Medium"}}]}]}
{"id": "24801976_1", "context": "Pain management discussion forum: serious interaction among frequently used drugs for chronic pain.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["among"]], "start": [[54]], "entity_id": ["T9"]}, "Effect": {"text": [["serious interaction"]], "start": [[34]], "entity_id": ["T6"]}, "Treatment": {"text": [["frequently used drugs"]], "start": [[60]], "entity_id": ["T7"], "Disorder": {"text": [["chronic pain"]], "start": [[86]], "entity_id": ["T8"]}, "Freq": {"text": [["frequently"]], "start": [[60]], "entity_id": ["T11"]}, "Drug": {"text": [["drugs"]], "start": [[76]], "entity_id": ["T12"]}}, "Severity": {"text": [["serious"]], "start": [[34]], "entity_id": ["T10"], "value": "Medium"}}]}]}
{"id": "15383642_13", "context": "This kind of reaction is seldom mentioned as occurring during co-administration with tizanidine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurring"]], "start": [[45]], "entity_id": ["T7"]}, "Effect": {"text": [["This kind of reaction"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["co-administration with tizanidine"]], "start": [[62]], "entity_id": ["T6"], "Drug": {"text": [["tizanidine"]], "start": [[85]], "entity_id": ["T8"]}}}]}]}
{"id": "91848_1", "context": "A retrospective epidemiological study of deaths from hepatic angiosarcoma (HAS) in the U.S. showed that during 1964--74 there were 168 such cases, of which 37 (22%) were associated with previously known causes (vinyl chloride, 'Thorotrast', and inorganic arsenic) and 4 (3.1%) of the remaining 131 cases with the use of androgenic-anabolic steroids.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[170]], "entity_id": ["T7"]}, "Subject": {"text": [["37 (22%)"]], "start": [[156]], "entity_id": ["T8"], "Population": {"text": [["37"]], "start": [[156]], "entity_id": ["T15"]}}, "Effect": {"text": [["hepatic angiosarcoma"]], "start": [[53]], "entity_id": ["T5"]}, "Treatment": {"text": [["vinyl chloride, 'Thorotrast', and inorganic arsenic"]], "start": [[211]], "entity_id": ["T6"], "Drug": {"text": [["vinyl chloride"], ["Thorotrast"], ["inorganic arsenic"]], "start": [[211], [228], [245]], "entity_id": ["T9", "T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[241]], "entity_id": ["T12"]}, "Drug": {"text": [["vinyl chloride"], ["Thorotrast"], ["inorganic arsenic"]], "start": [[211], [228], [245]], "entity_id": ["T9", "T10", "T11"]}}]}}, {"event_id": "E3", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[304]], "entity_id": ["T19"]}, "Effect": {"text": [["hepatic angiosarcoma"]], "start": [[53]], "entity_id": ["T5"]}, "Subject": {"text": [["4 (3.1%)"]], "start": [[268]], "entity_id": ["T16"], "Population": {"text": [["4"]], "start": [[268]], "entity_id": ["T17"]}}, "Treatment": {"text": [["androgenic-anabolic steroids"]], "start": [[320]], "entity_id": ["T18"], "Drug": {"text": [["androgenic-anabolic steroids"]], "start": [[320]], "entity_id": ["T13"]}}}]}]}
{"id": "9831311_4", "context": "Progressive hypokalemia developed during phosphate treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[24]], "entity_id": ["T4"]}, "Effect": {"text": [["Progressive hypokalemia"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["phosphate"]], "start": [[41]], "entity_id": ["T5"], "Drug": {"text": [["phosphate"]], "start": [[41]], "entity_id": ["T6"]}}}]}]}
{"id": "6702890_1", "context": "A 69-year-old man developed pure red cell aplasia after taking fenoprofen for ten months.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[18]], "entity_id": ["T4"]}, "Subject": {"text": [["A 69-year-old man"]], "start": [[0]], "entity_id": ["T3"], "Age": {"text": [["69-year-old"]], "start": [[2]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[14]], "entity_id": ["T8"]}}, "Effect": {"text": [["pure red cell aplasia"]], "start": [[28]], "entity_id": ["T5"]}, "Treatment": {"text": [["taking fenoprofen for ten months"]], "start": [[56]], "entity_id": ["T6"], "Drug": {"text": [["fenoprofen"]], "start": [[63]], "entity_id": ["T9"]}, "Time_elapsed": {"text": [["ten months"]], "start": [[78]], "entity_id": ["T10"]}}}]}]}
{"id": "20130478_1", "context": "Introduction of etanercept was also clinically effective but followed by development of severe heart failure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["development"]], "start": [[73]], "entity_id": ["T3"]}, "Treatment": {"text": [["etanercept"]], "start": [[16]], "entity_id": ["T4"], "Drug": {"text": [["etanercept"]], "start": [[16]], "entity_id": ["T6"]}}, "Effect": {"text": [["severe heart failure."]], "start": [[88]], "entity_id": ["T5"]}, "Severity": {"text": [["severe"]], "start": [[88]], "entity_id": ["T7"], "value": "High"}}]}]}
{"id": "11961411_2", "context": "Minimal change nephrotic syndrome developing during postoperative interferon-beta therapy for malignant melanoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developing"]], "start": [[34]], "entity_id": ["T4"]}, "Effect": {"text": [["Minimal change nephrotic syndrome"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["postoperative interferon-beta therapy for malignant melanoma"]], "start": [[52]], "entity_id": ["T5"], "Disorder": {"text": [["malignant melanoma"]], "start": [[94]], "entity_id": ["T6"]}, "Drug": {"text": [["postoperative interferon-beta"]], "start": [[52]], "entity_id": ["T8"]}}, "Severity": {"text": [["Minimal"]], "start": [[0]], "entity_id": ["T7"], "value": "Low"}}]}]}
{"id": "11816261_6", "context": "She was admitted following a fall and, after being given metoclopramide, developed movement disorder and a period of unresponsiveness.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[73]], "entity_id": ["T7"]}, "Treatment": {"text": [["metoclopramide"]], "start": [[57]], "entity_id": ["T5"], "Drug": {"text": [["metoclopramide"]], "start": [[57]], "entity_id": ["T11"]}}, "Subject": {"text": [["She was admitted following a fall"]], "start": [[0]], "entity_id": ["T8"], "Gender": {"text": [["She"]], "start": [[0]], "entity_id": ["T9"]}, "Disorder": {"text": [["fall"]], "start": [[29]], "entity_id": ["T10"]}}, "Effect": {"text": [["movement disorder and a period of unresponsiveness"]], "start": [[83]], "entity_id": ["T6"]}}]}]}
{"id": "12605322_1", "context": "We observed transient panhypogammaglobulinaemia in a patient with neuropsychiatric SLE after treatment with prednisolone and cyclophosphamide.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treatment"]], "start": [[93]], "entity_id": ["T7"]}, "Effect": {"text": [["transient panhypogammaglobulinaemia"]], "start": [[12]], "entity_id": ["T4"]}, "Subject": {"text": [["a patient with neuropsychiatric SLE"]], "start": [[51]], "entity_id": ["T5"]}, "Treatment": {"text": [["prednisolone and cyclophosphamide"]], "start": [[108]], "entity_id": ["T8"], "Drug": {"text": [["prednisolone"], ["cyclophosphamide"]], "start": [[108], [125]], "entity_id": ["T10", "T11"]}, "Disorder": {"text": [["neuropsychiatric SLE"]], "start": [[66]], "entity_id": ["T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[121]], "entity_id": ["T12"]}, "Drug": {"text": [["prednisolone"], ["cyclophosphamide"]], "start": [[108], [125]], "entity_id": ["T10", "T11"]}}]}, "Severity": {"text": [["transient"]], "start": [[12]], "entity_id": ["T14"], "value": "Low"}}]}]}
{"id": "4031907_2", "context": "Isoniazid inhibits the conversion of tryptophan to niacin and may induce pellagra, particularly in poorly nourished patients.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induce"]], "start": [[66]], "entity_id": ["T5"]}, "Subject": {"text": [["poorly nourished patients"]], "start": [[99]], "entity_id": ["T3"], "Disorder": {"text": [["poorly nourished"]], "start": [[99]], "entity_id": ["T7"]}}, "Effect": {"text": [["pellagra"]], "start": [[73]], "entity_id": ["T6"]}, "Treatment": {"text": [["Isoniazid"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Isoniazid"]], "start": [[0]], "entity_id": ["T8"]}}}]}]}
{"id": "9022114_5", "context": "The authors suggest that in patients with corneal ulcers refractory to conventional treatment who are receiving colchicine, cessation of colchicine therapy should be considered.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["receiving"]], "start": [[102]], "entity_id": ["T5"]}, "Treatment": {"text": [["colchicine"]], "start": [[112]], "entity_id": ["T4"], "Drug": {"text": [["colchicine"]], "start": [[112]], "entity_id": ["T8"]}, "Disorder": {"text": [["corneal ulcers"]], "start": [[42]], "entity_id": ["T9"]}}, "Subject": {"text": [["patients with corneal ulcers"]], "start": [[28]], "entity_id": ["T3"]}}]}]}
{"id": "6498095_1", "context": "After the patient discontinued rifampicin, the skin lesions cleared completely within 5 weeks without any systemic medication.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["After"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["patient discontinued rifampicin"]], "start": [[10]], "entity_id": ["T3"], "Drug": {"text": [["rifampicin"]], "start": [[31]], "entity_id": ["T6"]}, "Disorder": {"text": [["skin lesions"]], "start": [[47]], "entity_id": ["T7"]}, "Time_elapsed": {"text": [["within 5 weeks"]], "start": [[79]], "entity_id": ["T8"]}}, "Effect": {"text": [["skin lesions cleared completely within 5 weeks"]], "start": [[47]], "entity_id": ["T4"]}}]}]}
{"id": "15644988_3", "context": "Ziprasidone is an atypical antipsychotic drug that is believed to have a low propensity for inducing extrapyramidal symptoms, including tardive dyskinesia (TD).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["inducing"]], "start": [[92]], "entity_id": ["T8"]}, "Effect": {"text": [["extrapyramidal symptoms, including tardive dyskinesia (TD)"]], "start": [[101]], "entity_id": ["T7"]}, "Treatment": {"text": [["Ziprasidone"]], "start": [[0]], "entity_id": ["T10"], "Drug": {"text": [["Ziprasidone"]], "start": [[0]], "entity_id": ["T11"]}, "Disorder": {"text": [["antipsychotic"]], "start": [[27]], "entity_id": ["T12"]}}, "Severity": {"text": [["low propensity"]], "start": [[73]], "entity_id": ["T9"], "value": "Low"}}]}]}
{"id": "19003750_2", "context": "Acute ischaemia of the leg following accidental intra-arterial injection of dissolved flunitrazepam tablets.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[27]], "entity_id": ["T4"]}, "Effect": {"text": [["Acute ischaemia of the leg"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["intra-arterial injection of dissolved flunitrazepam tablets"]], "start": [[48]], "entity_id": ["T5"], "Route": {"text": [["injection"]], "start": [[63]], "entity_id": ["T6"]}, "Drug": {"text": [["flunitrazepam"]], "start": [[86]], "entity_id": ["T7"]}}}]}]}
{"id": "25157214_11", "context": "These findings suggest that prophylactic antibiotic use is unlikely to have a major impact on the recovery time from rocuronium-induced NMB with sugammadex reversal.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["use"]], "start": [[52]], "entity_id": ["T5"]}, "Treatment": {"text": [["prophylactic antibiotic"]], "start": [[28]], "entity_id": ["T8"], "Disorder": {"text": [["rocuronium-induced NMB with sugammadex reversal"]], "start": [[117]], "entity_id": ["T12"]}, "Drug": {"text": [["prophylactic antibiotic"]], "start": [[28]], "entity_id": ["T9"]}}, "Effect": {"text": [["unlikely to have a major impact on the recovery time"]], "start": [[59]], "entity_id": ["T6"]}, "Negated": {"text": [["unlikely"]], "start": [[59]], "entity_id": ["T10"], "value": true}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[128]], "entity_id": ["T15"]}, "Treatment": {"text": [["rocuronium"]], "start": [[117]], "entity_id": ["T14"], "Drug": {"text": [["rocuronium"]], "start": [[117]], "entity_id": ["T13"]}}, "Effect": {"text": [["NMB with sugammadex reversa"]], "start": [[136]], "entity_id": ["T16"]}}]}]}
{"id": "10530201_9", "context": "Emphasis is given to the differentiation of diphenylhydantoin induced gingival hyperplasia from the angiomatous enlargement of the gingiva before any treatment is planned.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[62]], "entity_id": ["T5"]}, "Treatment": {"text": [["diphenylhydantoin"]], "start": [[44]], "entity_id": ["T6"], "Drug": {"text": [["diphenylhydantoin"]], "start": [[44]], "entity_id": ["T8"]}}, "Effect": {"text": [["gingival hyperplasia", "the angiomatous enlargement of the gingiva"]], "start": [[70, 96]], "entity_id": ["T7"]}}]}]}
{"id": "11077455_2", "context": "Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["attributed"]], "start": [[131]], "entity_id": ["T4"]}, "Effect": {"text": [["visual field constriction"]], "start": [[142]], "entity_id": ["T3"]}, "Treatment": {"text": [["vigabatrin"]], "start": [[120]], "entity_id": ["T5"], "Drug": {"text": [["vigabatrin"]], "start": [[120]], "entity_id": ["T7"]}}, "Subject": {"text": [["patients"]], "start": [[106]], "entity_id": ["T6"]}}]}]}
{"id": "7655130_1", "context": "CASE SUMMARIES: Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with increased serum thyroid-stimulating hormone (TSH) concentrations after switching from 1 levothyroxine product to another.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[165]], "entity_id": ["T7"]}, "Effect": {"text": [["hypothyroidism with increased serum thyroid-stimulating hormone"]], "start": [[80]], "entity_id": ["T3"]}, "Treatment": {"text": [["switching from 1 levothyroxine product to another"]], "start": [[171]], "entity_id": ["T4"], "Disorder": {"text": [["stable hypothyroidism"]], "start": [[34]], "entity_id": ["T6"]}, "Drug": {"text": [["levothyroxine"]], "start": [[188]], "entity_id": ["T9"]}}, "Subject": {"text": [["Two patients with stable hypothyroidism"]], "start": [[16]], "entity_id": ["T10"], "Population": {"text": [["Two"]], "start": [[16]], "entity_id": ["T8"]}}}]}]}
{"id": "15482394_1", "context": "An objective causality assessment indicated a probable relationship between clotting abnormality and warfarin administration, although the degree of elevation of the INR was unusual in the light of the daily warfarin dose and duration of its exposure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["relationship"]], "start": [[55]], "entity_id": ["T4"]}, "Effect": {"text": [["clotting abnormality"]], "start": [[76]], "entity_id": ["T3"]}, "Treatment": {"text": [["warfarin"]], "start": [[101]], "entity_id": ["T5"], "Drug": {"text": [["warfarin"]], "start": [[101]], "entity_id": ["T6"]}}, "Speculated": {"text": [["probable"]], "start": [[46]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "12802933_2", "context": "The pathophysiological mechanisms remain unknown, although the drug could act through massive cytokines liberation after destruction of CD20 positive cells by rituximab.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["act"]], "start": [[74]], "entity_id": ["T7"]}, "Effect": {"text": [["massive cytokines liberation", "destruction of CD20 positive cells"]], "start": [[86, 121]], "entity_id": ["T5"]}, "Treatment": {"text": [["rituximab"]], "start": [[159]], "entity_id": ["T6"], "Drug": {"text": [["rituximab"]], "start": [[159]], "entity_id": ["T8"]}}}]}]}
{"id": "19499966_5", "context": "The more common grade 3 or 4 adverse effects of sunitinib include hypertension, fatigue, hand-foot syndrome, elevated lipase and lymphopenia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["adverse effects"]], "start": [[29]], "entity_id": ["T11"]}, "Treatment": {"text": [["sunitinib"]], "start": [[48]], "entity_id": ["T12"], "Drug": {"text": [["sunitinib"]], "start": [[48]], "entity_id": ["T14"]}}, "Effect": {"text": [["hypertension, fatigue, hand-foot syndrome, elevated lipase and lymphopenia"]], "start": [[66]], "entity_id": ["T13"]}}]}]}
{"id": "18446030_2", "context": "We report a 45-year-old psoriasis patient who developed eruptive mollusca contagiosa during an antipsoriatic treatment with efalizumab.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[46]], "entity_id": ["T5"]}, "Subject": {"text": [["45-year-old psoriasis patient"]], "start": [[12]], "entity_id": ["T3"], "Age": {"text": [["45-year-old"]], "start": [[12]], "entity_id": ["T8"]}}, "Effect": {"text": [["eruptive mollusca contagiosa"]], "start": [[56]], "entity_id": ["T6"]}, "Treatment": {"text": [["antipsoriatic treatment with efalizumab"]], "start": [[95]], "entity_id": ["T7"], "Disorder": {"text": [["psoriasis"]], "start": [[24]], "entity_id": ["T4"]}, "Drug": {"text": [["efalizumab"]], "start": [[124]], "entity_id": ["T9"]}}}]}]}
{"id": "9366852_2", "context": "Skin necrosis is a rare complication of subcutaneous heparin therapy that usually occurs at injection sites.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[24]], "entity_id": ["T7"]}, "Effect": {"text": [["Skin necrosis"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["subcutaneous heparin therapy"]], "start": [[40]], "entity_id": ["T8"], "Drug": {"text": [["heparin"]], "start": [[53]], "entity_id": ["T6"]}, "Route": {"text": [["subcutaneous"]], "start": [[40]], "entity_id": ["T9"]}}}]}]}
{"id": "12141409_1", "context": "Epsilon-aminocaproic acid and renal complications: case report and review of the literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complications"]], "start": [[36]], "entity_id": ["T5"]}, "Effect": {"text": [["renal complications"]], "start": [[30]], "entity_id": ["T3"]}, "Treatment": {"text": [["Epsilon-aminocaproic acid"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Epsilon-aminocaproic acid"]], "start": [[0]], "entity_id": ["T6"]}}}]}]}
{"id": "2746565_1", "context": "Ibuprofen rarely causes lower gastrointestinal adverse reactions but has been implicated in systemic and local side effects in patients with lupus.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["implicated in"]], "start": [[78]], "entity_id": ["T5"]}, "Treatment": {"text": [["Ibuprofen"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Ibuprofen"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["systemic and local side effects in patients with lupus"]], "start": [[92]], "entity_id": ["T4"]}}]}]}
{"id": "7606071_2", "context": "CASE SUMMARIES: While conducting a protocol evaluating the efficacy of intraperitoneal cisplatin and hyperthermia in the treatment of recurrent ovarian cancer, 3 patients were noted to exhibit anaphylactoid reactions.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["exhibit"]], "start": [[185]], "entity_id": ["T4"]}, "Subject": {"text": [["3 patients"]], "start": [[160]], "entity_id": ["T3"], "Population": {"text": [["3"]], "start": [[160]], "entity_id": ["T8"]}}, "Effect": {"text": [["anaphylactoid reactions"]], "start": [[193]], "entity_id": ["T5"]}, "Treatment": {"text": [["intraperitoneal cisplatin and hyperthermia"]], "start": [[71]], "entity_id": ["T6"], "Drug": {"text": [["cisplatin"]], "start": [[87]], "entity_id": ["T9"]}, "Route": {"text": [["intraperitoneal"]], "start": [[71]], "entity_id": ["T10"]}, "Disorder": {"text": [["recurrent ovarian cancer"]], "start": [[134]], "entity_id": ["T11"]}}}]}]}
{"id": "10774758_1", "context": "Perinatal vasoconstrictive renal insufficiency associated with maternal nimesulide use.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[47]], "entity_id": ["T4"]}, "Effect": {"text": [["Perinatal vasoconstrictive renal insufficiency"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["maternal nimesulide use"]], "start": [[63]], "entity_id": ["T5"], "Drug": {"text": [["nimesulide"]], "start": [[72]], "entity_id": ["T6"]}}}]}]}
{"id": "11020127_2", "context": "Protease inhibitors (ritonavir and saquinavir) were added to the treatment and the patient developed progressive ataxia related to carbamazepine toxicity.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[91]], "entity_id": ["T11"]}, "Treatment": {"text": [["Protease inhibitors (ritonavir and saquinavir) were added to the treatment", "carbamazepine"]], "start": [[0, 131]], "entity_id": ["T10"], "Drug": {"text": [["carbamazepine"], ["Protease inhibitors"]], "start": [[131], [0]], "entity_id": ["T13", "T9"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["added"]], "start": [[52]], "entity_id": ["T14"]}, "Drug": {"text": [["Protease inhibitors"], ["carbamazepine"]], "start": [[0], [131]], "entity_id": ["T9", "T13"]}}]}, "Effect": {"text": [["progressive ataxia related to carbamazepine toxicity"]], "start": [[101]], "entity_id": ["T12"]}, "Subject": {"text": [["the patient"]], "start": [[79]], "entity_id": ["T15"]}}]}]}
{"id": "10755579_2", "context": "The medical examiner's report indicated death caused by fluoxetine toxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[46]], "entity_id": ["T7"]}, "Effect": {"text": [["death"]], "start": [[40]], "entity_id": ["T8"]}, "Treatment": {"text": [["fluoxetine toxicity"]], "start": [[56]], "entity_id": ["T5"], "Drug": {"text": [["fluoxetine"]], "start": [[56]], "entity_id": ["T9"]}}}]}]}
{"id": "17448102_4", "context": "Hypertonic sodium bicarbonate is recognized as effective therapy for hypotension and arrhythmias.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["effective"]], "start": [[47]], "entity_id": ["T7"]}, "Treatment": {"text": [["Hypertonic sodium bicarbonate"]], "start": [[0]], "entity_id": ["T5"], "Disorder": {"text": [["hypotension and arrhythmias"]], "start": [[69]], "entity_id": ["T6"]}, "Drug": {"text": [["sodium bicarbonate"]], "start": [[11]], "entity_id": ["T8"]}}}]}]}
{"id": "19531695_14", "context": "Because toxicity may occur when flecainide is prescribed with paroxetine and other potent CYP2D6 inhibitors, flecainide plasma concentrations should be monitored closely with commencement of CYP2D6 inhibitors.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occur"]], "start": [[21]], "entity_id": ["T9"]}, "Effect": {"text": [["toxicity"]], "start": [[8]], "entity_id": ["T8"]}, "Treatment": {"text": [["flecainide is prescribed with paroxetine and other potent CYP2D6 inhibitors"]], "start": [[32]], "entity_id": ["T10"], "Drug": {"text": [["flecainide"], ["paroxetine"]], "start": [[32], [62]], "entity_id": ["T12", "T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["with"]], "start": [[57]], "entity_id": ["T14"]}, "Drug": {"text": [["flecainide"], ["paroxetine"]], "start": [[32], [62]], "entity_id": ["T12", "T13"]}}]}, "Speculated": {"text": [["may"]], "start": [[17]], "entity_id": ["T11"], "value": true}}]}]}
{"id": "788666_2", "context": "Gentamicin-associated acute renal failure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[11]], "entity_id": ["T4"]}, "Treatment": {"text": [["Gentamicin"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Gentamicin"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["acute renal failure"]], "start": [[22]], "entity_id": ["T5"]}}]}]}
{"id": "1359782_3", "context": "Sulfasalazine-induced lung disorder is an extremely rare entity which must be considered in all ulcerative colitis patients while on sulfasalazine therapy, despite the absence of pulmonary symptomatology.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[14]], "entity_id": ["T7"]}, "Treatment": {"text": [["Sulfasalazine"]], "start": [[0]], "entity_id": ["T6"], "Disorder": {"text": [["Sulfasalazine"]], "start": [[0]], "entity_id": ["T9"]}}, "Effect": {"text": [["lung disorder"]], "start": [[22]], "entity_id": ["T8"]}}]}]}
{"id": "2327115_3", "context": "Suspected ciprofloxacin-induced interstitial nephritis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[24]], "entity_id": ["T4"]}, "Treatment": {"text": [["ciprofloxacin"]], "start": [[10]], "entity_id": ["T3"], "Drug": {"text": [["ciprofloxacin"]], "start": [[10]], "entity_id": ["T6"]}}, "Effect": {"text": [["interstitial nephritis"]], "start": [[32]], "entity_id": ["T5"]}, "Speculated": {"text": [["Suspected"]], "start": [[0]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "15977922_2", "context": "Tegaserod-associated ischemic colitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[10]], "entity_id": ["T3"]}, "Treatment": {"text": [["Tegaserod"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Tegaserod"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["ischemic colitis"]], "start": [[21]], "entity_id": ["T5"]}}]}]}
{"id": "15162903_2", "context": "Clinicians should be aware of the signs and symptoms of neurotoxicity during treatment, as well as predisposing factors that put patients receiving methotrexate at risk for neurotoxic effects.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["risk"]], "start": [[164]], "entity_id": ["T5"]}, "Treatment": {"text": [["methotrexate"]], "start": [[148]], "entity_id": ["T3"], "Drug": {"text": [["methotrexate"]], "start": [[148]], "entity_id": ["T7"]}}, "Effect": {"text": [["neurotoxic effects"]], "start": [[173]], "entity_id": ["T4"]}, "Subject": {"text": [["patients"]], "start": [[129]], "entity_id": ["T6"]}}]}]}
{"id": "19122478_5", "context": "We report the first case of chlorambucil-induced DRESS syndrome in a 70-year-old man recently diagnosed with chronic lymphocytic leukaemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[41]], "entity_id": ["T7"]}, "Treatment": {"text": [["chlorambucil"]], "start": [[28]], "entity_id": ["T6"], "Drug": {"text": [["chlorambucil"]], "start": [[28]], "entity_id": ["T13"]}, "Disorder": {"text": [["chronic lymphocytic leukaemia"]], "start": [[109]], "entity_id": ["T14"]}}, "Effect": {"text": [["DRESS syndrome"]], "start": [[49]], "entity_id": ["T8"]}, "Subject": {"text": [["a 70-year-old man"]], "start": [[67]], "entity_id": ["T9"], "Age": {"text": [["70-year-old"]], "start": [[69]], "entity_id": ["T11"]}, "Gender": {"text": [["man"]], "start": [[81]], "entity_id": ["T12"]}}}]}]}
{"id": "19775485_1", "context": "Are nasal decongestants safer than rhinitis? A case of oxymetazoline-induced syncope.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[69]], "entity_id": ["T6"]}, "Treatment": {"text": [["oxymetazoline"]], "start": [[55]], "entity_id": ["T7"], "Drug": {"text": [["oxymetazoline"]], "start": [[55]], "entity_id": ["T5"]}}, "Effect": {"text": [["syncope"]], "start": [[77]], "entity_id": ["T8"]}}]}]}
{"id": "10410183_1", "context": "Marked elevation of serum creatine kinase associated with olanzapine therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[42]], "entity_id": ["T5"]}, "Treatment": {"text": [["olanzapine therapy"]], "start": [[58]], "entity_id": ["T4"], "Drug": {"text": [["olanzapine"]], "start": [[58]], "entity_id": ["T7"]}}, "Effect": {"text": [["Marked elevation of serum creatine kinase"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "19034138_1", "context": "After cessation of amantadine, the edema resolved, and the endothelial cell densities were <or=600/mm.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["After"]], "start": [[0]], "entity_id": ["T4"]}, "Effect": {"text": [["the edema resolved, and the endothelial cell densities were <or=600/mm"]], "start": [[31]], "entity_id": ["T3"]}, "Treatment": {"text": [["cessation of amantadine"]], "start": [[6]], "entity_id": ["T5"], "Drug": {"text": [["amantadine"]], "start": [[19]], "entity_id": ["T6"]}, "Dosage": {"text": [["<or=600/mm"]], "start": [[91]], "entity_id": ["T7"]}}}]}]}
{"id": "10410183_6", "context": "DISCUSSION: Olanzapine, like other atypical antipsychotic drugs, may cause muscle injury with concomitant elevations of serum CK of muscle origin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[69]], "entity_id": ["T9"]}, "Treatment": {"text": [["Olanzapine", "atypical antipsychotic drugs"]], "start": [[12, 35]], "entity_id": ["T7"], "Drug": {"text": [["Olanzapine"]], "start": [[12]], "entity_id": ["T10"]}}, "Effect": {"text": [["muscle injury with concomitant elevations of serum CK of muscle origin"]], "start": [[75]], "entity_id": ["T8"]}, "Severity": {"text": [["may"]], "start": [[65]], "entity_id": ["T11"], "value": "Medium"}}]}]}
{"id": "24755135_3", "context": "Study 202 was an open-label, add-on study in patients with partial or generalized epilepsy treated with valproic acid (VPA), carbamazepine (CBZ), phenytoin (PHT), or topiramate (TPM) as monotherapy.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[91]], "entity_id": ["T16"]}, "Subject": {"text": [["patients with partial or generalized epilepsy"]], "start": [[45]], "entity_id": ["T15"]}, "Treatment": {"text": [["valproic acid (VPA), carbamazepine (CBZ), phenytoin (PHT), or topiramate (TPM) as monotherapy"]], "start": [[104]], "entity_id": ["T17"], "Drug": {"text": [["valproic acid"], ["carbamazepine"], ["phenytoin"], ["topiramate"]], "start": [[104], [125], [146], [166]], "entity_id": ["T18", "T19", "T20", "T21"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["with"]], "start": [[99]], "entity_id": ["T22"]}, "Drug": {"text": [["valproic acid"], ["carbamazepine"], ["phenytoin"], ["topiramate"]], "start": [[104], [125], [146], [166]], "entity_id": ["T18", "T19", "T20", "T21"]}}]}}]}]}
{"id": "24477376_7", "context": "Dual antiplatelet therapy with aspirin and a P2Y12 receptor antagonist following placement of coronary stents is critical to prevent stent thrombosis and subsequent myocardial infarction.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["prevent"]], "start": [[125]], "entity_id": ["T7"]}, "Treatment": {"text": [["aspirin and a P2Y12 receptor antagonist following placement of coronary stents"]], "start": [[31]], "entity_id": ["T9"], "Disorder": {"text": [["stent thrombosis and subsequent myocardial infarction"]], "start": [[133]], "entity_id": ["T8"]}, "Drug": {"text": [["aspirin"], ["P2Y12 receptor antagonist"]], "start": [[31], [45]], "entity_id": ["T10", "T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[39]], "entity_id": ["T11"]}, "Drug": {"text": [["aspirin"], ["P2Y12 receptor antagonist"]], "start": [[31], [45]], "entity_id": ["T10", "T12"]}}]}}]}]}
{"id": "6536282_3", "context": "Organometals also compromise the limbic system and result in deficits in learning and memory.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["result"]], "start": [[51]], "entity_id": ["T6"]}, "Treatment": {"text": [["Organometals"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Organometals"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["compromise the limbic system", "deficits in learning and memory"]], "start": [[18, 61]], "entity_id": ["T5"]}}]}]}
{"id": "6233326_1", "context": "Optic neuropathy associated with penicillamine therapy in a patient with rheumatoid arthritis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[17]], "entity_id": ["T4"]}, "Effect": {"text": [["Optic neuropathy"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["penicillamine"]], "start": [[33]], "entity_id": ["T5"], "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[73]], "entity_id": ["T7"]}, "Drug": {"text": [["penicillamine"]], "start": [[33]], "entity_id": ["T8"]}}, "Subject": {"text": [["a patient with rheumatoid arthritis"]], "start": [[58]], "entity_id": ["T6"]}}]}]}
{"id": "7835785_3", "context": "We present the first case of ovarian endometrioid carcinoma and endometriosis in a postmenopausal patient who was treated with tamoxifen for breast cancer.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated with"]], "start": [[114]], "entity_id": ["T8"]}, "Effect": {"text": [["ovarian endometrioid carcinoma and endometriosis"]], "start": [[29]], "entity_id": ["T5"]}, "Subject": {"text": [["postmenopausal patient", "breast cancer."]], "start": [[83, 141]], "entity_id": ["T6"]}, "Treatment": {"text": [["tamoxifen"]], "start": [[127]], "entity_id": ["T7"], "Drug": {"text": [["tamoxifen"]], "start": [[127]], "entity_id": ["T10"]}, "Disorder": {"text": [["breast cancer"]], "start": [[141]], "entity_id": ["T11"]}}}]}]}
{"id": "6311654_5", "context": "There was a good correlation between the total dose of ACTH and the percentage decrease of brain parenchyma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["correlation"]], "start": [[17]], "entity_id": ["T5"]}, "Effect": {"text": [["percentage decrease of brain parenchyma"]], "start": [[68]], "entity_id": ["T4"]}, "Treatment": {"text": [["total dose of ACTH"]], "start": [[41]], "entity_id": ["T6"], "Drug": {"text": [["ACTH"]], "start": [[55]], "entity_id": ["T7"]}}}]}]}
{"id": "19423610_3", "context": "We noted that the delirium resembled serotonin toxicity and that the patient had been taking paroxetine until 2 days before surgery.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["taking"]], "start": [[86]], "entity_id": ["T6"]}, "Treatment": {"text": [["paroxetine until 2 days before surgery"]], "start": [[93]], "entity_id": ["T5"], "Drug": {"text": [["paroxetine"]], "start": [[93]], "entity_id": ["T8"]}}, "Effect": {"text": [["delirium resembled serotonin toxicity"]], "start": [[18]], "entity_id": ["T7"]}}]}]}
{"id": "19798640_2", "context": "Primary central nervous system lymphoma in a patient treated with natalizumab.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[53]], "entity_id": ["T6"]}, "Subject": {"text": [["a patient"]], "start": [[43]], "entity_id": ["T3"]}, "Effect": {"text": [["Primary central nervous system lymphoma"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["natalizumab"]], "start": [[66]], "entity_id": ["T5"], "Drug": {"text": [["natalizumab"]], "start": [[66]], "entity_id": ["T7"]}}}]}]}
{"id": "21751692_3", "context": "We retrospectively reviewed the records of 7 pediatric oncology patients who received low-dose ketamine in conjunction with propofol for total intravenous anesthesia (TIVA) repeatedly for radiation therapy.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["received"]], "start": [[77]], "entity_id": ["T11"]}, "Subject": {"text": [["7 pediatric oncology patients"]], "start": [[43]], "entity_id": ["T8"], "Population": {"text": [["7"]], "start": [[43]], "entity_id": ["T12"]}, "Age": {"text": [["pediatric"]], "start": [[45]], "entity_id": ["T14"]}}, "Treatment": {"text": [["low-dose ketamine in conjunction with propofol for total intravenous anesthesia (TIVA) repeatedly for radiation therapy"]], "start": [[86]], "entity_id": ["T9"], "Drug": {"text": [["propofol"], ["ketamine"]], "start": [[124], [95]], "entity_id": ["T15", "T16"]}, "Dosage": {"text": [["low-dose"]], "start": [[86]], "entity_id": ["T17"]}, "Disorder": {"text": [["oncology"]], "start": [[55]], "entity_id": ["T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["conjunction"]], "start": [[107]], "entity_id": ["T18"]}, "Drug": {"text": [["propofol"], ["ketamine"]], "start": [[124], [95]], "entity_id": ["T15", "T16"]}}]}}]}]}
{"id": "20666169_9", "context": "We presume the cause for multiple organ failure could be the result of drug-drug interaction, atorvastatin and verapamil, as verapamil is known to increase the serum concentration of atorvastatin significantly.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[15]], "entity_id": ["T13"]}, "Effect": {"text": [["multiple organ failure"]], "start": [[25]], "entity_id": ["T11"]}, "Treatment": {"text": [["interaction, atorvastatin and verapamil"]], "start": [[81]], "entity_id": ["T12"], "Drug": {"text": [["atorvastatin"], ["verapamil"]], "start": [[94], [111]], "entity_id": ["T14", "T15"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[81]], "entity_id": ["T16"]}, "Drug": {"text": [["atorvastatin"], ["verapamil"]], "start": [[94], [111]], "entity_id": ["T14", "T15"]}}]}, "Speculated": {"text": [["presume", "could"]], "start": [[3, 48]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "20190474_2", "context": "Hypersensitivity to zonisamide was confirmed by the skin patch test.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["to"]], "start": [[17]], "entity_id": ["T4"]}, "Effect": {"text": [["Hypersensitivity"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["zonisamide"]], "start": [[20]], "entity_id": ["T5"], "Drug": {"text": [["zonisamide"]], "start": [[20]], "entity_id": ["T6"]}}}]}]}
{"id": "3612639_2", "context": "Pulmonary edema occurred 24 hours after intravenous ritodrine therapy and 10 hours after subcutaneous terbutaline therapy.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurred"]], "start": [[16]], "entity_id": ["T4"]}, "Effect": {"text": [["Pulmonary edema"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["24 hours after intravenous ritodrine therapy and 10 hours after subcutaneous terbutaline therapy"]], "start": [[25]], "entity_id": ["T6"], "Time_elapsed": {"text": [["24 hours"], ["10 hours"]], "start": [[25], [74]], "entity_id": ["T7", "T10"]}, "Route": {"text": [["intravenous"], ["subcutaneous"]], "start": [[40], [89]], "entity_id": ["T8", "T11"]}, "Drug": {"text": [["ritodrine"], ["terbutaline"]], "start": [[52], [102]], "entity_id": ["T9", "T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[70]], "entity_id": ["T13"]}, "Drug": {"text": [["ritodrine"], ["terbutaline"]], "start": [[52], [102]], "entity_id": ["T9", "T12"]}}]}}]}]}
{"id": "6236730_3", "context": "Transient acute myopia resulting from isotretinoin (accutane) therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulting"]], "start": [[23]], "entity_id": ["T5"]}, "Effect": {"text": [["Transient acute myopia"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["isotretinoin (accutane) therapy"]], "start": [[38]], "entity_id": ["T6"], "Drug": {"text": [["isotretinoin"]], "start": [[38]], "entity_id": ["T7"]}}}]}]}
{"id": "6860059_2", "context": "We report a case of fatal fulminant hepatitis caused by the use of disulfiram in a man with previously normal hepatocellular function.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[46]], "entity_id": ["T5"]}, "Subject": {"text": [["a man"]], "start": [[81]], "entity_id": ["T3"], "Gender": {"text": [["man"]], "start": [[83]], "entity_id": ["T7"]}}, "Treatment": {"text": [["disulfiram"]], "start": [[67]], "entity_id": ["T4"], "Drug": {"text": [["disulfiram"]], "start": [[67]], "entity_id": ["T9"]}}, "Effect": {"text": [["fatal fulminant hepatitis"]], "start": [[20]], "entity_id": ["T6"]}, "Severity": {"text": [["fatal"]], "start": [[20]], "entity_id": ["T8"], "value": "High"}}]}]}
{"id": "9220046_6", "context": "OBJECTIVE: To describe two cases of rhabdomyolysis in patients taking lovastatin that were precipitated by the use of the newer macrolide antibiotics clarithromycin and azithromycin.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["taking"]], "start": [[63]], "entity_id": ["T7"]}, "Subject": {"text": [["two cases", "patients"]], "start": [[23, 54]], "entity_id": ["T5"], "Population": {"text": [["two"]], "start": [[23]], "entity_id": ["T9"]}}, "Effect": {"text": [["rhabdomyolysis"]], "start": [[36]], "entity_id": ["T8"]}, "Treatment": {"text": [["lovastatin that were precipitated by the use of the newer macrolide antibiotics clarithromycin and azithromycin"]], "start": [[70]], "entity_id": ["T6"], "Drug": {"text": [["lovastatin"], ["clarithromycin"], ["azithromycin"]], "start": [[70], [150], [169]], "entity_id": ["T10", "T11", "T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[165]], "entity_id": ["T13"]}, "Drug": {"text": [["clarithromycin"], ["azithromycin"]], "start": [[150], [169]], "entity_id": ["T11", "T12"]}}]}}]}]}
{"id": "11737689_3", "context": "Neutrophilic dermatoses in two children with idiopathic neutropenia: association with granulocyte colony-stimulating factor (G-CSF) therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["association"]], "start": [[69]], "entity_id": ["T5"]}, "Treatment": {"text": [["granulocyte colony-stimulating factor (G-CSF) therapy"]], "start": [[86]], "entity_id": ["T4"], "Disorder": {"text": [["idiopathic neutropenia"]], "start": [[45]], "entity_id": ["T10"]}, "Drug": {"text": [["granulocyte colony-stimulating facto"]], "start": [[86]], "entity_id": ["T11"]}}, "Subject": {"text": [["two children with idiopathic neutropenia"]], "start": [[27]], "entity_id": ["T6"], "Population": {"text": [["two"]], "start": [[27]], "entity_id": ["T8"]}, "Age": {"text": [["children"]], "start": [[31]], "entity_id": ["T9"]}}, "Effect": {"text": [["Neutrophilic dermatoses"]], "start": [[0]], "entity_id": ["T7"]}}]}]}
{"id": "21762153_9", "context": "The zinc/o-cymen-5-ol system has direct antimicrobial effects and inhibits oral disease-related processes.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["inhibits"]], "start": [[66]], "entity_id": ["T8"]}, "Treatment": {"text": [["zinc/o-cymen-5-ol system"]], "start": [[4]], "entity_id": ["T6"], "Drug": {"text": [["zinc"], ["o-cymen-5-ol"]], "start": [[4], [9]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E1", "event_type": "Combination", "Trigger": {"text": [["system"]], "start": [[22]], "entity_id": ["T12"]}, "Drug": {"text": [["zinc"], ["o-cymen-5-ol"]], "start": [[4], [9]], "entity_id": ["T10", "T11"]}}]}, "Effect": {"text": [["antimicrobial effects"], ["inhibits oral disease-related processes"]], "start": [[40], [66]], "entity_id": ["T7", "T9"]}}]}]}
{"id": "1388041_2", "context": "Paroxetine is a selective serotonin reuptake inhibitor possessing anti-depressant activity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["possessing"]], "start": [[55]], "entity_id": ["T6"]}, "Treatment": {"text": [["Paroxetine"]], "start": [[0]], "entity_id": ["T5"], "Disorder": {"text": [["anti-depressant activity"]], "start": [[66]], "entity_id": ["T7"]}, "Drug": {"text": [["Paroxetine"]], "start": [[0]], "entity_id": ["T8"]}}}]}]}
{"id": "11850606_1", "context": "A case of polymyositis with dilated cardiomyopathy associated with interferon alpha treatment for hepatitis B.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[51]], "entity_id": ["T5"]}, "Treatment": {"text": [["interferon alpha"]], "start": [[67]], "entity_id": ["T6"], "Disorder": {"text": [["hepatitis B"]], "start": [[98]], "entity_id": ["T7"]}, "Drug": {"text": [["interferon alpha"]], "start": [[67]], "entity_id": ["T10"]}}, "Subject": {"text": [["A case"]], "start": [[0]], "entity_id": ["T8"]}, "Effect": {"text": [["polymyositis with dilated cardiomyopathy"]], "start": [[10]], "entity_id": ["T9"]}}]}]}
{"id": "18315788_1", "context": "Phenytoin toxicity: an easily missed cause of cerebellar syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[37]], "entity_id": ["T5"]}, "Treatment": {"text": [["Phenytoin"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Phenytoin"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["cerebellar syndrome"]], "start": [[46]], "entity_id": ["T4"]}}]}]}
{"id": "11332679_2", "context": "Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in an infant who developed pancreatitis caused by meglumine antimoniate.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatment"]], "start": [[11]], "entity_id": ["T5"]}, "Subject": {"text": [["an infant who developed pancreatitis caused by meglumine antimoniate"]], "start": [[85]], "entity_id": ["T4"], "Disorder": {"text": [["pancreatitis caused by meglumine antimoniate"]], "start": [[109]], "entity_id": ["T7"]}, "Age": {"text": [["infant"]], "start": [[88]], "entity_id": ["T6"]}}, "Treatment": {"text": [["visceral leishmaniasis with allopurinol plus ketoconazole"]], "start": [[24]], "entity_id": ["T3"], "Disorder": {"text": [["visceral leishmaniasis"]], "start": [[24]], "entity_id": ["T11"]}, "Drug": {"text": [["allopurinol"], ["ketoconazole"]], "start": [[52], [69]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["plus"]], "start": [[64]], "entity_id": ["T8"]}, "Drug": {"text": [["ketoconazole"], ["allopurinol"]], "start": [[69], [52]], "entity_id": ["T10", "T9"]}}]}}, {"event_id": "E3", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[122]], "entity_id": ["T1"]}, "Effect": {"text": [["pancreatitis"]], "start": [[109]], "entity_id": ["T2"]}, "Treatment": {"text": [["meglumine antimoniate"]], "start": [[132]], "entity_id": ["T12"], "Drug": {"text": [["meglumine antimoniate"]], "start": [[132]], "entity_id": ["T13"]}}}]}]}
{"id": "19935411_1", "context": "Hepatotoxicity after high-dose methylprednisolone for demyelinating disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[15]], "entity_id": ["T4"]}, "Effect": {"text": [["Hepatotoxicity"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["high-dose methylprednisolone"]], "start": [[21]], "entity_id": ["T5"], "Dosage": {"text": [["high-dose"]], "start": [[21]], "entity_id": ["T7"]}, "Drug": {"text": [["methylprednisolone"]], "start": [[31]], "entity_id": ["T8"]}, "Disorder": {"text": [["demyelinating disease"]], "start": [[54]], "entity_id": ["T9"]}}}]}]}
{"id": "12796597_3", "context": "Interferon-alpha-induced focal segmental glomerulosclerosis in chronic myelogenous leukemia: a case report and review of the literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[17]], "entity_id": ["T4"]}, "Effect": {"text": [["focal segmental glomerulosclerosis in chronic myelogenous leukemia"]], "start": [[25]], "entity_id": ["T3"]}, "Treatment": {"text": [["Interferon-alpha"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Interferon-alpha"]], "start": [[0]], "entity_id": ["T6"]}}}]}]}
{"id": "6837655_1", "context": "Prior reports have emphasized the tubular and interstitial lesions associated with intermittent or discontinuous rifampin therapy for tuberculosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[67]], "entity_id": ["T4"]}, "Effect": {"text": [["tubular and interstitial lesions"]], "start": [[34]], "entity_id": ["T3"]}, "Treatment": {"text": [["intermittent or discontinuous rifampin therapy"]], "start": [[83]], "entity_id": ["T5"], "Drug": {"text": [["rifampin"]], "start": [[113]], "entity_id": ["T7"]}, "Disorder": {"text": [["tuberculosis"]], "start": [[134]], "entity_id": ["T8"]}}}]}]}
{"id": "2378415_3", "context": "Transtentorial herniation caused by an intracranial mass lesion following high-dose methotrexate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[64]], "entity_id": ["T6"]}, "Effect": {"text": [["an intracranial mass lesion", "Transtentorial herniation"]], "start": [[36, 0]], "entity_id": ["T5"]}, "Treatment": {"text": [["high-dose methotrexate"]], "start": [[74]], "entity_id": ["T7"], "Drug": {"text": [["methotrexate"]], "start": [[84]], "entity_id": ["T8"]}, "Dosage": {"text": [["high-dose"]], "start": [[74]], "entity_id": ["T9"]}}}]}]}
{"id": "961329_1", "context": "A case of prolonged suxamethonium apnoea successfully terminated by the infusion of a commercial preparation of serumcholinesterase is reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["terminated"]], "start": [[54]], "entity_id": ["T5"]}, "Effect": {"text": [["prolonged suxamethonium apnoea"]], "start": [[10]], "entity_id": ["T3"]}, "Treatment": {"text": [["the infusion of a commercial preparation of serumcholinesterase"]], "start": [[68]], "entity_id": ["T4"], "Drug": {"text": [["suxamethonium"], ["serumcholinesterase"]], "start": [[20], [112]], "entity_id": ["T6", "T8"]}, "Route": {"text": [["infusion"]], "start": [[72]], "entity_id": ["T7"]}}}]}]}
{"id": "16718947_2", "context": "53-year-old woman with a history of deep vein thrombosis and pulmonary embolism was receiving warfarin to prevent thromboembolic complications; her international normalized ratio (INR) had been stable for 1 month.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["prevent"]], "start": [[106]], "entity_id": ["T18"]}, "Subject": {"text": [["53-year-old woman with a history of deep vein thrombosis and pulmonary embolism"]], "start": [[0]], "entity_id": ["T7"], "Age": {"text": [["53-year-old"]], "start": [[0]], "entity_id": ["T13"]}, "Gender": {"text": [["woman"]], "start": [[12]], "entity_id": ["T14"]}}, "Treatment": {"text": [["warfarin"]], "start": [[94]], "entity_id": ["T10"], "Drug": {"text": [["warfarin"]], "start": [[94]], "entity_id": ["T15"]}, "Disorder": {"text": [["deep vein thrombosis"], ["pulmonary embolism"], ["thromboembolic complications;"]], "start": [[36], [61], [114]], "entity_id": ["T16", "T17", "T11"]}}}]}]}
{"id": "9161656_2", "context": "OBJECTIVE: To describe a patient with asymptomatic bronchial asthma and hypertension who developed an acute asthma attack after receiving sustained-release verapamil.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[122]], "entity_id": ["T7"]}, "Treatment": {"text": [["sustained-release verapamil"]], "start": [[138]], "entity_id": ["T8"], "Disorder": {"text": [["hypertension"]], "start": [[72]], "entity_id": ["T13"]}, "Drug": {"text": [["sustained-release verapamil"]], "start": [[138]], "entity_id": ["T14"]}}, "Subject": {"text": [["a patient with asymptomatic bronchial asthma and hypertension"]], "start": [[23]], "entity_id": ["T9"], "Disorder": {"text": [["asymptomatic bronchial asthma"]], "start": [[38]], "entity_id": ["T11"]}}, "Effect": {"text": [["acute asthma attack"]], "start": [[102]], "entity_id": ["T10"]}}]}]}
{"id": "7776854_2", "context": "Severe hepatotoxicity related to benzarone: a report of three cases with two fatalities.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[22]], "entity_id": ["T3"]}, "Treatment": {"text": [["benzarone"]], "start": [[33]], "entity_id": ["T4"], "Drug": {"text": [["benzarone"]], "start": [[33]], "entity_id": ["T8"]}}, "Effect": {"text": [["hepatotoxicity"]], "start": [[7]], "entity_id": ["T5"]}, "Subject": {"text": [["three cases"]], "start": [[56]], "entity_id": ["T6"], "Population": {"text": [["three"]], "start": [[56]], "entity_id": ["T7"]}}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T9"], "value": "High"}}]}]}
{"id": "9883483_3", "context": "We report on a 56-year-old female who exhibited drug refractory paroxysmal atrial fibrillation, in which marked prolongation of the QT interval and T wave inversion on electrocardiogram was demonstrated reproducibly shortly after the administration of oral pirmenol therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[224]], "entity_id": ["T8"]}, "Subject": {"text": [["a 56-year-old female"]], "start": [[13]], "entity_id": ["T5"], "Age": {"text": [["56-year-old"]], "start": [[15]], "entity_id": ["T9"]}, "Gender": {"text": [["female"]], "start": [[27]], "entity_id": ["T10"]}}, "Effect": {"text": [["drug refractory paroxysmal atrial fibrillation, in which marked prolongation of the QT interval and T wave inversion"]], "start": [[48]], "entity_id": ["T6"]}, "Treatment": {"text": [["pirmenol"]], "start": [[257]], "entity_id": ["T7"], "Drug": {"text": [["pirmenol"]], "start": [[257]], "entity_id": ["T11"]}, "Route": {"text": [["oral"]], "start": [[252]], "entity_id": ["T12"]}}}]}]}
{"id": "16284443_2", "context": "Insulin-induced lipohypertrophy: report of a case with histopathology.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[8]], "entity_id": ["T4"]}, "Treatment": {"text": [["Insulin"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Insulin"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["lipohypertrophy"]], "start": [[16]], "entity_id": ["T5"]}}]}]}
{"id": "15331204_2", "context": "OBJECTIVE: To study therapy with indapamide impairing carbohydrate metabolism in essential hypertension patients and achieve earlier prevention, diagnoses and treatment of diabetes induced by indapamide.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["therapy"]], "start": [[20]], "entity_id": ["T12"]}, "Treatment": {"text": [["indapamide"]], "start": [[33]], "entity_id": ["T11"], "Disorder": {"text": [["carbohydrate metabolism"], ["hypertension"]], "start": [[54], [91]], "entity_id": ["T13", "T18"]}, "Drug": {"text": [["indapamide"]], "start": [[33]], "entity_id": ["T17"]}}, "Subject": {"text": [["essential hypertension patients"]], "start": [[81]], "entity_id": ["T14"]}, "Speculated": {"text": [["study"]], "start": [[14]], "entity_id": ["T16"], "value": true}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[181]], "entity_id": ["T20"]}, "Effect": {"text": [["diabetes"]], "start": [[172]], "entity_id": ["T19"]}, "Treatment": {"text": [["indapamide"]], "start": [[192]], "entity_id": ["T21"], "Drug": {"text": [["indapamide"]], "start": [[192]], "entity_id": ["T22"]}}}]}]}
{"id": "14677199_2", "context": "We describe a patient with CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasia) who paradoxically experienced worsening of Raynaud's phenomenon when using yohimbine for ED.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["experienced"]], "start": [[154]], "entity_id": ["T4"]}, "Subject": {"text": [["a patient with CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasia)"]], "start": [[12]], "entity_id": ["T3"], "Disorder": {"text": [["CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasia)"]], "start": [[27]], "entity_id": ["T8"]}}, "Effect": {"text": [["worsening of Raynaud's phenomenon"]], "start": [[166]], "entity_id": ["T5"]}, "Treatment": {"text": [["yohimbine"]], "start": [[211]], "entity_id": ["T6"], "Disorder": {"text": [["ED"]], "start": [[225]], "entity_id": ["T7"]}, "Drug": {"text": [["yohimbine"]], "start": [[211]], "entity_id": ["T9"]}}}]}]}
{"id": "16326413_2", "context": "High-dose methotrexate-associated acute renal failure may be an avoidable complication.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[23]], "entity_id": ["T4"]}, "Treatment": {"text": [["High-dose methotrexate"]], "start": [[0]], "entity_id": ["T3"], "Dosage": {"text": [["High-dose"]], "start": [[0]], "entity_id": ["T6"]}, "Drug": {"text": [["methotrexate"]], "start": [[10]], "entity_id": ["T7"]}}, "Effect": {"text": [["acute renal failure"]], "start": [[34]], "entity_id": ["T5"]}}]}]}
{"id": "12796597_1", "context": "Chronic myelogenous leukemia (CML), hepatitis C, and interferon alpha (IFNalpha) have all been associated with renal dysfunction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[95]], "entity_id": ["T5"]}, "Effect": {"text": [["renal dysfunction"]], "start": [[111]], "entity_id": ["T6"]}, "Treatment": {"text": [["interferon alpha (IFNalpha)"]], "start": [[53]], "entity_id": ["T4"], "Drug": {"text": [["interferon alpha"]], "start": [[53]], "entity_id": ["T7"]}}}]}]}
{"id": "17277758_2", "context": "CONCLUSIONS: Infectious endophthalmitis is a potential complication of intravitreal bevacizumab injection.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[55]], "entity_id": ["T5"]}, "Effect": {"text": [["Infectious endophthalmitis"]], "start": [[13]], "entity_id": ["T3"]}, "Treatment": {"text": [["intravitreal bevacizumab injection"]], "start": [[71]], "entity_id": ["T4"], "Drug": {"text": [["bevacizumab"]], "start": [[84]], "entity_id": ["T7"]}, "Route": {"text": [["intravitreal", "injection"]], "start": [[71, 96]], "entity_id": ["T8"]}}, "Speculated": {"text": [["potential"]], "start": [[45]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "19844714_1", "context": "RESULTS: One case of recurrent primary peritoneal carcinoma previously treated with a carboplatin-based regimen, developed a platinum hypersensitivity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[113]], "entity_id": ["T3"]}, "Treatment": {"text": [["a carboplatin-based regimen"]], "start": [[84]], "entity_id": ["T4"], "Drug": {"text": [["carboplatin"]], "start": [[86]], "entity_id": ["T6"]}, "Disorder": {"text": [["recurrent primary peritoneal carcinoma"]], "start": [[21]], "entity_id": ["T7"]}}, "Effect": {"text": [["a platinum hypersensitivity"]], "start": [[123]], "entity_id": ["T5"]}}]}]}
{"id": "9220046_7", "context": "To our knowledge, these cases are the first published reports of lovastatin-induced rhabdomyolysis associated with azithromycin and clarithromycin.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[76]], "entity_id": ["T6"]}, "Treatment": {"text": [["lovastatin", "associated with azithromycin and clarithromycin"]], "start": [[65, 99]], "entity_id": ["T5"], "Drug": {"text": [["lovastatin"], ["azithromycin"], ["clarithromycin"]], "start": [[65], [115], [132]], "entity_id": ["T8", "T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["associated"]], "start": [[99]], "entity_id": ["T11"]}, "Drug": {"text": [["azithromycin"], ["clarithromycin"], ["lovastatin"]], "start": [[115], [132], [65]], "entity_id": ["T9", "T10", "T8"]}}]}, "Effect": {"text": [["rhabdomyolysis"]], "start": [[84]], "entity_id": ["T7"]}}]}]}
{"id": "20038831_3", "context": "Prick tests and intradermal tests with a series of dilutions of carboplatin and cisplatin were performed on three patients who had exhibited medium and severe hypersensitivity reactions to carboplatin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["exhibited"]], "start": [[131]], "entity_id": ["T5"]}, "Treatment": {"text": [["carboplatin"]], "start": [[189]], "entity_id": ["T3"], "Drug": {"text": [["carboplatin"]], "start": [[189]], "entity_id": ["T8"]}}, "Effect": {"text": [["medium and severe hypersensitivity reactions"]], "start": [[141]], "entity_id": ["T4"]}, "Subject": {"text": [["three patients"]], "start": [[108]], "entity_id": ["T6"]}, "Severity": {"text": [["medium and severe"]], "start": [[141]], "entity_id": ["T7"], "value": "High"}}]}]}
{"id": "15454180_1", "context": "A case of sideroblastic anemia is presented in a patient with a left ventricular assist device drive-line infection who was receiving linezolid, an antibiotic used for serious infections with gram-positive organisms.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["presented"]], "start": [[34]], "entity_id": ["T6"]}, "Effect": {"text": [["sideroblastic anemia"]], "start": [[10]], "entity_id": ["T3"]}, "Subject": {"text": [["a patient with a left ventricular assist device drive-line infection"]], "start": [[47]], "entity_id": ["T4"], "Disorder": {"text": [["left ventricular assist device drive-line infection"]], "start": [[64]], "entity_id": ["T7"]}}, "Treatment": {"text": [["receiving linezolid"]], "start": [[124]], "entity_id": ["T5"], "Drug": {"text": [["linezolid"]], "start": [[134]], "entity_id": ["T8"]}, "Disorder": {"text": [["serious infections with gram-positive organisms"]], "start": [[168]], "entity_id": ["T9"]}}}]}]}
{"id": "8651254_1", "context": "Development of nephrotic syndrome in a patient with acute myeloblastic leukemia after treatment with macrophage-colony-stimulating factor.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[80]], "entity_id": ["T3"]}, "Treatment": {"text": [["macrophage-colony-stimulating factor"]], "start": [[101]], "entity_id": ["T4"], "Drug": {"text": [["macrophage-colony-stimulating factor"]], "start": [[101]], "entity_id": ["T8"]}, "Disorder": {"text": [["acute myeloblastic leukemia"]], "start": [[52]], "entity_id": ["T9"]}}, "Effect": {"text": [["nephrotic syndrome"]], "start": [[15]], "entity_id": ["T5"]}, "Subject": {"text": [["a patient with acute myeloblastic leukemia"]], "start": [[37]], "entity_id": ["T6"]}}]}]}
{"id": "7724306_4", "context": "In patients with a known access to INH, seizures should be considered to be caused by INH toxicity unless proved otherwise.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[76]], "entity_id": ["T5"]}, "Treatment": {"text": [["INH"]], "start": [[35]], "entity_id": ["T3"], "Drug": {"text": [["INH"]], "start": [[35]], "entity_id": ["T6"]}}, "Effect": {"text": [["seizures"]], "start": [[40]], "entity_id": ["T4"]}}]}]}
{"id": "12889716_3", "context": "To our knowledge, this is the first case reported in the English literature of a generalized exanthem due to subcutaneous injection of enoxaparin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[102]], "entity_id": ["T6"]}, "Treatment": {"text": [["subcutaneous injection of enoxaparin"]], "start": [[109]], "entity_id": ["T3"], "Route": {"text": [["subcutaneous injection"]], "start": [[109]], "entity_id": ["T8"]}, "Drug": {"text": [["enoxaparin"]], "start": [[135]], "entity_id": ["T9"]}}, "Effect": {"text": [["generalized exanthem"]], "start": [[81]], "entity_id": ["T4"]}, "Subject": {"text": [["the first case"]], "start": [[26]], "entity_id": ["T5"]}, "Speculated": {"text": [["To our knowledge"]], "start": [[0]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "9634122_3", "context": "This case illustrates the potential decoupling of PSA response from disease status in flutamide withdrawal.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["illustrates"]], "start": [[10]], "entity_id": ["T5"]}, "Effect": {"text": [["potential decoupling of PSA response"]], "start": [[26]], "entity_id": ["T3"]}, "Treatment": {"text": [["flutamide withdrawa"]], "start": [[86]], "entity_id": ["T4"], "Drug": {"text": [["flutamide"]], "start": [[86]], "entity_id": ["T6"]}}}]}]}
{"id": "2369419_4", "context": "Upon discontinuation of MTX, her ascites resolved, and her arthritis became more active.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["resolved"]], "start": [[41]], "entity_id": ["T1"]}, "Treatment": {"text": [["discontinuation of MTX"]], "start": [[5]], "entity_id": ["T3"], "Disorder": {"text": [["ascites"]], "start": [[33]], "entity_id": ["T6"]}, "Drug": {"text": [["MTX"]], "start": [[24]], "entity_id": ["T7"]}}, "Subject": {"text": [["her"]], "start": [[29]], "entity_id": ["T2"], "Disorder": {"text": [["arthritis"]], "start": [[59]], "entity_id": ["T10"]}, "Gender": {"text": [["her"]], "start": [[29]], "entity_id": ["T9"]}}}, {"event_id": "E3", "event_type": "Adverse_event", "Trigger": {"text": [["active"]], "start": [[81]], "entity_id": ["T8"]}, "Treatment": {"text": [["discontinuation of MTX"]], "start": [[5]], "entity_id": ["T3"], "Disorder": {"text": [["ascites"]], "start": [[33]], "entity_id": ["T6"]}, "Drug": {"text": [["MTX"]], "start": [[24]], "entity_id": ["T7"]}}, "Subject": {"text": [["her"]], "start": [[29]], "entity_id": ["T2"], "Disorder": {"text": [["arthritis"]], "start": [[59]], "entity_id": ["T10"]}, "Gender": {"text": [["her"]], "start": [[29]], "entity_id": ["T9"]}}, "Effect": {"text": [["arthritis became more active"]], "start": [[59]], "entity_id": ["T5"]}}]}]}
{"id": "19949685_1", "context": "Colonic mucosal necrosis following administration of calcium polystryrene sulfonate (Kalimate) in a uremic patient.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["administration"]], "start": [[35]], "entity_id": ["T8"]}, "Effect": {"text": [["Colonic mucosal necrosis"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["calcium polystryrene sulfonate (Kalimate)"]], "start": [[53]], "entity_id": ["T5"], "Drug": {"text": [["calcium polystryrene sulfonate"]], "start": [[53]], "entity_id": ["T9"]}, "Disorder": {"text": [["uremic"]], "start": [[100]], "entity_id": ["T10"]}}, "Subject": {"text": [["uremic patient"]], "start": [[100]], "entity_id": ["T7"]}}]}]}
{"id": "6933231_1", "context": "Intracranial hemorrhage and focal seizures secondary to use of L-asparaginase during induction therapy of acute lymphocytic leukemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["secondary to"]], "start": [[43]], "entity_id": ["T6"]}, "Effect": {"text": [["Intracranial hemorrhage and focal seizures"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["L-asparaginase"]], "start": [[63]], "entity_id": ["T7"], "Drug": {"text": [["L-asparaginase"]], "start": [[63]], "entity_id": ["T8"]}}}]}]}
{"id": "21887897_2", "context": "A fatal poisoning case involving etizolam, phenobarbital, promethazine and chlorpromazine is presented.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["involving"]], "start": [[23]], "entity_id": ["T9"]}, "Treatment": {"text": [["etizolam, phenobarbital, promethazine and chlorpromazine"]], "start": [[33]], "entity_id": ["T7"], "Drug": {"text": [["etizolam"], ["phenobarbital"], ["promethazine"], ["chlorpromazine"]], "start": [[33], [43], [58], [75]], "entity_id": ["T12", "T13", "T14", "T15"]}}, "Effect": {"text": [["A fatal poisoning"]], "start": [[0]], "entity_id": ["T8"]}, "Subject": {"text": [["A fatal poisoning case"]], "start": [[0]], "entity_id": ["T10"]}, "Severity": {"text": [["fatal"]], "start": [[2]], "entity_id": ["T11"], "value": "Medium"}}]}]}
{"id": "19116715_3", "context": "Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[40]], "entity_id": ["T4"]}, "Treatment": {"text": [["gemcitabine"]], "start": [[28]], "entity_id": ["T3"], "Drug": {"text": [["gemcitabine"]], "start": [[28]], "entity_id": ["T8"]}, "Disorder": {"text": [["metastatic pancreatic adenocarcinoma"]], "start": [[92]], "entity_id": ["T9"]}}, "Effect": {"text": [["hemolytic uremic syndrome"]], "start": [[48]], "entity_id": ["T5"]}, "Subject": {"text": [["patient with metastatic pancreatic adenocarcinoma"]], "start": [[79]], "entity_id": ["T6"]}}]}]}
{"id": "19390192_1", "context": "Leukopenia due to parvovirus B19 in a Crohn's disease patient using azathioprine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[11]], "entity_id": ["T4"]}, "Effect": {"text": [["Leukopenia"]], "start": [[0]], "entity_id": ["T3"]}, "Subject": {"text": [["parvovirus B19 in a Crohn's disease patient"]], "start": [[18]], "entity_id": ["T5"], "Disorder": {"text": [["parvovirus B19"]], "start": [[18]], "entity_id": ["T1"]}}, "Treatment": {"text": [["azathioprine"]], "start": [[68]], "entity_id": ["T6"], "Disorder": {"text": [["Crohn's disease"]], "start": [[38]], "entity_id": ["T7"]}, "Drug": {"text": [["azathioprine"]], "start": [[68]], "entity_id": ["T8"]}}}]}]}
{"id": "1477441_3", "context": "Fixed drug eruption of the scrotum due to methylphenidate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[35]], "entity_id": ["T4"]}, "Effect": {"text": [["Fixed drug eruption of the scrotum"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["methylphenidate"]], "start": [[42]], "entity_id": ["T5"], "Drug": {"text": [["methylphenidate"]], "start": [[42]], "entity_id": ["T6"]}}}]}]}
{"id": "3470173_2", "context": "Cytarabine-induced cerebellar syndrome: case report and literature review.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T4"]}, "Treatment": {"text": [["Cytarabine"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Cytarabine"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["cerebellar syndrome"]], "start": [[19]], "entity_id": ["T5"]}}]}]}
{"id": "10513720_2", "context": "We report a case of glaucoma induced by doxetaxel therapy for metastatic breast cancer.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[29]], "entity_id": ["T5"]}, "Subject": {"text": [["a case"]], "start": [[10]], "entity_id": ["T3"]}, "Effect": {"text": [["glaucoma"]], "start": [[20]], "entity_id": ["T4"]}, "Treatment": {"text": [["doxetaxel therapy for metastatic breast cancer"]], "start": [[40]], "entity_id": ["T6"], "Drug": {"text": [["doxetaxel"]], "start": [[40]], "entity_id": ["T9"]}, "Disorder": {"text": [["metastatic breast cancer"]], "start": [[62]], "entity_id": ["T7"]}}}]}]}
{"id": "8301877_3", "context": "Myoclonus was induced and enhanced by L-dopa, developing into generalized seizures.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["induced and enhanced"]], "start": [[14]], "entity_id": ["T9"]}, "Treatment": {"text": [["L-dopa"]], "start": [[38]], "entity_id": ["T5"], "Drug": {"text": [["L-dopa"]], "start": [[38]], "entity_id": ["T6"]}}, "Effect": {"text": [["developing into generalized seizures", "Myoclonus"]], "start": [[46, 0]], "entity_id": ["T8"]}}]}]}
{"id": "15494638_4", "context": "During analysis of 28 patients receiving CAP with concomitant radiation (XRT) for pancreatic cancer (resected or locally advanced), two patients developed signs and symptoms consistent with peripheral neuropathy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[145]], "entity_id": ["T11"]}, "Treatment": {"text": [["CAP with concomitant radiation (XRT)"]], "start": [[41]], "entity_id": ["T9"], "Disorder": {"text": [["pancreatic cancer"]], "start": [[82]], "entity_id": ["T10"]}, "Drug": {"text": [["CAP"]], "start": [[41]], "entity_id": ["T14"]}, "Route": {"text": [["concomitant radiation"]], "start": [[50]], "entity_id": ["T15"]}}, "Subject": {"text": [["two patients"]], "start": [[132]], "entity_id": ["T8"], "Population": {"text": [["two"]], "start": [[132]], "entity_id": ["T13"]}}, "Effect": {"text": [["peripheral neuropathy"]], "start": [[190]], "entity_id": ["T12"]}}]}]}
{"id": "25515435_8", "context": "A liver biopsy in 2012 revealed marked fibrosis, leading the patient to start hepatitis C treatment with peginterferon alfa-2a, ribavirin and boceprevir.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatment"]], "start": [[90]], "entity_id": ["T10"]}, "Subject": {"text": [["fibrosis, leading the patient"]], "start": [[39]], "entity_id": ["T9"]}, "Treatment": {"text": [["peginterferon alfa-2a, ribavirin and boceprevir"]], "start": [[105]], "entity_id": ["T11"], "Disorder": {"text": [["fibrosis"]], "start": [[39]], "entity_id": ["T8"]}, "Drug": {"text": [["peginterferon alfa-2a"], ["ribavirin"], ["boceprevir"]], "start": [[105], [128], [142]], "entity_id": ["T12", "T13", "T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[138]], "entity_id": ["T15"]}, "Drug": {"text": [["ribavirin"], ["boceprevir"], ["peginterferon alfa-2a"]], "start": [[128], [142], [105]], "entity_id": ["T13", "T14", "T12"]}}]}}]}]}
{"id": "15494638_19", "context": "Knowledge regarding potential adverse effects of CAP is paramount and dose modification is indicated with development of neurotoxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["adverse effects"]], "start": [[30]], "entity_id": ["T5"]}, "Treatment": {"text": [["CAP"]], "start": [[49]], "entity_id": ["T6"], "Drug": {"text": [["CAP"]], "start": [[49]], "entity_id": ["T8"]}}, "Effect": {"text": [["neurotoxicity"]], "start": [[121]], "entity_id": ["T7"]}, "Speculated": {"text": [["potential"]], "start": [[20]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "11111942_2", "context": "We present a case of significant over-anticoagulation temporally associated with a bout of protracted diarrhea in a patient on warfarin therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["over-anticoagulation"]], "start": [[33]], "entity_id": ["T7"]}, "Effect": {"text": [["protracted diarrhea"]], "start": [[91]], "entity_id": ["T5"]}, "Treatment": {"text": [["warfarin"]], "start": [[127]], "entity_id": ["T6"], "Drug": {"text": [["warfarin"]], "start": [[127]], "entity_id": ["T8"]}}}]}]}
{"id": "11160777_1", "context": "New oral therapies for type 2 diabetes mellitus:", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["for"]], "start": [[19]], "entity_id": ["T5"]}, "Treatment": {"text": [["oral therapies"]], "start": [[4]], "entity_id": ["T3"], "Disorder": {"text": [["type 2 diabetes mellitus"]], "start": [[23]], "entity_id": ["T4"]}, "Route": {"text": [["oral"]], "start": [[4]], "entity_id": ["T7"]}}}]}]}
{"id": "10679548_3", "context": "The case histories are presented of two patients who developed lung disease associated with the use of nitrofurantoin with histological features of bronchiolitis obliterans organising pneumonia (BOOP), a rare but recognised form of drug induced injury.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[53]], "entity_id": ["T10"]}, "Treatment": {"text": [["the use of nitrofurantoin"]], "start": [[92]], "entity_id": ["T8"], "Drug": {"text": [["nitrofurantoin"]], "start": [[103]], "entity_id": ["T12"]}}, "Subject": {"text": [["two patients"]], "start": [[36]], "entity_id": ["T7"], "Population": {"text": [["two"]], "start": [[36]], "entity_id": ["T11"]}}, "Effect": {"text": [["lung disease", "with histological features of bronchiolitis obliterans organising pneumonia (BOOP)"]], "start": [[63, 118]], "entity_id": ["T9"]}}]}]}
{"id": "7226916_1", "context": "A 57-year-old woman with right bundle branch block +LPH and ventricular premature contractions developed complete heart block (CHB) following administration of disopyramide phosphate (Norpace).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[95]], "entity_id": ["T8"]}, "Subject": {"text": [["A 57-year-old woman with right bundle branch block +LPH and ventricular premature contractions"]], "start": [[0]], "entity_id": ["T7"], "Age": {"text": [["57-year-old"]], "start": [[2]], "entity_id": ["T11"]}, "Gender": {"text": [["woman"]], "start": [[14]], "entity_id": ["T12"]}, "Disorder": {"text": [["right bundle branch block +LPH"], ["ventricular premature contractions"]], "start": [[25], [60]], "entity_id": ["T13", "T14"]}}, "Effect": {"text": [["complete heart block (CHB)"]], "start": [[105]], "entity_id": ["T9"]}, "Treatment": {"text": [["disopyramide phosphate (Norpace)"]], "start": [[160]], "entity_id": ["T10"], "Drug": {"text": [["disopyramide phosphate"]], "start": [[160]], "entity_id": ["T15"]}}}]}]}
{"id": "14700673_3", "context": "METHODS: In an institutional practice setting, two women, aged 25 and 45, developed acute myopia after starting topiramate for epilepsy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[74]], "entity_id": ["T4"]}, "Subject": {"text": [["two women, aged 25 and 45"]], "start": [[47]], "entity_id": ["T3"], "Population": {"text": [["two"]], "start": [[47]], "entity_id": ["T8"]}, "Gender": {"text": [["women"]], "start": [[51]], "entity_id": ["T9"]}, "Age": {"text": [["aged 25 and 45"]], "start": [[58]], "entity_id": ["T10"]}}, "Effect": {"text": [["acute myopia"]], "start": [[84]], "entity_id": ["T5"]}, "Treatment": {"text": [["topiramate"]], "start": [[112]], "entity_id": ["T6"], "Drug": {"text": [["topiramate"]], "start": [[112]], "entity_id": ["T11"]}, "Disorder": {"text": [["epilepsy"]], "start": [[127]], "entity_id": ["T12"]}}}]}]}
{"id": "16411025_2", "context": "Diffusion-weighted MRI correlates of subacute methotrexate-related neurotoxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[59]], "entity_id": ["T6"]}, "Effect": {"text": [["subacute", "neurotoxicity"]], "start": [[37, 67]], "entity_id": ["T4"]}, "Treatment": {"text": [["methotrexate"]], "start": [[46]], "entity_id": ["T5"], "Drug": {"text": [["methotrexate"]], "start": [[46]], "entity_id": ["T3"]}}}]}]}
{"id": "16298824_3", "context": "ARDS is rarely associated with rituximab infusion for lympho-proliferative disorders, but it should be considered by those administering rituximab, especially when a patient develops severe pulmonary symptoms soon after infusion.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[214]], "entity_id": ["T8"]}, "Subject": {"text": [["a patient"]], "start": [[164]], "entity_id": ["T6"]}, "Effect": {"text": [["ARDS", "severe pulmonary symptoms"]], "start": [[0, 183]], "entity_id": ["T7"]}, "Treatment": {"text": [["infusion"], ["rituximab"]], "start": [[220], [137]], "entity_id": ["T9", "T10"], "Route": {"text": [["infusion"]], "start": [[220]], "entity_id": ["T13"]}, "Drug": {"text": [["rituximab"]], "start": [[137]], "entity_id": ["T11"]}}}]}]}
{"id": "7351000_3", "context": "Seven of the eight cases of acute leukemia occurred in a series of 553 patients treated with Treosulfan for ovarian cancer in the period from 1970 to 1977 and followed closely for a total of 1159 patient-years up to February 1978.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurred"]], "start": [[43]], "entity_id": ["T5"]}, "Effect": {"text": [["acute leukemia"]], "start": [[28]], "entity_id": ["T3"]}, "Treatment": {"text": [["Treosulfan"]], "start": [[93]], "entity_id": ["T4"], "Drug": {"text": [["Treosulfan"]], "start": [[93]], "entity_id": ["T10"]}, "Disorder": {"text": [["ovarian cancer"]], "start": [[108]], "entity_id": ["T11"]}}, "Subject": {"text": [["Seven of the eight cases"]], "start": [[0]], "entity_id": ["T6"], "Population": {"text": [["eight"]], "start": [[13]], "entity_id": ["T7"]}}}]}]}
{"id": "6833205_2", "context": "Desipramine-associated SIADH in an elderly woman: case report.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[12]], "entity_id": ["T4"]}, "Treatment": {"text": [["Desipramine"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Desipramine"]], "start": [[0]], "entity_id": ["T9"]}}, "Effect": {"text": [["SIADH"]], "start": [[23]], "entity_id": ["T5"]}, "Subject": {"text": [["an elderly woman"]], "start": [[32]], "entity_id": ["T6"], "Age": {"text": [["elderly"]], "start": [[35]], "entity_id": ["T7"]}, "Gender": {"text": [["woman"]], "start": [[43]], "entity_id": ["T8"]}}}]}]}
{"id": "16146480_1", "context": "Can propofol precipitate pancreatitis in patients with Cushing's syndrome?", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["precipitate"]], "start": [[13]], "entity_id": ["T4"]}, "Subject": {"text": [["patients with Cushing's syndrome?"]], "start": [[41]], "entity_id": ["T3"]}, "Treatment": {"text": [["propofol"]], "start": [[4]], "entity_id": ["T5"], "Drug": {"text": [["propofol"]], "start": [[4]], "entity_id": ["T8"]}, "Disorder": {"text": [["Cushing's syndrome"]], "start": [[55]], "entity_id": ["T10"]}}, "Effect": {"text": [["pancreatitis"]], "start": [[25]], "entity_id": ["T6"]}, "Speculated": {"text": [["Can"]], "start": [[0]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "23552010_3", "context": "This case presents the possibility of anaphylaxis to topical 5-FU treatments and/or the interaction with angiotensin converting enzyme inhibitors.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["to"]], "start": [[50]], "entity_id": ["T9"]}, "Effect": {"text": [["anaphylaxis"]], "start": [[38]], "entity_id": ["T7"]}, "Treatment": {"text": [["5-FU", "angiotensin converting enzyme inhibitors"]], "start": [[61, 105]], "entity_id": ["T8"], "Drug": {"text": [["5-FU"], ["angiotensin converting enzyme inhibitors"]], "start": [[61], [105]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[88]], "entity_id": ["T12"]}, "Drug": {"text": [["angiotensin converting enzyme inhibitors"], ["5-FU"]], "start": [[105], [61]], "entity_id": ["T11", "T10"]}}]}, "Speculated": {"text": [["possibility"]], "start": [[23]], "entity_id": ["T13"], "value": true}}]}]}
{"id": "15331204_8", "context": "After stopping indapamide, glucose tolerance impairing may be reversed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["stopping"]], "start": [[6]], "entity_id": ["T4"]}, "Treatment": {"text": [["indapamide, glucose tolerance impairing"]], "start": [[15]], "entity_id": ["T5"], "Disorder": {"text": [["glucose tolerance impairing"]], "start": [[27]], "entity_id": ["T3"]}, "Drug": {"text": [["indapamide"]], "start": [[15]], "entity_id": ["T9"]}}, "Speculated": {"text": [["may"]], "start": [[55]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "11424102_3", "context": "We describe a case of needle-track cutaneous seeding of hepatocellular carcinoma (HCC) after sonographically guided percutaneous ethanol injection (PEI).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[87]], "entity_id": ["T7"]}, "Effect": {"text": [["needle-track cutaneous seeding of hepatocellular carcinoma"]], "start": [[22]], "entity_id": ["T6"]}, "Treatment": {"text": [["sonographically guided percutaneous ethanol injection"]], "start": [[93]], "entity_id": ["T8"], "Route": {"text": [["injection"]], "start": [[137]], "entity_id": ["T9"]}, "Drug": {"text": [["ethanol"]], "start": [[129]], "entity_id": ["T10"]}}}]}]}
{"id": "8083821_3", "context": "Zidovudine use in pregnancy: a report on 104 cases and the occurrence of birth defects.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurrence"]], "start": [[59]], "entity_id": ["T4"]}, "Treatment": {"text": [["Zidovudine"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Zidovudine"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["birth defects"]], "start": [[73]], "entity_id": ["T5"]}}]}]}
{"id": "2369419_1", "context": "A patient with seropositive rheumatoid arthritis developed ascites while taking weekly doses of methotrexate (MTX).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[49]], "entity_id": ["T5"]}, "Subject": {"text": [["A patient with seropositive rheumatoid arthritis"]], "start": [[0]], "entity_id": ["T4"]}, "Effect": {"text": [["ascites"]], "start": [[59]], "entity_id": ["T6"]}, "Treatment": {"text": [["taking weekly doses of methotrexate (MTX)"]], "start": [[73]], "entity_id": ["T7"], "Disorder": {"text": [["seropositive rheumatoid arthritis"]], "start": [[15]], "entity_id": ["T8"]}, "Freq": {"text": [["weekly"]], "start": [[80]], "entity_id": ["T9"]}, "Drug": {"text": [["methotrexate"]], "start": [[96]], "entity_id": ["T10"]}}}]}]}
{"id": "18453852_1", "context": "High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["receiving"]], "start": [[55]], "entity_id": ["T7"]}, "Treatment": {"text": [["rifampicin and adjusted doses of lopinavir/ritonavir tablets"]], "start": [[65]], "entity_id": ["T8"], "Drug": {"text": [["rifampicin"], ["lopinavir"], ["ritonavir"]], "start": [[65], [98], [108]], "entity_id": ["T11", "T13", "T14"]}, "Route": {"text": [["tablets"]], "start": [[118]], "entity_id": ["T12"]}, "Dosage": {"text": [["adjusted doses"]], "start": [[80]], "entity_id": ["T16"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[76]], "entity_id": ["T15"]}, "Drug": {"text": [["rifampicin"], ["lopinavir"], ["ritonavir"]], "start": [[65], [98], [108]], "entity_id": ["T11", "T13", "T14"]}}]}, "Subject": {"text": [["healthy volunteers"]], "start": [[36]], "entity_id": ["T9"]}, "Effect": {"text": [["High incidence of adverse events"]], "start": [[0]], "entity_id": ["T10"]}}]}]}
{"id": "14735388_2", "context": "We report here a case of TEN after administration of ciprofloxacin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["administration"]], "start": [[35]], "entity_id": ["T6"]}, "Subject": {"text": [["a case"]], "start": [[15]], "entity_id": ["T3"]}, "Effect": {"text": [["TEN"]], "start": [[25]], "entity_id": ["T4"]}, "Treatment": {"text": [["ciprofloxacin"]], "start": [[53]], "entity_id": ["T5"], "Drug": {"text": [["ciprofloxacin"]], "start": [[53]], "entity_id": ["T7"]}}}]}]}
{"id": "20120657_3", "context": "Zidovudine induced pure red cell aplasia: a case report.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T4"]}, "Treatment": {"text": [["Zidovudine"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Zidovudine"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["pure red cell aplasia"]], "start": [[19]], "entity_id": ["T5"]}, "Subject": {"text": [["a case"]], "start": [[42]], "entity_id": ["T7"]}}]}]}
{"id": "17406804_1", "context": "A case of recall pneumonitis induced by gemcitabine is reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[29]], "entity_id": ["T3"]}, "Treatment": {"text": [["gemcitabine"]], "start": [[40]], "entity_id": ["T4"], "Drug": {"text": [["gemcitabine"]], "start": [[40]], "entity_id": ["T7"]}}, "Effect": {"text": [["recall pneumonitis"]], "start": [[10]], "entity_id": ["T5"]}, "Subject": {"text": [["A case"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "7893301_1", "context": "Albuterol-induced hypokalemia and its potential cardiac toxicity are discussed briefly.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[10]], "entity_id": ["T6"]}, "Treatment": {"text": [["Albuterol"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Albuterol"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["hypokalemia and its potential cardiac toxicity"]], "start": [[18]], "entity_id": ["T7"]}}]}]}
{"id": "9653495_15", "context": "In the absence of an ideal dose-intense FU monotherapy regimen, monthly FU with low-dose LV provides a simple and economical means by which to achieve adequate FU efficacy in the treatment of advanced colorectal cancer.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatment"]], "start": [[179]], "entity_id": ["T8"]}, "Treatment": {"text": [["monthly FU with low-dose LV"]], "start": [[64]], "entity_id": ["T10"], "Disorder": {"text": [["advanced colorectal cancer"]], "start": [[192]], "entity_id": ["T9"]}, "Freq": {"text": [["monthly"]], "start": [[64]], "entity_id": ["T11"]}, "Drug": {"text": [["FU"], ["LV"]], "start": [[72], [89]], "entity_id": ["T12", "T14"]}, "Dosage": {"text": [["low-dose"]], "start": [[80]], "entity_id": ["T15"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["with"]], "start": [[75]], "entity_id": ["T13"]}, "Drug": {"text": [["FU"], ["LV"]], "start": [[72], [89]], "entity_id": ["T12", "T14"]}}]}}]}]}
{"id": "12503933_6", "context": "OBJECTIVE: To report a patient developing fulminant liver failure while being treated with clarithromycin for pneumonia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[78]], "entity_id": ["T5"]}, "Effect": {"text": [["fulminant liver failure"]], "start": [[42]], "entity_id": ["T3"]}, "Subject": {"text": [["a patient"]], "start": [[21]], "entity_id": ["T6"]}, "Treatment": {"text": [["clarithromycin"]], "start": [[91]], "entity_id": ["T4"], "Drug": {"text": [["clarithromycin"]], "start": [[91]], "entity_id": ["T7"]}, "Disorder": {"text": [["pneumonia"]], "start": [[110]], "entity_id": ["T8"]}}}]}]}
{"id": "6529939_3", "context": "The abnormal rhythm disappeared with the withdrawal of propranolol and when the drug was restarted a 2/1 S-A block was seen.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["seen"]], "start": [[119]], "entity_id": ["T5"]}, "Treatment": {"text": [["propranolol"]], "start": [[55]], "entity_id": ["T3"], "Drug": {"text": [["propranolol"]], "start": [[55]], "entity_id": ["T6"]}}, "Effect": {"text": [["2/1 S-A block"]], "start": [[101]], "entity_id": ["T4"]}}]}]}
{"id": "19826099_3", "context": "The Naranjo probability scale indicated a probable relationship between apnea and exposure to lamotrigine through breast-feeding in this infant.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["a probable relationship"]], "start": [[40]], "entity_id": ["T4"]}, "Effect": {"text": [["apnea"]], "start": [[72]], "entity_id": ["T3"]}, "Treatment": {"text": [["lamotrigine through breast-feeding"]], "start": [[94]], "entity_id": ["T5"], "Drug": {"text": [["lamotrigine"]], "start": [[94]], "entity_id": ["T8"]}, "Route": {"text": [["breast-feeding"]], "start": [[114]], "entity_id": ["T10"]}}, "Subject": {"text": [["in this infant"]], "start": [[129]], "entity_id": ["T6"], "Age": {"text": [["infant"]], "start": [[137]], "entity_id": ["T7"]}}, "Speculated": {"text": [["probable"]], "start": [[42]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "16757971_2", "context": "Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[68]], "entity_id": ["T7"]}, "Treatment": {"text": [["temozolomide"]], "start": [[74]], "entity_id": ["T8"], "Drug": {"text": [["temozolomide"]], "start": [[74]], "entity_id": ["T10"]}}, "Effect": {"text": [["Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma"]], "start": [[0]], "entity_id": ["T9"]}}]}]}
{"id": "9920368_3", "context": "Since amiodarone was first marketed in 1992 in Japan, the incidence of amiodarone-induced thyrotoxicosis (AIT) has been increasing.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[82]], "entity_id": ["T6"]}, "Treatment": {"text": [["amiodarone"]], "start": [[71]], "entity_id": ["T5"], "Drug": {"text": [["amiodarone"], ["amiodarone"]], "start": [[71], [6]], "entity_id": ["T8", "T9"]}}, "Effect": {"text": [["thyrotoxicosis (AIT)"]], "start": [[90]], "entity_id": ["T7"]}}]}]}
{"id": "7619765_2", "context": "The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide, in a man with no risk factors for coronary heart disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[54]], "entity_id": ["T6"]}, "Treatment": {"text": [["chemotherapy containing etoposide"]], "start": [[60]], "entity_id": ["T3"], "Drug": {"text": [["etoposide"]], "start": [[84]], "entity_id": ["T8"]}}, "Effect": {"text": [["myocardial infarction"]], "start": [[20]], "entity_id": ["T4"]}, "Subject": {"text": [["a man with no risk factors for coronary heart disease"]], "start": [[98]], "entity_id": ["T5"], "Gender": {"text": [["man"]], "start": [[100]], "entity_id": ["T7"]}}}]}]}
{"id": "889156_1", "context": "The use of beclomethasone diproprionate inhaler complicated by the development of an eosinophilic pneumonia reaction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["development"]], "start": [[67]], "entity_id": ["T7"]}, "Treatment": {"text": [["beclomethasone diproprionate inhaler"]], "start": [[11]], "entity_id": ["T4"], "Route": {"text": [["inhaler"]], "start": [[40]], "entity_id": ["T5"]}, "Drug": {"text": [["beclomethasone diproprionate"]], "start": [[11]], "entity_id": ["T8"]}}, "Effect": {"text": [["eosinophilic pneumonia reaction"]], "start": [[85]], "entity_id": ["T6"]}}]}]}
{"id": "7577414_1", "context": "Nephrotic syndrome related to systemic lupus erythematosus after griseofulvin therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[59]], "entity_id": ["T6"]}, "Treatment": {"text": [["griseofulvin"]], "start": [[65]], "entity_id": ["T5"], "Drug": {"text": [["griseofulvin"]], "start": [[65]], "entity_id": ["T8"]}}, "Effect": {"text": [["Nephrotic syndrome related to systemic lupus erythematosus"]], "start": [[0]], "entity_id": ["T7"]}}]}]}
{"id": "9554064_3", "context": "Theoretical basal ganglia toxicologic mechanisms of methanol poisoning are reviewed, and the role of brain imaging studies will regard to diagnosis, prognosis and impact on management is discussed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["mechanisms"]], "start": [[38]], "entity_id": ["T5"]}, "Treatment": {"text": [["methanol"]], "start": [[52]], "entity_id": ["T3"], "Drug": {"text": [["methanol"]], "start": [[52]], "entity_id": ["T6"]}}, "Effect": {"text": [["poisoning"]], "start": [[61]], "entity_id": ["T4"]}}]}]}
{"id": "8485005_3", "context": "We report a case of drug-induced Kaposi's sarcoma (KS) on the sole of the right foot in a 71-year-old man, treated for 6 months with corticosteroid therapy (prednisolone 25 mg/day) for pericardial effusion.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[25]], "entity_id": ["T10"]}, "Subject": {"text": [["a case of", "a 71-year-old man", "for pericardial effusion"]], "start": [[10, 88, 181]], "entity_id": ["T9"], "Age": {"text": [["71-year-old"]], "start": [[90]], "entity_id": ["T13"]}, "Gender": {"text": [["man"]], "start": [[102]], "entity_id": ["T14"]}}, "Effect": {"text": [["Kaposi's sarcoma (KS)"]], "start": [[33]], "entity_id": ["T11"]}, "Treatment": {"text": [["6 months with corticosteroid therapy (prednisolone 25 mg/day)"]], "start": [[119]], "entity_id": ["T12"], "Duration": {"text": [["6 months"]], "start": [[119]], "entity_id": ["T16"]}, "Dosage": {"text": [["25 mg/day"]], "start": [[170]], "entity_id": ["T17"]}, "Drug": {"text": [["prednisolone"]], "start": [[157]], "entity_id": ["T19"]}, "Disorder": {"text": [["pericardial effusion"]], "start": [[185]], "entity_id": ["T20"]}}}]}]}
{"id": "16196187_3", "context": "We present a case of acute epinephrine toxicity resulting in acute myocardial ischemia in a young boy with combined variable immunodeficiency syndrome who developed severe allergic reaction to intravenous immunoglobulin, and was subsequently given epinephrine by mistake intravenously rather than subcutaneously.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["toxicity"]], "start": [[39]], "entity_id": ["T7"]}, "Subject": {"text": [["a young boy with combined variable immunodeficiency syndrome"]], "start": [[90]], "entity_id": ["T6"], "Age": {"text": [["young"]], "start": [[92]], "entity_id": ["T10"]}, "Gender": {"text": [["boy"]], "start": [[98]], "entity_id": ["T11"]}}, "Treatment": {"text": [["acute epinephrine", "intravenous immunoglobulin, and was subsequently given epinephrine by mistake intravenously rather than subcutaneously"]], "start": [[21, 193]], "entity_id": ["T8"], "Drug": {"text": [["epinephrine"], ["immunoglobulin"]], "start": [[27], [205]], "entity_id": ["T13", "T19"]}, "Disorder": {"text": [["combined variable immunodeficiency syndrome"]], "start": [[107]], "entity_id": ["T15"]}, "Route": {"text": [["intravenously"], ["intravenous"]], "start": [[271], [193]], "entity_id": ["T16", "T18"]}}, "Effect": {"text": [["acute myocardial ischemia", "severe allergic reaction"]], "start": [[61, 165]], "entity_id": ["T9"]}}]}]}
{"id": "8363533_1", "context": "Albeit rare among Western patients, such lithium-associated thyroid dysfunctions appeared to be more likely to occur in Hong Kong Chinese.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[49]], "entity_id": ["T4"]}, "Treatment": {"text": [["lithium"]], "start": [[41]], "entity_id": ["T3"], "Drug": {"text": [["lithium"]], "start": [[41]], "entity_id": ["T8"]}}, "Effect": {"text": [["thyroid dysfunctions"]], "start": [[60]], "entity_id": ["T5"]}, "Subject": {"text": [["Hong Kong Chinese"]], "start": [[120]], "entity_id": ["T6"], "Race": {"text": [["Hong Kong Chinese"]], "start": [[120]], "entity_id": ["T7"]}}}]}]}
{"id": "25671244_2", "context": "Metaxalone has only recently been associated with serotonin syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[34]], "entity_id": ["T4"]}, "Effect": {"text": [["serotonin syndrome"]], "start": [[50]], "entity_id": ["T5"]}, "Treatment": {"text": [["Metaxalone"]], "start": [[0]], "entity_id": ["T6"], "Drug": {"text": [["Metaxalone"]], "start": [[0]], "entity_id": ["T8"]}}}]}]}
{"id": "19235747_1", "context": "Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is reported in up to 18.6% of patients treated with intravenous bisphosphonates and can result in significant morbidity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[15]], "entity_id": ["T4"]}, "Effect": {"text": [["osteonecrosis of the jaw (BRONJ)"]], "start": [[23]], "entity_id": ["T5"]}, "Subject": {"text": [["18.6% of patients"]], "start": [[77]], "entity_id": ["T6"], "Population": {"text": [["18.6%"]], "start": [[77]], "entity_id": ["T3"]}}, "Treatment": {"text": [["intravenous bisphosphonates"]], "start": [[108]], "entity_id": ["T7"], "Drug": {"text": [["Bisphosphonate"], ["bisphosphonates"]], "start": [[0], [120]], "entity_id": ["T8", "T10"]}, "Route": {"text": [["intravenous"]], "start": [[108]], "entity_id": ["T9"]}}, "Severity": {"text": [["significant"]], "start": [[154]], "entity_id": ["T11"], "value": "High"}}]}]}
{"id": "8691927_3", "context": "Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["in"]], "start": [[31]], "entity_id": ["T6"]}, "Effect": {"text": [["Growth and adrenal suppression"]], "start": [[0]], "entity_id": ["T3"]}, "Subject": {"text": [["asthmatic children"]], "start": [[34]], "entity_id": ["T4"], "Age": {"text": [["children"]], "start": [[44]], "entity_id": ["T8"]}}, "Treatment": {"text": [["high-dose fluticasone propionate"]], "start": [[66]], "entity_id": ["T5"], "Drug": {"text": [["fluticasone propionate"]], "start": [[76]], "entity_id": ["T9"]}, "Dosage": {"text": [["high-dose"]], "start": [[66]], "entity_id": ["T10"]}, "Disorder": {"text": [["asthmatic"]], "start": [[34]], "entity_id": ["T11"]}}}]}]}
{"id": "14674674_1", "context": "A diagnosis of infliximab-induced lupus was made and the drug treatment was withdrawn.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[26]], "entity_id": ["T4"]}, "Treatment": {"text": [["infliximab"]], "start": [[15]], "entity_id": ["T3"], "Drug": {"text": [["infliximab"]], "start": [[15]], "entity_id": ["T6"]}}, "Effect": {"text": [["lupus"]], "start": [[34]], "entity_id": ["T5"]}}]}]}
{"id": "10510156_2", "context": "AIMS: To identify the  human cytochrome P450 enzyme (s) involved in the in vitro metabolism of rosiglitazone, a potential oral antidiabetic agent for the treatment of type 2 diabetes-mellitus.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["potential oral"]], "start": [[112]], "entity_id": ["T6"]}, "Treatment": {"text": [["rosiglitazone"]], "start": [[95]], "entity_id": ["T7"], "Drug": {"text": [["rosiglitazone"]], "start": [[95]], "entity_id": ["T10"]}, "Disorder": {"text": [["type 2 diabetes-mellitus."]], "start": [[167]], "entity_id": ["T11"]}, "Route": {"text": [["oral"]], "start": [[122]], "entity_id": ["T12"]}}}]}]}
{"id": "2011096_5", "context": "Neurotoxicity can occur at any time using high-dose cytosine therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occur"]], "start": [[18]], "entity_id": ["T7"]}, "Effect": {"text": [["Neurotoxicity"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["high-dose cytosine"]], "start": [[42]], "entity_id": ["T6"], "Dosage": {"text": [["high-dose"]], "start": [[42]], "entity_id": ["T9"]}, "Drug": {"text": [["cytosine"]], "start": [[52]], "entity_id": ["T10"]}}}]}]}
{"id": "3677571_15", "context": "The possibility of phenytoin hypersensitivity reactions should be considered when patients receiving phenytoin have unusual symptoms, particularly fever, rash, and lymphadenopathy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["receiving"]], "start": [[91]], "entity_id": ["T11"]}, "Effect": {"text": [["phenytoin hypersensitivity", "fever, rash, and lymphadenopathy"]], "start": [[19, 147]], "entity_id": ["T10"]}, "Treatment": {"text": [["phenytoin"]], "start": [[101]], "entity_id": ["T12"], "Drug": {"text": [["phenytoin"]], "start": [[101]], "entity_id": ["T14"]}}, "Speculated": {"text": [["possibility"]], "start": [[4]], "entity_id": ["T13"], "value": true}}]}]}
{"id": "9360190_2", "context": "Magnesium tocolysis as the cause of urinary calculus during pregnancy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[27]], "entity_id": ["T3"]}, "Treatment": {"text": [["Magnesium tocolysis"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Magnesium"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["urinary calculus during pregnancy"]], "start": [[36]], "entity_id": ["T5"]}}]}]}
{"id": "14601701_1", "context": "Ocular ethambutol toxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["toxicity"]], "start": [[18]], "entity_id": ["T6"]}, "Effect": {"text": [["toxicity"]], "start": [[18]], "entity_id": ["T5"]}, "Treatment": {"text": [["Ocular ethambutol"]], "start": [[0]], "entity_id": ["T4"], "Route": {"text": [["Ocular"]], "start": [[0]], "entity_id": ["T7"]}, "Drug": {"text": [["ethambutol"]], "start": [[7]], "entity_id": ["T8"]}}}]}]}
{"id": "8891729_1", "context": "Fatal intravascular autoimmune hemolytic anemia after fludarabine treatment for chronic lymphocytic leukemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[48]], "entity_id": ["T4"]}, "Effect": {"text": [["Fatal intravascular autoimmune hemolytic anemia"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["fludarabine treatment"]], "start": [[54]], "entity_id": ["T5"], "Drug": {"text": [["fludarabine"]], "start": [[54]], "entity_id": ["T7"]}, "Disorder": {"text": [["chronic lymphocytic leukemia"]], "start": [[80]], "entity_id": ["T8"]}}, "Severity": {"text": [["Fatal"]], "start": [[0]], "entity_id": ["T9"], "value": "High"}}]}]}
{"id": "14557583_1", "context": "A 74-year-old patient with idiopathic Parkinson's disease was evaluated for unintended sleep episodes that occurred after long-term treatment with 400 mg/day of L-dopa.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[116]], "entity_id": ["T6"]}, "Subject": {"text": [["A 74-year-old patient with idiopathic Parkinson's disease"]], "start": [[0]], "entity_id": ["T3"], "Age": {"text": [["74-year-old"]], "start": [[2]], "entity_id": ["T7"]}}, "Treatment": {"text": [["long-term treatment with 400 mg/day of L-dopa"]], "start": [[122]], "entity_id": ["T4"], "Disorder": {"text": [["idiopathic Parkinson's disease"]], "start": [[27]], "entity_id": ["T8"]}, "Dosage": {"text": [["400 mg/day"]], "start": [[147]], "entity_id": ["T9"]}, "Drug": {"text": [["L-dopa"]], "start": [[161]], "entity_id": ["T10"]}, "Duration": {"text": [["long-term treatment"]], "start": [[122]], "entity_id": ["T11"]}}, "Effect": {"text": [["unintended sleep episodes"]], "start": [[76]], "entity_id": ["T5"]}}]}]}
{"id": "6683487_2", "context": "Thrombotic thrombocytopenic purpura (TTP) developed in a patient with seropositive rheumatoid arthritis (RA) after 2 1/2 months of treatment with penicillamine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[42]], "entity_id": ["T10"]}, "Effect": {"text": [["Thrombotic thrombocytopenic purpura (TTP)"]], "start": [[0]], "entity_id": ["T9"]}, "Subject": {"text": [["a patient with seropositive rheumatoid arthritis (RA)"]], "start": [[55]], "entity_id": ["T11"]}, "Treatment": {"text": [["2 1/2 months of treatment with penicillamine"]], "start": [[115]], "entity_id": ["T12"], "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[83]], "entity_id": ["T13"]}, "Drug": {"text": [["penicillamine"]], "start": [[146]], "entity_id": ["T14"]}, "Duration": {"text": [["2 1/2 months"]], "start": [[115]], "entity_id": ["T1"]}}}]}]}
{"id": "9337441_1", "context": "Phenolphthalein-induced toxic epidermal necrolysis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[16]], "entity_id": ["T4"]}, "Treatment": {"text": [["Phenolphthalein"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Phenolphthalein"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["toxic epidermal necrolysis"]], "start": [[24]], "entity_id": ["T6"]}}]}]}
{"id": "1536494_2", "context": "We present a case of ethylenediamine-induced delayed hypersensitivity reaction in a 46-year-old woman who received parenteral aminophylline for an acute asthma exacerbation.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[37]], "entity_id": ["T5"]}, "Treatment": {"text": [["ethylenediamine"]], "start": [[21]], "entity_id": ["T4"], "Drug": {"text": [["ethylenediamine"]], "start": [[21]], "entity_id": ["T11"]}}, "Effect": {"text": [["delayed hypersensitivity reaction"]], "start": [[45]], "entity_id": ["T6"]}, "Subject": {"text": [["a 46-year-old woman"]], "start": [[82]], "entity_id": ["T7"], "Age": {"text": [["46-year-old"]], "start": [[84]], "entity_id": ["T9"]}, "Gender": {"text": [["woman"]], "start": [[96]], "entity_id": ["T10"]}}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["received"]], "start": [[106]], "entity_id": ["T13"]}, "Subject": {"text": [["a 46-year-old woman"]], "start": [[82]], "entity_id": ["T7"], "Age": {"text": [["46-year-old"]], "start": [[84]], "entity_id": ["T9"]}, "Gender": {"text": [["woman"]], "start": [[96]], "entity_id": ["T10"]}}, "Treatment": {"text": [["parenteral aminophylline"]], "start": [[115]], "entity_id": ["T14"], "Disorder": {"text": [["acute asthma exacerbation"]], "start": [[147]], "entity_id": ["T8"]}, "Route": {"text": [["parenteral"]], "start": [[115]], "entity_id": ["T15"]}, "Drug": {"text": [["aminophylline"]], "start": [[126]], "entity_id": ["T16"]}}}]}]}
{"id": "8730143_2", "context": "Physicians should be aware of the potentially lethal side effects of dapsone.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["of"]], "start": [[66]], "entity_id": ["T3"]}, "Treatment": {"text": [["dapsone"]], "start": [[69]], "entity_id": ["T4"], "Drug": {"text": [["dapsone"]], "start": [[69]], "entity_id": ["T8"]}}, "Effect": {"text": [["lethal side effects"]], "start": [[46]], "entity_id": ["T5"]}, "Speculated": {"text": [["potentially"]], "start": [[34]], "entity_id": ["T6"], "value": true}, "Severity": {"text": [["lethal"]], "start": [[46]], "entity_id": ["T7"], "value": "High"}}]}]}
{"id": "3753891_1", "context": "Acute myocardial necrosis during administration of amsacrine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[26]], "entity_id": ["T4"]}, "Effect": {"text": [["Acute myocardial necrosis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["amsacrine"]], "start": [[51]], "entity_id": ["T5"], "Drug": {"text": [["amsacrine"]], "start": [[51]], "entity_id": ["T6"]}}}]}]}
{"id": "12699871_2", "context": "Rapid identification of speech loss linked to FK506 may be important because reduction or cessation of the drug may be associated with reverse of speech loss.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["linked"]], "start": [[36]], "entity_id": ["T4"]}, "Effect": {"text": [["speech loss"]], "start": [[24]], "entity_id": ["T3"]}, "Treatment": {"text": [["FK506"]], "start": [[46]], "entity_id": ["T5"], "Drug": {"text": [["FK506"]], "start": [[46]], "entity_id": ["T7"]}}}]}]}
{"id": "667809_2", "context": "Fatal pulmonary fibrosis following 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[25]], "entity_id": ["T5"]}, "Effect": {"text": [["pulmonary fibrosis"]], "start": [[6]], "entity_id": ["T4"]}, "Treatment": {"text": [["1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) therapy"]], "start": [[35]], "entity_id": ["T6"], "Drug": {"text": [["1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)"]], "start": [[35]], "entity_id": ["T7"]}}, "Severity": {"text": [["Fatal"]], "start": [[0]], "entity_id": ["T8"], "value": "High"}}]}]}
{"id": "8862924_4", "context": "The increasing prevalence of methamphetamine abuse and the severity of the associated ulcers should alert ophthalmologists to the problem of methamphetamine-related keratitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[157]], "entity_id": ["T5"]}, "Effect": {"text": [["associated ulcers", "keratitis"]], "start": [[75, 165]], "entity_id": ["T6"]}, "Treatment": {"text": [["methamphetamine abuse", "methamphetamine"]], "start": [[29, 141]], "entity_id": ["T7"], "Drug": {"text": [["methamphetamine"], ["methamphetamine"]], "start": [[29], [141]], "entity_id": ["T9", "T10"]}}, "Severity": {"text": [["severity"]], "start": [[59]], "entity_id": ["T8"], "value": "Medium"}}]}]}
{"id": "15735923_5", "context": "MDS was diagnosed 8.4 months after beginning TMZ.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["diagnosed"]], "start": [[8]], "entity_id": ["T5"]}, "Effect": {"text": [["MDS"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["8.4 months after beginning TMZ"]], "start": [[18]], "entity_id": ["T6"], "Drug": {"text": [["TMZ"]], "start": [[45]], "entity_id": ["T7"]}, "Time_elapsed": {"text": [["8.4 months"]], "start": [[18]], "entity_id": ["T8"]}}}]}]}
{"id": "8979664_3", "context": "Uveitis associated with rifabutin therapy: a clinical alert.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[8]], "entity_id": ["T4"]}, "Effect": {"text": [["Uveitis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["rifabutin therapy"]], "start": [[24]], "entity_id": ["T5"], "Drug": {"text": [["rifabutin"]], "start": [[24]], "entity_id": ["T6"]}}}]}]}
{"id": "18698687_3", "context": "We report a case of a patient with ciprofloxacin-induced SJS and acute onset of VBDS, and reviewed the related literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[49]], "entity_id": ["T6"]}, "Treatment": {"text": [["ciprofloxacin"]], "start": [[35]], "entity_id": ["T5"], "Drug": {"text": [["ciprofloxacin"]], "start": [[35]], "entity_id": ["T10"]}}, "Effect": {"text": [["SJS"], ["acute onset of VBDS"]], "start": [[57], [65]], "entity_id": ["T7", "T8"]}, "Subject": {"text": [["a patient"]], "start": [[20]], "entity_id": ["T9"]}}]}]}
{"id": "8880251_3", "context": "This case supports the assessment that MH and diabetes are associated diseases and that cresol could possibly trigger MH.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["trigger"]], "start": [[110]], "entity_id": ["T3"]}, "Treatment": {"text": [["cresol"]], "start": [[88]], "entity_id": ["T5"], "Drug": {"text": [["cresol"]], "start": [[88]], "entity_id": ["T6"]}}, "Effect": {"text": [["MH"]], "start": [[118]], "entity_id": ["T4"]}, "Speculated": {"text": [["possibly"]], "start": [[101]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "12150593_1", "context": "Neonatal mydriasis: intravenous lidocaine adverse reaction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["adverse reaction"]], "start": [[42]], "entity_id": ["T5"]}, "Effect": {"text": [["Neonatal mydriasis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["lidocaine"]], "start": [[32]], "entity_id": ["T4"], "Drug": {"text": [["lidocaine"]], "start": [[32]], "entity_id": ["T6"]}}, "Subject": {"text": [["Neonatal"]], "start": [[0]], "entity_id": ["T7"], "Age": {"text": [["Neonatal"]], "start": [[0]], "entity_id": ["T8"]}}}]}]}
{"id": "3417739_1", "context": "Acute renal failure in a patient treated by continuous povidone-iodine mediastinal irrigation.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[20]], "entity_id": ["T4"]}, "Effect": {"text": [["Acute renal failure"]], "start": [[0]], "entity_id": ["T5"]}, "Subject": {"text": [["a patient"]], "start": [[23]], "entity_id": ["T6"]}, "Treatment": {"text": [["continuous povidone-iodine mediastinal irrigation"]], "start": [[44]], "entity_id": ["T7"], "Drug": {"text": [["povidone"], ["iodine"]], "start": [[55], [64]], "entity_id": ["T8", "T9"]}, "Route": {"text": [["irrigation"]], "start": [[83]], "entity_id": ["T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["-"]], "start": [[63]], "entity_id": ["T11"]}, "Drug": {"text": [["povidone"], ["iodine"]], "start": [[55], [64]], "entity_id": ["T8", "T9"]}}]}}]}]}
{"id": "7577414_2", "context": "To our knowledge, this is the first case of griseofulvin-exacerbated lupus in which nephrotic syndrome has been observed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["exacerbated"]], "start": [[57]], "entity_id": ["T6"]}, "Treatment": {"text": [["griseofulvin"]], "start": [[44]], "entity_id": ["T5"], "Drug": {"text": [["griseofulvin"]], "start": [[44]], "entity_id": ["T9"]}}, "Effect": {"text": [["lupus", "nephrotic syndrome"]], "start": [[69, 84]], "entity_id": ["T7"]}, "Subject": {"text": [["the first case"]], "start": [[26]], "entity_id": ["T10"]}, "Speculated": {"text": [["To our knowledge"]], "start": [[0]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "12630660_6", "context": "After reviewing the literature we suggest the CPM was a complication of lithium toxicity which affected the lateral geniculate nucleus which produced blindness.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[56]], "entity_id": ["T9"]}, "Effect": {"text": [["CPM", "lithium toxicity", "blindness"]], "start": [[46, 72, 150]], "entity_id": ["T8"]}, "Treatment": {"text": [["lithium"]], "start": [[72]], "entity_id": ["T10"], "Drug": {"text": [["lithium"]], "start": [[72]], "entity_id": ["T11"]}}, "Speculated": {"text": [["suggest"]], "start": [[34]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "1267457_1", "context": "A 71-year-old man, who had a history of a previous bullous drug reaction to a sulfonamide, began receiving an ophthalmic preparation that contained sulfacetamide sodium.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reaction"]], "start": [[64]], "entity_id": ["T6"]}, "Subject": {"text": [["A 71-year-old man"]], "start": [[0]], "entity_id": ["T3"], "Age": {"text": [["71-year-old"]], "start": [[2]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[14]], "entity_id": ["T8"]}}, "Treatment": {"text": [["sulfonamide"]], "start": [[78]], "entity_id": ["T4"], "Drug": {"text": [["sulfonamide"], ["sulfacetamide sodium"]], "start": [[78], [148]], "entity_id": ["T9", "T10"]}}, "Effect": {"text": [["bullous"]], "start": [[51]], "entity_id": ["T5"]}}]}]}
{"id": "9022114_4", "context": "The authors report on two patients with corneal ulcers refractory to conventional treatment while the patients were undergoing oral colchicine therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["undergoing"]], "start": [[116]], "entity_id": ["T4"]}, "Subject": {"text": [["two patients"]], "start": [[22]], "entity_id": ["T3"], "Population": {"text": [["two"]], "start": [[22]], "entity_id": ["T7"]}}, "Treatment": {"text": [["oral colchicine therapy"]], "start": [[127]], "entity_id": ["T5"], "Drug": {"text": [["colchicine"]], "start": [[132]], "entity_id": ["T8"]}, "Route": {"text": [["oral"]], "start": [[127]], "entity_id": ["T9"]}}, "Effect": {"text": [["corneal ulcers"]], "start": [[40]], "entity_id": ["T6"]}}]}]}
{"id": "2937155_3", "context": "Vancomycin-induced vasculitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T4"]}, "Treatment": {"text": [["Vancomycin"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Vancomycin"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["vasculitis"]], "start": [[19]], "entity_id": ["T5"]}}]}]}
{"id": "8641617_2", "context": "Based on our findings, it is thus concluded that cisplatin may cause C. difficile colitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[63]], "entity_id": ["T4"]}, "Treatment": {"text": [["cisplatin"]], "start": [[49]], "entity_id": ["T3"], "Drug": {"text": [["cisplatin"]], "start": [[49]], "entity_id": ["T7"]}}, "Effect": {"text": [["C. difficile colitis"]], "start": [[69]], "entity_id": ["T5"]}, "Speculated": {"text": [["may"]], "start": [[59]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "7249424_2", "context": "Nephrotic syndrome associated with lithium therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[19]], "entity_id": ["T4"]}, "Effect": {"text": [["Nephrotic syndrome"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["lithium therapy"]], "start": [[35]], "entity_id": ["T5"], "Drug": {"text": [["lithium"]], "start": [[35]], "entity_id": ["T6"]}}}]}]}
{"id": "10728450_1", "context": "We report 2 patients who developed polyarteritis nodosa following vaccination against hepatitis B.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[25]], "entity_id": ["T4"]}, "Subject": {"text": [["2 patients"]], "start": [[10]], "entity_id": ["T3"], "Population": {"text": [["2"]], "start": [[10]], "entity_id": ["T7"]}}, "Effect": {"text": [["polyarteritis nodosa"]], "start": [[35]], "entity_id": ["T5"]}, "Treatment": {"text": [["vaccination against hepatitis B"]], "start": [[66]], "entity_id": ["T6"], "Drug": {"text": [["vaccination against hepatitis B"]], "start": [[66]], "entity_id": ["T8"]}}}]}]}
{"id": "7594371_3", "context": "We recommend the cautious use of ketorolac in patients with underlying illnesses where NSAID-induced ototoxicity could result in adverse otologic consequences.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["where"]], "start": [[81]], "entity_id": ["T6"]}, "Treatment": {"text": [["ketorolac"]], "start": [[33]], "entity_id": ["T3"], "Drug": {"text": [["ketorolac"]], "start": [[33]], "entity_id": ["T9"]}}, "Subject": {"text": [["patients with underlying illnesses"]], "start": [[46]], "entity_id": ["T4"], "Disorder": {"text": [["underlying illnesses"]], "start": [[60]], "entity_id": ["T7"]}}, "Effect": {"text": [["NSAID-induced ototoxicity could result in adverse otologic consequences"]], "start": [[87]], "entity_id": ["T5"]}, "Speculated": {"text": [["could"]], "start": [[113]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "19660974_1", "context": "Colitis as a manifestation of infliximab-associated disseminated cryptococcosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[41]], "entity_id": ["T8"]}, "Effect": {"text": [["Colitis"]], "start": [[0]], "entity_id": ["T6"]}, "Treatment": {"text": [["infliximab"]], "start": [[30]], "entity_id": ["T7"], "Drug": {"text": [["infliximab"]], "start": [[30]], "entity_id": ["T9"]}}}]}]}
{"id": "8276031_2", "context": "A 15-month-old girl with rhinopharyngitis was treated with a nasal solution containing the imidazoline derivative naphazoline.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[46]], "entity_id": ["T7"]}, "Subject": {"text": [["A 15-month-old girl with rhinopharyngitis"]], "start": [[0]], "entity_id": ["T6"], "Age": {"text": [["15-month-old"]], "start": [[2]], "entity_id": ["T9"]}, "Gender": {"text": [["girl"]], "start": [[15]], "entity_id": ["T10"]}}, "Treatment": {"text": [["a nasal solution containing the imidazoline derivative naphazoline"]], "start": [[59]], "entity_id": ["T8"], "Disorder": {"text": [["rhinopharyngitis"]], "start": [[25]], "entity_id": ["T11"]}, "Drug": {"text": [["imidazoline derivative"]], "start": [[91]], "entity_id": ["T12"]}, "Route": {"text": [["naphazoline"]], "start": [[114]], "entity_id": ["T13"]}}}]}]}
{"id": "9804082_1", "context": "Three diabetic cases of acute dizziness due to initial administration of voglibose.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[40]], "entity_id": ["T5"]}, "Subject": {"text": [["Three diabetic cases"]], "start": [[0]], "entity_id": ["T3"], "Population": {"text": [["Three"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["acute dizziness"]], "start": [[24]], "entity_id": ["T4"]}, "Treatment": {"text": [["initial administration of voglibose"]], "start": [[47]], "entity_id": ["T6"], "Drug": {"text": [["voglibose"]], "start": [[73]], "entity_id": ["T9"]}, "Disorder": {"text": [["diabetic"]], "start": [[6]], "entity_id": ["T10"]}}}]}]}
{"id": "14607011_1", "context": "Fatal cold medication intoxication in an infant.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[35]], "entity_id": ["T5"]}, "Effect": {"text": [["Fatal cold medication intoxication"]], "start": [[0]], "entity_id": ["T6"]}, "Treatment": {"text": [["cold medication"]], "start": [[6]], "entity_id": ["T7"], "Drug": {"text": [["cold medication"]], "start": [[6]], "entity_id": ["T11"]}}, "Subject": {"text": [["infant"]], "start": [[41]], "entity_id": ["T8"], "Age": {"text": [["infant"]], "start": [[41]], "entity_id": ["T9"]}}}]}]}
{"id": "7779233_1", "context": "Case study: a modified topical treatment regimen for sodium warfarin-induced necrotizing fasciitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[69]], "entity_id": ["T4"]}, "Treatment": {"text": [["sodium warfarin"]], "start": [[53]], "entity_id": ["T3"], "Drug": {"text": [["sodium warfarin"]], "start": [[53]], "entity_id": ["T6"]}}, "Effect": {"text": [["necrotizing fasciitis"]], "start": [[77]], "entity_id": ["T5"]}}]}]}
{"id": "16211208_2", "context": "Marked QT prolongation and torsades de pointes secondary to acute ischemia in an elderly man taking dofetilide for atrial fibrillation: a cautionary tale.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["taking"]], "start": [[93]], "entity_id": ["T10"]}, "Treatment": {"text": [["dofetilide"]], "start": [[100]], "entity_id": ["T7"], "Drug": {"text": [["dofetilide"]], "start": [[100]], "entity_id": ["T14"]}, "Disorder": {"text": [["atrial fibrillation"]], "start": [[115]], "entity_id": ["T15"]}}, "Subject": {"text": [["an elderly man"]], "start": [[78]], "entity_id": ["T8"], "Age": {"text": [["elderly"]], "start": [[81]], "entity_id": ["T11"]}, "Gender": {"text": [["man"]], "start": [[89]], "entity_id": ["T12"]}}, "Effect": {"text": [["Marked QT prolongation and torsades de pointes secondary to acute ischemia"]], "start": [[0]], "entity_id": ["T9"]}}]}]}
{"id": "18431096_1", "context": "Methylphenidate and dextroamphetamine-induced peripheral vasculopathy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[38]], "entity_id": ["T5"]}, "Treatment": {"text": [["Methylphenidate and dextroamphetamine"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["dextroamphetamine"], ["Methylphenidate"]], "start": [[20], [0]], "entity_id": ["T7", "T8"]}}, "Effect": {"text": [["peripheral vasculopathy"]], "start": [[46]], "entity_id": ["T6"]}}]}]}
{"id": "8969033_3", "context": "The reversal of heparin by protamine may cause severe hemodynamic deterioration, characterized by systemic hypotension, pulmonary hypertension, and bronchoconstriction.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[41]], "entity_id": ["T10"]}, "Effect": {"text": [["severe hemodynamic deterioration", "systemic hypotension, pulmonary hypertension, and bronchoconstriction"]], "start": [[47, 98]], "entity_id": ["T9"]}, "Treatment": {"text": [["The reversal of heparin by protamine"]], "start": [[0]], "entity_id": ["T12"], "Drug": {"text": [["heparin"], ["protamine"]], "start": [[16], [27]], "entity_id": ["T16", "T17"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["reversal"]], "start": [[4]], "entity_id": ["T15"]}, "Drug": {"text": [["heparin"], ["protamine"]], "start": [[16], [27]], "entity_id": ["T16", "T17"]}}]}, "Speculated": {"text": [["may"]], "start": [[37]], "entity_id": ["T11"], "value": true}}]}]}
{"id": "19826099_1", "context": "OBJECTIVE: To report a case of severe apnea in an infant exposed to lamotrigine through breast-feeding.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[44]], "entity_id": ["T6"]}, "Effect": {"text": [["severe apnea"]], "start": [[31]], "entity_id": ["T3"]}, "Subject": {"text": [["an infant"]], "start": [[47]], "entity_id": ["T4"], "Age": {"text": [["infant"]], "start": [[50]], "entity_id": ["T7"]}}, "Treatment": {"text": [["exposed to lamotrigine through breast-feeding"]], "start": [[57]], "entity_id": ["T5"], "Drug": {"text": [["lamotrigine"]], "start": [[68]], "entity_id": ["T8"]}, "Route": {"text": [["breast-feeding"]], "start": [[88]], "entity_id": ["T9"]}}, "Severity": {"text": [["severe"]], "start": [[31]], "entity_id": ["T10"], "value": "Medium"}}]}]}
{"id": "1316047_1", "context": "Hemodynamic collapse following labetalol administration in preeclampsia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[21]], "entity_id": ["T6"]}, "Effect": {"text": [["Hemodynamic collapse"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["labetalol"]], "start": [[31]], "entity_id": ["T4"], "Drug": {"text": [["labetalol"]], "start": [[31]], "entity_id": ["T7"]}, "Disorder": {"text": [["preeclampsia"]], "start": [[59]], "entity_id": ["T8"]}}}]}]}
{"id": "18801826_3", "context": "We report a case of a 35-year old female who developed new onset type II diabetes mellitus with hyperosmolar hyperglycaemic coma and acute renal failure following treatment with a SGA for a first manic episode.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[45]], "entity_id": ["T10"]}, "Subject": {"text": [["35-year old female"]], "start": [[22]], "entity_id": ["T9"], "Age": {"text": [["35-year old"]], "start": [[22]], "entity_id": ["T13"]}, "Gender": {"text": [["female"]], "start": [[34]], "entity_id": ["T14"]}}, "Effect": {"text": [["type II diabetes mellitus with hyperosmolar hyperglycaemic coma and acute renal failure"]], "start": [[65]], "entity_id": ["T11"]}, "Treatment": {"text": [["treatment with a SGA"]], "start": [[163]], "entity_id": ["T12"], "Drug": {"text": [["SGA"]], "start": [[180]], "entity_id": ["T15"]}}}]}]}
{"id": "8503421_3", "context": "We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue-type plasminogen activator (t-PA).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurrence"]], "start": [[14]], "entity_id": ["T7"]}, "Treatment": {"text": [["thrombolytic therapy with intravenous recombinant tissue-type plasminogen activator (t-PA)"]], "start": [[92]], "entity_id": ["T9"], "Route": {"text": [["intravenous"]], "start": [[118]], "entity_id": ["T10"]}, "Drug": {"text": [["recombinant tissue-type plasminogen activator"]], "start": [[130]], "entity_id": ["T11"]}}, "Effect": {"text": [["renal failure due to cholesterol crystal embolization"]], "start": [[28]], "entity_id": ["T8"]}}]}]}
{"id": "9161656_8", "context": "The asthma resolved within 24 hours following three albuterol inhalations.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["resolved"]], "start": [[11]], "entity_id": ["T5"]}, "Treatment": {"text": [["three albuterol inhalations"]], "start": [[46]], "entity_id": ["T6"], "Disorder": {"text": [["asthma"]], "start": [[4]], "entity_id": ["T7"]}, "Dosage": {"text": [["three"]], "start": [[46]], "entity_id": ["T8"]}, "Drug": {"text": [["albuterol"]], "start": [[52]], "entity_id": ["T9"]}, "Time_elapsed": {"text": [["within 24 hours"]], "start": [[20]], "entity_id": ["T10"]}, "Route": {"text": [["inhalations"]], "start": [[62]], "entity_id": ["T4"]}}}]}]}
{"id": "2875665_2", "context": "Administration of amantadine was associated with psychotic decompensations in two schizophrenic patients being maintained on concomitant neuroleptic medication.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[33]], "entity_id": ["T10"]}, "Treatment": {"text": [["concomitant neuroleptic medication", "amantadine"]], "start": [[125, 18]], "entity_id": ["T9"], "Drug": {"text": [["amantadine"], ["neuroleptic"]], "start": [[18], [137]], "entity_id": ["T15", "T16"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["concomitant"]], "start": [[125]], "entity_id": ["T17"]}, "Drug": {"text": [["neuroleptic"], ["amantadine"]], "start": [[137], [18]], "entity_id": ["T16", "T15"]}}]}, "Effect": {"text": [["psychotic decompensations"]], "start": [[49]], "entity_id": ["T11"]}, "Subject": {"text": [["two schizophrenic patients"]], "start": [[78]], "entity_id": ["T12"], "Population": {"text": [["two"]], "start": [[78]], "entity_id": ["T13"]}, "Disorder": {"text": [["schizophrenic"]], "start": [[82]], "entity_id": ["T14"]}}}]}]}
{"id": "6998294_1", "context": "Clinicians should be aware of fasting hypoglycemia as an unusual but potentially serious complication of disopyramide therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[89]], "entity_id": ["T5"]}, "Treatment": {"text": [["disopyramide"]], "start": [[105]], "entity_id": ["T3"], "Drug": {"text": [["disopyramide"]], "start": [[105]], "entity_id": ["T9"]}}, "Effect": {"text": [["fasting hypoglycemia"]], "start": [[30]], "entity_id": ["T4"]}, "Speculated": {"text": [["potentially"]], "start": [[69]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "1569260_1", "context": "To the best of our knowledge, this is the first reported patient with captopril-induced pemphigus in whom no new lesions developed after subsequent treatment with enalapril.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[80]], "entity_id": ["T4"]}, "Treatment": {"text": [["captopril"]], "start": [[70]], "entity_id": ["T3"], "Drug": {"text": [["captopril"]], "start": [[70]], "entity_id": ["T7"]}}, "Effect": {"text": [["pemphigus"]], "start": [[88]], "entity_id": ["T5"]}, "Subject": {"text": [["patient"]], "start": [[57]], "entity_id": ["T6"]}}]}]}
{"id": "9494448_5", "context": "Fortunately, a hypersensitivity reaction to one formulation of cyclosporine does not preclude use of a different formulation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["to"]], "start": [[41]], "entity_id": ["T5"]}, "Effect": {"text": [["hypersensitivity reaction"]], "start": [[15]], "entity_id": ["T3"]}, "Treatment": {"text": [["one formulation of cyclosporine"]], "start": [[44]], "entity_id": ["T4"], "Drug": {"text": [["cyclosporine"]], "start": [[63]], "entity_id": ["T6"]}}}]}]}
{"id": "11302479_1", "context": "She developed a severe urticarial rash 3 weeks following initiation of therapy with Enoxaparin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[4]], "entity_id": ["T3"]}, "Effect": {"text": [["urticarial rash"]], "start": [[23]], "entity_id": ["T4"]}, "Treatment": {"text": [["Enoxaparin"]], "start": [[84]], "entity_id": ["T5"], "Time_elapsed": {"text": [["3 weeks following"]], "start": [[39]], "entity_id": ["T6"]}, "Drug": {"text": [["Enoxaparin"]], "start": [[84]], "entity_id": ["T7"]}}, "Severity": {"text": [["severe"]], "start": [[16]], "entity_id": ["T8"], "value": "High"}}]}]}
{"id": "9545161_3", "context": "Fatal toxic epidermal necrolysis related to lamotrigine administration.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related to"]], "start": [[33]], "entity_id": ["T4"]}, "Effect": {"text": [["Fatal toxic epidermal necrolysis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["lamotrigine administration"]], "start": [[44]], "entity_id": ["T5"], "Drug": {"text": [["lamotrigine"]], "start": [[44]], "entity_id": ["T7"]}}, "Severity": {"text": [["Fatal"]], "start": [[0]], "entity_id": ["T6"], "value": "Medium"}}]}]}
{"id": "11918514_3", "context": "OBJECTIVE: To document a case of serotonin syndrome (SS) associated with mirtazapine monotherapy, review the previously reported cases of SS associated with this tetracyclic antidepressant, and discuss the possible pathogenic mechanisms leading to this serious adverse drug reaction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[57]], "entity_id": ["T7"]}, "Subject": {"text": [["a case"]], "start": [[23]], "entity_id": ["T5"]}, "Effect": {"text": [["serotonin syndrome (SS)"]], "start": [[33]], "entity_id": ["T6"]}, "Treatment": {"text": [["mirtazapine monotherapy"]], "start": [[73]], "entity_id": ["T8"], "Drug": {"text": [["mirtazapine"]], "start": [[73]], "entity_id": ["T9"]}}}]}]}
{"id": "15331204_6", "context": "CONCLUSION: Therapy with indapamide may induce diabetes in essential hypertension patients.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induce"]], "start": [[40]], "entity_id": ["T10"]}, "Effect": {"text": [["diabetes"]], "start": [[47]], "entity_id": ["T8"]}, "Treatment": {"text": [["indapamide"]], "start": [[25]], "entity_id": ["T9"], "Drug": {"text": [["indapamide"]], "start": [[25]], "entity_id": ["T14"]}, "Disorder": {"text": [["essential hypertension"]], "start": [[59]], "entity_id": ["T15"]}}, "Subject": {"text": [["essential hypertension patients"]], "start": [[59]], "entity_id": ["T11"]}, "Speculated": {"text": [["may"]], "start": [[36]], "entity_id": ["T13"], "value": true}}]}]}
{"id": "11033836_2", "context": "Placebo-controlled clinical trials of recombinant human interleukin-11 (rhIL-11, also known as oprelvekin [Neumega]) in patients with nonmyeloid malignancies have demonstrated significant efficacy in preventing postchemotherapy platelet nadirs of < or = 20,000/microL, and reducing the need for platelet transfusions while continuing chemotherapy without dose reductions.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["preventing"]], "start": [[200]], "entity_id": ["T15"]}, "Subject": {"text": [["patients with nonmyeloid malignancies"]], "start": [[120]], "entity_id": ["T12"], "Disorder": {"text": [["nonmyeloid malignancies"]], "start": [[134]], "entity_id": ["T17"]}}, "Treatment": {"text": [["recombinant human interleukin-11 (rhIL-11, also known as oprelvekin [Neumega])"]], "start": [[38]], "entity_id": ["T11"], "Disorder": {"text": [["postchemotherapy platelet nadirs of < or = 20,000/microL"]], "start": [[211]], "entity_id": ["T16"]}, "Drug": {"text": [["recombinant human interleukin-11"]], "start": [[38]], "entity_id": ["T13"]}}}]}]}
{"id": "115078_1", "context": "A patient with rheumatoid arthritis developed an acute intrahepatic cholestasis after 100 mg of sodium aurothiomalate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[36]], "entity_id": ["T7"]}, "Subject": {"text": [["A patient with rheumatoid arthritis"]], "start": [[0]], "entity_id": ["T3"]}, "Effect": {"text": [["acute intrahepatic cholestasis"]], "start": [[49]], "entity_id": ["T5"]}, "Treatment": {"text": [["100 mg of sodium aurothiomalate"]], "start": [[86]], "entity_id": ["T8"], "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[15]], "entity_id": ["T4"]}, "Dosage": {"text": [["100 mg"]], "start": [[86]], "entity_id": ["T10"]}, "Drug": {"text": [["sodium aurothiomalate"]], "start": [[96]], "entity_id": ["T11"]}}}]}]}
{"id": "17965530_2", "context": "We concluded that the colonic ulcer and the sigmoidovesical fistula had been caused by the administration of calcium polystyrene sulfonate and sorbitol.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[77]], "entity_id": ["T7"]}, "Treatment": {"text": [["calcium polystyrene sulfonate and sorbitol"]], "start": [[109]], "entity_id": ["T8"], "Drug": {"text": [["calcium polystyrene sulfonate"], ["sorbitol"]], "start": [[109], [143]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[139]], "entity_id": ["T12"]}, "Drug": {"text": [["sorbitol"], ["calcium polystyrene sulfonate"]], "start": [[143], [109]], "entity_id": ["T11", "T10"]}}]}, "Effect": {"text": [["colonic ulcer and the sigmoidovesical fistula"]], "start": [[22]], "entity_id": ["T9"]}}]}]}
{"id": "15606443_2", "context": "Rosiglitazone, a thiazolidinedione antidiabetic medication used in the treatment of Type 2 diabetes mellitus, is predominantly metabolized by the cytochrome P450 (CYP) enzyme CYP2C8.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["used"]], "start": [[59]], "entity_id": ["T6"]}, "Treatment": {"text": [["Rosiglitazone", "a thiazolidinedione antidiabetic medication"]], "start": [[0, 15]], "entity_id": ["T5"], "Drug": {"text": [["Rosiglitazone"], ["thiazolidinedione antidiabetic medication"]], "start": [[0], [17]], "entity_id": ["T8", "T9"]}, "Disorder": {"text": [["Type 2 diabetes mellitus"]], "start": [[84]], "entity_id": ["T10"]}}}]}]}
{"id": "17873198_1", "context": "Interstitial lung disease (ILD) related to therapy with the drug gefitinib has been well reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[32]], "entity_id": ["T6"]}, "Effect": {"text": [["Interstitial lung disease (ILD)"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["therapy with the drug gefitinib"]], "start": [[43]], "entity_id": ["T7"], "Drug": {"text": [["gefitinib"]], "start": [[65]], "entity_id": ["T8"]}}}]}]}
{"id": "19540093_1", "context": "According to the Naranjo adverse drug reaction probability scale, tigecycline was the probable cause of her acute pancreatitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[95]], "entity_id": ["T6"]}, "Effect": {"text": [["acute pancreatitis"]], "start": [[108]], "entity_id": ["T3"]}, "Treatment": {"text": [["tigecycline"]], "start": [[66]], "entity_id": ["T4"], "Drug": {"text": [["tigecycline"]], "start": [[66]], "entity_id": ["T8"]}}, "Speculated": {"text": [["probable"]], "start": [[86]], "entity_id": ["T5"], "value": true}}]}]}
{"id": "15479299_2", "context": "We report a case of severe anemia, which responded well to steroid therapy, in a patient receiving IL-2 plus IFN-alpha for metastatic renal cell carcinoma.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E3", "event_type": "Adverse_event", "Trigger": {"text": [["receiving"]], "start": [[89]], "entity_id": ["T14"]}, "Treatment": {"text": [["IL-2 plus IFN-alpha"]], "start": [[99]], "entity_id": ["T6"], "Disorder": {"text": [["metastatic renal cell carcinoma"]], "start": [[123]], "entity_id": ["T9"]}, "Drug": {"text": [["IL-2"], ["IFN-alpha"]], "start": [[99], [109]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["plus"]], "start": [[104]], "entity_id": ["T12"]}, "Drug": {"text": [["IFN-alpha"], ["IL-2"]], "start": [[109], [99]], "entity_id": ["T11", "T10"]}}]}, "Subject": {"text": [["a patient"]], "start": [[79]], "entity_id": ["T7"]}, "Effect": {"text": [["severe anemia"]], "start": [[20]], "entity_id": ["T4"]}, "Severity": {"text": [["severe"]], "start": [[20]], "entity_id": ["T13"], "value": "High"}}, {"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["responded"]], "start": [[41]], "entity_id": ["T18"]}, "Treatment": {"text": [["steroid"]], "start": [[59]], "entity_id": ["T16"], "Disorder": {"text": [["severe anemia"]], "start": [[20]], "entity_id": ["T8"]}, "Drug": {"text": [["steroid"]], "start": [[59]], "entity_id": ["T17"]}}}]}]}
{"id": "17420198_17", "context": "The patient's movements resolved following diphenhydramine administration.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["resolved"]], "start": [[24]], "entity_id": ["T5"]}, "Treatment": {"text": [["diphenhydramine"]], "start": [[43]], "entity_id": ["T6"], "Drug": {"text": [["diphenhydramine"]], "start": [[43]], "entity_id": ["T7"]}, "Disorder": {"text": [["movements"]], "start": [[14]], "entity_id": ["T4"]}}}]}]}
{"id": "10679548_5", "context": "The spectrum of nitrofurantoin lung injury continues to widen.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["widen"]], "start": [[56]], "entity_id": ["T4"]}, "Effect": {"text": [["lung injury"]], "start": [[31]], "entity_id": ["T3"]}, "Treatment": {"text": [["nitrofurantoin"]], "start": [[16]], "entity_id": ["T5"], "Drug": {"text": [["nitrofurantoin"]], "start": [[16]], "entity_id": ["T6"]}}}]}]}
{"id": "12243603_10", "context": "We describe a patient with a complex medication regimen who was admitted for rhabdomyolysis and accompanying acute renal failure, along with acute hepatitis, thought to be secondary to a drug interaction between atorvastatin and diltiazem.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["secondary"]], "start": [[172]], "entity_id": ["T12"]}, "Subject": {"text": [["a patient"]], "start": [[12]], "entity_id": ["T9"]}, "Treatment": {"text": [["atorvastatin", "diltiazem"]], "start": [[212, 229]], "entity_id": ["T10"], "Drug": {"text": [["atorvastatin"], ["diltiazem"]], "start": [[212], [229]], "entity_id": ["T14", "T15"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[192]], "entity_id": ["T13"]}, "Drug": {"text": [["atorvastatin"], ["diltiazem"]], "start": [[212], [229]], "entity_id": ["T14", "T15"]}}]}, "Effect": {"text": [["rhabdomyolysis and accompanying acute renal failure, along with acute hepatitis"]], "start": [[77]], "entity_id": ["T11"]}}]}]}
{"id": "11077455_4", "context": "The current study investigated the visual fields and visual electrophysiology of eight patients with known vigabatrin-attributed visual field loss, three of whom were reported previously.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["attributed"]], "start": [[118]], "entity_id": ["T4"]}, "Treatment": {"text": [["vigabatrin"]], "start": [[107]], "entity_id": ["T3"], "Drug": {"text": [["vigabatrin"]], "start": [[107]], "entity_id": ["T8"]}}, "Effect": {"text": [["visual field loss"]], "start": [[129]], "entity_id": ["T5"]}, "Subject": {"text": [["eight patients"]], "start": [[81]], "entity_id": ["T6"], "Population": {"text": [["eight"]], "start": [[81]], "entity_id": ["T7"]}}}]}]}
{"id": "10840527_1", "context": "Although the literature on the use of risperidone in elderly patients with dementia consists largely of uncontrolled trials, case reports, and chart reviews, it appears that this agent is effective for managing agitation in this population and does so with a low frequency of extrapyramidal symptoms (EPS).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["is"]], "start": [[185]], "entity_id": ["T8"]}, "Treatment": {"text": [["use of risperidone"]], "start": [[31]], "entity_id": ["T5"], "Drug": {"text": [["risperidone"]], "start": [[38]], "entity_id": ["T11"]}, "Disorder": {"text": [["dementia"]], "start": [[75]], "entity_id": ["T12"]}}, "Subject": {"text": [["elderly patients with dementia"]], "start": [[53]], "entity_id": ["T6"], "Age": {"text": [["elderly"]], "start": [[53]], "entity_id": ["T9"]}}}]}]}
{"id": "18294121_4", "context": "Temozolomide-induced desquamative skin rash in a patient with metastatic melanoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[13]], "entity_id": ["T4"]}, "Treatment": {"text": [["Temozolomide"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Temozolomide"]], "start": [[0]], "entity_id": ["T8"]}, "Disorder": {"text": [["metastatic melanoma"]], "start": [[62]], "entity_id": ["T9"]}}, "Effect": {"text": [["desquamative skin rash"]], "start": [[21]], "entity_id": ["T5"]}, "Subject": {"text": [["a patient with metastatic melanoma"]], "start": [[47]], "entity_id": ["T6"]}}]}]}
{"id": "4066622_2", "context": "The calcium channel blockers are a group of drugs that have recently become available for the treatment of angina.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatment"]], "start": [[94]], "entity_id": ["T4"]}, "Treatment": {"text": [["calcium channel blockers"]], "start": [[4]], "entity_id": ["T6"], "Disorder": {"text": [["angina"]], "start": [[107]], "entity_id": ["T5"]}, "Drug": {"text": [["calcium channel blockers"]], "start": [[4]], "entity_id": ["T7"]}}}]}]}
{"id": "10723699_2", "context": "We report on a young adolescent with benign intracranial hypertension which we attribute to the use of minocycline for acne.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["attribute"]], "start": [[79]], "entity_id": ["T8"]}, "Treatment": {"text": [["minocycline"]], "start": [[103]], "entity_id": ["T9"], "Drug": {"text": [["minocycline"]], "start": [[103]], "entity_id": ["T13"]}, "Disorder": {"text": [["acne"]], "start": [[119]], "entity_id": ["T14"]}}, "Subject": {"text": [["a young adolescent"]], "start": [[13]], "entity_id": ["T7"], "Age": {"text": [["young adolescent"]], "start": [[15]], "entity_id": ["T12"]}}, "Effect": {"text": [["benign intracranial hypertension"]], "start": [[37]], "entity_id": ["T11"]}}]}]}
{"id": "18795_1", "context": "A 10-year-old asthmatic boy began to suffer from urticarial rash and moderately severe bronchospasm after 8 weeks' treatment with disodium cromoglycate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[100]], "entity_id": ["T7"]}, "Subject": {"text": [["A 10-year-old asthmatic boy"]], "start": [[0]], "entity_id": ["T5"], "Age": {"text": [["10-year-old"]], "start": [[2]], "entity_id": ["T9"]}, "Gender": {"text": [["boy"]], "start": [[24]], "entity_id": ["T11"]}}, "Effect": {"text": [["urticarial rash and moderately severe bronchospasm"]], "start": [[49]], "entity_id": ["T6"]}, "Treatment": {"text": [["8 weeks' treatment with disodium cromoglycate"]], "start": [[106]], "entity_id": ["T8"], "Time_elapsed": {"text": [["8 weeks'"]], "start": [[106]], "entity_id": ["T12"]}, "Drug": {"text": [["disodium cromoglycate"]], "start": [[130]], "entity_id": ["T13"]}, "Disorder": {"text": [["asthmatic"]], "start": [[14]], "entity_id": ["T14"]}}}]}]}
{"id": "2796025_1", "context": "Panic anxiety after abrupt discontinuation of mianserin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[14]], "entity_id": ["T5"]}, "Effect": {"text": [["Panic anxiety"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["abrupt discontinuation of mianserin"]], "start": [[20]], "entity_id": ["T4"], "Drug": {"text": [["mianserin"]], "start": [[46]], "entity_id": ["T6"]}}}]}]}
{"id": "17873198_4", "context": "This case and other published evidence should alert physicians to the possibility of fatal erlotinib-induced ILD.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[101]], "entity_id": ["T5"]}, "Subject": {"text": [["This case"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["erlotinib"]], "start": [[91]], "entity_id": ["T4"], "Drug": {"text": [["erlotinib"]], "start": [[91]], "entity_id": ["T7"]}}, "Effect": {"text": [["ILD"]], "start": [[109]], "entity_id": ["T6"]}, "Speculated": {"text": [["possibility"]], "start": [[70]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "17987285_3", "context": "Recent reports suggest that concomitant administration of CYP3A inhibitors with fentanyl may lead to dangerous drug interactions.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["lead"]], "start": [[93]], "entity_id": ["T8"]}, "Treatment": {"text": [["concomitant administration of CYP3A inhibitors with fentanyl"]], "start": [[28]], "entity_id": ["T7"], "Drug": {"text": [["CYP3A inhibitors"], ["fentanyl"]], "start": [[58], [80]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["concomitant"]], "start": [[28]], "entity_id": ["T13"]}, "Drug": {"text": [["CYP3A inhibitors"], ["fentanyl"]], "start": [[58], [80]], "entity_id": ["T10", "T11"]}}]}, "Effect": {"text": [["drug interactions"]], "start": [[111]], "entity_id": ["T9"]}, "Speculated": {"text": [["may"]], "start": [[89]], "entity_id": ["T12"], "value": true}, "Severity": {"text": [["dangerous"]], "start": [[101]], "entity_id": ["T14"], "value": "High"}}]}]}
{"id": "21751666_4", "context": "Post-exposure prophylaxis of H1N1 with oseltamivir was safe, effective and well tolerated to prevent H1N1 influenza A virus infection in newly transplanted renal allograft recipient receiving triple immunosuppression without any interaction with tacrolimus level.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["prophylaxis"]], "start": [[14]], "entity_id": ["T13"]}, "Subject": {"text": [["newly transplanted renal allograft recipient"]], "start": [[137]], "entity_id": ["T15"], "Disorder": {"text": [["transplanted renal allograft"]], "start": [[143]], "entity_id": ["T17"]}}, "Treatment": {"text": [["oseltamivir", "without any interaction with tacrolimus level"]], "start": [[39, 217]], "entity_id": ["T12"], "Disorder": {"text": [["H1N1"]], "start": [[29]], "entity_id": ["T16"]}, "Drug": {"text": [["oseltamivir"], ["tacrolimus"]], "start": [[39], [246]], "entity_id": ["T19", "T14"]}, "Combination": [{"event_id": "E3", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[229]], "entity_id": ["T24"]}, "Drug": {"text": [["tacrolimus"], ["oseltamivir"]], "start": [[246], [39]], "entity_id": ["T14", "T19"]}}]}, "Effect": {"text": [["safe, effective and well tolerated to prevent H1N1 influenza A virus infection"]], "start": [[55]], "entity_id": ["T21"]}}]}]}
{"id": "8672829_3", "context": "DISCUSSION: Central nervous system (CNS) toxicity has been described with ifosfamide, with most cases reported in the pediatric population.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["described"]], "start": [[59]], "entity_id": ["T7"]}, "Subject": {"text": [["in the pediatric population"]], "start": [[111]], "entity_id": ["T4"], "Age": {"text": [["pediatric"]], "start": [[118]], "entity_id": ["T8"]}}, "Treatment": {"text": [["ifosfamide"]], "start": [[74]], "entity_id": ["T6"], "Drug": {"text": [["ifosfamide"]], "start": [[74]], "entity_id": ["T9"]}}, "Effect": {"text": [["Central nervous system (CNS) toxicity"]], "start": [[12]], "entity_id": ["T5"]}}]}]}
{"id": "12796597_2", "context": "Despite the underlying hepatitis C, this case represents renal abnormalities consistent with IFNalpha therapy for CML.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["consistent"]], "start": [[77]], "entity_id": ["T5"]}, "Effect": {"text": [["renal abnormalities"]], "start": [[57]], "entity_id": ["T3"]}, "Subject": {"text": [["this case"]], "start": [[36]], "entity_id": ["T4"]}, "Treatment": {"text": [["IFNalpha therapy"]], "start": [[93]], "entity_id": ["T6"], "Drug": {"text": [["IFNalpha"]], "start": [[93]], "entity_id": ["T8"]}, "Disorder": {"text": [["CML"]], "start": [[114]], "entity_id": ["T9"]}}}]}]}
{"id": "11131346_4", "context": "CONCLUSION: To the best of our knowledge, this is the first time colchicine intoxication in this age group has been described in the English literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["intoxication"]], "start": [[76]], "entity_id": ["T3"]}, "Treatment": {"text": [["colchicine"]], "start": [[65]], "entity_id": ["T4"], "Drug": {"text": [["colchicine"]], "start": [[65]], "entity_id": ["T6"]}}, "Effect": {"text": [["colchicine intoxication"]], "start": [[65]], "entity_id": ["T5"]}}]}]}
{"id": "85289_2", "context": "We have seen a case of terminal malignant melanoma in which clinical manifestations, indicative of anterior spinal artery syndrome, developed following the injection of 0.3 ml of 10% phenol-glycerine into the cervical subarachnoid space at the C4--C5 level for the control of severe right arm pain.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[132]], "entity_id": ["T3"]}, "Effect": {"text": [["terminal malignant melanoma in which clinical manifestations, indicative of anterior spinal artery syndrome"]], "start": [[23]], "entity_id": ["T4"]}, "Treatment": {"text": [["the injection of 0.3 ml of 10% phenol-glycerine into the cervical subarachnoid space at the C4--C5 level"]], "start": [[152]], "entity_id": ["T5"], "Drug": {"text": [["10% phenol-glycerine"]], "start": [[179]], "entity_id": ["T7"]}, "Disorder": {"text": [["severe right arm pain"]], "start": [[276]], "entity_id": ["T8"]}, "Route": {"text": [["injection"], ["cervical subarachnoid space at the C4--C5 level"]], "start": [[156], [209]], "entity_id": ["T9", "T11"]}, "Dosage": {"text": [["0.3 ml"]], "start": [[169]], "entity_id": ["T10"]}}}]}]}
{"id": "10904571_2", "context": "Colchicine-induced myopathy in renal failure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T5"]}, "Treatment": {"text": [["Colchicine"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Colchicine"]], "start": [[0]], "entity_id": ["T7"]}, "Disorder": {"text": [["renal failure"]], "start": [[31]], "entity_id": ["T4"]}}, "Effect": {"text": [["myopathy"]], "start": [[19]], "entity_id": ["T6"]}}]}]}
{"id": "7679525_4", "context": "This report suggests that bleomycin lung toxicity may be reversible if treated aggressively.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["toxicity"]], "start": [[41]], "entity_id": ["T5"]}, "Treatment": {"text": [["bleomycin"]], "start": [[26]], "entity_id": ["T4"], "Drug": {"text": [["bleomycin"]], "start": [[26]], "entity_id": ["T7"]}}, "Effect": {"text": [["lung toxicity"]], "start": [[36]], "entity_id": ["T6"]}, "Speculated": {"text": [["may"]], "start": [[50]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "15840734_8", "context": "DISCUSSION: NMS is a rare but potentially fatal reaction associated with neuroleptic drugs.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[57]], "entity_id": ["T5"]}, "Treatment": {"text": [["neuroleptic drugs"]], "start": [[73]], "entity_id": ["T6"], "Drug": {"text": [["neuroleptic"]], "start": [[73]], "entity_id": ["T9"]}}, "Effect": {"text": [["NMS"]], "start": [[12]], "entity_id": ["T7"]}, "Severity": {"text": [["fatal"]], "start": [[42]], "entity_id": ["T8"], "value": "High"}}]}]}
{"id": "1378497_3", "context": "Scleroderma in association with the use of bleomycin: a report of 3 cases.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["association"]], "start": [[15]], "entity_id": ["T4"]}, "Effect": {"text": [["Scleroderma"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["bleomycin"]], "start": [[43]], "entity_id": ["T5"], "Drug": {"text": [["bleomycin"]], "start": [[43]], "entity_id": ["T8"]}}, "Subject": {"text": [["3 cases"]], "start": [[66]], "entity_id": ["T6"], "Population": {"text": [["3"]], "start": [[66]], "entity_id": ["T7"]}}}]}]}
{"id": "19733945_1", "context": "Linezolid-associated acute interstitial nephritis and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[10]], "entity_id": ["T8"]}, "Treatment": {"text": [["Linezolid"]], "start": [[0]], "entity_id": ["T7"], "Drug": {"text": [["Linezolid"]], "start": [[0]], "entity_id": ["T10"]}}, "Effect": {"text": [["acute interstitial nephritis and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome"]], "start": [[21]], "entity_id": ["T9"]}}]}]}
{"id": "16012330_5", "context": "A 3-year-old boy diagnosed with acute lymphoblastic leukemia received induction chemotherapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["received"]], "start": [[61]], "entity_id": ["T6"]}, "Subject": {"text": [["A 3-year-old boy diagnosed with acute lymphoblastic leukemia"]], "start": [[0]], "entity_id": ["T5"], "Age": {"text": [["3-year-old"]], "start": [[2]], "entity_id": ["T8"]}, "Gender": {"text": [["boy"]], "start": [[13]], "entity_id": ["T9"]}}, "Treatment": {"text": [["induction chemotherapy"]], "start": [[70]], "entity_id": ["T7"], "Disorder": {"text": [["acute lymphoblastic leukemia"]], "start": [[32]], "entity_id": ["T10"]}, "Route": {"text": [["induction chemotherapy"]], "start": [[70]], "entity_id": ["T11"]}}}]}]}
{"id": "17438184_8", "context": "Interferon and other immunostimulatory medications can lead to an exacerbation of this preexisting low-grade chronic inflammation that is quite similar to interferon-triggered sarcoidosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["lead"]], "start": [[55]], "entity_id": ["T8"]}, "Treatment": {"text": [["Interferon and other immunostimulatory medications"]], "start": [[0]], "entity_id": ["T11"], "Drug": {"text": [["Interferon"]], "start": [[0]], "entity_id": ["T13"]}}, "Effect": {"text": [["exacerbation of this preexisting low-grade chronic inflammation"]], "start": [[66]], "entity_id": ["T9"]}}]}]}
{"id": "2768785_1", "context": "Intravenous cytarabine and methotrexate appear to act synergistically to enhance the potential for central nervous system toxicity.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["enhance"]], "start": [[73]], "entity_id": ["T5"]}, "Treatment": {"text": [["Intravenous cytarabine and methotrexate"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["methotrexate"], ["cytarabine"]], "start": [[27], [12]], "entity_id": ["T7", "T8"]}, "Route": {"text": [["Intravenous"]], "start": [[0]], "entity_id": ["T9"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[23]], "entity_id": ["T10"]}, "Drug": {"text": [["methotrexate"], ["cytarabine"]], "start": [[27], [12]], "entity_id": ["T7", "T8"]}}]}, "Effect": {"text": [["central nervous system toxicity"]], "start": [[99]], "entity_id": ["T6"]}}]}]}
{"id": "12150593_3", "context": "We suggest adding this side effect to the list of untoward effects of lidocaine and to the differential diagnosis of fixed dilated pupils in neonates treated with lidocaine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[150]], "entity_id": ["T5"]}, "Treatment": {"text": [["lidocaine"]], "start": [[163]], "entity_id": ["T3"], "Drug": {"text": [["lidocaine"]], "start": [[163]], "entity_id": ["T8"]}}, "Subject": {"text": [["neonates"]], "start": [[141]], "entity_id": ["T4"], "Age": {"text": [["neonates"]], "start": [[141]], "entity_id": ["T7"]}}, "Effect": {"text": [["side effect"]], "start": [[23]], "entity_id": ["T6"]}}]}]}
{"id": "17444802_14", "context": "CONCLUSIONS: Topical INF alpha 2-beta is a valid choice for the treatment of CIN in patients for whom surgery is not possible.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["a valid choice"]], "start": [[41]], "entity_id": ["T5"]}, "Treatment": {"text": [["Topical INF alpha 2-beta"]], "start": [[13]], "entity_id": ["T4"], "Disorder": {"text": [["CIN"]], "start": [[77]], "entity_id": ["T6"]}, "Route": {"text": [["Topical"]], "start": [[13]], "entity_id": ["T8"]}, "Drug": {"text": [["INF alpha 2-beta"]], "start": [[21]], "entity_id": ["T9"]}}, "Subject": {"text": [["patients for whom surgery is not possible"]], "start": [[84]], "entity_id": ["T7"]}}]}]}
{"id": "9247841_4", "context": "We report 3 patients who developed cutaneous vasculitis which is a rare and serious side-effect during antithyroid drug therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[25]], "entity_id": ["T7"]}, "Subject": {"text": [["3 patients"]], "start": [[10]], "entity_id": ["T6"], "Population": {"text": [["3"]], "start": [[10]], "entity_id": ["T10"]}}, "Effect": {"text": [["cutaneous vasculitis"]], "start": [[35]], "entity_id": ["T8"]}, "Treatment": {"text": [["during antithyroid drug therapy"]], "start": [[96]], "entity_id": ["T9"], "Drug": {"text": [["antithyroid"]], "start": [[103]], "entity_id": ["T11"]}}}]}]}
{"id": "1621023_3", "context": "Prominent eye movements during NREM sleep and REM sleep behavior disorder associated with fluoxetine treatment of depression and obsessive-compulsive disorder.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[74]], "entity_id": ["T6"]}, "Effect": {"text": [["Prominent eye movements during NREM sleep and REM sleep behavior disorder"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["fluoxetine treatment"]], "start": [[90]], "entity_id": ["T7"], "Drug": {"text": [["fluoxetine"]], "start": [[90]], "entity_id": ["T11"]}, "Disorder": {"text": [["depression"], ["obsessive-compulsive disorder"]], "start": [[114], [129]], "entity_id": ["T12", "T13"]}}, "Subject": {"text": [["depression and obsessive-compulsive disorder"]], "start": [[114]], "entity_id": ["T8"]}}]}]}
{"id": "10963515_1", "context": "Allergic reaction to gemfibrozil manifesting as eosinophilic gastroenteritis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Allergic reaction"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["gemfibrozil"]], "start": [[21]], "entity_id": ["T3"], "Drug": {"text": [["gemfibrozil"]], "start": [[21]], "entity_id": ["T6"]}}, "Effect": {"text": [["eosinophilic gastroenteritis"]], "start": [[48]], "entity_id": ["T4"]}}]}]}
{"id": "16432996_14", "context": "We suggest that sarcoidosis may develop in chronic hepatitis C patients during interferon alpha and/or ribavirin treatment, and diagnostic tests for this adverse effect should be performed during the follow-ups.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["develop"]], "start": [[32]], "entity_id": ["T9"]}, "Effect": {"text": [["sarcoidosis"]], "start": [[16]], "entity_id": ["T8"]}, "Subject": {"text": [["chronic hepatitis C patients"]], "start": [[43]], "entity_id": ["T10"]}, "Treatment": {"text": [["interferon alpha and/or ribavirin"]], "start": [[79]], "entity_id": ["T11"], "Disorder": {"text": [["chronic hepatitis C"]], "start": [[43]], "entity_id": ["T12"]}, "Drug": {"text": [["interferon alpha"], ["ribavirin"]], "start": [[79], [103]], "entity_id": ["T14", "T15"]}}, "Speculated": {"text": [["may"]], "start": [[28]], "entity_id": ["T13"], "value": true}}]}]}
{"id": "25417855_2", "context": "Azole antifungals, prescribed prophylactically to avoid severe infections in immunosuppressed organ transplant recipients, can interact with drug substrates of CYP3A4.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["interact"]], "start": [[127]], "entity_id": ["T12"]}, "Treatment": {"text": [["Azole antifungals", "drug substrates of CYP3A4"]], "start": [[0, 141]], "entity_id": ["T5"], "Disorder": {"text": [["severe infections"]], "start": [[56]], "entity_id": ["T7"]}, "Drug": {"text": [["Azole antifungals"], ["drug substrates of CYP3A4"]], "start": [[0], [141]], "entity_id": ["T10", "T6"]}, "Combination": [{"event_id": "E3", "event_type": "Combination", "Trigger": {"text": [["interact"]], "start": [[127]], "entity_id": ["T11"]}, "Drug": {"text": [["drug substrates of CYP3A4"], ["Azole antifungals"]], "start": [[141], [0]], "entity_id": ["T6", "T10"]}}]}, "Subject": {"text": [["immunosuppressed organ transplant recipients"]], "start": [[77]], "entity_id": ["T8"], "Disorder": {"text": [["immunosuppressed organ transplant"]], "start": [[77]], "entity_id": ["T9"]}}}]}]}
{"id": "11576059_2", "context": "We present the case of a 5-year-old girl who developed bilateral vocal cord paralysis following preoperative peritonsillar bupivacaine infiltration.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[86]], "entity_id": ["T5"]}, "Subject": {"text": [["a 5-year-old girl"]], "start": [[23]], "entity_id": ["T3"], "Age": {"text": [["5-year-old"]], "start": [[25]], "entity_id": ["T7"]}, "Gender": {"text": [["girl"]], "start": [[36]], "entity_id": ["T8"]}}, "Effect": {"text": [["bilateral vocal cord paralysis"]], "start": [[55]], "entity_id": ["T4"]}, "Treatment": {"text": [["preoperative peritonsillar bupivacaine infiltration"]], "start": [[96]], "entity_id": ["T6"], "Drug": {"text": [["bupivacaine"]], "start": [[123]], "entity_id": ["T9"]}, "Route": {"text": [["peritonsillar", "infiltration"]], "start": [[109, 135]], "entity_id": ["T10"]}}}]}]}
{"id": "20338114_1", "context": "One patient suffered coronary artery vasospasm, attributed to the use of topical 1:1000 epinephrine during surgery.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["attributed"]], "start": [[48]], "entity_id": ["T3"]}, "Treatment": {"text": [["topical 1:1000 epinephrine during surgery"]], "start": [[73]], "entity_id": ["T4"], "Dosage": {"text": [["1:1000"]], "start": [[81]], "entity_id": ["T8"]}, "Drug": {"text": [["epinephrine"]], "start": [[88]], "entity_id": ["T9"]}}, "Effect": {"text": [["coronary artery vasospasm"]], "start": [[21]], "entity_id": ["T5"]}, "Subject": {"text": [["One patient"]], "start": [[0]], "entity_id": ["T6"], "Population": {"text": [["One"]], "start": [[0]], "entity_id": ["T7"]}}}]}]}
{"id": "16396068_1", "context": "Trimethoprim-sulfamethoxazole-induced aseptic meningitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[30]], "entity_id": ["T3"]}, "Effect": {"text": [["aseptic meningitis"]], "start": [[38]], "entity_id": ["T4"]}, "Treatment": {"text": [["Trimethoprim-sulfamethoxazole"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Trimethoprim-sulfamethoxazole"]], "start": [[0]], "entity_id": ["T6"]}}}]}]}
{"id": "9256906_4", "context": "We describe a patient with metastatic prostate cancer who developed nonoliguric renal failure during treatment with suramin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[94]], "entity_id": ["T3"]}, "Treatment": {"text": [["suramin"]], "start": [[116]], "entity_id": ["T4"], "Drug": {"text": [["suramin"]], "start": [[116]], "entity_id": ["T8"]}, "Disorder": {"text": [["metastatic prostate cancer"]], "start": [[27]], "entity_id": ["T9"]}}, "Subject": {"text": [["a patient with metastatic prostate cancer"]], "start": [[12]], "entity_id": ["T5"]}, "Effect": {"text": [["nonoliguric renal failure"]], "start": [[68]], "entity_id": ["T6"]}}]}]}
{"id": "10656221_10", "context": "In conclusion, this case strongly suggests that gliclazide can induce acute icteric liver necro-inflammation which may be misdiagnosed clinically as acute viral hepatitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induce"]], "start": [[63]], "entity_id": ["T9"]}, "Treatment": {"text": [["gliclazide"]], "start": [[48]], "entity_id": ["T7"], "Drug": {"text": [["gliclazide"]], "start": [[48]], "entity_id": ["T11"]}}, "Effect": {"text": [["acute icteric liver necro-inflammation"]], "start": [[70]], "entity_id": ["T8"]}, "Subject": {"text": [["this case"]], "start": [[15]], "entity_id": ["T6"]}, "Speculated": {"text": [["strongly suggests"]], "start": [[25]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "15685264_7", "context": "After administration of Oxybutynin concomitantly with an increase in the dose of Dantrolene, she presented the clinical symptoms and laboratory finding of Carbamazepine intoxication.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["After"]], "start": [[0]], "entity_id": ["T9"]}, "Subject": {"text": [["she"]], "start": [[93]], "entity_id": ["T10"], "Gender": {"text": [["she"]], "start": [[93]], "entity_id": ["T13"]}}, "Treatment": {"text": [["Oxybutynin concomitantly with an increase in the dose of Dantrolene", "Carbamazepine"]], "start": [[24, 155]], "entity_id": ["T11"], "Drug": {"text": [["Carbamazepine"], ["Oxybutynin"], ["Dantrolene"]], "start": [[155], [24], [81]], "entity_id": ["T14", "T15", "T16"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["with"]], "start": [[49]], "entity_id": ["T17"]}, "Drug": {"text": [["Oxybutynin"], ["Dantrolene"]], "start": [[24], [81]], "entity_id": ["T15", "T16"]}}]}, "Effect": {"text": [["clinical symptoms and laboratory finding of Carbamazepine intoxication"]], "start": [[111]], "entity_id": ["T12"]}}]}]}
{"id": "21597286_4", "context": "A methotrexate overdosage was shown at 36 h after infusion associated with a severe renal failure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[59]], "entity_id": ["T6"]}, "Effect": {"text": [["methotrexate overdosage was shown at 36 h after infusion", "severe renal failure"]], "start": [[2, 77]], "entity_id": ["T4"]}, "Treatment": {"text": [["methotrexate"]], "start": [[2]], "entity_id": ["T7"], "Drug": {"text": [["methotrexate"]], "start": [[2]], "entity_id": ["T8"]}}, "Severity": {"text": [["severe"]], "start": [[77]], "entity_id": ["T5"], "value": "Medium"}}]}]}
{"id": "18717612_1", "context": "Ceftriaxone-induced fixed drug eruption: first report.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[12]], "entity_id": ["T3"]}, "Treatment": {"text": [["Ceftriaxone"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Ceftriaxone"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["fixed drug eruption"]], "start": [[20]], "entity_id": ["T5"]}}]}]}
{"id": "7594371_4", "context": "We report the case of a 20-year-old female with polyarteritis nodosa (PAN) who developed bilateral sensorineural hearing loss 25 minutes after receiving 30 mg of intravenous ketoralac.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[79]], "entity_id": ["T7"]}, "Subject": {"text": [["20-year-old female with polyarteritis nodosa (PAN)"]], "start": [[24]], "entity_id": ["T3"], "Age": {"text": [["20-year-old"]], "start": [[24]], "entity_id": ["T8"]}, "Gender": {"text": [["female"]], "start": [[36]], "entity_id": ["T9"]}}, "Effect": {"text": [["bilateral sensorineural hearing loss"]], "start": [[89]], "entity_id": ["T5"]}, "Treatment": {"text": [["30 mg of intravenous ketoralac"]], "start": [[153]], "entity_id": ["T6"], "Disorder": {"text": [["polyarteritis nodosa"]], "start": [[48]], "entity_id": ["T10"]}, "Time_elapsed": {"text": [["25 minutes after"]], "start": [[126]], "entity_id": ["T11"]}, "Dosage": {"text": [["30 mg"]], "start": [[153]], "entity_id": ["T12"]}, "Route": {"text": [["intravenous"]], "start": [[162]], "entity_id": ["T13"]}, "Drug": {"text": [["ketoralac"]], "start": [[174]], "entity_id": ["T14"]}}}]}]}
{"id": "19915794_4", "context": "We report an 82-year-old man who developed ventricular tachycardia and Torsades de Pointes (TdP) after oral administration of garenoxacin, a novel quinolone antibiotic agent that differs from the third-generation quinolones, for pneumonia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[97]], "entity_id": ["T7"]}, "Treatment": {"text": [["oral administration of garenoxacin"]], "start": [[103]], "entity_id": ["T8"], "Disorder": {"text": [["pneumonia"]], "start": [[229]], "entity_id": ["T11"]}, "Route": {"text": [["oral"]], "start": [[103]], "entity_id": ["T14"]}, "Drug": {"text": [["garenoxacin"]], "start": [[126]], "entity_id": ["T15"]}}, "Subject": {"text": [["an 82-year-old man"]], "start": [[10]], "entity_id": ["T9"], "Age": {"text": [["82-year-old"]], "start": [[13]], "entity_id": ["T12"]}, "Gender": {"text": [["man"]], "start": [[25]], "entity_id": ["T13"]}}, "Effect": {"text": [["ventricular tachycardia and Torsades de Pointes (TdP)"]], "start": [[43]], "entity_id": ["T10"]}}]}]}
{"id": "12951892_1", "context": "Lethargy in a newborn: lithium toxicity or lab error?", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["toxicity"]], "start": [[31]], "entity_id": ["T8"]}, "Treatment": {"text": [["lithium"]], "start": [[23]], "entity_id": ["T5"], "Drug": {"text": [["lithium"]], "start": [[23]], "entity_id": ["T10"]}}, "Effect": {"text": [["Lethargy"]], "start": [[0]], "entity_id": ["T6"]}, "Subject": {"text": [["a newborn"]], "start": [[12]], "entity_id": ["T7"], "Age": {"text": [["newborn"]], "start": [[14]], "entity_id": ["T9"]}}}]}]}
{"id": "18344455_1", "context": "Simultaneous toxicities in a child on multiple anticonvulsants.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["on"]], "start": [[35]], "entity_id": ["T6"]}, "Subject": {"text": [["a child"]], "start": [[27]], "entity_id": ["T7"], "Age": {"text": [["child"]], "start": [[29]], "entity_id": ["T10"]}}, "Treatment": {"text": [["multiple anticonvulsants."]], "start": [[38]], "entity_id": ["T8"], "Drug": {"text": [["anticonvulsants"]], "start": [[47]], "entity_id": ["T11"]}}, "Effect": {"text": [["Simultaneous toxicities"]], "start": [[0]], "entity_id": ["T9"]}}]}]}
{"id": "17404582_3", "context": "We report a 71-year male with castration-resistant metastatic prostate cancer who was treated with weekly docetaxel for 12 weeks and developed significant eye irritation and dryness during treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[133]], "entity_id": ["T7"]}, "Effect": {"text": [["significant eye irritation and dryness"]], "start": [[143]], "entity_id": ["T6"]}, "Subject": {"text": [["a 71-year male with castration-resistant metastatic prostate cancer"]], "start": [[10]], "entity_id": ["T3"], "Age": {"text": [["71-year"]], "start": [[12]], "entity_id": ["T8"]}, "Gender": {"text": [["male"]], "start": [[20]], "entity_id": ["T9"]}}, "Treatment": {"text": [["weekly docetaxel for 12 weeks"]], "start": [[99]], "entity_id": ["T5"], "Disorder": {"text": [["castration-resistant metastatic prostate cancer"]], "start": [[30]], "entity_id": ["T4"]}, "Drug": {"text": [["docetaxel"]], "start": [[106]], "entity_id": ["T10"]}, "Freq": {"text": [["weekly"]], "start": [[99]], "entity_id": ["T11"]}, "Duration": {"text": [["12 weeks"]], "start": [[120]], "entity_id": ["T13"]}}}]}]}
{"id": "1621023_2", "context": "In addition, a 31-year-old man with obsessive-compulsive disorder developed RBD soon after starting fluoxetine therapy, which persisted at PSG study 19 months after fluoxetine discontinuation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[66]], "entity_id": ["T5"]}, "Subject": {"text": [["a 31-year-old man with obsessive-compulsive disorder"]], "start": [[13]], "entity_id": ["T4"], "Age": {"text": [["31-year-old"]], "start": [[15]], "entity_id": ["T8"]}, "Gender": {"text": [["man"]], "start": [[27]], "entity_id": ["T9"]}}, "Effect": {"text": [["RBD", "which persisted at PSG study 19 months after fluoxetine discontinuation"]], "start": [[76, 120]], "entity_id": ["T6"]}, "Treatment": {"text": [["starting fluoxetine therapy"]], "start": [[91]], "entity_id": ["T7"], "Drug": {"text": [["fluoxetine"]], "start": [[100]], "entity_id": ["T11"]}, "Time_elapsed": {"text": [["soon after starting"]], "start": [[80]], "entity_id": ["T12"]}, "Disorder": {"text": [["obsessive-compulsive disorder"]], "start": [[36]], "entity_id": ["T13"]}}}]}]}
{"id": "24791374_1", "context": "Propafenone associated severe central nervous system and cardiovascular toxicity due to mirtazapine: a case of severe drug interaction.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due to"]], "start": [[81]], "entity_id": ["T9"]}, "Treatment": {"text": [["Propafenone", "mirtazapine"]], "start": [[0, 88]], "entity_id": ["T10"], "Drug": {"text": [["mirtazapine"], ["Propafenone"]], "start": [[88], [0]], "entity_id": ["T12", "T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[123]], "entity_id": ["T14"]}, "Drug": {"text": [["Propafenone"], ["mirtazapine"]], "start": [[0], [88]], "entity_id": ["T13", "T12"]}}]}, "Effect": {"text": [["central nervous system and cardiovascular toxicity"]], "start": [[30]], "entity_id": ["T11"]}, "Severity": {"text": [["severe"]], "start": [[23]], "entity_id": ["T8"], "value": "High"}}]}]}
{"id": "582099_2", "context": "Neurotoxicity of intrathecal administration of amphotericin B.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["of"]], "start": [[14]], "entity_id": ["T5"]}, "Effect": {"text": [["Neurotoxicity"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["intrathecal administration of amphotericin B"]], "start": [[17]], "entity_id": ["T4"], "Drug": {"text": [["amphotericin B"]], "start": [[47]], "entity_id": ["T6"]}, "Route": {"text": [["intrathecal"]], "start": [[17]], "entity_id": ["T7"]}}}]}]}
{"id": "7724306_6", "context": "Parenteral pyridoxine, the specific antidote for INH-induced refractory seizures, should be readily available in every emergency department in the areas similarly experiencing increasing trends of TB.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[53]], "entity_id": ["T4"]}, "Treatment": {"text": [["INH"]], "start": [[49]], "entity_id": ["T3"], "Drug": {"text": [["INH"]], "start": [[49]], "entity_id": ["T6"]}}, "Effect": {"text": [["refractory seizures"]], "start": [[61]], "entity_id": ["T5"]}}]}]}
{"id": "9220046_3", "context": "DISCUSSION: Rhabdomyolysis is a clinical syndrome resulting from the destruction of skeletal muscle that may progress to renal failure Several drugs have been associated with rhabdomyolysis, including lovastatin, a hydroxymethylglutaryl-coenzyme A reductase inhibitor.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[159]], "entity_id": ["T3"]}, "Treatment": {"text": [["lovastatin, a hydroxymethylglutaryl-coenzyme A reductase inhibitor"]], "start": [[201]], "entity_id": ["T4"], "Drug": {"text": [["lovastatin"]], "start": [[201]], "entity_id": ["T6"]}}, "Effect": {"text": [["Rhabdomyolysis is a clinical syndrome resulting from the destruction of skeletal muscle that may progress to renal failure"]], "start": [[12]], "entity_id": ["T5"]}}]}]}
{"id": "20367573_2", "context": "Thrombocytosis associated with enoxaparin: A very rare cause in newborns.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[15]], "entity_id": ["T4"]}, "Effect": {"text": [["Thrombocytosis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["enoxaparin"]], "start": [[31]], "entity_id": ["T5"], "Drug": {"text": [["enoxaparin"]], "start": [[31]], "entity_id": ["T8"]}}, "Subject": {"text": [["newborns"]], "start": [[64]], "entity_id": ["T6"], "Age": {"text": [["newborns"]], "start": [[64]], "entity_id": ["T7"]}}}]}]}
{"id": "6837655_2", "context": "The spectrum of renal lesions occurring during antituberculous therapy, particularly in association with rifampin, may be wider than previously suspected.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[40]], "entity_id": ["T5"]}, "Treatment": {"text": [["antituberculous therapy, particularly in association with rifampin"]], "start": [[47]], "entity_id": ["T4"], "Drug": {"text": [["rifampin"], ["antituberculous therapy"]], "start": [[105], [47]], "entity_id": ["T6", "T7"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["association"]], "start": [[88]], "entity_id": ["T8"]}, "Drug": {"text": [["rifampin"], ["antituberculous therapy"]], "start": [[105], [47]], "entity_id": ["T6", "T7"]}}]}, "Effect": {"text": [["The spectrum of renal lesions occurring"]], "start": [[0]], "entity_id": ["T3"]}}]}]}
{"id": "16960880_3", "context": "Native arterial thrombosis, though recognized as a severe complication of thrombin injection, has not been well described in the literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[58]], "entity_id": ["T5"]}, "Effect": {"text": [["Native arterial thrombosis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["thrombin injection"]], "start": [[74]], "entity_id": ["T4"], "Drug": {"text": [["thrombin"]], "start": [[74]], "entity_id": ["T6"]}, "Route": {"text": [["injection"]], "start": [[83]], "entity_id": ["T7"]}}, "Severity": {"text": [["severe"]], "start": [[51]], "entity_id": ["T8"], "value": "High"}}]}]}
{"id": "21512888_8", "context": "After treatment with levetiracetam, seizures recurred and intravenous loading with valproic acid was administered, but resulted in a rapid increase in international normalized ratio (INR) to 7.6.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["recurred"]], "start": [[45]], "entity_id": ["T9"]}, "Treatment": {"text": [["levetiracetam"]], "start": [[21]], "entity_id": ["T8"], "Drug": {"text": [["levetiracetam"]], "start": [[21]], "entity_id": ["T7"]}}, "Effect": {"text": [["seizures"]], "start": [[36]], "entity_id": ["T10"]}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["administered"]], "start": [[101]], "entity_id": ["T14"]}, "Treatment": {"text": [["intravenous loading with valproic acid"]], "start": [[58]], "entity_id": ["T12"], "Disorder": {"text": [["seizures"]], "start": [[36]], "entity_id": ["T11"]}, "Route": {"text": [["intravenous"]], "start": [[58]], "entity_id": ["T13"]}, "Drug": {"text": [["valproic acid"]], "start": [[83]], "entity_id": ["T15"]}}}]}]}
{"id": "18396749_1", "context": "Acute hepatitis with prolonged cholestasis and disappearance of interlobular bile ducts following tibolone and Hypericum perforatum (St. John's wort).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[88]], "entity_id": ["T7"]}, "Treatment": {"text": [["tibolone and Hypericum perforatum (St. John's wort)"]], "start": [[98]], "entity_id": ["T8"], "Drug": {"text": [["tibolone"], ["Hypericum perforatum"]], "start": [[98], [111]], "entity_id": ["T9", "T10"]}}, "Effect": {"text": [["Acute hepatitis with prolonged cholestasis and disappearance of interlobular bile ducts"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "8002140_3", "context": "METHODS: Five cases of contact dermatitis due to budesonide, a nonhalogenated steroid, are described.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due to"]], "start": [[42]], "entity_id": ["T4"]}, "Effect": {"text": [["contact dermatitis"]], "start": [[23]], "entity_id": ["T3"]}, "Treatment": {"text": [["budesonide"]], "start": [[49]], "entity_id": ["T5"], "Drug": {"text": [["budesonide"]], "start": [[49]], "entity_id": ["T8"]}}, "Subject": {"text": [["Five cases"]], "start": [[9]], "entity_id": ["T6"], "Population": {"text": [["Five"]], "start": [[9]], "entity_id": ["T7"]}}}]}]}
{"id": "1124417_3", "context": "This sulfonamide like nephropathy should be differentiated from acetazolamide-related calcium phosphate nephrolithiasis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[78]], "entity_id": ["T3"]}, "Effect": {"text": [["calcium phosphate nephrolithiasis."]], "start": [[86]], "entity_id": ["T4"]}, "Treatment": {"text": [["acetazolamide"]], "start": [[64]], "entity_id": ["T5"], "Drug": {"text": [["acetazolamide"]], "start": [[64]], "entity_id": ["T6"]}}}]}]}
{"id": "17420198_18", "context": "Aripiprazole was subsequently discontinued secondary to its lack of efficacy for OCD and the development of a movement disorder.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["development"]], "start": [[93]], "entity_id": ["T9"]}, "Treatment": {"text": [["Aripiprazole"]], "start": [[0]], "entity_id": ["T7"], "Disorder": {"text": [["OCD"]], "start": [[81]], "entity_id": ["T10"]}, "Drug": {"text": [["Aripiprazole"]], "start": [[0]], "entity_id": ["T12"]}}, "Effect": {"text": [["a movement disorder"]], "start": [[108]], "entity_id": ["T8"]}}]}]}
{"id": "12187348_1", "context": "Gigantomastia induced by bucillamine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[14]], "entity_id": ["T6"]}, "Effect": {"text": [["Gigantomastia"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["bucillamine"]], "start": [[25]], "entity_id": ["T5"], "Drug": {"text": [["bucillamine"]], "start": [[25]], "entity_id": ["T7"]}}}]}]}
{"id": "20038831_2", "context": "Hypersensitivity to carboplatin has been reported in up to 44% of patients receiving this antineoplastic agent, usually occurring after several courses of treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["to"]], "start": [[17]], "entity_id": ["T6"]}, "Subject": {"text": [["44% of patients"]], "start": [[59]], "entity_id": ["T3"]}, "Effect": {"text": [["Hypersensitivity"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["carboplatin", "after several courses of treatment"]], "start": [[20, 130]], "entity_id": ["T4"], "Drug": {"text": [["carboplatin"]], "start": [[20]], "entity_id": ["T7"]}}}]}]}
{"id": "8908396_1", "context": "CONCLUSIONS: In our reported case, a local hyperproduction of TNF-alpha from macrophages that was induced by the injected insulin could explain the dedifferentiation of the adipocytes of the subcutaneous tissue and the reversion that was induced by the local injection of dexamethasone.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[98]], "entity_id": ["T7"]}, "Treatment": {"text": [["injected insulin"]], "start": [[113]], "entity_id": ["T5"], "Route": {"text": [["injected"]], "start": [[113]], "entity_id": ["T8"]}, "Drug": {"text": [["insulin"]], "start": [[122]], "entity_id": ["T9"]}}, "Effect": {"text": [["local hyperproduction of TNF-alpha from macrophages", "dedifferentiation of the adipocytes of the subcutaneous tissue"]], "start": [[37, 148]], "entity_id": ["T6"]}, "Subject": {"text": [["reported case"]], "start": [[20]], "entity_id": ["T10"]}}]}]}
{"id": "11144696_9", "context": "Both venlafaxine and trimipramine have been associated with seizures, mainly after overdose.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[44]], "entity_id": ["T6"]}, "Treatment": {"text": [["overdose", "venlafaxine and trimipramine"]], "start": [[83, 5]], "entity_id": ["T7"], "Drug": {"text": [["venlafaxine"], ["trimipramine"]], "start": [[5], [21]], "entity_id": ["T9", "T10"]}, "Dosage": {"text": [["overdose"]], "start": [[83]], "entity_id": ["T11"]}}, "Effect": {"text": [["seizures"]], "start": [[60]], "entity_id": ["T8"]}}]}]}
{"id": "9291634_4", "context": "Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside (ARA-C); among them, along with myelosuppression, five experienced fever, infectious complications, gastrointestinal tract symptoms and severe myalgias.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["experienced"]], "start": [[206]], "entity_id": ["T15"]}, "Effect": {"text": [["fever, infectious complications, gastrointestinal tract symptoms and severe myalgias"]], "start": [[218]], "entity_id": ["T13"]}, "Treatment": {"text": [["chemotherapy", "cytosine arabinoside (ARA-C)"]], "start": [[85, 130]], "entity_id": ["T14"], "Drug": {"text": [["cytosine arabinoside"]], "start": [[130]], "entity_id": ["T18"]}, "Duration": {"text": [["three-month"]], "start": [[43]], "entity_id": ["T19"]}}, "Subject": {"text": [["five"]], "start": [[201]], "entity_id": ["T16"], "Population": {"text": [["five"]], "start": [[201]], "entity_id": ["T17"]}}}]}]}
{"id": "14674674_2", "context": "Infliximab-induced lupus in Crohn's disease: a case report.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T4"]}, "Treatment": {"text": [["Infliximab"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Infliximab"]], "start": [[0]], "entity_id": ["T7"]}}, "Subject": {"text": [["a case"]], "start": [[45]], "entity_id": ["T6"]}, "Effect": {"text": [["lupus"]], "start": [[19]], "entity_id": ["T5"]}}]}]}
{"id": "10660641_7", "context": "The infection tended to subside with the AMPH administration.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["subside"]], "start": [[24]], "entity_id": ["T6"]}, "Treatment": {"text": [["AMPH administration"]], "start": [[41]], "entity_id": ["T4"], "Drug": {"text": [["AMPH"]], "start": [[41]], "entity_id": ["T7"]}}, "Effect": {"text": [["infection tended"]], "start": [[4]], "entity_id": ["T5"]}}]}]}
{"id": "17228132_2", "context": "CONTEXT: Acute drug induced hepatitis has not been commonly associated with epidermal growth factor receptor (EGFR) inhibitors.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[60]], "entity_id": ["T5"]}, "Treatment": {"text": [["epidermal growth factor receptor (EGFR) inhibitors"]], "start": [[76]], "entity_id": ["T7"], "Drug": {"text": [["epidermal growth factor receptor", "inhibitors"]], "start": [[76, 116]], "entity_id": ["T8"]}}, "Effect": {"text": [["Acute drug induced hepatitis"]], "start": [[9]], "entity_id": ["T6"]}, "Negated": {"text": [["not"]], "start": [[42]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "17873198_5", "context": "We report a case of fatal pulmonary toxicity in a patient with advanced non-small cell lung cancer who received erlotinib.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["received"]], "start": [[103]], "entity_id": ["T7"]}, "Treatment": {"text": [["erlotinib"]], "start": [[112]], "entity_id": ["T5"], "Disorder": {"text": [["advanced non-small cell lung cancer"]], "start": [[63]], "entity_id": ["T4"]}, "Drug": {"text": [["erlotinib"]], "start": [[112]], "entity_id": ["T8"]}}, "Effect": {"text": [["pulmonary toxicity"]], "start": [[26]], "entity_id": ["T6"]}, "Subject": {"text": [["a patient with advanced non-small cell lung cancer"]], "start": [[48]], "entity_id": ["T3"]}, "Severity": {"text": [["fatal"]], "start": [[20]], "entity_id": ["T9"], "value": "High"}}]}]}
{"id": "16200540_4", "context": "We describe a patient with idiopathic RLS who developed augmentation after 8 months of levodopa treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[46]], "entity_id": ["T5"]}, "Subject": {"text": [["a patient with idiopathic RLS"]], "start": [[12]], "entity_id": ["T3"]}, "Effect": {"text": [["augmentation"]], "start": [[56]], "entity_id": ["T6"]}, "Treatment": {"text": [["after 8 months of levodopa treatment"]], "start": [[69]], "entity_id": ["T7"], "Disorder": {"text": [["idiopathic RLS"]], "start": [[27]], "entity_id": ["T4"]}, "Time_elapsed": {"text": [["8 months"]], "start": [[75]], "entity_id": ["T8"]}, "Drug": {"text": [["levodopa"]], "start": [[87]], "entity_id": ["T9"]}}}]}]}
{"id": "12923827_3", "context": "This communication describes a patient who developed Schneiderian first-rank symptoms in the course of treatment with fluvoxamine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[43]], "entity_id": ["T4"]}, "Effect": {"text": [["Schneiderian first-rank symptoms"]], "start": [[53]], "entity_id": ["T3"]}, "Treatment": {"text": [["fluvoxamine"]], "start": [[118]], "entity_id": ["T5"], "Drug": {"text": [["fluvoxamine"]], "start": [[118]], "entity_id": ["T7"]}}, "Subject": {"text": [["a patient"]], "start": [[29]], "entity_id": ["T6"]}}]}]}
{"id": "3753891_2", "context": "In addition to the recognized arrhythmic complications, the authors emphasize myocardial necrosis as a possible further manifestation of amsacrine-related cardiotoxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[147]], "entity_id": ["T7"]}, "Effect": {"text": [["myocardial necrosis", "cardiotoxicity"]], "start": [[78, 155]], "entity_id": ["T5"]}, "Treatment": {"text": [["amsacrine"]], "start": [[137]], "entity_id": ["T6"], "Drug": {"text": [["amsacrine"]], "start": [[137]], "entity_id": ["T8"]}}, "Speculated": {"text": [["possible"]], "start": [[103]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "2857534_2", "context": "The authors caution that treatment with alprazolam may be complicated by the induction of mania.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induction of"]], "start": [[77]], "entity_id": ["T5"]}, "Treatment": {"text": [["treatment with alprazolam"]], "start": [[25]], "entity_id": ["T3"], "Drug": {"text": [["alprazolam"]], "start": [[40]], "entity_id": ["T6"]}}, "Effect": {"text": [["mania"]], "start": [[90]], "entity_id": ["T4"]}}]}]}
{"id": "17596682_2", "context": "The use of rituximab has been uncommonly associated with delayed pulmonary toxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[41]], "entity_id": ["T4"]}, "Treatment": {"text": [["rituximab"]], "start": [[11]], "entity_id": ["T3"], "Drug": {"text": [["rituximab"]], "start": [[11]], "entity_id": ["T6"]}}, "Effect": {"text": [["delayed pulmonary toxicity"]], "start": [[57]], "entity_id": ["T5"]}}]}]}
{"id": "18515982_6", "context": "We believe that the acute renal failure in our patient was associated with anastrozole.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[59]], "entity_id": ["T6"]}, "Effect": {"text": [["acute renal failure"]], "start": [[20]], "entity_id": ["T3"]}, "Subject": {"text": [["patient"]], "start": [[47]], "entity_id": ["T4"]}, "Treatment": {"text": [["anastrozole"]], "start": [[75]], "entity_id": ["T5"], "Drug": {"text": [["anastrozole"]], "start": [[75]], "entity_id": ["T7"]}}}]}]}
{"id": "8656412_1", "context": "On the fifth day of tocolysis with magnesium sulfate, nifedipine, terbutaline and betamethasone, edema developed in both labia.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[103]], "entity_id": ["T6"]}, "Effect": {"text": [["edema", "in both labia"]], "start": [[97, 113]], "entity_id": ["T8"]}, "Treatment": {"text": [["On the fifth day of tocolysis with magnesium sulfate, nifedipine, terbutaline and betamethasone"]], "start": [[0]], "entity_id": ["T7"], "Duration": {"text": [["the fifth day"]], "start": [[3]], "entity_id": ["T9"]}, "Drug": {"text": [["magnesium sulfate"], ["nifedipine"], ["terbutaline"], ["betamethasone"]], "start": [[35], [54], [66], [82]], "entity_id": ["T10", "T11", "T12", "T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[78]], "entity_id": ["T14"]}, "Drug": {"text": [["magnesium sulfate"], ["nifedipine"], ["terbutaline"], ["betamethasone"]], "start": [[35], [54], [66], [82]], "entity_id": ["T10", "T11", "T12", "T13"]}}]}}]}]}
{"id": "6159523_2", "context": "Two patients with extrinsic asthma and coexistent insulin-dependent diabetes mellitus sustained an anaphylactoid reaction after the intravenous administration of 50% solution of dextrose.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[122]], "entity_id": ["T7"]}, "Treatment": {"text": [["intravenous administration of 50% solution of dextrose"]], "start": [[132]], "entity_id": ["T8"], "Route": {"text": [["intravenous"]], "start": [[132]], "entity_id": ["T14"]}, "Drug": {"text": [["dextrose"]], "start": [[178]], "entity_id": ["T15"]}}, "Subject": {"text": [["Two patients with extrinsic asthma and coexistent insulin-dependent diabetes mellitus"]], "start": [[0]], "entity_id": ["T9"], "Population": {"text": [["Two"]], "start": [[0]], "entity_id": ["T11"]}, "Disorder": {"text": [["extrinsic asthma"], ["insulin-dependent diabetes mellitus"]], "start": [[18], [50]], "entity_id": ["T12", "T13"]}}, "Effect": {"text": [["anaphylactoid reaction"]], "start": [[99]], "entity_id": ["T10"]}}]}]}
{"id": "8936932_3", "context": "Cardiac arrest after esmolol administration: a review of acute beta-blocker toxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[15]], "entity_id": ["T3"]}, "Treatment": {"text": [["esmolol"]], "start": [[21]], "entity_id": ["T4"], "Drug": {"text": [["esmolol"]], "start": [[21]], "entity_id": ["T6"]}}, "Effect": {"text": [["Cardiac arrest"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "3680913_3", "context": "We suggest that nicotinic acid was the cause of his liver disease, that this case is of particular note because of the rather short period of therapy before the onset of liver injury and the severity of the hepatic failure, and that the probable increased use of nicotinic acid for serum cholesterol control makes it especially important for physicians and their patients to be alert to the signs of hepatotoxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[39]], "entity_id": ["T8"]}, "Treatment": {"text": [["nicotinic acid"]], "start": [[16]], "entity_id": ["T6"], "Drug": {"text": [["nicotinic acid"]], "start": [[16]], "entity_id": ["T9"]}}, "Effect": {"text": [["liver disease"]], "start": [[52]], "entity_id": ["T7"]}}]}]}
{"id": "17277758_3", "context": "METHODS: Two patients with exudative age-related macular degeneration were treated sequentially with an intravitreal injection of bevacizumab and developed signs of severe but painless infectious endophthalmitis 2 days later.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[146]], "entity_id": ["T8"]}, "Subject": {"text": [["Two patients"]], "start": [[9]], "entity_id": ["T5"], "Population": {"text": [["Two"]], "start": [[9]], "entity_id": ["T10"]}}, "Treatment": {"text": [["intravitreal injection of bevacizumab", "2 days later"]], "start": [[104, 212]], "entity_id": ["T7"], "Disorder": {"text": [["exudative age-related macular degeneration"]], "start": [[27]], "entity_id": ["T11"]}, "Route": {"text": [["intravitreal injection"]], "start": [[104]], "entity_id": ["T6"]}, "Drug": {"text": [["bevacizumab"]], "start": [[130]], "entity_id": ["T12"]}, "Time_elapsed": {"text": [["2 days later."]], "start": [[212]], "entity_id": ["T13"]}}, "Effect": {"text": [["infectious endophthalmitis"]], "start": [[185]], "entity_id": ["T9"]}, "Severity": {"text": [["severe"]], "start": [[165]], "entity_id": ["T14"], "value": "High"}}]}]}
{"id": "2586773_1", "context": "Ibuprofen-induced meningitis: detection of intrathecal IgG synthesis and immune complexes.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[10]], "entity_id": ["T4"]}, "Treatment": {"text": [["Ibuprofen"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Ibuprofen"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["meningitis"]], "start": [[18]], "entity_id": ["T5"]}}]}]}
{"id": "18020545_2", "context": "Tardive oculogyric crisis during treatment with clozapine: report of three cases.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[43]], "entity_id": ["T5"]}, "Effect": {"text": [["Tardive oculogyric crisis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["clozapine"]], "start": [[48]], "entity_id": ["T4"], "Drug": {"text": [["clozapine"]], "start": [[48]], "entity_id": ["T8"]}}, "Subject": {"text": [["three cases"]], "start": [[69]], "entity_id": ["T6"], "Population": {"text": [["three"]], "start": [[69]], "entity_id": ["T7"]}}}]}]}
{"id": "11506739_1", "context": "Myasthenia gravis during low-dose IFN-alpha therapy for chronic hepatitis C.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[18]], "entity_id": ["T5"]}, "Effect": {"text": [["Myasthenia gravis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["low-dose IFN-alpha therapy"]], "start": [[25]], "entity_id": ["T4"], "Dosage": {"text": [["low-dose"]], "start": [[25]], "entity_id": ["T7"]}, "Drug": {"text": [["IFN-alpha"]], "start": [[34]], "entity_id": ["T8"]}, "Disorder": {"text": [["chronic hepatitis C"]], "start": [[56]], "entity_id": ["T9"]}}}]}]}
{"id": "12424571_2", "context": "We herein report this rare case of acute onset of nephrotic syndrome during interferon-alpha retreatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[69]], "entity_id": ["T5"]}, "Effect": {"text": [["acute onset of nephrotic syndrome"]], "start": [[35]], "entity_id": ["T3"]}, "Treatment": {"text": [["interferon-alpha"]], "start": [[76]], "entity_id": ["T4"], "Drug": {"text": [["interferon-alpha"]], "start": [[76]], "entity_id": ["T6"]}}}]}]}
{"id": "7393795_2", "context": "Para-aminosalicylic acid-induced hypoglycaemia in a patient with diabetic nephropathy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[25]], "entity_id": ["T6"]}, "Subject": {"text": [["a patient with diabetic nephropathy"]], "start": [[50]], "entity_id": ["T3"], "Disorder": {"text": [["diabetic nephropathy"]], "start": [[65]], "entity_id": ["T4"]}}, "Treatment": {"text": [["Para-aminosalicylic acid"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Para-aminosalicylic acid"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["hypoglycaemia"]], "start": [[33]], "entity_id": ["T7"]}}]}]}
{"id": "3970339_2", "context": "Ischaemia following selfadministered intra-arterial injection of methylphenidate and diamorphine.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[10]], "entity_id": ["T5"]}, "Effect": {"text": [["Ischaemia"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["selfadministered intra-arterial injection of methylphenidate and diamorphine"]], "start": [[20]], "entity_id": ["T6"], "Drug": {"text": [["methylphenidate"], ["diamorphine"]], "start": [[65], [85]], "entity_id": ["T7", "T8"]}, "Route": {"text": [["intra-arterial injection"]], "start": [[37]], "entity_id": ["T9"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[81]], "entity_id": ["T10"]}, "Drug": {"text": [["methylphenidate"], ["diamorphine"]], "start": [[65], [85]], "entity_id": ["T7", "T8"]}}]}}]}]}
{"id": "9660541_2", "context": "Mitomycin C-related hemolytic uremic syndrome in cancer patients.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[12]], "entity_id": ["T4"]}, "Treatment": {"text": [["Mitomycin C"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Mitomycin C"]], "start": [[0]], "entity_id": ["T8"]}, "Disorder": {"text": [["cancer"]], "start": [[49]], "entity_id": ["T9"]}}, "Effect": {"text": [["hemolytic uremic syndrome"]], "start": [[20]], "entity_id": ["T5"]}, "Subject": {"text": [["cancer patients"]], "start": [[49]], "entity_id": ["T6"]}}]}]}
{"id": "7549443_1", "context": "The second had acute cystitis and was treated by sulphonamide and the third developed myopia coincident with metronidazole treatment for trichomonas vaginalis.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[76]], "entity_id": ["T4"]}, "Effect": {"text": [["myopia"]], "start": [[86]], "entity_id": ["T5"]}, "Treatment": {"text": [["metronidazole treatment"]], "start": [[109]], "entity_id": ["T14"], "Drug": {"text": [["metronidazole"]], "start": [[109]], "entity_id": ["T8"]}, "Disorder": {"text": [["trichomonas vaginalis"]], "start": [[137]], "entity_id": ["T9"]}}, "Subject": {"text": [["the third"]], "start": [[66]], "entity_id": ["T15"]}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[38]], "entity_id": ["T13"]}, "Treatment": {"text": [["sulphonamide"]], "start": [[49]], "entity_id": ["T6"], "Disorder": {"text": [["acute cystitis"]], "start": [[15]], "entity_id": ["T10"]}, "Drug": {"text": [["sulphonamide"]], "start": [[49]], "entity_id": ["T11"]}}}]}]}
{"id": "19669617_3", "context": "Acute bilateral phrenic neuropathy following treatment with adalimumab.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[35]], "entity_id": ["T4"]}, "Effect": {"text": [["Acute bilateral phrenic neuropathy"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["adalimumab"]], "start": [[60]], "entity_id": ["T5"], "Drug": {"text": [["adalimumab"]], "start": [[60]], "entity_id": ["T6"]}}}]}]}
{"id": "8921647_4", "context": "Hypoxemia improved during continuous tolazoline infusion, but gastrointestinal bleeding occurred.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurred"]], "start": [[88]], "entity_id": ["T3"]}, "Effect": {"text": [["gastrointestinal bleeding"]], "start": [[62]], "entity_id": ["T4"]}, "Treatment": {"text": [["Hypoxemia improved during continuous tolazoline infusion"]], "start": [[0]], "entity_id": ["T5"], "Disorder": {"text": [["Hypoxemia"]], "start": [[0]], "entity_id": ["T6"]}, "Drug": {"text": [["tolazoline"]], "start": [[37]], "entity_id": ["T7"]}, "Route": {"text": [["infusion"]], "start": [[48]], "entity_id": ["T8"]}}}]}]}
{"id": "18176653_3", "context": "BACKGROUND: NVP is a non-nucleoside reverse transcriptase inhibitor used in the treatment of Human Immunodeficiency Virus (HIV) infection.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["used"]], "start": [[68]], "entity_id": ["T6"]}, "Treatment": {"text": [["NVP"]], "start": [[12]], "entity_id": ["T7"], "Disorder": {"text": [["Human Immunodeficiency Virus (HIV) infection"]], "start": [[93]], "entity_id": ["T5"]}, "Drug": {"text": [["NVP"]], "start": [[12]], "entity_id": ["T8"]}}}]}]}
{"id": "7393795_1", "context": "A 62-year-old Indian with diabetic nephropathy controlled with metformin, developed miliary tuberculosis for which he was treated with rifampicin, isoniazid and ethambutol.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[74]], "entity_id": ["T13"]}, "Effect": {"text": [["miliary tuberculosis"]], "start": [[84]], "entity_id": ["T5"]}, "Subject": {"text": [["A 62-year-old Indian with diabetic nephropathy"]], "start": [[0]], "entity_id": ["T6"], "Age": {"text": [["62-year-old"]], "start": [[2]], "entity_id": ["T7"]}, "Race": {"text": [["Indian"]], "start": [[14]], "entity_id": ["T8"]}}, "Treatment": {"text": [["metformin"]], "start": [[63]], "entity_id": ["T4"], "Disorder": {"text": [["diabetic nephropathy"]], "start": [[26]], "entity_id": ["T11"]}, "Drug": {"text": [["metformin"]], "start": [[63]], "entity_id": ["T10"]}}}, {"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[122]], "entity_id": ["T15"]}, "Treatment": {"text": [["rifampicin, isoniazid and ethambutol"]], "start": [[135]], "entity_id": ["T3"], "Disorder": {"text": [["miliary tuberculosis"]], "start": [[84]], "entity_id": ["T16"]}, "Drug": {"text": [["ethambutol"], ["rifampicin"], ["isoniazid"]], "start": [[161], [135], [147]], "entity_id": ["T14", "T18", "T19"]}, "Combination": [{"event_id": "E3", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[157]], "entity_id": ["T17"]}, "Drug": {"text": [["ethambutol"], ["isoniazid"], ["rifampicin"]], "start": [[161], [147], [135]], "entity_id": ["T14", "T19", "T18"]}}]}}]}]}
{"id": "8438851_1", "context": "A patient with acute esophageal variceal bleeding developed fatal rhabdomyolysis during treatment with a continuous intravenous infusion of vasopressin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[81]], "entity_id": ["T3"]}, "Treatment": {"text": [["continuous intravenous infusion of vasopressin"]], "start": [[105]], "entity_id": ["T4"], "Route": {"text": [["continuous intravenous infusion"]], "start": [[105]], "entity_id": ["T9"]}, "Drug": {"text": [["vasopressin"]], "start": [[140]], "entity_id": ["T10"]}, "Disorder": {"text": [["acute esophageal variceal bleeding"]], "start": [[15]], "entity_id": ["T11"]}}, "Subject": {"text": [["A patient with acute esophageal variceal bleeding"]], "start": [[0]], "entity_id": ["T5"]}, "Effect": {"text": [["fatal rhabdomyolysis"]], "start": [[60]], "entity_id": ["T6"]}, "Severity": {"text": [["fatal"]], "start": [[60]], "entity_id": ["T8"], "value": "High"}}]}]}
{"id": "6159523_7", "context": "Preliminary results suggest that the higher concentrations of dextrose induce increased histamine release from blood cells, and that this phenomenon is more marked in diabetic, and particularly diabetic-allergic, individuals.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induce"]], "start": [[71]], "entity_id": ["T3"]}, "Treatment": {"text": [["higher concentrations of dextrose"]], "start": [[37]], "entity_id": ["T4"], "Drug": {"text": [["dextrose"]], "start": [[62]], "entity_id": ["T6"]}, "Dosage": {"text": [["higher concentrations"]], "start": [[37]], "entity_id": ["T8"]}}, "Effect": {"text": [["increased histamine release from blood cells"]], "start": [[78]], "entity_id": ["T5"]}, "Subject": {"text": [["diabetic, and particularly diabetic-allergic, individuals"]], "start": [[167]], "entity_id": ["T9"], "Disorder": {"text": [["diabetic"], ["diabetic-allergic"]], "start": [[167], [194]], "entity_id": ["T7", "T1"]}}}]}]}
{"id": "12243603_12", "context": "All patients beginning HMG-CoA reductase inhibitor therapy should be counseled regarding the signs and symptoms of muscle injury; particular attention should be paid to those patients who are taking medications that may interact.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["regarding"]], "start": [[79]], "entity_id": ["T10"]}, "Subject": {"text": [["All patients"]], "start": [[0]], "entity_id": ["T7"]}, "Treatment": {"text": [["HMG-CoA reductase inhibitor"]], "start": [[23]], "entity_id": ["T8"], "Drug": {"text": [["HMG-CoA reductase inhibitor"]], "start": [[23]], "entity_id": ["T11"]}}, "Effect": {"text": [["the signs and symptoms of muscle injury"]], "start": [[89]], "entity_id": ["T9"]}}]}]}
{"id": "16498048_4", "context": "Interferon-alpha-induced hyperthyroidism: a three-stage evolution from silent thyroiditis towards Graves' disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[17]], "entity_id": ["T3"]}, "Treatment": {"text": [["Interferon-alpha"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Interferon-alpha"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["hyperthyroidism", "Graves' disease"]], "start": [[25, 98]], "entity_id": ["T5"]}}]}]}
{"id": "16708747_1", "context": "Acute severe intoxication with carbamazepine is associated with seizures, coma and respiratory depression.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[48]], "entity_id": ["T8"]}, "Treatment": {"text": [["carbamazepine"]], "start": [[31]], "entity_id": ["T7"], "Drug": {"text": [["carbamazepine"]], "start": [[31]], "entity_id": ["T13"]}}, "Effect": {"text": [["Acute severe intoxication"]], "start": [[0]], "entity_id": ["T9"]}}]}]}
{"id": "11022272_2", "context": "CONCLUSION: We have introduced a case of anaphylaxis by calcitonin that suggest an IgE mediated hypersensitivity reaction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["by"]], "start": [[53]], "entity_id": ["T6"]}, "Subject": {"text": [["a case"]], "start": [[31]], "entity_id": ["T3"]}, "Effect": {"text": [["anaphylaxis"]], "start": [[41]], "entity_id": ["T4"]}, "Treatment": {"text": [["calcitonin"]], "start": [[56]], "entity_id": ["T5"], "Drug": {"text": [["calcitonin"]], "start": [[56]], "entity_id": ["T7"]}}}]}]}
{"id": "17188061_2", "context": "PURPOSE: To describe transient structured visual hallucinations in a patient with vascular age-related macular degeneration (AMD), following an intravitreal Avastin-injection.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[131]], "entity_id": ["T5"]}, "Effect": {"text": [["transient structured visual hallucinations"]], "start": [[21]], "entity_id": ["T3"]}, "Subject": {"text": [["a patient with vascular age-related macular degeneration (AMD)"]], "start": [[67]], "entity_id": ["T4"]}, "Treatment": {"text": [["an intravitreal Avastin-injection"]], "start": [[141]], "entity_id": ["T6"], "Disorder": {"text": [["vascular age-related macular degeneration (AMD)"]], "start": [[82]], "entity_id": ["T7"]}, "Drug": {"text": [["Avastin"]], "start": [[157]], "entity_id": ["T9"]}, "Route": {"text": [["intravitreal", "injection"]], "start": [[144, 165]], "entity_id": ["T10"]}}, "Severity": {"text": [["transient"]], "start": [[21]], "entity_id": ["T8"], "value": "Low"}}]}]}
{"id": "17556909_1", "context": "Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this first-in-class anticancer proteasome inhibitor.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T6"]}, "Treatment": {"text": [["Bortezomib"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Bortezomib"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["paralytic ileus"]], "start": [[19]], "entity_id": ["T7"]}}]}]}
{"id": "19904536_15", "context": "Fatal gemcitabine-induced pulmonary toxicity in metastatic   gallbladder adenocarcinoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[18]], "entity_id": ["T5"]}, "Effect": {"text": [["pulmonary toxicity"]], "start": [[26]], "entity_id": ["T3"]}, "Treatment": {"text": [["gemcitabine"]], "start": [[6]], "entity_id": ["T4"], "Disorder": {"text": [["metastatic   gallbladder adenocarcinoma"]], "start": [[48]], "entity_id": ["T6"]}, "Drug": {"text": [["gemcitabine"]], "start": [[6]], "entity_id": ["T7"]}}}]}]}
{"id": "2611886_1", "context": "It is suggested that the fatal stroke may have resulted from arterial spasm caused by ergotamine overdosage and possibly complicated by thrombosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[76]], "entity_id": ["T6"]}, "Effect": {"text": [["stroke", "arterial spasm"]], "start": [[31, 61]], "entity_id": ["T5"]}, "Treatment": {"text": [["ergotamine overdosage"]], "start": [[86]], "entity_id": ["T7"], "Drug": {"text": [["ergotamine"]], "start": [[86]], "entity_id": ["T8"]}}, "Speculated": {"text": [["may"]], "start": [[38]], "entity_id": ["T9"], "value": true}, "Severity": {"text": [["fatal"]], "start": [[25]], "entity_id": ["T10"], "value": "High"}}]}]}
{"id": "15770343_2", "context": "During the anti-tuberculous therapy, visual loss can be related to ethambutol toxicity or the tuberculosis infection itself.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[56]], "entity_id": ["T4"]}, "Effect": {"text": [["visual loss"]], "start": [[37]], "entity_id": ["T3"]}, "Treatment": {"text": [["ethambutol"]], "start": [[67]], "entity_id": ["T6"], "Drug": {"text": [["ethambutol"]], "start": [[67]], "entity_id": ["T8"]}, "Disorder": {"text": [["tuberculosis infection"]], "start": [[94]], "entity_id": ["T5"]}}}]}]}
{"id": "24429012_1", "context": "Elevated International Normalized Ratio in a patient concurrently using warfarin and vismodegib.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["using"]], "start": [[66]], "entity_id": ["T6"]}, "Treatment": {"text": [["warfarin and vismodegib"]], "start": [[72]], "entity_id": ["T7"], "Drug": {"text": [["warfarin"], ["vismodegib"]], "start": [[72], [85]], "entity_id": ["T11", "T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[81]], "entity_id": ["T10"]}, "Drug": {"text": [["warfarin"], ["vismodegib"]], "start": [[72], [85]], "entity_id": ["T11", "T12"]}}]}, "Effect": {"text": [["Elevated International Normalized Ratio"]], "start": [[0]], "entity_id": ["T8"]}, "Subject": {"text": [["a patient"]], "start": [[43]], "entity_id": ["T9"]}}]}]}
{"id": "8013261_3", "context": "Occurrence of IDDM during interferon therapy for chronic viral hepatitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[19]], "entity_id": ["T4"]}, "Effect": {"text": [["IDDM"]], "start": [[14]], "entity_id": ["T3"]}, "Treatment": {"text": [["interferon therapy"]], "start": [[26]], "entity_id": ["T5"], "Drug": {"text": [["interferon"]], "start": [[26]], "entity_id": ["T7"]}, "Disorder": {"text": [["chronic viral hepatitis"]], "start": [[49]], "entity_id": ["T8"]}}}]}]}
{"id": "3873709_2", "context": "Pseudomembranous colitis readily occurs in at least certain population groups receiving trimethoprim-sulfamethoxazole.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurs"]], "start": [[33]], "entity_id": ["T5"]}, "Effect": {"text": [["Pseudomembranous colitis"]], "start": [[0]], "entity_id": ["T4"]}, "Subject": {"text": [["certain population groups"]], "start": [[52]], "entity_id": ["T6"]}, "Treatment": {"text": [["trimethoprim-sulfamethoxazole"]], "start": [[88]], "entity_id": ["T7"], "Drug": {"text": [["trimethoprim"], ["sulfamethoxazole"]], "start": [[88], [101]], "entity_id": ["T8", "T9"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["-"]], "start": [[100]], "entity_id": ["T10"]}, "Drug": {"text": [["sulfamethoxazole"], ["trimethoprim"]], "start": [[101], [88]], "entity_id": ["T9", "T8"]}}]}}]}]}
{"id": "8002140_4", "context": "RESULTS: Budesonide use can cause contact dermatitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[28]], "entity_id": ["T5"]}, "Treatment": {"text": [["Budesonide"]], "start": [[9]], "entity_id": ["T4"], "Drug": {"text": [["Budesonide"]], "start": [[9]], "entity_id": ["T6"]}}, "Effect": {"text": [["contact dermatitis"]], "start": [[34]], "entity_id": ["T3"]}}]}]}
{"id": "8340162_1", "context": "Hypertension develops in most patients after transplantation when immunosuppression is based on cyclosporine and prednisone.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["when"]], "start": [[61]], "entity_id": ["T7"]}, "Effect": {"text": [["Hypertension"]], "start": [[0]], "entity_id": ["T4"]}, "Subject": {"text": [["most patients"]], "start": [[25]], "entity_id": ["T5"], "Population": {"text": [["most"]], "start": [[25]], "entity_id": ["T8"]}}, "Treatment": {"text": [["after transplantation", "immunosuppression is based on cyclosporine and prednisone"]], "start": [[39, 66]], "entity_id": ["T6"], "Drug": {"text": [["cyclosporine"], ["prednisone"]], "start": [[96], [113]], "entity_id": ["T9", "T10"]}}}]}]}
{"id": "9831311_3", "context": "It was concluded that potassium loss occurred by a non-renal (intestinal) route in phosphate-induced hypokalemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[93]], "entity_id": ["T7"]}, "Effect": {"text": [["potassium loss", "hypokalemia"]], "start": [[22, 101]], "entity_id": ["T5"]}, "Treatment": {"text": [["phosphate"]], "start": [[83]], "entity_id": ["T6"], "Drug": {"text": [["phosphate"]], "start": [[83]], "entity_id": ["T8"]}}}]}]}
{"id": "16498048_5", "context": "We have described three patients with hepatitis C for whom IFN-alpha and ribavirin were prescribed and who developed two successive phases of silent thyroiditis followed by hyperthryroidism relapse due to Graves' disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[107]], "entity_id": ["T10"]}, "Subject": {"text": [["three patients with hepatitis C"]], "start": [[18]], "entity_id": ["T7"], "Population": {"text": [["three"]], "start": [[18]], "entity_id": ["T11"]}, "Disorder": {"text": [["Graves' disease"]], "start": [[205]], "entity_id": ["T1"]}}, "Treatment": {"text": [["IFN-alpha and ribavirin"]], "start": [[59]], "entity_id": ["T8"], "Disorder": {"text": [["hepatitis C"]], "start": [[38]], "entity_id": ["T12"]}, "Drug": {"text": [["IFN-alpha"], ["ribavirin"]], "start": [[59], [73]], "entity_id": ["T13", "T14"]}}, "Effect": {"text": [["two successive phases of silent thyroiditis followed by hyperthryroidism relapse due to Graves' disease"]], "start": [[117]], "entity_id": ["T9"]}}]}]}
{"id": "3301251_2", "context": "Hepatotoxicity associated with choline magnesium trisalicylate: case report and review of salicylate-induced hepatotoxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[15]], "entity_id": ["T6"]}, "Effect": {"text": [["Hepatotoxicity"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["choline magnesium trisalicylate"]], "start": [[31]], "entity_id": ["T7"], "Drug": {"text": [["choline magnesium trisalicylate"]], "start": [[31]], "entity_id": ["T8"]}}, "Subject": {"text": [["case"]], "start": [[64]], "entity_id": ["T9"]}}]}]}
{"id": "10891991_3", "context": "CONCLUSIONS: The 3 cases presented here illustrate the development of reproductive endocrine disorders after the initiation of valproate therapy in women with epilepsy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["development"]], "start": [[55]], "entity_id": ["T4"]}, "Subject": {"text": [["The 3 cases", "women with epilepsy"]], "start": [[13, 148]], "entity_id": ["T3"], "Population": {"text": [["3"]], "start": [[17]], "entity_id": ["T9"]}, "Gender": {"text": [["women"]], "start": [[148]], "entity_id": ["T7"]}}, "Effect": {"text": [["reproductive endocrine disorders"]], "start": [[70]], "entity_id": ["T5"]}, "Treatment": {"text": [["after the initiation of valproate therapy"]], "start": [[103]], "entity_id": ["T6"], "Drug": {"text": [["valproate"]], "start": [[127]], "entity_id": ["T11"]}, "Disorder": {"text": [["epilepsy"]], "start": [[159]], "entity_id": ["T12"]}}}]}]}
{"id": "3346128_1", "context": "A 43-year-old white man developed a shallow erosion of a psoriatic plaque after chronic administration of methotrexate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[74]], "entity_id": ["T4"]}, "Subject": {"text": [["A 43-year-old white man"]], "start": [[0]], "entity_id": ["T3"], "Age": {"text": [["43-year-old"]], "start": [[2]], "entity_id": ["T7"]}, "Race": {"text": [["white"]], "start": [[14]], "entity_id": ["T8"]}, "Gender": {"text": [["man"]], "start": [[20]], "entity_id": ["T9"]}}, "Effect": {"text": [["shallow erosion of a psoriatic plaque"]], "start": [[36]], "entity_id": ["T5"]}, "Treatment": {"text": [["chronic administration of methotrexate"]], "start": [[80]], "entity_id": ["T6"], "Drug": {"text": [["methotrexate"]], "start": [[106]], "entity_id": ["T10"]}, "Disorder": {"text": [["psoriatic plaque"]], "start": [[57]], "entity_id": ["T11"]}, "Duration": {"text": [["chronic"]], "start": [[80]], "entity_id": ["T12"]}}}]}]}
{"id": "20126479_1", "context": "CONCLUSIONS: SD-OCT and AO detected abnormalities that correlate topographically with visual field loss from hydroxychloroquine toxicity as demonstrated by HVF 10-2 and may be useful in the detection of subclinical abnormalities that precede symptoms or objective visual field loss.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["from"]], "start": [[104]], "entity_id": ["T7"]}, "Effect": {"text": [["visual field loss"]], "start": [[86]], "entity_id": ["T5"]}, "Treatment": {"text": [["hydroxychloroquine"]], "start": [[109]], "entity_id": ["T6"], "Drug": {"text": [["hydroxychloroquine"]], "start": [[109]], "entity_id": ["T8"]}}}]}]}
{"id": "18805724_2", "context": "Leflunomide-induced toxic epidermal necrolysis in a patient with rheumatoid arthritis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[12]], "entity_id": ["T4"]}, "Treatment": {"text": [["Leflunomide"]], "start": [[0]], "entity_id": ["T3"], "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[65]], "entity_id": ["T7"]}, "Drug": {"text": [["Leflunomide"]], "start": [[0]], "entity_id": ["T9"]}}, "Effect": {"text": [["toxic epidermal necrolysis"]], "start": [[20]], "entity_id": ["T5"]}, "Subject": {"text": [["a patient with rheumatoid arthritis"]], "start": [[50]], "entity_id": ["T6"]}}]}]}
{"id": "2295443_2", "context": "Delayed bowel injury is an infrequently observed complication of chromic phosphate administration.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[49]], "entity_id": ["T5"]}, "Treatment": {"text": [["chromic phosphate administration"]], "start": [[65]], "entity_id": ["T3"], "Drug": {"text": [["chromic phosphate"]], "start": [[65]], "entity_id": ["T6"]}}, "Effect": {"text": [["Delayed bowel injury"]], "start": [[0]], "entity_id": ["T4"]}}]}]}
{"id": "19034138_7", "context": "Therefore, amantadine was permanently discontinued and the cornea cleared again.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["was"]], "start": [[22]], "entity_id": ["T5"]}, "Treatment": {"text": [["amantadine"]], "start": [[11]], "entity_id": ["T3"], "Drug": {"text": [["amantadine"]], "start": [[11]], "entity_id": ["T7"]}}, "Effect": {"text": [["cornea cleared"]], "start": [[59]], "entity_id": ["T4"]}}]}]}
{"id": "8530331_8", "context": "CONCLUSION: We believe that risperidone is not a substitute for clozapine in treating psychosis in parkinsonian patients and should be used with caution.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treating"]], "start": [[77]], "entity_id": ["T14"]}, "Treatment": {"text": [["risperidone"]], "start": [[28]], "entity_id": ["T11"], "Disorder": {"text": [["psychosis"]], "start": [[86]], "entity_id": ["T12"]}, "Drug": {"text": [["risperidone"]], "start": [[28]], "entity_id": ["T17"]}}, "Subject": {"text": [["parkinsonian patients"]], "start": [[99]], "entity_id": ["T10"], "Disorder": {"text": [["parkinsonian"]], "start": [[99]], "entity_id": ["T15"]}}, "Negated": {"text": [["not"]], "start": [[43]], "entity_id": ["T13"], "value": true}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treating"]], "start": [[77]], "entity_id": ["T14"]}, "Subject": {"text": [["parkinsonian patients"]], "start": [[99]], "entity_id": ["T10"], "Disorder": {"text": [["parkinsonian"]], "start": [[99]], "entity_id": ["T15"]}}, "Treatment": {"text": [["clozapine"]], "start": [[64]], "entity_id": ["T20"], "Drug": {"text": [["clozapine"]], "start": [[64]], "entity_id": ["T16"]}}}]}]}
{"id": "16767537_1", "context": "Spontaneous splenic infarction associated with sumatriptan use.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[31]], "entity_id": ["T4"]}, "Effect": {"text": [["Spontaneous splenic infarction"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["sumatriptan"]], "start": [[47]], "entity_id": ["T5"], "Drug": {"text": [["sumatriptan"]], "start": [[47]], "entity_id": ["T6"]}}}]}]}
{"id": "7606071_4", "context": "DISCUSSION: Anaphylactoid reactions have been described previously with cisplatin administration.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[67]], "entity_id": ["T5"]}, "Effect": {"text": [["Anaphylactoid reactions"]], "start": [[12]], "entity_id": ["T3"]}, "Treatment": {"text": [["cisplatin"]], "start": [[72]], "entity_id": ["T4"], "Drug": {"text": [["cisplatin"]], "start": [[72]], "entity_id": ["T6"]}}}]}]}
{"id": "20190474_3", "context": "The current report describes a man who was prescribed zonisamide for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high-grade fever, eosinophilia, liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[95]], "entity_id": ["T19"]}, "Effect": {"text": [["widespread skin rash, acute kidney injury, high-grade fever, eosinophilia, liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer"]], "start": [[105]], "entity_id": ["T15"]}, "Subject": {"text": [["a man"]], "start": [[29]], "entity_id": ["T16"], "Gender": {"text": [["man"]], "start": [[31]], "entity_id": ["T21"]}}, "Treatment": {"text": [["zonisamide for epilepsy"]], "start": [[54]], "entity_id": ["T17"], "Disorder": {"text": [["epilepsy"]], "start": [[69]], "entity_id": ["T18"]}, "Drug": {"text": [["zonisamide"]], "start": [[54]], "entity_id": ["T22"]}}}]}]}
{"id": "11197768_3", "context": "The toxicity of cadmium, zinc, and cadmium/zinc mixtures at concentrations ranging from 10000 to 10 microg/l was investigated.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["of"]], "start": [[13]], "entity_id": ["T8"]}, "Effect": {"text": [["toxicity"]], "start": [[4]], "entity_id": ["T6"]}, "Treatment": {"text": [["cadmium, zinc, and cadmium/zinc mixtures at concentrations ranging from 10000 to 10 microg/l"]], "start": [[16]], "entity_id": ["T7"], "Dosage": {"text": [["from 10000 to 10 microg/l"]], "start": [[83]], "entity_id": ["T9"]}, "Drug": {"text": [["cadmium"], ["zinc"], ["cadmium"], ["zinc"]], "start": [[16], [25], [35], [43]], "entity_id": ["T10", "T11", "T13", "T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["mixtures"]], "start": [[48]], "entity_id": ["T12"]}, "Drug": {"text": [["cadmium"], ["zinc"]], "start": [[35], [43]], "entity_id": ["T13", "T14"]}}]}}]}]}
{"id": "10475726_4", "context": "We present a case of an elderly woman with a pre-existing history of ischaemic heart disease, who was treated with venlafaxine, and developed acute myocardial ischaemia within the first week of treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[132]], "entity_id": ["T6"]}, "Treatment": {"text": [["venlafaxine"]], "start": [[115]], "entity_id": ["T5"], "Drug": {"text": [["venlafaxine"]], "start": [[115]], "entity_id": ["T12"]}, "Duration": {"text": [["within the first week"]], "start": [[169]], "entity_id": ["T13"]}}, "Effect": {"text": [["acute myocardial ischaemia within the first week of treatment"]], "start": [[142]], "entity_id": ["T7"]}, "Subject": {"text": [["an elderly woman with a pre-existing history of ischaemic heart disease"]], "start": [[21]], "entity_id": ["T3"], "Age": {"text": [["elderly"]], "start": [[24]], "entity_id": ["T8"]}, "Gender": {"text": [["woman"]], "start": [[32]], "entity_id": ["T9"]}, "Disorder": {"text": [["ischaemic heart disease"]], "start": [[69]], "entity_id": ["T10"]}}}]}]}
{"id": "15580406_1", "context": "Here, we describe a case of Vogt-Koyanagi-Harada disease occurring 4 months after the start of interferon alpha treatment, probably induced by the immunomodulatory effects of interferon.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurring"]], "start": [[57]], "entity_id": ["T5"]}, "Effect": {"text": [["Vogt-Koyanagi-Harada disease"]], "start": [[28]], "entity_id": ["T4"]}, "Treatment": {"text": [["4 months after the start of interferon alpha"]], "start": [[67]], "entity_id": ["T6"], "Time_elapsed": {"text": [["4 months"]], "start": [[67]], "entity_id": ["T10"]}, "Drug": {"text": [["interferon alpha"]], "start": [[95]], "entity_id": ["T11"]}}, "Subject": {"text": [["a case"]], "start": [[18]], "entity_id": ["T7"]}, "Speculated": {"text": [["probably"]], "start": [[123]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "17536204_3", "context": "Capecitabine-induced headache responding to diltiazem.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[13]], "entity_id": ["T3"]}, "Effect": {"text": [["headache"]], "start": [[21]], "entity_id": ["T4"]}, "Treatment": {"text": [["Capecitabine"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Capecitabine"]], "start": [[0]], "entity_id": ["T6"]}}}]}]}
{"id": "18171260_1", "context": "Serotonin syndrome after concomitant treatment with linezolid and meperidine.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[19]], "entity_id": ["T6"]}, "Effect": {"text": [["Serotonin syndrome"]], "start": [[0]], "entity_id": ["T7"]}, "Treatment": {"text": [["concomitant treatment with linezolid and meperidine"]], "start": [[25]], "entity_id": ["T8"], "Drug": {"text": [["linezolid"], ["meperidine"]], "start": [[52], [66]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["concomitant"]], "start": [[25]], "entity_id": ["T11"]}, "Drug": {"text": [["linezolid"], ["meperidine"]], "start": [[52], [66]], "entity_id": ["T9", "T10"]}}]}}]}]}
{"id": "8345435_3", "context": "We report on a child with fatal valproate-related hepatotoxic effects despite this supplementation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[42]], "entity_id": ["T6"]}, "Treatment": {"text": [["valproate"]], "start": [[32]], "entity_id": ["T5"], "Drug": {"text": [["valproate"]], "start": [[32]], "entity_id": ["T10"]}}, "Effect": {"text": [["hepatotoxic effects"]], "start": [[50]], "entity_id": ["T7"]}, "Subject": {"text": [["a child"]], "start": [[13]], "entity_id": ["T8"], "Age": {"text": [["child"]], "start": [[15]], "entity_id": ["T9"]}}, "Severity": {"text": [["fatal"]], "start": [[26]], "entity_id": ["T11"], "value": "High"}}]}]}
{"id": "7724306_2", "context": "Acute isoniazid neurotoxicity in an urban hospital.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[30]], "entity_id": ["T5"]}, "Treatment": {"text": [["isoniazid"]], "start": [[6]], "entity_id": ["T3"], "Drug": {"text": [["isoniazid"]], "start": [[6]], "entity_id": ["T6"]}}, "Effect": {"text": [["Acute", "neurotoxicity"]], "start": [[0, 16]], "entity_id": ["T4"]}}]}]}
{"id": "10555917_3", "context": "In vitro inhibition of hematopoiesis in a patient with systemic sclerosis treated with D-penicillamine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["inhibition"]], "start": [[9]], "entity_id": ["T6"]}, "Subject": {"text": [["a patient with systemic sclerosis"]], "start": [[40]], "entity_id": ["T3"]}, "Effect": {"text": [["vitro inhibition of hematopoiesis"]], "start": [[3]], "entity_id": ["T4"]}, "Treatment": {"text": [["D-penicillamine"]], "start": [[87]], "entity_id": ["T5"], "Disorder": {"text": [["systemic sclerosis"]], "start": [[55]], "entity_id": ["T8"]}, "Drug": {"text": [["D-penicillamine"]], "start": [[87]], "entity_id": ["T9"]}}}]}]}
{"id": "12243603_6", "context": "Rhabdomyolysis has been reported in patients receiving hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors when coadministered with agents that may inhibit their metabolism.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["receiving"]], "start": [[45]], "entity_id": ["T7"]}, "Effect": {"text": [["Rhabdomyolysis"]], "start": [[0]], "entity_id": ["T6"]}, "Treatment": {"text": [["hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors when coadministered with agents that may inhibit their metabolism"]], "start": [[55]], "entity_id": ["T8"], "Drug": {"text": [["hydroxymethylglutaryl coenzyme A"], ["agents that may inhibit their metabolism"]], "start": [[55], [144]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["coadministered"]], "start": [[124]], "entity_id": ["T12"]}, "Drug": {"text": [["hydroxymethylglutaryl coenzyme A"], ["agents that may inhibit their metabolism"]], "start": [[55], [144]], "entity_id": ["T10", "T11"]}}]}, "Subject": {"text": [["patients"]], "start": [[36]], "entity_id": ["T9"]}}]}]}
{"id": "16540070_1", "context": "A 55-year-old woman presented an episode of acute urticaria and labial angioedema 60 minutes after ingesting 500 mg of cloxacillin for a skin abscess.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["presented"]], "start": [[20]], "entity_id": ["T7"]}, "Subject": {"text": [["A 55-year-old woman", "a skin abscess"]], "start": [[0, 135]], "entity_id": ["T5"], "Age": {"text": [["55-year-old"]], "start": [[2]], "entity_id": ["T10"]}, "Gender": {"text": [["woman"]], "start": [[14]], "entity_id": ["T11"]}}, "Effect": {"text": [["acute urticaria and labial angioedema"]], "start": [[44]], "entity_id": ["T6"]}, "Treatment": {"text": [["ingesting 500 mg of cloxacillin"]], "start": [[99]], "entity_id": ["T8"], "Time_elapsed": {"text": [["60 minutes"]], "start": [[82]], "entity_id": ["T12"]}, "Route": {"text": [["ingesting"]], "start": [[99]], "entity_id": ["T13"]}, "Dosage": {"text": [["500 mg"]], "start": [[109]], "entity_id": ["T14"]}, "Drug": {"text": [["cloxacillin"]], "start": [[119]], "entity_id": ["T15"]}, "Disorder": {"text": [["skin abscess"]], "start": [[137]], "entity_id": ["T16"]}}}]}]}
{"id": "71813_2", "context": "Acne provoked by gold seems not to have been described elsewhere.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["provoked"]], "start": [[5]], "entity_id": ["T5"]}, "Effect": {"text": [["Acne"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["gold"]], "start": [[17]], "entity_id": ["T4"], "Drug": {"text": [["gold"]], "start": [[17]], "entity_id": ["T6"]}}}]}]}
{"id": "17260498_2", "context": "Taxanes are widely used chemotherapeutic agents with the potential to induce pulmonary injury through a variety of mechanisms.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induce"]], "start": [[70]], "entity_id": ["T6"]}, "Treatment": {"text": [["Taxanes"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Taxanes"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["pulmonary injury"]], "start": [[77]], "entity_id": ["T7"]}, "Speculated": {"text": [["potential"]], "start": [[57]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "17277758_4", "context": "PURPOSE: To report two cases of acute endophthalmitis following intravitreal bevacizumab injection.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[54]], "entity_id": ["T3"]}, "Treatment": {"text": [["intravitreal bevacizumab injection"]], "start": [[64]], "entity_id": ["T4"], "Route": {"text": [["intravitreal", "injection"]], "start": [[64, 89]], "entity_id": ["T8"]}, "Drug": {"text": [["bevacizumab"]], "start": [[77]], "entity_id": ["T9"]}}, "Subject": {"text": [["two cases"]], "start": [[19]], "entity_id": ["T5"], "Population": {"text": [["two"]], "start": [[19]], "entity_id": ["T7"]}}, "Effect": {"text": [["acute endophthalmitis"]], "start": [[32]], "entity_id": ["T6"]}}]}]}
{"id": "12621956_2", "context": "This is a case report of subtle, mild hypothermia in a 54-year old female patient receiving risperidone for schizophrenia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["receiving"]], "start": [[82]], "entity_id": ["T5"]}, "Effect": {"text": [["mild hypothermia"]], "start": [[33]], "entity_id": ["T3"]}, "Subject": {"text": [["a 54-year old female patient"]], "start": [[53]], "entity_id": ["T4"], "Age": {"text": [["54-year old"]], "start": [[55]], "entity_id": ["T7"]}, "Gender": {"text": [["female"]], "start": [[67]], "entity_id": ["T8"]}}, "Treatment": {"text": [["risperidone"]], "start": [[92]], "entity_id": ["T6"], "Drug": {"text": [["risperidone"]], "start": [[92]], "entity_id": ["T10"]}, "Disorder": {"text": [["schizophrenia"]], "start": [[108]], "entity_id": ["T11"]}}, "Severity": {"text": [["subtle"]], "start": [[25]], "entity_id": ["T9"], "value": "Medium"}}]}]}
{"id": "15866658_2", "context": "Mycophenolate mofetil-induced neutropenia in liver transplantation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[22]], "entity_id": ["T4"]}, "Treatment": {"text": [["Mycophenolate mofetil"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Mycophenolate mofetil"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["neutropenia in liver transplantation"]], "start": [[30]], "entity_id": ["T5"]}}]}]}
{"id": "3579660_1", "context": "Replicate brain magnetic resonance imaging examinations after six weeks and 11 months of penicillamine therapy documented the development of new brain lesions during this period, while liver biopsy specimen data disclosed that excellent hepatic decoppering had occurred.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["development"]], "start": [[126]], "entity_id": ["T5"]}, "Effect": {"text": [["new brain lesions"]], "start": [[141]], "entity_id": ["T6"]}, "Treatment": {"text": [["six weeks and 11 months of penicillamine therapy"]], "start": [[62]], "entity_id": ["T4"], "Duration": {"text": [["six weeks and 11 months"]], "start": [[62]], "entity_id": ["T7"]}, "Drug": {"text": [["penicillamine"]], "start": [[89]], "entity_id": ["T8"]}}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["occurred"]], "start": [[261]], "entity_id": ["T9"]}, "Treatment": {"text": [["six weeks and 11 months of penicillamine therapy"]], "start": [[62]], "entity_id": ["T4"], "Duration": {"text": [["six weeks and 11 months"]], "start": [[62]], "entity_id": ["T7"]}, "Drug": {"text": [["penicillamine"]], "start": [[89]], "entity_id": ["T8"]}}, "Effect": {"text": [["excellent hepatic decoppering"]], "start": [[227]], "entity_id": ["T10"]}}]}]}
{"id": "4054170_1", "context": "According to the literature, chlorambucil central nervous toxicity is found almost exclusively in childhood nephrotic syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["found"]], "start": [[70]], "entity_id": ["T6"]}, "Subject": {"text": [["childhood nephrotic syndrome"]], "start": [[98]], "entity_id": ["T3"], "Age": {"text": [["childhood"]], "start": [[98]], "entity_id": ["T7"]}, "Disorder": {"text": [["nephrotic syndrome"]], "start": [[108]], "entity_id": ["T8"]}}, "Treatment": {"text": [["chlorambucil"]], "start": [[29]], "entity_id": ["T4"], "Drug": {"text": [["chlorambucil"]], "start": [[29]], "entity_id": ["T9"]}}, "Effect": {"text": [["central nervous toxicity"]], "start": [[42]], "entity_id": ["T5"]}}]}]}
{"id": "9545161_2", "context": "Administration of lamotrigine, especially in combination with valproic acid, may lead to the development of TEN.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["development"]], "start": [[93]], "entity_id": ["T6"]}, "Effect": {"text": [["TEN"]], "start": [[108]], "entity_id": ["T5"]}, "Treatment": {"text": [["Administration of lamotrigine", "with valproic acid"]], "start": [[0, 57]], "entity_id": ["T7"], "Drug": {"text": [["valproic acid"], ["lamotrigine"]], "start": [[62], [18]], "entity_id": ["T11", "T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["with"]], "start": [[57]], "entity_id": ["T10"]}, "Drug": {"text": [["valproic acid"], ["lamotrigine"]], "start": [[62], [18]], "entity_id": ["T11", "T12"]}}]}, "Speculated": {"text": [["may"]], "start": [[77]], "entity_id": ["T4"], "value": true}}]}]}
{"id": "17404582_1", "context": "Docetaxel induced Meibomian duct inflammation and blockage is the likely cause of this presentation in a patient with no history of eyelid masses in the past.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[10]], "entity_id": ["T4"]}, "Treatment": {"text": [["Docetaxel"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Docetaxel"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["Meibomian duct inflammation and blockage"]], "start": [[18]], "entity_id": ["T5"]}, "Subject": {"text": [["a patient with no history of eyelid masses in the past"]], "start": [[103]], "entity_id": ["T6"]}, "Speculated": {"text": [["likely"]], "start": [[66]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "19660974_4", "context": "We describe a unique case of disseminated cryptococcosis presenting as colitis that mimicked an exacerbation of Crohn's disease in a TNF-alpha inhibitor recipient.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[128]], "entity_id": ["T9"]}, "Effect": {"text": [["an exacerbation of Crohn's disease"]], "start": [[93]], "entity_id": ["T6"]}, "Treatment": {"text": [["a TNF-alpha inhibitor"]], "start": [[131]], "entity_id": ["T7"], "Drug": {"text": [["TNF-alpha inhibitor"]], "start": [[133]], "entity_id": ["T10"]}}, "Subject": {"text": [["recipient"]], "start": [[153]], "entity_id": ["T8"]}}]}]}
{"id": "8438851_3", "context": "Rhabdomyolysis associated with the use of intravenous vasopressin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[15]], "entity_id": ["T4"]}, "Effect": {"text": [["Rhabdomyolysis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["intravenous vasopressin"]], "start": [[42]], "entity_id": ["T5"], "Drug": {"text": [["vasopressin"]], "start": [[54]], "entity_id": ["T6"]}}}]}]}
{"id": "3926849_1", "context": "Administration of intravenous nitroglycerin in a patient with idiopathic pulmonary hypertension resulted in an increase in pulmonary artery pressure associated with a decrease in blood flow that is best explained by an increase in pulmonary vascular resistance.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["Administration"]], "start": [[0]], "entity_id": ["T7"]}, "Treatment": {"text": [["intravenous nitroglycerin"]], "start": [[18]], "entity_id": ["T8"], "Disorder": {"text": [["idiopathic pulmonary hypertension"]], "start": [[62]], "entity_id": ["T11"]}, "Route": {"text": [["intravenous"]], "start": [[18]], "entity_id": ["T12"]}, "Drug": {"text": [["nitroglycerin"]], "start": [[30]], "entity_id": ["T13"]}}, "Subject": {"text": [["a patient with idiopathic pulmonary hypertension"]], "start": [[47]], "entity_id": ["T9"]}, "Effect": {"text": [["increase in pulmonary artery pressure associated with a decrease in blood flow that is best explained by an increase in pulmonary vascular resistance"]], "start": [[111]], "entity_id": ["T10"]}}]}]}
{"id": "11328247_5", "context": "The increased libido disappeared after fluvoxamine was discontinued.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[33]], "entity_id": ["T4"]}, "Effect": {"text": [["increased libido"]], "start": [[4]], "entity_id": ["T3"]}, "Treatment": {"text": [["fluvoxamine"]], "start": [[39]], "entity_id": ["T5"], "Drug": {"text": [["fluvoxamine"]], "start": [[39]], "entity_id": ["T6"]}}}]}]}
{"id": "9855339_2", "context": "Coadministration of antidepressant agents such as nefazodone, or any other drug that inhibits the CYP3A4 isoenzyme subfamily, should be anticipated to interfere with tacrolimus metabolism.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["interfere"]], "start": [[151]], "entity_id": ["T6"]}, "Treatment": {"text": [["tacrolimus"], ["Coadministration of antidepressant agents such as nefazodone, or any other drug that inhibits the CYP3A4 isoenzyme subfamily"]], "start": [[166], [0]], "entity_id": ["T7", "T4"], "Drug": {"text": [["tacrolimus"], ["nefazodone"]], "start": [[166], [50]], "entity_id": ["T11", "T10"]}, "Combination": [{"event_id": "E3", "event_type": "Combination", "Trigger": {"text": [["Coadministration"]], "start": [[0]], "entity_id": ["T5"]}, "Drug": {"text": [["nefazodone"], ["tacrolimus"]], "start": [[50], [166]], "entity_id": ["T10", "T11"]}}]}, "Effect": {"text": [["tacrolimus metabolism"]], "start": [[166]], "entity_id": ["T8"]}, "Speculated": {"text": [["should be anticipated"]], "start": [[126]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "7606071_3", "context": "CONCLUSIONS: We conclude that a high dose combined with a short infusion time increases the risk of anaphylactoid reactions with the administration of intraperitoneal cisplatin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[124]], "entity_id": ["T4"]}, "Effect": {"text": [["anaphylactoid reactions"]], "start": [[100]], "entity_id": ["T3"]}, "Treatment": {"text": [["a high dose combined with a short infusion time", "administration of intraperitoneal cisplatin"]], "start": [[30, 133]], "entity_id": ["T5"], "Dosage": {"text": [["high dose"]], "start": [[32]], "entity_id": ["T8"]}, "Drug": {"text": [["cisplatin"]], "start": [[167]], "entity_id": ["T10"]}, "Route": {"text": [["intraperitoneal"]], "start": [[151]], "entity_id": ["T9"]}}, "Speculated": {"text": [["risk"]], "start": [[92]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "8742573_3", "context": "Human insulin-induced lipoatrophy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[14]], "entity_id": ["T4"]}, "Treatment": {"text": [["Human insulin"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Human insulin"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["lipoatrophy"]], "start": [[22]], "entity_id": ["T5"]}}]}]}
{"id": "2332596_2", "context": "Severe hepatotoxicity from phenobarbital occurred in an infant boy who had a complicated illness with chronic bilateral subdural hematomas and sepsis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["from"]], "start": [[22]], "entity_id": ["T3"]}, "Treatment": {"text": [["phenobarbital"]], "start": [[27]], "entity_id": ["T4"], "Drug": {"text": [["phenobarbital"]], "start": [[27]], "entity_id": ["T12"]}, "Disorder": {"text": [["chronic bilateral subdural hematomas", "sepsis"]], "start": [[102, 143]], "entity_id": ["T13"]}}, "Effect": {"text": [["Severe hepatotoxicity"]], "start": [[0]], "entity_id": ["T5"]}, "Subject": {"text": [["an infant boy who had a complicated illness with chronic bilateral subdural hematomas and sepsis."]], "start": [[53]], "entity_id": ["T6"], "Age": {"text": [["infant"]], "start": [[56]], "entity_id": ["T7"]}, "Gender": {"text": [["boy"]], "start": [[63]], "entity_id": ["T8"]}}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T11"], "value": "High"}}]}]}
{"id": "8053440_1", "context": "Cholestatic liver disease with ductopenia (vanishing bile duct syndrome) after administration of clindamycin and trimethoprim-sulfamethoxazole.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[73]], "entity_id": ["T10"]}, "Treatment": {"text": [["clindamycin and trimethoprim-sulfamethoxazole"]], "start": [[97]], "entity_id": ["T11"], "Drug": {"text": [["clindamycin"], ["trimethoprim"], ["sulfamethoxazole"]], "start": [[97], [113], [126]], "entity_id": ["T13", "T14", "T15"]}, "Combination": [{"event_id": "E3", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[109]], "entity_id": ["T17"]}, "Drug": {"text": [["clindamycin"], ["sulfamethoxazole"], ["trimethoprim"]], "start": [[97], [126], [113]], "entity_id": ["T13", "T15", "T14"]}}]}, "Effect": {"text": [["Cholestatic liver disease with ductopenia (vanishing bile duct syndrome)"]], "start": [[0]], "entity_id": ["T12"]}}]}]}
{"id": "16012330_11", "context": "The authors suggest that in the absence of any proven benefit of itraconazole prophylaxis, and given the interaction of this drug with vincristine leading to severe and even potentially fatal toxicities, the combination use of these drugs should be avoided.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["leading"]], "start": [[147]], "entity_id": ["T7"]}, "Treatment": {"text": [["itraconazole", "vincristine"]], "start": [[65, 135]], "entity_id": ["T6"], "Drug": {"text": [["itraconazole"], ["vincristine"]], "start": [[65], [135]], "entity_id": ["T11", "T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[105]], "entity_id": ["T10"]}, "Drug": {"text": [["itraconazole"], ["vincristine"]], "start": [[65], [135]], "entity_id": ["T11", "T12"]}}]}, "Effect": {"text": [["severe and even potentially fatal toxicities"]], "start": [[158]], "entity_id": ["T8"]}, "Severity": {"text": [["severe and even potentially fatal"]], "start": [[158]], "entity_id": ["T9"], "value": "High"}}]}]}
{"id": "23042259_3", "context": "The determinant role of individual pharmacogenetic profile in the occurrence of tacrolimus nephrotoxicity is presented and discussed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurrence"]], "start": [[66]], "entity_id": ["T4"]}, "Effect": {"text": [["tacrolimus nephrotoxicity"]], "start": [[80]], "entity_id": ["T5"]}, "Treatment": {"text": [["tacrolimus"]], "start": [[80]], "entity_id": ["T6"], "Drug": {"text": [["tacrolimus"]], "start": [[80]], "entity_id": ["T7"]}}}]}]}
{"id": "10555917_4", "context": "These findings suggest that bicytopenia in this patient was caused by D-Pen and may be due to different sensitivities in the hematopoietic lineage.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[60]], "entity_id": ["T6"]}, "Treatment": {"text": [["D-Pen"]], "start": [[70]], "entity_id": ["T3"], "Drug": {"text": [["D-Pen"]], "start": [[70]], "entity_id": ["T7"]}}, "Effect": {"text": [["bicytopenia"]], "start": [[28]], "entity_id": ["T4"]}, "Subject": {"text": [["patient"]], "start": [[48]], "entity_id": ["T5"]}}]}]}
{"id": "2320800_7", "context": "We strongly suspect that this lethal anuria was mainly due to ifosfamide, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurring"]], "start": [[74]], "entity_id": ["T12"]}, "Effect": {"text": [["lethal anuria"]], "start": [[30]], "entity_id": ["T10"]}, "Treatment": {"text": [["ifosfamide", "having received previous cisplatin chemotherapy"]], "start": [[62, 97]], "entity_id": ["T11"], "Drug": {"text": [["ifosfamide"], ["cisplatin"]], "start": [[62], [122]], "entity_id": ["T16", "T17"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["received"]], "start": [[104]], "entity_id": ["T1"]}, "Drug": {"text": [["ifosfamide"], ["cisplatin"]], "start": [[62], [122]], "entity_id": ["T16", "T17"]}}]}, "Subject": {"text": [["a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension"]], "start": [[87]], "entity_id": ["T13"], "Disorder": {"text": [["poor kidney perfusion"]], "start": [[154]], "entity_id": ["T14"]}}, "Speculated": {"text": [["suspect"]], "start": [[12]], "entity_id": ["T15"], "value": true}}]}]}
{"id": "12680486_2", "context": "Clinicians have been aware of lithium toxicity for many years and traditionally have administered thiazide diuretics for lithium-induced polyuria and nephrogenic diabetes insipidus.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["administered"]], "start": [[85]], "entity_id": ["T10"]}, "Treatment": {"text": [["thiazide diuretics"]], "start": [[98]], "entity_id": ["T9"], "Disorder": {"text": [["polyuria", "nephrogenic diabetes insipidus"]], "start": [[137, 150]], "entity_id": ["T11"]}, "Drug": {"text": [["thiazide diuretics"]], "start": [[98]], "entity_id": ["T12"]}}}]}]}
{"id": "19281746_2", "context": "We report the first case of acute renal failure with hyperkalemia associated with the recently marketed direct renin inhibitor aliskiren.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[66]], "entity_id": ["T6"]}, "Effect": {"text": [["acute renal failure with hyperkalemia"]], "start": [[28]], "entity_id": ["T5"]}, "Treatment": {"text": [["renin inhibitor aliskiren"]], "start": [[111]], "entity_id": ["T7"], "Drug": {"text": [["aliskiren"]], "start": [[127]], "entity_id": ["T8"]}}}]}]}
{"id": "2803154_3", "context": "The authors describe a patient with hemiparesis who developed the syndrome of irreversible lithium-effectuated neurotoxicity (SILENT) while being treated with lithium for a manic episode.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[52]], "entity_id": ["T5"]}, "Subject": {"text": [["a patient with hemiparesis"]], "start": [[21]], "entity_id": ["T3"], "Disorder": {"text": [["hemiparesis"]], "start": [[36]], "entity_id": ["T4"]}}, "Effect": {"text": [["irreversible lithium-effectuated neurotoxicity (SILENT)"]], "start": [[78]], "entity_id": ["T6"]}, "Treatment": {"text": [["lithium for a manic episode"]], "start": [[159]], "entity_id": ["T7"], "Drug": {"text": [["lithium"]], "start": [[159]], "entity_id": ["T8"]}, "Disorder": {"text": [["manic episode"]], "start": [[173]], "entity_id": ["T9"]}}}]}]}
{"id": "8979664_2", "context": "over the past 3 years there have been several reports of uveitis associated with rifabutin therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[65]], "entity_id": ["T4"]}, "Effect": {"text": [["uveitis"]], "start": [[57]], "entity_id": ["T3"]}, "Treatment": {"text": [["rifabutin therapy"]], "start": [[81]], "entity_id": ["T5"], "Drug": {"text": [["rifabutin"]], "start": [[81]], "entity_id": ["T6"]}}}]}]}
{"id": "9247841_1", "context": "Propylthiouracil-induced cutaneous vasculitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[17]], "entity_id": ["T5"]}, "Treatment": {"text": [["Propylthiouracil"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Propylthiouracil"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["cutaneous vasculitis"]], "start": [[25]], "entity_id": ["T6"]}}]}]}
{"id": "17876386_1", "context": "It has been reported that fluoroquinolone antimicrobials prolong the corrected QT interval but rarely cause torsade de pointes.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["prolong"]], "start": [[57]], "entity_id": ["T4"]}, "Treatment": {"text": [["fluoroquinolone antimicrobials"]], "start": [[26]], "entity_id": ["T3"], "Drug": {"text": [["fluoroquinolone"]], "start": [[26]], "entity_id": ["T6"]}}, "Effect": {"text": [["corrected QT interval but rarely cause torsade de pointes"]], "start": [[69]], "entity_id": ["T5"]}}]}]}
{"id": "11414270_1", "context": "Succinylcholine-induced hyperkalemia in a patient with mucositis secondary to chemotherapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[16]], "entity_id": ["T9"]}, "Treatment": {"text": [["Succinylcholine"]], "start": [[0]], "entity_id": ["T8"], "Drug": {"text": [["Succinylcholine"]], "start": [[0]], "entity_id": ["T1"]}}, "Subject": {"text": [["a patient with mucositis"]], "start": [[40]], "entity_id": ["T10"], "Disorder": {"text": [["mucositis"]], "start": [[55]], "entity_id": ["T11"]}}, "Effect": {"text": [["hyperkalemia"]], "start": [[24]], "entity_id": ["T12"]}}]}]}
{"id": "19745701_4", "context": "To our knowledge, this is the first case of spontaneous remission of MTX-associated gastric LPD after discontinuation of MTX therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[73]], "entity_id": ["T5"]}, "Subject": {"text": [["the first case"]], "start": [[26]], "entity_id": ["T3"]}, "Treatment": {"text": [["MTX"]], "start": [[69]], "entity_id": ["T4"], "Drug": {"text": [["MTX"], ["MTX"]], "start": [[69], [121]], "entity_id": ["T7", "T8"]}}, "Effect": {"text": [["gastric LPD"]], "start": [[84]], "entity_id": ["T6"]}}]}]}
{"id": "8651254_5", "context": "We describe a patient with acute myeloblastic leukemia (AML) who developed nephrotic syndrome after receiving several courses of chemotherapy, including macrophage-colony-stimulating factor (M-CSF).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[94]], "entity_id": ["T4"]}, "Subject": {"text": [["a patient with acute myeloblastic leukemia (AML)"]], "start": [[12]], "entity_id": ["T5"]}, "Treatment": {"text": [["several courses of chemotherapy, including macrophage-colony-stimulating factor (M-CSF)"]], "start": [[110]], "entity_id": ["T6"], "Disorder": {"text": [["acute myeloblastic leukemia"]], "start": [[27]], "entity_id": ["T8"]}, "Drug": {"text": [["macrophage-colony-stimulating factor"]], "start": [[153]], "entity_id": ["T9"]}, "Route": {"text": [["chemotherapy"]], "start": [[129]], "entity_id": ["T1"]}}, "Effect": {"text": [["nephrotic syndrome"]], "start": [[75]], "entity_id": ["T7"]}}]}]}
{"id": "7991279_1", "context": "Actinomycin D associated hepatic veno-occlusive disease--a report of 2 cases.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[14]], "entity_id": ["T3"]}, "Treatment": {"text": [["Actinomycin D"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Actinomycin D"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["hepatic veno-occlusive disease"]], "start": [[25]], "entity_id": ["T5"]}}]}]}
{"id": "8604715_3", "context": "Our patient developed both nephrogenic diabetes insipidus and renal tubular acidosis with a temporal pattern that demonstrated a link between foscarnet therapy and these abnormalities.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[12]], "entity_id": ["T8"]}, "Treatment": {"text": [["foscarnet"]], "start": [[142]], "entity_id": ["T5"], "Drug": {"text": [["foscarnet"]], "start": [[142]], "entity_id": ["T9"]}}, "Effect": {"text": [["nephrogenic diabetes insipidus and renal tubular acidosis"]], "start": [[27]], "entity_id": ["T6"]}, "Subject": {"text": [["patient"]], "start": [[4]], "entity_id": ["T7"]}}]}]}
{"id": "1401493_1", "context": "We report a case of acne fulminans occurring during treatment with 13-cis-retinoic acid for cystic acne.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurring"]], "start": [[35]], "entity_id": ["T7"]}, "Subject": {"text": [["a case"]], "start": [[10]], "entity_id": ["T3"]}, "Treatment": {"text": [["13-cis-retinoic acid"]], "start": [[67]], "entity_id": ["T4"], "Drug": {"text": [["13-cis-retinoic acid"]], "start": [[67]], "entity_id": ["T8"]}, "Disorder": {"text": [["cystic acne"]], "start": [[92]], "entity_id": ["T9"]}}, "Effect": {"text": [["acne fulminans"]], "start": [[20]], "entity_id": ["T6"]}}]}]}
{"id": "12135176_2", "context": "Verapamil is widely used for the termination of paroxysmal supraventricular tachycardia (PSVT) with little proarrhythmic effect.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[95]], "entity_id": ["T7"]}, "Treatment": {"text": [["Verapamil"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Verapamil"]], "start": [[0]], "entity_id": ["T8"]}, "Disorder": {"text": [["paroxysmal supraventricular tachycardia"]], "start": [[48]], "entity_id": ["T9"]}}, "Effect": {"text": [["proarrhythmic effect"]], "start": [[107]], "entity_id": ["T5"]}, "Negated": {"text": [["little"]], "start": [[100]], "entity_id": ["T4"], "value": true}}]}]}
{"id": "20190474_1", "context": "Acute kidney injury caused by zonisamide-induced hypersensitivity syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[41]], "entity_id": ["T6"]}, "Treatment": {"text": [["zonisamide"]], "start": [[30]], "entity_id": ["T5"], "Drug": {"text": [["zonisamide"]], "start": [[30]], "entity_id": ["T8"]}}, "Effect": {"text": [["hypersensitivity syndrome"]], "start": [[49]], "entity_id": ["T7"]}}]}]}
{"id": "4004433_2", "context": "Our findings suggest that hyperkalemia can develop with the use of low-dose heparin, within seven days of initiating heparin therapy, and that patients with diabetes mellitus or chronic renal insufficiency are especially predisposed to this complication.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["develop"]], "start": [[43]], "entity_id": ["T5"]}, "Effect": {"text": [["hyperkalemia"]], "start": [[26]], "entity_id": ["T4"]}, "Treatment": {"text": [["low-dose heparin, within seven days of initiating heparin therapy"]], "start": [[67]], "entity_id": ["T6"], "Dosage": {"text": [["low-dose"]], "start": [[67]], "entity_id": ["T10"]}, "Drug": {"text": [["heparin"]], "start": [[76]], "entity_id": ["T11"]}, "Time_elapsed": {"text": [["within seven days"]], "start": [[85]], "entity_id": ["T12"]}}, "Subject": {"text": [["patients with diabetes mellitus or chronic renal insufficiency"]], "start": [[143]], "entity_id": ["T7"], "Disorder": {"text": [["diabetes mellitus"], ["chronic renal insufficiency"]], "start": [[157], [178]], "entity_id": ["T8", "T9"]}}}]}]}
{"id": "20120657_2", "context": "We report a case of Zidovudine induced anaemia and bone marrow aplasia in a patient infected with HIV.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[31]], "entity_id": ["T5"]}, "Effect": {"text": [["anaemia and bone marrow aplasia"]], "start": [[39]], "entity_id": ["T6"]}, "Treatment": {"text": [["Zidovudine"]], "start": [[20]], "entity_id": ["T7"], "Drug": {"text": [["Zidovudine"]], "start": [[20]], "entity_id": ["T10"]}, "Disorder": {"text": [["HIV"]], "start": [[98]], "entity_id": ["T11"]}}, "Subject": {"text": [["a patient infected with HIV"]], "start": [[74]], "entity_id": ["T8"]}}]}]}
{"id": "19390192_3", "context": "We present the case of an adult Crohn's disease patient with a parvovirus B19 infection and leukopenia during long-term AZA therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[103]], "entity_id": ["T4"]}, "Subject": {"text": [["adult Crohn's disease patient"]], "start": [[26]], "entity_id": ["T3"], "Age": {"text": [["adult"]], "start": [[26]], "entity_id": ["T7"]}}, "Treatment": {"text": [["long-term AZA therapy"]], "start": [[110]], "entity_id": ["T5"], "Disorder": {"text": [["Crohn's disease"]], "start": [[32]], "entity_id": ["T9"]}, "Drug": {"text": [["AZA"]], "start": [[120]], "entity_id": ["T10"]}, "Duration": {"text": [["long-term"]], "start": [[110]], "entity_id": ["T11"]}}, "Effect": {"text": [["a parvovirus B19 infection and leukopenia"]], "start": [[61]], "entity_id": ["T6"]}}]}]}
{"id": "18094347_7", "context": "Pathogenesis of methotrexate-induced papular eruption in psoriasis may involve immune mechanisms other than those of methotrexate-induced cutaneous vasculitis in collagen vascular disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[29]], "entity_id": ["T6"]}, "Treatment": {"text": [["methotrexate"]], "start": [[16]], "entity_id": ["T5"], "Drug": {"text": [["methotrexate"]], "start": [[16]], "entity_id": ["T8"]}}, "Effect": {"text": [["papular eruption in psoriasis", "cutaneous vasculitis in collagen vascular disease"]], "start": [[37, 138]], "entity_id": ["T7"]}}]}]}
{"id": "9205466_2", "context": "CASES: Two postmenopausal women treated with tamoxifen and progestational agents for breast carcinoma developed uterine enlargement and intermittent spotting.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[102]], "entity_id": ["T8"]}, "Subject": {"text": [["Two postmenopausal women"]], "start": [[7]], "entity_id": ["T5"], "Population": {"text": [["Two"]], "start": [[7]], "entity_id": ["T10"]}, "Gender": {"text": [["women"]], "start": [[26]], "entity_id": ["T11"]}}, "Treatment": {"text": [["tamoxifen and progestational"]], "start": [[45]], "entity_id": ["T6"], "Drug": {"text": [["tamoxifen"]], "start": [[45]], "entity_id": ["T12"]}, "Disorder": {"text": [["breast carcinoma"]], "start": [[85]], "entity_id": ["T13"]}}, "Effect": {"text": [["uterine enlargement and intermittent spotting"]], "start": [[112]], "entity_id": ["T9"]}}]}]}
{"id": "19570088_1", "context": "Tumor lysis syndrome after transcatheter arterial infusion of cisplatin and embolization therapy for liver metastases of melanoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[21]], "entity_id": ["T6"]}, "Effect": {"text": [["Tumor lysis syndrome"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["transcatheter arterial infusion of cisplatin and embolization"]], "start": [[27]], "entity_id": ["T4"], "Disorder": {"text": [["liver metastases of melanoma"]], "start": [[101]], "entity_id": ["T5"]}, "Route": {"text": [["transcatheter arterial infusion"]], "start": [[27]], "entity_id": ["T7"]}, "Drug": {"text": [["cisplatin"]], "start": [[62]], "entity_id": ["T8"]}}}]}]}
{"id": "18821094_1", "context": "Oxcarbazepine-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[14]], "entity_id": ["T6"]}, "Treatment": {"text": [["Oxcarbazepine"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Oxcarbazepine"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["Eosinophilia and Systemic Symptoms (DRESS)"]], "start": [[41]], "entity_id": ["T7"]}}]}]}
{"id": "3579660_4", "context": "Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[33]], "entity_id": ["T6"]}, "Effect": {"text": [["Worsening of neurologic syndrome"]], "start": [[0]], "entity_id": ["T3"]}, "Subject": {"text": [["patients with Wilson's disease"]], "start": [[36]], "entity_id": ["T4"]}, "Treatment": {"text": [["penicillamine therapy"]], "start": [[80]], "entity_id": ["T5"], "Drug": {"text": [["penicillamine"]], "start": [[80]], "entity_id": ["T8"]}, "Disorder": {"text": [["Wilson's disease"]], "start": [[50]], "entity_id": ["T9"]}}}]}]}
{"id": "15494638_7", "context": "Patient A reported right leg weakness (foot drop) during week 4 of CAP-XRT (1600 mg/m2).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[50]], "entity_id": ["T8"]}, "Subject": {"text": [["Patient A"]], "start": [[0]], "entity_id": ["T5"]}, "Effect": {"text": [["right leg weakness"]], "start": [[19]], "entity_id": ["T6"]}, "Treatment": {"text": [["week 4 of CAP-XRT (1600 mg/m2)"]], "start": [[57]], "entity_id": ["T7"], "Duration": {"text": [["week 4"]], "start": [[57]], "entity_id": ["T9"]}, "Drug": {"text": [["CAP-XRT"]], "start": [[67]], "entity_id": ["T10"]}, "Dosage": {"text": [["1600 mg/m2"]], "start": [[76]], "entity_id": ["T11"]}}}]}]}
{"id": "3763264_2", "context": "A child in whom a phenobarbital hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein-losing enteropathy, myositis, and nephritis, is described.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[63]], "entity_id": ["T15"]}, "Subject": {"text": [["A child"]], "start": [[0]], "entity_id": ["T12"], "Age": {"text": [["child"]], "start": [[2]], "entity_id": ["T16"]}}, "Treatment": {"text": [["phenobarbital"]], "start": [[18]], "entity_id": ["T13"], "Drug": {"text": [["phenobarbital"]], "start": [[18]], "entity_id": ["T17"]}}, "Effect": {"text": [["hypersensitivity drug reaction", "which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein-losing enteropathy, myositis, and nephritis"]], "start": [[32, 73]], "entity_id": ["T14"]}}]}]}
{"id": "10229976_1", "context": "Detection of activated eosinophils in nasal polyps of an aspirin-induced asthma patient.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[65]], "entity_id": ["T4"]}, "Treatment": {"text": [["aspirin"]], "start": [[57]], "entity_id": ["T3"], "Drug": {"text": [["aspirin"]], "start": [[57]], "entity_id": ["T6"]}}, "Effect": {"text": [["asthma"]], "start": [[73]], "entity_id": ["T5"]}}]}]}
{"id": "19540093_5", "context": "We recommend that clinicians monitor patients for signs and symptoms of pancreatitis, including abdominal pain, during treatment with tigecycline.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatment"]], "start": [[119]], "entity_id": ["T8"]}, "Treatment": {"text": [["tigecycline"]], "start": [[134]], "entity_id": ["T5"], "Drug": {"text": [["tigecycline"]], "start": [[134]], "entity_id": ["T9"]}}, "Effect": {"text": [["pancreatitis, including abdominal pain"]], "start": [[72]], "entity_id": ["T7"]}, "Speculated": {"text": [["recommend"]], "start": [[3]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "11568758_3", "context": "We describe a patient who experienced a lichenoid eruption after the initiation of salsalate for relief of arthritic pain.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[59]], "entity_id": ["T6"]}, "Subject": {"text": [["a patient"]], "start": [[12]], "entity_id": ["T4"]}, "Effect": {"text": [["lichenoid eruption"]], "start": [[40]], "entity_id": ["T5"]}, "Treatment": {"text": [["the initiation of salsalate"]], "start": [[65]], "entity_id": ["T7"], "Duration": {"text": [["initiation"]], "start": [[69]], "entity_id": ["T3"]}, "Drug": {"text": [["salsalate"]], "start": [[83]], "entity_id": ["T8"]}, "Disorder": {"text": [["arthritic pain"]], "start": [[107]], "entity_id": ["T9"]}}}]}]}
{"id": "12587815_2", "context": "Concomitant administration of lithium with olanzapine may place patients at risk for NMS.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["administration"]], "start": [[12]], "entity_id": ["T9"]}, "Treatment": {"text": [["lithium"], ["olanzapine"]], "start": [[30], [43]], "entity_id": ["T4", "T5"], "Drug": {"text": [["lithium"], ["olanzapine"]], "start": [[30], [43]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["with"]], "start": [[38]], "entity_id": ["T12"]}, "Drug": {"text": [["lithium"], ["olanzapine"]], "start": [[30], [43]], "entity_id": ["T10", "T11"]}}]}, "Subject": {"text": [["patients"]], "start": [[64]], "entity_id": ["T6"]}, "Effect": {"text": [["NMS"]], "start": [[85]], "entity_id": ["T7"]}, "Speculated": {"text": [["at risk for"]], "start": [[73]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "20203465_3", "context": "We report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea, shortness of breath, azotemia, and hyperkalemia shortly after completing a course of intravenous immunoglobulin (IVIG).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["presented"]], "start": [[76]], "entity_id": ["T15"]}, "Effect": {"text": [["nausea, shortness of breath, azotemia, and hyperkalemia"]], "start": [[91]], "entity_id": ["T16"]}, "Treatment": {"text": [["intravenous immunoglobulin"]], "start": [[184]], "entity_id": ["T17"], "Drug": {"text": [["immunoglobulin"]], "start": [[196]], "entity_id": ["T21"]}, "Disorder": {"text": [["myasthenia gravis"]], "start": [[54]], "entity_id": ["T22"]}, "Route": {"text": [["intravenous"]], "start": [[184]], "entity_id": ["T23"]}}, "Subject": {"text": [["an 87-year-old white woman with myasthenia gravis"]], "start": [[22]], "entity_id": ["T13"], "Age": {"text": [["87-year-old"]], "start": [[25]], "entity_id": ["T18"]}, "Race": {"text": [["white"]], "start": [[37]], "entity_id": ["T19"]}, "Gender": {"text": [["woman"]], "start": [[43]], "entity_id": ["T20"]}}}]}]}
{"id": "17655517_8", "context": "Linezolid should be discontinued immediately in patients experiencing these adverse effects.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["discontinued"]], "start": [[20]], "entity_id": ["T6"]}, "Effect": {"text": [["adverse effects"]], "start": [[76]], "entity_id": ["T4"]}, "Treatment": {"text": [["Linezolid"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Linezolid"]], "start": [[0]], "entity_id": ["T7"]}}, "Subject": {"text": [["patients"]], "start": [[48]], "entity_id": ["T8"]}}]}]}
{"id": "11077455_3", "context": "PURPOSE: Symptomatic visual field constriction thought to be associated with vigabatrin has been reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[61]], "entity_id": ["T4"]}, "Effect": {"text": [["Symptomatic visual field constriction"]], "start": [[9]], "entity_id": ["T3"]}, "Treatment": {"text": [["vigabatrin"]], "start": [[77]], "entity_id": ["T5"], "Drug": {"text": [["vigabatrin"]], "start": [[77]], "entity_id": ["T6"]}}}]}]}
{"id": "19857154_1", "context": "Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["adverse events"]], "start": [[23]], "entity_id": ["T14"]}, "Subject": {"text": [["two patients"]], "start": [[109]], "entity_id": ["T7"], "Population": {"text": [["two"]], "start": [[109]], "entity_id": ["T10"]}}, "Treatment": {"text": [["interaction between quetiapine and atazanavir-ritonavir"]], "start": [[50]], "entity_id": ["T6"], "Drug": {"text": [["quetiapine"], ["atazanavir-ritonavir"]], "start": [[70], [85]], "entity_id": ["T12", "T13"]}, "Combination": [{"event_id": "E1", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[50]], "entity_id": ["T9"]}, "Drug": {"text": [["quetiapine"], ["atazanavir-ritonavir"]], "start": [[70], [85]], "entity_id": ["T12", "T13"]}}]}, "Effect": {"text": [["Clinically significant"]], "start": [[0]], "entity_id": ["T8"]}, "Severity": {"text": [["significant"]], "start": [[11]], "entity_id": ["T11"], "value": "Medium"}}]}]}
{"id": "1477441_4", "context": "OBJECTIVE: To report two cases of fixed drug eruption induced by methylphenidate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[54]], "entity_id": ["T4"]}, "Subject": {"text": [["two cases"]], "start": [[21]], "entity_id": ["T3"], "Population": {"text": [["two"]], "start": [[21]], "entity_id": ["T7"]}}, "Treatment": {"text": [["methylphenidate"]], "start": [[65]], "entity_id": ["T5"], "Drug": {"text": [["methylphenidate"]], "start": [[65]], "entity_id": ["T8"]}}, "Effect": {"text": [["fixed drug eruption"]], "start": [[34]], "entity_id": ["T6"]}}]}]}
{"id": "17655517_2", "context": "Linezolid is an oxazolidinone antibacterial agent indicated for serious gram-positive infections.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["indicated"]], "start": [[50]], "entity_id": ["T6"]}, "Treatment": {"text": [["Linezolid"]], "start": [[0]], "entity_id": ["T5"], "Disorder": {"text": [["serious gram-positive infections"]], "start": [[64]], "entity_id": ["T7"]}, "Drug": {"text": [["Linezolid"]], "start": [[0]], "entity_id": ["T8"]}}}]}]}
{"id": "17675030_1", "context": "A search of the United States Food and Drug Administration's Adverse Event Reporting System identified nine cases of oxcarbazepine-associated angioedema in pediatric patients aged 16 years and younger.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[131]], "entity_id": ["T4"]}, "Treatment": {"text": [["oxcarbazepine"]], "start": [[117]], "entity_id": ["T3"], "Drug": {"text": [["oxcarbazepine"]], "start": [[117]], "entity_id": ["T8"]}}, "Effect": {"text": [["angioedema"]], "start": [[142]], "entity_id": ["T5"]}, "Subject": {"text": [["pediatric patients aged 16 years and younger"]], "start": [[156]], "entity_id": ["T6"], "Age": {"text": [["16 years and younger"]], "start": [[180]], "entity_id": ["T7"]}, "Disorder": {"text": [["pediatric"]], "start": [[156]], "entity_id": ["T1"]}}}]}]}
{"id": "2140997_2", "context": "Monitoring of liver function tests should be mandatory in patients receiving high doses of cyproterone acetate; the drug should be withdrawn immediately if abnormal liver function tests are found.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["abnormal"]], "start": [[156]], "entity_id": ["T6"]}, "Effect": {"text": [["abnormal liver function"]], "start": [[156]], "entity_id": ["T3"]}, "Treatment": {"text": [["receiving high doses of cyproterone acetate"]], "start": [[67]], "entity_id": ["T4"], "Drug": {"text": [["cyproterone acetate"]], "start": [[91]], "entity_id": ["T7"]}, "Dosage": {"text": [["high doses"]], "start": [[77]], "entity_id": ["T8"]}}, "Subject": {"text": [["patients"]], "start": [[58]], "entity_id": ["T5"]}}]}]}
{"id": "6311654_3", "context": "In six cases CT scans did not return to their original state after ACTH therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[61]], "entity_id": ["T6"]}, "Subject": {"text": [["six cases"]], "start": [[3]], "entity_id": ["T4"], "Population": {"text": [["six"]], "start": [[3]], "entity_id": ["T8"]}}, "Effect": {"text": [["CT scans did not return to their original state"]], "start": [[13]], "entity_id": ["T5"]}, "Treatment": {"text": [["ACTH"]], "start": [[67]], "entity_id": ["T7"], "Drug": {"text": [["ACTH"]], "start": [[67]], "entity_id": ["T9"]}}}]}]}
{"id": "16204273_2", "context": "This report describes a probable case of infliximab-induced membranous nephropathy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[52]], "entity_id": ["T4"]}, "Treatment": {"text": [["infliximab"]], "start": [[41]], "entity_id": ["T3"], "Drug": {"text": [["infliximab"]], "start": [[41]], "entity_id": ["T6"]}}, "Effect": {"text": [["membranous nephropathy"]], "start": [[60]], "entity_id": ["T5"]}}]}]}
{"id": "6683487_1", "context": "Thrombotic thrombocytopenic purpura during penicillamine therapy in rheumatoid arthritis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[36]], "entity_id": ["T6"]}, "Effect": {"text": [["Thrombotic thrombocytopenic purpura"]], "start": [[0]], "entity_id": ["T7"]}, "Treatment": {"text": [["penicillamine"]], "start": [[43]], "entity_id": ["T8"], "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[68]], "entity_id": ["T9"]}, "Drug": {"text": [["penicillamine"]], "start": [[43]], "entity_id": ["T10"]}}}]}]}
{"id": "10452772_3", "context": "OBJECTIVE: The purpose of this study was to determine whether desensitization to NPH insulin, as well as standard insulin desensitization, could control allergic symptoms in a patient allergic to both NPH and regular insulin.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["control"]], "start": [[145]], "entity_id": ["T6"]}, "Treatment": {"text": [["desensitization to NPH insulin, as well as standard insulin desensitization"]], "start": [[62]], "entity_id": ["T4"], "Disorder": {"text": [["allergic symptoms in a patient allergic to both NPH and regular insulin"]], "start": [[153]], "entity_id": ["T9"]}, "Drug": {"text": [["NPH insulin"], ["standard insulin"]], "start": [[81], [105]], "entity_id": ["T7", "T11"]}, "Route": {"text": [["desensitization"], ["desensitization"]], "start": [[62], [122]], "entity_id": ["T5", "T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["as well as"]], "start": [[94]], "entity_id": ["T10"]}, "Drug": {"text": [["NPH insulin"], ["standard insulin"]], "start": [[81], [105]], "entity_id": ["T7", "T11"]}}]}, "Subject": {"text": [["a patient allergic to both NPH and regular insulin"]], "start": [[174]], "entity_id": ["T13"]}, "Speculated": {"text": [["whether"]], "start": [[54]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "1261772_1", "context": "Fulminant hepatic failure developed in a 24-year-old black woman who had been treated with propylthiouracil and propranolol for hyperthyroidism.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[26]], "entity_id": ["T6"]}, "Subject": {"text": [["a 24-year-old black woman"]], "start": [[39]], "entity_id": ["T4"], "Age": {"text": [["24-year-old"]], "start": [[41]], "entity_id": ["T9"]}, "Race": {"text": [["black"]], "start": [[53]], "entity_id": ["T10"]}, "Gender": {"text": [["woman"]], "start": [[59]], "entity_id": ["T11"]}}, "Effect": {"text": [["Fulminant hepatic failure"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["propylthiouracil and propranolol"]], "start": [[91]], "entity_id": ["T7"], "Drug": {"text": [["propylthiouracil"], ["propranolol"]], "start": [[91], [112]], "entity_id": ["T12", "T13"]}, "Disorder": {"text": [["hyperthyroidism"]], "start": [[128]], "entity_id": ["T15"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[108]], "entity_id": ["T14"]}, "Drug": {"text": [["propranolol"], ["propylthiouracil"]], "start": [[112], [91]], "entity_id": ["T13", "T12"]}}]}}]}]}
{"id": "9195619_1", "context": "However, as the use of hepatitis B vaccination is growing, adverse side effects, including mental nerve neuropathy, should be observed with an increased frequency.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["observed"]], "start": [[126]], "entity_id": ["T5"]}, "Treatment": {"text": [["hepatitis B vaccination"]], "start": [[23]], "entity_id": ["T3"], "Drug": {"text": [["hepatitis B vaccination"]], "start": [[23]], "entity_id": ["T6"]}}, "Effect": {"text": [["mental nerve neuropathy"]], "start": [[91]], "entity_id": ["T4"]}}]}]}
{"id": "2292051_1", "context": "Acute coronary events following cisplatin-based chemotherapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[22]], "entity_id": ["T4"]}, "Effect": {"text": [["Acute coronary events"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["cisplatin-based chemotherapy"]], "start": [[32]], "entity_id": ["T5"], "Drug": {"text": [["cisplatin"]], "start": [[32]], "entity_id": ["T6"]}, "Route": {"text": [["chemotherapy"]], "start": [[48]], "entity_id": ["T7"]}}}]}]}
{"id": "15494638_3", "context": "Capecitabine (CAP) is a pro-drug of 5-FU and peripheral neuropathy associated with CAP has not been reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[67]], "entity_id": ["T8"]}, "Effect": {"text": [["peripheral neuropathy"]], "start": [[45]], "entity_id": ["T9"]}, "Treatment": {"text": [["CAP"]], "start": [[83]], "entity_id": ["T10"]}, "Negated": {"text": [["not"]], "start": [[91]], "entity_id": ["T11"], "value": true}}]}]}
{"id": "15126179_3", "context": "PURPOSE: To report a case of angiographically documented cystoid macula edema occurring after switching a pseudophakic patient from latanoprost to bimatoprost.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["switching"]], "start": [[94]], "entity_id": ["T4"]}, "Subject": {"text": [["a pseudophakic patient"]], "start": [[104]], "entity_id": ["T5"]}, "Treatment": {"text": [["from latanoprost to bimatoprost."]], "start": [[127]], "entity_id": ["T6"], "Drug": {"text": [["latanoprost"], ["bimatoprost"]], "start": [[132], [147]], "entity_id": ["T9", "T10"]}, "Disorder": {"text": [["pseudophakic"]], "start": [[106]], "entity_id": ["T11"]}}, "Effect": {"text": [["case of angiographically documented cystoid macula edema"]], "start": [[21]], "entity_id": ["T7"]}}]}]}
{"id": "15013892_4", "context": "The clinical picture was identical to that of chloroquine and hydroxychloroquine maculopathy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["identical"]], "start": [[25]], "entity_id": ["T6"]}, "Treatment": {"text": [["chloroquine and hydroxychloroquine"]], "start": [[46]], "entity_id": ["T4"], "Drug": {"text": [["chloroquine"], ["hydroxychloroquine"]], "start": [[46], [62]], "entity_id": ["T7", "T8"]}}, "Effect": {"text": [["maculopathy"]], "start": [[81]], "entity_id": ["T5"]}}]}]}
{"id": "19299370_2", "context": "CONCLUSION: A woman receiving enoxaparin every 12 hours developed signs and symptoms of hepatotoxicity after the second dose.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[56]], "entity_id": ["T5"]}, "Subject": {"text": [["A woman"]], "start": [[12]], "entity_id": ["T3"], "Gender": {"text": [["woman"]], "start": [[14]], "entity_id": ["T7"]}}, "Treatment": {"text": [["enoxaparin every 12 hours", "after the second dose"]], "start": [[30, 103]], "entity_id": ["T4"], "Drug": {"text": [["enoxaparin"]], "start": [[30]], "entity_id": ["T8"]}, "Freq": {"text": [["every 12 hours"]], "start": [[41]], "entity_id": ["T9"]}, "Dosage": {"text": [["the second dose."]], "start": [[109]], "entity_id": ["T10"]}}, "Effect": {"text": [["signs and symptoms of hepatotoxicity"]], "start": [[66]], "entity_id": ["T6"]}}]}]}
{"id": "1747495_2", "context": "A case of liver damage following treatment with Danazol for fibrocystic breast disease is reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[23]], "entity_id": ["T7"]}, "Effect": {"text": [["liver damage"]], "start": [[10]], "entity_id": ["T6"]}, "Treatment": {"text": [["Danazol"]], "start": [[48]], "entity_id": ["T8"], "Drug": {"text": [["Danazol"]], "start": [[48]], "entity_id": ["T10"]}, "Disorder": {"text": [["fibrocystic breast disease"]], "start": [[60]], "entity_id": ["T11"]}}}]}]}
{"id": "2257522_1", "context": "Antacid and sucralfate-induced hypophosphatemic osteomalacia: a case report and review of the literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[23]], "entity_id": ["T4"]}, "Treatment": {"text": [["Antacid and sucralfate"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["sucralfate"], ["Antacid"]], "start": [[12], [0]], "entity_id": ["T7", "T8"]}}, "Effect": {"text": [["hypophosphatemic osteomalacia"]], "start": [[31]], "entity_id": ["T5"]}, "Subject": {"text": [["a case"]], "start": [[62]], "entity_id": ["T6"]}}]}]}
{"id": "16268429_3", "context": "We report a case of senna-induced cholestatic hepatitis which was not diagnosed at presentation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[26]], "entity_id": ["T3"]}, "Treatment": {"text": [["senna"]], "start": [[20]], "entity_id": ["T4"], "Drug": {"text": [["senna"]], "start": [[20]], "entity_id": ["T7"]}}, "Subject": {"text": [["a case"]], "start": [[10]], "entity_id": ["T5"]}, "Effect": {"text": [["cholestatic hepatitis"]], "start": [[34]], "entity_id": ["T6"]}}]}]}
{"id": "788666_1", "context": "Five patients are described in whom only gentamicin sulfate appeared responsible for acute renal failure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["responsible"]], "start": [[69]], "entity_id": ["T6"]}, "Effect": {"text": [["acute renal failure"]], "start": [[85]], "entity_id": ["T3"]}, "Subject": {"text": [["Five patients"]], "start": [[0]], "entity_id": ["T4"], "Population": {"text": [["Five"]], "start": [[0]], "entity_id": ["T7"]}}, "Treatment": {"text": [["gentamicin sulfate"]], "start": [[41]], "entity_id": ["T5"], "Drug": {"text": [["gentamicin sulfate"]], "start": [[41]], "entity_id": ["T9"]}}, "Speculated": {"text": [["appeared"]], "start": [[60]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "12852380_1", "context": "However, in order to avoid neuropathic side effects, patients under thalidomide therapy should be monitored every 6 months with nerve conduction studies while taking the drug.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["under"]], "start": [[62]], "entity_id": ["T3"]}, "Effect": {"text": [["neuropathic side effects"]], "start": [[27]], "entity_id": ["T4"]}, "Subject": {"text": [["patients"]], "start": [[53]], "entity_id": ["T5"]}, "Treatment": {"text": [["thalidomide therapy"]], "start": [[68]], "entity_id": ["T6"], "Drug": {"text": [["thalidomide"]], "start": [[68]], "entity_id": ["T7"]}}}]}]}
{"id": "16200540_3", "context": "Videopolysomnographic and pharmacokinetic studies with monitoring of plasma levodopa levels demonstrated marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and flexor spasms, associated with painful dysesthesia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["demonstrated"]], "start": [[92]], "entity_id": ["T12"]}, "Treatment": {"text": [["levodopa"]], "start": [[76]], "entity_id": ["T11"], "Drug": {"text": [["levodopa"]], "start": [[76]], "entity_id": ["T14"]}}, "Effect": {"text": [["marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and flexor spasms, associated with painful dysesthesia"]], "start": [[105]], "entity_id": ["T13"]}}]}]}
{"id": "3873709_1", "context": "Antibiotic-associated colitis (pseudomembranous colitis) developed in four patients with spinal cord injury and taking oral trimethoprim-sulfamethoxazole.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[57]], "entity_id": ["T10"]}, "Subject": {"text": [["four patients with spinal cord injury"]], "start": [[70]], "entity_id": ["T7"], "Population": {"text": [["four"]], "start": [[70]], "entity_id": ["T11"]}}, "Treatment": {"text": [["oral trimethoprim-sulfamethoxazole"]], "start": [[119]], "entity_id": ["T8"], "Drug": {"text": [["sulfamethoxazole"], ["trimethoprim"]], "start": [[137], [124]], "entity_id": ["T13", "T14"]}, "Route": {"text": [["oral"]], "start": [[119]], "entity_id": ["T16"]}, "Disorder": {"text": [["spinal cord injury"]], "start": [[89]], "entity_id": ["T17"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["-"]], "start": [[136]], "entity_id": ["T15"]}, "Drug": {"text": [["trimethoprim"], ["sulfamethoxazole"]], "start": [[124], [137]], "entity_id": ["T14", "T13"]}}]}, "Effect": {"text": [["Antibiotic-associated colitis (pseudomembranous colitis)"]], "start": [[0]], "entity_id": ["T9"]}}]}]}
{"id": "16641839_5", "context": "We report the case of a 27-year-old Indian woman who developed maculopapular rash and angioedema secondary to carbamazepine administration.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[53]], "entity_id": ["T8"]}, "Subject": {"text": [["a 27-year-old Indian woman"]], "start": [[22]], "entity_id": ["T5"], "Age": {"text": [["27-year-old"]], "start": [[24]], "entity_id": ["T9"]}, "Race": {"text": [["Indian"]], "start": [[36]], "entity_id": ["T10"]}, "Gender": {"text": [["woman"]], "start": [[43]], "entity_id": ["T11"]}}, "Effect": {"text": [["maculopapular rash and angioedema"]], "start": [[63]], "entity_id": ["T6"]}, "Treatment": {"text": [["carbamazepine administration"]], "start": [[110]], "entity_id": ["T7"], "Drug": {"text": [["carbamazepine"]], "start": [[110]], "entity_id": ["T12"]}, "Route": {"text": [["administration"]], "start": [[124]], "entity_id": ["T13"]}}}]}]}
{"id": "16396068_3", "context": "We reviewed the literature in an attempt to characterize the pattern and predictors of TMP/SMX-induced aseptic meningitis.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[95]], "entity_id": ["T5"]}, "Treatment": {"text": [["TMP/SMX"]], "start": [[87]], "entity_id": ["T4"], "Drug": {"text": [["TMP"], ["SMX"]], "start": [[87], [91]], "entity_id": ["T7", "T8"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["/"]], "start": [[90]], "entity_id": ["T9"]}, "Drug": {"text": [["SMX"], ["TMP"]], "start": [[91], [87]], "entity_id": ["T8", "T7"]}}]}, "Effect": {"text": [["aseptic meningitis"]], "start": [[103]], "entity_id": ["T6"]}}]}]}
{"id": "12324937_4", "context": "Mean time between initiation of gemcitabine therapy and onset of HUS was 7.4 +/- 3.5 months, or 21.9 +/- 10.9 doses of gemcitabine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["onset"]], "start": [[56]], "entity_id": ["T5"]}, "Treatment": {"text": [["7.4 +/- 3.5 months, or 21.9 +/- 10.9 doses of gemcitabine"]], "start": [[73]], "entity_id": ["T4"], "Drug": {"text": [["gemcitabine"]], "start": [[119]], "entity_id": ["T7"]}, "Time_elapsed": {"text": [["7.4 +/- 3.5 months"]], "start": [[73]], "entity_id": ["T8"]}, "Dosage": {"text": [["21.9 +/- 10.9 doses"]], "start": [[96]], "entity_id": ["T9"]}}, "Effect": {"text": [["HUS"]], "start": [[65]], "entity_id": ["T6"]}}]}]}
{"id": "8684546_1", "context": "Aluminum intoxication, along with other factors, was considered to be the cause of TC development.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[74]], "entity_id": ["T7"]}, "Treatment": {"text": [["Aluminum intoxication"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Aluminum"]], "start": [[0]], "entity_id": ["T9"]}}, "Effect": {"text": [["TC development"]], "start": [[83]], "entity_id": ["T6"]}, "Speculated": {"text": [["considered"]], "start": [[53]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "11999915_1", "context": "Agranulocytosis during clozapine therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[16]], "entity_id": ["T4"]}, "Treatment": {"text": [["clozapine therapy"]], "start": [[23]], "entity_id": ["T5"], "Drug": {"text": [["clozapine"]], "start": [[23]], "entity_id": ["T6"]}}, "Effect": {"text": [["Agranulocytosis"]], "start": [[0]], "entity_id": ["T3"]}}]}]}
{"id": "14746605_1", "context": "It was highly suspected that finasteride was associated with the anterior subcapsular opacity on the lens, and the patient therefore discontinued use of finasteride.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[45]], "entity_id": ["T5"]}, "Treatment": {"text": [["finasteride"]], "start": [[29]], "entity_id": ["T4"], "Drug": {"text": [["finasteride"]], "start": [[29]], "entity_id": ["T9"]}}, "Effect": {"text": [["anterior subcapsular opacity on the lens"]], "start": [[65]], "entity_id": ["T6"]}, "Subject": {"text": [["the patient"]], "start": [[111]], "entity_id": ["T7"]}, "Speculated": {"text": [["highly suspected"]], "start": [[7]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "2811895_2", "context": "Life-threatening cranial dystonia following trihexyphenidyl withdrawal.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[34]], "entity_id": ["T4"]}, "Effect": {"text": [["cranial dystonia"]], "start": [[17]], "entity_id": ["T3"]}, "Treatment": {"text": [["trihexyphenidyl withdrawal"]], "start": [[44]], "entity_id": ["T5"], "Drug": {"text": [["trihexyphenidyl"]], "start": [[44]], "entity_id": ["T6"]}}, "Severity": {"text": [["Life-threatening"]], "start": [[0]], "entity_id": ["T7"], "value": "High"}}]}]}
{"id": "3982906_3", "context": "The risk of cardiac decompensation in infants with supraventricular tachycardia and congestive cardiac failure should be kept in mind prior to administration of verapamil.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["risk"]], "start": [[4]], "entity_id": ["T7"]}, "Effect": {"text": [["cardiac decompensation"]], "start": [[12]], "entity_id": ["T3"]}, "Treatment": {"text": [["verapamil"]], "start": [[161]], "entity_id": ["T6"], "Drug": {"text": [["verapamil"]], "start": [[161]], "entity_id": ["T9"]}, "Disorder": {"text": [["supraventricular tachycardia"]], "start": [[51]], "entity_id": ["T1"]}}, "Subject": {"text": [["infants with supraventricular tachycardia and congestive cardiac failure"]], "start": [[38]], "entity_id": ["T5"], "Disorder": {"text": [["congestive cardiac failure"]], "start": [[84]], "entity_id": ["T4"]}, "Age": {"text": [["infants"]], "start": [[38]], "entity_id": ["T8"]}}}]}]}
{"id": "18171260_5", "context": "We describe serotonin syndrome after concomitant use of linezolid and meperidine in a 27-year-old man with acute leukemia.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[31]], "entity_id": ["T13"]}, "Effect": {"text": [["serotonin syndrome"]], "start": [[12]], "entity_id": ["T9"]}, "Treatment": {"text": [["concomitant use of linezolid and meperidine"]], "start": [[37]], "entity_id": ["T10"], "Drug": {"text": [["linezolid"], ["meperidine"]], "start": [[56], [70]], "entity_id": ["T16", "T17"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[66]], "entity_id": ["T18"]}, "Drug": {"text": [["linezolid"], ["meperidine"]], "start": [[56], [70]], "entity_id": ["T16", "T17"]}}]}, "Subject": {"text": [["a 27-year-old man with acute leukemia"]], "start": [[84]], "entity_id": ["T11"], "Disorder": {"text": [["acute leukemia"]], "start": [[107]], "entity_id": ["T12"]}, "Age": {"text": [["27-year-old"]], "start": [[86]], "entity_id": ["T14"]}, "Gender": {"text": [["man"]], "start": [[98]], "entity_id": ["T15"]}}}]}]}
{"id": "9191742_1", "context": "Recent studies have shown that under experimental conditions ferrous sulfate may reduce the gastrointestinal absorption of orally administered levothyroxine sodium in patients with primary hypothyroidism.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reduce"]], "start": [[81]], "entity_id": ["T3"]}, "Effect": {"text": [["reduce the gastrointestinal absorption of orally administered levothyroxine sodium"]], "start": [[81]], "entity_id": ["T4"]}, "Treatment": {"text": [["ferrous sulfate", "orally administered levothyroxine sodium"]], "start": [[61, 123]], "entity_id": ["T5"], "Drug": {"text": [["ferrous sulfate"], ["levothyroxine sodium"]], "start": [[61], [143]], "entity_id": ["T9", "T12"]}, "Route": {"text": [["orally"]], "start": [[123]], "entity_id": ["T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["administered"]], "start": [[130]], "entity_id": ["T1"]}, "Drug": {"text": [["ferrous sulfate"], ["levothyroxine sodium"]], "start": [[61], [143]], "entity_id": ["T9", "T12"]}}]}, "Subject": {"text": [["patients with primary hypothyroidism"]], "start": [[167]], "entity_id": ["T6"], "Disorder": {"text": [["primary hypothyroidism"]], "start": [[181]], "entity_id": ["T7"]}}, "Speculated": {"text": [["may"]], "start": [[77]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "19775485_2", "context": "We report here a case of cardiovascular and neurological depression induced by oxymetalzoline in a toddler.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[68]], "entity_id": ["T3"]}, "Treatment": {"text": [["oxymetalzoline"]], "start": [[79]], "entity_id": ["T4"], "Drug": {"text": [["oxymetalzoline"]], "start": [[79]], "entity_id": ["T8"]}}, "Effect": {"text": [["cardiovascular and neurological depression"]], "start": [[25]], "entity_id": ["T5"]}, "Subject": {"text": [["a toddler"]], "start": [[97]], "entity_id": ["T6"], "Age": {"text": [["toddler"]], "start": [[99]], "entity_id": ["T7"]}}}]}]}
{"id": "10431414_3", "context": "The association between heparin and priapism is often recognized; abnormal platelet aggregation could play a role in the pathogenesis of this side effect.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["association"]], "start": [[4]], "entity_id": ["T7"]}, "Treatment": {"text": [["heparin"]], "start": [[24]], "entity_id": ["T5"], "Drug": {"text": [["heparin"]], "start": [[24]], "entity_id": ["T8"]}}, "Effect": {"text": [["priapism"]], "start": [[36]], "entity_id": ["T6"]}}]}]}
{"id": "12078977_2", "context": "Posterior leukoencephalopathy following cisplatin, bleomycin and vinblastine therapy for germ cell tumor of the ovary.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[30]], "entity_id": ["T8"]}, "Effect": {"text": [["Posterior leukoencephalopathy"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["cisplatin, bleomycin and vinblastine therapy for germ cell tumor of the ovary"]], "start": [[40]], "entity_id": ["T7"], "Disorder": {"text": [["germ cell tumor of the ovary"]], "start": [[89]], "entity_id": ["T6"]}, "Drug": {"text": [["cisplatin"], ["bleomycin"], ["vinblastine"]], "start": [[40], [51], [65]], "entity_id": ["T9", "T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[61]], "entity_id": ["T12"]}, "Drug": {"text": [["vinblastine"], ["bleomycin"], ["cisplatin"]], "start": [[65], [51], [40]], "entity_id": ["T11", "T10", "T9"]}}]}}]}]}
{"id": "12086549_2", "context": "OBJECTIVE: To report a case of cutaneous and hematologic toxicity in a patient treated with IL-2.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["case"]], "start": [[23]], "entity_id": ["T6"]}, "Subject": {"text": [["a patient"]], "start": [[69]], "entity_id": ["T3"]}, "Treatment": {"text": [["IL-2"]], "start": [[92]], "entity_id": ["T4"], "Drug": {"text": [["IL-2"]], "start": [[92]], "entity_id": ["T7"]}}, "Effect": {"text": [["cutaneous and hematologic toxicity"]], "start": [[31]], "entity_id": ["T5"]}}]}]}
{"id": "10707759_2", "context": "Flecainide is a rare cause of hypersensitivity pneumonitis, and few cases have been reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[21]], "entity_id": ["T4"]}, "Treatment": {"text": [["Flecainide"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Flecainide"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["hypersensitivity pneumonitis"]], "start": [[30]], "entity_id": ["T5"]}}]}]}
{"id": "17536204_5", "context": "The patient developed grade 3 capecitabine-induced headache.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[43]], "entity_id": ["T4"]}, "Treatment": {"text": [["capecitabine"]], "start": [[30]], "entity_id": ["T3"], "Drug": {"text": [["capecitabine"]], "start": [[30]], "entity_id": ["T6"]}}, "Effect": {"text": [["headache"]], "start": [[51]], "entity_id": ["T5"]}}]}]}
{"id": "1951476_2", "context": "We report a case of biopsy-proven acute tubulointerstitial nephritis associated with a second course of flurbiprofen, a nonsteroidal anti-inflammatory drug of the propionic acid class.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[69]], "entity_id": ["T3"]}, "Treatment": {"text": [["a second course of flurbiprofen"]], "start": [[85]], "entity_id": ["T4"], "Drug": {"text": [["flurbiprofen"]], "start": [[104]], "entity_id": ["T6"]}, "Freq": {"text": [["second course"]], "start": [[87]], "entity_id": ["T7"]}}, "Effect": {"text": [["biopsy-proven acute tubulointerstitial nephritis"]], "start": [[20]], "entity_id": ["T5"]}}]}]}
{"id": "1378497_1", "context": "Although an association between exposure to bleomycin and the development of scleroderma has been suspected, few cases are reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["development"]], "start": [[62]], "entity_id": ["T5"]}, "Treatment": {"text": [["bleomycin"]], "start": [[44]], "entity_id": ["T3"], "Drug": {"text": [["bleomycin"]], "start": [[44]], "entity_id": ["T9"]}}, "Effect": {"text": [["scleroderma"]], "start": [[77]], "entity_id": ["T4"]}, "Subject": {"text": [["few cases"]], "start": [[109]], "entity_id": ["T7"]}, "Speculated": {"text": [["suspected"]], "start": [[98]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "10987357_2", "context": "A 74-year-old man received oral administration of pilsicainide, a pure sodium channel blocker with slow recovery kinetics, to convert paroxysmal atrial fibrillation to sinus rhythm and developed loss of consciousness two days later.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[185]], "entity_id": ["T7"]}, "Subject": {"text": [["A 74-year-old man"]], "start": [[0]], "entity_id": ["T10"], "Age": {"text": [["74-year-old"]], "start": [[2]], "entity_id": ["T12"]}, "Gender": {"text": [["man"]], "start": [[14]], "entity_id": ["T13"]}}, "Treatment": {"text": [["oral administration of pilsicainide", "two days later"]], "start": [[27, 217]], "entity_id": ["T9"], "Route": {"text": [["oral"]], "start": [[27]], "entity_id": ["T14"]}, "Drug": {"text": [["pilsicainide"]], "start": [[50]], "entity_id": ["T15"]}, "Disorder": {"text": [["paroxysmal atrial fibrillation"]], "start": [[134]], "entity_id": ["T11"]}, "Time_elapsed": {"text": [["two days later"]], "start": [[217]], "entity_id": ["T16"]}}, "Effect": {"text": [["loss of consciousness"]], "start": [[195]], "entity_id": ["T8"]}}]}]}
{"id": "11876387_1", "context": "Aggressive endometrial carcinoma in a breast cancer patient treated with tamoxifen with normal transvaginal ultrasonography.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[60]], "entity_id": ["T6"]}, "Effect": {"text": [["Aggressive endometrial carcinoma"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["tamoxifen"]], "start": [[73]], "entity_id": ["T5"], "Disorder": {"text": [["breast cancer"]], "start": [[38]], "entity_id": ["T7"]}, "Drug": {"text": [["tamoxifen"]], "start": [[73]], "entity_id": ["T8"]}}, "Subject": {"text": [["breast cancer patient", "with normal transvaginal ultrasonography"]], "start": [[38, 83]], "entity_id": ["T4"]}}]}]}
{"id": "8792511_1", "context": "Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["include"]], "start": [[38]], "entity_id": ["T27"]}, "Treatment": {"text": [["dapsone"]], "start": [[30]], "entity_id": ["T25"], "Drug": {"text": [["dapsone"]], "start": [[30]], "entity_id": ["T28"]}}, "Effect": {"text": [["the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints"]], "start": [[46]], "entity_id": ["T26"]}}]}]}
{"id": "10475726_2", "context": "The association of venlafaxine treatment with ischaemic events could be explained by its unique pharmacological and haemodynamic properties.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["association"]], "start": [[4]], "entity_id": ["T5"]}, "Effect": {"text": [["ischaemic events"]], "start": [[46]], "entity_id": ["T3"]}, "Treatment": {"text": [["venlafaxine treatment"]], "start": [[19]], "entity_id": ["T4"], "Drug": {"text": [["venlafaxine"]], "start": [[19]], "entity_id": ["T8"]}}}]}]}
{"id": "17060191_5", "context": "This selective closure of the ductus arteriosus suggests that the affected twin was predisposed to hypoxia and thus was more susceptible to ductal closure in response to indomethacin exposure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["response"]], "start": [[158]], "entity_id": ["T10"]}, "Effect": {"text": [["ductal closure"]], "start": [[140]], "entity_id": ["T9"]}, "Treatment": {"text": [["indomethacin exposure"]], "start": [[170]], "entity_id": ["T11"], "Drug": {"text": [["indomethacin"]], "start": [[170]], "entity_id": ["T12"]}, "Route": {"text": [["exposure"]], "start": [[183]], "entity_id": ["T13"]}}, "Speculated": {"text": [["susceptible"]], "start": [[125]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "8903300_3", "context": "This pattern is suggestive of renal toxicity due to tobramycin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due to"]], "start": [[45]], "entity_id": ["T4"]}, "Effect": {"text": [["renal toxicity"]], "start": [[30]], "entity_id": ["T3"]}, "Treatment": {"text": [["tobramycin"]], "start": [[52]], "entity_id": ["T5"], "Drug": {"text": [["tobramycin"]], "start": [[52]], "entity_id": ["T7"]}}, "Speculated": {"text": [["suggestive"]], "start": [[16]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "8742573_4", "context": "OBJECTIVE: To evaluate the efficacy of the administration of insulin by a jet-injector device in stopping and reversing severe human insulin-induced lipoatrophy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[141]], "entity_id": ["T3"]}, "Effect": {"text": [["severe human", "lipoatrophy"]], "start": [[120, 149]], "entity_id": ["T4"]}, "Treatment": {"text": [["insulin"]], "start": [[133]], "entity_id": ["T5"], "Drug": {"text": [["insulin"]], "start": [[133]], "entity_id": ["T6"]}}}]}]}
{"id": "2442958_2", "context": "This is a unique autopsy case of hepatocellular carcinoma closely related to diethylstilbestrol (DES) therapy for prostatic cancer.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[66]], "entity_id": ["T4"]}, "Subject": {"text": [["a unique autopsy case"]], "start": [[8]], "entity_id": ["T5"]}, "Treatment": {"text": [["diethylstilbestrol (DES)"]], "start": [[77]], "entity_id": ["T6"], "Disorder": {"text": [["prostatic cancer"]], "start": [[114]], "entity_id": ["T7"]}, "Drug": {"text": [["diethylstilbestrol"]], "start": [[77]], "entity_id": ["T9"]}}, "Effect": {"text": [["hepatocellular carcinoma"]], "start": [[33]], "entity_id": ["T8"]}}]}]}
{"id": "12921505_2", "context": "Argatroban for heparin-induced thrombocytopenia in hepato-renal failure and CVVHD.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["for"]], "start": [[11]], "entity_id": ["T5"]}, "Treatment": {"text": [["Argatroban"]], "start": [[0]], "entity_id": ["T3"], "Disorder": {"text": [["hepato-renal failur"]], "start": [[51]], "entity_id": ["T4"]}, "Drug": {"text": [["Argatroban"]], "start": [[0]], "entity_id": ["T6"]}}}]}]}
{"id": "1592841_1", "context": "Falling backward in two elderly patients taking bupropion.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["taking"]], "start": [[41]], "entity_id": ["T3"]}, "Subject": {"text": [["two elderly patients"]], "start": [[20]], "entity_id": ["T4"], "Population": {"text": [["two"]], "start": [[20]], "entity_id": ["T7"]}, "Age": {"text": [["elderly"]], "start": [[24]], "entity_id": ["T8"]}}, "Treatment": {"text": [["bupropion"]], "start": [[48]], "entity_id": ["T5"], "Drug": {"text": [["bupropion"]], "start": [[48]], "entity_id": ["T9"]}}, "Effect": {"text": [["Falling backward"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "11881322_4", "context": "METHODS: Three patients with apparent itraconazole-induced liver injury were studied.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[51]], "entity_id": ["T4"]}, "Treatment": {"text": [["itraconazole"]], "start": [[38]], "entity_id": ["T3"], "Drug": {"text": [["itraconazole"]], "start": [[38]], "entity_id": ["T8"]}}, "Effect": {"text": [["liver injury"]], "start": [[59]], "entity_id": ["T5"]}, "Subject": {"text": [["Three patients"]], "start": [[9]], "entity_id": ["T6"], "Population": {"text": [["Three"]], "start": [[9]], "entity_id": ["T7"]}}}]}]}
{"id": "15907341_2", "context": "Six patients developed peripheral neuropathy and five patients bone marrow depression, blood transfusions were given to three patients and in all five patients bone marrow function normalized after cessation of linezolid.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["normalized"]], "start": [[181]], "entity_id": ["T9"]}, "Subject": {"text": [["all five patients"]], "start": [[142]], "entity_id": ["T21"], "Population": {"text": [["five"]], "start": [[146]], "entity_id": ["T25"]}}, "Treatment": {"text": [["cessation of linezolid"]], "start": [[198]], "entity_id": ["T22"], "Disorder": {"text": [["bone marrow depression"]], "start": [[63]], "entity_id": ["T18"]}, "Drug": {"text": [["linezolid"]], "start": [[211]], "entity_id": ["T23"]}}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[13]], "entity_id": ["T13"]}, "Treatment": {"text": [["linezolid"]], "start": [[211]], "entity_id": ["T6"], "Drug": {"text": [["linezolid"]], "start": [[211]], "entity_id": ["T12"]}}, "Subject": {"text": [["Six patients"]], "start": [[0]], "entity_id": ["T14"], "Population": {"text": [["Six"]], "start": [[0]], "entity_id": ["T15"]}}, "Effect": {"text": [["peripheral neuropathy"]], "start": [[23]], "entity_id": ["T16"]}}, {"event_id": "E3", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[13]], "entity_id": ["T13"]}, "Treatment": {"text": [["linezolid"]], "start": [[211]], "entity_id": ["T6"], "Drug": {"text": [["linezolid"]], "start": [[211]], "entity_id": ["T12"]}}, "Subject": {"text": [["five patients"]], "start": [[49]], "entity_id": ["T17"], "Population": {"text": [["five"]], "start": [[49]], "entity_id": ["T8"]}}, "Effect": {"text": [["bone marrow depression"]], "start": [[63]], "entity_id": ["T10"]}}, {"event_id": "E4", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["given"]], "start": [[111]], "entity_id": ["T20"]}, "Treatment": {"text": [["blood transfusions", "cessation of linezolid"]], "start": [[87, 198]], "entity_id": ["T5"], "Drug": {"text": [["linezolid"]], "start": [[211]], "entity_id": ["T11"]}}, "Subject": {"text": [["three patients"]], "start": [[120]], "entity_id": ["T19"], "Population": {"text": [["three"]], "start": [[120]], "entity_id": ["T24"]}}}]}]}
{"id": "12111771_5", "context": "To our knowledge, four cases of interstitial pneumonitis associated with fludarabine have been reported in medical literature.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[57]], "entity_id": ["T5"]}, "Effect": {"text": [["interstitial pneumonitis"]], "start": [[32]], "entity_id": ["T4"]}, "Treatment": {"text": [["fludarabine"]], "start": [[73]], "entity_id": ["T6"], "Drug": {"text": [["fludarabine"]], "start": [[73]], "entity_id": ["T3"]}}}]}]}
{"id": "20397038_1", "context": "Normalization of generalized retinal function and progression of maculopathy after cessation of therapy in a case of severe hydroxychloroquine retinopathy with 19 years follow-up.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["after"]], "start": [[77]], "entity_id": ["T3"]}, "Effect": {"text": [["Normalization of generalized retinal function and progression of maculopathy"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["cessation of therapy", "hydroxychloroquine"]], "start": [[83, 124]], "entity_id": ["T5"], "Drug": {"text": [["hydroxychloroquine"]], "start": [[124]], "entity_id": ["T8"]}, "Disorder": {"text": [["hydroxychloroquine retinopathy"]], "start": [[124]], "entity_id": ["T9"]}, "Time_elapsed": {"text": [["19 years"]], "start": [[160]], "entity_id": ["T11"]}}, "Subject": {"text": [["a case of severe hydroxychloroquine retinopathy"]], "start": [[107]], "entity_id": ["T6"]}, "Severity": {"text": [["severe"]], "start": [[117]], "entity_id": ["T10"], "value": "High"}}]}]}
{"id": "20118434_2", "context": "Interferon-induced psychosis as a \"psychiatric contraindication\" to hepatitis C treatment: a review and case-based discussion.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T3"]}, "Effect": {"text": [["psychosis"]], "start": [[19]], "entity_id": ["T4"]}, "Treatment": {"text": [["Interferon"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Interferon"]], "start": [[0]], "entity_id": ["T6"]}, "Disorder": {"text": [["hepatitis C"]], "start": [[68]], "entity_id": ["T7"]}}}]}]}
{"id": "10524732_1", "context": "Prolongation of the QT interval and ventricular tachyarrhymias have been described in patients on amiodarone therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["described"]], "start": [[73]], "entity_id": ["T8"]}, "Effect": {"text": [["Prolongation of the QT interval and ventricular tachyarrhymias"]], "start": [[0]], "entity_id": ["T5"]}, "Subject": {"text": [["patients"]], "start": [[86]], "entity_id": ["T6"]}, "Treatment": {"text": [["amiodarone therapy"]], "start": [[98]], "entity_id": ["T7"], "Drug": {"text": [["amiodarone"]], "start": [[98]], "entity_id": ["T9"]}}}]}]}
{"id": "17420198_9", "context": "Aripiprazole, 5 mg daily, was initiated in November 2004 as an augmentation strategy for the diagnosis of OCD.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["augmentation"]], "start": [[63]], "entity_id": ["T6"]}, "Treatment": {"text": [["Aripiprazole", "5 mg daily"]], "start": [[0, 14]], "entity_id": ["T4"], "Disorder": {"text": [["OCD"]], "start": [[106]], "entity_id": ["T5"]}, "Drug": {"text": [["Aripiprazole"]], "start": [[0]], "entity_id": ["T7"]}, "Dosage": {"text": [["5 mg"]], "start": [[14]], "entity_id": ["T8"]}, "Freq": {"text": [["daily"]], "start": [[19]], "entity_id": ["T9"]}}}]}]}
{"id": "11250985_4", "context": "Serious adverse events experienced by patients with chronic heart failure taking spironolactone.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["experienced"]], "start": [[23]], "entity_id": ["T6"]}, "Effect": {"text": [["Serious adverse events"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["spironolactone"]], "start": [[81]], "entity_id": ["T5"], "Drug": {"text": [["spironolactone"]], "start": [[81]], "entity_id": ["T9"]}}, "Subject": {"text": [["patients with chronic heart failure"]], "start": [[38]], "entity_id": ["T4"], "Disorder": {"text": [["chronic heart failure"]], "start": [[52]], "entity_id": ["T7"]}}}]}]}
{"id": "941054_2", "context": "Review of the literature relating to methicillin-induced nephropathy suggests a hypersensitivity origin for this disorder, but immunologic and ultrastructural investigation to date has failed to elucidate pathogenesis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[49]], "entity_id": ["T3"]}, "Treatment": {"text": [["methicillin"]], "start": [[37]], "entity_id": ["T4"], "Drug": {"text": [["methicillin"]], "start": [[37]], "entity_id": ["T8"]}}, "Effect": {"text": [["nephropathy", "hypersensitivity"]], "start": [[57, 80]], "entity_id": ["T5"]}, "Speculated": {"text": [["suggests"]], "start": [[69]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "16298824_2", "context": "ARDS has been associated with the administration of other monoclonal antibodies, such as infliximab, gemtuzumab ozogamicin, and OKT3 and is believed to be directly mediated by release of proinflammatory cytokines.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[14]], "entity_id": ["T6"]}, "Effect": {"text": [["ARDS"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["the administration of other monoclonal antibodies, such as infliximab, gemtuzumab ozogamicin, and OKT3"]], "start": [[30]], "entity_id": ["T7"], "Drug": {"text": [["infliximab"], ["gemtuzumab"], ["ozogamicin"], ["OKT3"]], "start": [[89], [101], [112], [128]], "entity_id": ["T8", "T9", "T10", "T11"]}}}]}]}
{"id": "12365708_3", "context": "CASE REPORT: Soon after initiation of amiodarone HCl (200 mg/day), a 76-year-old man came to us with symptoms of visual \"shining,\" glare, color vision anomalies, and gradually decreased vision.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after initiation"]], "start": [[18]], "entity_id": ["T11"]}, "Subject": {"text": [["a 76-year-old man"]], "start": [[67]], "entity_id": ["T9"], "Age": {"text": [["76-year-old"]], "start": [[69]], "entity_id": ["T13"]}, "Gender": {"text": [["man"]], "start": [[81]], "entity_id": ["T14"]}}, "Effect": {"text": [["symptoms of visual \"shining,\" glare, color vision anomalies, and gradually decreased vision"]], "start": [[101]], "entity_id": ["T10"]}, "Treatment": {"text": [["amiodarone HCl"]], "start": [[38]], "entity_id": ["T12"], "Drug": {"text": [["amiodarone HCl"]], "start": [[38]], "entity_id": ["T15"]}, "Dosage": {"text": [["(200 mg"]], "start": [[53]], "entity_id": ["T16"]}, "Freq": {"text": [["day"]], "start": [[61]], "entity_id": ["T17"]}}}]}]}
{"id": "527355_1", "context": "An insulin-dependent diabetic patient with nephropathy developed severe acidosis after treatment with acetazolamide for glaucoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[55]], "entity_id": ["T7"]}, "Effect": {"text": [["severe acidosis"]], "start": [[65]], "entity_id": ["T5"]}, "Subject": {"text": [["An insulin-dependent diabetic patient with nephropathy"]], "start": [[0]], "entity_id": ["T3"], "Disorder": {"text": [["diabetic"], ["nephropathy"]], "start": [[21], [43]], "entity_id": ["T8", "T9"]}}, "Treatment": {"text": [["acetazolamide for glaucoma"]], "start": [[102]], "entity_id": ["T6"], "Disorder": {"text": [["glaucoma"]], "start": [[120]], "entity_id": ["T4"]}, "Drug": {"text": [["acetazolamide"]], "start": [[102]], "entity_id": ["T11"]}}, "Severity": {"text": [["severe"]], "start": [[65]], "entity_id": ["T10"], "value": "Medium"}}]}]}
{"id": "15504988_1", "context": "Severe hypo-alpha-lipoproteinemia during treatment with rosiglitazone.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[34]], "entity_id": ["T4"]}, "Effect": {"text": [["hypo-alpha-lipoproteinemia"]], "start": [[7]], "entity_id": ["T3"]}, "Treatment": {"text": [["rosiglitazone"]], "start": [[56]], "entity_id": ["T5"], "Drug": {"text": [["rosiglitazone"]], "start": [[56]], "entity_id": ["T6"]}}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T7"], "value": "High"}}]}]}
{"id": "2445709_2", "context": "Peripheral neuropathy and cerebellar syndrome associated with amiodarone therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[46]], "entity_id": ["T5"]}, "Effect": {"text": [["Peripheral neuropathy and cerebellar syndrome"]], "start": [[0]], "entity_id": ["T6"]}, "Treatment": {"text": [["amiodarone"]], "start": [[62]], "entity_id": ["T7"], "Drug": {"text": [["amiodarone"]], "start": [[62]], "entity_id": ["T8"]}}}]}]}
{"id": "18691992_4", "context": "CONCLUSIONS: We report this case of the concomitant appearance of multiple skin cancers and nail changes associated with hydroxyurea use.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[105]], "entity_id": ["T7"]}, "Effect": {"text": [["multiple skin cancers and nail changes"]], "start": [[66]], "entity_id": ["T5"]}, "Treatment": {"text": [["hydroxyurea"]], "start": [[121]], "entity_id": ["T6"], "Drug": {"text": [["hydroxyurea"]], "start": [[121]], "entity_id": ["T10"]}}, "Subject": {"text": [["case"]], "start": [[28]], "entity_id": ["T8"]}}]}]}
{"id": "9847899_1", "context": "As this relapse coincided with development of a strong delayed-type hypersensitivity response to tuberculin and improved after treatment with the anti-inflammatory agent oxpentifylline, it was probably caused by restoration of pathogen-specific cellular immunity.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["development"]], "start": [[31]], "entity_id": ["T5"]}, "Effect": {"text": [["a strong delayed-type hypersensitivity response"]], "start": [[46]], "entity_id": ["T4"]}, "Treatment": {"text": [["tuberculin"]], "start": [[97]], "entity_id": ["T3"], "Drug": {"text": [["tuberculin"]], "start": [[97]], "entity_id": ["T7"]}}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["improved"]], "start": [[112]], "entity_id": ["T10"]}, "Treatment": {"text": [["anti-inflammatory agent oxpentifylline"]], "start": [[146]], "entity_id": ["T11"], "Disorder": {"text": [["this relapse"]], "start": [[3]], "entity_id": ["T9"]}, "Drug": {"text": [["oxpentifylline"]], "start": [[170]], "entity_id": ["T12"]}}}]}]}
{"id": "16012330_1", "context": "Itraconazole-related increased vincristine neurotoxicity: case report and review of literature.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[13]], "entity_id": ["T6"]}, "Treatment": {"text": [["Itraconazole"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Itraconazole"], ["vincristine"]], "start": [[0], [31]], "entity_id": ["T8", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["increased"]], "start": [[21]], "entity_id": ["T9"]}, "Drug": {"text": [["Itraconazole"], ["vincristine"]], "start": [[0], [31]], "entity_id": ["T8", "T10"]}}]}, "Effect": {"text": [["increased vincristine neurotoxicity"]], "start": [[21]], "entity_id": ["T7"]}}]}]}
{"id": "11837564_1", "context": "A 62-year-old Caucasian man with atrial fibrillation who was taking warfarin reported an episode of hematochezia; his international normalized ratio (INR) was 1.74.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["episode"]], "start": [[89]], "entity_id": ["T7"]}, "Subject": {"text": [["A 62-year-old Caucasian man with atrial fibrillation"]], "start": [[0]], "entity_id": ["T3"], "Age": {"text": [["62-year-old"]], "start": [[2]], "entity_id": ["T8"]}, "Race": {"text": [["Caucasian"]], "start": [[14]], "entity_id": ["T9"]}, "Gender": {"text": [["man"]], "start": [[24]], "entity_id": ["T10"]}}, "Treatment": {"text": [["warfarin"]], "start": [[68]], "entity_id": ["T5"], "Disorder": {"text": [["atrial fibrillation"]], "start": [[33]], "entity_id": ["T4"]}, "Drug": {"text": [["warfarin"]], "start": [[68]], "entity_id": ["T11"]}}, "Effect": {"text": [["hematochezia"]], "start": [[100]], "entity_id": ["T6"]}}]}]}
{"id": "22233409_1", "context": "Severe anaemia related to oseltamivir during treatment of chronic hepatitis C: a new drug interaction?", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[15]], "entity_id": ["T7"]}, "Effect": {"text": [["anaemia"]], "start": [[7]], "entity_id": ["T6"]}, "Treatment": {"text": [["oseltamivir during treatment of chronic hepatitis C"]], "start": [[26]], "entity_id": ["T8"], "Drug": {"text": [["oseltamivir"]], "start": [[26]], "entity_id": ["T11"]}, "Disorder": {"text": [["chronic hepatitis C"]], "start": [[58]], "entity_id": ["T9"]}}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T10"], "value": "Medium"}}]}]}
{"id": "10084639_1", "context": "BACKGROUND: How to best treat psychotic patients who have had past clozapine-induced agranulocytosis or granulocytopenia remains a problem.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[77]], "entity_id": ["T6"]}, "Subject": {"text": [["psychotic patients"]], "start": [[30]], "entity_id": ["T3"]}, "Treatment": {"text": [["clozapine"]], "start": [[67]], "entity_id": ["T4"], "Drug": {"text": [["clozapine"]], "start": [[67]], "entity_id": ["T8"]}, "Disorder": {"text": [["psychotic"]], "start": [[30]], "entity_id": ["T9"]}}, "Effect": {"text": [["agranulocytosis or granulocytopenia"]], "start": [[85]], "entity_id": ["T7"]}}]}]}
{"id": "15126179_1", "context": "Cystoid macular edema in a low-risk patient after switching from latanoprost to bimatoprost.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[22]], "entity_id": ["T7"]}, "Effect": {"text": [["Cystoid macular edema"]], "start": [[0]], "entity_id": ["T4"]}, "Subject": {"text": [["low-risk patient"]], "start": [[27]], "entity_id": ["T5"]}, "Treatment": {"text": [["switching from latanoprost to bimatoprost"]], "start": [[50]], "entity_id": ["T6"], "Drug": {"text": [["bimatoprost"], ["latanoprost"]], "start": [[80], [65]], "entity_id": ["T8", "T9"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["switching"]], "start": [[50]], "entity_id": ["T10"]}, "Drug": {"text": [["latanoprost"], ["bimatoprost"]], "start": [[65], [80]], "entity_id": ["T9", "T8"]}}]}}]}]}
{"id": "7439122_3", "context": "Physicians should therefore be aware of its occurrence and carefully monitor serum levels of CPK, GOT and GPT during the treatment of diabetes insipidus with clofibrate, especially in patients with associated hypothyroidism, latent or overt, which possibly favors the development of myopathy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["development"]], "start": [[268]], "entity_id": ["T4"]}, "Subject": {"text": [["patients with associated hypothyroidism, latent or overt"]], "start": [[184]], "entity_id": ["T3"], "Disorder": {"text": [["hypothyroidism"], ["latent"], ["overt"]], "start": [[209], [225], [235]], "entity_id": ["T8", "T1", "T2"]}}, "Treatment": {"text": [["clofibrate"]], "start": [[158]], "entity_id": ["T5"], "Disorder": {"text": [["diabetes insipidus"]], "start": [[134]], "entity_id": ["T7"]}, "Drug": {"text": [["clofibrate"]], "start": [[158]], "entity_id": ["T10"]}}, "Effect": {"text": [["myopathy."]], "start": [[283]], "entity_id": ["T6"]}, "Speculated": {"text": [["possibly"]], "start": [[248]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "1951476_1", "context": "Flurbiprofen-associated acute tubulointerstitial nephritis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[13]], "entity_id": ["T4"]}, "Treatment": {"text": [["Flurbiprofen"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Flurbiprofen"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["acute tubulointerstitial nephritis"]], "start": [[24]], "entity_id": ["T5"]}}]}]}
{"id": "9302445_1", "context": "CONCLUSION: We believe this to be the first reported case of rhGH-induced hypercalcemia in an HIV-infected patient.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[66]], "entity_id": ["T3"]}, "Treatment": {"text": [["rhGH"]], "start": [[61]], "entity_id": ["T4"], "Drug": {"text": [["rhGH"]], "start": [[61]], "entity_id": ["T8"]}, "Disorder": {"text": [["HIV"]], "start": [[94]], "entity_id": ["T9"]}}, "Effect": {"text": [["hypercalcemia"]], "start": [[74]], "entity_id": ["T5"]}, "Subject": {"text": [["an HIV-infected patient"]], "start": [[91]], "entity_id": ["T6"]}}]}]}
{"id": "7946029_2", "context": "A case of basilar invagination which is thought to have arisen from the patient's intrauterine exposure to phenytoin is presented.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["exposure"]], "start": [[95]], "entity_id": ["T7"]}, "Effect": {"text": [["basilar invagination"]], "start": [[10]], "entity_id": ["T5"]}, "Treatment": {"text": [["phenytoin"]], "start": [[107]], "entity_id": ["T6"], "Drug": {"text": [["phenytoin"]], "start": [[107]], "entity_id": ["T8"]}, "Route": {"text": [["intrauterine"]], "start": [[82]], "entity_id": ["T9"]}}}]}]}
{"id": "1495728_1", "context": "Methotrexate pneumonitis in nonsurgical treatment of ectopic pregnancy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[25]], "entity_id": ["T9"]}, "Treatment": {"text": [["nonsurgical treatment"]], "start": [[28]], "entity_id": ["T7"], "Disorder": {"text": [["ectopic pregnancy"]], "start": [[53]], "entity_id": ["T6"]}}, "Effect": {"text": [["Methotrexate pneumonitis"]], "start": [[0]], "entity_id": ["T8"]}}]}]}
{"id": "3767790_2", "context": "Two patients who were receiving Tolazoline by infusion developed duodenal ulceration and subsequent intestinal perforation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[55]], "entity_id": ["T7"]}, "Subject": {"text": [["Two patients"]], "start": [[0]], "entity_id": ["T5"], "Population": {"text": [["Two"]], "start": [[0]], "entity_id": ["T9"]}}, "Treatment": {"text": [["receiving Tolazoline by infusion"]], "start": [[22]], "entity_id": ["T6"], "Drug": {"text": [["Tolazoline"]], "start": [[32]], "entity_id": ["T10"]}, "Route": {"text": [["infusion"]], "start": [[46]], "entity_id": ["T11"]}}, "Effect": {"text": [["duodenal ulceration and subsequent intestinal perforation"]], "start": [[65]], "entity_id": ["T8"]}}]}]}
{"id": "20098333_2", "context": "We report the case of a 14-year-old female with acute promyelocytic leukemia who developed symptomatic cardiomyopathy only 4 months into treatment with a combination of daunomycin and all-trans retinoic acid (ATRA).", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[81]], "entity_id": ["T6"]}, "Subject": {"text": [["a 14-year-old female with acute promyelocytic leukemia"]], "start": [[22]], "entity_id": ["T5"], "Age": {"text": [["14-year-old"]], "start": [[24]], "entity_id": ["T9"]}, "Gender": {"text": [["female"]], "start": [[36]], "entity_id": ["T10"]}}, "Effect": {"text": [["symptomatic cardiomyopathy"]], "start": [[91]], "entity_id": ["T7"]}, "Treatment": {"text": [["4 months into treatment with a combination of daunomycin and all-trans retinoic acid (ATRA)"]], "start": [[123]], "entity_id": ["T8"], "Disorder": {"text": [["acute promyelocytic leukemia"]], "start": [[48]], "entity_id": ["T12"]}, "Time_elapsed": {"text": [["4 months"]], "start": [[123]], "entity_id": ["T13"]}, "Drug": {"text": [["daunomycin"], ["all-trans retinoic acid"]], "start": [[169], [184]], "entity_id": ["T15", "T16"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combination"]], "start": [[154]], "entity_id": ["T14"]}, "Drug": {"text": [["daunomycin"], ["all-trans retinoic acid"]], "start": [[169], [184]], "entity_id": ["T15", "T16"]}}]}, "Severity": {"text": [["acute"]], "start": [[48]], "entity_id": ["T17"], "value": "High"}}]}]}
{"id": "17228132_3", "context": "Hepatotoxicity seen with erlotinib, a small molecule tyrosine kinase inhibitor to EGFR, is usually transient with mild elevation of transaminases.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["seen"]], "start": [[15]], "entity_id": ["T7"]}, "Treatment": {"text": [["erlotinib"]], "start": [[25]], "entity_id": ["T6"], "Drug": {"text": [["erlotinib"]], "start": [[25]], "entity_id": ["T9"]}}, "Effect": {"text": [["Hepatotoxicity", "transient with mild elevation of transaminases"]], "start": [[0, 99]], "entity_id": ["T8"]}}]}]}
{"id": "18585545_5", "context": "RESULTS: A previously healthy 42-year-old woman presented with acute-onset delirium with psychotic features as a consequence of levofloxacin therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["as a consequence of"]], "start": [[108]], "entity_id": ["T5"]}, "Subject": {"text": [["A previously healthy 42-year-old woman"]], "start": [[9]], "entity_id": ["T3"], "Age": {"text": [["42-year-old"]], "start": [[30]], "entity_id": ["T7"]}, "Gender": {"text": [["woman"]], "start": [[42]], "entity_id": ["T8"]}}, "Effect": {"text": [["acute-onset delirium with psychotic features"]], "start": [[63]], "entity_id": ["T4"]}, "Treatment": {"text": [["levofloxacin therapy"]], "start": [[128]], "entity_id": ["T6"], "Drug": {"text": [["levofloxacin"]], "start": [[128]], "entity_id": ["T9"]}}}]}]}
{"id": "22791547_5", "context": "Although limb dyskinesia after methylphenidate is a commonly reported side effect, to the authors' knowledge this is only the second reported case to develop both orofacial and limb dyskinesia in the acute period after the first dose of methylphenidate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["develop"]], "start": [[150]], "entity_id": ["T8"]}, "Subject": {"text": [["the second reported case"]], "start": [[122]], "entity_id": ["T7"]}, "Effect": {"text": [["orofacial and limb dyskinesia"]], "start": [[163]], "entity_id": ["T9"]}, "Treatment": {"text": [["methylphenidate"]], "start": [[237]], "entity_id": ["T10"], "Drug": {"text": [["methylphenidate"], ["methylphenidate"]], "start": [[31], [237]], "entity_id": ["T11", "T12"]}}, "Speculated": {"text": [["only the second reported case"]], "start": [[117]], "entity_id": ["T13"], "value": true}}]}]}
{"id": "7995508_1", "context": "Phenylpropanolamine-induced psychosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[20]], "entity_id": ["T5"]}, "Treatment": {"text": [["Phenylpropanolamine"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Phenylpropanolamine"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["psychosis"]], "start": [[28]], "entity_id": ["T4"]}}]}]}
{"id": "3763264_1", "context": "Graft versus host-like illness in a child with phenobarbital hypersensitivity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["hypersensitivity"]], "start": [[61]], "entity_id": ["T10"]}, "Subject": {"text": [["a child"]], "start": [[34]], "entity_id": ["T7"], "Age": {"text": [["child"]], "start": [[36]], "entity_id": ["T13"]}}, "Effect": {"text": [["Graft versus host-like illness", "hypersensitivity"]], "start": [[0, 61]], "entity_id": ["T9"]}, "Treatment": {"text": [["phenobarbital"]], "start": [[47]], "entity_id": ["T12"], "Drug": {"text": [["phenobarbital"]], "start": [[47]], "entity_id": ["T8"]}}}]}]}
{"id": "8597009_4", "context": "The wide use of phenytoin during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to phenytoin toxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["suspect"]], "start": [[89]], "entity_id": ["T6"]}, "Treatment": {"text": [["phenytoin"]], "start": [[16]], "entity_id": ["T4"], "Duration": {"text": [["tuberculosis"]], "start": [[44]], "entity_id": ["T5"]}, "Drug": {"text": [["phenytoin"]], "start": [[16]], "entity_id": ["T9"]}}, "Effect": {"text": [["phenytoin toxicity"]], "start": [[185]], "entity_id": ["T7"]}, "Subject": {"text": [["patients"]], "start": [[122]], "entity_id": ["T8"]}, "Speculated": {"text": [["suspect"]], "start": [[89]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "9660541_3", "context": "We report a case of MMC-related hemolytic uremic syndrome, and discuss the etiologic parameters, clinical aspects, prognosis and treatment modalities of this severe syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[24]], "entity_id": ["T4"]}, "Treatment": {"text": [["MMC"]], "start": [[20]], "entity_id": ["T3"], "Drug": {"text": [["MMC"]], "start": [[20]], "entity_id": ["T6"]}}, "Effect": {"text": [["hemolytic uremic syndrome"]], "start": [[32]], "entity_id": ["T5"]}, "Severity": {"text": [["severe"]], "start": [[158]], "entity_id": ["T7"], "value": "High"}}]}]}
{"id": "3947272_3", "context": "Myasthenic patients receiving ampicillin should be closely monitored for possible acute exacerbations.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["receiving"]], "start": [[20]], "entity_id": ["T4"]}, "Treatment": {"text": [["ampicillin"]], "start": [[30]], "entity_id": ["T5"], "Disorder": {"text": [["Myasthenic"]], "start": [[0]], "entity_id": ["T8"]}, "Drug": {"text": [["ampicillin"]], "start": [[30]], "entity_id": ["T9"]}}, "Subject": {"text": [["Myasthenic patients"]], "start": [[0]], "entity_id": ["T6"]}, "Effect": {"text": [["acute exacerbations"]], "start": [[82]], "entity_id": ["T7"]}, "Speculated": {"text": [["possible"]], "start": [[73]], "entity_id": ["T3"], "value": true}}]}]}
{"id": "11999915_4", "context": "The male patient was treated with 225-mg/day clozapine and the time to the diagnosis of agranulocytosis was 6 weeks.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["diagnosis"]], "start": [[75]], "entity_id": ["T6"]}, "Subject": {"text": [["The male patient"]], "start": [[0]], "entity_id": ["T3"], "Gender": {"text": [["male"]], "start": [[4]], "entity_id": ["T7"]}}, "Treatment": {"text": [["225-mg/day clozapine"]], "start": [[34]], "entity_id": ["T4"], "Drug": {"text": [["clozapine"]], "start": [[45]], "entity_id": ["T8"]}, "Dosage": {"text": [["225-mg/day"]], "start": [[34]], "entity_id": ["T9"]}, "Duration": {"text": [["6 weeks"]], "start": [[108]], "entity_id": ["T10"]}}, "Effect": {"text": [["agranulocytosis"]], "start": [[88]], "entity_id": ["T5"]}}]}]}
{"id": "2862137_2", "context": "Alprazolam withdrawal delirium unresponsive to diazepam: case report.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["to"]], "start": [[44]], "entity_id": ["T5"]}, "Treatment": {"text": [["diazepam"]], "start": [[47]], "entity_id": ["T6"], "Disorder": {"text": [["Alprazolam withdrawal delirium"]], "start": [[0]], "entity_id": ["T3"]}, "Drug": {"text": [["diazepam"]], "start": [[47]], "entity_id": ["T7"]}}, "Negated": {"text": [["unresponsive"]], "start": [[31]], "entity_id": ["T4"], "value": true}}]}]}
{"id": "4036917_3", "context": "These findings support previous studies that showed that the use of aspirin during the antecedent illness may be a risk factor for the development of RS.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["development"]], "start": [[135]], "entity_id": ["T5"]}, "Treatment": {"text": [["aspirin"]], "start": [[68]], "entity_id": ["T4"], "Disorder": {"text": [["the antecedent illness"]], "start": [[83]], "entity_id": ["T3"]}, "Drug": {"text": [["aspirin"]], "start": [[68]], "entity_id": ["T8"]}}, "Effect": {"text": [["RS"]], "start": [[150]], "entity_id": ["T6"]}, "Speculated": {"text": [["may"]], "start": [[106]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "16405935_1", "context": "Chloroquine-induced bilateral ptosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[12]], "entity_id": ["T4"]}, "Treatment": {"text": [["Chloroquine"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Chloroquine"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["bilateral ptosis"]], "start": [[20]], "entity_id": ["T5"]}}]}]}
{"id": "17364199_14", "context": "DISCUSSION: To our knowledge this is the first reported case of tuberculous uveitis following treatment with etanercept.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[104]], "entity_id": ["T5"]}, "Effect": {"text": [["tuberculous uveitis"]], "start": [[64]], "entity_id": ["T4"]}, "Treatment": {"text": [["etanercept"]], "start": [[109]], "entity_id": ["T6"], "Drug": {"text": [["etanercept"]], "start": [[109]], "entity_id": ["T7"]}}}]}]}
{"id": "25538343_2", "context": "Hyponatremia is a known adverse effect of duloxetine, and it can lead to potentially life-threatening complications.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["adverse"]], "start": [[24]], "entity_id": ["T4"]}, "Treatment": {"text": [["duloxetine"]], "start": [[42]], "entity_id": ["T5"], "Drug": {"text": [["duloxetine"]], "start": [[42]], "entity_id": ["T8"]}}, "Effect": {"text": [["Hyponatremia"], ["potentially life-threatening complications"]], "start": [[0], [73]], "entity_id": ["T6", "T7"]}, "Severity": {"text": [["life-threatening"]], "start": [[85]], "entity_id": ["T9"], "value": "High"}}]}]}
{"id": "19003750_1", "context": "A 22-year-old drug-abuser injected flunitrazepam tablets dissolved in tap water into her left femoral artery and presented with clinical signs of acute ischaemia of the left leg.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["presented"]], "start": [[113]], "entity_id": ["T5"]}, "Subject": {"text": [["A 22-year-old drug-abuser"]], "start": [[0]], "entity_id": ["T3"], "Age": {"text": [["22-year-old"]], "start": [[2]], "entity_id": ["T7"]}, "Disorder": {"text": [["drug-abuser"]], "start": [[14]], "entity_id": ["T8"]}}, "Treatment": {"text": [["injected flunitrazepam tablets dissolved in tap water into her left femoral artery"]], "start": [[26]], "entity_id": ["T4"], "Drug": {"text": [["flunitrazepam"]], "start": [[35]], "entity_id": ["T9"]}, "Route": {"text": [["injected", "tablets dissolved in tap water"]], "start": [[26, 49]], "entity_id": ["T10"]}}, "Effect": {"text": [["acute ischaemia of the left leg"]], "start": [[146]], "entity_id": ["T6"]}}]}]}
{"id": "1348483_1", "context": "A patient with Parkinson's disease, initially treated with bromocriptine and subsequently with cabergoline, developed progressive pleuropulmonary abnormalities during the latter therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[108]], "entity_id": ["T4"]}, "Subject": {"text": [["A patient with Parkinson's disease"]], "start": [[0]], "entity_id": ["T6"]}, "Treatment": {"text": [["initially treated with bromocriptine and subsequently with cabergoline"]], "start": [[36]], "entity_id": ["T7"], "Disorder": {"text": [["Parkinson's disease"]], "start": [[15]], "entity_id": ["T8"]}, "Drug": {"text": [["bromocriptine"], ["cabergoline"]], "start": [[59], [95]], "entity_id": ["T9", "T10"]}}, "Effect": {"text": [["progressive pleuropulmonary abnormalities during the latter therapy"]], "start": [[118]], "entity_id": ["T5"]}}]}]}
{"id": "16432996_3", "context": "Although interferon gamma has been implicated in the pathogenesis of sarcoidosis, only a few cases of sarcoidosis associated with interferon alpha therapy have been reported.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["pathogenesis"]], "start": [[53]], "entity_id": ["T8"]}, "Treatment": {"text": [["interferon gamma"]], "start": [[9]], "entity_id": ["T7"], "Drug": {"text": [["interferon gamma"]], "start": [[9]], "entity_id": ["T10"]}}, "Effect": {"text": [["sarcoidosis"]], "start": [[69]], "entity_id": ["T9"]}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[114]], "entity_id": ["T14"]}, "Effect": {"text": [["sarcoidosis"]], "start": [[102]], "entity_id": ["T13"]}, "Treatment": {"text": [["interferon alpha"]], "start": [[130]], "entity_id": ["T15"], "Drug": {"text": [["interferon alpha"]], "start": [[130]], "entity_id": ["T16"]}}, "Speculated": {"text": [["only a few cases"]], "start": [[82]], "entity_id": ["T11"], "value": true}}]}]}
{"id": "3143551_3", "context": "Camptocormia, a new side effect of sodium valproate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["of"]], "start": [[32]], "entity_id": ["T4"]}, "Effect": {"text": [["Camptocormia"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["sodium valproate"]], "start": [[35]], "entity_id": ["T5"], "Drug": {"text": [["sodium valproate"]], "start": [[35]], "entity_id": ["T6"]}}}]}]}
{"id": "15028964_2", "context": "Many patients with cardiac arrhythmias require concomitant therapy with warfarin and amiodarone.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["require"]], "start": [[39]], "entity_id": ["T9"]}, "Subject": {"text": [["Many patients with cardiac arrhythmias"]], "start": [[0]], "entity_id": ["T7"]}, "Treatment": {"text": [["concomitant therapy with warfarin and amiodarone"]], "start": [[47]], "entity_id": ["T8"], "Drug": {"text": [["warfarin"], ["amiodarone"]], "start": [[72], [85]], "entity_id": ["T11", "T12"]}, "Disorder": {"text": [["cardiac arrhythmias"]], "start": [[19]], "entity_id": ["T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["concomitant"]], "start": [[47]], "entity_id": ["T13"]}, "Drug": {"text": [["warfarin"], ["amiodarone"]], "start": [[72], [85]], "entity_id": ["T11", "T12"]}}]}}]}]}
{"id": "11373877_2", "context": "We report the case histories of two patients with histologically confirmed adenocarcinoma of the prostate, both of whom had been treated with steroidal anti-androgen therapy in the form of cyproterone acetate prior to radical or palliative pelvic irradiation, and who subsequently developed femoral head avascular necrosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[129]], "entity_id": ["T4"]}, "Subject": {"text": [["two patients with histologically confirmed adenocarcinoma of the prostate"]], "start": [[32]], "entity_id": ["T3"], "Population": {"text": [["two"]], "start": [[32]], "entity_id": ["T7"]}}, "Treatment": {"text": [["steroidal anti-androgen therapy in the form of cyproterone acetate prior to radical or palliative pelvic irradiation"]], "start": [[142]], "entity_id": ["T5"], "Disorder": {"text": [["adenocarcinoma of the prostate"]], "start": [[75]], "entity_id": ["T8"]}, "Drug": {"text": [["cyproterone acetate"]], "start": [[189]], "entity_id": ["T1"]}}, "Effect": {"text": [["femoral head avascular necrosis."]], "start": [[291]], "entity_id": ["T6"]}}]}]}
{"id": "16284443_3", "context": "Thus, the possible in vivo effects of insulin on adipocytes were clearly observed in this case of insulin-induced lipohypertrophy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[106]], "entity_id": ["T4"]}, "Treatment": {"text": [["insulin"]], "start": [[98]], "entity_id": ["T3"], "Drug": {"text": [["insulin"]], "start": [[98]], "entity_id": ["T7"]}}, "Effect": {"text": [["lipohypertrophy"]], "start": [[114]], "entity_id": ["T5"]}, "Speculated": {"text": [["possible"]], "start": [[10]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "10599932_5", "context": "After the addition of citalopram, a desmethylclomipramine plasma level increase and an 8-hydroacy-desmethylclomipramine plasma level decrease were observed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["After"]], "start": [[0]], "entity_id": ["T7"]}, "Effect": {"text": [["desmethylclomipramine plasma level increase and an 8-hydroacy-desmethylclomipramine plasma level decrease"]], "start": [[36]], "entity_id": ["T5"]}, "Treatment": {"text": [["citalopram"]], "start": [[22]], "entity_id": ["T6"], "Drug": {"text": [["citalopram"]], "start": [[22]], "entity_id": ["T8"]}}}]}]}
{"id": "16791713_3", "context": "Here we present the case of a woman who received high doses of methylprednisolone (1 g iv daily) for active Graves' ophthalmopathy, and developed severe hypertension followed by myocardial infarction on the fifth day of treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["received"]], "start": [[40]], "entity_id": ["T6"]}, "Subject": {"text": [["a woman"]], "start": [[28]], "entity_id": ["T5"], "Gender": {"text": [["woman"]], "start": [[30]], "entity_id": ["T9"]}}, "Treatment": {"text": [["high doses of methylprednisolone (1 g iv daily)"]], "start": [[49]], "entity_id": ["T7"], "Drug": {"text": [["methylprednisolone"]], "start": [[63]], "entity_id": ["T10"]}, "Dosage": {"text": [["1 g"]], "start": [[83]], "entity_id": ["T11"]}, "Route": {"text": [["iv"]], "start": [[87]], "entity_id": ["T12"]}, "Freq": {"text": [["daily"]], "start": [[90]], "entity_id": ["T13"]}, "Disorder": {"text": [["active Graves' ophthalmopathy"]], "start": [[101]], "entity_id": ["T14"]}}, "Effect": {"text": [["severe hypertension followed by myocardial infarction on the fifth day of treatment."]], "start": [[146]], "entity_id": ["T8"]}, "Severity": {"text": [["severe"]], "start": [[146]], "entity_id": ["T15"], "value": "High"}}]}]}
{"id": "19875411_2", "context": "Severe cardiomyopathy following treatment with the tumour necrosis factor-alpha inhibitor adalimumab for Crohn's disease.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[22]], "entity_id": ["T4"]}, "Effect": {"text": [["cardiomyopathy"]], "start": [[7]], "entity_id": ["T3"]}, "Treatment": {"text": [["treatment with the tumour necrosis factor-alpha inhibitor adalimumab"]], "start": [[32]], "entity_id": ["T5"], "Drug": {"text": [["adalimumab"]], "start": [[90]], "entity_id": ["T7"]}, "Disorder": {"text": [["Crohn's disease"]], "start": [[105]], "entity_id": ["T8"]}}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T9"], "value": "High"}}]}]}
{"id": "7991279_2", "context": "There are now reports of liver failure following treatment of childhood cancers with AMD.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[39]], "entity_id": ["T5"]}, "Subject": {"text": [["childhood cancers"]], "start": [[62]], "entity_id": ["T3"], "Age": {"text": [["childhood"]], "start": [[62]], "entity_id": ["T7"]}}, "Effect": {"text": [["liver failure"]], "start": [[25]], "entity_id": ["T4"]}, "Treatment": {"text": [["AMD"]], "start": [[85]], "entity_id": ["T6"], "Disorder": {"text": [["cancers"]], "start": [[72]], "entity_id": ["T8"]}, "Drug": {"text": [["AMD"]], "start": [[85]], "entity_id": ["T9"]}}}]}]}
{"id": "18362995_2", "context": "Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[18]], "entity_id": ["T3"]}, "Effect": {"text": [["fatal acute hepatic failure"]], "start": [[26]], "entity_id": ["T4"]}, "Treatment": {"text": [["Imatinib mesylate"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Imatinib mesylate"]], "start": [[0]], "entity_id": ["T10"]}, "Disorder": {"text": [["chronic myeloid leukaemia"]], "start": [[72]], "entity_id": ["T11"]}}, "Subject": {"text": [["a patient with chronic myeloid leukaemia and chronic hepatitis B infection"]], "start": [[57]], "entity_id": ["T6"], "Disorder": {"text": [["chronic hepatitis B infection"]], "start": [[102]], "entity_id": ["T9"]}}, "Severity": {"text": [["fatal"]], "start": [[26]], "entity_id": ["T8"], "value": "High"}}]}]}
{"id": "11889149_3", "context": "This phase 3, randomized, double-blind 1-yr study assessed the effects of combined RLX and ALN in 331 postmenopausal women with osteoporosis (femoral neck BMD T-score, less than -2).", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["effects"]], "start": [[63]], "entity_id": ["T11"]}, "Treatment": {"text": [["combined RLX and ALN"]], "start": [[74]], "entity_id": ["T8"], "Disorder": {"text": [["osteoporosis"]], "start": [[128]], "entity_id": ["T14"]}, "Drug": {"text": [["RLX"], ["ALN"]], "start": [[83], [91]], "entity_id": ["T18", "T19"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combined"]], "start": [[74]], "entity_id": ["T20"]}, "Drug": {"text": [["RLX"], ["ALN"]], "start": [[83], [91]], "entity_id": ["T18", "T19"]}}]}, "Subject": {"text": [["331 postmenopausal women with osteoporosis (femoral neck BMD T-score, less than -2)"]], "start": [[98]], "entity_id": ["T9"], "Population": {"text": [["331"]], "start": [[98]], "entity_id": ["T12"]}, "Gender": {"text": [["women"]], "start": [[117]], "entity_id": ["T13"]}, "Age": {"text": [["postmenopausal"]], "start": [[102]], "entity_id": ["T16"]}}, "Speculated": {"text": [["assessed"]], "start": [[50]], "entity_id": ["T17"], "value": true}}]}]}
{"id": "8597009_1", "context": "Phenytoin toxicity due to concomitant antituberculosis therapy.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[19]], "entity_id": ["T3"]}, "Effect": {"text": [["Phenytoin toxicity"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["concomitant antituberculosis therapy."]], "start": [[26]], "entity_id": ["T5"], "Drug": {"text": [["Phenytoin"], ["antituberculosis"]], "start": [[0], [38]], "entity_id": ["T6", "T7"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["concomitant"]], "start": [[26]], "entity_id": ["T8"]}, "Drug": {"text": [["antituberculosis"], ["Phenytoin"]], "start": [[38], [0]], "entity_id": ["T7", "T6"]}}]}}]}]}
{"id": "7900744_2", "context": "Hemodialysis should be performed for rapid reversal of mannitol-induced ARF.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[64]], "entity_id": ["T4"]}, "Treatment": {"text": [["mannitol"]], "start": [[55]], "entity_id": ["T3"], "Drug": {"text": [["mannitol"]], "start": [[55]], "entity_id": ["T6"]}}, "Effect": {"text": [["ARF"]], "start": [[72]], "entity_id": ["T5"]}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["performed"]], "start": [[23]], "entity_id": ["T11"]}, "Treatment": {"text": [["Hemodialysis"]], "start": [[0]], "entity_id": ["T9"], "Drug": {"text": [["Hemodialysis"]], "start": [[0]], "entity_id": ["T10"]}, "Disorder": {"text": [["mannitol-induced ARF"]], "start": [[55]], "entity_id": ["T8"]}}}]}]}
{"id": "18067642_2", "context": "Amiodarone is well recognized as an anti-arrhythmic drug containing a high dose of iodine with considerable potential to cause thyroid dysfunction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["recognized"]], "start": [[19]], "entity_id": ["T4"]}, "Treatment": {"text": [["Amiodarone"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Amiodarone"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["potential to cause thyroid dysfunction"]], "start": [[108]], "entity_id": ["T5"]}}]}]}
{"id": "1359782_2", "context": "Pulmonary infiltrates and skin pigmentation associated with sulfasalazine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[44]], "entity_id": ["T5"]}, "Treatment": {"text": [["sulfasalazine"]], "start": [[60]], "entity_id": ["T6"], "Drug": {"text": [["sulfasalazine"]], "start": [[60]], "entity_id": ["T8"]}}, "Effect": {"text": [["Pulmonary infiltrates and skin pigmentation"]], "start": [[0]], "entity_id": ["T7"]}}]}]}
{"id": "998323_1", "context": "Lithium treatment was terminated in 1975 because of lithium intoxication with a diabetes insipidus-like syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["because"]], "start": [[41]], "entity_id": ["T9"]}, "Treatment": {"text": [["Lithium treatment"]], "start": [[0]], "entity_id": ["T7"], "Drug": {"text": [["Lithium"]], "start": [[0]], "entity_id": ["T10"]}}, "Effect": {"text": [["lithium intoxication with a diabetes insipidus-like syndrome"]], "start": [[52]], "entity_id": ["T8"]}}]}]}
{"id": "7304798_2", "context": "The authors report a longitudinal case study of a woman with a history of bipolar affective disorder in which L-dopa shortened the manic-depressive cycle length when administered in a double-blind trial.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["shortened"]], "start": [[117]], "entity_id": ["T6"]}, "Subject": {"text": [["a woman with a history of bipolar affective disorder"]], "start": [[48]], "entity_id": ["T7"], "Gender": {"text": [["woman"]], "start": [[50]], "entity_id": ["T10"]}, "Disorder": {"text": [["bipolar affective disorder"]], "start": [[74]], "entity_id": ["T11"]}}, "Treatment": {"text": [["L-dopa"]], "start": [[110]], "entity_id": ["T8"], "Drug": {"text": [["L-dopa"]], "start": [[110]], "entity_id": ["T12"]}}, "Effect": {"text": [["shortened the manic-depressive cycle length"]], "start": [[117]], "entity_id": ["T9"]}}]}]}
{"id": "19402273_1", "context": "Isoniazid causing breast tissue enlargement has been very rarely reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["causing"]], "start": [[10]], "entity_id": ["T5"]}, "Effect": {"text": [["breast tissue enlargement"]], "start": [[18]], "entity_id": ["T3"]}, "Treatment": {"text": [["Isoniazid"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Isoniazid"]], "start": [[0]], "entity_id": ["T7"]}}}]}]}
{"id": "7393795_3", "context": "The induction of hypoglycaemia with PAS in this patient suggests a potential role for PAS in the treatment of diabetes mellitus.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induction"]], "start": [[4]], "entity_id": ["T6"]}, "Effect": {"text": [["hypoglycaemia"]], "start": [[17]], "entity_id": ["T3"]}, "Treatment": {"text": [["PAS"]], "start": [[36]], "entity_id": ["T4"], "Drug": {"text": [["PAS"]], "start": [[36]], "entity_id": ["T8"]}, "Disorder": {"text": [["diabetes mellitus"]], "start": [[110]], "entity_id": ["T9"]}}, "Subject": {"text": [["this patient"]], "start": [[43]], "entity_id": ["T7"]}}]}]}
{"id": "8641617_1", "context": "Although both patients recovered from the colitis after the administration of vancomycin, the first case demonstrated a relapse of the colitis after receiving a subsequent course of the same chemotherapy with cisplatin.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["recovered"]], "start": [[23]], "entity_id": ["T7"]}, "Treatment": {"text": [["vancomycin"]], "start": [[78]], "entity_id": ["T4"], "Disorder": {"text": [["colitis"]], "start": [[42]], "entity_id": ["T9"]}, "Drug": {"text": [["vancomycin"]], "start": [[78]], "entity_id": ["T5"]}}, "Subject": {"text": [["both patients"]], "start": [[9]], "entity_id": ["T6"], "Population": {"text": [["both"]], "start": [[9]], "entity_id": ["T10"]}}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["receiving"]], "start": [[149]], "entity_id": ["T14"]}, "Effect": {"text": [["a relapse of the colitis"]], "start": [[118]], "entity_id": ["T11"]}, "Treatment": {"text": [["a subsequent course of the same chemotherapy with cisplatin"]], "start": [[159]], "entity_id": ["T12"], "Drug": {"text": [["cisplatin"]], "start": [[209]], "entity_id": ["T13"]}, "Route": {"text": [["chemotherapy"]], "start": [[191]], "entity_id": ["T8"]}}}]}]}
{"id": "15190230_1", "context": "Acute dystonia during pegylated interferon alpha therapy in a case with chronic hepatitis B infection.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["therapy"]], "start": [[49]], "entity_id": ["T5"]}, "Effect": {"text": [["Acute dystonia"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["pegylated interferon alpha"]], "start": [[22]], "entity_id": ["T4"], "Disorder": {"text": [["chronic hepatitis B infection"]], "start": [[72]], "entity_id": ["T7"]}, "Drug": {"text": [["pegylated interferon alpha"]], "start": [[22]], "entity_id": ["T8"]}}}]}]}
{"id": "7696938_3", "context": "I saw two patients with kala-azar resistant to sodium stibogluconate who developed cardiac arrest after amphotericin infusion (in spite of tolerating a test dose).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[73]], "entity_id": ["T4"]}, "Subject": {"text": [["two patients with kala-azar resistant to sodium stibogluconate"]], "start": [[6]], "entity_id": ["T3"], "Population": {"text": [["two"]], "start": [[6]], "entity_id": ["T7"]}, "Disorder": {"text": [["resistant to sodium stibogluconate"]], "start": [[34]], "entity_id": ["T1"]}}, "Effect": {"text": [["cardiac arrest"]], "start": [[83]], "entity_id": ["T5"]}, "Treatment": {"text": [["amphotericin infusion"]], "start": [[104]], "entity_id": ["T6"], "Disorder": {"text": [["kala-azar"]], "start": [[24]], "entity_id": ["T8"]}, "Drug": {"text": [["amphotericin"]], "start": [[104]], "entity_id": ["T9"]}, "Route": {"text": [["infusion"]], "start": [[117]], "entity_id": ["T10"]}}}]}]}
{"id": "18515982_2", "context": "CONCLUSIONS: Anastrozole may be the causative factor in patients with sclerosing glomerulonephritis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["causative"]], "start": [[36]], "entity_id": ["T6"]}, "Treatment": {"text": [["Anastrozole"]], "start": [[13]], "entity_id": ["T3"], "Drug": {"text": [["Anastrozole"]], "start": [[13]], "entity_id": ["T7"]}}, "Subject": {"text": [["patients"]], "start": [[56]], "entity_id": ["T4"]}, "Effect": {"text": [["sclerosing glomerulonephritis"]], "start": [[70]], "entity_id": ["T5"]}, "Speculated": {"text": [["may"]], "start": [[25]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "9399776_5", "context": "We describe two cases of acute pancreatitis that occurred after long term mesalamine therapy for ulcerative colitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurred"]], "start": [[49]], "entity_id": ["T4"]}, "Effect": {"text": [["acute pancreatitis"]], "start": [[25]], "entity_id": ["T3"]}, "Treatment": {"text": [["mesalamine"]], "start": [[74]], "entity_id": ["T5"], "Disorder": {"text": [["ulcerative colitis"]], "start": [[97]], "entity_id": ["T6"]}, "Drug": {"text": [["mesalamine"]], "start": [[74]], "entity_id": ["T7"]}}, "Subject": {"text": [["two cases"]], "start": [[12]], "entity_id": ["T8"]}}]}]}
{"id": "1673494_1", "context": "Amphotericin B (AmB) is effective, but its use is limited by toxicity: renal impairment, anaemia, fever, malaise, and hypokalaemia are common.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["by"]], "start": [[58]], "entity_id": ["T18"]}, "Effect": {"text": [["toxicity: renal impairment, anaemia, fever, malaise, and hypokalaemia"]], "start": [[61]], "entity_id": ["T16"]}, "Treatment": {"text": [["Amphotericin B (AmB)"]], "start": [[0]], "entity_id": ["T17"], "Drug": {"text": [["Amphotericin B"]], "start": [[0]], "entity_id": ["T19"]}}, "Speculated": {"text": [["common"]], "start": [[135]], "entity_id": ["T20"], "value": true}}]}]}
{"id": "1977935_6", "context": "We believe that a drug interaction between terfenadine and ketoconazole resulted in the elevated terfenadine levels in plasma and in the cardiotoxicity previously seen only in cases of terfenadine overdose.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulted"]], "start": [[72]], "entity_id": ["T9"]}, "Treatment": {"text": [["a drug interaction between terfenadine and ketoconazole"]], "start": [[16]], "entity_id": ["T8"], "Drug": {"text": [["terfenadine"], ["ketoconazole"]], "start": [[43], [59]], "entity_id": ["T12", "T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[23]], "entity_id": ["T11"]}, "Drug": {"text": [["terfenadine"], ["ketoconazole"]], "start": [[43], [59]], "entity_id": ["T12", "T13"]}}]}, "Effect": {"text": [["the elevated terfenadine levels in plasma and in the cardiotoxicity"]], "start": [[84]], "entity_id": ["T10"]}}]}]}
{"id": "3405528_1", "context": "A case of halothane induced hepatitis is reported in a middle aged woman who underwent gastric surgery for morbid obesity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[20]], "entity_id": ["T4"]}, "Subject": {"text": [["a middle aged woman"]], "start": [[53]], "entity_id": ["T3"], "Age": {"text": [["middle aged"]], "start": [[55]], "entity_id": ["T7"]}, "Gender": {"text": [["woman"]], "start": [[67]], "entity_id": ["T8"]}}, "Treatment": {"text": [["halothane", "gastric surgery for morbid obesity"]], "start": [[10, 87]], "entity_id": ["T5"], "Drug": {"text": [["halothane"]], "start": [[10]], "entity_id": ["T9"]}, "Disorder": {"text": [["morbid obesity"]], "start": [[107]], "entity_id": ["T10"]}}, "Effect": {"text": [["hepatitis"]], "start": [[28]], "entity_id": ["T6"]}}]}]}
{"id": "448845_2", "context": "Carbonic anhydrase inhibitors used in the treatment of glaucoma, seizure disorders, and hypertension are rarely associated with blood dyscrasias.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["rarely associated"]], "start": [[105]], "entity_id": ["T9"]}, "Treatment": {"text": [["Carbonic anhydrase inhibitors"]], "start": [[0]], "entity_id": ["T7"], "Drug": {"text": [["Carbonic anhydrase inhibitors"]], "start": [[0]], "entity_id": ["T11"]}, "Disorder": {"text": [["glaucoma, seizure disorders, and hypertension"]], "start": [[55]], "entity_id": ["T12"]}}, "Effect": {"text": [["blood dyscrasias"]], "start": [[128]], "entity_id": ["T10"]}}]}]}
{"id": "282937_1", "context": "Administration of intrathecal Ara-C in the same dose over longer intervals within 3-5 days between consecutive doses resulted in mild, transient neurological symptoms (paresthesias) in only one of 30 patients so treated.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulted"]], "start": [[117]], "entity_id": ["T4"]}, "Treatment": {"text": [["Administration of intrathecal Ara-C in the same dose over longer intervals within 3-5 days between consecutive doses"]], "start": [[0]], "entity_id": ["T3"], "Route": {"text": [["intrathecal"]], "start": [[18]], "entity_id": ["T8"]}, "Drug": {"text": [["Ara-C"]], "start": [[30]], "entity_id": ["T9"]}, "Freq": {"text": [["longer intervals within 3-5 days between consecutive doses"]], "start": [[58]], "entity_id": ["T10"]}}, "Effect": {"text": [["neurological symptoms"]], "start": [[145]], "entity_id": ["T5"]}, "Subject": {"text": [["one of 30 patients"]], "start": [[190]], "entity_id": ["T6"], "Population": {"text": [["one of 30"]], "start": [[190]], "entity_id": ["T7"]}}, "Severity": {"text": [["mild"]], "start": [[129]], "entity_id": ["T11"], "value": "Low"}}]}]}
{"id": "12751276_2", "context": "Anaphylaxis from isoniazid is a possible side effect to this commonly prescribed antibiotic.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["is"]], "start": [[27]], "entity_id": ["T8"]}, "Treatment": {"text": [["isoniazid", "commonly prescribed antibiotic"]], "start": [[17, 61]], "entity_id": ["T6"], "Drug": {"text": [["isoniazid"]], "start": [[17]], "entity_id": ["T9"]}}, "Effect": {"text": [["Anaphylaxis"]], "start": [[0]], "entity_id": ["T7"]}, "Severity": {"text": [["possible"]], "start": [[32]], "entity_id": ["T10"], "value": "Medium"}}]}]}
{"id": "9920368_2", "context": "Among 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking amiodarone for 4 years, developed thyrotoxicosis with subacute onset, accompanied by transiently positive thyrotropin (TSH) receptor antibody (TRAb), or thyrotropin-binding inhibiting immunoglobulin (TBII).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[133]], "entity_id": ["T9"]}, "Subject": {"text": [["a patient with arrhythmogenic right ventricular dysplasia"]], "start": [[30]], "entity_id": ["T7"]}, "Treatment": {"text": [["amiodarone for 4 years"]], "start": [[109]], "entity_id": ["T8"], "Duration": {"text": [["4 years"]], "start": [[124]], "entity_id": ["T12"]}, "Drug": {"text": [["amiodarone"]], "start": [[109]], "entity_id": ["T13"]}, "Disorder": {"text": [["arrhythmogenic right ventricular dysplasia"]], "start": [[45]], "entity_id": ["T14"]}}, "Effect": {"text": [["thyrotoxicosis with subacute onset, accompanied by transiently positive thyrotropin (TSH) receptor antibody (TRAb), or thyrotropin-binding inhibiting immunoglobulin (TBII)"]], "start": [[143]], "entity_id": ["T10"]}}]}]}
{"id": "18094347_5", "context": "Methotrexate-induced papular eruption following treatment of psoriasis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[13]], "entity_id": ["T4"]}, "Treatment": {"text": [["Methotrexate"]], "start": [[0]], "entity_id": ["T3"], "Disorder": {"text": [["psoriasis"]], "start": [[61]], "entity_id": ["T6"]}, "Drug": {"text": [["Methotrexate"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["papular eruption"]], "start": [[21]], "entity_id": ["T5"]}}]}]}
{"id": "18533420_3", "context": "Sexual dysfunction associated with intrathecal baclofen use: a report of two cases.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[19]], "entity_id": ["T4"]}, "Effect": {"text": [["Sexual dysfunction"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["intrathecal baclofen"]], "start": [[35]], "entity_id": ["T5"], "Route": {"text": [["intrathecal"]], "start": [[35]], "entity_id": ["T8"]}, "Drug": {"text": [["baclofen"]], "start": [[47]], "entity_id": ["T9"]}}, "Subject": {"text": [["two cases"]], "start": [[73]], "entity_id": ["T6"], "Population": {"text": [["two"]], "start": [[73]], "entity_id": ["T7"]}}}]}]}
{"id": "11030530_2", "context": "Patients treated with L-asparaginase may present with hemorrhagic and thrombotic cerebrovascular events.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["present"]], "start": [[41]], "entity_id": ["T7"]}, "Subject": {"text": [["Patients"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["L-asparaginase"]], "start": [[22]], "entity_id": ["T6"], "Drug": {"text": [["L-asparaginase"]], "start": [[22]], "entity_id": ["T9"]}}, "Effect": {"text": [["hemorrhagic and thrombotic cerebrovascular events"]], "start": [[54]], "entity_id": ["T8"]}, "Speculated": {"text": [["may"]], "start": [[37]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "15611427_3", "context": "Since imiquimod induces large amounts of type I interferon production from TLR7-expressing plasmacytoid dendritic cell precursors (PDCs), the natural interferon-producing cells of the peripheral blood, we asked whether PDCs are present in psoriatic skin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induces"]], "start": [[16]], "entity_id": ["T4"]}, "Treatment": {"text": [["imiquimod"]], "start": [[6]], "entity_id": ["T3"], "Drug": {"text": [["imiquimod"]], "start": [[6]], "entity_id": ["T6"]}}, "Effect": {"text": [["large amounts of type I interferon production"]], "start": [[24]], "entity_id": ["T5"]}}]}]}
{"id": "16405935_2", "context": "Ptosis occurring 24 h after chloroquine therapy, with full recovery 48 h after cessation of chloroquine, has not been described previously.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurring"]], "start": [[7]], "entity_id": ["T5"]}, "Effect": {"text": [["Ptosis"], ["full recovery 48 h after cessation of chloroquine"]], "start": [[0], [54]], "entity_id": ["T4", "T9"]}, "Treatment": {"text": [["chloroquine therapy"]], "start": [[28]], "entity_id": ["T6"], "Time_elapsed": {"text": [["24 h"]], "start": [[17]], "entity_id": ["T7"]}, "Drug": {"text": [["chloroquine"]], "start": [[28]], "entity_id": ["T8"]}}, "Severity": {"text": [["full recovery"]], "start": [[54]], "entity_id": ["T10"], "value": "Low"}}]}]}
{"id": "17494808_1", "context": "Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[43]], "entity_id": ["T4"]}, "Effect": {"text": [["Hypersensitivity pneumonitis-like syndrome"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["lenalidomide"]], "start": [[70]], "entity_id": ["T5"], "Drug": {"text": [["lenalidomide"]], "start": [[70]], "entity_id": ["T6"]}}}]}]}
{"id": "11033734_2", "context": "Incidence of seizures in pediatric cancer patients treated with imipenem/cilastatin.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[51]], "entity_id": ["T7"]}, "Effect": {"text": [["seizures"]], "start": [[13]], "entity_id": ["T4"]}, "Subject": {"text": [["pediatric cancer patients"]], "start": [[25]], "entity_id": ["T5"], "Age": {"text": [["pediatric"]], "start": [[25]], "entity_id": ["T8"]}, "Disorder": {"text": [["cancer"]], "start": [[35]], "entity_id": ["T9"]}}, "Treatment": {"text": [["imipenem/cilastatin"]], "start": [[64]], "entity_id": ["T6"], "Drug": {"text": [["imipenem"], ["cilastatin"]], "start": [[64], [73]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["/"]], "start": [[72]], "entity_id": ["T12"]}, "Drug": {"text": [["imipenem"], ["cilastatin"]], "start": [[64], [73]], "entity_id": ["T10", "T11"]}}]}}]}]}
{"id": "6260900_2", "context": "One of these was clofazimine, an aniline aposafranine derivative known to produce a ceroid-like pigment in the tissues of patients treated with this drug or lepromatous leprosy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["produce"]], "start": [[74]], "entity_id": ["T6"]}, "Treatment": {"text": [["clofazimine"]], "start": [[17]], "entity_id": ["T3"], "Disorder": {"text": [["lepromatous leprosy"]], "start": [[157]], "entity_id": ["T7"]}, "Drug": {"text": [["clofazimine"]], "start": [[17]], "entity_id": ["T8"]}}, "Effect": {"text": [["a ceroid-like pigment"]], "start": [[82]], "entity_id": ["T4"]}, "Subject": {"text": [["patients treated with this drug or lepromatous leprosy"]], "start": [[122]], "entity_id": ["T5"]}}]}]}
{"id": "331881_1", "context": "Deposits of plasma proteins in the skin during treatment with carbamazepine and diphenylhydantoin.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treatment"]], "start": [[47]], "entity_id": ["T4"]}, "Treatment": {"text": [["carbamazepine and diphenylhydantoin"]], "start": [[62]], "entity_id": ["T5"], "Drug": {"text": [["carbamazepine"], ["diphenylhydantoin"]], "start": [[62], [80]], "entity_id": ["T8", "T9"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[76]], "entity_id": ["T7"]}, "Drug": {"text": [["carbamazepine"], ["diphenylhydantoin"]], "start": [[62], [80]], "entity_id": ["T8", "T9"]}}]}, "Effect": {"text": [["Deposits of plasma proteins in the skin"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "14690166_1", "context": "2-Chloro-deoxyadenosine induces durable complete remission in Castleman's disease but may accelerate its transformation to non-Hodgkin's lymphoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["accelerate"]], "start": [[90]], "entity_id": ["T10"]}, "Treatment": {"text": [["2-Chloro-deoxyadenosine"]], "start": [[0]], "entity_id": ["T8"], "Drug": {"text": [["2-Chloro-deoxyadenosine"]], "start": [[0]], "entity_id": ["T12"]}, "Disorder": {"text": [["Castleman's disease"]], "start": [[62]], "entity_id": ["T13"]}}, "Effect": {"text": [["non-Hodgkin's lymphoma"]], "start": [[123]], "entity_id": ["T11"]}, "Speculated": {"text": [["may"]], "start": [[86]], "entity_id": ["T14"], "value": true}}]}]}
{"id": "10393393_1", "context": "Hypersensitivity to aspirin can be manifested as acute asthma, urticaria and/or angioedema, or a systemic anaphylactoid reaction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["manifested"]], "start": [[35]], "entity_id": ["T8"]}, "Treatment": {"text": [["aspirin"]], "start": [[20]], "entity_id": ["T7"], "Drug": {"text": [["aspirin"]], "start": [[20]], "entity_id": ["T12"]}}, "Effect": {"text": [["acute asthma", "urticaria", "angioedema", "systemic anaphylactoid reaction"], ["Hypersensitivity"]], "start": [[49, 63, 80, 97], [0]], "entity_id": ["T9", "T10"]}, "Speculated": {"text": [["can"]], "start": [[28]], "entity_id": ["T11"], "value": true}}]}]}
{"id": "19224802_1", "context": "An exaggerated hypertensive response to glycopyrrolate therapy for bradycardia associated with high-dose dexmedetomidine.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[79]], "entity_id": ["T8"]}, "Effect": {"text": [["bradycardia"]], "start": [[67]], "entity_id": ["T11"]}, "Treatment": {"text": [["high-dose dexmedetomidine"]], "start": [[95]], "entity_id": ["T9"], "Drug": {"text": [["dexmedetomidine"]], "start": [[105]], "entity_id": ["T12"]}, "Dosage": {"text": [["high-dose"]], "start": [[95]], "entity_id": ["T16"]}}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["response"]], "start": [[28]], "entity_id": ["T13"]}, "Treatment": {"text": [["glycopyrrolate"]], "start": [[40]], "entity_id": ["T14"], "Disorder": {"text": [["bradycardia"]], "start": [[67]], "entity_id": ["T17"]}, "Drug": {"text": [["glycopyrrolate"]], "start": [[40]], "entity_id": ["T15"]}}, "Effect": {"text": [["exaggerated hypertensive"]], "start": [[3]], "entity_id": ["T10"]}}]}]}
{"id": "8530331_7", "context": "Only one patient, the youngest, did well on risperidone therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["did well"]], "start": [[32]], "entity_id": ["T5"]}, "Subject": {"text": [["the youngest"]], "start": [[18]], "entity_id": ["T4"]}, "Treatment": {"text": [["risperidone"]], "start": [[44]], "entity_id": ["T6"], "Drug": {"text": [["risperidone"]], "start": [[44]], "entity_id": ["T7"]}}}]}]}
{"id": "7019786_3", "context": "Two elderly women suffered an acute deterioration of renal function after treatment with cefoxitin sodium.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[68]], "entity_id": ["T4"]}, "Subject": {"text": [["Two elderly women"]], "start": [[0]], "entity_id": ["T3"], "Population": {"text": [["Two"]], "start": [[0]], "entity_id": ["T7"]}, "Age": {"text": [["elderly"]], "start": [[4]], "entity_id": ["T8"]}, "Gender": {"text": [["women"]], "start": [[12]], "entity_id": ["T9"]}}, "Effect": {"text": [["acute deterioration of renal function"]], "start": [[30]], "entity_id": ["T5"]}, "Treatment": {"text": [["treatment with cefoxitin sodium"]], "start": [[74]], "entity_id": ["T6"], "Drug": {"text": [["cefoxitin sodium"]], "start": [[89]], "entity_id": ["T10"]}}}]}]}
{"id": "19904536_14", "context": "Physicians should suspect pulmonary toxicity in patients with respiratory distress after gemcitabine chemotherapy, mainly in elderly patients.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[83]], "entity_id": ["T10"]}, "Effect": {"text": [["pulmonary toxicity"]], "start": [[26]], "entity_id": ["T8"]}, "Subject": {"text": [["patients with respiratory distress", "mainly in elderly patients"]], "start": [[48, 115]], "entity_id": ["T9"]}, "Treatment": {"text": [["gemcitabine chemotherapy"]], "start": [[89]], "entity_id": ["T11"], "Drug": {"text": [["gemcitabin"]], "start": [[89]], "entity_id": ["T13"]}, "Disorder": {"text": [["respiratory distress"]], "start": [[62]], "entity_id": ["T14"]}, "Route": {"text": [["chemotherapy"]], "start": [[101]], "entity_id": ["T16"]}}, "Speculated": {"text": [["suspect"]], "start": [[18]], "entity_id": ["T15"], "value": true}}]}]}
{"id": "9022114_3", "context": "Delay of corneal wound healing in patients treated with colchicine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[43]], "entity_id": ["T6"]}, "Subject": {"text": [["patients"]], "start": [[34]], "entity_id": ["T3"]}, "Treatment": {"text": [["colchicine"]], "start": [[56]], "entity_id": ["T4"], "Drug": {"text": [["colchicine"]], "start": [[56]], "entity_id": ["T7"]}}, "Effect": {"text": [["Delay of corneal wound healing"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "9920368_1", "context": "Amiodarone-induced thyrotoxicosis associated with thyrotropin receptor antibody.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T6"]}, "Treatment": {"text": [["Amiodarone"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Amiodarone"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["thyrotoxicosis"]], "start": [[19]], "entity_id": ["T7"]}}]}]}
{"id": "18721173_1", "context": "CONCLUSION: All doctors need to be aware of the need to review the indications for gabapentin use during periods of acute illness, especially with regard to renal impairment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["regard"]], "start": [[147]], "entity_id": ["T5"]}, "Treatment": {"text": [["gabapentin"]], "start": [[83]], "entity_id": ["T3"], "Disorder": {"text": [["acute illness"]], "start": [[116]], "entity_id": ["T6"]}, "Drug": {"text": [["gabapentin"]], "start": [[83]], "entity_id": ["T7"]}}, "Effect": {"text": [["renal impairment"]], "start": [[157]], "entity_id": ["T4"]}}]}]}
{"id": "21751692_4", "context": "EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to propofol.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["observed"]], "start": [[14]], "entity_id": ["T14"]}, "Subject": {"text": [["all 7 patients"]], "start": [[26]], "entity_id": ["T11"], "Population": {"text": [["7"]], "start": [[30]], "entity_id": ["T15"]}}, "Treatment": {"text": [["propofol TIVA"], ["low-dose ketamine was added to propofol"]], "start": [[61], [152]], "entity_id": ["T12", "T17"], "Drug": {"text": [["propofol"], ["ketamine"], ["propofol"]], "start": [[61], [161], [183]], "entity_id": ["T16", "T19", "T20"]}, "Route": {"text": [["TIVA"]], "start": [[70]], "entity_id": ["T22"]}, "Dosage": {"text": [["low-dose"]], "start": [[152]], "entity_id": ["T18"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["added"]], "start": [[174]], "entity_id": ["T21"]}, "Drug": {"text": [["propofol"], ["ketamine"]], "start": [[183], [161]], "entity_id": ["T20", "T19"]}}]}, "Effect": {"text": [["EA signs"]], "start": [[0]], "entity_id": ["T13"]}}]}]}
{"id": "9788533_8", "context": "The cause of death was multiple drug intoxication following acute use of sertraline, the manner of death was suicide, and the mechanism of death is an unexplained drug interaction and/or toxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[50]], "entity_id": ["T9"]}, "Effect": {"text": [["multiple drug intoxication"]], "start": [[23]], "entity_id": ["T8"]}, "Treatment": {"text": [["sertraline"]], "start": [[73]], "entity_id": ["T10"], "Drug": {"text": [["sertraline"]], "start": [[73]], "entity_id": ["T11"]}}, "Speculated": {"text": [["unexplained"]], "start": [[151]], "entity_id": ["T12"], "value": true}}]}]}
{"id": "9362107_2", "context": "On the next day, after a total dose of only 600 mg of danazol, gingival bleeding and purpura occurred.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurred"]], "start": [[93]], "entity_id": ["T7"]}, "Effect": {"text": [["gingival bleeding and purpura"]], "start": [[63]], "entity_id": ["T5"]}, "Treatment": {"text": [["On the next day, after a total dose of only 600 mg of danazol"]], "start": [[0]], "entity_id": ["T6"], "Drug": {"text": [["danazol"]], "start": [[54]], "entity_id": ["T8"]}, "Dosage": {"text": [["a total dose of only 600 mg"]], "start": [[23]], "entity_id": ["T9"]}}}]}]}
{"id": "1393348_4", "context": "SLE receded after withdrawal of carbamazepine and treatment with anti-inflammatory drugs.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["after"]], "start": [[12]], "entity_id": ["T4"]}, "Treatment": {"text": [["withdrawal of carbamazepine and treatment with anti-inflammatory drugs"]], "start": [[18]], "entity_id": ["T3"], "Drug": {"text": [["carbamazepine"], ["anti-inflammatory"]], "start": [[32], [65]], "entity_id": ["T6", "T7"]}, "Disorder": {"text": [["SLE"]], "start": [[0]], "entity_id": ["T8"]}}}]}]}
{"id": "8828999_1", "context": "a 67-year-old man with bipolar disorder developed a Creutzfeldt-Jakob like syndrome during lithium carbonate treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[84]], "entity_id": ["T4"]}, "Subject": {"text": [["a 67-year-old man with bipolar disorder"]], "start": [[0]], "entity_id": ["T3"], "Age": {"text": [["67-year-old"]], "start": [[2]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[14]], "entity_id": ["T9"]}}, "Effect": {"text": [["Creutzfeldt-Jakob like syndrome"]], "start": [[52]], "entity_id": ["T5"]}, "Treatment": {"text": [["lithium carbonate"]], "start": [[91]], "entity_id": ["T6"], "Drug": {"text": [["lithium carbonate"]], "start": [[91]], "entity_id": ["T10"]}, "Disorder": {"text": [["bipolar disorder"]], "start": [[23]], "entity_id": ["T11"]}}}]}]}
{"id": "7679525_2", "context": "A 42 year old man, treated for testicular carcinoma with combination chemotherapy that included bleomycin, developed life threatening interstitial pneumonitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[107]], "entity_id": ["T10"]}, "Subject": {"text": [["42 year old man"]], "start": [[2]], "entity_id": ["T7"], "Age": {"text": [["42 year old"]], "start": [[2]], "entity_id": ["T11"]}, "Gender": {"text": [["man"]], "start": [[14]], "entity_id": ["T12"]}}, "Treatment": {"text": [["combination chemotherapy that included bleomycin,"]], "start": [[57]], "entity_id": ["T8"], "Disorder": {"text": [["testicular carcinoma"]], "start": [[31]], "entity_id": ["T14"]}, "Drug": {"text": [["bleomycin"]], "start": [[96]], "entity_id": ["T13"]}}, "Effect": {"text": [["interstitial pneumonitis"]], "start": [[134]], "entity_id": ["T9"]}, "Severity": {"text": [["life threatening"]], "start": [[117]], "entity_id": ["T15"], "value": "High"}}]}]}
{"id": "18446030_1", "context": "Disseminated eruptive giant mollusca contagiosa in an adult psoriasis patient during efalizumab therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[78]], "entity_id": ["T4"]}, "Treatment": {"text": [["efalizumab therapy"]], "start": [[85]], "entity_id": ["T3"], "Disorder": {"text": [["psoriasis"]], "start": [[60]], "entity_id": ["T8"]}, "Drug": {"text": [["efalizumab"]], "start": [[85]], "entity_id": ["T9"]}}, "Subject": {"text": [["an adult psoriasis patient"]], "start": [[51]], "entity_id": ["T5"], "Age": {"text": [["adult"]], "start": [[54]], "entity_id": ["T7"]}}, "Effect": {"text": [["Disseminated eruptive giant mollusca contagiosa"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "812008_2", "context": "Significant clinical improvement of the porphyria followed withdrawal of the diphenylhydantoin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["improvement"]], "start": [[21]], "entity_id": ["T8"]}, "Treatment": {"text": [["withdrawal of the diphenylhydantoin"]], "start": [[59]], "entity_id": ["T5"], "Disorder": {"text": [["porphyria"]], "start": [[40]], "entity_id": ["T3"]}, "Drug": {"text": [["diphenylhydantoin"]], "start": [[77]], "entity_id": ["T7"]}}}]}]}
{"id": "18294121_5", "context": "Temozolomide was restarted 2 months later; the patient again developed a fever.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[61]], "entity_id": ["T3"]}, "Effect": {"text": [["fever"]], "start": [[73]], "entity_id": ["T4"]}, "Subject": {"text": [["the patient"]], "start": [[43]], "entity_id": ["T5"]}, "Treatment": {"text": [["Temozolomide"]], "start": [[0]], "entity_id": ["T6"], "Drug": {"text": [["Temozolomide"]], "start": [[0]], "entity_id": ["T7"]}}}]}]}
{"id": "9337441_16", "context": "The patient's previous rash and the temporal relation of this event and the ingestion of phenolphthalein, as well as the similarity of this case to other reports, point to phenolphthalein as the cause of TEN in this patient.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[195]], "entity_id": ["T7"]}, "Treatment": {"text": [["ingestion of phenolphthalein"]], "start": [[76]], "entity_id": ["T6"], "Drug": {"text": [["phenolphthalein"]], "start": [[89]], "entity_id": ["T11"]}, "Route": {"text": [["ingestion"]], "start": [[76]], "entity_id": ["T12"]}}, "Effect": {"text": [["TEN"]], "start": [[204]], "entity_id": ["T8"]}, "Subject": {"text": [["The patient's previous rash"]], "start": [[0]], "entity_id": ["T9"], "Disorder": {"text": [["rash"]], "start": [[23]], "entity_id": ["T10"]}}}]}]}
{"id": "15592331_12", "context": "Ciprofloxacin greatly elevates plasma concentrations of tizanidine and dangerously potentiates its hypotensive and sedative effects, mainly by inhibiting its CYP1A2-mediated metabolism, at least when administered 1 hour before tizanidine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["elevates"]], "start": [[22]], "entity_id": ["T11"]}, "Treatment": {"text": [["Ciprofloxacin"]], "start": [[0]], "entity_id": ["T9"], "Drug": {"text": [["Ciprofloxacin"], ["tizanidine"], ["tizanidine"]], "start": [[0], [56], [227]], "entity_id": ["T13", "T14", "T15"]}}, "Effect": {"text": [["plasma concentrations of tizanidine and dangerously potentiates its hypotensive and sedative effects"]], "start": [[31]], "entity_id": ["T10"]}}]}]}
{"id": "11328247_4", "context": "RESULTS: The patient, a 27-year-old married Japanese woman with borderline personality disorder, developed an increased libido with the administration of fluvoxamine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[97]], "entity_id": ["T4"]}, "Subject": {"text": [["The patient, a 27-year-old married Japanese woman with borderline personality disorder"]], "start": [[9]], "entity_id": ["T3"], "Age": {"text": [["27-year-old"]], "start": [[24]], "entity_id": ["T7"]}, "Race": {"text": [["Japanese"]], "start": [[44]], "entity_id": ["T8"]}, "Gender": {"text": [["woman"]], "start": [[53]], "entity_id": ["T9"]}}, "Effect": {"text": [["increased libido"]], "start": [[110]], "entity_id": ["T6"]}, "Treatment": {"text": [["administration of fluvoxamine"]], "start": [[136]], "entity_id": ["T5"], "Disorder": {"text": [["borderline personality disorder"]], "start": [[64]], "entity_id": ["T11"]}, "Drug": {"text": [["fluvoxamine"]], "start": [[154]], "entity_id": ["T12"]}}}]}]}
{"id": "9403220_2", "context": "Acute renal failure with severe tubulointerstitial changes in a patient with minimal change nephrotic syndrome treated with enalapril.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[59]], "entity_id": ["T11"]}, "Treatment": {"text": [["enalapril"]], "start": [[124]], "entity_id": ["T6"], "Drug": {"text": [["enalapril"]], "start": [[124]], "entity_id": ["T13"]}, "Disorder": {"text": [["minimal change nephrotic syndrome"]], "start": [[77]], "entity_id": ["T14"]}}, "Subject": {"text": [["a patient with minimal change nephrotic syndrome"]], "start": [[62]], "entity_id": ["T7"]}, "Effect": {"text": [["Acute renal failure with severe tubulointerstitial changes"]], "start": [[0]], "entity_id": ["T5"]}, "Severity": {"text": [["severe"]], "start": [[25]], "entity_id": ["T10"], "value": "High"}}]}]}
{"id": "19667003_2", "context": "PURPOSE: A case of carbamazepine-induced hyperammonemia is presented.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[33]], "entity_id": ["T6"]}, "Subject": {"text": [["A case"]], "start": [[9]], "entity_id": ["T4"]}, "Treatment": {"text": [["carbamazepine"]], "start": [[19]], "entity_id": ["T5"], "Drug": {"text": [["carbamazepine"]], "start": [[19]], "entity_id": ["T8"]}}, "Effect": {"text": [["hyperammonemia"]], "start": [[41]], "entity_id": ["T7"]}}]}]}
{"id": "7919557_4", "context": "The cough continued for the duration of therapy with quinapril.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["continued"]], "start": [[10]], "entity_id": ["T4"]}, "Effect": {"text": [["cough"]], "start": [[4]], "entity_id": ["T3"]}, "Treatment": {"text": [["quinapril"]], "start": [[53]], "entity_id": ["T5"], "Drug": {"text": [["quinapril"]], "start": [[53]], "entity_id": ["T6"]}}}]}]}
{"id": "15685264_2", "context": "OBJECTIVE: To report a case of Carbamazepine toxicity following the administration of Oxybutynin and Dantrolene.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[54]], "entity_id": ["T8"]}, "Treatment": {"text": [["Carbamazepine", "Oxybutynin and Dantrolene"]], "start": [[31, 86]], "entity_id": ["T9"], "Drug": {"text": [["Oxybutynin"], ["Dantrolene"], ["Carbamazepine"]], "start": [[86], [101], [31]], "entity_id": ["T11", "T12", "T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["administration"]], "start": [[68]], "entity_id": ["T10"]}, "Drug": {"text": [["Carbamazepine"], ["Oxybutynin"], ["Dantrolene"]], "start": [[31], [86], [101]], "entity_id": ["T13", "T11", "T12"]}}]}, "Effect": {"text": [["Carbamazepine toxicity"]], "start": [[31]], "entity_id": ["T7"]}}]}]}
{"id": "9362107_1", "context": "Danazol induced thrombocytopenia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[8]], "entity_id": ["T3"]}, "Treatment": {"text": [["Danazol"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Danazol"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["thrombocytopenia"]], "start": [[16]], "entity_id": ["T5"]}}]}]}
{"id": "16005413_5", "context": "Four elderly LTCF residents treated with serotonergic antidepressants including selective serotonin reuptake inhibitor (SSRI) or mirtazapine and opioids.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[28]], "entity_id": ["T10"]}, "Subject": {"text": [["Four elderly LTCF residents"]], "start": [[0]], "entity_id": ["T9"], "Population": {"text": [["Four"]], "start": [[0]], "entity_id": ["T12"]}, "Age": {"text": [["elderly"]], "start": [[5]], "entity_id": ["T13"]}}, "Treatment": {"text": [["serotonergic antidepressants including selective serotonin reuptake inhibitor (SSRI) or mirtazapine and opioids"]], "start": [[41]], "entity_id": ["T11"], "Disorder": {"text": [["LTCF"]], "start": [[13]], "entity_id": ["T15"]}, "Drug": {"text": [["selective serotonin reuptake inhibitor"], ["mirtazapine"], ["opioids"]], "start": [[80], [129], [145]], "entity_id": ["T16", "T17", "T18"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[141]], "entity_id": ["T19"]}, "Drug": {"text": [["opioids"], ["mirtazapine"]], "start": [[145], [129]], "entity_id": ["T18", "T17"]}}]}}]}]}
{"id": "1772299_1", "context": "Detection of antineutrophil cytoplasmic antibody in a patient with L-tryptophan induced eosinophilia-myalgia syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[80]], "entity_id": ["T6"]}, "Subject": {"text": [["patient"]], "start": [[54]], "entity_id": ["T3"]}, "Effect": {"text": [["eosinophilia-myalgia syndrome"]], "start": [[88]], "entity_id": ["T5"]}, "Treatment": {"text": [["L-tryptophan"]], "start": [[67]], "entity_id": ["T7"], "Drug": {"text": [["L-tryptophan"]], "start": [[67]], "entity_id": ["T4"]}}}]}]}
{"id": "8942269_2", "context": "His impaired memory was found to be due to the atenolol he was on and he made a complete recovery on withdrawing the beta-blocker.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[36]], "entity_id": ["T3"]}, "Effect": {"text": [["impaired memory"]], "start": [[4]], "entity_id": ["T5"]}, "Subject": {"text": [["he"]], "start": [[56]], "entity_id": ["T6"], "Gender": {"text": [["he"]], "start": [[56]], "entity_id": ["T7"]}}, "Treatment": {"text": [["atenolol"]], "start": [[47]], "entity_id": ["T4"], "Drug": {"text": [["atenolol"]], "start": [[47]], "entity_id": ["T8"]}}}]}]}
{"id": "15388215_1", "context": "Tiagabine overdose causes an unusual array of neurological symptoms, many similar to reported adverse effects during therapeutic use.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["causes"]], "start": [[19]], "entity_id": ["T3"]}, "Treatment": {"text": [["Tiagabine overdose"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Tiagabine"]], "start": [[0]], "entity_id": ["T6"]}, "Dosage": {"text": [["overdose"]], "start": [[10]], "entity_id": ["T7"]}}, "Effect": {"text": [["an unusual array of neurological symptoms"]], "start": [[26]], "entity_id": ["T5"]}}]}]}
{"id": "8496127_2", "context": "This paper reports on a 6.9-year-old autistic male who developed repeated episodes of acute dystonic reactions associated with pimozide administration at the doses of 0.096 mg/kg/day and 0.032 mg/kg/day and 32 hours following pimozide withdrawal, as well as during subsequent thioridazine administration.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[111]], "entity_id": ["T7"]}, "Subject": {"text": [["6.9-year-old autistic male"]], "start": [[24]], "entity_id": ["T5"], "Age": {"text": [["6.9-year-old"]], "start": [[24]], "entity_id": ["T9"]}, "Disorder": {"text": [["autistic"]], "start": [[37]], "entity_id": ["T10"]}, "Gender": {"text": [["male"]], "start": [[46]], "entity_id": ["T11"]}}, "Effect": {"text": [["repeated episodes of acute dystonic reactions"]], "start": [[65]], "entity_id": ["T6"]}, "Treatment": {"text": [["pimozide administration at the doses of 0.096 mg/kg/day and 0.032 mg/kg/day and 32 hours following pimozide withdrawal, as well as during subsequent thioridazine administration"]], "start": [[127]], "entity_id": ["T8"], "Drug": {"text": [["pimozide"], ["pimozide"], ["thioridazine"]], "start": [[127], [226], [276]], "entity_id": ["T12", "T17", "T18"]}, "Dosage": {"text": [["0.096 mg/kg"], ["0.032 mg/kg"]], "start": [[167], [187]], "entity_id": ["T13", "T15"]}, "Freq": {"text": [["day"], ["day"]], "start": [[179], [199]], "entity_id": ["T14", "T16"]}}}]}]}
{"id": "9169264_1", "context": "Cephalexin rash in infectious mononucleosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[16]], "entity_id": ["T4"]}, "Effect": {"text": [["Cephalexin rash"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["Cephalexin"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Cephalexin"]], "start": [[0]], "entity_id": ["T6"]}, "Disorder": {"text": [["infectious mononucleosis"]], "start": [[19]], "entity_id": ["T8"]}}}]}]}
{"id": "19122478_6", "context": "He developed recurrent skin rash, fever, hypereosinophilia, and acute renal failure after rechallenge with chlorambucil.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[3]], "entity_id": ["T8"]}, "Effect": {"text": [["recurrent skin rash, fever, hypereosinophilia, and acute renal failure"]], "start": [[13]], "entity_id": ["T9"]}, "Treatment": {"text": [["rechallenge with chlorambucil"]], "start": [[90]], "entity_id": ["T10"], "Drug": {"text": [["chlorambucil"]], "start": [[107]], "entity_id": ["T11"]}}}]}]}
{"id": "464813_1", "context": "Lower extremity arterial insufficiency after long-term methysergide maleate therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[39]], "entity_id": ["T5"]}, "Effect": {"text": [["Lower extremity arterial insufficiency"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["long-term methysergide maleate therapy"]], "start": [[45]], "entity_id": ["T4"], "Drug": {"text": [["methysergide maleate"]], "start": [[55]], "entity_id": ["T6"]}, "Duration": {"text": [["long-term"]], "start": [[45]], "entity_id": ["T7"]}}}]}]}
{"id": "11788010_3", "context": "Hepatolithiasis (intrahepatic stone) during octreotide therapy for acromegaly: a case report.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[37]], "entity_id": ["T6"]}, "Effect": {"text": [["Hepatolithiasis (intrahepatic stone)"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["octreotide"]], "start": [[44]], "entity_id": ["T4"], "Drug": {"text": [["octreotide"]], "start": [[44]], "entity_id": ["T5"]}, "Disorder": {"text": [["acromegaly"]], "start": [[67]], "entity_id": ["T7"]}}}]}]}
{"id": "16527771_1", "context": "Acute unilateral total visual loss after retrogasserian phenol injection for the treatment of trigeminal neuralgia: a case report.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[35]], "entity_id": ["T4"]}, "Effect": {"text": [["Acute unilateral total visual loss"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["retrogasserian phenol injection"]], "start": [[41]], "entity_id": ["T5"], "Route": {"text": [["injection"]], "start": [[63]], "entity_id": ["T7"]}, "Drug": {"text": [["retrogasserian phenol"]], "start": [[41]], "entity_id": ["T8"]}, "Disorder": {"text": [["trigeminal neuralgia"]], "start": [[94]], "entity_id": ["T9"]}}}]}]}
{"id": "19995222_4", "context": "OBJECTIVE: Clozapine causes few extrapyramidal symptoms and is recommended as a treatment drug for severe tardive dyskinesia (TD).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["causes"]], "start": [[21]], "entity_id": ["T3"]}, "Treatment": {"text": [["Clozapine"]], "start": [[11]], "entity_id": ["T4"], "Drug": {"text": [["Clozapine"]], "start": [[11]], "entity_id": ["T6"]}}, "Effect": {"text": [["few extrapyramidal symptoms"]], "start": [[28]], "entity_id": ["T5"]}}]}]}
{"id": "22791547_1", "context": "Methylphenidate-induced acute orofacial and extremity dyskinesia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[16]], "entity_id": ["T5"]}, "Treatment": {"text": [["Methylphenidate"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Methylphenidate"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["acute orofacial and extremity dyskinesia"]], "start": [[24]], "entity_id": ["T6"]}}]}]}
{"id": "7946029_1", "context": "Basilar invagination and mid-line skeletal abnormalities due to in utero exposure to phenytoin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[57]], "entity_id": ["T6"]}, "Effect": {"text": [["Basilar invagination and mid-line skeletal abnormalities"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["utero exposure to phenytoin"]], "start": [[67]], "entity_id": ["T7"], "Drug": {"text": [["phenytoin"]], "start": [[85]], "entity_id": ["T8"]}}}]}]}
{"id": "18682542_2", "context": "DISCUSSION: To our knowledge, this is the first case report illustrating neuralgic amyotrophy triggered by exposure to the antibiotics vancomycin, tobramycin, and piperacillin/tazobactam.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["triggered"]], "start": [[94]], "entity_id": ["T7"]}, "Effect": {"text": [["neuralgic amyotrophy"]], "start": [[73]], "entity_id": ["T6"]}, "Treatment": {"text": [["antibiotics vancomycin, tobramycin, and piperacillin/tazobactam"]], "start": [[123]], "entity_id": ["T8"], "Drug": {"text": [["vancomycin"], ["tobramycin"], ["piperacillin"], ["tazobactam"]], "start": [[135], [147], [163], [176]], "entity_id": ["T9", "T10", "T11", "T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[159]], "entity_id": ["T13"]}, "Drug": {"text": [["vancomycin"], ["tobramycin"], ["piperacillin"], ["tazobactam"]], "start": [[135], [147], [163], [176]], "entity_id": ["T9", "T10", "T11", "T12"]}}]}}]}]}
{"id": "9840249_1", "context": "Alveolar-interstitial pneumopathy after gold-salts compounds administration, requiring mechanical ventilation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[34]], "entity_id": ["T3"]}, "Effect": {"text": [["Alveolar-interstitial pneumopathy"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["gold-salts compounds administration"]], "start": [[40]], "entity_id": ["T5"], "Drug": {"text": [["gold-salts compounds"]], "start": [[40]], "entity_id": ["T6"]}}}]}]}
{"id": "15373932_10", "context": "This study revealed that ketoconazole affected the disposition of rosiglitazone in humans, probably by the inhibition of CYP2C8 and CYP2C9, leading to increasing rosiglitazone concentrations that could increase the efficacy of rosiglitazone or its adverse events.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["leading to"]], "start": [[140]], "entity_id": ["T11"]}, "Effect": {"text": [["increasing rosiglitazone concentrations that could increase the efficacy of rosiglitazone or its adverse events"]], "start": [[151]], "entity_id": ["T10"]}, "Treatment": {"text": [["ketoconazole"]], "start": [[25]], "entity_id": ["T12"], "Drug": {"text": [["ketoconazole"]], "start": [[25]], "entity_id": ["T14"]}}, "Subject": {"text": [["humans"]], "start": [[83]], "entity_id": ["T13"]}}]}]}
{"id": "25538343_4", "context": "We report a case of duloxetine-induced hyponatremia in an elderly patient treated with thiazide diuretics.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[31]], "entity_id": ["T7"]}, "Treatment": {"text": [["duloxetine", "thiazide diuretics"]], "start": [[20, 87]], "entity_id": ["T8"], "Drug": {"text": [["duloxetine"], ["thiazide diuretics"]], "start": [[20], [87]], "entity_id": ["T12", "T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["treated with"]], "start": [[74]], "entity_id": ["T13"]}, "Drug": {"text": [["thiazide diuretics"], ["duloxetine"]], "start": [[87], [20]], "entity_id": ["T14", "T12"]}}]}, "Effect": {"text": [["hyponatremia"]], "start": [[39]], "entity_id": ["T9"]}, "Subject": {"text": [["an elderly patient"]], "start": [[55]], "entity_id": ["T10"], "Age": {"text": [["elderly"]], "start": [[58]], "entity_id": ["T11"]}}}]}]}
{"id": "3892171_1", "context": "Protamine-induced fatal anaphylaxis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[10]], "entity_id": ["T5"]}, "Treatment": {"text": [["Protamine"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Protamine"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["anaphylaxis"]], "start": [[24]], "entity_id": ["T6"]}, "Severity": {"text": [["fatal"]], "start": [[18]], "entity_id": ["T8"], "value": "High"}}]}]}
{"id": "9362107_3", "context": "We diagnosed this case as danazol induced thrombocytopenia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[34]], "entity_id": ["T4"]}, "Treatment": {"text": [["danazol"]], "start": [[26]], "entity_id": ["T3"], "Drug": {"text": [["danazol"]], "start": [[26]], "entity_id": ["T7"]}}, "Effect": {"text": [["thrombocytopenia"]], "start": [[42]], "entity_id": ["T5"]}, "Subject": {"text": [["this case"]], "start": [[13]], "entity_id": ["T6"]}}]}]}
{"id": "8530331_5", "context": "One patient required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment, but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treatment"]], "start": [[131]], "entity_id": ["T11"]}, "Subject": {"text": [["One patient"]], "start": [[0]], "entity_id": ["T8"], "Population": {"text": [["One"]], "start": [[0]], "entity_id": ["T12"]}}, "Effect": {"text": [["required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism"]], "start": [[12]], "entity_id": ["T9"]}, "Treatment": {"text": [["risperidone"]], "start": [[119]], "entity_id": ["T10"], "Drug": {"text": [["risperidone"]], "start": [[119]], "entity_id": ["T13"]}}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["after"]], "start": [[203]], "entity_id": ["T17"]}, "Subject": {"text": [["One patient"]], "start": [[0]], "entity_id": ["T8"], "Population": {"text": [["One"]], "start": [[0]], "entity_id": ["T12"]}}, "Effect": {"text": [["was able to return home and have the gastrostomy removed"]], "start": [[146]], "entity_id": ["T16"]}, "Treatment": {"text": [["switching from risperidone to clozapine"]], "start": [[209]], "entity_id": ["T18"], "Disorder": {"text": [["worsening parkinsonism"]], "start": [[89]], "entity_id": ["T21"]}, "Drug": {"text": [["risperidone"], ["clozapine"]], "start": [[224], [239]], "entity_id": ["T19", "T20"]}}}]}]}
{"id": "9776099_1", "context": "NMS is a drug-related response to various medications, such as Haloperidol, which the patient was receiving.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["response"]], "start": [[22]], "entity_id": ["T6"]}, "Treatment": {"text": [["Haloperidol"]], "start": [[63]], "entity_id": ["T3"], "Drug": {"text": [["Haloperidol"]], "start": [[63]], "entity_id": ["T7"]}}, "Subject": {"text": [["patient"]], "start": [[86]], "entity_id": ["T4"]}, "Effect": {"text": [["NMS"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "15770343_3", "context": "In addition, ethambutol rarely causes visual loss during the early period or when given at lower doses.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["causes"]], "start": [[31]], "entity_id": ["T4"]}, "Treatment": {"text": [["ethambutol", "during the early period or when given at lower doses"]], "start": [[13, 50]], "entity_id": ["T3"], "Drug": {"text": [["ethambutol"]], "start": [[13]], "entity_id": ["T7"]}, "Time_elapsed": {"text": [["early period"]], "start": [[61]], "entity_id": ["T8"]}, "Dosage": {"text": [["lower doses"]], "start": [[91]], "entity_id": ["T9"]}}, "Effect": {"text": [["visual loss"]], "start": [[38]], "entity_id": ["T5"]}}]}]}
{"id": "11215836_4", "context": "The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["stopped"]], "start": [[28]], "entity_id": ["T19"]}, "Effect": {"text": [["behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused"]], "start": [[98]], "entity_id": ["T20"]}, "Treatment": {"text": [["day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d"]], "start": [[4]], "entity_id": ["T21"], "Drug": {"text": [["clozapine"], ["clomipramine"]], "start": [[14], [66]], "entity_id": ["T24", "T25"]}, "Dosage": {"text": [["150 mg/d"]], "start": [[79]], "entity_id": ["T26"]}}, "Subject": {"text": [["he"]], "start": [[89]], "entity_id": ["T22"], "Gender": {"text": [["he"]], "start": [[89]], "entity_id": ["T23"]}}}]}]}
{"id": "9494448_4", "context": "CONCLUSIONS: Hypersensitivity reactions to cyclosporine are due to Cremophor EL.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[60]], "entity_id": ["T6"]}, "Effect": {"text": [["Hypersensitivity reactions to cyclosporine"]], "start": [[13]], "entity_id": ["T4"]}, "Treatment": {"text": [["Cremophor EL"]], "start": [[67]], "entity_id": ["T5"], "Drug": {"text": [["Cremophor EL"]], "start": [[67]], "entity_id": ["T7"]}}}]}]}
{"id": "10656221_2", "context": "There are few reports in the literature related to sulfonylurea-induced hepatotoxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[64]], "entity_id": ["T5"]}, "Treatment": {"text": [["sulfonylurea"]], "start": [[51]], "entity_id": ["T4"], "Drug": {"text": [["sulfonylurea"]], "start": [[51]], "entity_id": ["T7"]}}, "Effect": {"text": [["hepatotoxicity"]], "start": [[72]], "entity_id": ["T6"]}}]}]}
{"id": "17406804_4", "context": "Radiation recall pneumonitis induced by gemcitabine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[29]], "entity_id": ["T4"]}, "Effect": {"text": [["Radiation recall pneumonitis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["gemcitabine"]], "start": [[40]], "entity_id": ["T5"], "Drug": {"text": [["gemcitabine"]], "start": [[40]], "entity_id": ["T6"]}}}]}]}
{"id": "8266863_1", "context": "Four days after the initial injection of 3.6 mg of goserelin acetate, severe dyspnea developed due to worsening pleuritis carcinomatosa, which was considered as a flare-up.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[85]], "entity_id": ["T9"]}, "Treatment": {"text": [["injection of 3.6 mg of goserelin acetate"]], "start": [[28]], "entity_id": ["T7"], "Route": {"text": [["injection"]], "start": [[28]], "entity_id": ["T13"]}, "Dosage": {"text": [["3.6 mg"]], "start": [[41]], "entity_id": ["T14"]}, "Drug": {"text": [["goserelin acetate"]], "start": [[51]], "entity_id": ["T15"]}}, "Effect": {"text": [["severe dyspnea"], ["worsening pleuritis carcinomatosa"]], "start": [[70], [102]], "entity_id": ["T8", "T10"]}, "Severity": {"text": [["severe"]], "start": [[70]], "entity_id": ["T11"], "value": "Medium"}, "Speculated": {"text": [["considered"]], "start": [[147]], "entity_id": ["T12"], "value": true}}]}]}
{"id": "11675845_4", "context": "Ropinirole was added to his current therapy for Parkinson disease, with a corresponding decrease in the dose of levodopa/carbidopa to allow levodopa sparing.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["added"]], "start": [[15]], "entity_id": ["T8"]}, "Treatment": {"text": [["Ropinirole", "a corresponding decrease in the dose of levodopa/carbidopa to allow levodopa sparing"]], "start": [[0, 72]], "entity_id": ["T7"], "Drug": {"text": [["Ropinirole"], ["levodopa"], ["carbidopa"]], "start": [[0], [112], [121]], "entity_id": ["T10", "T12", "T13"]}, "Disorder": {"text": [["Parkinson disease"]], "start": [[48]], "entity_id": ["T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["with"]], "start": [[67]], "entity_id": ["T14"]}, "Drug": {"text": [["Ropinirole"], ["levodopa"], ["carbidopa"]], "start": [[0], [112], [121]], "entity_id": ["T10", "T12", "T13"]}}]}}]}]}
{"id": "11703329_2", "context": "Recognizing early signs of HMSN, such as areflexia and pes cavus deformity, can prevent severe neurotoxicity of polychemotherapy by avoiding vincristine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["by"]], "start": [[129]], "entity_id": ["T6"]}, "Effect": {"text": [["severe neurotoxicity of polychemotherapy"]], "start": [[88]], "entity_id": ["T4"]}, "Treatment": {"text": [["vincristine"]], "start": [[141]], "entity_id": ["T5"], "Disorder": {"text": [["HMSN"]], "start": [[27]], "entity_id": ["T3"]}, "Drug": {"text": [["vincristine"]], "start": [[141]], "entity_id": ["T8"]}}, "Severity": {"text": [["severe"]], "start": [[88]], "entity_id": ["T7"], "value": "Medium"}}]}]}
{"id": "17285101_3", "context": "This is the first report of pulmonary hypertension in an adult patient during lithium therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[71]], "entity_id": ["T4"]}, "Subject": {"text": [["an adult patient"]], "start": [[54]], "entity_id": ["T3"], "Age": {"text": [["adult"]], "start": [[57]], "entity_id": ["T7"]}}, "Treatment": {"text": [["lithium therapy."]], "start": [[78]], "entity_id": ["T5"], "Drug": {"text": [["lithium"]], "start": [[78]], "entity_id": ["T8"]}}, "Effect": {"text": [["pulmonary hypertension"]], "start": [[28]], "entity_id": ["T6"]}}]}]}
{"id": "15307435_2", "context": "In this report, we present a case of hypoglycaemic coma associated with SP, an adverse reaction that is likely to be underreported and expected to occur with greater frequency as the use of SP increases.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[56]], "entity_id": ["T6"]}, "Effect": {"text": [["hypoglycaemic coma", "an adverse reaction that is likely to be underreported and expected to occur with greater frequency as the use of SP increases"]], "start": [[37, 76]], "entity_id": ["T4"]}, "Treatment": {"text": [["SP"]], "start": [[72]], "entity_id": ["T5"], "Drug": {"text": [["SP"]], "start": [[72]], "entity_id": ["T7"]}}}]}]}
{"id": "7439122_2", "context": "However, we have recently had four cases of clofibrate-induced myopathy in patients with diabetes insipidus due to hypothalamic lesions.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[55]], "entity_id": ["T5"]}, "Subject": {"text": [["four cases", "diabetes insipidus due to hypothalamic lesions"]], "start": [[30, 89]], "entity_id": ["T3"], "Population": {"text": [["four"]], "start": [[30]], "entity_id": ["T8"]}}, "Treatment": {"text": [["clofibrate"]], "start": [[44]], "entity_id": ["T4"], "Drug": {"text": [["clofibrate"]], "start": [[44]], "entity_id": ["T9"]}, "Disorder": {"text": [["diabetes insipidus"]], "start": [[89]], "entity_id": ["T10"]}}, "Effect": {"text": [["myopathy"]], "start": [[63]], "entity_id": ["T6"]}}]}]}
{"id": "9052919_2", "context": "One patient had MRI T2 abnormalities compatible with cyclosporin neurotoxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["had"]], "start": [[12]], "entity_id": ["T8"]}, "Subject": {"text": [["One patient"]], "start": [[0]], "entity_id": ["T5"], "Population": {"text": [["One"]], "start": [[0]], "entity_id": ["T9"]}}, "Treatment": {"text": [["cyclosporin"]], "start": [[53]], "entity_id": ["T6"], "Drug": {"text": [["cyclosporin"]], "start": [[53]], "entity_id": ["T10"]}}, "Effect": {"text": [["neurotoxicity", "MRI T2 abnormalities"]], "start": [[65, 16]], "entity_id": ["T7"]}}]}]}
{"id": "21751666_1", "context": "Post-exposure prophylaxis for H1N1 with oseltamivir in renal allograft recipient--safe and effective without any immunosuppresive drug interaction.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["Post-exposure prophylaxis"]], "start": [[0]], "entity_id": ["T13"]}, "Treatment": {"text": [["oseltamivir"]], "start": [[40]], "entity_id": ["T10"], "Disorder": {"text": [["H1N1"]], "start": [[30]], "entity_id": ["T9"]}, "Drug": {"text": [["oseltamivir"]], "start": [[40]], "entity_id": ["T11"]}}, "Subject": {"text": [["renal allograft recipient"]], "start": [[55]], "entity_id": ["T12"], "Disorder": {"text": [["renal allograft"]], "start": [[55]], "entity_id": ["T14"]}}, "Effect": {"text": [["safe and effective without any immunosuppresive drug interaction"]], "start": [[82]], "entity_id": ["T1"]}}]}]}
{"id": "8140860_3", "context": "Seven days after the introduction of amoxycillin (500 mg/8 h) for a probable respiratory infection, the patient developed spontaneous bruising, with an INR of 7.1.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[112]], "entity_id": ["T9"]}, "Treatment": {"text": [["Seven days after the introduction of amoxycillin (500 mg/8 h)"]], "start": [[0]], "entity_id": ["T7"], "Disorder": {"text": [["a probable respiratory infection"]], "start": [[66]], "entity_id": ["T6"]}, "Time_elapsed": {"text": [["Seven days after"]], "start": [[0]], "entity_id": ["T11"]}, "Drug": {"text": [["amoxycillin"]], "start": [[37]], "entity_id": ["T12"]}, "Dosage": {"text": [["500 mg/8 h"]], "start": [[50]], "entity_id": ["T13"]}}, "Subject": {"text": [["the patient"]], "start": [[100]], "entity_id": ["T8"]}, "Effect": {"text": [["spontaneous bruising, with an INR of 7.1"]], "start": [[122]], "entity_id": ["T10"]}}]}]}
{"id": "15383642_2", "context": "To report a case in which significant hypotension occurred after initiation of tizanidine in a patient using the antihypertensive agent lisinopril.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[59]], "entity_id": ["T7"]}, "Effect": {"text": [["hypotension"]], "start": [[38]], "entity_id": ["T8"]}, "Treatment": {"text": [["initiation of tizanidine", "lisinopril"]], "start": [[65, 136]], "entity_id": ["T10"], "Drug": {"text": [["lisinopril"], ["tizanidine"]], "start": [[136], [79]], "entity_id": ["T12", "T13"]}}, "Subject": {"text": [["a patient"], ["a case"]], "start": [[93], [10]], "entity_id": ["T11", "T14"]}}]}]}
{"id": "23624139_3", "context": "We herein describe a case of severe hyponatremia complicated by seizure and coma due to the intake of non-steroidal anti-inflammatory drugs (NSAIDs) in a patient on DDAVP replacement therapy for central diabetes insipidus (DI).", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due to"]], "start": [[81]], "entity_id": ["T16"]}, "Effect": {"text": [["severe hyponatremia"], ["seizure and coma"]], "start": [[29], [64]], "entity_id": ["T12", "T17"]}, "Treatment": {"text": [["intake of non-steroidal anti-inflammatory drugs (NSAIDs)", "on DDAVP replacement therapy"]], "start": [[92, 162]], "entity_id": ["T15"], "Drug": {"text": [["non-steroidal anti-inflammatory drugs"], ["DDAVP"]], "start": [[102], [165]], "entity_id": ["T19", "T20"]}, "Disorder": {"text": [["central diabetes insipidus"]], "start": [[195]], "entity_id": ["T22"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["on"]], "start": [[162]], "entity_id": ["T21"]}, "Drug": {"text": [["DDAVP"], ["non-steroidal anti-inflammatory drugs"]], "start": [[165], [102]], "entity_id": ["T20", "T19"]}}]}, "Subject": {"text": [["a patient", "for central diabetes insipidus (DI)"]], "start": [[152, 191]], "entity_id": ["T13"]}, "Severity": {"text": [["severe"]], "start": [[29]], "entity_id": ["T18"], "value": "Medium"}}]}]}
{"id": "11213850_6", "context": "Each subject was treated according to the following sequence: baseline; phase 1 (days 1-6): cisapride 10 mg 4 times/day; washout (days 7-13); phase 2 (days 14-44): fluoxetine 20 mg/day; and phase 3 (days 45-52): cisapride 10 mg 4 times/day (days 45-51) plus fluoxetine 20 mg/day (days 45-52).", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[17]], "entity_id": ["T9"]}, "Subject": {"text": [["Each subject"]], "start": [[0]], "entity_id": ["T8"]}, "Treatment": {"text": [["baseline; phase 1 (days 1-6): cisapride 10 mg 4 times/day; washout (days 7-13); phase 2 (days 14-44): fluoxetine 20 mg/day; and phase 3 (days 45-52): cisapride 10 mg 4 times/day (days 45-51) plus fluoxetine 20 mg/day (days 45-52)"]], "start": [[62]], "entity_id": ["T10"], "Drug": {"text": [["cisapride"], ["fluoxetine"], ["cisapride"], ["fluoxetine"]], "start": [[92], [164], [212], [258]], "entity_id": ["T11", "T14", "T16", "T19"]}, "Dosage": {"text": [["10 mg"], ["20 mg/day"], ["10 mg"], ["20 mg/day"]], "start": [[102], [175], [222], [269]], "entity_id": ["T12", "T15", "T17", "T20"]}, "Freq": {"text": [["4 times/day"], ["4 times/day"]], "start": [[108], [228]], "entity_id": ["T13", "T18"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["plus"]], "start": [[253]], "entity_id": ["T21"]}, "Drug": {"text": [["cisapride"], ["fluoxetine"]], "start": [[212], [258]], "entity_id": ["T16", "T19"]}}]}}]}]}
{"id": "412488_7", "context": "These findings are consistent with an immune-complex form of glomerulopathy in which gold is neither the antigen nor a hapten in the glomerular deposits, and they suggest the hypothesis that antibodies to tubular epithelial antigens induced by gold therapy may be a causative factor in the renal disease associated with gold therapy in rheumatoid arthritis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[304]], "entity_id": ["T12"]}, "Treatment": {"text": [["gold therapy in rheumatoid arthritis"]], "start": [[320]], "entity_id": ["T13"], "Drug": {"text": [["gold"]], "start": [[320]], "entity_id": ["T17"]}, "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[336]], "entity_id": ["T14"]}}, "Effect": {"text": [["renal disease"]], "start": [[290]], "entity_id": ["T18"]}, "Speculated": {"text": [["may be"]], "start": [[257]], "entity_id": ["T15"], "value": true}}]}]}
{"id": "7304798_1", "context": "Induction of rapid mood cycling during L-dopa treatment in a bipolar patient.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[32]], "entity_id": ["T7"]}, "Effect": {"text": [["rapid mood cycling"]], "start": [[13]], "entity_id": ["T8"]}, "Treatment": {"text": [["L-dopa"]], "start": [[39]], "entity_id": ["T9"], "Drug": {"text": [["L-dopa"]], "start": [[39]], "entity_id": ["T12"]}, "Disorder": {"text": [["bipolar"]], "start": [[61]], "entity_id": ["T13"]}}, "Subject": {"text": [["a bipolar patient"]], "start": [[59]], "entity_id": ["T10"]}}]}]}
{"id": "11144696_2", "context": "To report a patient having a first-time seizure after receiving venlafaxine and trimipramine for depression.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["receiving"]], "start": [[54]], "entity_id": ["T8"]}, "Treatment": {"text": [["venlafaxine and trimipramine"]], "start": [[64]], "entity_id": ["T9"], "Drug": {"text": [["venlafaxine"], ["trimipramine"]], "start": [[64], [80]], "entity_id": ["T12", "T13"]}, "Disorder": {"text": [["depression"]], "start": [[97]], "entity_id": ["T15"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[76]], "entity_id": ["T14"]}, "Drug": {"text": [["venlafaxine"], ["trimipramine"]], "start": [[64], [80]], "entity_id": ["T12", "T13"]}}]}, "Effect": {"text": [["seizure"]], "start": [[40]], "entity_id": ["T10"]}, "Subject": {"text": [["patient"]], "start": [[12]], "entity_id": ["T11"]}}]}]}
{"id": "282937_3", "context": "Paraplegia following prophylactic intrathecal cytosine arabinoside (Ara-C) is described in a patient with acute myelogenous leukemia in remission who received doses of 100 mg/m2/d for 5 consecutive days.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[11]], "entity_id": ["T5"]}, "Effect": {"text": [["Paraplegia"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["prophylactic intrathecal cytosine arabinoside (Ara-C)", "doses of 100 mg/m2/d for 5 consecutive days"]], "start": [[21, 159]], "entity_id": ["T6"], "Drug": {"text": [["cytosine arabinoside"]], "start": [[46]], "entity_id": ["T9"]}, "Route": {"text": [["intrathecal"]], "start": [[34]], "entity_id": ["T10"]}, "Disorder": {"text": [["acute myelogenous leukemia in remission"]], "start": [[106]], "entity_id": ["T11"]}, "Dosage": {"text": [["100 mg/m2/d"]], "start": [[168]], "entity_id": ["T12"]}, "Duration": {"text": [["5 consecutive days"]], "start": [[184]], "entity_id": ["T13"]}}, "Subject": {"text": [["a patient with acute myelogenous leukemia in remission"]], "start": [[91]], "entity_id": ["T7"]}}]}]}
{"id": "19402273_2", "context": "Isoniazid induced gynaecomastia: a case report.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[10]], "entity_id": ["T3"]}, "Treatment": {"text": [["Isoniazid"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Isoniazid"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["gynaecomastia"]], "start": [[18]], "entity_id": ["T5"]}}]}]}
{"id": "17671884_7", "context": "One previous study of four transplant patients whose immediate post-transplantation immunosuppression utilized corticosteroids, cyclosporine, MMF, and anti-T-lymphocyte globulin noted anemia in 13% of them.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["noted"]], "start": [[178]], "entity_id": ["T10"]}, "Effect": {"text": [["anemia"]], "start": [[184]], "entity_id": ["T11"]}, "Subject": {"text": [["four transplant patients"]], "start": [[22]], "entity_id": ["T12"], "Population": {"text": [["four"]], "start": [[22]], "entity_id": ["T14"]}, "Disorder": {"text": [["transplant"]], "start": [[27]], "entity_id": ["T15"]}}, "Treatment": {"text": [["immediate post-transplantation immunosuppression utilized corticosteroids, cyclosporine, MMF, and anti-T-lymphocyte globulin"]], "start": [[53]], "entity_id": ["T13"], "Drug": {"text": [["corticosteroids"], ["cyclosporine"], ["MMF"], ["anti-T-lymphocyte globulin"]], "start": [[111], [128], [142], [151]], "entity_id": ["T16", "T17", "T18", "T19"]}, "Disorder": {"text": [["post-transplantation immunosuppression"]], "start": [[63]], "entity_id": ["T1"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[147]], "entity_id": ["T20"]}, "Drug": {"text": [["corticosteroids"], ["cyclosporine"], ["MMF"], ["anti-T-lymphocyte globulin"]], "start": [[111], [128], [142], [151]], "entity_id": ["T16", "T17", "T18", "T19"]}}]}}]}]}
{"id": "1348483_2", "context": "Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[24]], "entity_id": ["T6"]}, "Treatment": {"text": [["cabergoline"]], "start": [[101]], "entity_id": ["T3"], "Disorder": {"text": [["Parkinson's disease"]], "start": [[44]], "entity_id": ["T4"]}, "Drug": {"text": [["cabergoline"]], "start": [[101]], "entity_id": ["T7"]}}, "Effect": {"text": [["Pleuropulmonary changes"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "3982906_2", "context": "However, each infant demonstrated hemodynamic decompensation shortly after verapamil administration and required cardiopulmonary resuscitation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["demonstrated"]], "start": [[21]], "entity_id": ["T6"]}, "Subject": {"text": [["each infant"]], "start": [[9]], "entity_id": ["T3"], "Age": {"text": [["infant"]], "start": [[14]], "entity_id": ["T7"]}}, "Effect": {"text": [["hemodynamic decompensation"]], "start": [[34]], "entity_id": ["T4"]}, "Treatment": {"text": [["verapamil"]], "start": [[75]], "entity_id": ["T5"], "Drug": {"text": [["verapamil"]], "start": [[75]], "entity_id": ["T8"]}}}]}]}
{"id": "11160777_11", "context": "Long-term studies are needed to determine whether the insulin-sensitizing effects of the glitazones can prevent or delay premature atherosclerotic cardiovascular disease, morbidity, and death.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["prevent"]], "start": [[104]], "entity_id": ["T8"]}, "Treatment": {"text": [["glitazones"]], "start": [[89]], "entity_id": ["T7"], "Disorder": {"text": [["premature atherosclerotic cardiovascular disease, morbidity, and death"]], "start": [[121]], "entity_id": ["T9"]}, "Drug": {"text": [["glitazones"]], "start": [[89]], "entity_id": ["T10"]}}}]}]}
{"id": "7663030_1", "context": "Probable propafenone-induced transient global amnesia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[21]], "entity_id": ["T6"]}, "Treatment": {"text": [["propafenone"]], "start": [[9]], "entity_id": ["T5"], "Drug": {"text": [["propafenone"]], "start": [[9]], "entity_id": ["T8"]}}, "Effect": {"text": [["transient global amnesia"]], "start": [[29]], "entity_id": ["T7"]}}]}]}
{"id": "16119501_3", "context": "The patient continued to have fever and autonomic instability without evidence of infection which entirely resolved within 24 hours of reinstitution of full preadmission dosing of oral baclofen.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["have"]], "start": [[25]], "entity_id": ["T7"]}, "Treatment": {"text": [["24 hours of reinstitution of full preadmission dosing of oral baclofen"]], "start": [[123]], "entity_id": ["T5"], "Route": {"text": [["oral"]], "start": [[180]], "entity_id": ["T8"]}, "Drug": {"text": [["baclofen"]], "start": [[185]], "entity_id": ["T10"]}, "Time_elapsed": {"text": [["24 hours"]], "start": [[123]], "entity_id": ["T9"]}}, "Effect": {"text": [["fever and autonomic instability without evidence of infection which entirely resolved"]], "start": [[30]], "entity_id": ["T6"]}}]}]}
{"id": "16629074_2", "context": "Traumatic late flap dehiscence and Enterobacter keratitis following LASIK.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[58]], "entity_id": ["T6"]}, "Treatment": {"text": [["LASIK"]], "start": [[68]], "entity_id": ["T5"], "Drug": {"text": [["LASIK"]], "start": [[68]], "entity_id": ["T8"]}}, "Effect": {"text": [["Traumatic late flap dehiscence and Enterobacter keratitis"]], "start": [[0]], "entity_id": ["T7"]}}]}]}
{"id": "2305654_2", "context": "We report on a patient with subarachnoid haemorrhage who developed an acute life-threatening pseudo-obstruction of the colon, a variant of adynamic ileus, while being treated with intravenous nimodipine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[57]], "entity_id": ["T7"]}, "Subject": {"text": [["patient with subarachnoid haemorrhage"]], "start": [[15]], "entity_id": ["T5"]}, "Effect": {"text": [["pseudo-obstruction of the colon"]], "start": [[93]], "entity_id": ["T8"]}, "Treatment": {"text": [["intravenous nimodipine"]], "start": [[180]], "entity_id": ["T9"], "Disorder": {"text": [["subarachnoid haemorrhage"]], "start": [[28]], "entity_id": ["T10"]}, "Drug": {"text": [["nimodipine"]], "start": [[192]], "entity_id": ["T12"]}, "Route": {"text": [["intravenous"]], "start": [[180]], "entity_id": ["T13"]}}, "Severity": {"text": [["acute life-threatening"]], "start": [[70]], "entity_id": ["T11"], "value": "High"}}]}]}
{"id": "12111771_1", "context": "A 73-year-old woman presented with fever and cough 2 weeks after completing the third cycle of fludarabine for chronic lymphocytic leukemia (CLL).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["presented"]], "start": [[20]], "entity_id": ["T9"]}, "Subject": {"text": [["A 73-year-old woman"]], "start": [[0]], "entity_id": ["T5"], "Age": {"text": [["73-year-old"]], "start": [[2]], "entity_id": ["T10"]}, "Gender": {"text": [["woman"]], "start": [[14]], "entity_id": ["T11"]}}, "Effect": {"text": [["fever and cough"]], "start": [[35]], "entity_id": ["T6"]}, "Treatment": {"text": [["2 weeks after completing the third cycle of fludarabine for chronic lymphocytic leukemia (CLL)"]], "start": [[51]], "entity_id": ["T7"], "Disorder": {"text": [["chronic lymphocytic leukemia (CLL)"]], "start": [[111]], "entity_id": ["T8"]}, "Time_elapsed": {"text": [["2 weeks"]], "start": [[51]], "entity_id": ["T12"]}, "Drug": {"text": [["fludarabine"]], "start": [[95]], "entity_id": ["T13"]}}}]}]}
{"id": "15729090_2", "context": "We report a case of myoclonus induced by quetiapine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[30]], "entity_id": ["T5"]}, "Effect": {"text": [["myoclonus"]], "start": [[20]], "entity_id": ["T4"]}, "Treatment": {"text": [["quetiapine"]], "start": [[41]], "entity_id": ["T6"], "Drug": {"text": [["quetiapine"]], "start": [[41]], "entity_id": ["T7"]}}, "Subject": {"text": [["a case"]], "start": [[10]], "entity_id": ["T8"]}}]}]}
{"id": "1393348_1", "context": "A 21-year-old woman suffering from bipolar affective disorder developed systemic lupus erythematosus (SLE) with characteristic laboratory findings, 18 months after starting carbamazepine maintenance treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[62]], "entity_id": ["T6"]}, "Subject": {"text": [["A 21-year-old woman suffering from bipolar affective disorder"]], "start": [[0]], "entity_id": ["T5"], "Age": {"text": [["21-year-old"]], "start": [[2]], "entity_id": ["T9"]}, "Gender": {"text": [["woman"]], "start": [[14]], "entity_id": ["T10"]}}, "Effect": {"text": [["systemic lupus erythematosus (SLE)"]], "start": [[72]], "entity_id": ["T7"]}, "Treatment": {"text": [["18 months after starting carbamazepine maintenance treatment"]], "start": [[148]], "entity_id": ["T8"], "Disorder": {"text": [["bipolar affective disorder"]], "start": [[35]], "entity_id": ["T11"]}, "Time_elapsed": {"text": [["18 months"]], "start": [[148]], "entity_id": ["T12"]}, "Drug": {"text": [["carbamazepine"]], "start": [[173]], "entity_id": ["T13"]}}}]}]}
{"id": "7973922_2", "context": "Acyclovir produces neurologic symptoms that resemble extension of viral infection into the central nervous system.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["produces"]], "start": [[10]], "entity_id": ["T4"]}, "Treatment": {"text": [["Acyclovir"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Acyclovir"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["neurologic symptoms"]], "start": [[19]], "entity_id": ["T5"]}}]}]}
{"id": "12086549_3", "context": "Subcutaneous IL-2 is safe and well tolerated, with a mortality rate <3%.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[46]], "entity_id": ["T5"]}, "Treatment": {"text": [["Subcutaneous IL-2"]], "start": [[0]], "entity_id": ["T3"], "Route": {"text": [["Subcutaneous"]], "start": [[0]], "entity_id": ["T6"]}, "Drug": {"text": [["IL-2"]], "start": [[13]], "entity_id": ["T7"]}}, "Effect": {"text": [["mortality rate <3%"]], "start": [[53]], "entity_id": ["T4"]}}]}]}
{"id": "19434733_3", "context": "Two patients with HLH developed etoposide-related secondary acute myeloid leukemia (sAML) following therapy for HLH.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[42]], "entity_id": ["T5"]}, "Subject": {"text": [["Two patients with HLH"]], "start": [[0]], "entity_id": ["T6"], "Population": {"text": [["Two"]], "start": [[0]], "entity_id": ["T10"]}}, "Treatment": {"text": [["etoposide"]], "start": [[32]], "entity_id": ["T7"], "Disorder": {"text": [["HLH"]], "start": [[18]], "entity_id": ["T11"]}, "Drug": {"text": [["etoposide"]], "start": [[32]], "entity_id": ["T12"]}}, "Effect": {"text": [["secondary acute myeloid leukemia (sAML)"]], "start": [[50]], "entity_id": ["T9"]}}]}]}
{"id": "2250853_2", "context": "We report a case of secondary glaucoma caused by epithelial downgrowth in which filtration surgery was performed with adjunctive use of subconjunctival 5-fluorouracil.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[39]], "entity_id": ["T4"]}, "Effect": {"text": [["secondary glaucoma", "epithelial downgrowth"]], "start": [[20, 49]], "entity_id": ["T3"]}, "Treatment": {"text": [["filtration surgery was performed with adjunctive use of subconjunctival 5-fluorouracil"]], "start": [[80]], "entity_id": ["T5"], "Route": {"text": [["subconjunctival"]], "start": [[136]], "entity_id": ["T6"]}, "Drug": {"text": [["5-fluorouracil"]], "start": [[152]], "entity_id": ["T7"]}}}]}]}
{"id": "17189581_1", "context": "Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[24]], "entity_id": ["T6"]}, "Treatment": {"text": [["concurrent linezolid and fluoxetine"]], "start": [[40]], "entity_id": ["T7"], "Drug": {"text": [["linezolid"], ["fluoxetine"]], "start": [[51], [65]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[61]], "entity_id": ["T11"]}, "Drug": {"text": [["linezolid"], ["fluoxetine"]], "start": [[51], [65]], "entity_id": ["T9", "T10"]}}]}, "Effect": {"text": [["serotonin syndrome"]], "start": [[5]], "entity_id": ["T8"]}, "Severity": {"text": [["Mild"]], "start": [[0]], "entity_id": ["T12"], "value": "Low"}}]}]}
{"id": "8530331_1", "context": "Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatment"]], "start": [[36]], "entity_id": ["T9"]}, "Treatment": {"text": [["Risperidone versus clozapine"]], "start": [[0]], "entity_id": ["T8"], "Drug": {"text": [["Risperidone"], ["clozapine"]], "start": [[0], [19]], "entity_id": ["T14", "T15"]}, "Disorder": {"text": [["psychosis"]], "start": [[49]], "entity_id": ["T1"]}}, "Subject": {"text": [["six patients with Parkinson's disease and other akinetic-rigid syndromes"]], "start": [[62]], "entity_id": ["T10"], "Population": {"text": [["six"]], "start": [[62]], "entity_id": ["T11"]}, "Disorder": {"text": [["Parkinson's disease"], ["akinetic-rigid syndromes"]], "start": [[80], [110]], "entity_id": ["T12", "T13"]}}}]}]}
{"id": "18691992_5", "context": "Hydroxyurea associated with concomitant occurrence of diffuse longitudinal melanonychia and multiple squamous cell carcinomas in an elderly subject.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[12]], "entity_id": ["T6"]}, "Treatment": {"text": [["Hydroxyurea"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["Hydroxyurea"]], "start": [[0]], "entity_id": ["T10"]}}, "Effect": {"text": [["concomitant occurrence of diffuse longitudinal melanonychia and multiple squamous cell carcinomas"]], "start": [[28]], "entity_id": ["T7"]}, "Subject": {"text": [["an elderly subject"]], "start": [[129]], "entity_id": ["T8"], "Age": {"text": [["elderly"]], "start": [[132]], "entity_id": ["T9"]}}}]}]}
{"id": "11889149_4", "context": "Women (aged < or = 75 yr; > or = 2 yr since their last menstrual period) received placebo, RLX 60 mg/d, ALN 10 mg/d, or RLX 60 mg/d and ALN 10 mg/d combined.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["received"]], "start": [[73]], "entity_id": ["T11"]}, "Subject": {"text": [["Women (aged < or = 75 yr; > or = 2 yr since their last menstrual period)"]], "start": [[0]], "entity_id": ["T9"], "Gender": {"text": [["Women"]], "start": [[0]], "entity_id": ["T12"]}, "Age": {"text": [["aged < or = 75 yr; > or = 2 yr"]], "start": [[7]], "entity_id": ["T13"]}}, "Treatment": {"text": [["RLX 60 mg/d, ALN 10 mg/d, or RLX 60 mg/d and ALN 10 mg/d combined"]], "start": [[91]], "entity_id": ["T10"], "Dosage": {"text": [["60 mg/d"], ["10 mg/d"], ["60 mg/d"], ["10 mg/d"]], "start": [[95], [108], [124], [140]], "entity_id": ["T14", "T15", "T19", "T21"]}, "Drug": {"text": [["RLX"], ["ALN"], ["RLX"], ["ALN"]], "start": [[91], [104], [120], [136]], "entity_id": ["T16", "T17", "T18", "T20"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combined"]], "start": [[148]], "entity_id": ["T22"]}, "Drug": {"text": [["ALN"], ["RLX"]], "start": [[136], [120]], "entity_id": ["T20", "T18"]}}]}}]}]}
{"id": "8301877_2", "context": "Myoclonus and seizures in a patient with parkinsonism: induction by levodopa and its confirmation on SEPs.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induction"]], "start": [[55]], "entity_id": ["T7"]}, "Effect": {"text": [["Myoclonus and seizures"]], "start": [[0]], "entity_id": ["T5"]}, "Subject": {"text": [["a patient with parkinsonism"]], "start": [[26]], "entity_id": ["T6"]}, "Treatment": {"text": [["levodopa"]], "start": [[68]], "entity_id": ["T8"], "Disorder": {"text": [["parkinsonism"]], "start": [[41]], "entity_id": ["T10"]}, "Drug": {"text": [["levodopa"]], "start": [[68]], "entity_id": ["T11"]}}}]}]}
{"id": "7663030_2", "context": "OBJECTIVE: To describe a probable case of transient global amnesia caused by propafenone.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[67]], "entity_id": ["T6"]}, "Effect": {"text": [["transient global amnesia"]], "start": [[42]], "entity_id": ["T5"]}, "Treatment": {"text": [["propafenone"]], "start": [[77]], "entity_id": ["T7"], "Drug": {"text": [["propafenone"]], "start": [[77]], "entity_id": ["T8"]}}, "Speculated": {"text": [["probable"]], "start": [[25]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "458006_2", "context": "We report the development of squamous-cell carcinoma within a basal-cell epithelioma that was treated with intralesional injections of 5-FU.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[94]], "entity_id": ["T3"]}, "Treatment": {"text": [["intralesional injections of 5-FU"]], "start": [[107]], "entity_id": ["T4"], "Route": {"text": [["intralesional injections"]], "start": [[107]], "entity_id": ["T6"]}, "Drug": {"text": [["5-FU"]], "start": [[135]], "entity_id": ["T7"]}}, "Effect": {"text": [["squamous-cell carcinoma within a basal-cell epithelioma"]], "start": [[29]], "entity_id": ["T5"]}}]}]}
{"id": "10745478_1", "context": "This case report illustrates the use of continuous high-dose intracoronary nitroglycerin infusion through a 6 French coronary guiding catheter in the treatment of a patient with cocaine-induced refractory coronary vasospasm.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[186]], "entity_id": ["T4"]}, "Treatment": {"text": [["cocaine"]], "start": [[178]], "entity_id": ["T2"], "Drug": {"text": [["cocaine"]], "start": [[178]], "entity_id": ["T10"]}}, "Effect": {"text": [["refractory coronary vasospasm"]], "start": [[194]], "entity_id": ["T3"]}}, {"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatment"]], "start": [[150]], "entity_id": ["T1"]}, "Treatment": {"text": [["use of continuous high-dose intracoronary nitroglycerin infusion through a 6 French coronary guiding catheter"]], "start": [[33]], "entity_id": ["T5"], "Disorder": {"text": [["cocaine-induced refractory coronary vasospasm"]], "start": [[178]], "entity_id": ["T11"]}, "Drug": {"text": [["intracoronary nitroglycerin"]], "start": [[61]], "entity_id": ["T8"]}, "Route": {"text": [["infusion through a 6 French coronary guiding catheter"]], "start": [[89]], "entity_id": ["T9"]}, "Dosage": {"text": [["high-dose"]], "start": [[51]], "entity_id": ["T6"]}}}]}]}
{"id": "18585545_3", "context": "Here, we describe levofloxacin-induced delirium with psychotic features in a relatively young, otherwise healthy female.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[31]], "entity_id": ["T4"]}, "Treatment": {"text": [["levofloxacin"]], "start": [[18]], "entity_id": ["T3"], "Drug": {"text": [["levofloxacin"]], "start": [[18]], "entity_id": ["T6"]}}, "Effect": {"text": [["delirium with psychotic features"]], "start": [[39]], "entity_id": ["T5"]}, "Subject": {"text": [["relatively young, otherwise healthy female"]], "start": [[77]], "entity_id": ["T7"]}}]}]}
{"id": "9876809_1", "context": "Ticlopidine-induced phenytoin toxicity.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[12]], "entity_id": ["T5"]}, "Treatment": {"text": [["Ticlopidine"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Ticlopidine"], ["phenytoin"]], "start": [[0], [20]], "entity_id": ["T7", "T8"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["-"]], "start": [[11]], "entity_id": ["T9"]}, "Drug": {"text": [["phenytoin"], ["Ticlopidine"]], "start": [[20], [0]], "entity_id": ["T8", "T7"]}}]}, "Effect": {"text": [["toxicity"]], "start": [[30]], "entity_id": ["T6"]}}]}]}
{"id": "19540093_3", "context": "Pancreatitis has been associated with the tetracycline class of antibiotics and concerns about tigecycline-induced acute pancreatitis have recently been raised.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[107]], "entity_id": ["T3"]}, "Effect": {"text": [["acute pancreatitis"]], "start": [[115]], "entity_id": ["T4"]}, "Treatment": {"text": [["tigecycline"]], "start": [[95]], "entity_id": ["T5"], "Drug": {"text": [["tigecycline"]], "start": [[95]], "entity_id": ["T7"]}}, "Speculated": {"text": [["concerns"]], "start": [[80]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "2811895_1", "context": "Abrupt, accidental withdrawal of trihexyphenidyl triggered severe exacerbation of the cranial dystonia associated with inspiratory stridor and acute respiratory difficulties, prompting emergency admission.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["triggered"]], "start": [[49]], "entity_id": ["T8"]}, "Treatment": {"text": [["Abrupt, accidental withdrawal of trihexyphenidyl"]], "start": [[0]], "entity_id": ["T7"], "Drug": {"text": [["trihexyphenidyl"]], "start": [[33]], "entity_id": ["T10"]}}, "Effect": {"text": [["exacerbation of the cranial dystonia associated with inspiratory stridor and acute respiratory difficulties"]], "start": [[66]], "entity_id": ["T9"]}, "Severity": {"text": [["severe"]], "start": [[59]], "entity_id": ["T11"], "value": "High"}}]}]}
{"id": "3397227_2", "context": "We report two patients with anhedonic ejaculation (ejaculation without orgasm) associated with initiation of treatment with desipramine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[79]], "entity_id": ["T7"]}, "Subject": {"text": [["two patients"]], "start": [[10]], "entity_id": ["T6"], "Population": {"text": [["two"]], "start": [[10]], "entity_id": ["T9"]}}, "Treatment": {"text": [["desipramine"]], "start": [[124]], "entity_id": ["T8"], "Drug": {"text": [["desipramine"]], "start": [[124]], "entity_id": ["T11"]}}, "Effect": {"text": [["anhedonic ejaculation (ejaculation without orgasm)"]], "start": [[28]], "entity_id": ["T5"]}}]}]}
{"id": "18191947_3", "context": "We describe longitudinal diffusion-weighted MRI findings of sub-acute leukoencephalopathy following methotrexate therapy in a 24-year-old man diagnosed with pre-B-cell acute lymphoblastic leukemia (ALL), presenting with right-sided paralysis and aphasia after second consolidation with intrathecal triple-drug therapy given intrathecally.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[90]], "entity_id": ["T4"]}, "Effect": {"text": [["longitudinal diffusion-weighted MRI findings of sub-acute leukoencephalopathy"]], "start": [[12]], "entity_id": ["T3"]}, "Treatment": {"text": [["methotrexate"]], "start": [[100]], "entity_id": ["T5"], "Drug": {"text": [["methotrexate"]], "start": [[100]], "entity_id": ["T10"]}}, "Subject": {"text": [["a 24-year-old man"]], "start": [[124]], "entity_id": ["T6"], "Age": {"text": [["24-year-old"]], "start": [[126]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[138]], "entity_id": ["T8"]}}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[254]], "entity_id": ["T1"]}, "Subject": {"text": [["a 24-year-old man"]], "start": [[124]], "entity_id": ["T6"], "Age": {"text": [["24-year-old"]], "start": [[126]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[138]], "entity_id": ["T8"]}}, "Treatment": {"text": [["second consolidation with intrathecal triple-drug therapy given intrathecally"]], "start": [[260]], "entity_id": ["T2"], "Disorder": {"text": [["pre-B-cell acute lymphoblastic leukemia (ALL)"]], "start": [[157]], "entity_id": ["T9"]}, "Route": {"text": [["intrathecally"]], "start": [[324]], "entity_id": ["T12"]}}, "Effect": {"text": [["presenting with right-sided paralysis and aphasia"]], "start": [[204]], "entity_id": ["T11"]}}]}]}
{"id": "19915794_2", "context": "Therefore, although garenoxacin reportedly causes fewer adverse reactions for cardiac rhythms than third-generation quinolone antibiotics, one must be cautious of the interference of other drugs during hypokalemia in order to prevent TdP.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["causes"]], "start": [[43]], "entity_id": ["T10"]}, "Treatment": {"text": [["garenoxacin"]], "start": [[20]], "entity_id": ["T5"], "Drug": {"text": [["garenoxacin"]], "start": [[20]], "entity_id": ["T9"]}}, "Effect": {"text": [["adverse reactions for cardiac rhythms"]], "start": [[56]], "entity_id": ["T6"]}, "Negated": {"text": [["fewer"]], "start": [[50]], "entity_id": ["T7"], "value": true}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["prevent"]], "start": [[226]], "entity_id": ["T14"]}, "Treatment": {"text": [["garenoxacin"]], "start": [[20]], "entity_id": ["T5"], "Drug": {"text": [["garenoxacin"]], "start": [[20]], "entity_id": ["T9"]}}, "Subject": {"text": [["hypokalemia"]], "start": [[202]], "entity_id": ["T15"], "Disorder": {"text": [["hypokalemia"]], "start": [[202]], "entity_id": ["T8"]}}, "Effect": {"text": [["TdP"]], "start": [[234]], "entity_id": ["T13"]}, "Speculated": {"text": [["cautious"]], "start": [[151]], "entity_id": ["T16"], "value": true}}]}]}
{"id": "12792223_1", "context": "A 45-year-old woman with steroid-dependent Crohn's colitis, successfully managed with maintenance infliximab infusions and methotrexate, developed a lupus-like syndrome eight months after her initial infusion.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[137]], "entity_id": ["T6"]}, "Subject": {"text": [["A 45-year-old woman with steroid-dependent Crohn's colitis"]], "start": [[0]], "entity_id": ["T4"], "Age": {"text": [["45-year-old"]], "start": [[2]], "entity_id": ["T8"]}, "Gender": {"text": [["woman"]], "start": [[14]], "entity_id": ["T9"]}}, "Effect": {"text": [["lupus-like syndrome"]], "start": [[149]], "entity_id": ["T7"]}, "Treatment": {"text": [["maintenance infliximab infusions and methotrexate", "eight months after her initial infusion"]], "start": [[86, 169]], "entity_id": ["T5"], "Time_elapsed": {"text": [["eight months"]], "start": [[169]], "entity_id": ["T11"]}, "Drug": {"text": [["infliximab"], ["methotrexate"]], "start": [[98], [123]], "entity_id": ["T12", "T14"]}, "Route": {"text": [["infusions"]], "start": [[109]], "entity_id": ["T13"]}, "Disorder": {"text": [["steroid-dependent Crohn's colitis"]], "start": [[25]], "entity_id": ["T16"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[119]], "entity_id": ["T15"]}, "Drug": {"text": [["infliximab"], ["methotrexate"]], "start": [[98], [123]], "entity_id": ["T12", "T14"]}}]}}]}]}
{"id": "6292681_1", "context": "Severe neurotoxicity with methyl G: CALGB experience.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[21]], "entity_id": ["T5"]}, "Effect": {"text": [["neurotoxicity"]], "start": [[7]], "entity_id": ["T3"]}, "Treatment": {"text": [["methyl G"]], "start": [[26]], "entity_id": ["T4"], "Drug": {"text": [["methyl G"]], "start": [[26]], "entity_id": ["T6"]}}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T7"], "value": "High"}}]}]}
{"id": "3725284_2", "context": "We report a case of a 60-year-old woman affected by squamous lung carcinoma, who developed paroxysmal supraventricular tachycardia during cisplatin and etoposide combination chemotherapy.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[81]], "entity_id": ["T6"]}, "Subject": {"text": [["60-year-old woman affected by squamous lung carcinoma"]], "start": [[22]], "entity_id": ["T4"], "Age": {"text": [["60-year-old"]], "start": [[22]], "entity_id": ["T9"]}, "Gender": {"text": [["woman"]], "start": [[34]], "entity_id": ["T10"]}}, "Effect": {"text": [["paroxysmal supraventricular tachycardia"]], "start": [[91]], "entity_id": ["T7"]}, "Treatment": {"text": [["cisplatin and etoposide combination"]], "start": [[138]], "entity_id": ["T8"], "Drug": {"text": [["cisplatin"], ["etoposide"]], "start": [[138], [152]], "entity_id": ["T11", "T12"]}, "Disorder": {"text": [["squamous lung carcinoma,"]], "start": [[52]], "entity_id": ["T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combination"]], "start": [[162]], "entity_id": ["T13"]}, "Drug": {"text": [["etoposide"], ["cisplatin"]], "start": [[152], [138]], "entity_id": ["T12", "T11"]}}]}}]}]}
{"id": "9177620_2", "context": "The authors report a case of acute pancreatitis (AP) occurring in a patient under treatment with carbamazepine (CBZ) for post-traumatic petit mal epilepsy, and review the current literature of drug-induced AP.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurring"]], "start": [[53]], "entity_id": ["T8"]}, "Effect": {"text": [["acute pancreatitis"]], "start": [[29]], "entity_id": ["T4"]}, "Treatment": {"text": [["carbamazepine"]], "start": [[97]], "entity_id": ["T5"], "Disorder": {"text": [["post-traumatic petit mal epilepsy"]], "start": [[121]], "entity_id": ["T7"]}, "Drug": {"text": [["carbamazepine"]], "start": [[97]], "entity_id": ["T9"]}}, "Subject": {"text": [["a patient"]], "start": [[66]], "entity_id": ["T6"]}}]}]}
{"id": "19707032_1", "context": "Acute ocular ischemic change may be associated with intravitreal injection of bevacizumab in patients with vascular compromised diabetic retinopathy and/or underlying stenosis of the carotid artery.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[36]], "entity_id": ["T4"]}, "Effect": {"text": [["Acute ocular ischemic change"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["intravitreal injection of bevacizumab"]], "start": [[52]], "entity_id": ["T5"], "Drug": {"text": [["bevacizumab"]], "start": [[78]], "entity_id": ["T8"]}, "Dosage": {"text": [["intravitreal injection"]], "start": [[52]], "entity_id": ["T9"]}}, "Subject": {"text": [["patients with vascular compromised diabetic retinopathy and/or underlying stenosis of the carotid artery"]], "start": [[93]], "entity_id": ["T6"], "Disorder": {"text": [["vascular compromised diabetic retinopathy"], ["underlying stenosis of the carotid artery"]], "start": [[107], [156]], "entity_id": ["T7", "T1"]}}}]}]}
{"id": "17852449_2", "context": "All-trans-retinoic acid (ATRA) has been proved to be an effective treatment for acute promyelocytic leukemia (APL), inducing remission in more than 90% of cases.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["proved"]], "start": [[40]], "entity_id": ["T7"]}, "Treatment": {"text": [["All-trans-retinoic acid (ATRA)"]], "start": [[0]], "entity_id": ["T6"], "Disorder": {"text": [["acute promyelocytic leukemia (APL)"]], "start": [[80]], "entity_id": ["T8"]}, "Drug": {"text": [["All-trans-retinoic acid"]], "start": [[0]], "entity_id": ["T11"]}}, "Subject": {"text": [["more than 90% of cases"]], "start": [[138]], "entity_id": ["T9"], "Population": {"text": [["more than 90%"]], "start": [[138]], "entity_id": ["T10"]}}}]}]}
{"id": "18698687_2", "context": "Vanishing bile duct and Stevens-Johnson syndrome associated with ciprofloxacin treated with tacrolimus.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[49]], "entity_id": ["T6"]}, "Effect": {"text": [["Vanishing bile duct and Stevens-Johnson syndrome"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["ciprofloxacin"]], "start": [[65]], "entity_id": ["T7"], "Drug": {"text": [["ciprofloxacin"]], "start": [[65]], "entity_id": ["T8"]}}}]}]}
{"id": "9161656_5", "context": "Antiasthmatic medications were prescribed, but the asthma symptoms did not improve.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["improve"]], "start": [[75]], "entity_id": ["T6"]}, "Treatment": {"text": [["Antiasthmatic medications were prescribed"]], "start": [[0]], "entity_id": ["T5"], "Disorder": {"text": [["asthma"]], "start": [[51]], "entity_id": ["T8"]}, "Drug": {"text": [["Antiasthmatic medications"]], "start": [[0]], "entity_id": ["T9"]}}, "Negated": {"text": [["not"]], "start": [[71]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "12590235_1", "context": "Both 6-MP and AZA are widely used and are known to cause hepatotoxicity in a proportion of patients.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["used"]], "start": [[29]], "entity_id": ["T5"]}, "Subject": {"text": [["a proportion of patients"]], "start": [[75]], "entity_id": ["T4"]}, "Treatment": {"text": [["6-MP and AZA"]], "start": [[5]], "entity_id": ["T6"], "Drug": {"text": [["AZA"], ["6-MP"]], "start": [[14], [5]], "entity_id": ["T8", "T9"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[10]], "entity_id": ["T11"]}, "Drug": {"text": [["6-MP"], ["AZA"]], "start": [[5], [14]], "entity_id": ["T9", "T8"]}}]}, "Effect": {"text": [["hepatotoxicity"]], "start": [[57]], "entity_id": ["T7"]}}]}]}
{"id": "11889149_2", "context": "Both raloxifene (RLX) and alendronate (ALN) can treat and prevent new vertebral fractures, increase bone mineral density (BMD), and decrease biochemical markers of bone turnover in postmenopausal women with osteoporosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treat"]], "start": [[48]], "entity_id": ["T14"]}, "Treatment": {"text": [["Both raloxifene (RLX) and alendronate (ALN)"]], "start": [[0]], "entity_id": ["T13"], "Disorder": {"text": [["vertebral fractures"]], "start": [[70]], "entity_id": ["T19"]}, "Drug": {"text": [["raloxifene"], ["alendronate"]], "start": [[5], [26]], "entity_id": ["T15", "T18"]}}, "Subject": {"text": [["postmenopausal women with osteoporosis"]], "start": [[181]], "entity_id": ["T17"], "Disorder": {"text": [["osteoporosis"]], "start": [[207]], "entity_id": ["T16"]}}, "Effect": {"text": [["increase bone mineral density (BMD)"], ["decrease biochemical markers of bone turnover"]], "start": [[91], [132]], "entity_id": ["T1", "T2"]}}]}]}
{"id": "9840249_3", "context": "We report a case of severe respiratory failure due to gold salt toxicity in a patient suffering from rheumatoid arthritis requiring mechanical ventilation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[47]], "entity_id": ["T7"]}, "Effect": {"text": [["respiratory failure"]], "start": [[27]], "entity_id": ["T3"]}, "Treatment": {"text": [["gold salt"]], "start": [[54]], "entity_id": ["T4"], "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[101]], "entity_id": ["T6"]}, "Drug": {"text": [["gold"]], "start": [[54]], "entity_id": ["T8"]}}, "Subject": {"text": [["a patient suffering from rheumatoid arthritis"]], "start": [[76]], "entity_id": ["T5"]}, "Severity": {"text": [["severe"]], "start": [[20]], "entity_id": ["T9"], "value": "High"}}]}]}
{"id": "3628148_2", "context": "We describe rupture of a cerebral arterial aneurysm in a 32 year old hypertensive woman following the introduction of nifedipine treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[88]], "entity_id": ["T6"]}, "Effect": {"text": [["rupture of a cerebral arterial aneurysm"]], "start": [[12]], "entity_id": ["T3"]}, "Subject": {"text": [["a 32 year old hypertensive woman"]], "start": [[55]], "entity_id": ["T4"], "Age": {"text": [["32 year old"]], "start": [[57]], "entity_id": ["T7"]}, "Gender": {"text": [["woman"]], "start": [[82]], "entity_id": ["T9"]}}, "Treatment": {"text": [["nifedipine treatment"]], "start": [[118]], "entity_id": ["T5"], "Disorder": {"text": [["hypertensive"]], "start": [[69]], "entity_id": ["T8"]}, "Drug": {"text": [["nifedipine"]], "start": [[118]], "entity_id": ["T10"]}}}]}]}
{"id": "16882109_2", "context": "Factors that suggested an association between the severe angioedematous reaction and BP topical application include the strong reaction to BP in the patch-test, the temporal relationship, the complete resolution of symptoms after the drug was withdrawn and the absence of other identified explanations.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["association"]], "start": [[26]], "entity_id": ["T6"]}, "Effect": {"text": [["severe angioedematous reaction"]], "start": [[50]], "entity_id": ["T3"]}, "Treatment": {"text": [["BP topical application"]], "start": [[85]], "entity_id": ["T4"], "Drug": {"text": [["BP topical application"]], "start": [[85]], "entity_id": ["T8"]}}, "Speculated": {"text": [["suggested"]], "start": [[13]], "entity_id": ["T5"], "value": true}}]}]}
{"id": "11889149_14", "context": "RLX+ALN reduced bone turnover more than either drug alone, resulting in greater BMD increment, but whether this difference reflects better fracture risk reduction was not assessed in this study.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["reduced"]], "start": [[8]], "entity_id": ["T9"]}, "Treatment": {"text": [["RLX"], ["ALN"]], "start": [[0], [4]], "entity_id": ["T7", "T8"], "Drug": {"text": [["RLX"], ["ALN"]], "start": [[0], [4]], "entity_id": ["T12", "T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["+"]], "start": [[3]], "entity_id": ["T11"]}, "Drug": {"text": [["RLX"], ["ALN"]], "start": [[0], [4]], "entity_id": ["T12", "T13"]}}]}, "Effect": {"text": [["bone turnover more than either drug alone, resulting in greater BMD increment"]], "start": [[16]], "entity_id": ["T10"]}}]}]}
{"id": "11881322_3", "context": "Hepatotoxicity related to itraconazole: report of three cases.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[15]], "entity_id": ["T3"]}, "Treatment": {"text": [["itraconazole"]], "start": [[26]], "entity_id": ["T4"], "Drug": {"text": [["itraconazole"]], "start": [[26]], "entity_id": ["T8"]}}, "Effect": {"text": [["Hepatotoxicity"]], "start": [[0]], "entity_id": ["T5"]}, "Subject": {"text": [["three cases"]], "start": [[50]], "entity_id": ["T6"], "Population": {"text": [["three"]], "start": [[50]], "entity_id": ["T7"]}}}]}]}
{"id": "2295443_3", "context": "This report presents a case of colon perforation which occurred 4 months after treatment with intraperitoneal chromic phosphate for stage IB ovarian papillary serous cystadenocarcinoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurred"]], "start": [[55]], "entity_id": ["T4"]}, "Effect": {"text": [["colon perforation"]], "start": [[31]], "entity_id": ["T3"]}, "Treatment": {"text": [["intraperitoneal chromic phosphate"]], "start": [[94]], "entity_id": ["T5"], "Drug": {"text": [["chromic phosphate"]], "start": [[110]], "entity_id": ["T7"]}, "Time_elapsed": {"text": [["4 months"]], "start": [[64]], "entity_id": ["T8"]}, "Route": {"text": [["intraperitoneal"]], "start": [[94]], "entity_id": ["T9"]}, "Disorder": {"text": [["stage IB ovarian papillary serous cystadenocarcinoma"]], "start": [[132]], "entity_id": ["T10"]}}}]}]}
{"id": "9634122_1", "context": "Flutamide withdrawal syndrome is characterized by a decrease in prostate-specific antigen (PSA) after flutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["withdrawal"]], "start": [[112]], "entity_id": ["T7"]}, "Treatment": {"text": [["flutamide"]], "start": [[102]], "entity_id": ["T8"], "Disorder": {"text": [["progressing metastatic carcinoma of the prostate"]], "start": [[152]], "entity_id": ["T11"]}, "Drug": {"text": [["flutamide"]], "start": [[102]], "entity_id": ["T12"]}}, "Effect": {"text": [["decrease in prostate-specific antigen (PSA)"]], "start": [[52]], "entity_id": ["T9"]}, "Subject": {"text": [["subset of patients with progressing metastatic carcinoma of the prostate"]], "start": [[128]], "entity_id": ["T10"]}}]}]}
{"id": "7282702_2", "context": "Bradycardia and congestive heart failure associated with ocular timolol maleate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[41]], "entity_id": ["T6"]}, "Effect": {"text": [["Bradycardia and congestive heart failure"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["ocular timolol maleate"]], "start": [[57]], "entity_id": ["T7"], "Route": {"text": [["ocular"]], "start": [[57]], "entity_id": ["T8"]}, "Drug": {"text": [["timolol maleate"]], "start": [[64]], "entity_id": ["T9"]}}}]}]}
{"id": "19707032_4", "context": "CONCLUSIONS: Patients receiving intravitreal injections of bevacizumab should be evaluated for potential systemic risk factors such as carotid insufficiency, coagulopathy and poorly controlled diabetes mellitus.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["risk"]], "start": [[114]], "entity_id": ["T7"]}, "Effect": {"text": [["carotid insufficiency, coagulopathy and poorly controlled diabetes mellitus"]], "start": [[135]], "entity_id": ["T8"]}, "Treatment": {"text": [["intravitreal injections of bevacizumab"]], "start": [[32]], "entity_id": ["T9"], "Drug": {"text": [["bevacizumab"]], "start": [[59]], "entity_id": ["T10"]}, "Route": {"text": [["intravitreal injections"]], "start": [[32]], "entity_id": ["T11"]}}}]}]}
{"id": "25671244_13", "context": "Severe serotonin toxicity may result from metaxalone abuse in individuals using a selective serotonin reuptake inhibitor therapeutically.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["result"]], "start": [[30]], "entity_id": ["T7"]}, "Effect": {"text": [["serotonin toxicity"]], "start": [[7]], "entity_id": ["T6"]}, "Treatment": {"text": [["metaxalone abuse", "using a selective serotonin reuptake inhibitor therapeutically"]], "start": [[42, 74]], "entity_id": ["T8"], "Drug": {"text": [["metaxalone"], ["selective serotonin reuptake inhibitor"]], "start": [[42], [82]], "entity_id": ["T9", "T11"]}, "Dosage": {"text": [["abuse"]], "start": [[53]], "entity_id": ["T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["using"]], "start": [[74]], "entity_id": ["T12"]}, "Drug": {"text": [["metaxalone"], ["selective serotonin reuptake inhibitor"]], "start": [[42], [82]], "entity_id": ["T9", "T11"]}}]}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T13"], "value": "High"}}]}]}
{"id": "18504683_2", "context": "The purpose of this article is to present the first case-series of posterior reversible encephalopathy syndrome (PRES) associated with L-asparaginase treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[119]], "entity_id": ["T5"]}, "Treatment": {"text": [["L-asparaginase treatment"]], "start": [[135]], "entity_id": ["T6"], "Drug": {"text": [["L-asparaginase"]], "start": [[135]], "entity_id": ["T8"]}}, "Effect": {"text": [["posterior reversible encephalopathy syndrome (PRES)"]], "start": [[67]], "entity_id": ["T7"]}}]}]}
{"id": "16029707_1", "context": "Eruptive epidermoid cysts resulting from treatment with imiquimod.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulting"]], "start": [[26]], "entity_id": ["T3"]}, "Treatment": {"text": [["imiquimod"]], "start": [[56]], "entity_id": ["T4"], "Drug": {"text": [["imiquimod"]], "start": [[56]], "entity_id": ["T6"]}}, "Effect": {"text": [["Eruptive epidermoid cysts"]], "start": [[0]], "entity_id": ["T5"]}}]}]}
{"id": "12757344_1", "context": "Carbamazepine-related hyponatremia following cardiopulmonary bypass.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[14]], "entity_id": ["T4"]}, "Treatment": {"text": [["Carbamazepine"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Carbamazepine"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["hyponatremia"]], "start": [[22]], "entity_id": ["T5"]}}]}]}
{"id": "15379082_2", "context": "Fulminant hepatic failure is a rare complication of disulfiram treatment for alcoholism.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complication"]], "start": [[36]], "entity_id": ["T6"]}, "Effect": {"text": [["Fulminant hepatic failure"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["disulfiram"]], "start": [[52]], "entity_id": ["T4"], "Disorder": {"text": [["alcoholism"]], "start": [[77]], "entity_id": ["T5"]}, "Drug": {"text": [["disulfiram"]], "start": [[52]], "entity_id": ["T7"]}}}]}]}
{"id": "11049910_11", "context": "Implications: Clinicians should be aware of the possibility of increased toxicity of ropivacaine when used together with inhibitors of CYP1A2.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["increased"]], "start": [[63]], "entity_id": ["T8"]}, "Treatment": {"text": [["ropivacaine"], ["inhibitors of CYP1A2"]], "start": [[85], [121]], "entity_id": ["T7", "T10"], "Drug": {"text": [["ropivacaine"], ["inhibitors of CYP1A2"]], "start": [[85], [121]], "entity_id": ["T11", "T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["together with"]], "start": [[107]], "entity_id": ["T13"]}, "Drug": {"text": [["inhibitors of CYP1A2"], ["ropivacaine"]], "start": [[121], [85]], "entity_id": ["T12", "T11"]}}]}, "Effect": {"text": [["toxicity"]], "start": [[73]], "entity_id": ["T9"]}, "Speculated": {"text": [["possibility"]], "start": [[48]], "entity_id": ["T14"], "value": true}}]}]}
{"id": "3379435_1", "context": "Evidence obtained indicated that the Reye-like syndrome might be caused by calcium hopantenate possibly due to the induction of pantothenic acid deficiency.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[65]], "entity_id": ["T6"]}, "Effect": {"text": [["Reye-like syndrome"]], "start": [[37]], "entity_id": ["T5"]}, "Treatment": {"text": [["calcium hopantenate"]], "start": [[75]], "entity_id": ["T7"], "Drug": {"text": [["calcium hopantenate"]], "start": [[75]], "entity_id": ["T8"]}}, "Speculated": {"text": [["might"]], "start": [[56]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "3143551_5", "context": "Hepatopathy subsided after the cessation of carbamazepine and lynestrenol.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[21]], "entity_id": ["T5"]}, "Treatment": {"text": [["carbamazepine", "lynestrenol"]], "start": [[44, 62]], "entity_id": ["T4"], "Dosage": {"text": [["cessation"]], "start": [[31]], "entity_id": ["T7"]}, "Drug": {"text": [["carbamazepine"], ["lynestrenol"]], "start": [[44], [62]], "entity_id": ["T8", "T9"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[58]], "entity_id": ["T10"]}, "Drug": {"text": [["lynestrenol"], ["carbamazepine"]], "start": [[62], [44]], "entity_id": ["T9", "T8"]}}]}, "Effect": {"text": [["Hepatopathy subsided"]], "start": [[0]], "entity_id": ["T6"]}}]}]}
{"id": "8667442_2", "context": "This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["resulting"]], "start": [[110]], "entity_id": ["T7"]}, "Treatment": {"text": [["calcium carbonate and calcitriol"]], "start": [[77]], "entity_id": ["T6"], "Disorder": {"text": [["hypoparathyroidism"]], "start": [[37]], "entity_id": ["T5"]}, "Drug": {"text": [["calcium carbonate"], ["calcitriol"]], "start": [[77], [99]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[95]], "entity_id": ["T11"]}, "Drug": {"text": [["calcium carbonate"], ["calcitriol"]], "start": [[77], [99]], "entity_id": ["T9", "T10"]}}]}, "Effect": {"text": [["two admissions to the hospital for milk-alkali syndrome"]], "start": [[123]], "entity_id": ["T8"]}, "Subject": {"text": [["a patient with hypoparathyroidism"]], "start": [[22]], "entity_id": ["T4"]}}]}]}
{"id": "16997047_3", "context": "Recurrent hyponatremia associated with citalopram and mirtazapine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[23]], "entity_id": ["T5"]}, "Effect": {"text": [["Recurrent hyponatremia"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["citalopram and mirtazapine"]], "start": [[39]], "entity_id": ["T6"], "Drug": {"text": [["citalopram"], ["mirtazapine"]], "start": [[39], [54]], "entity_id": ["T7", "T8"]}}}]}]}
{"id": "24429012_2", "context": "A case report of a sharp rise in International Normalized Ratio (INR) values during a patient's concomitant use of warfarin and the antineoplastic agent vismodegib is presented.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[77]], "entity_id": ["T9"]}, "Effect": {"text": [["a sharp rise in International Normalized Ratio (INR) values"]], "start": [[17]], "entity_id": ["T8"]}, "Subject": {"text": [["a patient"]], "start": [[84]], "entity_id": ["T10"]}, "Treatment": {"text": [["concomitant use of warfarin and the antineoplastic agent vismodegib"]], "start": [[96]], "entity_id": ["T11"], "Drug": {"text": [["warfarin"], ["vismodegib"]], "start": [[115], [153]], "entity_id": ["T13", "T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["concomitant"]], "start": [[96]], "entity_id": ["T12"]}, "Drug": {"text": [["warfarin"], ["vismodegib"]], "start": [[115], [153]], "entity_id": ["T13", "T14"]}}]}}]}]}
{"id": "18810448_1", "context": "In this report we described a case of juvenile idiopathic arthritis patient who developed thymic enlargement (true thymic hyperplasia), mediastinal lymphadenopathy and pleurisy associated with systemic symptoms under Etanercept treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[80]], "entity_id": ["T11"]}, "Subject": {"text": [["a case of juvenile idiopathic arthritis patient"]], "start": [[28]], "entity_id": ["T9"], "Age": {"text": [["juvenile"]], "start": [[38]], "entity_id": ["T1"]}}, "Effect": {"text": [["thymic enlargement (true thymic hyperplasia), mediastinal lymphadenopathy and pleurisy associated with systemic symptoms"]], "start": [[90]], "entity_id": ["T12"]}, "Treatment": {"text": [["Etanercept"]], "start": [[217]], "entity_id": ["T13"], "Disorder": {"text": [["idiopathic arthritis"]], "start": [[47]], "entity_id": ["T10"]}, "Drug": {"text": [["Etanercept"]], "start": [[217]], "entity_id": ["T14"]}}}]}]}
{"id": "2445709_1", "context": "A 52-year-old woman developed symmetric sensorimotor polyneuropathy and cerebellar syndrome after 24 months of amiodarone treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[20]], "entity_id": ["T6"]}, "Subject": {"text": [["A 52-year-old woman"]], "start": [[0]], "entity_id": ["T5"], "Age": {"text": [["52-year-old"]], "start": [[2]], "entity_id": ["T9"]}, "Gender": {"text": [["woman"]], "start": [[14]], "entity_id": ["T10"]}}, "Effect": {"text": [["symmetric sensorimotor polyneuropathy", "cerebellar syndrome"]], "start": [[30, 72]], "entity_id": ["T7"]}, "Treatment": {"text": [["amiodarone"]], "start": [[111]], "entity_id": ["T8"], "Time_elapsed": {"text": [["24 months"]], "start": [[98]], "entity_id": ["T11"]}, "Drug": {"text": [["amiodarone"]], "start": [[111]], "entity_id": ["T12"]}}}]}]}
{"id": "18396749_3", "context": "The case of a patient under tibolone therapy for two years who developed a mixed-type liver injury with prolonged cholestasis and features of the vanishing bile duct syndrome following a ten weeks treatment with St. John wort (Hypericum Perforatum) infusions is reported.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[63]], "entity_id": ["T6"]}, "Treatment": {"text": [["under tibolone therapy", "a ten weeks treatment with St. John wort (Hypericum Perforatum) infusions"]], "start": [[22, 185]], "entity_id": ["T7"], "Drug": {"text": [["Hypericum Perforatum"], ["tibolone"]], "start": [[227], [28]], "entity_id": ["T10", "T13"]}, "Route": {"text": [["infusions"]], "start": [[249]], "entity_id": ["T11"]}, "Duration": {"text": [["ten weeks"]], "start": [[187]], "entity_id": ["T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["following"]], "start": [[175]], "entity_id": ["T14"]}, "Drug": {"text": [["tibolone"], ["Hypericum Perforatum"]], "start": [[28], [227]], "entity_id": ["T13", "T10"]}}]}, "Subject": {"text": [["a patient under tibolone therapy"]], "start": [[12]], "entity_id": ["T8"]}, "Effect": {"text": [["a mixed-type liver injury with prolonged cholestasis and features of the vanishing bile duct syndrome"]], "start": [[73]], "entity_id": ["T9"]}}]}]}
{"id": "18094347_6", "context": "OBJECTIVE: To report a case of a diffuse papular eruption following treatment of psoriasis with methotrexate injections.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[58]], "entity_id": ["T4"]}, "Effect": {"text": [["diffuse papular eruption"]], "start": [[33]], "entity_id": ["T5"]}, "Treatment": {"text": [["methotrexate injections"]], "start": [[96]], "entity_id": ["T3"], "Drug": {"text": [["methotrexate"]], "start": [[96]], "entity_id": ["T6"]}, "Route": {"text": [["injections"]], "start": [[109]], "entity_id": ["T7"]}, "Disorder": {"text": [["psoriasis"]], "start": [[81]], "entity_id": ["T8"]}}}]}]}
{"id": "10099659_1", "context": "Prolonged severe 5-fluorouracil-associated neurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiency.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[32]], "entity_id": ["T10"]}, "Treatment": {"text": [["5-fluorouracil"]], "start": [[17]], "entity_id": ["T8"], "Drug": {"text": [["5-fluorouracil"]], "start": [[17]], "entity_id": ["T11"]}, "Disorder": {"text": [["dihydropyrimidine dehydrogenase deficiency"]], "start": [[75]], "entity_id": ["T13"]}}, "Subject": {"text": [["a patient with dihydropyrimidine dehydrogenase deficiency"]], "start": [[60]], "entity_id": ["T7"]}, "Effect": {"text": [["neurotoxicity"]], "start": [[43]], "entity_id": ["T12"]}, "Severity": {"text": [["severe"]], "start": [[10]], "entity_id": ["T14"], "value": "High"}}]}]}
{"id": "18343993_3", "context": "Life-threatening interstitial lung disease associated with trastuzumab: case report.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[43]], "entity_id": ["T3"]}, "Treatment": {"text": [["trastuzumab"]], "start": [[59]], "entity_id": ["T4"], "Drug": {"text": [["trastuzumab"]], "start": [[59]], "entity_id": ["T6"]}}, "Effect": {"text": [["Life-threatening interstitial lung disease"]], "start": [[0]], "entity_id": ["T5"]}, "Subject": {"text": [["case"]], "start": [[72]], "entity_id": ["T7"]}}]}]}
{"id": "15694139_6", "context": "Thalidomide neuropathy is often associated with proximal weakness and may progress even after discontinuation of treatment, in the phenomenon of 'coasting'.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[32]], "entity_id": ["T8"]}, "Effect": {"text": [["neuropathy", "proximal weakness"]], "start": [[12, 48]], "entity_id": ["T9"]}, "Treatment": {"text": [["Thalidomide"]], "start": [[0]], "entity_id": ["T7"], "Drug": {"text": [["Thalidomide"]], "start": [[0]], "entity_id": ["T10"]}}, "Speculated": {"text": [["often"]], "start": [[26]], "entity_id": ["T11"], "value": true}}]}]}
{"id": "18607107_3", "context": "RESULTS: Our patient developed Crohn's disease while on Copaxone treatment as a consequence of long-term immunosuppression.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[21]], "entity_id": ["T5"]}, "Effect": {"text": [["Crohn's disease", "long-term immunosuppression"]], "start": [[31, 95]], "entity_id": ["T6"]}, "Subject": {"text": [["patient"]], "start": [[13]], "entity_id": ["T7"]}, "Treatment": {"text": [["Copaxone"]], "start": [[56]], "entity_id": ["T8"], "Drug": {"text": [["Copaxone"]], "start": [[56]], "entity_id": ["T9"]}}}]}]}
{"id": "19707032_2", "context": "Acute vision loss after intravitreal injection of bevacizumab (avastin) associated with ocular ischemic syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[18]], "entity_id": ["T8"]}, "Effect": {"text": [["Acute vision loss"], ["ocular ischemic syndrome"]], "start": [[0], [88]], "entity_id": ["T7", "T10"]}, "Treatment": {"text": [["intravitreal injection of bevacizumab (avastin)"]], "start": [[24]], "entity_id": ["T9"], "Route": {"text": [["intravitreal injection"]], "start": [[24]], "entity_id": ["T11"]}, "Drug": {"text": [["bevacizumab"]], "start": [[50]], "entity_id": ["T12"]}}}]}]}
{"id": "2663536_1", "context": "Development of persistent late onset asthma following treatment with captopril.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[44]], "entity_id": ["T3"]}, "Treatment": {"text": [["captopril"]], "start": [[69]], "entity_id": ["T4"], "Drug": {"text": [["captopril"]], "start": [[69]], "entity_id": ["T7"]}}, "Effect": {"text": [["persistent late onset asthma"]], "start": [[15]], "entity_id": ["T5"]}, "Severity": {"text": [["persistent"]], "start": [[15]], "entity_id": ["T6"], "value": "High"}}]}]}
{"id": "19717383_1", "context": "Herein, we describe a patient with AIDS who presented to medical attention with pancytopenia 48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["presented"]], "start": [[44]], "entity_id": ["T11"]}, "Subject": {"text": [["a patient with AIDS"]], "start": [[20]], "entity_id": ["T8"], "Disorder": {"text": [["AIDS"]], "start": [[35]], "entity_id": ["T13"]}}, "Treatment": {"text": [["48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (R-EPOCH)"]], "start": [[93]], "entity_id": ["T9"], "Disorder": {"text": [["diffuse large B-cell lymphoma"]], "start": [[220]], "entity_id": ["T10"]}, "Duration": {"text": [["48 months"]], "start": [[93]], "entity_id": ["T14"]}, "Drug": {"text": [["etoposide"], ["prednisone"], ["vincristine"], ["cyclophosphamide"], ["doxorubicin"], ["rituximab"]], "start": [[125], [136], [148], [161], [179], [196]], "entity_id": ["T16", "T17", "T18", "T19", "T20", "T21"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[192]], "entity_id": ["T15"]}, "Drug": {"text": [["etoposide"], ["prednisone"], ["vincristine"], ["cyclophosphamide"], ["doxorubicin"], ["rituximab"]], "start": [[125], [136], [148], [161], [179], [196]], "entity_id": ["T16", "T17", "T18", "T19", "T20", "T21"]}}]}, "Effect": {"text": [["medical attention with pancytopenia"]], "start": [[57]], "entity_id": ["T12"]}}]}]}
{"id": "8038468_2", "context": "However, prolongation of 5-FU half-life and an increase in INR have been reported with the concurrent use of 5-FU and warfarin.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["reported"]], "start": [[73]], "entity_id": ["T5"]}, "Effect": {"text": [["prolongation of 5-FU half-life and an increase in INR"]], "start": [[9]], "entity_id": ["T4"]}, "Treatment": {"text": [["the concurrent use of 5-FU and warfarin"]], "start": [[87]], "entity_id": ["T6"], "Drug": {"text": [["warfarin"], ["5-FU"]], "start": [[118], [109]], "entity_id": ["T7", "T8"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["concurrent"]], "start": [[91]], "entity_id": ["T9"]}, "Drug": {"text": [["5-FU"], ["warfarin"]], "start": [[109], [118]], "entity_id": ["T8", "T7"]}}]}}]}]}
{"id": "7718983_1", "context": "Graves' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[59]], "entity_id": ["T14"]}, "Effect": {"text": [["Graves' hyperthyroidism following transient thyrotoxicosis"]], "start": [[0]], "entity_id": ["T12"]}, "Treatment": {"text": [["interferon"]], "start": [[66]], "entity_id": ["T13"], "Drug": {"text": [["interferon"]], "start": [[66]], "entity_id": ["T15"]}, "Disorder": {"text": [["chronic hepatitis type C"]], "start": [[89]], "entity_id": ["T16"]}}}]}]}
{"id": "17083900_2", "context": "We report a case of acute generalized exanthematous pustulosis (AGEP) in a 50-year-old woman that was attributed to the ingestion of nimesulide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["attributed"]], "start": [[102]], "entity_id": ["T8"]}, "Effect": {"text": [["acute generalized exanthematous pustulosis (AGEP)"]], "start": [[20]], "entity_id": ["T5"]}, "Subject": {"text": [["a 50-year-old woman"]], "start": [[73]], "entity_id": ["T6"], "Age": {"text": [["50-year-old"]], "start": [[75]], "entity_id": ["T9"]}, "Gender": {"text": [["woman"]], "start": [[87]], "entity_id": ["T10"]}}, "Treatment": {"text": [["ingestion of nimesulide"]], "start": [[120]], "entity_id": ["T7"], "Drug": {"text": [["nimesulide"]], "start": [[133]], "entity_id": ["T11"]}, "Route": {"text": [["ingestion"]], "start": [[120]], "entity_id": ["T12"]}}}]}]}
{"id": "18191947_2", "context": "This case demonstrates the value of DWI in evaluation and diagnosis of sub-acute toxic leukoencephalopathy in patients being treated with methotrexate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[107]], "entity_id": ["T5"]}, "Effect": {"text": [["sub-acute toxic leukoencephalopathy"]], "start": [[71]], "entity_id": ["T3"]}, "Treatment": {"text": [["methotrexate"]], "start": [[138]], "entity_id": ["T4"], "Drug": {"text": [["methotrexate"]], "start": [[138]], "entity_id": ["T7"]}}, "Subject": {"text": [["patients"]], "start": [[110]], "entity_id": ["T6"]}}]}]}
{"id": "15785053_3", "context": "We report the first histopathologically documented case of oral mucosa pigmentation after OLP treatment with topical tacrolimus.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treatment"]], "start": [[94]], "entity_id": ["T3"]}, "Treatment": {"text": [["topical tacrolimus"]], "start": [[109]], "entity_id": ["T4"], "Drug": {"text": [["tacrolimus"]], "start": [[117]], "entity_id": ["T8"]}, "Disorder": {"text": [["OLP"]], "start": [[90]], "entity_id": ["T6"]}, "Route": {"text": [["topical"]], "start": [[109]], "entity_id": ["T7"]}}, "Effect": {"text": [["oral mucosa pigmentation"]], "start": [[59]], "entity_id": ["T5"]}}]}]}
{"id": "16298824_5", "context": "Progressive hypoxemia mandated endotracheal intubation 1 week after rituximab administration and led to death 4 weeks after admission.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[62]], "entity_id": ["T5"]}, "Effect": {"text": [["Progressive hypoxemia", "led to death"]], "start": [[0, 97]], "entity_id": ["T3"]}, "Treatment": {"text": [["rituximab administration"]], "start": [[68]], "entity_id": ["T4"], "Drug": {"text": [["rituximab"]], "start": [[68]], "entity_id": ["T6"]}, "Time_elapsed": {"text": [["1 week"]], "start": [[55]], "entity_id": ["T7"]}}}]}]}
{"id": "21751542_4", "context": "Angiotensin converting enzyme blockers and their influence on the endothelial dysfunction, but the risk of hyperpotassemia are showed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["showed"]], "start": [[127]], "entity_id": ["T8"]}, "Treatment": {"text": [["Angiotensin converting enzyme blockers"]], "start": [[0]], "entity_id": ["T6"], "Drug": {"text": [["Angiotensin converting enzyme blockers"]], "start": [[0]], "entity_id": ["T10"]}}, "Effect": {"text": [["hyperpotassemia"]], "start": [[107]], "entity_id": ["T7"]}, "Speculated": {"text": [["risk"]], "start": [[99]], "entity_id": ["T9"], "value": true}}]}]}
{"id": "24846936_2", "context": "This is the first report of a fatal outcome from serotonin toxicity, precipitated by an interaction between methylene blue and venlafaxine.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["precipitated"]], "start": [[69]], "entity_id": ["T7"]}, "Treatment": {"text": [["methylene blue", "venlafaxine"]], "start": [[108, 127]], "entity_id": ["T6"], "Drug": {"text": [["methylene blue"], ["venlafaxine"]], "start": [[108], [127]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[88]], "entity_id": ["T11"]}, "Drug": {"text": [["methylene blue"], ["venlafaxine"]], "start": [[108], [127]], "entity_id": ["T9", "T10"]}}]}, "Effect": {"text": [["serotonin toxicity"]], "start": [[49]], "entity_id": ["T8"]}, "Severity": {"text": [["fatal"]], "start": [[30]], "entity_id": ["T12"], "value": "High"}}]}]}
{"id": "19904536_10", "context": "A helicoidal CT scan showed diffuse and severe interstitial pneumonitis, and lung biopsy confirmed accelerated usual interstitial pneumonia consistent with drug-induced toxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[161]], "entity_id": ["T6"]}, "Effect": {"text": [["diffuse and severe interstitial pneumonitis", "accelerated usual interstitial pneumonia", "toxicity"]], "start": [[28, 99, 169]], "entity_id": ["T7"]}, "Treatment": {"text": [["drug"]], "start": [[156]], "entity_id": ["T9"], "Drug": {"text": [["drug"]], "start": [[156]], "entity_id": ["T10"]}}}]}]}
{"id": "10614572_3", "context": "We report a case of severe hypotension associated with intravenous valproate used to treat status epilepticus in an 11-year-old girl.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[39]], "entity_id": ["T4"]}, "Treatment": {"text": [["intravenous valproate"]], "start": [[55]], "entity_id": ["T3"], "Disorder": {"text": [["status epilepticus"]], "start": [[91]], "entity_id": ["T7"]}, "Route": {"text": [["intravenous"]], "start": [[55]], "entity_id": ["T10"]}, "Drug": {"text": [["valproate"]], "start": [[67]], "entity_id": ["T11"]}}, "Effect": {"text": [["hypotension"]], "start": [[27]], "entity_id": ["T5"]}, "Subject": {"text": [["an 11-year-old girl"]], "start": [[113]], "entity_id": ["T6"], "Age": {"text": [["11-year-old"]], "start": [[116]], "entity_id": ["T8"]}, "Gender": {"text": [["girl"]], "start": [[128]], "entity_id": ["T9"]}}, "Severity": {"text": [["severe"]], "start": [[20]], "entity_id": ["T12"], "value": "High"}}]}]}
{"id": "11489400_1", "context": "Relief by naloxone of morphine-induced spasm of the sphincter of Oddi in a post-cholecystectomy patient.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["Relief"]], "start": [[0]], "entity_id": ["T6"]}, "Treatment": {"text": [["naloxone"]], "start": [[10]], "entity_id": ["T5"], "Disorder": {"text": [["morphine-induced spasm of the sphincter of Oddi"]], "start": [[22]], "entity_id": ["T3"]}, "Drug": {"text": [["naloxone"]], "start": [[10]], "entity_id": ["T7"]}}, "Subject": {"text": [["post-cholecystectomy patient."]], "start": [[75]], "entity_id": ["T4"]}}, {"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[31]], "entity_id": ["T1"]}, "Subject": {"text": [["post-cholecystectomy patient."]], "start": [[75]], "entity_id": ["T4"]}, "Treatment": {"text": [["morphine"]], "start": [[22]], "entity_id": ["T2"], "Drug": {"text": [["morphine"]], "start": [[22]], "entity_id": ["T8"]}}, "Effect": {"text": [["spasm of the sphincter of Oddi"]], "start": [[39]], "entity_id": ["T9"]}}]}]}
{"id": "17610180_2", "context": "The results of the ultrasound examination combined with clinical anamnesis allowed diagnosis of gastric mucosa foveolar hyperplasia due to prolonged PGE1 therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[132]], "entity_id": ["T3"]}, "Treatment": {"text": [["prolonged PGE1 therapy"]], "start": [[139]], "entity_id": ["T4"], "Drug": {"text": [["PGE1"]], "start": [[149]], "entity_id": ["T6"]}, "Duration": {"text": [["prolonged"]], "start": [[139]], "entity_id": ["T7"]}}, "Effect": {"text": [["gastric mucosa foveolar hyperplasia"]], "start": [[96]], "entity_id": ["T5"]}}]}]}
{"id": "6683487_4", "context": "To our knowledge, no prior cases of penicillamine-induced TTP in RA have been reported.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[50]], "entity_id": ["T7"]}, "Treatment": {"text": [["penicillamine"]], "start": [[36]], "entity_id": ["T6"], "Drug": {"text": [["penicillamine"]], "start": [[36]], "entity_id": ["T9"]}}, "Effect": {"text": [["TTP"]], "start": [[58]], "entity_id": ["T8"]}, "Negated": {"text": [["no"]], "start": [[18]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "6529939_1", "context": "Alternating sinus rhythm and intermittent sinoatrial block induced by propranolol.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[59]], "entity_id": ["T6"]}, "Effect": {"text": [["Alternating sinus rhythm and intermittent sinoatrial block"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["propranolol"]], "start": [[70]], "entity_id": ["T7"], "Drug": {"text": [["propranolol"]], "start": [[70]], "entity_id": ["T8"]}}}]}]}
{"id": "9701106_5", "context": "The noted increase in the theophylline level after zafirlukast administration is in contrast to the original reports by the manufacturer.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[45]], "entity_id": ["T5"]}, "Effect": {"text": [["increase in the theophylline level"]], "start": [[10]], "entity_id": ["T4"]}, "Treatment": {"text": [["zafirlukast administration"]], "start": [[51]], "entity_id": ["T6"], "Drug": {"text": [["zafirlukast"]], "start": [[51]], "entity_id": ["T7"]}}}]}]}
{"id": "6947095_2", "context": "The cause is presumed to be secondary to hypercoagulability due to asparaginase-induced antithrombin III deficiency.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[80]], "entity_id": ["T4"]}, "Effect": {"text": [["antithrombin III deficiency"]], "start": [[88]], "entity_id": ["T3"]}, "Treatment": {"text": [["asparaginase"]], "start": [[67]], "entity_id": ["T5"], "Drug": {"text": [["asparaginase"]], "start": [[67]], "entity_id": ["T7"]}}, "Speculated": {"text": [["presumed"]], "start": [[13]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "10749332_5", "context": "Troglitazone-induced fulminant hepatic failure.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[13]], "entity_id": ["T4"]}, "Treatment": {"text": [["Troglitazone"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Troglitazone"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["fulminant hepatic failure"]], "start": [[21]], "entity_id": ["T5"]}}]}]}
{"id": "2320800_2", "context": "A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[87]], "entity_id": ["T10"]}, "Subject": {"text": [["A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin"]], "start": [[0]], "entity_id": ["T9"], "Age": {"text": [["sixty-year-old"]], "start": [[2]], "entity_id": ["T13"]}, "Gender": {"text": [["woman"]], "start": [[17]], "entity_id": ["T14"]}}, "Effect": {"text": [["an irreversible lethal renal failure with anuria"]], "start": [[97]], "entity_id": ["T11"]}, "Treatment": {"text": [["the day after 5 g/m2 bolus ifosfamide"]], "start": [[147]], "entity_id": ["T12"], "Disorder": {"text": [["advanced breast cancer"]], "start": [[28]], "entity_id": ["T15"]}, "Time_elapsed": {"text": [["the day after"]], "start": [[147]], "entity_id": ["T17"]}, "Dosage": {"text": [["5 g/m2"]], "start": [[161]], "entity_id": ["T18"]}, "Drug": {"text": [["ifosfamide"]], "start": [[174]], "entity_id": ["T19"]}}, "Severity": {"text": [["irreversible"]], "start": [[100]], "entity_id": ["T20"], "value": "High"}}]}]}
{"id": "10467499_2", "context": "With the negative viral serologies, the clinical picture was most consistent with an infectious mononucleosis-like syndrome produced by the minocycline ingestion.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["produced"]], "start": [[124]], "entity_id": ["T4"]}, "Treatment": {"text": [["minocycline ingestion"]], "start": [[140]], "entity_id": ["T3"], "Route": {"text": [["ingestion"]], "start": [[152]], "entity_id": ["T6"]}, "Drug": {"text": [["minocycline"]], "start": [[140]], "entity_id": ["T7"]}}, "Effect": {"text": [["infectious mononucleosis-like syndrome"]], "start": [[85]], "entity_id": ["T5"]}}]}]}
{"id": "15920338_2", "context": "High-grade endometrial stromal sarcoma after tamoxifen therapy for breast cancer.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[39]], "entity_id": ["T4"]}, "Effect": {"text": [["High-grade endometrial stromal sarcoma"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["tamoxifen"]], "start": [[45]], "entity_id": ["T5"], "Drug": {"text": [["tamoxifen"]], "start": [[45]], "entity_id": ["T7"]}, "Disorder": {"text": [["breast cancer"]], "start": [[67]], "entity_id": ["T6"]}}}]}]}
{"id": "16207263_2", "context": "We report here two cases of dyserythropoietic anaemia associated with long-term linezolid use that share striking similarities to chloramphenicol-associated myelotoxicity.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[54]], "entity_id": ["T7"]}, "Effect": {"text": [["dyserythropoietic anaemia"]], "start": [[28]], "entity_id": ["T5"]}, "Treatment": {"text": [["long-term linezolid"]], "start": [[70]], "entity_id": ["T6"], "Drug": {"text": [["linezolid"]], "start": [[80]], "entity_id": ["T8"]}, "Duration": {"text": [["long-term"]], "start": [[70]], "entity_id": ["T9"]}}}]}]}
{"id": "16503727_2", "context": "Dipyrone-induced granulocytopenia: a case for awareness.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[9]], "entity_id": ["T4"]}, "Treatment": {"text": [["Dipyrone"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Dipyrone"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["granulocytopenia"]], "start": [[17]], "entity_id": ["T5"]}, "Subject": {"text": [["a case"]], "start": [[35]], "entity_id": ["T6"]}}]}]}
{"id": "22233409_4", "context": "We report the case of a patient with chronic hepatitis C infection who developed severe anaemia during antiviral treatment with peginterferon alfa/ribavirin when oseltamivir was added to treat influenza.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[71]], "entity_id": ["T15"]}, "Effect": {"text": [["severe anaemia"]], "start": [[81]], "entity_id": ["T16"]}, "Treatment": {"text": [["peginterferon alfa/ribavirin", "oseltamivir"]], "start": [[128, 162]], "entity_id": ["T17"], "Disorder": {"text": [["chronic hepatitis C infection"], ["influenza"]], "start": [[37], [193]], "entity_id": ["T14", "T18"]}, "Drug": {"text": [["peginterferon alfa"], ["ribavirin"], ["oseltamivir"]], "start": [[128], [147], [162]], "entity_id": ["T19", "T20", "T22"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["/"]], "start": [[146]], "entity_id": ["T21"]}, "Drug": {"text": [["peginterferon alfa"], ["ribavirin"], ["oseltamivir"]], "start": [[128], [147], [162]], "entity_id": ["T19", "T20", "T22"]}}]}, "Subject": {"text": [["a patient with chronic hepatitis C infection"]], "start": [[22]], "entity_id": ["T13"]}}]}]}
{"id": "8641617_3", "context": "Both patients were then treated with a carboplatin alternative to cisplatin in the following courses, which resulted in neither a relapse of the colitis nor a recurrence of the malignancies up to this time.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["resulted"]], "start": [[108]], "entity_id": ["T5"]}, "Subject": {"text": [["Both patients"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["carboplatin"]], "start": [[39]], "entity_id": ["T4"], "Drug": {"text": [["carboplatin"]], "start": [[39]], "entity_id": ["T7"]}, "Disorder": {"text": [["colitis", "malignancies"]], "start": [[145, 177]], "entity_id": ["T6"]}}, "Effect": {"text": [["neither a relapse of the colitis nor a recurrence of the malignancies"]], "start": [[120]], "entity_id": ["T9"]}, "Negated": {"text": [["neither"]], "start": [[120]], "entity_id": ["T8"], "value": true}}]}]}
{"id": "18344455_2", "context": "It is rare to develop simultaneous toxicities while on anticonvulsants.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["develop"]], "start": [[14]], "entity_id": ["T5"]}, "Effect": {"text": [["toxicities"]], "start": [[35]], "entity_id": ["T6"]}, "Treatment": {"text": [["anticonvulsants"]], "start": [[55]], "entity_id": ["T7"], "Drug": {"text": [["anticonvulsants"]], "start": [[55]], "entity_id": ["T8"]}}}]}]}
{"id": "16211208_1", "context": "Because of serious side effects of an increase in the QT interval causing torsades de pointes, dofetilide must be initiated with close monitoring of the QT interval in an inpatient setting.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["increase"]], "start": [[38]], "entity_id": ["T5"]}, "Treatment": {"text": [["dofetilide"]], "start": [[95]], "entity_id": ["T6"], "Drug": {"text": [["dofetilide"]], "start": [[95]], "entity_id": ["T8"]}}, "Effect": {"text": [["QT interval causing torsades de pointes"]], "start": [[54]], "entity_id": ["T7"]}, "Severity": {"text": [["serious"]], "start": [[11]], "entity_id": ["T9"], "value": "High"}}]}]}
{"id": "8651254_2", "context": "It should be emphasized that the recurrence of nephrotic syndrome was observed after the following chemotherapy, including M-CSF, whereas the bone marrow still remained completely remitted.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[79]], "entity_id": ["T4"]}, "Effect": {"text": [["nephrotic syndrome", "the bone marrow still remained completely remitted"]], "start": [[47, 138]], "entity_id": ["T3"]}, "Treatment": {"text": [["chemotherapy, including M-CSF"]], "start": [[99]], "entity_id": ["T5"], "Drug": {"text": [["M-CSF"]], "start": [[123]], "entity_id": ["T6"]}}}]}]}
{"id": "8604715_4", "context": "We present a patient with human immunodeficiency virus infection under treatment with foscarnet for CMV retinitis who complained of thirst and polyuria.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["complained"]], "start": [[118]], "entity_id": ["T8"]}, "Subject": {"text": [["a patient with human immunodeficiency virus infection"]], "start": [[11]], "entity_id": ["T5"], "Disorder": {"text": [["human immunodeficiency virus infection"]], "start": [[26]], "entity_id": ["T10"]}}, "Treatment": {"text": [["foscarnet"]], "start": [[86]], "entity_id": ["T6"], "Disorder": {"text": [["CMV retinitis"]], "start": [[100]], "entity_id": ["T7"]}, "Drug": {"text": [["foscarnet"]], "start": [[86]], "entity_id": ["T11"]}}, "Effect": {"text": [["thirst and polyuria"]], "start": [[132]], "entity_id": ["T9"]}}]}]}
{"id": "8672829_6", "context": "This represents the first report of nonconvulsive status epilepticus induced by ifosfamide.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[69]], "entity_id": ["T4"]}, "Effect": {"text": [["nonconvulsive status epilepticus"]], "start": [[36]], "entity_id": ["T3"]}, "Treatment": {"text": [["ifosfamide"]], "start": [[80]], "entity_id": ["T5"], "Drug": {"text": [["ifosfamide"]], "start": [[80]], "entity_id": ["T6"]}}}]}]}
{"id": "17536204_2", "context": "BACKGROUND: Headaches have been reported as a potential side effect of capecitabine therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["of"]], "start": [[68]], "entity_id": ["T4"]}, "Effect": {"text": [["Headaches"]], "start": [[12]], "entity_id": ["T3"]}, "Treatment": {"text": [["capecitabine"]], "start": [[71]], "entity_id": ["T5"], "Drug": {"text": [["capecitabine"]], "start": [[71]], "entity_id": ["T6"]}}}]}]}
{"id": "18795_3", "context": "When DSCG was withdrawn, urticaria vanished and the child remained symptom-free.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["remained"]], "start": [[58]], "entity_id": ["T6"]}, "Effect": {"text": [["urticaria vanished", "symptom-free"]], "start": [[25, 67]], "entity_id": ["T4"]}, "Treatment": {"text": [["DSCG was withdrawn"]], "start": [[5]], "entity_id": ["T3"], "Drug": {"text": [["DSCG"]], "start": [[5]], "entity_id": ["T8"]}}, "Subject": {"text": [["the child"]], "start": [[48]], "entity_id": ["T5"], "Age": {"text": [["child"]], "start": [[52]], "entity_id": ["T7"]}}}]}]}
{"id": "8345435_1", "context": "Hepatotoxic effects in a child receiving valproate and carnitine.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["receiving"]], "start": [[31]], "entity_id": ["T6"]}, "Effect": {"text": [["Hepatotoxic effects"]], "start": [[0]], "entity_id": ["T4"]}, "Subject": {"text": [["a child"]], "start": [[23]], "entity_id": ["T5"], "Age": {"text": [["child"]], "start": [[25]], "entity_id": ["T8"]}}, "Treatment": {"text": [["valproate and carnitine"]], "start": [[41]], "entity_id": ["T7"], "Drug": {"text": [["valproate"], ["carnitine"]], "start": [[41], [55]], "entity_id": ["T9", "T10"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[51]], "entity_id": ["T11"]}, "Drug": {"text": [["valproate"], ["carnitine"]], "start": [[41], [55]], "entity_id": ["T9", "T10"]}}]}}]}]}
{"id": "7718983_5", "context": "We report a case of Graves' hyperthyroidism induced by long-term interferon (IFN) therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[44]], "entity_id": ["T6"]}, "Effect": {"text": [["Graves' hyperthyroidism"]], "start": [[20]], "entity_id": ["T4"]}, "Subject": {"text": [["a case"]], "start": [[10]], "entity_id": ["T5"]}, "Treatment": {"text": [["long-term interferon (IFN) therapy"]], "start": [[55]], "entity_id": ["T7"], "Time_elapsed": {"text": [["long-term"]], "start": [[55]], "entity_id": ["T8"]}, "Drug": {"text": [["interferon"]], "start": [[65]], "entity_id": ["T9"]}}}]}]}
{"id": "9211543_1", "context": "Bleomycin and cyclophosphamide toxicity simulating metastatic nodules to the lungs in childhood cancer.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["simulating"]], "start": [[40]], "entity_id": ["T9"]}, "Treatment": {"text": [["Bleomycin and cyclophosphamide toxicity"]], "start": [[0]], "entity_id": ["T8"], "Disorder": {"text": [["cancer"]], "start": [[96]], "entity_id": ["T13"]}, "Drug": {"text": [["Bleomycin"], ["cyclophosphamide"]], "start": [[0], [14]], "entity_id": ["T14", "T15"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[10]], "entity_id": ["T16"]}, "Drug": {"text": [["cyclophosphamide"], ["Bleomycin"]], "start": [[14], [0]], "entity_id": ["T15", "T14"]}}]}, "Effect": {"text": [["metastatic nodules to the lungs"]], "start": [[51]], "entity_id": ["T10"]}, "Subject": {"text": [["childhood cancer"]], "start": [[86]], "entity_id": ["T11"], "Age": {"text": [["childhood"]], "start": [[86]], "entity_id": ["T12"]}}}]}]}
{"id": "17266059_1", "context": "The patient presented with fulminant microangiopathic hemolytic anemia and thrombocytopenia within 48 hr of initiating therapy with trimethoprim-sulfamethoxazole.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["presented"]], "start": [[12]], "entity_id": ["T9"]}, "Subject": {"text": [["The patient"]], "start": [[0]], "entity_id": ["T10"]}, "Effect": {"text": [["fulminant microangiopathic hemolytic anemia and thrombocytopenia"]], "start": [[27]], "entity_id": ["T7"]}, "Treatment": {"text": [["within 48 hr of initiating therapy with trimethoprim-sulfamethoxazole"]], "start": [[92]], "entity_id": ["T8"], "Time_elapsed": {"text": [["48 hr"]], "start": [[99]], "entity_id": ["T11"]}, "Drug": {"text": [["trimethoprim"], ["sulfamethoxazole"]], "start": [[132], [145]], "entity_id": ["T12", "T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["-"]], "start": [[144]], "entity_id": ["T14"]}, "Drug": {"text": [["trimethoprim"], ["sulfamethoxazole"]], "start": [[132], [145]], "entity_id": ["T12", "T13"]}}]}}]}]}
{"id": "1792646_2", "context": "Pneumocystis pneumonia should be considered in asthmatic patients taking methotrexate who present with fever, pulmonary infiltrates, and hypoxia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["taking"]], "start": [[66]], "entity_id": ["T11"]}, "Effect": {"text": [["Pneumocystis pneumonia", "fever, pulmonary infiltrates, and hypoxia"]], "start": [[0, 103]], "entity_id": ["T9"]}, "Treatment": {"text": [["methotrexate"]], "start": [[73]], "entity_id": ["T10"], "Drug": {"text": [["methotrexate"]], "start": [[73]], "entity_id": ["T15"]}, "Disorder": {"text": [["asthmatic"]], "start": [[47]], "entity_id": ["T16"]}}, "Subject": {"text": [["asthmatic patients"]], "start": [[47]], "entity_id": ["T12"]}, "Speculated": {"text": [["should"]], "start": [[23]], "entity_id": ["T14"], "value": true}}]}]}
{"id": "16298824_1", "context": "Acute respiratory distress syndrome after rituximab infusion.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[36]], "entity_id": ["T4"]}, "Effect": {"text": [["Acute respiratory distress syndrome"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["rituximab infusion"]], "start": [[42]], "entity_id": ["T5"], "Drug": {"text": [["rituximab"]], "start": [[42]], "entity_id": ["T6"]}, "Route": {"text": [["infusion"]], "start": [[52]], "entity_id": ["T7"]}}}]}]}
{"id": "17406804_3", "context": "CONCLUSION: Gemcitabine-induced recall pneumonitis is a rarely reported phenomenon and should be taken into account even after extended time interval to the previous radiotherapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[24]], "entity_id": ["T4"]}, "Treatment": {"text": [["Gemcitabine"]], "start": [[12]], "entity_id": ["T3"], "Drug": {"text": [["Gemcitabine"]], "start": [[12]], "entity_id": ["T7"]}}, "Effect": {"text": [["recall pneumonitis"]], "start": [[32]], "entity_id": ["T5"]}}]}]}
{"id": "6519218_1", "context": "In a 61-year-old man receiving chronic low-dosage amiodarone an interstitial pneumopathy was observed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["observed"]], "start": [[93]], "entity_id": ["T6"]}, "Treatment": {"text": [["chronic low-dosage amiodarone"]], "start": [[31]], "entity_id": ["T3"], "Drug": {"text": [["amiodarone"]], "start": [[50]], "entity_id": ["T9"]}, "Dosage": {"text": [["low-dosage"]], "start": [[39]], "entity_id": ["T10"]}}, "Subject": {"text": [["a 61-year-old man"]], "start": [[3]], "entity_id": ["T4"], "Age": {"text": [["61-year-old"]], "start": [[5]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[17]], "entity_id": ["T8"]}}, "Effect": {"text": [["interstitial pneumopathy"]], "start": [[64]], "entity_id": ["T5"]}}]}]}
{"id": "12126225_2", "context": "A 75-year-old man developed bilateral lower leg edema 6 months after switching from troglitazone to pioglitazone.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[18]], "entity_id": ["T4"]}, "Subject": {"text": [["A 75-year-old man"]], "start": [[0]], "entity_id": ["T3"], "Age": {"text": [["75-year-old"]], "start": [[2]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[14]], "entity_id": ["T8"]}}, "Effect": {"text": [["bilateral lower leg edema"]], "start": [[28]], "entity_id": ["T5"]}, "Treatment": {"text": [["6 months after switching from troglitazone to pioglitazone"]], "start": [[54]], "entity_id": ["T6"], "Drug": {"text": [["pioglitazone"], ["6 months"], ["troglitazone"]], "start": [[100], [54], [84]], "entity_id": ["T9", "T10", "T12"]}}}]}]}
{"id": "10475726_1", "context": "An acute ischaemic event associated with the use of venlafaxine: a case report and proposed pathophysiological mechanisms.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[25]], "entity_id": ["T3"]}, "Treatment": {"text": [["venlafaxine"]], "start": [[52]], "entity_id": ["T4"], "Drug": {"text": [["venlafaxine"]], "start": [[52]], "entity_id": ["T7"]}}, "Effect": {"text": [["An acute ischaemic event"]], "start": [[0]], "entity_id": ["T5"]}, "Subject": {"text": [["a case"]], "start": [[65]], "entity_id": ["T6"]}}]}]}
{"id": "21751666_5", "context": "Oseltamivir was effective for post-exposure prophylaxis of H1N1 in close contact.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["post-exposure prophylaxis"]], "start": [[30]], "entity_id": ["T6"]}, "Treatment": {"text": [["Oseltamivir"]], "start": [[0]], "entity_id": ["T4"], "Disorder": {"text": [["H1N1"]], "start": [[59]], "entity_id": ["T5"]}, "Drug": {"text": [["Oseltamivir"]], "start": [[0]], "entity_id": ["T8"]}}}]}]}
{"id": "19365885_1", "context": "Herein, we present a patient with severe and prolonged hypoglycemia after long-acting octreotide treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[68]], "entity_id": ["T3"]}, "Treatment": {"text": [["long-acting octreotide treatment"]], "start": [[74]], "entity_id": ["T4"], "Drug": {"text": [["octreotide"]], "start": [[86]], "entity_id": ["T8"]}}, "Subject": {"text": [["a patient"]], "start": [[19]], "entity_id": ["T5"]}, "Effect": {"text": [["severe and prolonged hypoglycemia"]], "start": [[34]], "entity_id": ["T6"]}, "Severity": {"text": [["severe"]], "start": [[34]], "entity_id": ["T7"], "value": "High"}}]}]}
{"id": "25417855_1", "context": "Worsening pneumonitis due to a pharmacokinetic drug-drug interaction between everolimus and voriconazole in a renal transplant patient.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due to"]], "start": [[22]], "entity_id": ["T9"]}, "Subject": {"text": [["a renal transplant patient"]], "start": [[108]], "entity_id": ["T8"]}, "Effect": {"text": [["Worsening pneumonitis"]], "start": [[0]], "entity_id": ["T10"]}, "Treatment": {"text": [["pharmacokinetic drug-drug interaction between everolimus and voriconazole"]], "start": [[31]], "entity_id": ["T7"], "Drug": {"text": [["everolimus"], ["voriconazole"]], "start": [[77], [92]], "entity_id": ["T11", "T12"]}, "Disorder": {"text": [["renal transplant"]], "start": [[110]], "entity_id": ["T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[57]], "entity_id": ["T13"]}, "Drug": {"text": [["everolimus"], ["voriconazole"]], "start": [[77], [92]], "entity_id": ["T11", "T12"]}}]}}]}]}
{"id": "11576059_1", "context": "Vocal cord paralysis as a consequence of peritonsillar infiltration with bupivacaine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["consequence"]], "start": [[26]], "entity_id": ["T4"]}, "Effect": {"text": [["Vocal cord paralysis"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["peritonsillar infiltration with bupivacaine"]], "start": [[41]], "entity_id": ["T5"], "Route": {"text": [["peritonsillar infiltration"]], "start": [[41]], "entity_id": ["T6"]}, "Drug": {"text": [["bupivacaine"]], "start": [[73]], "entity_id": ["T7"]}}}]}]}
{"id": "1267457_3", "context": "The sulfonamides are the best verified drug-trigger for erythema multiforme and Stevens-Johnson syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E2", "event_type": "Adverse_event", "Trigger": {"text": [["drug-trigger"]], "start": [[39]], "entity_id": ["T9"]}, "Treatment": {"text": [["sulfonamides"]], "start": [[4]], "entity_id": ["T5"], "Drug": {"text": [["sulfonamides"]], "start": [[4]], "entity_id": ["T8"]}}, "Effect": {"text": [["erythema multiforme and Stevens-Johnson syndrome"]], "start": [[56]], "entity_id": ["T6"]}}]}]}
{"id": "576675_2", "context": "Edema associated with ibuprofen therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[6]], "entity_id": ["T4"]}, "Effect": {"text": [["Edema"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["ibuprofen"]], "start": [[22]], "entity_id": ["T5"], "Drug": {"text": [["ibuprofen"]], "start": [[22]], "entity_id": ["T6"]}}}]}]}
{"id": "3365032_1", "context": "A patient is presented with typical hyperthyroidism, who developed a severe proximal muscle weakness and a raised creatine phosphokinase after treatment for hyperthyroidism with propylthiouracil (100 mg orally, three times a day).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[137]], "entity_id": ["T7"]}, "Subject": {"text": [["A patient is presented with typical hyperthyroidism"]], "start": [[0]], "entity_id": ["T8"]}, "Effect": {"text": [["severe proximal muscle weakness and a raised creatine phosphokinase"]], "start": [[69]], "entity_id": ["T10"]}, "Treatment": {"text": [["treatment for hyperthyroidism with propylthiouracil (100 mg orally, three times a day)"]], "start": [[143]], "entity_id": ["T11"], "Disorder": {"text": [["hyperthyroidism"], ["typical hyperthyroidism"]], "start": [[157], [28]], "entity_id": ["T13", "T18"]}, "Drug": {"text": [["propylthiouracil"]], "start": [[178]], "entity_id": ["T14"]}, "Dosage": {"text": [["100 mg"]], "start": [[196]], "entity_id": ["T15"]}, "Route": {"text": [["orally"]], "start": [[203]], "entity_id": ["T16"]}, "Freq": {"text": [["three times a day"]], "start": [[211]], "entity_id": ["T17"]}}, "Severity": {"text": [["severe"]], "start": [[69]], "entity_id": ["T12"], "value": "Medium"}}]}]}
{"id": "12243603_7", "context": "Atorvastatin is the most potent of this class of agents currently available and is commonly used in the treatment of hyperlipidemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treatment"]], "start": [[104]], "entity_id": ["T8"]}, "Treatment": {"text": [["Atorvastatin"]], "start": [[0]], "entity_id": ["T5"], "Disorder": {"text": [["hyperlipidemia"]], "start": [[117]], "entity_id": ["T6"]}, "Drug": {"text": [["Atorvastatin"]], "start": [[0]], "entity_id": ["T9"]}}, "Effect": {"text": [["most potent"]], "start": [[20]], "entity_id": ["T7"]}}]}]}
{"id": "2935070_2", "context": "However, there are few reports in the literature of ampicillin as a cause of acute interstitial nephritis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[68]], "entity_id": ["T3"]}, "Treatment": {"text": [["ampicillin"]], "start": [[52]], "entity_id": ["T4"], "Drug": {"text": [["ampicillin"]], "start": [[52]], "entity_id": ["T6"]}}, "Effect": {"text": [["acute interstitial nephritis"]], "start": [[77]], "entity_id": ["T5"]}}]}]}
{"id": "2956288_3", "context": "Optic neuropathy in ethambutol-treated renal tuberculosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[31]], "entity_id": ["T6"]}, "Effect": {"text": [["Optic neuropathy"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["ethambutol"]], "start": [[20]], "entity_id": ["T4"], "Drug": {"text": [["ethambutol"]], "start": [[20]], "entity_id": ["T7"]}, "Disorder": {"text": [["renal tuberculosis"]], "start": [[39]], "entity_id": ["T8"]}}}]}]}
{"id": "7779233_2", "context": "This case study describes an atypical case of refractory, sodium warfarin-induced necrotizing fasciitis and myonecrosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[74]], "entity_id": ["T6"]}, "Treatment": {"text": [["sodium warfarin"]], "start": [[58]], "entity_id": ["T5"], "Drug": {"text": [["sodium warfarin"]], "start": [[58]], "entity_id": ["T8"]}}, "Effect": {"text": [["necrotizing fasciitis and myonecrosis"]], "start": [[82]], "entity_id": ["T7"]}}]}]}
{"id": "8384030_4", "context": "OBJECTIVE: To report a case of possible foscarnet-induced severe hypomagnesemia and other electrolyte disorders.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[50]], "entity_id": ["T8"]}, "Subject": {"text": [["a case"]], "start": [[21]], "entity_id": ["T5"]}, "Treatment": {"text": [["foscarnet"]], "start": [[40]], "entity_id": ["T7"], "Drug": {"text": [["foscarnet"]], "start": [[40]], "entity_id": ["T13"]}}, "Effect": {"text": [["severe hypomagnesemia and other electrolyte disorders"]], "start": [[58]], "entity_id": ["T9"]}, "Speculated": {"text": [["possible"]], "start": [[31]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "7673653_3", "context": "However, the occurrence and management of akathisia induced by fluvoxamine have not been described.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[52]], "entity_id": ["T4"]}, "Effect": {"text": [["akathisia"]], "start": [[42]], "entity_id": ["T3"]}, "Treatment": {"text": [["fluvoxamine"]], "start": [[63]], "entity_id": ["T5"], "Drug": {"text": [["fluvoxamine"]], "start": [[63]], "entity_id": ["T6"]}}}]}]}
{"id": "17009081_3", "context": "Nephrotic syndrome associated with interferon-beta-1b therapy for multiple sclerosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated with"]], "start": [[19]], "entity_id": ["T4"]}, "Effect": {"text": [["Nephrotic syndrome"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["interferon-beta-1b therapy"]], "start": [[35]], "entity_id": ["T5"], "Drug": {"text": [["interferon-beta-1b"]], "start": [[35]], "entity_id": ["T7"]}, "Disorder": {"text": [["multiple sclerosis."]], "start": [[66]], "entity_id": ["T8"]}}}]}]}
{"id": "17438184_3", "context": "OBSERVATIONS: A 48-year-old woman presented with disfiguring facial edema 10 weeks after she began antiviral therapy with peginterferon alfa-2a and ribavirin for chronic hepatitis C infection.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[83]], "entity_id": ["T8"]}, "Subject": {"text": [["A 48-year-old woman"]], "start": [[14]], "entity_id": ["T9"], "Age": {"text": [["48-year-old"]], "start": [[16]], "entity_id": ["T13"]}, "Gender": {"text": [["woman"]], "start": [[28]], "entity_id": ["T14"]}}, "Effect": {"text": [["disfiguring facial edema"]], "start": [[49]], "entity_id": ["T10"]}, "Treatment": {"text": [["10 weeks", "antiviral therapy with peginterferon alfa-2a and ribavirin"]], "start": [[74, 99]], "entity_id": ["T11"], "Disorder": {"text": [["chronic hepatitis C infection"]], "start": [[162]], "entity_id": ["T12"]}, "Time_elapsed": {"text": [["10 weeks"]], "start": [[74]], "entity_id": ["T15"]}, "Drug": {"text": [["peginterferon alfa-2a"], ["ribavirin"]], "start": [[122], [148]], "entity_id": ["T17", "T18"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[144]], "entity_id": ["T16"]}, "Drug": {"text": [["peginterferon alfa-2a"], ["ribavirin"]], "start": [[122], [148]], "entity_id": ["T17", "T18"]}}]}}]}]}
{"id": "4095247_3", "context": "Two of these patients, who also received the anti-emetic prochlorperazine, lost consciousness for 48-72 h and then fully recovered.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["lost"]], "start": [[75]], "entity_id": ["T6"]}, "Subject": {"text": [["Two of these patients"]], "start": [[0]], "entity_id": ["T3"], "Population": {"text": [["Two"]], "start": [[0]], "entity_id": ["T7"]}}, "Treatment": {"text": [["anti-emetic prochlorperazine"]], "start": [[45]], "entity_id": ["T4"], "Drug": {"text": [["prochlorperazine"]], "start": [[57]], "entity_id": ["T8"]}}, "Effect": {"text": [["lost consciousness for 48-72 h and then fully recovered"]], "start": [[75]], "entity_id": ["T5"]}}]}]}
{"id": "16986159_1", "context": "We present a depressive patient who developed mild parkinsonian signs and camptocormia after the introduction of olanzapine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[36]], "entity_id": ["T7"]}, "Effect": {"text": [["mild parkinsonian signs and camptocormia"]], "start": [[46]], "entity_id": ["T5"]}, "Treatment": {"text": [["introduction of olanzapine"]], "start": [[97]], "entity_id": ["T6"], "Drug": {"text": [["olanzapine"]], "start": [[113]], "entity_id": ["T11"]}, "Disorder": {"text": [["depressive"]], "start": [[13]], "entity_id": ["T12"]}}, "Subject": {"text": [["depressive patient"]], "start": [[13]], "entity_id": ["T8"]}, "Severity": {"text": [["mild"]], "start": [[46]], "entity_id": ["T10"], "value": "Medium"}}]}]}
{"id": "7379406_3", "context": "The case report discussed is, to our knowledge, the third of its kind regarding bone fluorosis resulting from use of this nicotinic derivative.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["use"]], "start": [[110]], "entity_id": ["T4"]}, "Treatment": {"text": [["nicotinic derivative"]], "start": [[122]], "entity_id": ["T5"], "Drug": {"text": [["nicotinic derivative"]], "start": [[122]], "entity_id": ["T7"]}}, "Effect": {"text": [["bone fluorosis"]], "start": [[80]], "entity_id": ["T6"]}}]}]}
{"id": "17266059_3", "context": "We report a case of Thrombotic Thrombocytopenic Purpura occurring as an allergic response to trimethoprim-sulfamethoxazole therapy (Bactrim, Septra) in a Jehovah's Witness patient.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["to"]], "start": [[90]], "entity_id": ["T6"]}, "Effect": {"text": [["Thrombotic Thrombocytopenic Purpura", "allergic response"]], "start": [[20, 72]], "entity_id": ["T4"]}, "Treatment": {"text": [["trimethoprim-sulfamethoxazole"]], "start": [[93]], "entity_id": ["T5"], "Drug": {"text": [["trimethoprim"], ["sulfamethoxazole"]], "start": [[93], [106]], "entity_id": ["T8", "T9"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["-"]], "start": [[105]], "entity_id": ["T10"]}, "Drug": {"text": [["trimethoprim"], ["sulfamethoxazole"]], "start": [[93], [106]], "entity_id": ["T8", "T9"]}}]}, "Subject": {"text": [["Jehovah's Witness patient"]], "start": [[154]], "entity_id": ["T7"]}}]}]}
{"id": "11144696_3", "context": "A 25-year-old white woman with chronic depression was treated with venlafaxine 150 mg/d and trimipramine 50 mg/d.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["treated"]], "start": [[54]], "entity_id": ["T9"]}, "Treatment": {"text": [["venlafaxine 150 mg/d and trimipramine 50 mg/d"]], "start": [[67]], "entity_id": ["T10"], "Disorder": {"text": [["chronic depression"]], "start": [[31]], "entity_id": ["T8"]}, "Drug": {"text": [["venlafaxine"], ["trimipramine"]], "start": [[67], [92]], "entity_id": ["T15", "T16"]}, "Dosage": {"text": [["150 mg/d"], ["50 mg/d"]], "start": [[79], [105]], "entity_id": ["T17", "T20"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[88]], "entity_id": ["T14"]}, "Drug": {"text": [["venlafaxine"], ["trimipramine"]], "start": [[67], [92]], "entity_id": ["T15", "T16"]}}]}, "Subject": {"text": [["A 25-year-old white woman with chronic depression"]], "start": [[0]], "entity_id": ["T7"], "Age": {"text": [["25-year-old"]], "start": [[2]], "entity_id": ["T11"]}, "Race": {"text": [["white"]], "start": [[14]], "entity_id": ["T12"]}, "Gender": {"text": [["woman"]], "start": [[20]], "entity_id": ["T13"]}}}]}]}
{"id": "12078977_1", "context": "A 31-year-old female developed multiple episodes of grand mal seizures after combination chemotherapy with cisplatin, vinblastine and bleomycin for germ cell ovarian cancer stage Ic.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[21]], "entity_id": ["T6"]}, "Subject": {"text": [["A 31-year-old female"]], "start": [[0]], "entity_id": ["T5"], "Age": {"text": [["31-year-old"]], "start": [[2]], "entity_id": ["T9"]}, "Gender": {"text": [["female"]], "start": [[14]], "entity_id": ["T10"]}}, "Effect": {"text": [["multiple episodes of grand mal seizures"]], "start": [[31]], "entity_id": ["T7"]}, "Treatment": {"text": [["combination chemotherapy with cisplatin, vinblastine and bleomycin"]], "start": [[77]], "entity_id": ["T8"], "Disorder": {"text": [["germ cell ovarian cancer stage Ic"]], "start": [[148]], "entity_id": ["T11"]}, "Drug": {"text": [["bleomycin"], ["vinblastine"], ["cisplatin"]], "start": [[134], [118], [107]], "entity_id": ["T12", "T13", "T14"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combination"]], "start": [[77]], "entity_id": ["T15"]}, "Drug": {"text": [["cisplatin"], ["vinblastine"], ["bleomycin"]], "start": [[107], [118], [134]], "entity_id": ["T14", "T13", "T12"]}}]}}]}]}
{"id": "8604715_1", "context": "Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["secondary"]], "start": [[58]], "entity_id": ["T6"]}, "Treatment": {"text": [["foscarnet"]], "start": [[71]], "entity_id": ["T5"], "Drug": {"text": [["foscarnet"]], "start": [[71]], "entity_id": ["T8"]}}, "Effect": {"text": [["Nephrogenic diabetes insipidus and renal tubular acidosis"]], "start": [[0]], "entity_id": ["T7"]}}]}]}
{"id": "16765687_1", "context": "PURPOSE: Topiramate-induced angle-closure glaucoma (TiACG) is believed to be related to its sulfonamide moiety.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[20]], "entity_id": ["T4"]}, "Treatment": {"text": [["Topiramate"]], "start": [[9]], "entity_id": ["T3"], "Drug": {"text": [["Topiramate"]], "start": [[9]], "entity_id": ["T6"]}}, "Effect": {"text": [["angle-closure glaucoma (TiACG)"]], "start": [[28]], "entity_id": ["T5"]}}]}]}
{"id": "18344455_4", "context": "These toxicities resolved after the cessation of anticonvulsants, and her seizures were managed acutely with scheduled lorazepam.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["managed"]], "start": [[88]], "entity_id": ["T6"]}, "Treatment": {"text": [["lorazepam"]], "start": [[119]], "entity_id": ["T7"], "Disorder": {"text": [["seizures"]], "start": [[74]], "entity_id": ["T5"]}, "Drug": {"text": [["lorazepam"]], "start": [[119]], "entity_id": ["T9"]}}}]}]}
{"id": "2728526_4", "context": "This article reports the occurrence of rifampin-associated thrombocytopenia in an indigent patient after a four-month lapse in therapy for pulmonary tuberculosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[48]], "entity_id": ["T8"]}, "Treatment": {"text": [["rifampin", "after a four-month lapse in therapy for pulmonary tuberculosis"]], "start": [[39, 99]], "entity_id": ["T7"], "Drug": {"text": [["rifampin"]], "start": [[39]], "entity_id": ["T6"]}, "Time_elapsed": {"text": [["four-month"]], "start": [[107]], "entity_id": ["T11"]}, "Disorder": {"text": [["pulmonary tuberculosis"]], "start": [[139]], "entity_id": ["T12"]}}, "Effect": {"text": [["thrombocytopenia"]], "start": [[59]], "entity_id": ["T9"]}, "Subject": {"text": [["an indigent patient"]], "start": [[79]], "entity_id": ["T10"]}}]}]}
{"id": "6721543_1", "context": "Drug-induced psychosis resulted from the administration of quinacrine hydrochloride at a dosage of 100 mg twice daily for the treatment of discoid lupus.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[5]], "entity_id": ["T5"]}, "Treatment": {"text": [["administration of quinacrine hydrochloride at a dosage of 100 mg twice daily"]], "start": [[41]], "entity_id": ["T3"], "Dosage": {"text": [["100 mg"]], "start": [[99]], "entity_id": ["T7"]}, "Freq": {"text": [["twice daily"]], "start": [[106]], "entity_id": ["T8"]}, "Disorder": {"text": [["discoid lupus"]], "start": [[139]], "entity_id": ["T9"]}, "Drug": {"text": [["quinacrine hydrochloride"]], "start": [[59]], "entity_id": ["T10"]}}, "Effect": {"text": [["psychosis resulted"]], "start": [[13]], "entity_id": ["T6"]}}]}]}
{"id": "10688731_3", "context": "We report a case of a scleroderma-like reaction induced by long-term administration of UFT.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[48]], "entity_id": ["T4"]}, "Effect": {"text": [["a scleroderma-like reaction"]], "start": [[20]], "entity_id": ["T3"]}, "Treatment": {"text": [["long-term administration of UFT"]], "start": [[59]], "entity_id": ["T5"], "Duration": {"text": [["long-term"]], "start": [[59]], "entity_id": ["T7"]}, "Drug": {"text": [["UFT"]], "start": [[87]], "entity_id": ["T8"]}}, "Subject": {"text": [["a case"]], "start": [[10]], "entity_id": ["T6"]}}]}]}
{"id": "16109609_4", "context": "We report four cases of hemodynamically significant pericardial effusion in patients with refractory lymphoma who were receiving gemcitabine, all of whom had a history of mediastinal radiation without subcarinal blocking.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["in"]], "start": [[73]], "entity_id": ["T6"]}, "Effect": {"text": [["hemodynamically significant pericardial effusion"]], "start": [[24]], "entity_id": ["T3"]}, "Subject": {"text": [["had a history of mediastinal radiation without subcarinal blocking"]], "start": [[154]], "entity_id": ["T4"], "Disorder": {"text": [["mediastinal radiation without subcarinal blocking"]], "start": [[171]], "entity_id": ["T8"]}, "Population": {"text": [["four"]], "start": [[10]], "entity_id": ["T1"]}}, "Treatment": {"text": [["gemcitabine"]], "start": [[129]], "entity_id": ["T5"], "Disorder": {"text": [["refractory lymphoma"]], "start": [[90]], "entity_id": ["T7"]}, "Drug": {"text": [["gemcitabine"]], "start": [[129]], "entity_id": ["T9"]}}}]}]}
{"id": "10679548_1", "context": "Both had impaired lung function and abnormal computed tomographic scans, and their condition improved when nitrofurantoin was withdrawn and corticosteroid treatment commenced.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["improved"]], "start": [[93]], "entity_id": ["T5"]}, "Treatment": {"text": [["nitrofurantoin was withdrawn and corticosteroid treatment commenced"]], "start": [[107]], "entity_id": ["T6"], "Drug": {"text": [["corticosteroid"], ["nitrofurantoin"]], "start": [[140], [107]], "entity_id": ["T11", "T12"]}, "Disorder": {"text": [["impaired lung function"]], "start": [[9]], "entity_id": ["T13"]}}, "Subject": {"text": [["Both had impaired lung function and abnormal computed tomographic scans"]], "start": [[0]], "entity_id": ["T7"], "Population": {"text": [["Both"]], "start": [[0]], "entity_id": ["T8"]}, "Disorder": {"text": [["abnormal computed tomographic scans"]], "start": [[36]], "entity_id": ["T10"]}}}]}]}
{"id": "18691992_6", "context": "OBJECTIVE: The purpose of this study was to report the concomitant occurrence of multiple squamous cell carcinomas and diffuse nail hyperpigmentation associated with hydroxyurea treatment, and to describe a successful therapeutic approach using imiquimod 5%.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[150]], "entity_id": ["T6"]}, "Effect": {"text": [["multiple squamous cell carcinomas and diffuse nail hyperpigmentation"]], "start": [[81]], "entity_id": ["T5"]}, "Treatment": {"text": [["hydroxyurea"]], "start": [[166]], "entity_id": ["T7"], "Drug": {"text": [["hydroxyurea"]], "start": [[166]], "entity_id": ["T8"]}}}]}]}
{"id": "17319250_2", "context": "We present a case report of a patient who developed a prolonged QT while being treated with oral methadone for a chronic pain syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[79]], "entity_id": ["T3"]}, "Treatment": {"text": [["oral methadone"]], "start": [[92]], "entity_id": ["T4"], "Drug": {"text": [["methadone"]], "start": [[97]], "entity_id": ["T7"]}, "Route": {"text": [["oral"]], "start": [[92]], "entity_id": ["T8"]}, "Disorder": {"text": [["chronic pain syndrome"]], "start": [[113]], "entity_id": ["T9"]}}, "Effect": {"text": [["prolonged QT"]], "start": [[54]], "entity_id": ["T5"]}, "Subject": {"text": [["a patient"]], "start": [[28]], "entity_id": ["T6"]}}]}]}
{"id": "19897274_3", "context": "In this article, we describe a Japanese patient with severe interstitial pneumonia probably caused by sorafenib treatment for metastatic renal cell carcinoma.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[92]], "entity_id": ["T5"]}, "Subject": {"text": [["a Japanese patient"]], "start": [[29]], "entity_id": ["T3"], "Race": {"text": [["Japanese"]], "start": [[31]], "entity_id": ["T8"]}}, "Effect": {"text": [["severe interstitial pneumonia"]], "start": [[53]], "entity_id": ["T4"]}, "Treatment": {"text": [["sorafenib"]], "start": [[102]], "entity_id": ["T6"], "Disorder": {"text": [["metastatic renal cell carcinoma"]], "start": [[126]], "entity_id": ["T7"]}, "Drug": {"text": [["sorafenib"]], "start": [[102]], "entity_id": ["T11"]}}, "Severity": {"text": [["severe"]], "start": [[53]], "entity_id": ["T9"], "value": "High"}, "Speculated": {"text": [["probably"]], "start": [[83]], "entity_id": ["T10"], "value": true}}]}]}
{"id": "15494638_17", "context": "Neurotoxicity occurs most often with intermittent high dose 5-FU as bolus injection or 24- to 48-h infusions.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["occurs"]], "start": [[14]], "entity_id": ["T4"]}, "Effect": {"text": [["Neurotoxicity"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["intermittent high dose 5-FU as bolus injection or 24- to 48-h infusions"]], "start": [[37]], "entity_id": ["T6"], "Dosage": {"text": [["high dose"]], "start": [[50]], "entity_id": ["T8"]}, "Drug": {"text": [["5-FU"]], "start": [[60]], "entity_id": ["T9"]}, "Route": {"text": [["injection"], ["infusions"]], "start": [[74], [99]], "entity_id": ["T10", "T11"]}}}]}]}
{"id": "14998226_7", "context": "Lovastatin also reportedly has caused increases in INR when coadministered with warfarin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[31]], "entity_id": ["T6"]}, "Treatment": {"text": [["Lovastatin"]], "start": [[0]], "entity_id": ["T7"], "Drug": {"text": [["Lovastatin"]], "start": [[0]], "entity_id": ["T9"]}}, "Effect": {"text": [["increases in INR"]], "start": [[38]], "entity_id": ["T8"]}}]}]}
{"id": "14998226_10", "context": "Pravastatin does not appear to interact with warfarin but has caused an increased INR when combined with the anticoagulant fluindione.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[62]], "entity_id": ["T10"]}, "Effect": {"text": [["increased INR"]], "start": [[72]], "entity_id": ["T11"]}, "Treatment": {"text": [["Pravastatin", "combined with the anticoagulant fluindion"]], "start": [[0, 91]], "entity_id": ["T12"], "Drug": {"text": [["Pravastatin"], ["anticoagulant fluindione"]], "start": [[0], [109]], "entity_id": ["T14", "T15"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["combined"]], "start": [[91]], "entity_id": ["T16"]}, "Drug": {"text": [["Pravastatin"], ["anticoagulant fluindione"]], "start": [[0], [109]], "entity_id": ["T14", "T15"]}}]}, "Negated": {"text": [["not"]], "start": [[17]], "entity_id": ["T13"], "value": true}}]}]}
{"id": "8120934_2", "context": "Bromocriptine-induced schizophrenia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[14]], "entity_id": ["T3"]}, "Treatment": {"text": [["Bromocriptine"]], "start": [[0]], "entity_id": ["T4"], "Drug": {"text": [["Bromocriptine"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["schizophrenia"]], "start": [[22]], "entity_id": ["T5"]}}]}]}
{"id": "17873198_2", "context": "Pulmonary toxicity associated with erlotinib.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[19]], "entity_id": ["T4"]}, "Effect": {"text": [["Pulmonary toxicity"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["erlotinib"]], "start": [[35]], "entity_id": ["T5"], "Drug": {"text": [["erlotinib"]], "start": [[35]], "entity_id": ["T6"]}}}]}]}
{"id": "2442958_1", "context": "Multicentric hepatocellular carcinoma following phosphate diethylstilbestrol therapy for prostatic cancer.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[38]], "entity_id": ["T4"]}, "Effect": {"text": [["Multicentric hepatocellular carcinoma"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["phosphate diethylstilbestrol"]], "start": [[48]], "entity_id": ["T5"], "Drug": {"text": [["phosphate diethylstilbestrol"]], "start": [[48]], "entity_id": ["T7"]}, "Disorder": {"text": [["prostatic cancer"]], "start": [[89]], "entity_id": ["T8"]}}}]}]}
{"id": "16025424_1", "context": "Rapid onset of quetiapine-induced diabetic ketoacidosis in an elderly patient: a case report.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[26]], "entity_id": ["T4"]}, "Treatment": {"text": [["quetiapine"]], "start": [[15]], "entity_id": ["T3"], "Drug": {"text": [["quetiapine"]], "start": [[15]], "entity_id": ["T8"]}}, "Effect": {"text": [["diabetic ketoacidosis"]], "start": [[34]], "entity_id": ["T5"]}, "Subject": {"text": [["an elderly patient"]], "start": [[59]], "entity_id": ["T6"], "Age": {"text": [["elderly"]], "start": [[62]], "entity_id": ["T7"]}}}]}]}
{"id": "3815268_1", "context": "A 57-year-old woman developed pulmonary sarcoidosis during therapy with interferon beta for advanced renal cell carcinoma metastatic to mediastinal lymph nodes.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[20]], "entity_id": ["T4"]}, "Subject": {"text": [["57-year-old woman"]], "start": [[2]], "entity_id": ["T3"], "Age": {"text": [["57-year-old"]], "start": [[2]], "entity_id": ["T8"]}, "Gender": {"text": [["woman"]], "start": [[14]], "entity_id": ["T9"]}}, "Effect": {"text": [["pulmonary sarcoidosis"]], "start": [[30]], "entity_id": ["T5"]}, "Treatment": {"text": [["interferon beta for advanced renal cell carcinoma metastatic to mediastinal lymph nodes"]], "start": [[72]], "entity_id": ["T6"], "Disorder": {"text": [["advanced renal cell carcinoma metastatic to mediastinal lymph nodes"]], "start": [[92]], "entity_id": ["T7"]}, "Drug": {"text": [["interferon beta"]], "start": [[72]], "entity_id": ["T10"]}}}]}]}
{"id": "9013348_2", "context": "Mesalamine-induced hypersensitivity pneumonitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[11]], "entity_id": ["T4"]}, "Treatment": {"text": [["Mesalamine"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Mesalamine"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["hypersensitivity pneumonitis"]], "start": [[19]], "entity_id": ["T5"]}}]}]}
{"id": "11737689_2", "context": "A girl with cystic fibrosis and cyclic neutropenia developed an erythematous papular eruption without fever or neutrophilia 7 months after commencing therapy with G-CSF.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[51]], "entity_id": ["T3"]}, "Treatment": {"text": [["7 months after commencing therapy with G-CSF."]], "start": [[124]], "entity_id": ["T4"], "Disorder": {"text": [["cyclic neutropenia"]], "start": [[32]], "entity_id": ["T9"]}, "Drug": {"text": [["G-CSF"]], "start": [[163]], "entity_id": ["T10"]}, "Time_elapsed": {"text": [["7 months"]], "start": [[124]], "entity_id": ["T11"]}}, "Subject": {"text": [["A girl with cystic fibrosis and cyclic neutropenia"]], "start": [[0]], "entity_id": ["T5"], "Gender": {"text": [["girl"]], "start": [[2]], "entity_id": ["T7"]}, "Disorder": {"text": [["cystic fibrosis"]], "start": [[12]], "entity_id": ["T8"]}}, "Effect": {"text": [["erythematous papular eruption without fever or neutrophilia"]], "start": [[64]], "entity_id": ["T6"]}}]}]}
{"id": "71813_3", "context": "Lichen planus and acne provoked by gold.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["provoked"]], "start": [[23]], "entity_id": ["T6"]}, "Effect": {"text": [["Lichen planus and acne"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["gold"]], "start": [[35]], "entity_id": ["T7"], "Drug": {"text": [["gold"]], "start": [[35]], "entity_id": ["T8"]}}}]}]}
{"id": "12153007_2", "context": "To the best of our knowledge only two previous cases of AML have been linked to treatment of HCL with purine analogs, both with 2-chlorodeoxyadenosine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["linked"]], "start": [[70]], "entity_id": ["T4"]}, "Effect": {"text": [["AML"]], "start": [[56]], "entity_id": ["T3"]}, "Treatment": {"text": [["purine analogs, both with 2-chlorodeoxyadenosine"]], "start": [[102]], "entity_id": ["T5"], "Drug": {"text": [["2-chlorodeoxyadenosine"]], "start": [[128]], "entity_id": ["T7"]}, "Disorder": {"text": [["HCL"]], "start": [[93]], "entity_id": ["T8"]}}}]}]}
{"id": "12656748_3", "context": "There are no previous reports in the literature about the emergence of CML during treatment with hydroxyurea.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[75]], "entity_id": ["T4"]}, "Effect": {"text": [["CML"]], "start": [[71]], "entity_id": ["T3"]}, "Treatment": {"text": [["treatment with hydroxyurea"]], "start": [[82]], "entity_id": ["T5"], "Drug": {"text": [["hydroxyurea"]], "start": [[97]], "entity_id": ["T6"]}}}]}]}
{"id": "10614572_1", "context": "Intravenous valproate associated with significant hypotension in the treatment of status epilepticus.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[22]], "entity_id": ["T3"]}, "Treatment": {"text": [["Intravenous valproate"]], "start": [[0]], "entity_id": ["T4"], "Disorder": {"text": [["status epilepticus"]], "start": [[82]], "entity_id": ["T6"]}, "Route": {"text": [["Intravenous"]], "start": [[0]], "entity_id": ["T7"]}, "Drug": {"text": [["valproate"]], "start": [[12]], "entity_id": ["T8"]}}, "Effect": {"text": [["significant hypotension"]], "start": [[38]], "entity_id": ["T5"]}}]}]}
{"id": "17876386_2", "context": "Torsade de pointes associated with moxifloxacin: a rare but potentially fatal adverse event.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[19]], "entity_id": ["T3"]}, "Treatment": {"text": [["moxifloxacin"]], "start": [[35]], "entity_id": ["T4"], "Drug": {"text": [["moxifloxacin"]], "start": [[35]], "entity_id": ["T7"]}}, "Effect": {"text": [["Torsade de pointes"]], "start": [[0]], "entity_id": ["T5"]}, "Severity": {"text": [["fatal"]], "start": [[72]], "entity_id": ["T6"], "value": "High"}}]}]}
{"id": "25417855_3", "context": "We report serious adverse effects due to interaction between orally administered voriconazole and everolimus in a renal transplant recipient.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due to"]], "start": [[34]], "entity_id": ["T7"]}, "Effect": {"text": [["serious adverse effects"]], "start": [[10]], "entity_id": ["T6"]}, "Treatment": {"text": [["interaction between orally administered voriconazole and everolimus"]], "start": [[41]], "entity_id": ["T8"], "Drug": {"text": [["voriconazole"], ["everolimus"]], "start": [[81], [98]], "entity_id": ["T12", "T13"]}, "Route": {"text": [["orally"]], "start": [[61]], "entity_id": ["T1"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[41]], "entity_id": ["T11"]}, "Drug": {"text": [["voriconazole"], ["everolimus"]], "start": [[81], [98]], "entity_id": ["T12", "T13"]}}]}, "Subject": {"text": [["a renal transplant recipient"]], "start": [[112]], "entity_id": ["T9"], "Disorder": {"text": [["renal transplant"]], "start": [[114]], "entity_id": ["T10"]}}}]}]}
{"id": "2554727_1", "context": "Horner's syndrome and demyelinating peripheral neuropathy caused by high-dose cytosine arabinoside.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[58]], "entity_id": ["T6"]}, "Effect": {"text": [["Horner's syndrome and demyelinating peripheral neuropathy"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["high-dose cytosine arabinoside"]], "start": [[68]], "entity_id": ["T7"], "Dosage": {"text": [["high-dose"]], "start": [[68]], "entity_id": ["T8"]}, "Drug": {"text": [["cytosine arabinoside"]], "start": [[78]], "entity_id": ["T9"]}}}]}]}
{"id": "16097572_1", "context": "Fatal radiation myelopathy after high-dose busulfan and melphalan chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[27]], "entity_id": ["T7"]}, "Effect": {"text": [["radiation myelopathy"]], "start": [[6]], "entity_id": ["T4"]}, "Treatment": {"text": [["high-dose busulfan", "melphalan"]], "start": [[33, 56]], "entity_id": ["T5"], "Dosage": {"text": [["high-dose"]], "start": [[33]], "entity_id": ["T8"]}, "Drug": {"text": [["busulfan"], ["melphalan"]], "start": [[43], [56]], "entity_id": ["T9", "T10"]}, "Disorder": {"text": [["Ewing's sarcoma:"]], "start": [[100]], "entity_id": ["T12"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[52]], "entity_id": ["T11"]}, "Drug": {"text": [["busulfan"], ["melphalan"]], "start": [[43], [56]], "entity_id": ["T9", "T10"]}}]}, "Severity": {"text": [["Fatal"]], "start": [[0]], "entity_id": ["T13"], "value": "High"}}]}]}
{"id": "8053440_4", "context": "This is the first description, to our knowledge, of ductopenia apparently caused by clindamycin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["caused"]], "start": [[74]], "entity_id": ["T4"]}, "Effect": {"text": [["ductopenia"]], "start": [[52]], "entity_id": ["T3"]}, "Treatment": {"text": [["clindamycin"]], "start": [[84]], "entity_id": ["T5"], "Drug": {"text": [["clindamycin"]], "start": [[84]], "entity_id": ["T7"]}}, "Speculated": {"text": [["to our knowledge"]], "start": [[31]], "entity_id": ["T6"], "value": true}}]}]}
{"id": "7781845_1", "context": "Mefloquine-associated hypoglycaemia in a cachectic AIDS patient.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[11]], "entity_id": ["T7"]}, "Treatment": {"text": [["Mefloquine"]], "start": [[0]], "entity_id": ["T6"], "Drug": {"text": [["Mefloquine"]], "start": [[0]], "entity_id": ["T11"]}}, "Effect": {"text": [["hypoglycaemia"]], "start": [[22]], "entity_id": ["T8"]}, "Subject": {"text": [["cachectic AIDS patient"]], "start": [[41]], "entity_id": ["T9"], "Disorder": {"text": [["cachectic AIDS"]], "start": [[41]], "entity_id": ["T10"]}}}]}]}
{"id": "19226083_17", "context": "Patients who commonly require linezolid as an antimicrobial are those with complex infections where other antibiotic treatment has failed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["require"]], "start": [[22]], "entity_id": ["T9"]}, "Subject": {"text": [["Patients", "complex infections"]], "start": [[0, 75]], "entity_id": ["T6"]}, "Treatment": {"text": [["linezolid as an antimicrobial"]], "start": [[30]], "entity_id": ["T7"], "Drug": {"text": [["linezolid"]], "start": [[30]], "entity_id": ["T10"]}, "Disorder": {"text": [["complex infections"]], "start": [[75]], "entity_id": ["T11"]}}}]}]}
{"id": "6245286_2", "context": "In three of these patients the infection was clinically unsuspected; in the fourth, cutaneous herpes zoster developed after administration of 300 mg of cytarabine daily for the preceding five days.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[108]], "entity_id": ["T6"]}, "Subject": {"text": [["three of these patients"]], "start": [[3]], "entity_id": ["T3"], "Population": {"text": [["three"]], "start": [[3]], "entity_id": ["T7"]}}, "Treatment": {"text": [["300 mg of cytarabine daily for the preceding five days"]], "start": [[142]], "entity_id": ["T4"], "Dosage": {"text": [["300 mg"]], "start": [[142]], "entity_id": ["T8"]}, "Drug": {"text": [["cytarabine"]], "start": [[152]], "entity_id": ["T9"]}, "Freq": {"text": [["daily"]], "start": [[163]], "entity_id": ["T10"]}, "Duration": {"text": [["preceding five days"]], "start": [[177]], "entity_id": ["T11"]}}, "Effect": {"text": [["cutaneous herpes zoster"]], "start": [[84]], "entity_id": ["T5"]}}]}]}
{"id": "17655517_9", "context": "Patients receiving linezolid for more than 28 days should be monitored for signs of peripheral and optic neuropathy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["monitored"]], "start": [[61]], "entity_id": ["T10"]}, "Treatment": {"text": [["linezolid for more than 28 days"]], "start": [[19]], "entity_id": ["T7"], "Drug": {"text": [["linezolid"]], "start": [[19]], "entity_id": ["T11"]}, "Duration": {"text": [["28 days"]], "start": [[43]], "entity_id": ["T13"]}}, "Subject": {"text": [["Patients"]], "start": [[0]], "entity_id": ["T8"]}, "Effect": {"text": [["peripheral and optic neuropathy"]], "start": [[84]], "entity_id": ["T9"]}, "Speculated": {"text": [["should"]], "start": [[51]], "entity_id": ["T12"], "value": true}}]}]}
{"id": "3941210_1", "context": "Atrioventricular block complicating amiodarone-induced hypothyroidism in a patient with pre-excitation and rate-dependent bilateral bundle branch block.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[47]], "entity_id": ["T7"]}, "Treatment": {"text": [["amiodarone"]], "start": [[36]], "entity_id": ["T6"], "Drug": {"text": [["amiodarone"]], "start": [[36]], "entity_id": ["T10"]}}, "Subject": {"text": [["a patient with pre-excitation and rate-dependent bilateral bundle branch block"]], "start": [[73]], "entity_id": ["T8"], "Disorder": {"text": [["pre-excitation"], ["rate-dependent bilateral bundle branch block"], ["Atrioventricular block"]], "start": [[88], [107], [0]], "entity_id": ["T9", "T1", "T2"]}}, "Effect": {"text": [["hypothyroidism"]], "start": [[55]], "entity_id": ["T5"]}}]}]}
{"id": "7249424_1", "context": "Lithium is known to cause acute renal failure and tubulo-interstitial disease, but the recently described association with proteinuria or nephrotic syndrome is little recognized.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["association"]], "start": [[106]], "entity_id": ["T11"]}, "Treatment": {"text": [["Lithium"]], "start": [[0]], "entity_id": ["T10"], "Drug": {"text": [["Lithium"]], "start": [[0]], "entity_id": ["T13"]}}, "Effect": {"text": [["acute renal failure and tubulo-interstitial disease", "proteinuria or nephrotic syndrome"]], "start": [[26, 123]], "entity_id": ["T12"]}}]}]}
{"id": "17509184_1", "context": "A 40-year-old man with advanced HIV infection and Mycobacterium avium complex infection experienced rapid cognitive decline after commencement of ethambutol, and symptoms fully resolved with cessation.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[124]], "entity_id": ["T6"]}, "Subject": {"text": [["40-year-old man with advanced HIV infection and Mycobacterium avium complex infection"]], "start": [[2]], "entity_id": ["T3"], "Age": {"text": [["40-year-old"]], "start": [[2]], "entity_id": ["T8"]}, "Gender": {"text": [["man"]], "start": [[14]], "entity_id": ["T9"]}}, "Effect": {"text": [["rapid cognitive decline"]], "start": [[100]], "entity_id": ["T5"]}, "Treatment": {"text": [["commencement of ethambutol"]], "start": [[130]], "entity_id": ["T7"], "Drug": {"text": [["ethambutol"]], "start": [[146]], "entity_id": ["T11"]}, "Disorder": {"text": [["ethambutol"], ["Mycobacterium avium complex infection"], ["HIV infection"]], "start": [[146], [50], [32]], "entity_id": ["T12", "T13", "T14"]}}}]}]}
{"id": "19892516_2", "context": "Ciprofloxacin-induced hemorrhagic vasculitis is a rare side effect.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[14]], "entity_id": ["T4"]}, "Treatment": {"text": [["Ciprofloxacin"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Ciprofloxacin"]], "start": [[0]], "entity_id": ["T6"]}}, "Effect": {"text": [["hemorrhagic vasculitis"]], "start": [[22]], "entity_id": ["T5"]}}]}]}
{"id": "15028964_7", "context": "Given that significant thyroid disorders may be only mildly symptomatic and thus may escape clinical detection, we suggest that thyroid function should be tested in any patient with otherwise unexplained changes in warfarin dose requirements, particularly if concomitantly treated with amiodarone.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["changes"]], "start": [[204]], "entity_id": ["T9"]}, "Effect": {"text": [["significant thyroid disorders"]], "start": [[11]], "entity_id": ["T7"]}, "Treatment": {"text": [["warfarin", "with amiodarone"]], "start": [[215, 281]], "entity_id": ["T8"], "Drug": {"text": [["warfarin"], ["amiodarone"]], "start": [[215], [286]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["concomitantly"]], "start": [[259]], "entity_id": ["T12"]}, "Drug": {"text": [["amiodarone"], ["warfarin"]], "start": [[286], [215]], "entity_id": ["T11", "T10"]}}]}}]}]}
{"id": "10367184_1", "context": "Myotonia associated with sarcoidosis: marked exacerbation with pravastatin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[9]], "entity_id": ["T3"]}, "Treatment": {"text": [["pravastatin"]], "start": [[63]], "entity_id": ["T4"], "Drug": {"text": [["pravastatin"]], "start": [[63]], "entity_id": ["T7"]}}, "Effect": {"text": [["exacerbation", "Myotonia"]], "start": [[45, 0]], "entity_id": ["T5"]}, "Subject": {"text": [["sarcoidosis"]], "start": [[25]], "entity_id": ["T8"], "Disorder": {"text": [["sarcoidosis"]], "start": [[25]], "entity_id": ["T6"]}}}]}]}
{"id": "7668127_5", "context": "This observation questions the suitability of aspirin as prophylaxis for vascular disease in patients with meningiomas.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["prophylaxis"]], "start": [[57]], "entity_id": ["T8"]}, "Treatment": {"text": [["aspirin"]], "start": [[46]], "entity_id": ["T7"], "Drug": {"text": [["aspirin"]], "start": [[46]], "entity_id": ["T12"]}, "Disorder": {"text": [["vascular disease"]], "start": [[73]], "entity_id": ["T13"]}}, "Subject": {"text": [["patients with meningiomas"]], "start": [[93]], "entity_id": ["T10"], "Disorder": {"text": [["meningiomas"]], "start": [[107]], "entity_id": ["T11"]}}, "Speculated": {"text": [["questions"]], "start": [[17]], "entity_id": ["T14"], "value": true}}]}]}
{"id": "8360712_2", "context": "Delayed neurotoxicity of intraventricular interleukin-2: a case report.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["of"]], "start": [[22]], "entity_id": ["T4"]}, "Effect": {"text": [["Delayed neurotoxicity"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["intraventricular interleukin-2"]], "start": [[25]], "entity_id": ["T5"], "Drug": {"text": [["interleukin-2"]], "start": [[42]], "entity_id": ["T7"]}, "Route": {"text": [["intraventricular"]], "start": [[25]], "entity_id": ["T8"]}}, "Subject": {"text": [["a case report"]], "start": [[57]], "entity_id": ["T6"]}}]}]}
{"id": "7776854_4", "context": "We stress the potential of benzarone to cause hepatotoxicity, which usually resembles severe chronic active hepatitis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["cause"]], "start": [[40]], "entity_id": ["T6"]}, "Effect": {"text": [["hepatotoxicity", "severe chronic active hepatitis"]], "start": [[46, 86]], "entity_id": ["T5"]}, "Treatment": {"text": [["benzarone"]], "start": [[27]], "entity_id": ["T7"], "Drug": {"text": [["benzarone"]], "start": [[27]], "entity_id": ["T11"]}}, "Speculated": {"text": [["potential"]], "start": [[14]], "entity_id": ["T9"], "value": true}, "Severity": {"text": [["severe"]], "start": [[86]], "entity_id": ["T10"], "value": "Medium"}}]}]}
{"id": "3579660_3", "context": "We describe a patient with Wilson's disease who presented with neurologic disease, was treated with D-penicillamine, and suffered sudden neurologic deterioration coincident with therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["suffered"]], "start": [[121]], "entity_id": ["T6"]}, "Subject": {"text": [["a patient with Wilson's disease who presented with neurologic disease"]], "start": [[12]], "entity_id": ["T3"], "Disorder": {"text": [["neurologic disease"]], "start": [[63]], "entity_id": ["T1"]}}, "Effect": {"text": [["sudden neurologic deterioration"]], "start": [[130]], "entity_id": ["T4"]}, "Treatment": {"text": [["D-penicillamine"]], "start": [[100]], "entity_id": ["T5"], "Disorder": {"text": [["Wilson's disease"]], "start": [[27]], "entity_id": ["T7"]}, "Drug": {"text": [["D-penicillamine"]], "start": [[100]], "entity_id": ["T8"]}}}]}]}
{"id": "16889287_3", "context": "We report the case of a 21-year-old female patient with dapsone hypersensitivity syndrome.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["with"]], "start": [[51]], "entity_id": ["T6"]}, "Subject": {"text": [["a 21-year-old female patient"]], "start": [[22]], "entity_id": ["T3"], "Age": {"text": [["21-year-old"]], "start": [[24]], "entity_id": ["T7"]}, "Gender": {"text": [["female"]], "start": [[36]], "entity_id": ["T8"]}}, "Treatment": {"text": [["dapsone"]], "start": [[56]], "entity_id": ["T4"], "Drug": {"text": [["dapsone"]], "start": [[56]], "entity_id": ["T9"]}}, "Effect": {"text": [["hypersensitivity syndrome"]], "start": [[64]], "entity_id": ["T5"]}}]}]}
{"id": "22233409_5", "context": "The adverse events related to ribavirin and drug-drug interactions during therapy for hepatitis C are discussed.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["related"]], "start": [[19]], "entity_id": ["T7"]}, "Treatment": {"text": [["ribavirin"]], "start": [[30]], "entity_id": ["T5"], "Drug": {"text": [["ribavirin"]], "start": [[30]], "entity_id": ["T9"]}, "Disorder": {"text": [["hepatitis C"]], "start": [[86]], "entity_id": ["T10"]}}, "Effect": {"text": [["adverse events"]], "start": [[4]], "entity_id": ["T8"]}}]}]}
{"id": "2309833_3", "context": "Insulin-dependent diabetes mellitus developed in a young woman 8 weeks after the initiation of danazol for treatment of pelvic endometriosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[71]], "entity_id": ["T3"]}, "Treatment": {"text": [["8 weeks after the initiation of danazol"]], "start": [[63]], "entity_id": ["T4"], "Disorder": {"text": [["pelvic endometriosis"]], "start": [[120]], "entity_id": ["T5"]}, "Time_elapsed": {"text": [["8 weeks"]], "start": [[63]], "entity_id": ["T10"]}, "Drug": {"text": [["danazol"]], "start": [[95]], "entity_id": ["T11"]}}, "Effect": {"text": [["Insulin-dependent diabetes mellitus"]], "start": [[0]], "entity_id": ["T6"]}, "Subject": {"text": [["a young woman"]], "start": [[49]], "entity_id": ["T7"], "Age": {"text": [["young"]], "start": [[51]], "entity_id": ["T8"]}, "Gender": {"text": [["woman"]], "start": [[57]], "entity_id": ["T9"]}}}]}]}
{"id": "417679_1", "context": "Four cases of fat embolism are described in infants receiving prolonged intravenous infusion of fat (Intralipid 20%).", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["receiving"]], "start": [[52]], "entity_id": ["T6"]}, "Effect": {"text": [["fat embolism"]], "start": [[14]], "entity_id": ["T3"]}, "Subject": {"text": [["Four cases", "infants"]], "start": [[0, 44]], "entity_id": ["T4"], "Age": {"text": [["infants"], ["Four"]], "start": [[44], [0]], "entity_id": ["T7", "T8"]}}, "Treatment": {"text": [["prolonged intravenous infusion of fat (Intralipid 20%)"]], "start": [[62]], "entity_id": ["T5"], "Route": {"text": [["intravenous infusion"]], "start": [[72]], "entity_id": ["T9"]}, "Drug": {"text": [["Intralipid"]], "start": [[101]], "entity_id": ["T10"]}}}]}]}
{"id": "18176653_1", "context": "Oral adverse effects due to the use of Nevirapine.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["due"]], "start": [[21]], "entity_id": ["T4"]}, "Treatment": {"text": [["Nevirapine"]], "start": [[39]], "entity_id": ["T5"], "Route": {"text": [["Oral"]], "start": [[0]], "entity_id": ["T6"]}, "Drug": {"text": [["Nevirapine"]], "start": [[39]], "entity_id": ["T7"]}}, "Effect": {"text": [["adverse effects"]], "start": [[5]], "entity_id": ["T3"]}}]}]}
{"id": "19299370_4", "context": "PURPOSE: A case of probable enoxaparin-induced hepatotoxicity is described.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[39]], "entity_id": ["T5"]}, "Treatment": {"text": [["enoxaparin"]], "start": [[28]], "entity_id": ["T4"], "Drug": {"text": [["enoxaparin"]], "start": [[28]], "entity_id": ["T7"]}}, "Effect": {"text": [["hepatotoxicity"]], "start": [[47]], "entity_id": ["T6"]}, "Speculated": {"text": [["probable"]], "start": [[19]], "entity_id": ["T3"], "value": true}}]}]}
{"id": "15383642_9", "context": "Tizanidine was used again after her BP had stabilized, but did not produce similar problems.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["produce"]], "start": [[67]], "entity_id": ["T7"]}, "Treatment": {"text": [["Tizanidine"]], "start": [[0]], "entity_id": ["T6"], "Drug": {"text": [["Tizanidine"]], "start": [[0]], "entity_id": ["T9"]}}, "Effect": {"text": [["problems"]], "start": [[83]], "entity_id": ["T8"]}, "Negated": {"text": [["not"]], "start": [[63]], "entity_id": ["T5"], "value": true}}]}]}
{"id": "424824_3", "context": "It is suggested therefore that methotrexate be added to the list of agents capable of inducing diffuse interstitial pulmonary fibrosis.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["inducing"]], "start": [[86]], "entity_id": ["T4"]}, "Treatment": {"text": [["methotrexate"]], "start": [[31]], "entity_id": ["T3"], "Drug": {"text": [["methotrexate"]], "start": [[31]], "entity_id": ["T6"]}}, "Effect": {"text": [["diffuse interstitial pulmonary fibrosis"]], "start": [[95]], "entity_id": ["T5"]}}]}]}
{"id": "8816294_1", "context": "The delayed encephalopathy developed 9 and 22 months respectively after the first dose of intrathecal methotrexate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[27]], "entity_id": ["T4"]}, "Effect": {"text": [["delayed encephalopathy"]], "start": [[4]], "entity_id": ["T3"]}, "Treatment": {"text": [["intrathecal methotrexate"]], "start": [[90]], "entity_id": ["T5"], "Time_elapsed": {"text": [["9 and 22 months"]], "start": [[37]], "entity_id": ["T6"]}, "Dosage": {"text": [["methotrexate"]], "start": [[102]], "entity_id": ["T7"]}, "Route": {"text": [["intrathecal"]], "start": [[90]], "entity_id": ["T8"]}}}]}]}
{"id": "3565435_2", "context": "Severe systemic hypersensitivity reaction to ibuprofen occurring after prolonged therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[65]], "entity_id": ["T3"]}, "Treatment": {"text": [["ibuprofen", "prolonged therapy"]], "start": [[45, 71]], "entity_id": ["T4"], "Drug": {"text": [["ibuprofen"]], "start": [[45]], "entity_id": ["T7"]}, "Time_elapsed": {"text": [["prolonged therapy"]], "start": [[71]], "entity_id": ["T8"]}}, "Effect": {"text": [["Severe systemic hypersensitivity reaction"]], "start": [[0]], "entity_id": ["T5"]}, "Severity": {"text": [["Severe"]], "start": [[0]], "entity_id": ["T6"], "value": "High"}}]}]}
{"id": "11250985_2", "context": "In patients with chronic heart failure, spironolactone added to conventional treatment may lead to serious and, occasionally, fatal hyperkalaemia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["lead"]], "start": [[91]], "entity_id": ["T8"]}, "Treatment": {"text": [["spironolactone"]], "start": [[40]], "entity_id": ["T3"], "Drug": {"text": [["spironolactone"]], "start": [[40]], "entity_id": ["T9"]}}, "Subject": {"text": [["patients with chronic heart failure"]], "start": [[3]], "entity_id": ["T4"], "Disorder": {"text": [["chronic heart failure"]], "start": [[17]], "entity_id": ["T5"]}}, "Effect": {"text": [["serious and, occasionally, fatal hyperkalaemia"]], "start": [[99]], "entity_id": ["T6"]}, "Speculated": {"text": [["may"]], "start": [[87]], "entity_id": ["T7"], "value": true}}]}]}
{"id": "10516999_2", "context": "We report a case of acute hyperphosphatemia secondary to rectal administration of sodium phosphate and sodium biphosphate (Fleet enema).", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["secondary"]], "start": [[44]], "entity_id": ["T5"]}, "Effect": {"text": [["acute hyperphosphatemia"]], "start": [[20]], "entity_id": ["T4"]}, "Treatment": {"text": [["rectal administration of sodium phosphate and sodium biphosphate (Fleet enema)"]], "start": [[57]], "entity_id": ["T6"], "Route": {"text": [["rectal"]], "start": [[57]], "entity_id": ["T7"]}, "Drug": {"text": [["sodium phosphate"], ["sodium biphosphate"]], "start": [[82], [103]], "entity_id": ["T8", "T9"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[99]], "entity_id": ["T10"]}, "Drug": {"text": [["sodium phosphate"], ["sodium biphosphate"]], "start": [[82], [103]], "entity_id": ["T8", "T9"]}}]}}]}]}
{"id": "12365708_4", "context": "Visual changes secondary to initiation of amiodarone: a case report and review involving ocular management in cardiac polypharmacy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["secondary"]], "start": [[15]], "entity_id": ["T5"]}, "Effect": {"text": [["Visual changes"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["amiodarone"]], "start": [[42]], "entity_id": ["T4"], "Drug": {"text": [["amiodarone"]], "start": [[42]], "entity_id": ["T7"]}}, "Subject": {"text": [["a case"]], "start": [[54]], "entity_id": ["T6"]}}]}]}
{"id": "14674674_3", "context": "This is the first case, to our knowledge, of onset of prolonged infliximab-induced lupus.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[75]], "entity_id": ["T3"]}, "Effect": {"text": [["lupus"]], "start": [[83]], "entity_id": ["T5"]}, "Treatment": {"text": [["infliximab"]], "start": [[64]], "entity_id": ["T4"], "Duration": {"text": [["prolonged"]], "start": [[54]], "entity_id": ["T6"]}, "Drug": {"text": [["infliximab"]], "start": [[64]], "entity_id": ["T7"]}}}]}]}
{"id": "17420198_19", "context": "A patient with developmental disabilities who had no history of movement disorders developed EPS following initiation of aripiprazole.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["following"]], "start": [[97]], "entity_id": ["T10"]}, "Effect": {"text": [["EPS"]], "start": [[93]], "entity_id": ["T9"]}, "Treatment": {"text": [["initiation of aripiprazole"]], "start": [[107]], "entity_id": ["T11"], "Drug": {"text": [["aripiprazole"]], "start": [[121]], "entity_id": ["T13"]}}, "Subject": {"text": [["A patient with developmental disabilities who had no history of movement disorders"]], "start": [[0]], "entity_id": ["T8"], "Disorder": {"text": [["developmental disabilities"]], "start": [[15]], "entity_id": ["T1"]}}}]}]}
{"id": "15307435_1", "context": "Case report: life-threatening hypoglycaemia associated with sulfadoxine-pyrimethamine, a commonly used antimalarial drug.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["associated"]], "start": [[44]], "entity_id": ["T4"]}, "Effect": {"text": [["life-threatening hypoglycaemia"]], "start": [[13]], "entity_id": ["T3"]}, "Treatment": {"text": [["sulfadoxine-pyrimethamine"]], "start": [[60]], "entity_id": ["T5"], "Drug": {"text": [["sulfadoxine-pyrimethamine"]], "start": [[60]], "entity_id": ["T7"]}}, "Subject": {"text": [["Case"]], "start": [[0]], "entity_id": ["T8"]}}]}]}
{"id": "12811715_2", "context": "Diphenhydramine-induced wide complex dysrhythmia responds to treatment with sodium bicarbonate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E2", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["to"]], "start": [[58]], "entity_id": ["T5"]}, "Treatment": {"text": [["treatment with sodium bicarbonate"]], "start": [[61]], "entity_id": ["T4"], "Disorder": {"text": [["Diphenhydramine-induced wide complex dysrhythmia"]], "start": [[0]], "entity_id": ["T3"]}, "Drug": {"text": [["Diphenhydramine"], ["sodium bicarbonate"]], "start": [[0], [76]], "entity_id": ["T7", "T8"]}}}]}]}
{"id": "228648_1", "context": "Prenatal cytomegalovirus (CMV) infection associated with severe brain damage was detected in an infant whose mother had been treated with prednisolone and azathioprine for systemic lupus erythematosus (SLE).", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["treated"]], "start": [[125]], "entity_id": ["T8"]}, "Effect": {"text": [["Prenatal cytomegalovirus (CMV) infection associated with severe brain damage"]], "start": [[0]], "entity_id": ["T7"]}, "Treatment": {"text": [["prednisolone and azathioprine"]], "start": [[138]], "entity_id": ["T9"], "Drug": {"text": [["prednisolone"], ["azathioprine"]], "start": [[138], [155]], "entity_id": ["T12", "T13"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["and"]], "start": [[151]], "entity_id": ["T14"]}, "Drug": {"text": [["prednisolone"], ["azathioprine"]], "start": [[138], [155]], "entity_id": ["T12", "T13"]}}]}, "Subject": {"text": [["an infant whose mother had been treated with prednisolone and azathioprine for systemic lupus erythematosus (SLE)"]], "start": [[93]], "entity_id": ["T10"], "Age": {"text": [["infant"]], "start": [[96]], "entity_id": ["T11"]}}}]}]}
{"id": "20178709_2", "context": "Methotrexate may rarely provoke serositis, even with low doses and after just a few weeks of therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["provoke"]], "start": [[24]], "entity_id": ["T5"]}, "Treatment": {"text": [["Methotrexate"]], "start": [[0]], "entity_id": ["T3"], "Drug": {"text": [["Methotrexate"]], "start": [[0]], "entity_id": ["T7"]}}, "Effect": {"text": [["serositis"]], "start": [[32]], "entity_id": ["T4"]}}]}]}
{"id": "21597286_6", "context": "Prescription analyses by pharmacists and literature research have permitted us to suggest that a drug-drug interaction between methotrexate and proton pump inhibitors (PPI) was responsible for this renal failure.", "is_mult_event": true, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["responsible"]], "start": [[177]], "entity_id": ["T9"]}, "Treatment": {"text": [["methotrexate and proton pump inhibitors (PPI)"]], "start": [[127]], "entity_id": ["T7"], "Drug": {"text": [["methotrexate"], ["proton pump inhibitors (PPI)"]], "start": [[127], [144]], "entity_id": ["T10", "T11"]}, "Combination": [{"event_id": "E2", "event_type": "Combination", "Trigger": {"text": [["interaction"]], "start": [[107]], "entity_id": ["T12"]}, "Drug": {"text": [["methotrexate"], ["proton pump inhibitors (PPI)"]], "start": [[127], [144]], "entity_id": ["T10", "T11"]}}]}, "Effect": {"text": [["renal failure"]], "start": [[198]], "entity_id": ["T8"]}}]}]}
{"id": "18795_2", "context": "Asthma and urticaria during disodium cromoglycate treatment.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[21]], "entity_id": ["T6"]}, "Effect": {"text": [["Asthma and urticaria"]], "start": [[0]], "entity_id": ["T5"]}, "Treatment": {"text": [["disodium cromoglycate treatment"]], "start": [[28]], "entity_id": ["T7"], "Drug": {"text": [["disodium cromoglycate"]], "start": [[28]], "entity_id": ["T8"]}}}]}]}
{"id": "10679548_7", "context": "We suggest that the previous classification of nitrofurantoin induced lung injury into \"acute\" and \"chronic\" injury is an oversimplification in view of the wide variety of pathological entities that have subsequently emerged.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[62]], "entity_id": ["T5"]}, "Treatment": {"text": [["nitrofurantoin"]], "start": [[47]], "entity_id": ["T3"], "Drug": {"text": [["nitrofurantoin"]], "start": [[47]], "entity_id": ["T6"]}}, "Effect": {"text": [["lung injury"]], "start": [[70]], "entity_id": ["T4"]}}]}]}
{"id": "2369419_2", "context": "Hepatitis with bridging fibrosis and reversible hepatic insufficiency in a woman with rheumatoid arthritis taking methotrexate.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["taking"]], "start": [[107]], "entity_id": ["T7"]}, "Treatment": {"text": [["methotrexate"]], "start": [[114]], "entity_id": ["T8"], "Disorder": {"text": [["rheumatoid arthritis"]], "start": [[86]], "entity_id": ["T12"]}, "Drug": {"text": [["methotrexate"]], "start": [[114]], "entity_id": ["T13"]}}, "Subject": {"text": [["a woman with rheumatoid arthritis"]], "start": [[73]], "entity_id": ["T9"], "Gender": {"text": [["woman"]], "start": [[75]], "entity_id": ["T11"]}}, "Effect": {"text": [["Hepatitis with bridging fibrosis and reversible hepatic insufficiency"]], "start": [[0]], "entity_id": ["T10"]}}]}]}
{"id": "16116136_4", "context": "Primary CNS lymphoma regressed on withdrawal of MM.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Potential_therapeutic_event", "Trigger": {"text": [["regressed"]], "start": [[21]], "entity_id": ["T5"]}, "Treatment": {"text": [["withdrawal of MM"]], "start": [[34]], "entity_id": ["T3"], "Drug": {"text": [["MM"]], "start": [[48]], "entity_id": ["T6"]}}, "Effect": {"text": [["Primary CNS lymphoma"]], "start": [[0]], "entity_id": ["T4"]}}]}]}
{"id": "6498095_2", "context": "Pemphigus foliaceus induced by rifampicin.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["induced"]], "start": [[20]], "entity_id": ["T6"]}, "Effect": {"text": [["Pemphigus foliaceus"]], "start": [[0]], "entity_id": ["T3"]}, "Treatment": {"text": [["rifampicin"]], "start": [[31]], "entity_id": ["T5"], "Drug": {"text": [["rifampicin"]], "start": [[31]], "entity_id": ["T7"]}}}]}]}
{"id": "2931445_3", "context": "L-T4 stimulated lymphocyte transformation in this patient.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["stimulated"]], "start": [[5]], "entity_id": ["T4"]}, "Treatment": {"text": [["L-T4"]], "start": [[0]], "entity_id": ["T5"], "Drug": {"text": [["L-T4"]], "start": [[0]], "entity_id": ["T8"]}}, "Effect": {"text": [["lymphocyte transformation"]], "start": [[16]], "entity_id": ["T6"]}, "Subject": {"text": [["this patient"]], "start": [[45]], "entity_id": ["T7"]}}]}]}
{"id": "12126225_1", "context": "A 53-year-old man developed lower leg edema 4 weeks after rosiglitazone was increased from 4 mg once/day to 4 mg twice/day.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[52]], "entity_id": ["T3"]}, "Subject": {"text": [["A 53-year-old man"]], "start": [[0]], "entity_id": ["T4"], "Age": {"text": [["53-year-old"]], "start": [[2]], "entity_id": ["T7"]}, "Gender": {"text": [["man"]], "start": [[14]], "entity_id": ["T8"]}}, "Effect": {"text": [["lower leg edema"]], "start": [[28]], "entity_id": ["T5"]}, "Treatment": {"text": [["4 weeks after rosiglitazone was increased from 4 mg once/day to 4 mg twice/day"]], "start": [[44]], "entity_id": ["T6"], "Time_elapsed": {"text": [["4 weeks"]], "start": [[44]], "entity_id": ["T9"]}, "Drug": {"text": [["rosiglitazone"]], "start": [[58]], "entity_id": ["T10"]}, "Dosage": {"text": [["4 mg"]], "start": [[108]], "entity_id": ["T11"]}, "Freq": {"text": [["twice/day"]], "start": [[113]], "entity_id": ["T12"]}}}]}]}
{"id": "3143551_2", "context": "A mentally retarded 23-year-old woman with myoclonic astatic epilepsy developed an abnormal posture of extreme forward flexion, called camptocormia, during valproate monotherapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["during"]], "start": [[149]], "entity_id": ["T5"]}, "Treatment": {"text": [["valproate"]], "start": [[156]], "entity_id": ["T6"], "Drug": {"text": [["valproate"]], "start": [[156]], "entity_id": ["T12"]}, "Disorder": {"text": [["myoclonic astatic epilepsy"]], "start": [[43]], "entity_id": ["T13"]}}, "Subject": {"text": [["A mentally retarded 23-year-old woman with myoclonic astatic epilepsy"]], "start": [[0]], "entity_id": ["T7"], "Disorder": {"text": [["mentally retarded"]], "start": [[2]], "entity_id": ["T9"]}, "Age": {"text": [["23-year-old"]], "start": [[20]], "entity_id": ["T10"]}}, "Effect": {"text": [["abnormal posture of extreme forward flexion, called camptocormia,"]], "start": [[83]], "entity_id": ["T8"]}}]}]}
{"id": "12086549_1", "context": "After 5 days of treatment with IL-2, the patient developed a hemorrhagic lesion that progressed to toxic epidermal necrolysis, as well as grade 4 pancytopenia.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["developed"]], "start": [[49]], "entity_id": ["T10"]}, "Treatment": {"text": [["5 days of treatment with IL-2"]], "start": [[6]], "entity_id": ["T7"], "Drug": {"text": [["IL-2"]], "start": [[31]], "entity_id": ["T11"]}, "Time_elapsed": {"text": [["After 5 days"]], "start": [[0]], "entity_id": ["T12"]}}, "Subject": {"text": [["patient"]], "start": [[41]], "entity_id": ["T8"]}, "Effect": {"text": [["a hemorrhagic lesion that progressed to toxic epidermal necrolysis, as well as grade 4 pancytopenia"]], "start": [[59]], "entity_id": ["T9"]}}]}]}
{"id": "9399776_1", "context": "Acute pancreatitis after long-term 5-aminosalicylic acid therapy.", "is_mult_event": false, "annotations": [{"events": [{"event_id": "E1", "event_type": "Adverse_event", "Trigger": {"text": [["after"]], "start": [[19]], "entity_id": ["T3"]}, "Effect": {"text": [["Acute pancreatitis"]], "start": [[0]], "entity_id": ["T4"]}, "Treatment": {"text": [["long-term 5-aminosalicylic acid therapy"]], "start": [[25]], "entity_id": ["T5"], "Drug": {"text": [["5-aminosalicylic acid"]], "start": [[35]], "entity_id": ["T6"]}, "Time_elapsed": {"text": [["long-term"]], "start": [[25]], "entity_id": ["T7"]}}}]}]}
